<SEC-DOCUMENT>0001280776-22-000021.txt : 20221103
<SEC-HEADER>0001280776-22-000021.hdr.sgml : 20221103
<ACCEPTANCE-DATETIME>20221103105246
ACCESSION NUMBER:		0001280776-22-000021
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		67
CONFORMED PERIOD OF REPORT:	20220930
FILED AS OF DATE:		20221103
DATE AS OF CHANGE:		20221103

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			IMMUNIC, INC.
		CENTRAL INDEX KEY:			0001280776
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				562358443
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36201
		FILM NUMBER:		221356784

	BUSINESS ADDRESS:	
		STREET 1:		1200 AVENUE OF THE AMERICAS
		STREET 2:		SUITE 200
		CITY:			NEW YORK
		STATE:			X1
		ZIP:			10036
		BUSINESS PHONE:		(332) 255-9818

	MAIL ADDRESS:	
		STREET 1:		1200 AVENUE OF THE AMERICAS
		STREET 2:		SUITE 200
		CITY:			NEW YORK
		STATE:			X1
		ZIP:			10036

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	VITAL THERAPIES INC
		DATE OF NAME CHANGE:	20040219
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>vtl-20220930.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:6944770f-821d-45aa-b4f3-cccabd82d2f9,g:32d5dde5-0858-4183-b548-263732a64d33,d:da7c333e3c58430eb83e8e950c50d811--><html xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns="http://www.w3.org/1999/xhtml" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:vtl="http://vitaltherapies.com/20220930" xmlns:srt="http://fasb.org/srt/2022" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>vtl-20220930</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80L2ZyYWc6ZmE4MGM5YTI1YTYzNGM3YWI0NmZmZTljMDQxZWE4ZjUvdGFibGU6NjI2OTVmM2ZlOTMzNDI0ZjlmNzdhMjAzYTdhMmM4NWYvdGFibGVyYW5nZTo2MjY5NWYzZmU5MzM0MjRmOWY3N2EyMDNhN2EyYzg1Zl8yLTEtMS0xLTMwNTAw_30266e45-0bbb-4bdd-91e2-77bc4fa443cb">2022</ix:nonNumeric><ix:nonNumeric contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80L2ZyYWc6ZmE4MGM5YTI1YTYzNGM3YWI0NmZmZTljMDQxZWE4ZjUvdGFibGU6NjI2OTVmM2ZlOTMzNDI0ZjlmNzdhMjAzYTdhMmM4NWYvdGFibGVyYW5nZTo2MjY5NWYzZmU5MzM0MjRmOWY3N2EyMDNhN2EyYzg1Zl8zLTEtMS0xLTMwNTAw_d1182955-6aab-492f-a519-180c091b5527">Q3</ix:nonNumeric><ix:nonNumeric contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930" name="dei:AmendmentFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80L2ZyYWc6ZmE4MGM5YTI1YTYzNGM3YWI0NmZmZTljMDQxZWE4ZjUvdGFibGU6NjI2OTVmM2ZlOTMzNDI0ZjlmNzdhMjAzYTdhMmM4NWYvdGFibGVyYW5nZTo2MjY5NWYzZmU5MzM0MjRmOWY3N2EyMDNhN2EyYzg1Zl80LTEtMS0xLTMwNTAw_cc74a2a0-6508-464f-8bfd-206c4e2c4541">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80L2ZyYWc6ZmE4MGM5YTI1YTYzNGM3YWI0NmZmZTljMDQxZWE4ZjUvdGV4dHJlZ2lvbjpmYTgwYzlhMjVhNjM0YzdhYjQ2ZmZlOWMwNDFlYThmNV8zOA_82a2040e-54d0-412a-8eac-5df3ebeaaf43">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80L2ZyYWc6ZmE4MGM5YTI1YTYzNGM3YWI0NmZmZTljMDQxZWE4ZjUvdGV4dHJlZ2lvbjpmYTgwYzlhMjVhNjM0YzdhYjQ2ZmZlOWMwNDFlYThmNV82Nw_e84f4836-bf68-4c86-8cda-6717abfe9daa">0001280776</ix:nonNumeric><ix:nonNumeric contextRef="ia09dc4bf851844ccaa07c02cfa96d7c3_D20220101-20220930" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8zNC9mcmFnOjZlNmZlYmNmYmQwYTRlNDE5NDE0ZWFhMGNlYTdjMWU2L3RleHRyZWdpb246NmU2ZmViY2ZiZDBhNGU0MTk0MTRlYWEwY2VhN2MxZTZfNDU2Mg_7c753206-cde1-40ce-856d-422289b6506b">P3Y</ix:nonNumeric><ix:nonNumeric contextRef="i8141d9aff5674330883906a3d1d82d52_D20220101-20220930" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80OS9mcmFnOjlhN2M1MTczZGE1ZTQ5ZjViYTk4YWRiODZhZWYwOWJkL3RleHRyZWdpb246OWE3YzUxNzNkYTVlNDlmNWJhOThhZGI4NmFlZjA5YmRfNTQ5NzU1ODI1NDIw_e9f71a48-2105-4fda-bdd7-59ddc0e82852">P3Y</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="vtl-20220930.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i47193a7aeac443c69053141ff75cc655_I20221028"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-10-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="ib2ba0b84078f4de2bc3079e992921b92_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i12246a01749f40d394a9437cb9938c91_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i25a8ea2d7c9f4bfd8f72223c8ac18c65_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib52579de36d54242a791b9e3f8019a00_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i69e8bcaae5bf44c9a03cf7f5bd08e6b8_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i10cadb43ee4f4d5983a19400b011767c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i009a2206cca94447b0821da5d321afd8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i385e3bff38de43c684e65b2b3be869c2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3f4fa8cb61dc4846bc63aadbbe138fd4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ida6ee8360c724bafba15cd5fadf3f86c_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icd575a0576f94d6abe3a754e65a57231_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5bfbb29080414e03b068322088956131_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i833e88d808f64f8db575748a84d92e85_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5521d4c179a3424b8300e7e1aa3bb508_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i48e85fbb9eaf443d833e5d74dad1457f_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:PublicOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i85e99d9786824edc9811205ccff0e2c1_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:PublicOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if0fe92136184445b9b403e48c306c7a0_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i37699bd784b74eff9b8044aa3d0f82c7_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i695cece83a314ed69b003d1805aa445f_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9f48eb2e56ec4c62bea71dbf94048968_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i70f7507e4b224e59ba619f034e88a2d9_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i85803ab216eb4675941bdbd496da6ed9_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i737e66e4d7604e7294bf339bc188faf1_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8ff3b5d8c53f48e598eabdf159ffe5a8_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2e65e2ba034b476992065fd432154ff5_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iff0dfca8fc4744b889817f531d94648d_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1888877c44594a0cbbf03d306681d074_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i22a1a97b6019485d898b3ada299277d4_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:PublicOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0620912ded354506af6d332f0bc83206_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:PublicOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1d21953862a4496690291cb9fd6c7a94_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8e38d9d8fc034a00a625f8563c6b5b60_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iafd4cef3856c4625a9d0b5d421a2c12c_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idb62eb795df54275a27ebfed4e80d684_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib052a6f4a0df4d008a91d46f1ee57c9c_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1fd2b9d5dc8348c987bb258a78754f1b_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0c6bb7a44c4b41a48b75959b450bca0a_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if2f7ecfa268042c1b6d8341deccf977e_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i866042db0ec3492ab88b30fc3d7eb0bf_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5b62286d567e4f259000b5a1b4c2dbbe_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8b90293a84aa4674a7bcf0617b17717e_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icbddd86c41c74f1ea8d5a18c99ee0215_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i854438f7be7f47f196c8a2c22e9b5e77_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i607bec8e45eb4e6d838d65f04d1d719f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if567f5fc4bef457ba7f7d0fa94a8a6ef_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iea3035acf49d4db7a54e9ead049bc20b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i77530ee1861747fda1f023dbac2a8d90_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib8e90b6ab1f24717b294f892b4a059b4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i26792f62773c456c934cf59dcefb4260_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7eb4374d1ee742ffa761b98e61b09caf_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie46dbf54043c469594e16cf8b3942872_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i26d6ec96c4a24603b58ef52fcbe09dbe_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iff342baa477241189847103920c9390b_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:A4SCRoyaltySettlementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i79dafe91dc2b4583bc7281b9ac581921_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:A4SCRoyaltySettlementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i47c50e6a28d840f58afe00251ea7cb63_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:A4SCRoyaltySettlementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic1b52eb993194bc79abd0bdb3ac2fb16_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1e4e96801dd14e038268468354ac544d_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i36785e9a44f44fa498d7a9e39d281de6_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id8c73d5dc8b3435d90082da759d26561_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie158d385723a4b6c94e8384571358a19_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iec8caa356ace43cea23a50885d4ce99a_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idbd4b40aa73a4833999ce49448a575c1_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i727b0a04077a4a8f8ed3d895673d106c_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4fcf02a24eb5413182bd309637981b5f_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3be90c8090ab461c8c2b38fd4278056a_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia452dd2fae424bb3853dcf4cf9a6a5f7_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3af9d520bc33490fb02d4e0e45e64528_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7cf65f44be454209a8ed367a2d506669_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i016c5728112e4750b50b637d6c871fe3_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i72dd476a4160417bb81e51d19d04fec4_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i39aae3cf38724522a40a6fc4e3254d97_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie8f986adcd0d4adb96a54c85ecec772d_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i75df6ae240184d6cbec2048c440c2cfd_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:July2021EquityIssuanceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5876ecf1449d4c42a057445d55680cd9_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:July2021EquityIssuanceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1c0c6c63355f4b9f94038593d420a3b7_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:July2021EquityIssuanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8803b9920af74191be48fe8d2de93d42_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic6c0192051924752911d006055eb26b5_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i53b949b08f1f4426aa11fcca407bc625_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib7a3b6923515465ba7ed8a9c9f8c50a2_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1c5dd6f726174024bdc176efa6738fd9_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3d48326594df4b61bdc5572faf307bb8_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9ea948d1a371446296c8cfe8ac8d3534_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if312c4804f8b4c99a0562a9d7368b18e_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:July2021PublicEquityOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iefba5660e6154047a65570c20050a670_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:July2021PublicEquityOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="employee"><xbrli:measure>vtl:employee</xbrli:measure></xbrli:unit><xbrli:unit id="program"><xbrli:measure>vtl:program</xbrli:measure></xbrli:unit><xbrli:context id="id96591a4131743fabd2bef215e14e27d_D20140417-20221031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2014-04-17</xbrli:startDate><xbrli:endDate>2022-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ied30ae8dfbe54606808411695b6e7a4d_I20221031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="financialinstitution"><xbrli:measure>vtl:financialInstitution</xbrli:measure></xbrli:unit><xbrli:context id="ia09dc4bf851844ccaa07c02cfa96d7c3_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i946f069c215c45208da865ab19d790c4_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iceee2385dd3a4cafb879b0088a931d62_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id906393de2c04b61842e3087515a35aa_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0635b165f76f479694e7564645ca75f5_D20221001-20221103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-11-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic5a53880f9da458c8abd6926ff69ddd8_D20221001-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib99098d9e41b4f74a0e5c17f2558443e_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic3f8af6eaf2d4e90a82b6ef6ea30ec32_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="lease"><xbrli:measure>vtl:lease</xbrli:measure></xbrli:unit><xbrli:context id="ic3a03035d5534d539979b07aedea62c1_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id8129f471bae49039a917f1451ac8087_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iefd1980314f44440b5198657ab592ad5_I20200407"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">vtl:GrafelfingGermanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id2f24df2744547978cca7abe63d3ddfa_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">vtl:NewYorkCityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i707a1cd4886c4397999788b4d4817cc8_D20210301-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">vtl:GrafelfingGermanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i23801a5cc9424606a18bc0c74d94ebc9_D20220801-20220801"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">vtl:GrafelfingGermanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-01</xbrli:startDate><xbrli:endDate>2022-08-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i85fd4b228c8e4e22aa84564d8a1092a4_D20160501-20160531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2016-05-01</xbrli:startDate><xbrli:endDate>2016-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i13be27ffd0404758995be06dca534f38_I20190412"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-04-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7ce199652934499fa56ce12df1fabbef_D20210331-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">vtl:ImmunicAGMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-31</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i42d359c425714cf8b47c82373a440814_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">vtl:ImmunicAGMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia5d5d1c95a774f429ad29d595bac0585_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8e0b1222c30b4269aa3c56e6ebee8dc4_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idc57905cd80143b29ea902574f63d2e8_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if643e711815d4b749376bea335780421_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5a48bc4ae7d7408f97f6eeb1dca78e8b_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib3b80cda8b6f452eb05a40cc72183236_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iecbaf68de7c649b39d49d2cd525bbdaf_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5815b7ec2c4048eaa79c592705f78a05_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i026a14121f5e41e6b31d1f3647017fab_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i66caad9103ff476d8d79ca94f9ff9ca7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i26c3332665024e968525d075f51dd2c3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieb7c3038fa504039b4299ec811876236_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7c78af0997974f8888e346839bbbb526_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieeee9cf1b4db4ae799c2820e753b57d4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibbf0f0e07da94302ac3cd78120a72738_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic2d55028ecbe47369972c9dc27a4983b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i452fc01435184aa6b440569b104a7b6a_I20201130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i37de57482ffb4464ab59f455ab94a18c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:December2020ATMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2867d1aebe414721a791386480b70c8f_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:December2020ATMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="d"><xbrli:measure>utr:D</xbrli:measure></xbrli:unit><xbrli:context id="ia9434666be04407c90f384a6f8cee2f8_I20221031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:December2020ATMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i731d9157c77642cf8b53fdb984854e80_I20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:May2022ATMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie383b6c67b2d4562a2b5fa326cbe5000_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:May2022ATMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9843b826ca9942c9abbeb49451438b66_I20220505"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:May2022ATMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic64d3d20dd7f42ebab0773713f0e2f62_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:December2020ATMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i13dc9f1a4e524f93b1138a442b35c8d0_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:December2020ATMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id7f3ba2151e24a8694efe8eededbb089_D20210715-20210715"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:July2021PublicEquityOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-15</xbrli:startDate><xbrli:endDate>2021-07-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i837eb6ff329b46d1b9063702464b7004_I20210715"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:July2021PublicEquityOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic1deecff015c411d9b86fcc68ba1683c_D20210719-20210719"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:July2021PublicEquityOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-19</xbrli:startDate><xbrli:endDate>2021-07-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iee6bdacd518b494c838da43db583331a_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2021EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ica07e01c9d0f47a59cbaee95aef0d158_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8d6a85cd1f8b48108c4b2aac7ded4bf3_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:TwoThousandFourteenEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vtl:EmployeeStockOptionsforFutureGrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i66a3a4fa022d420ebf30bfd5b338b14a_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vtl:EmployeeStockOptionsforFutureGrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2017InducementEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4b8e8ab0f2aa4d60b8640f5f1ddff361_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vtl:EmployeeStockOptionsforFutureGrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:TwoThousandNineteenOmnibusEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic696ef9959af49cdbf3fd974759bd0bc_D20210425-20210425"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2021EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-25</xbrli:startDate><xbrli:endDate>2021-04-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i08aa60800326487fbf99175d815ab200_I20210425"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2021EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6c48924db6c34718b6db57f2bcd38c0b_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2021EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie7370ee1ee9943cdacd5aaf69e8a6815_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2021EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2f6d9566f1a34310806423b83a871513_D20210425-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2021EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-25</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib000cfab8d3c42d09670f1d425af5286_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2021EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i590665700dea49f8bbef5c2cd33f5ab6_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2021EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0364a2ce088c4ade8ed67e8b0967db85_I20190731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2019OmnibusEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i97b48810b19f420aaff9dc7f71a98c22_D20190701-20190731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if69ea9bc126c4fa5a73a13a32babfa2b_D20200101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id40d762aabfc48f4a2944687c1be6b40_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2019OmnibusEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8925c9f347c0462dafcba58c8ff77fc0_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vtl:IncentiveEmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2019OmnibusEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8141d9aff5674330883906a3d1d82d52_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2019OmnibusEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vtl:NonStatutoryEmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaf64f27642a24cfd90a8b4b8fd99a4e3_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2019OmnibusEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vtl:NonStatutoryEmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7f827301d88e484985fc3a70f1380d98_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:TwoThousandNineteenOmnibusEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i89cb4fe99d71444395e3fc22f0e7e477_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:TwoThousandNineteenOmnibusEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i33c46859f4e1425b90a6f987327175f6_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:TwoThousandNineteenOmnibusEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1986a58a2c504c0b9c41f5d536a9502c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:TwoThousandNineteenOmnibusEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0c4254621dc64047a9c2d671aa842886_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:TwoThousandNineteenOmnibusEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3fc8f323372c48c49a066aa56341ee03_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:TwoThousandNineteenOmnibusEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i491c0053bc5f4054a60885ff43fbbc87_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2019OmnibusEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3b24c8dadaf44185922659d4e669111d_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2019OmnibusEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i65018cf301294210aa0bfac659e1638e_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vtl:EmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0c3b29676a4440ad86911f00449ac95c_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vtl:EmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i51d6b668f708464ebb2ff34b8eee66d8_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vtl:EmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i83d76f6d51a84bfaaf85c435fc1d50f8_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vtl:EmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9e6c05b057b542f6a6dc60098a6d004a_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vtl:EmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifcca3d7bc3b04230b95c604feca1b658_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vtl:EmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i600a6a4da2a14932ac6ebff843b1dc82_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vtl:EmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia17d3b4067d84bec848071ef0c64a422_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vtl:EmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i13791407fd49427ea3348fc4827a4293_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vtl:EmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib938f3761273465cb69e3854e10882fd_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vtl:EmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0c121149163740e0a14cb0c4c82c1e7a_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vtl:EmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i73bcd6c9a1664c7bbdd7d9ed12c94b42_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vtl:EmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6e53bb714b6644b6844692585589b9a1_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:TwoThousandFourteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i84a3ff1a38eb4f16b75117d13dc1cdf2_I20170930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2017InducementEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if4028463febd40cfa3197e55e2ea9e63_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2017InducementEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i991eea4739be41089733f8422d8cbd37_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2017InducementEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6197809d315e4cd680ef948f2e4723c8_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2017InducementEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5d76381e3d7b4d5e846b0b465a4f3f9a_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2017InducementEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0b4e3048cb3144a99e1401eb94392689_D20220706-20220706"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-06</xbrli:startDate><xbrli:endDate>2022-07-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifaeb8f92093c46299d0fff82d6b11f23_D20220706-20220706"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vtl:OptionsVestingInOneYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-06</xbrli:startDate><xbrli:endDate>2022-07-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibb08e53d8ed6456987432dc116d4c52f_D20220706-20220706"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vtl:OptionsVestingInThreeYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-06</xbrli:startDate><xbrli:endDate>2022-07-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7842ca3ec7d941b397d15eae864cf058_D20210415-20210415"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vtl:DuaneNashMDJDMBAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">vtl:ExecutiveChairmanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-15</xbrli:startDate><xbrli:endDate>2021-04-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4e522a1cd2c5463883ece885e48da850_D20210515-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vtl:DuaneNashMDJDMBAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">vtl:ExecutiveChairmanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-15</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic77ff01be43a48cfa612a7cac5ec9de0_D20210101-20210514"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vtl:DuaneNashMDJDMBAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">vtl:ExecutiveChairmanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-05-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8af8b2227bd540f38b6dc794af632800_D20220315-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vtl:DuaneNashMDJDMBAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">vtl:ExecutiveChairmanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-15</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iac9f9142fce04841b7cdeea2bfcabdb6_D20220315-20220315"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vtl:DuaneNashMDJDMBAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">vtl:ExecutiveChairmanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-15</xbrli:startDate><xbrli:endDate>2022-03-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id3d63a41fa5847168bff487d8106b2f5_D20221010-20221010"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-10</xbrli:startDate><xbrli:endDate>2022-10-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i04004da4d23642dd85e9052de2144a17_I20221010"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icc5700f8c4a44461ab5894f373a0d8ac_D20221010-20221010"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:PreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-10</xbrli:startDate><xbrli:endDate>2022-10-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1910349757c84c67942eeea2127e5dc4_I20221010"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:PreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4346a7f60eba4d42bfc2b801e8e1dc2b_D20221012-20221012"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-12</xbrli:startDate><xbrli:endDate>2022-10-12</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="ida7c333e3c58430eb83e8e950c50d811_1"></div><div style="min-height:27pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xL2ZyYWc6M2NiYWU3NWQ5ZGUzNDc4OTgxZTg2MDFjYzE1NDg1ZDUvdGV4dHJlZ2lvbjozY2JhZTc1ZDlkZTM0Nzg5ODFlODYwMWNjMTU0ODVkNV84Mg_59d7e16c-70c1-4c4a-b82e-6515d0fcbc3a">10-Q</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Mark One)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:4.756%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.044%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930" name="dei:DocumentQuarterlyReport" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xL2ZyYWc6M2NiYWU3NWQ5ZGUzNDc4OTgxZTg2MDFjYzE1NDg1ZDUvdGFibGU6MjE1M2ZlMmEyODQyNDA4OGI2ZjU4NTIxOTU0NmRlNjkvdGFibGVyYW5nZToyMTUzZmUyYTI4NDI0MDg4YjZmNTg1MjE5NTQ2ZGU2OV8wLTAtMS0xLTMwNTAw_148c0911-ad3a-4ec1-837a-34166658293a">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">For the quarterly period ended</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"> <ix:nonNumeric contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xL2ZyYWc6M2NiYWU3NWQ5ZGUzNDc4OTgxZTg2MDFjYzE1NDg1ZDUvdGV4dHJlZ2lvbjozY2JhZTc1ZDlkZTM0Nzg5ODFlODYwMWNjMTU0ODVkNV8xMzA_79d086c3-2bc6-452b-ab35-7438c4a45264">September 30, 2022</ix:nonNumeric> </span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">or</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:4.756%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.044%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xL2ZyYWc6M2NiYWU3NWQ5ZGUzNDc4OTgxZTg2MDFjYzE1NDg1ZDUvdGFibGU6YmJlMDFhNTg1ZTJiNDY3MzhlM2I3MmE4NjY4YmY3YTMvdGFibGVyYW5nZTpiYmUwMWE1ODVlMmI0NjczOGUzYjcyYTg2NjhiZjdhM18wLTAtMS0xLTMwNTAw_05c23095-d0bb-4376-80e2-49492ea69e23">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">For the transition period from </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Commission File Number:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"> <ix:nonNumeric contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xL2ZyYWc6M2NiYWU3NWQ5ZGUzNDc4OTgxZTg2MDFjYzE1NDg1ZDUvdGV4dHJlZ2lvbjozY2JhZTc1ZDlkZTM0Nzg5ODFlODYwMWNjMTU0ODVkNV8yMzg_c6ca9b49-a169-439a-afea-fd18572efb93">001-36201</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xL2ZyYWc6M2NiYWU3NWQ5ZGUzNDc4OTgxZTg2MDFjYzE1NDg1ZDUvdGV4dHJlZ2lvbjozY2JhZTc1ZDlkZTM0Nzg5ODFlODYwMWNjMTU0ODVkNV8yNDM_f35652cd-e834-478b-9271-db73bb9dcf7e">Immunic, Inc.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:53.654%"><tr><td style="width:1.0%"></td><td style="width:46.038%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.256%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.406%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xL2ZyYWc6M2NiYWU3NWQ5ZGUzNDc4OTgxZTg2MDFjYzE1NDg1ZDUvdGFibGU6MjljZGRhMTYyNGUxNDBiZWJlOGVmODk3NmEzMDUxN2IvdGFibGVyYW5nZToyOWNkZGExNjI0ZTE0MGJlYmU4ZWY4OTc2YTMwNTE3Yl8wLTAtMS0xLTMwNTAw_8d92a07a-20a5-4760-92af-5707e482d00c">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xL2ZyYWc6M2NiYWU3NWQ5ZGUzNDc4OTgxZTg2MDFjYzE1NDg1ZDUvdGFibGU6MjljZGRhMTYyNGUxNDBiZWJlOGVmODk3NmEzMDUxN2IvdGFibGVyYW5nZToyOWNkZGExNjI0ZTE0MGJlYmU4ZWY4OTc2YTMwNTE3Yl8wLTItMS0xLTMwNTAw_6d601f14-9ccb-4a01-ab85-b5d476d5f04d">56-2358443</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(State or other jurisdiction of incorporation or organization)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(I.R.S. Employer Identification No.)</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xL2ZyYWc6M2NiYWU3NWQ5ZGUzNDc4OTgxZTg2MDFjYzE1NDg1ZDUvdGFibGU6MjljZGRhMTYyNGUxNDBiZWJlOGVmODk3NmEzMDUxN2IvdGFibGVyYW5nZToyOWNkZGExNjI0ZTE0MGJlYmU4ZWY4OTc2YTMwNTE3Yl8zLTAtMS0xLTMwNTAw_ec8bb7a2-9364-4e7e-a5d8-60b6d5299a01">1200 Avenue of the Americas</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930" name="dei:EntityAddressAddressLine2" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xL2ZyYWc6M2NiYWU3NWQ5ZGUzNDc4OTgxZTg2MDFjYzE1NDg1ZDUvdGFibGU6MjljZGRhMTYyNGUxNDBiZWJlOGVmODk3NmEzMDUxN2IvdGFibGVyYW5nZToyOWNkZGExNjI0ZTE0MGJlYmU4ZWY4OTc2YTMwNTE3Yl80LTAtMS0xLTMwNTAw_4b45fce2-c209-4f95-b896-d01d6ff80f0e">Suite 200</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xL2ZyYWc6M2NiYWU3NWQ5ZGUzNDc4OTgxZTg2MDFjYzE1NDg1ZDUvdGFibGU6MjljZGRhMTYyNGUxNDBiZWJlOGVmODk3NmEzMDUxN2IvdGFibGVyYW5nZToyOWNkZGExNjI0ZTE0MGJlYmU4ZWY4OTc2YTMwNTE3Yl81LTAtMS0xLTMwNTAw_a7095ba2-e79d-4a34-aaf1-18b5dc9381a9">New York,</ix:nonNumeric> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xL2ZyYWc6M2NiYWU3NWQ5ZGUzNDc4OTgxZTg2MDFjYzE1NDg1ZDUvdGFibGU6MjljZGRhMTYyNGUxNDBiZWJlOGVmODk3NmEzMDUxN2IvdGFibGVyYW5nZToyOWNkZGExNjI0ZTE0MGJlYmU4ZWY4OTc2YTMwNTE3Yl81LTEtMS0xLTMwNTAw_80c783e3-db01-4af5-ad3d-c57f68110f1a">NY</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xL2ZyYWc6M2NiYWU3NWQ5ZGUzNDc4OTgxZTg2MDFjYzE1NDg1ZDUvdGFibGU6MjljZGRhMTYyNGUxNDBiZWJlOGVmODk3NmEzMDUxN2IvdGFibGVyYW5nZToyOWNkZGExNjI0ZTE0MGJlYmU4ZWY4OTc2YTMwNTE3Yl81LTItMS0xLTMwNTAw_280ad49a-d72f-4c28-8696-4b07f36872aa">10036</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Zip Code)</span></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xL2ZyYWc6M2NiYWU3NWQ5ZGUzNDc4OTgxZTg2MDFjYzE1NDg1ZDUvdGV4dHJlZ2lvbjozY2JhZTc1ZDlkZTM0Nzg5ODFlODYwMWNjMTU0ODVkNV8xOTY1_7511a2c7-a14b-413d-864b-8784d1132f89">332</ix:nonNumeric>) <ix:nonNumeric contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xL2ZyYWc6M2NiYWU3NWQ5ZGUzNDc4OTgxZTg2MDFjYzE1NDg1ZDUvdGV4dHJlZ2lvbjozY2JhZTc1ZDlkZTM0Nzg5ODFlODYwMWNjMTU0ODVkNV8xOTY2_ab25996d-889f-450f-aa63-34715eef2f4c">255-9818</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="padding-left:54pt;padding-right:54pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:73.976%"><tr><td style="width:1.0%"></td><td style="width:35.856%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.114%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Trading symbol(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xL2ZyYWc6M2NiYWU3NWQ5ZGUzNDc4OTgxZTg2MDFjYzE1NDg1ZDUvdGFibGU6OTk2MTk5Y2Q1NDg3NDg2MGE5Mzg0NGQxNmMzZTdhYWMvdGFibGVyYW5nZTo5OTYxOTljZDU0ODc0ODYwYTkzODQ0ZDE2YzNlN2FhY18xLTAtMS0xLTMwNTAw_b8e930ad-be58-4f75-9747-9a4aaec308f1">Common Stock, $0.0001 par value</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xL2ZyYWc6M2NiYWU3NWQ5ZGUzNDc4OTgxZTg2MDFjYzE1NDg1ZDUvdGFibGU6OTk2MTk5Y2Q1NDg3NDg2MGE5Mzg0NGQxNmMzZTdhYWMvdGFibGVyYW5nZTo5OTYxOTljZDU0ODc0ODYwYTkzODQ0ZDE2YzNlN2FhY18xLTEtMS0xLTMwNTAw_663091a4-2780-4a73-bc46-3bc24203e6c2">IMUX</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xL2ZyYWc6M2NiYWU3NWQ5ZGUzNDc4OTgxZTg2MDFjYzE1NDg1ZDUvdGFibGU6OTk2MTk5Y2Q1NDg3NDg2MGE5Mzg0NGQxNmMzZTdhYWMvdGFibGVyYW5nZTo5OTYxOTljZDU0ODc0ODYwYTkzODQ0ZDE2YzNlN2FhY18xLTItMS0xLTMwNTAw_e1d8621b-b667-400e-9a36-52d7017272d1">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr></table></div><div style="padding-left:54pt;padding-right:54pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xL2ZyYWc6M2NiYWU3NWQ5ZGUzNDc4OTgxZTg2MDFjYzE1NDg1ZDUvdGV4dHJlZ2lvbjozY2JhZTc1ZDlkZTM0Nzg5ODFlODYwMWNjMTU0ODVkNV83ODc_cd78f4a8-70e5-4ff4-9d43-fc2266b35612">Yes</ix:nonNumeric>  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xL2ZyYWc6M2NiYWU3NWQ5ZGUzNDc4OTgxZTg2MDFjYzE1NDg1ZDUvdGV4dHJlZ2lvbjozY2JhZTc1ZDlkZTM0Nzg5ODFlODYwMWNjMTU0ODVkNV8xMTI0_e7529060-6bbe-424d-8edc-6672e9f84b93">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:17.613%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:54.016%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.560%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.411%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Large&#160;accelerated&#160;filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9744;</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xL2ZyYWc6M2NiYWU3NWQ5ZGUzNDc4OTgxZTg2MDFjYzE1NDg1ZDUvdGFibGU6ZGIzYmU2YmMwMjE0NGI4NmE5NDYyYzdlZWRkMDY4OTYvdGFibGVyYW5nZTpkYjNiZTZiYzAyMTQ0Yjg2YTk0NjJjN2VlZGQwNjg5Nl8yLTAtMS0xLTMwNTAw_2955a591-2aa8-4e06-aa4b-d7316365d3e8">Non-accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Smaller&#160;reporting&#160;company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930" name="dei:EntitySmallBusiness" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xL2ZyYWc6M2NiYWU3NWQ5ZGUzNDc4OTgxZTg2MDFjYzE1NDg1ZDUvdGFibGU6ZGIzYmU2YmMwMjE0NGI4NmE5NDYyYzdlZWRkMDY4OTYvdGFibGVyYW5nZTpkYjNiZTZiYzAyMTQ0Yjg2YTk0NjJjN2VlZGQwNjg5Nl8yLTMtMS0xLTMwNTAw_e52a517b-2231-4dd6-8984-45cfb6ebb6dc">&#9746;</ix:nonNumeric></span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xL2ZyYWc6M2NiYWU3NWQ5ZGUzNDc4OTgxZTg2MDFjYzE1NDg1ZDUvdGFibGU6ZGIzYmU2YmMwMjE0NGI4NmE5NDYyYzdlZWRkMDY4OTYvdGFibGVyYW5nZTpkYjNiZTZiYzAyMTQ0Yjg2YTk0NjJjN2VlZGQwNjg5Nl80LTMtMS0xLTMwNTAw_6b6fc215-2986-401c-9688-caa673e5ea75">&#9744;</ix:nonNumeric></span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.       </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&#160;&#160;&#160;&#160;&#160;Yes&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930" name="dei:EntityShellCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xL2ZyYWc6M2NiYWU3NWQ5ZGUzNDc4OTgxZTg2MDFjYzE1NDg1ZDUvdGV4dHJlZ2lvbjozY2JhZTc1ZDlkZTM0Nzg5ODFlODYwMWNjMTU0ODVkNV8xODY4_5efca3c4-b8ab-44aa-8d4f-983ac69d0652">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9746;</span></div><div style="margin-top:6pt"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On October 28, 2022, <ix:nonFraction unitRef="shares" contextRef="i47193a7aeac443c69053141ff75cc655_I20221028" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xL2ZyYWc6M2NiYWU3NWQ5ZGUzNDc4OTgxZTg2MDFjYzE1NDg1ZDUvdGV4dHJlZ2lvbjozY2JhZTc1ZDlkZTM0Nzg5ODFlODYwMWNjMTU0ODVkNV8xOTAx_37c4484a-70ba-48d3-9027-1784020eb423">39,261,547</ix:nonFraction> shares of common stock, $0.0001 par value, were outstanding.</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="height:18pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="ida7c333e3c58430eb83e8e950c50d811_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IMMUNIC, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">INDEX</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:10.190%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:79.838%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.672%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Page&#160;No.</span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ida7c333e3c58430eb83e8e950c50d811_10">PART I - FINANCIAL INFORMATION</a></span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;1.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ida7c333e3c58430eb83e8e950c50d811_10">Condensed Consolidated Financial Statements (Unaudited)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ida7c333e3c58430eb83e8e950c50d811_10">Condensed Consolidated Balance Sheets</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ida7c333e3c58430eb83e8e950c50d811_10">3</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ida7c333e3c58430eb83e8e950c50d811_13">Condensed Consolidated Statements of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ida7c333e3c58430eb83e8e950c50d811_13">4</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ida7c333e3c58430eb83e8e950c50d811_16">Condensed Consolidated Statements of Comprehensive Loss</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ida7c333e3c58430eb83e8e950c50d811_16">5</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ida7c333e3c58430eb83e8e950c50d811_19">Condensed Consolidated Statements of Stockholders&#8217; Equity</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ida7c333e3c58430eb83e8e950c50d811_19">6</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ida7c333e3c58430eb83e8e950c50d811_25">Condensed Consolidated Statements of Cash Flows</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ida7c333e3c58430eb83e8e950c50d811_25">8</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ida7c333e3c58430eb83e8e950c50d811_28">Notes to Condensed Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ida7c333e3c58430eb83e8e950c50d811_28">9</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ida7c333e3c58430eb83e8e950c50d811_61">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ida7c333e3c58430eb83e8e950c50d811_61">24</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;3.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ida7c333e3c58430eb83e8e950c50d811_73">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ida7c333e3c58430eb83e8e950c50d811_73">37</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;4.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ida7c333e3c58430eb83e8e950c50d811_76">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ida7c333e3c58430eb83e8e950c50d811_76">38</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ida7c333e3c58430eb83e8e950c50d811_79">PART II - OTHER INFORMATION</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;1.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ida7c333e3c58430eb83e8e950c50d811_82">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ida7c333e3c58430eb83e8e950c50d811_82">39</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;1A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ida7c333e3c58430eb83e8e950c50d811_85">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ida7c333e3c58430eb83e8e950c50d811_85">39</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ida7c333e3c58430eb83e8e950c50d811_88">Unregistered Sales of Equity Securities</a> and Use of Proceeds</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ida7c333e3c58430eb83e8e950c50d811_88">39</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 3.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ida7c333e3c58430eb83e8e950c50d811_91">Defaults Upon Senior Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ida7c333e3c58430eb83e8e950c50d811_88">39</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;4.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ida7c333e3c58430eb83e8e950c50d811_94">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ida7c333e3c58430eb83e8e950c50d811_94">40</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;5.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ida7c333e3c58430eb83e8e950c50d811_97">Other Information </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ida7c333e3c58430eb83e8e950c50d811_97">40</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;6.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ida7c333e3c58430eb83e8e950c50d811_100">Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ida7c333e3c58430eb83e8e950c50d811_100">40</a></span></div></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="ida7c333e3c58430eb83e8e950c50d811_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">IMMUNIC, INC.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Balance Sheets</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except share and per share amounts)</span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"><tr><td style="width:1.0%"></td><td style="width:73.529%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.324%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.838%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.809%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2ba0b84078f4de2bc3079e992921b92_I20220930" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMC9mcmFnOjI3ZDM3ZTYwMzc3ODRlZTI5N2MzNDExNTk2NzI5YjJjL3RhYmxlOjk4ZGJlMzgxOWNiNTQxMDI5NjVjOTUzMmQwYWIyNzhlL3RhYmxlcmFuZ2U6OThkYmUzODE5Y2I1NDEwMjk2NWM5NTMyZDBhYjI3OGVfNC0xLTEtMS0zMDUwMA_1d68dede-e430-4cbc-b590-ee58a197ae38">72,771</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12246a01749f40d394a9437cb9938c91_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMC9mcmFnOjI3ZDM3ZTYwMzc3ODRlZTI5N2MzNDExNTk2NzI5YjJjL3RhYmxlOjk4ZGJlMzgxOWNiNTQxMDI5NjVjOTUzMmQwYWIyNzhlL3RhYmxlcmFuZ2U6OThkYmUzODE5Y2I1NDEwMjk2NWM5NTMyZDBhYjI3OGVfNC0zLTEtMS0zMDUwMA_b3e47a48-3079-4fd0-aae4-7a7218e68399">86,863</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets and prepaid expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2ba0b84078f4de2bc3079e992921b92_I20220930" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMC9mcmFnOjI3ZDM3ZTYwMzc3ODRlZTI5N2MzNDExNTk2NzI5YjJjL3RhYmxlOjk4ZGJlMzgxOWNiNTQxMDI5NjVjOTUzMmQwYWIyNzhlL3RhYmxlcmFuZ2U6OThkYmUzODE5Y2I1NDEwMjk2NWM5NTMyZDBhYjI3OGVfNS0xLTEtMS0zMDUwMA_5770780f-73a2-48ab-94e7-d89ca3570658">13,878</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12246a01749f40d394a9437cb9938c91_I20211231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMC9mcmFnOjI3ZDM3ZTYwMzc3ODRlZTI5N2MzNDExNTk2NzI5YjJjL3RhYmxlOjk4ZGJlMzgxOWNiNTQxMDI5NjVjOTUzMmQwYWIyNzhlL3RhYmxlcmFuZ2U6OThkYmUzODE5Y2I1NDEwMjk2NWM5NTMyZDBhYjI3OGVfNS0zLTEtMS0zMDUwMA_7f6e7f19-fa36-4c87-b601-b257eb2d125c">18,125</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2ba0b84078f4de2bc3079e992921b92_I20220930" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMC9mcmFnOjI3ZDM3ZTYwMzc3ODRlZTI5N2MzNDExNTk2NzI5YjJjL3RhYmxlOjk4ZGJlMzgxOWNiNTQxMDI5NjVjOTUzMmQwYWIyNzhlL3RhYmxlcmFuZ2U6OThkYmUzODE5Y2I1NDEwMjk2NWM5NTMyZDBhYjI3OGVfNi0xLTEtMS0zMDUwMA_af6ec076-7427-4ec5-9b95-aef7254082d1">86,649</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12246a01749f40d394a9437cb9938c91_I20211231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMC9mcmFnOjI3ZDM3ZTYwMzc3ODRlZTI5N2MzNDExNTk2NzI5YjJjL3RhYmxlOjk4ZGJlMzgxOWNiNTQxMDI5NjVjOTUzMmQwYWIyNzhlL3RhYmxlcmFuZ2U6OThkYmUzODE5Y2I1NDEwMjk2NWM5NTMyZDBhYjI3OGVfNi0zLTEtMS0zMDUwMA_69741c7a-60db-4a0d-99ef-2ee50603e217">104,988</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2ba0b84078f4de2bc3079e992921b92_I20220930" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMC9mcmFnOjI3ZDM3ZTYwMzc3ODRlZTI5N2MzNDExNTk2NzI5YjJjL3RhYmxlOjk4ZGJlMzgxOWNiNTQxMDI5NjVjOTUzMmQwYWIyNzhlL3RhYmxlcmFuZ2U6OThkYmUzODE5Y2I1NDEwMjk2NWM5NTMyZDBhYjI3OGVfNy0xLTEtMS0zMDUwMA_2e1910a5-ac71-413f-b21b-e7e26b54d1e3">159</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12246a01749f40d394a9437cb9938c91_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMC9mcmFnOjI3ZDM3ZTYwMzc3ODRlZTI5N2MzNDExNTk2NzI5YjJjL3RhYmxlOjk4ZGJlMzgxOWNiNTQxMDI5NjVjOTUzMmQwYWIyNzhlL3RhYmxlcmFuZ2U6OThkYmUzODE5Y2I1NDEwMjk2NWM5NTMyZDBhYjI3OGVfNy0zLTEtMS0zMDUwMA_ac76fe07-2aac-467f-9fdb-53c0e268ae55">152</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2ba0b84078f4de2bc3079e992921b92_I20220930" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMC9mcmFnOjI3ZDM3ZTYwMzc3ODRlZTI5N2MzNDExNTk2NzI5YjJjL3RhYmxlOjk4ZGJlMzgxOWNiNTQxMDI5NjVjOTUzMmQwYWIyNzhlL3RhYmxlcmFuZ2U6OThkYmUzODE5Y2I1NDEwMjk2NWM5NTMyZDBhYjI3OGVfOC0xLTEtMS0zMDUwMA_c59488e6-8e99-40bd-b8aa-f9c7b110223c">32,970</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12246a01749f40d394a9437cb9938c91_I20211231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMC9mcmFnOjI3ZDM3ZTYwMzc3ODRlZTI5N2MzNDExNTk2NzI5YjJjL3RhYmxlOjk4ZGJlMzgxOWNiNTQxMDI5NjVjOTUzMmQwYWIyNzhlL3RhYmxlcmFuZ2U6OThkYmUzODE5Y2I1NDEwMjk2NWM5NTMyZDBhYjI3OGVfOC0zLTEtMS0zMDUwMA_58c8bf16-3285-44bd-a718-4e369739159f">32,970</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2ba0b84078f4de2bc3079e992921b92_I20220930" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMC9mcmFnOjI3ZDM3ZTYwMzc3ODRlZTI5N2MzNDExNTk2NzI5YjJjL3RhYmxlOjk4ZGJlMzgxOWNiNTQxMDI5NjVjOTUzMmQwYWIyNzhlL3RhYmxlcmFuZ2U6OThkYmUzODE5Y2I1NDEwMjk2NWM5NTMyZDBhYjI3OGVfOS0xLTEtMS0zMDUwMA_7c984c9a-0faf-4ac3-be9f-880d06045bd8">1,263</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12246a01749f40d394a9437cb9938c91_I20211231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMC9mcmFnOjI3ZDM3ZTYwMzc3ODRlZTI5N2MzNDExNTk2NzI5YjJjL3RhYmxlOjk4ZGJlMzgxOWNiNTQxMDI5NjVjOTUzMmQwYWIyNzhlL3RhYmxlcmFuZ2U6OThkYmUzODE5Y2I1NDEwMjk2NWM5NTMyZDBhYjI3OGVfOS0zLTEtMS0zMDUwMA_0eaa0ea5-c7bc-4a83-8d79-d1adc274b881">948</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2ba0b84078f4de2bc3079e992921b92_I20220930" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMC9mcmFnOjI3ZDM3ZTYwMzc3ODRlZTI5N2MzNDExNTk2NzI5YjJjL3RhYmxlOjk4ZGJlMzgxOWNiNTQxMDI5NjVjOTUzMmQwYWIyNzhlL3RhYmxlcmFuZ2U6OThkYmUzODE5Y2I1NDEwMjk2NWM5NTMyZDBhYjI3OGVfMTAtMS0xLTEtMzA1MDA_9966dc1c-5bcc-4409-b2ac-46439222844c">42</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12246a01749f40d394a9437cb9938c91_I20211231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMC9mcmFnOjI3ZDM3ZTYwMzc3ODRlZTI5N2MzNDExNTk2NzI5YjJjL3RhYmxlOjk4ZGJlMzgxOWNiNTQxMDI5NjVjOTUzMmQwYWIyNzhlL3RhYmxlcmFuZ2U6OThkYmUzODE5Y2I1NDEwMjk2NWM5NTMyZDBhYjI3OGVfMTAtMy0xLTEtMzA1MDA_83fd39a3-aa01-4035-909a-18552265f875">42</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2ba0b84078f4de2bc3079e992921b92_I20220930" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMC9mcmFnOjI3ZDM3ZTYwMzc3ODRlZTI5N2MzNDExNTk2NzI5YjJjL3RhYmxlOjk4ZGJlMzgxOWNiNTQxMDI5NjVjOTUzMmQwYWIyNzhlL3RhYmxlcmFuZ2U6OThkYmUzODE5Y2I1NDEwMjk2NWM5NTMyZDBhYjI3OGVfMTEtMS0xLTEtMzA1MDA_61865b2c-679e-4fda-87cd-96fb3c4add94">121,083</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12246a01749f40d394a9437cb9938c91_I20211231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMC9mcmFnOjI3ZDM3ZTYwMzc3ODRlZTI5N2MzNDExNTk2NzI5YjJjL3RhYmxlOjk4ZGJlMzgxOWNiNTQxMDI5NjVjOTUzMmQwYWIyNzhlL3RhYmxlcmFuZ2U6OThkYmUzODE5Y2I1NDEwMjk2NWM5NTMyZDBhYjI3OGVfMTEtMy0xLTEtMzA1MDA_c908a451-9991-4e26-bb7a-d663d676541c">139,100</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities and Stockholders&#8217; Equity</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2ba0b84078f4de2bc3079e992921b92_I20220930" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMC9mcmFnOjI3ZDM3ZTYwMzc3ODRlZTI5N2MzNDExNTk2NzI5YjJjL3RhYmxlOjk4ZGJlMzgxOWNiNTQxMDI5NjVjOTUzMmQwYWIyNzhlL3RhYmxlcmFuZ2U6OThkYmUzODE5Y2I1NDEwMjk2NWM5NTMyZDBhYjI3OGVfMTQtMS0xLTEtMzA1MDA_6691a322-4e9e-4d42-a4b2-bf6eba7e096a">4,172</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12246a01749f40d394a9437cb9938c91_I20211231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMC9mcmFnOjI3ZDM3ZTYwMzc3ODRlZTI5N2MzNDExNTk2NzI5YjJjL3RhYmxlOjk4ZGJlMzgxOWNiNTQxMDI5NjVjOTUzMmQwYWIyNzhlL3RhYmxlcmFuZ2U6OThkYmUzODE5Y2I1NDEwMjk2NWM5NTMyZDBhYjI3OGVfMTQtMy0xLTEtMzA1MDA_b551caec-64fe-442b-95af-3b80fd21dc4d">3,745</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2ba0b84078f4de2bc3079e992921b92_I20220930" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMC9mcmFnOjI3ZDM3ZTYwMzc3ODRlZTI5N2MzNDExNTk2NzI5YjJjL3RhYmxlOjk4ZGJlMzgxOWNiNTQxMDI5NjVjOTUzMmQwYWIyNzhlL3RhYmxlcmFuZ2U6OThkYmUzODE5Y2I1NDEwMjk2NWM5NTMyZDBhYjI3OGVfMTUtMS0xLTEtMzA1MDA_3e77b0a7-af52-45e4-82a9-22e9294096af">6,623</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12246a01749f40d394a9437cb9938c91_I20211231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMC9mcmFnOjI3ZDM3ZTYwMzc3ODRlZTI5N2MzNDExNTk2NzI5YjJjL3RhYmxlOjk4ZGJlMzgxOWNiNTQxMDI5NjVjOTUzMmQwYWIyNzhlL3RhYmxlcmFuZ2U6OThkYmUzODE5Y2I1NDEwMjk2NWM5NTMyZDBhYjI3OGVfMTUtMy0xLTEtMzA1MDA_d8df8501-4ec6-466a-9aa8-10fee6a09903">7,071</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2ba0b84078f4de2bc3079e992921b92_I20220930" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMC9mcmFnOjI3ZDM3ZTYwMzc3ODRlZTI5N2MzNDExNTk2NzI5YjJjL3RhYmxlOjk4ZGJlMzgxOWNiNTQxMDI5NjVjOTUzMmQwYWIyNzhlL3RhYmxlcmFuZ2U6OThkYmUzODE5Y2I1NDEwMjk2NWM5NTMyZDBhYjI3OGVfMTYtMS0xLTEtMzA1MDA_15600d3d-a834-41c9-b7fb-dadea07c6b0b">719</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12246a01749f40d394a9437cb9938c91_I20211231" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMC9mcmFnOjI3ZDM3ZTYwMzc3ODRlZTI5N2MzNDExNTk2NzI5YjJjL3RhYmxlOjk4ZGJlMzgxOWNiNTQxMDI5NjVjOTUzMmQwYWIyNzhlL3RhYmxlcmFuZ2U6OThkYmUzODE5Y2I1NDEwMjk2NWM5NTMyZDBhYjI3OGVfMTYtMy0xLTEtMzA1MDA_eb343cb0-7c45-465d-9eda-2dcbeff30ce6">585</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2ba0b84078f4de2bc3079e992921b92_I20220930" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMC9mcmFnOjI3ZDM3ZTYwMzc3ODRlZTI5N2MzNDExNTk2NzI5YjJjL3RhYmxlOjk4ZGJlMzgxOWNiNTQxMDI5NjVjOTUzMmQwYWIyNzhlL3RhYmxlcmFuZ2U6OThkYmUzODE5Y2I1NDEwMjk2NWM5NTMyZDBhYjI3OGVfMTctMS0xLTEtMzA1MDA_1d32781c-0220-4966-95cf-f559c4ccc3b9">11,514</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12246a01749f40d394a9437cb9938c91_I20211231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMC9mcmFnOjI3ZDM3ZTYwMzc3ODRlZTI5N2MzNDExNTk2NzI5YjJjL3RhYmxlOjk4ZGJlMzgxOWNiNTQxMDI5NjVjOTUzMmQwYWIyNzhlL3RhYmxlcmFuZ2U6OThkYmUzODE5Y2I1NDEwMjk2NWM5NTMyZDBhYjI3OGVfMTctMy0xLTEtMzA1MDA_683f5358-4bc4-4f9c-a9cd-124c0f5ca402">11,401</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long term liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2ba0b84078f4de2bc3079e992921b92_I20220930" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMC9mcmFnOjI3ZDM3ZTYwMzc3ODRlZTI5N2MzNDExNTk2NzI5YjJjL3RhYmxlOjk4ZGJlMzgxOWNiNTQxMDI5NjVjOTUzMmQwYWIyNzhlL3RhYmxlcmFuZ2U6OThkYmUzODE5Y2I1NDEwMjk2NWM5NTMyZDBhYjI3OGVfMTktMS0xLTEtMzA1MDA_ac0093c3-aeba-4b91-9b4f-d5bb73870f21">759</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12246a01749f40d394a9437cb9938c91_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMC9mcmFnOjI3ZDM3ZTYwMzc3ODRlZTI5N2MzNDExNTk2NzI5YjJjL3RhYmxlOjk4ZGJlMzgxOWNiNTQxMDI5NjVjOTUzMmQwYWIyNzhlL3RhYmxlcmFuZ2U6OThkYmUzODE5Y2I1NDEwMjk2NWM5NTMyZDBhYjI3OGVfMTktMy0xLTEtMzA1MDA_5d023fd8-0243-4c95-bb16-792d4401bb1c">584</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long-term liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2ba0b84078f4de2bc3079e992921b92_I20220930" decimals="-3" name="us-gaap:LiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMC9mcmFnOjI3ZDM3ZTYwMzc3ODRlZTI5N2MzNDExNTk2NzI5YjJjL3RhYmxlOjk4ZGJlMzgxOWNiNTQxMDI5NjVjOTUzMmQwYWIyNzhlL3RhYmxlcmFuZ2U6OThkYmUzODE5Y2I1NDEwMjk2NWM5NTMyZDBhYjI3OGVfMjAtMS0xLTEtMzA1MDA_9ef448d2-b86d-4620-a2aa-55d9b9f70180">759</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12246a01749f40d394a9437cb9938c91_I20211231" decimals="-3" name="us-gaap:LiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMC9mcmFnOjI3ZDM3ZTYwMzc3ODRlZTI5N2MzNDExNTk2NzI5YjJjL3RhYmxlOjk4ZGJlMzgxOWNiNTQxMDI5NjVjOTUzMmQwYWIyNzhlL3RhYmxlcmFuZ2U6OThkYmUzODE5Y2I1NDEwMjk2NWM5NTMyZDBhYjI3OGVfMjAtMy0xLTEtMzA1MDA_391c2a16-6566-48e1-98b1-7ede491e03e5">584</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2ba0b84078f4de2bc3079e992921b92_I20220930" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMC9mcmFnOjI3ZDM3ZTYwMzc3ODRlZTI5N2MzNDExNTk2NzI5YjJjL3RhYmxlOjk4ZGJlMzgxOWNiNTQxMDI5NjVjOTUzMmQwYWIyNzhlL3RhYmxlcmFuZ2U6OThkYmUzODE5Y2I1NDEwMjk2NWM5NTMyZDBhYjI3OGVfMjEtMS0xLTEtMzA1MDA_a1cfda26-338c-4f47-ba5a-f54196787e6b">12,273</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12246a01749f40d394a9437cb9938c91_I20211231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMC9mcmFnOjI3ZDM3ZTYwMzc3ODRlZTI5N2MzNDExNTk2NzI5YjJjL3RhYmxlOjk4ZGJlMzgxOWNiNTQxMDI5NjVjOTUzMmQwYWIyNzhlL3RhYmxlcmFuZ2U6OThkYmUzODE5Y2I1NDEwMjk2NWM5NTMyZDBhYjI3OGVfMjEtMy0xLTEtMzA1MDA_ae3e8622-33fa-41c3-8561-12d6884b96c1">11,985</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and contingencies (Note 4)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="ib2ba0b84078f4de2bc3079e992921b92_I20220930" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMC9mcmFnOjI3ZDM3ZTYwMzc3ODRlZTI5N2MzNDExNTk2NzI5YjJjL3RhYmxlOjk4ZGJlMzgxOWNiNTQxMDI5NjVjOTUzMmQwYWIyNzhlL3RhYmxlcmFuZ2U6OThkYmUzODE5Y2I1NDEwMjk2NWM5NTMyZDBhYjI3OGVfMjItMS0xLTEtMzA1MDA_460d53bf-0750-447a-87ff-5076bdc24122"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i12246a01749f40d394a9437cb9938c91_I20211231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMC9mcmFnOjI3ZDM3ZTYwMzc3ODRlZTI5N2MzNDExNTk2NzI5YjJjL3RhYmxlOjk4ZGJlMzgxOWNiNTQxMDI5NjVjOTUzMmQwYWIyNzhlL3RhYmxlcmFuZ2U6OThkYmUzODE5Y2I1NDEwMjk2NWM5NTMyZDBhYjI3OGVfMjItMy0xLTEtMzA1MDA_2aa2bb36-5330-44ca-9f5d-0c6624cf8707"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders&#8217; equity:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i12246a01749f40d394a9437cb9938c91_I20211231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMC9mcmFnOjI3ZDM3ZTYwMzc3ODRlZTI5N2MzNDExNTk2NzI5YjJjL3RhYmxlOjk4ZGJlMzgxOWNiNTQxMDI5NjVjOTUzMmQwYWIyNzhlL3RhYmxlcmFuZ2U6OThkYmUzODE5Y2I1NDEwMjk2NWM5NTMyZDBhYjI3OGVfMjQtMC0xLTEtMzA1MDAvdGV4dHJlZ2lvbjo1YjljYjFkNWYwNmQ0ZmI2YjA5MzI3MWJmZTFhZjU1M18yMQ_50d65f47-0a1e-4c68-be6e-091a969bf814"><ix:nonFraction unitRef="usdPerShare" contextRef="ib2ba0b84078f4de2bc3079e992921b92_I20220930" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMC9mcmFnOjI3ZDM3ZTYwMzc3ODRlZTI5N2MzNDExNTk2NzI5YjJjL3RhYmxlOjk4ZGJlMzgxOWNiNTQxMDI5NjVjOTUzMmQwYWIyNzhlL3RhYmxlcmFuZ2U6OThkYmUzODE5Y2I1NDEwMjk2NWM5NTMyZDBhYjI3OGVfMjQtMC0xLTEtMzA1MDAvdGV4dHJlZ2lvbjo1YjljYjFkNWYwNmQ0ZmI2YjA5MzI3MWJmZTFhZjU1M18yMQ_7c37944c-9641-4b13-9542-eb40177ce1ab">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="ib2ba0b84078f4de2bc3079e992921b92_I20220930" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMC9mcmFnOjI3ZDM3ZTYwMzc3ODRlZTI5N2MzNDExNTk2NzI5YjJjL3RhYmxlOjk4ZGJlMzgxOWNiNTQxMDI5NjVjOTUzMmQwYWIyNzhlL3RhYmxlcmFuZ2U6OThkYmUzODE5Y2I1NDEwMjk2NWM5NTMyZDBhYjI3OGVfMjQtMC0xLTEtMzA1MDAvdGV4dHJlZ2lvbjo1YjljYjFkNWYwNmQ0ZmI2YjA5MzI3MWJmZTFhZjU1M18zNQ_050d30e1-0a01-448e-bb75-9b05df2ed6e7"><ix:nonFraction unitRef="shares" contextRef="i12246a01749f40d394a9437cb9938c91_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMC9mcmFnOjI3ZDM3ZTYwMzc3ODRlZTI5N2MzNDExNTk2NzI5YjJjL3RhYmxlOjk4ZGJlMzgxOWNiNTQxMDI5NjVjOTUzMmQwYWIyNzhlL3RhYmxlcmFuZ2U6OThkYmUzODE5Y2I1NDEwMjk2NWM5NTMyZDBhYjI3OGVfMjQtMC0xLTEtMzA1MDAvdGV4dHJlZ2lvbjo1YjljYjFkNWYwNmQ0ZmI2YjA5MzI3MWJmZTFhZjU1M18zNQ_58d7ed56-ec07-43d0-a3c2-919a1d0475d8">20,000,000</ix:nonFraction></ix:nonFraction> authorized and <ix:nonFraction unitRef="shares" contextRef="i12246a01749f40d394a9437cb9938c91_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMC9mcmFnOjI3ZDM3ZTYwMzc3ODRlZTI5N2MzNDExNTk2NzI5YjJjL3RhYmxlOjk4ZGJlMzgxOWNiNTQxMDI5NjVjOTUzMmQwYWIyNzhlL3RhYmxlcmFuZ2U6OThkYmUzODE5Y2I1NDEwMjk2NWM5NTMyZDBhYjI3OGVfMjQtMC0xLTEtMzA1MDAvdGV4dHJlZ2lvbjo1YjljYjFkNWYwNmQ0ZmI2YjA5MzI3MWJmZTFhZjU1M181Mw_11d64d49-8554-4816-9d2e-aa99f82b2faf"><ix:nonFraction unitRef="shares" contextRef="ib2ba0b84078f4de2bc3079e992921b92_I20220930" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMC9mcmFnOjI3ZDM3ZTYwMzc3ODRlZTI5N2MzNDExNTk2NzI5YjJjL3RhYmxlOjk4ZGJlMzgxOWNiNTQxMDI5NjVjOTUzMmQwYWIyNzhlL3RhYmxlcmFuZ2U6OThkYmUzODE5Y2I1NDEwMjk2NWM5NTMyZDBhYjI3OGVfMjQtMC0xLTEtMzA1MDAvdGV4dHJlZ2lvbjo1YjljYjFkNWYwNmQ0ZmI2YjA5MzI3MWJmZTFhZjU1M181Mw_3acceb37-8d7c-4cd7-91e5-0e147311e58e"><ix:nonFraction unitRef="shares" contextRef="i12246a01749f40d394a9437cb9938c91_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMC9mcmFnOjI3ZDM3ZTYwMzc3ODRlZTI5N2MzNDExNTk2NzI5YjJjL3RhYmxlOjk4ZGJlMzgxOWNiNTQxMDI5NjVjOTUzMmQwYWIyNzhlL3RhYmxlcmFuZ2U6OThkYmUzODE5Y2I1NDEwMjk2NWM5NTMyZDBhYjI3OGVfMjQtMC0xLTEtMzA1MDAvdGV4dHJlZ2lvbjo1YjljYjFkNWYwNmQ0ZmI2YjA5MzI3MWJmZTFhZjU1M181Mw_598d0e75-dc1d-4854-b8b8-59f1d85c8ee9"><ix:nonFraction unitRef="shares" contextRef="ib2ba0b84078f4de2bc3079e992921b92_I20220930" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMC9mcmFnOjI3ZDM3ZTYwMzc3ODRlZTI5N2MzNDExNTk2NzI5YjJjL3RhYmxlOjk4ZGJlMzgxOWNiNTQxMDI5NjVjOTUzMmQwYWIyNzhlL3RhYmxlcmFuZ2U6OThkYmUzODE5Y2I1NDEwMjk2NWM5NTMyZDBhYjI3OGVfMjQtMC0xLTEtMzA1MDAvdGV4dHJlZ2lvbjo1YjljYjFkNWYwNmQ0ZmI2YjA5MzI3MWJmZTFhZjU1M181Mw_a01b9a65-77f3-4c92-a9bc-d93f52f2adee">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued or outstanding at September 30, 2022 and December 31, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2ba0b84078f4de2bc3079e992921b92_I20220930" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMC9mcmFnOjI3ZDM3ZTYwMzc3ODRlZTI5N2MzNDExNTk2NzI5YjJjL3RhYmxlOjk4ZGJlMzgxOWNiNTQxMDI5NjVjOTUzMmQwYWIyNzhlL3RhYmxlcmFuZ2U6OThkYmUzODE5Y2I1NDEwMjk2NWM5NTMyZDBhYjI3OGVfMjQtMS0xLTEtMzA1MDA_5927107f-f4d8-48cf-9ef4-3251f517f6a2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12246a01749f40d394a9437cb9938c91_I20211231" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMC9mcmFnOjI3ZDM3ZTYwMzc3ODRlZTI5N2MzNDExNTk2NzI5YjJjL3RhYmxlOjk4ZGJlMzgxOWNiNTQxMDI5NjVjOTUzMmQwYWIyNzhlL3RhYmxlcmFuZ2U6OThkYmUzODE5Y2I1NDEwMjk2NWM5NTMyZDBhYjI3OGVfMjQtMy0xLTEtMzA1MDA_e483dfc8-e912-4456-9993-9fcecf483a4c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i12246a01749f40d394a9437cb9938c91_I20211231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMC9mcmFnOjI3ZDM3ZTYwMzc3ODRlZTI5N2MzNDExNTk2NzI5YjJjL3RhYmxlOjk4ZGJlMzgxOWNiNTQxMDI5NjVjOTUzMmQwYWIyNzhlL3RhYmxlcmFuZ2U6OThkYmUzODE5Y2I1NDEwMjk2NWM5NTMyZDBhYjI3OGVfMjUtMC0xLTEtMzA1MDAvdGV4dHJlZ2lvbjpjNmIzZTgyZjY1OGQ0NTVjOGYwMzM3MmI4MDdmZGNjYV8xOA_567a8182-ccba-4977-9e44-9e519ac902ca"><ix:nonFraction unitRef="usdPerShare" contextRef="ib2ba0b84078f4de2bc3079e992921b92_I20220930" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMC9mcmFnOjI3ZDM3ZTYwMzc3ODRlZTI5N2MzNDExNTk2NzI5YjJjL3RhYmxlOjk4ZGJlMzgxOWNiNTQxMDI5NjVjOTUzMmQwYWIyNzhlL3RhYmxlcmFuZ2U6OThkYmUzODE5Y2I1NDEwMjk2NWM5NTMyZDBhYjI3OGVfMjUtMC0xLTEtMzA1MDAvdGV4dHJlZ2lvbjpjNmIzZTgyZjY1OGQ0NTVjOGYwMzM3MmI4MDdmZGNjYV8xOA_dfec121d-3269-401f-bd00-b2c3d72320b9">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="ib2ba0b84078f4de2bc3079e992921b92_I20220930" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMC9mcmFnOjI3ZDM3ZTYwMzc3ODRlZTI5N2MzNDExNTk2NzI5YjJjL3RhYmxlOjk4ZGJlMzgxOWNiNTQxMDI5NjVjOTUzMmQwYWIyNzhlL3RhYmxlcmFuZ2U6OThkYmUzODE5Y2I1NDEwMjk2NWM5NTMyZDBhYjI3OGVfMjUtMC0xLTEtMzA1MDAvdGV4dHJlZ2lvbjpjNmIzZTgyZjY1OGQ0NTVjOGYwMzM3MmI4MDdmZGNjYV8zMg_5939c97d-9522-45e6-9158-142269f3251f"><ix:nonFraction unitRef="shares" contextRef="i12246a01749f40d394a9437cb9938c91_I20211231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMC9mcmFnOjI3ZDM3ZTYwMzc3ODRlZTI5N2MzNDExNTk2NzI5YjJjL3RhYmxlOjk4ZGJlMzgxOWNiNTQxMDI5NjVjOTUzMmQwYWIyNzhlL3RhYmxlcmFuZ2U6OThkYmUzODE5Y2I1NDEwMjk2NWM5NTMyZDBhYjI3OGVfMjUtMC0xLTEtMzA1MDAvdGV4dHJlZ2lvbjpjNmIzZTgyZjY1OGQ0NTVjOGYwMzM3MmI4MDdmZGNjYV8zMg_5b953ef0-4b2c-4d43-9055-15e4de75a4fd">130,000,000</ix:nonFraction></ix:nonFraction> shares authorized and <ix:nonFraction unitRef="shares" contextRef="ib2ba0b84078f4de2bc3079e992921b92_I20220930" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMC9mcmFnOjI3ZDM3ZTYwMzc3ODRlZTI5N2MzNDExNTk2NzI5YjJjL3RhYmxlOjk4ZGJlMzgxOWNiNTQxMDI5NjVjOTUzMmQwYWIyNzhlL3RhYmxlcmFuZ2U6OThkYmUzODE5Y2I1NDEwMjk2NWM5NTMyZDBhYjI3OGVfMjUtMC0xLTEtMzA1MDAvdGV4dHJlZ2lvbjpjNmIzZTgyZjY1OGQ0NTVjOGYwMzM3MmI4MDdmZGNjYV81NDk3NTU4MTQwODM_b6d4b937-2288-43d1-882b-b545a49c746a"><ix:nonFraction unitRef="shares" contextRef="ib2ba0b84078f4de2bc3079e992921b92_I20220930" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMC9mcmFnOjI3ZDM3ZTYwMzc3ODRlZTI5N2MzNDExNTk2NzI5YjJjL3RhYmxlOjk4ZGJlMzgxOWNiNTQxMDI5NjVjOTUzMmQwYWIyNzhlL3RhYmxlcmFuZ2U6OThkYmUzODE5Y2I1NDEwMjk2NWM5NTMyZDBhYjI3OGVfMjUtMC0xLTEtMzA1MDAvdGV4dHJlZ2lvbjpjNmIzZTgyZjY1OGQ0NTVjOGYwMzM3MmI4MDdmZGNjYV81NDk3NTU4MTQwODM_bc7d2389-479e-4bc3-9ff4-c93425842548">30,564,995</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i12246a01749f40d394a9437cb9938c91_I20211231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMC9mcmFnOjI3ZDM3ZTYwMzc3ODRlZTI5N2MzNDExNTk2NzI5YjJjL3RhYmxlOjk4ZGJlMzgxOWNiNTQxMDI5NjVjOTUzMmQwYWIyNzhlL3RhYmxlcmFuZ2U6OThkYmUzODE5Y2I1NDEwMjk2NWM5NTMyZDBhYjI3OGVfMjUtMC0xLTEtMzA1MDAvdGV4dHJlZ2lvbjpjNmIzZTgyZjY1OGQ0NTVjOGYwMzM3MmI4MDdmZGNjYV81NDk3NTU4MTQwOTY_7d1e5e09-7431-4377-843e-396a990cc952"><ix:nonFraction unitRef="shares" contextRef="i12246a01749f40d394a9437cb9938c91_I20211231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMC9mcmFnOjI3ZDM3ZTYwMzc3ODRlZTI5N2MzNDExNTk2NzI5YjJjL3RhYmxlOjk4ZGJlMzgxOWNiNTQxMDI5NjVjOTUzMmQwYWIyNzhlL3RhYmxlcmFuZ2U6OThkYmUzODE5Y2I1NDEwMjk2NWM5NTMyZDBhYjI3OGVfMjUtMC0xLTEtMzA1MDAvdGV4dHJlZ2lvbjpjNmIzZTgyZjY1OGQ0NTVjOGYwMzM3MmI4MDdmZGNjYV81NDk3NTU4MTQwOTY_c008ebf9-2748-445a-a66a-ba76a5fa10f7">26,335,418</ix:nonFraction></ix:nonFraction> shares issued and outstanding as of September 30, 2022 and December&#160;31, 2021, respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2ba0b84078f4de2bc3079e992921b92_I20220930" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMC9mcmFnOjI3ZDM3ZTYwMzc3ODRlZTI5N2MzNDExNTk2NzI5YjJjL3RhYmxlOjk4ZGJlMzgxOWNiNTQxMDI5NjVjOTUzMmQwYWIyNzhlL3RhYmxlcmFuZ2U6OThkYmUzODE5Y2I1NDEwMjk2NWM5NTMyZDBhYjI3OGVfMjUtMS0xLTEtMzA1MDA_0abd64b5-ffa4-43b0-8d24-7bc1622e41e7">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12246a01749f40d394a9437cb9938c91_I20211231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMC9mcmFnOjI3ZDM3ZTYwMzc3ODRlZTI5N2MzNDExNTk2NzI5YjJjL3RhYmxlOjk4ZGJlMzgxOWNiNTQxMDI5NjVjOTUzMmQwYWIyNzhlL3RhYmxlcmFuZ2U6OThkYmUzODE5Y2I1NDEwMjk2NWM5NTMyZDBhYjI3OGVfMjUtMy0xLTEtMzA1MDA_ed02c6af-7d41-4dca-94e2-1a8d5897ea29">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2ba0b84078f4de2bc3079e992921b92_I20220930" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMC9mcmFnOjI3ZDM3ZTYwMzc3ODRlZTI5N2MzNDExNTk2NzI5YjJjL3RhYmxlOjk4ZGJlMzgxOWNiNTQxMDI5NjVjOTUzMmQwYWIyNzhlL3RhYmxlcmFuZ2U6OThkYmUzODE5Y2I1NDEwMjk2NWM5NTMyZDBhYjI3OGVfMjYtMS0xLTEtMzA1MDA_476b1008-ef99-4362-95f5-6f8629545109">369,999</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12246a01749f40d394a9437cb9938c91_I20211231" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMC9mcmFnOjI3ZDM3ZTYwMzc3ODRlZTI5N2MzNDExNTk2NzI5YjJjL3RhYmxlOjk4ZGJlMzgxOWNiNTQxMDI5NjVjOTUzMmQwYWIyNzhlL3RhYmxlcmFuZ2U6OThkYmUzODE5Y2I1NDEwMjk2NWM5NTMyZDBhYjI3OGVfMjYtMy0xLTEtMzA1MDA_e0c57c0e-ef32-4dcd-bf60-fb147ede5572">324,237</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib2ba0b84078f4de2bc3079e992921b92_I20220930" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMC9mcmFnOjI3ZDM3ZTYwMzc3ODRlZTI5N2MzNDExNTk2NzI5YjJjL3RhYmxlOjk4ZGJlMzgxOWNiNTQxMDI5NjVjOTUzMmQwYWIyNzhlL3RhYmxlcmFuZ2U6OThkYmUzODE5Y2I1NDEwMjk2NWM5NTMyZDBhYjI3OGVfMjctMS0xLTEtMzA1MDA_bb0200ed-833e-4055-a61d-1094a1ab7304">386</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i12246a01749f40d394a9437cb9938c91_I20211231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMC9mcmFnOjI3ZDM3ZTYwMzc3ODRlZTI5N2MzNDExNTk2NzI5YjJjL3RhYmxlOjk4ZGJlMzgxOWNiNTQxMDI5NjVjOTUzMmQwYWIyNzhlL3RhYmxlcmFuZ2U6OThkYmUzODE5Y2I1NDEwMjk2NWM5NTMyZDBhYjI3OGVfMjctMy0xLTEtMzA1MDA_0778fd0b-4681-4c2a-809b-c283e7ae6aa1">252</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib2ba0b84078f4de2bc3079e992921b92_I20220930" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMC9mcmFnOjI3ZDM3ZTYwMzc3ODRlZTI5N2MzNDExNTk2NzI5YjJjL3RhYmxlOjk4ZGJlMzgxOWNiNTQxMDI5NjVjOTUzMmQwYWIyNzhlL3RhYmxlcmFuZ2U6OThkYmUzODE5Y2I1NDEwMjk2NWM5NTMyZDBhYjI3OGVfMjgtMS0xLTEtMzA1MDA_adce3dc4-062c-4c16-8fae-0ec78492f6d8">260,806</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i12246a01749f40d394a9437cb9938c91_I20211231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMC9mcmFnOjI3ZDM3ZTYwMzc3ODRlZTI5N2MzNDExNTk2NzI5YjJjL3RhYmxlOjk4ZGJlMzgxOWNiNTQxMDI5NjVjOTUzMmQwYWIyNzhlL3RhYmxlcmFuZ2U6OThkYmUzODE5Y2I1NDEwMjk2NWM5NTMyZDBhYjI3OGVfMjgtMy0xLTEtMzA1MDA_919bdbcf-9bf7-431e-8ba0-11de0a999301">196,873</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2ba0b84078f4de2bc3079e992921b92_I20220930" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMC9mcmFnOjI3ZDM3ZTYwMzc3ODRlZTI5N2MzNDExNTk2NzI5YjJjL3RhYmxlOjk4ZGJlMzgxOWNiNTQxMDI5NjVjOTUzMmQwYWIyNzhlL3RhYmxlcmFuZ2U6OThkYmUzODE5Y2I1NDEwMjk2NWM5NTMyZDBhYjI3OGVfMjktMS0xLTEtMzA1MDA_10a427d1-daa8-41d2-baad-694f119d6878">108,810</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12246a01749f40d394a9437cb9938c91_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMC9mcmFnOjI3ZDM3ZTYwMzc3ODRlZTI5N2MzNDExNTk2NzI5YjJjL3RhYmxlOjk4ZGJlMzgxOWNiNTQxMDI5NjVjOTUzMmQwYWIyNzhlL3RhYmxlcmFuZ2U6OThkYmUzODE5Y2I1NDEwMjk2NWM5NTMyZDBhYjI3OGVfMjktMy0xLTEtMzA1MDA_d9a885e7-4aee-4f0e-a11c-9c449f5a77c2">127,115</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; equity</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2ba0b84078f4de2bc3079e992921b92_I20220930" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMC9mcmFnOjI3ZDM3ZTYwMzc3ODRlZTI5N2MzNDExNTk2NzI5YjJjL3RhYmxlOjk4ZGJlMzgxOWNiNTQxMDI5NjVjOTUzMmQwYWIyNzhlL3RhYmxlcmFuZ2U6OThkYmUzODE5Y2I1NDEwMjk2NWM5NTMyZDBhYjI3OGVfMzAtMS0xLTEtMzA1MDA_24d21bda-ee3c-4635-bae7-2b777c4436b8">121,083</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12246a01749f40d394a9437cb9938c91_I20211231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMC9mcmFnOjI3ZDM3ZTYwMzc3ODRlZTI5N2MzNDExNTk2NzI5YjJjL3RhYmxlOjk4ZGJlMzgxOWNiNTQxMDI5NjVjOTUzMmQwYWIyNzhlL3RhYmxlcmFuZ2U6OThkYmUzODE5Y2I1NDEwMjk2NWM5NTMyZDBhYjI3OGVfMzAtMy0xLTEtMzA1MDA_33476811-031d-47da-b1fc-99308c413f02">139,100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="ida7c333e3c58430eb83e8e950c50d811_13"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">IMMUNIC, INC.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Operations</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In&#160;thousands,&#160;except&#160;share&#160;and&#160;per&#160;share&#160;amounts)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.812%"><tr><td style="width:1.0%"></td><td style="width:49.696%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.596%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.073%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.914%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.596%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.210%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months<br/>&#160;Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months<br/>&#160;Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25a8ea2d7c9f4bfd8f72223c8ac18c65_D20220701-20220930" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMy9mcmFnOjg4YzY5ZTc3YzFlYjQ2MjhiMTQ1OWVhNzg2ZjlkNmYyL3RhYmxlOjZmNGIwMTVmYzUwODRkZDBhOWE5ZWU3MjFiYjg0NjU1L3RhYmxlcmFuZ2U6NmY0YjAxNWZjNTA4NGRkMGE5YTllZTcyMWJiODQ2NTVfMy01LTEtMS0zMDUwMA_c216096b-4131-4c59-aa12-2d8221eb962f">16,537</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib52579de36d54242a791b9e3f8019a00_D20210701-20210930" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMy9mcmFnOjg4YzY5ZTc3YzFlYjQ2MjhiMTQ1OWVhNzg2ZjlkNmYyL3RhYmxlOjZmNGIwMTVmYzUwODRkZDBhOWE5ZWU3MjFiYjg0NjU1L3RhYmxlcmFuZ2U6NmY0YjAxNWZjNTA4NGRkMGE5YTllZTcyMWJiODQ2NTVfMy03LTEtMS0zMDUwMA_552889ba-c8c8-4c29-8ac4-6bb08877722a">15,480</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMy9mcmFnOjg4YzY5ZTc3YzFlYjQ2MjhiMTQ1OWVhNzg2ZjlkNmYyL3RhYmxlOjZmNGIwMTVmYzUwODRkZDBhOWE5ZWU3MjFiYjg0NjU1L3RhYmxlcmFuZ2U6NmY0YjAxNWZjNTA4NGRkMGE5YTllZTcyMWJiODQ2NTVfMy05LTEtMS0zMDUwMA_e50f2622-93bc-41c5-b3a9-2e7265f6e92b">50,520</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69e8bcaae5bf44c9a03cf7f5bd08e6b8_D20210101-20210930" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMy9mcmFnOjg4YzY5ZTc3YzFlYjQ2MjhiMTQ1OWVhNzg2ZjlkNmYyL3RhYmxlOjZmNGIwMTVmYzUwODRkZDBhOWE5ZWU3MjFiYjg0NjU1L3RhYmxlcmFuZ2U6NmY0YjAxNWZjNTA4NGRkMGE5YTllZTcyMWJiODQ2NTVfMy0xMS0xLTEtMzA1MDA_15af8217-1c77-47c8-927e-91f680c7da33">42,737</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25a8ea2d7c9f4bfd8f72223c8ac18c65_D20220701-20220930" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMy9mcmFnOjg4YzY5ZTc3YzFlYjQ2MjhiMTQ1OWVhNzg2ZjlkNmYyL3RhYmxlOjZmNGIwMTVmYzUwODRkZDBhOWE5ZWU3MjFiYjg0NjU1L3RhYmxlcmFuZ2U6NmY0YjAxNWZjNTA4NGRkMGE5YTllZTcyMWJiODQ2NTVfNC01LTEtMS0zMDUwMA_727f2419-cff4-4c08-abd1-b821b3625054">3,579</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib52579de36d54242a791b9e3f8019a00_D20210701-20210930" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMy9mcmFnOjg4YzY5ZTc3YzFlYjQ2MjhiMTQ1OWVhNzg2ZjlkNmYyL3RhYmxlOjZmNGIwMTVmYzUwODRkZDBhOWE5ZWU3MjFiYjg0NjU1L3RhYmxlcmFuZ2U6NmY0YjAxNWZjNTA4NGRkMGE5YTllZTcyMWJiODQ2NTVfNC03LTEtMS0zMDUwMA_b7ccf7bf-c0e7-4d46-ad3f-59c2296b56cd">2,907</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMy9mcmFnOjg4YzY5ZTc3YzFlYjQ2MjhiMTQ1OWVhNzg2ZjlkNmYyL3RhYmxlOjZmNGIwMTVmYzUwODRkZDBhOWE5ZWU3MjFiYjg0NjU1L3RhYmxlcmFuZ2U6NmY0YjAxNWZjNTA4NGRkMGE5YTllZTcyMWJiODQ2NTVfNC05LTEtMS0zMDUwMA_7c25a501-5bf9-4499-952f-eab4ca9e7d8e">11,641</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69e8bcaae5bf44c9a03cf7f5bd08e6b8_D20210101-20210930" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMy9mcmFnOjg4YzY5ZTc3YzFlYjQ2MjhiMTQ1OWVhNzg2ZjlkNmYyL3RhYmxlOjZmNGIwMTVmYzUwODRkZDBhOWE5ZWU3MjFiYjg0NjU1L3RhYmxlcmFuZ2U6NmY0YjAxNWZjNTA4NGRkMGE5YTllZTcyMWJiODQ2NTVfNC0xMS0xLTEtMzA1MDA_6bd22c85-69a4-4a18-9d80-205898587da1">9,957</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4SC Royalty Settlement (see Note 4)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25a8ea2d7c9f4bfd8f72223c8ac18c65_D20220701-20220930" decimals="-3" name="vtl:RoyaltySettlementAgreementSalesNet" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMy9mcmFnOjg4YzY5ZTc3YzFlYjQ2MjhiMTQ1OWVhNzg2ZjlkNmYyL3RhYmxlOjZmNGIwMTVmYzUwODRkZDBhOWE5ZWU3MjFiYjg0NjU1L3RhYmxlcmFuZ2U6NmY0YjAxNWZjNTA4NGRkMGE5YTllZTcyMWJiODQ2NTVfNS01LTEtMS0zMDUwMA_98e23c97-1155-45be-aa20-f85f1d439bd0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib52579de36d54242a791b9e3f8019a00_D20210701-20210930" decimals="-3" name="vtl:RoyaltySettlementAgreementSalesNet" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMy9mcmFnOjg4YzY5ZTc3YzFlYjQ2MjhiMTQ1OWVhNzg2ZjlkNmYyL3RhYmxlOjZmNGIwMTVmYzUwODRkZDBhOWE5ZWU3MjFiYjg0NjU1L3RhYmxlcmFuZ2U6NmY0YjAxNWZjNTA4NGRkMGE5YTllZTcyMWJiODQ2NTVfNS03LTEtMS0zMDUwMA_cf8dd1bb-7c5c-4d76-a4df-fd6ba4a0f992">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930" decimals="-3" name="vtl:RoyaltySettlementAgreementSalesNet" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMy9mcmFnOjg4YzY5ZTc3YzFlYjQ2MjhiMTQ1OWVhNzg2ZjlkNmYyL3RhYmxlOjZmNGIwMTVmYzUwODRkZDBhOWE5ZWU3MjFiYjg0NjU1L3RhYmxlcmFuZ2U6NmY0YjAxNWZjNTA4NGRkMGE5YTllZTcyMWJiODQ2NTVfNS05LTEtMS0zMDUwMA_6b169cbb-c796-45bb-a731-c8b4456d5435">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69e8bcaae5bf44c9a03cf7f5bd08e6b8_D20210101-20210930" decimals="-3" name="vtl:RoyaltySettlementAgreementSalesNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMy9mcmFnOjg4YzY5ZTc3YzFlYjQ2MjhiMTQ1OWVhNzg2ZjlkNmYyL3RhYmxlOjZmNGIwMTVmYzUwODRkZDBhOWE5ZWU3MjFiYjg0NjU1L3RhYmxlcmFuZ2U6NmY0YjAxNWZjNTA4NGRkMGE5YTllZTcyMWJiODQ2NTVfNS0xMS0xLTEtMzA1MDA_36ade33d-df8c-44d0-9636-9a5f1e5e0e50">17,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25a8ea2d7c9f4bfd8f72223c8ac18c65_D20220701-20220930" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMy9mcmFnOjg4YzY5ZTc3YzFlYjQ2MjhiMTQ1OWVhNzg2ZjlkNmYyL3RhYmxlOjZmNGIwMTVmYzUwODRkZDBhOWE5ZWU3MjFiYjg0NjU1L3RhYmxlcmFuZ2U6NmY0YjAxNWZjNTA4NGRkMGE5YTllZTcyMWJiODQ2NTVfNi01LTEtMS0zMDUwMA_3ef283b2-4ea8-473e-a315-a8e05b5083a3">20,116</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib52579de36d54242a791b9e3f8019a00_D20210701-20210930" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMy9mcmFnOjg4YzY5ZTc3YzFlYjQ2MjhiMTQ1OWVhNzg2ZjlkNmYyL3RhYmxlOjZmNGIwMTVmYzUwODRkZDBhOWE5ZWU3MjFiYjg0NjU1L3RhYmxlcmFuZ2U6NmY0YjAxNWZjNTA4NGRkMGE5YTllZTcyMWJiODQ2NTVfNi03LTEtMS0zMDUwMA_ceeb73f9-58a0-47fc-96a9-e3a2bbb018a8">18,387</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMy9mcmFnOjg4YzY5ZTc3YzFlYjQ2MjhiMTQ1OWVhNzg2ZjlkNmYyL3RhYmxlOjZmNGIwMTVmYzUwODRkZDBhOWE5ZWU3MjFiYjg0NjU1L3RhYmxlcmFuZ2U6NmY0YjAxNWZjNTA4NGRkMGE5YTllZTcyMWJiODQ2NTVfNi05LTEtMS0zMDUwMA_4369f36f-b328-458d-af0a-c6eba2c6c4bd">62,161</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69e8bcaae5bf44c9a03cf7f5bd08e6b8_D20210101-20210930" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMy9mcmFnOjg4YzY5ZTc3YzFlYjQ2MjhiMTQ1OWVhNzg2ZjlkNmYyL3RhYmxlOjZmNGIwMTVmYzUwODRkZDBhOWE5ZWU3MjFiYjg0NjU1L3RhYmxlcmFuZ2U6NmY0YjAxNWZjNTA4NGRkMGE5YTllZTcyMWJiODQ2NTVfNi0xMS0xLTEtMzA1MDA_c005f132-b802-4e5b-a328-44792a671731">69,944</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i25a8ea2d7c9f4bfd8f72223c8ac18c65_D20220701-20220930" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMy9mcmFnOjg4YzY5ZTc3YzFlYjQ2MjhiMTQ1OWVhNzg2ZjlkNmYyL3RhYmxlOjZmNGIwMTVmYzUwODRkZDBhOWE5ZWU3MjFiYjg0NjU1L3RhYmxlcmFuZ2U6NmY0YjAxNWZjNTA4NGRkMGE5YTllZTcyMWJiODQ2NTVfNy01LTEtMS0zMDUwMA_9cfc6e99-1122-45d3-a0c9-c695aeea4e9c">20,116</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib52579de36d54242a791b9e3f8019a00_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMy9mcmFnOjg4YzY5ZTc3YzFlYjQ2MjhiMTQ1OWVhNzg2ZjlkNmYyL3RhYmxlOjZmNGIwMTVmYzUwODRkZDBhOWE5ZWU3MjFiYjg0NjU1L3RhYmxlcmFuZ2U6NmY0YjAxNWZjNTA4NGRkMGE5YTllZTcyMWJiODQ2NTVfNy03LTEtMS0zMDUwMA_c1acd441-75e7-49ff-b63d-3778a595b424">18,387</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMy9mcmFnOjg4YzY5ZTc3YzFlYjQ2MjhiMTQ1OWVhNzg2ZjlkNmYyL3RhYmxlOjZmNGIwMTVmYzUwODRkZDBhOWE5ZWU3MjFiYjg0NjU1L3RhYmxlcmFuZ2U6NmY0YjAxNWZjNTA4NGRkMGE5YTllZTcyMWJiODQ2NTVfNy05LTEtMS0zMDUwMA_7f6a8983-c885-4f99-9663-308fc2e028e4">62,161</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i69e8bcaae5bf44c9a03cf7f5bd08e6b8_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMy9mcmFnOjg4YzY5ZTc3YzFlYjQ2MjhiMTQ1OWVhNzg2ZjlkNmYyL3RhYmxlOjZmNGIwMTVmYzUwODRkZDBhOWE5ZWU3MjFiYjg0NjU1L3RhYmxlcmFuZ2U6NmY0YjAxNWZjNTA4NGRkMGE5YTllZTcyMWJiODQ2NTVfNy0xMS0xLTEtMzA1MDA_53dd8384-0681-4649-9663-7dc542962d12">69,944</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense):</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25a8ea2d7c9f4bfd8f72223c8ac18c65_D20220701-20220930" decimals="-3" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMy9mcmFnOjg4YzY5ZTc3YzFlYjQ2MjhiMTQ1OWVhNzg2ZjlkNmYyL3RhYmxlOjZmNGIwMTVmYzUwODRkZDBhOWE5ZWU3MjFiYjg0NjU1L3RhYmxlcmFuZ2U6NmY0YjAxNWZjNTA4NGRkMGE5YTllZTcyMWJiODQ2NTVfOS01LTEtMS0zMDUwMA_6b848d6b-36c4-44a0-bc7d-81810f92f3cc">230</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib52579de36d54242a791b9e3f8019a00_D20210701-20210930" decimals="-3" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMy9mcmFnOjg4YzY5ZTc3YzFlYjQ2MjhiMTQ1OWVhNzg2ZjlkNmYyL3RhYmxlOjZmNGIwMTVmYzUwODRkZDBhOWE5ZWU3MjFiYjg0NjU1L3RhYmxlcmFuZ2U6NmY0YjAxNWZjNTA4NGRkMGE5YTllZTcyMWJiODQ2NTVfOS03LTEtMS0zMDUwMA_8f5e0e6b-b4ce-4863-9e2b-9f6821a800e3">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930" decimals="-3" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMy9mcmFnOjg4YzY5ZTc3YzFlYjQ2MjhiMTQ1OWVhNzg2ZjlkNmYyL3RhYmxlOjZmNGIwMTVmYzUwODRkZDBhOWE5ZWU3MjFiYjg0NjU1L3RhYmxlcmFuZ2U6NmY0YjAxNWZjNTA4NGRkMGE5YTllZTcyMWJiODQ2NTVfOS05LTEtMS0zMDUwMA_725b982b-8cad-4a2f-9e6d-c818e350b141">343</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69e8bcaae5bf44c9a03cf7f5bd08e6b8_D20210101-20210930" decimals="-3" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMy9mcmFnOjg4YzY5ZTc3YzFlYjQ2MjhiMTQ1OWVhNzg2ZjlkNmYyL3RhYmxlOjZmNGIwMTVmYzUwODRkZDBhOWE5ZWU3MjFiYjg0NjU1L3RhYmxlcmFuZ2U6NmY0YjAxNWZjNTA4NGRkMGE5YTllZTcyMWJiODQ2NTVfOS0xMS0xLTEtMzA1MDA_1c8ec57a-a462-42df-88f2-c61a5993d795">51</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other  income (expense), net</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i25a8ea2d7c9f4bfd8f72223c8ac18c65_D20220701-20220930" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMy9mcmFnOjg4YzY5ZTc3YzFlYjQ2MjhiMTQ1OWVhNzg2ZjlkNmYyL3RhYmxlOjZmNGIwMTVmYzUwODRkZDBhOWE5ZWU3MjFiYjg0NjU1L3RhYmxlcmFuZ2U6NmY0YjAxNWZjNTA4NGRkMGE5YTllZTcyMWJiODQ2NTVfMTAtNS0xLTEtMzA1MDA_fed80e72-600a-4fbc-aad8-d4fa0c197814">1,338</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib52579de36d54242a791b9e3f8019a00_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMy9mcmFnOjg4YzY5ZTc3YzFlYjQ2MjhiMTQ1OWVhNzg2ZjlkNmYyL3RhYmxlOjZmNGIwMTVmYzUwODRkZDBhOWE5ZWU3MjFiYjg0NjU1L3RhYmxlcmFuZ2U6NmY0YjAxNWZjNTA4NGRkMGE5YTllZTcyMWJiODQ2NTVfMTAtNy0xLTEtMzA1MDA_e9180067-4b4d-4ef8-a440-5429cf2c621d">915</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMy9mcmFnOjg4YzY5ZTc3YzFlYjQ2MjhiMTQ1OWVhNzg2ZjlkNmYyL3RhYmxlOjZmNGIwMTVmYzUwODRkZDBhOWE5ZWU3MjFiYjg0NjU1L3RhYmxlcmFuZ2U6NmY0YjAxNWZjNTA4NGRkMGE5YTllZTcyMWJiODQ2NTVfMTAtOS0xLTEtMzA1MDA_60a4538c-1fec-458b-ab35-7a76eba803d7">2,115</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i69e8bcaae5bf44c9a03cf7f5bd08e6b8_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMy9mcmFnOjg4YzY5ZTc3YzFlYjQ2MjhiMTQ1OWVhNzg2ZjlkNmYyL3RhYmxlOjZmNGIwMTVmYzUwODRkZDBhOWE5ZWU3MjFiYjg0NjU1L3RhYmxlcmFuZ2U6NmY0YjAxNWZjNTA4NGRkMGE5YTllZTcyMWJiODQ2NTVfMTAtMTEtMS0xLTMwNTAw_477f48c3-b5c1-4bb0-85a9-925a426dcaeb">1,867</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other expense</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i25a8ea2d7c9f4bfd8f72223c8ac18c65_D20220701-20220930" decimals="-3" sign="-" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMy9mcmFnOjg4YzY5ZTc3YzFlYjQ2MjhiMTQ1OWVhNzg2ZjlkNmYyL3RhYmxlOjZmNGIwMTVmYzUwODRkZDBhOWE5ZWU3MjFiYjg0NjU1L3RhYmxlcmFuZ2U6NmY0YjAxNWZjNTA4NGRkMGE5YTllZTcyMWJiODQ2NTVfMTEtNS0xLTEtMzA1MDA_a3eaaa45-bc1f-42f9-b660-2631135377e8">1,108</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib52579de36d54242a791b9e3f8019a00_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMy9mcmFnOjg4YzY5ZTc3YzFlYjQ2MjhiMTQ1OWVhNzg2ZjlkNmYyL3RhYmxlOjZmNGIwMTVmYzUwODRkZDBhOWE5ZWU3MjFiYjg0NjU1L3RhYmxlcmFuZ2U6NmY0YjAxNWZjNTA4NGRkMGE5YTllZTcyMWJiODQ2NTVfMTEtNy0xLTEtMzA1MDA_79548cc7-b8a0-4849-87c0-18292343d9da">905</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMy9mcmFnOjg4YzY5ZTc3YzFlYjQ2MjhiMTQ1OWVhNzg2ZjlkNmYyL3RhYmxlOjZmNGIwMTVmYzUwODRkZDBhOWE5ZWU3MjFiYjg0NjU1L3RhYmxlcmFuZ2U6NmY0YjAxNWZjNTA4NGRkMGE5YTllZTcyMWJiODQ2NTVfMTEtOS0xLTEtMzA1MDA_b5e737ae-8981-458a-a60b-7712754b2de5">1,772</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i69e8bcaae5bf44c9a03cf7f5bd08e6b8_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMy9mcmFnOjg4YzY5ZTc3YzFlYjQ2MjhiMTQ1OWVhNzg2ZjlkNmYyL3RhYmxlOjZmNGIwMTVmYzUwODRkZDBhOWE5ZWU3MjFiYjg0NjU1L3RhYmxlcmFuZ2U6NmY0YjAxNWZjNTA4NGRkMGE5YTllZTcyMWJiODQ2NTVfMTEtMTEtMS0xLTMwNTAw_592e117a-07ce-4ea6-8e29-c113539139b2">1,816</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i25a8ea2d7c9f4bfd8f72223c8ac18c65_D20220701-20220930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMy9mcmFnOjg4YzY5ZTc3YzFlYjQ2MjhiMTQ1OWVhNzg2ZjlkNmYyL3RhYmxlOjZmNGIwMTVmYzUwODRkZDBhOWE5ZWU3MjFiYjg0NjU1L3RhYmxlcmFuZ2U6NmY0YjAxNWZjNTA4NGRkMGE5YTllZTcyMWJiODQ2NTVfMTItNS0xLTEtMzA1MDA_13eccc70-1fa7-4f5d-a3ff-a8135cf3864f">21,224</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib52579de36d54242a791b9e3f8019a00_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMy9mcmFnOjg4YzY5ZTc3YzFlYjQ2MjhiMTQ1OWVhNzg2ZjlkNmYyL3RhYmxlOjZmNGIwMTVmYzUwODRkZDBhOWE5ZWU3MjFiYjg0NjU1L3RhYmxlcmFuZ2U6NmY0YjAxNWZjNTA4NGRkMGE5YTllZTcyMWJiODQ2NTVfMTItNy0xLTEtMzA1MDA_56ac083e-7639-4aa0-921a-9dba73801f08">19,292</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMy9mcmFnOjg4YzY5ZTc3YzFlYjQ2MjhiMTQ1OWVhNzg2ZjlkNmYyL3RhYmxlOjZmNGIwMTVmYzUwODRkZDBhOWE5ZWU3MjFiYjg0NjU1L3RhYmxlcmFuZ2U6NmY0YjAxNWZjNTA4NGRkMGE5YTllZTcyMWJiODQ2NTVfMTItOS0xLTEtMzA1MDA_ac090655-5665-47eb-a615-d5a144987334">63,933</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i69e8bcaae5bf44c9a03cf7f5bd08e6b8_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMy9mcmFnOjg4YzY5ZTc3YzFlYjQ2MjhiMTQ1OWVhNzg2ZjlkNmYyL3RhYmxlOjZmNGIwMTVmYzUwODRkZDBhOWE5ZWU3MjFiYjg0NjU1L3RhYmxlcmFuZ2U6NmY0YjAxNWZjNTA4NGRkMGE5YTllZTcyMWJiODQ2NTVfMTItMTEtMS0xLTMwNTAw_9237b974-1b0a-47f1-8ec0-acf23471139d">71,760</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share, basic and diluted</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i25a8ea2d7c9f4bfd8f72223c8ac18c65_D20220701-20220930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMy9mcmFnOjg4YzY5ZTc3YzFlYjQ2MjhiMTQ1OWVhNzg2ZjlkNmYyL3RhYmxlOjZmNGIwMTVmYzUwODRkZDBhOWE5ZWU3MjFiYjg0NjU1L3RhYmxlcmFuZ2U6NmY0YjAxNWZjNTA4NGRkMGE5YTllZTcyMWJiODQ2NTVfMTQtNS0xLTEtMzA1MDA_d6d8dca0-ec23-4ffd-b7c2-089cfffda6a2"><ix:nonFraction unitRef="usdPerShare" contextRef="i25a8ea2d7c9f4bfd8f72223c8ac18c65_D20220701-20220930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMy9mcmFnOjg4YzY5ZTc3YzFlYjQ2MjhiMTQ1OWVhNzg2ZjlkNmYyL3RhYmxlOjZmNGIwMTVmYzUwODRkZDBhOWE5ZWU3MjFiYjg0NjU1L3RhYmxlcmFuZ2U6NmY0YjAxNWZjNTA4NGRkMGE5YTllZTcyMWJiODQ2NTVfMTQtNS0xLTEtMzA1MDA_f70ebb75-e703-453f-903b-cc1c0c60b817">0.69</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ib52579de36d54242a791b9e3f8019a00_D20210701-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMy9mcmFnOjg4YzY5ZTc3YzFlYjQ2MjhiMTQ1OWVhNzg2ZjlkNmYyL3RhYmxlOjZmNGIwMTVmYzUwODRkZDBhOWE5ZWU3MjFiYjg0NjU1L3RhYmxlcmFuZ2U6NmY0YjAxNWZjNTA4NGRkMGE5YTllZTcyMWJiODQ2NTVfMTQtNy0xLTEtMzA1MDA_3c514ae2-c067-4785-9ce5-bfb3668ad25f"><ix:nonFraction unitRef="usdPerShare" contextRef="ib52579de36d54242a791b9e3f8019a00_D20210701-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMy9mcmFnOjg4YzY5ZTc3YzFlYjQ2MjhiMTQ1OWVhNzg2ZjlkNmYyL3RhYmxlOjZmNGIwMTVmYzUwODRkZDBhOWE5ZWU3MjFiYjg0NjU1L3RhYmxlcmFuZ2U6NmY0YjAxNWZjNTA4NGRkMGE5YTllZTcyMWJiODQ2NTVfMTQtNy0xLTEtMzA1MDA_47abcf9c-1cca-48a2-a03b-ae625b3ca587">0.76</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMy9mcmFnOjg4YzY5ZTc3YzFlYjQ2MjhiMTQ1OWVhNzg2ZjlkNmYyL3RhYmxlOjZmNGIwMTVmYzUwODRkZDBhOWE5ZWU3MjFiYjg0NjU1L3RhYmxlcmFuZ2U6NmY0YjAxNWZjNTA4NGRkMGE5YTllZTcyMWJiODQ2NTVfMTQtOS0xLTEtMzA1MDA_1e62b304-6f3e-42a7-8832-981ea11b287a"><ix:nonFraction unitRef="usdPerShare" contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMy9mcmFnOjg4YzY5ZTc3YzFlYjQ2MjhiMTQ1OWVhNzg2ZjlkNmYyL3RhYmxlOjZmNGIwMTVmYzUwODRkZDBhOWE5ZWU3MjFiYjg0NjU1L3RhYmxlcmFuZ2U6NmY0YjAxNWZjNTA4NGRkMGE5YTllZTcyMWJiODQ2NTVfMTQtOS0xLTEtMzA1MDA_baea6b49-0444-4f2d-afb7-88dac205c0e0">2.16</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i69e8bcaae5bf44c9a03cf7f5bd08e6b8_D20210101-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMy9mcmFnOjg4YzY5ZTc3YzFlYjQ2MjhiMTQ1OWVhNzg2ZjlkNmYyL3RhYmxlOjZmNGIwMTVmYzUwODRkZDBhOWE5ZWU3MjFiYjg0NjU1L3RhYmxlcmFuZ2U6NmY0YjAxNWZjNTA4NGRkMGE5YTllZTcyMWJiODQ2NTVfMTQtMTEtMS0xLTMwNTAw_9e7b6145-7f47-4ff0-8216-8521e69485ee"><ix:nonFraction unitRef="usdPerShare" contextRef="i69e8bcaae5bf44c9a03cf7f5bd08e6b8_D20210101-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMy9mcmFnOjg4YzY5ZTc3YzFlYjQ2MjhiMTQ1OWVhNzg2ZjlkNmYyL3RhYmxlOjZmNGIwMTVmYzUwODRkZDBhOWE5ZWU3MjFiYjg0NjU1L3RhYmxlcmFuZ2U6NmY0YjAxNWZjNTA4NGRkMGE5YTllZTcyMWJiODQ2NTVfMTQtMTEtMS0xLTMwNTAw_c708b409-b4c3-4c24-b579-8239f1e2512d">3.33</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding, basic and diluted</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i25a8ea2d7c9f4bfd8f72223c8ac18c65_D20220701-20220930" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMy9mcmFnOjg4YzY5ZTc3YzFlYjQ2MjhiMTQ1OWVhNzg2ZjlkNmYyL3RhYmxlOjZmNGIwMTVmYzUwODRkZDBhOWE5ZWU3MjFiYjg0NjU1L3RhYmxlcmFuZ2U6NmY0YjAxNWZjNTA4NGRkMGE5YTllZTcyMWJiODQ2NTVfMTYtNS0xLTEtMzA1MDA_25c0d990-a353-41b6-9a38-518a7d40ab9e"><ix:nonFraction unitRef="shares" contextRef="i25a8ea2d7c9f4bfd8f72223c8ac18c65_D20220701-20220930" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMy9mcmFnOjg4YzY5ZTc3YzFlYjQ2MjhiMTQ1OWVhNzg2ZjlkNmYyL3RhYmxlOjZmNGIwMTVmYzUwODRkZDBhOWE5ZWU3MjFiYjg0NjU1L3RhYmxlcmFuZ2U6NmY0YjAxNWZjNTA4NGRkMGE5YTllZTcyMWJiODQ2NTVfMTYtNS0xLTEtMzA1MDA_2d6d8ff8-f349-4e61-a35e-475bd51c14ec">30,564,995</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib52579de36d54242a791b9e3f8019a00_D20210701-20210930" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMy9mcmFnOjg4YzY5ZTc3YzFlYjQ2MjhiMTQ1OWVhNzg2ZjlkNmYyL3RhYmxlOjZmNGIwMTVmYzUwODRkZDBhOWE5ZWU3MjFiYjg0NjU1L3RhYmxlcmFuZ2U6NmY0YjAxNWZjNTA4NGRkMGE5YTllZTcyMWJiODQ2NTVfMTYtNy0xLTEtMzA1MDA_03a083fb-7c11-4a81-92ad-9335b0a94b24"><ix:nonFraction unitRef="shares" contextRef="ib52579de36d54242a791b9e3f8019a00_D20210701-20210930" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMy9mcmFnOjg4YzY5ZTc3YzFlYjQ2MjhiMTQ1OWVhNzg2ZjlkNmYyL3RhYmxlOjZmNGIwMTVmYzUwODRkZDBhOWE5ZWU3MjFiYjg0NjU1L3RhYmxlcmFuZ2U6NmY0YjAxNWZjNTA4NGRkMGE5YTllZTcyMWJiODQ2NTVfMTYtNy0xLTEtMzA1MDA_853c153f-a882-4d93-9c52-23257d30eac0">25,320,091</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMy9mcmFnOjg4YzY5ZTc3YzFlYjQ2MjhiMTQ1OWVhNzg2ZjlkNmYyL3RhYmxlOjZmNGIwMTVmYzUwODRkZDBhOWE5ZWU3MjFiYjg0NjU1L3RhYmxlcmFuZ2U6NmY0YjAxNWZjNTA4NGRkMGE5YTllZTcyMWJiODQ2NTVfMTYtOS0xLTEtMzA1MDA_40b5a33b-8509-4429-b57f-b379023c9432"><ix:nonFraction unitRef="shares" contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMy9mcmFnOjg4YzY5ZTc3YzFlYjQ2MjhiMTQ1OWVhNzg2ZjlkNmYyL3RhYmxlOjZmNGIwMTVmYzUwODRkZDBhOWE5ZWU3MjFiYjg0NjU1L3RhYmxlcmFuZ2U6NmY0YjAxNWZjNTA4NGRkMGE5YTllZTcyMWJiODQ2NTVfMTYtOS0xLTEtMzA1MDA_a7bdb752-33ac-48a5-8444-5d8e7aae1114">29,655,946</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i69e8bcaae5bf44c9a03cf7f5bd08e6b8_D20210101-20210930" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMy9mcmFnOjg4YzY5ZTc3YzFlYjQ2MjhiMTQ1OWVhNzg2ZjlkNmYyL3RhYmxlOjZmNGIwMTVmYzUwODRkZDBhOWE5ZWU3MjFiYjg0NjU1L3RhYmxlcmFuZ2U6NmY0YjAxNWZjNTA4NGRkMGE5YTllZTcyMWJiODQ2NTVfMTYtMTEtMS0xLTMwNTAw_6bebae0f-6394-4dff-9496-b4953983aa97"><ix:nonFraction unitRef="shares" contextRef="i69e8bcaae5bf44c9a03cf7f5bd08e6b8_D20210101-20210930" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMy9mcmFnOjg4YzY5ZTc3YzFlYjQ2MjhiMTQ1OWVhNzg2ZjlkNmYyL3RhYmxlOjZmNGIwMTVmYzUwODRkZDBhOWE5ZWU3MjFiYjg0NjU1L3RhYmxlcmFuZ2U6NmY0YjAxNWZjNTA4NGRkMGE5YTllZTcyMWJiODQ2NTVfMTYtMTEtMS0xLTMwNTAw_97a812ee-d46a-4f64-8039-86420ddcaabd">21,559,964</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="ida7c333e3c58430eb83e8e950c50d811_16"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">IMMUNIC, INC.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Comprehensive Loss</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In&#160;thousands)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.543%"><tr><td style="width:1.0%"></td><td style="width:55.298%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.589%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.852%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.431%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.852%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.063%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.852%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.589%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.174%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months<br/>&#160;Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months<br/>&#160;Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i25a8ea2d7c9f4bfd8f72223c8ac18c65_D20220701-20220930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xNi9mcmFnOmNhNTFhNDQ0OTY0MTQzZmNhZWZhYWI5NjUxOWZhZjdiL3RhYmxlOjUzYzg3ZDkyZGY2YTQ1N2Q5Nzk4NGE5NDQ0YzA2ZDAxL3RhYmxlcmFuZ2U6NTNjODdkOTJkZjZhNDU3ZDk3OTg0YTk0NDRjMDZkMDFfMi01LTEtMS0zMDUwMA_496b4f71-0c20-4611-a1b1-e5c749aca3bb">21,224</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib52579de36d54242a791b9e3f8019a00_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xNi9mcmFnOmNhNTFhNDQ0OTY0MTQzZmNhZWZhYWI5NjUxOWZhZjdiL3RhYmxlOjUzYzg3ZDkyZGY2YTQ1N2Q5Nzk4NGE5NDQ0YzA2ZDAxL3RhYmxlcmFuZ2U6NTNjODdkOTJkZjZhNDU3ZDk3OTg0YTk0NDRjMDZkMDFfMi03LTEtMS0zMDUwMA_ae88da84-a8ef-4794-a661-a46cb4760cc6">19,292</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xNi9mcmFnOmNhNTFhNDQ0OTY0MTQzZmNhZWZhYWI5NjUxOWZhZjdiL3RhYmxlOjUzYzg3ZDkyZGY2YTQ1N2Q5Nzk4NGE5NDQ0YzA2ZDAxL3RhYmxlcmFuZ2U6NTNjODdkOTJkZjZhNDU3ZDk3OTg0YTk0NDRjMDZkMDFfMi05LTEtMS0zMDUwMA_ac090655-5665-47eb-a615-d5a144987334">63,933</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i69e8bcaae5bf44c9a03cf7f5bd08e6b8_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xNi9mcmFnOmNhNTFhNDQ0OTY0MTQzZmNhZWZhYWI5NjUxOWZhZjdiL3RhYmxlOjUzYzg3ZDkyZGY2YTQ1N2Q5Nzk4NGE5NDQ0YzA2ZDAxL3RhYmxlcmFuZ2U6NTNjODdkOTJkZjZhNDU3ZDk3OTg0YTk0NDRjMDZkMDFfMi0xMS0xLTEtMzA1MDA_9237b974-1b0a-47f1-8ec0-acf23471139d">71,760</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss):</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25a8ea2d7c9f4bfd8f72223c8ac18c65_D20220701-20220930" decimals="-3" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xNi9mcmFnOmNhNTFhNDQ0OTY0MTQzZmNhZWZhYWI5NjUxOWZhZjdiL3RhYmxlOjUzYzg3ZDkyZGY2YTQ1N2Q5Nzk4NGE5NDQ0YzA2ZDAxL3RhYmxlcmFuZ2U6NTNjODdkOTJkZjZhNDU3ZDk3OTg0YTk0NDRjMDZkMDFfNC01LTEtMS0zMDUwMA_bbff4caa-3f69-4371-ab91-f745d48a3e8e">274</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib52579de36d54242a791b9e3f8019a00_D20210701-20210930" decimals="-3" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xNi9mcmFnOmNhNTFhNDQ0OTY0MTQzZmNhZWZhYWI5NjUxOWZhZjdiL3RhYmxlOjUzYzg3ZDkyZGY2YTQ1N2Q5Nzk4NGE5NDQ0YzA2ZDAxL3RhYmxlcmFuZ2U6NTNjODdkOTJkZjZhNDU3ZDk3OTg0YTk0NDRjMDZkMDFfNC03LTEtMS0zMDUwMA_9e5c394a-d4e7-4fb1-a820-8106c5990c67">598</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xNi9mcmFnOmNhNTFhNDQ0OTY0MTQzZmNhZWZhYWI5NjUxOWZhZjdiL3RhYmxlOjUzYzg3ZDkyZGY2YTQ1N2Q5Nzk4NGE5NDQ0YzA2ZDAxL3RhYmxlcmFuZ2U6NTNjODdkOTJkZjZhNDU3ZDk3OTg0YTk0NDRjMDZkMDFfNC05LTEtMS0zMDUwMA_429fc883-7200-47d9-89a3-3eb2bea08409">134</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69e8bcaae5bf44c9a03cf7f5bd08e6b8_D20210101-20210930" decimals="-3" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xNi9mcmFnOmNhNTFhNDQ0OTY0MTQzZmNhZWZhYWI5NjUxOWZhZjdiL3RhYmxlOjUzYzg3ZDkyZGY2YTQ1N2Q5Nzk4NGE5NDQ0YzA2ZDAxL3RhYmxlcmFuZ2U6NTNjODdkOTJkZjZhNDU3ZDk3OTg0YTk0NDRjMDZkMDFfNC0xMS0xLTEtMzA1MDA_7ef2869f-60c8-443d-b036-66c6c5e4e93d">3,312</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total comprehensive loss</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i25a8ea2d7c9f4bfd8f72223c8ac18c65_D20220701-20220930" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xNi9mcmFnOmNhNTFhNDQ0OTY0MTQzZmNhZWZhYWI5NjUxOWZhZjdiL3RhYmxlOjUzYzg3ZDkyZGY2YTQ1N2Q5Nzk4NGE5NDQ0YzA2ZDAxL3RhYmxlcmFuZ2U6NTNjODdkOTJkZjZhNDU3ZDk3OTg0YTk0NDRjMDZkMDFfNi01LTEtMS0zMDUwMA_7b909d95-f218-41d6-96a1-46146e716c28">20,950</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib52579de36d54242a791b9e3f8019a00_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xNi9mcmFnOmNhNTFhNDQ0OTY0MTQzZmNhZWZhYWI5NjUxOWZhZjdiL3RhYmxlOjUzYzg3ZDkyZGY2YTQ1N2Q5Nzk4NGE5NDQ0YzA2ZDAxL3RhYmxlcmFuZ2U6NTNjODdkOTJkZjZhNDU3ZDk3OTg0YTk0NDRjMDZkMDFfNi03LTEtMS0zMDUwMA_68989145-3728-4779-8db2-228f752ca191">18,694</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xNi9mcmFnOmNhNTFhNDQ0OTY0MTQzZmNhZWZhYWI5NjUxOWZhZjdiL3RhYmxlOjUzYzg3ZDkyZGY2YTQ1N2Q5Nzk4NGE5NDQ0YzA2ZDAxL3RhYmxlcmFuZ2U6NTNjODdkOTJkZjZhNDU3ZDk3OTg0YTk0NDRjMDZkMDFfNi05LTEtMS0zMDUwMA_33d363c0-364b-4d52-9dbd-69b120d3bd20">64,067</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i69e8bcaae5bf44c9a03cf7f5bd08e6b8_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xNi9mcmFnOmNhNTFhNDQ0OTY0MTQzZmNhZWZhYWI5NjUxOWZhZjdiL3RhYmxlOjUzYzg3ZDkyZGY2YTQ1N2Q5Nzk4NGE5NDQ0YzA2ZDAxL3RhYmxlcmFuZ2U6NTNjODdkOTJkZjZhNDU3ZDk3OTg0YTk0NDRjMDZkMDFfNi0xMS0xLTEtMzA1MDA_48a382ae-dffc-4e2c-94fe-be2d75c0fbb8">68,448</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="ida7c333e3c58430eb83e8e950c50d811_19"></div><hr style="page-break-after:always"/><div style="min-height:36.72pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:232%">IMMUNIC, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:232%">Condensed Consolidated Statements of  Stockholders&#8217; Equity</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In&#160;thousands,&#160;except&#160;share amounts)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.920%"><tr><td style="width:1.0%"></td><td style="width:43.092%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.690%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.358%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.832%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.366%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.832%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.366%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.815%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.366%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.398%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.366%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.819%"></td><td style="width:0.1%"></td></tr><tr><td colspan="36" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2022</span></td></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Additional<br/>Paid-In<br/>Capital</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Income (Loss)</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Stockholders&#8217;<br/>Equity</span></td></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at January 1, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i10cadb43ee4f4d5983a19400b011767c_I20211231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjM1OTg4NDc0ZGQ4ZDRiMjM5ZTA1OTA2NjJkMzEwMTk0L3RhYmxlcmFuZ2U6MzU5ODg0NzRkZDhkNGIyMzllMDU5MDY2MmQzMTAxOTRfMy0xLTEtMS0zMDUwMA_b53ca6b6-0418-42e4-b567-711821a65dc9">26,335,418</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10cadb43ee4f4d5983a19400b011767c_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjM1OTg4NDc0ZGQ4ZDRiMjM5ZTA1OTA2NjJkMzEwMTk0L3RhYmxlcmFuZ2U6MzU5ODg0NzRkZDhkNGIyMzllMDU5MDY2MmQzMTAxOTRfMy0zLTEtMS0zMDUwMA_06063696-56ba-40b2-acce-c2f531ae95c9">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i009a2206cca94447b0821da5d321afd8_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjM1OTg4NDc0ZGQ4ZDRiMjM5ZTA1OTA2NjJkMzEwMTk0L3RhYmxlcmFuZ2U6MzU5ODg0NzRkZDhkNGIyMzllMDU5MDY2MmQzMTAxOTRfMy01LTEtMS0zMDUwMA_b81ff215-4d30-4a26-abe7-a1d2d0f07ff7">324,237</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i385e3bff38de43c684e65b2b3be869c2_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjM1OTg4NDc0ZGQ4ZDRiMjM5ZTA1OTA2NjJkMzEwMTk0L3RhYmxlcmFuZ2U6MzU5ODg0NzRkZDhkNGIyMzllMDU5MDY2MmQzMTAxOTRfMy03LTEtMS0zMDUwMA_1ce7ef53-fd71-403c-ba19-5dcccaeb9101">252</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3f4fa8cb61dc4846bc63aadbbe138fd4_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjM1OTg4NDc0ZGQ4ZDRiMjM5ZTA1OTA2NjJkMzEwMTk0L3RhYmxlcmFuZ2U6MzU5ODg0NzRkZDhkNGIyMzllMDU5MDY2MmQzMTAxOTRfMy05LTEtMS0zMDUwMA_2d88497f-174b-442f-8b50-20d329e0fd4f">196,873</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12246a01749f40d394a9437cb9938c91_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjM1OTg4NDc0ZGQ4ZDRiMjM5ZTA1OTA2NjJkMzEwMTk0L3RhYmxlcmFuZ2U6MzU5ODg0NzRkZDhkNGIyMzllMDU5MDY2MmQzMTAxOTRfMy0xMS0xLTEtMzA1MDA_8fdb07e5-f987-4252-8f09-74fa65961efb">127,115</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ida6ee8360c724bafba15cd5fadf3f86c_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjM1OTg4NDc0ZGQ4ZDRiMjM5ZTA1OTA2NjJkMzEwMTk0L3RhYmxlcmFuZ2U6MzU5ODg0NzRkZDhkNGIyMzllMDU5MDY2MmQzMTAxOTRfNC05LTEtMS0zMDUwMA_171e8aef-705c-4445-a81e-8338b31277ee">20,808</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icd575a0576f94d6abe3a754e65a57231_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjM1OTg4NDc0ZGQ4ZDRiMjM5ZTA1OTA2NjJkMzEwMTk0L3RhYmxlcmFuZ2U6MzU5ODg0NzRkZDhkNGIyMzllMDU5MDY2MmQzMTAxOTRfNC0xMS0xLTEtMzA1MDA_a86027e2-ed93-4020-be84-1e0db4b80957">20,808</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bfbb29080414e03b068322088956131_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjM1OTg4NDc0ZGQ4ZDRiMjM5ZTA1OTA2NjJkMzEwMTk0L3RhYmxlcmFuZ2U6MzU5ODg0NzRkZDhkNGIyMzllMDU5MDY2MmQzMTAxOTRfNS01LTEtMS0zMDUwMA_c81201d9-6b5a-413c-900b-cea0bcfb81e5">2,069</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd575a0576f94d6abe3a754e65a57231_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjM1OTg4NDc0ZGQ4ZDRiMjM5ZTA1OTA2NjJkMzEwMTk0L3RhYmxlcmFuZ2U6MzU5ODg0NzRkZDhkNGIyMzllMDU5MDY2MmQzMTAxOTRfNS0xMS0xLTEtMzA1MDA_35bd23b2-9145-48ce-b4e2-1c2fd4266a90">2,069</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange translation adjustment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i833e88d808f64f8db575748a84d92e85_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjM1OTg4NDc0ZGQ4ZDRiMjM5ZTA1OTA2NjJkMzEwMTk0L3RhYmxlcmFuZ2U6MzU5ODg0NzRkZDhkNGIyMzllMDU5MDY2MmQzMTAxOTRfNi03LTEtMS0zMDUwMA_be6cb8d7-4a0b-487c-8233-2273dcc78c32">58</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icd575a0576f94d6abe3a754e65a57231_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjM1OTg4NDc0ZGQ4ZDRiMjM5ZTA1OTA2NjJkMzEwMTk0L3RhYmxlcmFuZ2U6MzU5ODg0NzRkZDhkNGIyMzllMDU5MDY2MmQzMTAxOTRfNi0xMS0xLTEtMzA1MDA_e4976b0a-5b8e-445b-a008-334123b9cc8b">58</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares issued in connection with the Company's stock option plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5521d4c179a3424b8300e7e1aa3bb508_D20220101-20220331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjM1OTg4NDc0ZGQ4ZDRiMjM5ZTA1OTA2NjJkMzEwMTk0L3RhYmxlcmFuZ2U6MzU5ODg0NzRkZDhkNGIyMzllMDU5MDY2MmQzMTAxOTRfNy0xLTEtMS0zMDUwMA_65078156-aed2-4c53-b8d9-32c3a2e16e97">852</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bfbb29080414e03b068322088956131_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjM1OTg4NDc0ZGQ4ZDRiMjM5ZTA1OTA2NjJkMzEwMTk0L3RhYmxlcmFuZ2U6MzU5ODg0NzRkZDhkNGIyMzllMDU5MDY2MmQzMTAxOTRfNy01LTEtMS0zMDUwMA_1758e85a-7a89-45f5-957c-8dceb32482c9">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd575a0576f94d6abe3a754e65a57231_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjM1OTg4NDc0ZGQ4ZDRiMjM5ZTA1OTA2NjJkMzEwMTk0L3RhYmxlcmFuZ2U6MzU5ODg0NzRkZDhkNGIyMzllMDU5MDY2MmQzMTAxOTRfNy0xMS0xLTEtMzA1MDA_3b8ddb1a-e418-449f-9d62-b7e5e8e77205">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock - at the market Sales Agreement net of issuance costs of $<ix:nonFraction unitRef="usd" contextRef="icd575a0576f94d6abe3a754e65a57231_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjM1OTg4NDc0ZGQ4ZDRiMjM5ZTA1OTA2NjJkMzEwMTk0L3RhYmxlcmFuZ2U6MzU5ODg0NzRkZDhkNGIyMzllMDU5MDY2MmQzMTAxOTRfOS0wLTEtMS0zMTM5MS90ZXh0cmVnaW9uOmU0MTExNGVkNDIyNjRiN2FhM2EwOGJhYzQ3M2YxOGE0XzIxOTkwMjMyNTU2NDU_73af9e60-4758-4934-8cb9-1ebb9e5d59df">918</ix:nonFraction></span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i48e85fbb9eaf443d833e5d74dad1457f_D20220101-20220331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjM1OTg4NDc0ZGQ4ZDRiMjM5ZTA1OTA2NjJkMzEwMTk0L3RhYmxlcmFuZ2U6MzU5ODg0NzRkZDhkNGIyMzllMDU5MDY2MmQzMTAxOTRfOS0xLTEtMS0zMTM5MQ_89fa3e9e-f2db-481b-94c0-2651960af032">2,904,113</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85e99d9786824edc9811205ccff0e2c1_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjM1OTg4NDc0ZGQ4ZDRiMjM5ZTA1OTA2NjJkMzEwMTk0L3RhYmxlcmFuZ2U6MzU5ODg0NzRkZDhkNGIyMzllMDU5MDY2MmQzMTAxOTRfOS01LTEtMS0zMTM5MQ_14bbdc44-6d3e-4db9-b205-f2d01300168f">29,638</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0fe92136184445b9b403e48c306c7a0_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjM1OTg4NDc0ZGQ4ZDRiMjM5ZTA1OTA2NjJkMzEwMTk0L3RhYmxlcmFuZ2U6MzU5ODg0NzRkZDhkNGIyMzllMDU5MDY2MmQzMTAxOTRfOS0xMS0xLTEtMzEzOTE_91df78e2-0244-4a41-b781-21e4b58488e8">29,638</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at March 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i37699bd784b74eff9b8044aa3d0f82c7_I20220331" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjM1OTg4NDc0ZGQ4ZDRiMjM5ZTA1OTA2NjJkMzEwMTk0L3RhYmxlcmFuZ2U6MzU5ODg0NzRkZDhkNGIyMzllMDU5MDY2MmQzMTAxOTRfOS0xLTEtMS0zMDUwMA_2c4253d9-191e-4a5c-b3b3-e94347a15a4d">29,240,383</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37699bd784b74eff9b8044aa3d0f82c7_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjM1OTg4NDc0ZGQ4ZDRiMjM5ZTA1OTA2NjJkMzEwMTk0L3RhYmxlcmFuZ2U6MzU5ODg0NzRkZDhkNGIyMzllMDU5MDY2MmQzMTAxOTRfOS0zLTEtMS0zMDUwMA_7d1de858-c4c1-475b-9c07-c2e1dd8561d9">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i695cece83a314ed69b003d1805aa445f_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjM1OTg4NDc0ZGQ4ZDRiMjM5ZTA1OTA2NjJkMzEwMTk0L3RhYmxlcmFuZ2U6MzU5ODg0NzRkZDhkNGIyMzllMDU5MDY2MmQzMTAxOTRfOS01LTEtMS0zMDUwMA_622f1119-4531-4175-815b-b4cd6ec6a7c8">355,949</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9f48eb2e56ec4c62bea71dbf94048968_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjM1OTg4NDc0ZGQ4ZDRiMjM5ZTA1OTA2NjJkMzEwMTk0L3RhYmxlcmFuZ2U6MzU5ODg0NzRkZDhkNGIyMzllMDU5MDY2MmQzMTAxOTRfOS03LTEtMS0zMDUwMA_1dba3be5-0130-4c69-b0c9-c7b3c5aeb0bf">310</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i70f7507e4b224e59ba619f034e88a2d9_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjM1OTg4NDc0ZGQ4ZDRiMjM5ZTA1OTA2NjJkMzEwMTk0L3RhYmxlcmFuZ2U6MzU5ODg0NzRkZDhkNGIyMzllMDU5MDY2MmQzMTAxOTRfOS05LTEtMS0zMDUwMA_3e81c4b5-0265-40fa-ae1a-085bde961517">217,681</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85803ab216eb4675941bdbd496da6ed9_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjM1OTg4NDc0ZGQ4ZDRiMjM5ZTA1OTA2NjJkMzEwMTk0L3RhYmxlcmFuZ2U6MzU5ODg0NzRkZDhkNGIyMzllMDU5MDY2MmQzMTAxOTRfOS0xMS0xLTEtMzA1MDA_0d09fc1b-2dfe-4f98-b2ce-f7ab4eeb64e3">137,961</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i737e66e4d7604e7294bf339bc188faf1_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjM1OTg4NDc0ZGQ4ZDRiMjM5ZTA1OTA2NjJkMzEwMTk0L3RhYmxlcmFuZ2U6MzU5ODg0NzRkZDhkNGIyMzllMDU5MDY2MmQzMTAxOTRfMTAtOS0xLTEtMzA1MDA_d843f785-2bfa-4e16-9cac-054ed54c279d">21,901</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8ff3b5d8c53f48e598eabdf159ffe5a8_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjM1OTg4NDc0ZGQ4ZDRiMjM5ZTA1OTA2NjJkMzEwMTk0L3RhYmxlcmFuZ2U6MzU5ODg0NzRkZDhkNGIyMzllMDU5MDY2MmQzMTAxOTRfMTAtMTEtMS0xLTMwNTAw_8965452d-1225-4a2e-8c53-4d47c5ae29f5">21,901</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e65e2ba034b476992065fd432154ff5_D20220401-20220630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjM1OTg4NDc0ZGQ4ZDRiMjM5ZTA1OTA2NjJkMzEwMTk0L3RhYmxlcmFuZ2U6MzU5ODg0NzRkZDhkNGIyMzllMDU5MDY2MmQzMTAxOTRfMTEtNS0xLTEtMzA1MDA_3779d24e-1d59-460b-9a02-df1f5348d64a">2,062</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ff3b5d8c53f48e598eabdf159ffe5a8_D20220401-20220630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjM1OTg4NDc0ZGQ4ZDRiMjM5ZTA1OTA2NjJkMzEwMTk0L3RhYmxlcmFuZ2U6MzU5ODg0NzRkZDhkNGIyMzllMDU5MDY2MmQzMTAxOTRfMTEtMTEtMS0xLTMwNTAw_245d29c3-1ab7-48ae-b480-10cd1ab35509">2,062</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange translation adjustment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff0dfca8fc4744b889817f531d94648d_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjM1OTg4NDc0ZGQ4ZDRiMjM5ZTA1OTA2NjJkMzEwMTk0L3RhYmxlcmFuZ2U6MzU5ODg0NzRkZDhkNGIyMzllMDU5MDY2MmQzMTAxOTRfMTItNy0xLTEtMzA1MDA_29bf3549-4e95-4359-9880-be9d8cdce222">350</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8ff3b5d8c53f48e598eabdf159ffe5a8_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjM1OTg4NDc0ZGQ4ZDRiMjM5ZTA1OTA2NjJkMzEwMTk0L3RhYmxlcmFuZ2U6MzU5ODg0NzRkZDhkNGIyMzllMDU5MDY2MmQzMTAxOTRfMTItMTEtMS0xLTMwNTAw_ede385ff-b313-431e-a601-7dc017a8e40a">350</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares issued in connection with the Company's Employee stock purchase plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1888877c44594a0cbbf03d306681d074_D20220401-20220630" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjM1OTg4NDc0ZGQ4ZDRiMjM5ZTA1OTA2NjJkMzEwMTk0L3RhYmxlcmFuZ2U6MzU5ODg0NzRkZDhkNGIyMzllMDU5MDY2MmQzMTAxOTRfMTMtMS0xLTEtMzEzNDE_1e2c7369-4def-4643-8ea3-5d338648aa06">24,612</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e65e2ba034b476992065fd432154ff5_D20220401-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjM1OTg4NDc0ZGQ4ZDRiMjM5ZTA1OTA2NjJkMzEwMTk0L3RhYmxlcmFuZ2U6MzU5ODg0NzRkZDhkNGIyMzllMDU5MDY2MmQzMTAxOTRfMTMtNS0xLTEtMzEzNDE_6e153c73-2b54-4a4b-8248-6bb2cdebd4e5">130</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ff3b5d8c53f48e598eabdf159ffe5a8_D20220401-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjM1OTg4NDc0ZGQ4ZDRiMjM5ZTA1OTA2NjJkMzEwMTk0L3RhYmxlcmFuZ2U6MzU5ODg0NzRkZDhkNGIyMzllMDU5MDY2MmQzMTAxOTRfMTMtMTEtMS0xLTMxMzQx_048f8ad7-8fe1-40ba-8088-50832572856f">130</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock - at the market Sales Agreement net of issuance costs of $<ix:nonFraction unitRef="usd" contextRef="i8ff3b5d8c53f48e598eabdf159ffe5a8_D20220401-20220630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjM1OTg4NDc0ZGQ4ZDRiMjM5ZTA1OTA2NjJkMzEwMTk0L3RhYmxlcmFuZ2U6MzU5ODg0NzRkZDhkNGIyMzllMDU5MDY2MmQzMTAxOTRfMTQtMC0xLTEtMzEzNDEvdGV4dHJlZ2lvbjo0MmRmOWMzMGY0Mzk0MDBlOWQ0NDhkMTQ2NzUwOTYxMl81NDk3NTU4MTM5ODE_3bcee1ae-ba45-472b-9937-e9184be86a53">308</ix:nonFraction></span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i22a1a97b6019485d898b3ada299277d4_D20220401-20220630" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjM1OTg4NDc0ZGQ4ZDRiMjM5ZTA1OTA2NjJkMzEwMTk0L3RhYmxlcmFuZ2U6MzU5ODg0NzRkZDhkNGIyMzllMDU5MDY2MmQzMTAxOTRfMTQtMS0xLTEtMzEzNDE_3aedbcd6-25c0-4147-af69-5c866e0f3707">1,300,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0620912ded354506af6d332f0bc83206_D20220401-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjM1OTg4NDc0ZGQ4ZDRiMjM5ZTA1OTA2NjJkMzEwMTk0L3RhYmxlcmFuZ2U6MzU5ODg0NzRkZDhkNGIyMzllMDU5MDY2MmQzMTAxOTRfMTQtNS0xLTEtMzEzNDE_d3db38ae-12c2-4b08-8d94-4edc94df2ef6">9,946</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d21953862a4496690291cb9fd6c7a94_D20220401-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjM1OTg4NDc0ZGQ4ZDRiMjM5ZTA1OTA2NjJkMzEwMTk0L3RhYmxlcmFuZ2U6MzU5ODg0NzRkZDhkNGIyMzllMDU5MDY2MmQzMTAxOTRfMTQtMTEtMS0xLTMxMzQx_7ae214fa-5004-4afa-91e4-55bdda116971">9,946</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at June 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8e38d9d8fc034a00a625f8563c6b5b60_I20220630" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjM1OTg4NDc0ZGQ4ZDRiMjM5ZTA1OTA2NjJkMzEwMTk0L3RhYmxlcmFuZ2U6MzU5ODg0NzRkZDhkNGIyMzllMDU5MDY2MmQzMTAxOTRfMTMtMS0xLTEtMzA1MDA_0cb59213-f087-4e3a-ae27-cc3548acceec">30,564,995</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e38d9d8fc034a00a625f8563c6b5b60_I20220630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjM1OTg4NDc0ZGQ4ZDRiMjM5ZTA1OTA2NjJkMzEwMTk0L3RhYmxlcmFuZ2U6MzU5ODg0NzRkZDhkNGIyMzllMDU5MDY2MmQzMTAxOTRfMTMtMy0xLTEtMzA1MDA_0b1a6092-0dca-4006-8a2c-c14c9d73ccc5">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iafd4cef3856c4625a9d0b5d421a2c12c_I20220630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjM1OTg4NDc0ZGQ4ZDRiMjM5ZTA1OTA2NjJkMzEwMTk0L3RhYmxlcmFuZ2U6MzU5ODg0NzRkZDhkNGIyMzllMDU5MDY2MmQzMTAxOTRfMTMtNS0xLTEtMzA1MDA_23543736-15ab-4895-b449-efdd14a36169">368,087</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idb62eb795df54275a27ebfed4e80d684_I20220630" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjM1OTg4NDc0ZGQ4ZDRiMjM5ZTA1OTA2NjJkMzEwMTk0L3RhYmxlcmFuZ2U6MzU5ODg0NzRkZDhkNGIyMzllMDU5MDY2MmQzMTAxOTRfMTMtNy0xLTEtMzA1MDA_f0774e4f-6d2b-47b9-8d26-818eea6897c0">660</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib052a6f4a0df4d008a91d46f1ee57c9c_I20220630" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjM1OTg4NDc0ZGQ4ZDRiMjM5ZTA1OTA2NjJkMzEwMTk0L3RhYmxlcmFuZ2U6MzU5ODg0NzRkZDhkNGIyMzllMDU5MDY2MmQzMTAxOTRfMTMtOS0xLTEtMzA1MDA_d8988bc4-5e76-40e1-ae9b-214b451ae682">239,582</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1fd2b9d5dc8348c987bb258a78754f1b_I20220630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjM1OTg4NDc0ZGQ4ZDRiMjM5ZTA1OTA2NjJkMzEwMTk0L3RhYmxlcmFuZ2U6MzU5ODg0NzRkZDhkNGIyMzllMDU5MDY2MmQzMTAxOTRfMTMtMTEtMS0xLTMwNTAw_3aaf77b0-f8e2-41bf-a32f-956a85972074">127,848</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0c6bb7a44c4b41a48b75959b450bca0a_D20220701-20220930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjM1OTg4NDc0ZGQ4ZDRiMjM5ZTA1OTA2NjJkMzEwMTk0L3RhYmxlcmFuZ2U6MzU5ODg0NzRkZDhkNGIyMzllMDU5MDY2MmQzMTAxOTRfMTQtOS0xLTEtMzA1MDA_2b816646-6f7b-42b3-a1de-f1963ae8ce12">21,224</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i25a8ea2d7c9f4bfd8f72223c8ac18c65_D20220701-20220930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjM1OTg4NDc0ZGQ4ZDRiMjM5ZTA1OTA2NjJkMzEwMTk0L3RhYmxlcmFuZ2U6MzU5ODg0NzRkZDhkNGIyMzllMDU5MDY2MmQzMTAxOTRfMTQtMTEtMS0xLTMwNTAw_97d5d863-dca8-4a5a-925a-ab506ded9d2d">21,224</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2f7ecfa268042c1b6d8341deccf977e_D20220701-20220930" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjM1OTg4NDc0ZGQ4ZDRiMjM5ZTA1OTA2NjJkMzEwMTk0L3RhYmxlcmFuZ2U6MzU5ODg0NzRkZDhkNGIyMzllMDU5MDY2MmQzMTAxOTRfMTUtNS0xLTEtMzA1MDA_bd2fac42-61dc-4ee9-bc1a-23e082a7d5ca">1,912</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25a8ea2d7c9f4bfd8f72223c8ac18c65_D20220701-20220930" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjM1OTg4NDc0ZGQ4ZDRiMjM5ZTA1OTA2NjJkMzEwMTk0L3RhYmxlcmFuZ2U6MzU5ODg0NzRkZDhkNGIyMzllMDU5MDY2MmQzMTAxOTRfMTUtMTEtMS0xLTMwNTAw_dcd1d7a7-9a78-4ae7-971f-9110a7dbeb2e">1,912</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange translation adjustment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i866042db0ec3492ab88b30fc3d7eb0bf_D20220701-20220930" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjM1OTg4NDc0ZGQ4ZDRiMjM5ZTA1OTA2NjJkMzEwMTk0L3RhYmxlcmFuZ2U6MzU5ODg0NzRkZDhkNGIyMzllMDU5MDY2MmQzMTAxOTRfMTYtNy0xLTEtMzA1MDA_487eab83-ecfe-44eb-9794-e68f18288b6f">274</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25a8ea2d7c9f4bfd8f72223c8ac18c65_D20220701-20220930" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjM1OTg4NDc0ZGQ4ZDRiMjM5ZTA1OTA2NjJkMzEwMTk0L3RhYmxlcmFuZ2U6MzU5ODg0NzRkZDhkNGIyMzllMDU5MDY2MmQzMTAxOTRfMTYtMTEtMS0xLTMwNTAw_51c02a47-7181-4e49-8b00-e704412bb459">274</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at September 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5b62286d567e4f259000b5a1b4c2dbbe_I20220930" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjM1OTg4NDc0ZGQ4ZDRiMjM5ZTA1OTA2NjJkMzEwMTk0L3RhYmxlcmFuZ2U6MzU5ODg0NzRkZDhkNGIyMzllMDU5MDY2MmQzMTAxOTRfMTgtMS0xLTEtMzA1MDA_f9180108-0de1-47ba-b23d-ffc609ad219a">30,564,995</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b62286d567e4f259000b5a1b4c2dbbe_I20220930" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjM1OTg4NDc0ZGQ4ZDRiMjM5ZTA1OTA2NjJkMzEwMTk0L3RhYmxlcmFuZ2U6MzU5ODg0NzRkZDhkNGIyMzllMDU5MDY2MmQzMTAxOTRfMTgtMy0xLTEtMzA1MDA_e44bbd74-acc6-496a-a9e0-0f7e70f05423">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b90293a84aa4674a7bcf0617b17717e_I20220930" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjM1OTg4NDc0ZGQ4ZDRiMjM5ZTA1OTA2NjJkMzEwMTk0L3RhYmxlcmFuZ2U6MzU5ODg0NzRkZDhkNGIyMzllMDU5MDY2MmQzMTAxOTRfMTgtNS0xLTEtMzA1MDA_e10b279b-78a5-4191-8532-0dac32281663">369,999</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icbddd86c41c74f1ea8d5a18c99ee0215_I20220930" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjM1OTg4NDc0ZGQ4ZDRiMjM5ZTA1OTA2NjJkMzEwMTk0L3RhYmxlcmFuZ2U6MzU5ODg0NzRkZDhkNGIyMzllMDU5MDY2MmQzMTAxOTRfMTgtNy0xLTEtMzA1MDA_82bd8f93-fb07-4807-a8dc-c1ca08d1f779">386</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i854438f7be7f47f196c8a2c22e9b5e77_I20220930" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjM1OTg4NDc0ZGQ4ZDRiMjM5ZTA1OTA2NjJkMzEwMTk0L3RhYmxlcmFuZ2U6MzU5ODg0NzRkZDhkNGIyMzllMDU5MDY2MmQzMTAxOTRfMTgtOS0xLTEtMzA1MDA_a1208d53-9c9a-456a-ad50-32f597882e65">260,806</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2ba0b84078f4de2bc3079e992921b92_I20220930" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjM1OTg4NDc0ZGQ4ZDRiMjM5ZTA1OTA2NjJkMzEwMTk0L3RhYmxlcmFuZ2U6MzU5ODg0NzRkZDhkNGIyMzllMDU5MDY2MmQzMTAxOTRfMTgtMTEtMS0xLTMwNTAw_099f64ad-a38e-4455-b773-ea8bd290b902">108,810</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="height:36.72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36.72pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.920%"><tr><td style="width:1.0%"></td><td style="width:42.950%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.690%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.508%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.832%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.508%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.407%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.508%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.956%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.508%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.540%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.791%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.102%"></td><td style="width:0.1%"></td></tr><tr><td colspan="36" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2021</span></td></tr><tr style="height:21pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Additional<br/>Paid-In<br/>Capital</span></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Income (Loss)</span></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Stockholders&#8217;<br/>Equity</span></td></tr><tr style="height:21pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at January 1, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i607bec8e45eb4e6d838d65f04d1d719f_I20201231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjY2NzM1ZjJmYmQ2YTQyNWJhOTQxMjljMDA3N2FiNjljL3RhYmxlcmFuZ2U6NjY3MzVmMmZiZDZhNDI1YmE5NDEyOWMwMDc3YWI2OWNfMy0xLTEtMS0zMDUwMA_0e3cba6d-b0db-43eb-8a8d-aba7285e4360">21,168,240</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i607bec8e45eb4e6d838d65f04d1d719f_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjY2NzM1ZjJmYmQ2YTQyNWJhOTQxMjljMDA3N2FiNjljL3RhYmxlcmFuZ2U6NjY3MzVmMmZiZDZhNDI1YmE5NDEyOWMwMDc3YWI2OWNfMy0zLTEtMS0zMDUwMA_0a248566-95b5-4286-a420-f300b0652383">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if567f5fc4bef457ba7f7d0fa94a8a6ef_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjY2NzM1ZjJmYmQ2YTQyNWJhOTQxMjljMDA3N2FiNjljL3RhYmxlcmFuZ2U6NjY3MzVmMmZiZDZhNDI1YmE5NDEyOWMwMDc3YWI2OWNfMy01LTEtMS0zMDUwMA_7d51b44a-9cce-4fc6-8770-fe9e7ad71f22">266,823</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iea3035acf49d4db7a54e9ead049bc20b_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjY2NzM1ZjJmYmQ2YTQyNWJhOTQxMjljMDA3N2FiNjljL3RhYmxlcmFuZ2U6NjY3MzVmMmZiZDZhNDI1YmE5NDEyOWMwMDc3YWI2OWNfMy03LTEtMS0zMDUwMA_006ab16f-7f56-489e-844a-6613b8c3089a">4,112</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i77530ee1861747fda1f023dbac2a8d90_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjY2NzM1ZjJmYmQ2YTQyNWJhOTQxMjljMDA3N2FiNjljL3RhYmxlcmFuZ2U6NjY3MzVmMmZiZDZhNDI1YmE5NDEyOWMwMDc3YWI2OWNfMy05LTEtMS0zMDUwMA_9dd57d3f-0034-4806-9b81-a38dc6738b79">103,928</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8e90b6ab1f24717b294f892b4a059b4_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjY2NzM1ZjJmYmQ2YTQyNWJhOTQxMjljMDA3N2FiNjljL3RhYmxlcmFuZ2U6NjY3MzVmMmZiZDZhNDI1YmE5NDEyOWMwMDc3YWI2OWNfMy0xMS0xLTEtMzA1MDA_688674a1-c037-4645-bcac-e2ef0a4743da">158,785</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i26792f62773c456c934cf59dcefb4260_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjY2NzM1ZjJmYmQ2YTQyNWJhOTQxMjljMDA3N2FiNjljL3RhYmxlcmFuZ2U6NjY3MzVmMmZiZDZhNDI1YmE5NDEyOWMwMDc3YWI2OWNfNC05LTEtMS0zMDUwMA_1c01c331-71ee-4bf6-9c02-4fe0a6834137">34,534</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7eb4374d1ee742ffa761b98e61b09caf_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjY2NzM1ZjJmYmQ2YTQyNWJhOTQxMjljMDA3N2FiNjljL3RhYmxlcmFuZ2U6NjY3MzVmMmZiZDZhNDI1YmE5NDEyOWMwMDc3YWI2OWNfNC0xMS0xLTEtMzA1MDA_c9daf492-9ffc-41d8-bc6c-b0b77fc2a6e7">34,534</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie46dbf54043c469594e16cf8b3942872_D20210101-20210331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjY2NzM1ZjJmYmQ2YTQyNWJhOTQxMjljMDA3N2FiNjljL3RhYmxlcmFuZ2U6NjY3MzVmMmZiZDZhNDI1YmE5NDEyOWMwMDc3YWI2OWNfNS01LTEtMS0zMDUwMA_ddb3063a-77cd-4f8f-b746-9cd19690f622">1,579</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7eb4374d1ee742ffa761b98e61b09caf_D20210101-20210331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjY2NzM1ZjJmYmQ2YTQyNWJhOTQxMjljMDA3N2FiNjljL3RhYmxlcmFuZ2U6NjY3MzVmMmZiZDZhNDI1YmE5NDEyOWMwMDc3YWI2OWNfNS0xMS0xLTEtMzA1MDA_7ed6bc95-72f9-4c0e-98c8-251d3414c43b">1,579</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange translation adjustment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26d6ec96c4a24603b58ef52fcbe09dbe_D20210101-20210331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjY2NzM1ZjJmYmQ2YTQyNWJhOTQxMjljMDA3N2FiNjljL3RhYmxlcmFuZ2U6NjY3MzVmMmZiZDZhNDI1YmE5NDEyOWMwMDc3YWI2OWNfNi03LTEtMS0zMDUwMA_7d374309-a9fb-4b6b-a8d5-073836f029d0">2,991</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7eb4374d1ee742ffa761b98e61b09caf_D20210101-20210331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjY2NzM1ZjJmYmQ2YTQyNWJhOTQxMjljMDA3N2FiNjljL3RhYmxlcmFuZ2U6NjY3MzVmMmZiZDZhNDI1YmE5NDEyOWMwMDc3YWI2OWNfNi0xMS0xLTEtMzA1MDA_5a579f1e-220e-461b-89e7-b4ff99c73a2c">2,991</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock in connection with the 4SC royalty settlement (see Note 4)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iff342baa477241189847103920c9390b_D20210401-20210630" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjY2NzM1ZjJmYmQ2YTQyNWJhOTQxMjljMDA3N2FiNjljL3RhYmxlcmFuZ2U6NjY3MzVmMmZiZDZhNDI1YmE5NDEyOWMwMDc3YWI2OWNfNy0xLTEtMS0zMTIyMg_efc40351-3af0-4574-ac08-5b766b2974a5">581,199</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79dafe91dc2b4583bc7281b9ac581921_D20210401-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjY2NzM1ZjJmYmQ2YTQyNWJhOTQxMjljMDA3N2FiNjljL3RhYmxlcmFuZ2U6NjY3MzVmMmZiZDZhNDI1YmE5NDEyOWMwMDc3YWI2OWNfNy01LTEtMS0zMTIyMg_dee0f55d-a201-4535-9fdb-c9eefd38e9b1">8,625</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47c50e6a28d840f58afe00251ea7cb63_D20210401-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjY2NzM1ZjJmYmQ2YTQyNWJhOTQxMjljMDA3N2FiNjljL3RhYmxlcmFuZ2U6NjY3MzVmMmZiZDZhNDI1YmE5NDEyOWMwMDc3YWI2OWNfNy0xMS0xLTEtMzEyMjI_29f1bded-de68-43c8-b9fa-a7004908055f">8,625</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at March 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic1b52eb993194bc79abd0bdb3ac2fb16_I20210331" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjY2NzM1ZjJmYmQ2YTQyNWJhOTQxMjljMDA3N2FiNjljL3RhYmxlcmFuZ2U6NjY3MzVmMmZiZDZhNDI1YmE5NDEyOWMwMDc3YWI2OWNfOC0xLTEtMS0zMDUwMA_14f132a9-1526-4423-bbca-37afc57bb2df">21,749,439</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1b52eb993194bc79abd0bdb3ac2fb16_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjY2NzM1ZjJmYmQ2YTQyNWJhOTQxMjljMDA3N2FiNjljL3RhYmxlcmFuZ2U6NjY3MzVmMmZiZDZhNDI1YmE5NDEyOWMwMDc3YWI2OWNfOC0zLTEtMS0zMDUwMA_3f9ccfea-40b3-4869-854a-ea20acc9c612">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e4e96801dd14e038268468354ac544d_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjY2NzM1ZjJmYmQ2YTQyNWJhOTQxMjljMDA3N2FiNjljL3RhYmxlcmFuZ2U6NjY3MzVmMmZiZDZhNDI1YmE5NDEyOWMwMDc3YWI2OWNfOC01LTEtMS0zMDUwMA_880ecadb-3a11-4acd-a0cb-6686ea5a3898">277,027</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i36785e9a44f44fa498d7a9e39d281de6_I20210331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjY2NzM1ZjJmYmQ2YTQyNWJhOTQxMjljMDA3N2FiNjljL3RhYmxlcmFuZ2U6NjY3MzVmMmZiZDZhNDI1YmE5NDEyOWMwMDc3YWI2OWNfOC03LTEtMS0zMDUwMA_10c63d8e-144f-43a3-b6af-b48a3b479ce2">1,121</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id8c73d5dc8b3435d90082da759d26561_I20210331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjY2NzM1ZjJmYmQ2YTQyNWJhOTQxMjljMDA3N2FiNjljL3RhYmxlcmFuZ2U6NjY3MzVmMmZiZDZhNDI1YmE5NDEyOWMwMDc3YWI2OWNfOC05LTEtMS0zMDUwMA_8629e835-fca7-4f37-bb94-e872f4c425c3">138,462</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie158d385723a4b6c94e8384571358a19_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjY2NzM1ZjJmYmQ2YTQyNWJhOTQxMjljMDA3N2FiNjljL3RhYmxlcmFuZ2U6NjY3MzVmMmZiZDZhNDI1YmE5NDEyOWMwMDc3YWI2OWNfOC0xMS0xLTEtMzA1MDA_3b581627-cf3b-42da-8c0b-39268b900ecf">137,446</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iec8caa356ace43cea23a50885d4ce99a_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjY2NzM1ZjJmYmQ2YTQyNWJhOTQxMjljMDA3N2FiNjljL3RhYmxlcmFuZ2U6NjY3MzVmMmZiZDZhNDI1YmE5NDEyOWMwMDc3YWI2OWNfOS05LTEtMS0zMDUwMA_29b8e8f2-fc20-4361-8d2b-e4556359f64a">17,934</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idbd4b40aa73a4833999ce49448a575c1_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjY2NzM1ZjJmYmQ2YTQyNWJhOTQxMjljMDA3N2FiNjljL3RhYmxlcmFuZ2U6NjY3MzVmMmZiZDZhNDI1YmE5NDEyOWMwMDc3YWI2OWNfOS0xMS0xLTEtMzA1MDA_dbcf73c9-dea3-4a62-a92d-0ec04d4a9923">17,934</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i727b0a04077a4a8f8ed3d895673d106c_D20210401-20210630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjY2NzM1ZjJmYmQ2YTQyNWJhOTQxMjljMDA3N2FiNjljL3RhYmxlcmFuZ2U6NjY3MzVmMmZiZDZhNDI1YmE5NDEyOWMwMDc3YWI2OWNfMTAtNS0xLTEtMzA1MDA_25eb00a1-ead1-463e-90e0-e2336f8faf15">1,507</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbd4b40aa73a4833999ce49448a575c1_D20210401-20210630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjY2NzM1ZjJmYmQ2YTQyNWJhOTQxMjljMDA3N2FiNjljL3RhYmxlcmFuZ2U6NjY3MzVmMmZiZDZhNDI1YmE5NDEyOWMwMDc3YWI2OWNfMTAtMTEtMS0xLTMwNTAw_0445f739-2a29-44e0-b64d-6d81950784bc">1,507</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange translation adjustment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4fcf02a24eb5413182bd309637981b5f_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjY2NzM1ZjJmYmQ2YTQyNWJhOTQxMjljMDA3N2FiNjljL3RhYmxlcmFuZ2U6NjY3MzVmMmZiZDZhNDI1YmE5NDEyOWMwMDc3YWI2OWNfMTEtNy0xLTEtMzA1MDA_a913b567-22f1-440c-8003-409e2bee76cf">277</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idbd4b40aa73a4833999ce49448a575c1_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjY2NzM1ZjJmYmQ2YTQyNWJhOTQxMjljMDA3N2FiNjljL3RhYmxlcmFuZ2U6NjY3MzVmMmZiZDZhNDI1YmE5NDEyOWMwMDc3YWI2OWNfMTEtMTEtMS0xLTMwNTAw_24a96e05-7f55-40c3-8e5d-2c333f888caa">277</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at June 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3be90c8090ab461c8c2b38fd4278056a_I20210630" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjY2NzM1ZjJmYmQ2YTQyNWJhOTQxMjljMDA3N2FiNjljL3RhYmxlcmFuZ2U6NjY3MzVmMmZiZDZhNDI1YmE5NDEyOWMwMDc3YWI2OWNfMTUtMS0xLTEtMzA1MDA_56604dcf-aced-43ed-b38d-953a892739b3">21,749,439</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3be90c8090ab461c8c2b38fd4278056a_I20210630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjY2NzM1ZjJmYmQ2YTQyNWJhOTQxMjljMDA3N2FiNjljL3RhYmxlcmFuZ2U6NjY3MzVmMmZiZDZhNDI1YmE5NDEyOWMwMDc3YWI2OWNfMTUtMy0xLTEtMzA1MDA_c001f595-459b-42f7-87c2-a84fa1a34248">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia452dd2fae424bb3853dcf4cf9a6a5f7_I20210630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjY2NzM1ZjJmYmQ2YTQyNWJhOTQxMjljMDA3N2FiNjljL3RhYmxlcmFuZ2U6NjY3MzVmMmZiZDZhNDI1YmE5NDEyOWMwMDc3YWI2OWNfMTUtNS0xLTEtMzA1MDA_b3fa30ca-0747-4f1b-b9b1-dab450afb525">278,534</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3af9d520bc33490fb02d4e0e45e64528_I20210630" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjY2NzM1ZjJmYmQ2YTQyNWJhOTQxMjljMDA3N2FiNjljL3RhYmxlcmFuZ2U6NjY3MzVmMmZiZDZhNDI1YmE5NDEyOWMwMDc3YWI2OWNfMTUtNy0xLTEtMzA1MDA_612cf3f2-a01a-4fa0-b4d2-c0e8cfe4d1c8">1,398</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7cf65f44be454209a8ed367a2d506669_I20210630" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjY2NzM1ZjJmYmQ2YTQyNWJhOTQxMjljMDA3N2FiNjljL3RhYmxlcmFuZ2U6NjY3MzVmMmZiZDZhNDI1YmE5NDEyOWMwMDc3YWI2OWNfMTUtOS0xLTEtMzA1MDA_1e7d93a5-72b5-49bf-91a3-9a1ff196f573">156,396</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i016c5728112e4750b50b637d6c871fe3_I20210630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjY2NzM1ZjJmYmQ2YTQyNWJhOTQxMjljMDA3N2FiNjljL3RhYmxlcmFuZ2U6NjY3MzVmMmZiZDZhNDI1YmE5NDEyOWMwMDc3YWI2OWNfMTUtMTEtMS0xLTMwNTAw_eba91e4f-d7f7-44e3-9e2f-e3f5c094993e">120,742</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i72dd476a4160417bb81e51d19d04fec4_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjY2NzM1ZjJmYmQ2YTQyNWJhOTQxMjljMDA3N2FiNjljL3RhYmxlcmFuZ2U6NjY3MzVmMmZiZDZhNDI1YmE5NDEyOWMwMDc3YWI2OWNfMTYtOS0xLTEtMzA1MDA_fe8a2af5-7ebb-4ad3-bb53-a702b3e0f770">19,292</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib52579de36d54242a791b9e3f8019a00_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjY2NzM1ZjJmYmQ2YTQyNWJhOTQxMjljMDA3N2FiNjljL3RhYmxlcmFuZ2U6NjY3MzVmMmZiZDZhNDI1YmE5NDEyOWMwMDc3YWI2OWNfMTYtMTEtMS0xLTMwNTAw_0d30cd09-7335-4789-929b-c45197d3cca8">19,292</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39aae3cf38724522a40a6fc4e3254d97_D20210701-20210930" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjY2NzM1ZjJmYmQ2YTQyNWJhOTQxMjljMDA3N2FiNjljL3RhYmxlcmFuZ2U6NjY3MzVmMmZiZDZhNDI1YmE5NDEyOWMwMDc3YWI2OWNfMTctNS0xLTEtMzA1MDA_094927ba-f4c7-4717-835e-09c41d5db76b">1,397</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib52579de36d54242a791b9e3f8019a00_D20210701-20210930" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjY2NzM1ZjJmYmQ2YTQyNWJhOTQxMjljMDA3N2FiNjljL3RhYmxlcmFuZ2U6NjY3MzVmMmZiZDZhNDI1YmE5NDEyOWMwMDc3YWI2OWNfMTctMTEtMS0xLTMwNTAw_b72481f4-6537-4c7a-a943-8103002e5959">1,397</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange translation adjustment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8f986adcd0d4adb96a54c85ecec772d_D20210701-20210930" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjY2NzM1ZjJmYmQ2YTQyNWJhOTQxMjljMDA3N2FiNjljL3RhYmxlcmFuZ2U6NjY3MzVmMmZiZDZhNDI1YmE5NDEyOWMwMDc3YWI2OWNfMTgtNy0xLTEtMzA1MDA_ad6b4048-e465-4df9-af23-92b90e1c1c9e">598</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib52579de36d54242a791b9e3f8019a00_D20210701-20210930" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjY2NzM1ZjJmYmQ2YTQyNWJhOTQxMjljMDA3N2FiNjljL3RhYmxlcmFuZ2U6NjY3MzVmMmZiZDZhNDI1YmE5NDEyOWMwMDc3YWI2OWNfMTgtMTEtMS0xLTMwNTAw_9e132896-9e41-4b1c-b538-5fcc7bd3d6f4">598</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock - July 2021 equity offering net of issuance costs of $2,980</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i75df6ae240184d6cbec2048c440c2cfd_D20210701-20210930" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjY2NzM1ZjJmYmQ2YTQyNWJhOTQxMjljMDA3N2FiNjljL3RhYmxlcmFuZ2U6NjY3MzVmMmZiZDZhNDI1YmE5NDEyOWMwMDc3YWI2OWNfMTktMS0xLTEtMzA1MDA_735bf044-89ce-4fdd-852c-dfee6c7b11b0">4,500,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75df6ae240184d6cbec2048c440c2cfd_D20210701-20210930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjY2NzM1ZjJmYmQ2YTQyNWJhOTQxMjljMDA3N2FiNjljL3RhYmxlcmFuZ2U6NjY3MzVmMmZiZDZhNDI1YmE5NDEyOWMwMDc3YWI2OWNfMTktMy0xLTEtMzA1MDA_38910698-dc16-4bc6-9018-f3c74a3c17e9">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5876ecf1449d4c42a057445d55680cd9_D20210701-20210930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjY2NzM1ZjJmYmQ2YTQyNWJhOTQxMjljMDA3N2FiNjljL3RhYmxlcmFuZ2U6NjY3MzVmMmZiZDZhNDI1YmE5NDEyOWMwMDc3YWI2OWNfMTktNS0xLTEtMzA1MDA_19b2785a-61e6-44cb-9a98-434ec650ec84">42,019</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c0c6c63355f4b9f94038593d420a3b7_D20210701-20210930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjY2NzM1ZjJmYmQ2YTQyNWJhOTQxMjljMDA3N2FiNjljL3RhYmxlcmFuZ2U6NjY3MzVmMmZiZDZhNDI1YmE5NDEyOWMwMDc3YWI2OWNfMTktMTEtMS0xLTMwNTAw_12bdf5ab-a19c-41dc-ab6a-426648057697">42,020</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at September 30, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8803b9920af74191be48fe8d2de93d42_I20210930" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjY2NzM1ZjJmYmQ2YTQyNWJhOTQxMjljMDA3N2FiNjljL3RhYmxlcmFuZ2U6NjY3MzVmMmZiZDZhNDI1YmE5NDEyOWMwMDc3YWI2OWNfMjAtMS0xLTEtMzA1MDA_ad09559f-ca84-4660-b8a0-8dba9ceaaab4">26,249,439</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8803b9920af74191be48fe8d2de93d42_I20210930" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjY2NzM1ZjJmYmQ2YTQyNWJhOTQxMjljMDA3N2FiNjljL3RhYmxlcmFuZ2U6NjY3MzVmMmZiZDZhNDI1YmE5NDEyOWMwMDc3YWI2OWNfMjAtMy0xLTEtMzA1MDA_47eac112-5eb1-49a1-b949-5bbb0f36dd19">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic6c0192051924752911d006055eb26b5_I20210930" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjY2NzM1ZjJmYmQ2YTQyNWJhOTQxMjljMDA3N2FiNjljL3RhYmxlcmFuZ2U6NjY3MzVmMmZiZDZhNDI1YmE5NDEyOWMwMDc3YWI2OWNfMjAtNS0xLTEtMzA1MDA_9b343787-82af-4d76-b73d-aa57732bb94a">321,950</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i53b949b08f1f4426aa11fcca407bc625_I20210930" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjY2NzM1ZjJmYmQ2YTQyNWJhOTQxMjljMDA3N2FiNjljL3RhYmxlcmFuZ2U6NjY3MzVmMmZiZDZhNDI1YmE5NDEyOWMwMDc3YWI2OWNfMjAtNy0xLTEtMzA1MDA_15397a89-0a1f-4d1d-ad52-715a43dc0aca">800</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib7a3b6923515465ba7ed8a9c9f8c50a2_I20210930" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjY2NzM1ZjJmYmQ2YTQyNWJhOTQxMjljMDA3N2FiNjljL3RhYmxlcmFuZ2U6NjY3MzVmMmZiZDZhNDI1YmE5NDEyOWMwMDc3YWI2OWNfMjAtOS0xLTEtMzA1MDA_373946ca-de3a-486f-b393-b018a5dc1d44">175,688</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c5dd6f726174024bdc176efa6738fd9_I20210930" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjY2NzM1ZjJmYmQ2YTQyNWJhOTQxMjljMDA3N2FiNjljL3RhYmxlcmFuZ2U6NjY3MzVmMmZiZDZhNDI1YmE5NDEyOWMwMDc3YWI2OWNfMjAtMTEtMS0xLTMwNTAw_3058ceaa-5d84-4109-b72e-8caabd1f8fd7">145,465</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="text-align:center;text-indent:36pt"><span><br/></span></div><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="height:36.72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><div id="ida7c333e3c58430eb83e8e950c50d811_25"></div><hr style="page-break-after:always"/><div style="min-height:27.36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">IMMUNIC, INC.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Cash Flows</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In&#160;thousands)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.622%"><tr><td style="width:1.0%"></td><td style="width:79.521%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.219%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.221%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months<br/>&#160;Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from operating activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8yNS9mcmFnOjVhMzRmMjNmOTE1YzQzMzI5YTc3YjI2MDc3YTk5MWJjL3RhYmxlOjBlNTMzMzJkM2YzNjRmY2I5YjQ1OGIyYWFmZmYwNWY5L3RhYmxlcmFuZ2U6MGU1MzMzMmQzZjM2NGZjYjliNDU4YjJhYWZmZjA1ZjlfMy0xLTEtMS0zMDUwMA_5fe1b7ec-985e-4839-827f-9ddda6552a19">63,933</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i69e8bcaae5bf44c9a03cf7f5bd08e6b8_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8yNS9mcmFnOjVhMzRmMjNmOTE1YzQzMzI5YTc3YjI2MDc3YTk5MWJjL3RhYmxlOjBlNTMzMzJkM2YzNjRmY2I5YjQ1OGIyYWFmZmYwNWY5L3RhYmxlcmFuZ2U6MGU1MzMzMmQzZjM2NGZjYjliNDU4YjJhYWZmZjA1ZjlfMy0zLTEtMS0zMDUwMA_ee6a5aed-76d1-49ac-b4f1-ec6e6c36d5ee">71,760</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8yNS9mcmFnOjVhMzRmMjNmOTE1YzQzMzI5YTc3YjI2MDc3YTk5MWJjL3RhYmxlOjBlNTMzMzJkM2YzNjRmY2I5YjQ1OGIyYWFmZmYwNWY5L3RhYmxlcmFuZ2U6MGU1MzMzMmQzZjM2NGZjYjliNDU4YjJhYWZmZjA1ZjlfNS0xLTEtMS0zMDUwMA_9e90db6e-9400-4bef-9fc8-e39a520b133c">58</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69e8bcaae5bf44c9a03cf7f5bd08e6b8_D20210101-20210930" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8yNS9mcmFnOjVhMzRmMjNmOTE1YzQzMzI5YTc3YjI2MDc3YTk5MWJjL3RhYmxlOjBlNTMzMzJkM2YzNjRmY2I5YjQ1OGIyYWFmZmYwNWY5L3RhYmxlcmFuZ2U6MGU1MzMzMmQzZjM2NGZjYjliNDU4YjJhYWZmZjA1ZjlfNS0zLTEtMS0zMDUwMA_a542e721-e995-4cc1-b3c8-71cb3a4711d5">45</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized foreign currency loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossUnrealized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8yNS9mcmFnOjVhMzRmMjNmOTE1YzQzMzI5YTc3YjI2MDc3YTk5MWJjL3RhYmxlOjBlNTMzMzJkM2YzNjRmY2I5YjQ1OGIyYWFmZmYwNWY5L3RhYmxlcmFuZ2U6MGU1MzMzMmQzZjM2NGZjYjliNDU4YjJhYWZmZjA1ZjlfNi0xLTEtMS0zMDUwMA_8e4a2675-83ac-4386-a18a-a5dd4c513ce5">4,217</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69e8bcaae5bf44c9a03cf7f5bd08e6b8_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossUnrealized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8yNS9mcmFnOjVhMzRmMjNmOTE1YzQzMzI5YTc3YjI2MDc3YTk5MWJjL3RhYmxlOjBlNTMzMzJkM2YzNjRmY2I5YjQ1OGIyYWFmZmYwNWY5L3RhYmxlcmFuZ2U6MGU1MzMzMmQzZjM2NGZjYjliNDU4YjJhYWZmZjA1ZjlfNi0zLTEtMS0zMDUwMA_dc7733c0-826c-4794-9d57-6eaa9243f02b">3,202</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8yNS9mcmFnOjVhMzRmMjNmOTE1YzQzMzI5YTc3YjI2MDc3YTk5MWJjL3RhYmxlOjBlNTMzMzJkM2YzNjRmY2I5YjQ1OGIyYWFmZmYwNWY5L3RhYmxlcmFuZ2U6MGU1MzMzMmQzZjM2NGZjYjliNDU4YjJhYWZmZjA1ZjlfOC0xLTEtMS0zMDUwMA_70fbc184-fb0f-4252-845c-b6e9630fbe3b">6,043</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69e8bcaae5bf44c9a03cf7f5bd08e6b8_D20210101-20210930" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8yNS9mcmFnOjVhMzRmMjNmOTE1YzQzMzI5YTc3YjI2MDc3YTk5MWJjL3RhYmxlOjBlNTMzMzJkM2YzNjRmY2I5YjQ1OGIyYWFmZmYwNWY5L3RhYmxlcmFuZ2U6MGU1MzMzMmQzZjM2NGZjYjliNDU4YjJhYWZmZjA1ZjlfOC0zLTEtMS0zMDUwMA_4d20290c-101d-4be4-ae2b-d15c797fdc5e">4,483</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common Stock issued in connection with the 4SC royalty settlement (see Note 4)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930" decimals="-3" name="us-gaap:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8yNS9mcmFnOjVhMzRmMjNmOTE1YzQzMzI5YTc3YjI2MDc3YTk5MWJjL3RhYmxlOjBlNTMzMzJkM2YzNjRmY2I5YjQ1OGIyYWFmZmYwNWY5L3RhYmxlcmFuZ2U6MGU1MzMzMmQzZjM2NGZjYjliNDU4YjJhYWZmZjA1ZjlfOS0xLTEtMS0zMDUwMA_875d6184-dbca-4a30-9191-49f9d2516ae8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69e8bcaae5bf44c9a03cf7f5bd08e6b8_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8yNS9mcmFnOjVhMzRmMjNmOTE1YzQzMzI5YTc3YjI2MDc3YTk5MWJjL3RhYmxlOjBlNTMzMzJkM2YzNjRmY2I5YjQ1OGIyYWFmZmYwNWY5L3RhYmxlcmFuZ2U6MGU1MzMzMmQzZjM2NGZjYjliNDU4YjJhYWZmZjA1ZjlfOS0zLTEtMS0zMDUwMA_a72a46cb-69d2-48cb-add6-a997ad09c468">8,625</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets and prepaid expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8yNS9mcmFnOjVhMzRmMjNmOTE1YzQzMzI5YTc3YjI2MDc3YTk5MWJjL3RhYmxlOjBlNTMzMzJkM2YzNjRmY2I5YjQ1OGIyYWFmZmYwNWY5L3RhYmxlcmFuZ2U6MGU1MzMzMmQzZjM2NGZjYjliNDU4YjJhYWZmZjA1ZjlfMTEtMS0xLTEtMzA1MDA_140ed609-4b45-4c5a-b536-2706162c9c82">2,061</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i69e8bcaae5bf44c9a03cf7f5bd08e6b8_D20210101-20210930" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8yNS9mcmFnOjVhMzRmMjNmOTE1YzQzMzI5YTc3YjI2MDc3YTk5MWJjL3RhYmxlOjBlNTMzMzJkM2YzNjRmY2I5YjQ1OGIyYWFmZmYwNWY5L3RhYmxlcmFuZ2U6MGU1MzMzMmQzZjM2NGZjYjliNDU4YjJhYWZmZjA1ZjlfMTEtMy0xLTEtMzA1MDA_9a6a9377-c040-44b5-a1e6-cb77e140ad03">6,305</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8yNS9mcmFnOjVhMzRmMjNmOTE1YzQzMzI5YTc3YjI2MDc3YTk5MWJjL3RhYmxlOjBlNTMzMzJkM2YzNjRmY2I5YjQ1OGIyYWFmZmYwNWY5L3RhYmxlcmFuZ2U6MGU1MzMzMmQzZjM2NGZjYjliNDU4YjJhYWZmZjA1ZjlfMTItMS0xLTEtMzA1MDA_802953a7-ee13-4603-9568-c1b53a4d98a1">1,151</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i69e8bcaae5bf44c9a03cf7f5bd08e6b8_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8yNS9mcmFnOjVhMzRmMjNmOTE1YzQzMzI5YTc3YjI2MDc3YTk5MWJjL3RhYmxlOjBlNTMzMzJkM2YzNjRmY2I5YjQ1OGIyYWFmZmYwNWY5L3RhYmxlcmFuZ2U6MGU1MzMzMmQzZjM2NGZjYjliNDU4YjJhYWZmZjA1ZjlfMTItMy0xLTEtMzA1MDA_42448723-8d76-4487-a4b1-0c2eb5daf5eb">261</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherCurrentLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8yNS9mcmFnOjVhMzRmMjNmOTE1YzQzMzI5YTc3YjI2MDc3YTk5MWJjL3RhYmxlOjBlNTMzMzJkM2YzNjRmY2I5YjQ1OGIyYWFmZmYwNWY5L3RhYmxlcmFuZ2U6MGU1MzMzMmQzZjM2NGZjYjliNDU4YjJhYWZmZjA1ZjlfMTMtMS0xLTEtMzA1MDA_e03294f0-f203-467d-9cf2-43d530068a20">465</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69e8bcaae5bf44c9a03cf7f5bd08e6b8_D20210101-20210930" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherCurrentLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8yNS9mcmFnOjVhMzRmMjNmOTE1YzQzMzI5YTc3YjI2MDc3YTk5MWJjL3RhYmxlOjBlNTMzMzJkM2YzNjRmY2I5YjQ1OGIyYWFmZmYwNWY5L3RhYmxlcmFuZ2U6MGU1MzMzMmQzZjM2NGZjYjliNDU4YjJhYWZmZjA1ZjlfMTMtMy0xLTEtMzA1MDA_8dac7dc8-8c9f-4b0a-8814-8b554692b046">2,760</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8yNS9mcmFnOjVhMzRmMjNmOTE1YzQzMzI5YTc3YjI2MDc3YTk5MWJjL3RhYmxlOjBlNTMzMzJkM2YzNjRmY2I5YjQ1OGIyYWFmZmYwNWY5L3RhYmxlcmFuZ2U6MGU1MzMzMmQzZjM2NGZjYjliNDU4YjJhYWZmZjA1ZjlfMTQtMS0xLTEtMzA1MDA_b7cdc444-83b8-4bad-8663-24afd0a38699">102</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i69e8bcaae5bf44c9a03cf7f5bd08e6b8_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8yNS9mcmFnOjVhMzRmMjNmOTE1YzQzMzI5YTc3YjI2MDc3YTk5MWJjL3RhYmxlOjBlNTMzMzJkM2YzNjRmY2I5YjQ1OGIyYWFmZmYwNWY5L3RhYmxlcmFuZ2U6MGU1MzMzMmQzZjM2NGZjYjliNDU4YjJhYWZmZjA1ZjlfMTQtMy0xLTEtMzA1MDA_448aed0c-1077-4630-a73b-6fa295efa1b5">341</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 61.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8yNS9mcmFnOjVhMzRmMjNmOTE1YzQzMzI5YTc3YjI2MDc3YTk5MWJjL3RhYmxlOjBlNTMzMzJkM2YzNjRmY2I5YjQ1OGIyYWFmZmYwNWY5L3RhYmxlcmFuZ2U6MGU1MzMzMmQzZjM2NGZjYjliNDU4YjJhYWZmZjA1ZjlfMTUtMS0xLTEtMzA1MDA_5dcb7ea1-5b49-4098-8027-c1088cc09aa6">50,040</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i69e8bcaae5bf44c9a03cf7f5bd08e6b8_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8yNS9mcmFnOjVhMzRmMjNmOTE1YzQzMzI5YTc3YjI2MDc3YTk5MWJjL3RhYmxlOjBlNTMzMzJkM2YzNjRmY2I5YjQ1OGIyYWFmZmYwNWY5L3RhYmxlcmFuZ2U6MGU1MzMzMmQzZjM2NGZjYjliNDU4YjJhYWZmZjA1ZjlfMTUtMy0xLTEtMzA1MDA_77deac30-b13f-4007-853f-86221d3d4913">59,552</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8yNS9mcmFnOjVhMzRmMjNmOTE1YzQzMzI5YTc3YjI2MDc3YTk5MWJjL3RhYmxlOjBlNTMzMzJkM2YzNjRmY2I5YjQ1OGIyYWFmZmYwNWY5L3RhYmxlcmFuZ2U6MGU1MzMzMmQzZjM2NGZjYjliNDU4YjJhYWZmZjA1ZjlfMjAtMS0xLTEtMzA1MDA_29599090-d3ff-4a5c-b9fa-a1a506b1a5c9">113</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i69e8bcaae5bf44c9a03cf7f5bd08e6b8_D20210101-20210930" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8yNS9mcmFnOjVhMzRmMjNmOTE1YzQzMzI5YTc3YjI2MDc3YTk5MWJjL3RhYmxlOjBlNTMzMzJkM2YzNjRmY2I5YjQ1OGIyYWFmZmYwNWY5L3RhYmxlcmFuZ2U6MGU1MzMzMmQzZjM2NGZjYjliNDU4YjJhYWZmZjA1ZjlfMjAtMy0xLTEtMzA1MDA_f8999838-b149-4f68-b17d-29c6f1171b6f">48</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 61.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8yNS9mcmFnOjVhMzRmMjNmOTE1YzQzMzI5YTc3YjI2MDc3YTk5MWJjL3RhYmxlOjBlNTMzMzJkM2YzNjRmY2I5YjQ1OGIyYWFmZmYwNWY5L3RhYmxlcmFuZ2U6MGU1MzMzMmQzZjM2NGZjYjliNDU4YjJhYWZmZjA1ZjlfMjItMS0xLTEtMzA1MDA_b6fe01c3-32c1-466a-98a7-9b27d807316a">113</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i69e8bcaae5bf44c9a03cf7f5bd08e6b8_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8yNS9mcmFnOjVhMzRmMjNmOTE1YzQzMzI5YTc3YjI2MDc3YTk5MWJjL3RhYmxlOjBlNTMzMzJkM2YzNjRmY2I5YjQ1OGIyYWFmZmYwNWY5L3RhYmxlcmFuZ2U6MGU1MzMzMmQzZjM2NGZjYjliNDU4YjJhYWZmZjA1ZjlfMjItMy0xLTEtMzA1MDA_56230233-54a6-46d6-bde6-656194bbe9bd">48</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from public offering of common stock through At The Market offering, net of issuance costs of $1,226</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d48326594df4b61bdc5572faf307bb8_D20220101-20220930" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8yNS9mcmFnOjVhMzRmMjNmOTE1YzQzMzI5YTc3YjI2MDc3YTk5MWJjL3RhYmxlOjBlNTMzMzJkM2YzNjRmY2I5YjQ1OGIyYWFmZmYwNWY5L3RhYmxlcmFuZ2U6MGU1MzMzMmQzZjM2NGZjYjliNDU4YjJhYWZmZjA1ZjlfMjUtMS0xLTEtMzA1MDA_ab26036d-6146-4482-9c8f-e8f680337d78">39,584</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ea948d1a371446296c8cfe8ac8d3534_D20210101-20210930" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8yNS9mcmFnOjVhMzRmMjNmOTE1YzQzMzI5YTc3YjI2MDc3YTk5MWJjL3RhYmxlOjBlNTMzMzJkM2YzNjRmY2I5YjQ1OGIyYWFmZmYwNWY5L3RhYmxlcmFuZ2U6MGU1MzMzMmQzZjM2NGZjYjliNDU4YjJhYWZmZjA1ZjlfMjUtMy0xLTEtMzA1MDA_888b3d3b-22db-4c2b-bd89-9f4bea97f038">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from exercise of stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8yNS9mcmFnOjVhMzRmMjNmOTE1YzQzMzI5YTc3YjI2MDc3YTk5MWJjL3RhYmxlOjBlNTMzMzJkM2YzNjRmY2I5YjQ1OGIyYWFmZmYwNWY5L3RhYmxlcmFuZ2U6MGU1MzMzMmQzZjM2NGZjYjliNDU4YjJhYWZmZjA1ZjlfMjYtMS0xLTEtMzA1MDA_1b11d516-a4fe-44f9-b66d-b278f9cd72af">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69e8bcaae5bf44c9a03cf7f5bd08e6b8_D20210101-20210930" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8yNS9mcmFnOjVhMzRmMjNmOTE1YzQzMzI5YTc3YjI2MDc3YTk5MWJjL3RhYmxlOjBlNTMzMzJkM2YzNjRmY2I5YjQ1OGIyYWFmZmYwNWY5L3RhYmxlcmFuZ2U6MGU1MzMzMmQzZjM2NGZjYjliNDU4YjJhYWZmZjA1ZjlfMjYtMy0xLTEtMzA1MDA_4a61feb8-52a8-4a84-88be-e319706989c4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from shares issued in connection with the Company's employee stock purchase plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8yNS9mcmFnOjVhMzRmMjNmOTE1YzQzMzI5YTc3YjI2MDc3YTk5MWJjL3RhYmxlOjBlNTMzMzJkM2YzNjRmY2I5YjQ1OGIyYWFmZmYwNWY5L3RhYmxlcmFuZ2U6MGU1MzMzMmQzZjM2NGZjYjliNDU4YjJhYWZmZjA1ZjlfMjctMS0xLTEtMzA1MDA_62a3ae1d-cc7b-4aa1-85fe-bd52bf7202ae">130</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69e8bcaae5bf44c9a03cf7f5bd08e6b8_D20210101-20210930" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8yNS9mcmFnOjVhMzRmMjNmOTE1YzQzMzI5YTc3YjI2MDc3YTk5MWJjL3RhYmxlOjBlNTMzMzJkM2YzNjRmY2I5YjQ1OGIyYWFmZmYwNWY5L3RhYmxlcmFuZ2U6MGU1MzMzMmQzZjM2NGZjYjliNDU4YjJhYWZmZjA1ZjlfMjctMy0xLTEtMzA1MDA_c3db5943-ed63-497d-a009-058978cc0072">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from July 2021 public equity offering, net of issuance costs of $<ix:nonFraction unitRef="usd" contextRef="if312c4804f8b4c99a0562a9d7368b18e_D20220101-20220930" decimals="-3" name="us-gaap:PaymentsOfStockIssuanceCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8yNS9mcmFnOjVhMzRmMjNmOTE1YzQzMzI5YTc3YjI2MDc3YTk5MWJjL3RhYmxlOjBlNTMzMzJkM2YzNjRmY2I5YjQ1OGIyYWFmZmYwNWY5L3RhYmxlcmFuZ2U6MGU1MzMzMmQzZjM2NGZjYjliNDU4YjJhYWZmZjA1ZjlfMjktMC0xLTEtMzA1MDAvdGV4dHJlZ2lvbjphZGUyMDMxYjdmYWY0Y2E4YTY5ZTMxMzUxYjk5MGNkMV83Nw_7d1e8f9c-a3f3-44a4-a6c9-dff50d7d48d8">2,980</ix:nonFraction></span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if312c4804f8b4c99a0562a9d7368b18e_D20220101-20220930" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8yNS9mcmFnOjVhMzRmMjNmOTE1YzQzMzI5YTc3YjI2MDc3YTk5MWJjL3RhYmxlOjBlNTMzMzJkM2YzNjRmY2I5YjQ1OGIyYWFmZmYwNWY5L3RhYmxlcmFuZ2U6MGU1MzMzMmQzZjM2NGZjYjliNDU4YjJhYWZmZjA1ZjlfMjktMS0xLTEtMzA1MDA_f541a157-6283-474c-bf7e-177f31276ad2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iefba5660e6154047a65570c20050a670_D20210101-20210930" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8yNS9mcmFnOjVhMzRmMjNmOTE1YzQzMzI5YTc3YjI2MDc3YTk5MWJjL3RhYmxlOjBlNTMzMzJkM2YzNjRmY2I5YjQ1OGIyYWFmZmYwNWY5L3RhYmxlcmFuZ2U6MGU1MzMzMmQzZjM2NGZjYjliNDU4YjJhYWZmZjA1ZjlfMjktMy0xLTEtMzA1MDA_9fa464ef-917a-4c43-a8b8-469c1f8397a0">42,020</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 61.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8yNS9mcmFnOjVhMzRmMjNmOTE1YzQzMzI5YTc3YjI2MDc3YTk5MWJjL3RhYmxlOjBlNTMzMzJkM2YzNjRmY2I5YjQ1OGIyYWFmZmYwNWY5L3RhYmxlcmFuZ2U6MGU1MzMzMmQzZjM2NGZjYjliNDU4YjJhYWZmZjA1ZjlfMzAtMS0xLTEtMzA1MDA_f5bb3e48-ce65-4170-914f-bbc25aa7748f">39,719</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69e8bcaae5bf44c9a03cf7f5bd08e6b8_D20210101-20210930" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8yNS9mcmFnOjVhMzRmMjNmOTE1YzQzMzI5YTc3YjI2MDc3YTk5MWJjL3RhYmxlOjBlNTMzMzJkM2YzNjRmY2I5YjQ1OGIyYWFmZmYwNWY5L3RhYmxlcmFuZ2U6MGU1MzMzMmQzZjM2NGZjYjliNDU4YjJhYWZmZjA1ZjlfMzAtMy0xLTEtMzA1MDA_27b717d9-0d95-4213-9e7c-7fbd4e760f91">42,020</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of exchange rate changes on cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8yNS9mcmFnOjVhMzRmMjNmOTE1YzQzMzI5YTc3YjI2MDc3YTk5MWJjL3RhYmxlOjBlNTMzMzJkM2YzNjRmY2I5YjQ1OGIyYWFmZmYwNWY5L3RhYmxlcmFuZ2U6MGU1MzMzMmQzZjM2NGZjYjliNDU4YjJhYWZmZjA1ZjlfMzEtMS0xLTEtMzA1MDA_cdac0694-7dc8-4c26-bd82-6148035ce886">3,658</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69e8bcaae5bf44c9a03cf7f5bd08e6b8_D20210101-20210930" decimals="-3" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8yNS9mcmFnOjVhMzRmMjNmOTE1YzQzMzI5YTc3YjI2MDc3YTk5MWJjL3RhYmxlOjBlNTMzMzJkM2YzNjRmY2I5YjQ1OGIyYWFmZmYwNWY5L3RhYmxlcmFuZ2U6MGU1MzMzMmQzZjM2NGZjYjliNDU4YjJhYWZmZjA1ZjlfMzEtMy0xLTEtMzA1MDA_fdc30af5-fd6f-410e-bf09-2deda8ad641e">572</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net change in cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8yNS9mcmFnOjVhMzRmMjNmOTE1YzQzMzI5YTc3YjI2MDc3YTk5MWJjL3RhYmxlOjBlNTMzMzJkM2YzNjRmY2I5YjQ1OGIyYWFmZmYwNWY5L3RhYmxlcmFuZ2U6MGU1MzMzMmQzZjM2NGZjYjliNDU4YjJhYWZmZjA1ZjlfMzItMS0xLTEtMzA1MDA_427923b1-e267-47cc-8d25-d10cd7c1c124">14,092</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i69e8bcaae5bf44c9a03cf7f5bd08e6b8_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8yNS9mcmFnOjVhMzRmMjNmOTE1YzQzMzI5YTc3YjI2MDc3YTk5MWJjL3RhYmxlOjBlNTMzMzJkM2YzNjRmY2I5YjQ1OGIyYWFmZmYwNWY5L3RhYmxlcmFuZ2U6MGU1MzMzMmQzZjM2NGZjYjliNDU4YjJhYWZmZjA1ZjlfMzItMy0xLTEtMzA1MDA_08ea4e2c-7f14-41a8-b8c2-a8d8d8287ff8">17,008</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents, beginning of period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12246a01749f40d394a9437cb9938c91_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8yNS9mcmFnOjVhMzRmMjNmOTE1YzQzMzI5YTc3YjI2MDc3YTk5MWJjL3RhYmxlOjBlNTMzMzJkM2YzNjRmY2I5YjQ1OGIyYWFmZmYwNWY5L3RhYmxlcmFuZ2U6MGU1MzMzMmQzZjM2NGZjYjliNDU4YjJhYWZmZjA1ZjlfMzMtMS0xLTEtMzA1MDA_a90477ac-244b-4b9a-a8b4-ef3a7767b374">86,863</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8e90b6ab1f24717b294f892b4a059b4_I20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8yNS9mcmFnOjVhMzRmMjNmOTE1YzQzMzI5YTc3YjI2MDc3YTk5MWJjL3RhYmxlOjBlNTMzMzJkM2YzNjRmY2I5YjQ1OGIyYWFmZmYwNWY5L3RhYmxlcmFuZ2U6MGU1MzMzMmQzZjM2NGZjYjliNDU4YjJhYWZmZjA1ZjlfMzMtMy0xLTEtMzA1MDA_49d1d2c2-0b20-492d-9c7d-c58f0cd70119">127,452</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents, end of period</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2ba0b84078f4de2bc3079e992921b92_I20220930" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8yNS9mcmFnOjVhMzRmMjNmOTE1YzQzMzI5YTc3YjI2MDc3YTk5MWJjL3RhYmxlOjBlNTMzMzJkM2YzNjRmY2I5YjQ1OGIyYWFmZmYwNWY5L3RhYmxlcmFuZ2U6MGU1MzMzMmQzZjM2NGZjYjliNDU4YjJhYWZmZjA1ZjlfMzQtMS0xLTEtMzA1MDA_92cecfa7-8d4d-400f-8998-66ef757adf0e">72,771</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c5dd6f726174024bdc176efa6738fd9_I20210930" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8yNS9mcmFnOjVhMzRmMjNmOTE1YzQzMzI5YTc3YjI2MDc3YTk5MWJjL3RhYmxlOjBlNTMzMzJkM2YzNjRmY2I5YjQ1OGIyYWFmZmYwNWY5L3RhYmxlcmFuZ2U6MGU1MzMzMmQzZjM2NGZjYjliNDU4YjJhYWZmZjA1ZjlfMzQtMy0xLTEtMzA1MDA_a7096726-844c-42a6-8961-9fefc5bd9f3f">110,444</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental disclosure of noncash investing and financing activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common Stock issued in connection with the 4SC royalty settlement (see Note 4)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930" decimals="-3" name="us-gaap:StockIssued1" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8yNS9mcmFnOjVhMzRmMjNmOTE1YzQzMzI5YTc3YjI2MDc3YTk5MWJjL3RhYmxlOjBlNTMzMzJkM2YzNjRmY2I5YjQ1OGIyYWFmZmYwNWY5L3RhYmxlcmFuZ2U6MGU1MzMzMmQzZjM2NGZjYjliNDU4YjJhYWZmZjA1ZjlfMzktMS0xLTEtMzA1MDA_6915e0b2-bad8-4b51-bdb8-259fa60300fc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69e8bcaae5bf44c9a03cf7f5bd08e6b8_D20210101-20210930" decimals="-3" name="us-gaap:StockIssued1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8yNS9mcmFnOjVhMzRmMjNmOTE1YzQzMzI5YTc3YjI2MDc3YTk5MWJjL3RhYmxlOjBlNTMzMzJkM2YzNjRmY2I5YjQ1OGIyYWFmZmYwNWY5L3RhYmxlcmFuZ2U6MGU1MzMzMmQzZjM2NGZjYjliNDU4YjJhYWZmZjA1ZjlfMzktMy0xLTEtMzA1MDA_8cb51d60-a3af-47d6-a9dc-285150640aa1">8,625</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of use asset obtained in exchange for lease obligation</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8yNS9mcmFnOjVhMzRmMjNmOTE1YzQzMzI5YTc3YjI2MDc3YTk5MWJjL3RhYmxlOjBlNTMzMzJkM2YzNjRmY2I5YjQ1OGIyYWFmZmYwNWY5L3RhYmxlcmFuZ2U6MGU1MzMzMmQzZjM2NGZjYjliNDU4YjJhYWZmZjA1ZjlfNDAtMS0xLTEtMzA1MDA_52c4c2e1-4e8e-442f-818f-92f7c5d7de67">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69e8bcaae5bf44c9a03cf7f5bd08e6b8_D20210101-20210930" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8yNS9mcmFnOjVhMzRmMjNmOTE1YzQzMzI5YTc3YjI2MDc3YTk5MWJjL3RhYmxlOjBlNTMzMzJkM2YzNjRmY2I5YjQ1OGIyYWFmZmYwNWY5L3RhYmxlcmFuZ2U6MGU1MzMzMmQzZjM2NGZjYjliNDU4YjJhYWZmZjA1ZjlfNDAtMy0xLTEtMzA1MDA_8d411792-82a2-4676-9ab0-8974fb441311">435</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></div><div style="height:27.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><div id="ida7c333e3c58430eb83e8e950c50d811_28"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">IMMUNIC, INC.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Condensed Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div id="ida7c333e3c58430eb83e8e950c50d811_31"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1. <ix:nonNumeric contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8zMS9mcmFnOjQ1NGJjMjRjY2NiNjQ3ZjBiNjVhZTVmNTA3YzM2MmQwL3RleHRyZWdpb246NDU0YmMyNGNjY2I2NDdmMGI2NWFlNWY1MDdjMzYyZDBfNTQ2Mw_85bea815-491a-40d1-adee-3e59fadf0f4a" continuedAt="i77f6a346ce2f45c196507e71bfbd2901" escape="true">Description of Business and Basis of Financial Statements</ix:nonNumeric></span></div><ix:continuation id="i77f6a346ce2f45c196507e71bfbd2901" continuedAt="i0b3febedb71c4272a053ec25635f8cb5"><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Description of Business</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Immunic, Inc. ("Immunic" or the "Company") is a clinical-stage biopharmaceutical company with a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases. The Company is headquartered in New York City with its main operations in Gr&#228;felfing near Munich, Germany.  The Company currently has approximately <ix:nonFraction unitRef="employee" contextRef="ib2ba0b84078f4de2bc3079e992921b92_I20220930" decimals="INF" name="dei:EntityNumberOfEmployees" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8zMS9mcmFnOjQ1NGJjMjRjY2NiNjQ3ZjBiNjVhZTVmNTA3YzM2MmQwL3RleHRyZWdpb246NDU0YmMyNGNjY2I2NDdmMGI2NWFlNWY1MDdjMzYyZDBfNzE0NjgyNTU5MzczOA_b4c82b56-66d0-4195-927e-32ab45b2b22f">65</ix:nonFraction> employees.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company is currently pursuing <ix:nonFraction unitRef="program" contextRef="ib2ba0b84078f4de2bc3079e992921b92_I20220930" decimals="INF" name="vtl:NumberOfDevelopmentProgramsPursued" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8zMS9mcmFnOjQ1NGJjMjRjY2NiNjQ3ZjBiNjVhZTVmNTA3YzM2MmQwL3RleHRyZWdpb246NDU0YmMyNGNjY2I2NDdmMGI2NWFlNWY1MDdjMzYyZDBfMTA5OTUxMTYzNTM5NA_e1d95e58-64e8-486c-abf2-8d9cd86db70c">three</ix:nonFraction> development programs. These include the vidofludimus calcium (IMU-838) program, which is focused on the development of oral formulations of a small molecule inhibitor of the enzyme dihydroorotate dehydrogenase (&#8220;DHODH&#8221;); the IMU-935 program, which is focused on an inverse agonist of retinoic acid receptor-related orphan nuclear receptor gamma truncated (&#8220;ROR&#947;t&#8221;), an immune cell-specific isoform of ROR&#947;; and the IMU-856 program, which involves the development of a drug targeting the restoration of intestinal barrier function and regeneration of bowel epithelium. These product candidates are being developed to address diseases such as multiple sclerosis ("MS"), psoriasis and gastrointestinal diseases. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company&#8217;s business, operating results, financial condition and growth prospects are subject to significant risks and uncertainties, including the failure of its clinical trials to meet their endpoints, failure to obtain regulatory approval and the inability to obtain on acceptable terms, if at all, additional funding to complete the development and commercialization of the Company's three development programs.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity and Financial Condition</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immunic has no products approved for commercial sale and has not generated any revenue from product sales. It has never been profitable and has incurred operating losses in each year since inception in 2016.  The Company has an accumulated deficit of approximately $<ix:nonFraction unitRef="usd" contextRef="ib2ba0b84078f4de2bc3079e992921b92_I20220930" decimals="-5" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8zMS9mcmFnOjQ1NGJjMjRjY2NiNjQ3ZjBiNjVhZTVmNTA3YzM2MmQwL3RleHRyZWdpb246NDU0YmMyNGNjY2I2NDdmMGI2NWFlNWY1MDdjMzYyZDBfMTA5OTUxMTY0MDk2Mg_3cddd271-e32d-49e8-b6f4-b45290becadf">260.8</ix:nonFraction> million as of September 30, 2022 and $<ix:nonFraction unitRef="usd" contextRef="i12246a01749f40d394a9437cb9938c91_I20211231" decimals="-5" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8zMS9mcmFnOjQ1NGJjMjRjY2NiNjQ3ZjBiNjVhZTVmNTA3YzM2MmQwL3RleHRyZWdpb246NDU0YmMyNGNjY2I2NDdmMGI2NWFlNWY1MDdjMzYyZDBfMTA5OTUxMTYzODUyNA_061cbf6e-8719-44b6-96e6-c0ef2eb752bc">196.9</ix:nonFraction> million as of December 31, 2021.  Substantially all of Immunic's operating losses resulted from expenses incurred in connection with its research and development programs and from general and administrative costs associated with its operations.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immunic expects to incur significant expenses and increasing operating losses for the foreseeable future as it initiates and continues the preclinical and clinical development of its product candidates and adds personnel necessary to advance its clinical pipeline of product candidates.  Immunic expects that its operating losses will fluctuate significantly from quarter-to-quarter and year-to-year due to timing of clinical development programs.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From inception through October 31, 2022, Immunic has raised net cash of approximately $<ix:nonFraction unitRef="usd" contextRef="id96591a4131743fabd2bef215e14e27d_D20140417-20221031" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8zMS9mcmFnOjQ1NGJjMjRjY2NiNjQ3ZjBiNjVhZTVmNTA3YzM2MmQwL3RleHRyZWdpb246NDU0YmMyNGNjY2I2NDdmMGI2NWFlNWY1MDdjMzYyZDBfNTQ5NzU1ODI3MzE2_d1aef92a-0f74-4d33-86ad-624bf2aa9257">355.5</ix:nonFraction> million from private and public offerings of preferred and common stock. As of September 30, 2022, the Company had cash and cash equivalents of approximately $<ix:nonFraction unitRef="usd" contextRef="ied30ae8dfbe54606808411695b6e7a4d_I20221031" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8zMS9mcmFnOjQ1NGJjMjRjY2NiNjQ3ZjBiNjVhZTVmNTA3YzM2MmQwL3RleHRyZWdpb246NDU0YmMyNGNjY2I2NDdmMGI2NWFlNWY1MDdjMzYyZDBfNTQ5NzU1ODI3MjA5_5cbf2073-5186-4c45-b25a-33e218913bbd">72.8</ix:nonFraction> million.  With these funds, and the $<ix:nonFraction unitRef="usd" contextRef="ied30ae8dfbe54606808411695b6e7a4d_I20221031" decimals="-5" name="us-gaap:CashCashEquivalentsAndFederalFundsSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8zMS9mcmFnOjQ1NGJjMjRjY2NiNjQ3ZjBiNjVhZTVmNTA3YzM2MmQwL3RleHRyZWdpb246NDU0YmMyNGNjY2I2NDdmMGI2NWFlNWY1MDdjMzYyZDBfNTQ5NzU1ODI3MzIz_ad64a7d3-4a51-48b2-8bfe-590c01b42092">56.4</ix:nonFraction> million of cash raised in October 2022, Immunic expects to be able to fund its operations beyond twelve months from the date of the issuance of the accompanying condensed consolidated financial statements.</span></div><ix:nonNumeric contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8zMS9mcmFnOjQ1NGJjMjRjY2NiNjQ3ZjBiNjVhZTVmNTA3YzM2MmQwL3RleHRyZWdpb246NDU0YmMyNGNjY2I2NDdmMGI2NWFlNWY1MDdjMzYyZDBfNTQ2Ng_d3fa6ecd-5174-4688-8a2b-c7cc691277a9" continuedAt="i3f54154c08d54fc190da92f2d1f65e81" escape="true"><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation and Consolidation</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements have been prepared in conformity with United States generally accepted accounting principles, ("U.S. GAAP") and include the accounts of Immunic and its wholly-owned subsidiaries, Immunic AG (which began operations in 2016) and Immunic Research GmbH (which began operations in 2016 and was merged into Immunic AG in September, 2022) and Immunic Australia Pty Ltd. (which began operations in 2018).  All intercompany accounts and transactions have been eliminated in consolidation. Immunic manages its operations as a single reportable segment for the purposes of assessing performance and making operating decisions. </span></div></ix:nonNumeric></ix:continuation><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="padding-left:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:continuation id="i0b3febedb71c4272a053ec25635f8cb5" continuedAt="i6c0e767c34d5409d8137be10a10a5f45"><ix:continuation id="i3f54154c08d54fc190da92f2d1f65e81" continuedAt="ic09f9c64b28f411984cce0e8487954c7">Unaudited Interim Financial Information</ix:continuation></ix:continuation></span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i6c0e767c34d5409d8137be10a10a5f45"><ix:continuation id="ic09f9c64b28f411984cce0e8487954c7">Immunic has prepared the accompanying interim unaudited condensed consolidated financial statements in accordance with United States generally accepted accounting principles, (&#8220;US GAAP&#8221;), for interim financial information and with the instructions to Form 10-Q and Regulation S-X of the SEC. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. These interim unaudited condensed consolidated financial statements reflect all adjustments consisting of normal recurring accruals which, in the opinion of management, are necessary to present fairly Immunic&#8217;s consolidated financial position, consolidated results of operations, consolidated statement of stockholders&#8217; equity and consolidated cash flows for the periods and as of the dates presented. The Company&#8217;s fiscal year ends on December 31. The condensed consolidated balance sheet as of December 31, 2021 was derived from audited consolidated financial statements but does not include all disclosures required by U.S. GAAP. These condensed consolidated financial statements should be read in conjunction with the annual consolidated financial statements and the notes thereto included on the Company's Annual Report on Form 10-K filed on February 24, 2022. The nature of Immunic&#8217;s business is such that the results of any interim period may not be indicative of the results to be expected for the entire year.</ix:continuation></ix:continuation> </span></div><div id="ida7c333e3c58430eb83e8e950c50d811_34"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2. <ix:nonNumeric contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8zNC9mcmFnOjZlNmZlYmNmYmQwYTRlNDE5NDE0ZWFhMGNlYTdjMWU2L3RleHRyZWdpb246NmU2ZmViY2ZiZDBhNGU0MTk0MTRlYWEwY2VhN2MxZTZfMTc1MzE_ec8d69a6-f451-45bc-92c2-2bfa60b49e97" continuedAt="ica14909cce18433ea63e96bb13e6a974" escape="true">Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="ica14909cce18433ea63e96bb13e6a974" continuedAt="iddf60d6511f7459faa095180e048bea3"><ix:nonNumeric contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8zNC9mcmFnOjZlNmZlYmNmYmQwYTRlNDE5NDE0ZWFhMGNlYTdjMWU2L3RleHRyZWdpb246NmU2ZmViY2ZiZDBhNGU0MTk0MTRlYWEwY2VhN2MxZTZfMTc1NDQ_0a6a41e5-fc8a-4f17-bd09-2441d90d0767" escape="true"><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires the Company to make certain estimates and assumptions that affect the reported amounts of assets, liabilities, expenses and the disclosure of contingent assets and liabilities in the Company&#8217;s consolidated financial statements. The most significant estimates in the Company&#8217;s financial statements and accompanying notes relate to clinical trial expenses and share-based compensation. Management believes its estimates to be reasonable under the circumstances. Actual results could differ materially from those estimates and assumptions.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8zNC9mcmFnOjZlNmZlYmNmYmQwYTRlNDE5NDE0ZWFhMGNlYTdjMWU2L3RleHRyZWdpb246NmU2ZmViY2ZiZDBhNGU0MTk0MTRlYWEwY2VhN2MxZTZfMTc1NDc_1fb01afa-509a-4bf4-aac2-d67d7af45d73" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Translation and Presentation</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s reporting currency is United States (&#8220;U.S.&#8221;) dollars. Immunic AG and Immunic Research GmbH&#8217;s operations are located in Germany with the euro being their functional currency. Immunic Australia Pty Ltd.&#8217;s functional currency is the Australian dollar. All amounts in the financial statements where the functional currency is not the U.S. dollar are translated into U.S. dollar equivalents at exchange rates as follows:</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:180%">&#8226; assets and liabilities at reporting period-end rates;</span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:180%">&#8226; income statement accounts at average exchange rates for the reporting period; and</span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:180%">&#8226; components of equity at historical rates.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gains and losses from translation of the financial statements into U.S. dollars are recorded in stockholders&#8217; equity as a component of accumulated other comprehensive income (loss). Realized and unrealized gains and losses resulting from foreign currency transactions denominated in currencies other than the functional currency are reflected as general and administrative expenses in the Consolidated Statements of Operations. Foreign currency transaction gains and losses related to long-term intercompany loans that are payable in the foreseeable future are recorded in Other Income (Expense). The Consolidated Statements of Cash Flows were prepared by using the average exchange rate in effect during the reporting period which reasonably approximates the timing of the cash flows.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8zNC9mcmFnOjZlNmZlYmNmYmQwYTRlNDE5NDE0ZWFhMGNlYTdjMWU2L3RleHRyZWdpb246NmU2ZmViY2ZiZDBhNGU0MTk0MTRlYWEwY2VhN2MxZTZfMTc1MzM_89678cf2-6de6-42f8-b88d-8bc72cced780" continuedAt="i4417ff6177314f5eb76631e006ec1817" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents.</span></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i4417ff6177314f5eb76631e006ec1817">Cash and cash equivalents consist of cash on hand and deposits in banks located in the U.S., Germany and Australia. The Company maintains cash and cash equivalent balances denominated in Euro and U.S. dollars with major financial institutions in the U.S. and Germany in excess of the deposit limits insured by the government. Management periodically reviews the credit standing of these financial institutions and believes that the Company is not exposed to any significant credit risk. The Company currently deposits its cash and cash equivalents with <ix:nonFraction unitRef="financialinstitution" contextRef="ib2ba0b84078f4de2bc3079e992921b92_I20220930" decimals="INF" name="vtl:NumberOfFinancialInstitutionsUsedForCashDeposits" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8zNC9mcmFnOjZlNmZlYmNmYmQwYTRlNDE5NDE0ZWFhMGNlYTdjMWU2L3RleHRyZWdpb246NmU2ZmViY2ZiZDBhNGU0MTk0MTRlYWEwY2VhN2MxZTZfMjgyNA_4de37a18-60d3-4726-a28d-feed41e15b85">two</ix:nonFraction> large financial institutions.</ix:continuation> </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="iddf60d6511f7459faa095180e048bea3" continuedAt="i8c7e777363fa46d68ef17da87fcbc3e0"><ix:nonNumeric contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8zNC9mcmFnOjZlNmZlYmNmYmQwYTRlNDE5NDE0ZWFhMGNlYTdjMWU2L3RleHRyZWdpb246NmU2ZmViY2ZiZDBhNGU0MTk0MTRlYWEwY2VhN2MxZTZfMTc1Mzg_55f386b7-ed64-4fe1-9b71-cba63cbb340d" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurement</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the price that would be received to sell an asset or be paid to transfer a liability in an orderly transaction between market participants on the measurement date. Accounting guidance establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The standard describes three levels of inputs that may be used to measure fair value:</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;1&#8212;Quoted prices in active markets for identical assets or liabilities. Level 1 assets consisted of money market funds for the periods presented. The Company had no Level 1 liabilities for the periods presented.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;2&#8212; Inputs other than observable quoted prices for the asset or liability, either directly or indirectly; these include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. The Company had no Level 2 assets or liabilities for the periods presented.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;3&#8212;Unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of assets or liabilities. The Company had no Level 3 assets or liabilities for the periods presented.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying value of cash and cash equivalents, other current assets and prepaid expenses, accounts payable, accrued expenses, and other current liabilities approximates fair value due to the short period of time to maturity.</span></div></ix:nonNumeric><div style="margin-top:18pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8zNC9mcmFnOjZlNmZlYmNmYmQwYTRlNDE5NDE0ZWFhMGNlYTdjMWU2L3RleHRyZWdpb246NmU2ZmViY2ZiZDBhNGU0MTk0MTRlYWEwY2VhN2MxZTZfMTc1Mzk_8b023748-9aad-4a0b-99b1-ff27d0736ba8" continuedAt="i01dd2c20b704472faf3b5d074f415b43" escape="true">Property and Equipment</ix:nonNumeric></span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i01dd2c20b704472faf3b5d074f415b43">Property and equipment is stated at cost. Depreciation is computed using the straight-line method based on the estimated service lives of the assets, which range from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8zNC9mcmFnOjZlNmZlYmNmYmQwYTRlNDE5NDE0ZWFhMGNlYTdjMWU2L3RleHRyZWdpb246NmU2ZmViY2ZiZDBhNGU0MTk0MTRlYWEwY2VhN2MxZTZfNDU2Mg_7c753206-cde1-40ce-856d-422289b6506b">three</span> to <ix:nonNumeric contextRef="i946f069c215c45208da865ab19d790c4_D20220101-20220930" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8zNC9mcmFnOjZlNmZlYmNmYmQwYTRlNDE5NDE0ZWFhMGNlYTdjMWU2L3RleHRyZWdpb246NmU2ZmViY2ZiZDBhNGU0MTk0MTRlYWEwY2VhN2MxZTZfNDU2OA_0c9b3176-f8a7-44ea-8802-71f912aa057d">thirteen years</ix:nonNumeric>.</ix:continuation> Depreciation expense was $<ix:nonFraction unitRef="usd" contextRef="ib52579de36d54242a791b9e3f8019a00_D20210701-20210930" decimals="-3" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8zNC9mcmFnOjZlNmZlYmNmYmQwYTRlNDE5NDE0ZWFhMGNlYTdjMWU2L3RleHRyZWdpb246NmU2ZmViY2ZiZDBhNGU0MTk0MTRlYWEwY2VhN2MxZTZfNDU5Nw_9ecedd5c-fdff-4f1a-a2b8-dd27d61f53a2">17,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="iceee2385dd3a4cafb879b0088a931d62_D20200701-20200930" decimals="-3" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8zNC9mcmFnOjZlNmZlYmNmYmQwYTRlNDE5NDE0ZWFhMGNlYTdjMWU2L3RleHRyZWdpb246NmU2ZmViY2ZiZDBhNGU0MTk0MTRlYWEwY2VhN2MxZTZfNDYwNA_1151ed3b-ecfe-4248-8b66-efe2e8147c35">16,000</ix:nonFraction> for the three months ended September 30, 2022 and 2021, respectively. Depreciation expense was $<ix:nonFraction unitRef="usd" contextRef="i69e8bcaae5bf44c9a03cf7f5bd08e6b8_D20210101-20210930" decimals="-3" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8zNC9mcmFnOjZlNmZlYmNmYmQwYTRlNDE5NDE0ZWFhMGNlYTdjMWU2L3RleHRyZWdpb246NmU2ZmViY2ZiZDBhNGU0MTk0MTRlYWEwY2VhN2MxZTZfNDcwMg_48e57e6c-cd51-49f8-b8c8-40a53d333f0f">58,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="id906393de2c04b61842e3087515a35aa_D20200101-20200930" decimals="-3" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8zNC9mcmFnOjZlNmZlYmNmYmQwYTRlNDE5NDE0ZWFhMGNlYTdjMWU2L3RleHRyZWdpb246NmU2ZmViY2ZiZDBhNGU0MTk0MTRlYWEwY2VhN2MxZTZfNDcwOQ_3c3ef925-baf2-46a5-9ddb-0d84334a0c6c">45,000</ix:nonFraction> for the nine months ended September 30, 2022 and 2021, respectively.</span></div><div style="margin-top:18pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8zNC9mcmFnOjZlNmZlYmNmYmQwYTRlNDE5NDE0ZWFhMGNlYTdjMWU2L3RleHRyZWdpb246NmU2ZmViY2ZiZDBhNGU0MTk0MTRlYWEwY2VhN2MxZTZfMTc1MzQ_aec533a9-7961-4ce6-a231-cf9dfc8f8aa0" continuedAt="i285ab73df6e94928a3e57b80b5600996" escape="true">Impairment of Long-Lived Assets</ix:nonNumeric></span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i285ab73df6e94928a3e57b80b5600996">The Company records impairment losses on long-lived assets used in operations when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets&#8217; carrying amount. Impaired assets are then recorded at their estimated fair value.</ix:continuation> There were <ix:nonFraction unitRef="usd" contextRef="id906393de2c04b61842e3087515a35aa_D20200101-20200930" decimals="INF" name="us-gaap:TangibleAssetImpairmentCharges" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8zNC9mcmFnOjZlNmZlYmNmYmQwYTRlNDE5NDE0ZWFhMGNlYTdjMWU2L3RleHRyZWdpb246NmU2ZmViY2ZiZDBhNGU0MTk0MTRlYWEwY2VhN2MxZTZfNTEyNg_03d19bc8-e687-406f-8ac0-8f003ae7f51a"><ix:nonFraction unitRef="usd" contextRef="iceee2385dd3a4cafb879b0088a931d62_D20200701-20200930" decimals="INF" name="us-gaap:TangibleAssetImpairmentCharges" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8zNC9mcmFnOjZlNmZlYmNmYmQwYTRlNDE5NDE0ZWFhMGNlYTdjMWU2L3RleHRyZWdpb246NmU2ZmViY2ZiZDBhNGU0MTk0MTRlYWEwY2VhN2MxZTZfNTEyNg_74057324-8f63-4734-adc0-92559f58467c"><ix:nonFraction unitRef="usd" contextRef="ib52579de36d54242a791b9e3f8019a00_D20210701-20210930" decimals="INF" name="us-gaap:TangibleAssetImpairmentCharges" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8zNC9mcmFnOjZlNmZlYmNmYmQwYTRlNDE5NDE0ZWFhMGNlYTdjMWU2L3RleHRyZWdpb246NmU2ZmViY2ZiZDBhNGU0MTk0MTRlYWEwY2VhN2MxZTZfNTEyNg_7ba17b86-ea43-4599-a35a-eee041715fcb"><ix:nonFraction unitRef="usd" contextRef="i69e8bcaae5bf44c9a03cf7f5bd08e6b8_D20210101-20210930" decimals="INF" name="us-gaap:TangibleAssetImpairmentCharges" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8zNC9mcmFnOjZlNmZlYmNmYmQwYTRlNDE5NDE0ZWFhMGNlYTdjMWU2L3RleHRyZWdpb246NmU2ZmViY2ZiZDBhNGU0MTk0MTRlYWEwY2VhN2MxZTZfNTEyNg_8d098a65-a0f8-4695-b2d5-9929dc534222">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> impairment losses during the three and nine months ended September 30, 2022 and 2021.</span></div><ix:nonNumeric contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930" name="us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8zNC9mcmFnOjZlNmZlYmNmYmQwYTRlNDE5NDE0ZWFhMGNlYTdjMWU2L3RleHRyZWdpb246NmU2ZmViY2ZiZDBhNGU0MTk0MTRlYWEwY2VhN2MxZTZfMTc1NDA_6fa78a88-248d-4114-a411-d3da7fce1b4c" continuedAt="i76b8e3dbfb3f4e14966b0e585459e492" escape="true"><div style="margin-top:12pt;padding-left:20.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:174%">Goodwill</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Business combinations are accounted for under the acquisition method. The total purchase price of an acquisition is allocated to the underlying identifiable net assets, based on their respective estimated fair values as of the acquisition date. Determining the fair value of assets acquired and liabilities assumed requires management&#8217;s judgment and often involves the use of significant estimates and assumptions, including assumptions with respect to future cash inflows and outflows, probabilities of success, discount rates, and asset lives, among other items. Assets acquired and liabilities assumed are recorded at their estimated fair values. The excess of the purchase price over the estimated fair values of the net assets acquired is recorded as goodwill.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill is tested for impairment at the reporting unit level annually in the fourth quarter, or more frequently when events or changes in circumstances indicate that the asset might be impaired. Examples of such events or circumstances include, but are not limited to, an unfavorable clinical trial result, a significant adverse change in legal or business climate, industry market conditions, an adverse regulatory action, sustained decrease in stock price or unanticipated competition. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When conducting the Company&#8217;s interim goodwill impairment assessment, we considered the Company&#8217;s history of reported losses and negative cash flows from operating activities, along with the downturn in macroeconomic conditions and the broader mid-cap and micro-cap equity markets in 2022. Given the period of time between the commencement of the downturn in macroeconomic and general equity market conditions as of September 30, 2022, management believes that the fluctuation in prices of our common stock, consistent with the broader market, is not other-than-temporary and not indicative of any fundamental change in the value or prospects of the underlying business as of the measurement date.</span></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i8c7e777363fa46d68ef17da87fcbc3e0" continuedAt="i2ab42d4e03e549d7a042643190782bf1"><ix:continuation id="i76b8e3dbfb3f4e14966b0e585459e492"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As another data point, the Company also performed a quantitative goodwill impairment analysis comparing the estimated fair value of the Company&#8217;s reporting unit to its carrying or book value as of the current period presented herein. In performing the quantitative analysis, the Company compared the fair value of the reporting unit to its carrying or book value to determine if the fair value of the reporting unit exceeded its carrying value as of the testing date, in which case the standard indicates that goodwill would not be impaired, and no further testing was necessary. The fair value of a reporting unit refers to the price that would be received to sell the reporting unit as a whole in an orderly transaction between market participants at the measurement date. Quoted market prices in active markets are considered to be the best evidence of fair value and should be used as the basis for fair value measurement, if available. When using quoted market prices to estimate the fair value of a reporting unit, we consider all available evidence. In certain circumstances, such as a distressed market, it may be appropriate to consider recent trends in the Company&#8217;s stock price, instead of a single day&#8217;s stock price in evaluating fair value. In these circumstances, averages over relatively short periods of time are used to determine representative market values.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subsequent to September 30, 2022, the company raised $<ix:nonFraction unitRef="usd" contextRef="i0635b165f76f479694e7564645ca75f5_D20221001-20221103" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8zNC9mcmFnOjZlNmZlYmNmYmQwYTRlNDE5NDE0ZWFhMGNlYTdjMWU2L3RleHRyZWdpb246NmU2ZmViY2ZiZDBhNGU0MTk0MTRlYWEwY2VhN2MxZTZfNDk0NzgwMjM4NjAwMQ_66b4bea5-bd8b-4597-9512-14a8269be181">60</ix:nonFraction>&#160;million of common stock at a premium to the company's market pricing.  Management further considered this as an indication of the value and related premium to market values prior to and as of September 30, 2022.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on this qualitative analysis,  the Company concluded that goodwill was not &#8220;more likely than not&#8221; impaired as of September 30, 2022.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 20, 2022, the Company announced the outcome of a  significant interim analysis of its Phase 1b clinical trial of IMU-935 in patients with moderate-to-severe psoriasis that were not deemed positive progress. On October 21, 2022, the Company experienced a significant decrease in the Company's market capitalization.  The Company considered this to be a triggering event indicating that it is more likely than not that goodwill is impaired.  As a result, the Company anticipates it will incur an approximately $<ix:nonFraction unitRef="usd" contextRef="ic5a53880f9da458c8abd6926ff69ddd8_D20221001-20221231" decimals="-5" name="us-gaap:GoodwillImpairmentLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8zNC9mcmFnOjZlNmZlYmNmYmQwYTRlNDE5NDE0ZWFhMGNlYTdjMWU2L3RleHRyZWdpb246NmU2ZmViY2ZiZDBhNGU0MTk0MTRlYWEwY2VhN2MxZTZfNDk0NzgwMjM4NTk4Ng_9d87a629-1931-4005-aeb9-630d72a05c47">33.0</ix:nonFraction>&#160;million goodwill impairment charge in the fourth quarter of 2022 as a result of this analysis (See Note 10).</span></div></ix:continuation><ix:nonNumeric contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8zNC9mcmFnOjZlNmZlYmNmYmQwYTRlNDE5NDE0ZWFhMGNlYTdjMWU2L3RleHRyZWdpb246NmU2ZmViY2ZiZDBhNGU0MTk0MTRlYWEwY2VhN2MxZTZfMTc1MzU_af5da3ca-4a47-4856-8e0b-987cedda5112" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Research and Development Expenses</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">These costs primarily include external development expenses and internal personnel expenses for the three development programs, vidofludimus calcium, IMU-935 and IMU-856. Immunic has spent the majority of its research and development resources on vidofludimus calcium, the Company's lead development program for clinical trials in RRMS, UC and COVID-19.  </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses consist of expenses incurred in research and development activities, which include clinical trials, contract research services, certain milestone payments, salaries and related employee benefits, allocated facility costs and other outsourced services. Research and development expenses are charged to operations as incurred.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into agreements with contract research organizations (&#8220;CROs&#8221;) to provide clinical trial services for individual studies and projects by executing individual work orders governed by a Master Service Arrangement (&#8220;MSA&#8221;). The MSAs and associated work orders provide for regular recurrent payments and payments upon the completion of certain milestones. The Company regularly assesses the timing of payments against actual costs incurred to ensure a proper accrual of related expenses in the appropriate accounting period.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930" name="us-gaap:CollaborativeArrangementAccountingPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8zNC9mcmFnOjZlNmZlYmNmYmQwYTRlNDE5NDE0ZWFhMGNlYTdjMWU2L3RleHRyZWdpb246NmU2ZmViY2ZiZDBhNGU0MTk0MTRlYWEwY2VhN2MxZTZfMTc1NDY_8b36606c-4cf9-4743-8f47-7fb9223de79b" continuedAt="ib19e5260c50342c18bfa20733e215ebf" escape="true"><div style="margin-top:18pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration Arrangements</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain collaboration and license agreements may include payments to or from the Company of one or more of the following: non-refundable or partially refundable upfront or license fees; development, regulatory and commercial milestone payments; payment for manufacturing supply services; partial or complete reimbursement of research and development costs; and royalties on net sales of licensed products. The Company assesses whether such contracts are within the scope of Financial Accounting Standards Board (FASB) Accounting Standards Update (&#8220;ASU&#8221;) 2014-09 &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; and ASU No. 2018-18, &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ("ASU 2018-18"). ASU 2018-18, clarifies that certain elements of collaborative arrangements could qualify as transactions with customers in the scope of ASC 606.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, the Company entered into an option and license agreement (the "Daiichi Sankyo Agreement") with Daiichi Sankyo Co., Ltd. ("Daiichi Sankyo") which granted the Company the right to license a group of compounds, designated by the Company as IMU-856, as a potential new oral treatment option for gastrointestinal diseases such as celiac disease, inflammatory bowel disease, irritable bowel syndrome with diarrhea and other barrier function associated diseases. During the option period, the Company performed agreed upon research and development activities for which it was reimbursed by Daiichi </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i2ab42d4e03e549d7a042643190782bf1" continuedAt="i67ee2757c60e43259672712295bfdba3"><ix:continuation id="ib19e5260c50342c18bfa20733e215ebf"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sankyo up to a maximum agreed-upon limit. Such reimbursement was recorded as other income. There are no additional research and development reimbursements expected under this agreement.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On January 5, 2020, the Company exercised its option to obtain the exclusive worldwide right to commercialization of IMU-856. Among other things, the option exercise grants Immunic AG the rights to Daiichi Sankyo&#8217;s patent application related to IMU-856, for which the Company received a notice of allowance from the US Patent &amp; Trademark Office in August 2022. In connection with the option exercise, the Company paid a one-time upfront licensing fee to Daiichi Sankyo. Under the Daiichi Sankyo Agreement, Daiichi Sankyo is also eligible to receive future development, regulatory and sales milestone payments, as well as royalties related to IMU-856.</span></div></ix:continuation><ix:nonNumeric contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930" name="us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8zNC9mcmFnOjZlNmZlYmNmYmQwYTRlNDE5NDE0ZWFhMGNlYTdjMWU2L3RleHRyZWdpb246NmU2ZmViY2ZiZDBhNGU0MTk0MTRlYWEwY2VhN2MxZTZfMTc1Mjg_c5bebae0-425a-4e28-91f6-d09a9cc2c9af" escape="true"><div style="margin-top:18pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative Expenses</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses consist primarily of salaries and related costs for personnel in executive, finance, business development and other support functions. Other general and administrative expenses include, but are not limited to, stock-based compensation, insurance costs, professional fees for legal, accounting and tax services, consulting, related facility costs and travel.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8zNC9mcmFnOjZlNmZlYmNmYmQwYTRlNDE5NDE0ZWFhMGNlYTdjMWU2L3RleHRyZWdpb246NmU2ZmViY2ZiZDBhNGU0MTk0MTRlYWEwY2VhN2MxZTZfMTc1NDg_1a6a27f3-27c4-405e-b4e0-aa0ac27e831e" escape="true"><div style="margin-top:18pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation&#160;</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures the cost of employee and non-employee services received in exchange for equity awards based on the grant-date fair value of the award recognized generally as an expense (i) on a straight-line basis over the requisite service period for those awards whose vesting is based upon a service condition, and (ii) on an accelerated method for awards whose vesting is based upon a performance condition, but only to the extent it is probable that the performance condition will be met. Stock-based compensation is (i) estimated at the date of grant based on the award&#8217;s fair value for equity classified awards and (ii) final measurement date for liability classified awards. Forfeitures are recorded in the period in which they occur.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates the fair value of stock options using the Black-Scholes-Merton option-pricing model ("BSM"), which requires the use of estimates and subjective assumptions, including the risk-free interest rate, the fair value of the underlying common stock, the expected dividend yield of the Company&#8217;s common stock, the expected volatility of the price of the Company&#8217;s common stock, and the expected term of the option. These estimates involve inherent uncertainties and the application of management&#8217;s judgment. If factors change and different assumptions are used, the Company&#8217;s stock-based compensation expense could be materially different in the future.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930" name="us-gaap:LesseeLeasesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8zNC9mcmFnOjZlNmZlYmNmYmQwYTRlNDE5NDE0ZWFhMGNlYTdjMWU2L3RleHRyZWdpb246NmU2ZmViY2ZiZDBhNGU0MTk0MTRlYWEwY2VhN2MxZTZfMTc1NDE_9f792fad-c5b3-4c62-84de-f1e5fa853acc" escape="true"><div style="margin-top:18pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:18pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company leases office space and office equipment. The underlying lease agreements have lease terms of less than <ix:nonNumeric contextRef="ib99098d9e41b4f74a0e5c17f2558443e_I20220930" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8zNC9mcmFnOjZlNmZlYmNmYmQwYTRlNDE5NDE0ZWFhMGNlYTdjMWU2L3RleHRyZWdpb246NmU2ZmViY2ZiZDBhNGU0MTk0MTRlYWEwY2VhN2MxZTZfNTQ5NzU1ODU1MTk4_45079ef0-c849-4ba2-8d65-40996c80bf36">12</ix:nonNumeric> months and up to <ix:nonNumeric contextRef="ic3f8af6eaf2d4e90a82b6ef6ea30ec32_I20220930" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8zNC9mcmFnOjZlNmZlYmNmYmQwYTRlNDE5NDE0ZWFhMGNlYTdjMWU2L3RleHRyZWdpb246NmU2ZmViY2ZiZDBhNGU0MTk0MTRlYWEwY2VhN2MxZTZfNTQ5NzU1ODU1MjEy_2ba99a5c-af5d-40c2-bf6a-167ed264220d">60</ix:nonNumeric> months. Leases with terms of 12 months or less at inception are not included in the operating lease right of use asset and operating lease liability.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has <ix:nonFraction unitRef="lease" contextRef="ib2ba0b84078f4de2bc3079e992921b92_I20220930" decimals="INF" name="vtl:LesseeOperatingLeasesNumberOfExistingLeases" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8zNC9mcmFnOjZlNmZlYmNmYmQwYTRlNDE5NDE0ZWFhMGNlYTdjMWU2L3RleHRyZWdpb246NmU2ZmViY2ZiZDBhNGU0MTk0MTRlYWEwY2VhN2MxZTZfNTQ5NzU1ODU1Mzc1_80079bb7-5c36-473e-82cf-6d052314ddeb"><ix:nonFraction unitRef="lease" contextRef="ib2ba0b84078f4de2bc3079e992921b92_I20220930" decimals="INF" name="vtl:LesseeOperatingLeasesNumberOfExistingLeases" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8zNC9mcmFnOjZlNmZlYmNmYmQwYTRlNDE5NDE0ZWFhMGNlYTdjMWU2L3RleHRyZWdpb246NmU2ZmViY2ZiZDBhNGU0MTk0MTRlYWEwY2VhN2MxZTZfNTQ5NzU1ODU1Mzc1_8257bf78-4ee9-4959-b0ad-5f2f7728c549">two</ix:nonFraction></ix:nonFraction> existing leases for office space. At inception of a lease agreement, the Company determines whether an agreement represents a lease and at commencement each lease agreement is assessed as to classification as an operating or financing lease. The Company's <ix:nonFraction unitRef="lease" contextRef="ib2ba0b84078f4de2bc3079e992921b92_I20220930" decimals="INF" name="vtl:LesseeOperatingLeasesNumberOfExistingLeases" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8zNC9mcmFnOjZlNmZlYmNmYmQwYTRlNDE5NDE0ZWFhMGNlYTdjMWU2L3RleHRyZWdpb246NmU2ZmViY2ZiZDBhNGU0MTk0MTRlYWEwY2VhN2MxZTZfNTQ5NzU1ODU1NjM1_80079bb7-5c36-473e-82cf-6d052314ddeb"><ix:nonFraction unitRef="lease" contextRef="ib2ba0b84078f4de2bc3079e992921b92_I20220930" decimals="INF" name="vtl:LesseeOperatingLeasesNumberOfExistingLeases" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8zNC9mcmFnOjZlNmZlYmNmYmQwYTRlNDE5NDE0ZWFhMGNlYTdjMWU2L3RleHRyZWdpb246NmU2ZmViY2ZiZDBhNGU0MTk0MTRlYWEwY2VhN2MxZTZfNTQ5NzU1ODU1NjM1_8257bf78-4ee9-4959-b0ad-5f2f7728c549">two</ix:nonFraction></ix:nonFraction> leases have been classified as operating leases and an operating lease right-of-use asset and an operating lease liability have been recorded on the Company&#8217;s balance sheet. A right-of-use lease asset represents the Company&#8217;s right to use the underlying asset for the lease term and the lease obligation represents its commitment to make the lease payments arising from the lease. Right-of-use lease assets and obligations are recognized at the commencement date based on the present value of remaining lease payments over the lease term. As the Company&#8217;s leases do not provide an implicit rate, the Company has used an estimated incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. The right-of-use lease asset includes any lease payments made prior to commencement and excludes any lease incentives. The lease term used in estimating future lease payments may include options to extend when it is reasonably certain that the Company will exercise that option. Operating lease expense is recognized on a straight-line basis over the lease term, subject to any changes in the lease or changes in expectations regarding the lease term. Variable lease costs such as common area costs and property taxes are expensed as incurred. Leases with an initial term of twelve months or less are not recorded on the balance sheet.</span></div></ix:nonNumeric></ix:continuation><div style="margin-top:18pt;text-indent:24.75pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i67ee2757c60e43259672712295bfdba3"><ix:nonNumeric contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8zNC9mcmFnOjZlNmZlYmNmYmQwYTRlNDE5NDE0ZWFhMGNlYTdjMWU2L3RleHRyZWdpb246NmU2ZmViY2ZiZDBhNGU0MTk0MTRlYWEwY2VhN2MxZTZfMTc1MzY_a0b78c88-c9bb-43d8-91c8-cbbb01643f3b" escape="true"><div style="margin-top:18pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Income (Loss)</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive income (loss) is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. Accumulated other comprehensive income (loss) has been reflected as a separate component of stockholders&#8217; equity in the accompanying Consolidated Balance Sheets and consists of foreign currency translation adjustments (net of tax).</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930" name="us-gaap:IncomeTaxPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8zNC9mcmFnOjZlNmZlYmNmYmQwYTRlNDE5NDE0ZWFhMGNlYTdjMWU2L3RleHRyZWdpb246NmU2ZmViY2ZiZDBhNGU0MTk0MTRlYWEwY2VhN2MxZTZfMTc1Mjk_f9966b2c-38c6-4a07-ae2c-04ca9cdd2500" escape="true"><div style="margin-top:18pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to corporate income tax laws and regulations in the U.S., Germany and Australia. Tax regulations within each jurisdiction are subject to the interpretation of the related tax laws and regulations and require significant judgment in their application.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company utilizes the asset and liability method of accounting for income taxes which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the audited consolidated financial statements. Deferred income tax assets and liabilities are determined based on the differences between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of changes in tax rates on deferred tax assets and liabilities is recognized in operations in the period that includes the enactment date. Deferred taxes are reduced by a valuation allowance when, in the opinion of management, it is more likely than not some portion or the entire deferred tax asset will not be realized.  As of September 30, 2022 and 2021, respectively, the Company maintained a full valuation allowance against the balance of deferred tax assets.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is the Company&#8217;s policy to provide for uncertain tax positions and the related interest and penalties based upon management&#8217;s assessment of whether a tax benefit is more likely than not to be sustained upon examination by tax authorities. The Company recognizes interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense.  The Company is subject to U.S. federal, New York, California, Texas, German and Australian income taxes. The Company is subject to U.S. federal or state income tax examination by tax authorities for tax returns filed for the years 2003 and forward due to the carryforward of NOLs. Tax years 2016 through 2021 are subject to audit by German and Australian tax authorities. The Company is not currently under examination by any tax jurisdictions.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930" name="us-gaap:EarningsPerSharePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8zNC9mcmFnOjZlNmZlYmNmYmQwYTRlNDE5NDE0ZWFhMGNlYTdjMWU2L3RleHRyZWdpb246NmU2ZmViY2ZiZDBhNGU0MTk0MTRlYWEwY2VhN2MxZTZfMTc1NDI_b799c06d-2569-4a44-8dbb-62004fb5d75e" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss Per Share</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share attributable to common stockholders is calculated by dividing the net loss by the weighted-average number of common shares outstanding for the period, without consideration for common stock equivalents. Diluted net loss per share attributable to common stockholders is computed by dividing the net loss by the weighted-average number of common shares and, if dilutive, common stock equivalents outstanding for the period determined using the treasury-stock method. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company&#8217;s net loss position.</span></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:12pt;text-indent:22.5pt"><ix:nonNumeric contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8zNC9mcmFnOjZlNmZlYmNmYmQwYTRlNDE5NDE0ZWFhMGNlYTdjMWU2L3RleHRyZWdpb246NmU2ZmViY2ZiZDBhNGU0MTk0MTRlYWEwY2VhN2MxZTZfMTc1NDk_a5cc9bc0-9375-4997-acb9-9359cae15192" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Potentially dilutive securities, not included in the calculation of diluted net loss per share attributable to common stockholders because to do so would be anti-dilutive, are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"><tr><td style="width:1.0%"></td><td style="width:73.751%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.953%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.955%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic3a03035d5534d539979b07aedea62c1_D20220101-20220930" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8zNC9mcmFnOjZlNmZlYmNmYmQwYTRlNDE5NDE0ZWFhMGNlYTdjMWU2L3RhYmxlOmM0ZjViMmM4OTkxYTQ4MDM4NTI2Mzc0NzJiZjk0NTIwL3RhYmxlcmFuZ2U6YzRmNWIyYzg5OTFhNDgwMzg1MjYzNzQ3MmJmOTQ1MjBfMi0xLTEtMS0zMDUwMA_61ae7e72-1a1f-4d1e-9f68-f8e1ddaffcb7">3,799,573</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id8129f471bae49039a917f1451ac8087_D20210101-20210930" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8zNC9mcmFnOjZlNmZlYmNmYmQwYTRlNDE5NDE0ZWFhMGNlYTdjMWU2L3RhYmxlOmM0ZjViMmM4OTkxYTQ4MDM4NTI2Mzc0NzJiZjk0NTIwL3RhYmxlcmFuZ2U6YzRmNWIyYzg5OTFhNDgwMzg1MjYzNzQ3MmJmOTQ1MjBfMi0zLTEtMS0zMDUwMA_907be8b6-4323-4c56-9c6e-fe87cda67373">2,045,960</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:nonNumeric></div><ix:nonNumeric contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8zNC9mcmFnOjZlNmZlYmNmYmQwYTRlNDE5NDE0ZWFhMGNlYTdjMWU2L3RleHRyZWdpb246NmU2ZmViY2ZiZDBhNGU0MTk0MTRlYWEwY2VhN2MxZTZfMTc1MzA_6e9d7498-b951-46e6-84fe-04a55fd0af2a" escape="true"><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued and/or Adopted Accounting Standards</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are no recently issued accounting standards that would have a significant impact on the company's consolidated financial statements.</span></div></ix:nonNumeric></ix:continuation><div id="ida7c333e3c58430eb83e8e950c50d811_37"></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3. <ix:nonNumeric contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930" name="us-gaap:SupplementalBalanceSheetDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8zNy9mcmFnOmVhYWM3YjljYjM4ZDQyZTM4OTQwZjgyZWE3Y2E4NDJkL3RleHRyZWdpb246ZWFhYzdiOWNiMzhkNDJlMzg5NDBmODJlYTdjYTg0MmRfMzU1_c9346d98-ff99-450a-a5a3-9c827c2c526a" continuedAt="i51488175ca7b464f85d5c5f0ac22cac0" escape="true">Balance Sheet Details</ix:nonNumeric></span></div><ix:continuation id="i51488175ca7b464f85d5c5f0ac22cac0"><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Current Assets and Prepaid Expenses</span></div><div style="margin-top:12pt;text-indent:22.5pt"><ix:nonNumeric contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930" name="us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8zNy9mcmFnOmVhYWM3YjljYjM4ZDQyZTM4OTQwZjgyZWE3Y2E4NDJkL3RleHRyZWdpb246ZWFhYzdiOWNiMzhkNDJlMzg5NDBmODJlYTdjYTg0MmRfMzQ4_b1d6b67a-796e-4b7a-9688-7cfdf127b6b0" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other Current Assets and Prepaid Expenses consist of (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.315%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.157%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.969%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.059%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid clinical and related costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2ba0b84078f4de2bc3079e992921b92_I20220930" decimals="-3" name="vtl:PrepaidClinicalAndRelatedCostsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8zNy9mcmFnOmVhYWM3YjljYjM4ZDQyZTM4OTQwZjgyZWE3Y2E4NDJkL3RhYmxlOjIwZWFkZWZjNmY4YzQ5YjlhOGVjZTE2ZDA3ZDU3ZGJhL3RhYmxlcmFuZ2U6MjBlYWRlZmM2ZjhjNDliOWE4ZWNlMTZkMDdkNTdkYmFfMi0xLTEtMS0zMDUwMA_d230af58-3ed8-446c-8d37-81da5e7b9914">8,938</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12246a01749f40d394a9437cb9938c91_I20211231" decimals="-3" name="vtl:PrepaidClinicalAndRelatedCostsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8zNy9mcmFnOmVhYWM3YjljYjM4ZDQyZTM4OTQwZjgyZWE3Y2E4NDJkL3RhYmxlOjIwZWFkZWZjNmY4YzQ5YjlhOGVjZTE2ZDA3ZDU3ZGJhL3RhYmxlcmFuZ2U6MjBlYWRlZmM2ZjhjNDliOWE4ZWNlMTZkMDdkNTdkYmFfMi0zLTEtMS0zMDUwMA_9561c2ec-ba68-4f89-a6e2-bca89955dd20">14,853</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">VAT receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2ba0b84078f4de2bc3079e992921b92_I20220930" decimals="-3" name="us-gaap:ValueAddedTaxReceivableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8zNy9mcmFnOmVhYWM3YjljYjM4ZDQyZTM4OTQwZjgyZWE3Y2E4NDJkL3RhYmxlOjIwZWFkZWZjNmY4YzQ5YjlhOGVjZTE2ZDA3ZDU3ZGJhL3RhYmxlcmFuZ2U6MjBlYWRlZmM2ZjhjNDliOWE4ZWNlMTZkMDdkNTdkYmFfMy0xLTEtMS0zMDUwMA_ea518522-d152-49b7-a442-5c283208ddab">241</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12246a01749f40d394a9437cb9938c91_I20211231" decimals="-3" name="us-gaap:ValueAddedTaxReceivableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8zNy9mcmFnOmVhYWM3YjljYjM4ZDQyZTM4OTQwZjgyZWE3Y2E4NDJkL3RhYmxlOjIwZWFkZWZjNmY4YzQ5YjlhOGVjZTE2ZDA3ZDU3ZGJhL3RhYmxlcmFuZ2U6MjBlYWRlZmM2ZjhjNDliOWE4ZWNlMTZkMDdkNTdkYmFfMy0zLTEtMS0zMDUwMA_ad6c83c7-a3d4-4f75-8df4-cd5e87e644bc">279</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Australian research and development tax incentive</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2ba0b84078f4de2bc3079e992921b92_I20220930" decimals="-3" name="vtl:ResearchAndDevelopmentTaxIncentiveCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8zNy9mcmFnOmVhYWM3YjljYjM4ZDQyZTM4OTQwZjgyZWE3Y2E4NDJkL3RhYmxlOjIwZWFkZWZjNmY4YzQ5YjlhOGVjZTE2ZDA3ZDU3ZGJhL3RhYmxlcmFuZ2U6MjBlYWRlZmM2ZjhjNDliOWE4ZWNlMTZkMDdkNTdkYmFfNC0xLTEtMS0zMDUwMA_8832733b-b1d6-4399-bdad-34b7e26195f7">3,150</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12246a01749f40d394a9437cb9938c91_I20211231" decimals="-3" name="vtl:ResearchAndDevelopmentTaxIncentiveCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8zNy9mcmFnOmVhYWM3YjljYjM4ZDQyZTM4OTQwZjgyZWE3Y2E4NDJkL3RhYmxlOjIwZWFkZWZjNmY4YzQ5YjlhOGVjZTE2ZDA3ZDU3ZGJhL3RhYmxlcmFuZ2U6MjBlYWRlZmM2ZjhjNDliOWE4ZWNlMTZkMDdkNTdkYmFfNC0zLTEtMS0zMDUwMA_86f48ccd-cae8-477e-b99d-330211021f28">1,871</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2ba0b84078f4de2bc3079e992921b92_I20220930" decimals="-3" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8zNy9mcmFnOmVhYWM3YjljYjM4ZDQyZTM4OTQwZjgyZWE3Y2E4NDJkL3RhYmxlOjIwZWFkZWZjNmY4YzQ5YjlhOGVjZTE2ZDA3ZDU3ZGJhL3RhYmxlcmFuZ2U6MjBlYWRlZmM2ZjhjNDliOWE4ZWNlMTZkMDdkNTdkYmFfNS0xLTEtMS0zMDUwMA_9dda7117-25b3-40bd-bd40-5fbf64b67389">1,549</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12246a01749f40d394a9437cb9938c91_I20211231" decimals="-3" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8zNy9mcmFnOmVhYWM3YjljYjM4ZDQyZTM4OTQwZjgyZWE3Y2E4NDJkL3RhYmxlOjIwZWFkZWZjNmY4YzQ5YjlhOGVjZTE2ZDA3ZDU3ZGJhL3RhYmxlcmFuZ2U6MjBlYWRlZmM2ZjhjNDliOWE4ZWNlMTZkMDdkNTdkYmFfNS0zLTEtMS0zMDUwMA_24b61a60-20dd-4252-b5d5-ce568af1185d">1,122</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2ba0b84078f4de2bc3079e992921b92_I20220930" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8zNy9mcmFnOmVhYWM3YjljYjM4ZDQyZTM4OTQwZjgyZWE3Y2E4NDJkL3RhYmxlOjIwZWFkZWZjNmY4YzQ5YjlhOGVjZTE2ZDA3ZDU3ZGJhL3RhYmxlcmFuZ2U6MjBlYWRlZmM2ZjhjNDliOWE4ZWNlMTZkMDdkNTdkYmFfNi0xLTEtMS0zMDUwMA_11f84083-aab2-4034-9722-dde117982cec">13,878</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12246a01749f40d394a9437cb9938c91_I20211231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8zNy9mcmFnOmVhYWM3YjljYjM4ZDQyZTM4OTQwZjgyZWE3Y2E4NDJkL3RhYmxlOjIwZWFkZWZjNmY4YzQ5YjlhOGVjZTE2ZDA3ZDU3ZGJhL3RhYmxlcmFuZ2U6MjBlYWRlZmM2ZjhjNDliOWE4ZWNlMTZkMDdkNTdkYmFfNi0zLTEtMS0zMDUwMA_cf2584dd-eaa0-4960-9016-6e7d708e4db0">18,125</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Payable</span></div><div style="margin-top:12pt;text-indent:22.5pt"><ix:nonNumeric contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930" name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8zNy9mcmFnOmVhYWM3YjljYjM4ZDQyZTM4OTQwZjgyZWE3Y2E4NDJkL3RleHRyZWdpb246ZWFhYzdiOWNiMzhkNDJlMzg5NDBmODJlYTdjYTg0MmRfMzUz_60d021f7-6318-45f7-bcf2-1796e04d6e9c" continuedAt="ifa1dd42c89bd4f7089951fdec213e676" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts Payable consist of (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.046%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.969%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.474%"></td><td style="width:0.1%"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2ba0b84078f4de2bc3079e992921b92_I20220930" decimals="-3" name="vtl:ClinicalCostsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8zNy9mcmFnOmVhYWM3YjljYjM4ZDQyZTM4OTQwZjgyZWE3Y2E4NDJkL3RhYmxlOjI2YjExNjY5Njg4OTQ2MjY5ZDhhZTczNWI5OTIzMzQ5L3RhYmxlcmFuZ2U6MjZiMTE2Njk2ODg5NDYyNjlkOGFlNzM1Yjk5MjMzNDlfMi0xLTEtMS0zMDUwMA_dc11b11b-642e-4746-b7e6-2323b21a877b">3,748</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12246a01749f40d394a9437cb9938c91_I20211231" decimals="-3" name="vtl:ClinicalCostsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8zNy9mcmFnOmVhYWM3YjljYjM4ZDQyZTM4OTQwZjgyZWE3Y2E4NDJkL3RhYmxlOjI2YjExNjY5Njg4OTQ2MjY5ZDhhZTczNWI5OTIzMzQ5L3RhYmxlcmFuZ2U6MjZiMTE2Njk2ODg5NDYyNjlkOGFlNzM1Yjk5MjMzNDlfMi0zLTEtMS0zMDUwMA_63aebabd-1ff5-4fa3-9977-34318d469697">3,427</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legal and audit costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2ba0b84078f4de2bc3079e992921b92_I20220930" decimals="-3" name="vtl:LegalAndAuditCostsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8zNy9mcmFnOmVhYWM3YjljYjM4ZDQyZTM4OTQwZjgyZWE3Y2E4NDJkL3RhYmxlOjI2YjExNjY5Njg4OTQ2MjY5ZDhhZTczNWI5OTIzMzQ5L3RhYmxlcmFuZ2U6MjZiMTE2Njk2ODg5NDYyNjlkOGFlNzM1Yjk5MjMzNDlfMy0xLTEtMS0zMDUwMA_96054060-be7c-451d-bb07-a3b74749749d">114</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12246a01749f40d394a9437cb9938c91_I20211231" decimals="-3" name="vtl:LegalAndAuditCostsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8zNy9mcmFnOmVhYWM3YjljYjM4ZDQyZTM4OTQwZjgyZWE3Y2E4NDJkL3RhYmxlOjI2YjExNjY5Njg4OTQ2MjY5ZDhhZTczNWI5OTIzMzQ5L3RhYmxlcmFuZ2U6MjZiMTE2Njk2ODg5NDYyNjlkOGFlNzM1Yjk5MjMzNDlfMy0zLTEtMS0zMDUwMA_65d67307-a47b-4973-9b39-900d9a2efb63">72</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2ba0b84078f4de2bc3079e992921b92_I20220930" decimals="-3" name="us-gaap:AccountsPayableOtherCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8zNy9mcmFnOmVhYWM3YjljYjM4ZDQyZTM4OTQwZjgyZWE3Y2E4NDJkL3RhYmxlOjI2YjExNjY5Njg4OTQ2MjY5ZDhhZTczNWI5OTIzMzQ5L3RhYmxlcmFuZ2U6MjZiMTE2Njk2ODg5NDYyNjlkOGFlNzM1Yjk5MjMzNDlfNS0xLTEtMS0zMDUwMA_0b6b8558-995c-4caa-82b2-e0d8a061b4c4">310</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12246a01749f40d394a9437cb9938c91_I20211231" decimals="-3" name="us-gaap:AccountsPayableOtherCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8zNy9mcmFnOmVhYWM3YjljYjM4ZDQyZTM4OTQwZjgyZWE3Y2E4NDJkL3RhYmxlOjI2YjExNjY5Njg4OTQ2MjY5ZDhhZTczNWI5OTIzMzQ5L3RhYmxlcmFuZ2U6MjZiMTE2Njk2ODg5NDYyNjlkOGFlNzM1Yjk5MjMzNDlfNS0zLTEtMS0zMDUwMA_642cd634-3de9-41bf-a663-9cb88ecf64a7">246</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2ba0b84078f4de2bc3079e992921b92_I20220930" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8zNy9mcmFnOmVhYWM3YjljYjM4ZDQyZTM4OTQwZjgyZWE3Y2E4NDJkL3RhYmxlOjI2YjExNjY5Njg4OTQ2MjY5ZDhhZTczNWI5OTIzMzQ5L3RhYmxlcmFuZ2U6MjZiMTE2Njk2ODg5NDYyNjlkOGFlNzM1Yjk5MjMzNDlfNi0xLTEtMS0zMDUwMA_89841f2c-3563-407d-9902-4603b7d96c84">4,172</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12246a01749f40d394a9437cb9938c91_I20211231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8zNy9mcmFnOmVhYWM3YjljYjM4ZDQyZTM4OTQwZjgyZWE3Y2E4NDJkL3RhYmxlOjI2YjExNjY5Njg4OTQ2MjY5ZDhhZTczNWI5OTIzMzQ5L3RhYmxlcmFuZ2U6MjZiMTE2Njk2ODg5NDYyNjlkOGFlNzM1Yjk5MjMzNDlfNi0zLTEtMS0zMDUwMA_7d11af9e-89cd-401c-ab87-39b18dba8949">3,745</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Expenses</span></div><div style="margin-top:12pt;text-indent:22.5pt"><ix:continuation id="ifa1dd42c89bd4f7089951fdec213e676"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consist of (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.484%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued clinical and related costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2ba0b84078f4de2bc3079e992921b92_I20220930" decimals="-3" name="vtl:AccruedClinicalCostsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8zNy9mcmFnOmVhYWM3YjljYjM4ZDQyZTM4OTQwZjgyZWE3Y2E4NDJkL3RhYmxlOjhjYWQ4MTBiZTM0NjQ4NTY5YzM1ZDJlY2FkMTY0NDYyL3RhYmxlcmFuZ2U6OGNhZDgxMGJlMzQ2NDg1NjljMzVkMmVjYWQxNjQ0NjJfMi0xLTEtMS0zMDUwMA_4fa4e824-da1e-47a7-81ef-5c3f6d9ea2c8">5,504</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12246a01749f40d394a9437cb9938c91_I20211231" decimals="-3" name="vtl:AccruedClinicalCostsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8zNy9mcmFnOmVhYWM3YjljYjM4ZDQyZTM4OTQwZjgyZWE3Y2E4NDJkL3RhYmxlOjhjYWQ4MTBiZTM0NjQ4NTY5YzM1ZDJlY2FkMTY0NDYyL3RhYmxlcmFuZ2U6OGNhZDgxMGJlMzQ2NDg1NjljMzVkMmVjYWQxNjQ0NjJfMi0zLTEtMS0zMDUwMA_4eb7001f-3d0f-4194-8da1-20872f36e887">6,214</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued legal and audit costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2ba0b84078f4de2bc3079e992921b92_I20220930" decimals="-3" name="vtl:AccruedLegalAndAuditCostsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8zNy9mcmFnOmVhYWM3YjljYjM4ZDQyZTM4OTQwZjgyZWE3Y2E4NDJkL3RhYmxlOjhjYWQ4MTBiZTM0NjQ4NTY5YzM1ZDJlY2FkMTY0NDYyL3RhYmxlcmFuZ2U6OGNhZDgxMGJlMzQ2NDg1NjljMzVkMmVjYWQxNjQ0NjJfMy0xLTEtMS0zMDUwMA_2d474d36-5134-427f-926e-418fb98b2138">85</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12246a01749f40d394a9437cb9938c91_I20211231" decimals="-3" name="vtl:AccruedLegalAndAuditCostsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8zNy9mcmFnOmVhYWM3YjljYjM4ZDQyZTM4OTQwZjgyZWE3Y2E4NDJkL3RhYmxlOjhjYWQ4MTBiZTM0NjQ4NTY5YzM1ZDJlY2FkMTY0NDYyL3RhYmxlcmFuZ2U6OGNhZDgxMGJlMzQ2NDg1NjljMzVkMmVjYWQxNjQ0NjJfMy0zLTEtMS0zMDUwMA_71fa7b0b-a8d2-49fe-81b0-dba3a4e4dfd1">96</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2ba0b84078f4de2bc3079e992921b92_I20220930" decimals="-3" name="vtl:AccruedCompensationCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8zNy9mcmFnOmVhYWM3YjljYjM4ZDQyZTM4OTQwZjgyZWE3Y2E4NDJkL3RhYmxlOjhjYWQ4MTBiZTM0NjQ4NTY5YzM1ZDJlY2FkMTY0NDYyL3RhYmxlcmFuZ2U6OGNhZDgxMGJlMzQ2NDg1NjljMzVkMmVjYWQxNjQ0NjJfNC0xLTEtMS0zMDUwMA_66aea635-1fbc-41a7-93d2-685b05e93481">881</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12246a01749f40d394a9437cb9938c91_I20211231" decimals="-3" name="vtl:AccruedCompensationCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8zNy9mcmFnOmVhYWM3YjljYjM4ZDQyZTM4OTQwZjgyZWE3Y2E4NDJkL3RhYmxlOjhjYWQ4MTBiZTM0NjQ4NTY5YzM1ZDJlY2FkMTY0NDYyL3RhYmxlcmFuZ2U6OGNhZDgxMGJlMzQ2NDg1NjljMzVkMmVjYWQxNjQ0NjJfNC0zLTEtMS0zMDUwMA_8323b6ee-9cd6-4601-903d-2cc28e9bdd41">674</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2ba0b84078f4de2bc3079e992921b92_I20220930" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8zNy9mcmFnOmVhYWM3YjljYjM4ZDQyZTM4OTQwZjgyZWE3Y2E4NDJkL3RhYmxlOjhjYWQ4MTBiZTM0NjQ4NTY5YzM1ZDJlY2FkMTY0NDYyL3RhYmxlcmFuZ2U6OGNhZDgxMGJlMzQ2NDg1NjljMzVkMmVjYWQxNjQ0NjJfNS0xLTEtMS0zMDUwMA_afa51968-59a4-489a-8acb-4ddbdeea2488">153</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12246a01749f40d394a9437cb9938c91_I20211231" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8zNy9mcmFnOmVhYWM3YjljYjM4ZDQyZTM4OTQwZjgyZWE3Y2E4NDJkL3RhYmxlOjhjYWQ4MTBiZTM0NjQ4NTY5YzM1ZDJlY2FkMTY0NDYyL3RhYmxlcmFuZ2U6OGNhZDgxMGJlMzQ2NDg1NjljMzVkMmVjYWQxNjQ0NjJfNS0zLTEtMS0zMDUwMA_45a65edc-db0c-44ff-93c3-4d300556c319">87</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2ba0b84078f4de2bc3079e992921b92_I20220930" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8zNy9mcmFnOmVhYWM3YjljYjM4ZDQyZTM4OTQwZjgyZWE3Y2E4NDJkL3RhYmxlOjhjYWQ4MTBiZTM0NjQ4NTY5YzM1ZDJlY2FkMTY0NDYyL3RhYmxlcmFuZ2U6OGNhZDgxMGJlMzQ2NDg1NjljMzVkMmVjYWQxNjQ0NjJfNi0xLTEtMS0zMDUwMA_c44967c6-1ee2-453c-927b-daaaa13d9ed0">6,623</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12246a01749f40d394a9437cb9938c91_I20211231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8zNy9mcmFnOmVhYWM3YjljYjM4ZDQyZTM4OTQwZjgyZWE3Y2E4NDJkL3RhYmxlOjhjYWQ4MTBiZTM0NjQ4NTY5YzM1ZDJlY2FkMTY0NDYyL3RhYmxlcmFuZ2U6OGNhZDgxMGJlMzQ2NDg1NjljMzVkMmVjYWQxNjQ0NjJfNi0zLTEtMS0zMDUwMA_f6663456-7f9a-4814-ae67-92636067e20d">7,071</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Current Liabilities</span></div><div style="margin-top:12pt;text-indent:22.5pt"><ix:nonNumeric contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930" name="us-gaap:OtherCurrentLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8zNy9mcmFnOmVhYWM3YjljYjM4ZDQyZTM4OTQwZjgyZWE3Y2E4NDJkL3RleHRyZWdpb246ZWFhYzdiOWNiMzhkNDJlMzg5NDBmODJlYTdjYTg0MmRfMzU0_7f880802-5000-492d-8b2b-01ac247ef445" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other Current Liabilities consist of (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.469%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.527%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.752%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.912%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.740%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2ba0b84078f4de2bc3079e992921b92_I20220930" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8zNy9mcmFnOmVhYWM3YjljYjM4ZDQyZTM4OTQwZjgyZWE3Y2E4NDJkL3RhYmxlOjAyM2Q4ODJhZDIzNjRhZDhhYzE0ZDdiMDFhNzIxOTUwL3RhYmxlcmFuZ2U6MDIzZDg4MmFkMjM2NGFkOGFjMTRkN2IwMWE3MjE5NTBfMi0xLTEtMS0zMDUwMA_0492016e-12d0-48ad-a5db-4d409a0d7b66">395</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12246a01749f40d394a9437cb9938c91_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8zNy9mcmFnOmVhYWM3YjljYjM4ZDQyZTM4OTQwZjgyZWE3Y2E4NDJkL3RhYmxlOjAyM2Q4ODJhZDIzNjRhZDhhYzE0ZDdiMDFhNzIxOTUwL3RhYmxlcmFuZ2U6MDIzZDg4MmFkMjM2NGFkOGFjMTRkN2IwMWE3MjE5NTBfMi0zLTEtMS0zMDUwMA_1ea556c1-8fff-4a8a-a68e-af945455ca88">408</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2ba0b84078f4de2bc3079e992921b92_I20220930" decimals="-3" name="us-gaap:OtherSundryLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8zNy9mcmFnOmVhYWM3YjljYjM4ZDQyZTM4OTQwZjgyZWE3Y2E4NDJkL3RhYmxlOjAyM2Q4ODJhZDIzNjRhZDhhYzE0ZDdiMDFhNzIxOTUwL3RhYmxlcmFuZ2U6MDIzZDg4MmFkMjM2NGFkOGFjMTRkN2IwMWE3MjE5NTBfMy0xLTEtMS0zMDUwMA_9c200a7d-2675-43ed-b1f8-a20e3beda365">324</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12246a01749f40d394a9437cb9938c91_I20211231" decimals="-3" name="us-gaap:OtherSundryLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8zNy9mcmFnOmVhYWM3YjljYjM4ZDQyZTM4OTQwZjgyZWE3Y2E4NDJkL3RhYmxlOjAyM2Q4ODJhZDIzNjRhZDhhYzE0ZDdiMDFhNzIxOTUwL3RhYmxlcmFuZ2U6MDIzZDg4MmFkMjM2NGFkOGFjMTRkN2IwMWE3MjE5NTBfMy0zLTEtMS0zMDUwMA_0e8f16b1-6767-49e2-9b2a-f863579230da">177</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2ba0b84078f4de2bc3079e992921b92_I20220930" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8zNy9mcmFnOmVhYWM3YjljYjM4ZDQyZTM4OTQwZjgyZWE3Y2E4NDJkL3RhYmxlOjAyM2Q4ODJhZDIzNjRhZDhhYzE0ZDdiMDFhNzIxOTUwL3RhYmxlcmFuZ2U6MDIzZDg4MmFkMjM2NGFkOGFjMTRkN2IwMWE3MjE5NTBfNC0xLTEtMS0zMDUwMA_f4c57551-28a3-4185-9ab1-49241afba009">719</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12246a01749f40d394a9437cb9938c91_I20211231" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8zNy9mcmFnOmVhYWM3YjljYjM4ZDQyZTM4OTQwZjgyZWE3Y2E4NDJkL3RhYmxlOjAyM2Q4ODJhZDIzNjRhZDhhYzE0ZDdiMDFhNzIxOTUwL3RhYmxlcmFuZ2U6MDIzZDg4MmFkMjM2NGFkOGFjMTRkN2IwMWE3MjE5NTBfNC0zLTEtMS0zMDUwMA_aa899fd6-9969-409e-94d5-ff638c4096b3">585</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></ix:nonNumeric></div></ix:continuation><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><div id="ida7c333e3c58430eb83e8e950c50d811_40"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4. <ix:nonNumeric contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80MC9mcmFnOmI3MzFjZTk4M2NmOTRlZWY5MTMzMTgwMzhmYTM5Mzg4L3RleHRyZWdpb246YjczMWNlOTgzY2Y5NGVlZjkxMzMxODAzOGZhMzkzODhfNTE0NQ_e9b2c7a4-2f06-4f9f-ab39-372d6a15eb9a" continuedAt="i1d2c483eeb86447cb8a7a2e78f0a364c" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><ix:continuation id="i1d2c483eeb86447cb8a7a2e78f0a364c" continuedAt="i5245b7435cd842f792d32ade632d620d"><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Leases</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases certain office space under non-cancelable operating leases. The leases terminate on April 30, 2023 for the New York City office and on June 30, 2025 for the Gr&#228;felfing, Germany office.  These leases include both lease (e.g., fixed rent) and non-lease components (e.g., common-area and other maintenance costs). The non-lease components are deemed to be executory costs and are therefore excluded from the minimum lease payments used to determine the present value of the operating lease obligation and related right-of-use asset. The New York City lease has renewal options, but they were not included in calculating the right of use asset and liabilities.  On April 7, 2020, the Company signed a <ix:nonNumeric contextRef="iefd1980314f44440b5198657ab592ad5_I20200407" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80MC9mcmFnOmI3MzFjZTk4M2NmOTRlZWY5MTMzMTgwMzhmYTM5Mzg4L3RleHRyZWdpb246YjczMWNlOTgzY2Y5NGVlZjkxMzMxODAzOGZhMzkzODhfNDk0NzgwMjMzNTg0Nw_7386c233-f590-4501-93ee-1a3246dadac5">five year</ix:nonNumeric> lease for its facility in Gr&#228;felfing, Germany. On March 1, 2021, and August 1, 2022, the Company added additional lease space at the Gr&#228;felfing, Germany office.  Renewal options were not included in calculating the right of use asset and liabilities for this facility. The leases do not have concessions, leasehold improvement incentives or other build-out clauses. Further, the leases do not contain contingent rent provisions. The New York City lease had a <ix:nonNumeric contextRef="id2f24df2744547978cca7abe63d3ddfa_D20220101-20220930" name="vtl:LesseeOperatingLeaseRentHolidayPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80MC9mcmFnOmI3MzFjZTk4M2NmOTRlZWY5MTMzMTgwMzhmYTM5Mzg4L3RleHRyZWdpb246YjczMWNlOTgzY2Y5NGVlZjkxMzMxODAzOGZhMzkzODhfNDk0NzgwMjMzNTg0OA_8bd9daa4-8a86-46bb-828d-27011f82acb3">six month</ix:nonNumeric> rent holiday at the beginning of the lease.  There were net additions to right of use assets of $<ix:nonFraction unitRef="usd" contextRef="i707a1cd4886c4397999788b4d4817cc8_D20210301-20210331" decimals="-3" name="vtl:IncreaseDecreaseInOperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80MC9mcmFnOmI3MzFjZTk4M2NmOTRlZWY5MTMzMTgwMzhmYTM5Mzg4L3RleHRyZWdpb246YjczMWNlOTgzY2Y5NGVlZjkxMzMxODAzOGZhMzkzODhfNTQ5NzU1ODIyODk2_41fddddb-d524-47be-9f02-dde6227bfcbb">435,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i23801a5cc9424606a18bc0c74d94ebc9_D20220801-20220801" decimals="-3" name="vtl:IncreaseDecreaseInOperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80MC9mcmFnOmI3MzFjZTk4M2NmOTRlZWY5MTMzMTgwMzhmYTM5Mzg4L3RleHRyZWdpb246YjczMWNlOTgzY2Y5NGVlZjkxMzMxODAzOGZhMzkzODhfNDk0NzgwMjMzNjkyMQ_54f92779-ee94-4d3e-b98d-d63002160a58">642,000</ix:nonFraction> as a result of signing for additional lease space at the Gr&#228;felfing, Germany office in March 2021 and August 2022, respectively.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;The leases do not provide an implicit rate and, due to the lack of a commercially salable product, the Company is generally considered unable to obtain commercial credit. Therefore, the Company estimated its incremental interest rate to be <ix:nonFraction unitRef="number" contextRef="ib2ba0b84078f4de2bc3079e992921b92_I20220930" decimals="2" name="vtl:OperatingLeaseIncrementalBorrowingRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80MC9mcmFnOmI3MzFjZTk4M2NmOTRlZWY5MTMzMTgwMzhmYTM5Mzg4L3RleHRyZWdpb246YjczMWNlOTgzY2Y5NGVlZjkxMzMxODAzOGZhMzkzODhfNTQ5NzU1ODIzMjQw_eedec0d8-e61b-44d2-9ece-6b2129522d7e">6</ix:nonFraction>%, considering the quoted rates for the lowest investment-grade debt and the interest rates implicit in recent financing leases. Immunic used its estimated incremental borrowing rate and other information available at the lease commencement date in determining the present value of the lease payments.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;Immunic&#8217;s operating lease costs and variable lease costs were $<ix:nonFraction unitRef="usd" contextRef="i25a8ea2d7c9f4bfd8f72223c8ac18c65_D20220701-20220930" decimals="-3" name="vtl:OperatingAndVariableLeasesCost" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80MC9mcmFnOmI3MzFjZTk4M2NmOTRlZWY5MTMzMTgwMzhmYTM5Mzg4L3RleHRyZWdpb246YjczMWNlOTgzY2Y5NGVlZjkxMzMxODAzOGZhMzkzODhfNDk0NzgwMjMzNjM4NQ_e5f3b4ea-1c90-4862-8763-c6681f86b7c6">232,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="ib52579de36d54242a791b9e3f8019a00_D20210701-20210930" decimals="-3" name="vtl:OperatingAndVariableLeasesCost" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80MC9mcmFnOmI3MzFjZTk4M2NmOTRlZWY5MTMzMTgwMzhmYTM5Mzg4L3RleHRyZWdpb246YjczMWNlOTgzY2Y5NGVlZjkxMzMxODAzOGZhMzkzODhfNDk0NzgwMjMzNjM5NQ_8b4a22c9-5dd5-4a59-a9e1-1c19fdadf26e">133,000</ix:nonFraction> for the three months ended September 30, 2022 and 2021, respectively and $<ix:nonFraction unitRef="usd" contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930" decimals="-3" name="vtl:OperatingAndVariableLeasesCost" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80MC9mcmFnOmI3MzFjZTk4M2NmOTRlZWY5MTMzMTgwMzhmYTM5Mzg4L3RleHRyZWdpb246YjczMWNlOTgzY2Y5NGVlZjkxMzMxODAzOGZhMzkzODhfNDk0NzgwMjMzNjQwNQ_eaf2de8a-3eb1-4964-8b9a-f885e4b39789">498,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i69e8bcaae5bf44c9a03cf7f5bd08e6b8_D20210101-20210930" decimals="-3" name="vtl:OperatingAndVariableLeasesCost" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80MC9mcmFnOmI3MzFjZTk4M2NmOTRlZWY5MTMzMTgwMzhmYTM5Mzg4L3RleHRyZWdpb246YjczMWNlOTgzY2Y5NGVlZjkxMzMxODAzOGZhMzkzODhfNDk0NzgwMjMzNjQxNQ_68054d1e-87c6-449d-a5e5-b6d2332e2e5e">372,000</ix:nonFraction> for the nine months ended September 30, 2022 and 2021, respectively.  Variable lease costs consist primarily of common area maintenance costs, insurance and taxes which are paid based upon actual costs incurred by the lessor.</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-indent:22.5pt"><ix:nonNumeric contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80MC9mcmFnOmI3MzFjZTk4M2NmOTRlZWY5MTMzMTgwMzhmYTM5Mzg4L3RleHRyZWdpb246YjczMWNlOTgzY2Y5NGVlZjkxMzMxODAzOGZhMzkzODhfNTE0NA_0d726821-c1c5-469a-93a8-13ad398cca1a" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of the operating lease obligation are as follows as of September 30, 2022 (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.660%"><tr><td style="width:1.0%"></td><td style="width:84.079%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.596%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.925%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2ba0b84078f4de2bc3079e992921b92_I20220930" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80MC9mcmFnOmI3MzFjZTk4M2NmOTRlZWY5MTMzMTgwMzhmYTM5Mzg4L3RhYmxlOmMxZTU4ODVkZTJmMDRlNDU4MzM1MTI1MjE5ZGY4Y2FhL3RhYmxlcmFuZ2U6YzFlNTg4NWRlMmYwNGU0NTgzMzUxMjUyMTlkZjhjYWFfMC0yLTEtMS0zMDUwMA_c932ec3e-7aad-4648-9393-29b06a03de33">169</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2ba0b84078f4de2bc3079e992921b92_I20220930" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80MC9mcmFnOmI3MzFjZTk4M2NmOTRlZWY5MTMzMTgwMzhmYTM5Mzg4L3RhYmxlOmMxZTU4ODVkZTJmMDRlNDU4MzM1MTI1MjE5ZGY4Y2FhL3RhYmxlcmFuZ2U6YzFlNTg4NWRlMmYwNGU0NTgzMzUxMjUyMTlkZjhjYWFfMS0yLTEtMS0zMDUwMA_10d8478d-7e5b-4024-bdda-6fcf434f613a">528</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2ba0b84078f4de2bc3079e992921b92_I20220930" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80MC9mcmFnOmI3MzFjZTk4M2NmOTRlZWY5MTMzMTgwMzhmYTM5Mzg4L3RhYmxlOmMxZTU4ODVkZTJmMDRlNDU4MzM1MTI1MjE5ZGY4Y2FhL3RhYmxlcmFuZ2U6YzFlNTg4NWRlMmYwNGU0NTgzMzUxMjUyMTlkZjhjYWFfMi0yLTEtMS0zMDUwMA_de2f5b64-43cb-40b7-a40a-33675d009f7f">454</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2ba0b84078f4de2bc3079e992921b92_I20220930" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80MC9mcmFnOmI3MzFjZTk4M2NmOTRlZWY5MTMzMTgwMzhmYTM5Mzg4L3RhYmxlOmMxZTU4ODVkZTJmMDRlNDU4MzM1MTI1MjE5ZGY4Y2FhL3RhYmxlcmFuZ2U6YzFlNTg4NWRlMmYwNGU0NTgzMzUxMjUyMTlkZjhjYWFfMy0yLTEtMS0zMDUwMA_c7cc130d-1272-4a01-8dfd-857586c80bfd">227</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2ba0b84078f4de2bc3079e992921b92_I20220930" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80MC9mcmFnOmI3MzFjZTk4M2NmOTRlZWY5MTMzMTgwMzhmYTM5Mzg4L3RhYmxlOmMxZTU4ODVkZTJmMDRlNDU4MzM1MTI1MjE5ZGY4Y2FhL3RhYmxlcmFuZ2U6YzFlNTg4NWRlMmYwNGU0NTgzMzUxMjUyMTlkZjhjYWFfNC0yLTEtMS0zMDUwMA_fbade485-2f13-4918-889e-4502bf085610">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2ba0b84078f4de2bc3079e992921b92_I20220930" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80MC9mcmFnOmI3MzFjZTk4M2NmOTRlZWY5MTMzMTgwMzhmYTM5Mzg4L3RhYmxlOmMxZTU4ODVkZTJmMDRlNDU4MzM1MTI1MjE5ZGY4Y2FhL3RhYmxlcmFuZ2U6YzFlNTg4NWRlMmYwNGU0NTgzMzUxMjUyMTlkZjhjYWFfNS0yLTEtMS0zMDUwMA_47baf050-a796-417d-aa53-113a241da6f7">1,378</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2ba0b84078f4de2bc3079e992921b92_I20220930" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80MC9mcmFnOmI3MzFjZTk4M2NmOTRlZWY5MTMzMTgwMzhmYTM5Mzg4L3RhYmxlOmMxZTU4ODVkZTJmMDRlNDU4MzM1MTI1MjE5ZGY4Y2FhL3RhYmxlcmFuZ2U6YzFlNTg4NWRlMmYwNGU0NTgzMzUxMjUyMTlkZjhjYWFfNi0yLTEtMS0zMDUwMA_ea922b37-8538-426e-9a02-be07933aa682">104</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PV of obligation</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2ba0b84078f4de2bc3079e992921b92_I20220930" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80MC9mcmFnOmI3MzFjZTk4M2NmOTRlZWY5MTMzMTgwMzhmYTM5Mzg4L3RhYmxlOmMxZTU4ODVkZTJmMDRlNDU4MzM1MTI1MjE5ZGY4Y2FhL3RhYmxlcmFuZ2U6YzFlNTg4NWRlMmYwNGU0NTgzMzUxMjUyMTlkZjhjYWFfNy0yLTEtMS0zMDUwMA_e0d136ff-a250-4c76-842e-057e893d3da3">1,274</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-top:12pt;text-indent:22.5pt"><span><br/></span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contractual Obligations</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2022, the Company has non-cancelable contractual obligations under certain agreements related to its development programs IMU-838, IMU-935 and IMU-856 totaling approximately $<ix:nonFraction unitRef="usd" contextRef="ib2ba0b84078f4de2bc3079e992921b92_I20220930" decimals="-5" name="us-gaap:ContractualObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80MC9mcmFnOmI3MzFjZTk4M2NmOTRlZWY5MTMzMTgwMzhmYTM5Mzg4L3RleHRyZWdpb246YjczMWNlOTgzY2Y5NGVlZjkxMzMxODAzOGZhMzkzODhfNTQ5NzU1ODI0ODAw_0e3491fd-7dc3-497d-ad16-e9d19a440634">2.7</ix:nonFraction> million, which is expected to be paid over the next twelve months.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Commitments and Obligations</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2016, the Company entered into a purchase agreement (the &#8220;Agreement&#8221;) with 4SC AG, whereby the Company acquired certain assets, including the rights to patents and patent applications, trademarks and know-how. This transaction has </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i5245b7435cd842f792d32ade632d620d"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">been accounted for as an asset acquisition under Accounting Standards Update 2017-01 - Business Combinations (Topic 805): Clarifying the Definition of a Business. The Agreement included payments (Tranches III and IV) that were contingent upon the occurrence of certain events and required the Company to pay royalties equal to <ix:nonFraction unitRef="number" contextRef="i85fd4b228c8e4e22aa84564d8a1092a4_D20160501-20160531" decimals="3" name="vtl:AssetPurchaseAgreementRoyaltiesAsPercentOfAggregatedNetSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80MC9mcmFnOmI3MzFjZTk4M2NmOTRlZWY5MTMzMTgwMzhmYTM5Mzg4L3RleHRyZWdpb246YjczMWNlOTgzY2Y5NGVlZjkxMzMxODAzOGZhMzkzODhfMzU2NA_e1518e15-4d8a-4bb6-90a5-2e9ec5b70ed5">4.4</ix:nonFraction>% of the aggregated net sales for a certain period as defined in the Agreement (Tranche III) upon commercialization of the acquired assets. Effective April 12, 2019, the parties agreed to settle Tranche IV by issuing <ix:nonFraction unitRef="shares" contextRef="i13be27ffd0404758995be06dca534f38_I20190412" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80MC9mcmFnOmI3MzFjZTk4M2NmOTRlZWY5MTMzMTgwMzhmYTM5Mzg4L3RleHRyZWdpb246YjczMWNlOTgzY2Y5NGVlZjkxMzMxODAzOGZhMzkzODhfMzc4Mg_80b9d73c-2328-4cd2-901d-66231815114e">120,070</ix:nonFraction> shares of the Company&#8217;s common stock, immediately following the Transaction, to 4SC AG while keeping Tranche III in effect. Approximately $<ix:nonFraction unitRef="usd" contextRef="i13be27ffd0404758995be06dca534f38_I20190412" decimals="-5" name="us-gaap:CommonStockValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80MC9mcmFnOmI3MzFjZTk4M2NmOTRlZWY5MTMzMTgwMzhmYTM5Mzg4L3RleHRyZWdpb246YjczMWNlOTgzY2Y5NGVlZjkxMzMxODAzOGZhMzkzODhfMzkyMw_783e4288-4970-491a-a5f2-c0866b80dde9">1.5</ix:nonFraction> million of expense was recorded as a result of the issuance of these shares on April 12, 2019. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 31, 2021, Immunic AG, a wholly-owned subsidiary of the Company, and 4SC AG entered into a Settlement Agreement, pursuant to which Immunic AG settled its remaining obligation of the <ix:nonFraction unitRef="number" contextRef="i7ce199652934499fa56ce12df1fabbef_D20210331-20210331" decimals="3" name="vtl:AssetPurchaseAgreementRoyaltiesAsPercentOfAggregatedNetSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80MC9mcmFnOmI3MzFjZTk4M2NmOTRlZWY5MTMzMTgwMzhmYTM5Mzg4L3RleHRyZWdpb246YjczMWNlOTgzY2Y5NGVlZjkxMzMxODAzOGZhMzkzODhfNDIwNA_b45d13e6-98df-41da-a8a5-e1a050c3e0ef">4.4</ix:nonFraction>% royalty on net sales for $<ix:nonFraction unitRef="usd" contextRef="i7ce199652934499fa56ce12df1fabbef_D20210331-20210331" decimals="-4" name="vtl:RoyaltySettlementAgreementSalesNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80MC9mcmFnOmI3MzFjZTk4M2NmOTRlZWY5MTMzMTgwMzhmYTM5Mzg4L3RleHRyZWdpb246YjczMWNlOTgzY2Y5NGVlZjkxMzMxODAzOGZhMzkzODhfNDIzMg_1902f41d-9e48-46b0-8ac9-e86dbf23a705">17.25</ix:nonFraction>&#160;million (Tranche III of the Agreement). The payment was made <ix:nonFraction unitRef="number" contextRef="i42d359c425714cf8b47c82373a440814_I20210331" decimals="INF" name="vtl:RoyaltySettlementAgreementCashPaymentPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80MC9mcmFnOmI3MzFjZTk4M2NmOTRlZWY5MTMzMTgwMzhmYTM5Mzg4L3RleHRyZWdpb246YjczMWNlOTgzY2Y5NGVlZjkxMzMxODAzOGZhMzkzODhfNDI4OA_3f4ad396-9dca-48da-9597-38b52cb3f438">50</ix:nonFraction>% in cash and <ix:nonFraction unitRef="number" contextRef="i42d359c425714cf8b47c82373a440814_I20210331" decimals="INF" name="vtl:RoyaltySettlementAgreementSharesPaymentPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80MC9mcmFnOmI3MzFjZTk4M2NmOTRlZWY5MTMzMTgwMzhmYTM5Mzg4L3RleHRyZWdpb246YjczMWNlOTgzY2Y5NGVlZjkxMzMxODAzOGZhMzkzODhfNDMwMw_dc5e4dfa-f6e5-48f6-a2ac-acd4da0238ee">50</ix:nonFraction>% in shares of Immunic&#8217;s common stock (the &#8220;Shares&#8221;). Pursuant to the Agreement, the Company filed a resale shelf registration statement on Form S-3 covering the resale of the Shares. With the execution of the Agreement, no further payment obligations remain between Immunic AG and 4SC AG.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Proceedings</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is not currently a party to any litigation, nor is it aware of any pending or threatened litigation, that it believes would materially affect its business, operating results, financial condition or cash flows. However, its industry is characterized by frequent claims and litigation including securities litigation, claims regarding patent and other intellectual property rights and claims for product liability. As a result, in the future, the Company may be involved in various legal proceedings from time to time.</span></div></ix:continuation><div id="ida7c333e3c58430eb83e8e950c50d811_43"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5. <ix:nonNumeric contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80My9mcmFnOmNiYTRjYmUyYjAxMDQwYjI4YjFlYWFmZjY2NGJlOWE5L3RleHRyZWdpb246Y2JhNGNiZTJiMDEwNDBiMjhiMWVhYWZmNjY0YmU5YTlfODcw_ee7ada36-0c74-4dea-9949-581824dd5d6c" continuedAt="i48830e3ebc574c9781b70c8e0e4bb3c1" escape="true">Fair Value</ix:nonNumeric></span></div><ix:continuation id="i48830e3ebc574c9781b70c8e0e4bb3c1" continuedAt="i33a56e72eccd45ca9e5bc169033de4c3"><ix:nonNumeric contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80My9mcmFnOmNiYTRjYmUyYjAxMDQwYjI4YjFlYWFmZjY2NGJlOWE5L3RleHRyZWdpb246Y2JhNGNiZTJiMDEwNDBiMjhiMWVhYWZmNjY0YmU5YTlfODY2_7cefb7df-0729-4dc1-a4b8-1192f3a0394e" escape="true"><div style="margin-bottom:6pt;margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following fair value hierarchy tables present information about each major category of the Company&#8217;s financial assets and liabilities measured at fair value on a recurring basis (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:50.888%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.092%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.830%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.092%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.830%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.240%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.830%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.098%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurement at September 30, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair&#160;Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level&#160;3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5d5d1c95a774f429ad29d595bac0585_I20220930" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80My9mcmFnOmNiYTRjYmUyYjAxMDQwYjI4YjFlYWFmZjY2NGJlOWE5L3RhYmxlOmVkYTU1ZjQzYmVhNTQ3OGQ4NmJmZjA4NWVjMTc0YjU4L3RhYmxlcmFuZ2U6ZWRhNTVmNDNiZWE1NDc4ZDg2YmZmMDg1ZWMxNzRiNThfMy0xLTEtMS0zMDUwMA_f3202f16-d79a-4132-ab21-efc59356279c">31,471</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e0b1222c30b4269aa3c56e6ebee8dc4_I20220930" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80My9mcmFnOmNiYTRjYmUyYjAxMDQwYjI4YjFlYWFmZjY2NGJlOWE5L3RhYmxlOmVkYTU1ZjQzYmVhNTQ3OGQ4NmJmZjA4NWVjMTc0YjU4L3RhYmxlcmFuZ2U6ZWRhNTVmNDNiZWE1NDc4ZDg2YmZmMDg1ZWMxNzRiNThfMy0zLTEtMS0zMDUwMA_a554f24a-7e28-4295-a765-921d06252420">31,471</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc57905cd80143b29ea902574f63d2e8_I20220930" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80My9mcmFnOmNiYTRjYmUyYjAxMDQwYjI4YjFlYWFmZjY2NGJlOWE5L3RhYmxlOmVkYTU1ZjQzYmVhNTQ3OGQ4NmJmZjA4NWVjMTc0YjU4L3RhYmxlcmFuZ2U6ZWRhNTVmNDNiZWE1NDc4ZDg2YmZmMDg1ZWMxNzRiNThfMy01LTEtMS0zMDUwMA_2debc412-0cd0-45cb-835e-ec14e9c126f0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if643e711815d4b749376bea335780421_I20220930" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80My9mcmFnOmNiYTRjYmUyYjAxMDQwYjI4YjFlYWFmZjY2NGJlOWE5L3RhYmxlOmVkYTU1ZjQzYmVhNTQ3OGQ4NmJmZjA4NWVjMTc0YjU4L3RhYmxlcmFuZ2U6ZWRhNTVmNDNiZWE1NDc4ZDg2YmZmMDg1ZWMxNzRiNThfMy03LTEtMS0zMDUwMA_cda5ed42-0ec4-4365-a5fb-be4d29ad98ee">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets at fair value</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a48bc4ae7d7408f97f6eeb1dca78e8b_I20220930" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80My9mcmFnOmNiYTRjYmUyYjAxMDQwYjI4YjFlYWFmZjY2NGJlOWE5L3RhYmxlOmVkYTU1ZjQzYmVhNTQ3OGQ4NmJmZjA4NWVjMTc0YjU4L3RhYmxlcmFuZ2U6ZWRhNTVmNDNiZWE1NDc4ZDg2YmZmMDg1ZWMxNzRiNThfNC0xLTEtMS0zMDUwMA_eb811689-1bef-4bc0-8e4f-ca46cd1b49c6">31,471</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3b80cda8b6f452eb05a40cc72183236_I20220930" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80My9mcmFnOmNiYTRjYmUyYjAxMDQwYjI4YjFlYWFmZjY2NGJlOWE5L3RhYmxlOmVkYTU1ZjQzYmVhNTQ3OGQ4NmJmZjA4NWVjMTc0YjU4L3RhYmxlcmFuZ2U6ZWRhNTVmNDNiZWE1NDc4ZDg2YmZmMDg1ZWMxNzRiNThfNC0zLTEtMS0zMDUwMA_35f40fc1-2c3b-484a-b401-cdb6ba365bdf">31,471</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecbaf68de7c649b39d49d2cd525bbdaf_I20220930" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80My9mcmFnOmNiYTRjYmUyYjAxMDQwYjI4YjFlYWFmZjY2NGJlOWE5L3RhYmxlOmVkYTU1ZjQzYmVhNTQ3OGQ4NmJmZjA4NWVjMTc0YjU4L3RhYmxlcmFuZ2U6ZWRhNTVmNDNiZWE1NDc4ZDg2YmZmMDg1ZWMxNzRiNThfNC01LTEtMS0zMDUwMA_482b3669-1868-423d-8ef5-a747acec73cc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5815b7ec2c4048eaa79c592705f78a05_I20220930" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80My9mcmFnOmNiYTRjYmUyYjAxMDQwYjI4YjFlYWFmZjY2NGJlOWE5L3RhYmxlOmVkYTU1ZjQzYmVhNTQ3OGQ4NmJmZjA4NWVjMTc0YjU4L3RhYmxlcmFuZ2U6ZWRhNTVmNDNiZWE1NDc4ZDg2YmZmMDg1ZWMxNzRiNThfNC03LTEtMS0zMDUwMA_2893bc35-8b9d-4f21-a782-0f8c8b6de3f4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:50.888%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.092%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.830%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.092%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.830%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.240%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.830%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.098%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurement at Fair&#160;Value&#160;Measurement&#160;at&#160;December&#160;31,&#160;2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair&#160;Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level&#160;3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i026a14121f5e41e6b31d1f3647017fab_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80My9mcmFnOmNiYTRjYmUyYjAxMDQwYjI4YjFlYWFmZjY2NGJlOWE5L3RhYmxlOmNlNzIwMTY0MzdiODQwZDM5YmY2MTI5ZDA3OWI4Mzg5L3RhYmxlcmFuZ2U6Y2U3MjAxNjQzN2I4NDBkMzliZjYxMjlkMDc5YjgzODlfMy0xLTEtMS0zMDUwMA_efddafab-f7bd-435b-9761-dc1661cdcb6f">31,630</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66caad9103ff476d8d79ca94f9ff9ca7_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80My9mcmFnOmNiYTRjYmUyYjAxMDQwYjI4YjFlYWFmZjY2NGJlOWE5L3RhYmxlOmNlNzIwMTY0MzdiODQwZDM5YmY2MTI5ZDA3OWI4Mzg5L3RhYmxlcmFuZ2U6Y2U3MjAxNjQzN2I4NDBkMzliZjYxMjlkMDc5YjgzODlfMy0zLTEtMS0zMDUwMA_c6ee48fc-a18f-4673-af70-7f42104ccf2e">31,630</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26c3332665024e968525d075f51dd2c3_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80My9mcmFnOmNiYTRjYmUyYjAxMDQwYjI4YjFlYWFmZjY2NGJlOWE5L3RhYmxlOmNlNzIwMTY0MzdiODQwZDM5YmY2MTI5ZDA3OWI4Mzg5L3RhYmxlcmFuZ2U6Y2U3MjAxNjQzN2I4NDBkMzliZjYxMjlkMDc5YjgzODlfMy01LTEtMS0zMDUwMA_0a69cc00-bde0-4d0c-9e54-fa9d1dd1cd22">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb7c3038fa504039b4299ec811876236_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80My9mcmFnOmNiYTRjYmUyYjAxMDQwYjI4YjFlYWFmZjY2NGJlOWE5L3RhYmxlOmNlNzIwMTY0MzdiODQwZDM5YmY2MTI5ZDA3OWI4Mzg5L3RhYmxlcmFuZ2U6Y2U3MjAxNjQzN2I4NDBkMzliZjYxMjlkMDc5YjgzODlfMy03LTEtMS0zMDUwMA_86ef938b-224e-4178-914e-02377a442d2f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c78af0997974f8888e346839bbbb526_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80My9mcmFnOmNiYTRjYmUyYjAxMDQwYjI4YjFlYWFmZjY2NGJlOWE5L3RhYmxlOmNlNzIwMTY0MzdiODQwZDM5YmY2MTI5ZDA3OWI4Mzg5L3RhYmxlcmFuZ2U6Y2U3MjAxNjQzN2I4NDBkMzliZjYxMjlkMDc5YjgzODlfNC0xLTEtMS0zMDUwMA_54925cc1-4aca-4048-abd1-63664b46bc38">31,630</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieeee9cf1b4db4ae799c2820e753b57d4_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80My9mcmFnOmNiYTRjYmUyYjAxMDQwYjI4YjFlYWFmZjY2NGJlOWE5L3RhYmxlOmNlNzIwMTY0MzdiODQwZDM5YmY2MTI5ZDA3OWI4Mzg5L3RhYmxlcmFuZ2U6Y2U3MjAxNjQzN2I4NDBkMzliZjYxMjlkMDc5YjgzODlfNC0zLTEtMS0zMDUwMA_e57bb2f2-761b-4d77-b1f2-7697da789435">31,630</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbf0f0e07da94302ac3cd78120a72738_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80My9mcmFnOmNiYTRjYmUyYjAxMDQwYjI4YjFlYWFmZjY2NGJlOWE5L3RhYmxlOmNlNzIwMTY0MzdiODQwZDM5YmY2MTI5ZDA3OWI4Mzg5L3RhYmxlcmFuZ2U6Y2U3MjAxNjQzN2I4NDBkMzliZjYxMjlkMDc5YjgzODlfNC01LTEtMS0zMDUwMA_cfce4391-55a9-4869-9179-466c18c7cdea">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2d55028ecbe47369972c9dc27a4983b_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80My9mcmFnOmNiYTRjYmUyYjAxMDQwYjI4YjFlYWFmZjY2NGJlOWE5L3RhYmxlOmNlNzIwMTY0MzdiODQwZDM5YmY2MTI5ZDA3OWI4Mzg5L3RhYmxlcmFuZ2U6Y2U3MjAxNjQzN2I4NDBkMzliZjYxMjlkMDc5YjgzODlfNC03LTEtMS0zMDUwMA_e673a75f-9aed-43e6-a327-ad1f8e1aa7a0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no transfers between Level&#160;1, Level&#160;2 or Level&#160;3 assets during the periods presented.  </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the Company&#8217;s money market funds, which are included as a component of cash and cash equivalents on the consolidated balance sheet, realized gains and losses are included in interest income (expense) on the consolidated statements of operations. </span></div></ix:continuation><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i33a56e72eccd45ca9e5bc169033de4c3">The carrying amounts of other current assets and prepaid expenses, accounts payable, accrued expenses, and other current liabilities approximate their fair values due to their short-term nature. The fair value and book value of the money market funds presented in the table above are the same.</ix:continuation> </span></div><div id="ida7c333e3c58430eb83e8e950c50d811_46"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6. <ix:nonNumeric contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80Ni9mcmFnOjM5MzBmZWViZmI2YTRjODdiYWNlNGRlOWQxYjNlMjgwL3RleHRyZWdpb246MzkzMGZlZWJmYjZhNGM4N2JhY2U0ZGU5ZDFiM2UyODBfNzg0MQ_50750d90-d1ce-47e6-87e3-29c6fe557e7e" continuedAt="i51d0599c717a4f8eb1a306f0ea24599c" escape="true">Common Stock</ix:nonNumeric></span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i51d0599c717a4f8eb1a306f0ea24599c" continuedAt="i669efd00785042998bd46a20ae3fe5ad">In November 2020, Immunic filed a shelf registration statement on Form S-3. The 2020 Shelf Registration Statement permits the offering, issuance and sale of up to $<ix:nonFraction unitRef="usd" contextRef="i452fc01435184aa6b440569b104a7b6a_I20201130" decimals="-5" name="vtl:MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80Ni9mcmFnOjM5MzBmZWViZmI2YTRjODdiYWNlNGRlOWQxYjNlMjgwL3RleHRyZWdpb246MzkzMGZlZWJmYjZhNGM4N2JhY2U0ZGU5ZDFiM2UyODBfNTQ5NzU1ODI5NTky_004fb91a-2ddb-4450-bfcb-319b108f625e">250.0</ix:nonFraction>&#160;million of common stock, preferred stock, warrants, debt securities, and/or units in one or more offerings and in any combination of the foregoing.  As of October 31, 2022, there is $<ix:nonFraction unitRef="usd" contextRef="ied30ae8dfbe54606808411695b6e7a4d_I20221031" decimals="-5" name="vtl:ShelfRegistrationStatementAmountRemaining" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80Ni9mcmFnOjM5MzBmZWViZmI2YTRjODdiYWNlNGRlOWQxYjNlMjgwL3RleHRyZWdpb246MzkzMGZlZWJmYjZhNGM4N2JhY2U0ZGU5ZDFiM2UyODBfNTQ5NzU1ODI5NzY3_44af067e-ff7b-40a7-9e7a-df5d3ef585e6">75.0</ix:nonFraction>&#160;million remaining on this shelf registration statement </ix:continuation></span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i669efd00785042998bd46a20ae3fe5ad" continuedAt="i0c23682de8e64bd3a6c991dd90e82ecf"><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, the Company filed a Prospectus Supplement for the offering, issuance and sale of up to a maximum aggregate offering price of $<ix:nonFraction unitRef="usd" contextRef="i37de57482ffb4464ab59f455ab94a18c_I20201231" decimals="-5" name="vtl:MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80Ni9mcmFnOjM5MzBmZWViZmI2YTRjODdiYWNlNGRlOWQxYjNlMjgwL3RleHRyZWdpb246MzkzMGZlZWJmYjZhNGM4N2JhY2U0ZGU5ZDFiM2UyODBfNTQ5NzU1ODI5OTYz_4b8f4444-3221-47d2-9e93-0a38a7d18c4d">50.0</ix:nonFraction>&#160;million of common stock that may be issued and sold under an at-the-market sales agreement ("December 2020 ATM") with SVB Leerink as agent. The Company has used, and intends to continue to use the net proceeds from the offering to continue to fund the ongoing clinical development of its product candidates and for other general corporate purposes, including funding existing and potential new clinical programs and product candidates. The December 2020 ATM will terminate upon the earlier of (i) the issuance and sale of all of the shares through SVB Leerink on the terms and subject to the conditions set forth in the December 2020 ATM or (ii) termination of the December 2020 ATM as otherwise permitted thereby. The December 2020 ATM may be terminated at any time by either party upon <ix:nonFraction unitRef="d" contextRef="i2867d1aebe414721a791386480b70c8f_I20220930" decimals="INF" name="vtl:ShelfRegistrationTerminationPriorWrittenNotice" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80Ni9mcmFnOjM5MzBmZWViZmI2YTRjODdiYWNlNGRlOWQxYjNlMjgwL3RleHRyZWdpb246MzkzMGZlZWJmYjZhNGM4N2JhY2U0ZGU5ZDFiM2UyODBfNTQ5NzU1ODMwNzUy_bfb6b0d8-08d8-4335-85e2-623831ec448b">ten</ix:nonFraction> days&#8217; prior notice, or by SVB Leerink at any time in certain circumstances, including the occurrence of a material adverse effect on the Company.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of October 31, 2022, $<ix:nonFraction unitRef="usd" contextRef="ia9434666be04407c90f384a6f8cee2f8_I20221031" decimals="-5" name="vtl:SaleOfStockRemainingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80Ni9mcmFnOjM5MzBmZWViZmI2YTRjODdiYWNlNGRlOWQxYjNlMjgwL3RleHRyZWdpb246MzkzMGZlZWJmYjZhNGM4N2JhY2U0ZGU5ZDFiM2UyODBfNTQ5NzU1ODMwOTI0_f1c98152-fd70-42a2-9248-0381e119be99">8.4</ix:nonFraction>&#160;million in capacity remains under the December 2020 ATM.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2022, the Company filed a Prospectus Supplement for the offering, issuance and sale of up to a maximum aggregate offering price of $<ix:nonFraction unitRef="usd" contextRef="i731d9157c77642cf8b53fdb984854e80_I20220510" decimals="-5" name="vtl:MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80Ni9mcmFnOjM5MzBmZWViZmI2YTRjODdiYWNlNGRlOWQxYjNlMjgwL3RleHRyZWdpb246MzkzMGZlZWJmYjZhNGM4N2JhY2U0ZGU5ZDFiM2UyODBfNTQ5NzU1ODMxMTE4_735ba211-757c-4f23-b8d6-3d5c364eb5d7">80.0</ix:nonFraction>&#160;million of common stock that may be issued and sold under another at-the-market sales agreement ("May 2022 ATM") with SVB Leerink as agent. The Company intends to use the net proceeds from the offering to continue to fund the ongoing clinical development of its product candidates and for other general corporate purposes, including funding existing and potential new clinical programs and product candidates. The May 2022 ATM will terminate upon the earlier of (i) the issuance and sale of all of the shares through SVB Leerink on the terms and subject to the conditions set forth in the May 2022 ATM or (ii) termination of the May 2022 ATM as otherwise permitted thereby. The May 2022 ATM may be terminated at any time by either party upon <ix:nonFraction unitRef="d" contextRef="ie383b6c67b2d4562a2b5fa326cbe5000_I20220930" decimals="INF" name="vtl:ShelfRegistrationTerminationPriorWrittenNotice" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80Ni9mcmFnOjM5MzBmZWViZmI2YTRjODdiYWNlNGRlOWQxYjNlMjgwL3RleHRyZWdpb246MzkzMGZlZWJmYjZhNGM4N2JhY2U0ZGU5ZDFiM2UyODBfNTQ5NzU1ODMxODU2_8f4f5be8-77f5-48d3-89a7-49d4307ba2ab">ten</ix:nonFraction> days&#8217; prior notice, or by SVB Leerink at any time in certain circumstances, including the occurrence of a material adverse effect on the Company.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of October 31, 2022, $<ix:nonFraction unitRef="usd" contextRef="i9843b826ca9942c9abbeb49451438b66_I20220505" decimals="-5" name="vtl:SaleOfStockRemainingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80Ni9mcmFnOjM5MzBmZWViZmI2YTRjODdiYWNlNGRlOWQxYjNlMjgwL3RleHRyZWdpb246MzkzMGZlZWJmYjZhNGM4N2JhY2U0ZGU5ZDFiM2UyODBfNTQ5NzU1ODMyMDI4_899d5c83-293f-4135-86dd-6be4c3352798">80.0</ix:nonFraction>&#160;million in capacity remains under the May 2022 ATM.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;The Company has agreed to pay SVB Leerink a commission equal to <ix:nonFraction unitRef="number" contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930" decimals="3" name="vtl:ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80Ni9mcmFnOjM5MzBmZWViZmI2YTRjODdiYWNlNGRlOWQxYjNlMjgwL3RleHRyZWdpb246MzkzMGZlZWJmYjZhNGM4N2JhY2U0ZGU5ZDFiM2UyODBfNTQ5NzU1ODMyMTQy_31b5daf7-6159-4c39-922e-a37c2f9fc3e7">3.0</ix:nonFraction>% of the gross proceeds from the sales of common shares pursuant to both ATM's and has agreed to provide SVB Leerink with customary indemnification and contribution rights.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the three months ended September 30, 2022, the Company did not raise any proceeds under its ATM facilities.  In the nine months ended September 30, 2022, the Company raised gross proceeds of $<ix:nonFraction unitRef="usd" contextRef="ic64d3d20dd7f42ebab0773713f0e2f62_D20220701-20220930" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80Ni9mcmFnOjM5MzBmZWViZmI2YTRjODdiYWNlNGRlOWQxYjNlMjgwL3RleHRyZWdpb246MzkzMGZlZWJmYjZhNGM4N2JhY2U0ZGU5ZDFiM2UyODBfNTQ5NzU1ODMyNzA0_573a4251-2417-4930-b653-20281bd9c9fd">40.9</ix:nonFraction>&#160;million pursuant to the December 2020 ATM through the sale of <ix:nonFraction unitRef="shares" contextRef="i13dc9f1a4e524f93b1138a442b35c8d0_D20220101-20220930" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80Ni9mcmFnOjM5MzBmZWViZmI2YTRjODdiYWNlNGRlOWQxYjNlMjgwL3RleHRyZWdpb246MzkzMGZlZWJmYjZhNGM4N2JhY2U0ZGU5ZDFiM2UyODBfNTQ5NzU1ODMyNzYy_1ba401b6-e6ed-4428-868b-1e261b8d1931">4,204,113</ix:nonFraction> shares of common stock at a weighted average price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i13dc9f1a4e524f93b1138a442b35c8d0_D20220101-20220930" decimals="2" name="vtl:SharesIssuedWeightedAverageSharePricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80Ni9mcmFnOjM5MzBmZWViZmI2YTRjODdiYWNlNGRlOWQxYjNlMjgwL3RleHRyZWdpb246MzkzMGZlZWJmYjZhNGM4N2JhY2U0ZGU5ZDFiM2UyODBfNTQ5NzU1ODMyODIw_41097e6d-b0c8-412e-a0b6-d52306ed2aa9">9.72</ix:nonFraction> per share. The net proceeds from the December 2020 ATM were $<ix:nonFraction unitRef="usd" contextRef="i13dc9f1a4e524f93b1138a442b35c8d0_D20220101-20220930" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80Ni9mcmFnOjM5MzBmZWViZmI2YTRjODdiYWNlNGRlOWQxYjNlMjgwL3RleHRyZWdpb246MzkzMGZlZWJmYjZhNGM4N2JhY2U0ZGU5ZDFiM2UyODBfNTQ5NzU1ODMyODg0_81cf45d9-fdab-4e12-9284-08075ee2486a">39.6</ix:nonFraction>&#160;million after deducting underwriter commissions of $<ix:nonFraction unitRef="usd" contextRef="i13dc9f1a4e524f93b1138a442b35c8d0_D20220101-20220930" decimals="-5" name="us-gaap:PaymentsForCommissions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80Ni9mcmFnOjM5MzBmZWViZmI2YTRjODdiYWNlNGRlOWQxYjNlMjgwL3RleHRyZWdpb246MzkzMGZlZWJmYjZhNGM4N2JhY2U0ZGU5ZDFiM2UyODBfNTQ5NzU1ODMyOTMx_18e7e715-9e0f-4408-80eb-0de270e126cd">1.2</ix:nonFraction>&#160;million. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company did not have any ATM activity during the three or nine months ended September 30, 2021.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Public Equity Offerings</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">July 2021 Public Equity Offering</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 15, 2021, the Company entered into an underwriting agreement with Piper Sandler &amp; Co., in connection with the</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Company&#8217;s public offering of <ix:nonFraction unitRef="shares" contextRef="id7f3ba2151e24a8694efe8eededbb089_D20210715-20210715" decimals="0" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80Ni9mcmFnOjM5MzBmZWViZmI2YTRjODdiYWNlNGRlOWQxYjNlMjgwL3RleHRyZWdpb246MzkzMGZlZWJmYjZhNGM4N2JhY2U0ZGU5ZDFiM2UyODBfNDk0NzgwMjM0NjgyOA_427a09d3-242c-4c31-988e-2fb2c3108b36">4,500,000</ix:nonFraction> shares of the Company&#8217;s common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i837eb6ff329b46d1b9063702464b7004_I20210715" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80Ni9mcmFnOjM5MzBmZWViZmI2YTRjODdiYWNlNGRlOWQxYjNlMjgwL3RleHRyZWdpb246MzkzMGZlZWJmYjZhNGM4N2JhY2U0ZGU5ZDFiM2UyODBfNDk0NzgwMjM0NjgzOQ_271f1b3b-5e0e-44d0-9450-0b5937731865">0.0001</ix:nonFraction> par value per share, at a public</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">offering price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i837eb6ff329b46d1b9063702464b7004_I20210715" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80Ni9mcmFnOjM5MzBmZWViZmI2YTRjODdiYWNlNGRlOWQxYjNlMjgwL3RleHRyZWdpb246MzkzMGZlZWJmYjZhNGM4N2JhY2U0ZGU5ZDFiM2UyODBfNDk0NzgwMjM0Njg0OA_6870f454-1f95-45ca-9540-43a666edce11">10.00</ix:nonFraction> per share.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 19, 2021, the Company closed the Offering. The net proceeds to the Company from the Offering was</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">approximately $<ix:nonFraction unitRef="usd" contextRef="ic1deecff015c411d9b86fcc68ba1683c_D20210719-20210719" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80Ni9mcmFnOjM5MzBmZWViZmI2YTRjODdiYWNlNGRlOWQxYjNlMjgwL3RleHRyZWdpb246MzkzMGZlZWJmYjZhNGM4N2JhY2U0ZGU5ZDFiM2UyODBfNDk0NzgwMjM0Njg1Ng_39708f2c-0a85-40e8-a0b7-6d5dc087cbae">42.0</ix:nonFraction>&#160;million, after deducting underwriting discounts and commissions and estimated offering expenses payable</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">by the Company.</span></div><div style="margin-top:12pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Common Stock</span></div><div style="margin-top:12pt;padding-right:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2022, the Company&#8217;s certificate of incorporation, as amended and restated, authorized the Company to issue <ix:nonFraction unitRef="shares" contextRef="ib2ba0b84078f4de2bc3079e992921b92_I20220930" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80Ni9mcmFnOjM5MzBmZWViZmI2YTRjODdiYWNlNGRlOWQxYjNlMjgwL3RleHRyZWdpb246MzkzMGZlZWJmYjZhNGM4N2JhY2U0ZGU5ZDFiM2UyODBfNTQ5NzU1ODMzMTY2_67e39ee5-133b-47b2-9423-cd4e1719f865">130,000,000</ix:nonFraction> shares of common stock, par value of $<ix:nonFraction unitRef="usdPerShare" contextRef="ib2ba0b84078f4de2bc3079e992921b92_I20220930" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80Ni9mcmFnOjM5MzBmZWViZmI2YTRjODdiYWNlNGRlOWQxYjNlMjgwL3RleHRyZWdpb246MzkzMGZlZWJmYjZhNGM4N2JhY2U0ZGU5ZDFiM2UyODBfNTQ5NzU1ODMzMjA3_8f657c9e-0f2d-4f6c-8a9e-1de383f1d9ec">0.0001</ix:nonFraction> per share. The voting, dividend and liquidation rights of the holders of the Company&#8217;s common stock are subject to and qualified by the rights, powers and preferences of any holders of preferred stock.</span></div><div style="margin-top:12pt;padding-right:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each share of common stock entitles the holder to one vote on all matters submitted to a vote of the Company&#8217;s stockholders. Common stockholders are entitled to receive dividends, as may be declared by the board of directors, if any. Through September 30, 2022, <ix:nonFraction unitRef="usdPerShare" contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80Ni9mcmFnOjM5MzBmZWViZmI2YTRjODdiYWNlNGRlOWQxYjNlMjgwL3RleHRyZWdpb246MzkzMGZlZWJmYjZhNGM4N2JhY2U0ZGU5ZDFiM2UyODBfNTQ5NzU1ODMzNjcw_48f33ff6-3b8c-47be-af82-85b808191ae3"><ix:nonFraction unitRef="usdPerShare" contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930" decimals="INF" name="us-gaap:CommonStockDividendsPerShareCashPaid" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80Ni9mcmFnOjM5MzBmZWViZmI2YTRjODdiYWNlNGRlOWQxYjNlMjgwL3RleHRyZWdpb246MzkzMGZlZWJmYjZhNGM4N2JhY2U0ZGU5ZDFiM2UyODBfNTQ5NzU1ODMzNjcw_87b7f66b-d62f-4509-8a74-2553eff0d324">no</ix:nonFraction></ix:nonFraction> cash dividends had been declared or paid.</span></div></ix:continuation><div style="margin-top:12pt;text-indent:22.5pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i0c23682de8e64bd3a6c991dd90e82ecf"><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preferred Stock</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s certificate of incorporation, as amended and restated, authorizes the Company to issue <ix:nonFraction unitRef="shares" contextRef="ib2ba0b84078f4de2bc3079e992921b92_I20220930" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80Ni9mcmFnOjM5MzBmZWViZmI2YTRjODdiYWNlNGRlOWQxYjNlMjgwL3RleHRyZWdpb246MzkzMGZlZWJmYjZhNGM4N2JhY2U0ZGU5ZDFiM2UyODBfNTQ5NzU1ODMzODM1_8066c3ff-fecf-4470-b556-2a3f5d929170">20</ix:nonFraction> million shares of $<ix:nonFraction unitRef="usdPerShare" contextRef="ib2ba0b84078f4de2bc3079e992921b92_I20220930" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80Ni9mcmFnOjM5MzBmZWViZmI2YTRjODdiYWNlNGRlOWQxYjNlMjgwL3RleHRyZWdpb246MzkzMGZlZWJmYjZhNGM4N2JhY2U0ZGU5ZDFiM2UyODBfNTQ5NzU1ODMzODQ5_da031462-8396-4a4d-ad3d-78204d304f70">0.0001</ix:nonFraction> par value preferred stock, having rights and preferences to be set by the Board of Directors. <ix:nonFraction unitRef="shares" contextRef="ib2ba0b84078f4de2bc3079e992921b92_I20220930" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80Ni9mcmFnOjM5MzBmZWViZmI2YTRjODdiYWNlNGRlOWQxYjNlMjgwL3RleHRyZWdpb246MzkzMGZlZWJmYjZhNGM4N2JhY2U0ZGU5ZDFiM2UyODBfNTQ5NzU1ODMzOTQ3_2915a014-cf24-4932-a63a-21ad2af0b230">No</ix:nonFraction> preferred shares were outstanding as of September 30, 2022.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Reserved for Future Issuance</span></div><div style="margin-top:12pt;text-indent:22.5pt"><ix:nonNumeric contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930" name="vtl:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80Ni9mcmFnOjM5MzBmZWViZmI2YTRjODdiYWNlNGRlOWQxYjNlMjgwL3RleHRyZWdpb246MzkzMGZlZWJmYjZhNGM4N2JhY2U0ZGU5ZDFiM2UyODBfNzg0Ng_248bf50f-4694-441d-a84f-668caa6c9826" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares reserved for future issuance at September 30, 2022 are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:86.162%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.638%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of<br/>Shares</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock reserved for issuance for:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;2021 Employee stock Purchase Plan    </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iee6bdacd518b494c838da43db583331a_I20220930" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80Ni9mcmFnOjM5MzBmZWViZmI2YTRjODdiYWNlNGRlOWQxYjNlMjgwL3RhYmxlOjI1ZTIzNTIzYzk3MTQyY2NhZjUxZjJjMTgyY2RmZTZiL3RhYmxlcmFuZ2U6MjVlMjM1MjNjOTcxNDJjY2FmNTFmMmMxODJjZGZlNmJfMi0xLTEtMS0zMDUwMA_1cc09a05-5689-4aaf-952c-94c03f0c5b49">162,630</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ica07e01c9d0f47a59cbaee95aef0d158_I20220930" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80Ni9mcmFnOjM5MzBmZWViZmI2YTRjODdiYWNlNGRlOWQxYjNlMjgwL3RhYmxlOjI1ZTIzNTIzYzk3MTQyY2NhZjUxZjJjMTgyY2RmZTZiL3RhYmxlcmFuZ2U6MjVlMjM1MjNjOTcxNDJjY2FmNTFmMmMxODJjZGZlNmJfMy0xLTEtMS0zMDUwMA_771da427-71ad-4713-9c08-d5998651e694">3,799,573</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock options available for future grant:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2014 Equity Incentive Plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8d6a85cd1f8b48108c4b2aac7ded4bf3_I20220930" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80Ni9mcmFnOjM5MzBmZWViZmI2YTRjODdiYWNlNGRlOWQxYjNlMjgwL3RhYmxlOjI1ZTIzNTIzYzk3MTQyY2NhZjUxZjJjMTgyY2RmZTZiL3RhYmxlcmFuZ2U6MjVlMjM1MjNjOTcxNDJjY2FmNTFmMmMxODJjZGZlNmJfNS0xLTEtMS0zMDUwMA_b1100c2a-ea77-44ed-8164-0424a0287fbc">43,311</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2017 Inducement Equity Incentive Plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i66a3a4fa022d420ebf30bfd5b338b14a_I20220930" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80Ni9mcmFnOjM5MzBmZWViZmI2YTRjODdiYWNlNGRlOWQxYjNlMjgwL3RhYmxlOjI1ZTIzNTIzYzk3MTQyY2NhZjUxZjJjMTgyY2RmZTZiL3RhYmxlcmFuZ2U6MjVlMjM1MjNjOTcxNDJjY2FmNTFmMmMxODJjZGZlNmJfNi0xLTEtMS0zMDUwMA_2d29cbc2-6740-4c9d-8d3e-acd0a60e21cf">46,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019 Omnibus Equity Incentive Plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4b8e8ab0f2aa4d60b8640f5f1ddff361_I20220930" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80Ni9mcmFnOjM5MzBmZWViZmI2YTRjODdiYWNlNGRlOWQxYjNlMjgwL3RhYmxlOjI1ZTIzNTIzYzk3MTQyY2NhZjUxZjJjMTgyY2RmZTZiL3RhYmxlcmFuZ2U6MjVlMjM1MjNjOTcxNDJjY2FmNTFmMmMxODJjZGZlNmJfNy0xLTEtMS0zMDUwMA_c0629103-ade0-44b8-8b4b-e9405085d51c">180,770</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total common shares reserved for future issuance</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib2ba0b84078f4de2bc3079e992921b92_I20220930" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80Ni9mcmFnOjM5MzBmZWViZmI2YTRjODdiYWNlNGRlOWQxYjNlMjgwL3RhYmxlOjI1ZTIzNTIzYzk3MTQyY2NhZjUxZjJjMTgyY2RmZTZiL3RhYmxlcmFuZ2U6MjVlMjM1MjNjOTcxNDJjY2FmNTFmMmMxODJjZGZlNmJfOC0xLTEtMS0zMDUwMA_bb89d25e-b0e4-4e06-a421-925ee5253e02">4,232,534</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div></ix:continuation><div><span><br/></span></div><div id="ida7c333e3c58430eb83e8e950c50d811_49"></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7. <ix:nonNumeric contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80OS9mcmFnOjlhN2M1MTczZGE1ZTQ5ZjViYTk4YWRiODZhZWYwOWJkL3RleHRyZWdpb246OWE3YzUxNzNkYTVlNDlmNWJhOThhZGI4NmFlZjA5YmRfNjAzMQ_e25a2cbd-f145-43fd-b520-7dcbc85307c7" continuedAt="if2dd5250b0e144078c2cfbf7f749eb59" escape="true">Stock-Based Compensation Plans</ix:nonNumeric></span></div><ix:continuation id="if2dd5250b0e144078c2cfbf7f749eb59" continuedAt="i83fc31f64bda4fd5a5ed743548095343"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2021 Employee Stock Purchase Plan</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 25, 2021, the Company adopted the 2021 Employee Stock Purchase Plan ("ESPP"), which was approved by stockholder vote at the 2021 Annual Meeting of Stockholders held on June 10, 2021. The ESPP provides eligible employees of the Company with an opportunity to purchase common stock of the Company through accumulated payroll deductions, which are included in other current liabilities until they are used to purchase Company shares. Eligible employees participating in the bi-annual offering period can choose to have up to the lesser of <ix:nonFraction unitRef="number" contextRef="ic696ef9959af49cdbf3fd974759bd0bc_D20210425-20210425" decimals="INF" name="us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80OS9mcmFnOjlhN2M1MTczZGE1ZTQ5ZjViYTk4YWRiODZhZWYwOWJkL3RleHRyZWdpb246OWE3YzUxNzNkYTVlNDlmNWJhOThhZGI4NmFlZjA5YmRfNTQ5NzU1ODIxNjk0_4fc1e24d-8e23-4263-99c9-a7c9e5eebe79">15</ix:nonFraction>% of their annual base earnings or the IRS annual share purchase limit of $25,000 in aggregate market value to purchase shares of the Company&#8217;s common stock. The purchase price of the stock is the lesser of (i) <ix:nonFraction unitRef="number" contextRef="ic696ef9959af49cdbf3fd974759bd0bc_D20210425-20210425" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80OS9mcmFnOjlhN2M1MTczZGE1ZTQ5ZjViYTk4YWRiODZhZWYwOWJkL3RleHRyZWdpb246OWE3YzUxNzNkYTVlNDlmNWJhOThhZGI4NmFlZjA5YmRfNTQ5NzU1ODIxOTA3_059db86e-0996-4d32-b0f9-96981098cd21">85</ix:nonFraction>% of the closing market price on the date of purchase and (ii) the closing market price at the beginning of the bi-annual offering period. The maximum number of shares reserved for delivery under the plan is <ix:nonFraction unitRef="shares" contextRef="i08aa60800326487fbf99175d815ab200_I20210425" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80OS9mcmFnOjlhN2M1MTczZGE1ZTQ5ZjViYTk4YWRiODZhZWYwOWJkL3RleHRyZWdpb246OWE3YzUxNzNkYTVlNDlmNWJhOThhZGI4NmFlZjA5YmRfNTQ5NzU1ODIyMTE3_d31a9433-be98-45fd-b0c2-682c6272c051">200,000</ix:nonFraction> shares.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">     </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company issued  zero and <ix:nonFraction unitRef="shares" contextRef="i6c48924db6c34718b6db57f2bcd38c0b_D20220701-20220930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80OS9mcmFnOjlhN2M1MTczZGE1ZTQ5ZjViYTk4YWRiODZhZWYwOWJkL3RleHRyZWdpb246OWE3YzUxNzNkYTVlNDlmNWJhOThhZGI4NmFlZjA5YmRfNTQ5NzU1ODIyMTU1_c67a8281-3b08-4c15-ba4f-6f11b053b9c6"><ix:nonFraction unitRef="shares" contextRef="ie7370ee1ee9943cdacd5aaf69e8a6815_D20220101-20220930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80OS9mcmFnOjlhN2M1MTczZGE1ZTQ5ZjViYTk4YWRiODZhZWYwOWJkL3RleHRyZWdpb246OWE3YzUxNzNkYTVlNDlmNWJhOThhZGI4NmFlZjA5YmRfNTQ5NzU1ODIyMTU1_f1c65fd5-7735-4607-87c9-0a187364867d">24,612</ix:nonFraction></ix:nonFraction> shares under the ESPP for the three and nine months ended September 30, 2022 and <ix:nonFraction unitRef="shares" contextRef="i2f6d9566f1a34310806423b83a871513_D20210425-20220930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80OS9mcmFnOjlhN2M1MTczZGE1ZTQ5ZjViYTk4YWRiODZhZWYwOWJkL3RleHRyZWdpb246OWE3YzUxNzNkYTVlNDlmNWJhOThhZGI4NmFlZjA5YmRfNTQ5NzU1ODIyMjM0_d7e74c2e-a941-4581-9c20-80df7847c2cb">37,370</ix:nonFraction> shares life to date.  The Company recognized ESPP expense of $<ix:nonFraction unitRef="usd" contextRef="i6c48924db6c34718b6db57f2bcd38c0b_D20220701-20220930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80OS9mcmFnOjlhN2M1MTczZGE1ZTQ5ZjViYTk4YWRiODZhZWYwOWJkL3RleHRyZWdpb246OWE3YzUxNzNkYTVlNDlmNWJhOThhZGI4NmFlZjA5YmRfNDk0NzgwMjM0MTA5NQ_8a1ebc8a-54b3-4491-96f0-acb451e6d46f">21,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="ib000cfab8d3c42d09670f1d425af5286_D20210701-20210930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80OS9mcmFnOjlhN2M1MTczZGE1ZTQ5ZjViYTk4YWRiODZhZWYwOWJkL3RleHRyZWdpb246OWE3YzUxNzNkYTVlNDlmNWJhOThhZGI4NmFlZjA5YmRfNDk0NzgwMjM0MTEwNA_5da40c03-6e42-47b5-99d4-6e730c6a19e0">18,000</ix:nonFraction>  for the three months ended September 30, 2022 and 2021, respectively, and  ESPP expense of $<ix:nonFraction unitRef="usd" contextRef="ie7370ee1ee9943cdacd5aaf69e8a6815_D20220101-20220930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80OS9mcmFnOjlhN2M1MTczZGE1ZTQ5ZjViYTk4YWRiODZhZWYwOWJkL3RleHRyZWdpb246OWE3YzUxNzNkYTVlNDlmNWJhOThhZGI4NmFlZjA5YmRfNDk0NzgwMjM0MTExMw_3fe0d492-a7a6-4c9b-a972-3c9a9e73e9c3">74,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i590665700dea49f8bbef5c2cd33f5ab6_D20210101-20210930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80OS9mcmFnOjlhN2M1MTczZGE1ZTQ5ZjViYTk4YWRiODZhZWYwOWJkL3RleHRyZWdpb246OWE3YzUxNzNkYTVlNDlmNWJhOThhZGI4NmFlZjA5YmRfNDk0NzgwMjM0MTEyMg_b5a5b8a2-7cfb-4a98-b75a-dd592d4d0564">18,000</ix:nonFraction> related to the nine months ended September 30, 2022 and 2021, respectively. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Option Programs</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2019, the Company&#8217;s stockholders approved the 2019 Omnibus Equity Incentive Plan (the &#8220;2019 Plan&#8221;) which was adopted by the Board with an effective date of June 14, 2019. The 2019 Plan allows for the grant of equity awards to employees, consultants and non-employee directors. An initial maximum of <ix:nonFraction unitRef="shares" contextRef="i0364a2ce088c4ade8ed67e8b0967db85_I20190731" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80OS9mcmFnOjlhN2M1MTczZGE1ZTQ5ZjViYTk4YWRiODZhZWYwOWJkL3RleHRyZWdpb246OWE3YzUxNzNkYTVlNDlmNWJhOThhZGI4NmFlZjA5YmRfNTQ5NzU1ODI0MzQ0_6e940dfe-1a9e-47eb-af6f-b978a772c8ea">1,500,000</ix:nonFraction> shares of the Company&#8217;s common stock were available for grant under the 2019 Plan. The 2019 Plan includes an evergreen provision that allows for the annual addition of up to <ix:nonFraction unitRef="number" contextRef="i97b48810b19f420aaff9dc7f71a98c22_D20190701-20190731" decimals="INF" name="vtl:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80OS9mcmFnOjlhN2M1MTczZGE1ZTQ5ZjViYTk4YWRiODZhZWYwOWJkL3RleHRyZWdpb246OWE3YzUxNzNkYTVlNDlmNWJhOThhZGI4NmFlZjA5YmRfNTQ5NzU1ODI0NTIy_27772d16-d5ae-4fad-bb3e-2fa8b02e2fd1">4</ix:nonFraction>% of the Company&#8217;s fully-diluted outstanding stock, with a maximum allowable increase of <ix:nonFraction unitRef="shares" contextRef="i97b48810b19f420aaff9dc7f71a98c22_D20190701-20190731" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80OS9mcmFnOjlhN2M1MTczZGE1ZTQ5ZjViYTk4YWRiODZhZWYwOWJkL3RleHRyZWdpb246OWE3YzUxNzNkYTVlNDlmNWJhOThhZGI4NmFlZjA5YmRfNTQ5NzU1ODI0NjEz_c6d305da-07c1-42a7-9083-de7de7cfbf5f">4,900,000</ix:nonFraction> shares over the term of the 2019 Plan. In accordance with this provision, the shares available for grant were increased in 2020 through 2022 by a total of <ix:nonFraction unitRef="shares" contextRef="if69ea9bc126c4fa5a73a13a32babfa2b_D20200101-20210930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80OS9mcmFnOjlhN2M1MTczZGE1ZTQ5ZjViYTk4YWRiODZhZWYwOWJkL3RleHRyZWdpb246OWE3YzUxNzNkYTVlNDlmNWJhOThhZGI4NmFlZjA5YmRfNTQ5NzU1ODI0Nzcy_261e0ea6-b107-49f5-9b05-6e7dedecc7c7">2,481,195</ix:nonFraction> shares. The 2019 Plan is currently administered by the Board, or, at the discretion of the Board, by a committee of the Board, which determines the exercise prices, vesting schedules and other restrictions of awards under the 2019 Plan at its discretion. Options to purchase stock may not have an exercise price that is less than the fair market value of underlying shares on the date of grant, and may not have a term greater than <ix:nonNumeric contextRef="id40d762aabfc48f4a2944687c1be6b40_D20220101-20220930" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80OS9mcmFnOjlhN2M1MTczZGE1ZTQ5ZjViYTk4YWRiODZhZWYwOWJkL3RleHRyZWdpb246OWE3YzUxNzNkYTVlNDlmNWJhOThhZGI4NmFlZjA5YmRfNTQ5NzU1ODI1MjA4_39ae4021-16fa-45c8-97c6-8a0a1dd83c6c">ten years</ix:nonNumeric>. Incentive stock options granted to employees typically vest over <ix:nonNumeric contextRef="i8925c9f347c0462dafcba58c8ff77fc0_D20220101-20220930" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80OS9mcmFnOjlhN2M1MTczZGE1ZTQ5ZjViYTk4YWRiODZhZWYwOWJkL3RleHRyZWdpb246OWE3YzUxNzNkYTVlNDlmNWJhOThhZGI4NmFlZjA5YmRfNTQ5NzU1ODI1Mjc4_042592a9-dea8-47ff-aa5c-ad577725ca9f">four years</ix:nonNumeric>. Non-statutory options granted to employees, officers, members of the Board, advisors, and consultants of the Company typically vest over <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80OS9mcmFnOjlhN2M1MTczZGE1ZTQ5ZjViYTk4YWRiODZhZWYwOWJkL3RleHRyZWdpb246OWE3YzUxNzNkYTVlNDlmNWJhOThhZGI4NmFlZjA5YmRfNTQ5NzU1ODI1NDIw_e9f71a48-2105-4fda-bdd7-59ddc0e82852">three</span> or <ix:nonNumeric contextRef="iaf64f27642a24cfd90a8b4b8fd99a4e3_D20220101-20220930" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80OS9mcmFnOjlhN2M1MTczZGE1ZTQ5ZjViYTk4YWRiODZhZWYwOWJkL3RleHRyZWdpb246OWE3YzUxNzNkYTVlNDlmNWJhOThhZGI4NmFlZjA5YmRfNTQ5NzU1ODI1NDI3_f9c8b25c-205e-455d-9158-c33bb878bd52">four years</ix:nonNumeric>. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i83fc31f64bda4fd5a5ed743548095343" continuedAt="i628815afe28944eeabbe5461de720656"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares that are expired, terminated, surrendered or canceled under the 2019 Plan without having been fully exercised will be available for future awards. </span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Movements during the year </span></div><ix:nonNumeric contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80OS9mcmFnOjlhN2M1MTczZGE1ZTQ5ZjViYTk4YWRiODZhZWYwOWJkL3RleHRyZWdpb246OWE3YzUxNzNkYTVlNDlmNWJhOThhZGI4NmFlZjA5YmRfNjAzNg_4019d019-dfc0-4b91-b43c-63d175f19163" escape="true"><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock option activity for the nine months ended September 30, 2022 and 2021, respectively, for the 2019 Plan:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.929%"><tr><td style="width:1.0%"></td><td style="width:52.444%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.307%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.307%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.759%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.421%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term&#160;(Years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of January 1, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7f827301d88e484985fc3a70f1380d98_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80OS9mcmFnOjlhN2M1MTczZGE1ZTQ5ZjViYTk4YWRiODZhZWYwOWJkL3RhYmxlOjFlN2E4MzVmY2UxMDQxYjQ5YmVhZThmOWUxOTAwZTMwL3RhYmxlcmFuZ2U6MWU3YTgzNWZjZTEwNDFiNDliZWFlOGY5ZTE5MDBlMzBfMS0xLTEtMS0zMDUwMA_cdf43e8e-2eac-48a0-b1f0-67e5623f5946">2,157,460</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7f827301d88e484985fc3a70f1380d98_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80OS9mcmFnOjlhN2M1MTczZGE1ZTQ5ZjViYTk4YWRiODZhZWYwOWJkL3RhYmxlOjFlN2E4MzVmY2UxMDQxYjQ5YmVhZThmOWUxOTAwZTMwL3RhYmxlcmFuZ2U6MWU3YTgzNWZjZTEwNDFiNDliZWFlOGY5ZTE5MDBlMzBfMS0zLTEtMS0zMDUwMA_29eda7a1-e8da-45d2-b88c-dc93eea32028">13.54</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i89cb4fe99d71444395e3fc22f0e7e477_D20220101-20220930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80OS9mcmFnOjlhN2M1MTczZGE1ZTQ5ZjViYTk4YWRiODZhZWYwOWJkL3RhYmxlOjFlN2E4MzVmY2UxMDQxYjQ5YmVhZThmOWUxOTAwZTMwL3RhYmxlcmFuZ2U6MWU3YTgzNWZjZTEwNDFiNDliZWFlOGY5ZTE5MDBlMzBfMi0xLTEtMS0zMDUwMA_6fb35b9e-6f8e-421f-9174-a4f1119ea81a">1,837,513</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i89cb4fe99d71444395e3fc22f0e7e477_D20220101-20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80OS9mcmFnOjlhN2M1MTczZGE1ZTQ5ZjViYTk4YWRiODZhZWYwOWJkL3RhYmxlOjFlN2E4MzVmY2UxMDQxYjQ5YmVhZThmOWUxOTAwZTMwL3RhYmxlcmFuZ2U6MWU3YTgzNWZjZTEwNDFiNDliZWFlOGY5ZTE5MDBlMzBfMi0zLTEtMS0zMDUwMA_80bdf327-3122-4b04-ac5f-4d41e18b6cdc">8.90</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i89cb4fe99d71444395e3fc22f0e7e477_D20220101-20220930" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80OS9mcmFnOjlhN2M1MTczZGE1ZTQ5ZjViYTk4YWRiODZhZWYwOWJkL3RhYmxlOjFlN2E4MzVmY2UxMDQxYjQ5YmVhZThmOWUxOTAwZTMwL3RhYmxlcmFuZ2U6MWU3YTgzNWZjZTEwNDFiNDliZWFlOGY5ZTE5MDBlMzBfMy0xLTEtMS0zMDUwMA_1989018f-43f2-4f7c-833f-ef62dbaad18b">852</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i89cb4fe99d71444395e3fc22f0e7e477_D20220101-20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80OS9mcmFnOjlhN2M1MTczZGE1ZTQ5ZjViYTk4YWRiODZhZWYwOWJkL3RhYmxlOjFlN2E4MzVmY2UxMDQxYjQ5YmVhZThmOWUxOTAwZTMwL3RhYmxlcmFuZ2U6MWU3YTgzNWZjZTEwNDFiNDliZWFlOGY5ZTE5MDBlMzBfMy0zLTEtMS0zMDUwMA_46fff0ec-ad06-4fb8-a5d1-574cc92096be">5.67</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited or expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i89cb4fe99d71444395e3fc22f0e7e477_D20220101-20220930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80OS9mcmFnOjlhN2M1MTczZGE1ZTQ5ZjViYTk4YWRiODZhZWYwOWJkL3RhYmxlOjFlN2E4MzVmY2UxMDQxYjQ5YmVhZThmOWUxOTAwZTMwL3RhYmxlcmFuZ2U6MWU3YTgzNWZjZTEwNDFiNDliZWFlOGY5ZTE5MDBlMzBfNC0xLTEtMS0zMDUwMA_fdd7f2f2-4b28-4045-952a-d619099b2094">194,548</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i89cb4fe99d71444395e3fc22f0e7e477_D20220101-20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80OS9mcmFnOjlhN2M1MTczZGE1ZTQ5ZjViYTk4YWRiODZhZWYwOWJkL3RhYmxlOjFlN2E4MzVmY2UxMDQxYjQ5YmVhZThmOWUxOTAwZTMwL3RhYmxlcmFuZ2U6MWU3YTgzNWZjZTEwNDFiNDliZWFlOGY5ZTE5MDBlMzBfNC0zLTEtMS0zMDUwMA_1c5ba5d7-2e6e-4708-a9f7-021357bb158f">11.62</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of September 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i33c46859f4e1425b90a6f987327175f6_I20220930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80OS9mcmFnOjlhN2M1MTczZGE1ZTQ5ZjViYTk4YWRiODZhZWYwOWJkL3RhYmxlOjFlN2E4MzVmY2UxMDQxYjQ5YmVhZThmOWUxOTAwZTMwL3RhYmxlcmFuZ2U6MWU3YTgzNWZjZTEwNDFiNDliZWFlOGY5ZTE5MDBlMzBfNS0xLTEtMS0zMDUwMA_700fccff-4da2-4c1d-8b23-30861b3aa3e6">3,799,573</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i33c46859f4e1425b90a6f987327175f6_I20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80OS9mcmFnOjlhN2M1MTczZGE1ZTQ5ZjViYTk4YWRiODZhZWYwOWJkL3RhYmxlOjFlN2E4MzVmY2UxMDQxYjQ5YmVhZThmOWUxOTAwZTMwL3RhYmxlcmFuZ2U6MWU3YTgzNWZjZTEwNDFiNDliZWFlOGY5ZTE5MDBlMzBfNS0zLTEtMS0zMDUwMA_f9c95162-6f63-47d2-b451-ffca0463d762">11.40</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i89cb4fe99d71444395e3fc22f0e7e477_D20220101-20220930" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80OS9mcmFnOjlhN2M1MTczZGE1ZTQ5ZjViYTk4YWRiODZhZWYwOWJkL3RhYmxlOjFlN2E4MzVmY2UxMDQxYjQ5YmVhZThmOWUxOTAwZTMwL3RhYmxlcmFuZ2U6MWU3YTgzNWZjZTEwNDFiNDliZWFlOGY5ZTE5MDBlMzBfNS01LTEtMS0zMDUwMA_12a835a7-e22b-4d9d-a1ec-c104335ecefb">8.59</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33c46859f4e1425b90a6f987327175f6_I20220930" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80OS9mcmFnOjlhN2M1MTczZGE1ZTQ5ZjViYTk4YWRiODZhZWYwOWJkL3RhYmxlOjFlN2E4MzVmY2UxMDQxYjQ5YmVhZThmOWUxOTAwZTMwL3RhYmxlcmFuZ2U6MWU3YTgzNWZjZTEwNDFiNDliZWFlOGY5ZTE5MDBlMzBfNS03LTEtMS0zMDUwMA_c6a54083-24b8-4d54-b1c0-f681ccd6050a">2,400</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options vested and expected to vest as of September 30, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i33c46859f4e1425b90a6f987327175f6_I20220930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80OS9mcmFnOjlhN2M1MTczZGE1ZTQ5ZjViYTk4YWRiODZhZWYwOWJkL3RhYmxlOjFlN2E4MzVmY2UxMDQxYjQ5YmVhZThmOWUxOTAwZTMwL3RhYmxlcmFuZ2U6MWU3YTgzNWZjZTEwNDFiNDliZWFlOGY5ZTE5MDBlMzBfNi0xLTEtMS0zMDUwMA_8a4aff33-94c7-4af8-9223-192de5bdff58">3,799,573</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i33c46859f4e1425b90a6f987327175f6_I20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80OS9mcmFnOjlhN2M1MTczZGE1ZTQ5ZjViYTk4YWRiODZhZWYwOWJkL3RhYmxlOjFlN2E4MzVmY2UxMDQxYjQ5YmVhZThmOWUxOTAwZTMwL3RhYmxlcmFuZ2U6MWU3YTgzNWZjZTEwNDFiNDliZWFlOGY5ZTE5MDBlMzBfNi0zLTEtMS0zMDUwMA_57fefdf7-002b-4318-b664-eef099bd4367">11.40</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i89cb4fe99d71444395e3fc22f0e7e477_D20220101-20220930" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80OS9mcmFnOjlhN2M1MTczZGE1ZTQ5ZjViYTk4YWRiODZhZWYwOWJkL3RhYmxlOjFlN2E4MzVmY2UxMDQxYjQ5YmVhZThmOWUxOTAwZTMwL3RhYmxlcmFuZ2U6MWU3YTgzNWZjZTEwNDFiNDliZWFlOGY5ZTE5MDBlMzBfNi01LTEtMS0zMDUwMA_c262a617-b0a3-484b-8bc8-cf9594c8deb2">8.59</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33c46859f4e1425b90a6f987327175f6_I20220930" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80OS9mcmFnOjlhN2M1MTczZGE1ZTQ5ZjViYTk4YWRiODZhZWYwOWJkL3RhYmxlOjFlN2E4MzVmY2UxMDQxYjQ5YmVhZThmOWUxOTAwZTMwL3RhYmxlcmFuZ2U6MWU3YTgzNWZjZTEwNDFiNDliZWFlOGY5ZTE5MDBlMzBfNi03LTEtMS0zMDUwMA_84b5b624-90ae-4b33-87a9-c38ee7093888">2,400</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercisable as of September 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i33c46859f4e1425b90a6f987327175f6_I20220930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80OS9mcmFnOjlhN2M1MTczZGE1ZTQ5ZjViYTk4YWRiODZhZWYwOWJkL3RhYmxlOjFlN2E4MzVmY2UxMDQxYjQ5YmVhZThmOWUxOTAwZTMwL3RhYmxlcmFuZ2U6MWU3YTgzNWZjZTEwNDFiNDliZWFlOGY5ZTE5MDBlMzBfNy0xLTEtMS0zMDUwMA_ecf6cab2-f4f7-46b2-b53d-58150dae822e">1,248,875</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i33c46859f4e1425b90a6f987327175f6_I20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80OS9mcmFnOjlhN2M1MTczZGE1ZTQ5ZjViYTk4YWRiODZhZWYwOWJkL3RhYmxlOjFlN2E4MzVmY2UxMDQxYjQ5YmVhZThmOWUxOTAwZTMwL3RhYmxlcmFuZ2U6MWU3YTgzNWZjZTEwNDFiNDliZWFlOGY5ZTE5MDBlMzBfNy0zLTEtMS0zMDUwMA_a2ba0374-5eb3-4771-aac9-9260ab68a158">13.63</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i89cb4fe99d71444395e3fc22f0e7e477_D20220101-20220930" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80OS9mcmFnOjlhN2M1MTczZGE1ZTQ5ZjViYTk4YWRiODZhZWYwOWJkL3RhYmxlOjFlN2E4MzVmY2UxMDQxYjQ5YmVhZThmOWUxOTAwZTMwL3RhYmxlcmFuZ2U6MWU3YTgzNWZjZTEwNDFiNDliZWFlOGY5ZTE5MDBlMzBfNy01LTEtMS0zMDUwMA_45283b54-501e-4529-9418-edc808a37556">7.64</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33c46859f4e1425b90a6f987327175f6_I20220930" decimals="0" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80OS9mcmFnOjlhN2M1MTczZGE1ZTQ5ZjViYTk4YWRiODZhZWYwOWJkL3RhYmxlOjFlN2E4MzVmY2UxMDQxYjQ5YmVhZThmOWUxOTAwZTMwL3RhYmxlcmFuZ2U6MWU3YTgzNWZjZTEwNDFiNDliZWFlOGY5ZTE5MDBlMzBfNy03LTEtMS0zMDUwMA_cf3955da-b4e4-4f26-9b0e-c0bd9acb94d1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.883%"><tr><td style="width:1.0%"></td><td style="width:51.442%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.531%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.570%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.531%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.570%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.993%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.570%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.693%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term&#160;(Years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of January 1, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1986a58a2c504c0b9c41f5d536a9502c_I20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80OS9mcmFnOjlhN2M1MTczZGE1ZTQ5ZjViYTk4YWRiODZhZWYwOWJkL3RhYmxlOmRhZmM1ZTUyMzM2ZDRlY2ZiMmE2MDViNjQ5MTZjNTljL3RhYmxlcmFuZ2U6ZGFmYzVlNTIzMzZkNGVjZmIyYTYwNWI2NDkxNmM1OWNfMS0xLTEtMS0zMDUwMA_aa429bff-446f-49ec-863c-85190bedad98">1,117,160</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1986a58a2c504c0b9c41f5d536a9502c_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80OS9mcmFnOjlhN2M1MTczZGE1ZTQ5ZjViYTk4YWRiODZhZWYwOWJkL3RhYmxlOmRhZmM1ZTUyMzM2ZDRlY2ZiMmE2MDViNjQ5MTZjNTljL3RhYmxlcmFuZ2U6ZGFmYzVlNTIzMzZkNGVjZmIyYTYwNWI2NDkxNmM1OWNfMS0zLTEtMS0zMDUwMA_8ba01d37-fe81-44f9-85b6-a566e6e309ac">12.96</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0c4254621dc64047a9c2d671aa842886_D20210101-20210930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80OS9mcmFnOjlhN2M1MTczZGE1ZTQ5ZjViYTk4YWRiODZhZWYwOWJkL3RhYmxlOmRhZmM1ZTUyMzM2ZDRlY2ZiMmE2MDViNjQ5MTZjNTljL3RhYmxlcmFuZ2U6ZGFmYzVlNTIzMzZkNGVjZmIyYTYwNWI2NDkxNmM1OWNfMi0xLTEtMS0zMDUwMA_aadbaa9e-647c-48e3-b4c0-f08e16f6c45d">1,033,809</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0c4254621dc64047a9c2d671aa842886_D20210101-20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80OS9mcmFnOjlhN2M1MTczZGE1ZTQ5ZjViYTk4YWRiODZhZWYwOWJkL3RhYmxlOmRhZmM1ZTUyMzM2ZDRlY2ZiMmE2MDViNjQ5MTZjNTljL3RhYmxlcmFuZ2U6ZGFmYzVlNTIzMzZkNGVjZmIyYTYwNWI2NDkxNmM1OWNfMi0zLTEtMS0zMDUwMA_7760116d-e93d-4976-b6ce-3aa22b6f257e">14.95</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0c4254621dc64047a9c2d671aa842886_D20210101-20210930" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80OS9mcmFnOjlhN2M1MTczZGE1ZTQ5ZjViYTk4YWRiODZhZWYwOWJkL3RhYmxlOmRhZmM1ZTUyMzM2ZDRlY2ZiMmE2MDViNjQ5MTZjNTljL3RhYmxlcmFuZ2U6ZGFmYzVlNTIzMzZkNGVjZmIyYTYwNWI2NDkxNmM1OWNfMy0xLTEtMS0zMDUwMA_6914c780-2ea9-4917-845a-50a1a1c1aff3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0c4254621dc64047a9c2d671aa842886_D20210101-20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80OS9mcmFnOjlhN2M1MTczZGE1ZTQ5ZjViYTk4YWRiODZhZWYwOWJkL3RhYmxlOmRhZmM1ZTUyMzM2ZDRlY2ZiMmE2MDViNjQ5MTZjNTljL3RhYmxlcmFuZ2U6ZGFmYzVlNTIzMzZkNGVjZmIyYTYwNWI2NDkxNmM1OWNfMy0zLTEtMS0zMDUwMA_8675b8a1-5fd0-465a-841b-dc380b41b458">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited or expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i0c4254621dc64047a9c2d671aa842886_D20210101-20210930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80OS9mcmFnOjlhN2M1MTczZGE1ZTQ5ZjViYTk4YWRiODZhZWYwOWJkL3RhYmxlOmRhZmM1ZTUyMzM2ZDRlY2ZiMmE2MDViNjQ5MTZjNTljL3RhYmxlcmFuZ2U6ZGFmYzVlNTIzMzZkNGVjZmIyYTYwNWI2NDkxNmM1OWNfNC0xLTEtMS0zMDUwMA_9095fee4-3d3a-45fd-bcc8-6b249a673828">105,009</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0c4254621dc64047a9c2d671aa842886_D20210101-20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80OS9mcmFnOjlhN2M1MTczZGE1ZTQ5ZjViYTk4YWRiODZhZWYwOWJkL3RhYmxlOmRhZmM1ZTUyMzM2ZDRlY2ZiMmE2MDViNjQ5MTZjNTljL3RhYmxlcmFuZ2U6ZGFmYzVlNTIzMzZkNGVjZmIyYTYwNWI2NDkxNmM1OWNfNC0zLTEtMS0zMDUwMA_86de6e71-db89-41f7-b129-5829514976db">14.32</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of September 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3fc8f323372c48c49a066aa56341ee03_I20210930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80OS9mcmFnOjlhN2M1MTczZGE1ZTQ5ZjViYTk4YWRiODZhZWYwOWJkL3RhYmxlOmRhZmM1ZTUyMzM2ZDRlY2ZiMmE2MDViNjQ5MTZjNTljL3RhYmxlcmFuZ2U6ZGFmYzVlNTIzMzZkNGVjZmIyYTYwNWI2NDkxNmM1OWNfNS0xLTEtMS0zMDUwMA_107e2651-e10b-44ae-ac5e-66dd2d04c82e">2,045,960</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3fc8f323372c48c49a066aa56341ee03_I20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80OS9mcmFnOjlhN2M1MTczZGE1ZTQ5ZjViYTk4YWRiODZhZWYwOWJkL3RhYmxlOmRhZmM1ZTUyMzM2ZDRlY2ZiMmE2MDViNjQ5MTZjNTljL3RhYmxlcmFuZ2U6ZGFmYzVlNTIzMzZkNGVjZmIyYTYwNWI2NDkxNmM1OWNfNS0zLTEtMS0zMDUwMA_1e68762e-520b-49fb-88d2-f4934b3cb072">13.90</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0c4254621dc64047a9c2d671aa842886_D20210101-20210930" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80OS9mcmFnOjlhN2M1MTczZGE1ZTQ5ZjViYTk4YWRiODZhZWYwOWJkL3RhYmxlOmRhZmM1ZTUyMzM2ZDRlY2ZiMmE2MDViNjQ5MTZjNTljL3RhYmxlcmFuZ2U6ZGFmYzVlNTIzMzZkNGVjZmIyYTYwNWI2NDkxNmM1OWNfNS01LTEtMS0zMDUwMA_ed3a62f3-965d-4d8f-bcd5-07a38039bf66">8.91</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fc8f323372c48c49a066aa56341ee03_I20210930" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80OS9mcmFnOjlhN2M1MTczZGE1ZTQ5ZjViYTk4YWRiODZhZWYwOWJkL3RhYmxlOmRhZmM1ZTUyMzM2ZDRlY2ZiMmE2MDViNjQ5MTZjNTljL3RhYmxlcmFuZ2U6ZGFmYzVlNTIzMzZkNGVjZmIyYTYwNWI2NDkxNmM1OWNfNS03LTEtMS0zMDUwMA_eef031ee-c4e7-4200-9661-b1aa266cd15e">74,460</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options vested and expected to vest as of September 30, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3fc8f323372c48c49a066aa56341ee03_I20210930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80OS9mcmFnOjlhN2M1MTczZGE1ZTQ5ZjViYTk4YWRiODZhZWYwOWJkL3RhYmxlOmRhZmM1ZTUyMzM2ZDRlY2ZiMmE2MDViNjQ5MTZjNTljL3RhYmxlcmFuZ2U6ZGFmYzVlNTIzMzZkNGVjZmIyYTYwNWI2NDkxNmM1OWNfNi0xLTEtMS0zMDUwMA_379c5f39-b3db-4cf7-9460-a5923aa05e15">2,045,960</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3fc8f323372c48c49a066aa56341ee03_I20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80OS9mcmFnOjlhN2M1MTczZGE1ZTQ5ZjViYTk4YWRiODZhZWYwOWJkL3RhYmxlOmRhZmM1ZTUyMzM2ZDRlY2ZiMmE2MDViNjQ5MTZjNTljL3RhYmxlcmFuZ2U6ZGFmYzVlNTIzMzZkNGVjZmIyYTYwNWI2NDkxNmM1OWNfNi0zLTEtMS0zMDUwMA_52e637fb-5e8f-4b29-9c0d-01125a6c349f">13.90</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0c4254621dc64047a9c2d671aa842886_D20210101-20210930" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80OS9mcmFnOjlhN2M1MTczZGE1ZTQ5ZjViYTk4YWRiODZhZWYwOWJkL3RhYmxlOmRhZmM1ZTUyMzM2ZDRlY2ZiMmE2MDViNjQ5MTZjNTljL3RhYmxlcmFuZ2U6ZGFmYzVlNTIzMzZkNGVjZmIyYTYwNWI2NDkxNmM1OWNfNi01LTEtMS0zMDUwMA_1592ae36-485f-4cc6-943e-5fe9dc8e2f07">8.91</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fc8f323372c48c49a066aa56341ee03_I20210930" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80OS9mcmFnOjlhN2M1MTczZGE1ZTQ5ZjViYTk4YWRiODZhZWYwOWJkL3RhYmxlOmRhZmM1ZTUyMzM2ZDRlY2ZiMmE2MDViNjQ5MTZjNTljL3RhYmxlcmFuZ2U6ZGFmYzVlNTIzMzZkNGVjZmIyYTYwNWI2NDkxNmM1OWNfNi03LTEtMS0zMDUwMA_5d9fd82f-f870-41ac-b09f-6afcc3e3dd6b">74,460</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercisable as of September 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3fc8f323372c48c49a066aa56341ee03_I20210930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80OS9mcmFnOjlhN2M1MTczZGE1ZTQ5ZjViYTk4YWRiODZhZWYwOWJkL3RhYmxlOmRhZmM1ZTUyMzM2ZDRlY2ZiMmE2MDViNjQ5MTZjNTljL3RhYmxlcmFuZ2U6ZGFmYzVlNTIzMzZkNGVjZmIyYTYwNWI2NDkxNmM1OWNfNy0xLTEtMS0zMDUwMA_699ee8d7-fcc3-4ecd-8246-be3bebb657b7">665,168</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3fc8f323372c48c49a066aa56341ee03_I20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80OS9mcmFnOjlhN2M1MTczZGE1ZTQ5ZjViYTk4YWRiODZhZWYwOWJkL3RhYmxlOmRhZmM1ZTUyMzM2ZDRlY2ZiMmE2MDViNjQ5MTZjNTljL3RhYmxlcmFuZ2U6ZGFmYzVlNTIzMzZkNGVjZmIyYTYwNWI2NDkxNmM1OWNfNy0zLTEtMS0zMDUwMA_2dabdb38-60a5-4116-b75f-6fd508c3b19f">13.39</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0c4254621dc64047a9c2d671aa842886_D20210101-20210930" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80OS9mcmFnOjlhN2M1MTczZGE1ZTQ5ZjViYTk4YWRiODZhZWYwOWJkL3RhYmxlOmRhZmM1ZTUyMzM2ZDRlY2ZiMmE2MDViNjQ5MTZjNTljL3RhYmxlcmFuZ2U6ZGFmYzVlNTIzMzZkNGVjZmIyYTYwNWI2NDkxNmM1OWNfNy01LTEtMS0zMDUwMA_03925124-5966-4e4b-bb7f-8c0032afa9f9">8.33</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fc8f323372c48c49a066aa56341ee03_I20210930" decimals="0" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80OS9mcmFnOjlhN2M1MTczZGE1ZTQ5ZjViYTk4YWRiODZhZWYwOWJkL3RhYmxlOmRhZmM1ZTUyMzM2ZDRlY2ZiMmE2MDViNjQ5MTZjNTljL3RhYmxlcmFuZ2U6ZGFmYzVlNTIzMzZkNGVjZmIyYTYwNWI2NDkxNmM1OWNfNy03LTEtMS0zMDUwMA_b1667a76-096b-4041-a14f-8ed2553815ad">43,121</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Measurement</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average assumptions used in the BSM option pricing model to determine the fair value of the employee and non-employee stock option grants relating to the 2019 Plan were as follows:</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk-Free Interest Rate</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The risk-free rate assumption is based on U.S. Treasury instruments with maturities similar to the expected term of the stock options.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Dividend Yield</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company has not issued any dividends and does not expect to issue dividends over the life of the options. As a result, the Company has estimated the dividend yield to be <ix:nonFraction unitRef="number" contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80OS9mcmFnOjlhN2M1MTczZGE1ZTQ5ZjViYTk4YWRiODZhZWYwOWJkL3RleHRyZWdpb246OWE3YzUxNzNkYTVlNDlmNWJhOThhZGI4NmFlZjA5YmRfNTQ5NzU1ODI3MjA0_cbe89d14-0d61-43ca-981e-ec07694b55f3">zero</ix:nonFraction>.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Volatility</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the Company&#8217;s limited operating history and a lack of company specific historical and implied volatility data, the Company estimates expected volatility based on the historical volatility of its own stock combined with a group of comparable companies that are publicly traded. The historical volatility data was computed using the daily closing prices for the selected companies&#8217; shares during the equivalent period of the calculated expected term of the stock-based awards.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Term </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i628815afe28944eeabbe5461de720656"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The expected term of options is estimated considering the vesting period at the grant date, the life of the option and the average length of time similar grants have remained outstanding in the past.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average grant date fair value of stock options granted under the 2019 Plan during the nine months ended September 30, 2022 and 2021 was $<ix:nonFraction unitRef="usdPerShare" contextRef="i491c0053bc5f4054a60885ff43fbbc87_D20220101-20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80OS9mcmFnOjlhN2M1MTczZGE1ZTQ5ZjViYTk4YWRiODZhZWYwOWJkL3RleHRyZWdpb246OWE3YzUxNzNkYTVlNDlmNWJhOThhZGI4NmFlZjA5YmRfNTQ5NzU1ODI4MTQz_2ab4481d-fc9e-4f43-81f5-abe5e8845d3a">6.94</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="i3b24c8dadaf44185922659d4e669111d_D20210101-20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80OS9mcmFnOjlhN2M1MTczZGE1ZTQ5ZjViYTk4YWRiODZhZWYwOWJkL3RleHRyZWdpb246OWE3YzUxNzNkYTVlNDlmNWJhOThhZGI4NmFlZjA5YmRfNTQ5NzU1ODI4MTY0_594ee444-652e-4c43-b292-65772968a00a">11.14</ix:nonFraction>, respectively. <ix:nonNumeric contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80OS9mcmFnOjlhN2M1MTczZGE1ZTQ5ZjViYTk4YWRiODZhZWYwOWJkL3RleHRyZWdpb246OWE3YzUxNzNkYTVlNDlmNWJhOThhZGI4NmFlZjA5YmRfNjAzMw_ade6bdd9-48da-47c6-b2d3-8aba04dfd60f" continuedAt="i239a97cc92f34279b71613a0ab571e8a" escape="true">The following are the underlying assumptions used in the Black-Scholes-Merton option pricing model to determine the fair value of stock options granted to employees and to non-employees under this stock plan:</ix:nonNumeric></span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><ix:continuation id="i239a97cc92f34279b71613a0ab571e8a"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.812%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.443%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.445%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine  Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i491c0053bc5f4054a60885ff43fbbc87_D20220101-20220930" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80OS9mcmFnOjlhN2M1MTczZGE1ZTQ5ZjViYTk4YWRiODZhZWYwOWJkL3RhYmxlOjQwYzk3MWU2NzJlZjQxMjFhNDcyZDIxNjQ5MjI2ZWE3L3RhYmxlcmFuZ2U6NDBjOTcxZTY3MmVmNDEyMWE0NzJkMjE2NDkyMjZlYTdfMi0xLTEtMS0zMDUwMA_169b85c5-aaae-4b6c-835f-98f6ee7f4291">2.04</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3b24c8dadaf44185922659d4e669111d_D20210101-20210930" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80OS9mcmFnOjlhN2M1MTczZGE1ZTQ5ZjViYTk4YWRiODZhZWYwOWJkL3RhYmxlOjQwYzk3MWU2NzJlZjQxMjFhNDcyZDIxNjQ5MjI2ZWE3L3RhYmxlcmFuZ2U6NDBjOTcxZTY3MmVmNDEyMWE0NzJkMjE2NDkyMjZlYTdfMi0yLTEtMS0zMDUwMA_69ddd372-f97d-433a-a062-463dcd80d10a">0.88</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i491c0053bc5f4054a60885ff43fbbc87_D20220101-20220930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80OS9mcmFnOjlhN2M1MTczZGE1ZTQ5ZjViYTk4YWRiODZhZWYwOWJkL3RhYmxlOjQwYzk3MWU2NzJlZjQxMjFhNDcyZDIxNjQ5MjI2ZWE3L3RhYmxlcmFuZ2U6NDBjOTcxZTY3MmVmNDEyMWE0NzJkMjE2NDkyMjZlYTdfMy0xLTEtMS0zMDUwMA_20358787-1133-456b-a500-0d4ca4ec0b60">0</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3b24c8dadaf44185922659d4e669111d_D20210101-20210930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80OS9mcmFnOjlhN2M1MTczZGE1ZTQ5ZjViYTk4YWRiODZhZWYwOWJkL3RhYmxlOjQwYzk3MWU2NzJlZjQxMjFhNDcyZDIxNjQ5MjI2ZWE3L3RhYmxlcmFuZ2U6NDBjOTcxZTY3MmVmNDEyMWE0NzJkMjE2NDkyMjZlYTdfMy0yLTEtMS0zMDUwMA_2ed0dd88-fac3-443f-8716-09fecb3635fb">0</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i491c0053bc5f4054a60885ff43fbbc87_D20220101-20220930" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80OS9mcmFnOjlhN2M1MTczZGE1ZTQ5ZjViYTk4YWRiODZhZWYwOWJkL3RhYmxlOjQwYzk3MWU2NzJlZjQxMjFhNDcyZDIxNjQ5MjI2ZWE3L3RhYmxlcmFuZ2U6NDBjOTcxZTY3MmVmNDEyMWE0NzJkMjE2NDkyMjZlYTdfNC0xLTEtMS0zMDUwMA_34390804-bc7a-4d7d-82fe-9a75e3a8ca26">97.8</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3b24c8dadaf44185922659d4e669111d_D20210101-20210930" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80OS9mcmFnOjlhN2M1MTczZGE1ZTQ5ZjViYTk4YWRiODZhZWYwOWJkL3RhYmxlOjQwYzk3MWU2NzJlZjQxMjFhNDcyZDIxNjQ5MjI2ZWE3L3RhYmxlcmFuZ2U6NDBjOTcxZTY3MmVmNDEyMWE0NzJkMjE2NDkyMjZlYTdfNC0yLTEtMS0zMDUwMA_f59219e4-5c59-40fd-9dc1-21eed0c9d931">92.4</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term of options (years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i491c0053bc5f4054a60885ff43fbbc87_D20220101-20220930" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80OS9mcmFnOjlhN2M1MTczZGE1ZTQ5ZjViYTk4YWRiODZhZWYwOWJkL3RhYmxlOjQwYzk3MWU2NzJlZjQxMjFhNDcyZDIxNjQ5MjI2ZWE3L3RhYmxlcmFuZ2U6NDBjOTcxZTY3MmVmNDEyMWE0NzJkMjE2NDkyMjZlYTdfNS0xLTEtMS0zMDUwMA_c98140ad-2364-4925-be44-dc5433e6b720">6.00</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3b24c8dadaf44185922659d4e669111d_D20210101-20210930" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80OS9mcmFnOjlhN2M1MTczZGE1ZTQ5ZjViYTk4YWRiODZhZWYwOWJkL3RhYmxlOjQwYzk3MWU2NzJlZjQxMjFhNDcyZDIxNjQ5MjI2ZWE3L3RhYmxlcmFuZ2U6NDBjOTcxZTY3MmVmNDEyMWE0NzJkMjE2NDkyMjZlYTdfNS0yLTEtMS0zMDUwMA_017a931a-2363-4a6c-aae6-158b5578f1b8">5.95</ix:nonNumeric></span></td></tr></table></ix:continuation></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation Expense</span></div><ix:nonNumeric contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80OS9mcmFnOjlhN2M1MTczZGE1ZTQ5ZjViYTk4YWRiODZhZWYwOWJkL3RleHRyZWdpb246OWE3YzUxNzNkYTVlNDlmNWJhOThhZGI4NmFlZjA5YmRfNjAyOA_aba01f4f-244d-4df1-bb2a-6d44ee714ea3" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total stock-based compensation expense for all stock awards recognized in the accompanying unaudited condensed consolidated statements of operations is as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.391%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.186%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months<br/>&#160;Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months<br/>&#160;Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65018cf301294210aa0bfac659e1638e_D20220701-20220930" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80OS9mcmFnOjlhN2M1MTczZGE1ZTQ5ZjViYTk4YWRiODZhZWYwOWJkL3RhYmxlOjAxZDg2YjY5NWU0NDQ1ZGFiODZmNDIxZTRmN2UxMWU5L3RhYmxlcmFuZ2U6MDFkODZiNjk1ZTQ0NDVkYWI4NmY0MjFlNGY3ZTExZTlfMi01LTEtMS0zMDUwMA_dabd09fd-f899-40ea-8878-3941ccc20539">831,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c3b29676a4440ad86911f00449ac95c_D20210701-20210930" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80OS9mcmFnOjlhN2M1MTczZGE1ZTQ5ZjViYTk4YWRiODZhZWYwOWJkL3RhYmxlOjAxZDg2YjY5NWU0NDQ1ZGFiODZmNDIxZTRmN2UxMWU5L3RhYmxlcmFuZ2U6MDFkODZiNjk1ZTQ0NDVkYWI4NmY0MjFlNGY3ZTExZTlfMi03LTEtMS0zMDUwMA_4d6bd893-ca77-40fc-98d3-4255cd59c574">456,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51d6b668f708464ebb2ff34b8eee66d8_D20220101-20220930" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80OS9mcmFnOjlhN2M1MTczZGE1ZTQ5ZjViYTk4YWRiODZhZWYwOWJkL3RhYmxlOjAxZDg2YjY5NWU0NDQ1ZGFiODZmNDIxZTRmN2UxMWU5L3RhYmxlcmFuZ2U6MDFkODZiNjk1ZTQ0NDVkYWI4NmY0MjFlNGY3ZTExZTlfMi05LTEtMS0zMDUwMA_32e98ba9-f3f7-4baf-85d4-60b0b6f16008">2,392,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83d76f6d51a84bfaaf85c435fc1d50f8_D20210101-20210930" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80OS9mcmFnOjlhN2M1MTczZGE1ZTQ5ZjViYTk4YWRiODZhZWYwOWJkL3RhYmxlOjAxZDg2YjY5NWU0NDQ1ZGFiODZmNDIxZTRmN2UxMWU5L3RhYmxlcmFuZ2U6MDFkODZiNjk1ZTQ0NDVkYWI4NmY0MjFlNGY3ZTExZTlfMi0xMS0xLTEtMzA1MDA_070e9b23-9c7c-46f9-91ca-d3e13c78c67c">1,279,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e6c05b057b542f6a6dc60098a6d004a_D20220701-20220930" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80OS9mcmFnOjlhN2M1MTczZGE1ZTQ5ZjViYTk4YWRiODZhZWYwOWJkL3RhYmxlOjAxZDg2YjY5NWU0NDQ1ZGFiODZmNDIxZTRmN2UxMWU5L3RhYmxlcmFuZ2U6MDFkODZiNjk1ZTQ0NDVkYWI4NmY0MjFlNGY3ZTExZTlfMy01LTEtMS0zMDUwMA_209d2ddf-43d7-4efb-8a44-6708576b131f">1,081,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifcca3d7bc3b04230b95c604feca1b658_D20210701-20210930" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80OS9mcmFnOjlhN2M1MTczZGE1ZTQ5ZjViYTk4YWRiODZhZWYwOWJkL3RhYmxlOjAxZDg2YjY5NWU0NDQ1ZGFiODZmNDIxZTRmN2UxMWU5L3RhYmxlcmFuZ2U6MDFkODZiNjk1ZTQ0NDVkYWI4NmY0MjFlNGY3ZTExZTlfMy03LTEtMS0zMDUwMA_164de072-da90-46c5-8f37-530e75a279ed">941,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i600a6a4da2a14932ac6ebff843b1dc82_D20220101-20220930" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80OS9mcmFnOjlhN2M1MTczZGE1ZTQ5ZjViYTk4YWRiODZhZWYwOWJkL3RhYmxlOjAxZDg2YjY5NWU0NDQ1ZGFiODZmNDIxZTRmN2UxMWU5L3RhYmxlcmFuZ2U6MDFkODZiNjk1ZTQ0NDVkYWI4NmY0MjFlNGY3ZTExZTlfMy05LTEtMS0zMDUwMA_0c4a57fe-ab9b-4c31-866e-d64c0c9c50e4">3,651,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia17d3b4067d84bec848071ef0c64a422_D20210101-20210930" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80OS9mcmFnOjlhN2M1MTczZGE1ZTQ5ZjViYTk4YWRiODZhZWYwOWJkL3RhYmxlOjAxZDg2YjY5NWU0NDQ1ZGFiODZmNDIxZTRmN2UxMWU5L3RhYmxlcmFuZ2U6MDFkODZiNjk1ZTQ0NDVkYWI4NmY0MjFlNGY3ZTExZTlfMy0xMS0xLTEtMzA1MDA_bddf6c1c-ac48-4943-acc8-e3cc288ca3ef">3,204,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13791407fd49427ea3348fc4827a4293_D20220701-20220930" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80OS9mcmFnOjlhN2M1MTczZGE1ZTQ5ZjViYTk4YWRiODZhZWYwOWJkL3RhYmxlOjAxZDg2YjY5NWU0NDQ1ZGFiODZmNDIxZTRmN2UxMWU5L3RhYmxlcmFuZ2U6MDFkODZiNjk1ZTQ0NDVkYWI4NmY0MjFlNGY3ZTExZTlfNC01LTEtMS0zMDUwMA_753dcdc5-85d6-4588-ba91-5b857feea57f">1,912,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib938f3761273465cb69e3854e10882fd_D20210701-20210930" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80OS9mcmFnOjlhN2M1MTczZGE1ZTQ5ZjViYTk4YWRiODZhZWYwOWJkL3RhYmxlOjAxZDg2YjY5NWU0NDQ1ZGFiODZmNDIxZTRmN2UxMWU5L3RhYmxlcmFuZ2U6MDFkODZiNjk1ZTQ0NDVkYWI4NmY0MjFlNGY3ZTExZTlfNC03LTEtMS0zMDUwMA_dc68498b-b482-4728-9435-ed25351c20e5">1,397,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c121149163740e0a14cb0c4c82c1e7a_D20220101-20220930" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80OS9mcmFnOjlhN2M1MTczZGE1ZTQ5ZjViYTk4YWRiODZhZWYwOWJkL3RhYmxlOjAxZDg2YjY5NWU0NDQ1ZGFiODZmNDIxZTRmN2UxMWU5L3RhYmxlcmFuZ2U6MDFkODZiNjk1ZTQ0NDVkYWI4NmY0MjFlNGY3ZTExZTlfNC05LTEtMS0zMDUwMA_cc6d75e2-74d3-42f8-ae6e-ce35487b76bb">6,043,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73bcd6c9a1664c7bbdd7d9ed12c94b42_D20210101-20210930" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80OS9mcmFnOjlhN2M1MTczZGE1ZTQ5ZjViYTk4YWRiODZhZWYwOWJkL3RhYmxlOjAxZDg2YjY5NWU0NDQ1ZGFiODZmNDIxZTRmN2UxMWU5L3RhYmxlcmFuZ2U6MDFkODZiNjk1ZTQ0NDVkYWI4NmY0MjFlNGY3ZTExZTlfNC0xMS0xLTEtMzA1MDA_238b0887-071b-47a7-b799-37ff79401bd1">4,483,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2022, there was $<ix:nonFraction unitRef="usd" contextRef="ib2ba0b84078f4de2bc3079e992921b92_I20220930" decimals="-3" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80OS9mcmFnOjlhN2M1MTczZGE1ZTQ5ZjViYTk4YWRiODZhZWYwOWJkL3RleHRyZWdpb246OWE3YzUxNzNkYTVlNDlmNWJhOThhZGI4NmFlZjA5YmRfNDgzMQ_daa715e1-526f-4877-ad16-c511303f3ab6">17.6</ix:nonFraction> million in total unrecognized compensation expense relating to the 2019 Plan to be recognized over a weighted average period of <ix:nonNumeric contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80OS9mcmFnOjlhN2M1MTczZGE1ZTQ5ZjViYTk4YWRiODZhZWYwOWJkL3RleHRyZWdpb246OWE3YzUxNzNkYTVlNDlmNWJhOThhZGI4NmFlZjA5YmRfMjc0ODc3OTA4NTkzNQ_a959ac31-fe4e-4cda-96d6-ccc177e8ac97">2.91</ix:nonNumeric> years.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Summary of Equity Incentive Plans Assumed from Vital</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon completion of the Transaction with Vital Therapies ("Vital") on April 12, 2019, Vital&#8217;s 2012 Stock Option Plan (the &#8220;2012 Plan&#8221;), Vital&#8217;s 2014 Equity Incentive Plan (the &#8220;2014 Plan&#8221;) and Vital&#8217;s 2017 Inducement Equity Incentive Plan (the &#8220;Inducement Plan&#8221;), were assumed by the Company. All awards granted under these plans have either been forfeited or expired.  </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There remain <ix:nonFraction unitRef="shares" contextRef="i6e53bb714b6644b6844692585589b9a1_I20220930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80OS9mcmFnOjlhN2M1MTczZGE1ZTQ5ZjViYTk4YWRiODZhZWYwOWJkL3RleHRyZWdpb246OWE3YzUxNzNkYTVlNDlmNWJhOThhZGI4NmFlZjA5YmRfNTM3NA_a4052869-a5d2-443c-bebc-6d4949c68808">43,311</ix:nonFraction> shares available for grant under the 2014 Plan as of September 30, 2022.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 2017, Vital&#8217;s board of directors approved the Inducement Plan, which was amended and restated in November 2017. Under the Inducement Plan <ix:nonFraction unitRef="shares" contextRef="i84a3ff1a38eb4f16b75117d13dc1cdf2_I20170930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80OS9mcmFnOjlhN2M1MTczZGE1ZTQ5ZjViYTk4YWRiODZhZWYwOWJkL3RleHRyZWdpb246OWE3YzUxNzNkYTVlNDlmNWJhOThhZGI4NmFlZjA5YmRfNTQ5NzU1ODI5NDgy_3fecbcaa-a8dc-4b8a-9a9c-e26a34300c18">46,250</ix:nonFraction> shares of Vital&#8217;s common stock were reserved to be used exclusively for non-qualified grants to individuals who were not previously employees or directors as an inducement material to a grantee's entry into employment within the meaning of Rule 5635(c)(4) of the Nasdaq Listing Rules.  </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="if4028463febd40cfa3197e55e2ea9e63_D20200101-20200930" decimals="INF" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80OS9mcmFnOjlhN2M1MTczZGE1ZTQ5ZjViYTk4YWRiODZhZWYwOWJkL3RleHRyZWdpb246OWE3YzUxNzNkYTVlNDlmNWJhOThhZGI4NmFlZjA5YmRfMzI5ODUzNDg4OTM2NQ_367f8e11-8a8b-4c46-b766-c14a3bd24a5b"><ix:nonFraction unitRef="usd" contextRef="i991eea4739be41089733f8422d8cbd37_D20210101-20210930" decimals="INF" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80OS9mcmFnOjlhN2M1MTczZGE1ZTQ5ZjViYTk4YWRiODZhZWYwOWJkL3RleHRyZWdpb246OWE3YzUxNzNkYTVlNDlmNWJhOThhZGI4NmFlZjA5YmRfMzI5ODUzNDg4OTM2NQ_53da847f-06eb-416f-9a4e-a71752283a82"><ix:nonFraction unitRef="usd" contextRef="i6197809d315e4cd680ef948f2e4723c8_D20200701-20200930" decimals="INF" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80OS9mcmFnOjlhN2M1MTczZGE1ZTQ5ZjViYTk4YWRiODZhZWYwOWJkL3RleHRyZWdpb246OWE3YzUxNzNkYTVlNDlmNWJhOThhZGI4NmFlZjA5YmRfMzI5ODUzNDg4OTM2NQ_b3653163-0c4a-4d46-85f7-62d9f606ab97"><ix:nonFraction unitRef="usd" contextRef="i5d76381e3d7b4d5e846b0b465a4f3f9a_D20210701-20210930" decimals="INF" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80OS9mcmFnOjlhN2M1MTczZGE1ZTQ5ZjViYTk4YWRiODZhZWYwOWJkL3RleHRyZWdpb246OWE3YzUxNzNkYTVlNDlmNWJhOThhZGI4NmFlZjA5YmRfMzI5ODUzNDg4OTM2NQ_de6f062c-e3e8-4928-aa07-29c37aaf0c4d">No</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> expense was recorded for the plans assumed from Vital during the three and nine months ended September 30, 2022 and 2021, respectively.</span></div></ix:continuation><div style="margin-top:17.6pt;text-align:justify;text-indent:27pt"><span><br/></span></div><div id="ida7c333e3c58430eb83e8e950c50d811_748"></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8. <ix:nonNumeric contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930" name="vtl:ChangesInBoardOfDirectorsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV83NDgvZnJhZzplMmMwNzAyYTViZjI0MGM3ODAxNGQ2MTg1YzA0MGIxZC90ZXh0cmVnaW9uOmUyYzA3MDJhNWJmMjQwYzc4MDE0ZDYxODVjMDQwYjFkXzQ5NDc4MDIzMjY4MDQ_fa82733c-a051-4e32-9b8f-13ad791e3052" continuedAt="icd7532ade06342aea3b0716dafbd5010" escape="true">Changes in Board of Directors</ix:nonNumeric></span></div><ix:continuation id="icd7532ade06342aea3b0716dafbd5010"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 6, 2022, the Company announced the appointment of Monika Maria T&#246;rns&#233;n as a member of the Board of Directors of the Company, effective as of July 5, 2022. As a Class III director, Ms. T&#246;rns&#233;n&#8217;s term lasts until the Company&#8217;s 2023 annual meeting of stockholders.  Ms. T&#246;rns&#233;n is not a party to, and does not have any direct or indirect material interest in, any transaction requiring disclosure under Item 404(a) of Regulation S-K. There are no arrangements or understandings between Ms. T&#246;rns&#233;n and any other persons pursuant to which she was selected as a director.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with her appointment as director, Ms. T&#246;rns&#233;n was granted a long-term equity incentive grant in the form of an option to purchase a total of <ix:nonFraction unitRef="shares" contextRef="i0b4e3048cb3144a99e1401eb94392689_D20220706-20220706" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV83NDgvZnJhZzplMmMwNzAyYTViZjI0MGM3ODAxNGQ2MTg1YzA0MGIxZC90ZXh0cmVnaW9uOmUyYzA3MDJhNWJmMjQwYzc4MDE0ZDYxODVjMDQwYjFkXzU0OTc1NTgxNDcyNQ_d2c77abd-817c-42ca-8b7b-fe976b220fed">30,000</ix:nonFraction> shares of the Company&#8217;s common stock, with an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i0b4e3048cb3144a99e1401eb94392689_D20220706-20220706" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV83NDgvZnJhZzplMmMwNzAyYTViZjI0MGM3ODAxNGQ2MTg1YzA0MGIxZC90ZXh0cmVnaW9uOmUyYzA3MDJhNWJmMjQwYzc4MDE0ZDYxODVjMDQwYjFkXzU0OTc1NTgxNDc5Mw_aba93bbe-5330-491e-898e-959b5a885b17">4.30</ix:nonFraction> per share, which is equal to the closing price of the Company's common stock on The Nasdaq Stock Market on the date of grant, July 8, 2022. The option to purchase <ix:nonFraction unitRef="shares" contextRef="ifaeb8f92093c46299d0fff82d6b11f23_D20220706-20220706" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV83NDgvZnJhZzplMmMwNzAyYTViZjI0MGM3ODAxNGQ2MTg1YzA0MGIxZC90ZXh0cmVnaW9uOmUyYzA3MDJhNWJmMjQwYzc4MDE0ZDYxODVjMDQwYjFkXzU0OTc1NTgxNDk2MA_906d2af3-2fb2-4ec0-b357-87cbfb62e5f3">10,000</ix:nonFraction> shares vests in monthly increments over a period of <ix:nonNumeric contextRef="ifaeb8f92093c46299d0fff82d6b11f23_D20220706-20220706" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV83NDgvZnJhZzplMmMwNzAyYTViZjI0MGM3ODAxNGQ2MTg1YzA0MGIxZC90ZXh0cmVnaW9uOmUyYzA3MDJhNWJmMjQwYzc4MDE0ZDYxODVjMDQwYjFkXzU0OTc1NTgxNTAxNg_41d14482-b097-4d55-805c-dfd5caadf43b">one year</ix:nonNumeric> from the grant date, and the option to purchase <ix:nonFraction unitRef="shares" contextRef="ibb08e53d8ed6456987432dc116d4c52f_D20220706-20220706" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV83NDgvZnJhZzplMmMwNzAyYTViZjI0MGM3ODAxNGQ2MTg1YzA0MGIxZC90ZXh0cmVnaW9uOmUyYzA3MDJhNWJmMjQwYzc4MDE0ZDYxODVjMDQwYjFkXzU0OTc1NTgxNTA2OA_c8bcea7b-23b2-4b70-abd2-a9222e9d1efb">20,000</ix:nonFraction> shares vests in monthly increments over a period of <ix:nonNumeric contextRef="ibb08e53d8ed6456987432dc116d4c52f_D20220706-20220706" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV83NDgvZnJhZzplMmMwNzAyYTViZjI0MGM3ODAxNGQ2MTg1YzA0MGIxZC90ZXh0cmVnaW9uOmUyYzA3MDJhNWJmMjQwYzc4MDE0ZDYxODVjMDQwYjFkXzU0OTc1NTgxNTEyNA_005050d3-143c-40a0-906a-236b66b1b609">three years</ix:nonNumeric> from the grant date. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, Ms. T&#246;rns&#233;n and the Company entered into the Company&#8217;s standard form of indemnification agreement for directors and executive officers.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Concurrently, the Company also announced that current Class III director, Jan Van den Bossche, resigned from the Board. The Board accepted Mr. Van den Bossche&#8217;s resignation effective July 5, 2022. Mr. Van den Bossche&#8217;s decision to resign did not result from any disagreement with the Company on any matter relating to Company operations, policies or practices.</span></div></ix:continuation><div><span><br/></span></div><div id="ida7c333e3c58430eb83e8e950c50d811_55"></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9. <ix:nonNumeric contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV81NS9mcmFnOjU0NWNmNzgwODVmZjRlYjlhOGU4MDA0NDk1YWE3MDM1L3RleHRyZWdpb246NTQ1Y2Y3ODA4NWZmNGViOWE4ZTgwMDQ0OTVhYTcwMzVfMTEyMw_468accac-cb3e-4d1d-bf7b-186de2b14564" continuedAt="i5aa2a28815b649cdb9e82aec7259c231" escape="true">Related Party Transactions</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i5aa2a28815b649cdb9e82aec7259c231"><div style="margin-top:12pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Executive Chairman Agreement with Duane Nash</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 15, 2020, the compensation committee of the Board of Directors of the Company independently reviewed and approved entering into an employment agreement with the current Chairman of the Board, Duane Nash, MD, JD, MBA (the &#8220;Executive Chairman Agreement&#8221;) and pursuant to such approval, on April 17, 2020, the Company and Dr. Nash entered into the Executive Chairman Agreement. The Executive Chairman Agreement establishes an &#8220;at will&#8221; employment relationship pursuant to which Dr. Nash serves as Executive Chairman and contemplated a term that ends on October 15, 2020, which was subsequently extended to April 15, 2021. On April 15, 2021, the Company and Dr. Nash entered into an addendum (the &#8220;Addendum&#8221;) to extend the term of the Executive Chairman Agreement to April 15, 2022.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Addendum, the Company made a one-time award to Dr. Nash of an option to purchase <ix:nonFraction unitRef="shares" contextRef="i7842ca3ec7d941b397d15eae864cf058_D20210415-20210415" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV81NS9mcmFnOjU0NWNmNzgwODVmZjRlYjlhOGU4MDA0NDk1YWE3MDM1L3RleHRyZWdpb246NTQ1Y2Y3ODA4NWZmNGViOWE4ZTgwMDQ0OTVhYTcwMzVfNTQ5NzU1ODIwMzY3_bc98f03b-cfb2-4334-994b-df45ef05b7b3">90,000</ix:nonFraction> shares of Company common stock, which vests monthly commencing on May 15, 2021, and to increase Dr. Nash&#8217;s monthly base salary to $<ix:nonFraction unitRef="usd" contextRef="i4e522a1cd2c5463883ece885e48da850_D20210515-20211231" decimals="0" name="vtl:SalaryCostsMonthlyBaseSalary" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV81NS9mcmFnOjU0NWNmNzgwODVmZjRlYjlhOGU4MDA0NDk1YWE3MDM1L3RleHRyZWdpb246NTQ1Y2Y3ODA4NWZmNGViOWE4ZTgwMDQ0OTVhYTcwMzVfNTQ5NzU1ODIwNTAx_ded6205c-4d5b-481a-b22e-99fc284434d5">27,960</ix:nonFraction> from $<ix:nonFraction unitRef="usd" contextRef="ic77ff01be43a48cfa612a7cac5ec9de0_D20210101-20210514" decimals="0" name="vtl:SalaryCostsMonthlyBaseSalary" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV81NS9mcmFnOjU0NWNmNzgwODVmZjRlYjlhOGU4MDA0NDk1YWE3MDM1L3RleHRyZWdpb246NTQ1Y2Y3ODA4NWZmNGViOWE4ZTgwMDQ0OTVhYTcwMzVfNTQ5NzU1ODIwNTEw_cb416b89-83aa-4b20-a465-09e6a3be7118">25,417</ix:nonFraction>. Effective March 15, 2022, the Company extended the term of employment from April 15, 2022 to December 31, 2022 with a base salary of $<ix:nonFraction unitRef="usd" contextRef="i8af8b2227bd540f38b6dc794af632800_D20220315-20221231" decimals="0" name="vtl:SalaryCostsMonthlyBaseSalary" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV81NS9mcmFnOjU0NWNmNzgwODVmZjRlYjlhOGU4MDA0NDk1YWE3MDM1L3RleHRyZWdpb246NTQ1Y2Y3ODA4NWZmNGViOWE4ZTgwMDQ0OTVhYTcwMzVfNTQ5NzU1ODIwNjQ4_d0ce1c2a-dabb-4622-b1e6-7d1c65ea444e">29,358</ix:nonFraction> per month (which includes the cash retainer payable for serving on the Company&#8217;s Board or for acting as the Chairman of the Board). In connection with this extension, the Company made a one-time award to Dr. Nash of an option to purchase <ix:nonFraction unitRef="shares" contextRef="iac9f9142fce04841b7cdeea2bfcabdb6_D20220315-20220315" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV81NS9mcmFnOjU0NWNmNzgwODVmZjRlYjlhOGU4MDA0NDk1YWE3MDM1L3RleHRyZWdpb246NTQ1Y2Y3ODA4NWZmNGViOWE4ZTgwMDQ0OTVhYTcwMzVfNTQ5NzU1ODIwODkw_62e22705-2f4f-430b-bfc9-9b934ec42754">75,000</ix:nonFraction> shares of the Company&#8217;s common stock, which vests monthly commencing on April 10, 2022.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All other terms of the Executive Chairman Agreement remain the same.</span></div></ix:continuation><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><div id="ida7c333e3c58430eb83e8e950c50d811_58"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10. <ix:nonNumeric contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930" name="us-gaap:SubsequentEventsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV81OC9mcmFnOjUzOTAzZDJhY2NjYTQ2NjRiZDg3NDM4Y2UxNjNiMmY0L3RleHRyZWdpb246NTM5MDNkMmFjY2NhNDY2NGJkODc0MzhjZTE2M2IyZjRfNzE0NjgyNTU4MTAzNw_cf77d6af-8a8a-4e53-9de8-5b24fc1def03" continuedAt="ibf03433c5c96405dba5d5e962391c906" escape="true">Subsequent Events </ix:nonNumeric></span></div><ix:continuation id="ibf03433c5c96405dba5d5e962391c906" continuedAt="if94a783268c44371bf22c274bee1346f"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$60 Million Private Placement Equity Financing</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 10, 2022, Immunic entered into a Securities Purchase Agreement (the &#8220;Purchase Agreement&#8221;) for a private placement (the &#8220;Private Placement&#8221;) with select accredited investors and certain existing investors (each, a &#8220;Purchaser&#8221; and collectively, the &#8220;Purchasers&#8221;). Pursuant to the Purchase Agreement, the Company agreed to sell to the Purchasers (i) <ix:nonFraction unitRef="shares" contextRef="id3d63a41fa5847168bff487d8106b2f5_D20221010-20221010" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV81OC9mcmFnOjUzOTAzZDJhY2NjYTQ2NjRiZDg3NDM4Y2UxNjNiMmY0L3RleHRyZWdpb246NTM5MDNkMmFjY2NhNDY2NGJkODc0MzhjZTE2M2IyZjRfNDk0NzgwMjMzNDg2MQ_95a0f2ca-a26f-4b67-8208-97ac1b3c0263">8,696,552</ix:nonFraction> shares of the Company&#8217;s common stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="i04004da4d23642dd85e9052de2144a17_I20221010" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV81OC9mcmFnOjUzOTAzZDJhY2NjYTQ2NjRiZDg3NDM4Y2UxNjNiMmY0L3RleHRyZWdpb246NTM5MDNkMmFjY2NhNDY2NGJkODc0MzhjZTE2M2IyZjRfNDk0NzgwMjMzNDg3Mg_8ad55dac-3031-4629-a9fc-943eb1cc732f">0.0001</ix:nonFraction> per share (the &#8220;Shares&#8221;), at a purchase price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i04004da4d23642dd85e9052de2144a17_I20221010" decimals="INF" name="us-gaap:SharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV81OC9mcmFnOjUzOTAzZDJhY2NjYTQ2NjRiZDg3NDM4Y2UxNjNiMmY0L3RleHRyZWdpb246NTM5MDNkMmFjY2NhNDY2NGJkODc0MzhjZTE2M2IyZjRfNDk0NzgwMjMzNDg4MQ_4b6ac2cf-e7f4-4e39-8da6-6fd5b61501b1">4.35</ix:nonFraction> per Share, and (ii) <ix:nonFraction unitRef="shares" contextRef="icc5700f8c4a44461ab5894f373a0d8ac_D20221010-20221010" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV81OC9mcmFnOjUzOTAzZDJhY2NjYTQ2NjRiZDg3NDM4Y2UxNjNiMmY0L3RleHRyZWdpb246NTM5MDNkMmFjY2NhNDY2NGJkODc0MzhjZTE2M2IyZjRfNDk0NzgwMjMzNDg4OA_97eedfc9-4434-4ff2-909e-7f6e0ed7ca92">5,096,552</ix:nonFraction> pre-funded warrants (the &#8220;Pre-Funded Warrants&#8221;) to purchase Common Stock (the &#8220;Warrant Shares&#8221; and together with the Shares and the Pre-Funded Warrants, the &#8220;Securities&#8221;), at a purchase price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i1910349757c84c67942eeea2127e5dc4_I20221010" decimals="INF" name="us-gaap:SharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV81OC9mcmFnOjUzOTAzZDJhY2NjYTQ2NjRiZDg3NDM4Y2UxNjNiMmY0L3RleHRyZWdpb246NTM5MDNkMmFjY2NhNDY2NGJkODc0MzhjZTE2M2IyZjRfNDk0NzgwMjMzNDg5OQ_fba57657-3fce-4354-b33d-8a1358df85a0">4.34</ix:nonFraction> per Pre-Funded Warrant. The Pre-Funded Warrants will have an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i1910349757c84c67942eeea2127e5dc4_I20221010" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV81OC9mcmFnOjUzOTAzZDJhY2NjYTQ2NjRiZDg3NDM4Y2UxNjNiMmY0L3RleHRyZWdpb246NTM5MDNkMmFjY2NhNDY2NGJkODc0MzhjZTE2M2IyZjRfNDk0NzgwMjMzNDkwNg_b0a4d3f5-60da-47aa-bc60-f2a7cab36d95">0.01</ix:nonFraction> per share of Common Stock, be immediately exercisable and remain exercisable until exercised in full. The holders of Pre-Funded Warrants may not exercise a Pre-Funded Warrant if the holder, together with its affiliates, would beneficially own more than <ix:nonFraction unitRef="number" contextRef="i04004da4d23642dd85e9052de2144a17_I20221010" decimals="4" name="vtl:EquityMethodInvestmentWarrantsExercisableOwnershipLimitationPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV81OC9mcmFnOjUzOTAzZDJhY2NjYTQ2NjRiZDg3NDM4Y2UxNjNiMmY0L3RleHRyZWdpb246NTM5MDNkMmFjY2NhNDY2NGJkODc0MzhjZTE2M2IyZjRfNDk0NzgwMjM0MDk5MA_3ed642b3-f7b6-418a-9446-d5433e96f720">9.99</ix:nonFraction>% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise. The holders of Pre-Funded Warrants may increase or decrease such percentages not in excess of <ix:nonFraction unitRef="number" contextRef="i1910349757c84c67942eeea2127e5dc4_I20221010" decimals="4" name="vtl:EquityMethodInvestmentWarrantsExercisableOwnershipLimitationMaximumIncreaseDecreasePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV81OC9mcmFnOjUzOTAzZDJhY2NjYTQ2NjRiZDg3NDM4Y2UxNjNiMmY0L3RleHRyZWdpb246NTM5MDNkMmFjY2NhNDY2NGJkODc0MzhjZTE2M2IyZjRfNDk0NzgwMjM0MDk5Nw_81881bad-6e16-4c6f-ab70-e8125cd5421f">19.99</ix:nonFraction>% by providing at least <ix:nonNumeric contextRef="i1910349757c84c67942eeea2127e5dc4_I20221010" name="vtl:EquityMethodInvestmentWarrantsExercisableSharesChangeLimitationNoticePeriod" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV81OC9mcmFnOjUzOTAzZDJhY2NjYTQ2NjRiZDg3NDM4Y2UxNjNiMmY0L3RleHRyZWdpb246NTM5MDNkMmFjY2NhNDY2NGJkODc0MzhjZTE2M2IyZjRfNDk0NzgwMjM0MTAwNA_24b8d435-babf-4cf9-ac8d-897129a7500c">61</ix:nonNumeric> days&#8217; prior notice to the Company.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Private Placement closed on October 12, 2022. The gross proceeds of the Private Placement were approximately $<ix:nonFraction unitRef="usd" contextRef="i4346a7f60eba4d42bfc2b801e8e1dc2b_D20221012-20221012" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV81OC9mcmFnOjUzOTAzZDJhY2NjYTQ2NjRiZDg3NDM4Y2UxNjNiMmY0L3RleHRyZWdpb246NTM5MDNkMmFjY2NhNDY2NGJkODc0MzhjZTE2M2IyZjRfNDk0NzgwMjMzNDkxMw_96e40ec1-be0c-4cf6-9b18-9376e614b384">60.0</ix:nonFraction>&#160;million, before deducting offering expenses payable by the Company. The Company intends to use the net proceeds from the Private Placement to fund the ongoing clinical development of its three lead product candidates, vidofludimus calcium (IMU-838), IMU-935 and IMU-856, and for other general corporate purposes.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Purchase Agreement provides for the registration for resale of the Securities (including the Warrant Shares) pursuant to a registration statement (the &#8220;Registration Statement&#8221;) to be filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;) on or prior to December 9, 2022. The Company has agreed to use its best efforts to cause the Registration Statement to be declared effective as soon as possible, but in no event later than 60 days after the closing of the Private Placement (or 90 days in the event of a review of the Registration Statement by, and comments from, the SEC), and to keep the Registration Statement continuously effective from the date on which the SEC declares the Registration Statement to be effective until such date that all Registrable Securities (as such term is defined in the Purchase Agreement) covered by the Registration Statement have been sold pursuant to a registration statement under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), or under Rule 144 as promulgated by the SEC under the Securities Act, or otherwise shall have ceased to be Registrable Securities.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pre-Planned Phase 1b Interim Analysis of IMU-935 in Moderate-to-Severe Psoriasis</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On October 20, 2022, Immunic announced the outcome of a pre-planned interim group-level data analysis of its Phase 1b clinical trial of IMU-935 in patients with moderate-to-severe psoriasis. The overall trial is ongoing and remains blinded. The pre-planned interim analysis revealed that the group averages for Psoriasis Area and Severity Index ("PASI&#8221;) reductions in the two active arms did not separate from placebo at four weeks. Although the active arms performed in line with prior expectations, based on similarly designed trials, the trial experienced a greater decrease than expected in PASI in the placebo arm. Although the safety data remains blinded, administration of IMU-935 and placebo in this trial were demonstrated to be safe and well-tolerated, and no new safety signals were observed. The Company expects to continue IMU-935&#8217;s development in psoriasis and will further analyze the available data to determine next steps for the program.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Goodwill Impairment Analysis</span></div></ix:continuation><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:continuation id="if94a783268c44371bf22c274bee1346f">Following the announcement of our interim group level data of the Phase 1b clinical trial of IMU-935 in Psoriasis on October 20, 2022, our stock price experienced a significant decline from the prices preceding the announcement.  The Company considered this to be a triggering event indicating that it is more likely than not that goodwill is impaired.  As a result, the Company anticipates it will incur a full impairment of its goodwill of approximately $<ix:nonFraction unitRef="usd" contextRef="ic5a53880f9da458c8abd6926ff69ddd8_D20221001-20221231" decimals="-5" name="us-gaap:GoodwillImpairmentLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV81OC9mcmFnOjUzOTAzZDJhY2NjYTQ2NjRiZDg3NDM4Y2UxNjNiMmY0L3RleHRyZWdpb246NTM5MDNkMmFjY2NhNDY2NGJkODc0MzhjZTE2M2IyZjRfNDk0NzgwMjM0MjY0MQ_049fbe5c-4583-45a9-b8ab-5a5f0702bb47">33.0</ix:nonFraction>&#160;million in the quarter ended December 31, 2022.</ix:continuation> </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> </span></div><div style="margin-top:12pt;padding-left:22.5pt;text-align:justify"><span><br/></span></div><div style="margin-top:12pt;padding-left:22.5pt;text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><div id="ida7c333e3c58430eb83e8e950c50d811_61"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The following discussion and analysis of financial condition and results of operations should be read in conjunction with our unaudited interim condensed consolidated financial statements and notes thereto included in Item&#160;1 &#8220;Financial Statements&#8221; in this Quarterly Report on Form 10-Q (the "Quarterly Report") and the audited Consolidated Financial Statements in our Annual Report on Form 10-K. filed with the Securities and Exchange Commission ("SEC"), on February 24, 2022. As used in this report, unless the context suggests otherwise, &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; &#8220;the Company&#8221; or &#8220;Immunic&#8221; refer to Immunic, Inc. and its subsidiaries.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Forward-Looking Statements</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to historical information, this Quarterly Report includes forward-looking statements within the meaning of federal securities laws. Forward-looking statements are subject to certain risks and uncertainties, many of which are beyond our control. Such statements include, but are not limited to, statements preceded by, followed by or that otherwise include the words, &#8220;believe,&#8221; &#8220;may,&#8221; &#8220;might,&#8221; &#8220;can,&#8221; &#8220;could,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; &#8220;should,&#8221; &#8220;estimate,&#8221; &#8220;continue,&#8221; &#8220;anticipate,&#8221; &#8220;intend,&#8221; &#8220;seek,&#8221; &#8220;plan,&#8221; &#8220;project,&#8221; &#8220;expect,&#8221; &#8220;potential,&#8221; &#8220;predicts,&#8221; or similar expressions and the negatives of those terms.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forward-looking statements discuss matters that are not historical facts. Our forward-looking statements involve assumptions that, if they ever materialize or prove correct, could cause our results to differ materially from those expressed or implied by such forward-looking statements. In this Quarterly Report, for example, we make forward-looking statements, among others, regarding potential strategic options; financial estimates and projections; and the sufficiency of our capital resources to fund our operations.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The inclusion of any forward-looking statements in this Quarterly Report should not be regarded as a representation that any of our plans will be achieved. Our actual results may differ from those anticipated in our forward-looking statements as a result of various factors, including those noted below under the caption &#8220;Part II, Item 1A-Risk Factors,&#8221; and the differences may be material. These risk factors include, but are not limited to statements relating to our three development programs and the targeted diseases; the potential for vidofludimus calcium, IMU-935 and IMU-856 to safely and effectively target diseases; the nature, strategy and focus of the Company; expectations regarding our capitalization and financial resources; the development and commercial potential of any product candidates of the Company; and our ability to retain certain personnel important to our ongoing operations and to maintain effective internal control over financial reporting.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although our forward-looking statements reflect the good faith judgment of our management, these statements are based only on facts and factors currently known by us. As a result, investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and we undertake no obligation to revise or update such statements to reflect events or circumstances after the date hereof, except as required by law.</span></div><div id="ida7c333e3c58430eb83e8e950c50d811_64"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Immunic, Inc. ("Immunic," &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our&#8221; or the "Company") is a clinical-stage biopharmaceutical company with a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases. We are headquartered in New York City with our main operations in Gr&#228;felfing near Munich, Germany. We currently have approximately 65 employees.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We are currently pursuing three development programs. These include the vidofludimus calcium (IMU-838) program, which is focused on the development of oral formulations of a small molecule inhibitor of the enzyme dihydroorotate dehydrogenase (&#8220;DHODH&#8221;); the IMU-935 program, which is focused on an inverse agonist of retinoic acid receptor-related orphan nuclear receptor gamma truncated (&#8220;ROR&#947;t&#8221;), an immune cell-specific isoform of ROR&#947;; and the IMU-856 program, which involves the development of a drug targeting the restoration of intestinal barrier function and regeneration of bowel epithelium. These product candidates are being developed to address diseases such as multiple sclerosis ("MS"), psoriasis and gastrointestinal diseases. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the potential indications, clinical targets and clinical development status of our three product candidates:</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><img src="vtl-20220930_g1.jpg" alt="vtl-20220930_g1.jpg" style="height:226px;margin-bottom:5pt;vertical-align:text-bottom;width:654px"/></div><div style="margin-top:12pt;text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our most advanced drug candidate, vidofludimus calcium (IMU-838), targets DHODH, a key enzyme in the intracellular metabolism of immune cells in the body. In the third quarter of 2020, we reported positive results from our Phase 2 EMPhASIS trial of vidofludimus calcium in relapsing-remitting multiple sclerosis (&#8220;RRMS&#8221;), achieving both primary and key secondary endpoints with high statistical significance. The first patient in our Phase 3 ENSURE program of vidofludimus calcium in relapsing multiple sclerosis (&#8220;RMS&#8221;), comprising twin studies evaluating efficacy, safety, and tolerability of vidofludimus calcium versus placebo, was enrolled in November 2021. The first patient in our supportive Phase 2 CALLIPER trial of vidofludimus calcium in progressive multiple sclerosis (&#8220;PMS&#8221;) was enrolled in September 2021. Our current goal is to report data from the interim analysis of the CALLIPER trial in the second half of 2023 and to read-out top-line data at the end of 2024. Moreover, the read-out of the first of the ENSURE trials is currently targeted for end of 2025. Although we currently believe that each of these goals is achievable, they are each dependent on numerous factors which are not under our direct control and can be difficult to predict. We plan to periodically review this assessment and provide updates of material changes as appropriate.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Additional antiviral-directed development activities remain ongoing through preclinical research examining the potential to treat a broad set of viral indications with vidofludimus calcium and other DHODH inhibitors and further antiviral molecules. Immunic is exploring several options to support further development of our antiviral portfolio, including a potential spin-off into a new or existing company and potential licensing transactions. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">If approved, we believe that vidofludimus calcium has the potential to be a unique treatment option matched to the biology of MS with (1) anti-inflammatory effects, (2) antiviral effects, and (3) neuroprotective effects.  Recent evidence also indicates that vidofludimus calcium activates a yet-to-be-disclosed target with neuroprotective properties, which may enhance its potential benefit for patients. Additionally, vidofludimus calcium has an attractive pharmacokinetic, safety and tolerability profile and has already been exposed to more than 1,100 human subjects and patients in either of the drug&#8217;s formulations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our second drug candidate, IMU-935, is a highly potent and selective inverse agonist of a transcription factor called ROR&#947;t. We believe that the nuclear receptor ROR&#947;t is a main driver for the differentiation of T-helper 17 (&#8220;Th17&#8221;) cells and the release of cytokines involved in various inflammatory and autoimmune diseases. We believe this target is an attractive alternative to approved antibodies as acting on interleukin-23 (&#8220;IL-23&#8221;), the IL-17 receptor and IL-17. We have observed strong cytokine inhibition targeting both Th1 and Th17 responses in preclinical testing, as well as indications of activity in animal models for psoriasis, graft versus host disease, MS and inflammatory bowel disease ("IBD"). Preclinical experiments indicated that, while leading to a potent inhibition of Th17 differentiation, inhibition of cytokine secretion, and induction of regulatory T cells, IMU-935 did not affect thymocyte maturation, one of the important physiological functions of ROR&#947;t that should be maintained. Based on these preclinical data and the selectivity of the effect maintaining important physiological functions while providing the desired anti-Th17 effect, we believe that IMU-935 has potential to be a best-in-class therapy for various autoimmune diseases. A Phase 1 clinical trial exploring safety, tolerability, pharmacodynamics, pharmacokinetics and exploratory efficacy of IMU-935 in psoriasis patients is currently ongoing. A pre-planned group-level interim analysis revealed on October 20, 2022 noted that the initial two active dose cohorts did not separate from placebo at four weeks. The overall trial is ongoing and remains blinded. Although the safety data also remains blinded, administration of IMU-935 and placebo in this trial were demonstrated to be safe and well-tolerated, and no new safety signals were observed. We expect to continue IMU-935&#8217;s development in psoriasis and will further analyze the available data to determine next steps for the program. An exploratory Phase 1 trial investigating the drug-drug interaction (&#8220;DDI&#8221;) potential of IMU-935 was completed in the second quarter of 2022. Additionally, IMU-935 has been shown in preclinical models to target an established mechanism of treatment resistance to androgen receptor therapy, making it a potential treatment option for patients with metastatic castration-resistant </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">prostate cancer (&#8220;mCRPC&#8221;). A Phase 1 clinical trial exploring safety and tolerability of increasing doses of IMU-935 to establish the maximum tolerated dose and the recommended Phase 2 dose is currently ongoing in patients with mCRPC.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">   </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our third program, IMU-856, which we believe to be novel, is an orally available small molecule modulator that targets a protein which serves as a transcriptional regulator of intestinal barrier function and regeneration of bowel epithelium. We have not yet disclosed the molecular target for IMU-856 to the public. Based on preclinical data, we believe this compound may represent a new treatment approach, as the mechanism of action targets the restoration of the intestinal barrier function and bowel wall architecture in patients suffering from gastrointestinal diseases such as celiac disease, IBD, irritable bowel syndrome with diarrhea and other intestinal barrier function associated diseases. We believe that, because IMU-856 has been shown in preclinical investigations to avoid suppression of immune cells, it may therefore have the potential to maintain immune surveillance for patients during therapy, an important advantage versus chronic treatment with potentially immunosuppressive medications. The final portion of a Phase 1 clinical trial exploring the safety and tolerability of IMU-856 in celiac disease patients during periods of gluten-free diet and gluten challenge is currently ongoing and we expect initial results to be available in 2023.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to continue to lead most of our research and development activities from our Gr&#228;felfing, Germany location, where dedicated scientific, regulatory, clinical and medical teams conduct their activities. Due to these teams' key relationships with local and international service providers, we anticipate that this will result in timely, cost-effective execution of our development programs. In addition, we are using our subsidiary in Melbourne, Australia to expedite the early clinical trials for IMU-935 and IMU-856. We also conduct preclinical work in Halle/Saale, Germany through a collaboration with the Fraunhofer Institute.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our business, operating results, financial condition and growth prospects are subject to significant risks and uncertainties, including the failure of our clinical trials to meet their endpoints, failure to obtain regulatory approval and failure to obtain needed additional funding on acceptable terms, if at all, to complete the development and commercialization of our three development programs.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity and Financial Condition</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have no products approved for commercial sale and have not generated any revenue from product sales. We have never been profitable and have incurred operating losses in each year since our inception in 2016. We have an accumulated deficit of approximately $260.8 million as of September 30, 2022 and $196.9 million as of December 31, 2021. Substantially all of our operating losses resulted from expenses incurred in connection with our research and development programs and from general and administrative costs associated with our operations.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to incur significant expenses and increasing operating losses for the foreseeable future as we initiate and continue the preclinical and clinical development of our product candidates and add personnel necessary to advance our clinical pipeline of product candidates.  We expect that our operating losses will fluctuate significantly from quarter-to-quarter and year-to-year due to timing of clinical development programs.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From inception through October 31, 2022, Immunic has raised net cash of approximately $355.5 million from private and public offerings of preferred and common stock. As of September 30, 2022, the Company had cash and cash equivalents of approximately $72.8 million.  With these funds, and the $56.4 million of cash raised in October 2022, Immunic expects to be able to fund its operations beyond twelve months from the date of the issuance of the accompanying condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Events</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">$60 Million Private Placement Equity Financing</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 10, 2022, we entered into a Securities Purchase Agreement for a private placement with select accredited investors and certain existing investors. Pursuant to the Purchase Agreement, the Company agreed to sell to the Purchasers (i) 8,696,552 shares of the Company&#8217;s common stock, par value $0.0001 per share (the &#8220;Shares&#8221;), at a purchase price of $4.35 per Share, and (ii) 5,096,552 pre-funded warrants to purchase Common Stock, at a purchase price of $4.34 per Pre-Funded Warrant. The Pre-Funded Warrants will have an exercise price of $0.01 per share of Common Stock, be immediately exercisable and remain exercisable until exercised in full. The holders of Pre-Funded Warrants may not exercise a Pre-Funded Warrant if the holder, together with its affiliates, would beneficially own more than 9.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise. The holders of Pre-Funded Warrants may increase or decrease such percentages not in excess of 19.99% by providing at least 61 days&#8217; prior notice to the Company.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Private Placement closed on October 12, 2022. The gross proceeds of the Private Placement were approximately $60.0 million, before deducting offering expenses payable by the Company. The Company intends to use the net proceeds from the Private Placement to fund the ongoing clinical development of its three lead product candidates, vidofludimus calcium (IMU-838), IMU-935 and IMU-856, and for other general corporate purposes.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pre-Planned Phase 1b Interim Analysis of IMU-935 in Moderate-to-Severe Psoriasis and Goodwill Impairment</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On October 20, 2022, we announced the outcome of a pre-planned interim group-level data analysis of our Phase 1b clinical trial of IMU-935 in patients with moderate-to-severe psoriasis. The overall trial is ongoing and remains blinded. The pre-planned interim analysis revealed that the group averages for Psoriasis Area and Severity Index ("PASI&#8221;) reductions in the two active arms did not separate from placebo at four weeks. Although the active arms performed in line with prior expectations, based on similarly designed trials, the trial experienced a greater decrease than expected in PASI in the placebo arm. Although the safety data remains blinded, administration of IMU-935 and placebo in this trial were demonstrated to be safe and well-tolerated, and no new safety signals were observed. We expect to continue IMU-935&#8217;s development in psoriasis and will further analyze the available data to determine next steps for the program. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> Following the announcement of our interim group level data on October 20, 2022, our stock price experienced a significant decline from the prices preceding the announcement and the recent prices raised in our October 10, 2022 Private Placement.  We considered these to be triggering events indicating that it is more likely than not that goodwill is impaired.  As a result, we anticipate we will incur a full impairment of its goodwill of approximately $33.0 million in the quarter ended December 31, 2022. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">IMU-935 Composition-of-Matter Patents Granted</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 2, 2022, we received a Notice of Allowance from the U.S. Patent and Trademark Office ("USPTO") for patent application 16/644581, entitled, &#8220;IL-17 and IFN-gamma inhibition for the treatment of autoimmune diseases and chronic inflammation&#8221;. We also received notice of allowance of patent application EP18762111.5 in Europe, and notice of grant of patent application 2018330633 in Australia. All three patents cover composition-of-matter of IMU-935 and related formulations, and are expected to provide protection into at least 2038, without accounting for potential Patent Term Extension ("PTE") in the United States or Supplementary Protection Certificates in Europe, respectively.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Results of Exploratory Phase 1 DDI Study of IMU-935</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">An exploratory Phase 1 study was completed in 15 evaluable healthy human subjects to assess the DDI potential of IMU-935. No relevant signals for DDI potential were observed and treatment was safe and well-tolerated.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:102%">Phase 1 Clinical Trial of IMU-935, Results of Parts A and B in Healthy Human Subjects</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 12, 2021, we provided an update on our IMU-935 program, including new preclinical and clinical data. The main result from preclinical investigations was that IMU-935 inhibits cytokine production (thought to be a pre-condition for its use in immunological and autoimmune diseases) while maintaining the known and required physiological functions of maturing T lymphocytes. In </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ex vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> mouse cell differentiation and maturation assays, IMU-935 was observed to selectively inhibit ROR&#947;t-dependent gene expression during Th17 differentiation without affecting either ROR&#947;t-dependent gene regulation relevant to thymocyte development, or the viability of these cells. In third-party research, impairment of thymocyte development has been shown to be associated with serious safety issues, including, among others, T cell malfunction and potential lymphoma formation. We believe that IMU-935's observed selectivity may enable it to inhibit both the generation of Th17 cells and the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">production of IL-17 cytokines that are responsible for the development of autoimmune diseases, without impairing thymocyte development, which is associated with the potential risk of lymphoma seen with other, third-party ROR&#947;t programs.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 14, 2021, we provided an update on the preclinical and clinical development of IMU-935, announcing that:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Unblinded data from the single ascending dose part of the ongoing Phase 1 clinical trial of a new powder-in-capsule formulation of IMU-935, in which healthy human subjects were treated with 100 mg, 200 mg, 300 mg and 400 mg of this new formulation or placebo, found these single ascending daily doses of IMU-935 to be safe and well-tolerated, and no maximum tolerated dose was reached. No serious adverse events occurred. A dose-proportional pharmacokinetic profile was observed across the investigated dose range.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Unblinded data from the multiple ascending dose part of the ongoing Phase 1 clinical trial, in which healthy human subjects were dosed for 14 days with 150 mg either once or twice daily doses of IMU-935 or placebo, found these multiple ascending doses of IMU-935 to be safe and well-tolerated, and no maximum tolerated dose was reached. Treatment emergent adverse events were generally mild in severity, with moderate treatment emergent adverse events reported in one of eleven IMU-935 treated subjects, compared with one of four subjects on placebo. No serious adverse events were reported. No dose-dependent changes in laboratory values (including no effects on liver enzymes or in hematological parameters), vital signs or in electrocardiographic evaluations were found. Pharmacokinetic analysis showed that stable steady-state plasma concentrations were achieved within the first week of dosing with an accumulation factor for IMU-935 allowing predictable trough levels during daily dosing.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Based on the favorable safety and tolerability data observed in healthy human subjects, our Phase 1 clinical trial of IMU-935 was expanded in October 2021 to include a third portion, part C, in which moderate-to-severe psoriasis patients are randomized to 28-day treatment of IMU-935 or placebo. Assessments include safety, tolerability, pharmacokinetic and pharmacodynamic markers, as well as skin evaluations. </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In previous preclinical </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vitro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> data, it was shown that IMU-935 selectively inhibits Th17 differentiation and IL-17 production, whereas ROR&#947;t was unaffected by IMU-935 during thymocyte maturation and, therefore, does not harm normal thymocyte maturation. Data from acute and chronic treatment of mice corroborated </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> that IMU-935 is the first molecule observed to impact neither thymus size, thymocyte numbers, nor the maturation status of thymocytes, in contrast to two other known inhibitors of ROR&#947;t.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Phase 1 Clinical Trial of IMU-935 in mCRPC </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On August 4, 2022, we announced that initial safety data available so far for the Phase 1 clinical trial of IMU-935 in mCRPC with dosing up to 600 mg daily show a promising safety profile, with only benign adverse events and no dose limiting toxicities. We plan to provide </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">a</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> more comprehensive update on safety and also on potential signs of anti-tumor activity of IMU-935 in this trial as soon as data from the planned dose expansion part are available. Meanwhile, patients are being enrolled in the third, 900 mg cohort of the trial.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:102%">Phase 1 Clinical Trial of IMU-856, Results of Parts A and B in Healthy Human Subjects</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On September 20, 2022, we announced positive unblinded safety, tolerability and pharmacokinetic (&#8220;PK&#8221;) results from Part A (single ascending doses) and Part B (multiple ascending doses) of our Phase 1 clinical trial of IMU-856 in healthy human subjects.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In the single ascending doses part, healthy human subjects were randomized in a double-blinded manner to either placebo or active treatment with single ascending doses of IMU-856 at 10 mg, 20 mg, 40 mg, 80 mg, 120 mg and 160 mg. Single ascending doses of IMU-856 were found to be safe and well-tolerated and no maximum tolerated dose was reached. No serious adverse events occurred. Moreover, a dose-linear PK profile was observed across the investigated dose range.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In the multiple ascending doses part, healthy human subjects were dosed for 14 consecutive days with 40 mg, 80 mg or 160 mg once-daily of IMU-856 or placebo in a double-blinded manner. Multiple ascending doses of IMU-856 were found to be safe and well-tolerated and no maximum tolerated dose was reached. Treatment emergent adverse events were mostly mild in severity. No Investigational Medicinal Product-related serious adverse events were reported. No dose-dependent changes in laboratory parameters (including no effects on liver enzymes or in hematological parameters), vital signs, physical examination or electrocardiographic evaluations were found. PK analysis showed a quick achievement of stable steady-state plasma concentrations within the first week and stable steady-state trough levels over the 14-day treatment period with a low </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">accumulation factor for IMU-856, allowing predictable trough levels during daily dosing. PK parameters in steady-state revealed a Tmax (time to reach maximum plasma concentration) of 2 to 3 hours post-dose, a plasma half-life of 17.4 to 21.5 hours and dose proportional increases in Cmax (maximum plasma drug concentration) and AUC (area under the concentration-time curve).</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">IMU-856 Composition-of-Matter Patent Granted</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On August 16, 2022, we announced that we have received a Notice of Allowance from the USPTO for patent application 16/646130, entitled, &#8220;Compound Having Cyclic Structure.&#8221; The patent covers composition-of-matter of IMU-856 and related pharmaceutical compositions and is expected to provide protection into at least 2038, without accounting for potential PTE.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Start of Patient Cohorts in Phase 1 Clinical Trial of IMU-856 in Celiac Disease</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On May 5, 2022, we announced the start of the patient cohorts in our ongoing Phase 1 clinical trial of IMU-856 in patients with celiac disease. Part C is structured as a 28-day, double-blind, placebo-controlled trial designed to assess the safety, tolerability, pharmacokinetics, pharmacodynamic and biomarker responses of IMU-856 in patients with celiac disease during periods of gluten-free diet and gluten challenge. Approximately 42 patients are planned to be enrolled in two consecutive cohorts with IMU-856 given once-daily over 28 days. Secondary objectives include pharmacokinetics and disease markers, including those evaluating gastrointestinal architecture and inflammation. Sites in Australia and New Zealand are participating in Part C.   Initial results are expected to be available in 2023.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Publication of Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in RRMS in Peer Reviewed Journal</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 15, 2022, we announced that data from our Phase 2 EMPhASIS trial of vidofludimus calcium in patients with RRMS has been published in the peer reviewed journal, Annals of Clinical and Translational Neurology. The paper, authored by coordinating investigator, Robert J. Fox, M.D., Staff Neurologist, Mellen Center for Multiple Sclerosis, Vice-Chair for Research, Neurologic Institute, Cleveland Clinic, Cleveland, Ohio, is entitled, &#8220;Safety and efficacy of vidofludimus calcium, a selective dihydroorotate dehydrogenase inhibitor, in relapsing-remitting multiple sclerosis (EMPhASIS): a double-blind, randomized, placebo-controlled Phase 2 trial.&#8221;</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Update on the Use of Steroids in the Phase 2 EMPhASIS Trial in RRMS</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Based on the observed interaction between vidofludimus calcium and chronic steroid use in the CALDOSE-1 trial in ulcerative colitis patients, we performed a post-hoc analysis of our Phase 2 EMPhASIS data in RRMS patients to explore the potential influence of steroids on these study results. As anticipated, steroid use was rare and among those RRMS patients who received any steroids, the majority received only short steroid courses following relapse events or acute neurological events. Only four patients received any steroids for reasons other than relapse (COVID-19 infection, eczema, acute bronchitis, and contact urticaria, one patient each). Most patients only had one single short course of steroids, and only nine patients had two or more steroid courses. The average duration of steroid treatment in this RRMS trial was 4.4 days with a maximum duration of 10 days. This indicates to us that steroids are rarely used in MS patients and mostly for a very short duration. In conclusion, comparing patients who received at least one dose of corticosteroids with those who did not, we do not see any difference in clinical parameters or any evidence that the rare, short-term use of steroids in RRMS patients has any influence on the effectiveness of vidofludimus calcium in this patient population.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Top-Line Data from Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Patients with Moderate-to-Severe Ulcerative Colitis</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 2, 2022, we reported top-line data from our Phase 2 CALDOSE-1 trial of vidofludimus calcium in patients with moderate-to-severe ulcerative colitis (&#8220;UC&#8221;). The trial did not achieve the primary endpoint of clinical remission for the pooled 30 and 45 mg/day active dose groups of vidofludimus calcium versus placebo at week 10. In addition, no meaningful differences were observed between the three active dose groups for the overall intent-to-treat patient population (10 mg/day: 14.9%, 30 mg/day: 10.6%, 45 mg/day: 13.6%, placebo: 12.5%) or for the trial&#8217;s other secondary endpoints, including symptomatic remission, or endoscopic healing.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consistent with prior data sets in other patient populations, administration of vidofludimus calcium in this trial was observed to be safe and well-tolerated. No new safety signals were observed. As compared to placebo, there were no increased rates of infections and infestations, no elevated rates of liver events or liver enzyme elevations, and no elevated rates for </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">changes in hematology-related laboratory variables. The most common adverse events in this trial were anemia (15/263 patients, 5.7%), headache (9/263 patients, 3.4%) and COVID-19 (7/263 patients, 2.7%). Most adverse events were generally mild in severity.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As is common for the design of clinical trials in UC, the use of oral systemic corticosteroids (&#8804;20 mg/day prednisolone equivalent) was allowed in CALDOSE-1 in patients who had been treated with corticosteroids for at least four weeks before randomization. Doses of corticosteroids were required to be kept constant throughout the induction phase (weaning was not allowed in this phase of the trial), and the distribution of patients using corticosteroids was equal throughout all treatment groups. Surprisingly, CALDOSE-1 data suggest a previously unknown treatment interference between the efficacy of vidofludimus calcium and the concurrent use of corticosteroids in the UC patient population. More specifically, the non-steroid patient population showed an 11.4% advantage in clinical remission for vidofludimus calcium over placebo (pooled vidofludimus calcium treatment groups at week 10: 14.7%, placebo: 3.3%). Such a difference in clinical remission between active treatment and placebo would traditionally be considered as confirming therapeutic activity. In contrast, patients concomitantly taking vidofludimus calcium and corticosteroids during induction treatment had a lower rate of clinical remission at week 10 (11.5%) than placebo patients (20.6%) and also lower than the group of vidofludimus calcium monotherapy without concurrent use of steroids (14.7%). This treatment interference between vidofludimus calcium and corticosteroids was not expected by currently available preclinical or clinical data.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on these results, we announced that our development programs in the IBD indications will not be continued without a partner.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investigator-Sponsored Phase 2 IONIC Trial in Moderate-to-Severe COVID-19 Closed Down</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On June 23, 2022, sponsor and lead site, University Hospitals Coventry and Warwickshire NHS Trust, London, United Kingdom, informed us that the investigator-sponsored Phase 2 IONIC trial for the treatment of patients with moderate-to-severe COVID-19 is being closed down. Recruitment for the trial ended on May 20, 2022 and the last patient follow-up is due on September 21, 2022.  On September 29, 2022, we were informed that the sponsor submitted the end of trial declaration. The trial was a prospective, randomized, parallel-group, open-label Phase 2b trial, designed to evaluate efficacy and safety of vidofludimus calcium in combination with the neuraminidase inhibitor, Oseltamivir (Tamiflu&#9415;), in approximately 120 adult patients with moderate-to-severe COVID-19.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Goodwill Impairment Analysis</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Following the announcement of our interim group level data of the Phase 1b clinical trial of IMU-935 in Psoriasis on October 20, 2022, our stock price experienced a significant decline from the prices preceding the announcement.  The Company considered this to be a triggering event indicating that it is more likely than not that goodwill is impaired.  As a result, the Company anticipates it will incur a full impairment of its goodwill of approximately $33.0 million in the quarter ended December 31, 2022.   </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Changes in Board of Directors</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On July 6, 2022, we announced the appointment of Monika Maria T&#246;rns&#233;n as a member of our Board of Directors, effective as of July 5, 2022. As a Class III director, Ms. T&#246;rns&#233;n&#8217;s term lasts until the Company&#8217;s 2023 annual meeting of stockholders. Concurrently, we also announced that current Class III director, Jan Van den Bossche, resigned from the Board. The Board accepted Mr. Van den Bossche&#8217;s resignation effective July 5, 2022. Mr. Van den Bossche&#8217;s decision to resign did not result from any disagreement with the Company on any matter relating to Company operations, policies or practices.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Executive Chairman Agreement with Duane Nash</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 15, 2020, the compensation committee of the Board of Directors of the Company independently reviewed and approved entering into an employment agreement with the current Chairman of the Board, Duane Nash, MD, JD, MBA (the &#8220;Executive Chairman Agreement&#8221;) and pursuant to such approval, on April 17, 2020, the Company and Dr. Nash entered into the Executive Chairman Agreement. The Executive Chairman Agreement establishes an &#8220;at will&#8221; employment relationship pursuant to which Dr. Nash serves as Executive Chairman and contemplated a term that ends on October 15, 2020, which was subsequently extended to April 15, 2021. On April 15, 2021, the Company and Dr. Nash entered into an addendum (the &#8220;Addendum&#8221;) to extend the term of the Executive Chairman Agreement to April 15, 2022.  In connection with the Addendum, the Company made a one-time award to Dr. Nash of an option to purchase 90,000 shares of Company common stock, which vests monthly commencing on May 15, 2021, and to increase Dr. Nash&#8217;s monthly base salary to $27,960 from $25,417. Effective March 15, 2022, the Company extended the term of employment from April 15, 2022 to December 31, 2022 with a base salary of $29,358 per month (which includes the cash retainer payable for serving on the Company&#8217;s Board or for acting as the Chairman of the Board). In connection with this extension, the Company made a one-time award to Dr. Nash of an option to purchase 75,000 shares of the Company&#8217;s common stock, which vests monthly commencing on April 10, 2022.  All other terms of the Executive Chairman Agreement remain the same.</span></div><div id="ida7c333e3c58430eb83e8e950c50d811_67"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Components of Results of Operations </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">To date, we have not generated any revenue from product sales and do not expect to generate any revenue from the sale of products in the foreseeable future. If our development efforts for our product candidates are successful and result in regulatory approval, we may generate revenue in the future from product sales. We cannot predict if, when, or to what extent we will generate revenue from the commercialization and sale of our product candidates. We may never succeed in obtaining regulatory approval for any of our product candidates or achieving market acceptance and commercial success for any product that does receive regulatory approval.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses consist of costs associated with our research activities, including our product discovery efforts and the development of our product candidates. Our research and development expenses include: </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">external research and development expenses and milestone payments incurred under arrangements with third parties, such as CROs, contract manufacturing organizations, collaborations with partners, consultants, and our scientific advisors; and</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">internal personnel expenses.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expense research and development costs as incurred. Non-refundable advance payments for goods and services that will be used in future research and development activities are capitalized as prepaid expenses and expensed when the service has been performed or when the goods have been received.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since our inception in March 2016, we have spent a total of approximately $193.8 million in research and development expenses through September 30, 2022. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">These costs primarily include external development expenses and internal personnel expenses for the three development programs, vidofludimus calcium, IMU-935 and IMU-856. We have spent the majority of our research and development resources on vidofludimus calcium, our lead development program, for clinical trials in MS, UC, COVID-19 and PSC.  </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2019, Immunic AG received a grant of up to approximately $730,000 from the German Federal Ministry of Education and Research, in support of the InnoMuNiCH (Innovations through Munich-Nippon Cooperation in Healthcare) project.  The grant funds have been used to fund a three-year research project relating to autoimmune diseases by us and our three project partners.  Since the inception of the grant, we have recorded $706,000 of income in total of which $100,000 and $249,000 of which were recorded in 2022 and 2021, respectively, and were classified in Other Income in the accompanying consolidated statement of operations. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our research and development expenses are expected to increase in the foreseeable future as we continue to conduct ongoing regulatory and development activities, initiate new preclinical and clinical trials and build our pipeline of product </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">candidates.   Our research and development expenses may also increase in the foreseeable future due to the current inflationary environment as well as supply chain shortages, which result in increased costs. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The process of conducting clinical trials and preclinical studies necessary to obtain regulatory approval is costly and time consuming. We may never succeed in achieving regulatory approval for any of our product candidates.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Successful development of product candidates is highly uncertain and may not result in approved products. Completion dates and completion costs can vary significantly for each product candidate and are difficult to predict. We anticipate that we will make determinations as to which programs to pursue and how much funding to direct to each program on an ongoing basis in response to the development and regulatory success of each product candidate, and ongoing assessments as to each product candidate&#8217;s commercial potential.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General and Administrative Expenses</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses consist primarily of personnel expenses, professional fees for legal, accounting, tax and business consulting services, insurance premiums and stock-based compensation.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Income (Expense), Net</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Income</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income consists of interest earned on our money market funds and bank accounts which are a portion of our cash and cash equivalents balance. Our interest income has not been significant due to low interest rates earned on invested balances.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Income (Expense), Net</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income (expense) consists primarily of a research and development tax incentive related to clinical trials performed in Australia and foreign currency transaction gains and losses related to long-term intercompany loans that are payable in the foreseeable future.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of the Three Months Ended September 30, 2022 and 2021 </span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our operating expenses for the three months ended September 30, 2022 and 2021:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:43.621%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.949%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.826%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.949%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.826%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.949%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.826%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.954%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(dollars in thousands)</span></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="9" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="9" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,537&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,480&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,057&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,579&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,907&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">672&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,116&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,387&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,729&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,116)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,387)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,729)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other income (expense)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,108)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(905)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(203)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,224)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,292)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,932)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Research and development expenses increased by $1.1 million during the three months ended September 30, 2022, as compared to the three months ended September 30, 2021. The increase reflects (i) a $1.2 million increase in external development costs related to the Phase 3 program of vidofludimus calcium in relapsing multiple sclerosis, (ii) a $0.5 million increase in external development costs related to the Phase 1 clinical trial of IMU-856, (iii) a $0.6 million increase in personnel expense in research and development, $0.4 million of which is related to non-cash stock compensation expense and the remainder of which is related to an increase in headcount, (iv) a $0.4 million increase in external development costs related to the clinical trials of IMU-935, and (v) $0.3 million related to increased costs across numerous categories.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The increases were partially offset by (i) a decrease of $1.6 million in external development costs related to the Phase 2 clinical trial of vidofludimus calcium in ulcerative colitis, and (ii) a decrease of $0.3 million in external development costs related to the Phase 2 clinical trial of vidofludimus calcium in relapsing-remitting multiple sclerosis.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses increased by $0.7 million during the three months ended September 30, 2022, as compared to the three months ended September 30, 2021. The increase was primarily due to (i) a $0.4 million increase in personnel expense in general and administrative, $0.1 million of which is related to non-cash stock compensation expense and the remainder of which is related to an increase of headcount, and (ii) a $0.3 million aggregate increase across numerous categories. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other expense increased by $0.2 million during the three months ended September 30, 2022, as compared to the three months ended September 30, 2021. The increase was primarily attributable to a $0.9 million increase in the loss on an intercompany loan between Immunic, Inc. and Immunic AG as a result of changes in currency exchange rates. The increase was partially offset by (i) a $0.2 million increase in interest income, (ii) a $0.1 million increase of grants, (iii) a $0.1 million increase in research and development tax incentives for clinical trials in Australia as a result of increased spending on clinical trials in Australia, and (iv) a $0.3 million increase in currency transaction gains.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Comparison of the Nine Months Ended September 30, 2022 and 2021 </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our operating expenses for the nine months ended September 30, 2022 and 2021:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:43.621%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.949%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.826%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.949%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.826%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.949%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.826%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.954%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(dollars in thousands)</span></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="9" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="9" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,520&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,737&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,783&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,641&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,957&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,684&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4SC Royalty Settlement (see Note 4)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,250)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,161&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,944&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,783)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(62,161)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(69,944)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,783&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other income (expense)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,772)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,816)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(63,933)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(71,760)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,827&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Research and development expenses increased by $7.8 million during the nine months ended September 30, 2022, as compared to the nine months ended September 30, 2021. The increase reflects (i) a $6.6 million increase in external development costs related to the Phase 3 program of vidofludimus calcium in relapsing multiple sclerosis, (ii) a $3.5 million increase in external development costs related to the clinical trials of IMU-935, (iii) a $3.1 million increase in external development costs related to the Phase 2 clinical trial of vidofludimus calcium in progressive multiple sclerosis, (iv) a $2.3 million increase in personnel expense in research and development, $1.1 million of which is related to non-cash stock compensation expense and the remainder of which is related to an increase in headcount, and (v) a $0.8 million increase in external development costs related to the Phase 1 clinical trial of IMU-856.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The increases were partially offset by (i) a decrease of $3.7 million in external development costs related to the Phase 2 clinical trial of vidofludimus calcium in ulcerative colitis, (ii) a $2.8 million decrease in external development costs related to the Phase 2 clinical trial of vidofludimus calcium in COVID-19, (iii) a decrease of $1.5 million in external development costs related to the Phase 2 clinical trial of vidofludimus calcium in relapsing-remitting multiple sclerosis, and (iv) a decrease of $0.5 million in external development costs across numerous categories.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses increased by $1.7 million during the nine months ended September 30, 2022, as compared to the nine months ended September 30, 2021. The increase was primarily due to (i) a $1.3 million increase in personnel expense in general and administrative, $0.5 million of which is related to non-cash stock compensation expense and the remainder of which is related to an increase in headcount, and (ii) a $0.4 million aggregate increase across numerous categories. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 31, 2021, Immunic AG and 4SC AG entered into a Settlement Agreement, pursuant to which Immunic AG settled its remaining obligation of the 4.4% royalty on net sales for $17.25 million (Tranche III of the Agreement). The payment was made 50% in cash and 50% in shares of Immunic&#8217;s common stock.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No further payment obligations remain between Immunic and 4SC AG.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other expense was substantially unchanged in total during the nine months ended September 30, 2022, as compared to the nine months ended September 30, 2021. However, we had a $1.2 million increase in the loss on an intercompany loan between Immunic, Inc. and Immunic AG. This was offset by (i) a $0.3 million increase in interest income as a result of higher interest </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">rates, (ii) a $0.2 million increase in research and development tax incentives for clinical trials in Australia as a result of increased spending on clinical trials in Australia, (iii) a $0.2 million foreign exchange gain in the first three quarters of 2022 on an intercompany loan between Immunic AG and Immunic Australia Pty Ltd, (iv) a $0.2 million increase in grants, and (v) a $0.3 million increase in currency transaction gains.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div id="ida7c333e3c58430eb83e8e950c50d811_70"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financial Condition</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have no products approved for commercial sale and have not generated any revenue from product sales. We have never been profitable and have incurred operating losses in each year since our inception in 2016.  We have an accumulated deficit of approximately $260.8 million at September 30, 2022 and $196.9 million as of December 31, 2021.  Substantially all of our operating losses resulted from expenses incurred in connection with our research and development programs and from general and administrative costs associated with our operations.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We expect to continue to incur significant expenses and increasing operating losses for the foreseeable future as we initiate and continue the preclinical and clinical development of our product candidates and add personnel necessary to operate as a company with an advanced clinical pipeline of product candidates. We also expect our expenses and operating losses to increase due to the current inflationary environment and supply chain shortages, which result in higher prices.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">To the extent additional funds are necessary to meet long-term liquidity needs as we continue to execute our business strategy, we anticipate that they will be obtained through the incurrence of indebtedness, additional equity financings or a combination of these potential sources of funds, although we can provide no assurance that these sources of funding will be available on reasonable terms.  However, we expect the cost of indebtedness to continue to increase if interest rates continue to rise.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Raising equity will also be more difficult for at least the foreseeable future because of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">general volatility in the equity markets for companies like us, as well as the recent significant decline in the trading price of our stock following our announcement on October 21, 2022 of the Phase 1b interim analysis of IMU-935 in moderate-to-severe psoriasis. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From inception through October 31, 2022, we have raised net cash of approximately $355.5 million from private and public offerings of preferred and common stock. As of September 30, 2022, we had cash and cash equivalents of approximately $72.8 million.  With these funds, and the $56.4 million of cash raised in October 2022, Immunic expects to be able to fund its operations beyond twelve months from the date of the issuance of the accompanying condensed consolidated financial statements. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2020, we filed a shelf registration statement on Form S-3 (the "2020 Shelf Registration Statement").   The 2020 Shelf Registration Statement permits the offering, issuance and sale of up to $250.0&#160;million of common stock, preferred stock, warrants, debt securities, and/or units in one or more offerings and in any combination of the foregoing. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, we filed a Prospectus Supplement for the offering, issuance and sale of up to a maximum aggregate offering price of $50.0 million of common stock that may be issued and sold under an at-the-market sales agreement with SVB Leerink as agent ("December 2020 ATM"). We have used and intend to continue to use the net proceeds from the offering to continue to fund the ongoing clinical development of our product candidates and for other general corporate purposes, including funding existing and potential new clinical programs and product candidates. The December 2020 ATM will terminate upon the earlier of (i) the issuance and sale of all of the shares through SVB Leerink on the terms and subject to the conditions set forth in the December 2020 ATM or (ii) termination of the December 2020 ATM as otherwise permitted thereby. The December 2020 ATM may be terminated at any time by either party upon ten days&#8217; prior notice, or by SVB Leerink at any time in certain circumstances, including the occurrence of a material adverse effect on us.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of October 28, 2022, $8.4 million in capacity remains under the December 2020 ATM.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">   </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2022, we filed a Prospectus Supplement for the offering, issuance and sale of up to a maximum aggregate offering price of $80.0 million of common stock that may be issued and sold under another at-the-market sales agreement ("May 2022 ATM") with SVB Leerink as agent. We intend to use the net proceeds from the offering to continue to fund the ongoing clinical development of our product candidates and for other general corporate purposes, including funding existing and potential new clinical programs and product candidates. The May 2022 ATM will terminate upon the earlier of (i) the issuance and sale of all of the shares through SVB Leerink on the terms and subject to the conditions set forth in the May 2022 ATM or (ii) termination of the May 2022 ATM as otherwise permitted thereby. The May 2022 ATM may be terminated at any time by either party upon </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ten days&#8217; prior notice, or by SVB Leerink at any time in certain circumstances, including the occurrence of a material adverse effect on the Company.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of October 28, 2022, $80.0 million in capacity remains under the April 2022 ATM.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the three months ended September 30, 2022, we did not have any ATM activity.  In the nine months ended September 30, 2022, we raised gross proceeds of $40.9&#160;million pursuant to the December 2020 ATM through the sale of 4,204,113 shares of common stock at a weighted average price of $9.72 per share. The net proceeds from the December 2020 ATM were $39.6&#160;million after deducting underwriter commissions of $1.2&#160;million. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company did not have any ATM activity during the three or nine months ended September 30, 2021.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Future Capital Requirements</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As noted above, we have not generated any revenue from product sales and we do not know when, or if, we will generate any revenue from product sales. We do not expect to generate any revenue from product sales unless and until we obtain regulatory approval for and commercialize any of our product candidates. At the same time, we expect our expenses to increase as we continue the ongoing research, development, manufacture and clinical trials of, and seek regulatory approval for, our product candidates. We also incur additional costs associated with operating as a public company. In addition, subject to obtaining regulatory approval of any of our product candidates, we anticipate that we will need substantial additional funding in connection with our continuing operations.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future expenses and capital requirements are difficult to forecast and will depend on many factors, including, but not limited to:</span></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing and structure of any strategic options and transactions, if any;</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost, timing and outcome of any future litigation;</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">personnel-related expenses, including salaries, benefits, stock-based compensation expense and other compensation expenses related to retention and termination of personnel;</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the scope, progress, results and costs of research and development and ongoing clinical trials;</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost and timing of future regulatory submissions;</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost and timing of developing and validating the manufacturing processes for any potential product candidates;</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost and timing of any commercialization activities, including reimbursement, marketing, sales and distribution costs;</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to establish new collaborations, licensing or other arrangements and the financial terms of such agreements;</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the number and characteristics of any future product candidates we pursue;</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs involved with being a public company;</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs involved in preparing, filing, prosecuting, maintaining, defending and enforcing patents, including litigation costs and the outcome of such litigation; and</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing, receipt and amount from the sales of, or royalties on, any future products.</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Until such time, if ever, as we can generate substantial product revenues, we expect to finance our cash needs through a combination of stock offerings, debt financings, strategic alliances, collaborations and licensing arrangements. Recent developments, however, will make it more difficult and costly for us to obtain funding for our cash needs. We do not expect to achieve revenue from product sales prior to the use of the net proceeds from our public and private offerings to date. We do not have any committed external source of funds. Additional funds may not be available on acceptable terms, if at all. To the extent that we raise additional capital through the sale of equity securities, the ownership interest of our stockholders will be diluted and it may be on terms that are not favorable to us or our stockholders.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Sales of equity securities will also be more difficult for at least the foreseeable future because of general volatility in the equity markets for companies like us, as well as the significant decline in the trading price of our stock following our announcement on October 21, 2022 of the Phase 1b interim analysis of IMU-935 in moderate-to-severe psoriasis. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Debt financing, if available, may involve covenants restricting our operations or our ability to incur additional debt or other terms that are not favorable to us or our stockholders. Also, the cost of debt financing has increased due to the rise in interest rates beginning in March 2022.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">If we raise additional funds through collaborations and licensing arrangements with third parties, we would expect to relinquish substantial rights to our technologies or our future products, or grant licenses on terms that may not be favorable to us. If we were to complete a merger, we may relinquish all control over the organization and could experience detrimental tax effects.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">If we are unable to raise adequate funds, we may have to liquidate some or all of our assets. Any of these factors could harm our operating results and could result in substantial declines in the trading price of our common stock.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2022, we had cash and cash equivalents of approximately $72.8 million.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows </span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows a summary of our cash flows for the nine months ended September 30, 2022 and 2021:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.438%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.620%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash (used in) provided by:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating activities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50,040)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59,552)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(113)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,719&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,020&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating activities</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September 30, 2022, operating activities used $50.0&#160;million of cash. The use of cash primarily resulted from (i) our net loss of $63.9 million adjusted for non-cash charges of $10.3 million related to $4.2 million for an unrealized foreign currency loss and $6.1 million related to stock-based compensation and depreciation and amortization and a $3.6&#160;million net increase in operating assets and liabilities. Changes in our operating assets and liabilities during the nine months ended September 30, 2022 consisted primarily of (i) a $2.0 million increase in our other current assets and prepaid expenses and (ii) an increase of $1.6 million in our other current liabilities. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September 30, 2021, operating activities used $59.6 million of cash. The use of cash primarily resulted from (i) our net loss of $71.8 million adjusted for non-cash charges of $8.6 million related to common stock issued for the 4SC AG transaction, $3.2 million for an unrealized foreign currency loss, $4.5 million related to stock-based compensation and depreciation and amortization as well as a $4.1 million net increase in our operating assets and liabilities. Changes in our operating assets and liabilities during the nine months ended September 30, 2021 consisted primarily of (i) an increase of $6.3 million in other current assets and prepaid expenses, partially offset by an increase of $2.2 million in our current liabilities. </span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investing activities</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in investing activities was $113,000 and $48,000 during the nine months ended September 30, 2022, and 2021, respectively, which was related to the purchase of property and equipment.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financing Activities</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities was $39.7 million during the nine months ended September 30, 2022 consisting primarily of net cash proceeds from the sale of common stock under our 2020 ATM facility. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities was $42.0 million during the nine months ended September 30, 2021 consisting of net cash proceeds from the sale of common stock under the July 2021 equity offering. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Off-Balance Sheet Arrangements</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through September 30, 2022, we have not entered into and did not have any relationships with unconsolidated entities or financial collaborations, such as entities often referred to as structured finance or special purpose entities, established for the purpose of facilitating off-balance sheet arrangements or other contractually narrow or limited purpose.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contractual Obligations</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of the operating lease obligation are as follows as of September 30, 2022:</span></div><div style="margin-top:12pt;text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.099%"><tr><td style="width:1.0%"></td><td style="width:84.294%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.439%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.867%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">528,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">454,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">227,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,378,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PV of obligation</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,274,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2022, we have non-cancelable contractual obligations under certain agreements related to our development programs IMU-838, IMU-935 and IMU-856 totaling approximately $2.7 million, all of which is expected to be paid over the next twelve months.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Estimates</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our unaudited condensed consolidated financial statements are prepared in conformity with U.S. GAAP. The preparation of our unaudited condensed consolidated financial statements and related disclosures requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, costs and expenses, and the disclosure of contingent assets and liabilities in our financial statements. We base our estimates on historical experience, known trends and events and various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. We evaluate our estimates and assumptions on an ongoing basis. Our actual results may differ from these estimates under different assumptions or conditions. We have reviewed these critical accounting policies and related disclosures with the Audit Committee of our Board.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the first nine months of 2022, there were no significant changes in our critical accounting policies or in the methodology used for estimates. Our significant accounting policies are described in more detail in (i) Note 2 to our unaudited condensed consolidated financial statements included elsewhere in this Quarterly Report and (ii) our audited consolidated financial statements for the years ended December 31, 2021 and 2020 filed in our Annual Report on Form 10-K on February 24, 2022.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Issued Accounting Standards</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are no recently issued accounting standards that would have a significant impact on the company's consolidated financial statements. </span></div><div style="margin-top:12pt;text-align:justify"><span><br/></span></div><div style="margin-top:12pt;text-align:justify"><span><br/></span></div><div id="ida7c333e3c58430eb83e8e950c50d811_73"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;3. Quantitative and Qualitative Disclosures about Market Risk</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Rate Sensitivity</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had cash and cash equivalents of $72.8 million as of September 30, 2022, which were held for working capital purposes. We do not enter into investments for trading or speculative purposes. We do not believe that we have any material exposure to changes in the fair value of these investments as a result of changes in interest rates due to their short-term nature. However, $40.2 million of these funds are held in German bank accounts that were earning no interest as of September 30, 2022.  Decreases or increases in interest rates, however, will reduce or increase future investment income, respectively, to the extent we have funds available for investment.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Exchange Risk</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary research and development operations are conducted in our facilities in Germany. We have entered and may continue to enter into international agreements, primarily related to our clinical studies. Accordingly, we have exposure to foreign currency exchange rates and fluctuations between the U.S. dollar and foreign currencies, primarily the euro and the Australian dollar, which could adversely affect our financial results, including income and losses as well as assets and liabilities. To date, we have not entered into, and do not have any current plans to enter into, any foreign currency hedging transactions or derivative financial transactions. Our exposure to foreign currency risk will fluctuate in future periods as our research and clinical development activities in Europe and Australia change. We currently maintain a significant amount of our assets outside of the U.S.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The functional currencies of our foreign subsidiaries are the applicable local currencies. Accordingly, the effects of exchange rate fluctuations on the net assets of these operations are accounted for as translation gains or losses in accumulated other comprehensive income (loss) within stockholders&#8217; equity.  Foreign currency transaction gains and losses related to long-term intercompany loans that are payable in the foreseeable future are recorded in Other Income (Expense). Our German subsidiaries are currently a significant portion of our business and, accordingly, a change of 10% in the currency exchange rates, primarily the euro, could have a material impact on their financial position or results of operations.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although operating in local currencies may limit the impact of currency rate fluctuations on the results of operations of our German and Australian subsidiaries, rate fluctuations may impact the consolidated financial position as the assets and liabilities of our foreign operations are translated into U.S. dollars in preparing our condensed consolidated balance sheets. As of September 30, 2022, our German and Australian subsidiaries had net current assets (defined as current assets less current liabilities), subject to foreign currency translation risk, of $42.9 million. A decrease of approximately $4.3 million in net current assets would result as of September 30, 2022, from a hypothetical 10% adverse change in quoted foreign currency exchange rates, primarily due to the euro.  In addition, a 10% change in the foreign currency exchange rates for the nine months ended September 30, 2022, would have impacted our net loss by approximately $5.3 million, primarily due to the euro.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Effects of Inflation</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have experienced a general increase in costs as a result of global inflation, however, we do not believe that inflation and changing prices had a material impact on our results of operations for any periods presented herein.</span></div><div id="ida7c333e3c58430eb83e8e950c50d811_76"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;4. Controls and Procedures</span></div><div style="margin-bottom:8.85pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An evaluation was carried out, under the supervision of and with the participation of our management, including our Chief Executive Officer and our Principal Financial Officer, of the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15 (e)) under the Securities Exchange Act of 1934 ("the Exchange Act"), as of the end of the period covered by this report. Based on such evaluation, our Chief Executive Officer and our Principal Financial Officer have concluded that our disclosure controls and procedures are effective to ensure that the information required to be disclosed by us in the reports we file or submit under the Exchange Act was recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Control over Financial Reporting</span></div><div style="margin-bottom:0.2pt;margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There was no change in our internal control over financial reporting that occurred during the nine months ended September 30, 2022 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</span></div><div id="ida7c333e3c58430eb83e8e950c50d811_79"></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><div id="ida7c333e3c58430eb83e8e950c50d811_82"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Part II - OTHER INFORMATION</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1. Legal Proceedings</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are not currently a party to any litigation, nor are we aware of any pending or threatened litigation against us, that we believe would materially affect our business, operating results, financial condition or cash flows. Our industry is characterized by frequent claims and litigation including securities litigation, claims regarding patent and other intellectual property rights and claims for product liability. It is not uncommon for lawsuits to be filed alleging lack of process or breach of fiduciary duties by directors, and we may face such suits in the future. As a result, in the future, we may be involved in various legal proceedings from time to time.</span></div><div id="ida7c333e3c58430eb83e8e950c50d811_85"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1A.&#160;Risk Factors</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our clinical trials could be delayed or suspended, and costs would increase, as a result of the military action by Russia in the Ukraine.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In February 2022, Russia invaded Ukraine. As a result, the United States and other countries imposed economic and other sanctions on Russia and could impose further sanctions, which have and may continue to disrupt international commerce and damage the global economy. The continuing conflict may impair our ability to recruit patients in Ukraine, Russia and Belarus for current and upcoming clinical trials, which could result in delays of our trials and additional recruitment costs.  Although we are making efforts to compensate for our temporary stop of patient recruitment in Ukraine, Russia and Belarus, seeking activation of other countries and additional sites in currently participating countries, the broader or longer-term consequences of this conflict or the sanctions imposed to date or in the future could adversely affect clinical trials we are currently conducting or are planning to conduct in this region by delaying or preventing their completion and increasing our costs. Alternative sites to fully and timely compensate for delays in our clinical trial activities in Ukraine, Russia and Belarus may not be available or may not fully compensate for a lack of enrollment in Ukraine, Russia and Belarus. Although the route, length and impact of this continuing conflict are highly unpredictable, vendors, investigators or clinical trial sites in Ukraine, Russia and Belarus could suspend or terminate any trials being conducted, and patients could be forced to discontinue further study participation or to evacuate or voluntarily choose to relocate far from clinical trial sites, making them unavailable for further dosing or necessary follow-up. If our clinical trials are materially interrupted or otherwise negatively impacted, we may have insufficient data to support regulatory approvals of vidofludimus calcium, and any commercialization may be delayed, which could limit our potential revenue and hurt the competitive position of any products we may successfully develop.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Uncertainty in global economic conditions could negatively affect our business, results of operations and financial condition.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will continue to evaluate the recoverability of the carrying amount of our goodwill on an ongoing basis, and we may incur substantial impairment charges, which would adversely affect our consolidated financial results. There can be no assurance that the outcome of such reviews in the future will not result in substantial impairment charges. Impairment assessment inherently involves judgment as to assumptions about expected future cash flows and the impact of market conditions on those assumptions. Future events and changing market conditions may impact our assumptions as to prices, costs, holding periods or other factors that may result in changes in our estimates of future cash flows. Although we believe the assumptions we used in testing for impairment are reasonable, significant changes in any one of our assumptions could produce a significantly different result.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our losses from operations and net loss would increase if inflation continues of increases in rate in the countries in which we operate, or if a global recession were to occur.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The economies of Germany, the United States, Australia and other countries in which we do business have experienced high rates of inflation during 2022.  We have already seen a general increase in many of our costs as a result of inflation, although inflation has not yet had a material impact on our results of operations. If inflation were to continue for a prolonged period of time, however, or the rate of inflation in our markets were to increase, or if a global recession were to occur, our expenses could increase substantially resulting in increased losses from operations and net loss.  </span></div><div id="ida7c333e3c58430eb83e8e950c50d811_88"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;2. Unregistered Sales of Equity Securities and Use of Proceeds</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="ida7c333e3c58430eb83e8e950c50d811_91"></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. Defaults Upon Senior Securities </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="ida7c333e3c58430eb83e8e950c50d811_94"></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. Mine Safety Disclosures </span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="ida7c333e3c58430eb83e8e950c50d811_97"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;5. Other Information</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="ida7c333e3c58430eb83e8e950c50d811_100"></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span><br/></span></div><div style="-sec-extract:summary;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;6. Exhibits </span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;6. Exhibits </span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBITS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:53.432%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.332%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.596%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Incorporated by Reference</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit Title</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Form</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Filing Date</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1280776/000119380519000646/e618557_ex3-1.htm">Amended and Restated Articles of Incorporation.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 17, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1280776/000119380519000646/e618557_ex3-2.htm">Third Amended and Restated Bylaws.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 17, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1280776/000119380519000837/e618652_ex4-2.htm">2019 Omnibus Equity Incentive Plan.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-8</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 20, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;4.2*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit42111111.htm">Description of Registrant's Securities</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 26, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1280776/000119380522001344/e621975_ex4-1.htm">Form of Pre-Funded Warrant</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 11, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1280776/000119380519000646/e618557_ex10-1.htm">Sales Agreement, dated July 17, 2019, between Immunic, Inc. and SVB Leerink LLC.</a></span></div><div><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 17, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1280776/000119380519000646/e618557_ex10-2.htm">Option and License Agreement, dated September 27, 2018, between Immunic AG and Daiichi Sankyo Company, Ltd.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 17, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1280776/000119380519000646/e618557_ex10-3.htm">Asset Purchase Agreement, dated May 13, 2016, between Immunic AG and 4SC AG.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 17, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1280776/000119380519000646/e618557_ex10-4.htm">Form of Indemnification Agreement.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 17, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1280776/000119380519000646/e618557_ex10-5.htm">Employment Agreement between Dr. Daniel Vitt and Immunic AG.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 17, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1280776/000119380519000797/e618637_ex10-1.htm">Addendum to Service Agreement between Immunic AG and Dr. Daniel Vitt.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 5, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1280776/000119380519000646/e618557_ex10-6.htm">Employment Agreement between Dr. Manfred Groeppel and Immunic AG.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 17, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1280776/000119380519000797/e618637_ex10-2.htm">Addendum to Service Agreement between Immunic AG and Dr. Manfred Groeppel.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 5, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.9+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1280776/000119380520000499/e619564_ex10-2.htm">Employment Agreement dated April 17, 2020, between Immunic, Inc. and Duane Nash.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 20, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.10+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1280776/000119380521000513/e620493_ex10-1.htm">Second Addendum to Employment Agreement dated October 15, 2020, between Immunic, Inc. and Duane Nash.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 19, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.11</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1280776/000119380520000519/e619576_ex10-1.htm">Placement Agency Agreement, dated April 23, 2020, between Immunic, Inc. and Roth Capital Partners, LLC</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 20, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.12</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1280776/000119380520000519/e619576_ex10-2.htm">Form of Securities Purchase Agreement, dated April 23, 2020, between Immunic, Inc. and the investors party thereto.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 20, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.13</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1280776/000119380520000688/e619697_ex10-1.htm">Placement Agency Agreement, dated June 10, 2020, between Immunic, Inc.  and the Roth Partners, LLC</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 12, 2020</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:53.432%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.332%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.596%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.14</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1280776/000119380520000688/e619697_ex10-2.htm">Form of Securities Purchase Agreement, dated June 10, 2020, between Immunic, Inc. and the investors party thereto</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 12, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.15</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1280776/000119380520000975/e619841_ex1-1.htm">Underwriting Agreement, dated August 4, 2020, by and between Immunic, Inc. and SVB Leerink LLC.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 10, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.16</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1280776/000119380520001296/e620006_ex10-1.htm">Finance Contract, dated October 19, 2020, between Immunic, Inc., Immunic AG and European Investment Bank</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 20, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.17</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1280776/000119380520001296/e620006_ex10-2.htm">Form of Guarantee Agreement between Immunic, Inc., Immunic AG and European Investment Bank.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 20, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.18</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001280776/000119380521000002/e620187_ex10-1.htm">Sales Agreement, dated December 29, 2020 between Immunic, Inc. and SVB Leerink LLC</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 4, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.19</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1280776/000119380520001425/e620080_ex10-1.htm">Amendment Letter, dated November 11, 2020</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 13, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.20</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1280776/000119380521000441/e620436_ex10-1.htm">Settlement Agreement, dated March 31, 2021, between Immunic AG and 4SC AG.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.21+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001280776/000119380521000513/e620493_ex10-1.htm">Addendum No. 2 to Employment Agreement dated April 15, 2021 between Immunic, Inc. and Duane Nash</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 15, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.22+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001280776/000119380521000860/e620704_ex10-1.htm">Second Addendum to Service Agreement between Immunic AG and Dr. Daniel Vitt</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 10, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.23+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001280776/000119380521000860/e620704_ex10-2.htm">Second Addendum, dated June 10, 2021 to Service Agreement between Immunic AG and Dr. Andreas Muehler</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 10, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.24+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001280776/000119380521000860/e620704_ex10-3.htm">Employment Agreement, dated June 10, 2021 between Immunic, Inc. and Dr. Andreas Muehler</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 10, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.25+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001280776/000119380521000860/e620704_ex10-4.htm">Employment Agreement, dated June 10, 2021 between Immunic, Inc. and Glenn Whaley</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 10, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.26+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001280776/000119380521001043/e620806_ex1-1.htm">Underwriting Agreement, dated July 15, 2021, by and between Immunic, Inc. and Piper Sandler &amp; Co</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 15, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.27+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001280776/000119380521001455/e621010_ex10-1.htm">Employment Agreement, dated October 14, 2021, between Immunic, Inc. and Patrick Walsh</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 14, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.28+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001280776/000119380522000023/e621200_ex10-1.htm">Third Addendum, dated January 5, 2022, to Service Agreement between Immunic AG and Dr. Daniel Vitt</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 10, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.29+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001280776/000119380522000023/e621200_ex10-2.htm">Third Addendum, dated January 5, 2022, to Service Agreement between Immunic AG and Dr. Andreas Muehler</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 10, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.30+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001280776/000119380522000023/e621200_ex10-3.htm">Third Addendum, dated January 5, 2022, to Service Agreement between Immunic AG and Dr. Hella Kohlhof</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 10, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.31+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001280776/000119380522000504/e621458_ex10-1.htm">Addendum No. 3 to Employment Agreement, dated March 15, 2022, between Immunic, Inc. and Duane Nash</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 15, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.32</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1280776/000119380522000711/e621604_ex10-1.htm">Sales Agreement dated as of May 2, 2022, between SVB Securities LLC and Immunic, Inc.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 2, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.33</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1280776/000119380522001344/e621975_ex10-1.htm">Securities Purchase Agreement, dated October 10, 2022, by and among the Company and the Purchasers</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 11, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="imux-093022xexhibit311.htm">Certification of Principal Executive Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:53.432%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.332%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.596%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="imux-093022xexhibit312.htm">Certification of Principal Financial Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="imux-093022xexhibit321.htm">Certification of Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.2*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="imux-093022xexhibit322.htm">Certification of Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.1+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1280776/000119380519000797/e618637_ex99-3.htm">Employment Agreement, dated September 4, 2019, between Immunic, Inc. and Dr. Andreas Muehler.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 5, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.2+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1280776/000119380519000797/e618637_ex99-2.htm">Addendum, dated September 4, 2019, to Service Agreement between Immunic AG and Dr. Andreas Muehler.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 5, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.3+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1280776/000119380519000797/e618637_ex99-4.htm">Addendum, dated September 4, 2019, to Service Agreement between Immunic AG and Dr. Hella Kohlhof.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 5, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.4+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001280776/000119380521000860/e620704_ex99-2.htm">Second Addendum, dated June 10, 2021, to Service Agreement between Immunic AG and Dr. Hella Kohlhof</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 10, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Instance Document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Schema Document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Calculation Linkbase Document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Definition Linkbase Database.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Label Linkbase Document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Presentation Linkbase Document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:4.756%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.044%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indicates a management contract or compensatory plan or arrangement.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In accordance with Item&#160;601(b)(32)(ii) of Regulation S-K and SEC Release No.&#160;33-8238 and 34-47986, Final Rule: Management&#8217;s Reports on Internal Control Over Financial Reporting and Certification of Disclosure in Exchange Act Periodic Reports, the certifications furnished in Exhibits 32.1 and 32.2 hereto are deemed to accompany this Form 10-K and will not be deemed &#8220;filed&#8221; for purposes of Section&#160;18 of the Exchange Act. Such certifications will not be deemed to be incorporated by reference into any filings under the Securities Act or the Exchange Act, except to the extent that the registrant specifically incorporates it by reference.</span></td></tr></table></div><div><span><br/></span></div><div style="margin-top:12pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><div id="ida7c333e3c58430eb83e8e950c50d811_103"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span><br/></span></div><div style="text-indent:288pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">IMMUNIC, INC.</span></div><div><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date: November&#160;3, 2022&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;By:   </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">/s/ Daniel Vitt                                 </span></div><div style="text-indent:288pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">         &#160;&#160;&#160;&#160;Daniel Vitt</span></div><div style="text-indent:288pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">         &#160;&#160;&#160;&#160;Chief Executive Officer and President</span></div><div style="text-indent:288pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span><br/></span></div><div style="margin-top:12pt;text-indent:49.5pt"><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.2
<SEQUENCE>2
<FILENAME>exhibit42111111.htm
<DESCRIPTION>EX-4.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i281b1f5788db432cb0fb3a01e22cdea3_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 4.2</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">DESCRIPTION OF CAPITAL STOCK </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">General</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our authorized capital stock consists of 130,000,000 shares of common stock, par value $0.0001 per share, and 20,000,000 shares of preferred stock, par value $0.0001 per share.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following description of our common stock summarizes its material terms and provisions, but it is not complete. For the complete terms of our common stock, please refer to our certificate of incorporation and our bylaws that are incorporated by reference into the Annual Report on Form 10-K of which this exhibit is a part.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Common Stock</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of December 31, 2020, there were 21,168,240 shares of common stock outstanding. The holders of our common stock are entitled to one vote for each share held of record on all matters submitted to a vote of the stockholders. The holders of common stock are not entitled to cumulative voting rights with respect to the election of directors, and as a consequence, minority stockholders will not be able to elect directors on the basis of their votes alone.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Subject to preferences that may be applicable to any then outstanding shares of preferred stock, holders of common stock are entitled to receive ratably such dividends as may be declared by the board of directors out of funds legally available therefor. In the event of a liquidation, dissolution or winding up of us, holders of the common stock are entitled to share ratably in all assets remaining after payment of liabilities and the liquidation preferences of any then outstanding shares of preferred stock. Holders of common stock have no preemptive rights and no right to convert their common stock into any other securities. There are no redemption or sinking fund provisions applicable to our common stock. All outstanding shares of common stock are fully paid and non-assessable. The rights, preferences and privileges of holders of our common stock are subject to, and may be adversely affected by, the rights of the holders of shares of any of our outstanding preferred stock.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Listing</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our common stock is listed on the Nasdaq Global Select Market under the symbol &#8220;IMUX.&#8221;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Transfer Agent and Registrar</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The transfer agent and registrar for our common stock is American Stock Transfer &#38; Trust Company, LLC (&#8220;AST&#8221;). The transfer agent and registrar&#8217;s address is 6201 15th Avenue, Brooklyn, New York 11219.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Dividends</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have not declared any cash dividends on our common stock since inception and we do not anticipate paying any cash dividends on our common stock in the foreseeable future.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Possible Anti-Takeover Effects of Delaware Law and our Charter Documents</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Some provisions of Delaware law, our amended and restated certificate of incorporation and our amended and restated bylaws could make the following transactions more difficult&#58; an acquisition of us by means of a tender offer, an acquisition of us by means of a proxy contest or otherwise, or the removal of our incumbent officers and directors. It is possible that these provisions could make it more difficult to accomplish or could deter transactions that stockholders may otherwise consider to be in their best interest or in our best interest, including transactions which provide for payment of a premium over the market price for our shares.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">These provisions, summarized below, are intended to discourage coercive takeover practices and inadequate takeover bids. These provisions are also designed to encourage persons seeking to acquire control of us to first negotiate with our board of directors. We believe that the benefits of the increased protection of our potential ability to negotiate with the proponent of an unfriendly or unsolicited proposal to acquire or restructure us outweigh the disadvantages of discouraging these proposals because negotiation of these proposals could result in an improvement of their terms.</font></div><div><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Delaware Anti-Takeover Statute</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are subject to Section 203 of the Delaware General Corporation Law (the &#8220;DGCL&#8221;), an anti-takeover statute. In general, Section 203 of the DGCL prohibits a publicly held Delaware corporation from engaging in a &#8220;business combination&#8221; with an &#8220;interested stockholder&#8221; for a period of three years following the time the person became an interested stockholder, unless the business combination or the acquisition of shares that resulted in a stockholder becoming an interested stockholder is approved in a prescribed manner. Generally, a &#8220;business combination&#8221; includes a merger, asset or stock sale, or other transaction resulting in a financial benefit to the interested stockholder. Generally, an &#8220;interested stockholder&#8221; is a person who, together with affiliates and associates, owns (or within three years prior to the determination of interested stockholder status did own) 15% or more of a corporation&#8217;s voting stock. The existence of this provision would be expected to have an anti-takeover effect with respect to transactions not approved in advance by our board of directors, including discouraging attempts that might result in a premium over the market price for the shares of common stock held by our stockholders.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Undesignated Preferred Stock.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The ability of our board of directors, without action by the stockholders, to issue up to 20,000,000 shares of undesignated preferred stock with voting or other rights or preferences as designated by our board of directors could impede the success of any attempt to effect a change in control of us. These and other provisions may have the effect of deferring hostile takeovers or delaying changes in control or management of our company.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Requirements for Advance Notification of Stockholder Nominations and Proposals.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our amended and restated bylaws establish advance notice procedures with respect to stockholder proposals to be brought before a stockholder meeting and the nomination of candidates for election as directors, other than nominations made by or at the direction of the board of directors or a committee of the board of directors.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Elimination of Stockholder Action by Written Consent.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our amended and restated certificate of incorporation eliminates the right of stockholders to act by written consent without a meeting.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Staggered Board.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our board of directors is divided into three classes. The directors in each class will serve for a three-year term, one class being elected each year by our stockholders. This system of electing and removing directors may tend to discourage a third party from making a tender offer or otherwise attempting to obtain control of us, because it generally makes it more difficult for stockholders to replace a majority of the directors.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Removal of Directors.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our amended and restated certificate of incorporation provides that no member of our board of directors may be removed from office by our stockholders except for cause and, in addition to any other vote required by law, upon the approval of the holders of at least two-thirds in voting power of the outstanding shares of stock entitled to vote in the election of directors.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Stockholders Not Entitled to Cumulative Voting.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our amended and restated certificate of incorporation does not permit stockholders to cumulate their votes in the election of directors. Accordingly, the holders of a majority of the outstanding shares of our common stock entitled to vote in any election of directors can elect all of the directors standing for election, if they choose, other than any directors that holders of our preferred stock may be entitled to elect.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Authorized but Unissued Shares</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our authorized but unissued shares of common stock and preferred stock will be available for future issuance without stockholder approval. We may use additional shares for a variety of purposes, including future public offerings to raise additional capital, to fund acquisitions and as employee compensation. The existence of authorized but unissued shares of undesignated preferred stock may enable our board of directors to render more difficult or to discourage an attempt to obtain control of us by means of a merger, tender offer, proxy contest or otherwise. For example, if in the due exercise of its fiduciary </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">obligations, our board of directors were to determine that a takeover proposal is not in the best interests of us or our stockholders, our board of directors could cause shares of preferred stock to be issued without stockholder approval in one or more private offerings or other transactions that might dilute the voting or other rights of the proposed acquirer, stockholder or stockholder group. The rights of holders of our common stock described above will be subject to, and may be adversely affected by, the rights of any preferred stock that we may designate and issue in the future. The issuance of shares of undesignated preferred stock could decrease the amount of earnings and assets available for distribution to holders of shares of common stock. The issuance may also adversely affect the rights and powers, including voting rights, of these holders and may have the effect of delaying, deterring or preventing a change in control of us.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Director Liability</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our bylaws limit the extent to which our directors are personally liable to us and our stockholders, to the fullest extent permitted by the DGCL. The inclusion of this provision in our bylaws may reduce the likelihood of derivative litigation against directors and may discourage or deter stockholders or management from bringing a lawsuit against directors for breach of their duty of care.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The provisions of Delaware law, our amended and restated certificate of incorporation and our amended and restated bylaws could have the effect of discouraging others from attempting hostile takeovers and, as a consequence, they may also inhibit temporary fluctuations in the market price of our common stock that often result from actual or rumored hostile takeover attempts. These provisions may also have the effect of preventing changes in the composition of our board and management. It is possible that these provisions could make it more difficult to accomplish transactions that stockholders may otherwise deem to be in their best interest.</font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>imux-093022xexhibit311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ia1bc7435e0b64e7db089b5966a719082_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATIONS</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Daniel Vitt, certify that&#58;</font></div><div style="margin-top:12pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1. I have reviewed this Quarterly Report on Form 10-Q of Immunic, Inc.&#59;</font></div><div style="margin-top:12pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:12pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of and for the periods presented in this report&#59;</font></div><div style="margin-top:12pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4. The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:6pt;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:6pt;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:6pt;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c) Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:6pt;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d) Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:12pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5. The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:6pt;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:6pt;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:56.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.171%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; November 3, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Daniel Vitt</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Daniel Vitt</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer and President</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>imux-093022xexhibit312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i4854cb87a32b445abfa39a1e8cfcd23d_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATIONS</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Glenn Whaley, certify that&#58;</font></div><div style="margin-top:12pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1. I have reviewed this Quarterly Report on Form 10-Q of Immunic, Inc.&#59;</font></div><div style="margin-top:12pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:12pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of and for the periods presented in this report&#59;</font></div><div style="margin-top:12pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4. The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:6pt;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:6pt;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:6pt;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c) Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:6pt;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d) Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:12pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5. The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:6pt;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:6pt;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:56.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.171%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; November 3, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Glenn Whaley</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Glenn Whaley</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial Officer)</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>5
<FILENAME>imux-093022xexhibit321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i86a51df0d0944ed8bc2c7af861f1fe2d_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Quarterly Report on Form 10-Q of Immunic, Inc. (the &#8220;Company&#8221;) for the period ended September 30, 2022 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), the undersigned, Daniel Vitt, Chief Executive Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section&#160;1350, that to his knowledge&#58;</font></div><div style="margin-top:12pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) the Report fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-top:12pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:56.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.171%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; November 3, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Daniel Vitt</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Daniel Vitt</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer and President</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>6
<FILENAME>imux-093022xexhibit322.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ied9e89335426435189ff8a6e1a4edfc3_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.2</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Quarterly Report on Form 10-Q of Immunic, Inc. (the &#8220;Company&#8221;) for the period ended September 30, 2022 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), the undersigned, Glenn Whaley, Chief Financial Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section&#160;1350, that to his knowledge&#58;</font></div><div style="margin-top:12pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) the Report fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-top:12pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:56.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.171%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; November 3, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Glenn Whaley</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Glenn Whaley</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial  Officer)</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>vtl-20220930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:6944770f-821d-45aa-b4f3-cccabd82d2f9,g:32d5dde5-0858-4183-b548-263732a64d33-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:vtl="http://vitaltherapies.com/20220930" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://vitaltherapies.com/20220930">
  <xs:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="vtl-20220930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="vtl-20220930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="vtl-20220930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="vtl-20220930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://vitaltherapies.com/role/CoverPage">
        <link:definition>0000001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheets" roleURI="http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets">
        <link:definition>0000002 - Statement - Condensed Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsParenthetical" roleURI="http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheetsParenthetical">
        <link:definition>0000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofOperations" roleURI="http://vitaltherapies.com/role/CondensedConsolidatedStatementsofOperations">
        <link:definition>0000004 - Statement - Condensed Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofComprehensiveLoss" roleURI="http://vitaltherapies.com/role/CondensedConsolidatedStatementsofComprehensiveLoss">
        <link:definition>0000005 - Statement - Condensed Consolidated Statements of Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofStockholdersEquity" roleURI="http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity">
        <link:definition>0000006 - Statement - Condensed Consolidated Statements of Stockholders&#8217; Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofStockholdersEquityParenthetical" roleURI="http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical">
        <link:definition>0000007 - Statement - Condensed Consolidated Statements of Stockholders&#8217; Equity (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementofCashFlows" roleURI="http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows">
        <link:definition>0000008 - Statement - Condensed Consolidated Statement of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofCashFlowsParenthetical" roleURI="http://vitaltherapies.com/role/CondensedConsolidatedStatementsofCashFlowsParenthetical">
        <link:definition>0000009 - Statement - Condensed Consolidated Statements of Cash Flows (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DescriptionofBusinessandBasisofFinancialStatements" roleURI="http://vitaltherapies.com/role/DescriptionofBusinessandBasisofFinancialStatements">
        <link:definition>0000010 - Disclosure - Description of Business and Basis of Financial Statements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://vitaltherapies.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>0000011 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetDetails" roleURI="http://vitaltherapies.com/role/BalanceSheetDetails">
        <link:definition>0000012 - Disclosure - Balance Sheet Details</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://vitaltherapies.com/role/CommitmentsandContingencies">
        <link:definition>0000013 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValue" roleURI="http://vitaltherapies.com/role/FairValue">
        <link:definition>0000014 - Disclosure - Fair Value</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommonStock" roleURI="http://vitaltherapies.com/role/CommonStock">
        <link:definition>0000015 - Disclosure - Common Stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationPlans" roleURI="http://vitaltherapies.com/role/StockBasedCompensationPlans">
        <link:definition>0000016 - Disclosure - Stock-Based Compensation Plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ChangesinBoardofDirectors" roleURI="http://vitaltherapies.com/role/ChangesinBoardofDirectors">
        <link:definition>0000017 - Disclosure - Changes in Board of Directors</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactions" roleURI="http://vitaltherapies.com/role/RelatedPartyTransactions">
        <link:definition>0000018 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvents" roleURI="http://vitaltherapies.com/role/SubsequentEvents">
        <link:definition>0000019 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>0000020 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesTables" roleURI="http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesTables">
        <link:definition>0000021 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetDetailsTables" roleURI="http://vitaltherapies.com/role/BalanceSheetDetailsTables">
        <link:definition>0000022 - Disclosure - Balance Sheet Details (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesTables" roleURI="http://vitaltherapies.com/role/CommitmentsandContingenciesTables">
        <link:definition>0000023 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueTables" roleURI="http://vitaltherapies.com/role/FairValueTables">
        <link:definition>0000024 - Disclosure - Fair Value (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommonStockTables" roleURI="http://vitaltherapies.com/role/CommonStockTables">
        <link:definition>0000025 - Disclosure - Common Stock (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationPlansTables" roleURI="http://vitaltherapies.com/role/StockBasedCompensationPlansTables">
        <link:definition>0000026 - Disclosure - Stock-Based Compensation Plans (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DescriptionofBusinessandBasisofFinancialStatementsDetails" roleURI="http://vitaltherapies.com/role/DescriptionofBusinessandBasisofFinancialStatementsDetails">
        <link:definition>0000027 - Disclosure - Description of Business and Basis of Financial Statements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" roleURI="http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails">
        <link:definition>0000028 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofDilutedNetLossperShareDetails" roleURI="http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofDilutedNetLossperShareDetails">
        <link:definition>0000029 - Disclosure - Summary of Significant Accounting Policies - Schedule of Potentially Dilutive Securities Not Included in Calculation of Diluted Net Loss per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetDetailsScheduleofOtherCurrentAssetsandPrepaidExpensesDetail" roleURI="http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofOtherCurrentAssetsandPrepaidExpensesDetail">
        <link:definition>0000030 - Disclosure - Balance Sheet Details - Schedule of Other Current Assets and Prepaid Expenses (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetDetailsScheduleofAccountsPayableDetail" roleURI="http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofAccountsPayableDetail">
        <link:definition>0000031 - Disclosure - Balance Sheet Details - Schedule of Accounts Payable (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetDetailsScheduleofAccruedExpensesDetail" roleURI="http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofAccruedExpensesDetail">
        <link:definition>0000032 - Disclosure - Balance Sheet Details - Schedule of Accrued Expenses (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetDetailsScheduleofOtherCurrentLiabilitiesDetail" roleURI="http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofOtherCurrentLiabilitiesDetail">
        <link:definition>0000033 - Disclosure - Balance Sheet Details - Schedule of Other Current Liabilities (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesAdditionalInformationDetails" roleURI="http://vitaltherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetails">
        <link:definition>0000034 - Disclosure - Commitments and Contingencies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesMaturitiesofOperatingLeaseObligationDetails" roleURI="http://vitaltherapies.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseObligationDetails">
        <link:definition>0000035 - Disclosure - Commitments and Contingencies - Maturities of Operating Lease Obligation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesMaturitiesofOperatingLeaseObligationDetails_1" roleURI="http://vitaltherapies.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseObligationDetails_1">
        <link:definition>0000035 - Disclosure - Commitments and Contingencies - Maturities of Operating Lease Obligation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" roleURI="http://vitaltherapies.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails">
        <link:definition>0000036 - Disclosure - Fair Value - Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommonStockShelfRegistrationStatementDetails" roleURI="http://vitaltherapies.com/role/CommonStockShelfRegistrationStatementDetails">
        <link:definition>0000037 - Disclosure - Common Stock - Shelf Registration Statement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommonStockPublicEquityOfferingDetails" roleURI="http://vitaltherapies.com/role/CommonStockPublicEquityOfferingDetails">
        <link:definition>0000038 - Disclosure - Common Stock - Public Equity Offering (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommonStockCommonStockDetails" roleURI="http://vitaltherapies.com/role/CommonStockCommonStockDetails">
        <link:definition>0000039 - Disclosure - Common Stock - Common Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommonStockPreferredStockDetails" roleURI="http://vitaltherapies.com/role/CommonStockPreferredStockDetails">
        <link:definition>0000040 - Disclosure - Common Stock - Preferred Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommonStockSharesReservedforFutureIssuanceDetails" roleURI="http://vitaltherapies.com/role/CommonStockSharesReservedforFutureIssuanceDetails">
        <link:definition>0000041 - Disclosure - Common Stock - Shares Reserved for Future Issuance (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationPlansAdditionalInformationDetails" roleURI="http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails">
        <link:definition>0000042 - Disclosure - Stock-Based Compensation Plans - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationPlansSummaryofStockOptionActivityDetails" roleURI="http://vitaltherapies.com/role/StockBasedCompensationPlansSummaryofStockOptionActivityDetails">
        <link:definition>0000043 - Disclosure - Stock-Based Compensation Plans - Summary of Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationPlansRangesofUnderlyingAssumptionsUsedinBSMOptionPricingModeltoDetermineFairValueofStockOptionsGrantedtoEmployeesandNonemployeesDetail" roleURI="http://vitaltherapies.com/role/StockBasedCompensationPlansRangesofUnderlyingAssumptionsUsedinBSMOptionPricingModeltoDetermineFairValueofStockOptionsGrantedtoEmployeesandNonemployeesDetail">
        <link:definition>0000044 - Disclosure - Stock-Based Compensation Plans - Ranges of Underlying Assumptions Used in BSM Option Pricing Model to Determine Fair Value of Stock Options Granted to Employees and Nonemployees (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationPlansScheduleofStockbasedCompensationExpenseforStockAwardsRecognizedDetails" roleURI="http://vitaltherapies.com/role/StockBasedCompensationPlansScheduleofStockbasedCompensationExpenseforStockAwardsRecognizedDetails">
        <link:definition>0000045 - Disclosure - Stock-Based Compensation Plans - Schedule of Stock-based Compensation Expense for Stock Awards Recognized (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ChangesinBoardofDirectorsDetails" roleURI="http://vitaltherapies.com/role/ChangesinBoardofDirectorsDetails">
        <link:definition>0000046 - Disclosure - Changes in Board of Directors (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactionsAdditionalInformationDetails" roleURI="http://vitaltherapies.com/role/RelatedPartyTransactionsAdditionalInformationDetails">
        <link:definition>0000047 - Disclosure - Related Party Transactions - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEventsDetails" roleURI="http://vitaltherapies.com/role/SubsequentEventsDetails">
        <link:definition>0000048 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="vtl_TwoThousandNineteenOmnibusEquityIncentivePlanMember" abstract="true" name="TwoThousandNineteenOmnibusEquityIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vtl_NonStatutoryEmployeeStockOptionMember" abstract="true" name="NonStatutoryEmployeeStockOptionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vtl_OperatingAndVariableLeasesCost" abstract="false" name="OperatingAndVariableLeasesCost" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vtl_December2020ATMMember" abstract="true" name="December2020ATMMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vtl_EmployeeMember" abstract="true" name="EmployeeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vtl_OperatingLeaseIncrementalBorrowingRate" abstract="false" name="OperatingLeaseIncrementalBorrowingRate" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="vtl_NewYorkCityMember" abstract="true" name="NewYorkCityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vtl_A4SCRoyaltySettlementMember" abstract="true" name="A4SCRoyaltySettlementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vtl_LegalAndAuditCostsPayableCurrent" abstract="false" name="LegalAndAuditCostsPayableCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vtl_May2022ATMMember" abstract="true" name="May2022ATMMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vtl_ImmunicAGMember" abstract="true" name="ImmunicAGMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vtl_OptionsVestingInOneYearMember" abstract="true" name="OptionsVestingInOneYearMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vtl_EquityMethodInvestmentWarrantsExercisableOwnershipLimitationPercentage" abstract="false" name="EquityMethodInvestmentWarrantsExercisableOwnershipLimitationPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="vtl_ShelfRegistrationTerminationPriorWrittenNotice" abstract="false" name="ShelfRegistrationTerminationPriorWrittenNotice" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="vtl_ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock" abstract="false" name="ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="vtl_RoyaltySettlementAgreementCashPaymentPercent" abstract="false" name="RoyaltySettlementAgreementCashPaymentPercent" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="vtl_ExecutiveChairmanAgreementMember" abstract="true" name="ExecutiveChairmanAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vtl_SaleOfStockRemainingCapacity" abstract="false" name="SaleOfStockRemainingCapacity" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vtl_A2021EmployeeStockPurchasePlanMember" abstract="true" name="A2021EmployeeStockPurchasePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vtl_NumberOfFinancialInstitutionsUsedForCashDeposits" abstract="false" name="NumberOfFinancialInstitutionsUsedForCashDeposits" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="vtl_EmployeeStockOptionsforFutureGrantMember" abstract="true" name="EmployeeStockOptionsforFutureGrantMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vtl_ResearchAndDevelopmentTaxIncentiveCurrent" abstract="false" name="ResearchAndDevelopmentTaxIncentiveCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vtl_AccruedLegalAndAuditCostsCurrent" abstract="false" name="AccruedLegalAndAuditCostsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vtl_GrafelfingGermanyMember" abstract="true" name="GrafelfingGermanyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vtl_PublicOfferingMember" abstract="true" name="PublicOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vtl_EquityMethodInvestmentWarrantsExercisableOwnershipLimitationMaximumIncreaseDecreasePercent" abstract="false" name="EquityMethodInvestmentWarrantsExercisableOwnershipLimitationMaximumIncreaseDecreasePercent" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="vtl_RoyaltySettlementAgreementSharesPaymentPercent" abstract="false" name="RoyaltySettlementAgreementSharesPaymentPercent" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="vtl_A2019OmnibusEquityIncentivePlanMember" abstract="true" name="A2019OmnibusEquityIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vtl_SharesIssuedWeightedAverageSharePricePerShare" abstract="false" name="SharesIssuedWeightedAverageSharePricePerShare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="vtl_EquityMethodInvestmentWarrantsExercisableSharesChangeLimitationNoticePeriod" abstract="false" name="EquityMethodInvestmentWarrantsExercisableSharesChangeLimitationNoticePeriod" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="vtl_ShelfRegistrationStatementAmountRemaining" abstract="false" name="ShelfRegistrationStatementAmountRemaining" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vtl_AccruedCompensationCurrent" abstract="false" name="AccruedCompensationCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vtl_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" abstract="false" name="IncreaseDecreaseInOperatingLeaseRightOfUseAsset" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vtl_ClinicalCostsPayableCurrent" abstract="false" name="ClinicalCostsPayableCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vtl_OptionsVestingInThreeYearsMember" abstract="true" name="OptionsVestingInThreeYearsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vtl_AccruedClinicalCostsCurrent" abstract="false" name="AccruedClinicalCostsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vtl_PrepaidClinicalAndRelatedCostsCurrent" abstract="false" name="PrepaidClinicalAndRelatedCostsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vtl_PreFundedWarrantsMember" abstract="true" name="PreFundedWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vtl_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" abstract="false" name="ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="vtl_NumberOfDevelopmentProgramsPursued" abstract="false" name="NumberOfDevelopmentProgramsPursued" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="vtl_IncentiveEmployeeStockOptionMember" abstract="true" name="IncentiveEmployeeStockOptionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vtl_MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration" abstract="false" name="MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vtl_ChangesInBoardOfDirectorsDisclosureTextBlock" abstract="false" name="ChangesInBoardOfDirectorsDisclosureTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="vtl_DuaneNashMDJDMBAMember" abstract="true" name="DuaneNashMDJDMBAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vtl_July2021PublicEquityOfferingMember" abstract="true" name="July2021PublicEquityOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vtl_RoyaltySettlementAgreementSalesNet" abstract="false" name="RoyaltySettlementAgreementSalesNet" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vtl_TwoThousandFourteenEquityIncentivePlanMember" abstract="true" name="TwoThousandFourteenEquityIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vtl_TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember" abstract="true" name="TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vtl_AssetPurchaseAgreementRoyaltiesAsPercentOfAggregatedNetSales" abstract="false" name="AssetPurchaseAgreementRoyaltiesAsPercentOfAggregatedNetSales" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="vtl_July2021EquityIssuanceMember" abstract="true" name="July2021EquityIssuanceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vtl_SalaryCostsMonthlyBaseSalary" abstract="false" name="SalaryCostsMonthlyBaseSalary" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vtl_LesseeOperatingLeasesNumberOfExistingLeases" abstract="false" name="LesseeOperatingLeasesNumberOfExistingLeases" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="vtl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="vtl_LesseeOperatingLeaseRentHolidayPeriod" abstract="false" name="LesseeOperatingLeaseRentHolidayPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="vtl_A2017InducementEquityIncentivePlanMember" abstract="true" name="A2017InducementEquityIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>vtl-20220930_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:6944770f-821d-45aa-b4f3-cccabd82d2f9,g:32d5dde5-0858-4183-b548-263732a64d33-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="vtl-20220930.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_4d57ca5e-d8c6-435c-a56d-b520d6b2ff9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_d997b9e1-c996-4fb7-84ad-95c3609fd6bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_4d57ca5e-d8c6-435c-a56d-b520d6b2ff9b" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_d997b9e1-c996-4fb7-84ad-95c3609fd6bf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_922ab463-e3c2-4d26-9f1d-d6cd9c725a87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_4d57ca5e-d8c6-435c-a56d-b520d6b2ff9b" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_922ab463-e3c2-4d26-9f1d-d6cd9c725a87" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_825d2fcd-45cb-49db-9ba4-b1ee39779635" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_4d57ca5e-d8c6-435c-a56d-b520d6b2ff9b" xlink:to="loc_us-gaap_AccountsPayableCurrent_825d2fcd-45cb-49db-9ba4-b1ee39779635" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_e09b6716-f898-4161-84be-85a509e5d246" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_52c88711-3ac0-4806-8bcd-4f258961505a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_e09b6716-f898-4161-84be-85a509e5d246" xlink:to="loc_us-gaap_AssetsCurrent_52c88711-3ac0-4806-8bcd-4f258961505a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_9470980b-27f3-45c9-8b40-a974d2be8a66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_e09b6716-f898-4161-84be-85a509e5d246" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_9470980b-27f3-45c9-8b40-a974d2be8a66" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_f6dc21e2-dbad-4773-b4e2-4b59ae96c796" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_e09b6716-f898-4161-84be-85a509e5d246" xlink:to="loc_us-gaap_Goodwill_f6dc21e2-dbad-4773-b4e2-4b59ae96c796" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_8cda2c1a-6d57-45a1-ae8c-428548e97870" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_e09b6716-f898-4161-84be-85a509e5d246" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_8cda2c1a-6d57-45a1-ae8c-428548e97870" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_b9391709-7365-48b3-97e2-09487bfbdc07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_e09b6716-f898-4161-84be-85a509e5d246" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_b9391709-7365-48b3-97e2-09487bfbdc07" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_b844fa74-efcd-4acd-8a86-0d0f1b4d2784" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_97fdc012-4ecc-4503-b6db-812a545e6df3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_b844fa74-efcd-4acd-8a86-0d0f1b4d2784" xlink:to="loc_us-gaap_StockholdersEquity_97fdc012-4ecc-4503-b6db-812a545e6df3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_fb396fbe-e4fe-4b73-bc31-e75320e904d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_b844fa74-efcd-4acd-8a86-0d0f1b4d2784" xlink:to="loc_us-gaap_Liabilities_fb396fbe-e4fe-4b73-bc31-e75320e904d2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_db343e25-b5d2-495d-b346-8e55b4262203" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_b844fa74-efcd-4acd-8a86-0d0f1b4d2784" xlink:to="loc_us-gaap_CommitmentsAndContingencies_db343e25-b5d2-495d-b346-8e55b4262203" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_5a1dc0b8-2a4d-4361-aed0-1ff8da21c7e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_6a20cf1f-b867-4df6-9633-f2ffd3f4680e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_5a1dc0b8-2a4d-4361-aed0-1ff8da21c7e2" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_6a20cf1f-b867-4df6-9633-f2ffd3f4680e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_20de52cc-ba98-438f-9741-c47aabe9104f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_9536ff34-369a-4074-ab1a-eb4958bc0a54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_20de52cc-ba98-438f-9741-c47aabe9104f" xlink:to="loc_us-gaap_PreferredStockValue_9536ff34-369a-4074-ab1a-eb4958bc0a54" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_05fee61b-b8a0-452e-84be-3d84f4436ee2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_20de52cc-ba98-438f-9741-c47aabe9104f" xlink:to="loc_us-gaap_CommonStockValue_05fee61b-b8a0-452e-84be-3d84f4436ee2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_10bfedda-2194-4eb8-8ffd-46265d045904" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_20de52cc-ba98-438f-9741-c47aabe9104f" xlink:to="loc_us-gaap_AdditionalPaidInCapital_10bfedda-2194-4eb8-8ffd-46265d045904" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_36d8e48c-074c-49fa-9e91-7ed04caf27b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_20de52cc-ba98-438f-9741-c47aabe9104f" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_36d8e48c-074c-49fa-9e91-7ed04caf27b9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_6723c740-4c39-4e8f-9411-be6b7017b953" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_20de52cc-ba98-438f-9741-c47aabe9104f" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_6723c740-4c39-4e8f-9411-be6b7017b953" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_a4d611c8-8b87-4e35-ae09-c231c0b2a389" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_bca1e3c5-e03e-4a5a-a498-ff8af7fb6f2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_a4d611c8-8b87-4e35-ae09-c231c0b2a389" xlink:to="loc_us-gaap_LiabilitiesCurrent_bca1e3c5-e03e-4a5a-a498-ff8af7fb6f2c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_62ece40b-f5a6-4578-b442-f9d7e6dc7ba1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_a4d611c8-8b87-4e35-ae09-c231c0b2a389" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_62ece40b-f5a6-4578-b442-f9d7e6dc7ba1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_66ce2d8a-2b75-4a29-ad3c-cc5df101c703" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_5731a5fa-6d4e-4005-ba42-9424b899708c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_66ce2d8a-2b75-4a29-ad3c-cc5df101c703" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_5731a5fa-6d4e-4005-ba42-9424b899708c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_b85bb34a-16f9-4f86-a901-4ae627606872" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_66ce2d8a-2b75-4a29-ad3c-cc5df101c703" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_b85bb34a-16f9-4f86-a901-4ae627606872" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="vtl-20220930.xsd#CondensedConsolidatedStatementsofOperations"/>
  <link:calculationLink xlink:role="http://vitaltherapies.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_e169a332-4c0f-4bee-9946-ee959ba41a2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_4b1c3088-36de-45bb-97e6-0b64fcaad380" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_e169a332-4c0f-4bee-9946-ee959ba41a2d" xlink:to="loc_us-gaap_OperatingIncomeLoss_4b1c3088-36de-45bb-97e6-0b64fcaad380" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_35f5507b-45d1-48a1-ad89-fa91b62a82b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_e169a332-4c0f-4bee-9946-ee959ba41a2d" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_35f5507b-45d1-48a1-ad89-fa91b62a82b1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_2add1b76-819c-43c8-b6a2-b736b14a82d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_49007cb5-7a75-4dde-b2ab-4309d493496a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_2add1b76-819c-43c8-b6a2-b736b14a82d7" xlink:to="loc_us-gaap_OperatingExpenses_49007cb5-7a75-4dde-b2ab-4309d493496a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_9c1736e3-e9a4-4e7d-97f0-c4dc31d6c703" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_df154741-7597-428a-94c9-82d9655f3ca6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_9c1736e3-e9a4-4e7d-97f0-c4dc31d6c703" xlink:to="loc_us-gaap_InvestmentIncomeInterest_df154741-7597-428a-94c9-82d9655f3ca6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_a296beec-4230-4d24-bd31-8f522e306279" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_9c1736e3-e9a4-4e7d-97f0-c4dc31d6c703" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_a296beec-4230-4d24-bd31-8f522e306279" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_b3719096-d36c-4d11-8112-1a66379fd47a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_8bf194d4-ce2d-4a4d-af6b-29a123db85f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_b3719096-d36c-4d11-8112-1a66379fd47a" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_8bf194d4-ce2d-4a4d-af6b-29a123db85f4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_f90b643f-ca16-42e5-86f0-b0cefce256b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_b3719096-d36c-4d11-8112-1a66379fd47a" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_f90b643f-ca16-42e5-86f0-b0cefce256b5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_RoyaltySettlementAgreementSalesNet_a84a1b71-e721-4ad0-bda4-ef7ebcc313e1" xlink:href="vtl-20220930.xsd#vtl_RoyaltySettlementAgreementSalesNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_b3719096-d36c-4d11-8112-1a66379fd47a" xlink:to="loc_vtl_RoyaltySettlementAgreementSalesNet_a84a1b71-e721-4ad0-bda4-ef7ebcc313e1" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" xlink:type="simple" xlink:href="vtl-20220930.xsd#CondensedConsolidatedStatementsofComprehensiveLoss"/>
  <link:calculationLink xlink:role="http://vitaltherapies.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_ec31e7c4-cc5b-4a9c-a08f-ce4ea7d31b09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_dbe162b9-9bed-4494-a7c3-16b2866a3738" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_ec31e7c4-cc5b-4a9c-a08f-ce4ea7d31b09" xlink:to="loc_us-gaap_NetIncomeLoss_dbe162b9-9bed-4494-a7c3-16b2866a3738" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_eccf21ea-e919-4f26-a595-67b2aff437e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_ec31e7c4-cc5b-4a9c-a08f-ce4ea7d31b09" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_eccf21ea-e919-4f26-a595-67b2aff437e5" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows" xlink:type="simple" xlink:href="vtl-20220930.xsd#CondensedConsolidatedStatementofCashFlows"/>
  <link:calculationLink xlink:role="http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0073dd52-0639-459e-8e4c-f930d8a0930f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_aa158b42-07c4-4b8a-8ba5-7ab1f5f34f66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0073dd52-0639-459e-8e4c-f930d8a0930f" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_aa158b42-07c4-4b8a-8ba5-7ab1f5f34f66" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_f9046524-78e1-4962-a1ea-5667ff490cfc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0073dd52-0639-459e-8e4c-f930d8a0930f" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_f9046524-78e1-4962-a1ea-5667ff490cfc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_22f04525-0a9a-49eb-9426-f8695bea82cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0073dd52-0639-459e-8e4c-f930d8a0930f" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_22f04525-0a9a-49eb-9426-f8695bea82cb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2bbe4791-e64d-465f-922c-6e2a6af62de6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f91c467d-1080-4a8a-aa4e-9176a9b79e9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2bbe4791-e64d-465f-922c-6e2a6af62de6" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f91c467d-1080-4a8a-aa4e-9176a9b79e9f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_d5c39c15-feb6-42d8-8486-d019e05bb549" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2bbe4791-e64d-465f-922c-6e2a6af62de6" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_d5c39c15-feb6-42d8-8486-d019e05bb549" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f7da3799-1188-4889-a26f-364938ac5810" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2bbe4791-e64d-465f-922c-6e2a6af62de6" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f7da3799-1188-4889-a26f-364938ac5810" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b7551f18-05ad-4534-b991-de3cb9c309b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2bbe4791-e64d-465f-922c-6e2a6af62de6" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b7551f18-05ad-4534-b991-de3cb9c309b8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_266b936f-ff60-4822-9e59-29d826910987" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_71908dd0-c787-4c1d-8b3a-2bf7dab5a41c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_266b936f-ff60-4822-9e59-29d826910987" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_71908dd0-c787-4c1d-8b3a-2bf7dab5a41c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d556622b-9560-474c-a929-4ca5c4892b48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_da020eb3-2180-4cb6-aea7-2ed6916f0be0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d556622b-9560-474c-a929-4ca5c4892b48" xlink:to="loc_us-gaap_NetIncomeLoss_da020eb3-2180-4cb6-aea7-2ed6916f0be0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_135c0e49-9125-4599-98af-18044a1a377e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d556622b-9560-474c-a929-4ca5c4892b48" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_135c0e49-9125-4599-98af-18044a1a377e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_fa1a0dcc-87de-41f3-afff-217659c0c179" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d556622b-9560-474c-a929-4ca5c4892b48" xlink:to="loc_us-gaap_ShareBasedCompensation_fa1a0dcc-87de-41f3-afff-217659c0c179" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_677d7baa-2b07-4633-bd14-ce020f410e96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d556622b-9560-474c-a929-4ca5c4892b48" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_677d7baa-2b07-4633-bd14-ce020f410e96" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_93739d81-d4b0-4ccc-b30a-dd40a03690ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d556622b-9560-474c-a929-4ca5c4892b48" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_93739d81-d4b0-4ccc-b30a-dd40a03690ef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_a819cd76-cd10-4725-bfc7-b05648d43b6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d556622b-9560-474c-a929-4ca5c4892b48" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_a819cd76-cd10-4725-bfc7-b05648d43b6c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_59f548a2-44a9-4348-b753-65657fb9fc18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d556622b-9560-474c-a929-4ca5c4892b48" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_59f548a2-44a9-4348-b753-65657fb9fc18" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_34435eb0-fbd6-4d77-aee7-cf5f45bcb719" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d556622b-9560-474c-a929-4ca5c4892b48" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_34435eb0-fbd6-4d77-aee7-cf5f45bcb719" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable_63bc1a12-22eb-407b-8702-77e1a16e1aa4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d556622b-9560-474c-a929-4ca5c4892b48" xlink:to="loc_us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable_63bc1a12-22eb-407b-8702-77e1a16e1aa4" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofOtherCurrentAssetsandPrepaidExpensesDetail" xlink:type="simple" xlink:href="vtl-20220930.xsd#BalanceSheetDetailsScheduleofOtherCurrentAssetsandPrepaidExpensesDetail"/>
  <link:calculationLink xlink:role="http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofOtherCurrentAssetsandPrepaidExpensesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_f5c1aa5a-715a-4f4a-a404-5f59051f392f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_PrepaidClinicalAndRelatedCostsCurrent_0cfc9268-f24e-4187-b84a-997398b86ca8" xlink:href="vtl-20220930.xsd#vtl_PrepaidClinicalAndRelatedCostsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_f5c1aa5a-715a-4f4a-a404-5f59051f392f" xlink:to="loc_vtl_PrepaidClinicalAndRelatedCostsCurrent_0cfc9268-f24e-4187-b84a-997398b86ca8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_ResearchAndDevelopmentTaxIncentiveCurrent_09c644fb-c291-4b19-8acd-ac62ff24ff44" xlink:href="vtl-20220930.xsd#vtl_ResearchAndDevelopmentTaxIncentiveCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_f5c1aa5a-715a-4f4a-a404-5f59051f392f" xlink:to="loc_vtl_ResearchAndDevelopmentTaxIncentiveCurrent_09c644fb-c291-4b19-8acd-ac62ff24ff44" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_af455941-59f1-4e62-8895-63641962c0c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_f5c1aa5a-715a-4f4a-a404-5f59051f392f" xlink:to="loc_us-gaap_OtherAssetsCurrent_af455941-59f1-4e62-8895-63641962c0c5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValueAddedTaxReceivableCurrent_72ec37b0-3540-41c0-ae41-0bc0f6a3a46f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValueAddedTaxReceivableCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_f5c1aa5a-715a-4f4a-a404-5f59051f392f" xlink:to="loc_us-gaap_ValueAddedTaxReceivableCurrent_72ec37b0-3540-41c0-ae41-0bc0f6a3a46f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofAccountsPayableDetail" xlink:type="simple" xlink:href="vtl-20220930.xsd#BalanceSheetDetailsScheduleofAccountsPayableDetail"/>
  <link:calculationLink xlink:role="http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofAccountsPayableDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_8dbd66a2-316b-4f07-a361-e887d0fceae2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_ClinicalCostsPayableCurrent_8e9451e9-4307-4ef1-9013-c74edc0eed9b" xlink:href="vtl-20220930.xsd#vtl_ClinicalCostsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableCurrent_8dbd66a2-316b-4f07-a361-e887d0fceae2" xlink:to="loc_vtl_ClinicalCostsPayableCurrent_8e9451e9-4307-4ef1-9013-c74edc0eed9b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_LegalAndAuditCostsPayableCurrent_72e5b4db-d41a-4652-abc6-9db8ffe0aed2" xlink:href="vtl-20220930.xsd#vtl_LegalAndAuditCostsPayableCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableCurrent_8dbd66a2-316b-4f07-a361-e887d0fceae2" xlink:to="loc_vtl_LegalAndAuditCostsPayableCurrent_72e5b4db-d41a-4652-abc6-9db8ffe0aed2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableOtherCurrent_14c54608-f9e3-4c6c-9646-7ef73714c8a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableOtherCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableCurrent_8dbd66a2-316b-4f07-a361-e887d0fceae2" xlink:to="loc_us-gaap_AccountsPayableOtherCurrent_14c54608-f9e3-4c6c-9646-7ef73714c8a1" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofAccruedExpensesDetail" xlink:type="simple" xlink:href="vtl-20220930.xsd#BalanceSheetDetailsScheduleofAccruedExpensesDetail"/>
  <link:calculationLink xlink:role="http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofAccruedExpensesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_2a3bf9fa-f17e-44d1-98a7-afe9943d521a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_459e7a09-f544-4ddf-a572-ba19397b28f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_2a3bf9fa-f17e-44d1-98a7-afe9943d521a" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_459e7a09-f544-4ddf-a572-ba19397b28f2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_AccruedClinicalCostsCurrent_dc1c23a2-1844-4998-886f-cc300f0a6191" xlink:href="vtl-20220930.xsd#vtl_AccruedClinicalCostsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_2a3bf9fa-f17e-44d1-98a7-afe9943d521a" xlink:to="loc_vtl_AccruedClinicalCostsCurrent_dc1c23a2-1844-4998-886f-cc300f0a6191" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_AccruedCompensationCurrent_7f2058ca-277f-401f-9be2-bebed4ec5023" xlink:href="vtl-20220930.xsd#vtl_AccruedCompensationCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_2a3bf9fa-f17e-44d1-98a7-afe9943d521a" xlink:to="loc_vtl_AccruedCompensationCurrent_7f2058ca-277f-401f-9be2-bebed4ec5023" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_AccruedLegalAndAuditCostsCurrent_67d6d10a-5d9b-4d0b-92ed-4a095ed272b0" xlink:href="vtl-20220930.xsd#vtl_AccruedLegalAndAuditCostsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_2a3bf9fa-f17e-44d1-98a7-afe9943d521a" xlink:to="loc_vtl_AccruedLegalAndAuditCostsCurrent_67d6d10a-5d9b-4d0b-92ed-4a095ed272b0" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofOtherCurrentLiabilitiesDetail" xlink:type="simple" xlink:href="vtl-20220930.xsd#BalanceSheetDetailsScheduleofOtherCurrentLiabilitiesDetail"/>
  <link:calculationLink xlink:role="http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofOtherCurrentLiabilitiesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_9a92c248-88b6-4e8b-9acf-c9018ba28e01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherSundryLiabilitiesCurrent_7585dd45-34e3-4ff4-a9d3-a13d04627356" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherSundryLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_9a92c248-88b6-4e8b-9acf-c9018ba28e01" xlink:to="loc_us-gaap_OtherSundryLiabilitiesCurrent_7585dd45-34e3-4ff4-a9d3-a13d04627356" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_e2bf934c-9a12-44a7-b700-3928a8414f69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_9a92c248-88b6-4e8b-9acf-c9018ba28e01" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_e2bf934c-9a12-44a7-b700-3928a8414f69" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseObligationDetails" xlink:type="simple" xlink:href="vtl-20220930.xsd#CommitmentsandContingenciesMaturitiesofOperatingLeaseObligationDetails"/>
  <link:calculationLink xlink:role="http://vitaltherapies.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseObligationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_3489ac5a-d52c-4b2e-bef6-b8fa3c2ae034" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_e13ab080-7280-4256-a66b-d4474e8b40f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_3489ac5a-d52c-4b2e-bef6-b8fa3c2ae034" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_e13ab080-7280-4256-a66b-d4474e8b40f3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_ee46aa57-0aa6-4084-9b6e-1402e583c674" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_3489ac5a-d52c-4b2e-bef6-b8fa3c2ae034" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_ee46aa57-0aa6-4084-9b6e-1402e583c674" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_b5a0f69a-1aec-4084-a3cd-d6ac65ebc070" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_3489ac5a-d52c-4b2e-bef6-b8fa3c2ae034" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_b5a0f69a-1aec-4084-a3cd-d6ac65ebc070" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_9f51bfd3-941d-4033-9776-de4698e95432" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_3489ac5a-d52c-4b2e-bef6-b8fa3c2ae034" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_9f51bfd3-941d-4033-9776-de4698e95432" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_27227db1-1b36-4f04-a804-720d429ebf45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_3489ac5a-d52c-4b2e-bef6-b8fa3c2ae034" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_27227db1-1b36-4f04-a804-720d429ebf45" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseObligationDetails_1" xlink:type="simple" xlink:href="vtl-20220930.xsd#CommitmentsandContingenciesMaturitiesofOperatingLeaseObligationDetails_1"/>
  <link:calculationLink xlink:role="http://vitaltherapies.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseObligationDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_814b466a-2605-4dd8-b3de-14ff94bcbb84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_7d41254d-0ca3-4397-a8c5-9b81d3926fff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_814b466a-2605-4dd8-b3de-14ff94bcbb84" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_7d41254d-0ca3-4397-a8c5-9b81d3926fff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_13c7ed0d-bcdb-46e9-967d-7adad6a456ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_814b466a-2605-4dd8-b3de-14ff94bcbb84" xlink:to="loc_us-gaap_OperatingLeaseLiability_13c7ed0d-bcdb-46e9-967d-7adad6a456ec" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>vtl-20220930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:6944770f-821d-45aa-b4f3-cccabd82d2f9,g:32d5dde5-0858-4183-b548-263732a64d33-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="vtl-20220930.xsd#CondensedConsolidatedStatementsofStockholdersEquity"/>
  <link:definitionLink xlink:role="http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="extended" id="ic40573fc2d484abb9b3aa3139b990b43_CondensedConsolidatedStatementsofStockholdersEquity">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_27fbe2c9-2309-452e-9e19-8d5df08c2e09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_138db75b-e44e-4d99-8ee5-2164d014de6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_27fbe2c9-2309-452e-9e19-8d5df08c2e09" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_138db75b-e44e-4d99-8ee5-2164d014de6a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_b8b89597-1dec-4680-8c8f-57c1f84a5c32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_138db75b-e44e-4d99-8ee5-2164d014de6a" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_b8b89597-1dec-4680-8c8f-57c1f84a5c32" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_53bbaaf4-e8a8-4c37-b68d-bae2f79a230f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_138db75b-e44e-4d99-8ee5-2164d014de6a" xlink:to="loc_us-gaap_StockholdersEquity_53bbaaf4-e8a8-4c37-b68d-bae2f79a230f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_76d4e4c8-fc81-4e42-98d8-2aa193079fd4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_138db75b-e44e-4d99-8ee5-2164d014de6a" xlink:to="loc_us-gaap_NetIncomeLoss_76d4e4c8-fc81-4e42-98d8-2aa193079fd4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_04ffaa51-4237-4509-af74-46edefd3f5e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_138db75b-e44e-4d99-8ee5-2164d014de6a" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_04ffaa51-4237-4509-af74-46edefd3f5e7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_9b81e43f-da37-4e5e-a6c4-86f8db17a988" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_138db75b-e44e-4d99-8ee5-2164d014de6a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_9b81e43f-da37-4e5e-a6c4-86f8db17a988" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_840e5d20-3ee8-4e27-aee1-40e4a9cb5ce4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_138db75b-e44e-4d99-8ee5-2164d014de6a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_840e5d20-3ee8-4e27-aee1-40e4a9cb5ce4" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_fab2b90b-7178-4ca4-9306-e1d355a5c456" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_138db75b-e44e-4d99-8ee5-2164d014de6a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_fab2b90b-7178-4ca4-9306-e1d355a5c456" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_c3acab66-1e52-41ee-a259-e6929b3482d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_2ddbee1a-6c76-48f1-94c8-bd0efdd54e15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_3891ae63-ef74-4f72-974e-a9f018df9416" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_27fbe2c9-2309-452e-9e19-8d5df08c2e09" xlink:to="loc_us-gaap_StatementTable_3891ae63-ef74-4f72-974e-a9f018df9416" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_61bde220-f226-45f7-8bb4-9aa6e4379ea3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_3891ae63-ef74-4f72-974e-a9f018df9416" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_61bde220-f226-45f7-8bb4-9aa6e4379ea3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_61bde220-f226-45f7-8bb4-9aa6e4379ea3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_61bde220-f226-45f7-8bb4-9aa6e4379ea3" xlink:to="loc_us-gaap_EquityComponentDomain_61bde220-f226-45f7-8bb4-9aa6e4379ea3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_6c1d12b3-4443-43ea-8964-e3d5a7495600" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_61bde220-f226-45f7-8bb4-9aa6e4379ea3" xlink:to="loc_us-gaap_EquityComponentDomain_6c1d12b3-4443-43ea-8964-e3d5a7495600" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_47fb7847-43f6-47c6-bfd6-fda2640dcf9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_6c1d12b3-4443-43ea-8964-e3d5a7495600" xlink:to="loc_us-gaap_CommonStockMember_47fb7847-43f6-47c6-bfd6-fda2640dcf9d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_91c0ccda-2dde-4a47-bdb3-7370de07b82e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_6c1d12b3-4443-43ea-8964-e3d5a7495600" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_91c0ccda-2dde-4a47-bdb3-7370de07b82e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_5d728ff8-ae25-4be4-a00b-2332ef496dc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_6c1d12b3-4443-43ea-8964-e3d5a7495600" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_5d728ff8-ae25-4be4-a00b-2332ef496dc3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_21a8e13b-fa33-4dcc-b5c4-c3dce9ad3926" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_6c1d12b3-4443-43ea-8964-e3d5a7495600" xlink:to="loc_us-gaap_RetainedEarningsMember_21a8e13b-fa33-4dcc-b5c4-c3dce9ad3926" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_6790a79c-dda7-4006-939b-817fb794672f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_3891ae63-ef74-4f72-974e-a9f018df9416" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_6790a79c-dda7-4006-939b-817fb794672f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6790a79c-dda7-4006-939b-817fb794672f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_6790a79c-dda7-4006-939b-817fb794672f" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6790a79c-dda7-4006-939b-817fb794672f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_d8469378-dbe4-42ec-8a9a-f4333e9e8d1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_6790a79c-dda7-4006-939b-817fb794672f" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_d8469378-dbe4-42ec-8a9a-f4333e9e8d1d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_July2021EquityIssuanceMember_19e48fdc-b36f-4ba9-b473-8c5bd653603c" xlink:href="vtl-20220930.xsd#vtl_July2021EquityIssuanceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_d8469378-dbe4-42ec-8a9a-f4333e9e8d1d" xlink:to="loc_vtl_July2021EquityIssuanceMember_19e48fdc-b36f-4ba9-b473-8c5bd653603c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_PublicOfferingMember_69aa8af5-bfd9-491f-a318-dc4138928740" xlink:href="vtl-20220930.xsd#vtl_PublicOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_d8469378-dbe4-42ec-8a9a-f4333e9e8d1d" xlink:to="loc_vtl_PublicOfferingMember_69aa8af5-bfd9-491f-a318-dc4138928740" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_A4SCRoyaltySettlementMember_54400adf-696b-46c4-b36b-d2363e91d02c" xlink:href="vtl-20220930.xsd#vtl_A4SCRoyaltySettlementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_d8469378-dbe4-42ec-8a9a-f4333e9e8d1d" xlink:to="loc_vtl_A4SCRoyaltySettlementMember_54400adf-696b-46c4-b36b-d2363e91d02c" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical" xlink:type="simple" xlink:href="vtl-20220930.xsd#CondensedConsolidatedStatementsofStockholdersEquityParenthetical"/>
  <link:definitionLink xlink:role="http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical" xlink:type="extended" id="i30bca150d46548c9b5737a05992c7bfa_CondensedConsolidatedStatementsofStockholdersEquityParenthetical">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_3d4e0408-32f8-4ce0-a29d-a7b07d3d4678" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_ee7262c8-93fe-4f13-b376-d0f0e9f933eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3d4e0408-32f8-4ce0-a29d-a7b07d3d4678" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_ee7262c8-93fe-4f13-b376-d0f0e9f933eb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_fad29f13-6241-40a2-a8ec-145f096d3782" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_3d4e0408-32f8-4ce0-a29d-a7b07d3d4678" xlink:to="loc_us-gaap_StatementTable_fad29f13-6241-40a2-a8ec-145f096d3782" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_1a5ef7df-e5a5-4a9f-9c9d-f48da5094ca6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_fad29f13-6241-40a2-a8ec-145f096d3782" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_1a5ef7df-e5a5-4a9f-9c9d-f48da5094ca6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1a5ef7df-e5a5-4a9f-9c9d-f48da5094ca6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_1a5ef7df-e5a5-4a9f-9c9d-f48da5094ca6" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1a5ef7df-e5a5-4a9f-9c9d-f48da5094ca6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_17ee7b72-aff2-4d26-a22b-c2527d102601" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_1a5ef7df-e5a5-4a9f-9c9d-f48da5094ca6" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_17ee7b72-aff2-4d26-a22b-c2527d102601" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_July2021EquityIssuanceMember_7d5e7966-83a9-4593-8d1c-557923c5e52c" xlink:href="vtl-20220930.xsd#vtl_July2021EquityIssuanceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_17ee7b72-aff2-4d26-a22b-c2527d102601" xlink:to="loc_vtl_July2021EquityIssuanceMember_7d5e7966-83a9-4593-8d1c-557923c5e52c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows" xlink:type="simple" xlink:href="vtl-20220930.xsd#CondensedConsolidatedStatementofCashFlows"/>
  <link:definitionLink xlink:role="http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows" xlink:type="extended" id="i4763f41a4c284856a153902563945c3e_CondensedConsolidatedStatementofCashFlows">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_63ba5bd2-f474-4c70-a69d-c87a2a2338cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_b76bcc1c-8a7b-41aa-a910-dbb19cf031e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_63ba5bd2-f474-4c70-a69d-c87a2a2338cb" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_b76bcc1c-8a7b-41aa-a910-dbb19cf031e8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_02c2239c-053f-421b-9cfe-99676aba80a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_b76bcc1c-8a7b-41aa-a910-dbb19cf031e8" xlink:to="loc_us-gaap_NetIncomeLoss_02c2239c-053f-421b-9cfe-99676aba80a7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_76dace63-4b7a-4c1a-81fc-17cf5b9617a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_b76bcc1c-8a7b-41aa-a910-dbb19cf031e8" xlink:to="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_76dace63-4b7a-4c1a-81fc-17cf5b9617a1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_afdec29e-bd56-4439-a652-89398fdaf842" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_76dace63-4b7a-4c1a-81fc-17cf5b9617a1" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_afdec29e-bd56-4439-a652-89398fdaf842" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_58e94a47-28cf-4676-983a-b482df651fc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_76dace63-4b7a-4c1a-81fc-17cf5b9617a1" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_58e94a47-28cf-4676-983a-b482df651fc3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_7afc7276-7c5d-4002-9658-c7d311fd936e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_76dace63-4b7a-4c1a-81fc-17cf5b9617a1" xlink:to="loc_us-gaap_ShareBasedCompensation_7afc7276-7c5d-4002-9658-c7d311fd936e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable_dce51a74-1467-42b8-b034-002490763b5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_76dace63-4b7a-4c1a-81fc-17cf5b9617a1" xlink:to="loc_us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable_dce51a74-1467-42b8-b034-002490763b5b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e962d934-30b6-46bd-9b42-4d746f546363" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_76dace63-4b7a-4c1a-81fc-17cf5b9617a1" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e962d934-30b6-46bd-9b42-4d746f546363" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_0e8cf0b6-f071-4c03-bd90-09d050658f5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e962d934-30b6-46bd-9b42-4d746f546363" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_0e8cf0b6-f071-4c03-bd90-09d050658f5b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_9de314bc-c7b4-49c3-8bd5-ab3e2b85e506" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e962d934-30b6-46bd-9b42-4d746f546363" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_9de314bc-c7b4-49c3-8bd5-ab3e2b85e506" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_79b9bfaa-303e-4ff3-ad42-f2ba07fc7256" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e962d934-30b6-46bd-9b42-4d746f546363" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_79b9bfaa-303e-4ff3-ad42-f2ba07fc7256" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_83d98658-f4bb-4392-aa07-362bfcc0754a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e962d934-30b6-46bd-9b42-4d746f546363" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_83d98658-f4bb-4392-aa07-362bfcc0754a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6a70c907-939f-41bc-865a-03a77135f457" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_b76bcc1c-8a7b-41aa-a910-dbb19cf031e8" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6a70c907-939f-41bc-865a-03a77135f457" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_bc4c8b7c-6818-41b8-a539-3fa98348e063" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_63ba5bd2-f474-4c70-a69d-c87a2a2338cb" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_bc4c8b7c-6818-41b8-a539-3fa98348e063" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_37fa978d-6d33-46ae-a21e-8b9f40cf8c3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_bc4c8b7c-6818-41b8-a539-3fa98348e063" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_37fa978d-6d33-46ae-a21e-8b9f40cf8c3b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_35754527-7a18-4fc4-bcae-611709737195" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_bc4c8b7c-6818-41b8-a539-3fa98348e063" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_35754527-7a18-4fc4-bcae-611709737195" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_d052155f-a2e3-4ea7-81bf-52d53bb138f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_63ba5bd2-f474-4c70-a69d-c87a2a2338cb" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_d052155f-a2e3-4ea7-81bf-52d53bb138f3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_7d50a118-9f40-445c-ba25-089f7e51ecb7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_d052155f-a2e3-4ea7-81bf-52d53bb138f3" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_7d50a118-9f40-445c-ba25-089f7e51ecb7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_1dd769f2-5919-4cff-b410-1cc3ea9d5f4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_d052155f-a2e3-4ea7-81bf-52d53bb138f3" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_1dd769f2-5919-4cff-b410-1cc3ea9d5f4d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_bb3a096d-4199-4258-95f9-34f3b4f3ec0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_d052155f-a2e3-4ea7-81bf-52d53bb138f3" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_bb3a096d-4199-4258-95f9-34f3b4f3ec0a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0ff6efae-4543-4aeb-b0f5-e6eece801dd5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_d052155f-a2e3-4ea7-81bf-52d53bb138f3" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0ff6efae-4543-4aeb-b0f5-e6eece801dd5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e276b428-3157-415d-b2c7-7a678a13cbe6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_63ba5bd2-f474-4c70-a69d-c87a2a2338cb" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e276b428-3157-415d-b2c7-7a678a13cbe6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_be854b25-5b21-4254-8d2a-18e62b548437" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_63ba5bd2-f474-4c70-a69d-c87a2a2338cb" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_be854b25-5b21-4254-8d2a-18e62b548437" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_31723d7e-03a5-4c71-a5ff-b7755e41592f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_63ba5bd2-f474-4c70-a69d-c87a2a2338cb" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_31723d7e-03a5-4c71-a5ff-b7755e41592f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7e3f8578-3287-4fb0-9858-1b1efaf23ec6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_54e571f9-1aa1-49dc-98fc-f2ebf8e8882a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_63ba5bd2-f474-4c70-a69d-c87a2a2338cb" xlink:to="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_54e571f9-1aa1-49dc-98fc-f2ebf8e8882a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssued1_9b495f4c-f117-4f6c-96df-a1eeaa6e3ad0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssued1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_54e571f9-1aa1-49dc-98fc-f2ebf8e8882a" xlink:to="loc_us-gaap_StockIssued1_9b495f4c-f117-4f6c-96df-a1eeaa6e3ad0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_456a1994-39de-4255-8163-e412c54f175b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_54e571f9-1aa1-49dc-98fc-f2ebf8e8882a" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_456a1994-39de-4255-8163-e412c54f175b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_6796862d-0d95-4e07-8583-5ffc21b1e8c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_63ba5bd2-f474-4c70-a69d-c87a2a2338cb" xlink:to="loc_us-gaap_StatementTable_6796862d-0d95-4e07-8583-5ffc21b1e8c7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_b3796f95-5f9b-4b74-a3cb-c87753354b44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_6796862d-0d95-4e07-8583-5ffc21b1e8c7" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_b3796f95-5f9b-4b74-a3cb-c87753354b44" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b3796f95-5f9b-4b74-a3cb-c87753354b44_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_b3796f95-5f9b-4b74-a3cb-c87753354b44" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b3796f95-5f9b-4b74-a3cb-c87753354b44_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_16d44736-bffc-43fe-8695-701cad2bb878" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_b3796f95-5f9b-4b74-a3cb-c87753354b44" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_16d44736-bffc-43fe-8695-701cad2bb878" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_PublicOfferingMember_78e270a6-956c-4c6e-8734-9b0aa06f9119" xlink:href="vtl-20220930.xsd#vtl_PublicOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_16d44736-bffc-43fe-8695-701cad2bb878" xlink:to="loc_vtl_PublicOfferingMember_78e270a6-956c-4c6e-8734-9b0aa06f9119" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_July2021PublicEquityOfferingMember_9b400d76-f6aa-4396-8f35-56ae54982150" xlink:href="vtl-20220930.xsd#vtl_July2021PublicEquityOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_16d44736-bffc-43fe-8695-701cad2bb878" xlink:to="loc_vtl_July2021PublicEquityOfferingMember_9b400d76-f6aa-4396-8f35-56ae54982150" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/CondensedConsolidatedStatementsofCashFlowsParenthetical" xlink:type="simple" xlink:href="vtl-20220930.xsd#CondensedConsolidatedStatementsofCashFlowsParenthetical"/>
  <link:definitionLink xlink:role="http://vitaltherapies.com/role/CondensedConsolidatedStatementsofCashFlowsParenthetical" xlink:type="extended" id="i96d46e239c78487b958bfccc1238d712_CondensedConsolidatedStatementsofCashFlowsParenthetical">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_6a3fed6c-5bee-4495-84ed-84829f00eb7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_730945c2-ff47-43aa-b163-cacbe85cfb59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6a3fed6c-5bee-4495-84ed-84829f00eb7a" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_730945c2-ff47-43aa-b163-cacbe85cfb59" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_9323e930-d25d-4b4c-8b5c-fa3549a1eb88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_6a3fed6c-5bee-4495-84ed-84829f00eb7a" xlink:to="loc_us-gaap_StatementTable_9323e930-d25d-4b4c-8b5c-fa3549a1eb88" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_3cf58627-9310-43e1-95f5-a92ad42d22ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_9323e930-d25d-4b4c-8b5c-fa3549a1eb88" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_3cf58627-9310-43e1-95f5-a92ad42d22ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3cf58627-9310-43e1-95f5-a92ad42d22ee_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_3cf58627-9310-43e1-95f5-a92ad42d22ee" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3cf58627-9310-43e1-95f5-a92ad42d22ee_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_8fc64d8f-6f4f-4728-bdab-2ce3184a1b54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_3cf58627-9310-43e1-95f5-a92ad42d22ee" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_8fc64d8f-6f4f-4728-bdab-2ce3184a1b54" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_PublicOfferingMember_3b058a06-8981-4047-a46b-4734453d45b2" xlink:href="vtl-20220930.xsd#vtl_PublicOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_8fc64d8f-6f4f-4728-bdab-2ce3184a1b54" xlink:to="loc_vtl_PublicOfferingMember_3b058a06-8981-4047-a46b-4734453d45b2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_July2021PublicEquityOfferingMember_d5423d0e-8c82-4b52-852d-c9bf8a9b6453" xlink:href="vtl-20220930.xsd#vtl_July2021PublicEquityOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_8fc64d8f-6f4f-4728-bdab-2ce3184a1b54" xlink:to="loc_vtl_July2021PublicEquityOfferingMember_d5423d0e-8c82-4b52-852d-c9bf8a9b6453" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/DescriptionofBusinessandBasisofFinancialStatementsDetails" xlink:type="simple" xlink:href="vtl-20220930.xsd#DescriptionofBusinessandBasisofFinancialStatementsDetails"/>
  <link:definitionLink xlink:role="http://vitaltherapies.com/role/DescriptionofBusinessandBasisofFinancialStatementsDetails" xlink:type="extended" id="i5a783544facd413aaf2b202f147e10a1_DescriptionofBusinessandBasisofFinancialStatementsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0fc5347d-40f6-4f2f-85ac-1f852079c331" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityNumberOfEmployees_82ddba59-66ad-4098-875f-e9789d8a7970" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityNumberOfEmployees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0fc5347d-40f6-4f2f-85ac-1f852079c331" xlink:to="loc_dei_EntityNumberOfEmployees_82ddba59-66ad-4098-875f-e9789d8a7970" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_NumberOfDevelopmentProgramsPursued_d7ab5664-b887-403e-b61f-a9c200687bcd" xlink:href="vtl-20220930.xsd#vtl_NumberOfDevelopmentProgramsPursued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0fc5347d-40f6-4f2f-85ac-1f852079c331" xlink:to="loc_vtl_NumberOfDevelopmentProgramsPursued_d7ab5664-b887-403e-b61f-a9c200687bcd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_275349f0-8fbc-40c0-a3ef-08a8d847d642" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0fc5347d-40f6-4f2f-85ac-1f852079c331" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_275349f0-8fbc-40c0-a3ef-08a8d847d642" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_20371703-549a-4428-a90a-8d24d5d24566" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0fc5347d-40f6-4f2f-85ac-1f852079c331" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_20371703-549a-4428-a90a-8d24d5d24566" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_cef02813-de69-4177-b329-c213453debd3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0fc5347d-40f6-4f2f-85ac-1f852079c331" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_cef02813-de69-4177-b329-c213453debd3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndFederalFundsSold_9abfef9c-1513-4729-90f0-0e5a068a4743" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndFederalFundsSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0fc5347d-40f6-4f2f-85ac-1f852079c331" xlink:to="loc_us-gaap_CashCashEquivalentsAndFederalFundsSold_9abfef9c-1513-4729-90f0-0e5a068a4743" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f6a700e3-03b9-41d0-b329-f34313b7f118" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0fc5347d-40f6-4f2f-85ac-1f852079c331" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f6a700e3-03b9-41d0-b329-f34313b7f118" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_0648ef1f-5cd3-46f6-a0a7-7865fdbf88e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f6a700e3-03b9-41d0-b329-f34313b7f118" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_0648ef1f-5cd3-46f6-a0a7-7865fdbf88e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_0648ef1f-5cd3-46f6-a0a7-7865fdbf88e6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_0648ef1f-5cd3-46f6-a0a7-7865fdbf88e6" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_0648ef1f-5cd3-46f6-a0a7-7865fdbf88e6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_657548df-a348-4319-8914-d6bb4662e8fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_0648ef1f-5cd3-46f6-a0a7-7865fdbf88e6" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_657548df-a348-4319-8914-d6bb4662e8fc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_64de0545-893f-498a-8072-377d34242314" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_657548df-a348-4319-8914-d6bb4662e8fc" xlink:to="loc_us-gaap_SubsequentEventMember_64de0545-893f-498a-8072-377d34242314" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple" xlink:href="vtl-20220930.xsd#SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="extended" id="ib8e4ed47992747b0934c362b43e909b7_SummaryofSignificantAccountingPoliciesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8d15936f-ce02-4d41-bde2-211dfd1e0542" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_NumberOfFinancialInstitutionsUsedForCashDeposits_3e2f726a-b0ac-481d-9f88-29c52922825f" xlink:href="vtl-20220930.xsd#vtl_NumberOfFinancialInstitutionsUsedForCashDeposits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8d15936f-ce02-4d41-bde2-211dfd1e0542" xlink:to="loc_vtl_NumberOfFinancialInstitutionsUsedForCashDeposits_3e2f726a-b0ac-481d-9f88-29c52922825f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_bbda824d-c069-49eb-9b5c-cca2d1a7ecad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8d15936f-ce02-4d41-bde2-211dfd1e0542" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_bbda824d-c069-49eb-9b5c-cca2d1a7ecad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_7cf9a5b4-6ac2-4706-bb21-9a992e7120d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8d15936f-ce02-4d41-bde2-211dfd1e0542" xlink:to="loc_us-gaap_Depreciation_7cf9a5b4-6ac2-4706-bb21-9a992e7120d5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TangibleAssetImpairmentCharges_b2884204-849f-46f1-990e-912631e565ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TangibleAssetImpairmentCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8d15936f-ce02-4d41-bde2-211dfd1e0542" xlink:to="loc_us-gaap_TangibleAssetImpairmentCharges_b2884204-849f-46f1-990e-912631e565ce" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_9b964f18-c6fe-45e4-9ca3-5031afce2a76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8d15936f-ce02-4d41-bde2-211dfd1e0542" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_9b964f18-c6fe-45e4-9ca3-5031afce2a76" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_e9232f61-ff42-4be5-b74d-7712de5740d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8d15936f-ce02-4d41-bde2-211dfd1e0542" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_e9232f61-ff42-4be5-b74d-7712de5740d5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_2351c059-a44d-4c26-af63-a88fdbffd470" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8d15936f-ce02-4d41-bde2-211dfd1e0542" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_2351c059-a44d-4c26-af63-a88fdbffd470" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_LesseeOperatingLeasesNumberOfExistingLeases_b995ef02-e52e-4b22-a05a-859c7ad63d48" xlink:href="vtl-20220930.xsd#vtl_LesseeOperatingLeasesNumberOfExistingLeases"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8d15936f-ce02-4d41-bde2-211dfd1e0542" xlink:to="loc_vtl_LesseeOperatingLeasesNumberOfExistingLeases_b995ef02-e52e-4b22-a05a-859c7ad63d48" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_b80b147f-a66b-4f50-b6fb-e6dae99fa311" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8d15936f-ce02-4d41-bde2-211dfd1e0542" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_b80b147f-a66b-4f50-b6fb-e6dae99fa311" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_f15bfc38-7b24-491a-88f3-739b10b2ece2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_b80b147f-a66b-4f50-b6fb-e6dae99fa311" xlink:to="loc_srt_RangeAxis_f15bfc38-7b24-491a-88f3-739b10b2ece2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f15bfc38-7b24-491a-88f3-739b10b2ece2_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_f15bfc38-7b24-491a-88f3-739b10b2ece2" xlink:to="loc_srt_RangeMember_f15bfc38-7b24-491a-88f3-739b10b2ece2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_991a5395-2b76-4a0d-8e06-c723ff1efa95" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_f15bfc38-7b24-491a-88f3-739b10b2ece2" xlink:to="loc_srt_RangeMember_991a5395-2b76-4a0d-8e06-c723ff1efa95" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_b0d9ca1c-ece0-4786-8615-d4b735930c34" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_991a5395-2b76-4a0d-8e06-c723ff1efa95" xlink:to="loc_srt_MinimumMember_b0d9ca1c-ece0-4786-8615-d4b735930c34" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_f2b6e42e-d8ee-4cc4-895c-60d139a95ec1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_991a5395-2b76-4a0d-8e06-c723ff1efa95" xlink:to="loc_srt_MaximumMember_f2b6e42e-d8ee-4cc4-895c-60d139a95ec1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_25bb830c-d2c0-41d0-aa59-37b5d215157c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_b80b147f-a66b-4f50-b6fb-e6dae99fa311" xlink:to="loc_srt_StatementScenarioAxis_25bb830c-d2c0-41d0-aa59-37b5d215157c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_25bb830c-d2c0-41d0-aa59-37b5d215157c_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_25bb830c-d2c0-41d0-aa59-37b5d215157c" xlink:to="loc_srt_ScenarioUnspecifiedDomain_25bb830c-d2c0-41d0-aa59-37b5d215157c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_19513870-f172-4086-ad95-f851d62b1ffa" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_25bb830c-d2c0-41d0-aa59-37b5d215157c" xlink:to="loc_srt_ScenarioUnspecifiedDomain_19513870-f172-4086-ad95-f851d62b1ffa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_94ae0105-7a5a-49b2-a774-5b471727676e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_19513870-f172-4086-ad95-f851d62b1ffa" xlink:to="loc_srt_ScenarioForecastMember_94ae0105-7a5a-49b2-a774-5b471727676e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_7cf1c3c7-3563-479b-9c1a-79b19942d398" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_b80b147f-a66b-4f50-b6fb-e6dae99fa311" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_7cf1c3c7-3563-479b-9c1a-79b19942d398" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_7cf1c3c7-3563-479b-9c1a-79b19942d398_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_7cf1c3c7-3563-479b-9c1a-79b19942d398" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_7cf1c3c7-3563-479b-9c1a-79b19942d398_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_0dea17b5-9695-4e44-9d78-52b31e645f2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_7cf1c3c7-3563-479b-9c1a-79b19942d398" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_0dea17b5-9695-4e44-9d78-52b31e645f2c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_eff4a41c-777d-44c9-a58c-6ce39c6ad1b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_0dea17b5-9695-4e44-9d78-52b31e645f2c" xlink:to="loc_us-gaap_SubsequentEventMember_eff4a41c-777d-44c9-a58c-6ce39c6ad1b2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_c6df16f0-3346-4635-92d3-5ef888064195" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_b80b147f-a66b-4f50-b6fb-e6dae99fa311" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_c6df16f0-3346-4635-92d3-5ef888064195" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_c6df16f0-3346-4635-92d3-5ef888064195_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_c6df16f0-3346-4635-92d3-5ef888064195" xlink:to="loc_us-gaap_EquityComponentDomain_c6df16f0-3346-4635-92d3-5ef888064195_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_29687407-4ae4-4725-a824-cdae7a2c385e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_c6df16f0-3346-4635-92d3-5ef888064195" xlink:to="loc_us-gaap_EquityComponentDomain_29687407-4ae4-4725-a824-cdae7a2c385e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_bc330395-c2a4-4d51-8f12-3ecf549cdd95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_29687407-4ae4-4725-a824-cdae7a2c385e" xlink:to="loc_us-gaap_CommonStockMember_bc330395-c2a4-4d51-8f12-3ecf549cdd95" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofDilutedNetLossperShareDetails" xlink:type="simple" xlink:href="vtl-20220930.xsd#SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofDilutedNetLossperShareDetails"/>
  <link:definitionLink xlink:role="http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofDilutedNetLossperShareDetails" xlink:type="extended" id="iba1b859109c942a4bf60db8a8a34e94f_SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofDilutedNetLossperShareDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_edfb17e6-b202-43c9-a8a8-b6b357ed94d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_589e8491-d484-472b-926f-4df86fa0ab6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_edfb17e6-b202-43c9-a8a8-b6b357ed94d1" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_589e8491-d484-472b-926f-4df86fa0ab6a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_c6975bdd-0ecc-4aa2-8a28-f2058446ae29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_edfb17e6-b202-43c9-a8a8-b6b357ed94d1" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_c6975bdd-0ecc-4aa2-8a28-f2058446ae29" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_3d2c7230-09a8-4823-8fcb-5f63d6aa8685" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_c6975bdd-0ecc-4aa2-8a28-f2058446ae29" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_3d2c7230-09a8-4823-8fcb-5f63d6aa8685" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3d2c7230-09a8-4823-8fcb-5f63d6aa8685_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_3d2c7230-09a8-4823-8fcb-5f63d6aa8685" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3d2c7230-09a8-4823-8fcb-5f63d6aa8685_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_d3769e44-f549-47a8-8acb-30cc822ac4ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_3d2c7230-09a8-4823-8fcb-5f63d6aa8685" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_d3769e44-f549-47a8-8acb-30cc822ac4ff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOptionMember_420bcd39-c8c7-422c-9784-6b04fedccd32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_d3769e44-f549-47a8-8acb-30cc822ac4ff" xlink:to="loc_us-gaap_StockOptionMember_420bcd39-c8c7-422c-9784-6b04fedccd32" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetails" xlink:type="simple" xlink:href="vtl-20220930.xsd#CommitmentsandContingenciesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://vitaltherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetails" xlink:type="extended" id="idc46cf90ae3b4686af7617fa2dd6ac52_CommitmentsandContingenciesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_d7aa0f85-c8ce-4f3f-a419-89cfd4a8532e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_8041207e-8a45-4f8c-8e36-1914427282ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_d7aa0f85-c8ce-4f3f-a419-89cfd4a8532e" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_8041207e-8a45-4f8c-8e36-1914427282ac" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_LesseeOperatingLeaseRentHolidayPeriod_cbe9ff18-e052-4172-87ca-23ea248d8601" xlink:href="vtl-20220930.xsd#vtl_LesseeOperatingLeaseRentHolidayPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_d7aa0f85-c8ce-4f3f-a419-89cfd4a8532e" xlink:to="loc_vtl_LesseeOperatingLeaseRentHolidayPeriod_cbe9ff18-e052-4172-87ca-23ea248d8601" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_dbf6e87d-9efe-43f9-8e6f-4db792c0bcb3" xlink:href="vtl-20220930.xsd#vtl_IncreaseDecreaseInOperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_d7aa0f85-c8ce-4f3f-a419-89cfd4a8532e" xlink:to="loc_vtl_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_dbf6e87d-9efe-43f9-8e6f-4db792c0bcb3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_OperatingLeaseIncrementalBorrowingRate_f0020c49-93ab-4a1d-8809-8be8884cf48f" xlink:href="vtl-20220930.xsd#vtl_OperatingLeaseIncrementalBorrowingRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_d7aa0f85-c8ce-4f3f-a419-89cfd4a8532e" xlink:to="loc_vtl_OperatingLeaseIncrementalBorrowingRate_f0020c49-93ab-4a1d-8809-8be8884cf48f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_OperatingAndVariableLeasesCost_e33cc13f-9ef4-41a9-9421-0832d8c6d15f" xlink:href="vtl-20220930.xsd#vtl_OperatingAndVariableLeasesCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_d7aa0f85-c8ce-4f3f-a419-89cfd4a8532e" xlink:to="loc_vtl_OperatingAndVariableLeasesCost_e33cc13f-9ef4-41a9-9421-0832d8c6d15f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligation_dc10d81d-f7a9-4c3f-b27f-218e4c94ce93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractualObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_d7aa0f85-c8ce-4f3f-a419-89cfd4a8532e" xlink:to="loc_us-gaap_ContractualObligation_dc10d81d-f7a9-4c3f-b27f-218e4c94ce93" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_AssetPurchaseAgreementRoyaltiesAsPercentOfAggregatedNetSales_6fe5e6d8-f2a5-4c3d-a889-cbcea837032a" xlink:href="vtl-20220930.xsd#vtl_AssetPurchaseAgreementRoyaltiesAsPercentOfAggregatedNetSales"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_d7aa0f85-c8ce-4f3f-a419-89cfd4a8532e" xlink:to="loc_vtl_AssetPurchaseAgreementRoyaltiesAsPercentOfAggregatedNetSales_6fe5e6d8-f2a5-4c3d-a889-cbcea837032a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_0c045afb-6262-4be2-bf52-a1749f7d98a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_d7aa0f85-c8ce-4f3f-a419-89cfd4a8532e" xlink:to="loc_us-gaap_CommonStockSharesIssued_0c045afb-6262-4be2-bf52-a1749f7d98a9" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_d3569262-adb1-4c8a-9f28-6364656305b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_d7aa0f85-c8ce-4f3f-a419-89cfd4a8532e" xlink:to="loc_us-gaap_CommonStockValue_d3569262-adb1-4c8a-9f28-6364656305b6" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_RoyaltySettlementAgreementSalesNet_e8115416-44f0-4069-965b-5016bace6a3b" xlink:href="vtl-20220930.xsd#vtl_RoyaltySettlementAgreementSalesNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_d7aa0f85-c8ce-4f3f-a419-89cfd4a8532e" xlink:to="loc_vtl_RoyaltySettlementAgreementSalesNet_e8115416-44f0-4069-965b-5016bace6a3b" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_RoyaltySettlementAgreementCashPaymentPercent_17849a01-59f4-4b3d-b6b4-bce7376b7715" xlink:href="vtl-20220930.xsd#vtl_RoyaltySettlementAgreementCashPaymentPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_d7aa0f85-c8ce-4f3f-a419-89cfd4a8532e" xlink:to="loc_vtl_RoyaltySettlementAgreementCashPaymentPercent_17849a01-59f4-4b3d-b6b4-bce7376b7715" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_RoyaltySettlementAgreementSharesPaymentPercent_72725840-14b4-4982-9be7-1d10f2225d90" xlink:href="vtl-20220930.xsd#vtl_RoyaltySettlementAgreementSharesPaymentPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_d7aa0f85-c8ce-4f3f-a419-89cfd4a8532e" xlink:to="loc_vtl_RoyaltySettlementAgreementSharesPaymentPercent_72725840-14b4-4982-9be7-1d10f2225d90" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_fd117773-0318-4fb0-8720-1f1c2028a880" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_d7aa0f85-c8ce-4f3f-a419-89cfd4a8532e" xlink:to="loc_us-gaap_LossContingenciesTable_fd117773-0318-4fb0-8720-1f1c2028a880" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_999b2021-f1ee-4dad-a458-ad89d66d1e7e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_fd117773-0318-4fb0-8720-1f1c2028a880" xlink:to="loc_srt_StatementGeographicalAxis_999b2021-f1ee-4dad-a458-ad89d66d1e7e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_999b2021-f1ee-4dad-a458-ad89d66d1e7e_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_999b2021-f1ee-4dad-a458-ad89d66d1e7e" xlink:to="loc_srt_SegmentGeographicalDomain_999b2021-f1ee-4dad-a458-ad89d66d1e7e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_4c46d56e-5faa-4e61-bbc0-a342443e5c9f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_999b2021-f1ee-4dad-a458-ad89d66d1e7e" xlink:to="loc_srt_SegmentGeographicalDomain_4c46d56e-5faa-4e61-bbc0-a342443e5c9f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_GrafelfingGermanyMember_1375c6ab-4ba5-49ef-9a4f-634332bcedc8" xlink:href="vtl-20220930.xsd#vtl_GrafelfingGermanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_4c46d56e-5faa-4e61-bbc0-a342443e5c9f" xlink:to="loc_vtl_GrafelfingGermanyMember_1375c6ab-4ba5-49ef-9a4f-634332bcedc8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_NewYorkCityMember_d36bf83a-d3a7-49a9-93c5-f7ce60f2153b" xlink:href="vtl-20220930.xsd#vtl_NewYorkCityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_4c46d56e-5faa-4e61-bbc0-a342443e5c9f" xlink:to="loc_vtl_NewYorkCityMember_d36bf83a-d3a7-49a9-93c5-f7ce60f2153b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_5813f406-925f-4f34-a2ad-0fa63b0893a1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_fd117773-0318-4fb0-8720-1f1c2028a880" xlink:to="loc_dei_LegalEntityAxis_5813f406-925f-4f34-a2ad-0fa63b0893a1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_5813f406-925f-4f34-a2ad-0fa63b0893a1_default" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_5813f406-925f-4f34-a2ad-0fa63b0893a1" xlink:to="loc_dei_EntityDomain_5813f406-925f-4f34-a2ad-0fa63b0893a1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_a27db245-32bc-43e8-806d-72086c997e46" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_5813f406-925f-4f34-a2ad-0fa63b0893a1" xlink:to="loc_dei_EntityDomain_a27db245-32bc-43e8-806d-72086c997e46" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_ImmunicAGMember_68bf7c67-8241-4a2f-88d9-7ca42bb9d3af" xlink:href="vtl-20220930.xsd#vtl_ImmunicAGMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_a27db245-32bc-43e8-806d-72086c997e46" xlink:to="loc_vtl_ImmunicAGMember_68bf7c67-8241-4a2f-88d9-7ca42bb9d3af" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="simple" xlink:href="vtl-20220930.xsd#FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://vitaltherapies.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="extended" id="i2f85ab4d6c8b4b60a51416284af35325_FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d7d4cf3f-e3b5-4bce-9ae4-c34ec97ea9a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_8e1c8547-222c-4a07-a849-bda7f0d454ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d7d4cf3f-e3b5-4bce-9ae4-c34ec97ea9a0" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_8e1c8547-222c-4a07-a849-bda7f0d454ef" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_14506c12-f64b-466a-b03b-bd41a8780b6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_8e1c8547-222c-4a07-a849-bda7f0d454ef" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_14506c12-f64b-466a-b03b-bd41a8780b6f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_87e7c69e-c3ba-40b8-9ed1-ee33a0672377" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d7d4cf3f-e3b5-4bce-9ae4-c34ec97ea9a0" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_87e7c69e-c3ba-40b8-9ed1-ee33a0672377" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_bdfd29a1-3df8-450a-b717-733c45be5cdc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_87e7c69e-c3ba-40b8-9ed1-ee33a0672377" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_bdfd29a1-3df8-450a-b717-733c45be5cdc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_bdfd29a1-3df8-450a-b717-733c45be5cdc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_bdfd29a1-3df8-450a-b717-733c45be5cdc" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_bdfd29a1-3df8-450a-b717-733c45be5cdc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6d78c746-47af-43c8-9959-dcf70d371e4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_bdfd29a1-3df8-450a-b717-733c45be5cdc" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6d78c746-47af-43c8-9959-dcf70d371e4b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_301d9575-2c2b-4fd4-9063-8ee5f47e3c52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6d78c746-47af-43c8-9959-dcf70d371e4b" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_301d9575-2c2b-4fd4-9063-8ee5f47e3c52" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_2c9fba59-f57b-471a-ad97-b035374a719c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6d78c746-47af-43c8-9959-dcf70d371e4b" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_2c9fba59-f57b-471a-ad97-b035374a719c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_c092c798-f4a6-4713-840c-d38b64e8e660" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6d78c746-47af-43c8-9959-dcf70d371e4b" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_c092c798-f4a6-4713-840c-d38b64e8e660" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_6d15f2ec-2d82-42d4-bfb9-069acdd1d743" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_87e7c69e-c3ba-40b8-9ed1-ee33a0672377" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_6d15f2ec-2d82-42d4-bfb9-069acdd1d743" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_6d15f2ec-2d82-42d4-bfb9-069acdd1d743_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_6d15f2ec-2d82-42d4-bfb9-069acdd1d743" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_6d15f2ec-2d82-42d4-bfb9-069acdd1d743_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_eb7900c1-0404-4f64-b4de-0e79f850eb80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_6d15f2ec-2d82-42d4-bfb9-069acdd1d743" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_eb7900c1-0404-4f64-b4de-0e79f850eb80" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_13d3feb9-7487-4a1a-b116-c1515684ed28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_eb7900c1-0404-4f64-b4de-0e79f850eb80" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_13d3feb9-7487-4a1a-b116-c1515684ed28" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_074db084-087f-46ad-a76a-a91b7a182ce8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_87e7c69e-c3ba-40b8-9ed1-ee33a0672377" xlink:to="loc_us-gaap_InvestmentTypeAxis_074db084-087f-46ad-a76a-a91b7a182ce8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_074db084-087f-46ad-a76a-a91b7a182ce8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_074db084-087f-46ad-a76a-a91b7a182ce8" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_074db084-087f-46ad-a76a-a91b7a182ce8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_482abde2-3cca-4362-b69b-13bd2d46783d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_074db084-087f-46ad-a76a-a91b7a182ce8" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_482abde2-3cca-4362-b69b-13bd2d46783d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_e7883586-7b8f-4b6e-b047-65a0c45564e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_482abde2-3cca-4362-b69b-13bd2d46783d" xlink:to="loc_us-gaap_MoneyMarketFundsMember_e7883586-7b8f-4b6e-b047-65a0c45564e5" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/CommonStockShelfRegistrationStatementDetails" xlink:type="simple" xlink:href="vtl-20220930.xsd#CommonStockShelfRegistrationStatementDetails"/>
  <link:definitionLink xlink:role="http://vitaltherapies.com/role/CommonStockShelfRegistrationStatementDetails" xlink:type="extended" id="i144a17f5f65a4934adc06f8499fae4e6_CommonStockShelfRegistrationStatementDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_d8fa1011-87a3-4b4f-82e3-304de2c7d28d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration_2c17259e-600d-440b-b122-e6b48cb8cac9" xlink:href="vtl-20220930.xsd#vtl_MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_d8fa1011-87a3-4b4f-82e3-304de2c7d28d" xlink:to="loc_vtl_MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration_2c17259e-600d-440b-b122-e6b48cb8cac9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_ShelfRegistrationStatementAmountRemaining_ba071694-a1d9-49f5-bf22-3eef7ec18fb3" xlink:href="vtl-20220930.xsd#vtl_ShelfRegistrationStatementAmountRemaining"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_d8fa1011-87a3-4b4f-82e3-304de2c7d28d" xlink:to="loc_vtl_ShelfRegistrationStatementAmountRemaining_ba071694-a1d9-49f5-bf22-3eef7ec18fb3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_ShelfRegistrationTerminationPriorWrittenNotice_cba23eec-4c7a-4a7e-8eeb-731e58b8c64a" xlink:href="vtl-20220930.xsd#vtl_ShelfRegistrationTerminationPriorWrittenNotice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_d8fa1011-87a3-4b4f-82e3-304de2c7d28d" xlink:to="loc_vtl_ShelfRegistrationTerminationPriorWrittenNotice_cba23eec-4c7a-4a7e-8eeb-731e58b8c64a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_SaleOfStockRemainingCapacity_3c06e65c-2d8a-410f-b7d8-5a3dbe7bdef6" xlink:href="vtl-20220930.xsd#vtl_SaleOfStockRemainingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_d8fa1011-87a3-4b4f-82e3-304de2c7d28d" xlink:to="loc_vtl_SaleOfStockRemainingCapacity_3c06e65c-2d8a-410f-b7d8-5a3dbe7bdef6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock_26013bad-f80f-42f1-a3e1-adfdb00f938b" xlink:href="vtl-20220930.xsd#vtl_ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_d8fa1011-87a3-4b4f-82e3-304de2c7d28d" xlink:to="loc_vtl_ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock_26013bad-f80f-42f1-a3e1-adfdb00f938b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_842b2c16-9ad4-4e21-8984-dda5699a164d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_d8fa1011-87a3-4b4f-82e3-304de2c7d28d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_842b2c16-9ad4-4e21-8984-dda5699a164d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_64a36977-72b0-4578-afa9-9236bbd83535" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_d8fa1011-87a3-4b4f-82e3-304de2c7d28d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_64a36977-72b0-4578-afa9-9236bbd83535" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_SharesIssuedWeightedAverageSharePricePerShare_441b5966-243a-4444-a5b4-3ea561ab929c" xlink:href="vtl-20220930.xsd#vtl_SharesIssuedWeightedAverageSharePricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_d8fa1011-87a3-4b4f-82e3-304de2c7d28d" xlink:to="loc_vtl_SharesIssuedWeightedAverageSharePricePerShare_441b5966-243a-4444-a5b4-3ea561ab929c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_67e8ba4c-04d7-424d-ac97-cf3c1d46ee77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_d8fa1011-87a3-4b4f-82e3-304de2c7d28d" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_67e8ba4c-04d7-424d-ac97-cf3c1d46ee77" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForCommissions_5accbe10-d25a-43f7-b27f-115d7be5f3cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForCommissions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_d8fa1011-87a3-4b4f-82e3-304de2c7d28d" xlink:to="loc_us-gaap_PaymentsForCommissions_5accbe10-d25a-43f7-b27f-115d7be5f3cf" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_5421d380-2d75-4572-9b06-e5aae5fcd21d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_d8fa1011-87a3-4b4f-82e3-304de2c7d28d" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_5421d380-2d75-4572-9b06-e5aae5fcd21d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_e2d2e5b7-508e-40fc-bec5-2c8588d70709" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_5421d380-2d75-4572-9b06-e5aae5fcd21d" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_e2d2e5b7-508e-40fc-bec5-2c8588d70709" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e2d2e5b7-508e-40fc-bec5-2c8588d70709_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_e2d2e5b7-508e-40fc-bec5-2c8588d70709" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e2d2e5b7-508e-40fc-bec5-2c8588d70709_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_be57a5f3-1556-4799-8df1-438faa66d4e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_e2d2e5b7-508e-40fc-bec5-2c8588d70709" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_be57a5f3-1556-4799-8df1-438faa66d4e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_December2020ATMMember_f9fa7c93-390d-4092-aa97-a8b2a62e7e9b" xlink:href="vtl-20220930.xsd#vtl_December2020ATMMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_be57a5f3-1556-4799-8df1-438faa66d4e7" xlink:to="loc_vtl_December2020ATMMember_f9fa7c93-390d-4092-aa97-a8b2a62e7e9b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_May2022ATMMember_4c04c30a-0717-4f1f-a369-45c8a3b3ebb5" xlink:href="vtl-20220930.xsd#vtl_May2022ATMMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_be57a5f3-1556-4799-8df1-438faa66d4e7" xlink:to="loc_vtl_May2022ATMMember_4c04c30a-0717-4f1f-a369-45c8a3b3ebb5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_0ae1f745-0899-4e04-be78-8f207be3ff3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_5421d380-2d75-4572-9b06-e5aae5fcd21d" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_0ae1f745-0899-4e04-be78-8f207be3ff3a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_0ae1f745-0899-4e04-be78-8f207be3ff3a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_0ae1f745-0899-4e04-be78-8f207be3ff3a" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_0ae1f745-0899-4e04-be78-8f207be3ff3a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_2a1e7cc4-e84d-4061-b004-0a9ace0771e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_0ae1f745-0899-4e04-be78-8f207be3ff3a" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_2a1e7cc4-e84d-4061-b004-0a9ace0771e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_43e88b3e-1f1c-4358-aa5b-bc6510395df7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_2a1e7cc4-e84d-4061-b004-0a9ace0771e7" xlink:to="loc_us-gaap_SubsequentEventMember_43e88b3e-1f1c-4358-aa5b-bc6510395df7" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/CommonStockPublicEquityOfferingDetails" xlink:type="simple" xlink:href="vtl-20220930.xsd#CommonStockPublicEquityOfferingDetails"/>
  <link:definitionLink xlink:role="http://vitaltherapies.com/role/CommonStockPublicEquityOfferingDetails" xlink:type="extended" id="ia14d2221491f4afc9c528c9729a05448_CommonStockPublicEquityOfferingDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_cac7afe6-2d27-4865-b585-cab8237dcb9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_7f538c21-df83-4587-801d-224078a6c150" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_cac7afe6-2d27-4865-b585-cab8237dcb9b" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_7f538c21-df83-4587-801d-224078a6c150" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_16b5a72a-2f92-44de-8c63-627063ad3c5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_cac7afe6-2d27-4865-b585-cab8237dcb9b" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_16b5a72a-2f92-44de-8c63-627063ad3c5a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_68b6b9f3-cb39-4759-a788-7cb125bc70cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_cac7afe6-2d27-4865-b585-cab8237dcb9b" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_68b6b9f3-cb39-4759-a788-7cb125bc70cb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_1e0ddcc6-22fd-4c45-bdcb-ec30b2d60c26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_cac7afe6-2d27-4865-b585-cab8237dcb9b" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_1e0ddcc6-22fd-4c45-bdcb-ec30b2d60c26" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_022db10c-e334-4a3d-b8bf-c228b63ab3e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_cac7afe6-2d27-4865-b585-cab8237dcb9b" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_022db10c-e334-4a3d-b8bf-c228b63ab3e0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_44fe9393-da0d-42f5-a588-f7958e57d6d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_022db10c-e334-4a3d-b8bf-c228b63ab3e0" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_44fe9393-da0d-42f5-a588-f7958e57d6d6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_44fe9393-da0d-42f5-a588-f7958e57d6d6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_44fe9393-da0d-42f5-a588-f7958e57d6d6" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_44fe9393-da0d-42f5-a588-f7958e57d6d6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7c636a25-49bd-453e-89b4-f3cde0adc3c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_44fe9393-da0d-42f5-a588-f7958e57d6d6" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7c636a25-49bd-453e-89b4-f3cde0adc3c4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_July2021PublicEquityOfferingMember_b7c4cb27-2e4a-4571-9a8f-1ecac15eb8a7" xlink:href="vtl-20220930.xsd#vtl_July2021PublicEquityOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7c636a25-49bd-453e-89b4-f3cde0adc3c4" xlink:to="loc_vtl_July2021PublicEquityOfferingMember_b7c4cb27-2e4a-4571-9a8f-1ecac15eb8a7" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/CommonStockSharesReservedforFutureIssuanceDetails" xlink:type="simple" xlink:href="vtl-20220930.xsd#CommonStockSharesReservedforFutureIssuanceDetails"/>
  <link:definitionLink xlink:role="http://vitaltherapies.com/role/CommonStockSharesReservedforFutureIssuanceDetails" xlink:type="extended" id="i89b5f59974174a358e9ad62176be9b28_CommonStockSharesReservedforFutureIssuanceDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_6a1e6403-981c-4e14-8fb5-ae2de97dbe55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_2980434d-546a-49f1-bbd4-e32905265561" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_6a1e6403-981c-4e14-8fb5-ae2de97dbe55" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_2980434d-546a-49f1-bbd4-e32905265561" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_9cfd7155-9c30-4dae-9a97-b6990450cf0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_6a1e6403-981c-4e14-8fb5-ae2de97dbe55" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_9cfd7155-9c30-4dae-9a97-b6990450cf0b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_cdccf223-7a0e-47b0-9df4-8fdf50d3c325" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_9cfd7155-9c30-4dae-9a97-b6990450cf0b" xlink:to="loc_us-gaap_PlanNameAxis_cdccf223-7a0e-47b0-9df4-8fdf50d3c325" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_cdccf223-7a0e-47b0-9df4-8fdf50d3c325_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_cdccf223-7a0e-47b0-9df4-8fdf50d3c325" xlink:to="loc_us-gaap_PlanNameDomain_cdccf223-7a0e-47b0-9df4-8fdf50d3c325_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_9d0320cc-453d-4edf-aa1a-bbb79aad8acf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_cdccf223-7a0e-47b0-9df4-8fdf50d3c325" xlink:to="loc_us-gaap_PlanNameDomain_9d0320cc-453d-4edf-aa1a-bbb79aad8acf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_A2021EmployeeStockPurchasePlanMember_d2acb86b-088b-4181-91eb-304c566ec323" xlink:href="vtl-20220930.xsd#vtl_A2021EmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_9d0320cc-453d-4edf-aa1a-bbb79aad8acf" xlink:to="loc_vtl_A2021EmployeeStockPurchasePlanMember_d2acb86b-088b-4181-91eb-304c566ec323" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_TwoThousandFourteenEquityIncentivePlanMember_ea0b2718-d7f8-4917-823a-a519b8de6d9b" xlink:href="vtl-20220930.xsd#vtl_TwoThousandFourteenEquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_9d0320cc-453d-4edf-aa1a-bbb79aad8acf" xlink:to="loc_vtl_TwoThousandFourteenEquityIncentivePlanMember_ea0b2718-d7f8-4917-823a-a519b8de6d9b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_A2017InducementEquityIncentivePlanMember_3e515369-d82f-4aac-9cc6-a7764e0de3f8" xlink:href="vtl-20220930.xsd#vtl_A2017InducementEquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_9d0320cc-453d-4edf-aa1a-bbb79aad8acf" xlink:to="loc_vtl_A2017InducementEquityIncentivePlanMember_3e515369-d82f-4aac-9cc6-a7764e0de3f8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_TwoThousandNineteenOmnibusEquityIncentivePlanMember_725a7154-ccf3-4537-ab05-e864fb81e0a0" xlink:href="vtl-20220930.xsd#vtl_TwoThousandNineteenOmnibusEquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_9d0320cc-453d-4edf-aa1a-bbb79aad8acf" xlink:to="loc_vtl_TwoThousandNineteenOmnibusEquityIncentivePlanMember_725a7154-ccf3-4537-ab05-e864fb81e0a0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_80d12b1b-9d79-4047-9b6a-18c1b192858b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_9cfd7155-9c30-4dae-9a97-b6990450cf0b" xlink:to="loc_us-gaap_AwardTypeAxis_80d12b1b-9d79-4047-9b6a-18c1b192858b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_80d12b1b-9d79-4047-9b6a-18c1b192858b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_80d12b1b-9d79-4047-9b6a-18c1b192858b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_80d12b1b-9d79-4047-9b6a-18c1b192858b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8fca4ed4-444a-4030-9d7c-505cfb5fdb84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_80d12b1b-9d79-4047-9b6a-18c1b192858b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8fca4ed4-444a-4030-9d7c-505cfb5fdb84" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_0c48baa2-48a6-470b-9024-52bcac7d4ead" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8fca4ed4-444a-4030-9d7c-505cfb5fdb84" xlink:to="loc_us-gaap_EmployeeStockOptionMember_0c48baa2-48a6-470b-9024-52bcac7d4ead" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_EmployeeStockOptionsforFutureGrantMember_5ed0484b-cc09-43f0-a90f-91b0f85e3585" xlink:href="vtl-20220930.xsd#vtl_EmployeeStockOptionsforFutureGrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8fca4ed4-444a-4030-9d7c-505cfb5fdb84" xlink:to="loc_vtl_EmployeeStockOptionsforFutureGrantMember_5ed0484b-cc09-43f0-a90f-91b0f85e3585" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails" xlink:type="simple" xlink:href="vtl-20220930.xsd#StockBasedCompensationPlansAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails" xlink:type="extended" id="i516120e7e59b43f9ab704d4717794059_StockBasedCompensationPlansAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7eb24280-0f88-440a-af04-b6e9ec940a68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_28b53ddd-a273-4208-8fbd-eb6b493d5b31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7eb24280-0f88-440a-af04-b6e9ec940a68" xlink:to="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_28b53ddd-a273-4208-8fbd-eb6b493d5b31" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_6835b2ce-2a63-477e-810f-7ecd3c21e60e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7eb24280-0f88-440a-af04-b6e9ec940a68" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_6835b2ce-2a63-477e-810f-7ecd3c21e60e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_38479c84-36c7-4e3c-a998-8e8e88e6e9f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7eb24280-0f88-440a-af04-b6e9ec940a68" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_38479c84-36c7-4e3c-a998-8e8e88e6e9f2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1abdbb9b-2168-4d5c-97a9-c5a6f14d2247" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7eb24280-0f88-440a-af04-b6e9ec940a68" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1abdbb9b-2168-4d5c-97a9-c5a6f14d2247" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_e1dc7d1d-e840-4aa0-a882-97e60c48e0c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7eb24280-0f88-440a-af04-b6e9ec940a68" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_e1dc7d1d-e840-4aa0-a882-97e60c48e0c4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent_6afa14fe-88d5-4647-8021-51a4f6e8a478" xlink:href="vtl-20220930.xsd#vtl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7eb24280-0f88-440a-af04-b6e9ec940a68" xlink:to="loc_vtl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent_6afa14fe-88d5-4647-8021-51a4f6e8a478" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_b1fc988e-c529-477d-9ac3-2a881e31123a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7eb24280-0f88-440a-af04-b6e9ec940a68" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_b1fc988e-c529-477d-9ac3-2a881e31123a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_ef86d267-4862-4ff2-854c-ff73c85a3f76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7eb24280-0f88-440a-af04-b6e9ec940a68" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_ef86d267-4862-4ff2-854c-ff73c85a3f76" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_8b5f808b-d024-4040-9296-049e55d8923c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7eb24280-0f88-440a-af04-b6e9ec940a68" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_8b5f808b-d024-4040-9296-049e55d8923c" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_a77bdb59-893f-44a1-adb3-347063fb105c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7eb24280-0f88-440a-af04-b6e9ec940a68" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_a77bdb59-893f-44a1-adb3-347063fb105c" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_48e589be-b58a-449b-b190-2da42a66c864" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7eb24280-0f88-440a-af04-b6e9ec940a68" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_48e589be-b58a-449b-b190-2da42a66c864" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_792455e2-a245-4ad3-9dc4-1175ce1d6f3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7eb24280-0f88-440a-af04-b6e9ec940a68" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_792455e2-a245-4ad3-9dc4-1175ce1d6f3a" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_e9cc83c2-35e2-4ff9-bb33-bc85f98dd763" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7eb24280-0f88-440a-af04-b6e9ec940a68" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_e9cc83c2-35e2-4ff9-bb33-bc85f98dd763" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cb406110-47e4-468a-be11-cb6a62396af4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7eb24280-0f88-440a-af04-b6e9ec940a68" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cb406110-47e4-468a-be11-cb6a62396af4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_bb836131-1dd5-498a-874e-185f9a3982dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cb406110-47e4-468a-be11-cb6a62396af4" xlink:to="loc_us-gaap_PlanNameAxis_bb836131-1dd5-498a-874e-185f9a3982dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_bb836131-1dd5-498a-874e-185f9a3982dd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_bb836131-1dd5-498a-874e-185f9a3982dd" xlink:to="loc_us-gaap_PlanNameDomain_bb836131-1dd5-498a-874e-185f9a3982dd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_3e137722-5286-4369-8589-f302b8efad45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_bb836131-1dd5-498a-874e-185f9a3982dd" xlink:to="loc_us-gaap_PlanNameDomain_3e137722-5286-4369-8589-f302b8efad45" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_A2021EmployeeStockPurchasePlanMember_54969535-1d90-4dd1-89b1-183eea93e95e" xlink:href="vtl-20220930.xsd#vtl_A2021EmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_3e137722-5286-4369-8589-f302b8efad45" xlink:to="loc_vtl_A2021EmployeeStockPurchasePlanMember_54969535-1d90-4dd1-89b1-183eea93e95e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_A2019OmnibusEquityIncentivePlanMember_8281d0b9-0a35-48d7-a7e5-86170e4036e8" xlink:href="vtl-20220930.xsd#vtl_A2019OmnibusEquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_3e137722-5286-4369-8589-f302b8efad45" xlink:to="loc_vtl_A2019OmnibusEquityIncentivePlanMember_8281d0b9-0a35-48d7-a7e5-86170e4036e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember_3c6039f0-2a9e-41a7-872f-66305e0ebeab" xlink:href="vtl-20220930.xsd#vtl_TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vtl_A2019OmnibusEquityIncentivePlanMember_8281d0b9-0a35-48d7-a7e5-86170e4036e8" xlink:to="loc_vtl_TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember_3c6039f0-2a9e-41a7-872f-66305e0ebeab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_TwoThousandFourteenEquityIncentivePlanMember_de6b45e7-4512-4dbf-9222-bb2c026af7b4" xlink:href="vtl-20220930.xsd#vtl_TwoThousandFourteenEquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_3e137722-5286-4369-8589-f302b8efad45" xlink:to="loc_vtl_TwoThousandFourteenEquityIncentivePlanMember_de6b45e7-4512-4dbf-9222-bb2c026af7b4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_A2017InducementEquityIncentivePlanMember_404d1c11-5f4d-4ebb-9634-eecb0292d3e3" xlink:href="vtl-20220930.xsd#vtl_A2017InducementEquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_3e137722-5286-4369-8589-f302b8efad45" xlink:to="loc_vtl_A2017InducementEquityIncentivePlanMember_404d1c11-5f4d-4ebb-9634-eecb0292d3e3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_f825c2d1-ffbd-49ce-8fa2-348c39ada824" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cb406110-47e4-468a-be11-cb6a62396af4" xlink:to="loc_srt_RangeAxis_f825c2d1-ffbd-49ce-8fa2-348c39ada824" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f825c2d1-ffbd-49ce-8fa2-348c39ada824_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_f825c2d1-ffbd-49ce-8fa2-348c39ada824" xlink:to="loc_srt_RangeMember_f825c2d1-ffbd-49ce-8fa2-348c39ada824_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_41f0ea59-a76a-4790-b50a-631af086fa8e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_f825c2d1-ffbd-49ce-8fa2-348c39ada824" xlink:to="loc_srt_RangeMember_41f0ea59-a76a-4790-b50a-631af086fa8e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_5645253b-f0b0-4b5f-8216-7faa6d5ed408" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_41f0ea59-a76a-4790-b50a-631af086fa8e" xlink:to="loc_srt_MaximumMember_5645253b-f0b0-4b5f-8216-7faa6d5ed408" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_c8232a83-528d-4d57-8b15-7ef1181fd8dc" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_41f0ea59-a76a-4790-b50a-631af086fa8e" xlink:to="loc_srt_MinimumMember_c8232a83-528d-4d57-8b15-7ef1181fd8dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_9dd5a063-49f8-46c4-9996-3932448ae81d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cb406110-47e4-468a-be11-cb6a62396af4" xlink:to="loc_us-gaap_AwardTypeAxis_9dd5a063-49f8-46c4-9996-3932448ae81d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9dd5a063-49f8-46c4-9996-3932448ae81d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_9dd5a063-49f8-46c4-9996-3932448ae81d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9dd5a063-49f8-46c4-9996-3932448ae81d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cb765e5c-5ae2-4f6a-8521-290ae8a46a18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_9dd5a063-49f8-46c4-9996-3932448ae81d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cb765e5c-5ae2-4f6a-8521-290ae8a46a18" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_IncentiveEmployeeStockOptionMember_afb30610-59cf-41d5-80ad-461fd806945c" xlink:href="vtl-20220930.xsd#vtl_IncentiveEmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cb765e5c-5ae2-4f6a-8521-290ae8a46a18" xlink:to="loc_vtl_IncentiveEmployeeStockOptionMember_afb30610-59cf-41d5-80ad-461fd806945c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_NonStatutoryEmployeeStockOptionMember_2e6d4449-12e4-43c7-a064-b87fbb0b8fde" xlink:href="vtl-20220930.xsd#vtl_NonStatutoryEmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cb765e5c-5ae2-4f6a-8521-290ae8a46a18" xlink:to="loc_vtl_NonStatutoryEmployeeStockOptionMember_2e6d4449-12e4-43c7-a064-b87fbb0b8fde" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/StockBasedCompensationPlansSummaryofStockOptionActivityDetails" xlink:type="simple" xlink:href="vtl-20220930.xsd#StockBasedCompensationPlansSummaryofStockOptionActivityDetails"/>
  <link:definitionLink xlink:role="http://vitaltherapies.com/role/StockBasedCompensationPlansSummaryofStockOptionActivityDetails" xlink:type="extended" id="i38762cf021a0405c83682b04b526d49b_StockBasedCompensationPlansSummaryofStockOptionActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4e87bb0c-6205-4d1a-a949-73fdfedec404" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_dbf7a925-59f5-4638-9690-0173c737031e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4e87bb0c-6205-4d1a-a949-73fdfedec404" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_dbf7a925-59f5-4638-9690-0173c737031e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_ee9f1161-25f0-4d2b-95f2-75fdf31e93f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_dbf7a925-59f5-4638-9690-0173c737031e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_ee9f1161-25f0-4d2b-95f2-75fdf31e93f3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c89db2f0-e707-489e-b08f-30659929f8de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_dbf7a925-59f5-4638-9690-0173c737031e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c89db2f0-e707-489e-b08f-30659929f8de" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_c2f41a29-1002-4dcb-a238-2f0cbd089e78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_dbf7a925-59f5-4638-9690-0173c737031e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_c2f41a29-1002-4dcb-a238-2f0cbd089e78" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_60c68b95-bc37-4829-8f26-583372c1c268" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_dbf7a925-59f5-4638-9690-0173c737031e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_60c68b95-bc37-4829-8f26-583372c1c268" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_49505ccf-ce22-4a71-8684-1af5b5dd19a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_79d1672d-17f5-4b3e-8828-3c98339b1815" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4e87bb0c-6205-4d1a-a949-73fdfedec404" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_79d1672d-17f5-4b3e-8828-3c98339b1815" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_1af97237-2234-44ee-96a4-0008089ffced" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4e87bb0c-6205-4d1a-a949-73fdfedec404" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_1af97237-2234-44ee-96a4-0008089ffced" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_ca229630-2add-40d9-a98d-6f2887984f7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4e87bb0c-6205-4d1a-a949-73fdfedec404" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_ca229630-2add-40d9-a98d-6f2887984f7d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_19948178-0dc2-4198-94e8-f0ae60fec009" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_ca229630-2add-40d9-a98d-6f2887984f7d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_19948178-0dc2-4198-94e8-f0ae60fec009" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_a0692705-dc29-4bb8-8e7e-83725f4a5124" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_ca229630-2add-40d9-a98d-6f2887984f7d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_a0692705-dc29-4bb8-8e7e-83725f4a5124" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_47d3672c-4ce8-4de8-82a9-06ae9d8ee9a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_ca229630-2add-40d9-a98d-6f2887984f7d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_47d3672c-4ce8-4de8-82a9-06ae9d8ee9a0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_f805490b-800a-415f-a0a8-fcbde63f4404" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_ca229630-2add-40d9-a98d-6f2887984f7d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_f805490b-800a-415f-a0a8-fcbde63f4404" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2409a1cf-2c1d-4f63-af2f-0d5ee8d549c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_1b955177-d9d7-4ac6-91ad-fe121b95bd32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4e87bb0c-6205-4d1a-a949-73fdfedec404" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_1b955177-d9d7-4ac6-91ad-fe121b95bd32" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_832cea66-14eb-4842-b1c4-7cf9ac8171f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4e87bb0c-6205-4d1a-a949-73fdfedec404" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_832cea66-14eb-4842-b1c4-7cf9ac8171f7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_81d69ad5-d5d0-489d-8abf-76b26888b902" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4e87bb0c-6205-4d1a-a949-73fdfedec404" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_81d69ad5-d5d0-489d-8abf-76b26888b902" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_946ec0a0-d090-4319-9b46-6d5378472449" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_81d69ad5-d5d0-489d-8abf-76b26888b902" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_946ec0a0-d090-4319-9b46-6d5378472449" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_718fb6ae-0aad-4c0c-8ed2-d750705e1cbd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_81d69ad5-d5d0-489d-8abf-76b26888b902" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_718fb6ae-0aad-4c0c-8ed2-d750705e1cbd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_43016b63-052d-4562-bba9-c8ae3491d78a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_81d69ad5-d5d0-489d-8abf-76b26888b902" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_43016b63-052d-4562-bba9-c8ae3491d78a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_b32b3bb7-f498-4003-a3e7-649f7d93d14b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_81d69ad5-d5d0-489d-8abf-76b26888b902" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_b32b3bb7-f498-4003-a3e7-649f7d93d14b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_a423b1cf-1e49-4136-b83f-b212aa677119" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_81d69ad5-d5d0-489d-8abf-76b26888b902" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_a423b1cf-1e49-4136-b83f-b212aa677119" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_7a159efd-24e8-41a2-87c5-4f54ab5b33b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_81d69ad5-d5d0-489d-8abf-76b26888b902" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_7a159efd-24e8-41a2-87c5-4f54ab5b33b9" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_061f93fd-7287-4256-ad40-0150b11b6615" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4e87bb0c-6205-4d1a-a949-73fdfedec404" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_061f93fd-7287-4256-ad40-0150b11b6615" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_4d24a80c-ddba-4742-b57c-ba666955f95d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_061f93fd-7287-4256-ad40-0150b11b6615" xlink:to="loc_us-gaap_PlanNameAxis_4d24a80c-ddba-4742-b57c-ba666955f95d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_4d24a80c-ddba-4742-b57c-ba666955f95d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_4d24a80c-ddba-4742-b57c-ba666955f95d" xlink:to="loc_us-gaap_PlanNameDomain_4d24a80c-ddba-4742-b57c-ba666955f95d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_88d23497-f81d-4101-9e4e-e46ea6e96aa7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_4d24a80c-ddba-4742-b57c-ba666955f95d" xlink:to="loc_us-gaap_PlanNameDomain_88d23497-f81d-4101-9e4e-e46ea6e96aa7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_TwoThousandNineteenOmnibusEquityIncentivePlanMember_9e20e199-30d7-4419-b722-da4981dc81b4" xlink:href="vtl-20220930.xsd#vtl_TwoThousandNineteenOmnibusEquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_88d23497-f81d-4101-9e4e-e46ea6e96aa7" xlink:to="loc_vtl_TwoThousandNineteenOmnibusEquityIncentivePlanMember_9e20e199-30d7-4419-b722-da4981dc81b4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_999f4bd7-d9a2-4ec9-92c2-43cefe397233" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_061f93fd-7287-4256-ad40-0150b11b6615" xlink:to="loc_us-gaap_AwardTypeAxis_999f4bd7-d9a2-4ec9-92c2-43cefe397233" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_999f4bd7-d9a2-4ec9-92c2-43cefe397233_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_999f4bd7-d9a2-4ec9-92c2-43cefe397233" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_999f4bd7-d9a2-4ec9-92c2-43cefe397233_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6b6c4abe-36c8-427e-a258-767db1efc2a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_999f4bd7-d9a2-4ec9-92c2-43cefe397233" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6b6c4abe-36c8-427e-a258-767db1efc2a8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_7f40274a-0d7f-4003-8820-721f989a9828" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6b6c4abe-36c8-427e-a258-767db1efc2a8" xlink:to="loc_us-gaap_EmployeeStockOptionMember_7f40274a-0d7f-4003-8820-721f989a9828" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/StockBasedCompensationPlansRangesofUnderlyingAssumptionsUsedinBSMOptionPricingModeltoDetermineFairValueofStockOptionsGrantedtoEmployeesandNonemployeesDetail" xlink:type="simple" xlink:href="vtl-20220930.xsd#StockBasedCompensationPlansRangesofUnderlyingAssumptionsUsedinBSMOptionPricingModeltoDetermineFairValueofStockOptionsGrantedtoEmployeesandNonemployeesDetail"/>
  <link:definitionLink xlink:role="http://vitaltherapies.com/role/StockBasedCompensationPlansRangesofUnderlyingAssumptionsUsedinBSMOptionPricingModeltoDetermineFairValueofStockOptionsGrantedtoEmployeesandNonemployeesDetail" xlink:type="extended" id="i1b7ea3beed2d4600bc718e143f24b2f5_StockBasedCompensationPlansRangesofUnderlyingAssumptionsUsedinBSMOptionPricingModeltoDetermineFairValueofStockOptionsGrantedtoEmployeesandNonemployeesDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0d5a568e-5655-4394-9fe4-38f1bff604ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_1695c09b-a9b2-422f-bf45-3e190ff67e55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0d5a568e-5655-4394-9fe4-38f1bff604ba" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_1695c09b-a9b2-422f-bf45-3e190ff67e55" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_ffa6b1a5-bcfb-433e-acfc-d64c718e4240" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0d5a568e-5655-4394-9fe4-38f1bff604ba" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_ffa6b1a5-bcfb-433e-acfc-d64c718e4240" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_7827a515-2621-4901-b54d-c7cf73c31ee0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0d5a568e-5655-4394-9fe4-38f1bff604ba" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_7827a515-2621-4901-b54d-c7cf73c31ee0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_9b1c66fc-79bd-46a1-9723-88192372edde" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0d5a568e-5655-4394-9fe4-38f1bff604ba" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_9b1c66fc-79bd-46a1-9723-88192372edde" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_14b7fdcc-553e-441e-9388-ffc2ec098074" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0d5a568e-5655-4394-9fe4-38f1bff604ba" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_14b7fdcc-553e-441e-9388-ffc2ec098074" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_9f101503-2ac9-4c31-80ee-2cd2e6a0e6d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_14b7fdcc-553e-441e-9388-ffc2ec098074" xlink:to="loc_us-gaap_PlanNameAxis_9f101503-2ac9-4c31-80ee-2cd2e6a0e6d6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_9f101503-2ac9-4c31-80ee-2cd2e6a0e6d6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_9f101503-2ac9-4c31-80ee-2cd2e6a0e6d6" xlink:to="loc_us-gaap_PlanNameDomain_9f101503-2ac9-4c31-80ee-2cd2e6a0e6d6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_7f35d67a-836c-4c0e-86f5-5a6f9618c191" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_9f101503-2ac9-4c31-80ee-2cd2e6a0e6d6" xlink:to="loc_us-gaap_PlanNameDomain_7f35d67a-836c-4c0e-86f5-5a6f9618c191" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_A2019OmnibusEquityIncentivePlanMember_a7bf8fa8-f4f8-4ab4-b733-a1e16165769e" xlink:href="vtl-20220930.xsd#vtl_A2019OmnibusEquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_7f35d67a-836c-4c0e-86f5-5a6f9618c191" xlink:to="loc_vtl_A2019OmnibusEquityIncentivePlanMember_a7bf8fa8-f4f8-4ab4-b733-a1e16165769e" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/StockBasedCompensationPlansScheduleofStockbasedCompensationExpenseforStockAwardsRecognizedDetails" xlink:type="simple" xlink:href="vtl-20220930.xsd#StockBasedCompensationPlansScheduleofStockbasedCompensationExpenseforStockAwardsRecognizedDetails"/>
  <link:definitionLink xlink:role="http://vitaltherapies.com/role/StockBasedCompensationPlansScheduleofStockbasedCompensationExpenseforStockAwardsRecognizedDetails" xlink:type="extended" id="i8c5804a2e7994db68a93e87a4e774732_StockBasedCompensationPlansScheduleofStockbasedCompensationExpenseforStockAwardsRecognizedDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_2196b342-24a7-496a-9c97-5d584eff0ac7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_d3c3400c-9b32-4ef6-b993-cf1dec15e1f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_2196b342-24a7-496a-9c97-5d584eff0ac7" xlink:to="loc_us-gaap_ShareBasedCompensation_d3c3400c-9b32-4ef6-b993-cf1dec15e1f7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_56edec30-fc57-4f9d-8c73-e08b8bf1f65b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_2196b342-24a7-496a-9c97-5d584eff0ac7" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_56edec30-fc57-4f9d-8c73-e08b8bf1f65b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_d53c360e-7be0-4c15-afc8-210884c6863b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_56edec30-fc57-4f9d-8c73-e08b8bf1f65b" xlink:to="loc_srt_TitleOfIndividualAxis_d53c360e-7be0-4c15-afc8-210884c6863b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_d53c360e-7be0-4c15-afc8-210884c6863b_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_d53c360e-7be0-4c15-afc8-210884c6863b" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_d53c360e-7be0-4c15-afc8-210884c6863b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_970faa1d-2b49-4f28-98a6-06c56f70227e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_d53c360e-7be0-4c15-afc8-210884c6863b" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_970faa1d-2b49-4f28-98a6-06c56f70227e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_EmployeeMember_afbb44be-3bad-4195-a341-813fd7fc06b3" xlink:href="vtl-20220930.xsd#vtl_EmployeeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_970faa1d-2b49-4f28-98a6-06c56f70227e" xlink:to="loc_vtl_EmployeeMember_afbb44be-3bad-4195-a341-813fd7fc06b3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_b6bb3df0-f2ba-4a33-9dc4-caae34e29453" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_56edec30-fc57-4f9d-8c73-e08b8bf1f65b" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_b6bb3df0-f2ba-4a33-9dc4-caae34e29453" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_b6bb3df0-f2ba-4a33-9dc4-caae34e29453_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_b6bb3df0-f2ba-4a33-9dc4-caae34e29453" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_b6bb3df0-f2ba-4a33-9dc4-caae34e29453_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_de481d72-a3f3-4fd6-b272-f76a6f09f2bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_b6bb3df0-f2ba-4a33-9dc4-caae34e29453" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_de481d72-a3f3-4fd6-b272-f76a6f09f2bf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_6693ad29-fca1-4d50-8a42-713c67bdf692" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_de481d72-a3f3-4fd6-b272-f76a6f09f2bf" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_6693ad29-fca1-4d50-8a42-713c67bdf692" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_3aac76f7-ec55-4f77-aa45-3a1324cd83e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_de481d72-a3f3-4fd6-b272-f76a6f09f2bf" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_3aac76f7-ec55-4f77-aa45-3a1324cd83e8" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/ChangesinBoardofDirectorsDetails" xlink:type="simple" xlink:href="vtl-20220930.xsd#ChangesinBoardofDirectorsDetails"/>
  <link:definitionLink xlink:role="http://vitaltherapies.com/role/ChangesinBoardofDirectorsDetails" xlink:type="extended" id="i17b487a118574a9f9f35e8a35bf376ba_ChangesinBoardofDirectorsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_29d3a302-a173-4704-ad94-9e5795968480" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_75849213-9592-4c9a-b6b3-eaf66cfba4bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_29d3a302-a173-4704-ad94-9e5795968480" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_75849213-9592-4c9a-b6b3-eaf66cfba4bd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c673a13b-482c-45c0-9427-0c534b6d1909" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_29d3a302-a173-4704-ad94-9e5795968480" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c673a13b-482c-45c0-9427-0c534b6d1909" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_ea670408-1ed3-4cfd-8426-5b60516c9a57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_29d3a302-a173-4704-ad94-9e5795968480" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_ea670408-1ed3-4cfd-8426-5b60516c9a57" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_14e0f18a-d916-44cd-a736-6dd29ac6b574" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_29d3a302-a173-4704-ad94-9e5795968480" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_14e0f18a-d916-44cd-a736-6dd29ac6b574" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_fb5d71ed-e1b4-4786-a3b5-72883ffbf721" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_14e0f18a-d916-44cd-a736-6dd29ac6b574" xlink:to="loc_srt_TitleOfIndividualAxis_fb5d71ed-e1b4-4786-a3b5-72883ffbf721" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_fb5d71ed-e1b4-4786-a3b5-72883ffbf721_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_fb5d71ed-e1b4-4786-a3b5-72883ffbf721" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_fb5d71ed-e1b4-4786-a3b5-72883ffbf721_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_6a63f85a-71a3-40d4-9533-b805c72c406e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_fb5d71ed-e1b4-4786-a3b5-72883ffbf721" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_6a63f85a-71a3-40d4-9533-b805c72c406e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember_8488c02a-9e48-4de5-b905-e49a4ac2a47b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_DirectorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_6a63f85a-71a3-40d4-9533-b805c72c406e" xlink:to="loc_srt_DirectorMember_8488c02a-9e48-4de5-b905-e49a4ac2a47b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_8e49c510-a7e8-4586-87a5-c0e49637ac44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_14e0f18a-d916-44cd-a736-6dd29ac6b574" xlink:to="loc_us-gaap_AwardTypeAxis_8e49c510-a7e8-4586-87a5-c0e49637ac44" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8e49c510-a7e8-4586-87a5-c0e49637ac44_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_8e49c510-a7e8-4586-87a5-c0e49637ac44" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8e49c510-a7e8-4586-87a5-c0e49637ac44_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fa772e77-9e52-471a-9f52-cd9366d55f1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_8e49c510-a7e8-4586-87a5-c0e49637ac44" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fa772e77-9e52-471a-9f52-cd9366d55f1f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_OptionsVestingInOneYearMember_d2d32692-82fe-4424-9af3-84c8ade090a7" xlink:href="vtl-20220930.xsd#vtl_OptionsVestingInOneYearMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fa772e77-9e52-471a-9f52-cd9366d55f1f" xlink:to="loc_vtl_OptionsVestingInOneYearMember_d2d32692-82fe-4424-9af3-84c8ade090a7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_OptionsVestingInThreeYearsMember_e050e960-b696-4e7e-900e-0a917192b732" xlink:href="vtl-20220930.xsd#vtl_OptionsVestingInThreeYearsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fa772e77-9e52-471a-9f52-cd9366d55f1f" xlink:to="loc_vtl_OptionsVestingInThreeYearsMember_e050e960-b696-4e7e-900e-0a917192b732" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/RelatedPartyTransactionsAdditionalInformationDetails" xlink:type="simple" xlink:href="vtl-20220930.xsd#RelatedPartyTransactionsAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://vitaltherapies.com/role/RelatedPartyTransactionsAdditionalInformationDetails" xlink:type="extended" id="iec8f6a58419d459aa953c570c3990e9b_RelatedPartyTransactionsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_86141ef7-a9bb-484f-b7aa-0bb61a38ddc2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_3518b1ee-f1d9-4f53-a282-8c3e20943157" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_86141ef7-a9bb-484f-b7aa-0bb61a38ddc2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_3518b1ee-f1d9-4f53-a282-8c3e20943157" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_SalaryCostsMonthlyBaseSalary_5ecf4a33-d692-4c4b-8f4c-de81857c2903" xlink:href="vtl-20220930.xsd#vtl_SalaryCostsMonthlyBaseSalary"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_86141ef7-a9bb-484f-b7aa-0bb61a38ddc2" xlink:to="loc_vtl_SalaryCostsMonthlyBaseSalary_5ecf4a33-d692-4c4b-8f4c-de81857c2903" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_9fa2741f-44e9-414b-bfc1-19d0ebb78e08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_86141ef7-a9bb-484f-b7aa-0bb61a38ddc2" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_9fa2741f-44e9-414b-bfc1-19d0ebb78e08" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_56ce8bc7-f9c9-48e6-a027-f26b7f184b8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_9fa2741f-44e9-414b-bfc1-19d0ebb78e08" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_56ce8bc7-f9c9-48e6-a027-f26b7f184b8c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_56ce8bc7-f9c9-48e6-a027-f26b7f184b8c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_56ce8bc7-f9c9-48e6-a027-f26b7f184b8c" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_56ce8bc7-f9c9-48e6-a027-f26b7f184b8c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_6d054707-eb05-46c3-a8ff-c86a9174c252" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_56ce8bc7-f9c9-48e6-a027-f26b7f184b8c" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_6d054707-eb05-46c3-a8ff-c86a9174c252" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_ExecutiveChairmanAgreementMember_a2985ec2-445d-4d0c-b258-7f1456fdb813" xlink:href="vtl-20220930.xsd#vtl_ExecutiveChairmanAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_6d054707-eb05-46c3-a8ff-c86a9174c252" xlink:to="loc_vtl_ExecutiveChairmanAgreementMember_a2985ec2-445d-4d0c-b258-7f1456fdb813" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_232db689-3aa4-41e5-a9fb-2cd86054f906" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_9fa2741f-44e9-414b-bfc1-19d0ebb78e08" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_232db689-3aa4-41e5-a9fb-2cd86054f906" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_232db689-3aa4-41e5-a9fb-2cd86054f906_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_232db689-3aa4-41e5-a9fb-2cd86054f906" xlink:to="loc_us-gaap_RelatedPartyDomain_232db689-3aa4-41e5-a9fb-2cd86054f906_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_e2ca1bd0-c6ca-4bc1-8751-25a2fc3c1486" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_232db689-3aa4-41e5-a9fb-2cd86054f906" xlink:to="loc_us-gaap_RelatedPartyDomain_e2ca1bd0-c6ca-4bc1-8751-25a2fc3c1486" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember_4c48622a-4352-4b41-973f-91d2eb7cc12f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_AffiliatedEntityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_e2ca1bd0-c6ca-4bc1-8751-25a2fc3c1486" xlink:to="loc_srt_AffiliatedEntityMember_4c48622a-4352-4b41-973f-91d2eb7cc12f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_7febb14c-f2a3-46b2-a282-bfd9743bc398" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_9fa2741f-44e9-414b-bfc1-19d0ebb78e08" xlink:to="loc_srt_CounterpartyNameAxis_7febb14c-f2a3-46b2-a282-bfd9743bc398" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7febb14c-f2a3-46b2-a282-bfd9743bc398_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_7febb14c-f2a3-46b2-a282-bfd9743bc398" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7febb14c-f2a3-46b2-a282-bfd9743bc398_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_98794e5a-2edf-4de0-b2f6-448781964ee5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_7febb14c-f2a3-46b2-a282-bfd9743bc398" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_98794e5a-2edf-4de0-b2f6-448781964ee5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_DuaneNashMDJDMBAMember_f45c3296-f629-487d-9b16-7e24c2cbb49a" xlink:href="vtl-20220930.xsd#vtl_DuaneNashMDJDMBAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_98794e5a-2edf-4de0-b2f6-448781964ee5" xlink:to="loc_vtl_DuaneNashMDJDMBAMember_f45c3296-f629-487d-9b16-7e24c2cbb49a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_7990d66f-4cd3-40c5-ad6f-843ae0846098" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_9fa2741f-44e9-414b-bfc1-19d0ebb78e08" xlink:to="loc_srt_TitleOfIndividualAxis_7990d66f-4cd3-40c5-ad6f-843ae0846098" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_7990d66f-4cd3-40c5-ad6f-843ae0846098_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_7990d66f-4cd3-40c5-ad6f-843ae0846098" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_7990d66f-4cd3-40c5-ad6f-843ae0846098_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_55b1fcb5-fdc8-49cd-b2f0-bd849c8633a3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_7990d66f-4cd3-40c5-ad6f-843ae0846098" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_55b1fcb5-fdc8-49cd-b2f0-bd849c8633a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_BoardOfDirectorsChairmanMember_4f820075-04df-43aa-8d02-18262c4b30f6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_BoardOfDirectorsChairmanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_55b1fcb5-fdc8-49cd-b2f0-bd849c8633a3" xlink:to="loc_srt_BoardOfDirectorsChairmanMember_4f820075-04df-43aa-8d02-18262c4b30f6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_1e97a7c9-1836-4d8e-be53-73c8e9fd4bbf" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_9fa2741f-44e9-414b-bfc1-19d0ebb78e08" xlink:to="loc_srt_StatementScenarioAxis_1e97a7c9-1836-4d8e-be53-73c8e9fd4bbf" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_1e97a7c9-1836-4d8e-be53-73c8e9fd4bbf_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_1e97a7c9-1836-4d8e-be53-73c8e9fd4bbf" xlink:to="loc_srt_ScenarioUnspecifiedDomain_1e97a7c9-1836-4d8e-be53-73c8e9fd4bbf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_4da306ce-c86d-477d-8f3d-49c2fde1b0f7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_1e97a7c9-1836-4d8e-be53-73c8e9fd4bbf" xlink:to="loc_srt_ScenarioUnspecifiedDomain_4da306ce-c86d-477d-8f3d-49c2fde1b0f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_59e5602f-13bc-4535-80bf-a8d459921967" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_4da306ce-c86d-477d-8f3d-49c2fde1b0f7" xlink:to="loc_srt_ScenarioForecastMember_59e5602f-13bc-4535-80bf-a8d459921967" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="vtl-20220930.xsd#SubsequentEventsDetails"/>
  <link:definitionLink xlink:role="http://vitaltherapies.com/role/SubsequentEventsDetails" xlink:type="extended" id="i39e560bc64aa4c599f2e51dcb3c8f459_SubsequentEventsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_42d3bc09-bbb6-47b3-a7c1-4a11f4ad2e67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_51b7f742-ba92-4faa-84f9-1cba8d7c082f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_42d3bc09-bbb6-47b3-a7c1-4a11f4ad2e67" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_51b7f742-ba92-4faa-84f9-1cba8d7c082f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_6737af71-2e08-49a5-a6a6-e2810b0b7553" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_42d3bc09-bbb6-47b3-a7c1-4a11f4ad2e67" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_6737af71-2e08-49a5-a6a6-e2810b0b7553" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_0afb2c7c-58f9-43de-b5f6-40479cbba982" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_42d3bc09-bbb6-47b3-a7c1-4a11f4ad2e67" xlink:to="loc_us-gaap_SharePrice_0afb2c7c-58f9-43de-b5f6-40479cbba982" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_EquityMethodInvestmentWarrantsExercisableOwnershipLimitationPercentage_b8bb98db-6731-4187-8a46-859993fc2993" xlink:href="vtl-20220930.xsd#vtl_EquityMethodInvestmentWarrantsExercisableOwnershipLimitationPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_42d3bc09-bbb6-47b3-a7c1-4a11f4ad2e67" xlink:to="loc_vtl_EquityMethodInvestmentWarrantsExercisableOwnershipLimitationPercentage_b8bb98db-6731-4187-8a46-859993fc2993" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_EquityMethodInvestmentWarrantsExercisableOwnershipLimitationMaximumIncreaseDecreasePercent_df946cdf-54b0-4de3-a520-4d8eb6b73923" xlink:href="vtl-20220930.xsd#vtl_EquityMethodInvestmentWarrantsExercisableOwnershipLimitationMaximumIncreaseDecreasePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_42d3bc09-bbb6-47b3-a7c1-4a11f4ad2e67" xlink:to="loc_vtl_EquityMethodInvestmentWarrantsExercisableOwnershipLimitationMaximumIncreaseDecreasePercent_df946cdf-54b0-4de3-a520-4d8eb6b73923" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_EquityMethodInvestmentWarrantsExercisableSharesChangeLimitationNoticePeriod_ba9abf41-dfee-4f8d-a09b-391e4f6cda01" xlink:href="vtl-20220930.xsd#vtl_EquityMethodInvestmentWarrantsExercisableSharesChangeLimitationNoticePeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_42d3bc09-bbb6-47b3-a7c1-4a11f4ad2e67" xlink:to="loc_vtl_EquityMethodInvestmentWarrantsExercisableSharesChangeLimitationNoticePeriod_ba9abf41-dfee-4f8d-a09b-391e4f6cda01" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_2320eeb9-3e78-4706-8275-13f1840e9583" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_42d3bc09-bbb6-47b3-a7c1-4a11f4ad2e67" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_2320eeb9-3e78-4706-8275-13f1840e9583" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_88b3a9c9-0fc0-4858-b16e-1e28f488a941" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_42d3bc09-bbb6-47b3-a7c1-4a11f4ad2e67" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_88b3a9c9-0fc0-4858-b16e-1e28f488a941" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_a245febf-9800-4627-8160-2cf68b8d7243" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_42d3bc09-bbb6-47b3-a7c1-4a11f4ad2e67" xlink:to="loc_us-gaap_SubsequentEventTable_a245febf-9800-4627-8160-2cf68b8d7243" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_53015324-450b-4d86-8631-d32badb8bc3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_a245febf-9800-4627-8160-2cf68b8d7243" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_53015324-450b-4d86-8631-d32badb8bc3f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_53015324-450b-4d86-8631-d32badb8bc3f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_53015324-450b-4d86-8631-d32badb8bc3f" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_53015324-450b-4d86-8631-d32badb8bc3f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5d5f08da-ac77-470e-aa07-c45aa996b69d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_53015324-450b-4d86-8631-d32badb8bc3f" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5d5f08da-ac77-470e-aa07-c45aa996b69d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_9116356f-a847-4b27-af80-2bc315321eb6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5d5f08da-ac77-470e-aa07-c45aa996b69d" xlink:to="loc_us-gaap_CommonStockMember_9116356f-a847-4b27-af80-2bc315321eb6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_PreFundedWarrantsMember_c16a0996-37d6-4b6c-a6c1-a2dbee5b4377" xlink:href="vtl-20220930.xsd#vtl_PreFundedWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5d5f08da-ac77-470e-aa07-c45aa996b69d" xlink:to="loc_vtl_PreFundedWarrantsMember_c16a0996-37d6-4b6c-a6c1-a2dbee5b4377" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_e19de89e-5546-4bb5-b57c-f837c4afedc1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_a245febf-9800-4627-8160-2cf68b8d7243" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_e19de89e-5546-4bb5-b57c-f837c4afedc1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_e19de89e-5546-4bb5-b57c-f837c4afedc1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_e19de89e-5546-4bb5-b57c-f837c4afedc1" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_e19de89e-5546-4bb5-b57c-f837c4afedc1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_df3c0514-df3c-4d52-bd07-4e52de96dfc7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_e19de89e-5546-4bb5-b57c-f837c4afedc1" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_df3c0514-df3c-4d52-bd07-4e52de96dfc7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_37f2873a-2fb9-45a2-be52-31b2da74a6bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_df3c0514-df3c-4d52-bd07-4e52de96dfc7" xlink:to="loc_us-gaap_SubsequentEventMember_37f2873a-2fb9-45a2-be52-31b2da74a6bf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_f74cb5a1-326a-4d7e-916f-33d8cdaa80e3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_a245febf-9800-4627-8160-2cf68b8d7243" xlink:to="loc_srt_StatementScenarioAxis_f74cb5a1-326a-4d7e-916f-33d8cdaa80e3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_f74cb5a1-326a-4d7e-916f-33d8cdaa80e3_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_f74cb5a1-326a-4d7e-916f-33d8cdaa80e3" xlink:to="loc_srt_ScenarioUnspecifiedDomain_f74cb5a1-326a-4d7e-916f-33d8cdaa80e3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_4e55a8a0-4d68-4a90-b805-1f2670413b20" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_f74cb5a1-326a-4d7e-916f-33d8cdaa80e3" xlink:to="loc_srt_ScenarioUnspecifiedDomain_4e55a8a0-4d68-4a90-b805-1f2670413b20" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_abc6df2c-4a1d-4569-9c3c-f512b8293781" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_4e55a8a0-4d68-4a90-b805-1f2670413b20" xlink:to="loc_srt_ScenarioForecastMember_abc6df2c-4a1d-4569-9c3c-f512b8293781" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>vtl-20220930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:6944770f-821d-45aa-b4f3-cccabd82d2f9,g:32d5dde5-0858-4183-b548-263732a64d33-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4fc22dc2-e30e-42c0-9661-990799a9b39e_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_8beba69c-667b-4943-8af2-46efa4572042_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_dc4cbcd4-b4b2-460d-9880-39adcf5475b8_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Translation and Presentation</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_a82cd51a-1d20-4890-8cb2-917d413b5ac4_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_14aad782-72f6-4e34-adb6-6d1fc7b8170a_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_04a2790d-9e09-4d56-93b2-f01e0c09ff16_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_cffb6761-91cd-44b0-bd3f-3f6bde2ce825_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_8c4aedeb-078d-45de-9c6c-23e0741e418e_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (in USD per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_d5b3bdb7-2a67-4691-bd3c-4a526f06b96b_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_8a3a7985-adfb-4000-b4b5-87be8668685d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_311d88d0-fb45-464f-a588-fc11d7e109d1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_d372e331-fb49-48fb-9086-8585606a2ca2_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_ac3de901-785f-49af-b44f-3bcd1ddfc550_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_ba138f1b-287c-45f6-8d24-87e6c6a261a6_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_384300f3-9670-4327-95d6-4167101827dc_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average common shares outstanding, diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_e6aa0ee0-00ac-4825-8aa8-02c86e067947_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_3e88637c-7c9e-40fa-bd06-3f989fb60735_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term of options (years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_c1ab7da0-d3cf-4f59-b7f1-e8afd88b5797_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_label_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems" xlink:to="lab_us-gaap_LossContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_OptionsVestingInOneYearMember_2413f901-d830-4e0f-8b02-b3b0d3cab949_terseLabel_en-US" xlink:label="lab_vtl_OptionsVestingInOneYearMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options Vesting In One Year</link:label>
    <link:label id="lab_vtl_OptionsVestingInOneYearMember_label_en-US" xlink:label="lab_vtl_OptionsVestingInOneYearMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options Vesting In One Year [Member]</link:label>
    <link:label id="lab_vtl_OptionsVestingInOneYearMember_documentation_en-US" xlink:label="lab_vtl_OptionsVestingInOneYearMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options Vesting In One Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_OptionsVestingInOneYearMember" xlink:href="vtl-20220930.xsd#vtl_OptionsVestingInOneYearMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_OptionsVestingInOneYearMember" xlink:to="lab_vtl_OptionsVestingInOneYearMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareCashPaid_c7dd08b0-9429-4199-a4ec-6a3230d8de42_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareCashPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, cash dividends paid (in USD per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareCashPaid_label_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareCashPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Dividends, Per Share, Cash Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareCashPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockDividendsPerShareCashPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockDividendsPerShareCashPaid" xlink:to="lab_us-gaap_CommonStockDividendsPerShareCashPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_ClinicalCostsPayableCurrent_ec217ef6-e6bb-48e5-828a-31a6aa3eb0f8_terseLabel_en-US" xlink:label="lab_vtl_ClinicalCostsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical costs</link:label>
    <link:label id="lab_vtl_ClinicalCostsPayableCurrent_label_en-US" xlink:label="lab_vtl_ClinicalCostsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical Costs Payable, Current</link:label>
    <link:label id="lab_vtl_ClinicalCostsPayableCurrent_documentation_en-US" xlink:label="lab_vtl_ClinicalCostsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical Costs Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_ClinicalCostsPayableCurrent" xlink:href="vtl-20220930.xsd#vtl_ClinicalCostsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_ClinicalCostsPayableCurrent" xlink:to="lab_vtl_ClinicalCostsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_f17f1924-a31e-4a43-8294-f6477b2b324e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement</link:label>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_label_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_25b3528f-4187-4b18-85a7-42414ad8a330_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.0001 par value; 130,000,000 shares authorized and 30,564,995 and 26,335,418 shares issued and outstanding as of September 30, 2022 and December&#160;31, 2021, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_ff88ed76-7ec8-4d72-afb5-a76f179241d4_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock issued</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_98dd7c70-38a8-4835-92ae-c95105b13a3c_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_94f0ec85-3970-4ed1-bc7b-4f67a0007d7e_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_EquityMethodInvestmentWarrantsExercisableOwnershipLimitationMaximumIncreaseDecreasePercent_e9aa8807-1d09-476c-ac2a-00adb420760a_terseLabel_en-US" xlink:label="lab_vtl_EquityMethodInvestmentWarrantsExercisableOwnershipLimitationMaximumIncreaseDecreasePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase or decrease not in excess of percentage</link:label>
    <link:label id="lab_vtl_EquityMethodInvestmentWarrantsExercisableOwnershipLimitationMaximumIncreaseDecreasePercent_label_en-US" xlink:label="lab_vtl_EquityMethodInvestmentWarrantsExercisableOwnershipLimitationMaximumIncreaseDecreasePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Warrants, Exercisable Ownership Limitation, Maximum Increase (Decrease), Percent</link:label>
    <link:label id="lab_vtl_EquityMethodInvestmentWarrantsExercisableOwnershipLimitationMaximumIncreaseDecreasePercent_documentation_en-US" xlink:label="lab_vtl_EquityMethodInvestmentWarrantsExercisableOwnershipLimitationMaximumIncreaseDecreasePercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Warrants, Exercisable Ownership Limitation, Maximum Increase (Decrease), Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_EquityMethodInvestmentWarrantsExercisableOwnershipLimitationMaximumIncreaseDecreasePercent" xlink:href="vtl-20220930.xsd#vtl_EquityMethodInvestmentWarrantsExercisableOwnershipLimitationMaximumIncreaseDecreasePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_EquityMethodInvestmentWarrantsExercisableOwnershipLimitationMaximumIncreaseDecreasePercent" xlink:to="lab_vtl_EquityMethodInvestmentWarrantsExercisableOwnershipLimitationMaximumIncreaseDecreasePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_242a64b4-5f0e-4218-91ff-d29a0a1cca8a_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_6d85039b-0b99-419d-a39b-5532048aafbb_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation expense</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_d8f03915-16c9-4663-a785-1c70dfe13c08_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_645e5938-1fb0-4ed5-a9ce-ceaeef0a236c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Potentially Dilutive Securities Not Included in Calculation of Diluted Net Loss per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_ef9d5760-a881-4191-8a22-58adf8558fb8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_cf970326-1e12-4b6c-a2c9-2c782002ff62_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercisable, Aggregate Intrinsic Value, Ending balance</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cce4e22b-bb24-41f2-9d84-27936b215b36_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_e45a8947-725e-4cda-9595-db71a9762867_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_A2019OmnibusEquityIncentivePlanMember_ce7011f6-69cf-424d-a843-1e608557e430_terseLabel_en-US" xlink:label="lab_vtl_A2019OmnibusEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 Omnibus Equity Incentive Plan</link:label>
    <link:label id="lab_vtl_A2019OmnibusEquityIncentivePlanMember_label_en-US" xlink:label="lab_vtl_A2019OmnibusEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 Omnibus Equity Incentive Plan [Member]</link:label>
    <link:label id="lab_vtl_A2019OmnibusEquityIncentivePlanMember_documentation_en-US" xlink:label="lab_vtl_A2019OmnibusEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 Omnibus Equity Incentive Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_A2019OmnibusEquityIncentivePlanMember" xlink:href="vtl-20220930.xsd#vtl_A2019OmnibusEquityIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_A2019OmnibusEquityIncentivePlanMember" xlink:to="lab_vtl_A2019OmnibusEquityIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_94328f06-267c-445b-8734-a420c16b6ca8_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents, beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_053aa89e-869a-4b12-baf3-75bd0656a879_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents, end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_July2021PublicEquityOfferingMember_5821cd3c-cf4a-464f-96f9-6a2f52ca5bf0_terseLabel_en-US" xlink:label="lab_vtl_July2021PublicEquityOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">July 2021 Public Equity Offering</link:label>
    <link:label id="lab_vtl_July2021PublicEquityOfferingMember_label_en-US" xlink:label="lab_vtl_July2021PublicEquityOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">July 2021 Public Equity Offering [Member]</link:label>
    <link:label id="lab_vtl_July2021PublicEquityOfferingMember_documentation_en-US" xlink:label="lab_vtl_July2021PublicEquityOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">July 2021 Public Equity Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_July2021PublicEquityOfferingMember" xlink:href="vtl-20220930.xsd#vtl_July2021PublicEquityOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_July2021PublicEquityOfferingMember" xlink:to="lab_vtl_July2021PublicEquityOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_2ab7c6f5-08da-4001-b688-d9a5d6f60c82_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_891868ae-f5ea-4c9a-9129-4f6db13163e0_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_May2022ATMMember_77210549-a275-4373-8e1c-58109892668a_terseLabel_en-US" xlink:label="lab_vtl_May2022ATMMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">May 2022 ATM</link:label>
    <link:label id="lab_vtl_May2022ATMMember_label_en-US" xlink:label="lab_vtl_May2022ATMMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">May 2022 ATM [Member]</link:label>
    <link:label id="lab_vtl_May2022ATMMember_documentation_en-US" xlink:label="lab_vtl_May2022ATMMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">May 2022 ATM</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_May2022ATMMember" xlink:href="vtl-20220930.xsd#vtl_May2022ATMMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_May2022ATMMember" xlink:to="lab_vtl_May2022ATMMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_660cf8ac-3359-4eb4-83e9-eb85544aebfc_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from exercise of stock options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_13520a9a-d4a3-47e3-a39f-fafeb4b44d54_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Current Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_13a30743-117e-466c-8ed2-184ef8406fd6_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_696a17fd-0cfe-4524-8a14-d59d624d829d_terseLabel_en-US" xlink:label="lab_vtl_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions to right-of-use assets</link:label>
    <link:label id="lab_vtl_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_vtl_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Operating Lease, Right-Of-Use Asset</link:label>
    <link:label id="lab_vtl_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_documentation_en-US" xlink:label="lab_vtl_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Operating Lease, Right-Of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:href="vtl-20220930.xsd#vtl_IncreaseDecreaseInOperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:to="lab_vtl_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_cc2d86ab-ac81-4cee-af2b-236881041d75_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_0d3ed37a-bedc-43ba-aba0-1daa7da9fabf_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_a89e68a6-2b6e-4d0c-a63c-a0d00158208d_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_BoardOfDirectorsChairmanMember_599ec084-64db-4014-9dd1-5e2dca309471_terseLabel_en-US" xlink:label="lab_srt_BoardOfDirectorsChairmanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Board of Directors Chairman</link:label>
    <link:label id="lab_srt_BoardOfDirectorsChairmanMember_label_en-US" xlink:label="lab_srt_BoardOfDirectorsChairmanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Board of Directors Chairman [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_BoardOfDirectorsChairmanMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_BoardOfDirectorsChairmanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_BoardOfDirectorsChairmanMember" xlink:to="lab_srt_BoardOfDirectorsChairmanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c32b2c96-6718-4043-84b4-531ba7093625_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options to purchase common stock ( in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_73b6c28f-5e56-49b1-901c-e8b6f0386c63_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_dab1a1b7-52d4-4a24-8aa7-b686aec440ba_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a73aaf1f-dd75-4dcc-b84a-d2fdc0f12e95_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_206c83d9-a2d6-42d7-ac4b-308b48137644_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_07c3b61e-65dc-4fcb-8751-80d6ec293bc1_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_43aee17f-77b0-4058-a09e-2fc9a309a13c_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_228b1dc0-b71b-4554-a8ef-dfae4fd3e0f8_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementScenarioAxis_babfa3d1-10b4-4961-892d-724e2f87ea53_terseLabel_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:label id="lab_srt_StatementScenarioAxis_label_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis" xlink:to="lab_srt_StatementScenarioAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_ExecutiveChairmanAgreementMember_ff8c3fdb-4303-4531-bde8-7a24143f3209_terseLabel_en-US" xlink:label="lab_vtl_ExecutiveChairmanAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Executive Chairman Agreement</link:label>
    <link:label id="lab_vtl_ExecutiveChairmanAgreementMember_label_en-US" xlink:label="lab_vtl_ExecutiveChairmanAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Executive Chairman Agreement [Member]</link:label>
    <link:label id="lab_vtl_ExecutiveChairmanAgreementMember_documentation_en-US" xlink:label="lab_vtl_ExecutiveChairmanAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Executive Chairman Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_ExecutiveChairmanAgreementMember" xlink:href="vtl-20220930.xsd#vtl_ExecutiveChairmanAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_ExecutiveChairmanAgreementMember" xlink:to="lab_vtl_ExecutiveChairmanAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_feba03b9-1256-4ebb-939c-bfe446672eea_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeAxis" xlink:to="lab_us-gaap_InvestmentTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_d4933841-62da-4770-8dfe-561c0c28a883_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets at fair value</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_40417075-7982-42d6-bf41-a71f4a29db2f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign exchange translation adjustment</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_EmployeeMember_a65ce65b-17b0-4330-9d77-a4a67645061f_terseLabel_en-US" xlink:label="lab_vtl_EmployeeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employees</link:label>
    <link:label id="lab_vtl_EmployeeMember_label_en-US" xlink:label="lab_vtl_EmployeeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee [Member]</link:label>
    <link:label id="lab_vtl_EmployeeMember_documentation_en-US" xlink:label="lab_vtl_EmployeeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_EmployeeMember" xlink:href="vtl-20220930.xsd#vtl_EmployeeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_EmployeeMember" xlink:to="lab_vtl_EmployeeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_9cd3dfe9-72cc-4bf8-bf0c-00ab31380e95_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_ImmunicAGMember_c1af25f3-cf5b-4436-9b7e-83bf8ef7be94_terseLabel_en-US" xlink:label="lab_vtl_ImmunicAGMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Immunic AG</link:label>
    <link:label id="lab_vtl_ImmunicAGMember_label_en-US" xlink:label="lab_vtl_ImmunicAGMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Immunic AG [Member]</link:label>
    <link:label id="lab_vtl_ImmunicAGMember_documentation_en-US" xlink:label="lab_vtl_ImmunicAGMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Immunic AG [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_ImmunicAGMember" xlink:href="vtl-20220930.xsd#vtl_ImmunicAGMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_ImmunicAGMember" xlink:to="lab_vtl_ImmunicAGMember" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_AssetPurchaseAgreementRoyaltiesAsPercentOfAggregatedNetSales_d04e4a69-a32b-4b26-9153-f6eef2d9023a_terseLabel_en-US" xlink:label="lab_vtl_AssetPurchaseAgreementRoyaltiesAsPercentOfAggregatedNetSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset purchase agreement, royalties as percent of aggregated net sales</link:label>
    <link:label id="lab_vtl_AssetPurchaseAgreementRoyaltiesAsPercentOfAggregatedNetSales_label_en-US" xlink:label="lab_vtl_AssetPurchaseAgreementRoyaltiesAsPercentOfAggregatedNetSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Purchase Agreement, Royalties As Percent Of Aggregated Net Sales</link:label>
    <link:label id="lab_vtl_AssetPurchaseAgreementRoyaltiesAsPercentOfAggregatedNetSales_documentation_en-US" xlink:label="lab_vtl_AssetPurchaseAgreementRoyaltiesAsPercentOfAggregatedNetSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Purchase Agreement, Royalties As Percent Of Aggregated Net Sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_AssetPurchaseAgreementRoyaltiesAsPercentOfAggregatedNetSales" xlink:href="vtl-20220930.xsd#vtl_AssetPurchaseAgreementRoyaltiesAsPercentOfAggregatedNetSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_AssetPurchaseAgreementRoyaltiesAsPercentOfAggregatedNetSales" xlink:to="lab_vtl_AssetPurchaseAgreementRoyaltiesAsPercentOfAggregatedNetSales" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_a1d173b2-7621-45d4-a66d-9b67c856eecd_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_f6169cc2-1aff-4fec-abc4-2c5eeba70b85_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_18b14e5f-06c3-4f7b-8a75-932a5d727ca6_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_38a9a970-116b-4bbe-b8d8-c94edc9544a8_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_0515f8a9-9f25-46d8-a795-6f92e75599c1_totalLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_efb12305-d641-42e3-8398-2ee6a29e7c4f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_LesseeOperatingLeasesNumberOfExistingLeases_b8228da3-a5ba-4f4b-8b91-1e1abec1d749_terseLabel_en-US" xlink:label="lab_vtl_LesseeOperatingLeasesNumberOfExistingLeases" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of existing leases</link:label>
    <link:label id="lab_vtl_LesseeOperatingLeasesNumberOfExistingLeases_label_en-US" xlink:label="lab_vtl_LesseeOperatingLeasesNumberOfExistingLeases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases, Number Of Existing Leases</link:label>
    <link:label id="lab_vtl_LesseeOperatingLeasesNumberOfExistingLeases_documentation_en-US" xlink:label="lab_vtl_LesseeOperatingLeasesNumberOfExistingLeases" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases, Number Of Existing Leases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_LesseeOperatingLeasesNumberOfExistingLeases" xlink:href="vtl-20220930.xsd#vtl_LesseeOperatingLeasesNumberOfExistingLeases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_LesseeOperatingLeasesNumberOfExistingLeases" xlink:to="lab_vtl_LesseeOperatingLeasesNumberOfExistingLeases" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_6595fc20-805d-40e0-9a9a-44dc97361ee7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Disclosures</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2fd4469a-edd8-4778-91db-d4c1fae0d07e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercisable, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TangibleAssetImpairmentCharges_281a25bb-2cbc-4634-b969-adc11507e218_terseLabel_en-US" xlink:label="lab_us-gaap_TangibleAssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment losses</link:label>
    <link:label id="lab_us-gaap_TangibleAssetImpairmentCharges_label_en-US" xlink:label="lab_us-gaap_TangibleAssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tangible Asset Impairment Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TangibleAssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TangibleAssetImpairmentCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TangibleAssetImpairmentCharges" xlink:to="lab_us-gaap_TangibleAssetImpairmentCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_50bce181-2158-4f05-ab89-93767d2e5475_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_RoyaltySettlementAgreementSalesNet_0c7ae9f7-dc46-4141-9a39-8ba6c1c3733c_terseLabel_en-US" xlink:label="lab_vtl_RoyaltySettlementAgreementSalesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4SC Royalty Settlement (see Note 4)</link:label>
    <link:label id="lab_vtl_RoyaltySettlementAgreementSalesNet_label_en-US" xlink:label="lab_vtl_RoyaltySettlementAgreementSalesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Settlement Agreement, Sales Net</link:label>
    <link:label id="lab_vtl_RoyaltySettlementAgreementSalesNet_documentation_en-US" xlink:label="lab_vtl_RoyaltySettlementAgreementSalesNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Settlement Agreement, Sales Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_RoyaltySettlementAgreementSalesNet" xlink:href="vtl-20220930.xsd#vtl_RoyaltySettlementAgreementSalesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_RoyaltySettlementAgreementSalesNet" xlink:to="lab_vtl_RoyaltySettlementAgreementSalesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_b9d01559-976e-4222-aa06-607e16f45533_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_6b60787d-e90b-457c-acf5-205122a0e4f9_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrent_d135fb95-35b8-4a72-84e6-0688000073e5_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total long-term liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrent" xlink:to="lab_us-gaap_LiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_7839bac5-a003-4db9-b7a7-96bffa95070f_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_bf8cf79d-aa5a-4efa-97a3-f9a1e0ebf09f_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_aedb07fb-e9c1-4e27-ac69-e8082e5ad6bc_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_be529597-3147-4e43-986b-27359872498f_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease term (in months)</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_8f294b36-3ce4-4e92-824c-0aee08817426_verboseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease term (in years)</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesTableTextBlock_d60c523f-bb2c-4900-999e-988277a9f390_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Other Current Liabilities</link:label>
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Current Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCurrentLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_eb6c7f82-7b1d-41db-912e-5870219e762d_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_A2017InducementEquityIncentivePlanMember_1d8985e1-556c-4537-b82f-6b66dbab7e97_terseLabel_en-US" xlink:label="lab_vtl_A2017InducementEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2017 Inducement Equity Incentive Plan</link:label>
    <link:label id="lab_vtl_A2017InducementEquityIncentivePlanMember_label_en-US" xlink:label="lab_vtl_A2017InducementEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2017 Inducement Equity Incentive Plan [Member]</link:label>
    <link:label id="lab_vtl_A2017InducementEquityIncentivePlanMember_documentation_en-US" xlink:label="lab_vtl_A2017InducementEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2017 Inducement Equity Incentive Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_A2017InducementEquityIncentivePlanMember" xlink:href="vtl-20220930.xsd#vtl_A2017InducementEquityIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_A2017InducementEquityIncentivePlanMember" xlink:to="lab_vtl_A2017InducementEquityIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_6fe851fc-5376-4f5f-8a10-78662101de8f_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, Weighted-Average Remaining Contractual Term, Ending balance</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_9f27650c-1aba-49e4-ad82-0cf9f39ef4bb_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_f03a1191-4e19-40dd-9341-83dcd3cf68c3_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableOtherCurrent_89f49668-cf42-4903-b7da-9a393a6af934_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableOtherCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_AccountsPayableOtherCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableOtherCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Other, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableOtherCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableOtherCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableOtherCurrent" xlink:to="lab_us-gaap_AccountsPayableOtherCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_81f1abaa-396f-4cb1-8e27-017410905139_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForCommissions_08ed3a15-1f06-48a9-b4ed-31ee57056556_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForCommissions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Underwriter commissions</link:label>
    <link:label id="lab_us-gaap_PaymentsForCommissions_label_en-US" xlink:label="lab_us-gaap_PaymentsForCommissions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Commissions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForCommissions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForCommissions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForCommissions" xlink:to="lab_us-gaap_PaymentsForCommissions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_4e4acccb-d0e1-4e52-baec-6196ebeb10ce_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_GrafelfingGermanyMember_54d88969-5bdd-4c41-bb61-c324b0b1601e_terseLabel_en-US" xlink:label="lab_vtl_GrafelfingGermanyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grafelfing, Germany</link:label>
    <link:label id="lab_vtl_GrafelfingGermanyMember_label_en-US" xlink:label="lab_vtl_GrafelfingGermanyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grafelfing, Germany [Member]</link:label>
    <link:label id="lab_vtl_GrafelfingGermanyMember_documentation_en-US" xlink:label="lab_vtl_GrafelfingGermanyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grafelfing, Germany</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_GrafelfingGermanyMember" xlink:href="vtl-20220930.xsd#vtl_GrafelfingGermanyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_GrafelfingGermanyMember" xlink:to="lab_vtl_GrafelfingGermanyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_f84c3a8b-1070-4289-bbef-5071845d80f3_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_999aaab3-8e06-44d0-9404-e657c2a1901f_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_628ed733-c458-433d-b296-7eacc65bfac8_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0b2d208d-29fc-4d7b-a3b0-f99d9a383885_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_b7723d9e-ca10-4300-bfb9-e910f6c59266_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation and Consolidation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2fdfa8b7-e98d-4464-afa7-b495d5572916_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of exchange rate changes on cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_05bf73ef-b767-4c03-9df3-0d935e2dbf17_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_95c49cbd-581b-4d3e-9761-db11c1d2b40b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementAccountingPolicy_db0ef1fb-1f19-4e3b-8371-35d7815c835a_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Arrangements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementAccountingPolicy_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Accounting Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementAccountingPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:to="lab_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5fa9acaf-d9a0-4cf6-8ff0-02058d1ca2a0_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_A4SCRoyaltySettlementMember_35425e97-9a32-4a0e-a4fe-0f7d642119da_terseLabel_en-US" xlink:label="lab_vtl_A4SCRoyaltySettlementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4SC Royalty Settlement</link:label>
    <link:label id="lab_vtl_A4SCRoyaltySettlementMember_label_en-US" xlink:label="lab_vtl_A4SCRoyaltySettlementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4SC Royalty Settlement [Member]</link:label>
    <link:label id="lab_vtl_A4SCRoyaltySettlementMember_documentation_en-US" xlink:label="lab_vtl_A4SCRoyaltySettlementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4SC Royalty Settlement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_A4SCRoyaltySettlementMember" xlink:href="vtl-20220930.xsd#vtl_A4SCRoyaltySettlementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_A4SCRoyaltySettlementMember" xlink:to="lab_vtl_A4SCRoyaltySettlementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_d6fe8226-2a73-42f5-9830-0ddbf82912b5_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain" xlink:to="lab_us-gaap_RelatedPartyTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_ChangesInBoardOfDirectorsDisclosureTextBlock_2b73cf45-38ea-4322-97c8-a8a25da67ab4_terseLabel_en-US" xlink:label="lab_vtl_ChangesInBoardOfDirectorsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in Board of Directors</link:label>
    <link:label id="lab_vtl_ChangesInBoardOfDirectorsDisclosureTextBlock_label_en-US" xlink:label="lab_vtl_ChangesInBoardOfDirectorsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes In Board of Directors Disclosure [Text Block]</link:label>
    <link:label id="lab_vtl_ChangesInBoardOfDirectorsDisclosureTextBlock_documentation_en-US" xlink:label="lab_vtl_ChangesInBoardOfDirectorsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes In Board of Directors Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_ChangesInBoardOfDirectorsDisclosureTextBlock" xlink:href="vtl-20220930.xsd#vtl_ChangesInBoardOfDirectorsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_ChangesInBoardOfDirectorsDisclosureTextBlock" xlink:to="lab_vtl_ChangesInBoardOfDirectorsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_1b948fa2-e9b7-4be4-8583-e7d688b6f7c3_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_4e9d031d-4933-4eea-b928-2f4c16728071_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_942d3edd-94a8-480d-a4b7-3daa61c1a9e2_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Relationship to Entity [Domain]</link:label>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_label_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_8e2fb663-702e-4ae1-982d-7cf41397797f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility (as percent)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_4f8a4c4f-4510-490e-8018-8eca4dc5b914_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum annual contributions per employee (as a percent)</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:to="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LegalEntityAxis_b2d13252-04e9-4722-ade3-fdbeb79c66bc_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:label id="lab_dei_LegalEntityAxis_label_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_becec815-0899-4e6e-a439-0d34135a7e7c_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense), net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_b61be29f-1fa0-4ac9-a6fd-9d3d5193bef7_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock, price per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_8584d7ac-22f5-473f-ac75-a5b045b0e7f7_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_3fd202f9-b223-4820-90e3-a33c3e3be497_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_a74cc7f7-8d36-417d-abc0-fa758b4b62dc_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_69b27a00-46e1-4b65-908d-27981b1aafe2_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6ffdfc83-3d81-46a0-95d5-aae6fdf3938a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_9f876b6a-f817-4276-ba01-52bfe7b6f035_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_NumberOfDevelopmentProgramsPursued_a5f42ac6-0302-4d40-a48a-b7008f621afd_terseLabel_en-US" xlink:label="lab_vtl_NumberOfDevelopmentProgramsPursued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of development programs pursued</link:label>
    <link:label id="lab_vtl_NumberOfDevelopmentProgramsPursued_label_en-US" xlink:label="lab_vtl_NumberOfDevelopmentProgramsPursued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Development Programs Pursued</link:label>
    <link:label id="lab_vtl_NumberOfDevelopmentProgramsPursued_documentation_en-US" xlink:label="lab_vtl_NumberOfDevelopmentProgramsPursued" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Development Programs Pursued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_NumberOfDevelopmentProgramsPursued" xlink:href="vtl-20220930.xsd#vtl_NumberOfDevelopmentProgramsPursued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_NumberOfDevelopmentProgramsPursued" xlink:to="lab_vtl_NumberOfDevelopmentProgramsPursued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_8cfc6583-283a-41e0-bd20-a3cff0a895ab_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_66b17302-42c2-4cc9-be08-0d5c62e3da8e_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_722cc2dc-5130-4638-b3ca-fbeb8ddc6e02_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_0aca42f3-43d8-47fd-933d-9b262339754d_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_fd54663c-1548-4829-819b-1c9171e4eedd_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_3bb65ccb-d06b-4a99-92eb-5b9f0f284515_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7ac11f48-e3d8-4d15-a67c-f4ed5a29d074_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_d90c854a-f2e8-47a6-8219-2dc91d267114_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_9bb8e2c8-9e8b-4d73-a2dd-e435b3919a9a_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_1ec1c1af-7a2a-47dd-a9f0-04d73ce16ee4_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_edb10c56-9d67-423d-adec-547dd374726e_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_f0dc6b4d-3298-470f-85c1-972a30e7e95a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndFederalFundsSold_157f32ab-afd3-4a44-9f6b-f056b5ffa8ab_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndFederalFundsSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash funds</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndFederalFundsSold_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndFederalFundsSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, and Federal Funds Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndFederalFundsSold" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndFederalFundsSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndFederalFundsSold" xlink:to="lab_us-gaap_CashCashEquivalentsAndFederalFundsSold" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_395b303a-b0a7-4b40-89a9-72675c1071bc_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_168858f2-19bc-4093-9506-619ff01180bf_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated useful life (in years)</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_71e5315a-2683-4b14-9a3c-44b09b411ea2_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_5567e086-4c18-4846-8717-7eb863fee453_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable_d1604fa9-0d97-46d1-ba8a-6644be2d945c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock issued in connection with the 4SC royalty settlement (see Note 4)</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Consideration Transferred, Equity Interest Issued and Issuable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable" xlink:to="lab_us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_092ba1e0-310c-44fc-872f-1538949bd370_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited or expired (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareDeclared_a6c8c1e0-55b8-4af9-8ea7-8ac8a515b1b5_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, cash dividends declared (in USD per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareDeclared_label_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Dividends, Per Share, Declared</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockDividendsPerShareDeclared" xlink:to="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_44225732-1210-4f09-ac01-c41ede24379d_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_AccruedLegalAndAuditCostsCurrent_2bf59c62-a99a-4c0d-bb72-28ea86a7f792_terseLabel_en-US" xlink:label="lab_vtl_AccruedLegalAndAuditCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued legal and audit costs</link:label>
    <link:label id="lab_vtl_AccruedLegalAndAuditCostsCurrent_label_en-US" xlink:label="lab_vtl_AccruedLegalAndAuditCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Legal And Audit Costs, Current</link:label>
    <link:label id="lab_vtl_AccruedLegalAndAuditCostsCurrent_documentation_en-US" xlink:label="lab_vtl_AccruedLegalAndAuditCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Legal And Audit Costs, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_AccruedLegalAndAuditCostsCurrent" xlink:href="vtl-20220930.xsd#vtl_AccruedLegalAndAuditCostsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_AccruedLegalAndAuditCostsCurrent" xlink:to="lab_vtl_AccruedLegalAndAuditCostsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_TwoThousandFourteenEquityIncentivePlanMember_7c05cbc0-9f61-4ae6-9850-357bd4717936_terseLabel_en-US" xlink:label="lab_vtl_TwoThousandFourteenEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2014 Equity Incentive Plan</link:label>
    <link:label id="lab_vtl_TwoThousandFourteenEquityIncentivePlanMember_label_en-US" xlink:label="lab_vtl_TwoThousandFourteenEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Fourteen Equity Incentive Plan [Member]</link:label>
    <link:label id="lab_vtl_TwoThousandFourteenEquityIncentivePlanMember_documentation_en-US" xlink:label="lab_vtl_TwoThousandFourteenEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Fourteen Equity Incentive Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_TwoThousandFourteenEquityIncentivePlanMember" xlink:href="vtl-20220930.xsd#vtl_TwoThousandFourteenEquityIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_TwoThousandFourteenEquityIncentivePlanMember" xlink:to="lab_vtl_TwoThousandFourteenEquityIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_December2020ATMMember_21e47ad6-6365-45dc-8589-d012dd623f22_terseLabel_en-US" xlink:label="lab_vtl_December2020ATMMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">December 2020 ATM</link:label>
    <link:label id="lab_vtl_December2020ATMMember_label_en-US" xlink:label="lab_vtl_December2020ATMMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">December 2020 ATM [Member]</link:label>
    <link:label id="lab_vtl_December2020ATMMember_documentation_en-US" xlink:label="lab_vtl_December2020ATMMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">December 2020 ATM</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_December2020ATMMember" xlink:href="vtl-20220930.xsd#vtl_December2020ATMMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_December2020ATMMember" xlink:to="lab_vtl_December2020ATMMember" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_PrepaidClinicalAndRelatedCostsCurrent_4e6e283f-fc7a-4c4d-8ab7-a92416ade42f_terseLabel_en-US" xlink:label="lab_vtl_PrepaidClinicalAndRelatedCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid clinical and related costs</link:label>
    <link:label id="lab_vtl_PrepaidClinicalAndRelatedCostsCurrent_label_en-US" xlink:label="lab_vtl_PrepaidClinicalAndRelatedCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Clinical And Related Costs, Current</link:label>
    <link:label id="lab_vtl_PrepaidClinicalAndRelatedCostsCurrent_documentation_en-US" xlink:label="lab_vtl_PrepaidClinicalAndRelatedCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Clinical And Related Costs, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_PrepaidClinicalAndRelatedCostsCurrent" xlink:href="vtl-20220930.xsd#vtl_PrepaidClinicalAndRelatedCostsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_PrepaidClinicalAndRelatedCostsCurrent" xlink:to="lab_vtl_PrepaidClinicalAndRelatedCostsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_876e6815-a993-4e50-9883-d3f87df6e764_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_df92b276-12ba-4f7e-ba14-28ec2d391be2_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total unrecognized compensation expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_5fc578f9-a61e-4583-86e2-6c8e6c7cf3aa_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_60fc03dd-d8fd-42ee-bd0a-f0f8541e7a93_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock_d877619f-95af-41a0-bdba-90a7a6a74d17_terseLabel_en-US" xlink:label="lab_vtl_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Reserved for Future Issuance</link:label>
    <link:label id="lab_vtl_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock_label_en-US" xlink:label="lab_vtl_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Common Stock Reserved For Future Issuance [Table Text Block]</link:label>
    <link:label id="lab_vtl_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock_documentation_en-US" xlink:label="lab_vtl_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Common Stock Reserved For Future Issuance [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" xlink:href="vtl-20220930.xsd#vtl_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" xlink:to="lab_vtl_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent_576a83ef-aa74-4db2-9a2b-3c8abb49a9ce_terseLabel_en-US" xlink:label="lab_vtl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional shares authorized, percent</link:label>
    <link:label id="lab_vtl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent_label_en-US" xlink:label="lab_vtl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement By Share-Based Payment Award, Additional Shares Authorized, Percent</link:label>
    <link:label id="lab_vtl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent_documentation_en-US" xlink:label="lab_vtl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement By Share-Based Payment Award, Additional Shares Authorized, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent" xlink:href="vtl-20220930.xsd#vtl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent" xlink:to="lab_vtl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5233a9cb-c1f2-4542-8094-d2a1ed5fbae5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_9908137d-bc5a-4a65-bbb6-259c3f80bf08_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_fed3c097-fd99-4af3-9999-7860c592c527_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_bf6848d2-bb27-4cc3-8da6-8869b7692d6b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, Aggregate Intrinsic Value, Ending balance</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_SharesIssuedWeightedAverageSharePricePerShare_f903362c-ccd8-4b33-8d83-d8bc5dfb093a_terseLabel_en-US" xlink:label="lab_vtl_SharesIssuedWeightedAverageSharePricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of stock (in USD per share)</link:label>
    <link:label id="lab_vtl_SharesIssuedWeightedAverageSharePricePerShare_label_en-US" xlink:label="lab_vtl_SharesIssuedWeightedAverageSharePricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Weighted Average Share Price Per Share</link:label>
    <link:label id="lab_vtl_SharesIssuedWeightedAverageSharePricePerShare_documentation_en-US" xlink:label="lab_vtl_SharesIssuedWeightedAverageSharePricePerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Weighted Average Share Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_SharesIssuedWeightedAverageSharePricePerShare" xlink:href="vtl-20220930.xsd#vtl_SharesIssuedWeightedAverageSharePricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_SharesIssuedWeightedAverageSharePricePerShare" xlink:to="lab_vtl_SharesIssuedWeightedAverageSharePricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_30ed4eac-e32d-4551-99da-f354a514d1f6_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_AccruedCompensationCurrent_ab4ad897-495e-433c-904b-2a15a14dadb1_terseLabel_en-US" xlink:label="lab_vtl_AccruedCompensationCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation</link:label>
    <link:label id="lab_vtl_AccruedCompensationCurrent_label_en-US" xlink:label="lab_vtl_AccruedCompensationCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Compensation, Current</link:label>
    <link:label id="lab_vtl_AccruedCompensationCurrent_documentation_en-US" xlink:label="lab_vtl_AccruedCompensationCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Compensation, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_AccruedCompensationCurrent" xlink:href="vtl-20220930.xsd#vtl_AccruedCompensationCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_AccruedCompensationCurrent" xlink:to="lab_vtl_AccruedCompensationCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_AffiliatedEntityMember_bf11335d-ef1d-4163-a08f-fa790c24a65c_terseLabel_en-US" xlink:label="lab_srt_AffiliatedEntityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliated Entity</link:label>
    <link:label id="lab_srt_AffiliatedEntityMember_label_en-US" xlink:label="lab_srt_AffiliatedEntityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliated Entity [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_AffiliatedEntityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_AffiliatedEntityMember" xlink:to="lab_srt_AffiliatedEntityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_9b5593d1-60ce-4296-a2bf-9fc7e710c4fa_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_bdf5d5bc-54c1-4569-9448-269030469adc_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_NewYorkCityMember_a3d4b99a-05f8-4d1d-87e5-82dc6e948e46_terseLabel_en-US" xlink:label="lab_vtl_NewYorkCityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New York City</link:label>
    <link:label id="lab_vtl_NewYorkCityMember_label_en-US" xlink:label="lab_vtl_NewYorkCityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New York City [Member]</link:label>
    <link:label id="lab_vtl_NewYorkCityMember_documentation_en-US" xlink:label="lab_vtl_NewYorkCityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New York City</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_NewYorkCityMember" xlink:href="vtl-20220930.xsd#vtl_NewYorkCityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_NewYorkCityMember" xlink:to="lab_vtl_NewYorkCityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_fadf1e98-6ada-4f7b-af12-c65f121ebda3_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance costs</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_8e4b02f2-274f-429f-9140-fa083da3be11_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_1ad542c0-4f9d-4cfb-a0bb-2f09747c8850_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_f916d93e-cec6-4e42-8964-08d32b1e8b16_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PV of obligation</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_bc00d41a-5759-47f4-a5cc-fcc47d41afe8_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_EquityMethodInvestmentWarrantsExercisableOwnershipLimitationPercentage_c5305561-319e-4613-8864-7e812e535b87_terseLabel_en-US" xlink:label="lab_vtl_EquityMethodInvestmentWarrantsExercisableOwnershipLimitationPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">May not exercise of percentage</link:label>
    <link:label id="lab_vtl_EquityMethodInvestmentWarrantsExercisableOwnershipLimitationPercentage_label_en-US" xlink:label="lab_vtl_EquityMethodInvestmentWarrantsExercisableOwnershipLimitationPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Warrants, Exercisable Ownership Limitation, Percentage</link:label>
    <link:label id="lab_vtl_EquityMethodInvestmentWarrantsExercisableOwnershipLimitationPercentage_documentation_en-US" xlink:label="lab_vtl_EquityMethodInvestmentWarrantsExercisableOwnershipLimitationPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Warrants, Exercisable Ownership Limitation, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_EquityMethodInvestmentWarrantsExercisableOwnershipLimitationPercentage" xlink:href="vtl-20220930.xsd#vtl_EquityMethodInvestmentWarrantsExercisableOwnershipLimitationPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_EquityMethodInvestmentWarrantsExercisableOwnershipLimitationPercentage" xlink:to="lab_vtl_EquityMethodInvestmentWarrantsExercisableOwnershipLimitationPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_5afbd373-494e-41d5-a388-24bc20d9ff87_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_a414674e-5047-4643-b01e-7d24d1682113_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_NumberOfFinancialInstitutionsUsedForCashDeposits_4fdeee98-f236-46ee-b536-b1ae7c4af04c_terseLabel_en-US" xlink:label="lab_vtl_NumberOfFinancialInstitutionsUsedForCashDeposits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of financial institutions used for cash deposits</link:label>
    <link:label id="lab_vtl_NumberOfFinancialInstitutionsUsedForCashDeposits_label_en-US" xlink:label="lab_vtl_NumberOfFinancialInstitutionsUsedForCashDeposits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Financial Institutions Used For Cash Deposits</link:label>
    <link:label id="lab_vtl_NumberOfFinancialInstitutionsUsedForCashDeposits_documentation_en-US" xlink:label="lab_vtl_NumberOfFinancialInstitutionsUsedForCashDeposits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Financial Institutions Used For Cash Deposits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_NumberOfFinancialInstitutionsUsedForCashDeposits" xlink:href="vtl-20220930.xsd#vtl_NumberOfFinancialInstitutionsUsedForCashDeposits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_NumberOfFinancialInstitutionsUsedForCashDeposits" xlink:to="lab_vtl_NumberOfFinancialInstitutionsUsedForCashDeposits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1ec6239b-cc67-4859-8899-02b8960dadab_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_79720aaa-8ea1-4160-9976-61f1da6b51a9_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Stockholders&#8217; Equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_4bf885e3-9739-452b-8efe-532b704ab111_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts Payable and Accrued Expenses</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_a6a25206-6995-47c2-bf71-20c67e3866aa_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_20fa6100-64c5-4584-aa41-fcb6494a9749_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_80aae034-fce0-4c59-9c50-e023e57ad152_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_53c30bec-63d3-4b59-9f46-30d9a0deac81_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_001c232d-b83f-4022-aa65-023c8e859b47_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_29f051c1-a4c5-4b24-80be-a5a916f3c072_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited or expired (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_d07b41bf-7dbe-454f-81f6-141a9f8854e6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_8af00d15-75de-482f-b70c-408b8f6e9f74_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_4ac5644b-313c-4be5-a8e1-1978b8251cb8_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_17b199dd-ebe4-42d3-9610-a183b800dfb1_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of stock</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_170329a2-5418-4ea8-8e8f-22595aa847ce_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_ba2189e9-01d9-499f-9188-9899b6cc4fa6_totalLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_efee90a6-c213-422f-805a-d4826d3635d9_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_cdf8a45b-d235-4f45-82e7-b9979ce0cf78_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets and prepaid expenses</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_ac99ee2b-3564-45ed-ae3c-d52eef3ea94f_totalLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_7c11bda0-5e8d-4295-9f25-1a156c577d49_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options vested and expected to vest , Aggregate Intrinsic Value, Ending balance</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityNumberOfEmployees_0795fbaa-26fb-4cd2-b343-e36cb63a2fd8_terseLabel_en-US" xlink:label="lab_dei_EntityNumberOfEmployees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of employees</link:label>
    <link:label id="lab_dei_EntityNumberOfEmployees_label_en-US" xlink:label="lab_dei_EntityNumberOfEmployees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Number of Employees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityNumberOfEmployees" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityNumberOfEmployees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityNumberOfEmployees" xlink:to="lab_dei_EntityNumberOfEmployees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_a9e00a7f-b224-453e-9fa5-6240d201f6d9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Valuation Assumptions Used</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_EquityMethodInvestmentWarrantsExercisableSharesChangeLimitationNoticePeriod_6c7e048a-b249-4932-849c-be72756f6e3c_terseLabel_en-US" xlink:label="lab_vtl_EquityMethodInvestmentWarrantsExercisableSharesChangeLimitationNoticePeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase or decrease not In excess of prior notice period</link:label>
    <link:label id="lab_vtl_EquityMethodInvestmentWarrantsExercisableSharesChangeLimitationNoticePeriod_label_en-US" xlink:label="lab_vtl_EquityMethodInvestmentWarrantsExercisableSharesChangeLimitationNoticePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Warrants, Exercisable Shares Change Limitation, Notice Period</link:label>
    <link:label id="lab_vtl_EquityMethodInvestmentWarrantsExercisableSharesChangeLimitationNoticePeriod_documentation_en-US" xlink:label="lab_vtl_EquityMethodInvestmentWarrantsExercisableSharesChangeLimitationNoticePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Warrants, Exercisable Shares Change Limitation, Notice Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_EquityMethodInvestmentWarrantsExercisableSharesChangeLimitationNoticePeriod" xlink:href="vtl-20220930.xsd#vtl_EquityMethodInvestmentWarrantsExercisableSharesChangeLimitationNoticePeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_EquityMethodInvestmentWarrantsExercisableSharesChangeLimitationNoticePeriod" xlink:to="lab_vtl_EquityMethodInvestmentWarrantsExercisableSharesChangeLimitationNoticePeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_44d8996a-099c-425e-ae8d-78756470766f_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_a4c81827-c7ff-446c-a131-7621891634ef_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Details</link:label>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Balance Sheet Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_db4643d2-4677-4a47-bf5f-be5d33a2b4d3_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_f9ed6e8a-600d-4837-9e8d-e3fda3a8bacd_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_1748a457-14ce-41f3-84e1-a46c7478c2c6_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_99d6a7c7-2bbd-4e1b-a8ad-9d7906045176_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common stock at premium</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_d6c0777a-fe1d-41cc-aaba-5c6caa9aba30_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average common shares outstanding, basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b8c0f0a4-cca3-47d4-a443-e40ada6c7c80_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Award [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_0a752fb2-6ddd-4f43-86b4-74d23ba64a3d_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period over which compensation cost will be recognized (in years)</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_5535e40f-c4cc-4dba-8d6d-38fd41745bab_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercisable, Weighted-Average Remaining Contractual Term, Ending balance</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock_2e55b309-cb7f-4531-8314-e9adc2ef2e75_terseLabel_en-US" xlink:label="lab_vtl_ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commission, percent of gross proceeds from sale of common stock</link:label>
    <link:label id="lab_vtl_ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock_label_en-US" xlink:label="lab_vtl_ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shelf Registration Agreement, Commission, Percent Of Gross Proceeds On Sale Of Common Stock</link:label>
    <link:label id="lab_vtl_ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock_documentation_en-US" xlink:label="lab_vtl_ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shelf Registration Agreement, Commission, Percent Of Gross Proceeds On Sale Of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock" xlink:href="vtl-20220930.xsd#vtl_ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock" xlink:to="lab_vtl_ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_OperatingAndVariableLeasesCost_7ead8305-7a8b-4f5b-8c2b-34567f5e72ae_terseLabel_en-US" xlink:label="lab_vtl_OperatingAndVariableLeasesCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating and variable lease costs</link:label>
    <link:label id="lab_vtl_OperatingAndVariableLeasesCost_label_en-US" xlink:label="lab_vtl_OperatingAndVariableLeasesCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating And Variable Leases, Cost</link:label>
    <link:label id="lab_vtl_OperatingAndVariableLeasesCost_documentation_en-US" xlink:label="lab_vtl_OperatingAndVariableLeasesCost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating And Variable Leases, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_OperatingAndVariableLeasesCost" xlink:href="vtl-20220930.xsd#vtl_OperatingAndVariableLeasesCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_OperatingAndVariableLeasesCost" xlink:to="lab_vtl_OperatingAndVariableLeasesCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_1306ee21-04d3-4d56-ab17-c0252833bca2_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_550597a3-47d5-41ab-b211-fc63746dbfd0_terseLabel_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosure of noncash investing and financing activities:</link:label>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_label_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Investing and Financing Items [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_55824ac1-dfc5-4421-8c57-a141c6413939_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies (Note 4)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_a0b82a34-7d77-489b-bd84-5cc6952c0a49_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_3ec09b4f-73c4-49a0-89e1-6aa1a78f1016_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_255ec9d8-661d-4b6f-beda-7484b8f22bba_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_a0787b20-82f2-4c19-aea8-8e4145af4ddf_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, beginning balance (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_07bf6c53-e699-46a5-b5e8-53512f1a2929_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, ending balance (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_438a6c21-a4db-4bbe-bf94-0b93d43d4789_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_ba2db855-fc99-47f6-b602-1f22a42dddad_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock issued (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_bf6f19fa-a3ac-433c-8ce0-df900e5cb454_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_9d13d8b7-a42e-401e-873d-4bcd969d50d6_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssued1_5900509c-d780-49a7-a982-fc25234c191a_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssued1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock issued in connection with the 4SC royalty settlement (see Note 4)</link:label>
    <link:label id="lab_us-gaap_StockIssued1_label_en-US" xlink:label="lab_us-gaap_StockIssued1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssued1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssued1" xlink:to="lab_us-gaap_StockIssued1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_87ba0800-b504-4603-a62d-ca0ff7f728ff_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, $0.0001 par value; 20,000,000 authorized and no shares issued or outstanding at September 30, 2022 and December 31, 2021</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_b89d3f71-80bb-4530-bf29-500fd83f8763_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected dividend yield (as percent)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_ResearchAndDevelopmentTaxIncentiveCurrent_1920afc6-17c8-4f1d-ac6e-3e221b3fa5d8_terseLabel_en-US" xlink:label="lab_vtl_ResearchAndDevelopmentTaxIncentiveCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Australian research and development tax incentive</link:label>
    <link:label id="lab_vtl_ResearchAndDevelopmentTaxIncentiveCurrent_label_en-US" xlink:label="lab_vtl_ResearchAndDevelopmentTaxIncentiveCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Tax Incentive, Current</link:label>
    <link:label id="lab_vtl_ResearchAndDevelopmentTaxIncentiveCurrent_documentation_en-US" xlink:label="lab_vtl_ResearchAndDevelopmentTaxIncentiveCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Tax Incentive, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_ResearchAndDevelopmentTaxIncentiveCurrent" xlink:href="vtl-20220930.xsd#vtl_ResearchAndDevelopmentTaxIncentiveCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_ResearchAndDevelopmentTaxIncentiveCurrent" xlink:to="lab_vtl_ResearchAndDevelopmentTaxIncentiveCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_ShelfRegistrationStatementAmountRemaining_5e26bf9a-208b-4742-a8a5-013d3e324824_terseLabel_en-US" xlink:label="lab_vtl_ShelfRegistrationStatementAmountRemaining" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shelf registration statement, amount remaining</link:label>
    <link:label id="lab_vtl_ShelfRegistrationStatementAmountRemaining_label_en-US" xlink:label="lab_vtl_ShelfRegistrationStatementAmountRemaining" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shelf Registration Statement, Amount Remaining</link:label>
    <link:label id="lab_vtl_ShelfRegistrationStatementAmountRemaining_documentation_en-US" xlink:label="lab_vtl_ShelfRegistrationStatementAmountRemaining" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shelf Registration Statement, Amount Remaining</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_ShelfRegistrationStatementAmountRemaining" xlink:href="vtl-20220930.xsd#vtl_ShelfRegistrationStatementAmountRemaining"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_ShelfRegistrationStatementAmountRemaining" xlink:to="lab_vtl_ShelfRegistrationStatementAmountRemaining" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_EmployeeStockOptionsforFutureGrantMember_6408d3b8-2675-44fb-a304-98cf2a36c508_terseLabel_en-US" xlink:label="lab_vtl_EmployeeStockOptionsforFutureGrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock options available for future grant:</link:label>
    <link:label id="lab_vtl_EmployeeStockOptionsforFutureGrantMember_label_en-US" xlink:label="lab_vtl_EmployeeStockOptionsforFutureGrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Options for Future Grant [Member]</link:label>
    <link:label id="lab_vtl_EmployeeStockOptionsforFutureGrantMember_documentation_en-US" xlink:label="lab_vtl_EmployeeStockOptionsforFutureGrantMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Options for Future Grant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_EmployeeStockOptionsforFutureGrantMember" xlink:href="vtl-20220930.xsd#vtl_EmployeeStockOptionsforFutureGrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_EmployeeStockOptionsforFutureGrantMember" xlink:to="lab_vtl_EmployeeStockOptionsforFutureGrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_062a0849-b659-441a-a180-056119c6dff7_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_c12ca0bc-d3af-4784-b892-995298c93a6b_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_9088400a-9ee4-41a5-9e1c-e51e0d64ff29_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_TwoThousandNineteenOmnibusEquityIncentivePlanMember_f676b5e8-f5c8-4293-80c3-5d11ed02009d_terseLabel_en-US" xlink:label="lab_vtl_TwoThousandNineteenOmnibusEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 Omnibus Equity Incentive Plan</link:label>
    <link:label id="lab_vtl_TwoThousandNineteenOmnibusEquityIncentivePlanMember_label_en-US" xlink:label="lab_vtl_TwoThousandNineteenOmnibusEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Nineteen Omnibus Equity Incentive Plan [Member]</link:label>
    <link:label id="lab_vtl_TwoThousandNineteenOmnibusEquityIncentivePlanMember_documentation_en-US" xlink:label="lab_vtl_TwoThousandNineteenOmnibusEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Nineteen Omnibus Equity Incentive Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_TwoThousandNineteenOmnibusEquityIncentivePlanMember" xlink:href="vtl-20220930.xsd#vtl_TwoThousandNineteenOmnibusEquityIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_TwoThousandNineteenOmnibusEquityIncentivePlanMember" xlink:to="lab_vtl_TwoThousandNineteenOmnibusEquityIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_AccruedClinicalCostsCurrent_86cdef52-59f4-450e-915d-3a3c8ace182a_terseLabel_en-US" xlink:label="lab_vtl_AccruedClinicalCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued clinical and related costs</link:label>
    <link:label id="lab_vtl_AccruedClinicalCostsCurrent_label_en-US" xlink:label="lab_vtl_AccruedClinicalCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Clinical Costs, Current</link:label>
    <link:label id="lab_vtl_AccruedClinicalCostsCurrent_documentation_en-US" xlink:label="lab_vtl_AccruedClinicalCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Clinical Costs, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_AccruedClinicalCostsCurrent" xlink:href="vtl-20220930.xsd#vtl_AccruedClinicalCostsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_AccruedClinicalCostsCurrent" xlink:to="lab_vtl_AccruedClinicalCostsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_9c2c5612-4b39-4537-8701-035118de7988_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total common shares reserved for future issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_99b5d2c5-1f07-451a-9cba-f07c3cba3289_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_fc74e576-16f1-49aa-948a-6635e2347a70_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long term liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Noncurrent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_ShelfRegistrationTerminationPriorWrittenNotice_2d8d791e-3c14-4c71-948a-d0ce779f89fd_terseLabel_en-US" xlink:label="lab_vtl_ShelfRegistrationTerminationPriorWrittenNotice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shelf registration, termination, prior written notice</link:label>
    <link:label id="lab_vtl_ShelfRegistrationTerminationPriorWrittenNotice_label_en-US" xlink:label="lab_vtl_ShelfRegistrationTerminationPriorWrittenNotice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shelf Registration, Termination, Prior Written Notice</link:label>
    <link:label id="lab_vtl_ShelfRegistrationTerminationPriorWrittenNotice_documentation_en-US" xlink:label="lab_vtl_ShelfRegistrationTerminationPriorWrittenNotice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shelf Registration, Termination, Prior Written Notice</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_ShelfRegistrationTerminationPriorWrittenNotice" xlink:href="vtl-20220930.xsd#vtl_ShelfRegistrationTerminationPriorWrittenNotice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_ShelfRegistrationTerminationPriorWrittenNotice" xlink:to="lab_vtl_ShelfRegistrationTerminationPriorWrittenNotice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_f86d4269-e99d-4874-b1cc-406bbad68c40_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_3b9b50d4-b9ab-47ac-805c-1654a1ae0308_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level&#160;3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_OptionsVestingInThreeYearsMember_4330efb3-b2c9-4b88-91e5-f65bb6887813_terseLabel_en-US" xlink:label="lab_vtl_OptionsVestingInThreeYearsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options Vesting In Three Years</link:label>
    <link:label id="lab_vtl_OptionsVestingInThreeYearsMember_label_en-US" xlink:label="lab_vtl_OptionsVestingInThreeYearsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options Vesting In Three Years [Member]</link:label>
    <link:label id="lab_vtl_OptionsVestingInThreeYearsMember_documentation_en-US" xlink:label="lab_vtl_OptionsVestingInThreeYearsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options Vesting In Three Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_OptionsVestingInThreeYearsMember" xlink:href="vtl-20220930.xsd#vtl_OptionsVestingInThreeYearsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_OptionsVestingInThreeYearsMember" xlink:to="lab_vtl_OptionsVestingInThreeYearsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_8a42cd2f-8d70-49fc-acd1-f3512648113f_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill Impairment</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_11cee96d-b4b1-4f47-861d-70a1d01b7de1_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation Plans</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_726dc911-12b2-4b12-9373-d68b0e945940_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_350ff72b-bdcd-43ae-ab1f-6217d3c6a119_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Other Current Assets and Prepaid Expenses</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Other Current Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_105725b1-9aed-428c-9b52-5ae4321ca052_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_56eab026-29b7-4a51-ab1f-89bd6a862a4e_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_RoyaltySettlementAgreementCashPaymentPercent_5cb800b5-aa49-4ac0-8b1c-f501f00570c5_terseLabel_en-US" xlink:label="lab_vtl_RoyaltySettlementAgreementCashPaymentPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty settlement agreement, cash payment, percent</link:label>
    <link:label id="lab_vtl_RoyaltySettlementAgreementCashPaymentPercent_label_en-US" xlink:label="lab_vtl_RoyaltySettlementAgreementCashPaymentPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Settlement Agreement, Cash Payment, Percent</link:label>
    <link:label id="lab_vtl_RoyaltySettlementAgreementCashPaymentPercent_documentation_en-US" xlink:label="lab_vtl_RoyaltySettlementAgreementCashPaymentPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Settlement Agreement, Cash Payment, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_RoyaltySettlementAgreementCashPaymentPercent" xlink:href="vtl-20220930.xsd#vtl_RoyaltySettlementAgreementCashPaymentPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_RoyaltySettlementAgreementCashPaymentPercent" xlink:to="lab_vtl_RoyaltySettlementAgreementCashPaymentPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_75fb87d2-5aad-4aa1-a0ec-b541e00e4891_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in USD per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_ec3a18a6-5b3d-4513-b624-b39d596ccf42_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Domain]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:to="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractualObligation_003c2df1-0a9d-4191-9031-cf5088c99147_terseLabel_en-US" xlink:label="lab_us-gaap_ContractualObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual obligation</link:label>
    <link:label id="lab_us-gaap_ContractualObligation_label_en-US" xlink:label="lab_us-gaap_ContractualObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractualObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractualObligation" xlink:to="lab_us-gaap_ContractualObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioForecastMember_4d43b946-aaf6-40be-a499-7688b71a7362_terseLabel_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast</link:label>
    <link:label id="lab_srt_ScenarioForecastMember_label_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioForecastMember" xlink:to="lab_srt_ScenarioForecastMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_90023148-e2a2-4a15-8a1f-ba1547180bd0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate (as percent)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_090ac829-c2e0-4c4f-962a-7b42572e03b2_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_6acb97fe-b98b-442a-bd0f-1b055da3a8e3_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharePrice_718d164c-48f6-4178-85b3-759af0337674_terseLabel_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share price (in USD per share)</link:label>
    <link:label id="lab_us-gaap_SharePrice_label_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharePrice" xlink:to="lab_us-gaap_SharePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_55ff32c4-1829-4645-9989-3e91faa6bd5d_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_b56e42fc-102a-4e30-a8dd-d38bf402b3e5_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_96ac01e2-c9a3-41c7-8f45-7dca15c7e271_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_511fcd64-5816-469e-99ae-63e2c608c762_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized foreign currency loss</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transaction Gain (Loss), Unrealized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_d5fd2a27-4f78-4a77-b8a3-c434b2483d64_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from shares issued in connection with the Company's employee stock purchase plan</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Excluding Option Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_071c8a75-8f77-4499-80b1-2d1249ef5a07_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_6abcdc61-081c-42e7-a0ad-21254533b65b_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_688db242-bb83-4c6d-970a-a2f44c1f2528_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_57766ef0-85a1-48f9-86b9-dd8551bf14d7_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options vested and expected to vest , Weighted-Average Remaining Contractual Term, Ending balance</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_be820c86-4063-4f35-8210-5117a4964b8a_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualAxis_31050f13-d6c6-467f-848a-89223db87ad8_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:label id="lab_srt_TitleOfIndividualAxis_label_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis" xlink:to="lab_srt_TitleOfIndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_f9c92f31-e55b-4ff7-9cac-8432268b55c2_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level&#160;2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_7bb04d02-0a60-4548-80ef-6e61b57300d2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_48a79430-df4d-4fd4-9274-23b202b0cffa_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_0e3364c2-5fd0-4928-a079-0f350fab330c_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_4b3976dc-8194-4f40-ad8e-38b5062e0908_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share, diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_2c70d66a-f978-41ff-8880-891acf8f3180_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options vested and expected to vest, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_NonStatutoryEmployeeStockOptionMember_4e6bf6bd-c539-4f76-8689-4bccc7a1a09a_terseLabel_en-US" xlink:label="lab_vtl_NonStatutoryEmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-statutory options</link:label>
    <link:label id="lab_vtl_NonStatutoryEmployeeStockOptionMember_label_en-US" xlink:label="lab_vtl_NonStatutoryEmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Statutory Employee Stock Option [Member]</link:label>
    <link:label id="lab_vtl_NonStatutoryEmployeeStockOptionMember_documentation_en-US" xlink:label="lab_vtl_NonStatutoryEmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Statutory Employee Stock Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_NonStatutoryEmployeeStockOptionMember" xlink:href="vtl-20220930.xsd#vtl_NonStatutoryEmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_NonStatutoryEmployeeStockOptionMember" xlink:to="lab_vtl_NonStatutoryEmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_8b6e0ccd-4ed4-4164-aadd-e86c5dbc064d_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_11ecf76f-d054-44d2-b4b3-e48c1d8deff5_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_7f73ae17-7578-4b95-9c6c-d0eb9ae80c4d_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss):</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_a77bea46-4542-4fd8-abe8-5d274232d388_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting period (in years)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockOptionMember_999b9442-b66b-4209-a9af-fb483a8a5e16_terseLabel_en-US" xlink:label="lab_us-gaap_StockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options to purchase common stock</link:label>
    <link:label id="lab_us-gaap_StockOptionMember_label_en-US" xlink:label="lab_us-gaap_StockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockOptionMember" xlink:to="lab_us-gaap_StockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_14d07678-1ba4-4305-9c37-f7f2402454c4_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_7abe155e-4054-48c5-8dc9-b3ed14d0e23c_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_32ea28d9-fb39-4cad-9a5f-fdaad51b5089_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_bc57aa99-484e-44b0-aacc-c3e29476fc33_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_94386f32-0a5f-435e-a346-ec9baab83546_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_0c3cc056-c1b6-4cee-ad3a-b2b78df37524_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_PublicOfferingMember_e8c4526d-c13c-4e81-ad90-e2eac0427d82_terseLabel_en-US" xlink:label="lab_vtl_PublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public Offering</link:label>
    <link:label id="lab_vtl_PublicOfferingMember_label_en-US" xlink:label="lab_vtl_PublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public Offering [Member]</link:label>
    <link:label id="lab_vtl_PublicOfferingMember_documentation_en-US" xlink:label="lab_vtl_PublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_PublicOfferingMember" xlink:href="vtl-20220930.xsd#vtl_PublicOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_PublicOfferingMember" xlink:to="lab_vtl_PublicOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_9a7e48f2-2d0b-4b50-9d48-e0b2d325cd73_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_a8d49dc5-9657-42fc-9ae8-c4b044ebbf56_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValueAddedTaxReceivableCurrent_0ab95f68-f761-4c4e-9aa6-db3c867cd589_terseLabel_en-US" xlink:label="lab_us-gaap_ValueAddedTaxReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">VAT receivable</link:label>
    <link:label id="lab_us-gaap_ValueAddedTaxReceivableCurrent_label_en-US" xlink:label="lab_us-gaap_ValueAddedTaxReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Value Added Tax Receivable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValueAddedTaxReceivableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValueAddedTaxReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValueAddedTaxReceivableCurrent" xlink:to="lab_us-gaap_ValueAddedTaxReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherSundryLiabilitiesCurrent_c14a07dc-28bf-4bdf-bfe8-1a47ed66c638_terseLabel_en-US" xlink:label="lab_us-gaap_OtherSundryLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherSundryLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherSundryLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Sundry Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherSundryLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherSundryLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherSundryLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherSundryLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_A2021EmployeeStockPurchasePlanMember_f96efada-e3d6-44cc-a61b-eb34dfad8b1b_terseLabel_en-US" xlink:label="lab_vtl_A2021EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 Employee stock Purchase Plan</link:label>
    <link:label id="lab_vtl_A2021EmployeeStockPurchasePlanMember_label_en-US" xlink:label="lab_vtl_A2021EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 Employee Stock Purchase Plan [Member]</link:label>
    <link:label id="lab_vtl_A2021EmployeeStockPurchasePlanMember_documentation_en-US" xlink:label="lab_vtl_A2021EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 Employee Stock Purchase Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_A2021EmployeeStockPurchasePlanMember" xlink:href="vtl-20220930.xsd#vtl_A2021EmployeeStockPurchasePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_A2021EmployeeStockPurchasePlanMember" xlink:to="lab_vtl_A2021EmployeeStockPurchasePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_6c9965f7-f566-43d4-9144-4c50af07ec90_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share, basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_IncentiveEmployeeStockOptionMember_9153e0a0-a3b6-4e3a-9fd5-cbec47344cd7_terseLabel_en-US" xlink:label="lab_vtl_IncentiveEmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incentive stock options</link:label>
    <link:label id="lab_vtl_IncentiveEmployeeStockOptionMember_label_en-US" xlink:label="lab_vtl_IncentiveEmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incentive Employee Stock Option [Member]</link:label>
    <link:label id="lab_vtl_IncentiveEmployeeStockOptionMember_documentation_en-US" xlink:label="lab_vtl_IncentiveEmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incentive Employee Stock Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_IncentiveEmployeeStockOptionMember" xlink:href="vtl-20220930.xsd#vtl_IncentiveEmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_IncentiveEmployeeStockOptionMember" xlink:to="lab_vtl_IncentiveEmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_0596371c-aaff-4887-a212-b7ff2cfc1c1e_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_LesseeOperatingLeaseRentHolidayPeriod_c664c2e5-d6d6-4e38-9f79-6ab7f3094f8d_terseLabel_en-US" xlink:label="lab_vtl_LesseeOperatingLeaseRentHolidayPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rent holiday period</link:label>
    <link:label id="lab_vtl_LesseeOperatingLeaseRentHolidayPeriod_label_en-US" xlink:label="lab_vtl_LesseeOperatingLeaseRentHolidayPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Rent Holiday Period</link:label>
    <link:label id="lab_vtl_LesseeOperatingLeaseRentHolidayPeriod_documentation_en-US" xlink:label="lab_vtl_LesseeOperatingLeaseRentHolidayPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Rent Holiday Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_LesseeOperatingLeaseRentHolidayPeriod" xlink:href="vtl-20220930.xsd#vtl_LesseeOperatingLeaseRentHolidayPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_LesseeOperatingLeaseRentHolidayPeriod" xlink:to="lab_vtl_LesseeOperatingLeaseRentHolidayPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_366d05d5-cebf-43dd-9f40-9addbe7dd5bf_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense):</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_DuaneNashMDJDMBAMember_04efc50c-fc0e-4418-9a68-b5e861030342_terseLabel_en-US" xlink:label="lab_vtl_DuaneNashMDJDMBAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Duane Nash, MD, JD, MBA</link:label>
    <link:label id="lab_vtl_DuaneNashMDJDMBAMember_label_en-US" xlink:label="lab_vtl_DuaneNashMDJDMBAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Duane Nash, MD, JD, MBA [Member]</link:label>
    <link:label id="lab_vtl_DuaneNashMDJDMBAMember_documentation_en-US" xlink:label="lab_vtl_DuaneNashMDJDMBAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Duane Nash, MD, JD, MBA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_DuaneNashMDJDMBAMember" xlink:href="vtl-20220930.xsd#vtl_DuaneNashMDJDMBAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_DuaneNashMDJDMBAMember" xlink:to="lab_vtl_DuaneNashMDJDMBAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_904cb7f3-2fb1-448e-b899-0c979c176e09_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturities of Operating Lease Obligation</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_85d896a9-bf35-4df3-a385-294b99e1f4b3_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_23d434bf-438a-4d9f-b1bd-8d1c0d92ce2b_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_aec4dfcd-e3ca-4ca6-bddc-9e7b17021cdd_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_240ed2a7-7932-4cf4-bdcf-2b76d640c95d_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_dd3662de-5730-4ced-a2ae-bd5b3df77c32_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_5d01c829-7623-49a4-a274-bb2997f7bd96_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_DirectorMember_ed90d0ce-e2b1-4313-9e31-6bd5d0dc7318_terseLabel_en-US" xlink:label="lab_srt_DirectorMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Director</link:label>
    <link:label id="lab_srt_DirectorMember_label_en-US" xlink:label="lab_srt_DirectorMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Director [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_DirectorMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_DirectorMember" xlink:to="lab_srt_DirectorMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_ccccb2de-3e18-41a9-8d8b-c4f5d4ec0f39_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_PreFundedWarrantsMember_f6654ddc-eb6d-4d7c-ae74-e276669b9983_terseLabel_en-US" xlink:label="lab_vtl_PreFundedWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-Funded Warrants</link:label>
    <link:label id="lab_vtl_PreFundedWarrantsMember_label_en-US" xlink:label="lab_vtl_PreFundedWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-Funded Warrants [Member]</link:label>
    <link:label id="lab_vtl_PreFundedWarrantsMember_documentation_en-US" xlink:label="lab_vtl_PreFundedWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-Funded Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_PreFundedWarrantsMember" xlink:href="vtl-20220930.xsd#vtl_PreFundedWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_PreFundedWarrantsMember" xlink:to="lab_vtl_PreFundedWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_7be359d5-6c75-46dd-85f3-fc0b6386441b_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_1b58a0da-5e62-42f1-8bc8-d966719e3192_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued in private placement transaction (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_July2021EquityIssuanceMember_d6d8092e-9070-4307-820b-593b46750dee_terseLabel_en-US" xlink:label="lab_vtl_July2021EquityIssuanceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">July 2021 Equity Issuance</link:label>
    <link:label id="lab_vtl_July2021EquityIssuanceMember_label_en-US" xlink:label="lab_vtl_July2021EquityIssuanceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">July 2021 Equity Issuance [Member]</link:label>
    <link:label id="lab_vtl_July2021EquityIssuanceMember_documentation_en-US" xlink:label="lab_vtl_July2021EquityIssuanceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">July 2021 Equity Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_July2021EquityIssuanceMember" xlink:href="vtl-20220930.xsd#vtl_July2021EquityIssuanceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_July2021EquityIssuanceMember" xlink:to="lab_vtl_July2021EquityIssuanceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_40e7d4cc-958d-4cf8-a60e-a1f895b43de8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_528cf07a-eadc-4e25-8666-27727fedd454_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_SaleOfStockRemainingCapacity_800daef8-3ce4-44dc-bd28-c0bd16beaa21_terseLabel_en-US" xlink:label="lab_vtl_SaleOfStockRemainingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock, remaining capacity</link:label>
    <link:label id="lab_vtl_SaleOfStockRemainingCapacity_label_en-US" xlink:label="lab_vtl_SaleOfStockRemainingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Remaining Capacity</link:label>
    <link:label id="lab_vtl_SaleOfStockRemainingCapacity_documentation_en-US" xlink:label="lab_vtl_SaleOfStockRemainingCapacity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Remaining Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_SaleOfStockRemainingCapacity" xlink:href="vtl-20220930.xsd#vtl_SaleOfStockRemainingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_SaleOfStockRemainingCapacity" xlink:to="lab_vtl_SaleOfStockRemainingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_fc30dac1-2e12-4af8-8765-61846851df9e_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_3d55e21a-396e-46b3-90e9-a921679a8340_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_7b866759-78f2-46c7-9449-0d0c545c0f97_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTable_925f45c9-620c-4a54-9175-65a6929f5aac_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_528f04da-8cb8-4668-a087-795c1199d21f_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_9874da12-cc54-4f4b-a3f2-6c120d8becc5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase price of the stock, at discount from market price at purchase date (as a percent)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Discount from Market Price, Purchase Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_acd66caa-374a-44e4-b172-b02e62cb43cf_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_91d61df3-037c-4152-957d-486813987b82_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock-based Compensation Expense for Stock Awards Recognized</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_e456deb3-3fb7-43b5-bfef-d2fae6d55fca_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_25f20b09-0294-4688-bba6-1c05f522f52d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_bcc5011b-7cc6-456b-8d82-d2c9e35c946e_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_6c7aa182-d533-45bc-9fd0-ba393905910b_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_0ea07a1c-940b-4856-8e88-5dd9c3540cb7_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_bd34a12c-b4d7-4779-b361-89f1c2784f5d_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_3ca038c5-3668-4ff5-bc09-e3e1be42a42c_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_ae3a745a-e90d-4039-b4e2-1f495f121dad_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net change in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_1734e4d7-d15f-41e8-9576-a841bd0c8259_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_ad9fdb84-229d-4fa6-bf50-fcb469ddfdd3_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_83cc69b1-f81a-4896-be15-4bac1940c54e_negatedLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_168717d7-1f5d-40f8-ad80-e4535e3e97a4_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_c4ec0476-ee9c-4862-8a7d-9be62784f20e_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_14b77800-ef0f-4807-8046-9abaae8fffc5_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_dc7fdcbd-3370-4918-ad63-7ab527b8f389_terseLabel_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario, Unspecified [Domain]</link:label>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_label_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioUnspecifiedDomain" xlink:to="lab_srt_ScenarioUnspecifiedDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_6c14f89f-ed09-4b46-93a0-ccb5ffa44998_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_7d53f382-1522-4d53-aae9-c35f9c8d370a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_04784424-ca66-4a56-b727-4dd507826717_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expenses</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember_5b9fa352-81ac-4df8-a3f0-2a457299ef90_terseLabel_en-US" xlink:label="lab_vtl_TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 Omnibus Equity Incentive Plan, Evergreen Provision</link:label>
    <link:label id="lab_vtl_TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember_label_en-US" xlink:label="lab_vtl_TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Nineteen Omnibus Equity Incentive Plan, Evergreen Provision [Member]</link:label>
    <link:label id="lab_vtl_TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember_documentation_en-US" xlink:label="lab_vtl_TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Nineteen Omnibus Equity Incentive Plan, Evergreen Provision</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember" xlink:href="vtl-20220930.xsd#vtl_TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember" xlink:to="lab_vtl_TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_e96b54c6-dcef-488e-a9c5-1c13d2140cde_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurements, Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_ca243b77-89f0-4cc7-80de-32ea43811b02_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of private placement</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Private Placement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_b7611d6b-7909-4f5d-b398-a6ee0eb2e344_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercisable, weighted-average exercise price, ending balance (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b93cf2ac-0766-4c2b-a4f9-9370c94af494_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_9f780903-bd83-4472-8ef0-2b95f83096f3_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_77bfe8db-ab6d-46e1-9852-5d414d4355ec_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_2cc002ac-e5db-45dd-befd-fea850e9df21_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued other</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_LegalAndAuditCostsPayableCurrent_21f0022f-b26d-4bad-9d77-c11e01d451dd_terseLabel_en-US" xlink:label="lab_vtl_LegalAndAuditCostsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal and audit costs</link:label>
    <link:label id="lab_vtl_LegalAndAuditCostsPayableCurrent_label_en-US" xlink:label="lab_vtl_LegalAndAuditCostsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal And Audit Costs Payable, Current</link:label>
    <link:label id="lab_vtl_LegalAndAuditCostsPayableCurrent_documentation_en-US" xlink:label="lab_vtl_LegalAndAuditCostsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal And Audit Costs Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_LegalAndAuditCostsPayableCurrent" xlink:href="vtl-20220930.xsd#vtl_LegalAndAuditCostsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_LegalAndAuditCostsPayableCurrent" xlink:to="lab_vtl_LegalAndAuditCostsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_954afe2f-6be1-4b89-b7a7-6c86eca05b38_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityDomain_f01b1bb4-9cb6-417b-ba89-16ea0ca99f45_terseLabel_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:label id="lab_dei_EntityDomain_label_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_da9a17bc-a2a0-4175-a15c-733dc599ec9c_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_5139c089-2b6b-4d16-92a1-78a21436555e_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_bab12088-b9d0-4d26-bc50-fd3de2fea2b5_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_b71c18d6-471c-4721-99b6-40de7fcdebb6_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_9b174869-d971-4e7a-b426-372a9401a885_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expenses</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expenses, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_01303c0b-6070-4005-a913-d9ac89e60b3c_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other expense</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_RoyaltySettlementAgreementSharesPaymentPercent_7c050fba-d101-48a3-9aa2-49d710d5cf9d_terseLabel_en-US" xlink:label="lab_vtl_RoyaltySettlementAgreementSharesPaymentPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty settlement agreement, shares payment, percent</link:label>
    <link:label id="lab_vtl_RoyaltySettlementAgreementSharesPaymentPercent_label_en-US" xlink:label="lab_vtl_RoyaltySettlementAgreementSharesPaymentPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Settlement Agreement, Shares Payment, Percent</link:label>
    <link:label id="lab_vtl_RoyaltySettlementAgreementSharesPaymentPercent_documentation_en-US" xlink:label="lab_vtl_RoyaltySettlementAgreementSharesPaymentPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Settlement Agreement, Shares Payment, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_RoyaltySettlementAgreementSharesPaymentPercent" xlink:href="vtl-20220930.xsd#vtl_RoyaltySettlementAgreementSharesPaymentPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_RoyaltySettlementAgreementSharesPaymentPercent" xlink:to="lab_vtl_RoyaltySettlementAgreementSharesPaymentPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_5914fd6e-daf6-4b94-8cbb-06540537da47_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_29e24fc3-ec60-4d4b-a471-a27cfddc3045_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_089e6cb3-32df-47d0-ae03-48b15023913b_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesTable_87c538c3-2019-49b3-b2e5-7441df581f49_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesTable_label_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable" xlink:to="lab_us-gaap_LossContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_226db72f-a4d2-41fb-bf0c-42357aa8590a_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets, net</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_67ad7fb6-f8c6-4204-9d50-4e6cf755892e_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_b91a45dc-8a6f-4009-a374-8a7f494f3a48_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_78bbd947-bc08-4fbc-bbb7-ca7b4520df6e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_fdac1c1f-2cf8-4672-8775-f592810f9de7_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_dec95261-59eb-4360-ad53-f9061a49635b_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Long-Lived Assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_896172f7-ab76-48a4-a6dd-87ba07d68ac7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options granted in period, weighted-average grant date fair value (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_4d70a783-dfc8-42b0-8947-c74126e528ca_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options vested and expected to vest, weighted-average exercise price, ending balance (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_73592bc3-4e31-478b-ab09-9610bab9f9a5_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_e6b84929-2942-48d6-b091-ab9cefdb4650_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_47d3b272-a4fa-4195-a562-2199255e1f38_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_4e6ffe2a-52d7-49b6-8c4f-d8cbcc4e2125_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Stock Option Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_c489b619-7f6e-4e4a-8fc5-e5442bf405b4_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_2ea5fa25-a75d-4fed-9821-61bdf7a5b06d_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_OperatingLeaseIncrementalBorrowingRate_c59fc6d0-eca1-4bea-bb24-b75b90d03558_terseLabel_en-US" xlink:label="lab_vtl_OperatingLeaseIncrementalBorrowingRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental borrowing rate on operating leases</link:label>
    <link:label id="lab_vtl_OperatingLeaseIncrementalBorrowingRate_label_en-US" xlink:label="lab_vtl_OperatingLeaseIncrementalBorrowingRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Incremental Borrowing Rate</link:label>
    <link:label id="lab_vtl_OperatingLeaseIncrementalBorrowingRate_documentation_en-US" xlink:label="lab_vtl_OperatingLeaseIncrementalBorrowingRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Incremental Borrowing Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_OperatingLeaseIncrementalBorrowingRate" xlink:href="vtl-20220930.xsd#vtl_OperatingLeaseIncrementalBorrowingRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_OperatingLeaseIncrementalBorrowingRate" xlink:to="lab_vtl_OperatingLeaseIncrementalBorrowingRate" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_SalaryCostsMonthlyBaseSalary_a6aa11b4-9226-44e6-b2c1-09b7a923b0b5_terseLabel_en-US" xlink:label="lab_vtl_SalaryCostsMonthlyBaseSalary" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Monthly base salary</link:label>
    <link:label id="lab_vtl_SalaryCostsMonthlyBaseSalary_label_en-US" xlink:label="lab_vtl_SalaryCostsMonthlyBaseSalary" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Salary Costs, Monthly Base Salary</link:label>
    <link:label id="lab_vtl_SalaryCostsMonthlyBaseSalary_documentation_en-US" xlink:label="lab_vtl_SalaryCostsMonthlyBaseSalary" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Salary Costs, Monthly Base Salary</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_SalaryCostsMonthlyBaseSalary" xlink:href="vtl-20220930.xsd#vtl_SalaryCostsMonthlyBaseSalary"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_SalaryCostsMonthlyBaseSalary" xlink:to="lab_vtl_SalaryCostsMonthlyBaseSalary" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_36f47d77-331e-4508-a1a4-6d465d616e9d_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recently Issued and/or Adopted Accounting Standards</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_4db58a2c-6326-468a-a578-27600c38b635_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of use asset obtained in exchange for lease obligation</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_33113902-d2fb-44ca-bf9c-8d6e04c446a1_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets and prepaid expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration_49eb4a22-7d39-48c0-9a46-f2d2756b7540_terseLabel_en-US" xlink:label="lab_vtl_MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum aggregate offering price of securities under shelf registration</link:label>
    <link:label id="lab_vtl_MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration_label_en-US" xlink:label="lab_vtl_MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Aggregate Offering Price Of Securities Under Shelf Registration</link:label>
    <link:label id="lab_vtl_MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration_documentation_en-US" xlink:label="lab_vtl_MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Aggregate Offering Price Of Securities Under Shelf Registration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration" xlink:href="vtl-20220930.xsd#vtl_MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration" xlink:to="lab_vtl_MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_3ab524a0-3120-44dc-b356-ff7aa2bdb3be_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_73a789ee-e25e-47c4-afab-1eaf8faef128_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_9028d927-46a2-4093-b6b9-9c8ccac5d2e7_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_3bb1d1b6-0483-41e4-9657-b6e66c79e83f_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of Business and Basis of Financial Statements</link:label>
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Description and Basis of Presentation [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_d06add5e-32c3-4385-b10a-b07116712d26_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>vtl-20220930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:6944770f-821d-45aa-b4f3-cccabd82d2f9,g:32d5dde5-0858-4183-b548-263732a64d33-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://vitaltherapies.com/role/CoverPage" xlink:type="simple" xlink:href="vtl-20220930.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_cdca4701-1781-46d9-88d5-16495edfa6b9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_268229f5-6f57-4370-b1b5-0b744abf4fe1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cdca4701-1781-46d9-88d5-16495edfa6b9" xlink:to="loc_dei_DocumentType_268229f5-6f57-4370-b1b5-0b744abf4fe1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_628de671-19a3-4b89-8978-37803991b721" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cdca4701-1781-46d9-88d5-16495edfa6b9" xlink:to="loc_dei_DocumentQuarterlyReport_628de671-19a3-4b89-8978-37803991b721" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_34020b1c-24c7-4f15-8968-b1071c7c651d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cdca4701-1781-46d9-88d5-16495edfa6b9" xlink:to="loc_dei_DocumentPeriodEndDate_34020b1c-24c7-4f15-8968-b1071c7c651d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_753ebdb6-dd80-46bf-b6ac-0aad8a396f8d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cdca4701-1781-46d9-88d5-16495edfa6b9" xlink:to="loc_dei_DocumentTransitionReport_753ebdb6-dd80-46bf-b6ac-0aad8a396f8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_fd919870-b176-49ce-98d9-b029a8c38940" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cdca4701-1781-46d9-88d5-16495edfa6b9" xlink:to="loc_dei_EntityFileNumber_fd919870-b176-49ce-98d9-b029a8c38940" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_930f1b9f-2470-4e7a-8cbb-15a9f95f7fbb" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cdca4701-1781-46d9-88d5-16495edfa6b9" xlink:to="loc_dei_EntityRegistrantName_930f1b9f-2470-4e7a-8cbb-15a9f95f7fbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_4763e5c4-b3a6-45ea-bed8-f8ae0430fd66" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cdca4701-1781-46d9-88d5-16495edfa6b9" xlink:to="loc_dei_EntityIncorporationStateCountryCode_4763e5c4-b3a6-45ea-bed8-f8ae0430fd66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_23fff8ec-c64e-420a-b4f0-a0c40d24a456" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cdca4701-1781-46d9-88d5-16495edfa6b9" xlink:to="loc_dei_EntityTaxIdentificationNumber_23fff8ec-c64e-420a-b4f0-a0c40d24a456" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_87b5907d-d1b2-4253-b1d5-0b3a0143ee73" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cdca4701-1781-46d9-88d5-16495edfa6b9" xlink:to="loc_dei_EntityAddressAddressLine1_87b5907d-d1b2-4253-b1d5-0b3a0143ee73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_d7c02654-aee6-444e-a81c-6a9852943b8d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cdca4701-1781-46d9-88d5-16495edfa6b9" xlink:to="loc_dei_EntityAddressAddressLine2_d7c02654-aee6-444e-a81c-6a9852943b8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_c14d6d4a-5031-4712-a392-a21904baebea" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cdca4701-1781-46d9-88d5-16495edfa6b9" xlink:to="loc_dei_EntityAddressCityOrTown_c14d6d4a-5031-4712-a392-a21904baebea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_734196fe-c726-48cf-b6b0-85f4becd3839" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cdca4701-1781-46d9-88d5-16495edfa6b9" xlink:to="loc_dei_EntityAddressStateOrProvince_734196fe-c726-48cf-b6b0-85f4becd3839" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_655da137-b85f-4cfb-8c2b-45491f6e9165" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cdca4701-1781-46d9-88d5-16495edfa6b9" xlink:to="loc_dei_EntityAddressPostalZipCode_655da137-b85f-4cfb-8c2b-45491f6e9165" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_a398d53d-f6f4-41e6-abe5-a92ad12434c7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cdca4701-1781-46d9-88d5-16495edfa6b9" xlink:to="loc_dei_CityAreaCode_a398d53d-f6f4-41e6-abe5-a92ad12434c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_5c5bd91a-508d-491f-9c96-fc0370647859" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cdca4701-1781-46d9-88d5-16495edfa6b9" xlink:to="loc_dei_LocalPhoneNumber_5c5bd91a-508d-491f-9c96-fc0370647859" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_30efce6e-e587-4715-b323-8efc11785b95" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cdca4701-1781-46d9-88d5-16495edfa6b9" xlink:to="loc_dei_Security12bTitle_30efce6e-e587-4715-b323-8efc11785b95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_93c6eb59-431b-489c-bb8c-41a2e66680a2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cdca4701-1781-46d9-88d5-16495edfa6b9" xlink:to="loc_dei_TradingSymbol_93c6eb59-431b-489c-bb8c-41a2e66680a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_a87622e8-3ff9-45d6-a6ed-ad92c50779c3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cdca4701-1781-46d9-88d5-16495edfa6b9" xlink:to="loc_dei_SecurityExchangeName_a87622e8-3ff9-45d6-a6ed-ad92c50779c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_2cbcc510-698a-4669-9b55-42b2180778f9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cdca4701-1781-46d9-88d5-16495edfa6b9" xlink:to="loc_dei_EntityCurrentReportingStatus_2cbcc510-698a-4669-9b55-42b2180778f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_ba768c4e-6b15-4396-a951-5d7b2469a51a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cdca4701-1781-46d9-88d5-16495edfa6b9" xlink:to="loc_dei_EntityInteractiveDataCurrent_ba768c4e-6b15-4396-a951-5d7b2469a51a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_7b9d44b2-e5b5-44c9-b0eb-89b09a5ad8f5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cdca4701-1781-46d9-88d5-16495edfa6b9" xlink:to="loc_dei_EntityFilerCategory_7b9d44b2-e5b5-44c9-b0eb-89b09a5ad8f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_6d7a43b6-afbc-40f3-838f-99c10d088d5d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cdca4701-1781-46d9-88d5-16495edfa6b9" xlink:to="loc_dei_EntitySmallBusiness_6d7a43b6-afbc-40f3-838f-99c10d088d5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_1d6f7257-fb46-49ea-b265-6737f85eb1f0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cdca4701-1781-46d9-88d5-16495edfa6b9" xlink:to="loc_dei_EntityEmergingGrowthCompany_1d6f7257-fb46-49ea-b265-6737f85eb1f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_78415165-c2a2-4e04-bee7-d1676346602e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cdca4701-1781-46d9-88d5-16495edfa6b9" xlink:to="loc_dei_EntityShellCompany_78415165-c2a2-4e04-bee7-d1676346602e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_bf7e5111-7234-490b-9773-82a2a96f583f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cdca4701-1781-46d9-88d5-16495edfa6b9" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_bf7e5111-7234-490b-9773-82a2a96f583f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_19373acb-d59e-40f2-bc3d-76a06801377b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cdca4701-1781-46d9-88d5-16495edfa6b9" xlink:to="loc_dei_DocumentFiscalYearFocus_19373acb-d59e-40f2-bc3d-76a06801377b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_e27101b8-9645-43d7-a0c0-1735127dd837" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cdca4701-1781-46d9-88d5-16495edfa6b9" xlink:to="loc_dei_DocumentFiscalPeriodFocus_e27101b8-9645-43d7-a0c0-1735127dd837" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_c651dfb2-f755-4518-bc56-4415ec4c6fd6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cdca4701-1781-46d9-88d5-16495edfa6b9" xlink:to="loc_dei_AmendmentFlag_c651dfb2-f755-4518-bc56-4415ec4c6fd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_d70c4956-1135-4a4c-916d-5bd44f7f5359" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cdca4701-1781-46d9-88d5-16495edfa6b9" xlink:to="loc_dei_CurrentFiscalYearEndDate_d70c4956-1135-4a4c-916d-5bd44f7f5359" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_2879d8ee-c8df-4546-b361-4ef9db6231c1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cdca4701-1781-46d9-88d5-16495edfa6b9" xlink:to="loc_dei_EntityCentralIndexKey_2879d8ee-c8df-4546-b361-4ef9db6231c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="vtl-20220930.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_703f1ec1-4cd2-4d30-be01-7a201ee5a53f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_7c92c0fb-2b7c-4928-9407-3ee31e79291f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_703f1ec1-4cd2-4d30-be01-7a201ee5a53f" xlink:to="loc_us-gaap_AssetsAbstract_7c92c0fb-2b7c-4928-9407-3ee31e79291f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_7d7af681-7ae0-4f6e-8550-031752ed44a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_7c92c0fb-2b7c-4928-9407-3ee31e79291f" xlink:to="loc_us-gaap_AssetsCurrentAbstract_7d7af681-7ae0-4f6e-8550-031752ed44a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_9540a081-e41c-4dcd-9361-20c71b16cb11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_7d7af681-7ae0-4f6e-8550-031752ed44a2" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_9540a081-e41c-4dcd-9361-20c71b16cb11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_756fb77e-a48e-409d-9bc7-24fbead9604f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_7d7af681-7ae0-4f6e-8550-031752ed44a2" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_756fb77e-a48e-409d-9bc7-24fbead9604f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_e4aaff59-d172-4b29-b1ee-741e2fac2f1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_7d7af681-7ae0-4f6e-8550-031752ed44a2" xlink:to="loc_us-gaap_AssetsCurrent_e4aaff59-d172-4b29-b1ee-741e2fac2f1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_cd35f012-293d-4fee-8a1a-76722b767fcd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_7c92c0fb-2b7c-4928-9407-3ee31e79291f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_cd35f012-293d-4fee-8a1a-76722b767fcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_1c58256f-c77c-4941-acf6-4dfa75731675" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_7c92c0fb-2b7c-4928-9407-3ee31e79291f" xlink:to="loc_us-gaap_Goodwill_1c58256f-c77c-4941-acf6-4dfa75731675" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_507ce98e-919d-4876-b136-d25d735e4eb9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_7c92c0fb-2b7c-4928-9407-3ee31e79291f" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_507ce98e-919d-4876-b136-d25d735e4eb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_f1db4aee-1c96-4c01-aebb-d7f03d73a32a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_7c92c0fb-2b7c-4928-9407-3ee31e79291f" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_f1db4aee-1c96-4c01-aebb-d7f03d73a32a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_11a230bb-8287-4af7-b2d9-05849866296b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_7c92c0fb-2b7c-4928-9407-3ee31e79291f" xlink:to="loc_us-gaap_Assets_11a230bb-8287-4af7-b2d9-05849866296b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_ecbf37f4-124a-4e0f-a685-e67afbce0af5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_703f1ec1-4cd2-4d30-be01-7a201ee5a53f" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_ecbf37f4-124a-4e0f-a685-e67afbce0af5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_caa0482b-7339-4c64-995a-9350c33f3587" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_ecbf37f4-124a-4e0f-a685-e67afbce0af5" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_caa0482b-7339-4c64-995a-9350c33f3587" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_9061c85a-3756-4f66-8e10-c3753dd4c150" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_caa0482b-7339-4c64-995a-9350c33f3587" xlink:to="loc_us-gaap_AccountsPayableCurrent_9061c85a-3756-4f66-8e10-c3753dd4c150" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_7d89824f-f418-406d-8a0b-923d3f0634e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_caa0482b-7339-4c64-995a-9350c33f3587" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_7d89824f-f418-406d-8a0b-923d3f0634e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_0494ce03-a074-49cb-ad09-162cf65cf6c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_caa0482b-7339-4c64-995a-9350c33f3587" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_0494ce03-a074-49cb-ad09-162cf65cf6c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_233a3d56-4f3f-4765-bb0a-1765dfad5243" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_caa0482b-7339-4c64-995a-9350c33f3587" xlink:to="loc_us-gaap_LiabilitiesCurrent_233a3d56-4f3f-4765-bb0a-1765dfad5243" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_98282fc5-7a6f-4f62-af2f-1dccc25d652c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_ecbf37f4-124a-4e0f-a685-e67afbce0af5" xlink:to="loc_us-gaap_LiabilitiesNoncurrentAbstract_98282fc5-7a6f-4f62-af2f-1dccc25d652c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_c63e49f2-f7dc-4853-aed6-bae71e29d0e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_98282fc5-7a6f-4f62-af2f-1dccc25d652c" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_c63e49f2-f7dc-4853-aed6-bae71e29d0e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_23806360-bbb5-4e4a-9f4e-4b4f9c74efd2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_98282fc5-7a6f-4f62-af2f-1dccc25d652c" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_23806360-bbb5-4e4a-9f4e-4b4f9c74efd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_a337f133-6316-4701-b3da-bc8b6034ce7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_ecbf37f4-124a-4e0f-a685-e67afbce0af5" xlink:to="loc_us-gaap_Liabilities_a337f133-6316-4701-b3da-bc8b6034ce7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_b33034bb-7954-40d0-b697-dfddde2bbf9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_ecbf37f4-124a-4e0f-a685-e67afbce0af5" xlink:to="loc_us-gaap_CommitmentsAndContingencies_b33034bb-7954-40d0-b697-dfddde2bbf9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_684008ad-f17a-495e-aa64-4b5337a4bd81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_ecbf37f4-124a-4e0f-a685-e67afbce0af5" xlink:to="loc_us-gaap_StockholdersEquityAbstract_684008ad-f17a-495e-aa64-4b5337a4bd81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_bc738ff9-5508-47ff-9516-f0af8f55371a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_684008ad-f17a-495e-aa64-4b5337a4bd81" xlink:to="loc_us-gaap_PreferredStockValue_bc738ff9-5508-47ff-9516-f0af8f55371a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_409a884a-cae5-4592-a27a-b12fa2706dff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_684008ad-f17a-495e-aa64-4b5337a4bd81" xlink:to="loc_us-gaap_CommonStockValue_409a884a-cae5-4592-a27a-b12fa2706dff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_dc8d6b15-8b2c-45b6-8122-d376f7c27663" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_684008ad-f17a-495e-aa64-4b5337a4bd81" xlink:to="loc_us-gaap_AdditionalPaidInCapital_dc8d6b15-8b2c-45b6-8122-d376f7c27663" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_789908a1-923c-4ae4-a293-40df1eb9a555" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_684008ad-f17a-495e-aa64-4b5337a4bd81" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_789908a1-923c-4ae4-a293-40df1eb9a555" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_3e771787-23eb-45cf-89f0-9259d7d45f2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_684008ad-f17a-495e-aa64-4b5337a4bd81" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_3e771787-23eb-45cf-89f0-9259d7d45f2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_dc16cbfc-8f31-470d-ba17-e031a2143a41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_684008ad-f17a-495e-aa64-4b5337a4bd81" xlink:to="loc_us-gaap_StockholdersEquity_dc16cbfc-8f31-470d-ba17-e031a2143a41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_9035117d-224d-4d0e-b7e9-ee9d7e925c69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_ecbf37f4-124a-4e0f-a685-e67afbce0af5" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_9035117d-224d-4d0e-b7e9-ee9d7e925c69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="vtl-20220930.xsd#CondensedConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_12b09c85-7015-4eea-b8dd-f5922a6f79d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_f7a0d08c-715c-48cd-a88e-ed1f29268a9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_12b09c85-7015-4eea-b8dd-f5922a6f79d3" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_f7a0d08c-715c-48cd-a88e-ed1f29268a9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_13d28b13-648d-4cc1-a8d0-8d2564deed5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_12b09c85-7015-4eea-b8dd-f5922a6f79d3" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_13d28b13-648d-4cc1-a8d0-8d2564deed5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_1fb4f427-9fe0-45ba-82e7-be2489cc8f9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_12b09c85-7015-4eea-b8dd-f5922a6f79d3" xlink:to="loc_us-gaap_PreferredStockSharesIssued_1fb4f427-9fe0-45ba-82e7-be2489cc8f9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_11092b32-0b8e-4b96-90d0-16c4089c6ff9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_12b09c85-7015-4eea-b8dd-f5922a6f79d3" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_11092b32-0b8e-4b96-90d0-16c4089c6ff9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_354e25b7-97eb-47cd-9405-a0bc12ef7be5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_12b09c85-7015-4eea-b8dd-f5922a6f79d3" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_354e25b7-97eb-47cd-9405-a0bc12ef7be5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_4bde2cc6-829a-477b-bc20-ba1a4f40364b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_12b09c85-7015-4eea-b8dd-f5922a6f79d3" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_4bde2cc6-829a-477b-bc20-ba1a4f40364b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_8f8a410c-348f-4db9-864b-2a74ddcad397" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_12b09c85-7015-4eea-b8dd-f5922a6f79d3" xlink:to="loc_us-gaap_CommonStockSharesIssued_8f8a410c-348f-4db9-864b-2a74ddcad397" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_36a27ba0-c4df-41b9-b2a6-247d2b2bed69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_12b09c85-7015-4eea-b8dd-f5922a6f79d3" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_36a27ba0-c4df-41b9-b2a6-247d2b2bed69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="vtl-20220930.xsd#CondensedConsolidatedStatementsofOperations"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_058c1e3e-41d3-4238-aa02-b4bfbdbe8751" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_c39e1df8-2614-4dd5-903d-854d7bdc1768" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_058c1e3e-41d3-4238-aa02-b4bfbdbe8751" xlink:to="loc_us-gaap_OperatingExpensesAbstract_c39e1df8-2614-4dd5-903d-854d7bdc1768" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_83a01858-cfdb-4540-8382-0281e2c8ffae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_c39e1df8-2614-4dd5-903d-854d7bdc1768" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_83a01858-cfdb-4540-8382-0281e2c8ffae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_731c4c54-9787-425e-9f4f-7f9b7f0ec337" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_c39e1df8-2614-4dd5-903d-854d7bdc1768" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_731c4c54-9787-425e-9f4f-7f9b7f0ec337" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_RoyaltySettlementAgreementSalesNet_247f6d4a-5b34-4009-bed2-68ac5d454414" xlink:href="vtl-20220930.xsd#vtl_RoyaltySettlementAgreementSalesNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_c39e1df8-2614-4dd5-903d-854d7bdc1768" xlink:to="loc_vtl_RoyaltySettlementAgreementSalesNet_247f6d4a-5b34-4009-bed2-68ac5d454414" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_8e36e8bc-c5b9-4aad-b7d5-02e7c862eca1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_c39e1df8-2614-4dd5-903d-854d7bdc1768" xlink:to="loc_us-gaap_OperatingExpenses_8e36e8bc-c5b9-4aad-b7d5-02e7c862eca1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_d1ce1b3b-5832-47a0-ba6d-925611493bcf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_058c1e3e-41d3-4238-aa02-b4bfbdbe8751" xlink:to="loc_us-gaap_OperatingIncomeLoss_d1ce1b3b-5832-47a0-ba6d-925611493bcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_bf568f69-63dc-48ab-9601-88af3f94e160" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_058c1e3e-41d3-4238-aa02-b4bfbdbe8751" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_bf568f69-63dc-48ab-9601-88af3f94e160" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_381f04f3-2aeb-4aec-b7d6-eeed1f8d4976" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_bf568f69-63dc-48ab-9601-88af3f94e160" xlink:to="loc_us-gaap_InvestmentIncomeInterest_381f04f3-2aeb-4aec-b7d6-eeed1f8d4976" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_6165418a-35d0-48a7-8b24-be4dd154a461" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_bf568f69-63dc-48ab-9601-88af3f94e160" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_6165418a-35d0-48a7-8b24-be4dd154a461" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_0d380882-94aa-4adb-87ed-7e2cbbad22d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_bf568f69-63dc-48ab-9601-88af3f94e160" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_0d380882-94aa-4adb-87ed-7e2cbbad22d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_f12a30ff-eab7-40f4-94d3-abd9d298f901" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_058c1e3e-41d3-4238-aa02-b4bfbdbe8751" xlink:to="loc_us-gaap_NetIncomeLoss_f12a30ff-eab7-40f4-94d3-abd9d298f901" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_8830fe56-41e3-4f07-b1c1-462d474f7a18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_058c1e3e-41d3-4238-aa02-b4bfbdbe8751" xlink:to="loc_us-gaap_EarningsPerShareBasic_8830fe56-41e3-4f07-b1c1-462d474f7a18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_f2e4fa4e-a289-42c1-b4ca-5ca65a3aec06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_058c1e3e-41d3-4238-aa02-b4bfbdbe8751" xlink:to="loc_us-gaap_EarningsPerShareDiluted_f2e4fa4e-a289-42c1-b4ca-5ca65a3aec06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_37ef891e-6d8a-46b7-a910-cabbe54c1f3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_058c1e3e-41d3-4238-aa02-b4bfbdbe8751" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_37ef891e-6d8a-46b7-a910-cabbe54c1f3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_99956140-8fc2-44f0-9dd4-255b1429ba05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_058c1e3e-41d3-4238-aa02-b4bfbdbe8751" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_99956140-8fc2-44f0-9dd4-255b1429ba05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" xlink:type="simple" xlink:href="vtl-20220930.xsd#CondensedConsolidatedStatementsofComprehensiveLoss"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_37315e5b-a910-41a9-9931-75591aba3288" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_5250586a-61f7-4d03-889d-00cde682e80a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_37315e5b-a910-41a9-9931-75591aba3288" xlink:to="loc_us-gaap_NetIncomeLoss_5250586a-61f7-4d03-889d-00cde682e80a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_c9f49aee-9785-4023-97c3-194f89d06b4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_37315e5b-a910-41a9-9931-75591aba3288" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_c9f49aee-9785-4023-97c3-194f89d06b4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_ba43d110-2698-417e-a23b-163a168d9070" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_c9f49aee-9785-4023-97c3-194f89d06b4c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_ba43d110-2698-417e-a23b-163a168d9070" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_33f05a01-5711-454f-b19d-1789e355b81b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_37315e5b-a910-41a9-9931-75591aba3288" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_33f05a01-5711-454f-b19d-1789e355b81b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="vtl-20220930.xsd#CondensedConsolidatedStatementsofStockholdersEquity"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_4e19f4b7-69d5-45d5-ba8d-e8adbc141518" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_3891ae63-ef74-4f72-974e-a9f018df9416" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_4e19f4b7-69d5-45d5-ba8d-e8adbc141518" xlink:to="loc_us-gaap_StatementTable_3891ae63-ef74-4f72-974e-a9f018df9416" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_61bde220-f226-45f7-8bb4-9aa6e4379ea3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_3891ae63-ef74-4f72-974e-a9f018df9416" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_61bde220-f226-45f7-8bb4-9aa6e4379ea3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_6c1d12b3-4443-43ea-8964-e3d5a7495600" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_61bde220-f226-45f7-8bb4-9aa6e4379ea3" xlink:to="loc_us-gaap_EquityComponentDomain_6c1d12b3-4443-43ea-8964-e3d5a7495600" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_47fb7847-43f6-47c6-bfd6-fda2640dcf9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_6c1d12b3-4443-43ea-8964-e3d5a7495600" xlink:to="loc_us-gaap_CommonStockMember_47fb7847-43f6-47c6-bfd6-fda2640dcf9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_91c0ccda-2dde-4a47-bdb3-7370de07b82e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_6c1d12b3-4443-43ea-8964-e3d5a7495600" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_91c0ccda-2dde-4a47-bdb3-7370de07b82e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_5d728ff8-ae25-4be4-a00b-2332ef496dc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_6c1d12b3-4443-43ea-8964-e3d5a7495600" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_5d728ff8-ae25-4be4-a00b-2332ef496dc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_21a8e13b-fa33-4dcc-b5c4-c3dce9ad3926" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_6c1d12b3-4443-43ea-8964-e3d5a7495600" xlink:to="loc_us-gaap_RetainedEarningsMember_21a8e13b-fa33-4dcc-b5c4-c3dce9ad3926" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_6790a79c-dda7-4006-939b-817fb794672f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_3891ae63-ef74-4f72-974e-a9f018df9416" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_6790a79c-dda7-4006-939b-817fb794672f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_d8469378-dbe4-42ec-8a9a-f4333e9e8d1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_6790a79c-dda7-4006-939b-817fb794672f" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_d8469378-dbe4-42ec-8a9a-f4333e9e8d1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_July2021EquityIssuanceMember_19e48fdc-b36f-4ba9-b473-8c5bd653603c" xlink:href="vtl-20220930.xsd#vtl_July2021EquityIssuanceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_d8469378-dbe4-42ec-8a9a-f4333e9e8d1d" xlink:to="loc_vtl_July2021EquityIssuanceMember_19e48fdc-b36f-4ba9-b473-8c5bd653603c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_PublicOfferingMember_69aa8af5-bfd9-491f-a318-dc4138928740" xlink:href="vtl-20220930.xsd#vtl_PublicOfferingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_d8469378-dbe4-42ec-8a9a-f4333e9e8d1d" xlink:to="loc_vtl_PublicOfferingMember_69aa8af5-bfd9-491f-a318-dc4138928740" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_A4SCRoyaltySettlementMember_54400adf-696b-46c4-b36b-d2363e91d02c" xlink:href="vtl-20220930.xsd#vtl_A4SCRoyaltySettlementMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_d8469378-dbe4-42ec-8a9a-f4333e9e8d1d" xlink:to="loc_vtl_A4SCRoyaltySettlementMember_54400adf-696b-46c4-b36b-d2363e91d02c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_27fbe2c9-2309-452e-9e19-8d5df08c2e09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_3891ae63-ef74-4f72-974e-a9f018df9416" xlink:to="loc_us-gaap_StatementLineItems_27fbe2c9-2309-452e-9e19-8d5df08c2e09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_138db75b-e44e-4d99-8ee5-2164d014de6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_27fbe2c9-2309-452e-9e19-8d5df08c2e09" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_138db75b-e44e-4d99-8ee5-2164d014de6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_b8b89597-1dec-4680-8c8f-57c1f84a5c32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_138db75b-e44e-4d99-8ee5-2164d014de6a" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_b8b89597-1dec-4680-8c8f-57c1f84a5c32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_53bbaaf4-e8a8-4c37-b68d-bae2f79a230f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_138db75b-e44e-4d99-8ee5-2164d014de6a" xlink:to="loc_us-gaap_StockholdersEquity_53bbaaf4-e8a8-4c37-b68d-bae2f79a230f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_76d4e4c8-fc81-4e42-98d8-2aa193079fd4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_138db75b-e44e-4d99-8ee5-2164d014de6a" xlink:to="loc_us-gaap_NetIncomeLoss_76d4e4c8-fc81-4e42-98d8-2aa193079fd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_04ffaa51-4237-4509-af74-46edefd3f5e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_138db75b-e44e-4d99-8ee5-2164d014de6a" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_04ffaa51-4237-4509-af74-46edefd3f5e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_9b81e43f-da37-4e5e-a6c4-86f8db17a988" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_138db75b-e44e-4d99-8ee5-2164d014de6a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_9b81e43f-da37-4e5e-a6c4-86f8db17a988" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_840e5d20-3ee8-4e27-aee1-40e4a9cb5ce4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_138db75b-e44e-4d99-8ee5-2164d014de6a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_840e5d20-3ee8-4e27-aee1-40e4a9cb5ce4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_fab2b90b-7178-4ca4-9306-e1d355a5c456" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_138db75b-e44e-4d99-8ee5-2164d014de6a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_fab2b90b-7178-4ca4-9306-e1d355a5c456" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_c3acab66-1e52-41ee-a259-e6929b3482d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_138db75b-e44e-4d99-8ee5-2164d014de6a" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_c3acab66-1e52-41ee-a259-e6929b3482d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_2ddbee1a-6c76-48f1-94c8-bd0efdd54e15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_138db75b-e44e-4d99-8ee5-2164d014de6a" xlink:to="loc_us-gaap_StockholdersEquity_2ddbee1a-6c76-48f1-94c8-bd0efdd54e15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical" xlink:type="simple" xlink:href="vtl-20220930.xsd#CondensedConsolidatedStatementsofStockholdersEquityParenthetical"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_df9f1ad8-2574-4c11-89e4-ff009e4f2bba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_fad29f13-6241-40a2-a8ec-145f096d3782" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_df9f1ad8-2574-4c11-89e4-ff009e4f2bba" xlink:to="loc_us-gaap_StatementTable_fad29f13-6241-40a2-a8ec-145f096d3782" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_1a5ef7df-e5a5-4a9f-9c9d-f48da5094ca6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_fad29f13-6241-40a2-a8ec-145f096d3782" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_1a5ef7df-e5a5-4a9f-9c9d-f48da5094ca6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_17ee7b72-aff2-4d26-a22b-c2527d102601" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_1a5ef7df-e5a5-4a9f-9c9d-f48da5094ca6" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_17ee7b72-aff2-4d26-a22b-c2527d102601" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_July2021EquityIssuanceMember_7d5e7966-83a9-4593-8d1c-557923c5e52c" xlink:href="vtl-20220930.xsd#vtl_July2021EquityIssuanceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_17ee7b72-aff2-4d26-a22b-c2527d102601" xlink:to="loc_vtl_July2021EquityIssuanceMember_7d5e7966-83a9-4593-8d1c-557923c5e52c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_3d4e0408-32f8-4ce0-a29d-a7b07d3d4678" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_fad29f13-6241-40a2-a8ec-145f096d3782" xlink:to="loc_us-gaap_StatementLineItems_3d4e0408-32f8-4ce0-a29d-a7b07d3d4678" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_ee7262c8-93fe-4f13-b376-d0f0e9f933eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3d4e0408-32f8-4ce0-a29d-a7b07d3d4678" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_ee7262c8-93fe-4f13-b376-d0f0e9f933eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows" xlink:type="simple" xlink:href="vtl-20220930.xsd#CondensedConsolidatedStatementofCashFlows"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_bc0f4f80-9452-46a2-9e55-9ffa6275ebd1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_6796862d-0d95-4e07-8583-5ffc21b1e8c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_bc0f4f80-9452-46a2-9e55-9ffa6275ebd1" xlink:to="loc_us-gaap_StatementTable_6796862d-0d95-4e07-8583-5ffc21b1e8c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_b3796f95-5f9b-4b74-a3cb-c87753354b44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_6796862d-0d95-4e07-8583-5ffc21b1e8c7" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_b3796f95-5f9b-4b74-a3cb-c87753354b44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_16d44736-bffc-43fe-8695-701cad2bb878" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_b3796f95-5f9b-4b74-a3cb-c87753354b44" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_16d44736-bffc-43fe-8695-701cad2bb878" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_PublicOfferingMember_78e270a6-956c-4c6e-8734-9b0aa06f9119" xlink:href="vtl-20220930.xsd#vtl_PublicOfferingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_16d44736-bffc-43fe-8695-701cad2bb878" xlink:to="loc_vtl_PublicOfferingMember_78e270a6-956c-4c6e-8734-9b0aa06f9119" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_July2021PublicEquityOfferingMember_9b400d76-f6aa-4396-8f35-56ae54982150" xlink:href="vtl-20220930.xsd#vtl_July2021PublicEquityOfferingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_16d44736-bffc-43fe-8695-701cad2bb878" xlink:to="loc_vtl_July2021PublicEquityOfferingMember_9b400d76-f6aa-4396-8f35-56ae54982150" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_63ba5bd2-f474-4c70-a69d-c87a2a2338cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_6796862d-0d95-4e07-8583-5ffc21b1e8c7" xlink:to="loc_us-gaap_StatementLineItems_63ba5bd2-f474-4c70-a69d-c87a2a2338cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_b76bcc1c-8a7b-41aa-a910-dbb19cf031e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_63ba5bd2-f474-4c70-a69d-c87a2a2338cb" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_b76bcc1c-8a7b-41aa-a910-dbb19cf031e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_02c2239c-053f-421b-9cfe-99676aba80a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_b76bcc1c-8a7b-41aa-a910-dbb19cf031e8" xlink:to="loc_us-gaap_NetIncomeLoss_02c2239c-053f-421b-9cfe-99676aba80a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_76dace63-4b7a-4c1a-81fc-17cf5b9617a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_b76bcc1c-8a7b-41aa-a910-dbb19cf031e8" xlink:to="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_76dace63-4b7a-4c1a-81fc-17cf5b9617a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_afdec29e-bd56-4439-a652-89398fdaf842" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_76dace63-4b7a-4c1a-81fc-17cf5b9617a1" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_afdec29e-bd56-4439-a652-89398fdaf842" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_58e94a47-28cf-4676-983a-b482df651fc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_76dace63-4b7a-4c1a-81fc-17cf5b9617a1" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_58e94a47-28cf-4676-983a-b482df651fc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_7afc7276-7c5d-4002-9658-c7d311fd936e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_76dace63-4b7a-4c1a-81fc-17cf5b9617a1" xlink:to="loc_us-gaap_ShareBasedCompensation_7afc7276-7c5d-4002-9658-c7d311fd936e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable_dce51a74-1467-42b8-b034-002490763b5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_76dace63-4b7a-4c1a-81fc-17cf5b9617a1" xlink:to="loc_us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable_dce51a74-1467-42b8-b034-002490763b5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e962d934-30b6-46bd-9b42-4d746f546363" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_76dace63-4b7a-4c1a-81fc-17cf5b9617a1" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e962d934-30b6-46bd-9b42-4d746f546363" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_0e8cf0b6-f071-4c03-bd90-09d050658f5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e962d934-30b6-46bd-9b42-4d746f546363" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_0e8cf0b6-f071-4c03-bd90-09d050658f5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_9de314bc-c7b4-49c3-8bd5-ab3e2b85e506" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e962d934-30b6-46bd-9b42-4d746f546363" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_9de314bc-c7b4-49c3-8bd5-ab3e2b85e506" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_79b9bfaa-303e-4ff3-ad42-f2ba07fc7256" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e962d934-30b6-46bd-9b42-4d746f546363" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_79b9bfaa-303e-4ff3-ad42-f2ba07fc7256" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_83d98658-f4bb-4392-aa07-362bfcc0754a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e962d934-30b6-46bd-9b42-4d746f546363" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_83d98658-f4bb-4392-aa07-362bfcc0754a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6a70c907-939f-41bc-865a-03a77135f457" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_b76bcc1c-8a7b-41aa-a910-dbb19cf031e8" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6a70c907-939f-41bc-865a-03a77135f457" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_bc4c8b7c-6818-41b8-a539-3fa98348e063" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_63ba5bd2-f474-4c70-a69d-c87a2a2338cb" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_bc4c8b7c-6818-41b8-a539-3fa98348e063" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_37fa978d-6d33-46ae-a21e-8b9f40cf8c3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_bc4c8b7c-6818-41b8-a539-3fa98348e063" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_37fa978d-6d33-46ae-a21e-8b9f40cf8c3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_35754527-7a18-4fc4-bcae-611709737195" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_bc4c8b7c-6818-41b8-a539-3fa98348e063" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_35754527-7a18-4fc4-bcae-611709737195" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_d052155f-a2e3-4ea7-81bf-52d53bb138f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_63ba5bd2-f474-4c70-a69d-c87a2a2338cb" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_d052155f-a2e3-4ea7-81bf-52d53bb138f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_7d50a118-9f40-445c-ba25-089f7e51ecb7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_d052155f-a2e3-4ea7-81bf-52d53bb138f3" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_7d50a118-9f40-445c-ba25-089f7e51ecb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_1dd769f2-5919-4cff-b410-1cc3ea9d5f4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_d052155f-a2e3-4ea7-81bf-52d53bb138f3" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_1dd769f2-5919-4cff-b410-1cc3ea9d5f4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_bb3a096d-4199-4258-95f9-34f3b4f3ec0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_d052155f-a2e3-4ea7-81bf-52d53bb138f3" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_bb3a096d-4199-4258-95f9-34f3b4f3ec0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0ff6efae-4543-4aeb-b0f5-e6eece801dd5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_d052155f-a2e3-4ea7-81bf-52d53bb138f3" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0ff6efae-4543-4aeb-b0f5-e6eece801dd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e276b428-3157-415d-b2c7-7a678a13cbe6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_63ba5bd2-f474-4c70-a69d-c87a2a2338cb" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e276b428-3157-415d-b2c7-7a678a13cbe6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_be854b25-5b21-4254-8d2a-18e62b548437" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_63ba5bd2-f474-4c70-a69d-c87a2a2338cb" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_be854b25-5b21-4254-8d2a-18e62b548437" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_31723d7e-03a5-4c71-a5ff-b7755e41592f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_63ba5bd2-f474-4c70-a69d-c87a2a2338cb" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_31723d7e-03a5-4c71-a5ff-b7755e41592f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7e3f8578-3287-4fb0-9858-1b1efaf23ec6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_63ba5bd2-f474-4c70-a69d-c87a2a2338cb" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7e3f8578-3287-4fb0-9858-1b1efaf23ec6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_54e571f9-1aa1-49dc-98fc-f2ebf8e8882a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_63ba5bd2-f474-4c70-a69d-c87a2a2338cb" xlink:to="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_54e571f9-1aa1-49dc-98fc-f2ebf8e8882a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssued1_9b495f4c-f117-4f6c-96df-a1eeaa6e3ad0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssued1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_54e571f9-1aa1-49dc-98fc-f2ebf8e8882a" xlink:to="loc_us-gaap_StockIssued1_9b495f4c-f117-4f6c-96df-a1eeaa6e3ad0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_456a1994-39de-4255-8163-e412c54f175b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_54e571f9-1aa1-49dc-98fc-f2ebf8e8882a" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_456a1994-39de-4255-8163-e412c54f175b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/CondensedConsolidatedStatementsofCashFlowsParenthetical" xlink:type="simple" xlink:href="vtl-20220930.xsd#CondensedConsolidatedStatementsofCashFlowsParenthetical"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/CondensedConsolidatedStatementsofCashFlowsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_f444e41b-bc15-4416-929a-5c12a15e1efb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_9323e930-d25d-4b4c-8b5c-fa3549a1eb88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f444e41b-bc15-4416-929a-5c12a15e1efb" xlink:to="loc_us-gaap_StatementTable_9323e930-d25d-4b4c-8b5c-fa3549a1eb88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_3cf58627-9310-43e1-95f5-a92ad42d22ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_9323e930-d25d-4b4c-8b5c-fa3549a1eb88" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_3cf58627-9310-43e1-95f5-a92ad42d22ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_8fc64d8f-6f4f-4728-bdab-2ce3184a1b54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_3cf58627-9310-43e1-95f5-a92ad42d22ee" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_8fc64d8f-6f4f-4728-bdab-2ce3184a1b54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_PublicOfferingMember_3b058a06-8981-4047-a46b-4734453d45b2" xlink:href="vtl-20220930.xsd#vtl_PublicOfferingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_8fc64d8f-6f4f-4728-bdab-2ce3184a1b54" xlink:to="loc_vtl_PublicOfferingMember_3b058a06-8981-4047-a46b-4734453d45b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_July2021PublicEquityOfferingMember_d5423d0e-8c82-4b52-852d-c9bf8a9b6453" xlink:href="vtl-20220930.xsd#vtl_July2021PublicEquityOfferingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_8fc64d8f-6f4f-4728-bdab-2ce3184a1b54" xlink:to="loc_vtl_July2021PublicEquityOfferingMember_d5423d0e-8c82-4b52-852d-c9bf8a9b6453" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_6a3fed6c-5bee-4495-84ed-84829f00eb7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_9323e930-d25d-4b4c-8b5c-fa3549a1eb88" xlink:to="loc_us-gaap_StatementLineItems_6a3fed6c-5bee-4495-84ed-84829f00eb7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_730945c2-ff47-43aa-b163-cacbe85cfb59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6a3fed6c-5bee-4495-84ed-84829f00eb7a" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_730945c2-ff47-43aa-b163-cacbe85cfb59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/DescriptionofBusinessandBasisofFinancialStatements" xlink:type="simple" xlink:href="vtl-20220930.xsd#DescriptionofBusinessandBasisofFinancialStatements"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/DescriptionofBusinessandBasisofFinancialStatements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_91aa23d3-d365-457e-89e0-288240038c8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_aca8cdad-4046-490a-af46-8d99463cd74d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_91aa23d3-d365-457e-89e0-288240038c8f" xlink:to="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_aca8cdad-4046-490a-af46-8d99463cd74d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="vtl-20220930.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_c860ea71-c03d-461d-8a2e-e55475d173b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_34876d5a-ae34-41d7-8ccc-ea356335b1c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c860ea71-c03d-461d-8a2e-e55475d173b0" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_34876d5a-ae34-41d7-8ccc-ea356335b1c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/BalanceSheetDetails" xlink:type="simple" xlink:href="vtl-20220930.xsd#BalanceSheetDetails"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/BalanceSheetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_96d3649d-ffdd-46c5-99b7-437dcd89f889" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_3c9d491f-8eb6-4496-8a4e-eeb508b50a4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_96d3649d-ffdd-46c5-99b7-437dcd89f889" xlink:to="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_3c9d491f-8eb6-4496-8a4e-eeb508b50a4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="vtl-20220930.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2ac8f855-492b-4756-b76b-bf7044867775" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_55d3850c-8a9e-4e36-ab6c-1dd919a2f4fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2ac8f855-492b-4756-b76b-bf7044867775" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_55d3850c-8a9e-4e36-ab6c-1dd919a2f4fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/FairValue" xlink:type="simple" xlink:href="vtl-20220930.xsd#FairValue"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/FairValue" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_fe5cf012-611e-4280-98bc-cdb1d2389543" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_b2205e21-e37c-424a-b7d9-b8664f71b474" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_fe5cf012-611e-4280-98bc-cdb1d2389543" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_b2205e21-e37c-424a-b7d9-b8664f71b474" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/CommonStock" xlink:type="simple" xlink:href="vtl-20220930.xsd#CommonStock"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/CommonStock" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_7bb6a680-a89a-43fc-a715-fae61e8aa138" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_7e22f766-b5d8-4ecd-a53c-50bb5db40e31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_7bb6a680-a89a-43fc-a715-fae61e8aa138" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_7e22f766-b5d8-4ecd-a53c-50bb5db40e31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/StockBasedCompensationPlans" xlink:type="simple" xlink:href="vtl-20220930.xsd#StockBasedCompensationPlans"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/StockBasedCompensationPlans" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4bd08e10-1cf7-47a6-9423-98b9ba119340" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_2d83db6f-dc5c-4c11-ac9d-a7a3af2a8c3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4bd08e10-1cf7-47a6-9423-98b9ba119340" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_2d83db6f-dc5c-4c11-ac9d-a7a3af2a8c3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/ChangesinBoardofDirectors" xlink:type="simple" xlink:href="vtl-20220930.xsd#ChangesinBoardofDirectors"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/ChangesinBoardofDirectors" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a7392490-aeff-4d2d-b1f0-b76c7fc2eae5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_ChangesInBoardOfDirectorsDisclosureTextBlock_61a862e9-929a-4ea0-a1b2-8112fc91dd80" xlink:href="vtl-20220930.xsd#vtl_ChangesInBoardOfDirectorsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a7392490-aeff-4d2d-b1f0-b76c7fc2eae5" xlink:to="loc_vtl_ChangesInBoardOfDirectorsDisclosureTextBlock_61a862e9-929a-4ea0-a1b2-8112fc91dd80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/RelatedPartyTransactions" xlink:type="simple" xlink:href="vtl-20220930.xsd#RelatedPartyTransactions"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/RelatedPartyTransactions" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_e06f91d2-0606-4eff-b37e-761f94f824b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_b6e9eed6-29d5-4d40-95db-adfc2c189856" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_e06f91d2-0606-4eff-b37e-761f94f824b0" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_b6e9eed6-29d5-4d40-95db-adfc2c189856" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/SubsequentEvents" xlink:type="simple" xlink:href="vtl-20220930.xsd#SubsequentEvents"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/SubsequentEvents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_3b627048-798f-492b-8753-426e1d76e85d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_b5bae721-eccf-439f-bfb8-fd8a4247cec4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_3b627048-798f-492b-8753-426e1d76e85d" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_b5bae721-eccf-439f-bfb8-fd8a4247cec4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="vtl-20220930.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_5c6499da-17e7-4726-a7dc-1c09e3e9ddd2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_f0feaec4-2ec8-468b-a90a-dde8ed64c381" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5c6499da-17e7-4726-a7dc-1c09e3e9ddd2" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_f0feaec4-2ec8-468b-a90a-dde8ed64c381" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_ae10ab3a-7fe9-4777-8cad-f8eac92a8f25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5c6499da-17e7-4726-a7dc-1c09e3e9ddd2" xlink:to="loc_us-gaap_UseOfEstimates_ae10ab3a-7fe9-4777-8cad-f8eac92a8f25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_848a9bfc-f0ef-42b8-aa4f-8c467813035d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5c6499da-17e7-4726-a7dc-1c09e3e9ddd2" xlink:to="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_848a9bfc-f0ef-42b8-aa4f-8c467813035d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_d6d550ee-928b-4e42-959f-2728a1da1b93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5c6499da-17e7-4726-a7dc-1c09e3e9ddd2" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_d6d550ee-928b-4e42-959f-2728a1da1b93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_50b26215-348d-4303-91c6-42a358cf1950" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5c6499da-17e7-4726-a7dc-1c09e3e9ddd2" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_50b26215-348d-4303-91c6-42a358cf1950" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_06a7e577-a33e-4637-be2d-be80703f83f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5c6499da-17e7-4726-a7dc-1c09e3e9ddd2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_06a7e577-a33e-4637-be2d-be80703f83f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_5b743823-e21a-4070-89c8-fb695ad3b88a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5c6499da-17e7-4726-a7dc-1c09e3e9ddd2" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_5b743823-e21a-4070-89c8-fb695ad3b88a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_c1ae71c9-11df-45b7-b5f0-a709315073da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5c6499da-17e7-4726-a7dc-1c09e3e9ddd2" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_c1ae71c9-11df-45b7-b5f0-a709315073da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_8428a296-d36c-4604-8e1c-824acb00ae26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5c6499da-17e7-4726-a7dc-1c09e3e9ddd2" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_8428a296-d36c-4604-8e1c-824acb00ae26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementAccountingPolicy_f38b7e8b-5aa1-4354-a432-141f91a9bc75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementAccountingPolicy"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5c6499da-17e7-4726-a7dc-1c09e3e9ddd2" xlink:to="loc_us-gaap_CollaborativeArrangementAccountingPolicy_f38b7e8b-5aa1-4354-a432-141f91a9bc75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_9e1b289b-1d97-40a5-a8f1-c95e7fc3163d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5c6499da-17e7-4726-a7dc-1c09e3e9ddd2" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_9e1b289b-1d97-40a5-a8f1-c95e7fc3163d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_0cd1167f-ebf6-49c8-a00b-bdc23aa848d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5c6499da-17e7-4726-a7dc-1c09e3e9ddd2" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_0cd1167f-ebf6-49c8-a00b-bdc23aa848d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_277206c9-f3e5-4fce-9c7c-43e464422604" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5c6499da-17e7-4726-a7dc-1c09e3e9ddd2" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_277206c9-f3e5-4fce-9c7c-43e464422604" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_0e5883a1-9b39-4ceb-9bdc-00f7b86d3d33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5c6499da-17e7-4726-a7dc-1c09e3e9ddd2" xlink:to="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_0e5883a1-9b39-4ceb-9bdc-00f7b86d3d33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_40ded1f2-1b15-476f-bb5f-345197144630" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5c6499da-17e7-4726-a7dc-1c09e3e9ddd2" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_40ded1f2-1b15-476f-bb5f-345197144630" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_a2d2b93d-ce8a-4a3a-9772-9153320a1b92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5c6499da-17e7-4726-a7dc-1c09e3e9ddd2" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_a2d2b93d-ce8a-4a3a-9772-9153320a1b92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_2e649ded-8f17-4bcb-a643-ebd7df96d5b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5c6499da-17e7-4726-a7dc-1c09e3e9ddd2" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_2e649ded-8f17-4bcb-a643-ebd7df96d5b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="vtl-20220930.xsd#SummaryofSignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_bec666e5-f91a-4d58-975c-2e13b7bd8743" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_1557f9ff-f4a9-4ca5-87ae-022a56f4d777" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_bec666e5-f91a-4d58-975c-2e13b7bd8743" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_1557f9ff-f4a9-4ca5-87ae-022a56f4d777" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/BalanceSheetDetailsTables" xlink:type="simple" xlink:href="vtl-20220930.xsd#BalanceSheetDetailsTables"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/BalanceSheetDetailsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_50942ed8-04f1-4e35-a172-47d07654e12c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_22815f4e-cd54-488d-8beb-492ecffd6341" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_50942ed8-04f1-4e35-a172-47d07654e12c" xlink:to="loc_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_22815f4e-cd54-488d-8beb-492ecffd6341" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_1890ed41-0e0b-4849-97cc-6bd5aea0a537" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_50942ed8-04f1-4e35-a172-47d07654e12c" xlink:to="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_1890ed41-0e0b-4849-97cc-6bd5aea0a537" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesTableTextBlock_bfeb7d0e-beb7-402b-a7a0-7aa9c8690c84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCurrentLiabilitiesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_50942ed8-04f1-4e35-a172-47d07654e12c" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesTableTextBlock_bfeb7d0e-beb7-402b-a7a0-7aa9c8690c84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/CommitmentsandContingenciesTables" xlink:type="simple" xlink:href="vtl-20220930.xsd#CommitmentsandContingenciesTables"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/CommitmentsandContingenciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_eacce02c-c8b1-4ced-8f89-f2abf5bd3d37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_737f855c-b1ca-4e0b-be0b-46652a9b53a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_eacce02c-c8b1-4ced-8f89-f2abf5bd3d37" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_737f855c-b1ca-4e0b-be0b-46652a9b53a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/FairValueTables" xlink:type="simple" xlink:href="vtl-20220930.xsd#FairValueTables"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/FairValueTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_e36729af-88c9-4f7c-9e44-136c8c422b09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_895cb5d9-1dde-4415-b489-26574a7889c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_e36729af-88c9-4f7c-9e44-136c8c422b09" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_895cb5d9-1dde-4415-b489-26574a7889c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/CommonStockTables" xlink:type="simple" xlink:href="vtl-20220930.xsd#CommonStockTables"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/CommonStockTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_c7741066-93e1-437b-84db-ba5a7cef1d3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock_27e539ec-2cf2-446c-bb69-25e0d2a9098b" xlink:href="vtl-20220930.xsd#vtl_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_c7741066-93e1-437b-84db-ba5a7cef1d3e" xlink:to="loc_vtl_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock_27e539ec-2cf2-446c-bb69-25e0d2a9098b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/StockBasedCompensationPlansTables" xlink:type="simple" xlink:href="vtl-20220930.xsd#StockBasedCompensationPlansTables"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/StockBasedCompensationPlansTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f170c46f-7272-40cc-9d88-bc71db421a1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_fad709e6-b8a1-4c88-876f-794b57004ed3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f170c46f-7272-40cc-9d88-bc71db421a1c" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_fad709e6-b8a1-4c88-876f-794b57004ed3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_74919b1d-b421-4cb4-8caa-7d1eb3c6316a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f170c46f-7272-40cc-9d88-bc71db421a1c" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_74919b1d-b421-4cb4-8caa-7d1eb3c6316a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_132a4014-df81-4ff5-adcf-4b883fbfb94d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f170c46f-7272-40cc-9d88-bc71db421a1c" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_132a4014-df81-4ff5-adcf-4b883fbfb94d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/DescriptionofBusinessandBasisofFinancialStatementsDetails" xlink:type="simple" xlink:href="vtl-20220930.xsd#DescriptionofBusinessandBasisofFinancialStatementsDetails"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/DescriptionofBusinessandBasisofFinancialStatementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_e81852f1-c4b9-4b2d-84ad-686adc5b96d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f6a700e3-03b9-41d0-b329-f34313b7f118" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e81852f1-c4b9-4b2d-84ad-686adc5b96d4" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f6a700e3-03b9-41d0-b329-f34313b7f118" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_0648ef1f-5cd3-46f6-a0a7-7865fdbf88e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f6a700e3-03b9-41d0-b329-f34313b7f118" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_0648ef1f-5cd3-46f6-a0a7-7865fdbf88e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_657548df-a348-4319-8914-d6bb4662e8fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_0648ef1f-5cd3-46f6-a0a7-7865fdbf88e6" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_657548df-a348-4319-8914-d6bb4662e8fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_64de0545-893f-498a-8072-377d34242314" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_657548df-a348-4319-8914-d6bb4662e8fc" xlink:to="loc_us-gaap_SubsequentEventMember_64de0545-893f-498a-8072-377d34242314" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0fc5347d-40f6-4f2f-85ac-1f852079c331" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f6a700e3-03b9-41d0-b329-f34313b7f118" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0fc5347d-40f6-4f2f-85ac-1f852079c331" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityNumberOfEmployees_82ddba59-66ad-4098-875f-e9789d8a7970" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityNumberOfEmployees"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0fc5347d-40f6-4f2f-85ac-1f852079c331" xlink:to="loc_dei_EntityNumberOfEmployees_82ddba59-66ad-4098-875f-e9789d8a7970" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_NumberOfDevelopmentProgramsPursued_d7ab5664-b887-403e-b61f-a9c200687bcd" xlink:href="vtl-20220930.xsd#vtl_NumberOfDevelopmentProgramsPursued"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0fc5347d-40f6-4f2f-85ac-1f852079c331" xlink:to="loc_vtl_NumberOfDevelopmentProgramsPursued_d7ab5664-b887-403e-b61f-a9c200687bcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_275349f0-8fbc-40c0-a3ef-08a8d847d642" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0fc5347d-40f6-4f2f-85ac-1f852079c331" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_275349f0-8fbc-40c0-a3ef-08a8d847d642" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_20371703-549a-4428-a90a-8d24d5d24566" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0fc5347d-40f6-4f2f-85ac-1f852079c331" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_20371703-549a-4428-a90a-8d24d5d24566" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_cef02813-de69-4177-b329-c213453debd3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0fc5347d-40f6-4f2f-85ac-1f852079c331" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_cef02813-de69-4177-b329-c213453debd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndFederalFundsSold_9abfef9c-1513-4729-90f0-0e5a068a4743" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndFederalFundsSold"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0fc5347d-40f6-4f2f-85ac-1f852079c331" xlink:to="loc_us-gaap_CashCashEquivalentsAndFederalFundsSold_9abfef9c-1513-4729-90f0-0e5a068a4743" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple" xlink:href="vtl-20220930.xsd#SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_fc577bb1-b70a-4afe-9673-e819f2e8b465" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_b80b147f-a66b-4f50-b6fb-e6dae99fa311" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_fc577bb1-b70a-4afe-9673-e819f2e8b465" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_b80b147f-a66b-4f50-b6fb-e6dae99fa311" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_f15bfc38-7b24-491a-88f3-739b10b2ece2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_b80b147f-a66b-4f50-b6fb-e6dae99fa311" xlink:to="loc_srt_RangeAxis_f15bfc38-7b24-491a-88f3-739b10b2ece2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_991a5395-2b76-4a0d-8e06-c723ff1efa95" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_f15bfc38-7b24-491a-88f3-739b10b2ece2" xlink:to="loc_srt_RangeMember_991a5395-2b76-4a0d-8e06-c723ff1efa95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_b0d9ca1c-ece0-4786-8615-d4b735930c34" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_991a5395-2b76-4a0d-8e06-c723ff1efa95" xlink:to="loc_srt_MinimumMember_b0d9ca1c-ece0-4786-8615-d4b735930c34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_f2b6e42e-d8ee-4cc4-895c-60d139a95ec1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_991a5395-2b76-4a0d-8e06-c723ff1efa95" xlink:to="loc_srt_MaximumMember_f2b6e42e-d8ee-4cc4-895c-60d139a95ec1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_25bb830c-d2c0-41d0-aa59-37b5d215157c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_b80b147f-a66b-4f50-b6fb-e6dae99fa311" xlink:to="loc_srt_StatementScenarioAxis_25bb830c-d2c0-41d0-aa59-37b5d215157c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_19513870-f172-4086-ad95-f851d62b1ffa" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_25bb830c-d2c0-41d0-aa59-37b5d215157c" xlink:to="loc_srt_ScenarioUnspecifiedDomain_19513870-f172-4086-ad95-f851d62b1ffa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_94ae0105-7a5a-49b2-a774-5b471727676e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_19513870-f172-4086-ad95-f851d62b1ffa" xlink:to="loc_srt_ScenarioForecastMember_94ae0105-7a5a-49b2-a774-5b471727676e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_7cf1c3c7-3563-479b-9c1a-79b19942d398" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_b80b147f-a66b-4f50-b6fb-e6dae99fa311" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_7cf1c3c7-3563-479b-9c1a-79b19942d398" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_0dea17b5-9695-4e44-9d78-52b31e645f2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_7cf1c3c7-3563-479b-9c1a-79b19942d398" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_0dea17b5-9695-4e44-9d78-52b31e645f2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_eff4a41c-777d-44c9-a58c-6ce39c6ad1b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_0dea17b5-9695-4e44-9d78-52b31e645f2c" xlink:to="loc_us-gaap_SubsequentEventMember_eff4a41c-777d-44c9-a58c-6ce39c6ad1b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_c6df16f0-3346-4635-92d3-5ef888064195" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_b80b147f-a66b-4f50-b6fb-e6dae99fa311" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_c6df16f0-3346-4635-92d3-5ef888064195" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_29687407-4ae4-4725-a824-cdae7a2c385e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_c6df16f0-3346-4635-92d3-5ef888064195" xlink:to="loc_us-gaap_EquityComponentDomain_29687407-4ae4-4725-a824-cdae7a2c385e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_bc330395-c2a4-4d51-8f12-3ecf549cdd95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_29687407-4ae4-4725-a824-cdae7a2c385e" xlink:to="loc_us-gaap_CommonStockMember_bc330395-c2a4-4d51-8f12-3ecf549cdd95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8d15936f-ce02-4d41-bde2-211dfd1e0542" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_b80b147f-a66b-4f50-b6fb-e6dae99fa311" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8d15936f-ce02-4d41-bde2-211dfd1e0542" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_NumberOfFinancialInstitutionsUsedForCashDeposits_3e2f726a-b0ac-481d-9f88-29c52922825f" xlink:href="vtl-20220930.xsd#vtl_NumberOfFinancialInstitutionsUsedForCashDeposits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8d15936f-ce02-4d41-bde2-211dfd1e0542" xlink:to="loc_vtl_NumberOfFinancialInstitutionsUsedForCashDeposits_3e2f726a-b0ac-481d-9f88-29c52922825f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_bbda824d-c069-49eb-9b5c-cca2d1a7ecad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8d15936f-ce02-4d41-bde2-211dfd1e0542" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_bbda824d-c069-49eb-9b5c-cca2d1a7ecad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_7cf9a5b4-6ac2-4706-bb21-9a992e7120d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8d15936f-ce02-4d41-bde2-211dfd1e0542" xlink:to="loc_us-gaap_Depreciation_7cf9a5b4-6ac2-4706-bb21-9a992e7120d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TangibleAssetImpairmentCharges_b2884204-849f-46f1-990e-912631e565ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TangibleAssetImpairmentCharges"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8d15936f-ce02-4d41-bde2-211dfd1e0542" xlink:to="loc_us-gaap_TangibleAssetImpairmentCharges_b2884204-849f-46f1-990e-912631e565ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_9b964f18-c6fe-45e4-9ca3-5031afce2a76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8d15936f-ce02-4d41-bde2-211dfd1e0542" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_9b964f18-c6fe-45e4-9ca3-5031afce2a76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_e9232f61-ff42-4be5-b74d-7712de5740d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8d15936f-ce02-4d41-bde2-211dfd1e0542" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_e9232f61-ff42-4be5-b74d-7712de5740d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_2351c059-a44d-4c26-af63-a88fdbffd470" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8d15936f-ce02-4d41-bde2-211dfd1e0542" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_2351c059-a44d-4c26-af63-a88fdbffd470" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_LesseeOperatingLeasesNumberOfExistingLeases_b995ef02-e52e-4b22-a05a-859c7ad63d48" xlink:href="vtl-20220930.xsd#vtl_LesseeOperatingLeasesNumberOfExistingLeases"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8d15936f-ce02-4d41-bde2-211dfd1e0542" xlink:to="loc_vtl_LesseeOperatingLeasesNumberOfExistingLeases_b995ef02-e52e-4b22-a05a-859c7ad63d48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofDilutedNetLossperShareDetails" xlink:type="simple" xlink:href="vtl-20220930.xsd#SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofDilutedNetLossperShareDetails"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofDilutedNetLossperShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0536e9c0-f886-46d3-9c7e-f4ec2613fbcf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_c6975bdd-0ecc-4aa2-8a28-f2058446ae29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0536e9c0-f886-46d3-9c7e-f4ec2613fbcf" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_c6975bdd-0ecc-4aa2-8a28-f2058446ae29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_3d2c7230-09a8-4823-8fcb-5f63d6aa8685" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_c6975bdd-0ecc-4aa2-8a28-f2058446ae29" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_3d2c7230-09a8-4823-8fcb-5f63d6aa8685" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_d3769e44-f549-47a8-8acb-30cc822ac4ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_3d2c7230-09a8-4823-8fcb-5f63d6aa8685" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_d3769e44-f549-47a8-8acb-30cc822ac4ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOptionMember_420bcd39-c8c7-422c-9784-6b04fedccd32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_d3769e44-f549-47a8-8acb-30cc822ac4ff" xlink:to="loc_us-gaap_StockOptionMember_420bcd39-c8c7-422c-9784-6b04fedccd32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_edfb17e6-b202-43c9-a8a8-b6b357ed94d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_c6975bdd-0ecc-4aa2-8a28-f2058446ae29" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_edfb17e6-b202-43c9-a8a8-b6b357ed94d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_589e8491-d484-472b-926f-4df86fa0ab6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_edfb17e6-b202-43c9-a8a8-b6b357ed94d1" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_589e8491-d484-472b-926f-4df86fa0ab6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofOtherCurrentAssetsandPrepaidExpensesDetail" xlink:type="simple" xlink:href="vtl-20220930.xsd#BalanceSheetDetailsScheduleofOtherCurrentAssetsandPrepaidExpensesDetail"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofOtherCurrentAssetsandPrepaidExpensesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2c8d799c-ebb6-4675-bfc8-92d7a5d7c56c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_PrepaidClinicalAndRelatedCostsCurrent_3ae6d062-2cd4-4e38-9e95-a781607b533f" xlink:href="vtl-20220930.xsd#vtl_PrepaidClinicalAndRelatedCostsCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2c8d799c-ebb6-4675-bfc8-92d7a5d7c56c" xlink:to="loc_vtl_PrepaidClinicalAndRelatedCostsCurrent_3ae6d062-2cd4-4e38-9e95-a781607b533f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValueAddedTaxReceivableCurrent_1957b551-29bd-43b7-b61e-ff6e2f931f10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValueAddedTaxReceivableCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2c8d799c-ebb6-4675-bfc8-92d7a5d7c56c" xlink:to="loc_us-gaap_ValueAddedTaxReceivableCurrent_1957b551-29bd-43b7-b61e-ff6e2f931f10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_ResearchAndDevelopmentTaxIncentiveCurrent_219604ad-c279-4485-80e1-3d9772a0dcd1" xlink:href="vtl-20220930.xsd#vtl_ResearchAndDevelopmentTaxIncentiveCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2c8d799c-ebb6-4675-bfc8-92d7a5d7c56c" xlink:to="loc_vtl_ResearchAndDevelopmentTaxIncentiveCurrent_219604ad-c279-4485-80e1-3d9772a0dcd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_5c7e8ace-c6f8-4d00-9bea-fda2ac08146b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2c8d799c-ebb6-4675-bfc8-92d7a5d7c56c" xlink:to="loc_us-gaap_OtherAssetsCurrent_5c7e8ace-c6f8-4d00-9bea-fda2ac08146b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_915c1d7a-97ec-4119-9b45-840272d8ac66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2c8d799c-ebb6-4675-bfc8-92d7a5d7c56c" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_915c1d7a-97ec-4119-9b45-840272d8ac66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofAccountsPayableDetail" xlink:type="simple" xlink:href="vtl-20220930.xsd#BalanceSheetDetailsScheduleofAccountsPayableDetail"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofAccountsPayableDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b3eb79f2-fdfd-4948-85b8-acb3e6560144" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_ClinicalCostsPayableCurrent_d09d1b57-c720-4460-bc9c-b007ed7fd887" xlink:href="vtl-20220930.xsd#vtl_ClinicalCostsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b3eb79f2-fdfd-4948-85b8-acb3e6560144" xlink:to="loc_vtl_ClinicalCostsPayableCurrent_d09d1b57-c720-4460-bc9c-b007ed7fd887" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_LegalAndAuditCostsPayableCurrent_e780522b-79b2-4fc7-bdfd-6e000241cda6" xlink:href="vtl-20220930.xsd#vtl_LegalAndAuditCostsPayableCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b3eb79f2-fdfd-4948-85b8-acb3e6560144" xlink:to="loc_vtl_LegalAndAuditCostsPayableCurrent_e780522b-79b2-4fc7-bdfd-6e000241cda6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableOtherCurrent_2b121a83-b213-402f-abd9-2ed1b860c368" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableOtherCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b3eb79f2-fdfd-4948-85b8-acb3e6560144" xlink:to="loc_us-gaap_AccountsPayableOtherCurrent_2b121a83-b213-402f-abd9-2ed1b860c368" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_11a7863e-0f6a-4b7c-aa51-beba2fc40d6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b3eb79f2-fdfd-4948-85b8-acb3e6560144" xlink:to="loc_us-gaap_AccountsPayableCurrent_11a7863e-0f6a-4b7c-aa51-beba2fc40d6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofAccruedExpensesDetail" xlink:type="simple" xlink:href="vtl-20220930.xsd#BalanceSheetDetailsScheduleofAccruedExpensesDetail"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofAccruedExpensesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_df1acec2-a5e2-4b46-b111-fd8f575eba75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_AccruedClinicalCostsCurrent_2f219a3c-d219-4871-8d94-4701e7d2eef3" xlink:href="vtl-20220930.xsd#vtl_AccruedClinicalCostsCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_df1acec2-a5e2-4b46-b111-fd8f575eba75" xlink:to="loc_vtl_AccruedClinicalCostsCurrent_2f219a3c-d219-4871-8d94-4701e7d2eef3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_AccruedLegalAndAuditCostsCurrent_a1d761ce-a8de-4e87-ae80-2be7e1be16cf" xlink:href="vtl-20220930.xsd#vtl_AccruedLegalAndAuditCostsCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_df1acec2-a5e2-4b46-b111-fd8f575eba75" xlink:to="loc_vtl_AccruedLegalAndAuditCostsCurrent_a1d761ce-a8de-4e87-ae80-2be7e1be16cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_AccruedCompensationCurrent_3deabdf5-0e2b-4241-affa-7e4e41cf10ec" xlink:href="vtl-20220930.xsd#vtl_AccruedCompensationCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_df1acec2-a5e2-4b46-b111-fd8f575eba75" xlink:to="loc_vtl_AccruedCompensationCurrent_3deabdf5-0e2b-4241-affa-7e4e41cf10ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_bddcc9d7-7b79-48fe-af40-9d416d76f46a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_df1acec2-a5e2-4b46-b111-fd8f575eba75" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_bddcc9d7-7b79-48fe-af40-9d416d76f46a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_ccb9cce9-c287-4692-a229-bfbad83fa827" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_df1acec2-a5e2-4b46-b111-fd8f575eba75" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_ccb9cce9-c287-4692-a229-bfbad83fa827" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofOtherCurrentLiabilitiesDetail" xlink:type="simple" xlink:href="vtl-20220930.xsd#BalanceSheetDetailsScheduleofOtherCurrentLiabilitiesDetail"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofOtherCurrentLiabilitiesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_62133c29-0e20-4656-af0d-be6c9dfa01dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_75a3110b-38da-4f3e-ac42-e0bfc71f9470" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_62133c29-0e20-4656-af0d-be6c9dfa01dc" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_75a3110b-38da-4f3e-ac42-e0bfc71f9470" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherSundryLiabilitiesCurrent_079dfbf5-a1e5-4d9d-814b-f8fdfa114539" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherSundryLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_62133c29-0e20-4656-af0d-be6c9dfa01dc" xlink:to="loc_us-gaap_OtherSundryLiabilitiesCurrent_079dfbf5-a1e5-4d9d-814b-f8fdfa114539" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_b03aa8aa-10e5-4713-8352-a1cc7c493d32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_62133c29-0e20-4656-af0d-be6c9dfa01dc" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_b03aa8aa-10e5-4713-8352-a1cc7c493d32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetails" xlink:type="simple" xlink:href="vtl-20220930.xsd#CommitmentsandContingenciesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_91e88316-f64d-48c6-ab58-4c7458a6aa70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_fd117773-0318-4fb0-8720-1f1c2028a880" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_91e88316-f64d-48c6-ab58-4c7458a6aa70" xlink:to="loc_us-gaap_LossContingenciesTable_fd117773-0318-4fb0-8720-1f1c2028a880" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_999b2021-f1ee-4dad-a458-ad89d66d1e7e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_fd117773-0318-4fb0-8720-1f1c2028a880" xlink:to="loc_srt_StatementGeographicalAxis_999b2021-f1ee-4dad-a458-ad89d66d1e7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_4c46d56e-5faa-4e61-bbc0-a342443e5c9f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_999b2021-f1ee-4dad-a458-ad89d66d1e7e" xlink:to="loc_srt_SegmentGeographicalDomain_4c46d56e-5faa-4e61-bbc0-a342443e5c9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_GrafelfingGermanyMember_1375c6ab-4ba5-49ef-9a4f-634332bcedc8" xlink:href="vtl-20220930.xsd#vtl_GrafelfingGermanyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_4c46d56e-5faa-4e61-bbc0-a342443e5c9f" xlink:to="loc_vtl_GrafelfingGermanyMember_1375c6ab-4ba5-49ef-9a4f-634332bcedc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_NewYorkCityMember_d36bf83a-d3a7-49a9-93c5-f7ce60f2153b" xlink:href="vtl-20220930.xsd#vtl_NewYorkCityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_4c46d56e-5faa-4e61-bbc0-a342443e5c9f" xlink:to="loc_vtl_NewYorkCityMember_d36bf83a-d3a7-49a9-93c5-f7ce60f2153b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_5813f406-925f-4f34-a2ad-0fa63b0893a1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_fd117773-0318-4fb0-8720-1f1c2028a880" xlink:to="loc_dei_LegalEntityAxis_5813f406-925f-4f34-a2ad-0fa63b0893a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_a27db245-32bc-43e8-806d-72086c997e46" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_5813f406-925f-4f34-a2ad-0fa63b0893a1" xlink:to="loc_dei_EntityDomain_a27db245-32bc-43e8-806d-72086c997e46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_ImmunicAGMember_68bf7c67-8241-4a2f-88d9-7ca42bb9d3af" xlink:href="vtl-20220930.xsd#vtl_ImmunicAGMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_a27db245-32bc-43e8-806d-72086c997e46" xlink:to="loc_vtl_ImmunicAGMember_68bf7c67-8241-4a2f-88d9-7ca42bb9d3af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_d7aa0f85-c8ce-4f3f-a419-89cfd4a8532e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_fd117773-0318-4fb0-8720-1f1c2028a880" xlink:to="loc_us-gaap_LossContingenciesLineItems_d7aa0f85-c8ce-4f3f-a419-89cfd4a8532e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_8041207e-8a45-4f8c-8e36-1914427282ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_d7aa0f85-c8ce-4f3f-a419-89cfd4a8532e" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_8041207e-8a45-4f8c-8e36-1914427282ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_LesseeOperatingLeaseRentHolidayPeriod_cbe9ff18-e052-4172-87ca-23ea248d8601" xlink:href="vtl-20220930.xsd#vtl_LesseeOperatingLeaseRentHolidayPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_d7aa0f85-c8ce-4f3f-a419-89cfd4a8532e" xlink:to="loc_vtl_LesseeOperatingLeaseRentHolidayPeriod_cbe9ff18-e052-4172-87ca-23ea248d8601" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_dbf6e87d-9efe-43f9-8e6f-4db792c0bcb3" xlink:href="vtl-20220930.xsd#vtl_IncreaseDecreaseInOperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_d7aa0f85-c8ce-4f3f-a419-89cfd4a8532e" xlink:to="loc_vtl_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_dbf6e87d-9efe-43f9-8e6f-4db792c0bcb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_OperatingLeaseIncrementalBorrowingRate_f0020c49-93ab-4a1d-8809-8be8884cf48f" xlink:href="vtl-20220930.xsd#vtl_OperatingLeaseIncrementalBorrowingRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_d7aa0f85-c8ce-4f3f-a419-89cfd4a8532e" xlink:to="loc_vtl_OperatingLeaseIncrementalBorrowingRate_f0020c49-93ab-4a1d-8809-8be8884cf48f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_OperatingAndVariableLeasesCost_e33cc13f-9ef4-41a9-9421-0832d8c6d15f" xlink:href="vtl-20220930.xsd#vtl_OperatingAndVariableLeasesCost"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_d7aa0f85-c8ce-4f3f-a419-89cfd4a8532e" xlink:to="loc_vtl_OperatingAndVariableLeasesCost_e33cc13f-9ef4-41a9-9421-0832d8c6d15f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligation_dc10d81d-f7a9-4c3f-b27f-218e4c94ce93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractualObligation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_d7aa0f85-c8ce-4f3f-a419-89cfd4a8532e" xlink:to="loc_us-gaap_ContractualObligation_dc10d81d-f7a9-4c3f-b27f-218e4c94ce93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_AssetPurchaseAgreementRoyaltiesAsPercentOfAggregatedNetSales_6fe5e6d8-f2a5-4c3d-a889-cbcea837032a" xlink:href="vtl-20220930.xsd#vtl_AssetPurchaseAgreementRoyaltiesAsPercentOfAggregatedNetSales"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_d7aa0f85-c8ce-4f3f-a419-89cfd4a8532e" xlink:to="loc_vtl_AssetPurchaseAgreementRoyaltiesAsPercentOfAggregatedNetSales_6fe5e6d8-f2a5-4c3d-a889-cbcea837032a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_0c045afb-6262-4be2-bf52-a1749f7d98a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_d7aa0f85-c8ce-4f3f-a419-89cfd4a8532e" xlink:to="loc_us-gaap_CommonStockSharesIssued_0c045afb-6262-4be2-bf52-a1749f7d98a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_d3569262-adb1-4c8a-9f28-6364656305b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_d7aa0f85-c8ce-4f3f-a419-89cfd4a8532e" xlink:to="loc_us-gaap_CommonStockValue_d3569262-adb1-4c8a-9f28-6364656305b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_RoyaltySettlementAgreementSalesNet_e8115416-44f0-4069-965b-5016bace6a3b" xlink:href="vtl-20220930.xsd#vtl_RoyaltySettlementAgreementSalesNet"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_d7aa0f85-c8ce-4f3f-a419-89cfd4a8532e" xlink:to="loc_vtl_RoyaltySettlementAgreementSalesNet_e8115416-44f0-4069-965b-5016bace6a3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_RoyaltySettlementAgreementCashPaymentPercent_17849a01-59f4-4b3d-b6b4-bce7376b7715" xlink:href="vtl-20220930.xsd#vtl_RoyaltySettlementAgreementCashPaymentPercent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_d7aa0f85-c8ce-4f3f-a419-89cfd4a8532e" xlink:to="loc_vtl_RoyaltySettlementAgreementCashPaymentPercent_17849a01-59f4-4b3d-b6b4-bce7376b7715" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_RoyaltySettlementAgreementSharesPaymentPercent_72725840-14b4-4982-9be7-1d10f2225d90" xlink:href="vtl-20220930.xsd#vtl_RoyaltySettlementAgreementSharesPaymentPercent"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_d7aa0f85-c8ce-4f3f-a419-89cfd4a8532e" xlink:to="loc_vtl_RoyaltySettlementAgreementSharesPaymentPercent_72725840-14b4-4982-9be7-1d10f2225d90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseObligationDetails" xlink:type="simple" xlink:href="vtl-20220930.xsd#CommitmentsandContingenciesMaturitiesofOperatingLeaseObligationDetails"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseObligationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_30c43219-19fb-4746-b105-ac2c04024d74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_11ba9893-9867-4d1d-841f-5cc347542264" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_30c43219-19fb-4746-b105-ac2c04024d74" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_11ba9893-9867-4d1d-841f-5cc347542264" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_27c556ba-652f-451d-b2c4-97fbb960d97c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_30c43219-19fb-4746-b105-ac2c04024d74" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_27c556ba-652f-451d-b2c4-97fbb960d97c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_872511d6-ca11-4314-aabe-33e5009b2c03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_30c43219-19fb-4746-b105-ac2c04024d74" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_872511d6-ca11-4314-aabe-33e5009b2c03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_0fa76024-cd3d-48d0-94ed-1e134b814e74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_30c43219-19fb-4746-b105-ac2c04024d74" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_0fa76024-cd3d-48d0-94ed-1e134b814e74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_d1d876fd-b043-400e-9077-3b81baf2cc02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_30c43219-19fb-4746-b105-ac2c04024d74" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_d1d876fd-b043-400e-9077-3b81baf2cc02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_7f4bcfa4-bf9e-4f29-99e7-64781e898f53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_30c43219-19fb-4746-b105-ac2c04024d74" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_7f4bcfa4-bf9e-4f29-99e7-64781e898f53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_e30effae-d3b5-43f4-8df5-2d316c39db3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_30c43219-19fb-4746-b105-ac2c04024d74" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_e30effae-d3b5-43f4-8df5-2d316c39db3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_7b92b96e-d713-4fc0-ad6e-0f6b3600dc80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_30c43219-19fb-4746-b105-ac2c04024d74" xlink:to="loc_us-gaap_OperatingLeaseLiability_7b92b96e-d713-4fc0-ad6e-0f6b3600dc80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseObligationDetails_1" xlink:type="simple" xlink:href="vtl-20220930.xsd#CommitmentsandContingenciesMaturitiesofOperatingLeaseObligationDetails_1"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseObligationDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://vitaltherapies.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="simple" xlink:href="vtl-20220930.xsd#FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_c5265c70-8b20-42e4-a590-f702f328fc33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_87e7c69e-c3ba-40b8-9ed1-ee33a0672377" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_c5265c70-8b20-42e4-a590-f702f328fc33" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_87e7c69e-c3ba-40b8-9ed1-ee33a0672377" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_bdfd29a1-3df8-450a-b717-733c45be5cdc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_87e7c69e-c3ba-40b8-9ed1-ee33a0672377" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_bdfd29a1-3df8-450a-b717-733c45be5cdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6d78c746-47af-43c8-9959-dcf70d371e4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_bdfd29a1-3df8-450a-b717-733c45be5cdc" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6d78c746-47af-43c8-9959-dcf70d371e4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_301d9575-2c2b-4fd4-9063-8ee5f47e3c52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6d78c746-47af-43c8-9959-dcf70d371e4b" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_301d9575-2c2b-4fd4-9063-8ee5f47e3c52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_2c9fba59-f57b-471a-ad97-b035374a719c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6d78c746-47af-43c8-9959-dcf70d371e4b" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_2c9fba59-f57b-471a-ad97-b035374a719c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_c092c798-f4a6-4713-840c-d38b64e8e660" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6d78c746-47af-43c8-9959-dcf70d371e4b" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_c092c798-f4a6-4713-840c-d38b64e8e660" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_6d15f2ec-2d82-42d4-bfb9-069acdd1d743" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_87e7c69e-c3ba-40b8-9ed1-ee33a0672377" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_6d15f2ec-2d82-42d4-bfb9-069acdd1d743" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_eb7900c1-0404-4f64-b4de-0e79f850eb80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_6d15f2ec-2d82-42d4-bfb9-069acdd1d743" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_eb7900c1-0404-4f64-b4de-0e79f850eb80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_13d3feb9-7487-4a1a-b116-c1515684ed28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_eb7900c1-0404-4f64-b4de-0e79f850eb80" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_13d3feb9-7487-4a1a-b116-c1515684ed28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_074db084-087f-46ad-a76a-a91b7a182ce8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_87e7c69e-c3ba-40b8-9ed1-ee33a0672377" xlink:to="loc_us-gaap_InvestmentTypeAxis_074db084-087f-46ad-a76a-a91b7a182ce8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_482abde2-3cca-4362-b69b-13bd2d46783d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_074db084-087f-46ad-a76a-a91b7a182ce8" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_482abde2-3cca-4362-b69b-13bd2d46783d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_e7883586-7b8f-4b6e-b047-65a0c45564e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_482abde2-3cca-4362-b69b-13bd2d46783d" xlink:to="loc_us-gaap_MoneyMarketFundsMember_e7883586-7b8f-4b6e-b047-65a0c45564e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d7d4cf3f-e3b5-4bce-9ae4-c34ec97ea9a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_87e7c69e-c3ba-40b8-9ed1-ee33a0672377" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d7d4cf3f-e3b5-4bce-9ae4-c34ec97ea9a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_8e1c8547-222c-4a07-a849-bda7f0d454ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d7d4cf3f-e3b5-4bce-9ae4-c34ec97ea9a0" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_8e1c8547-222c-4a07-a849-bda7f0d454ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_14506c12-f64b-466a-b03b-bd41a8780b6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_8e1c8547-222c-4a07-a849-bda7f0d454ef" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_14506c12-f64b-466a-b03b-bd41a8780b6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/CommonStockShelfRegistrationStatementDetails" xlink:type="simple" xlink:href="vtl-20220930.xsd#CommonStockShelfRegistrationStatementDetails"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/CommonStockShelfRegistrationStatementDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_45d7de61-f68e-4339-a62e-ef5b517410b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_5421d380-2d75-4572-9b06-e5aae5fcd21d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_45d7de61-f68e-4339-a62e-ef5b517410b1" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_5421d380-2d75-4572-9b06-e5aae5fcd21d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_e2d2e5b7-508e-40fc-bec5-2c8588d70709" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_5421d380-2d75-4572-9b06-e5aae5fcd21d" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_e2d2e5b7-508e-40fc-bec5-2c8588d70709" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_be57a5f3-1556-4799-8df1-438faa66d4e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_e2d2e5b7-508e-40fc-bec5-2c8588d70709" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_be57a5f3-1556-4799-8df1-438faa66d4e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_December2020ATMMember_f9fa7c93-390d-4092-aa97-a8b2a62e7e9b" xlink:href="vtl-20220930.xsd#vtl_December2020ATMMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_be57a5f3-1556-4799-8df1-438faa66d4e7" xlink:to="loc_vtl_December2020ATMMember_f9fa7c93-390d-4092-aa97-a8b2a62e7e9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_May2022ATMMember_4c04c30a-0717-4f1f-a369-45c8a3b3ebb5" xlink:href="vtl-20220930.xsd#vtl_May2022ATMMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_be57a5f3-1556-4799-8df1-438faa66d4e7" xlink:to="loc_vtl_May2022ATMMember_4c04c30a-0717-4f1f-a369-45c8a3b3ebb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_0ae1f745-0899-4e04-be78-8f207be3ff3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_5421d380-2d75-4572-9b06-e5aae5fcd21d" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_0ae1f745-0899-4e04-be78-8f207be3ff3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_2a1e7cc4-e84d-4061-b004-0a9ace0771e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_0ae1f745-0899-4e04-be78-8f207be3ff3a" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_2a1e7cc4-e84d-4061-b004-0a9ace0771e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_43e88b3e-1f1c-4358-aa5b-bc6510395df7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_2a1e7cc4-e84d-4061-b004-0a9ace0771e7" xlink:to="loc_us-gaap_SubsequentEventMember_43e88b3e-1f1c-4358-aa5b-bc6510395df7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_d8fa1011-87a3-4b4f-82e3-304de2c7d28d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_5421d380-2d75-4572-9b06-e5aae5fcd21d" xlink:to="loc_us-gaap_ClassOfStockLineItems_d8fa1011-87a3-4b4f-82e3-304de2c7d28d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration_2c17259e-600d-440b-b122-e6b48cb8cac9" xlink:href="vtl-20220930.xsd#vtl_MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_d8fa1011-87a3-4b4f-82e3-304de2c7d28d" xlink:to="loc_vtl_MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration_2c17259e-600d-440b-b122-e6b48cb8cac9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_ShelfRegistrationStatementAmountRemaining_ba071694-a1d9-49f5-bf22-3eef7ec18fb3" xlink:href="vtl-20220930.xsd#vtl_ShelfRegistrationStatementAmountRemaining"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_d8fa1011-87a3-4b4f-82e3-304de2c7d28d" xlink:to="loc_vtl_ShelfRegistrationStatementAmountRemaining_ba071694-a1d9-49f5-bf22-3eef7ec18fb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_ShelfRegistrationTerminationPriorWrittenNotice_cba23eec-4c7a-4a7e-8eeb-731e58b8c64a" xlink:href="vtl-20220930.xsd#vtl_ShelfRegistrationTerminationPriorWrittenNotice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_d8fa1011-87a3-4b4f-82e3-304de2c7d28d" xlink:to="loc_vtl_ShelfRegistrationTerminationPriorWrittenNotice_cba23eec-4c7a-4a7e-8eeb-731e58b8c64a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_SaleOfStockRemainingCapacity_3c06e65c-2d8a-410f-b7d8-5a3dbe7bdef6" xlink:href="vtl-20220930.xsd#vtl_SaleOfStockRemainingCapacity"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_d8fa1011-87a3-4b4f-82e3-304de2c7d28d" xlink:to="loc_vtl_SaleOfStockRemainingCapacity_3c06e65c-2d8a-410f-b7d8-5a3dbe7bdef6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock_26013bad-f80f-42f1-a3e1-adfdb00f938b" xlink:href="vtl-20220930.xsd#vtl_ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_d8fa1011-87a3-4b4f-82e3-304de2c7d28d" xlink:to="loc_vtl_ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock_26013bad-f80f-42f1-a3e1-adfdb00f938b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_842b2c16-9ad4-4e21-8984-dda5699a164d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_d8fa1011-87a3-4b4f-82e3-304de2c7d28d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_842b2c16-9ad4-4e21-8984-dda5699a164d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_64a36977-72b0-4578-afa9-9236bbd83535" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_d8fa1011-87a3-4b4f-82e3-304de2c7d28d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_64a36977-72b0-4578-afa9-9236bbd83535" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_SharesIssuedWeightedAverageSharePricePerShare_441b5966-243a-4444-a5b4-3ea561ab929c" xlink:href="vtl-20220930.xsd#vtl_SharesIssuedWeightedAverageSharePricePerShare"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_d8fa1011-87a3-4b4f-82e3-304de2c7d28d" xlink:to="loc_vtl_SharesIssuedWeightedAverageSharePricePerShare_441b5966-243a-4444-a5b4-3ea561ab929c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_67e8ba4c-04d7-424d-ac97-cf3c1d46ee77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_d8fa1011-87a3-4b4f-82e3-304de2c7d28d" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_67e8ba4c-04d7-424d-ac97-cf3c1d46ee77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForCommissions_5accbe10-d25a-43f7-b27f-115d7be5f3cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForCommissions"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_d8fa1011-87a3-4b4f-82e3-304de2c7d28d" xlink:to="loc_us-gaap_PaymentsForCommissions_5accbe10-d25a-43f7-b27f-115d7be5f3cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/CommonStockPublicEquityOfferingDetails" xlink:type="simple" xlink:href="vtl-20220930.xsd#CommonStockPublicEquityOfferingDetails"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/CommonStockPublicEquityOfferingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_7750384a-4dd1-41d8-85e9-d77d28c4027c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_022db10c-e334-4a3d-b8bf-c228b63ab3e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_7750384a-4dd1-41d8-85e9-d77d28c4027c" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_022db10c-e334-4a3d-b8bf-c228b63ab3e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_44fe9393-da0d-42f5-a588-f7958e57d6d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_022db10c-e334-4a3d-b8bf-c228b63ab3e0" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_44fe9393-da0d-42f5-a588-f7958e57d6d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7c636a25-49bd-453e-89b4-f3cde0adc3c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_44fe9393-da0d-42f5-a588-f7958e57d6d6" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7c636a25-49bd-453e-89b4-f3cde0adc3c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_July2021PublicEquityOfferingMember_b7c4cb27-2e4a-4571-9a8f-1ecac15eb8a7" xlink:href="vtl-20220930.xsd#vtl_July2021PublicEquityOfferingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7c636a25-49bd-453e-89b4-f3cde0adc3c4" xlink:to="loc_vtl_July2021PublicEquityOfferingMember_b7c4cb27-2e4a-4571-9a8f-1ecac15eb8a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_cac7afe6-2d27-4865-b585-cab8237dcb9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_022db10c-e334-4a3d-b8bf-c228b63ab3e0" xlink:to="loc_us-gaap_ClassOfStockLineItems_cac7afe6-2d27-4865-b585-cab8237dcb9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_7f538c21-df83-4587-801d-224078a6c150" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_cac7afe6-2d27-4865-b585-cab8237dcb9b" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_7f538c21-df83-4587-801d-224078a6c150" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_16b5a72a-2f92-44de-8c63-627063ad3c5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_cac7afe6-2d27-4865-b585-cab8237dcb9b" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_16b5a72a-2f92-44de-8c63-627063ad3c5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_68b6b9f3-cb39-4759-a788-7cb125bc70cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_cac7afe6-2d27-4865-b585-cab8237dcb9b" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_68b6b9f3-cb39-4759-a788-7cb125bc70cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_1e0ddcc6-22fd-4c45-bdcb-ec30b2d60c26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_cac7afe6-2d27-4865-b585-cab8237dcb9b" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_1e0ddcc6-22fd-4c45-bdcb-ec30b2d60c26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/CommonStockCommonStockDetails" xlink:type="simple" xlink:href="vtl-20220930.xsd#CommonStockCommonStockDetails"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/CommonStockCommonStockDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_94c6ab32-633c-411c-a8c1-15425d197605" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_0262d266-f4df-487e-969e-ac894de4d406" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_94c6ab32-633c-411c-a8c1-15425d197605" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_0262d266-f4df-487e-969e-ac894de4d406" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_737ea684-2e82-4ea6-b492-cb6ca025e9b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_94c6ab32-633c-411c-a8c1-15425d197605" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_737ea684-2e82-4ea6-b492-cb6ca025e9b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared_60d71d7a-7701-4339-9eeb-d0c24a9910ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_94c6ab32-633c-411c-a8c1-15425d197605" xlink:to="loc_us-gaap_CommonStockDividendsPerShareDeclared_60d71d7a-7701-4339-9eeb-d0c24a9910ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareCashPaid_237ab068-72d2-4831-a522-a3ff0145ecf2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockDividendsPerShareCashPaid"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_94c6ab32-633c-411c-a8c1-15425d197605" xlink:to="loc_us-gaap_CommonStockDividendsPerShareCashPaid_237ab068-72d2-4831-a522-a3ff0145ecf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/CommonStockPreferredStockDetails" xlink:type="simple" xlink:href="vtl-20220930.xsd#CommonStockPreferredStockDetails"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/CommonStockPreferredStockDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_87fb5076-c37d-4106-a585-eaa1b654a059" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_36848398-2c2d-412d-b69d-8fe69127d7c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_87fb5076-c37d-4106-a585-eaa1b654a059" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_36848398-2c2d-412d-b69d-8fe69127d7c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_716a7c31-50de-444b-aecd-65edf72774cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_87fb5076-c37d-4106-a585-eaa1b654a059" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_716a7c31-50de-444b-aecd-65edf72774cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_005a6c5e-cddf-4c48-907d-a030ef815184" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_87fb5076-c37d-4106-a585-eaa1b654a059" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_005a6c5e-cddf-4c48-907d-a030ef815184" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/CommonStockSharesReservedforFutureIssuanceDetails" xlink:type="simple" xlink:href="vtl-20220930.xsd#CommonStockSharesReservedforFutureIssuanceDetails"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/CommonStockSharesReservedforFutureIssuanceDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_ec977aaf-22f2-4c9d-94f9-ec3de3c848e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_9cfd7155-9c30-4dae-9a97-b6990450cf0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_ec977aaf-22f2-4c9d-94f9-ec3de3c848e6" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_9cfd7155-9c30-4dae-9a97-b6990450cf0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_cdccf223-7a0e-47b0-9df4-8fdf50d3c325" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_9cfd7155-9c30-4dae-9a97-b6990450cf0b" xlink:to="loc_us-gaap_PlanNameAxis_cdccf223-7a0e-47b0-9df4-8fdf50d3c325" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_9d0320cc-453d-4edf-aa1a-bbb79aad8acf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_cdccf223-7a0e-47b0-9df4-8fdf50d3c325" xlink:to="loc_us-gaap_PlanNameDomain_9d0320cc-453d-4edf-aa1a-bbb79aad8acf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_A2021EmployeeStockPurchasePlanMember_d2acb86b-088b-4181-91eb-304c566ec323" xlink:href="vtl-20220930.xsd#vtl_A2021EmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_9d0320cc-453d-4edf-aa1a-bbb79aad8acf" xlink:to="loc_vtl_A2021EmployeeStockPurchasePlanMember_d2acb86b-088b-4181-91eb-304c566ec323" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_TwoThousandFourteenEquityIncentivePlanMember_ea0b2718-d7f8-4917-823a-a519b8de6d9b" xlink:href="vtl-20220930.xsd#vtl_TwoThousandFourteenEquityIncentivePlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_9d0320cc-453d-4edf-aa1a-bbb79aad8acf" xlink:to="loc_vtl_TwoThousandFourteenEquityIncentivePlanMember_ea0b2718-d7f8-4917-823a-a519b8de6d9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_A2017InducementEquityIncentivePlanMember_3e515369-d82f-4aac-9cc6-a7764e0de3f8" xlink:href="vtl-20220930.xsd#vtl_A2017InducementEquityIncentivePlanMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_9d0320cc-453d-4edf-aa1a-bbb79aad8acf" xlink:to="loc_vtl_A2017InducementEquityIncentivePlanMember_3e515369-d82f-4aac-9cc6-a7764e0de3f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_TwoThousandNineteenOmnibusEquityIncentivePlanMember_725a7154-ccf3-4537-ab05-e864fb81e0a0" xlink:href="vtl-20220930.xsd#vtl_TwoThousandNineteenOmnibusEquityIncentivePlanMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_9d0320cc-453d-4edf-aa1a-bbb79aad8acf" xlink:to="loc_vtl_TwoThousandNineteenOmnibusEquityIncentivePlanMember_725a7154-ccf3-4537-ab05-e864fb81e0a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_80d12b1b-9d79-4047-9b6a-18c1b192858b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_9cfd7155-9c30-4dae-9a97-b6990450cf0b" xlink:to="loc_us-gaap_AwardTypeAxis_80d12b1b-9d79-4047-9b6a-18c1b192858b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8fca4ed4-444a-4030-9d7c-505cfb5fdb84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_80d12b1b-9d79-4047-9b6a-18c1b192858b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8fca4ed4-444a-4030-9d7c-505cfb5fdb84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_0c48baa2-48a6-470b-9024-52bcac7d4ead" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8fca4ed4-444a-4030-9d7c-505cfb5fdb84" xlink:to="loc_us-gaap_EmployeeStockOptionMember_0c48baa2-48a6-470b-9024-52bcac7d4ead" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_EmployeeStockOptionsforFutureGrantMember_5ed0484b-cc09-43f0-a90f-91b0f85e3585" xlink:href="vtl-20220930.xsd#vtl_EmployeeStockOptionsforFutureGrantMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8fca4ed4-444a-4030-9d7c-505cfb5fdb84" xlink:to="loc_vtl_EmployeeStockOptionsforFutureGrantMember_5ed0484b-cc09-43f0-a90f-91b0f85e3585" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_6a1e6403-981c-4e14-8fb5-ae2de97dbe55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_9cfd7155-9c30-4dae-9a97-b6990450cf0b" xlink:to="loc_us-gaap_ClassOfStockLineItems_6a1e6403-981c-4e14-8fb5-ae2de97dbe55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_2980434d-546a-49f1-bbd4-e32905265561" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_6a1e6403-981c-4e14-8fb5-ae2de97dbe55" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_2980434d-546a-49f1-bbd4-e32905265561" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails" xlink:type="simple" xlink:href="vtl-20220930.xsd#StockBasedCompensationPlansAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1856f08e-99fe-476f-8afe-64265c4b0e98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cb406110-47e4-468a-be11-cb6a62396af4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1856f08e-99fe-476f-8afe-64265c4b0e98" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cb406110-47e4-468a-be11-cb6a62396af4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_bb836131-1dd5-498a-874e-185f9a3982dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cb406110-47e4-468a-be11-cb6a62396af4" xlink:to="loc_us-gaap_PlanNameAxis_bb836131-1dd5-498a-874e-185f9a3982dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_3e137722-5286-4369-8589-f302b8efad45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_bb836131-1dd5-498a-874e-185f9a3982dd" xlink:to="loc_us-gaap_PlanNameDomain_3e137722-5286-4369-8589-f302b8efad45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_A2021EmployeeStockPurchasePlanMember_54969535-1d90-4dd1-89b1-183eea93e95e" xlink:href="vtl-20220930.xsd#vtl_A2021EmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_3e137722-5286-4369-8589-f302b8efad45" xlink:to="loc_vtl_A2021EmployeeStockPurchasePlanMember_54969535-1d90-4dd1-89b1-183eea93e95e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_A2019OmnibusEquityIncentivePlanMember_8281d0b9-0a35-48d7-a7e5-86170e4036e8" xlink:href="vtl-20220930.xsd#vtl_A2019OmnibusEquityIncentivePlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_3e137722-5286-4369-8589-f302b8efad45" xlink:to="loc_vtl_A2019OmnibusEquityIncentivePlanMember_8281d0b9-0a35-48d7-a7e5-86170e4036e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember_3c6039f0-2a9e-41a7-872f-66305e0ebeab" xlink:href="vtl-20220930.xsd#vtl_TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vtl_A2019OmnibusEquityIncentivePlanMember_8281d0b9-0a35-48d7-a7e5-86170e4036e8" xlink:to="loc_vtl_TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember_3c6039f0-2a9e-41a7-872f-66305e0ebeab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_TwoThousandFourteenEquityIncentivePlanMember_de6b45e7-4512-4dbf-9222-bb2c026af7b4" xlink:href="vtl-20220930.xsd#vtl_TwoThousandFourteenEquityIncentivePlanMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_3e137722-5286-4369-8589-f302b8efad45" xlink:to="loc_vtl_TwoThousandFourteenEquityIncentivePlanMember_de6b45e7-4512-4dbf-9222-bb2c026af7b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_A2017InducementEquityIncentivePlanMember_404d1c11-5f4d-4ebb-9634-eecb0292d3e3" xlink:href="vtl-20220930.xsd#vtl_A2017InducementEquityIncentivePlanMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_3e137722-5286-4369-8589-f302b8efad45" xlink:to="loc_vtl_A2017InducementEquityIncentivePlanMember_404d1c11-5f4d-4ebb-9634-eecb0292d3e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_f825c2d1-ffbd-49ce-8fa2-348c39ada824" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cb406110-47e4-468a-be11-cb6a62396af4" xlink:to="loc_srt_RangeAxis_f825c2d1-ffbd-49ce-8fa2-348c39ada824" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_41f0ea59-a76a-4790-b50a-631af086fa8e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_f825c2d1-ffbd-49ce-8fa2-348c39ada824" xlink:to="loc_srt_RangeMember_41f0ea59-a76a-4790-b50a-631af086fa8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_5645253b-f0b0-4b5f-8216-7faa6d5ed408" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_41f0ea59-a76a-4790-b50a-631af086fa8e" xlink:to="loc_srt_MaximumMember_5645253b-f0b0-4b5f-8216-7faa6d5ed408" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_c8232a83-528d-4d57-8b15-7ef1181fd8dc" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_41f0ea59-a76a-4790-b50a-631af086fa8e" xlink:to="loc_srt_MinimumMember_c8232a83-528d-4d57-8b15-7ef1181fd8dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_9dd5a063-49f8-46c4-9996-3932448ae81d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cb406110-47e4-468a-be11-cb6a62396af4" xlink:to="loc_us-gaap_AwardTypeAxis_9dd5a063-49f8-46c4-9996-3932448ae81d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cb765e5c-5ae2-4f6a-8521-290ae8a46a18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_9dd5a063-49f8-46c4-9996-3932448ae81d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cb765e5c-5ae2-4f6a-8521-290ae8a46a18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_IncentiveEmployeeStockOptionMember_afb30610-59cf-41d5-80ad-461fd806945c" xlink:href="vtl-20220930.xsd#vtl_IncentiveEmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cb765e5c-5ae2-4f6a-8521-290ae8a46a18" xlink:to="loc_vtl_IncentiveEmployeeStockOptionMember_afb30610-59cf-41d5-80ad-461fd806945c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_NonStatutoryEmployeeStockOptionMember_2e6d4449-12e4-43c7-a064-b87fbb0b8fde" xlink:href="vtl-20220930.xsd#vtl_NonStatutoryEmployeeStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cb765e5c-5ae2-4f6a-8521-290ae8a46a18" xlink:to="loc_vtl_NonStatutoryEmployeeStockOptionMember_2e6d4449-12e4-43c7-a064-b87fbb0b8fde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7eb24280-0f88-440a-af04-b6e9ec940a68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cb406110-47e4-468a-be11-cb6a62396af4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7eb24280-0f88-440a-af04-b6e9ec940a68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_28b53ddd-a273-4208-8fbd-eb6b493d5b31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7eb24280-0f88-440a-af04-b6e9ec940a68" xlink:to="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_28b53ddd-a273-4208-8fbd-eb6b493d5b31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_6835b2ce-2a63-477e-810f-7ecd3c21e60e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7eb24280-0f88-440a-af04-b6e9ec940a68" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_6835b2ce-2a63-477e-810f-7ecd3c21e60e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_38479c84-36c7-4e3c-a998-8e8e88e6e9f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7eb24280-0f88-440a-af04-b6e9ec940a68" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_38479c84-36c7-4e3c-a998-8e8e88e6e9f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1abdbb9b-2168-4d5c-97a9-c5a6f14d2247" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7eb24280-0f88-440a-af04-b6e9ec940a68" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1abdbb9b-2168-4d5c-97a9-c5a6f14d2247" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_e1dc7d1d-e840-4aa0-a882-97e60c48e0c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7eb24280-0f88-440a-af04-b6e9ec940a68" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_e1dc7d1d-e840-4aa0-a882-97e60c48e0c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent_6afa14fe-88d5-4647-8021-51a4f6e8a478" xlink:href="vtl-20220930.xsd#vtl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7eb24280-0f88-440a-af04-b6e9ec940a68" xlink:to="loc_vtl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent_6afa14fe-88d5-4647-8021-51a4f6e8a478" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_b1fc988e-c529-477d-9ac3-2a881e31123a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7eb24280-0f88-440a-af04-b6e9ec940a68" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_b1fc988e-c529-477d-9ac3-2a881e31123a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_ef86d267-4862-4ff2-854c-ff73c85a3f76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7eb24280-0f88-440a-af04-b6e9ec940a68" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_ef86d267-4862-4ff2-854c-ff73c85a3f76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_8b5f808b-d024-4040-9296-049e55d8923c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7eb24280-0f88-440a-af04-b6e9ec940a68" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_8b5f808b-d024-4040-9296-049e55d8923c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_a77bdb59-893f-44a1-adb3-347063fb105c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7eb24280-0f88-440a-af04-b6e9ec940a68" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_a77bdb59-893f-44a1-adb3-347063fb105c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_48e589be-b58a-449b-b190-2da42a66c864" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7eb24280-0f88-440a-af04-b6e9ec940a68" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_48e589be-b58a-449b-b190-2da42a66c864" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_792455e2-a245-4ad3-9dc4-1175ce1d6f3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7eb24280-0f88-440a-af04-b6e9ec940a68" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_792455e2-a245-4ad3-9dc4-1175ce1d6f3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_e9cc83c2-35e2-4ff9-bb33-bc85f98dd763" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7eb24280-0f88-440a-af04-b6e9ec940a68" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_e9cc83c2-35e2-4ff9-bb33-bc85f98dd763" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/StockBasedCompensationPlansSummaryofStockOptionActivityDetails" xlink:type="simple" xlink:href="vtl-20220930.xsd#StockBasedCompensationPlansSummaryofStockOptionActivityDetails"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/StockBasedCompensationPlansSummaryofStockOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_37b6e799-40ed-4243-8b03-417f06e6b931" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_061f93fd-7287-4256-ad40-0150b11b6615" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_37b6e799-40ed-4243-8b03-417f06e6b931" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_061f93fd-7287-4256-ad40-0150b11b6615" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_4d24a80c-ddba-4742-b57c-ba666955f95d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_061f93fd-7287-4256-ad40-0150b11b6615" xlink:to="loc_us-gaap_PlanNameAxis_4d24a80c-ddba-4742-b57c-ba666955f95d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_88d23497-f81d-4101-9e4e-e46ea6e96aa7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_4d24a80c-ddba-4742-b57c-ba666955f95d" xlink:to="loc_us-gaap_PlanNameDomain_88d23497-f81d-4101-9e4e-e46ea6e96aa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_TwoThousandNineteenOmnibusEquityIncentivePlanMember_9e20e199-30d7-4419-b722-da4981dc81b4" xlink:href="vtl-20220930.xsd#vtl_TwoThousandNineteenOmnibusEquityIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_88d23497-f81d-4101-9e4e-e46ea6e96aa7" xlink:to="loc_vtl_TwoThousandNineteenOmnibusEquityIncentivePlanMember_9e20e199-30d7-4419-b722-da4981dc81b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_999f4bd7-d9a2-4ec9-92c2-43cefe397233" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_061f93fd-7287-4256-ad40-0150b11b6615" xlink:to="loc_us-gaap_AwardTypeAxis_999f4bd7-d9a2-4ec9-92c2-43cefe397233" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6b6c4abe-36c8-427e-a258-767db1efc2a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_999f4bd7-d9a2-4ec9-92c2-43cefe397233" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6b6c4abe-36c8-427e-a258-767db1efc2a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_7f40274a-0d7f-4003-8820-721f989a9828" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6b6c4abe-36c8-427e-a258-767db1efc2a8" xlink:to="loc_us-gaap_EmployeeStockOptionMember_7f40274a-0d7f-4003-8820-721f989a9828" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4e87bb0c-6205-4d1a-a949-73fdfedec404" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_061f93fd-7287-4256-ad40-0150b11b6615" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4e87bb0c-6205-4d1a-a949-73fdfedec404" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_dbf7a925-59f5-4638-9690-0173c737031e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4e87bb0c-6205-4d1a-a949-73fdfedec404" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_dbf7a925-59f5-4638-9690-0173c737031e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_ee9f1161-25f0-4d2b-95f2-75fdf31e93f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_dbf7a925-59f5-4638-9690-0173c737031e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_ee9f1161-25f0-4d2b-95f2-75fdf31e93f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c89db2f0-e707-489e-b08f-30659929f8de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_dbf7a925-59f5-4638-9690-0173c737031e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c89db2f0-e707-489e-b08f-30659929f8de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_c2f41a29-1002-4dcb-a238-2f0cbd089e78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_dbf7a925-59f5-4638-9690-0173c737031e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_c2f41a29-1002-4dcb-a238-2f0cbd089e78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_60c68b95-bc37-4829-8f26-583372c1c268" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_dbf7a925-59f5-4638-9690-0173c737031e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_60c68b95-bc37-4829-8f26-583372c1c268" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_49505ccf-ce22-4a71-8684-1af5b5dd19a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_dbf7a925-59f5-4638-9690-0173c737031e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_49505ccf-ce22-4a71-8684-1af5b5dd19a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_79d1672d-17f5-4b3e-8828-3c98339b1815" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4e87bb0c-6205-4d1a-a949-73fdfedec404" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_79d1672d-17f5-4b3e-8828-3c98339b1815" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_1af97237-2234-44ee-96a4-0008089ffced" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4e87bb0c-6205-4d1a-a949-73fdfedec404" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_1af97237-2234-44ee-96a4-0008089ffced" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_ca229630-2add-40d9-a98d-6f2887984f7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4e87bb0c-6205-4d1a-a949-73fdfedec404" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_ca229630-2add-40d9-a98d-6f2887984f7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_19948178-0dc2-4198-94e8-f0ae60fec009" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_ca229630-2add-40d9-a98d-6f2887984f7d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_19948178-0dc2-4198-94e8-f0ae60fec009" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_a0692705-dc29-4bb8-8e7e-83725f4a5124" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_ca229630-2add-40d9-a98d-6f2887984f7d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_a0692705-dc29-4bb8-8e7e-83725f4a5124" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_47d3672c-4ce8-4de8-82a9-06ae9d8ee9a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_ca229630-2add-40d9-a98d-6f2887984f7d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_47d3672c-4ce8-4de8-82a9-06ae9d8ee9a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_f805490b-800a-415f-a0a8-fcbde63f4404" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_ca229630-2add-40d9-a98d-6f2887984f7d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_f805490b-800a-415f-a0a8-fcbde63f4404" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2409a1cf-2c1d-4f63-af2f-0d5ee8d549c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_ca229630-2add-40d9-a98d-6f2887984f7d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2409a1cf-2c1d-4f63-af2f-0d5ee8d549c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_1b955177-d9d7-4ac6-91ad-fe121b95bd32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4e87bb0c-6205-4d1a-a949-73fdfedec404" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_1b955177-d9d7-4ac6-91ad-fe121b95bd32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_832cea66-14eb-4842-b1c4-7cf9ac8171f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4e87bb0c-6205-4d1a-a949-73fdfedec404" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_832cea66-14eb-4842-b1c4-7cf9ac8171f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_81d69ad5-d5d0-489d-8abf-76b26888b902" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4e87bb0c-6205-4d1a-a949-73fdfedec404" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_81d69ad5-d5d0-489d-8abf-76b26888b902" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_946ec0a0-d090-4319-9b46-6d5378472449" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_81d69ad5-d5d0-489d-8abf-76b26888b902" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_946ec0a0-d090-4319-9b46-6d5378472449" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_718fb6ae-0aad-4c0c-8ed2-d750705e1cbd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_81d69ad5-d5d0-489d-8abf-76b26888b902" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_718fb6ae-0aad-4c0c-8ed2-d750705e1cbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_43016b63-052d-4562-bba9-c8ae3491d78a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_81d69ad5-d5d0-489d-8abf-76b26888b902" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_43016b63-052d-4562-bba9-c8ae3491d78a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_b32b3bb7-f498-4003-a3e7-649f7d93d14b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_81d69ad5-d5d0-489d-8abf-76b26888b902" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_b32b3bb7-f498-4003-a3e7-649f7d93d14b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_a423b1cf-1e49-4136-b83f-b212aa677119" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_81d69ad5-d5d0-489d-8abf-76b26888b902" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_a423b1cf-1e49-4136-b83f-b212aa677119" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_7a159efd-24e8-41a2-87c5-4f54ab5b33b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_81d69ad5-d5d0-489d-8abf-76b26888b902" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_7a159efd-24e8-41a2-87c5-4f54ab5b33b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/StockBasedCompensationPlansRangesofUnderlyingAssumptionsUsedinBSMOptionPricingModeltoDetermineFairValueofStockOptionsGrantedtoEmployeesandNonemployeesDetail" xlink:type="simple" xlink:href="vtl-20220930.xsd#StockBasedCompensationPlansRangesofUnderlyingAssumptionsUsedinBSMOptionPricingModeltoDetermineFairValueofStockOptionsGrantedtoEmployeesandNonemployeesDetail"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/StockBasedCompensationPlansRangesofUnderlyingAssumptionsUsedinBSMOptionPricingModeltoDetermineFairValueofStockOptionsGrantedtoEmployeesandNonemployeesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f93d85fe-10ed-4a25-8888-fbf421697ca5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_14b7fdcc-553e-441e-9388-ffc2ec098074" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f93d85fe-10ed-4a25-8888-fbf421697ca5" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_14b7fdcc-553e-441e-9388-ffc2ec098074" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_9f101503-2ac9-4c31-80ee-2cd2e6a0e6d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_14b7fdcc-553e-441e-9388-ffc2ec098074" xlink:to="loc_us-gaap_PlanNameAxis_9f101503-2ac9-4c31-80ee-2cd2e6a0e6d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_7f35d67a-836c-4c0e-86f5-5a6f9618c191" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_9f101503-2ac9-4c31-80ee-2cd2e6a0e6d6" xlink:to="loc_us-gaap_PlanNameDomain_7f35d67a-836c-4c0e-86f5-5a6f9618c191" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_A2019OmnibusEquityIncentivePlanMember_a7bf8fa8-f4f8-4ab4-b733-a1e16165769e" xlink:href="vtl-20220930.xsd#vtl_A2019OmnibusEquityIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_7f35d67a-836c-4c0e-86f5-5a6f9618c191" xlink:to="loc_vtl_A2019OmnibusEquityIncentivePlanMember_a7bf8fa8-f4f8-4ab4-b733-a1e16165769e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0d5a568e-5655-4394-9fe4-38f1bff604ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_14b7fdcc-553e-441e-9388-ffc2ec098074" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0d5a568e-5655-4394-9fe4-38f1bff604ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_1695c09b-a9b2-422f-bf45-3e190ff67e55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0d5a568e-5655-4394-9fe4-38f1bff604ba" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_1695c09b-a9b2-422f-bf45-3e190ff67e55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_ffa6b1a5-bcfb-433e-acfc-d64c718e4240" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0d5a568e-5655-4394-9fe4-38f1bff604ba" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_ffa6b1a5-bcfb-433e-acfc-d64c718e4240" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_7827a515-2621-4901-b54d-c7cf73c31ee0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0d5a568e-5655-4394-9fe4-38f1bff604ba" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_7827a515-2621-4901-b54d-c7cf73c31ee0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_9b1c66fc-79bd-46a1-9723-88192372edde" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0d5a568e-5655-4394-9fe4-38f1bff604ba" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_9b1c66fc-79bd-46a1-9723-88192372edde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/StockBasedCompensationPlansScheduleofStockbasedCompensationExpenseforStockAwardsRecognizedDetails" xlink:type="simple" xlink:href="vtl-20220930.xsd#StockBasedCompensationPlansScheduleofStockbasedCompensationExpenseforStockAwardsRecognizedDetails"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/StockBasedCompensationPlansScheduleofStockbasedCompensationExpenseforStockAwardsRecognizedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1a9f19df-3f89-4269-982c-a123859c4271" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_56edec30-fc57-4f9d-8c73-e08b8bf1f65b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1a9f19df-3f89-4269-982c-a123859c4271" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_56edec30-fc57-4f9d-8c73-e08b8bf1f65b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_d53c360e-7be0-4c15-afc8-210884c6863b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_56edec30-fc57-4f9d-8c73-e08b8bf1f65b" xlink:to="loc_srt_TitleOfIndividualAxis_d53c360e-7be0-4c15-afc8-210884c6863b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_970faa1d-2b49-4f28-98a6-06c56f70227e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_d53c360e-7be0-4c15-afc8-210884c6863b" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_970faa1d-2b49-4f28-98a6-06c56f70227e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_EmployeeMember_afbb44be-3bad-4195-a341-813fd7fc06b3" xlink:href="vtl-20220930.xsd#vtl_EmployeeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_970faa1d-2b49-4f28-98a6-06c56f70227e" xlink:to="loc_vtl_EmployeeMember_afbb44be-3bad-4195-a341-813fd7fc06b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_b6bb3df0-f2ba-4a33-9dc4-caae34e29453" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_56edec30-fc57-4f9d-8c73-e08b8bf1f65b" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_b6bb3df0-f2ba-4a33-9dc4-caae34e29453" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_de481d72-a3f3-4fd6-b272-f76a6f09f2bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_b6bb3df0-f2ba-4a33-9dc4-caae34e29453" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_de481d72-a3f3-4fd6-b272-f76a6f09f2bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_6693ad29-fca1-4d50-8a42-713c67bdf692" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_de481d72-a3f3-4fd6-b272-f76a6f09f2bf" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_6693ad29-fca1-4d50-8a42-713c67bdf692" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_3aac76f7-ec55-4f77-aa45-3a1324cd83e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_de481d72-a3f3-4fd6-b272-f76a6f09f2bf" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_3aac76f7-ec55-4f77-aa45-3a1324cd83e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_2196b342-24a7-496a-9c97-5d584eff0ac7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_56edec30-fc57-4f9d-8c73-e08b8bf1f65b" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_2196b342-24a7-496a-9c97-5d584eff0ac7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_d3c3400c-9b32-4ef6-b993-cf1dec15e1f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_2196b342-24a7-496a-9c97-5d584eff0ac7" xlink:to="loc_us-gaap_ShareBasedCompensation_d3c3400c-9b32-4ef6-b993-cf1dec15e1f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/ChangesinBoardofDirectorsDetails" xlink:type="simple" xlink:href="vtl-20220930.xsd#ChangesinBoardofDirectorsDetails"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/ChangesinBoardofDirectorsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_45e37dc3-0a49-442c-99ba-619a00718dfa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_14e0f18a-d916-44cd-a736-6dd29ac6b574" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_45e37dc3-0a49-442c-99ba-619a00718dfa" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_14e0f18a-d916-44cd-a736-6dd29ac6b574" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_fb5d71ed-e1b4-4786-a3b5-72883ffbf721" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_14e0f18a-d916-44cd-a736-6dd29ac6b574" xlink:to="loc_srt_TitleOfIndividualAxis_fb5d71ed-e1b4-4786-a3b5-72883ffbf721" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_6a63f85a-71a3-40d4-9533-b805c72c406e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_fb5d71ed-e1b4-4786-a3b5-72883ffbf721" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_6a63f85a-71a3-40d4-9533-b805c72c406e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember_8488c02a-9e48-4de5-b905-e49a4ac2a47b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_DirectorMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_6a63f85a-71a3-40d4-9533-b805c72c406e" xlink:to="loc_srt_DirectorMember_8488c02a-9e48-4de5-b905-e49a4ac2a47b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_8e49c510-a7e8-4586-87a5-c0e49637ac44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_14e0f18a-d916-44cd-a736-6dd29ac6b574" xlink:to="loc_us-gaap_AwardTypeAxis_8e49c510-a7e8-4586-87a5-c0e49637ac44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fa772e77-9e52-471a-9f52-cd9366d55f1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_8e49c510-a7e8-4586-87a5-c0e49637ac44" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fa772e77-9e52-471a-9f52-cd9366d55f1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_OptionsVestingInOneYearMember_d2d32692-82fe-4424-9af3-84c8ade090a7" xlink:href="vtl-20220930.xsd#vtl_OptionsVestingInOneYearMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fa772e77-9e52-471a-9f52-cd9366d55f1f" xlink:to="loc_vtl_OptionsVestingInOneYearMember_d2d32692-82fe-4424-9af3-84c8ade090a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_OptionsVestingInThreeYearsMember_e050e960-b696-4e7e-900e-0a917192b732" xlink:href="vtl-20220930.xsd#vtl_OptionsVestingInThreeYearsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fa772e77-9e52-471a-9f52-cd9366d55f1f" xlink:to="loc_vtl_OptionsVestingInThreeYearsMember_e050e960-b696-4e7e-900e-0a917192b732" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_29d3a302-a173-4704-ad94-9e5795968480" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_14e0f18a-d916-44cd-a736-6dd29ac6b574" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_29d3a302-a173-4704-ad94-9e5795968480" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_75849213-9592-4c9a-b6b3-eaf66cfba4bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_29d3a302-a173-4704-ad94-9e5795968480" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_75849213-9592-4c9a-b6b3-eaf66cfba4bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c673a13b-482c-45c0-9427-0c534b6d1909" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_29d3a302-a173-4704-ad94-9e5795968480" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c673a13b-482c-45c0-9427-0c534b6d1909" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_ea670408-1ed3-4cfd-8426-5b60516c9a57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_29d3a302-a173-4704-ad94-9e5795968480" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_ea670408-1ed3-4cfd-8426-5b60516c9a57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/RelatedPartyTransactionsAdditionalInformationDetails" xlink:type="simple" xlink:href="vtl-20220930.xsd#RelatedPartyTransactionsAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/RelatedPartyTransactionsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_14aae975-8d53-4d78-bf1d-634b8cdf349d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_9fa2741f-44e9-414b-bfc1-19d0ebb78e08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_14aae975-8d53-4d78-bf1d-634b8cdf349d" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_9fa2741f-44e9-414b-bfc1-19d0ebb78e08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_56ce8bc7-f9c9-48e6-a027-f26b7f184b8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_9fa2741f-44e9-414b-bfc1-19d0ebb78e08" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_56ce8bc7-f9c9-48e6-a027-f26b7f184b8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_6d054707-eb05-46c3-a8ff-c86a9174c252" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_56ce8bc7-f9c9-48e6-a027-f26b7f184b8c" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_6d054707-eb05-46c3-a8ff-c86a9174c252" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_ExecutiveChairmanAgreementMember_a2985ec2-445d-4d0c-b258-7f1456fdb813" xlink:href="vtl-20220930.xsd#vtl_ExecutiveChairmanAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_6d054707-eb05-46c3-a8ff-c86a9174c252" xlink:to="loc_vtl_ExecutiveChairmanAgreementMember_a2985ec2-445d-4d0c-b258-7f1456fdb813" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_232db689-3aa4-41e5-a9fb-2cd86054f906" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_9fa2741f-44e9-414b-bfc1-19d0ebb78e08" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_232db689-3aa4-41e5-a9fb-2cd86054f906" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_e2ca1bd0-c6ca-4bc1-8751-25a2fc3c1486" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_232db689-3aa4-41e5-a9fb-2cd86054f906" xlink:to="loc_us-gaap_RelatedPartyDomain_e2ca1bd0-c6ca-4bc1-8751-25a2fc3c1486" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember_4c48622a-4352-4b41-973f-91d2eb7cc12f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_AffiliatedEntityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_e2ca1bd0-c6ca-4bc1-8751-25a2fc3c1486" xlink:to="loc_srt_AffiliatedEntityMember_4c48622a-4352-4b41-973f-91d2eb7cc12f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_7febb14c-f2a3-46b2-a282-bfd9743bc398" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_9fa2741f-44e9-414b-bfc1-19d0ebb78e08" xlink:to="loc_srt_CounterpartyNameAxis_7febb14c-f2a3-46b2-a282-bfd9743bc398" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_98794e5a-2edf-4de0-b2f6-448781964ee5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_7febb14c-f2a3-46b2-a282-bfd9743bc398" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_98794e5a-2edf-4de0-b2f6-448781964ee5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_DuaneNashMDJDMBAMember_f45c3296-f629-487d-9b16-7e24c2cbb49a" xlink:href="vtl-20220930.xsd#vtl_DuaneNashMDJDMBAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_98794e5a-2edf-4de0-b2f6-448781964ee5" xlink:to="loc_vtl_DuaneNashMDJDMBAMember_f45c3296-f629-487d-9b16-7e24c2cbb49a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_7990d66f-4cd3-40c5-ad6f-843ae0846098" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_9fa2741f-44e9-414b-bfc1-19d0ebb78e08" xlink:to="loc_srt_TitleOfIndividualAxis_7990d66f-4cd3-40c5-ad6f-843ae0846098" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_55b1fcb5-fdc8-49cd-b2f0-bd849c8633a3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_7990d66f-4cd3-40c5-ad6f-843ae0846098" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_55b1fcb5-fdc8-49cd-b2f0-bd849c8633a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_BoardOfDirectorsChairmanMember_4f820075-04df-43aa-8d02-18262c4b30f6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_BoardOfDirectorsChairmanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_55b1fcb5-fdc8-49cd-b2f0-bd849c8633a3" xlink:to="loc_srt_BoardOfDirectorsChairmanMember_4f820075-04df-43aa-8d02-18262c4b30f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_1e97a7c9-1836-4d8e-be53-73c8e9fd4bbf" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_9fa2741f-44e9-414b-bfc1-19d0ebb78e08" xlink:to="loc_srt_StatementScenarioAxis_1e97a7c9-1836-4d8e-be53-73c8e9fd4bbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_4da306ce-c86d-477d-8f3d-49c2fde1b0f7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_1e97a7c9-1836-4d8e-be53-73c8e9fd4bbf" xlink:to="loc_srt_ScenarioUnspecifiedDomain_4da306ce-c86d-477d-8f3d-49c2fde1b0f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_59e5602f-13bc-4535-80bf-a8d459921967" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_4da306ce-c86d-477d-8f3d-49c2fde1b0f7" xlink:to="loc_srt_ScenarioForecastMember_59e5602f-13bc-4535-80bf-a8d459921967" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_86141ef7-a9bb-484f-b7aa-0bb61a38ddc2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_9fa2741f-44e9-414b-bfc1-19d0ebb78e08" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_86141ef7-a9bb-484f-b7aa-0bb61a38ddc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_3518b1ee-f1d9-4f53-a282-8c3e20943157" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_86141ef7-a9bb-484f-b7aa-0bb61a38ddc2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_3518b1ee-f1d9-4f53-a282-8c3e20943157" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_SalaryCostsMonthlyBaseSalary_5ecf4a33-d692-4c4b-8f4c-de81857c2903" xlink:href="vtl-20220930.xsd#vtl_SalaryCostsMonthlyBaseSalary"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_86141ef7-a9bb-484f-b7aa-0bb61a38ddc2" xlink:to="loc_vtl_SalaryCostsMonthlyBaseSalary_5ecf4a33-d692-4c4b-8f4c-de81857c2903" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="vtl-20220930.xsd#SubsequentEventsDetails"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/SubsequentEventsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_91c95639-b077-4dfe-97c0-a0cb6701736c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_a245febf-9800-4627-8160-2cf68b8d7243" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_91c95639-b077-4dfe-97c0-a0cb6701736c" xlink:to="loc_us-gaap_SubsequentEventTable_a245febf-9800-4627-8160-2cf68b8d7243" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_53015324-450b-4d86-8631-d32badb8bc3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_a245febf-9800-4627-8160-2cf68b8d7243" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_53015324-450b-4d86-8631-d32badb8bc3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5d5f08da-ac77-470e-aa07-c45aa996b69d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_53015324-450b-4d86-8631-d32badb8bc3f" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5d5f08da-ac77-470e-aa07-c45aa996b69d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_9116356f-a847-4b27-af80-2bc315321eb6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5d5f08da-ac77-470e-aa07-c45aa996b69d" xlink:to="loc_us-gaap_CommonStockMember_9116356f-a847-4b27-af80-2bc315321eb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_PreFundedWarrantsMember_c16a0996-37d6-4b6c-a6c1-a2dbee5b4377" xlink:href="vtl-20220930.xsd#vtl_PreFundedWarrantsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5d5f08da-ac77-470e-aa07-c45aa996b69d" xlink:to="loc_vtl_PreFundedWarrantsMember_c16a0996-37d6-4b6c-a6c1-a2dbee5b4377" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_e19de89e-5546-4bb5-b57c-f837c4afedc1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_a245febf-9800-4627-8160-2cf68b8d7243" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_e19de89e-5546-4bb5-b57c-f837c4afedc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_df3c0514-df3c-4d52-bd07-4e52de96dfc7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_e19de89e-5546-4bb5-b57c-f837c4afedc1" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_df3c0514-df3c-4d52-bd07-4e52de96dfc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_37f2873a-2fb9-45a2-be52-31b2da74a6bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_df3c0514-df3c-4d52-bd07-4e52de96dfc7" xlink:to="loc_us-gaap_SubsequentEventMember_37f2873a-2fb9-45a2-be52-31b2da74a6bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_f74cb5a1-326a-4d7e-916f-33d8cdaa80e3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_a245febf-9800-4627-8160-2cf68b8d7243" xlink:to="loc_srt_StatementScenarioAxis_f74cb5a1-326a-4d7e-916f-33d8cdaa80e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_4e55a8a0-4d68-4a90-b805-1f2670413b20" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_f74cb5a1-326a-4d7e-916f-33d8cdaa80e3" xlink:to="loc_srt_ScenarioUnspecifiedDomain_4e55a8a0-4d68-4a90-b805-1f2670413b20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_abc6df2c-4a1d-4569-9c3c-f512b8293781" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_4e55a8a0-4d68-4a90-b805-1f2670413b20" xlink:to="loc_srt_ScenarioForecastMember_abc6df2c-4a1d-4569-9c3c-f512b8293781" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_42d3bc09-bbb6-47b3-a7c1-4a11f4ad2e67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_a245febf-9800-4627-8160-2cf68b8d7243" xlink:to="loc_us-gaap_SubsequentEventLineItems_42d3bc09-bbb6-47b3-a7c1-4a11f4ad2e67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_51b7f742-ba92-4faa-84f9-1cba8d7c082f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_42d3bc09-bbb6-47b3-a7c1-4a11f4ad2e67" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_51b7f742-ba92-4faa-84f9-1cba8d7c082f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_6737af71-2e08-49a5-a6a6-e2810b0b7553" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_42d3bc09-bbb6-47b3-a7c1-4a11f4ad2e67" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_6737af71-2e08-49a5-a6a6-e2810b0b7553" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_0afb2c7c-58f9-43de-b5f6-40479cbba982" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_42d3bc09-bbb6-47b3-a7c1-4a11f4ad2e67" xlink:to="loc_us-gaap_SharePrice_0afb2c7c-58f9-43de-b5f6-40479cbba982" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_EquityMethodInvestmentWarrantsExercisableOwnershipLimitationPercentage_b8bb98db-6731-4187-8a46-859993fc2993" xlink:href="vtl-20220930.xsd#vtl_EquityMethodInvestmentWarrantsExercisableOwnershipLimitationPercentage"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_42d3bc09-bbb6-47b3-a7c1-4a11f4ad2e67" xlink:to="loc_vtl_EquityMethodInvestmentWarrantsExercisableOwnershipLimitationPercentage_b8bb98db-6731-4187-8a46-859993fc2993" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_EquityMethodInvestmentWarrantsExercisableOwnershipLimitationMaximumIncreaseDecreasePercent_df946cdf-54b0-4de3-a520-4d8eb6b73923" xlink:href="vtl-20220930.xsd#vtl_EquityMethodInvestmentWarrantsExercisableOwnershipLimitationMaximumIncreaseDecreasePercent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_42d3bc09-bbb6-47b3-a7c1-4a11f4ad2e67" xlink:to="loc_vtl_EquityMethodInvestmentWarrantsExercisableOwnershipLimitationMaximumIncreaseDecreasePercent_df946cdf-54b0-4de3-a520-4d8eb6b73923" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_EquityMethodInvestmentWarrantsExercisableSharesChangeLimitationNoticePeriod_ba9abf41-dfee-4f8d-a09b-391e4f6cda01" xlink:href="vtl-20220930.xsd#vtl_EquityMethodInvestmentWarrantsExercisableSharesChangeLimitationNoticePeriod"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_42d3bc09-bbb6-47b3-a7c1-4a11f4ad2e67" xlink:to="loc_vtl_EquityMethodInvestmentWarrantsExercisableSharesChangeLimitationNoticePeriod_ba9abf41-dfee-4f8d-a09b-391e4f6cda01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_2320eeb9-3e78-4706-8275-13f1840e9583" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_42d3bc09-bbb6-47b3-a7c1-4a11f4ad2e67" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_2320eeb9-3e78-4706-8275-13f1840e9583" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_88b3a9c9-0fc0-4858-b16e-1e28f488a941" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_42d3bc09-bbb6-47b3-a7c1-4a11f4ad2e67" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_88b3a9c9-0fc0-4858-b16e-1e28f488a941" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>vtl-20220930_g1.jpg
<TEXT>
begin 644 vtl-20220930_g1.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_X0 B17AI9@  34T *@    @  0$2  ,
M   !  $       #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T      ! !+
M  $  0$L     0 !_^)]$$E#0U]04D]&24Q%  $2  B <$%$0D4"$   <')T
M<D--64M,86(@!]  !P :  4 *0 U86-S<$%04$P     041"10
M             /;6  $     TRU!1$)%
M                                   *9&5S8P   /P   !T8W!R=
M 7     K=W1P=    9P    403)",    ;   *(&03)",@   ;   *(&03)"
M,0  H[@  *(&0C)!,  !1<   CBT0C)!,0 #?G0  CBT0C)!,@ %MR@  CBT
M9V%M=  '[]P  )"19&5S8P         :52Y3+B!796(@0V]A=&5D("A35T]0
M*2!V,@
M                                                  !T97AT
M $-O<'ER:6=H=" R,# P($%D;V)E(%-Y<W1E;7,L($EN8RX  %A96B
M  "U6@  O&<  )(P;69T,@     $ PD   $                    !
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M*ZLLGRV3+H<O?#!P,60R63---$$U-C8K-R$X%CD+.@ Z]COM/.,]VS[3/\M
MQ$&]0K=#LD2L1:9&H4><2)=)E$J02XY,BTV*3HE/B%"(48E2B%.(5(A5B%:)
M5XI8BUF-6H];D5R3799>F%^;8)UAGV*@8Z%DHV6D9J9GIVBH::EJJFNJ;*MM
MJVZK;ZMPJ7&H<J5SHW2@=9UVF7>5>)%YC'J'>X)\?'UV?F]_:8!A@5J"48-(
MA#Z%-88KAR&(%XD,B@**]XOMC.*-V([-C\.0N9&ODJ63G)22E8F6@)=XF'"9
M:IICFUZ<69U5GE*?4*!/H4^B4*-2I%6E6:9?IV:H;JEXJH*KCJR<K:NNNZ_,
ML-^Q\[,)M""U.+91MVRXA[FDNL*[X;T!OB&_0\!EP8?"JL/.Q/'&%<<YR%[)
M@LJFR\K,[<X0SS+05-%TTI33LM3/U>O7!M@>V3;:3-MAW'3=A]Z8WZ?@L^&^
MXL?CS>31Y=+FT.?,Z,3INNJLZYOLA^UO[ECO7/!;\5;R3/,]]"KU$O7V]M;W
ML_B-^6+Z+_KT^['\9OT1_;/^3?[A_W'__P   =D#C04)!E0'?PB6":$*I N?
M#),-@@YP#U\03!$W$B$3"1/P%-85NQ:?%X,8@1E]&G0;9AQ5'4$>+!\7(  @
MZB'3(KTCIB20)7HF9"=.*#DI)2H0*OTKZBS7+<0NL2^>,(PQ>3)G,U4T1#4R
M-B(W$3@!./$YXCK3.\0\M3VF/I@_BD!]06]"8D-51$E%/$8P1R-(%TD+2?]*
M\TOH3-Q-T$[%3[E0K5&A4I53B%1Z56U67U=16$-9-5HF6QA<"5SZ7>M>W%_,
M8+UAK&*;8XED>&5F9E1G0F@P:1YJ"VKX:^5LTFV^;JIOEG""<6QR5G- ="EU
M$G7[=N1WS7BV>9YZAGMN?%9]/GXE?PU_](#;@<*"J(.-A'*%5X8[AR"(!8CJ
MB<^*LXN8C'V-8HY'CRV0$I#XD=Z2Q).JE)&5>)9@ET>8+YD8F@&:ZIO4G+^=
MJIZ6GX.@<:%?HD^C/Z0PI2*F%:<(I_VH\ZGJJN*KVZS5K="NRZ_'L,2QPK+!
ML\&TPK7%MLBWS;C3N=NZX[OMO/B^!+\1P"#!,,) PU+$9L5ZQH_'ILB^R=;*
M\<P,S2K.1\]CT(#1G]*_T^#5 ]8GUTS8<]F;VL3;[]T:WD;?<^"AX<_C N1-
MY9GFY^@VZ8;JV.PK[8#NU_ Q\9#R[_1-]:KW!/A:^:OZ]OPZ_7O^N____P"
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M$52! XNWXRF#),R5S*^"-L4[M9B!9;Y#G@. RK?+A@F :;'=;7> ,ZR-4\:
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M<!:UJJ&'7Z*P;Y[?3HFKDYT'/'VG.IRL*+BCX)IN$$ZD!HL&  ",&8  CR;
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M[:/Y+02!NIYP"(^!KH7)R)&&KLL]M,V%=,38H"^$2;YZBNJ#2[AH=36"CK,
M7M6"!JZU1TJ!DZK6+)>!7IXF"$J!-86;P@>6O76$KUF4BG8+G V2@W:7A_"0
MKG<V<OB/!W?S70:-E'C+1;F,<GFF*P.,3GJ,!JF,_WR<P+R5?7\LKE.34'[+
MFQ214WY^AP&/B'Y3<@F-[7Y/7!R,B'YM1,Z+;WZ9*B>+0W[Z!BR+;( 7OXZ4
M5XC8K1B2-(>=F?N0-H9UA>2.>(6)</^,ZH3&6RB+DH0O0_&*@8.Z*6.*38.Y
M!;Z*"H,FOF^309*GJ^21*)"9F+F/-XZAA,B-<(SC;^N+](MF6C"*J(H<0QF)
MGHD1**J)98CG!5^(UX.AO4>29YR%JL^03IFREYF.89<#@Y6,JI2%;MF+*))!
M64")ZY!20E.(Y(['* B(H([*!0V'T(-JO#R1OZ:&J<6/J:+XEI"-O)^'@I>,
M!YQ*;?"*AYE16&V)0):[0:>(/)3?)WR'\)0[!,B&\X,\NUN1.;"GJ.F/):Q?
ME;2--:@L@<"+?J0T;2R*!*"85\:(O9V#01F'J9N5)PN'59B^!(^&/(,5NJ20
MS[L!J#:.O;8 E/F,RK$/@02+#JQ>;'F)E*@P5RB(5Z370)V'0*+<)JJ&UIHD
M!&"%IH+VNAJ0?,6ZIZ>.;< #E%N,>+I2@&"*MK3R:^*)-[!.5J>'^ZT20"V&
M[*C$)DB&@9GB!#N%+X+=LL.@>G3#H4B=B'5.CSR:QW7B?&B8/7:,:+&5Z7=3
M4^B3VG@R/:&217D,(V>227G4 4J067RZL;"?8'WFH'V<:WV8CGR9K'UC>ZJ7
M)'U19^R4V'UF4R22TGV=/-N10'WA(KF1,WY4 2R.S'_=L+N>1H<.GWF;7(7T
MC8^8FX3Y>K:6((0S9P63W8.<4E"1X8,Q/!V04X+N(AZ0-8,[ 1&-;X"YK[R=
M4Y QGFB:;8Y@C&Z7M(RV>;>5,(LS9A.2^HGZ47Z1!8CS.VZ/>(@Y(96/2HBS
M /J,0("IKM6<<)F*G7:9DY<$BW*6XI2G>+.499)S93&2&Y""4+:0,X[N.LJ.
MIXW<(1>.;8XO .:+/8"<K?.;S*,(G*R8[I_1BJF6.)R^=^"3O)GE9&.1?9=7
M3_^/BI4].CB-_I02(*F-MY+@ -:*8X"1K3*;3:R@F^R8;ZC!B>B5MZ3^=R63
M.J%^8[J0_YYF3VZ/"IOQ.<*-:IL"(%6-%I7< ,B)KH"'K)":Z[9JFU"8#;'C
MB4B54:UU=H62SJE68R"0DZ7+3N:.IZ-*.5F- *%;( R,D)6K +V)&X" K!2:
MG,"=FM.7OKMOB+Z5 +96=?>2>+&B8I^0.:W-3GJ.3*M=./R,KJ9E'[Z,/I5V
M +2(I8!ZI FJD70YDY^F['2\@K&C?'5/<06@177\7G.=2G;%2KR:J'>B-5>8
MOGAK&T"9:WCL  "-GG\1HS"IEGSCDPNEYWR;@B2B<'QS<':?-'QP7=J<.7R7
M2B*9FWS>-+^7K7TM&M"8-7V8  ",;(  HG.HBH6(DC^DY(2%@6RA9H.D;[*>
M,8+^71^;/(*(27F8HX)$-"R6LH(K&FV7&8+&  "+8(  H;"GE8XOD6.C]HR#
M@'V@@(K^;MN=1(FR7%6:68BK2,N7Q8?A,Z&5T8=X&A.6&H@X  "*=X  H..F
MU);FD)>C-92:?ZF?PI)_;@*<B)"?6YR9B8[V2"R6_8V_,R:5 HTO&<B5+8SM
M  ")KX  H#JF(I_>C^VBB9SS?OR?%IHU;5:;VI>V6OB8VI6&1Z"6.9/E,KN4
M.Y.)&8245I#J  ")!X  GYVEH:CRCV>B!:5G?G>>BJ(&;,B;1I[S6FZ83IQ;
M1RJ5LIJ3,F*3G9H0&5"3HI$=  "(?(  GQ:E0[(TCN:AI*X0??2>(ZH5;$B:
MVJ9Z6?67X*.41KZ53*(.,A&3+I]T&2:3$)$!  "("X  GJJD^;O>CGVA5+<A
M?82=T+*+:]>:@ZYZ69"7AJN#1FR4[ZE",<Z2V*&L&/>2M9#A  "'L(  E?&U
M"'/$AGVPN'0W=I"LHG3"9>^HQ75L5&>E*W8Q0:*B"'<#+/"?^'>L$FZB''>L
M  ")?H  E56T(GP!AA^OQ7NT=C2KGGN098ZGLGN64_ND$7O(03B@Z7P:+(^>
MR7QI$E2@G7RO  "(Q(  E-6S&80LA8RNPX,T=;"JDX)E9/RFJ8'84V^C!X%_
M0+V?X(%;+"^=M(%G$C^?/X()  "((8  E$ZR'XQ3A.RMSXK"=/NII(E@9%FE
ML8@_4M:B&(=H0#V>\H;8*]*<NH;!$BN>!H;*  "'DX  D[NQ4Y22A%2M!))P
M=%FHW)"(8[*DZ8[?4DJA0(V$/\B>'XRA*X&;VXRH$AN<[HKB  "'&8  DRJP
MMYSY@\NL9II+<]2H.)?58R^D096M4<Z@E)/E/V:=69+#*T";"Y,3$A";\HPV
M  "&LX  DKZP):6%@V"KU:)+<VBGI9]*8L:CK9RG46Z@ 9J./QN<OYEZ*Q":
M1IB4$@F;#(PR  "&7H  DE.OQ:Y%@QNK;*IX<R:G+*;C8GBC'Z/)41V?;:&-
M/LZ</:"Z*MJ9RISY$@>:78PQ  "&&8  D?NO>K=L@LJK%[,1<M6FT*[Q8BJB
MOZM\4-R?":ES/IZ;U*;-*KR99)SE$@:9YHPP  "%XH  B':_Y7-1>>&Z]7.M
M:MFV0W0K6R>QRG3,2HJMGG6'.).J%'9&)%*H*W:W"EBJ!W<7  "&#(  B!Z_
M!7LN>;FZ"'K4:JZU/'JL6O2PJWJV2D^L;GKN.%^HU7M#)#2FQWN!"I^H+GQB
M  "%MH  A]Z]\H+I>6*X_8'T:EZT)H$N6I:OCX"U2?:K3(!T.!JGK(!L)!.E
M@8"4"M^F@X$F  "%:X  AY>\YXJ8>0&W]8D;:>>S(H?46BRN@8;7292J088M
M-\^FG875(_*D6X88"Q>E!X51  "%*8  ASZ\"I)@>*6W%I!B:82R08ZF6<"M
MGHTS23^I3HP<-X^EK(N6(]>C5HP^"TJCN8>B  "$\8  AM^[8II3>%"V9Y?6
M:36QB)6<676LWY.]2/FHC))5-UVDTY'&(\.B:Y'H"W2BE(>_  "$PH  AH>Z
MWJ)?> FUVI]D:/6P[YRN63FL/IIK2,*G[)C;-SFD+)BJ([JAF):C"YRAE(?9
M  "$FH  ADVZ8JJ5=]6U6J<>:,:P:Z/V60^KLZ%E2)JG7I_E-Q2CII\*(ZJ@
M_)@="\"@M(?R  "$>X  A@VZ$;,^=\"T^*\Y:+>O\ZN#6/6K(ZBH2(BFO:<Y
M-Q.B_:0/(\*@8)@M"_&@'8@3  "$88  >V[+,7+];9G%MG,W7UC ?W.:4'.[
M@G0G0)ZVWW3++T6S(75D&P:Q^'5K V^P37>)  "#)(  >VC*0'J(;:O$PGH1
M7UZ_:WG94'"Z27G:0)FUAWH-+U*QJ'I6&T>P,7I?! NN+WQ&  "#(H  >W+)
M$H'9;9?#GH#87T>^/8 /4$ZY"W^@0'VT.G]M+U"P1W]W&WVNDG^K!)>L28!U
M  "#(8  >W#'Z(D4;7W"<X>>7Q>]$89G4"6WU(6%0%ZS 84"+TJO H3?&ZVM
M'86$!1*JFX-N  "#'X  >UO&[)!E;67!<(Z 7OZ\!(SH4 *VPHNE0$^QWXK/
M+U"MW(JL&]^KT(LP!8&I)(.Y  "#'H  >SG&)9?D;53 FI607O>['Y..4 .U
MU9'V0$^P[I#L+V&LTI$!'!6JII +!>2GX8/[  "#'8  >Q?%A)]U;4>_ZIRS
M7O>Z8)I'4 JU#)AF0%NP)9==+WFL )=Y'$NIHY,A!CNFSH0W  "#'8  >O;%
M!J<P;3^_6Z/]7ORYP:$L4!:T89\40&>O=9Y9+XVK5IS3''BHX)- !H>EZX1J
M  "#'(  >MS$G:\^;3Z^X:N37PFY.*A;4"JSS*8S0(6NUZ3.+[FJL*!%'+.H
M,9-G!LBE1H26  "#'(  YA]V<',8T!MW2W/QN8!X'W3,HBIXZG6OBB1YLG:A
M<6-Z?W>C5X9[3WB?.R]\,7F6%IU](7GHY ]TAWYHSFMUB7X;M_IV?'WEH,MW
M97W*B-UX2WW-<"YY,WWD5EMZ%7WY.@=Z[WX2%2![5'W!XC%R\(G2S)IT HAD
MME]U"H<2GT9V"H7]AWYW"(41;O-X!H1"53YX]H-Y./EYQ(+$$\1YU8(+X&EQ
MDY4XRLURKI*_M)QSP)!LG;%TT8Y,AA%UYHQV;;)V]HK"5"IW\HDA-_YXLH>W
M$I1XBX7LWLEP=:"=R3)QDITOLP)RJYGGG"MSQ9;5A*YTY9/X;'QV!Y%I4R-W
M"X[Z-Q5WNXS^$8]W<8D_W6QOF*P-Q]EPM*>ZL:IQRZ-_FMMRZ)]Z@W=T#YNT
M:UAU-9@S4BYV094/-D)VX9+%$+1VA(M+W$YNZ[>,QL%P!+);L(MQ%:TQF;YR
M,*@\@G)S7:.::G)TBI],45IUE)MU-8]V)9DE#_YUOXK0VV]N;<,>Q>5O@;T5
MKZ-PB+<$F,MQF[$C@85RR:NL::1S_::V4*]U":)[-/1UA9ZU#VIU'XILVLMN
M&\[&Q41O*<?DKNMP(<#SE_]Q)[HV@+MR3[/\:.MS@ZY]4 ITCJI)-&-T_:,H
M#O1TGXH<UA5_#G&VP>5_$'+*K/1_'7//EQ]_-731@'5_5G7=:.Y_B';V4#%_
MSW@(-)J 67D'#UB!\GD\U(Q]47Q_P+)]<WQZJ\Y]EWQ\E?Y]P'R/?U-]\WRY
M9]-^-WSW3QY^C7TT,Y!_$GUR#D& 2'V#TP![TH=0OP=\ H9"JD%\,X5$E(%\
M<81O??Y\NX.]9J)]%8,F3@M]=H*8,I-][8(E#4Q^TH&#T6YZAI(8O65ZO) 9
MJ*%Z]XXPDPU[0(QI?*I[H8K=97A\#(ER30E\=H@A,:U\WH<>#'A]C83\S_-Y
M<ISIN^]YJIH+IRUY[9=!D:1Z/Y28>V9ZI9(<9%M[(H_G3!E[DXWA,-Q[ZHQ_
M"\)\=X?SSK-XFZ?2NK-XU*0?I?)Y%:!QD')Y:ISF>DIYUIF18U9Z4Y:$2SYZ
MS)/F,"%[%9*""RE[C8>+S:YW\;+3N;!X*JY.I.IX9:F_CVQXN:54>5IY+*$T
M8H5YKIUQ2H1Z(9I++X-Z7)AR"JIZRX<VS.1W<[WQN.-WJKB@I!!WW+,UCHMX
M)ZWK>(%XFZD)8<1Y)Z2W2>5YG*%K+OQYP9U."D)Z+8;PS%5W'LD^N$IW4<,C
MHU]W=[S@C<MWM;;"=\AX)+$O82!XL*Q[251Y)ZCR+GUY09]O"?!YKX:XQGZ(
M&'"*L_R',W&^H)*&<G+:C!N%T7/N=K>%1W4+8%R$W'8U2+2$GG=5+<6$]'A2
M"-R&3WE@Q4:&@'JXLNJ%NWKJGW.%#'L;BP>$=7M7=:J#^7NG7UN#G'P)1[J#
M:'QI+-B#LGS ""^$JGUUQ!*%#H3YL:B$7(0QGE^#LX-RB=F#+(+2=(>"NH)4
M7E&":X'S1L>"1(&?*_N"A8%N!YB#.8$+PJV#QX\JL#&#%HV-G,F"?(OWB'&"
M (I\<T*!J(DV736!:X@21=6!2H<3*RR!>(9^!Q2!^(0HP52"O9EAKMB"#9;]
MFW6!>I2=ARF!!9)1<AN L) M7#6 A(Y410" :(R\*GB A(P)!J. YH1]P#"!
M[:.^K;B!0*"6FE> JYUDAA2 .)I%<1Q_YY=:6U%_MI3"1$1_H9*T*==_L)(3
M!D1__H0]OT2!2:XWK,N GZI.F62 !:9+A2!_CJ);<#U_1)ZX6I)_&)N"0Z9^
M]IDB*5%^^)="!?9_/X0(OI" SKC:K!" )K0RF)E_A*]@A$Y_ JJ?;W-^MZ9.
M6=A^E:*I0PQ^=Z!P*-]^7IN"!;9^HX/<OA2 >,/!JX)_T[YCE^Q_)+C!@Y-^
MD[,U;L9^0*Y)645^(*IS0I-^!Z<P*'E]YIM>!8-^)H.ZMUR15V^QIC6/GG#M
ME"&.''(2@/2,R7,N;,N+F'145Y.*E76&0.^)X':D)H&*.W>! RJ*)'F]MEB/
MX7E3I4..1WF>DQZ,U'GI?_F+AWH_:]:*7WJI5JJ)9GLD0 J(M7N8);*(^GOT
M MN(A'UIM4F.BX+JI R- H)=D@.+DH'3?M>*4X%I:LR)-X$95;N(2H#C/S:'
MGH"Z)/J'SH"X I6'%H"BM"R-38R5HM2+RXL^D+:*:HGH?;F)*HBT:;V('X>L
M5,Z'/H;'/FN&F(8-)%"&MH7F EF%V8&6LP6,2Y9)H<**RY0XCYR);Y(M?(N(
M.I W:+"',8YK4]^&88SE/:6%O8NO([.%Q(NY B6$RH%SL@:+A: ?H+Z*"9U9
MCIB(K)J/>Y*'>9?:9\J&<95;4Q*%F),Q//Z$]Y&N(RR$[)$A ?F#Y8%6L36*
MZ:H.G^N)<::6C<"(#Z,->KR&V9^=9P6%U9Q[4FJ$_9G4/'6$2I@^(L"$,)6=
M =6#)X$]L)**<K0GGT"(_K "C0F'EJN^>@*&5J>79E&%4*/A4<:$@Z#T._"#
MSI]?(F&#E)<_ ;B"C8$IL""*&KZ+GKR(JKG"C&Z'.[3&>5V%[Z_N9;F$XJO
M442$$ZCF.W^#9*4Q(?^#(I;\ :""$H$9J)N:Z6\(F(Z8<W!!AZ66/'%I=;"4
M/'*,8K62:'.W3I*0U73G.-2/PG7T'J.0AG:$  "*<GM%I\J9G7@GE]*7/7B
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M98A*B0V>8X=$>1B;AH93:$Z8V86$5H"6<X3C0Y.49(1J+MZ2_X0K%0>4/H2
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M  " ((  IN*$'*,RELB#1:"(A:V"=IVL<YF!PIK*8,2!-Y@F30" S97R-\>
M=I2Z'E& ;))7  "  (  IDJ#CZT(EB."OJFZA/B!YZ8F<N&!)J*,8!* EY]6
M3%. .9S9-S=_WYNU'?A_IY1$  "  (  I>.#+;<:E:2"8+,SA%Z!?*[K<CR
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M/(J[71ZU'(G)4$2Q (C<0IZM#8@0,_RID8>2(YVG.H? #^:GJX:X  "9D(
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MU'>["QR.R'=]  "  (  A4B3L'P6=_Z1_'Q,:<R077QS6J:.VGR72DN-C'S
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M]7S25.FOK'R_2+ZL77RM.[FI-'R<+8ZFE7RB'1FECGR9">JEB'T9  ".P8
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M;+B!>'DJ782!,GFH30"!#7H>.R.!!WJ!)RR!,GJK#6:!T7I=  "  (  ATJ
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M7H\K5LR:2HZ;2M.8'(V^/=B5_8S;+ZZ41(QV'XN3?HRO#(F3)8AZ  "%(8
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M-))^3 RD>I(B0*>ANI%5-"Z?(Y"D)F>=+Y"9%B:<]HWD!6J8<(.I  "!@(
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MA&(34@%[,634/YU[[V=>*SQ\Q6E;$-Y^4&E@  "  '8)C5)UX6&Z@!!VF61
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M0G?@9;F!'7B160Z ZGDB2UV MWF8/)F DWG\*^B J7I"&$B _WH3 FZ!1'O
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ML9096*V&(9-\3,N%39)3/^&$3Y$&,>.#<Y!N(@*"[9 J#MN"78H+  "  (
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M:G9@0\J>TW;P..2=*'=5+.N;GG>1'UB:UW><#MB;J7=> '&3VGI4  "  (
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MR(&S6\MSO8';3_9T:X'%0PMTXX&,-.EU.8%C)/=U+X%D$:EUVH&)  "  (
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M>87+4'1[^87.149\&X5X.09[\83]*V][MH3#&XU[6H4;"5)\7(/?  "  (
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M-(DS15J%1HE .KF$\XB]+Q"$.(@4(>V#@X@:$>2#'8<D M>!M('L  "  (
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MN&CH.]V7#&HI,5Z66&M ):B5TFP*%_N63&Q+"'65#VRO  "'QG0O  "  (
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M  "  (  5DA[6EJS3%1\'UU 07M\R5^J-3Y]7V'7)U-^ F.1%FM^^V0O!(J
MMF56  "  ',D  "  (  52MWHF'U2S%XDF/]0%9Y567D-%AY]V>:)HAZ?VCF
M%=-Z^&DO!'-]W&IO  "  '@@  "  (  5!IT.6E'2BEU4FK./U5V+VPV,V)V
MT&UL)>)W-VY8%4=WA&Y>!%I[:6_C  "  'QR  "  (  4R9Q+'"K24-R;W&[
M/H1S9'*F,J%T!G-G)3=T/7/K%05TAW/3!&)Y0W7?  "  (    "  (  4E%N
M=W@*2'-OYWBI/<1P]GD:,?5QEGEK)*%QFWF?%*)R)GF !)!X2GMS  "  (
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M  "  (  28V"5%]'0!>"R&%/-:N#(V,K*@&#@62_'""$,66K"XB$MV7"  "
MJFK>  "  'KK  "  (  2)M^\68\/R=_CV?.-,)__FDW*1Z 3VI7&Y6 P6KX
M"SN!8&K]  "  '!Y  "  'Z^  "  (  1[I[XFU,/DU\L&YP,_Y]-F]H*'%]
M?7 B&OM]IG!L"Q-^AG"'  "  '95  "  (    "  (  1OAY,71=/95Z+74=
M,UQZRW6G)^9[!78#&G)ZYW83"M1\-G9L  "  'M'  "  (    "  (  1D]V
MT'ML/.MX WO0,KUXO'OX)UUX[7P &?IXA'O["FUZ;WRM  "  ']X  "  (
M  "  (  1=-TVX*\/(=V1(+@,F]W((*?)SIW.8)+&B1V<H);"LYXM8(&  "
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M  "  (  /)J+%&*:,W2+:60F*42+K65T'9F,(F9+#Z>-$&9G IF)Q6B'  "
M '0$  "  (    "  (  .\N'\FE=,J:(AVJ!*)"(Y6MK'0:)0FOQ#S^)I&O6
M J:' VXP  "  'D[  "  (    "  (  .Q6%*7 I,?2%_G#O)_B&=W%Y'(V&
MOW&T#N>&KG&& I:$Q713  "  'V8  "  (    "  (  .GR"NW<*,5V#SW=\
M)W:$97>N'"Z$EW>H#J.$27>2 FZ# GHK  "  (    "  (    "  (  .@V
MJGXG,.>!]GY/)PN"K'XQ&^."S'X!#I&"7'XN HF!B'[_  "  (    "  (
M  "  (    #__P  __\  /__  !M9G0R      0#"0   0
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M[W;P5?$S\@_RZO/#])SU<_9)]Q[W\_C&^97Z8?LI^^O\I_U<_@O^M/]:__\
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MD8DIB&)0PH>'AJ\^4(7OA/(LQ81+@Q"_)Y&^FR:M=(^8F#&;/(V7E5&(BXO
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M<TIB-)93=,=2D9,C=G!#2H_8>#XT:(QQ>E\FHHCA?.2=-J'T=Z./)YZJ> Z
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M@:PKAXQG@4DBVX>E@/-[&:I^C 9OLZ9EBKYC_J(LB618%IW8B E,.YEOAKM
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ML'93@;Q04'@+@3P^07G[@+8M'7PP@!BZNVV?CGNI^&\;C028C7"+BWJ&C7(
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M%'P&G$-RHGO\F(QC WPDE,A3<WR D/)$:GSQC0 UV'V8B-0H:WYKA'N>Z'O
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M67QI@'BBA6W'CF>4-V\MC2^%-G")B\-UG7'UBC9EP'.(B*55TG5-AQ-&2W=
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M'9@1=4Q-_)4B=G=#M)(9=[XYHH\!>2,P.8O>>J GE8C%?$$@5X75?>IK.)P
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M:XQC4G3N;AI3N';#<,=$>WC <YDULWL%=K0H(7V3>C&<&FOU;16.N6V\;M>
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M=H4K-8*6>1PB"H*/>]UXX8+O<31N6X*L<IAC8()?<_)8!((1=4Y,3('2=KE
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M:V)D7E_5;@Y5!F3J<-A&'6I$<\HWR'  =PLJUW7X>K&<=TF#;56.XDY\;P6
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M7*0RX8W9878KNXPC9I,E08IZ:^0?E(CV<6\;&8>T=N=-S)#Z5;E'4H_M67U
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MY(0"=B(WAH.+=WLQ3(+U>/(K6H)M>H(F$H'W?!<A6X' ?9P=I(&N?N]*3((
M>2]#YX*7>?(]E8*O>I\W5H)>>U@Q+8'J?#(K18&+?2 F&H$R?A8AA($9?OD=
MVH$L?[1)^X!\?J5#EX%2?ML]58&=?N8W,8%L?ODQ)($/?S K5(#*?WPF*("6
M?]$AFH">@!L>!8#$@%0  /__  #__P  __\  &UF=#$      P0A   !
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MYO^F.3+_HD9*_:!-8/&D3'+FITR$VJA0EL^F6:;'I62QQ*=OML&G>+N]IX'
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MTZU_HM.M?Z+3K7^BTZU_HM.M?Z+3K7^BTZU_HM.M?Z+3K7^BT_^C.2K_GT9
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M_YI12O^=4EGWGU1I[:!7>..?7(?:G&>5TIEPH<R6>ZO&E(2SQ).+ML*/C[K
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MNL)PJ:ZZ=[2CM'R]FJ^!PY*LA<B+J8K,A*>2SX"FG-" HZ7/@*&FSH"AILZ
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MW)9QDM63>YS/D(2DRXZ,J\B*D+#%AY2TPX28M\*!F[G!?YZZP7VBN\![IKS
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MJ\>/C;'$C)&VPH>5N<&#F;N_?YV^OGVBO[UZJ,"\>:_!M'FPP;!ZL,"P>K#
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MY<E6==S.9'K,QFF-OKYNG+*V=*BGL'FRGJM^NI6FA,".HXO$B*&2QX2?FLF
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M?;&UH7VXMIU^N+6:?[FTF8"ZLYF NK.9@+JSF8"ZLYF NK.9@+JSF8"ZLYF
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M^YY>8/2;96KMEFQSYY!V?.&*@(3;A(F+TWZ1DLYXF9C)=*&<QG&IG\)PLJ+
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M8&3CHFAMW)US=M&5>H+)C8*+PH>*D[R"D9JW?9F?LGJAHZ]WJ::K=K.GJ7;
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M<8"QGGB*J9A^DZ*3A9J;CXV@EHR5I9&)G:B-AZ>KBH>RK(B'OZR(A\"KB(;
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M2S__CTL__X]+/_^/2S__CTL__X]+/_^/2S__CTL__X]+/_^/2Z_& @"BU@(
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M8]^!U&/?@=1CWX'48]^!U&/?@=1CWX'48]^!U&/?@?]U) ;_=C40_W=#'/^
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M/?^+74?_AV11_X)L6OM\=&+W>']I\W2(;_!PD'3M;)=XZVJ>>^EGI'[H9JJ
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M8T3TL61#]+5D0_2U9$/TM61#]+5D0_2U9$/TM61#]+5D0_2U9-:R! #$O@8
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M;TW5Z'!.S.ER3LSI<D[,Z7).S.ER3LSI<D[,Z7).S.ER3LSI<O^2$0'_IQ$
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M(L>N4#&]J%D_LZ)@2ZN=9U:CF&Y?G)1U9Y:0?&V0C8-SBXJ+>(:(E'R!AIV
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M_Z$8 ?:Q% #9P0L TL\+ ,C2' &\T2X)L<X[%Z;+1B6<R$\SD<16/XC!74F
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M6T;<]5M&W/5;1MSU6T;<]5M&W/5;1MSU6^V<! #1K00 PK@% +?#!0"MT0@
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M9/]<) /_8R8$_V\F!?][+PO_@CD1_X9!&/^'22#_A5$H^()9,/)]8#CM=VI
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M5TG+X%9)R?!81\?Z64C%^UI(Q?M:2,7[6DC%^UI(Q?M:2,7[6O>1! #4H@(
MQZ\$ +JY P"PQ 4 I] ) )_A$ "8X2$#C^ P"8;@.Q)]WT0;==Y-)&[=52MG
MW%PR8MMD-UW;:SM9VG(_5=IZ0U+:@T5.VHU(3-J82DG:I4M(V[-,1]S$3$;<
MWDQ&VNU,1-CY3T/8^T]#V/M/0]C[3T/8^T]#V/M/0]C[3]N:  #*J0( N[,"
M +"] P"ER04 F]8) )3H% &,Z24$A.@S"WOH/!1SZ$0;:^A+(F3G4BA>YUDM
M6>=@,E7G:#52YV\X3^=W.TSG@#U)YXD_1^B4043HGT)"Z:Q#0>FZ1$#JS41
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M,C'_UC(Q_]8R,?_6,C'_UC(Q_]8R,?_6,K*O  "EN@  F,8  (O2  !_WP(
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M8%6BW&!5H>]@5I_W7U><]U]7G/=?5YSW7U><]U]7G/=?5YSW7_]Z# #]BPD
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M0D'1_D1!T?Y$0='^1$'1_D1!T?Y$0='^1-&8  ##I0  M:X  *FX  ">PP(
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M6V6%W%MEA?!:9H7[66>#_%AG@_Q79X/\5V>#_%=G@_Q79X/\5_]L#@#_>PP
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M3TVE_T].I/]/3J3_3TZD_T].I/]/3J3_3_I_  #8C@  R9L! +ZE @"TK0$
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M+CK<_2XZW/TN.MS]+L"?  "QIP  I+   )BZ  "-PP  @<T" ';7!P!NZ \
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M_T::7/]&FES_1O]5%P'_8!(!_VL4 ?]T%P#_>AP!\G\B >>!*0+>@C,$TW]
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M4'-RW5!T<_!/='/]371S_TQT<_],='/_3'1S_TQT<_],='/_3/]B#@#_;PP
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M3%V'_TM>AO]+7H;_2UZ&_TM>AO]+7H;_2_]M!0#J?   U8@  ,J2 P#!F@,
MN: # +&F"0"IIQD HJ<I YJE-@F2HT$2BZ%*&H2?4B%^G5HH>9M@+G299S-O
MEVXX:Y9U/&>4?4!CDX9#8)&01ER1G$E:D*E+6)"X3%>0S$Q7D.=+5X_W2E>.
M_TI8CO])6([_25B._TE8CO])6([_2?]Q 0#@@   SXP  ,26 @"[G@( LJ0
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M/T6K_S]%J_\_1:O_/]J#  #'D0  NYP  *^D  "EJP  FK(  )"Z 0"&P0D
M@<(8 'O"* )UPC4&;\% #&G 21)DOU$77[Y8'%N^7R!7O68D5+QN)U&\=BI-
MNW\M2KN*,$B[EC)%NZ,T0[NR-$*[Q35#N^(T0KGS-4&X_3= M_\W0+?_-T"W
M_S= M_\W0+?_-\Z+  "_F   LJ$  *>I  "<L   D;@  (;  @![R < =,L2
M '#,(@%KRS #9LL\!V'+10Q<RDX16,I6%53*71E1R60<3LEL'TO)=")(R'XD
M1<B()T/(E2A!R*(J/\BQ*S[)Q"L^R>$J/L?R*SW&_"T\Q?\N/,7_+CS%_RX\
MQ?\N/,7_+L23  "VGP  J:8  )VN  "2MP  AK\  'O' P!PSP< 9]8- &37
M&@!@V"H!7-@V UC80094V$H*4-A2#4W86A!*UV(31]=I%D77<AA"UWP:0-B'
M'#W8DQX\V*$?.MFP(#G9PR YV=\@.=?O(#C5^2(WU/\C-]3_(S?4_R,WU/\C
M-]3_([F<  "KI   GZP  ).U  "'O@  >\8  '#. P!EU@< 7>,. %KC&P!6
MXR<!4N0R D[D/ 1*Y$0&1^5-"$7E50I"Y5P,0.5D#C[F;! [YG82.>: %#?G
MC!4UYYD6-.>H%S+HN!@RZ,P8,>CE&#'F]!@QY?P8,>7\&#'E_!@QY?P8,>7\
M&*ZB  "AJ@  E+,  (B]  ![Q@  ;\X  &/6 0!8W@4 5.X0 %'O&P!-[R8!
M2? O D7P. -!\3\$/O%'!3SR3@8Z\E4'-_)<"#7S9 DS\VT*,?1W#"_T@@TM
M](\.*_6=#RKVJQ I]KP0*/;.$2?WYA$G]?$1)_7Q$2?U\1$G]?$1)_7Q$:.H
M  "6L@  B+L  'O%  !OS@  8M<  %;>  !.\ < 2OH0 $;[&0!"^R(!/_PJ
M 3O],@(X_3D"-?X_ S+^1@,P_TP$+O]3!2O_6@4I_V(&)_]K!B3_=@<C_X((
M(?^0""#_G0D?_ZL)'O^Z"1W_R0D<_]T)'/_="1S_W0D<_]T)'/_="9BP  "*
MN@  ?,0  &_-  !BV   5=X  $GD  !$^P4 /_\. #O_%0 X_QP -/\D 3'_
M*P$M_S$!*O\V B?_/ (E_T("(_]( B#_3@,>_U4#'/]= QG_9P07_W($%?]_
M!!3_C 43_YH%$O^F!1'_L@41_[P%$?^\!1'_O 41_[P%$?^\!8RX  !]P@
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M'*UM8B*H:FDGI6AQ+*%F>"^>9( SFV*'-IAACSB68)@[DU^A/9%>JS^/7KA
MC5[(08M>X4&*7_- B5__/XE@_SZ(8/\^B&#_/8A@_SV(8/\]B&#_/?]7#P#_
M8@P _VP, /AT# #I>@P WGX, -*!%0#(@2<!P'\V!KA\0@VR>$T5K'56&Z=R
M7R*B;V8GGFQN+)MJ=3"7:'PSE&>$-I%EC#F.9)4\C&.>/HEBJ$"'8K5"A6+%
M0H1BWD.#8_%"@F/]08)D_T""9/\_@F3_/X)D_S^"9/\_@F3_/_]9#@#_9 L
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M0VMS_T)L<_]!;'/_0&QS_T!L<_] ;'/_0/]A!0#Z;@$ W7D  -"" @#'B00
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M,FJ(>S9FAX0Y8X:./&"%F3]=A*9!6X2T0EJ$QT-:A.-"6H/T05N#_T!;@_]
M6X/_/UN#_S];@_\_6X/_/_]J  #>>   S8,  ,*,  "YDP  L)@  *>= @"@
MGQ( F9\C 9.>,06,G3P+A9M&$G^93AAZEU8>=99=(W"48RALDFHL:)%Q,&60
M>31ACH(W7HV,.EJ,ESU8C*0_5HNR0%2+Q4!4B^% 5(KS/U6*_C]5B?\^58G_
M/E6)_SY5B?\^58G_/N]O  #6?   R(<  +V1  "TF   JIP  *"B  "9I!
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M#B[BLPXNX\<.+>/C#BW@\@XLW_L/+-_]$"S?_1 LW_T0+-_]$*B@  "<IP
MC[   (.X  !VP0  :LD  %[/  !3U0$ 2=P& $7I#P!"Z1D 0.HD #WJ+@ Z
MZS8!..P^ 3;L1@(S[4T#,>U5 R_N700M[F4%*^YP!2GO>P8H[XD')O"7!R7P
MIP@D\;@((_',""+RY0@B\/,((N_U""+O]0@B[_4((N_U")ZF  "1KP  A+@
M '?!  !JR0  7=   %'7  !&W0  /^H% #SV#@ Y]A< -O<@ #/W*  Q^#
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M,9E2XC&74_(QEE/_,954_S&45/\PE%3_,)14_S"45/\PE%3_,/]/#@#_6 L
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M-WAD_S9X9/\U>&3_-7AD_S5X9/\U>&3_-?]7!0#_8@$ X6P  -1S @#+> 0
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M-F-S_S9C<_\V8W/_-O]A  #@;0  SW<  ,1_  "[A0  LXD  *J+ P"CC!,
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M(#RPMR \L,P@/*_H(#NN]R$ZK?\B.JS_(SJL_R,ZK/\C.JS_(\"&  "SD@
MIYD  )R?  "0I@  A*P  'FQ  !MMP  8;P% %V]$@!:OB  6+XM 52^. )1
MOD($3KY*!DR^4@A)OED*1KY@#$2^: Y!O7$1/[U\$SR]B!4ZO946.+VD%S>]
MM1@VO<H8-[SG%S6[]ADUNO\:-+G_&S2Y_QLTN?\;-+G_&[B/  "JF   GY\
M ).F  "'K   >[,  &^Y  !CO@  6,0$ %#(# !-R!< 3,DE $K*,0!'RCL!
M1<I$ D/*3 -!RE0$/LI<!CS*9 <ZRVX).,MX"C;+A0PTRY(-,LNB#C'+L@\P
MS,</,,OE#B_)]0\NR/T1+L?_$B['_Q(NQ_\2+L?_$JZ7  "AG@  E:4  (FM
M  !\M   <+L  &3!  !9Q@  3LL# $70"  ^U0X /=4: #S6)@ [US$ .=@[
M #C910$VV4T!-=E6 C/:7@(QVF@#,-MS!"[;?P4LVXT%*MR=!BG<K08HW<$&
M*-W>!B?;[P<FV?D()MC^"2;8_@DFV/X))MC^":2=  "8I0  BZT  'ZT  !Q
MO   9<,  %G)  !-S0  0],! #K9!@ UY T ,^06 #'D(  PY2H +N8S "WF
M/  KYT0 *N=, 2CH5 $GZ%T!)>EG B/I<P(BZH$"(.J1 Q_KH0,=Z[(#'.S'
M QSLX0,;ZO$#&^GY QOI^0,;Z?D#&^GY YJD  "-K   ?[4  '*]  !EQ0
M6<L  $S0  !!U0  .-P  "_A @ M\0T *_$3 "CR'  F\B0 )/,K "+T,@ A
M]#D '_5! !WU20 ;]E$ &?=: 1?W90$5^'(!%/F! 1/YD@$2^J("$?JS A#[
MQ@(0^]T"$/OI A#[Z0(0^^D"$/OI H^K  "!M   <[T  &;&  !9S0  2],
M $#9   UW@  +.,  ";Q   D_@H (?\0 !__%@ <_QP &?\B !?_*  5_RX
M$_\U !+_/  0_T, #O],  W_5@ +_V( "?]O  C_?P$'_Y !!?^@ 03_K@$$
M_[P! __' 0/_QP$#_\<! __' 8.T  !UO0  9\8  %K/  !+U0  /]P  #/A
M   IY0  (>P  ![]   :_P4 %_\, !7_$  2_Q0 $/\9  [_'@ -_R, "_\H
M  C_+@ &_S4  _\]  #_1@  _U$  /]=  #_:P  _WL  /^+  #_F0  _Z4
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M&[5!Z!NR0?8=L$'_'JY!_QZM0?\>K$'_'JQ!_QZL0?\>K$'_'O]"$0#_1PT
M_T\. /]3$0#_5A4 \U<< .A6)0#@53$!UU,_ L]23 7*4%<)QDYA#<-,:A#
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M*8A4_RF'5/\HAU3_*(=4_RB'5/\HAU3_*/],!0#_5@$ Z5T  -QC @#19P4
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M*VYC_RMN8_\K;F/_*_]5  #E8   TVD  ,AP  "_=   MW<! +!W!P"H>!4
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M:_\L96O_+/1;  #=9@  RV\  ,!V  "W>P  KWX  *9^ 0"??Q  F8 ? ).
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M)TF+M2A(B\HH2(KG)TF)]RA)B/\G28?_)TF'_R=)A_\G28?_)]%O  #!>P
MM80  *N,  "@D   E90  (F7  !^F@  =YL. '.<' !OG2D!:YPU F:</P5B
MFT<(7YI/"UR:5@]8F5P259AC%5.8:Q=0EW,:399]'4J5B1]'E94A196D(T24
MLR-#E,@C0Y3E(T.2]21#D?\D0Y#_)$.0_R1#D/\D0Y#_),IU  "[@0  L(L
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M#S&V\A PM/P1,+/_$C"S_Q,PL_\3,+/_$[*.  "EE0  FIL  (ZB  ""J
M=:T  &FS  !>MP  4[L  $? !0!#PA  0L(; $##)P _PS( /L0\ #S$1 $Z
MQ$T!.,15 C;$70,UQ&8$,\5P!#'%? 8OQ8H&+<6:!RO%J@@JQ;X(*L7:""K$
M\ @IPOL)*,'_"BC!_PLHP?\+*,'_"ZB5  "=FP  D:(  (2I  !XKP  :[4
M %^[  !4OP  2<,  #_(!  VS0D ,\X1 #+/'  QSR< ,- Q "_0.@ NT4,
M+=%, "O250 JTE\!*--I 2?3=@$ETX0")-24 B+4I@(AU;D"(=72 B#3ZP(@
MTO8#']'_!!_1_P0?T?\$']'_!)^;  "4H@  AZD  'FQ  !MN   8+X  %3#
M  !)QP  /LL  #70 0 MU08 )=L+ "3>$@ CWAP (M\E "'@+@ @X#< '^%
M ![A2@ =XE, '.-> !OC:@ :Y'@ &.2( 1?EF@$6YJP!%>;  13GW0$3Y>\!
M$^/Z 1/C^@$3X_H!$^/Z 9:B  ")J0  >[$  &ZY  !AP   5,8  $C*   ]
MSP  ,],  "K9   BW@( 'NL* !SL$  ;[1< &>T? !?N)@ 5[BT %.\U !/P
M/0 1\$8 $/%0  _R6P .\FD #?-X  STB@ +]9P "O6N  GVP@ )]MD "/7M
M  CU[0 (]>T "/7M (NI  !]L@  ;[H  &+"  !5R0  1\X  #O2   QV
M)]T  !_A   9Z   %O@& !3Z#0 2^Q( $/P7  [\'0 -_2, #/TI  K^,  (
M_S@ !O]!  /_3   _U@  /]F  #_=P  _XD  /^;  #_JP  _[L  /_.  #_
MSP  _\\  /_/ '^R  !QN@  8\,  %;+  !(T0  .M8  "_=   EX0  '.4
M !3I   1]P  #_\!  W_"0 +_PT "/\0  ;_%  #_Q@  /\>  #_(P  _RH
M /\R  #_/   _T<  /]4  #_8P  _W,  /^%  #_EP  _Z0  /^R  #_L@
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M!=8J[0?2*O@)SRO_"LTJ_PO,*O\,RRK_#,LJ_PS+*O\,RRK_#/\R%P#_-1(
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M&)]!_QF>0?\9G4'_&9U"_QB=0O\8G4+_&/] "0#_1@4 _TP% /%/!P#F4 D
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M)6];_"-O6_\B;UO_(F];_R%O6_\A;UO_(?I/  #A6@  SV(  ,1G  "[:P
MLVP  *QJ! "D:Q( GFPA )EL+P&4:SH#CVE$!HIH30F&9E4-@V5<$(!D8A-]
M8FD5>F)P&'AA>!IU8( =<U^*'W!?E"%N7J C;%ZM)6M>O"9J7M$F:5[L)6I?
M^R1J7_\C:E__(FI?_R)J7_\B:E__(O!2  #=70  RV4  ,!K  "W;@  KV\
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M(EQJ_R)<:O\B7&K_(N-;  #.9@  P&X  +9T  "L>0  HWL  )AY  "0>@L
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M'LIM  "Z>   KX$  *6'  ":BP  CXT  (&.  !TD0  ;I,* &F4%0!FE2(
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M#C2EJ0\SI;L/,Z74#S.D[@\RHOL0,J'_$3*A_Q$RH?\1,J'_$;2"  "HC
MG9(  )*7  "&G   >:$  &VE  !AJ0  5:P  $NO!0!'L!  1; < $2Q)P!"
ML3( 0;([ #^R0P$]LDL!.[)3 CFR6P,WLF0$-;)N!3.R>08QLH<'+[&6""ZR
MI@@MLK@)+++0""RP[ DKK_D**Z[_"RJM_PLJK?\+*JW_"ZV+  "@D@  E9@
M (F=  !]HP  <:@  &2M  !9L0  3;0  $*X   [N@H .+L3 #>\'@ UO"D
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M  S@T@ +W^T #-[W  S=^P ,W?L #-W[ )*?  "%IP  =ZX  &JU  !=O
M4,$  $3%   XR0  +LT  "71   >U0  %MH! !'>!@ 0YPT #N<2  WH&0 ,
MZ"$ "^DI  KJ,0 )ZCL !^M%  7K40 $ZUX  ^MN  'K@   ZI0  .JG  #K
MO   Z](  .OI  #L[P  [.\  .SO (>G  !YKP  :[<  %Z^  !1Q0  0\D
M #?-   MT0  (]8  !O;   3WP  #N,   SN @ *]@H !_8.  7V$@ #]A@
M /4>  #U)0  ]2X  /4W  #V0@  ]DX  /9=  #V;@  ]H$  /:5  #WIP
M][<  /C'  #XT   ^-   /C0 'NO  !MN   8,   %+(  !$S0  -]$  "O7
M   AW   &.   !'D   ,YP  !^\   3Z   !_P,  /\(  #_#0  _A   /X4
M  #_&@  _R$  /\I  #_,P  _SX  /]+  #_6P  _VP  /^   #_D@  _Z$
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M"ZPUU NI-NH,IC;X#:4V_PZC-_\.HC?_#J(W_PZB-_\.HC?_#O\W!P#_.P(
M_T # /)"!0#I0@D Y3\. -@^%@#.0"< QT$V ,)!1 &]04\"N4!9 [8_802T
M/FD&L3UQ!Z\]> BN/'\)K#R&"JH[C0NI.Y4,ISN=#:4[I@VC.K .HCN\#Z [
MS0^>.^80FSSU$9H\_Q&9//\1F#S_$9@\_Q&8//\1F#S_$?\Z 0#_0   [T4
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M&'Y+_!A^2_\7?4O_%WU+_Q9]2_\6?4O_%O]#  #F3   UE,  ,E8  # 60
MNE@! +16"0"L5Q8 IE@E *%8,@&=5SX"F%9(!)5540:25%@(CU)?"HQ29@R*
M46T.B%!T$(5/>Q*#3X03@4Z-%7].EQ=]3J$8>TVN&7I.O1IX3M$:=T[K&G=/
M^AEV3_\9=D__&'9/_Q=V3_\7=D__%_A&  #B4   T%<  ,1<  "[7@  M%T
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M&F5:_QEE6O\995K_&>A/  #360  Q&$  +EF  "P:   IVD  )YE  "79@T
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M&=1<  ##9@  MFX  *QT  "B=P  EG8  (EU  "!=@$ >G</ '9X&P!R>2<
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M%4* J19!@+H60(#2%D%_[19!?OL607W_%D%]_Q9!??\607W_%L)J  "U=0
MJGT  )^"  "2@P  A80  'F%  !JB0  9(H# &",$ !=C1L 6XXG %B.,@!5
MCCL!4XY# E".2@-.C5(%3(U9!DF,8 A'C&@*18MR#$*+?0Y BHD//HJ8$3R*
MIQ([BK@2.HK/$CN(ZQ([A_H3.X;_$SN&_Q,[AO\3.X;_$[QQ  "O>P  I8,
M )F'  ",B   ?XD  '.,  !ED   7),  %>5# !4EA8 4I8B %"7+0!-ES8
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M!":KY ,EJ?4$):C_!26G_P4EI_\%):?_!:>)  ";CP  D90  (29  !XG@
M:Z(  %^F  !3J@  2*T  #VP   TLP, +[4. "VU%@ LM2  *[8I "JV,@ I
MMSH *+=# ">W3  FN%4 )+A? ".X:P BN'@!(+B( 1^XF0$=N:L!'+G  1RX
MWP$<MO(!&[7\ ANT_P(;M/\"&[3_ I^/  "4E0  B)L  'NA  !NI@  8JL
M %:P  !*LP  /[8  #6Y   LO   )+\& !_"#0 =PA0 ',(> !O#)@ :PR\
M&<0X !C$00 7Q$H %L55 !7%80 4QF\ $\9_ !+&D0 1QZ0 $,>Y  _'U  0
MQNX $,3Z !##_P 0P_\ $,/_ )>6  "+G   ?J(  '&I  !DKP  6+0  $NX
M  ! NP  -;X  "O!   CQ0  &\D! !3,!@ 0T L #M$1  W1&0 -T2$ #-$J
M  S1-  +TCX "M))  G350 )TV( "--R  ;4A  %U)@ !-2K  /5P  !U=P
M =7M  '5]@ !U?8  =7V (Z=  " I   <ZL  &:Q  !9N   3+T  #_    T
MPP  *L<  "'*   9S@  $M(   W6 0 )VP4 !MP-  3<$0 #W1@  =X@  #>
M*   WS$  . \  #A1P  XE0  .-C  #C=   Y(@  .2;  #EK@  Y<$  .75
M  #FYP  YN<  .;G (.D  !UK   :+,  %J[  !-P0  0,0  #/(   HS
M']   !?4   0V0  "]T   7A    Y    .4'  #F#0  YQ$  .@6  #I'0
MZB4  .LN  #M.0  [T4  /!3  #Q9   \78  /**  #SG   \ZT  /2[  #T
MR   ],@  /3( '>M  !JM0  7+T  $_$  ! R0  ,\T  "?1   =U@  %-P
M  [@   (XP   >8   #J    [@   .X   #O!   \ H  /$.  #S$@  ]!@
M /8@  #X*@  ^C4  /U#  #^4@  _V,  /]V  #_B0  _YH  /^F  #_L
M_[   /^P /\6(P#_%2$ _Q$A /\-) #_"2L _P8W /\#1 #_ %$ _P!= /\
M: #_ '( _P![ /\ @P#_ (H _P"1 /\ E@#_ )P _P"A /T I@#[ *P ^0"S
M /< NP#U ,4 \P#1 /( Y #Q /$ [P#Z .X _P#N /\ [0#_ .T _P#M /\
M[0#_ /\9( #_&!T _Q4= /\0'P#_#BD _PPT /\*00#_!TT _P59 /\$9 #_
M!&X _P-W /\#@ #_ X< _P.- /T"DP#[ ID ^0*> /<"I #U JH \P&P /$!
MN #O <( [0'/ .L!XP#J >\ Z +[ .<$_P#F!?\ Y@;_ .8&_P#F!O\ Y@;_
M /\<&P#_&QD _Q<8 /\5'0#_$R4 _Q$P /\0/0#_#DD _PQ5 /\+8 #_"VH
M_0MS /L+? #Y"H, ]PJ* /4*D #T"I8 \PJ; /$*H0#O":< [0FN .L)M@#H
M"<  Y@G- .0)X@#B"O  WPO[ -X,_P#<#?\ W W_ -L-_P';#?\!VPW_ ?\?
M%P#_'A, _QL2 /\<&0#_&R( _Q@L /\5. #_$T0 _A)0 /D16P#U$&8 \Q!O
M / 0=P#N$'\ [!"& .H0C #I$)( Z!"8 .8/G@#E#Z4 XP^L .$/M #@#[X
MW@_, -H0X0#5$?  TA+[ ,\2_P'.$_\!S1/_ <T3_P',$_\!S!/_ ?\B$@#_
M(@\ _R$/ /\B% #_(AP _R G /\=,@#X&SX \AE+ .X85@#J%V  YQ9J .06
M<@#B%GH X!:" -X6B #<%H\ VQ:5 -D6FP#6%J( U!:I -(6L0#0%[L SA?)
M ,P8W@#(&>X!Q1K[ <,:_P+!&_\"P!O_ L ;_P+ &_\"P!O_ O\F#@#_)0L
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M"I0V_0J3-_\*DC?_"I(W_PJ2-_\*DC?_"O\S  #V.@  Y#\  -A"  #.0@$
MR3X& ,0[#P"[/AT M3\L +$_.@"M/T4!J3]/ :8^6 *C/5\#H3UG!)\\;06=
M/'0&G#M[!IH[@@>8.XH(ECN3"94ZG J3.J8+D3JR"Y [P R..]4,C#SL#8H\
M^PV)//\-B3S_#(@\_PR(//\,B#S_#/\W  #J/P  W$4  ,Y)  #%20  OT8"
M +I## "S1!D K44G *A&-0"D14$!H$5+ IU$4P*:0UL#F$-B!99":0:407 '
MDD%V")! ?@F.0(8*C4"."XM F R)0*(-AT"N#H5 O ^$0,\/@D'I#X%!^0^
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M$7%+_Q!Q2_\0<4O_$.Q#  #93   R%,  +U7  "T6   K%<  *52 0">4P\
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M$MQ0  #'60  NF   *]D  "D90  F60  )!@  "(808 @F(1 'YC'0!Z8RH
M=F,T 7-B/0%O8D8";&%-!&IA5 5G8%H'96!A"&-?:0IA7W$,7UYZ#EU>A1!;
M7I$265V>%%A=K!577;T65EW5%E9=[A577?P45UW_$U==_Q)77?\25UW_$M93
M  #$7   MV,  *QH  "@:   E6<  (IC  "#90( ?68/ 'AF&@!T9R< <6<R
M &YG.P%K9D,":&9+ V5E4@5C95D&861?"%YD9PI<8V\,6F-X#EAC@Q!68H\2
M5&*<$U-BJA528KL546+2%5%A[1528?L44F'_$U-A_Q)38?\24V'_$M%6  #
M7P  LV8  *EK  "<:P  D&H  (5G  !]:0  =VH- '-K%P!O:R0 ;&PO &EL
M. %F:T$"8VM) V%K4 1>:E<&7&I=!UII90E8:6T+56AV#5-H@0]19XT13V>:
M$DYGJ11-9[D43&?/%$QFZQ1-9OL336;_$DYE_Q).9?\23F7_$LQ:  "\8P
ML&H  *5O  "8;@  C&T  (!L  !W;0  <6X+ &UO% !I<"$ 9G$L &1Q-@%A
M<3X!7G%& EQP30-9<%0%5W!;!E5O8@A3;VH*4&YS#$YN?@Y,;8H02FV8$4EL
MIQ)(;+@31VS-$T=LZA-(:_H22&O_$DAJ_Q%(:O\12&K_$<=>  "X9P  K&X
M *%R  "3<@  AW$  'IQ  !Q<@  :W0' &9U$0!C=AT 8'<H %YW,P!;>#P!
M67=# E9W2P-4=U($4G99!5!V8 =.=6@(2W5Q"DET? Q'=(@.17.6#T-SI1!"
M<[8107/+$4)RZ!%"<O@10G'_$$-P_Q!#</\00W#_$,%C  "S;   J',  )MV
M  ".=0  @78  '5V  !I>   8WH" %Y\#@!<?1D 67XD %=_+P!5?S@!4W]
M 5!_2 ).?D\#3'Y6!$I^705(?64&1GUN"$-\>0I!?(8+/WN4#3Y[HPX\>[,.
M/'O(#CQZY@X\>?<./'C_#CQX_PX]=_\./7?_#KQH  "O<@  I'D  )9Z  "(
M>@  ?'H  '!\  !C?P  7((  %>$"P!3A10 488@ $^&*@!.AS0 3(<\ 4J'
M1 %(ATL"1H=3 D2&6@-"AF($0(9L!CZ%=@<[A8,(.861"CB$H LVA+$+-H3&
M"S:#Y LV@O8+-H'_##: _PPV@/\,-H#_#+9O  "J>   GW\  )!^  "#?P
M=X   &N"  !>AP  58H  $Z,!@!*CA  2(\: $>/)0!%D"\ 1) X $*00 !
MD$<!/Y!/ 3V05@([D%\".9!H S>/<P0UCX %,X^.!C&/G@<PCJ\'+X[#!R^.
MX0<OC/0(+XO_""^*_P@OBO\)+XK_";!V  "E?P  F(0  (J$  !]A0  <(<
M &6*  !:C@  3Y(  $:5  !!F P /I@4 #V9'P [F2@ .IHQ #F:.@ WFD(
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M !.N_P$3KO\!$Z[_ 9J-  "0D@  A)<  '6:  !HGP  6Z,  %"H  !%K
M.[   #&R   GM0  (+@  !BZ!P 4O X $[P5 !*\'@ 1O28 $;TN !"]-P 0
MOD$ #KY,  Z^5P -OF4 #+]T  N_A@ *OID "+ZL  >^P@ 'OM\ "+[P  B]
M^@ (O?P "+W\ ).4  "'F0  >I\  &RE  !@J@  4Z\  $>S   \M@  ,;@
M ">[   ?O@  %\$  !'$ 0 ,R @ ",D.  ?)%  &R1P !<DD  3*+  #RC8
M LI   #+3   RUD  ,MH  #+>0  S(P  ,N?  #+LP  R\@  ,SB  #,[P
MS/$  ,SQ (J:  !\H0  ;Z<  &*M  !5LP  2+@  #N[   PO@  )L$  !W$
M   5R   #\L   K.   $T@(  -,*  #3#P  U!0  -4:  #6(@  URH  -DT
M  #:/P  W$L  -Q:  #=:@  W7T  -V1  #=I   WK8  -[(  #>W@  WN(
M -[B '^B  !QJ0  9+   %:W  !)O   /,   "_$   DQP  &\L  !//   -
MT@  !]8   #;    W@   -\#  #@"0  X0X  .(2  #C%P  Y1X  .8G  #H
M,0  ZCT  .Q+  #L6@  [6P  .Z   #NE   [J4  .ZT  #NP@  [L8  .[&
M '2J  !FL@  6+D  $O    ]Q0  +\D  "3-   9T0  $=8   O;   #W@
M .$   #E    Z    .D   #J    ZP8  .T+  #O#P  \!,  /(:  #T(P
M]RX  /D[  #[2@  _%L  /UM  #]@   _I,  /ZB  #^K0  _J\  /ZO /\0
M'P#_#AT _PH= /\!( #_ "@ _P U /\ 00#_ $X _P!: /\ 90#_ &X _P!W
M /\ ?P#^ (8 _ ", /L D@#Y )< ^ "< /< H@#V *< ]0"M /, M0#R +T
M\0#) .\ W #N .L [0#W .P _P#K /\ Z@#_ .H _P#J /\ Z@#_ /\3' #_
M$1D _PT9 /\&' #_ R4 _P Q /\ /@#_ $H _P!6 /\ 80#_ &L _0!S /H
M>P#W (, ]0") /0 CP#R )0 \0"9 /  GP#N *0 [0"K .P L@#J +H Z #&
M .< U@#E .@ Y #U ., _@#B /\ X0#_ .$ _P#A /\ X0#_ /\5& #_$Q0
M_P\4 /\-&0#_"R( _P@M /\$.0#_ 48 _P!1 /X 7 #Z &8 ]@!O /( =P#O
M 'X [0"% .L BP#J )$ Z "6 .< G #F *$ Y "H ., KP#A +@ WP## -T
MT0#; .8 V0#S -< _0#5 O\ U +_ -0#_P#4 _\ U /_ /\8$P#_%1  _Q(/
M /\2%0#_$1T _PXH /\,- #_"D$ ^0A, /4&5P#Q!F$ [09J .D%<@#F!7H
MY 6! .(%AP#@!HT WP:2 -T&F #;!IX V0:E -<&K0#4!K4 T@;  - 'SP#.
M".4 S GT ,H+_P#(#/\ QPS_ ,<,_P#&#/\ Q@S_ /\;#@#_&0P _Q@- /\8
M$0#_%Q@ _Q0B /L1+@#S$#H [0Y& .@-4@#E#5P X0UE -X-;0#;#74 V U\
M -4-@@#3#8D T0V/ - -E0#.#9P S0ZC ,L.JP#)#K0 R [  ,8.SP##$.8
MP!'U +T2_P"\$O\ NQ+_ +H2_P&Z$O\!NA+_ ?\?"@#_' 0 _Q\( /\?#0#_
M'1( ^!H; .X6)@#F%#, X!,_ -H32P#4$U8 T!-? ,X4: #+%&\ R11W ,<5
M?0#&%80 Q!6* ,,5D0#!%I@ P!:? +X6IP"\%[  NQ>\ +D7RP"W&.( LQGR
M ;$:_P&O&_\!KAO_ :X;_P&M&_\!K1O_ ?\B! #_(@  _R4" /PD!P#W(0P
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M!X,W_P>"-_\'@C?_!_0R  #C.P  TD$  ,9$  "]0P  MS\  +$["0"J.Q0
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M"^!$  #+30  O5(  +)6  "F50  G%(  )5.  ".3@D B4\4 (50( "!4"P
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M#5A4IPY65;@/5E7,#U95Z0Y65?D-5E7_#5=4_PQ75/\,5U3_#-%-  # 5@
MLUP  *=>  ":70  CUP  (98  !_60  >5H- '1;%P!Q6R, ;ELN &M;-P!H
M6T !95M' 6-:3@)A6E4#7UI<!%U:8P5<6FL&6EET"%A9?PI668L+5%F8#5-8
MI@Y26;8.45G*#U%9YPY16/@-4EC_#5)8_PQ26/\,4EC_#,U1  "\60  L%\
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M#$)GX@Q"9O4,0V;_"T-E_PM#9?\+0V7_"[]<  "Q9   IFH  )9I  "):0
M?6D  '%I  !G:@  8FP! %UM#0!9;A8 5V\A %5P*P!3<#4 47 ] %!P10%.
M<$P!3'!3 DIP6@-(<&($1F]K!41O=09";X('0&Z/"3]NG@H];J\*/6[""CQN
MX H];?0*/6S_"CUK_PH^:_\*/FO_"KI@  "M:0  H&X  )%M  "$;0  >&T
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M!"F$_P0IA/\$*83_!*IT  ">>P  CGH  (!Z  !T>P  :'X  %V!  !2A0
M28D  $&,   YD 4 -9$/ #.2%P RDB$ ,9(I #"3,@ NDSH +9-! "R32@ K
ME%( *I1< "B49P GE',!)92" 224DP$BDZ0!(9.W 2"3SP$ADNP!()#Z B"/
M_P(@C_\"((__ J1\  "7@   AW\  'N   !N@@  8H4  %>)  !-C@  0I(
M #J6   RF0  *IP) "B=$0 FG1D )9TB "2>*@ CGC( (IXZ "&>0@ @GDL
M'Y]5 !Z?8  <GVT &Y]\ !J?C0 8GY\ %Y^R !:?R0 6GN@ %ISW !:;_P$7
MF_\!%YO_ 9V#  "/A@  @H8  '2'  !GBP  6X\  %"3  !&F   /)P  #.@
M   KHP  (Z8  !RH"P :J1$ &*D8 !>I(0 6JBD %:HQ !2J.0 3JD, $ZM-
M !*K6  1JV4 $*MT  ZKA@ .JYD #:NL  RKP0 ,JM\ #*GR  VH_  -J/\
M#:C_ ):*  ")C   >HT  &R1  !@E0  5)H  $F?   _HP  -:<  "NJ   C
MK@  &[   !2S 0 /M0H #;80  RV%@ +MA\ "K8G  FV+P (MCD ![=#  :W
M3P $MUL  [=J  *W>P  MXX  +>A  "VM   MLL  +;E  "U\0  M?<  +7W
M (^1  "!E   <I<  &6<  !8H0  3*8  $&K   WKP  ++(  ".U   :N
M$[L   Z]   )P 4  \$-  #!$0  P1<  ,(>  #")@  PB\  ,,Y  #$1
MQ%   ,1>  #%;P  Q8$  ,65  #%J   Q;P  ,31  #$Y@  Q.X  ,3N (:8
M  !YG@  :Z,  %VI  !0K@  1+,  #>V   LN0  (KP  !F_   1P@  #,4
M  ;(    RP   ,P'  #,#0  S1$  ,T6  #.'0  SR0  - M  #2.   U$0
M -12  #580  U7,  -:'  #6FP  UJT  ->_  #8S@  V-T  -C= 'N@  !N
MI@  8*T  %.S  !%N   .+P  "N_   AP@  %\8  !#)   *S    M    #4
M    UP   -@   #:!0  VPL  -P.  #>$P  WQD  .$A  #C*@  Y38  .=#
M  #G4P  Z&0  .EW  #IC   ZI\  .JN  #JN@  ZL,  .K# '"H  !BKP
M5;8  $>\   YP   +,0  "#(   6S   #M    ?4    V0   -T   #A
MXP   .0   #F    YP$  .D'  #K#   [!   .X5  #P'0  \R<  /8S  #W
M0P  ^%0  /EF  #Y>@  ^HX  /J>  #[J0  ^[   /NP /\+&P#_!QD _P 9
M /\ ' #_ "4 _P R /\ /P#_ $L _P!7 /\ 8@#_ &L _P!S /T >P#[ ((
M^@"( /@ C0#W )( ]@"8 /4 G0#T *( \P"I /$ L #O +@ [@## .P T0#K
M .8 Z0#S .@ _@#H /\ Z #_ .@ _P#H /\ Z #_ /\.& #_"A4 _P$4 /\
M& #_ "( _P N /\ .P#_ $< _P!3 /T 7@#Z &< ]P!O /4 =P#S 'X \@"$
M /  B0#O (\ [@"4 .P F@#K )\ Z0"E .@ K #F +0 Y "_ ., S #A .(
MWP#P -X ^P#> /\ W0#_ -T _P#< /\ W #_ /\0$P#_#1$ _P80 /\"%0#_
M !X _P I /\ -@#_ $( ^@!. /0 60#Q &( [@!K .P <@#J 'D Z !_ .<
MA0#E (L Y "0 .( E@#A )P WP"B -T J0#: +$ V "[ -4 R #2 -T T0#M
M -  ^0#/ /\ S@#_ ,T _P#- /\ S0#_ /\1#P#_#@T _PP- /\+$@#_!QD
M_P(D /\ , #V #P [P!) .H 4P#G %T Y !F .$ ;0#? '0 W0![ -L @0#9
M (8 U@", -0 D@#2 )@ T "> ,X I@#, *X R@"X ,@ Q #& -< Q0#J ,,
M]P#" /\ P0'_ , "_P#  O\ P +_ /\4"P#_$ 8 _Q ) /\0#@#_#A0 _PH>
M /4&*0#K!#8 XP-" -\#3@#;!%< U@1@ -,$: #0!&\ S@5V ,P%? #*!8(
MR06( ,<%C@#&!90 Q 6; ,(%HP# !JL O@:U +T&P@"["-0 N@GI +<+^ "U
M#/\ M S_ +0,_P"T#/\ M S_ /\7! #_%   _Q8# /\4"0#_$0X \@X5 .@,
M(0#>"BX U@L[ - ,1P#,#%$ R0Q: ,8-8@#$#6H P@UQ , -=P"_#7T O0Z#
M +P.B@"Z#I$ N0Z8 +<.H "V#JD M ^T +(/P0"Q$-0 KA'K *L2^@"I$O\
MJ!/_ *<3_P"G$_\ IQ/_ /\:  #_&P  ^1L  .L9  #E% 8 Y1 . -D.%P#/
M$28 R!(T ,030 "_%$L O!14 +D570"W%60 M15K +05<0"R%7@ L19^ *\6
MA0"N%HP K!:4 *L7G "I%Z8 IQBP *88O0"D&,\ HAKG )\:]P"=&_\!G!O_
M 9P;_P&;&_\!FQO_ ?\=  #W(0  Z"0  -TE  #4(0$ SQL( ,H7$0#"&B
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M!.<U  #2/0  PT(  +A$  "L0@  I#X  )\Y  ":. X E#H9 ) Z)@"-.S$
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M!F)#IP=A1+8(8$3*"&!$Y@A?1?@'7T7_!V!%_P9@1/\&8$3_!M9!  ##20
MMDX  *=/  ";30  DDL  (Q'  "%1P0 @$<0 'Q(&@!X2"8 =4DP '-).@!P
M24( ;DE) 6Q(4 %J2%8!:$A= F9(9 )E2&P#8TAU!&%'?P5@1XH&7DB7!UU(
MI0A;2+0(6TC'"5I(Y A:2?8(6DG_!UI(_P9:2/\&6DC_!M%%  "_3   LE(
M *-1  "74   C4X  (9*  " 2@$ >DL. '9,%P!R3", ;TPM &U--@!J3#\
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M"4M4WPE,5/,(3%/_!TQ3_P=-4_\&35/_!L5.  "V5@  IUH  )A9  "+6
M@5<  '=4  !P50  :E8& &97$ !B5QH 8%@D %U8+@!;63< 65D_ %=91@!6
M64T!5%E4 5-96P)166,"3UAL TY8=@1,6((%2EB/!DE8G@=(6*X(1UC "$=8
MW0A'6/((1U?_!TA7_P=(5_\&2%?_!L%1  "R60  HUP  )1;  "'6P  ?5H
M ')8  !K60  95H# &!;#@!=7!< 6EPA %A=*P!6730 5%X\ %->1 !17DL!
M4%Y2 4Y>60),7F$"2UUJ TE== 1'78 %15V-!D1=G =#7:P'0EV^"$)=V@A"
M7/$'0ES^!T-;_P9#6_\&0UO_!KU5  "O70  GU\  )!>  "#7@  >%T  &U<
M  !E70  7U\  %I@# !7810 56(> %)B* !18S$ 3V,Y $YC00!,8T@ 2V-/
M 4EC5@%'8UX"16-G D1C<0-"8WT$0&*+!3]BF@8^8JH&/6*\!SQBU@<]8>\&
M/6']!CY@_P8^8/\&/F#_!KE9  "K80  FF$  (MA  !_80  =&$  &EA  !?
M8@  660  %1F"0!19Q$ 3F<: $QH) !+:2T 26DV $AI/@!&:D4 16I, $-J
M5 %":EP!0&EE CYI;P(\:7L#.VF)!#EIF 4X:*@%-VBZ!3=ITP4W:.X%-V?\
M!3AF_P4X9O\%.&;_!;1>  "G90  E64  (9D  !Z90  ;V4  &1F  !9:
M4FH  $UL! !);@X 1VX6 $5O( !$<"D 0G R $%P.@! <4( /W%) #UQ40 \
M<5D!.G%B 3AQ; (V<'@"-7"& S-PE0,R<*8$,7"X!#!PT 0Q;^P$,6[[!#%M
M_P0Q;/\$,6S_!*]D  "A:0  CV@  (%H  !U:0  :VD  &!K  !5;@  37$
M $9S  !"=0L /W82 #UW'  \=R4 .G@M #EX-0 X>3T -WE% #9Y30 U>54
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M 9UW  ",=@  ?78  ')W  !E>0  6GP  %"   !&A   /(D  #2,   MD
M)9," !^5#  =EA( ')8: !N7(@ :ERH &9<R !B8.@ 7F$, %IA- !686  4
MF&0 $YAS !&8A  0F)8 $)BI  Z8OP .E]T #Y;R !"5_  0E/\ $)3_ )5]
M  "%?   >'P  &M^  !?@0  5(8  $J*  ! CP  -I,  "V7   FF@  'IT
M !>@ P 2H@P $*,2 !"C&0 /HR$ #J0I  ZD,0 -I#H #*1%  ND4  *I%P
M":1J  >D>P &HXX !*.A  *CM  #HLL  Z+F  .A\P #H?L  Z'[ (V#  !_
M@@  <80  &2'  !8C   39$  $*6   XF@  +YX  ":B   >I0  %Z@  !&K
M   ,K@< !Z\-  .O$@ "KQD  :\A  "O*0  L#(  + \  "P1P  L%,  +!A
M  "P<0  L(,  *^7  "OJ@  K[\  *[9  "NZP  KO0  *[T (>)  !XB@
M:HX  %V3  !1F   19T  #NB   PI@  )ZH  !ZN   6L0  $+0   NV   %
MN0,  +H*  "Z#@  NA,  +L9  "[(0  O"@  +PQ  "]/   OD@  +Y6  "^
M90  OG<  +Z,  "^GP  O;,  +['  "^W@  O>L  +WK '^2  !PE0  8IH
M %6?  !)I0  /:L  #*O   HM   'K8  !6Y   .O   ";\   +"    Q
M ,4$  #&"@  Q@X  ,<2  #(&   R1\  ,HG  #,,   SCP  ,Y)  #/60
MSVH  ,]^  #/DP  SZ8  ,^X  #/R   S]L  ,_; '><  !HH0  6Z<  $ZN
M  !!M   -+<  "BZ   =O0  $\    W$   &QP   ,H   #.    T    -$
M  #2 @  TP@  -4,  #6$   V14  -L<  #=)   X"\  .(\  #C2P  Y%P
M .1O  #E@P  Y9@  .6I  #EM@  Y<,  .7# &RE  !?K   4;(  $2Y   U
MO   *,   !S$   2R   #,L   //    TP   -@   #<    WP   -\   #A
M    XP   .0#  #F"   Z T  .D1  #L&   [B(  /$N  #S/   ]$T  /5?
M  #V<P  ]X<  />9  #XI0  ^+   /BP /\#%P#_ !4 _P 5 /\ & #_ ",
M_P O /\ / #_ $@ _P!4 /\ 7@#_ &< _0!O /L =@#Y 'T ^ "# /8 B #U
M (X ] "3 /( F #Q )X \ "D .X JP#M +, ZP"] .H RP#H .$ YP#Q .8
M_0#E /\ Y #_ .0 _P#D /\ Y #_ /\'$P#_ !$ _P 1 /\ %0#_ !\ _P K
M /\ -P#_ $0 _@!/ /H 6@#W &, ] !K /( <@#P 'D [P!_ .T A #K (H
MZ@"/ .@ E #G )H Y0"@ .0 IP#B *\ X "Y -X Q@#< -H V@#L -@ ^0#6
M /\ U@#_ -< _P#8 /\ V #_ /\*$ #_ PX _P - /\ $@#_ !H _P F /P
M,@#W #\ ] !* /$ 50#M %X Z@!F .@ ;@#E '0 XP!Z .( @ #@ (4 W@"+
M -P D #; )8 V "< -4 HP#3 *L T0"U ,X P0#, -$ RP#G ,D ]0#( /\
MR #_ ,@ _P#( /\ R #_ /\,# #_!@@ _P(* /\ #P#_ !4 _  @ /$ + #L
M #D Z0!% .4 3P#A %D W@!A -L : #7 &\ U !U -( >P#0 (  S@"& ,P
MC #+ )( R0"8 ,< H #% *@ PP"Q ,$ O "_ ,L O0#C +P \@"[ /T NP#_
M +H _P"Z /\ N@#_ /\.!0#_"0  _PD% /\&"P#_ 1  \  9 .8 )0#A #(
MW  _ -8 20#1 %, S@!; ,L 8P#( &H Q@!P ,4 =@## 'L P0"! ,  AP"^
M (X O "4 +L G "Y *0 MP"N +4 N0"S ,@ L0#? + ![P"O ?L K@+_ *T#
M_P"M _\ K0/_ /\0  #_#@  _PT  /8+ P#R!PH X@$1 -L"'0#2 RL S ,W
M ,@$0P#$!$T P016 +X%70"\!60 N@5K +@%<0"W!78 M05\ +,&@P"R!HD
ML :1 *\'F0"M!Z$ JP>K *D(MP"H"<8 I@K= *4+\ "C#/T H@W_ *$-_P"A
M#?\ H W_ /\1  #\$@  [!,  .(3  #;#P, U@D+ ,X(% #&"B( P PP +P-
M/ "X#48 M0U/ +(.5P"P#E\ K@YE *T.:P"K#G$ J@YX *@.?@"G#X4 I0^-
M *0/E@"B$)\ H!"I )\0M0"=$<4 FQ'> )D2\0"7$_\ EA3_ )44_P"5%/\
ME!3_ /\5  #M&P  X!\  -(?  #)&P  Q!0% ,$0#@"Z$AL M!,I + 4-0"L
M%4  J15) *854@"D%ED HA9@ *$69@"?%FP GA9R )P6>0";%X  F1>( )@7
MD0"6&)L E!BF ),9L@"1&<$ D!K8 (T;[@"+'/T BAS_ (H<_P")'/\ B1S_
M /0=  #D)0  TRD  ,<J  "\)@  MB   +09"P"N&A4 J!PC *0=+P"A'CH
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M 7,OJ )Q+[8"<##) F\PY0)N,?<";3'_ FTQ_P)M,?\";3'_ M\R  #).0
MNSX  *P]  "A.@  FC<  )4S  "0,0H C#$4 (<R( "$,RL @3,U '\S/@!]
M,T8 >S-- 'DS5 !W,UH =C-A '0S9P%R-&\!<31W 6\T@0%N-(P";#28 FHU
MI0)I-;,#:#7& V<VX@-F-O4#9C;_ F8V_P)F-O\"9C;_ M@W  #$/@  M4(
M *9!  ";/P  DSP  (TX  "(-@< A#<1 ( W' !\."< >C@Q '<Y.@!U.4(
M<SE) '$Y4 !P.5< ;CE= &PY9 %K.6L!:3ET 6@Y?@)F.8D"9#F5 V,ZH@-B
M.K$#83K# V [X 1?._,#7SO_ U\[_P-?._\"7SO_ M$[  # 0@  L$4  *%$
M  "50P  C4   (<]  "".P( ?3L. 'D\& !U/2, <STM ' ]-@!N/3\ ;#U&
M &L]30!I/5, 9SU: &8]80%D/6@!8SUQ 6$^>P)?/H8"7CZ3 UP^H -;/Z\$
M6C_!!%H_W019/_($63__ UD__P-9/_\#63__ \P_  "\1@  JT@  )Q'  "1
M1@  B$0  ()   !\/P  =T , '- %0!O02  ;$$J &I!,P!H03L 9D)# &1"
M2@!C05  84%7 &!"7@%>0F4!74)N EM"> ):0H0#6$*0 U="G@160ZT$54._
M!%1#V@140_$$5$/^ U1#_P-40_\#5$/_ \A"  "X20  ITL  )A*  "-20
M@T<  'U#  !V0P  <40* &U$$@!J11T 9T4G &1%, !B13@ 8$4_ %]%1P!=
M14T 6T54 %I&6P%91F,!5T9L 59&=@)41H$#4T:. U)'G 101ZL$4$>]!$]'
MU@5/1^\$3T?]!$]'_P-/1_\#4$?_ \1%  "U30  HTT  )5,  ")2P  ?TH
M 'A&  !Q1P  ;$<' &A($ !D2!H 84DD %])+0!=234 6TD] %E)1 !724H
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M T)2_P-"4O\#0E'_ [I/  "J5   F%0  (E4  !]4P  <U,  &E1  !B4@
M7%,  %A4"@!451( 4E4; $]6) !.5BT 3%<U $M7/ !*5T0 2%=+ $=84@!&
M6%H!1%AC 4-8;0%!6'D"0%B& CY8E0,]6*4#/%BW!#Q8S00\5^H#/%?Z SU6
M_P,]5O\#/5;_ [93  "E5P  E%<  (56  !Y5@  ;U8  &55  !<5@  5U@
M %)9!P!.6A  3%H8 $I;(0!(7"H 1UPR $5<.@!$74$ 0UU( $)=4 ! 75@
M/UUA 3U=:P$\778".EV$ CE=DP(X7:,#-UVU S9=RP,V7.@#-USY S=;_P,X
M6_\#.%K_ [)7  "@6@  CUD  (%9  !U60  :UD  &!:  !66P  45T  $Q>
M @!(8 T 16 4 $1A'@!"8B8 0&(N #]B-@ ^8SX /6-% #QC30 [8U4 .6->
M #AC: $V8W0!-6.! 3-CD0(R8Z$",6.S C%CR (Q8N<",6'X C%A_P(R8/\"
M,F#_ JY<  ";70  BET  'Q=  !P70  9ET  %Q>  !28   3&(  $5E  !!
M9@H /F<1 #QH&@ [:"( .6DK #AI,@ W:CH -FI! #5J20 T:E( ,VI; #%J
M90 P:G !+FI^ 2UJC@$L:I\!*VJP 2IJQ@$J:>4!*FCV BMG_P(K9_\"*V?_
M JEA  "58   A&   '=@  !L80  8F$  %AC  !.9@  1V@  $!K   Z;@4
M-F\. #1P%0 S<!X ,G$F #!Q+@ O<34 +G(] "UR10 L<DT *W)7 "IR80 I
M<FT )W)[ "9RBP D<IP!(W*N 2-RPP$C<>(!(W#T 2-O_P$C;O\!(V[_ :%E
M  ".9   ?V0  ')D  !H90  7F8  %1I  !);   0F\  #MR   T=0  +G@*
M "MY$0 J>1@ *7HA "=Z*  F>C  )7LX "1[0  C>T@ (GM2 "%[7  @>V@
M'WQV !U\A@ <>Y@ &WNJ !I[OP :>]X &GGR !MX_@ ;=_\!&W?_ 9EI  "(
M:0  >6D  &UI  !C:@  66P  $]O  !%<P  /7<  #5Z   N?0  )X$# "*#
M#0 @A!( 'X0: !V$(@ <A2H &X4Q !J%.0 9A4( &(9, !>&5@ 6AF, %89Q
M !2&@0 2AI, $8:F !&%NP 0A=8 $8/O !&"^P 2@O\ $H'_ )%N  "!;0
M=&X  &EN  !=<   4W,  $EW  ! ?   -X   "^#   GAP  (8H  !J-!@ 5
MCPT $Y 3 !*0&@ 2D"( $9 J !"1,@ 0D3L #Y%$  Z13P -D5P #)%J  N1
M>@ *D8T ")"?  >0LP 'C\D !X_F  >.]  (C?P "(W_ (ES  ![<P  ;W,
M &-U  !7>   37T  $.!   YA@  ,(H  "B.   AD0  &I4  !.7   .F@@
M"YP.  F<$P (G!H !YPB  :<*@ $G#,  YP]  *=2   G50  )UB  "<<@
MG(0  )R7  ";J@  F[\  )K;  ":[   FO4  )GX ()Y  !V>0  :'H  %Q^
M  !1@@  1H<  #R,   RD0  *94  "&9   9G0  $J    ZC   )I@4  Z<,
M  "G$   IQ4  *@<  "H(P  J"L  *DT  "I/P  J4L  *E9  "I:   J7H
M *F.  "IH0  J+4  *C+  "GY   I^\  *?S 'V   !O@0  880  %6)  !)
MC@  /I0  #29   JG@  (:(  !FF   2J0  #:P   >O    L@   +,'  "S
M#   LQ   +05  "T&P  M2(  +8K  "W-0  MT   +A.  "X70  N&X  +B"
M  "XEP  N*H  +>^  "WT@  M^8  +?J ':(  !GBP  6I   $Z6  !"G
M-Z(  "RG   BJP  &:\  !&S   +M@  !+D   "\    O@   +X   "_!@
MP L  ,$/  #"$P  PQD  ,0@  #%*0  QS0  ,A"  #)40  R6(  ,EU  #)
MB@  R9\  ,JQ  #*P0  R=$  ,G9 &Z3  !@F   4YX  $:D   ZJP  +[
M "2U   9N   $+P   J_   !P0   ,0   #(    R@   ,H   #,    S0,
M ,X(  #0#0  T1   -,6  #6'@  VB@  -TT  #>0P  WU0  -]G  #@?
MX)$  ."D  #@L@  X+X  .## &:?  !9I@  3*T  #^T   RN   )+P  !B_
M   0PP  ",<   #*    S0   -$   #5    V    -D   #;    W0   -\
M  #A!   XPH  .4.  #G$P  ZAP  .TG  #P-0  \48  /)8  #S:P  \X
M /24  #THP  ]*X  /2R /\ $P#_ !$ _P 1 /\ %0#_ !\ _P L /\ .0#_
M $4 _P!0 /\ 6@#^ &, ^P!K /D <@#W '@ ]0!^ /0 A #R (D \0". /
MDP#N )D [0"? .P I@#J *X Z "X .8 Q0#E -L XP#M .( ^P#B /\ X0#_
M .$ _P#A /\ X0#_ /\ $ #_  X _P - /\ $@#_ !L _P H /\ - #^ $$
M^P!, /< 5@#T %\ \0!F .\ ;0#L '0 Z@!Z .D ?P#G (4 Y@"* .4 CP#C
M )4 X0"; .  H@#> *H VP"T -D P #6 -  TP#H -( ]P#1 /\ T0#_ -
M_P#0 /\ T #_ /\ #0#_  D _P * /\ #P#_ !8 ^P B /< +P#T #L \ !'
M .T 40#I %H Y0!B .( :0#@ &\ W@!U -P >@#: (  V "% -4 BP#3 )$
MT0"7 ,\ G@#- *8 RP"O ,D N@#' ,D Q0#B ,0 \@## /X P@#_ ,$ _P#"
M /\ P@#_ /\#!@#_  $ _P & /\ # #Y !$ \0 = .L *0#G #8 XP!! -\
M2P#; %0 U0!< -( 8P#/ &H S0!P ,L =0#) 'L R "  ,8 A@#% (P PP"3
M ,$ F@"_ *( O0"K +L M@"Y ,0 MP#: +8 [0"T /H M #_ +0 _P"T /\
MM #_ /\$  #_    _P   /\ !@#L  T Y0 6 -X (@#7 "\ T0 [ ,T 10#*
M $X Q@!7 ,0 7@#! &0 OP!J +T < "\ '4 N@![ +D @0"W (< M0". +,
ME0"R )X L "G *X L@"L +\ J@#1 *@ Z "H /< IP#_ *< _P"F /\ I@#_
M /\&  #_!0  \0,  .@   #A  < U0 0 ,T &P#' "< PP S +\ /@"\ $@
MN0!1 +8 6 "T %\ L@!E +  :@"O '  K0!V *P ? "J (( J0") *< D0"E
M )H HP"D *$ K@"@ +L G@'- )T"Y@"<!/0 FP3_ )H%_P":!?\ F07_ /\*
M  #Q#@  Y!   -D/  #."P  R ,+ ,( $P"\ A\ MP,L +,$-P"P!4( K09*
M *H&4@"H!UD I@=? *4'90"C!VL H@AQ * (=P"?"'X G0B% )L)C@":"9<
MF JA )8*K "5"[H DPO, )(,Y0"0#?8 CP[_ (X._P".#O\ C0[_ /81  #F
M%P  UAL  ,<9  "^%0  N1   +<*#0"Q"Q< K TD *@., "E#CL H@Y$ )\/
M3 "=#U, FP]: )H/8 "8$&8 EQ!L )40<@"3$'D DA"! ) 0B@"/$90 C1&?
M (L1J@"*$K@ B!++ (83Y@"%%/< @Q7_ (,5_P""%?\ @A7_ .T:  #<(0
MRB4  +LB  "Q'P  JQH  *D4!@"E$A$ H!0> )P5*@"9%34 EA8^ )061P"2
M%DX D!95 (X76P",%V$ BQ=G (D7;0"(%W0 AAA\ (48A@"#&9  @1F; ( :
MIP!^&K4 ?1O' 'P<X@!Z'?4 >1W_ '@=_P!X'?\ >!W_ .4B  #0*0  ORP
M + J  "G)P  H",  )T?  ":&@X E1P8 )$=) ".'B\ C!XY (D>00"''TD
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M 6$PU0%@,.\!7S#] 5\P_P%?,/\!7S#_ <TT  "\.P  J3H  )LZ  "0.
MB34  (,R  !_, $ >R\. '<P%@!T,"$ <3$K &\Q- !M,3P :S%# &HQ2@!H
M,E  9S)7 &4R70!D,F4 8C)M &$S=P!?,X(!7C.. 5TTG %;-*H!6C6[ 5HU
MT@%9->T!637\ 5@U_P%8-?\!637_ <@X  "W/@  I#X  )8]  "+/   @SH
M 'TW  !X-   =#0+ ' U$P!M-1T :C4G &@V, !F-C@ 9#8_ &,V1@!A-DT
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M DE!_P))0?\!24'_ ;U#  "J10  F$4  (I%  !_10  =D,  &]   !H0
M8T$! %]!#0!<010 64(= %=")@!50BX 4T(V %%"/0!/0D, 3T-+ $Y#4@!-
M1%H 3$1C $I$;0%)17@!2$6% 4=%E %%1:,"14:T D1&R0)$1N<"1$7X D1%
M_P)%1?\"147_ ;I&  "F2   E$@  (9(  ![1P  <D8  &I"  !C0P  7D0
M %I%"P!611( 5$8; %%&(P!/1BL 3D8S $Q'.@!+1T$ 2D=) $E(4 !(2%@
M1TAA $9):P!$278!0TF# 4))D@%!2:("0$FS C]*QP(_2N4"/TGW D!)_P)
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M :Y/  "93P  B4\  'M/  !P3P  9D\  %Q.  !43P  3U$  $I2 0!&4PP
M0U02 $%4&P! 52, /E4K #U6,@ \5CH .U9! #I620 Y5U$ .%=: #978P U
M5V\ -%=\ 3-7C $Q5YP!,%>M 3!7P@$P5^ !,%;T 3%6_P$Q5?\!,57_ :A2
M  "54@  A%(  '=2  !L4@  8E(  %A3  !/5   258  $17  ! 60@ /5H0
M #M:%P Y6R  .%LG #=<+P V7#8 -5P^ #1<1@ S74X ,5U7 #!=80 O76P
M+EUZ "Q=B0 K79H!*EVK 2I=OP$I7=X!*ESR 2I;_@$K6_\!*UK_ :-5  "/
M50  ?U4  ')5  !G5@  7E8  %17  !,60  15L  #]=   Z7P0 -F - #1A
M$P R8AP ,6(C #!B*P O8S( +F,Z "UC0@ L8TH *F13 "ED70 H9&D )V1V
M "9DA@ E9)< )&2I "-DO0 B9-H (V/Q "-B_0$D8?\!)&'_ 9Q8  ")6
M>ED  &Y9  !C60  6EH  %!<  !(7@  06   #IC   T9@  +V@* "QI$  J
M:1< *6H? "AJ)@ G:BX )FLU "5K/0 D:T8 (VM/ ")L60 @;&4 'VQR !YL
M@@ =;)0 '&RF !MKN@ ::]0 &VKN !QI_  <:/\ '&C_ )5<  "#7   =5P
M &E=  !?70  5EX  $QA  !#9   /&<  #5J   O;0  *' $ "-R#0 A<A(
M(',: !]S(0 ><R@ '70P !QT.  ;=$  &G1* !ET5  7=6  %G5N !5U?@ 4
M=9  $W2B !)TM@ 1=,\ $G/L !)R^@ 3<?\ $W'_ (Y@  !]8   ;V$  &5A
M  !;8@  460  $AG   ^:P  -VX  #!Q   I=0  (G@  !Q[!P 7?0X %GT3
M !5]&P 4?B( $WXJ !)^,0 1?CH $7Y$ !!_3@ /?UH #G]H  U_>  ,?XH
M"WZ=  I^L  )?<8 "GWD  I\]  +>_T "WK_ (9E  !W90  :F4  &%F  !6
M:   3&L  $)O   Y<P  ,7<  "IZ   C?@  '($  !6$   0AP@ #8D.  R)
M%  ,B1L "XDC  J)*P )B3, "(D]  :)2  %B50 !(EA  *)<0 !B8,  (F6
M  "(J0  A[X  (?:  "&[   AO4  (;Z 'YJ  !Q:@  9VL  %ML  !0<
M1G0  #QX   S?0  *H$  ".%   <B   %8P  !"/   ,D@8 !I,,  *3$0
ME!8  )0=  "4)   E2P  )4U  "50   E4P  )99  "6:0  E7H  )6.  "4
MH0  E+4  )/,  "2Y@  DO(  )+W 'AP  !M<   8'(  %1U  !)>0  /WX
M #6#   LB   (XT  !N1   4E   #Y<   J:   $G0,  )X)  "?#@  GQ(
M * 7  "@'0  H24  *(M  "B-P  HT,  *-0  "C7P  HW$  *.$  "BF0
MHJT  *'"  "AW   H>L  *#R '-V  !F=P  67L  $V   !"A0  .(L  "Z0
M   DE0  &YH  !2>   .H0  ":0   *G    J@   *L$  "K"@  K T  *T1
M  "M%@  KAP  *\D  "P+0  L3D  +%&  "R50  LF8  +)Y  "RC@  L:,
M +*W  "QR@  L>   +'I &Q^  !?@@  4H<  $:-   [DP  ,)D  ":>   <
MHP  $Z<   VK   'K@   +(   "U    MP   +@   "Y @  N0@  +H,  "[
M$   O!0  +T;  "_(P  P2T  ,(Z  #"20  PUH  ,-L  #$@@  Q)<  ,2K
M  #$O   Q,L  ,3: &6)  !8C@  2Y4  #^;   SH@  **@  !VM   4L0
M#;8   :Y    O    +\   ##    Q    ,4   #&    QP   ,D$  #*"0
MRPT  ,T1  #/&   TB$  -4M  #6/   V$T  -E?  #:<P  VHH  -N>  #;
MK@  V[H  -S# %Z6  !1G   1*,  #BJ   LL0  (+<  !6[   -O@  !,(
M  #%    R0   ,T   #0    T@   -(   #5    U@   -D   #;    W@4
M . *  #B#P  Y18  .@@  #L+0  [3X  .U1  #N90  [WH  .^/  #PGP
M\*L  /"S /\ $ #_  X _P . /\ $@#_ !T _P I /\ -0#_ $$ _P!- /X
M5@#[ %\ ^ !F /8 ;0#T '0 \@!Y /$ ?P#P (0 [@") .T CP#K )4 Z@";
M .@ H@#F *H Y0"S ., P #A -( X #J -\ ^0#= /\ W0#_ -T _P#> /\
MW@#_ /\ #0#_  H _P ) /\ #P#_ !@ _P D /X ,0#[ #T ^ !( /0 4@#P
M %H [0!B .L :0#I &\ YP!U .4 >@#C '\ X@"% .  B@#> )  W "6 -H
MG0#8 *4 U0"O -( N@#0 ,H S@#C ,T ] #+ /\ RP#_ ,L _P#+ /\ RP#_
M /\ " #_  , _P % /\ # #\ !0 ]P ? /( *P#O #< ZP!" .< 3 #D %4
MX != -T 9 #: &H V !P -4 =0#2 'H T "  ,\ A0#- (L RP"2 ,D F0#'
M *$ Q0"J ,, M0#! ,, OP#: +X [@"] /P O #_ +P _P"\ /\ O #_ /\
M  #_    _P   /D !P#Q !  Z@ : .0 )0#? #$ VP \ -< 1P#2 %  S@!7
M ,L 7@#) &4 Q@!J ,4 < ## '4 P0!Z ,  @ "^ (8 O "- +H E "Y )P
MMP"E +4 L "S +T L0#/ *\ Z "N /@ K@#_ *T _P"M /\ K0#_ /\   #_
M    _0   .X  0#C  P V@ 4 -$ 'P#, "L R  V ,4 0 #" $H OP!2 +P
M60"Z %\ N !E +8 :@"T &\ LP!U +$ >@"P ($ K@"( *T CP"K )@ J0"A
M *< JP"E +@ HP#( *( X@"A /, H #^ *  _P"@ /\ H #_ /\   #V
MZ@   .    #3  8 R0 / ,( & "] "0 N0 O +8 .@"T $, L0!, *X 4P"L
M %D J@!? *D 9 "G &H I@!O *0 =0"C 'L H0"" *  B@"> ), G "= )H
MIP"8 +0 E@## )4 W "4 .\ DP#[ ), _P"3 /\ D@#_ /D%  #J"P  W T
M ,L*  #"!0  O  * +8 $0"Q !P K@ H *H ,P"G #T I !% *( 30"@ %,
MG@!9 )P 7P"; &0 F@!J )@ < "7 '8 E0!^ ), A@"2 8\ D &9 (X"I ",
M K$ BP/  (D%U@"(!NT B ?Z (<(_P"&"/\ A@C_ .\/  #>%   RA4  +P2
M  "S$   K@P  *L&#0"G Q4 H@4@ )\'+ "<"#8 F0@_ )<)1P"5"4X DPE4
M )$*6@"0"E\ C@IE (T*:P"+"G( B@MY (@+@@"'"XP A0R7 (,,H@"!#;
M@ W  '\-V !]#N\ ? _] 'L/_P![$/\ >Q#_ .87  #1'@  O1T  *\<  "F
M&0  H14  )X0! "=#0\ F X9 )0.)0"1#R\ CQ Y (P000"*$$@ B!!/ (<0
M50"%$%L A!%A ((19P" $6X ?Q%U 'T1?@!\$H@ >A*4 '@2H !W$ZX =1.^
M '04U0!S%>X <1;] '$6_P!Q%O\ <!;_ -P?  #&)0  LR4  *4C  "<(0
MEAX  )(9  "1% L C104 (D5'P"&%BD @Q8S ($7/ " %T, ?A=* 'P74 !Z
M%U8 >1A< '<88@!V&&D =!AQ ',9>@!Q&80 ;QJ0 &X:G0!L&ZL :QR[ &H<
MT !I'>P :![[ &@>_P!G'O\ 9Q[_ -$F  "]*@  JRH  )TJ  "3*   C24
M (@B  "&'08 @QL0 '\<&@!\'20 >ATN '<>-@!V'CX =!Y% '(?2P!Q'U$
M;Q]8 &X?7@!L'V4 :R!M &D@=@!H(8$ 9B&- &4BF@!C(J@ 8B.X &$CS0!@
M).D 8"3Z %\D_P!?)/\ 7R3_ ,HL  "V+P  I"\  )8O  ",+0  A2H  ( H
M  !])   >B(- '8C%0!S(R  <20I &\D,@!M)#H :R5! &HE1P!H)4T 9B54
M &4E6@!D)F$ 8B9I &$F<@!?)WT 7B>* %THEP!;*:4 6BFU %HJR@!9*N<
M6"KX %@J_P!8*O\ 6"K_ ,4Q  "O,P  GC,  ) S  "&,@  ?R\  'DM  !U
M*@  <B@* &\H$@!K*1L :2DE &<J+0!E*C4 8RH] &(J0P!@*DH 7RM0 %XK
M5P!<*UX 6RQF %DL;P!8+7H 5RV' %8NE0!4+J, 4R^S %,OQP!2+^4 4B_W
M %(O_P!2+_\ 4B__ ,$V  "J-@  F38  (LV  "!-0  >3,  ',Q  !O+P
M:RX& &@M$ !D+A@ 8BXA & O*@!>+S$ 7"\Y %LO0 !9+T8 6"]- %<P4P!6
M,%L 5#%C %,Q; !2,G< 43*$ $\SD@!.,Z$ 33.Q $TTQ0%,-.,!3#3V $PT
M_P!,-/\ 3#/_ +LY  "F.0  E3D  (<Y  !\.0  =#<  &XT  !I,P  93("
M &$R#0!>,A0 7#,> %HS)@!8,RX 5C,U %4T/ !3-$, 4C1* %$T4 !0-5@
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M :Y   ":0   B4$  'Q!  !Q00  :$   &$\  !;/0  5CX  %(^!0!./PX
M3#\5 $D_'0!'0"4 1D L $1 ,P!#0#H 0D%" $%!20! 05$ /T): #Y"8P ]
M0V\ /$-\ #M#BP Z1)L .42K 3E$O@$X1-L!.43Q 3E#_@$Y0_\!.4/_ :I"
M  "60P  AD,  'A#  !N0P  94,  %U   !60   44(  $U" @!)0PP 1D,2
M $1$&@!"1"( 040J #]%,0 ^13@ /44_ #Q&1P [1D\ .D97 #E'80 X1VP
M-T=Z #9(B0 U2)D -$BJ #1(O0 S2-D -$CP #1'_0 T1_\ -4;_ *9$  "2
M10  @D8  '5&  !J1@  844  %E$  !11   3$8  $A'  !$1PH 04@0 #])
M&  ]22  /$DG #I*+@ Y2C8 .$H] #=+1  V2TP -4M5 #1,7P S3&H ,DQW
M #%,A@ P3)< +TVH "Y-NP N3=4 +DSO "],_0 O2_\ ,$O_ *%'  ".2
M?D@  '%(  !F20  74@  %5(  !,20  1TH  $)+   _3 8 .TT. #E.%0 W
M3AT -D\D #5/*P S3S, ,E Z #%00@ P4$H +U%2 "Y17  M46< +%%U "M1
MA  J4I4 *5*F "E2N0 H4M( *5'N "E0_  J4/\ *D__ )Q*  ")2@  >DL
M &U+  !C3   6DP  %%,  !(30  0T\  #U0   Y4@( -5,, #-4$@ Q5!D
M,%4A "Y5*  M52\ +%8W "M6/@ J5D8 *59/ "A760 G5V0 )E=R "57@0 D
M5Y( (U>D ")7MP B5\\ (E?L "-6^@ C5?\ )%7_ )9-  "$3@  =4X  &E.
M  !?3P  5D\  $U0  !%4@  /U,  #E6   S6   +UH( "M;#P J6Q4 *%P=
M "=<)  F7"L )5PS "1=.@ C74, (EU, "%=5@ @7F$ 'UYN !Y>?@ =7H\
M'%ZA !M>M  :7<P &UWI !M<^0 <6_\ '%O_ )!1  !^40  <%$  &12  !;
M4@  4E,  $I4  !!5P  .UD  #5;   N7@  *& # "1B#  B8Q$ (6,8 !]D
M(  >9"< '60N !QD-@ ;93X &F5' !EE40 895T %V5J !9E>@ 598L %&6>
M !-EL0 29<@ $F3G !-C]P 48O\ %&+_ (E4  !X50  :U4  &!6  !75@
M3U<  $99   ]7   -E\  #!B   I9   (V<  !UJ!P 9; X &&P3 !9M&@ 5
M;2$ %&TI !1M,  3;3D _^)]$$E#0U]04D]&24Q%  <2$FY" !%N3  0;E@
M#VYE  YN=0 -;H< #6Z:  QMK0 +;<( "VS@  QK\P -:_T #6K_ ()9  !R
M60  9ED  %Q:  !46@  2EP  $%?   Y8P  ,68  "II   D;   '6\  !=R
M   2=0D #W</  YW%  .=QL #7<C  QW*@ +=S, "G<\  EW1P (=U( !W=?
M  5W;P $=X   W>4  %VIP  =KL  775  %TZP "=/8  G3\ 'M=  !M70
M8EX  %E>  !.8   16,  #QG   S:P  *VX  "1R   >=0  %WD  !)\   -
M?P8 "8$,  6!$0 #@18  H$=  &!)   @2T  ((V  ""0   @DP  ()9  ""
M:   @GD  (*-  "!H   @+0  (#+  !_YP  ?O(  '[Y '1B  !H8@  7F(
M %-D  !)9P  /VL  #9P   M=   )7@  !Y\   7@   $8,   V&   (B00
M HL*  "+#@  BQ,  (P8  ",'P  C28  (TO  "..0  CD0  (Y1  ".8
MCG$  (Z%  ".F0  C:T  (S#  ",WP  B^X  (OV &YH  !D9P  6&D  $UL
M  !"<0  .'8  "][   F?P  'H0  !:(   0C   #(\   :2    E0   )8'
M  "7#   EP\  )@3  "9&   FA\  )LF  ";,   G#L  )Q(  "<5P  G&@
M )Q[  "<D   FZ4  )NZ  ":T   FN<  )KQ &IM  !>;P  47(  $9W   [
M?   ,8(  ">'   >C   %I$  !"5   *F0  !)P   "@    H@   *,!  "C
M!@  I L  *4.  "F$@  IQ<  *@>  "J)@  JS$  *L^  "L30  K%T  *QP
M  "LA0  K)L  *NO  "KPP  J]D  *KH &1U  !7>0  2WX  #^$   TB@
M*9   !^6   6FP  $)\   FC   !IP   *H   "N    L    +    "Q
ML@,  +0(  "U#0  MA   +<5  "Y'0  NR8  +PS  "]00  O5(  +UD  "^
M>0  OI   +VD  "]MP  O<8  +W7 %Q_  !0A0  1(L  #B2   LF0  (9\
M !>D   0J0  ":X   "R    M@   +D   "]    OP   +\   #     P0
M ,,   #$!0  Q@H  ,<.  #)$P  RQP  ,XF  #0-0  T44  -)7  #2:P
MTX(  -.7  #3J0  TK@  -+$ %6,  !)DP  /9H  #"B   EJ   &JX  !&T
M   )N0   +T   #!    Q    ,@   #+    S0   ,T   #/    T    -(
M  #4    V    -H&  #=#   X!$  .,:  #F)P  YS@  .A*  #I70  ZG(
M .N(  #KFP  [*@  .RR /\ #0#_  L _P + /\ $ #_ !H _P F /\ ,@#_
M #T _P!( /L 4@#X %H ]@!B /, :0#Q &\ \ !U .X >@#L '\ ZP"$ .D
MB@#H )  Y@"6 .0 G0#B *4 X0"O -\ NP#= ,L VP#F -D ]P#8 /\ V #_
M -< _P#7 /\ U #_ /\ " #_  0 _P $ /\ #0#_ !4 _@ A /H + #W #@
M] !# /  30#M %4 Z@!= .< 9 #D &H X@!P .  =0#> 'H W0!_ -L A0#9
M (L U0"1 -, F0#1 *  SP"J ,T M0#+ ,0 R0#= ,@ \0#' /\ Q@#_ ,8
M_P#& /\ QP#_ /\   #_    _P   /\ "@#X !$ \0 < .P )P#I #( Y@ ]
M .( 1P#= %  V0!8 -4 7P#2 &4 T !J ,X < #, '4 R@!Z ,D ?P#' (4
MQ0", ,, E #! )P OP"E +T L "[ +T N@#0 +@ ZP"W /L M@#_ +8 _P"V
M /\ M@#_ /\   #_    _0   /, !0#I  X X0 6 -L (0#5 "T T0 W ,X
M00#* $H QP!2 ,0 60#" %\ P !E +X :@"\ &\ NP!T +D >@"W (  M@"'
M +0 C@"R )< L "@ *X J@"M +< JP#( *D XP"H /4 IP#_ *< _P"G /\
MI@#_ /\   #^    \0   .4   #7  H S0 1 ,< ' #" "8 OP Q +P .P"Z
M $0 MP!, +0 4P"R %D L0!? *\ 9 "M &D K !O *H = "I 'H IP"! *8
MB0"D )$ H@"; *  I0"> +( G0#! )L V@": .\ F0#] )@ _P"8 /\ F #_
M /T   #P    X0   -$   #&  0 O0 - +< %0"S "  L  K *T -0"K #X
MJ !& *8 30"D %0 HP!9 *$ 7P"@ &0 G@!I )T ;@"; '4 F@![ )@ @P"6
M (P E0"6 ), H0"1 *T CP"[ (T SP", .D BP#X (P _P", /\ C #_ /,"
M  #B!P  S <  +\$  "W    L0 ( *L $ "G !D I  D *  +@"> #< G !
M )H 1P"8 $X E@!4 )4 60"3 %X D@!D )  :0"/ &\ C0!V (L ?@"* (@
MB "2 (8 G0"% *D @P"X ($ R@"  .4 @ #U '\ _P!_ /\ ?P#_ .@-  #0
M$   OA   +$.  "H#0  HP@  * "# "< !, F  = )4 )P"2 #$ D  Y (X!
M00", 4@ B@). (D"5 "' ED A@)? (0#9 "# VL @0-R ( $>@!^!(0 ?06.
M 'L%F@!Y!J< > :U '8'R !U"., =0GT '0*_P!S"O\ <PK_ -T5  #$%P
ML1<  *46  "<$P  EA$  )0-! "3" T C@<5 (L)( "("2H A0HS (,+.P"!
M"T( @ M) 'X+3P!]#%0 >PQ: 'H,8 !X#&< =PQN '4-=@!T#8  <@V, ' -
MF0!O#J8 ;0ZU &P.R0!K#^8 :A#W &D0_P!I$/\ :1#_ - =  "Y'@  J!X
M )L=  "2&P  BQD  (@5  "'$0< A0X0 ($/&@!^$"0 >Q M 'D0-@!W$3T
M=A%$ '012@!S$5  <1%6 ' 17 !N$F( ;1)J &L2<P!I$WT :!.) &83E@!E
M%*, 8Q6S &(5Q@!B%N, 81;V & 7_P!@%_\ 8!?_ ,<B  "P(P  GR0  )(C
M  ")(@  @B   'X=  !\&0  >A4- '<5%0!T%A\ <18H &\7, !N%S@ ;!<_
M &L710!I&$L :!A1 &886 !E&%X 8QEF &(9;P!@&7D 7QJ% %T;D@!<&Z$
M6QRP %H<PP!9'>  6![T %@>_P!8'O\ 6![_ +\G  "I*   F2@  (LH  ""
M)P  >R4  '8C  !S(   <1P) &X<$0!K'!H :1TC &<=+ !E'3, 8QXZ &(>
M00!@'D< 7QY- %X>5 !<'UL 6Q]B %D@:P!8('8 5B&" %4AD !4(IX 4R*N
M %(CP !1(]T 423R %$D_P!1)/\ 42/_ +DK  "C+   DRP  (8M  !\+
M="H  &\H  !K)0  :2(% &8A#@!C(A8 82(? %\C)P!=(R\ 7",V %HC/0!9
M)$, 5R1* %8D4 !5)%< 4R5? %(E: !1)G, 3R9_ $XGC0!-*)P 3"BL $LI
MO@!+*=H 2BGQ $HI_P!+*?\ 2RG_ +,N  ">+P  CC   ($P  !W+P  ;RX
M &HK  !E*@  8R<! %\G# !<)Q, 6B<; %@H) !6*"L 52@R %,H.0!2*4
M4"E& $\I30!.*50 32I< $PJ90!**W  22M\ $@LBP!'+9H 1BVJ $4NO !%
M+M8 12[O $4N_@!%+O\ 12W_ *XQ  ":,@  B3,  'PS  !R,P  :S$  &4O
M  !@+0  72P  %DL"0!6+!  5"P8 %(L( !0+"@ 3BTO $TM-@!,+3P 2BU#
M $DM2@!(+E$ 1RY9 $8O8P!%,&T 0S!Z $(QB0!!,9@ 03*H $ RNP _,M,
M/S+N $ R_0! ,O\ 0#+_ *HS  "6-0  AC4  'DV  !N-0  9C4  &$R  !<
M,   5S   %0P!@!1, X 3C 5 $PQ'0!*,24 2#$L $<Q,@!&,3D 1#%  $,R
M1P!",D\ 03-7 $ S8  _-&L /C5X #TUAP \-I8 .S:G #LVN0 Z-M$ .C;M
M #LV_  [-O\ .S;_ *8V  "2-P  @C@  '4X  !K.   8S<  %TV  !7,P
M4S0  $\T P!+- P 2302 $8U&@!%-2( 0S4I $$U+P! -38 /S8] #XV1  ]
M-TP /#=5 #LX7@ Z.&D .3EV #@YA0 W.I4 -SJE #8ZN  U.L\ -CKL #8Z
M^P V.?\ -SG_ *(X  "..0  ?CH  '([  !H.P  7SH  %DY  !3-@  3C<
M $HX  !&. H 1#D0 $$Y%P _.1\ /CDF #PY+0 [.C0 .CH[ #D[0@ X.TH
M-SM3 #8\7  U/&< -#UT #,]@P S/I, ,CZD #$^M@ Q/LT ,3[J #$^^@ R
M/?\ ,CW_ )X[  "+/   >SP  &X]  !D/0  7#T  %4\  !..@  23L  $4\
M  !!/0< /CT. #P]%0 Z/AP .3XC #<^*@ V/S$ -3\X #0_0  S0$@ ,D!0
M #% 6@ P064 +T%R "Y"@0 M0I$ +4*B "Q"M0 K0LL +$+I "Q"^0 M0?\
M+4'_ )D]  "'/@  =S\  &L_  !A0   63\  %(_  !)/@  1#\  $!    \
M000 .4(- #="$@ U0QD ,T,A #)#*  Q1"\ ,$0V "]$/0 N144 +45. "Q%
M6  K1F, *D9O "E&?@ H1H\ )T>A "9'LP F1\D )D;G "=&^  H1?\ *$7_
M )5   ""00  <T(  &="  !>0@  54(  $Y"  !%0@  /T0  #M%   W1@
M-$<* #%($  O2!8 +DD> "Q))0 K22P *DDS "E*.@ H2D( )TI+ "9+50 E
M2V  )$MM "-+?  B2XT (4R? "%,L0 @3,< ($OF "%+]P B2O\ (DK_ )!#
M  !^1   ;T0  &1%  !:10  4D4  $I&  !!1P  /$@  #=)   R2P  +DT'
M "M.#@ I3A, )T\: "9/(0 E3R@ )$\P "-0-P B4#\ (5!( "!04@ ?45T
M'E%J !U1>0 <48H &U&< !I1KP 94<4 &5'D !I0]@ ;3_\ '$__ (I&  !Y
M1P  :T<  &!(  !62   3D@  $=)   ^2P  .4P  #-.   N4   *%," "14
M"P B51  (%46 !]6'@ >5B0 '58L !Q6,P ;5SL &E=$ !E73@ 85UD %UAF
M !58=0 46(< %%B: !-7K  25\( $E?A !-6]  45?\ %%7_ (1)  !T2@
M9DL  %Q+  !32P  2TP  $1-   \3P  -5$  "]4   I5@  )%D  !Y;!P :
M70T &%T2 !==&0 67B  %5XG !1>+@ 37C< $EY  !%?2@ 17U4 $%]B  ]?
M<0 .7X, #5^6  U?J0 ,7KX #%[:  U=\  -7/P #ES_ 'Y-  !N3@  8DX
M %A/  !/3P  2%   $!2   X5   ,%<  "I:   D70  'U\  !EB 0 390D
M$68/ !!F%  /9AL #F<B  UG*0 -9S( #&<[  MG10 *9U  "6==  =G;  &
M9WT !6>0  1FHP "9K<  V7/  1EZ0 $9/4 !&3\ '=1  !I4@  75(  %12
M  !,4P  0U4  #M8   S6P  *UX  "5A   ?9   &6<  !-J   /;08 "W ,
M  AP$0 '<!8 !7 =  1P)  #<"P  G U  !P/P  <$H  '!7  !P90  <'8
M '"*  !OG@  ;[(  &[(  !MY0  ;?(  &WY '!6  !C5@  658  %%7  !'
M6   /EL  #9?   N8@  )F8  !]J   9;0  $W    YS   +=@0 !7@+  %X
M#P  >1,  'D9  !Y'P  >B8  'HO  !Z.0  >D0  'I0  !Z7P  >G   'J#
M  !ZF   >JP  'G"  !XWP  >.\  '?W &I;  !?6P  5EL  $Q<  !"8
M.6,  #!H   H;   ('   !ET   3=P  #GL   E^   $@0(  (((  "##0
M@Q   (04  "%&0  AB   (8H  "',0  ASP  (=)  "'5P  AV@  (=[  "'
MD   AJ4  (6Z  "%TP  A.H  (3T &5@  !<8   46$  $9D   \:0  ,FT
M "ER   A=P  &7L  !*    -@P  "(<   **    C0   (X$  "."0  CPT
M ) 0  "1%   DAD  ),@  "4*0  E3,  )5   "63@  EE\  )5R  "5B
ME9T  )2R  "4R   D^(  )/N &%E  !69@  2FH  #]N   U=   *WD  "%_
M   9A   $8D   R-   &D0   )0   "8    F@   )L   "< @  G0<  )X+
M  "?#@  H1(  *(8  "C(   I2D  *8V  "F1   IE4  *9H  "F?0  II0
M *6I  "DO0  I-$  *3D %ML  !/<   0W4  #A[   M@0  (X<  !F-   1
MD@  "Y<   2<    H    *,   "F    J    *D   "J    K    *T$  "N
M"0  L T  +$1  "S%P  M2   +8K  "W.@  MTL  +A<  "X<0  N(@  +B=
M  "XL0  M\(  +?0 %1V  !(?   /((  #&)   FD   &Y<  !*=   ,H@
M Z<   "K    K@   +(   "V    N    +@   "Z    NP   +T   "^
MP 4  ,$+  ##$   QA8  ,D@  #*+@  RSX  ,Q0  #,9   S7H  ,V1  #-
MI   S;0  ,W  $V#  !!B@  -9$  "F9   >H   $Z8   RL   #L0   +8
M  "Z    O@   ,(   #&    R    ,@   #*    RP   ,T   #.    T
M -(!  #5"   V0X  -T5  #A(0  XC$  .1#  #E5@  YFL  .:"  #GE@
MYZ4  .:P /\ "0#_  4 _P & /\ #@#_ !8 _P A /\ +0#_ #@ _0!# /D
M30#U %4 \@!= /  8P#N &D [ !O .H = #I 'H YP!_ .8 A0#D (L XP"1
M .$ F0#? *$ W "J -H M@#7 ,8 U0#A -, ] #2 /\ T0#_ -$ _P#/ /\
MR@#_ /\  0#_    _P ! /\ # #_ !( ^@ = /8 * #S #, \  ^ .P 2 #H
M %  Y0!8 .( 7@#? &0 W0!J -L ;P#9 '0 U@!Z -0 ?P#2 (4 T ", ,X
MDP#, )P R0"E ,< L #& +X Q #4 ,( [@#! /X P #_ ,  _P"_ /\ O@#_
M /\   #_    _P   /H !P#Q  \ ZP 8 .8 (P#B "X X  X -L 0@#5 $L
MT0!2 ,X 60#+ %\ R0!E ,< :@#& &\ Q !T ,( >@#! (  OP"& +T C@"[
M )8 N0"@ +< J@"V +< M #* +( Y@"Q /@ L #_ *\ _P"O /\ L #_ /\
M  #_    ]P   .H  @#A  P UP 3 -  '0#, "@ R0 R ,8 / #" $4 OP!-
M +P 4P"Z %D N !? +< 9 "U &D M !N +( = "Q 'H KP"  *T B "L )$
MJ@": *@ I0"F +$ I #! *, W "A /( H0#_ *  _P"@ /\ H0#_ /\   #W
M    Z    -D   #+  @ PP 0 +T & "Y "( M@ L +0 -@"R #\ KP!' *P
M30"K %0 J0!9 *< 7@"F &, I0!H *, ;@"B '0 H !Z )X @@"< (L FP"5
M )D GP"8 *P E@"Z )0 SP"3 .L D@#[ )( _P"2 /\ D0#_ /<   #G
MTP   ,8   "[  ( LP , *T $@"J !P IP F *0 , "C #@ H !  )X 1P"<
M $X F@!3 )D 6 "7 %T E@!C )4 : "3 &X D@!T )  ? "/ (4 C0"/ (L
MF@"* *< B "U (8 QP"% .0 A #U (0 _P"# /\ @P#_ .P   #3    P0$
M +0   "L    I@ ' *  #@"= !8 F@ @ )< *0"5 #( DP Z )$ 00"/ $@
MC0!- (P 4P"+ %@ B0!= (@ 8P"' &D A0!O (, =P"" (  @ "* 'X E@!]
M *, >P"P 'H P@!Y -T > #Q '< _0!X /\ > #_ -X*  #$"P  L@P  *8+
M  "="   F00  )4 "@"1 !$ C@ 9 (L (P") "P AP T (4 .P"# $( @@!(
M (  3@!_ %, ?0!8 'P 7@![ &0 >0!J '@ <@!V 'L = "& ', D@!Q )\
M< "M &X O@!M =8 ;0+M &P#^@!L _\ ; /_ ,X0  "W$0  IA(  )H1  "1
M$   BPX  (D+ P"'!0P A $3 ($!' !^ B4 ? ,N 'H#-@!X!#P =P1# '4%
M2 !T!4X <P54 '$%60!P!E\ ;@9F &T&;@!K!W@ :@># &@(D !G"9T 90FL
M &0)O !C"M0 8POL &(,^@!B#/\ 8@S_ ,,6  "M%P  G1@  ) 8  "'%@
M@10  'T1  !\#@8 ? H. '@*%@!U"Q\ <@LH ' ,, !O##< ;0P^ &P,1 !K
M#4H :0U/ &@-50!G#5P 90UC &,.:P!B#G4 8 Z! %\.C@!=#YP 7!"K %L0
MO0!:$-8 61'P %D1_0!9$?\ 61'_ +D;  "E'0  E!X  (@>  !^'0  >!L
M '08  !Q%0  <1$) &\0$0!L$!D :1 B &<1*@!F$3( 9!$Y &,1/P!B$44
M8!)+ %\240!=$E@ 7!)? %H3: !9$W( 5Q1] %84BP!4%9D 4Q6I %(6N@!1
M%M( 41?M %$7_0!1%_\ 41?_ +(@  ">(@  CB(  ($C  !W(@  <"$  &P>
M  !I&P  9Q@$ &85#@!C%A4 818> %\6)@!=%BT 7!<T %H7.P!9%T$ 6!A'
M %8830!5&%0 4QA< %(99 !1&6X 3QIZ $X;B !-&Y< 2QRF $H<N !*'<\
M21WK $D=^P!)'?\ 2AW_ *PD  "8)0  B"8  'LG  !Q)@  :B4  &8C  !B
M(0  8!X  %X<"P!;&Q( 61P: %<<(@!5'"D 5!PP %,=-P!1'3T 4!U# $\=
M2@!-'E$ 3!Y8 $L?80!)'VL 2"!W $<@A0!&(90 1"*D $0BM@!#(LP 0R/I
M $,C^@!#(_\ 0R+_ *8G  "3*0  @RH  '8J  !M*@  92D  & G  !<)0
M62,  %<A!P!5(0\ 4B$6 % A'@!.(24 32(L $PB,P!*(CD 22)  $@B1@!'
M(TT 12-5 $0D7@!#)&D 0B5U $ F@P _)I( /B>C #XGM  ])\H /2CH #TH
M^0 ])_\ /B?_ *(J  ".*P  ?RT  '(M  !H+0  82P  %PK  !8*   5"8
M %$F! !.)0T 3"43 $HF&@!()B( 1R8I $4F+P!$)C8 0R<\ $$G0P! )TL
M/RA3 #XI7  ]*68 /"IR #LJ@0 Z*Y  .2NA #@LL@ W+,@ -RSF #@L^  X
M+/\ ."S_ )TL  "*+@  >R\  &\P  !E,   72\  %@N  !3*P  4"H  $PJ
M  !)*@L 1BH1 $0J%P!"*A\ 02HE #\J+  ^*S, /2LY #PK0  [+$@ .BQ0
M #DM60 X+F0 -RYP #8O?P U+X\ -#"? #,PL0 R,,< ,C#E #,P]P S,/\
M-"__ )DO  "',0  =S(  &LR  !B,@  6C(  %0Q  !/+P  2RT  $<N  !$
M+@@ 02X. #\N%  ]+AP .RXB #DO*0 X+R\ -R\V #8P/@ U,$8 -3%. #0Q
M5P S,F( ,C)N #$S?0 P,XT +S2> "XTL  M-,4 +33C "XT]@ O,_\ +S/_
M )4Q  "#,P  =#0  &@U  !>-0  5S0  %$T  !+,@  1C$  $(R   _,@4
M/#(- #DS$@ X,QD -C,@ #0S)@ S,RT ,C0T #$T.P P-4, ,#5, "\V50 N
M-F  +3=L "PW>P K-XL *CB< "DXK@ H.,, *#CB "DX]0 J-_\ *C?_ )(T
M  !_-0  <38  &4W  !;-P  5#<  $TV  !'-@  0C4  #TV   Z-@( -S<+
M #0W$  R-Q8 ,3@= "\X)  N."L +3DR "PY.0 K.4$ *CI) "HZ4P I.UX
M*#MJ "<[>0 F/(D )3R; "0\K0 C/,( (SS@ "0\]  E._\ )3O_ (TV  !\
M.   ;3D  &(Y  !8.@  43D  $HY  !$.0  /3D  #DZ   U.P  ,CL( "\\
M#@ M/10 +#T: "H](0 I/2@ *#XO "<^-@ F/CX )3]' "0_4  C0%L (D!H
M "% =@ @0(< 'T&9 !]!JP >0<  'D'> !] \P ?0/X (#__ (DY  !X.@
M:3L  %X\  !5/   33P  $<\  ! /   .#T  #0^   P0   +4$% "I"#  G
M0A$ )D,8 "1#'@ C0R4 (D,L "%$,P @1#L 'T1$ !Y%3@ =15D '$5E !M%
M=  :184 &4:7 !E&J0 81KX %T7< !A%\0 91/T &D3_ (0\  !S/0  9CX
M %L_  !2/P  2C\  $0_   ]0   -D$  #%#   L1   )T8! "1'"@ A2 \
M($D4 !Y)&P =22( '$DI !M*,  :2C@ &4I! !A*2P 72U4 %DMB !5+<0 4
M2X( $TN4 !)+IP 22[P $4O9 !)*\  32OP %$G_ '\_  !O0   84$  %="
M  !.0@  1T(  $%"   Z0P  ,D4  "U'   H20  (TL  !Y-!@ ;3PT &% 1
M !=0%P 64!X %5 E !10+  3430 $E$] !%11P 145( $%%?  ]2;0 .4GX
M#5&1  U1I  ,4;@ #%'1  U0[  -4/H #D__ 'E#  !J1   740  %-%  !+
M10  1$4  #Y&   V2   +TH  "E,   D3P  'U$  !I3   45@D $5<. !!8
M$P 06!D #U@@  Y8*  -6#  #5@Y  Q80P +6$X "EA:  A8:  '6'D !EB,
M  58GP $6+, !%?*  57Y@ %5_, !E;\ '-&  !D1P  64@  %!(  !(2
M04D  #I*   R30  *U   "52   @50  &E@  !5:   0708 #& ,  I@$  )
M8!4 "& <  =@(P %8"L !& T  -@/0 !8$D  &!5  !@8P  8',  &"&  !?
MF@  7ZX  %_$  !>X@  7O   %[X &Q*  !?2P  54L  $Q,  !%3   /4X
M #50   N4P  )U8  "!9   :7   %5\  !!B   -900 "&<+  -G#@  :!,
M &@8  !H'P  :28  &DN  !I.   :4,  &E/  !I70  :6T  &F   !IE
M:*D  &B_  !GW   9NX  &;W &9/  !:3P  44\  $I/  !!40  .%0  #!7
M   H6P  (5X  !IB   490  $&@   QK   ';@,  7 )  !P#0  <1   '$4
M  !R&@  <R$  ',H  !S,0  <SP  '1(  !S5@  <V8  '-Y  !SC@  <Z,
M '*Y  !QT@  <>L  '#T &%3  !64P  3U,  $55   [6   ,EP  "I@   B
M9   &V@  !1L   /;P  "W(   9V    >0   'H&  !Z"@  >PX  'P1  !]
M%0  ?AL  '\B  " *@  @#4  (!!  " 3P  @%\  (!Q  " A@  @)T  '^R
M  !^R@  ?N4  'WQ %Q8  !46   25H  #]=   U80  +&4  "-J   ;;P
M%',   YW   )>P   W\   ""    A    (8!  "&!@  B H  (D-  "*$
MBQ4  (P;  ".(@  CRP  (\X  "/1@  CU8  (]H  "/?@  CY4  (ZK  "-
MP0  C=P  (SK %E=  !.7P  0V(  #AF   N;   )'$  !QW   4?   #H$
M  B%    B0   (T   "0    D@   ),   "4    E@,  )<(  "8#   F@\
M )L3  "=&@  GR,  * N  "@/   H$P  *!>  "@=   GXP  )^B  "?MP
MGLL  )[@ %-D  !':   /&T  #%S   G>0  '7\  !2%   -BP  !I    "4
M    F    )P   "?    H0   *(   "D    I0   *<   "H!   J@D  *P-
M  "M$@  L!D  +(C  "R,0  LD(  +)4  "R:0  LH   +*8  "QK   LK\
M +'. $QN  ! <P  -7H  "J!   ?B   %8X   Z5   &F@   )\   "D
MJ    *P   "O    L0   +$   "S    M0   +8   "X    N@   +P&  "^
M#   P!$  ,,9  #%)@  Q3<  ,9)  #&70  QW(  ,>*  #(GP  R*\  ,B\
M $9Z   Y@0  +HD  "*0   7F   #Y\   >E    J@   *\   "S    MP
M +P   "_    P0   ,(   #$    Q0   ,<   #)    RP   ,T   #/ P
MT@H  -80  #<&@  W2H  -X\  #?4   X&4  .%[  #AD0  XJ(  .*M /\
M @#_    _P # /\ # #_ !, _P = /\ * #^ #, ^P ^ /< 2 #S %  \ !7
M .T 7@#K &0 Z !I .< ;P#E '0 XP!Y .( ?P#@ (4 W@", -P DP#9 )P
MU@"F -, L0#1 ,  SP#: ,X \0#, /\ RP#_ ,L _P#& /\ P0#_ /\   #_
M    _P   /\ " #[ !  ]@ 9 /( ) #O "X [0 Y .@ 0@#C $L X !2 -T
M60#9 %\ U@!D -, :0#1 &X SP!T ,X >0#, '\ R@"& ,@ C@#& )8 Q "@
M ,( JP#  +D O@#- +P Z@"[ /P N@#_ +H _P"Z /\ M@#_ /\   #_
M_@   /0 ! #K  T Y  4 -\ 'P#; "D V  S -, /0#. $4 R@!- ,< 4P#%
M %D PP!? ,$ 9 "_ &D O0!N +L <P"Z 'D N "  +8 B "T )  L@": +$
MI0"O +( K0#$ *P X0"K /8 J@#_ *H _P"J /\ J@#_ /\   #]    [@
M .(   #5  H S0 1 ,< &0#$ ", P0 M +\ -P"[ #\ MP!' +4 3@"R %,
ML !9 *\ 7@"M &, K !H *L ;0"I ', J !Z *8 @0"D (H HP"4 *$ GP"?
M *P G@"[ )P T@"; .X F@#_ )H _P"9 /\ F0#_ /X   #N    W@   ,L
M  #!  4 N0 - +0 % "Q !X K@ G *L , "J #D IP!! *0 2 "B $T H0!3
M )\ 6 "> %T G0!B )L 9P": &T F !S )< >P"5 (0 E ". )( F0"0 *8
MC@"T (T R ", .8 BP#Y (H _P"* /\ BP#_ /    #;    QP   +H   "P
M    J  * *0 $ "@ !@ G0 A )L *@": #, F  [ )8 00"4 $@ D@!- )$
M4@"/ %< C@!< (P 80"+ &< B@!N (@ =0"' 'X A0"( (, E "" *  @ "O
M '\ P !^ -T ?0#R 'T _P!] /\ ?0#_ .    #&    M0   *H   "B
MFP % )4 #0"2 !, D  < (T ) "+ "T B@ T (@ .P"& $( A0!' (, 30""
M %( @0!7 '\ 7 !^ &( ?0!H 'L < !Z 'D > "# '8 CP!U )P = "J '(
MN@!Q -$ < #L '  ^P!P /\ < #_ ,T$  "W!@  IP<  )L&  "3!   C@
M (H " "&  \ A  6 ($ '@!_ "< ?0 N 'P -@!Z #P >0!" '< 1P!V $P
M=0!2 ', 5P!R %T <0!C &\ :P!N '0 ; !^ &L B@!I )@ : "F &< M@!F
M ,L 90#G &4 ]P!E /\ 90#_ , ,  "K#0  FPX  (\.  "&#0  @0L  'X'
M 0!\ 0L >0 1 '< & !U "$ <P I '$ , !O #8 ;@ \ &P 0@!K $< :@!-
M &D 4@!H %@ 9@!? &4 9P!C '  8@%Z & !AP!? I4 7@*C %P#LP!< \<
M6P3D %L%] !;!OX 6P;_ +40  "A$@  D1,  (43  !\$@  =A$  ',.  !R
M# 0 <0<- &X$$@!L!!L :04C &<%*@!F!C$ 9 8W &,&/0!B!T, 80=) %\'
M3@!>"%4 70A< %L)8P!:"6T 6 IX %<*A0!6"Y, 5 NB %,+LP!2#,< 4@SD
M %$-]0!1#?\ 40W_ *T5  "9%P  B1@  'T9  !T&   ;1<  &H4  !G$0
M9PX' &8,#@!C#!4 80P= %\,)0!=#2P 7 TS %L-.0!:#3\ 6 U% %<-2P!6
M#E$ 50Y9 %,.80!2#FL 4 ]V $X0@P!-$)( 3!"B $L0L@!*$<@ 21'E $D1
M]P!)$O\ 21'_ *49  "2'   @QT  '8>  !M'0  9AP  &(:  !?%P  7A0!
M %X1"@!;$!$ 61$8 %<1( !5$2< 5!$N %,1- !1$3L 4!)! $\21P!.$DX
M3!)5 $L37@!)$V< 2!1S $84@ !%%8\ 1!6? $,6L !"%L4 0A?C $(7]@!"
M%_\ 0A?_ )\=  ",(   ?2$  '$B  !H(@  82$  %P?  !9'   5QD  %46
M!@!4%0X 4144 $\6' !.%B, 3!8J $L6, !*%C< 21<] $<70P!&%TH 11A2
M $,86@!"&60 01EP #\:?0 ^&XT /1N= #P<K@ [',, .QSA #L=]0 ['/\
M/!S_ )HA  "'(P  >"0  &PE  !C)0  7"0  %<C  !3(   41X  $\< @!-
M&PP 2QH1 $@;& !'&R  11LF $0;+0!#'#, 0APY $ <0  _'4< /AU/ #T>
M6  \'F( .A]M #D?>P X((L -R&; #8AK0 U(<$ -2'? #4A\P V(?\ -B'_
M )8C  "#)@  ="<  &@H  !?*   6"<  %,F  !/)   3"(  $D@  !'( D
M1!\/ $(?%0! (!P /R C #X@*0 \("\ .R$V #HA/0 Y(40 ."), #<B50 V
M(U\ -"-K #,D>0 R)8D ,26: # EJP P)K\ +R;< # F\@ P)O\ ,27_ )$F
M  !_*   <2H  &4J  !<*@  52H  $\I  !+*   2"4  $0D  !!) 4 /R0-
M #TD$@ [)!D .20? #<D)@ V)"P -24S #0E.@ S)D$ ,B9* #$G4P P)UT
M+RAI "XI=P M*8< +"F8 "LJJ@ J*KT *BK: "LJ\0 K*OX +"G_ (TH  !\
M*@  ;2P  &(M  !9+0  42T  $PL  !'*P  0R@  #\H   \* ( .2@+ #<H
M$  U*!8 ,R@< #(H(P P*"D +RDP "\J-P N*C\ +2M' "PK40 K+%L *BQG
M "DM=0 H+84 )RV7 "8NJ  E+KP )2[8 "8N\  F+OT )RW_ (HK  !X+0
M:BX  %\O  !6+P  3B\  $@N  !#+0  /RP  #LL   W+   -"P) #(L#@ P
M+1, +BT: "TM(  K+2< *BXM "HN-0 I+ST *"]% "<P3@ F,%D )3%E "0Q
M<P C,8, (C*5 "$RIP A,KL (#+4 "$R[P B,?P (C'_ (8M  !U+P  9S
M %PQ  !3,0  2S$  $4Q  ! ,   .S   #8P   S,   ,#$& "TQ#0 K,1$
M*3(7 "@R'@ G,B0 )3,K "4S,@ D,SH (S1# "(T3  A-5< (#5C !\U<0 >
M-H$ '3:3 !PVI0 ;-KD &S;2 !PV[0 =-OL '37_ ((P  !Q,@  8S,  %DT
M  !0-   230  $(S   ],P  -S,  #$T   N-0  *S4" "@V"P E-Q  )#<5
M "(W&P A."( (#@H !\X,  >.#< '3E  !PY20 ;.E0 &CI@ !DZ;@ 8.G\
M%SN1 !<[I  6.[< %3O0 !8Z[  7.OH &#G_ 'TR  !M-   8#4  %4V  !-
M-@  1C8  $ V   Z-@  -#8  "XX   J.0  )CH  ",["  @/ X 'CT2 !T]
M&  </1\ &SXE !H^+0 9/C0 %SX] !8_1P 5/U$ %#]> !0_;  30'P $D"/
M !% H@ 10+8 $$#. !$_ZP 2/_D $C[_ 'DU  !I-P  7#@  %(Y  !*.0
M0SD  #TY   W.0  ,3H  "L\   G/0  (C\  !Y!!  :0@L &$,0 !=#%0 5
M1!L %$0B !-$*0 31#$ $D0Z !%%0P 014X $$5;  Y%:0 .17D #46,  U%
MGP ,1;( "T7)  Q%Y0 -1/8 #43_ '0Y  !E.@  6#L  $\[  !'/   0#P
M #H\   T/   +CX  "A    C0@  'T0  !I&   52 @ $DH- !%*$@ 02A@
M#TL>  Y+)0 -2RT #4LV  Q+0  +2TH "DM6  E+9  (2W0 !TN'  5+F@ $
M2ZX !$K$  5*X  %2O  !DGZ &X\  !@/0  5#X  $L^  !$/@  /3X  #<_
M   Q0   *D(  "1%   ?1P  &DD  !5,   13@4 #E$+  M1$  *410 "5$;
M  A1(@ '42D !5$R  12.P #4D8  5)2  !27P  4F\  %*!  !1E@  4:D
M %&_  !0W   4.X  %#W &A   !;00  4$$  $A!  !!00  .T(  #1#   M
M10  )D@  "!+   ;30  %E   !%3   .500 "E@*  98#@ "6!(  %D7  !9
M'0  624  %DM  !9-@  64$  %E-  !:6@  6FD  %E\  !9D   6:4  %BZ
M  !8U0  5^P  %?V &-$  !610  344  $5%   _10  -T<  "])   H3
M(D\  !M2   650  $5@   U:   )70, !%\)  !@#0  8!   &$4  !A&0
M8B   &(G  !B,0  8CL  &)'  !B50  8V0  &)V  !BBP  8J   &&V  !A
MSP  8.H  &#U %U(  !220  2D@  $-(   Z2@  ,DT  "I0   C4P  '%<
M !9:   170  #6    AC   #9@$  &<&  !H"P  :0X  &H1  !K%0  ;!L
M &TB  !M*@  ;30  &U   !M3@  ;5T  &UO  !MA   ;)H  &RP  !KR
M:^8  &KS %A-  !.30  2$P  #Y.   U40  +%0  "18   =7   %F   !!D
M   ,9P  !VL   %N    <    '(#  !R!P  <PL  '4.  !V$0  =Q8  '@<
M  !Y(P  >BT  'HY  !Z1P  >E8  'EH  !Z?   >90  'BJ  !XP0  =]\
M '?O %11  !,40  0E(  #A5   O60  )EX  !YB   69P  $&L   MO   %
M<P   '<   !Z    ?    'X   !_ @  @ 8  ($*  "##0  A!$  (85  "(
M'   B24  (HP  "*/@  B4T  (E?  ")<P  B(L  (BB  "'N0  A]$  (;H
M %)6  !'5P  /%H  #)?   H9   'VD  !9O   0=   "GD   )]    @0
M (4   "(    B@   (P   "-    CP   ) $  "2"   DPP  )40  "7%0
MF1T  )LG  ";-   FT0  )I6  "::@  F8(  )J:  "8L   F,<  )?> $M<
M  ! 8   -64  "MJ   A<0  %W<  !!]   )@P   8@   ",    D0   )4
M  "8    F@   )L   "=    GP   *    "B    I 4  *8*  "H#@  JA0
M *T=  "M*@  K3D  *U+  "M7P  K7<  *R0  "KIP  J[H  *O+ $5F   Y
M:P  +G$  "-X   9?P  $(8   F-    DP   )@   "=    H0   *4   "H
M    JP   *L   "N    KP   +$   "S    M0   +<!  "Y!P  O T  +\3
M  #"'P  PBX  ,)   #"5   P6L  ,&#  # FP  P:T  ,&\ #YR   R>
M)X   !R(   2D   "I<   "=    HP   *@   "M    L@   +8   "Y
MNP   +P   "^    P    ,(   #$    Q@   ,@   #+    S@4  -$-  #6
M%   UR,  -@U  #920  VEX  -MU  #;C   W)\  -RK /\   #_    _P
M /\ "0#_ !  _P 9 /X ) #\ "\ ^0 Y /0 0P#P $L [0!2 .H 60#G %\
MY !D .( :0#@ &X W@!S -P >0#: '\ UP"& -0 C@#1 )8 SP"A ,P K #*
M +L R #2 ,8 [@#& /\ Q0#_ ,4 _P"_ /\ N@#_ /\   #_    _P   /X
M!0#W  X \@ 5 .X 'P#K "H Z0 T ., /0#> $4 V0!- -0 4P#1 %D S@!>
M ,P 8P#* &@ R0!M ,< <P#% 'D PP"  ,$ B "_ )  O0"; +L I@"Y +0
MMP#( +8 Y@"U /L M #_ +0 _P"S /\ K@#_ /\   #_    ^    .T   #E
M  L W0 1 -< &@#2 "0 SP N ,L -P#' $  PP!' ,  3@"^ %, O !9 +H
M7@"X &, M@!H +4 ;0"S ', L0!Y *\ @0"M (H JP"4 *D H "H *T I@"^
M *4 VP"D /0 I #_ *, _P"C /\ H@#_ /\   #V    Y@   -<   #+  8
MQ  . +X %0"[ !\ N0 H +< ,0"T #H L !! *T 2 "K $X J0!3 *< 6 "F
M %P I !A *, 9P"A &P H !S )X >@"= (, FP". )D F0"7 *8 E@"V )4
MS "4 .L DP#] ), _P"3 /\ DP#_ /<   #D    T    ,$   "W  ( KP +
M *L $0"G !D I0 B *, *P"B #, GP [ )P 0@"; $@ F0!- )< 4@"6 %<
ME0!; ), 80"2 &8 D !M (\ = "- 'T C "' (H DP"( *  AP"O (4 P@"%
M .( A #W (0 _P"$ /\ A #_ .4   #-    O    *\   "F    G@ ' )H
M#@"6 !0 E  = )( )0"1 "T D  U (T / ", $( B@!' (@ 3 "' %$ A@!6
M (0 6P"# &  @0!G (  ;@!^ '< ?0"! 'L C0!Z )H > "I '< N@!V -,
M=@#O '8 _@!U /\ =0#_ -    "[    JP   )\   "7    D  " (L "P"(
M !  A@ 7 (0 ( "" "< @0 O '\ -0!] #P ? !! 'L 1@!Y $L > !0 '<
M50!V %L = !A ', :0!Q '$ < ![ &X AP!M )4 :P"C &H M !J ,D :0#H
M &D ^0!I /\ :0#_ ,    "L    G (  ) "  "(    @P   '\ !@![  T
M>0 2 '< &@!V "( =  I ', , !Q #8 <  \ &\ 00!M $8 ; !+ &L 4 !J
M %8 : !< &< 9 !E &P 9 !V &, @@!A )  8 "? %\ KP!> ,, 7@#A %X
M] != /\ 70#_ +0'  "@"0  D L  (0+  !\"@  =P<  '0$  !Q  D ;P /
M &T %0!K !P :0 C &@ *@!G #$ 90 V &0 / !C $$ 8@!& &  3 !? %(
M7@!8 %T 7P!; &@ 6@!R %@ ?@!7 (P 5@"; %4 JP!4 +X 5 #: %, [P!4
M /L 5 #_ *D-  "6#@  AQ   'H0  !R$   ; X  &D,  !G"0, 9@0+ &0
M$ !B !< 8  > %X )0!= "L 7  Q %H -P!9 #P 6 !" %<!1P!6 4X 50)4
M %,"7 !2 V4 40-O $\$>P!.!(H 3069 $P%J0!+!;P 2@;4 $H'[0!*!_D
M2@?_ *$0  ".$@  ?A0  ',4  !J%   9!,  & 1  !>#P  70T% %T)#0!:
M!A( 6 <9 %8'( !5!R< 4P<M %((,P!1"#@ 4 @^ $\)1 !."4H 3 E1 $L*
M60!*"F( 2 MM $<+>@!&#(@ 1 R8 $,,J0!"#;P 0@W5 $(-[@!"#?L 0@W_
M )H4  "'%@  >!@  &P9  !C&0  71@  %D6  !6$P  5!$  %0." !3#0X
M40T4 $\-&P!-#2( 3 TH $L-+@!*#30 20TZ $<.00!&#D< 10Y/ $0.5P!"
M#V$ 01!L #\0>0 ^$(@ /1&8 #L1J0 [$;P .A'6 #H1\  Z$OT .Q'_ ),8
M  "!&@  <QP  &<=  !>'0  6!P  %,;  !0&   3A8  $P3 P!,$0L 2A 0
M $@1%P!&$1X 11$D $01*@!"$3  01$W $ 2/0 _$D0 /1), #P35  [$UX
M.11I #@4=@ W%84 -A66 #06IP T%KH ,Q;3 #,6[@ T%OP -!;_ (X;  !\
M'0  ;A\  &,@  !:(   4R   $X>  !*'0  2!H  $88  !%%@< 0Q4. $$5
M$P _%1H /A4@ #T5)P [%2T .A8S #D6.@ X%D$ -Q=) #4740 T&%L ,QEF
M #(9<P P&H, +QJ4 "X;I0 M&[@ +1O0 "T;[  N&_L +AO_ (H>  !X(
M:B(  %\C  !6(P  3R(  $HA  !&(   0QX  $$;   _&@, /1H, #L9$0 Y
M&18 -QH= #8:(P U&BD -!HP #,;-@ Q&SX ,!Q& "\<3P N'5D +1UD "P>
M<0 K'X$ *A^2 "D?I  H(+< )R#. "<@ZP H(/H *1__ (8@  !T(P  9R0
M %PE  !3)0  3"4  $<D  !"(P  /R$  #T?   Z'@  -QX) #4>#@ S'A,
M,1X: # >(  O'B8 +A\M "T?,P L(#L *R!# "HA3  I(58 *")B "8B;P E
M(W\ )".0 ",CH@ B)+4 (B3, "(DZ0 C)/D )"/_ ((C  !Q)0  8R8  %DG
M  !0*   22<  $,G   _)@  .R0  #@B   U(@  ,B(& # B#0 N(A$ +"(7
M "HB'0 I(B, *",J "<C,0 F)#@ )25! "0E2@ C)E0 (B9@ "$G;0 @)WT
M'R>/ !XHH0 >*+0 '2C* !THZ  >*/@ 'R?_ 'XE  !N)P  8"D  %8I  !-
M*@  1BH  $$I   \*   -R<  #0F   P)@  +28# "LG"P H)Q  )R<4 "4G
M&@ D)R$ (R@G "(H+@ A*38 ("D^ !\J2  >*E( '2M> !PK:P ;*WL &BR-
M !DLGP 8++( &"S) !@LYP 9*_< &BO_ 'HG  !J*@  72L  %,L  !*+
M0RP  #XK   Y*P  -"H  # J   K*@  *2L  "8K"  C+ X (BP2 " L&  ?
M+!X 'BTE !TM+  <+3, &RX\ !HN10 9+U  &"]< !<O:0 6,'D %3"+ !0P
MG@ 4,+$ $S#' !,PY0 4,/8 %2__ '8J  !G+   6BT  % N  !(+@  02X
M #LN   V+0  ,2T  "PM   G+P  )"\  "$P!0 ?,0P '#$0 !LR%0 :,AP
M&3(B !@R*0 7,S$ %C,Y !4S0P 4-$T $S19 !(T9P 1-7< $36) ! UG  0
M-;  #C7&  \TY  0-/4 $#3_ '(L  !C+@  5S   $TP  !%,   /C   #@P
M   S,   +S   "DQ   D,@  (3,  !TU @ :-@D %S<. !4W$P 4.!D $S@?
M !(X)@ 2."X $3DV ! Y0  0.4L #CE7  XZ9  -.G0 ##J&  PZF0 +.:P
M"CG!  HYW@ +.?$ ##C\ &XO  !?,0  4S(  $HS  !",P  .S,  #8S   Q
M,@  +#,  "<T   A-@  '3@  !DY   5.P8 $CT, ! ^$  0/A4 #CX<  X^
M(P -/BH ##XS  P^/  +/T< "C]2  @_8  '/V\ !C^!  4_E  $/Z@  SZ\
M  0^UP %/NP !3[W &DS  !;-   4#4  $<U   _-0  .34  #0U   N-0
M*3<  ",X   >.P  &CP  !8_   2000 #D,*  Q$#@ *1!, "409  A$(  '
M1"< !D0O  5$.  #14(  D5.  !%6P  16H  $5\  !%D   1*0  $2Y  !$
MT0  1.H  $/U &0V  !7-P  3#@  $,X   \.   -S@  #$X   K.0  )3L
M " ]   :0   %D(  !)$   .1P0 "TD)  =*#0 $2Q$  4L6  !+'   2R,
M $LK  !+-   2SX  $Q)  !,5P  3&8  $QW  !+C   2Z$  $NU  !*S@
M2ND  $KU %\Z  !2.P  2#L  $ [   Z.P  -#L  "X\   G/@  (D$  !Q#
M   61@  $DD   Y+   +3@, !U (  )1#   41   %(3  !3&   4Q\  %,F
M  !3+P  4SD  %-%  !34@  4V$  %-R  !3AP  4IP  %*Q  !1R@  4><
M %'T %D^  !./@  13X  #X^   X/@  ,$   "E"   C1   '4<  !=*   2
M30  #E    M3   &50(  %<'  !8"P  60X  %H1  !:%0  6QH  %PA  !<
M*@  7#0  %P_  !<30  7%L  %QL  !<@0  6Y<  %NM  !:Q0  6N0  %GS
M %1"  !*0@  0D(  #Q"   T0P  +$8  "5)   >3   %T\  !)3   .5@
M"ED   5;    7@   & $  !A"   8@P  &,.  !D$0  918  &8<  !G(P
M9RT  &<Y  !G1@  9U4  &=F  !G>@  9I$  &6H  !EP   9-X  &3P $]&
M  !'1@  0$4  #='   O2@  )DT  !]1   850  $ED   U<   (8    F,
M  !F    :    &H   !K!   ; @  &T,  !O#@  <!(  '(7  !S'0  ="8
M '0R  !T/P  =$X  '-?  !T<@  <XH  '*A  !QN   <=0  '#L $Q*  !%
M2@  .TL  #).   I4@  (%8  !A;   27P  #60   =H    :P   &\   !R
M    =0   '8   !W    >0(  'H&  !\"@  ?@X  ( 1  ""%@  A!X  (0I
M  "$-@  A$4  (16  "#:@  @X$  (*9  "!L0  @,D  (#E $I.   _4
M-5,  "M7   B7   &6(  !)G   ,;   !7$   !U    >0   'T   "!
M@P   (4   "&    B    (D   "+!   C0@  (\-  "2$   E!8  )8@  "6
M+   ECL  )9,  "58   E78  )20  "3IP  DKT  )+5 $15   Y60  +UT
M "1C   ::0  $F\   QU   $>P   (    "%    B0   (T   "1    DP
M )0   "6    F    )H   "<    G@   * &  "B"P  I1   *@7  "I(P
MJ3$  *E#  "I5@  J&T  *:'  "GG@  IK,  *7' #Y>   R8P  )VH  !UP
M   3>   #'\   .%    BP   )$   "6    FP   )\   "B    I    *4
M  "G    J0   *L   "M    L    +(   "U @  MPD  +L0  "^&   OB8
M +XX  "^2P  O6$  +QZ  "[E   NJD  +JY #=J   K<   ('@  !:    -
MB   !8\   "6    G    *(   "G    K    +    "S    M@   +<   "Y
M    NP   +T   "_    P@   ,4   #(    R@   ,X(  #2$   U1L  -4L
M  #40   U%<  --N  #4A@  U)L  -.K /\   #_    _P   /\ !0#_  X
M_P 5 /P ( #Y "H ]@ T /$ /0#M $8 Z0!- .8 4P#D %D X0!> -X 8P#<
M &@ V0!N -4 <P#3 'D T "  ,X B #+ )$ R0"< ,8 IP#$ +< P@#, ,
M[ "_ /\ O@#_ +T _P"W /\ L@#_ /\   #_    _P   /H  0#S  L [0 2
M .@ &P#E "4 Y  N -\ . #8 $  T@!' ,X 3@#+ %0 R !9 ,8 7@#$ &,
MP@!G ,  ;0"_ ', O0!Z +L @0"Y (L M@"5 +0 H0"R *\ L #" *X XP"N
M /H K #_ *T _P"I /\ I@#_ /\   #_    \@   .8   #=  < T@ . ,T
M%@#* "  R  I ,4 ,@#  #H O !" +D 2 "W $X M0!3 +, 6 "Q %T L !B
M *X 9P"L &P J@!S *D >P"G (0 I0". *, F@"A *@ GP"Y )X T@"= /(
MG #_ )T _P"< /\ F0#_ /P   #N    W0   ,P   #!  ( N@ , +8 $@"R
M !H L  C *\ + "M #0 J0 \ *8 0@"D $@ H@!- *  4@"> %< G0!; )P
M8 ": &8 F0!L )< = "5 'T DP"' )$ DP"0 *$ C@"Q (T Q@", .@ BP#]
M (P _P", /\ C #_ .T   #8    Q0   +<   "L    I@ ( *$ #@"? !4
MG0 > )L )@": "X EP U )4 / "3 $( D0!' )  3 ". %$ C0!5 (L 6@"*
M &  B0!F (< ;0"% '8 A "  (( C "  )H ?P"I 'T O !\ -P ? #U 'P
M_P!\ /\ ? #_ -D   #!    L0   *0   "<    E  # )  # "- !$ BP 8
M (D ( ") "@ AP O (4 -@"# #P @@!! (  1@!_ $L ?0!/ 'P 5 ![ %H
M>0!@ '@ 9P!V '  =0!Z ', A@!Q ), < "B &\ M !N ,P ;@#M &X _@!N
M /\ ;@#_ ,0   "O    H    )0   ",    A@   ($ " !^  X ?  4 'L
M&P!Y "( >  I '< , !U #8 =  [ '( 0 !Q $4 < !* &\ 3P!M %0 ; !;
M &L 8@!I &H : !T &8 @ !E (X 8P"= &( K0!A ,( 80#D &$ ^ !A /\
M80#_ +0   "@    D0   (8   !^    >0   '4  P!Q  L ;P 0 &T %@!L
M !T :P D &L *@!I #  :  V &8 .P!E $  9 !% &, 2@!A $\ 8 !6 %\
M70!= &4 7 !O %H >@!9 (@ 6 "8 %< J !6 +L 5@#8 %8 \0!6 /\ 5@#_
M *@!  "4!0  A0<  'H'  !R!@  ; 0  &D!  !G  < 9  - &, $0!A !@
M8  ? %\ )0!> "L 70 P %L -@!: #L 60!  %@ 10!7 $L 5@!1 %4 6 !3
M &$ 4@!J %  =@!/ (0 3@"3 $T I !, +8 3 #- $P ZP!, /H 3 #_ )T)
M  "+"P  ? T  ' -  !H#0  8@P  %\*  !=!@$ 7 $) %H #@!8 !, 5P 9
M %8 ( !5 "8 4P K %( ,0!1 #8 4  [ $\ 00!. $< 30!- $L 50!* %T
M20!G $< <P!& (  10"0 $0 H0!# +( 0P#( $, Y@!# /4 0P#_ )4-  "#
M#P  =!   &D1  !@$0  6A   %8.  !4#0  4PH$ %,&"P!1 Q  3P$5 $X!
M&P!, 2$ 2P$G $H"+ !) C( 2 (W $<#/0!% T, 1 -* $,$40!"!%H 0 5D
M #\%<  ^!GX /0:. #P'GP [![$ .@?& #H'XP Z!_, .@C\ (X0  !\$@
M;A0  &(5  !:%0  5!0  % 3  !-$0  2PX  $L-!@!*"@P 20@1 $<(%@!%
M"!T 1 @C $((* !!"2X 0 DS #\).0 ^"D  /0I' #P*3P Z"U@ .0MC #@,
M;P V#'X -0R. #0-GP S#;$ ,@W' #(-XP R#?0 ,@W^ (@3  !W%0  :1<
M %X8  !5&   3Q@  $H6  !'%0  11,  $,0 @!##@@ 0@T. $ -$@ _#1@
M/0T? #P-)  [#2H .0TP #@.-P W#CT -@Y% #4.30 S#U< ,@]B #$0;@ O
M$'T +A". "T1H  L$;( *Q'( "L1Y@ K$?8 +!'_ (,6  !R&0  9!H  %D;
M  !1&P  2QL  $8:  !"&   /Q<  #X4   \$@0 .Q$* #H0$  X$!4 -Q ;
M #41(0 T$2< ,Q$M #(1,P P$3H +Q)" "X22P M$U0 *Q-? "H4;  I%'L
M*!2, "<5G@ F%;  )17& "45Y  E%?8 )A7_ 'X9  !N&P  8!T  %8>  !-
M'@  1QX  $(=   ^'   .AH  #@8   W%@  -14' #04#0 R%!( ,!07 "\4
M'0 M%", +!4J "L5,  J%3< *18_ "@62  G%U( )AA= "08:@ C&7D (AF*
M "$9G  @&:\ 'QG$ !\9X@ @&?0 (!G_ 'H;  !J'@  71\  %,@  !*(
M1"   #X?   Z'@  -QT  #0<   R&0  ,!D$ "X8"P L&!  *A@4 "D8&@ G
M&"  )ADF "49+0 D&C4 (QH] "(;1@ A&U  (!Q; !\=:  >'7< '1V( !P>
MFP ;'JT &A[# !H>X  :'?, &QW_ '<=  !G(   6B$  % B  !((@  02(
M #LB   W(0  ,R   # ?   M'0  *QT  "@="  F'0X )1T2 ",=%P A'1T
M(1TD " >*@ ?'C( 'A\Z !T?0P <($T &R%9 !HA9@ 9(74 &"*' !<BF0 6
M(JP %2+! !4BWP 5(?( %B'^ ',@  !D(@  5R,  $TD  !%)0  /B0  #DD
M   T(P  ,"(  "PB   I(0  )B$  "0A!@ B(0P ("$0 !XA%0 =(AL &R(A
M !LB*  :(R\ &2,X !@D00 7)$L %B57 !4E9  4)G, $R:% !(FF  1)JL
M$2;  ! FW0 1)?$ $B7] ' B  !A)   5"8  $HF  !")P  /"8  #8F   Q
M)0  +24  "DD   F)   (B4  !\E P =)@H &R8. !DG$@ 8)Q@ %R<? !8G
M)0 5*"T %"@U !,I/@ 2*4D $2E5 !$J8@ 0*G$ #RJ#  XJE@ .*JD #2J]
M  TJUP -*NX #BG[ &PD  !=)@  42@  $@H  ! *0  .2@  #0H   O*
M*R<  "<G   B*   'BD  !LJ   8*P< %BL- !0L$0 3+!8 $BP< !$M(P 0
M+2H $"TR  \N/  .+D8 #2Y2  TN7P ,+VX "R]_  HOD@ )+Z4 "2ZY  @N
MT  )+ND "B[W &@G  !:*0  3BH  $4K   ]*P  -RL  #$J   M*@  *2H
M "0J   @*P  &RT  !@N   5+P0 $C$* ! R#@ /,A, #C(9  TR(  -,B<
M##(O  LS.  *,T( "3-.  @S6P &-&H !31[  0SC@ #,Z(  C.V  (SS0 #
M,^< !#+S &0J  !6+   2RT  $(M   Z+0  -"T  "\L   K+   )BP  "(M
M   =+P  &3$  !4R   2- , #S8)  PX#0 *.!$ "3@6  @X'0 '."0 !C@L
M  0X-  #.#X  CE*   Y5P  .64  #EW   YBP  .)\  #BS   XR@  ..8
M #?R %\M  !2+@  2"\  #\P   X+P  ,B\  "TO   I+P  )#   !\Q   :
M,P  %34  !(W   /.0, ##L(  @]#0 %/A   SX4   ^&@  /B$  #XH   ^
M,0  /SL  #]&   _4P  /V$  #]S   _AP  /IP  #ZP   ]QP  />0  #WR
M %HP  !.,@  1#(  #PR   U,@  ,#$  "LQ   F,@  (#0  !LV   6.
M$CL   \]   ,/P, "$$(  1##   0PX  $02  !%%@  11T  $4D  !%+0
M1C8  $9"  !&3@  1ET  $9N  !%@@  19@  $2M  !$Q   0^,  $/R %4T
M  !*-0  034  #DU   S-   +C0  "@U   B-P  '3H  !<\   2/P  #T$
M  Q$   (1@$  T@&  !)"@  2@T  $L0  !,%   31D  $X@  !.*   3C(
M $T]  !.2@  3E@  $UI  !-?0  3)0  $RJ  !+P0  2^$  $KR % X  !&
M.   /3@  #<X   Q-P  *CD  "0[   >/0  &$   !-#   /1@  "TD   =+
M   "3@   % $  !1"   4@L  %,.  !4$0  514  %8;  !7(P  5RP  %<X
M  !71   5U(  %9C  !6=P  5HX  %6E  !4O0  4]T  %/P $L\  !"/
M.SL  #4[   M/   )C\  !]"   910  $T@   Y+   +3P  !5$   !4
M5P   %@!  !:!0  6P@  %P,  !=#@  7Q$  & 6  !B'0  8B8  &(Q  !B
M/@  84P  &%=  !A<   8(@  &"@  !?MP  7M0  %WN $=    _/P  .C\
M #%    I0P  (48  !I*   33@  #E$   I5   $6    %L   !>    80
M &,   !D 0  900  &<(  !H"P  :@X  &P2  !N%P  ;R   &\J  !O-@
M;D4  &Y5  !N:   ;7\  &V8  !LL   :\H  &KH $1$   ^0P  -40  "M'
M   C2P  &T\  !-4   .6   "%P   )@    9    &<   !K    ;0   &\
M  !P    <@   '0"  !U!@  =PH  'D.  !\$@  ?A@  '\B  !_+@  ?ST
M 'Y-  !]80  ?7<  'R0  ![J   >L   'G? $-'   Y20  +TP  "50   <
M50  %%L   Y@   '90   &H   !N    <@   '8   !Y    ?    'X   !_
M    @0   (,   "%    AP,  (H(  ",#0  CQ$  )(9  "2)0  DC,  ))$
M  "15P  D&T  (^&  ".GP  C;4  (S- #U.   R40  *%8  !Y<   58@
M#F@   =N    =    'D   !^    @@   (8   ")    C    (X   "0
MD@   )0   "6    F    )L   ">!@  H0P  *01  "F&P  IBD  *8Z  "E
M30  I6(  *1[  "CE   H:L  *&_ #97   L7   (6(  !=I   /<   !W<
M  !^    A    (H   "/    E    )@   ";    G@   )\   "B    I
M *8   "H    JP   *T   "P    LP0  +<,  "[$@  NQ\  +LP  "[0P
MNE@  +EP  "WBP  MZ$  +>S #!B   E:0  &G   !!X   )@    (@   "/
M    E@   )L   "A    I@   *H   "N    L    +$   "T    M@   +@
M  "[    O0   ,    ##    QP   ,L#  #/#   TQ4  -(E  #2.   T4X
M -!E  #/?@  S98  ,RI /\   #_    _P   /\  P#_  L _  1 /D &P#W
M "4 \P O .X . #I $  Y@!( .( 3@#? %0 W !9 -D 7@#5 &, TP!H -
M;0#. ', RP!Z ,@ @@#& (P PP"7 ,  HP"^ +( O #( +H Z@"Y /\ N #_
M +$ _P"J /\ IP#_ /\   #_    ^P   /8   #M  < YP / .( %@#? "
MW@ I -D ,P#1 #L S !" ,@ 2 #% $X P@!3 ,  6 "^ %T O !B +H 9P"Y
M &T MP!T +4 >P"R (4 L "0 *X G "L *H J0"] *< W@"F /D I0#_ *,
M_P"= /\ FP#_ /T   #V    ZP   -\   #1  , R@ , ,4 $@## !L P  D
M +X + "Y #4 M@ \ +, 0P"P $@ K@!. *P 4@"K %< J0!< *< 80"F &<
MI !M *( = "@ 'T G@"( )P E0": *, F "T )8 S0"5 /$ E #_ )4 _P"0
M /\ C@#_ /,   #F    T0   ,(   "X    L0 ( *T #P"J !8 J  > *@
M)P"F "\ H@ V )\ / "= $( FP!' )D 3 "7 %$ E@!5 )0 6@"3 &  D0!F
M )  ;@". '8 C "! (H C0"( )L A@"L (4 P0"$ .8 @P#] (0 _P"# /\
M@0#_ .0   #+    N@   *P   "B    G  $ )@ # "6 !$ E  9 ), (0"2
M "@ CP P (T -@"+ #P B0!! (@ 1@"& $L A0!/ (0 5 "" %H @0!@ '\
M9P!^ &\ ? !Z 'H A@!X )0 =P"D '4 MP!T -0 <P#T '0 _P!T /\ = #_
M ,L   "V    I@   )H   "2    B@   (8 " "#  X @0 4 ($ &P"  ",
M?P J 'T , ![ #8 >@ [ '@ 0 !W $4 =0!) '0 3@!S %0 <0!: '  80!N
M &D ;0!S &L ?P!I (T : "= &< K@!F ,< 90#J &8 _P!F /\ 9P#_ +@
M  "D    E0   (H   "!    ?    '8 ! !T  P <@ 0 '$ %@!P !T <  D
M &X *@!M #  :P U &H .@!I #\ : !$ &< 20!E $X 9 !4 &, 6P!A &,
M8 !M %X >0!= (< 6P"6 %H J !9 +T 60#? %D ^ !: /\ 6@#_ *@   "5
M    AP   'L   !S    ;@   &H  0!G  @ 90 . &0 $@!C !@ 8P ? &(
M)0!A "H 7P P %X -0!= #H 7  ^ %L 1 !9 $D 6 !/ %< 5@!6 %X 5 !H
M %, <P!1 ($ 4 "1 $\ H@!. +4 3@#0 $X \ !. /\ 3P#_ )P   ")
M>P,  ' #  !H P  8@$  %\   !=  0 6P + %D #P!8 !0 5P 9 %< ( !6
M "4 50 J %, , !2 #0 40 Y %  /P!/ $0 3@!+ $T 4@!+ %H 2@!C $D
M;P!' 'P 1@", $4 G0!% +  1 #' $0 Z !$ /H 10#_ )($  " !P  <0H
M &8*  !>"@  60D  %4'  !4!   4@ ' %  # !/ !  3@ 5 $T &P!, "
M2P F $H *P!) #  2  U $< .@!& $  10!& $, 3@!" %8 00!? $  :P ^
M '@ /0"( #P F0 \ *L / #! #L X  [ /0 .P#_ (D*  !X#   :@X  %\.
M  !7#@  40X  $T,  !+"P  2@@" $D$"0!(  T 1@ 1 $4 %@!$ !P 0P A
M $( )@!! "L /P Q #X -@ ] #P / !# #L 2@ Z %( .0!< #@ :  V '4
M-0"% #0 E@ T *@ ,P"\ #, V  S .\ ,P#[ ((-  !Q#P  9!   %D1  !1
M$0  2Q$  $<0  !$#@  0@T  $$+!0!!!PL /P4. #X#$@ \ A@ .P(= #H#
M(@ Y R@ . ,M #<#,@ V!#D -00_ #0%1P S!5  ,09: # &9@ O!W, +@>#
M "T'E0 L!Z< *P>Z "L'T@ K!^L *P?W 'T0  !L$0  7Q,  %04  !,%
M1A0  $(3   ^$@  /!   #H. 0 Z#08 .@H, #@)$  V"!0 -0@9 #0)'P R
M"20 ,0DI # )+P O"C8 +@H] "T*10 L"TX *PM9 "D,90 H#', )PR# "8-
ME0 E#:< ) V[ ",-T@ C#>L (PWW '@2  !H%   6Q8  %$7  !(%P  0A8
M #T6   Y%0  -Q,  #41   S$ , ,PX( #(-#0 P#1$ +PT6 "T-&P L#2$
M*PTG "H-+0 I#C0 * X[ "<.1  E#DX ) ]9 ",090 A$', (!"$ !\0E@ >
M$*D '1"] !P0V  =$.X '1#Y ',4  !D%@  5Q@  $T9  !%&0  /QD  #H8
M   U%P  ,A8  # 5   N$P  +1$$ "P0"@ K$ X *1 2 "@0&  F$!X )1 D
M "00*@ C$3$ (A$Y "$10@ @$DL 'A)6 !T38P <$W$ &A." !D4E0 8%*<
M%Q2[ !<3U  7$^X &!/Z ' 6  !@&0  5!H  $H;  !"'   /!L  #8;   R
M&@  +QD  "P8   J%@  *!0! "83!P E$PP (Q,0 "(3%0 @$QH 'Q,A !X4
M)P =%"X '!4V !L5/P :%DD &194 !@780 6%W  %1B! !08DP 3&*8 $ABZ
M !(7T@ 2%^P $Q?Z &P9  !=&P  41T  $<=   _'@  .1T  #0=   O'
M*QL  "@:   F&0  )!@  "(7!  @%PH 'A<. !P7$@ :%Q< &1@> !D8)  8
M&2P %QDT !8:/0 5&D< %!M2 !,;7P 2'&X $1Q_ ! <D@ 0'*4 #QRY  X<
MT  .&^H #QOX &D;  !:'0  3A\  $4?   ](   -A\  #$?   M'@  *1T
M "4=   C'   (!L  !T; 0 ;&P< &1P- !<<$  6'!4 %1P; !0=(@ 3'2D
M$AXQ !$>.@ 1'T4 $!]0  \@70 .(&P #2!\  T@CP ,(*( "R"U  L@R@ +
M(.4 #!_T &4=  !7'P  3"$  $(A   Z(0  -"$  "\A   J(   )A\  ",?
M   @'@  '1X  !D@   6( 0 %" + !(A#@ 1(1, $2(9 ! B'P /(B8 #B,O
M  XC-P -(T$ #"1-  LD60 *)&< "21X  @DBP '))X !R2Q  8DQP &(^,
M!R/Q &(?  !4(0  22,  $ C   X(P  ,B,  "PC   H(@  )"$  "$A   >
M(0  &B$  !8C   3) , $24(  \F#0 .)Q$ #2<6  PG'0 +)R, "B<K  DH
M-  (*#X !RA)  8H50 %*60 !"ET  ,IAP "*9L  2BO   HQ0 !*.$  2?P
M %XB  !1)   1B4  #TE   U)0  +R4  "HD   F)   (B,  !\C   ;)
M&"4  !0F   1* , #RD(  PL#  *+!  ""P4  <L&@ &+"$ !2PH  ,M,  "
M+3H  2U%   M4@  +F   "YQ   MA   +9D  "VM   LP@  +.   "SP %HD
M  !-)@  0R<  #HG   S)P  +2<  "@F   D)@  (28  !TF   9)P  %2D
M !$K   /+ , #2X'  DP#  &,0X  S$2  $R%P  ,AX  #(E   R+0  ,C8
M #-"   S3@  ,UT  #-M   S@0  ,I8  #*K   QP0  ,=\  #'P %8G  !*
M*0  /RH  #<J   P*@  *RD  "<H   C*   'BD  !HJ   6+   $BX   \P
M   -,0( "C0'  4U"P "-@X  #<0   X%   .!H  #@B   X*@  .3,  #D^
M   Y2@  .5D  #EI   Y?0  .),  #BH   WOP  -]X  #;P %$K  !&+
M/"P  #0L   N+   *BL  "4K   @+   &RT  !<O   3,0  $#,   TU   )
M-P( !3H&  $["@  / T  #T/   ^$@  /Q<  $ >  ! )0  0"\  $ Z  !
M1@  0%0  $!E   _>   /X\  #ZF   ^O0  /=P  #WP $TN  !"+P  .2\
M #(O   M+@  *"X  "(O   =,   &#(  !,U   0-P  ##H   D\   %/@
M $$$  !""   0PL  $0-  !&$   1Q0  $@9  !((0  2"H  $@U  !(00
M2$\  $A@  !'<P  1XH  $:B  !%N0  1=D  $3P $@R   ^,@  -C(  # Q
M   K,0  )3(  !\T   9-@  $SD  ! \   ,/P  "$(   -$    1@   $@"
M  !*!0  2P@  $P+  !.#@  3Q$  %$5  !2'   4B4  %(P  !2/   44H
M %%:  !1;0  4(0  $^=  !.M0  3=(  $WN $,V   [-@  -#4  "\T   G
M-0  (3@  !H[   4/@  $$$   Q$   '1P   DH   !-    3P   %$   !3
M @  5 4  %4(  !7"P  60X  %L1  !=%P  71\  %TJ  !=-@  7$0  %Q4
M  !;9P  6WX  %J7  !9KP  6,L  %?J #\Y   X.0  ,S@  "LY   C/
M'#\  !5#   01P  "TH   5.    40   %0   !7    6@   %P   !=
M7P   & $  !B!P  9 L  &8.  !H$@  :QD  &LC  !J+@  :CP  &I-  !I
M7P  :'4  &>/  !FJ   9<(  &3C #T]   W/   +CT  "5    =1   %DD
M !!-   *40  !%4   !:    70   &    !C    9@   &@   !J    :P
M &T   !O @  <08  '0*  !V#@  >1,  'L;  ![)P  >C4  'E%  !X60
M>&T  '>&  !VGP  =;<  '32 #Q!   R0@  *$4  "!*   73@  $%0   I9
M   "7@   &,   !G    :P   &\   !R    =0   '<   !Y    >P   'T
M  !_    @@   (0#  "'"0  B@X  (X3  "/'@  CBL  (X[  "-3@  BV,
M (I\  "*E0  B*T  (?% #9'   L2P  (D\  !E5   06P  "F$   %G
M;0   '(   !W    >P   '\   "#    A@   (@   "*    C0   (\   "1
M    E    )<   ": 0  G0<  *$-  "E%   I"$  *0Q  "C1   HED  *!P
M  "?BP  G:(  )VW #!0   E50  &UL  !)B   +:0   7    !W    ?0
M (,   "(    C0   )$   "5    F    )H   "<    GP   *$   "C
MI@   *D   "L    L    +0'  "X#@  NA@  +HG  "Y.0  N$X  +=E  "V
M?@  M98  +.K "E;   >8@  %&D   QQ   ">0   ($   ")    CP   )8
M  ";    H    *0   "H    JP   *P   "O    L@   +0   "V    N0
M +P   #     Q    ,@   #-!P  TA   -(=  #1+P  T$0  ,];  #-<P
MRXT  ,JA /\   #_    ^P   /H   #\  @ ^  / /4 %P#T "  \0 J .L
M,P#F #L X@!# -X 20#: $\ U@!4 -, 60#0 %X S@!C ,L : #) &X Q@!U
M ,, ?0#! (8 O@"2 +L G@"Y *X M@## +0 Z "S /\ KP#_ *4 _P"> /\
MFP#_ /T   #W    \@   /    #G  , X0 , -P $@#8 !L U@ D -( +0#,
M #8 Q@ ] ,( 0P"_ $D O !. +H 4P"X %@ M@!= +4 8@"S &< L0!N *\
M=@"L '\ J@"* *@ EP"E *8 HP"Y *$ V0"@ /D G@#_ )@ _P"2 /\ CP#_
M /,   #L    XP   -,   #(    P0 ) +T #P"[ !8 N0 ? +< )P"S "\
MKP W *P /0"J $, J !( *8 30"D %( HP!6 *$ 6P"? &$ G@!G )P ;P":
M '@ EP"# )4 D "3 )X D0"P )  R ". /  C0#_ (H _P"% /\ @@#_ .<
M  #=    Q@   +@   "N    J  $ *4 # "A !( H0 9 *  (@"? "D FP P
M )@ -P"6 #T DP!" )( 1P"0 $L CP!0 (T 50", %H B@!A (@ : "' '
MA0![ (, B "! )8 ?P"G 'T O !\ ., ? #] 'P _P!X /\ =@#_ -8   #
M    KP   *,   "9    DP   (\ "0"-  X BP 4 (H ' "* ", B  J (4
M, "# #8 @@ [ (  0 !_ $4 ?@!* 'P 3P![ %0 >@!: '@ 80!V &D =0!S
M ', @ !Q (X ;P"? &X L@!M ,\ ; #T &P _P!K /\ :0#_ ,    "K
MFP   (\   "'    @    'P ! !Z  P >  1 '@ %P!X !X =P D '4 *@!S
M #  <0 U '  .@!N #\ ;0!$ &P 20!K $X :@!4 &@ 6P!G &, 90!M &0
M> !B (< 8 "7 %\ J@!> ,( 7@#I %X _P!> /\ 70#_ *P   "9    B@
M '\   !W    <0   &T   !J  @ :0 . &@ $@!G !@ 9P ? &< )0!E "H
M8P O &( - !A #D 8  ^ %\ 0P!> $@ 70!. %L 50!: %T 6 !G %< <@!5
M ($ 5 "1 %, HP!2 +@ 40#< %$ ^0!2 /\ 4@#_ )T   "+    ?    '$
M  !I    9    &    !>  4 7  + %L #P!; !0 6@ 9 %H 'P!9 "4 5P J
M %8 +P!5 #0 5  X %, /0!2 $, 4 !) $\ 4 !. %@ 30!B $L ;0!* 'H
M20"+ $@ G0!' +$ 1P#, $8 \ !' /\ 1P#_ )    !^    <    &8   !>
M    60   %8   !3  $ 4@ ( %  #0!/ !  3P 5 $X &@!. "  30 E $P
M*@!* "X 20 S $@ . !' #X 1@!$ $4 2P!$ %, 0P!= $$ : !  '4 /P"%
M #X EP ] *L /0## #T Y@ ] /L /@#_ (<   !U P  : 8  %T'  !5!@
M4 8  $P$  !* 0  20 $ $< "@!&  X 10 1 $4 %@!$ !L 0P @ $( )0!!
M "H 0  O #\ -  ^ #H /0!  #L 1P Z $\ .0!9 #@ 9  W '$ -@"! #4
MDP T *8 - "[ #0 W0 T /4 -0#_ 'X&  !M"0  8 L  %8,  !.#   2 L
M $0*  !""   0 4! #\!!P ^  L /0 . #P $@ [ !< .P < #H (0 Y "4
M-P J #8 ,  U #4 -  \ #, 0P R $P ,0!5 #  8  O &T +@!] "T CP L
M *( + "V "P T  L .X + #\ '<*  !G#   6@X  % .  !)#@  0PX  #X-
M   [#   .0L  #@) P W!0@ -@(- #4!$  T !, ,P 8 #( '0 Q "( ,  G
M "\ +  N #( +0 X "P 0  K $D *@!2 "D 70 H &L )P%Z "8!C  E )\
M)0"R "4 R@ E .@ )0#W '(-  !B#@  5A   $P1  !$$0  /A$  #D0   V
M#P  ,PX  #$- 0 P"P4 , @* "\&#0 N!1$ + 04 "L#&0 J QX *0,C "@$
M*0 G!"\ )@4U "4%/0 D!48 (P90 "(&7  A!VD ( =Y !\'BP >!YT '@>P
M !T&Q@ =!N, '07S &T.  !>$0  4A(  $@3  ! $P  .A,  #42   Q$0
M+A   "P/   J#@, *@T' "D+"P H"0X )PD1 "4(%@ D"!L (PD@ "())@ A
M"2P ( HS !\*.P >"T0 '0M/ !P,6P ;#&D &@QY !@,BP 8#)X %PRP !8,
MQ0 6#.$ %@OP &D0  !:$@  3A0  $45   ]%0  -Q4  #$4   M$P  *A(
M "@1   F$ $ )! $ ",."  C#0P (@P/ " ,$P ?#!@ '@T= !T-(P <#2H
M&PTR !H..@ 8#D0 %PY0 !8/7  5#VH $Q![ !(0C0 1$*  $1"S ! /R0 0
M#^0 $0_R &42  !7%   2Q8  $(7   Z%P  -!<  "\6   J%0  )Q0  "03
M   B$P  (!(# !X1!@ =$ D '! - !L/$  9$!4 &! ; !<0(0 6$"@ %1$P
M !01.0 3$4, $A). !$26@ 0$FD $!-Y  X3C  .$YX #1.Q  T2Q0 ,$N$
M#1+Q &(4  !4%@  21@  #\9   W&0  ,1D  "P8   H%P  )!8  "$6   ?
M%0  '!0" !H3!  9$@8 %Q(+ !42#@ 4$A( $Q,8 !(3'P 1$R8 $10M ! 4
M-@ /%4$ #A5,  X65P -%F4 #!=U  L7AP *%YH "1:M  @6P0 (%MT "17N
M %\6  !1&   1AH  #T:   U&P  +QH  "H:   E&0  (A@  !\8   <%P
M&18! !<6 P 5%@0 $Q8) !$6#0 0%Q$ #Q<6  X7'  .&", #1@J  P9,P ,
M&3P "QI'  H:4P )&F$ !QMQ  8;@P %&Y< !!JJ  ,:OP #&=H !!GL %P8
M  !.&@  0QP  #H<   S'   +!P  "<<   C&P  (!H  !T9   :&0  %Q@!
M !48 @ 2&00 $!L'  X;#  -'!  #!P3  L<&0 *'!\ "1TG  @=+P ''CD
M!AY#  0>4  #'UX  A]N  $?@   'Y4  !ZI   >O0  '=@  !WL %@:  !+
M'   01X  #@>   P'@  *AX  "4=   A'   'AP  !L;   8&P  %AL! !,;
M @ 1' 0 #AX'  P?"P *( X "" 2  8A%P %(1T !"$D  (B+  !(C4  ")
M   C30  (UH  "-K   C?@  (Y,  "*G   BO   (=<  "'M %4=  !('P
M/B   #4@   N(   *"   ",?   @'@  '1T  !H=   6'0  $QX  !$? @ .
M( 0 #2('  HD"P &)0T !"40  (F%   )AH  "8A   G*0  )S(  "<]   G
M20  *%<  "AG   G>P  )Y   ">E   FNP  )M8  "7M %$@  !%(0  .R(
M #(B   L(@  )B$  "(A   >(   &Q\  !@@   4(   $2(   \C   -)0,
M"B8&  8H"@ #*0T  "L/   L$@  +!<  "P>   L)@  +2\  "TY   M1@
M+50  "UD   M=P  +(T  "RD   KN@  *]8  "KN $TB  !!)   ."0  # D
M   I)   )",  "$B   =(@  &2(  !4C   2)   #R8   TH   **@( !BP%
M  (N"0  +PL  # .   R$   ,Q4  #,;   S(@  ,RL  #,V   S0@  ,U
M #-@   S<P  ,HH  #*A   QN   ,-8  ##O $DE   ^)@  -"<  "TG   H
M)@  (R4  !\D   ;)0  %B8  !(H   0*@  #2P   HN   &, $  C($   T
M!P  -0H  #<,   X#@  .A(  #H7   Z'P  .B<  #HR   Z/@  .DP  #I<
M   Z;P  .88  #B>   XM@  -]0  #;O $0I   Z*0  ,2D  "LI   F*
M(B<  !TH   8*0  $RL  ! N   -,   "3(   4U   !-P   #D"   [!0
M/ @  #X+   _#0  01   $,4  !#&P  0R,  $,N  !#.0  0T<  $)7  !"
M:@  08$  $":   _L@  /L\  #[O #\L   V+   +RP  "HK   E*@  'RL
M !DM   4+P  $#(   TU   (.   !#H    \    /P   $$   !# @  104
M $8(  !("P  2@X  $P1  !-%@  31X  $TH  !--   3$(  $Q1  !+9
M2WL  $J4  !)K0  2,H  $?L #LP   S+P  +2\  "@M   B+P  &S$  !4T
M   0-P  #3H   @]   "0    $,   !&    2    $H   !,    3@$  $\$
M  !1!P  4PL  %4.  !8$@  61D  %@B  !8+@  5SP  %=+  !67@  5G,
M %6-  !4IP  4L(  %+F #@S   Q,@  +#$  "4R   =-0  %C@  !$\   ,
M0   !T0   !'    2@   $T   !0    4P   %4   !7    60   %H   !<
M P  7@<  &$+  !D#@  9A,  &<<  !F)P  9C0  &5$  !D5P  9&L  &*%
M  !AGP  8+D  %[< #4W   P-0  *#<  " Z   8/0  $4(   Q&   &2@
M $\   !3    5@   %D   !<    7P   &$   !D    90   &<   !I
M; $  &X&  !Q"P  = \  '<5  !W(   =BT  '8]  !U3P  =&,  '-[  !R
ME0  <*\  &_) #4Z   K.P  (C\  !I#   22   #$T   52    5P   %P
M  !@    9    &@   !K    ;@   '$   !S    =0   '<   !Z    ?
M '\   ""!   A@H  (H/  ",%P  BR0  (HS  ")10  AUL  (9R  "%BP
M@Z4  (*\ "]    E1   '$D  !-.   -5   !%H   !A    9@   &L   !O
M    =    'D   !]    @    (,   "%    AP   (H   ",    CP   )(
M  "6    F0(  )X)  "B$   HAH  *$I  "@.P  GU   )UG  ":@0  FID
M )FO "E)   ?3@  %50   Y;   %8@   &D   !P    =P   'T   ""
MA@   (L   "/    DP   )4   "7    F@   )T   "@    HP   *8   "J
M    K@   +(   "W"@  NQ$  +H?  "Y,   MT4  +5<  "T=   L8X  *^D
M ")4   86P  $&(   =J    <P   'L   ""    B0   )    "5    F@
M )\   "C    I@   *@   "K    K@   +    "S    M@   +H   "]
MP@   ,<   #, 0  TPL  -05  #3)@  T3H  -!1  #-:   RX$  ,J6 /P
M  #V    \@   /$   #S  4 ]  , /( $P#P !P [0 E .@ +@#B #8 W@ ^
M -D 1 #4 $H T0!/ ,X 5 #+ %D R0!> ,8 8P#$ &D P0!P +X > "\ ($
MN0"- +8 F@"S *L L0#  *\ Y@"N /\ I0#_ )H _P"4 /\ CP#_ /0   #L
M    Z    .<   #?    V0 ) -( $ #/ !< SP @ ,P * #& #  P  W +P
M/@"Y $0 MP!) +4 3@"S %, L0!7 *\ 70"M &( JP!I *D <0"G 'H I0"%
M *( DP"@ *( G0"V )L U "9 /D E@#_ (T _P"( /\ A #_ .@   #?
MV0   ,D   "_    N  $ +4 #0"S !( L0 : +  (@"M "H J0 Q *8 . "D
M #T H@!# *  2 "> $P G !1 )L 5@"9 %P EP!B )4 :0"3 '( D0!] (\
MBP"- )H BP"L (D Q0"( .X A@#_ '\ _P!Z /\ > #_ -D   #_XGT024-#
M7U!23T9)3$4 "!+-    NP   *X   "E    GP   )P "0"9  \ F0 5 )D
M'0"8 "0 E  K )$ ,0". #< C  \ (L 00") $8 B !+ (8 4 "% %4 @P!;
M (( 8@"  &L ?@!U 'P @@!Z )( > "C '< N0!V .  =0#_ '( _P!N /\
M; #_ ,<   "U    I0   )D   "/    B0   (4 ! "$  P @@ 1 (( %P""
M !X @  E 'X *P!\ #$ >@ V 'D .P!W $  =@!$ '4 20!S $\ <@!5 '
M7 !O &0 ;0!N &P >@!J (H : "; &< KP!F ,P 90#U &0 _P!A /\ 8 #_
M +0   "@    D    (4   !]    =P   ',   !P  @ ;P . &\ $@!O !@
M;P ? &T )0!K "H :0 P &@ - !G #D 9@ ^ &4 0P!C $@ 8@!. &$ 50!?
M %X 7@!G %P <P!; (( 60"3 %@ I@!7 +\ 5P#J %< _P!6 /\ 5 #_ *$
M  ".    ?P   '4   !L    :    &0   !A  0 8  + %\ #P!? !, 7P 9
M %\ 'P!= "4 7  J %L +P!9 #, 6  X %< /0!6 $, 50!) %, 4 !2 %@
M40!A %  ;0!. 'L 30", $P GP!+ +4 2@#< $H ^@!* /\ 2@#_ )(   "
M    <@   &<   !?    6@   %<   !5  $ 4P ' %( # !2 !  4@ 4 %(
M&@!1 !\ 3P D $X *0!- "X 3  S $L . !* #T 20!# $@ 2@!& %( 10!<
M $0 9P!# '4 0@"& $$ F !  *X 0 #+ #\ \@!  /\ 0 #_ (4   !T
M9P   %T   !5    3P   $P   !*    2  $ $< "@!'  T 1@ 1 $8 %0!&
M !H 10 ? $0 ) !# "D 0@ M $$ ,P _ #@ /@ ^ #T 10 \ $X .P!7 #H
M8@ Y &\ . "  #< DP V *< -@#  #8 Z  V /X -@#_ 'P   !K    7@(
M %0#  !- P  1P,  $,!  !!    /P ! #X !P ]  L /0 . #P $0 \ !8
M/  : #H 'P Y "0 .  I #< +@ V #, -0 Z #0 00 S $D ,@!3 #$ 7@ P
M &L +P![ "X C@ M *( +0"X "T W0 M /@ +@#_ ',!  !D!0  5P<  $T(
M  !&"   0 @  #L'   X!0  -P,  #8 !  U  @ -  , #0 #P T !( ,P 6
M #( &P Q "  ,  D "\ *0 N "\ +0 V "P /0 K $4 *@!/ "D 6@ H &<
M)P!W "8 B0 F )T )0"S "4 SP E /  )@#_ &T&  !>"0  4@L  $@,  !
M#   .@L  #8+   R"@  , @  "X& @ N P8 +0 * "P #0 L !  *P 3 "H
M%P I !P *  @ "< )0 F "L )0 R "0 .0 C $( (@!+ "( 5P A &0 ( !S
M !\ A0 ? )D '@"N !X QP > .D 'P#Z &@)  !9#   30T  $,.   \#@
M-@X  #$-   M#0  *@P  "@+   G"00 )@8( "8$"P E PX ) $0 "0!%  B
M 1@ (0$= "$ (@ @ "@ 'P N !X!-@ = 3\ ' %) !L!5  : 6$ &@%P !D!
M@@ 8 )8 & "J !@ P0 8 .$ & #T &,,  !5#@  20\  $ 0   X$   ,A
M "T/   I#@  )@X  ",-   B# , ( L& " )"0 ?!PP '@8. !X%$0 <!14
M&P4: !H%'P :!24 &04K !@%,P 7!CP %@9& !8&4@ 5!U\ % =N !,'@  2
M!Y0 $@:G !(%O  2!-D $@/O %\.  !1#P  1A   #P1   U$0  +Q$  "H1
M   F$   (A   " /   =#@( ' T% !H-!P :"PH &0H- !@)$  7"1( %@D7
M !4)'  4"2( % HI !,*,0 2"CH $@M% !$+40 0#%\ #PQN  X,@  .#)0
M#0NG  T+N@ -"M( #0KJ %P/  !.$0  0Q(  #H3   R$P  +!,  "<2   C
M$0  'Q$  !P0   :$ ( & \$ !8.!P 5#@D % T+ !,,#0 2#!  $@P4 !$,
M&@ 1#2  $ TH  \-,  .#CL #0Y&  T.40 ,#UX "P]M  H/?P )#Y, "0^F
M  @.N0 (#M  !P[H %@1  !+$@  0!,  #<4   P%   *10  "44   A$P
M'1(  !H2   7$0( %1$% !,0!P 2$ D $0\* ! .#  .#@X #@\2  T0&  -
M$!X #! E  P0+0 +$38 "A%!  D130 ($EH !Q)J  82?  %$I  !!*D  ,1
MN  #$<\  A'H %42  !)%   /A4  #46   M%@  )Q8  "(5   >%   &Q0
M !@3   5$@, $Q(% !(1!P 0$0D #Q$*  T1"P ,$@X "Q(1  H2%0 )$QL
M"1,B  @3*@ '%#, !10^  052@ #%5@  A5G  $5>@  %8X  !6C   4MP
M%,\  !/I %(4  !&%@  .Q<  #(7   K%P  )1<  "$6   <%@  &14  !84
M 0 4$P0 $A,& !$2"  /$@@ #A,)  P4"@ *%0T "!80  86$P %%AD !!<?
M  ,7)P "&#   1@[   91P  &54  !ED   9=P  &8P  !BB   8MP  %\\
M !?J $\6  !#&   .1D  # 9   I&0  (QD  !\8   ;%P  &!8  !45 @ 3
M%04 $10& ! 4!@ .%0< #!8(  H7"@ '&0P !!H.  (;$@ !&Q8  !L=   <
M)   '"T  !PX   =1   '5(  !UB   ==0  '8H  !R@   <M@  &]   !KK
M $P8  ! &@  -AL  "T;   F&P  (1H  !T9   9&0  %Q@  !07 P 2%@0
M$!<$  X7!  ,&04 "AH'  <<"0 #'0L  !\-   @$   (!0  "$:   A(@
M(2H  "$U   B00  (D\  ")?   B<@  (8@  "&?   @M@  ']$  !_M $@:
M   ]'   ,QT  "L=   D'0  (!P  !P;   8&@  %AD! !,9 0 1&0$ #AH!
M  P< @ *'0, !Q\%  ,A"   (@H  "0,   F#@  )A(  "88   G'P  )R<
M "<R   G/@  )TL  "=<   G;@  )H4  ":=   EM   )-$  "/N $0=   Y
M'P  ,!\  "@?   C'@  'AT  !L<   8&P  %!P  !$<   .'0  #1\   HA
M   &(@$  R0$   F!@  * @  "H+   K#0  +1   "T5   M'   +20  "XN
M   N.@  +D@  "U8   M:@  +8$  "R:   KL@  *M   "GO $ @   V(0
M+2$  "8A   A(   '1\  !H>   6'@  $A\   \A   -(@  "B0   8F   "
M*    "L"   M!   +P8  # )   R#   - X  #42   U&   -2   #4J   U
M-@  -4,  #53   T9@  -'P  #.6   RKP  ,<T  ##O #PC   R)   *B0
M "0C   @(@  '"$  !<A   3(P  $"4   TG   )*0  !2L   $N    ,
M #(    T 0  -@0  #@&   Z"0  / T  #X0   ^%   /AP  #XF   ^,0
M/C\  #U.   ]80  /'<  #N1   ZJP  .<D  #CM #<G   O)P  *"8  ",E
M   ?)   &24  !0F   0*   #2L   DN   %,    #,    U    .    #H
M   \    /@$  $ #  !"!P  1 H  $8-  !)$0  21<  $@A  !(+   1SH
M $=)  !&6P  17$  $2+  !#I0  0L,  $'H #0J   L*@  )R@  "(G   <
M*   %BH  !$M   -,   "3,   ,V    .0   #P    ^    00   $,   !&
M    2    $H   !, P  3@8  % *  !3#@  5!,  %0<  !3)P  4S0  %-#
M  !250  46H  %"#  !/G@  3;D  $S@ # M   K+   )BL  !\L   8+@
M$C(   TU   (.0   CT   !     0P   $8   !)    3    $X   !1
M4P   %4   !7    60$  %P&  !?"@  8@X  &,5  !C'P  8BP  &$\  !@
M3@  7V(  %Y[  !<E@  6[   %G/ "\P   J+P  (C   !HS   3-P  #CL
M  @_   !1    $@   !,    3P   %(   !5    6    %L   !=    8
M &(   !D    9@   &D   !M!0  < L  '00  !T&   <R4  '(T  !R10
M<%D  &]Q  !MBP  :Z8  &K  "XS   E-0  '3@  !0\   .00  !T<   !,
M    40   %4   !9    70   &$   !E    :    &L   !M    ;P   '(
M  !T    =P   'H   !^    @@0  (8+  "*$0  B1P  (@K  "&/0  A%(
M (-G  "!@0  ?YL  'ZR "DZ   @/0  %D(   ](   (3@   %0   !:
M8    &0   !I    ;@   '(   !V    >@   'T   "     @@   (4   "(
M    BP   (X   "2    E@   )L#  "@#   HA,  * A  "?,P  G4<  )I>
M  "8=P  EX\  )6G "-#   92   $4X   E5    7    &,   !J    <0
M '8   ![    @    (8   "*    C@   )$   "3    E@   )D   "<
MH    *,   "G    JP   +    "V!   O T  +H7  "Y*   MSP  +12  "R
M:@  KX4  *V< !Q.   35   "UP   %D    ;    '0   !\    @P   (D
M  "/    E    )H   "?    H@   *0   "G    J@   *X   "Q    M
M +@   "\    P0   ,<   #-    U 4  -@0  #5'@  TS$  -!(  #-7P
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M__________________________________________________\
M             0,$!08("0H+#0X/$1(3%!87&!H;'!T?("$B)"4F*"DJ*RTN
M+S R,S0V-S@Y.SP]/D!!0D1%1D=)2DM-3D]04E-455=865M<75Y@86)C969G
M:6IK;&YO<'%S='5W>'EZ?'U^@(&"@X6&AXB*BXR.CY"1DY25EIB9FIR=GI^A
MHJ.DIJ>HJJNLK:^PL;.TM;:XN;J[O;Z_P<+#Q,;'R,G+S,W/T-'2U-76U]G:
MV]W>W^#BX^3FY^CIZ^SM[O#Q\O3U]O?Y^OO\_O______________________
M________________________________                      $#! 4&
M" D*"PT.#Q$2$Q06%Q@:&QP='R A(B0E)B@I*BLM+B\P,C,T-C<X.3L\/3Y
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M      ,$(0   0                    $                    !
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M:FUO<71V>7Q^@8.&B8N.D)*5EYF;G9^AHZ6GJ*JLK:^PLK.UMK>YNKN\O;_
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MI9>2YJ67DN:EEY+FI9>2YJ67DN;:RPD;Z,T..NG,$&#<R Z2R[HRK,:W4+3
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MVXZ>B=N.GHG;CIZ)VXZ>B=O3S0H8U=,+-M34"U_.RPF7P;XPK[JW4[BULFS
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MCIS<H(Z<W*".G-R@CIS<H(Z<W*".G-R@CIS<H(Z<W*".G-SUP@X4]<(4,/;
M'5/JNB-\RZI!K,:H6;/"IFVZOJ1]O[JDA\6WH8?*LY^'S["=A]2NFXC8JYF)
MW*F8B]^GF([BI9>2YJ"6F>"<DYO=G).;W9R3F]V<DYO=G).;W9R3F]V<DYO=
MG).;W9R3F]V<DYO=G).;W9R3F]V<DYO=G).;W9R3F]WTP@T4]<,4,/; '%/J
MNR)\RJI K,:H6+/"IFRZOJ1\O[JEA<6VHX?+LZ&'T+"?A]6MG8C:JIV*W:>;
MC."DFH[BGYB/XYV:F.&9EYO=F9>;W9F7F]V9EYO=F9>;W9F7F]V9EYO=F9>;
MW9F7F]V9EYO=F9>;W9F7F]V9EYO=F9>;W9F7F]WRPPT4],,3,/7!&U/JO"%\
MRJL_K<:I5[/"IVNZOJ5[O[JFA,6VI8?+LJ.'T:^AA]:KGXC:IYV)W:2<BM^@
MFXO@FYJ-XI>:D^&7G)O>EYR;WI><F]Z7G)O>EYR;WI><F]Z7G)O>EYR;WI><
MF]Z7G)O>EYR;WI><F]Z7G)O>EYR;WI><F][PPPT4],03+_7"&E+JO2!\RJL^
MK,:J5K/"J&NZOJ=YO[JH@\6VIX?,LJ6'T:RBA]:HH(?9I)Z(W*&=B-V<G(G>
MEYN+X).;C^"2G9?>DIV7WI*=E]Z2G9?>DIV7WI*=E]Z2G9?>DIV7WI*=E]Z2
MG9?>DIV7WI*=E]Z2G9?>DIV7WI*=E][MQ P3\\42+_3"&5+JO1]\RJP\K,:K
M5;/"J&JYOJEWO[JJ@,6UJ8?,KZ6'TJJBA]:EH(;8H9^&VIV>A]N9G8?=E)V)
MWI"<C=Z.G9/=CIV3W8Z=D]V.G9/=CIV3W8Z=D]V.G9/=CIV3W8Z=D]V.G9/=
MCIV3W8Z=D]V.G9/=CIV3W8Z=D]WJQ0P3\L41+_/#&%+JOAU\RZTZK,:L5+/"
MJ6FYOJQSO[JM?L6RJ8?,K*6&T:>CAM6BH877GJ"%V)J@A=J6GX;;D9Z(W(V>
MB]R+GH_<BYZ/W(N>C]R+GH_<BYZ/W(N>C]R+GH_<BYZ/W(N>C]R+GH_<BYZ/
MW(N>C]R+GH_<BYZ/W(N>C]SFQ0L3\<81+_+$%U+JP!M\RZ\XK,:M4K+"JV:Y
MO[!OOK>M?L:PJ8?-JJ:&T:2DA=.?HX35FZ*$UI>AA=B3H(79CZ"'V8N?BMJ(
MGXW:B)^-VHB?C=J(GXW:B)^-VHB?C=J(GXW:B)^-VHB?C=J(GXW:B)^-VHB?
MC=J(GXW:B)^-VHB?C=KAQ@H3\,<0+O#&%E'JP1E\R[ UJ\>O3[+#L&"XO+)L
MO[*M?L>MJ8;,IZ>%SZ&EA-*<I(33F*.$U)2CA-60HH76C:&&UXFAB-B'H8O8
MAZ&+V(>AB]B'H8O8AZ&+V(>AB]B'H8O8AZ&+V(>AB]B'H8O8AZ&+V(>AB]B'
MH8O8AZ&+V(>AB]C;QPD2[LD/+N[(%%'KQ!9\S+,PJ\>Q3+'$N%:WMK%NP:ZM
M?\>IJH;+HZB$SIZG@\^9IH/1E:6#TI&DA-..I(74BZ.&U(BCB-6%HXK5A:.*
MU86CBM6%HXK5A:.*U86CBM6%HXK5A:.*U86CBM6%HXK5A:.*U86CBM6%HXK5
MA:.*U86CBM7:R D2Z\L-+>O*$5#KQQ)\S+8JJLBW1+"ZMEFZK[%PPJJM?\>F
MJX7*H*J$S)JH@\V6J(/.DJ>#SX^FA-",IH71B:6&T8>EA]*%I8G2A:6)TH6E
MB=*%I8G2A:6)TH6EB=*%I8G2A:6)TH6EB=*%I8G2A:6)TH6EB=*%I8G2A:6)
MTH6EB=+8R0D1W\T++.?-#T_HRPY[S;PBJ,*\/+&QM5Z\J;%RPJ:N?\6BK83'
MG*N#R9>J@\J3JH3+D*F$S(VIA,V+J(7-B*B&SH:GA\Z$IXG/A*>)SX2GB<^$
MIXG/A*>)SX2GB<^$IXG/A*>)SX2GB<^$IXG/A*>)SX2GB<^$IXG/A*>)SX2G
MB<_5R0D0V,\**]K3"T[8T MZS<,6J+.Z1K6IM&*]I+%TP:&P?\.>KH3%F:V$
MQY2LA,B0JX3)CJN$RHNJA<N)JH;+AZF'S(6IB,R#J8G,@ZF)S(.IB<R#J8G,
M@ZF)S(.IB<R#J8G,@ZF)S(.IB<R#J8G,@ZF)S(.IB<R#J8G,@ZF)S(.IB<S2
MRPD/U-$**=75"TS0T I^N+\EKJBX3[BAM&:\GK)UOYVQ?\&;L(3#EJZ$Q9&N
MA,:.K87'BZR%QXFLALB'K(?)AJN'R82KB<F"JXK*@JN*RH*KBLJ"JXK*@JN*
MRH*KBLJ"JXK*@JN*RH*KBLJ"JXK*@JN*RH*KBLJ"JXK*@JN*RH*KBLK/S D-
MT-(**,[4"E+%T0J#JL,MJ)ZW5[B;M6B[FK1UOIFR?[^7L83!D["%PH^OA<.,
MKX7$BJZ&Q8BNA\6&KHC&A*V(QH.MBL:!K8O'@:V+QX&MB\>!K8O'@:V+QX&M
MB\>!K8O'@:V+QX&MB\>!K8O'@:V+QX&MB\>!K8O'@:V+QX&MB\?,S0D,R],*
M+<?4"EFRV N GLTKFIC!4*N6N&>WE;5UO)2T?KZ4LX6_D+*%P(RQAL&*L8?"
MB+"'PH:PB,*%L(G#@["*PX*OB\.!KXS#@:^,PX&OC,.!KXS#@:^,PX&OC,.!
MKXS#@:^,PX&OC,.!KXS#@:^,PX&OC,.!KXS#@:^,PX&OC,/'SP@0Q=0)-+C9
M"ENBYQ)VE]HEB9#/19B.QUVCC<%NJXV]>;&,NH&TB;B#MX:WA;F$MH:Z@[6'
MNX*UB+R!M(F]@+2*O7^TB[Y^LXR^?K.,OGZSC+Y^LXR^?K.,OGZSC+Y^LXR^
M?K.,OGZSC+Y^LXR^?K.,OGZSC+Y^LXR^?K.,OGZSC+["T0<6O=8(.J?Q#E6;
M\1MHD>8M>(G=0(6%U5:/@\]GEX++<YU^R'BA>\9\I'G$?Z9WPX*H=<*$J73"
MA:ISP8>K<L&(JW+ BJQQP(NL<<"+K'' BZQQP(NL<<"+K'' BZQQP(NL<<"+
MK'' BZQQP(NL<<"+K'' BZQQP(NL<<"+K'' BZS_N!0._[@>)_^T*D;WKS9I
MWJ="C\>;8K'$FW*VPIM_N<";B+V^F8G O)6*P[J1B\:XC8W(MXJ/RK:(D<RU
MA9/-M(.6S[.!F="S@)W1LG^CT;!^I-&P?J31L'ZDT;!^I-&P?J31L'ZDT;!^
MI-&P?J31L'ZDT;!^I-&P?J31L'ZDT;!^I-'_N!0._[@>)_^T*D;WKS9IWJ="
MC\>;8K'$FW*VPIM_N<";B+V^F8G O)6*P[J1B\:XC8W(MXJ/RK:(D<RUA9/-
MM(.6S[.!F="S@)W1LG^CT;!^I-&P?J31L'ZDT;!^I-&P?J31L'ZDT;!^I-&P
M?J31L'ZDT;!^I-&P?J31L'ZDT;!^I-'_N!0._[@>)_^T*D;WKS9IWJ="C\>;
M8K'$FW*VPIM_N<";B+V^F8G O)6*P[J1B\:XC8W(MXJ/RK:(D<RUA9/-M(.6
MS[.!F="S@)W1LG^CT;!^I-&P?J31L'ZDT;!^I-&P?J31L'ZDT;!^I-&P?J31
ML'ZDT;!^I-&P?J31L'ZDT;!^I-'_N!0._[@>)_^T*D;WKS9IWJ="C\>;8K'$
MFW*VPIM_N<";B+V^F8G O)6*P[J1B\:XC8W(MXJ/RK:(D<RUA9/-M(.6S[.!
MF="S@)W1LG^CT;!^I-&P?J31L'ZDT;!^I-&P?J31L'ZDT;!^I-&P?J31L'ZD
MT;!^I-&P?J31L'ZDT;!^I-'_N!0._[@>)_^T*D;WKS9IWJ="C\>;8K'$FW*V
MPIM_N<";B+V^F8G O)6*P[J1B\:XC8W(MXJ/RK:(D<RUA9/-M(.6S[.!F="S
M@)W1LG^CT;!^I-&P?J31L'ZDT;!^I-&P?J31L'ZDT;!^I-&P?J31L'ZDT;!^
MI-&P?J31L'ZDT;!^I-'_N!0._[@>)_^T*D;WKS9IWJ="C\>;8K'$FW*VPIM_
MN<";B+V^F8G O)6*P[J1B\:XC8W(MXJ/RK:(D<RUA9/-M(.6S[.!F="S@)W1
MLG^CT;!^I-&P?J31L'ZDT;!^I-&P?J31L'ZDT;!^I-&P?J31L'ZDT;!^I-&P
M?J31L'ZDT;!^I-'_N!0._[@>)_^T*D;WKS9IWJ="C\>;8K'$FW*VPIM_N<";
MB+V^F8G O)6*P[J1B\:XC8W(MXJ/RK:(D<RUA9/-M(.6S[.!F="S@)W1LG^C
MT;!^I-&P?J31L'ZDT;!^I-&P?J31L'ZDT;!^I-&P?J31L'ZDT;!^I-&P?J31
ML'ZDT;!^I-'_N!0._[@>)_^T*D;WKS9IWJ="C\>;8K'$FW*VPIM_N<";B+V^
MF8G O)6*P[J1B\:XC8W(MXJ/RK:(D<RUA9/-M(.6S[.!F="S@)W1LG^CT;!^
MI-&P?J31L'ZDT;!^I-&P?J31L'ZDT;!^I-&P?J31L'ZDT;!^I-&P?J31L'ZD
MT;!^I-'_N!0._[@>)_^T*D;WKS9IWJ="C\>;8K'$FW*VPIM_N<";B+V^F8G
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MC:Z%Q8JNAL:(K8;&AZV'QH6MB,>#K8G'@:V+QX"LB\> K(O'@*R+QX"LB\>
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ME7*PQ95]M<.7A;C!EXN[OY.,O;Z/CL"\C(_"NXF2Q+J&E,6Y@Y;&N8&9Q[B
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M_ZHG%_^G-B__HD1*^IU29>J77W[<DVZ3SY)XI<:2@K3$DHFVPY&.N,&.D+K
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MGZJ$RYBH@\V0IX30B:6&TH2DBM. I)#3?Z67TG^FH-!_I:;.@*"HRX"@J,N
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M_YA55/>486GKE&9[X))OC-:1>)K.D(*FR(^)L,2/C[;#BY&WPHB4N<&$E[K
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MFVNLQ9MUM,.;?KC FX>\O9>*P+J1C,6WBI#*M(27S[* H]*H?Z7/HX"HRZ"
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M7DCXD%](^)!?2/B07TCXD%](^)!?2/B07TCXD%](^)!?2/B07TCXD%^UQP(
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MLJO+<+:KRV^\J\APP*O$<<"JQ'' JL1QP*K$<<"JQ'' JL1QP*K$<<"JQ''
MJL1QP*K_D1(!_Y4G"_^5.QS_DTLO_X]90_^,9%3[C&MC\HIR<>J(?'WCAH2'
MWH**C]I_CY;6?92;TWJ8G]%XG*+0=Y^DSG6BILUTIJC-<JFIS'&MJLQPLJO+
M<+:KRV^\J\APP*O$<<"JQ'' JL1QP*K$<<"JQ'' JL1QP*K$<<"JQ'' JL1Q
MP*K_D1(!_Y4G"_^5.QS_DTLO_X]90_^,9%3[C&MC\HIR<>J(?'WCAH2'WH**
MC]I_CY;6?92;TWJ8G]%XG*+0=Y^DSG6BILUTIJC-<JFIS'&MJLQPLJO+<+:K
MRV^\J\APP*O$<<"JQ'' JL1QP*K$<<"JQ'' JL1QP*K$<<"JQ'' JL1QP*K_
MDA(!_Y8G"O^6.QS_E$LP_Y!90_^/8U3ZCFED\8UP<NF+>G[BB8*)W(6)DMB"
MCIG4?Y.>T7V7HL][FZ;->9ZHS'>BJLMVI:S*=*FMR7.MKLERLJ_)<;>OR'&\
MK\)SO:Z^=+VOOG2]K[YTO:^^=+VOOG2]K[YTO:^^=+VOOG2]K[YTO:__DQ(!
M_Y<G"O^8.QS_E4LP_Y%91/^18%7ZD&9D\(]M<^B-=X#AC("+VXB'E-6%C9S2
M@I&ASW^6ILQ]F:G+>YVLR7FAKLAWI;#'=JFQQG6MLL9TLK/&<[FSPG6ZL[QU
MNK.X=KJSN':ZL[AVNK.X=KJSN':ZL[AVNK.X=KJSN':ZL[AVNK/_E!$!_Y@G
M"O^9.QS_EDLP_Y)91/^27E7ZDF1E\)%J=.>/<X'@CGV,V8N%EM2(BY[0A9"D
MS8*4J<I_F*W(?9RPQWN@LL9YI+3%>*BUQ':NML1UM+;!=K>VO'>WMK=WM[:S
M>+>VLWBWMK-XM[:S>+>VLWBWMK-XM[:S>+>VLWBWMK-XM[;_E1$!_YDG"O^9
M.QS_ETHP_Y-81/^47%7ZE&%E\)-G=.>1<(+?CWJ.V(V#F-*+BJ#.AX^GRX23
MK,B!E[#&?YNSQ'V?M<-[I+?">:FYPG>ON<)VM;F\>+:XN'BVN+-XMK>P>;>W
ML'FWM[!YM[>P>;>WL'FWM[!YM[>P>;>WL'FWM[!YM[?_EA$!_YHG"O^:.QS_
METHQ_Y151/^6657ZEEYE\)5D=.>3;(+>D7:.V(]_F=&-B*+-BHZIR8>2KL:$
MEK/$@9JVPGZ?N<)[I+K!>:JZP7>QNKUXM;JW>+6YLWFUN:]YMKBL>K:WK'JV
MMZQZMK>L>K:WK'JVMZQZMK>L>K:WK'JVMZQZMK?_EQ$!_YLF"O^;.QS_F$DQ
M_Y931/^85U7ZF%ME\)=A=.>6:(+>DW*/UI%[FM"/A*/+C8RKQXJ1L<2&E;;#
M@YFXP7^>NL%[I+O >:N\OW>SO+AXL[NR>;2[KGFUNJMZM;FH>[:XJ'NVN*A[
MMKBH>[:XJ'NVN*A[MKBH>[:XJ'NVN*A[MKC_EQ$!_YLF"O^<.AS_F$DQ_YA1
M1/^:5%3ZFUAD\)I==.>88X+>EFV/UI-WFM"1@*3*CXFLQHV/L\.)E+?"A)BZ
MP'^>O+][I;Z_>:Z^N7BROK)YLKVM>K.\J7NTNJ9[M;FD?+:XI'RVN*1\MKBD
M?+:XI'RVN*1\MKBD?+:XI'RVN*1\MKC_F!$!_YPF"O^<.1S_F4@Q_YE/1/^<
M4E3[G55C\9U:<^>;7X'>F6F/UI9RFL^3?*7*D86MQ9"-M,.+DKC!A9:[OX"=
MOKU[I<&[>:_!LGJPP*Q[L;ZH>[.]I7RTNZ)]M;F@?;:XH'VVN*!]MKB@?;:X
MH'VVN*!]MKB@?;:XH'VVN*!]MKC_F1$!_YTF"O^=.1S_F4<Q_YM-0_^>3U/[
MGU)C\:!6<NB?6X#?G62.UYIMFM"7=Z3*E(&MQ9**M<*.D+F_AY6]O8"<P;M[
MI\2S>JW$JWNOPJ9\L;^C?;*]H'ZTNYY_M;F<?[:XG'^VN)Q_MKB<?[:XG'^V
MN)Q_MKB<?[:XG'^VN)Q_MKC_F1$!_YXF"O^=.!S_FD<Q_YQ+0O^@35+\HE!B
M\J-3<>FC5W_@H5Z,V)YGF-";<:/*F'NMQ96%M,*2C;J^BI*_NH&;Q;=\J<FK
M?*O'I'VNPZ!^L,"=?[*]FX"SNYF!M;J8@;:XF(&VN)B!MKB8@;:XF(&VN)B!
MMKB8@;:XF(&VN)B!MKC_FA$!_YXF"O^>.!S_FD8R_YY)0O^B2E']I$U@\Z90
M;^JG5'WAIEB*VJ1BEM*A:Z'+G76KQIJ L\*8BKJ\CH_"MH.9RZQ]ILZB?ZK)
MG8"MQ)J!L,"8@K*^EX.SO)6#M;J4@[:XE(.VN)2#MKB4@[:XE(.VN)2#MKB4
M@[:XE(.VN)2#MKC_FA$!_Y\F"O^>-QS_FT8R_Y]'0?^D2%#^ITI?]*E,;>NK
M4'OCK%2'W*M<D]2I99W.IF^GR*-ZL,.?A+B[EHO$L(R9SJ"#I-&9A*G*EH6M
MQ92%K\&3A;&^DH6SO)&%M+J1A;6YD86UN9&%M;F1A;6YD86UN9&%M;F1A;6Y
MD86UN9&%M;G_FQ$!_Y\F"O^?-QS_FT4R_Z%%0/^F1D__JD==]JU):^VP3'CF
MLT^#W[15CMFU7Y?3M6F@SK5VI\&K?+:PGX7$H962SI2.H]*0BZC+CXJLQHZ*
MK\*.B;&_CHFRO8Z(M+N.B+6YCHBUN8Z(M;F.B+6YCHBUN8Z(M;F.B+6YCHBU
MN8Z(M;G_FQ$!_Z F"O^?-AS_G$0Q_Z-#/_^H0T[_K41;^+%%:/"V2'3INTQ^
MX\!1A]_&6X[6R&N4QKUQIK6S>+6EJ('#E)^-S8F<HM*'E*?,B)&KQXF/KL.)
MCK# B8VROHJ,L[R*B[2ZBHNTNHJ+M+J*B[2ZBHNTNHJ+M+J*B[2ZBHNTNHJ+
MM+K_G! !_Z$F"O^@-AS_GD(Q_Z5 /O^K0$S_L4!9^K=!9/.]1&_NQ4EWY<Y2
M?-W68G_,SFB2O,5NI*N[=K2:L7_!BJJ*RW^GG<^ GZC,@IFKQX.5K<2$DZ_!
MA9&QOX:/L[V'CK2[AXZTNX>.M+N'CK2[AXZTNX>.M+N'CK2[AXZTNX>.M+O_
MG1 !_Z(F"O^@-1S_H#\P_Z<]/?^N/$K_M3Q5^KT]8/#&0F?FT4ILWMY.=LW:
M5X>^T&*6KL5NI:&\>;*5M(.]AJV(QGNJE,IXJZC)>Z*KQWZ<K<2 F:_"@9:P
MP(*4LKZ#DK.\@Y*SO(.2L[R#DK.\@Y*SO(.2L[R#DK.\@Y*SO(.2L[S_GA !
M_Z(F"O^A-!S_HCPN_ZHZ._^R.$?\NS=1\L4Z6.;105S;WD)IS>)&?+[748RN
MS%^;H<-MJ)B\>;*1M82[A;&)PGRND<5XKI_%=:VLQ7BEKL1ZH*_"?)RPP'Z9
ML;Y_EK*]?Y:RO7^6LKU_EK*]?Y:RO7^6LKU_EK*]?Y:RO7^6LKW_GA !_Z,E
M"?^B-!S_I3DM_ZXU./^X,T+TPS-*Y] X3MG>.5K+YCUNON!"@*[44)"ARU^=
MF,-MJ)&]>;&+N(.X@[2(O7VQD,%YL9K!=;&EP7*OK\)UJ*_!=Z.PP'F?L;][
MG+*]>YRRO7N<LKU[G+*]>YRRO7N<LKU[G+*]>YRRO7N<LKW_H! !_Z0D"?^C
M,AS_J#0K_[,O-/F_+3SIS2] V=XO2LKG-%^]ZCISK]Y!@Z'349&7RV"=D,1N
MIHR_>JV&NX&S?[B'N'JVC;MWM96\=;6?O'*TJ+UNL[*^<:RROG2GLKYVH[*]
M=J.RO7:CLKUVH[*]=J.RO7:CLKUVH[*]=J.RO7:CLKW_H1 !_Z4C"?^D,1S_
MK2XG_[DI+^[()C/:W"8WRN<L3[WR,F.OZ#EUH=U"A);44Y"/S6*:BL=PHH;#
M>JB OX"M>[V%L7:[B[1SN9*U<;F:MG"YH[5MN:NV:KBTN&NRMKANK+:X;JRV
MN&ZLMKANK+:X;JRVN&ZLMKANK+:X;JRVN&ZLMKC_HQ !_Z<B"?^E+QO_LR<B
M],(A)MW8'23+YR,\O?(J4Z_S,F:AYSMVE=Y&@XW65HV'T&26A,MQG'_(>*%Z
MQ7ZE=L*#J7+!B:MOOX^M;+^6KFN^G:YJOZ:N:+^NKF6]N+!EN;NP9;F[L&6Y
MN[!EN;NP9;F[L&6YN[!EN;NP9;F[L&6YN[#_I1 !_Z@@"/^L)A?\NQT:X]$3
M&<SE&2F]\B)!K_TJ5:'S-&:6Z3]TC.%+?X7;68B U6:/?-%OE'?.=IESRWR<
M<,F!GVW(AZ%JQXRC:,:2I&;%F:5DQ:"E9,6HI6/&LJ1@Q+NF8,2[IF#$NZ9@
MQ+NF8,2[IF#$NZ9@Q+NF8,2[IF#$NZ;_J!  _ZH>"/^S'1'LR0X/SN,.%;[R
M&"VO_B)#H?\M59;T.62,[$5OA.51>7[@7(!YW&>&=-ENBG#6=(YLTWF1:=)_
MDV?0A)5DSXJ78LZ/F&#-E9E?S9R:7LVBFUW-JYM<S;2:7,VTFES-M)I<S;2:
M7,VTFES-M)I<S;2:7,VTFES-M)K_JP\ _ZT:!_+ #0C.TPH&OO .&J_^&3"A
M_R1#E?\R4HOX/UZ#\4MH?>Q6<'?H7W9QY&5Z;.%L?FG?<H%FW7B$8]Q]AF';
M@HA?VH>)7=F,BUO8DHQ9UYB-6-:>C5?6I8Y6U:R.5M6LCE;5K(Y6U:R.5M6L
MCE;5K(Y6U:R.5M6LCE;5K([_KPT _[<. \W)" &^V D)KOT0'*'_'"^5_RD_
MB_\W3(+^159\^5!>=?199&[Q7VEH[F1M9.MJ<&'J<'-?Z'5U7>=Z=UOF?WA9
MY81Y6.2)>U;CCGQ5XI-]5.*8?E+AGGY1X:5_4>&E?U'AI7]1X:5_4>&E?U'A
MI7]1X:5_4>&E?U'AI7_QM @ SL & +W.!P&NX <+H/\2')3_("N*_R\X@?\]
M0WK_24MS_U)1;/Y75V7[75MA^6->7O=H8%OU;6)8]')D5O-W9E7R>V=3\8!H
M4?"$:5#PB6I/[XYK3NZ3;$SNF6U+[9]N2^V?;DOMGVY+[9]N2^V?;DOMGVY+
M[9]N2^V?;DOMGV[1N0, O,4% *W6 P&?^ L+D_\6&(G_)"2 _S0O>?]!-W#_
M2#YH_T]#8O]51UW_6DM9_V!-5O]E4%/_:E%1_VY33_]R5$[_=E5,_GM62_U_
M5TG]A%A(_(A91_N-6D;[DUM%^IA<1?J87$7ZF%Q%^IA<1?J87$7ZF%Q%^IA<
M1?J87$7ZF%R]O0, K<T! )[?  &2_PT(A_\9$G[_*1MU_S4C;/\\*F3_0R]>
M_THT6/]0-U3_5CI1_UL\3O]@/DO_9$!*_VA!2/]L0D;_<$-%_W1$1/]X14+_
M?49!_X%'0/^&2#__C$D]_Y%*/?^12CW_D4H]_Y%*/?^12CW_D4H]_Y%*/?^1
M2CW_D4JNQ0  GM<  (_U  &&_P\$?/\;"W'_)!%G_RP77_\U'%G_/2%4_T4F
M3_]+*4S_4BQ(_U<O1O]=,$3_83)"_V8S0/]J-3__;C8]_W,W//]W.#O_?#DZ
M_X$Z./^&.C?_C#LV_Y(\-O^2/#;_DCPV_Y(\-O^2/#;_DCPV_Y(\-O^2/#;_
MDCS_@Q,!_X0B!O^%-13_@T8D_W]5-/^!7D+_@690_W]N7/E\=V;S>H!O[G>(
M=^IUCWWG<I6"Y'":A>-NGHCA;**+X&NGC=]IJX[>:*^0W6>TD=UFNI'<9<&2
MW&7)DMMET)+29]*1SFC2D<YHTI'.:-*1SFC2D<YHTI'.:-*1SFC2D<YHTI'_
M@Q,!_X0B!O^%-13_@T8D_W]5-/^!7D+_@690_W]N7/E\=V;S>H!O[G>(=^IU
MCWWG<I6"Y'":A>-NGHCA;**+X&NGC=]IJX[>:*^0W6>TD=UFNI'<9<&2W&7)
MDMMET)+29]*1SFC2D<YHTI'.:-*1SFC2D<YHTI'.:-*1SFC2D<YHTI'_@Q,!
M_X0B!O^%-13_@T8D_W]5-/^!7D+_@690_W]N7/E\=V;S>H!O[G>(=^IUCWWG
M<I6"Y'":A>-NGHCA;**+X&NGC=]IJX[>:*^0W6>TD=UFNI'<9<&2W&7)DMME
MT)+29]*1SFC2D<YHTI'.:-*1SFC2D<YHTI'.:-*1SFC2D<YHTI'_A!,!_X4B
M!O^&-13_A$8D_X!5-/^$74/_A650_X-M7?B =6CR?7YQ['J&>>AWC7_E=9.%
MXG*8B>!PG8S?;J*.W6RFD-QKJY+;::^4VFBUE=IGNY7:9L.6VF;,EM-HSY;,
M:<^5R&K/ELAJSY;(:L^6R&K/ELAJSY;(:L^6R&K/ELAJSY;_A1(!_X<B!O^'
M-13_A48D_X14-?^(7$/_B&11_H=K7O>#<FGQ@'QSZWV%>^=ZC(+C=Y*'X'27
MC-YRG(_<<*&2VVZFE-ELJI;9:K"8V&FVF==HO9G7:,::TVC,FLQJS)G&:\R:
MPFS,FL)LS)K";,R:PFS,FL)LS)K";,R:PFS,FL)LS)K_AA(!_X@A!O^(-13_
MAD8E_X=3-?^+6T/_C&)1_HIJ7O:'<6KPA'ITZH"#?>5]BH3B>I"*WG:6C]QT
MFY+:<:"5V&^EF-9MJYK5:[";U6JWG-1IOYW4:<F=S&O*G<9LR9W ;<F=O6[)
MG;UNR9V];LF=O6[)G;UNR9V];LF=O6[)G;UNR9W_AQ(!_XDA!O^*-13_B$8E
M_XI2-?^.6D/_CV%1_HYH7O:+;VKOAWAUZ82!?N2 B(;@?(^,W7F4D=IVFI78
M<Y^9U7"EF]1NJI[3;;&?TFNXH-)KPJ'-;,>AQF['H<!NQZ&[;\>AN'#'H;AP
MQZ&X<,>AN'#'H;APQZ&X<,>AN'#'H;APQZ'_B!$!_XHA!O^+-13_B48E_XU1
M-?^26$/_DEY1_I!E7O:.;&OOBW5VZ(=^@..$AHC>?XV/VWN3E-AXF9G5=9Z<
MTW*DG]%PJJ+0;K*CT&VZI,YLQ*7&;\2DOW#$I;IQQ*6U<<2ELG+$I+)RQ*2R
M<L2DLG+$I+)RQ*2R<L2DLG+$I+)RQ*3_B1$!_XLA!O^,-!3_BD8E_Y!/-/^4
M5D/_E%M1_I-A7O:1:&ONCG!VZ(M[@.*'@XG=@XJ1V7Z1E]5ZEYS3=YV@T'2D
MH\]QJJ;.;[.GS6Z]J,=PPJB^<<&IN'+!J;1SP:FO=,*HK73"IZUTPJ>M=,*G
MK73"IZUTPJ>M=,*GK73"IZUTPJ?_BA$!_XPA!O^--!3_BT8F_Y-.-/^64T+_
MEUA0_I9>7O:49&KNDFQVYX]V@>&,@(K<AXB2V(*/F=-]E9_0>9RCSG6CI\QR
MJZK+<+2KR'"_K+]SOJRW=+ZMLG6^K*YVOZRJ=K^KJ'? JJAWP*JH=\"JJ'?
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M!O^5-!7_GCL@_Z4Y*_^L.C7_LST_^[I"1_'!2$[HR5%2W]%;6<_*8&W!PF>
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M-S7_C#@S_Y0X,_^8.3/_F#DS_Y@Y,_^8.3/_F#DS_Y@Y,_^8.3/_F#FGPP
ME]0  (CD  " _PH!<O\. F?_$P5?_QT)5_\F#5'_+Q%,_S<51_\^%T/_11E
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MC+IIUHRZ:=:,NFG6C+IIUHS_>Q,!_WD= _]Z, W_?#\:_X5()O^*4#/_C%A
M_XM?3/^(9U?\A&YA]G]X:O%[@G+M=XIYZ7.2?N9OF8/D;*&'XFJHBN!GKXS?
M9;B.WF3$C]MDTH_.9]./QFC3D+]JTY"Z:].0M6S3D+1LTX^T;-./M&S3C[1L
MTX^T;-./M&S3C[1LTX__?!,!_WH= _][, W_?SX:_XE&)O^/3C+_D58__Y!=
M2_^.9%;\B6MA]H1S:_!_?G/L>X=ZZ':0@>1REX;A;I^*WVNGCMUHL)#<9KN2
MVV7*D]!HT9/&:M"4OFO0E+ALT)2S;="4KV[1DZYNT9.N;M&3KF[1DZYNT9.N
M;M&3KF[1DZYNT9/_?1(!_WL< _]\+PW_@SP9_XU%)?^333'_E5,^_Y192O^2
M8%7]CVA@]HIP:O"$>73K?X-\YGJ,@^)UE8C?<9Z-W6VGD=MIL9399[^6U&?.
ME\=KS9B];,V8MF[-F+!OS9BL<,Z7J7'.EJAQSY:H<<^6J''/EJAQSY:H<<^6
MJ''/EJAQSY;_?A(!_WP< _]^+PW_ACL9_Y%#)/^62S#_F% \_YA52/^67%3]
MDV-?]X]K:?"*='/KA']\YGZ)A.%XDHO=<YR0VFZFE=AJLYG6:,6;R6O+F[UN
MRIRT;\J<KG'*G*IRRYNF<\N:HW/,F:)TS9BB=,V8HG3-F*)TS9BB=,V8HG3-
MF*)TS9C_?Q(!_WT; _]_+PW_B3H8_Y1"(_^91R__FTP[_YQ21O^;6%+_F5]=
M^)5F:/&0;G+KBGE[Y8.$A.!\CXS<=IJ3V&^FF=)KM9W.:LB?OF[(G[-QQZ"L
M<L>@IW3(GZ-UR9Z@=LJ=GG;+FYUVRYJ==LN:G7;+FIUVRYJ==LN:G7;+FIUV
MRYK_@!$!_WX; _^ +PW_C#@8_Y= (O^<1"W_GTDY_Z!.1/^@54_\GEM:]9QB
M9>Z7:F_HD71YX8I_@]F#BHS/>Y65R'6@G,-PKJ&^;[^CLW+%HZITQ:.D=L6C
MH'?&H9UXQZ";>,B>F7G*G9AYRIR8><J<F'G*G)AYRIR8><J<F'G*G)AYRIS_
M@!$!_W\; _^!+PW_CS<7_YH_(?^?0BS_HD8W_Z1,0O^D4DSWI%A7[Z-?8>>@
M9FO@FG%UU9-\@<N*A8W#@H^6NWN:GK5VIZ2P=+BGJ';"IZ%XPZ:=><2EFGK%
MHYA[QJ*6>\>@E'O)GI1\R9V4?,F=E'S)G91\R9V4?,F=E'S)G91\R9W_@1$!
M_X ; _^"+@[_D386_YP\(/^A0"K_I40T_ZA*/_JI4$GRJE92ZJI=7.*I9F;7
MHF]RRYEX@<&0@8VXB(J7KX&5H*A\HJ:C>K*IGGK!J9E\P:B6?<.FE'[$I))^
MQ:.1?L>AD'[(GY!^R9Z0?LF>D'[)GI!^R9Z0?LF>D'[)GI!^R9[_@A$!_X$;
M _^$+@W_E#46_YXZ'O^D/BC_J$(R_ZQ'._:O343ML51-Y;-;5=RP96'.J&QQ
MPY]T@+B6?(VNCX:8I8B1H9V#G:>7@*VKDX"_JY&!P:F/@<*GCH'#I8V!Q:.-
M@<:BC('(GXR!R)^,@<B?C('(GXR!R)^,@<B?C('(GXR!R)__@A$!_X$: _^&
M+0W_EC05_Z Y'?^F/";_JT O^[!%./*T2S_IN5-&X;U<3=.V8F#&K6EPNZ5Q
M?["=>8REE8*7FX^-H9.*F:>,AZFKB(>_K(B'P*J(AL*HB(7#IHB%Q:2(A,:B
MB(3(H(B$R)^(A,B?B(3(GXB$R)^(A,B?B(3(GXB$R)__@Q !_X(: _^(*PS_
MF3(4_Z(W&_^I.23_KSTL][5",^V[23GEPE(^VL)83,RZ8%^_LF=OLZMN?JBC
M=HN=G'Z7DI>)H(F2EJ>"CZ6K?H^ZK("-P*J!B\*H@HK#IH.)Q:2#B,:BA(?(
MH(2'R)^$A\B?A(?(GX2'R)^$A\B?A(?(GX2'R)__A! !_X,: _^+*@S_G#$2
M_Z4T&O^L-B'^LSHH\[M +>G#2#'ARU$WTL=62\7 7EVXN&5NK+%L?:"J<XJ4
MI'N5BI^&GH";DJ5YF**J=)BWJW>5P:EZD<*G?(_#I7V-Q:-^C,:A?XK(GW^*
MR)]_BLB??XK(GW^*R)]_BLB??XK(GW^*R)__A1 !_X0: _^.* O_GS$1_Z<R
M%_^P,QWYN38B[L(])N;-1R;;TTPUR\Q42;[%7%NQOF-LI+AJ>IBR<8>,K'F3
M@:B"G'>DCZ-PHI^G;**TJ&Z?PJ=RF<.F=97$I'>2QJ)XD,>A>H[(GWJ.R9YZ
MCLF>>H[)GGJ.R9YZCLF>>H[)GGJ.R9[_AA !_X49 _^1)@K_H2\/_ZLN%?^U
M+QGTOS(<Z<LZ'-_91!W1VDHSQ-)21[?+6EFIQF%IG,!G>)"Z;H2$MG:/>;*
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M6#_\LUD^_+]:/OO16CW[VUH]^]M:/?O;6CW[VUH]^]M:/?O;6CW[VUK2K0
MO;@" *[% @"AU0( EO<+ HW_& B$_R81?/\Q&G'_.")H_SXI8/]%+UK_3#-4
M_U,W4/]:.DS_8#Q)_V8^1O]M0$3_=$)!_WM#/_^#13W_C$8[_Y5'.O^>23G_
MITHX_[%*-_^^2S?_PDLW_\)+-__"2S?_PDLW_\)+-__"2S?_PDN_LP  KKX
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M:4O9ZVI,S^QM3L?K;T_ ZG!/P.IP3\#J<$_ ZG!/P.IP3\#J<$_ ZG#_B0L
MZ: ! -"Q! #!O 4 M\D& *[:"0"D]1<%F_4G$)+U-!R(]CXG?_9',G;V3CML
M]E1"9/9:2%WV8DU7]FM14O9U54WW@%A(^(U:1?B;7$+XJUY!][Y?0/??8$/N
M[&!'X_%?2-OQ84G2\F-)TO)C2=+R8TG2\F-)TO)C2=+R8TG2\F/^E0  U*D
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M.RW_ZSPM_^L\+?_K/"W_ZSPM_^L\+?_K/"W_ZSRXL   J+P  )K)  ",V0
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M4434_%-%S_Q41<_\5$7/_%1%S_Q41<_\5$7/_%3AE0  RZ8  +NP  "NNP$
MHL@" )C5!0"0^ \!B?@@!(+X+@MY^3<3</D_&VCY1B)@^DTH6OI4+53Z7#%/
M^V4U2_MM.$?\=SM#_(,]/_V0/SS]GT$Z_J]#./_&1#?_ZD4V_/U%._+_1#[J
M_T0^YO]&/N;_1C[F_T8^YO]&/N;_1C[F_T;0GP  O:P  *ZU  "BP@  E<\
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M8%.E]F!5H?9@5:'V8%6A]F!5H?9@5:'V8%6A]F#_=P@ ZXP  -.;  #&J (
MN[$" +*[ @"JQP8 HM,* )W6&@&5UBP&C-0Z$8/21AUZT$\G<LY8,6K-8#AD
MRV@_7LIR15C*?$E4R8A-3\F544S)I5-*R;E42<K<4T?(]U5(P/Q82KC[64RR
M^UI.K?I:3JWZ6DZM^EI.K?I:3JWZ6DZM^EK_?P  W),  ,JB  "\K $ L;4
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M.#GE_S@YY?\X.>7_.#GE_SC(G@  MJD  *BR  ";O0  C\@  (/4  !YZ <
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M7&.*^EMDA_M:98;[666&^UEEAOM998;[666&^UG_9@T _W<# ..'  #3DP$
MRIX$ ,*G! "[KP0 M;8- *ZW(0*EMC()G;,_%92P2B",K5,KA*I;-'VH8SQV
MI6I#<*-R2FJA>T]EH(948)Z16%N=GUM8G;!=5IW'75:=ZUQ7FOI;6I7Z6ER1
M^UE>COQ87XW\5U^-_%=?C?Q77XW\5U^-_%?_:@H _WP  -R,  #-F   PZ,#
M +JJ @"SLP$ K+P* *:]'0&>O"\&EKH\$8VX1QR%M5 G?;-9,':Q8#AOKV@_
M::UP16.K>4I>JH1/6JF04E6HGE52IZ]74:C&5U"GZE=0I?Q74Y_]5U6:_597
MEOY66)7^55B5_E58E?Y56)7^55B5_E7_;P0 YH(  -*1  #&G0  NZ8! +*N
M  "JMP$ HL(% )S$& "5PRH$C<(Y#87 1!A]ODXA=;Q6*FZZ7C)HN68X8K=N
M/EVV>$-8M8)'5+2/2U"TG4Y-LZY02[3%4$NSZE!*L?]13*O_4DZE_U)0H?]2
M49[_45&>_U%1GO]149[_45&>_U'_=@  W8D  ,J7  "^H@  LZH  *FS  "@
MO ( F,8& )',$@"+S"4"A,LT"7S)0!)UR$H;;<=3(V?%7"IAQ&0P7,-M-E?"
M=CI3PH$_3\&.0DO!G45(P:Y&1\'%1D?!ZD9$OO])1;G_2D>S_TM)K?],2JO_
M3$JK_TQ*J_],2JO_3$JK_TSI?P  T9   ,*>  "UIP  JJ\  *"X  "6P0(
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M! O_A00*_Y8%"?^H!0C_N04'_] %!__C!0?_XP4'_^,%!__C!0?_XP6-N@
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M2(MD_TB+9/](BV3_2(MD_TC_4!8!_UP0 /]H#0#_<@X _WH0 /:!$@#IAA<
MWHH@ =**, 3)AD .P8)-&;I]5R.T>6$LKG5J-*ER<CJD;WM H&R$1)UJC4B9
M:)=,E6>A3Y)FK5&09;U2CF744XQF\%&+9_]0B&?_3H=H_TR&:/]+A6?_285G
M_TF%9_])A6?_285G_TG_4A0!_U\. /]K"P#_=0P ^7X- /"%#@#CBQ  UH\:
M ,R.+@3#BST-NX=*&+2#52*M?EXKIWMG,Z)W;SJ=='A F7* 195OB4F1;9--
MC6R>4(IJJE.':KE4A6K/5(1K[E.#;/]1@FS_3X%K_TV :_],@&O_2H!K_TJ
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M56&&X51AAOE28X3_4&6!_T]F?_]-9W[_3&=^_TQG?O],9W[_3&=^_TS_80H
M_V\  .!^  #0B0  QI,! +^; P"XH0( L:8+ *JH'@&CIR\%FZ4]#Y2B2!F,
MGU$BA9Q9*W^:83)YF&DY=)5Q/V^3>41JDH-(99".3&&/FT]>CJI26XZ]4EJ.
MWE);C?A07(O_3UZ(_TY@A?],88/_2V&#_TMA@_]+88/_2V&#_TO_9 4 ]70
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M1$FE_T1+H/]$39S_1$V<_T1-G/]$39S_1$V<_T3J=0  TH8  ,.3  "WG0
MK*0  **K  "8LP  CKL! (7!# "!PAT >\(M W7!.@EOP$41:;]/&&.^5QY>
MO5\C6;QH*%6[<2U1NWLP3;J'-$JZE3='NJ4Y1;JX.D2ZUSE#N/4[0K;_/4*S
M_SY$KO\^1:G_/D6I_SY%J?\^1:G_/D6I_S[@?0  R8T  +N:  "NH@  HZD
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M("WB_R MXO\@+>+_("WB_R"ZF@  JJ,  )VK  "0M   @[T  '?&  !KSP
M7]8  %3>! !1\!  3? ; $KP)@%&\3 "0O(Z S[R0P0[\TL%./-4!S;T70@S
M]&@),/5T"R[U@0PL]I$.*O:B#RCWMQ G^-81)_;T$2;S_Q$F\?\1)?'_$R7Q
M_Q,E\?\3)?'_$R7Q_Q.MH0  H*D  )*S  "$O   =L8  &G/  !=V   4=\
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M P#_[ .(N0  >,0  &G0  !;W0  2^,  #[I   R[@  *_\  ";_   A_P
M'?\( !K_#0 6_Q$ $_\6 !#_&@ ._Q\ "_\D  G_*@ &_S   O\W 0#_0 $
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M0ID?[4&A(.Q!J2'J0+(BZ$"\(N= RB/D0=\CX$'O)-Q _"?80/\IU#__*L]
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MB%__.XA?_SO_3A$ _U@* /]C!P#Z; 8 YW,& -UX" #:>PL T7X7 ,A^*P+
M?#L(N7E($;)V4QFL<ETAIV]F**-M;BZ?:G<SFVA_-YAFB#N599$^D6.;08YB
MIT.,8;1%B6''18ABY46&8OI#AF/_0H1C_T"#8_\^@F/_/8)C_SR"8_\\@F/_
M/()C_SS_4 \ _UL' /]F P#L;P( W'8# -1\!P#1@ D RH(4 ,*#* *Z@3D'
MLWY&$*Q[41FF=UHAH71C*)QR:RZ8;W,SE&U\-Y%KA#N-:HX_BFB80H9GHT2$
M9K%&@6;#1W]FX4=_9_A%?FC_0WYH_T%]9_\_?&?_/GQG_SU\9_\]?&?_/7QG
M_SW_4@X _UT# /UI  #A<@  UGH" ,Y_!0#*@P@ Q882 +R')@&UAC8&KH-#
M#Z> 3ABA?%@@FWE@)Y9W:2V2=' SCG)Y-XIP@3R&;HL_@VV50W]LH45\:ZY'
M>FN_2'AKW4AX;/9&>&S_1'=L_T)W:_] =VK_/W=J_SYW:O\^=VK_/G=J_S[_
M5 P _U\  /)L  #==@  T'T" ,F#! #$AP8 OXH0 +>,(P&PBC0%J8A!#J*%
M3!><@54?EG]>)I%\9BV,>6XRB'=V-X1U?SN =(@_?'*20WAQGD9U<*Q(<V^]
M27%PV4EQ</1'<7'_1')P_T)R;_]!<F[_/W)N_SYR;O\^<F[_/G)N_S[_5@H
M_V(  .9O  #7>0  S($! ,6' P"_BP0 N8X. +*0( &KCS$%I(P_#9V*2A:6
MAU,>D81<)8N!9"R&?VLQ@GUS-GY[?#MZ>88_=G>00G)VG$5O=:E(;'6Z26MU
MU$EK=?)':W7_16QU_T-M<_]!;7+_/VUR_S]M<O\_;7+_/VUR_S__60< _V4
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M0UF&_T%;@_] 78'_/EV _SY=@/\^78#_/EV _S[_8@  Y'$  ,]^  ##B
MN9$  +"7  "GFP  GJ$  )BC$P"3HR4!C:(T!H:A0 V GTH5>9U3''2;6B-O
MF6(H:IAJ+F:6<C)AE7PW792&.EF2DSY6DJ% 4Y&R05*2R4)2D>M!4I#_0%*/
M_S]5B_\^5HC_/5>'_SU7A_\]5X?_/5>'_SWY9P  W78  ,F#  "]C0  LY4
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M,D&F_S)!IO\R0:;_,D&F_S+5?   PHH  +66  "HG0  G:,  )*J  "'L0
M?+<  '"^ P!HP@X 9L,= &/#+0%>PSD$6L-$"%;"3@Q2PE<03\%?%$O!:1=(
MP7,:1<!^'4+ C" _P)LB/<"M(SS!Q",\P.DC.K[^)CB\_R@WN_\I.+C_*CBV
M_RLXMO\K.+;_*SBV_RO)A0  N9,  *R<  "@H@  E*H  (BQ  !\N   <;X
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M"Q_J_PNHGP  FZ8  (VO  !_N   <<$  &3*  !8T   3-8  $'=   XY
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M 0#_<P$ _X<! /^= 0#_L@$ _\H! /_J 0#_\P$ __,! /_S 0#_\P&$MP
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M.8-=U#F"7O X@5__-H!?_S2 7_\S?U__,7Y?_S!^7_\P?E__,'Y?_S#_30D
M_U8  .YA  #=:0  T6\  ,IS P#%=08 P'80 +AX(P"Q>#,#JW9!":5S3!"?
M<%87FVY?'99L9R*3:F\GCVAW*XQG?R^)98@RA622-8)CG3> 8JHY?6*Y.GMB
MSSMZ8NXY>F/_.'IC_S9Y8_\T>6/_,GEB_S%Y8O\Q>6+_,7EB_S'_3P< _UD
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M.6AQ_S=H</\U:6__-&EN_S-I;O\S:6[_,VEN_S/_5@  ZV(  -AN  #)=@
MOWT  +>"  "PA0  J(<& **)%P"<BBD!EHDW!I"'0PR+A4T3A8)5&8" 71]\
M?V4D>'UM*71[=2UP>GXQ;7F(-&EWE#=F=J$Z8W:P.V%VQ#QA=N4[87;[.6)V
M_S=C=?\U8W/_-&1R_S-D<O\S9'+_,V1R_S/_6   YF8  -)Q  #%>@  NX$
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M,5*$_S%2A/\Q4H3_,5*$_S'J90  TG,  ,)_  "VB   K)   **4  "8F
MC)P  (2?"@" H!D ?*$I 7>@-@5RGT$*;9Y+#VB=4Q1DG%L98)MC'5R::R%8
MF70E59A^*5&7BBQ.EI@N2Y:H,$J6O#%)EMPP293V,$F3_S!)DO\P2I#_+TN-
M_R]+C?\O2XW_+TN-_R_B:P  RGD  +R%  "QCP  II0  )N9  "1G0  AJ(
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M(#.R_R#!@P  M)$  *:8  ";G@  CZ4  (*K  !VL0  :[8  %^\  !4P0,
M3,4- $O%&0!)QB@ 2,8U $7'0 %#QTH#0,=3!#['708[QV<(.<=S"C?'@ PT
MQY -,L>A#C'(M0\PR-,/,,;T$"[$_Q,MPO\5+,'_%BO _Q<KP/\7*\#_%RO
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M AWII (;Z;P"&NKB AKF_ (9Y?\#&>3_!!CC_P48X_\%&./_!1CC_P6CG0
MEJ0  (BL  !ZM0  ;+T  %_$  !3R@  1\X  #S3   RV@  *M\  "7N"0 C
M\!$ (?$9 !_Q(@ =\BL &_,T !GT/@ 7]$@ %?52 !/V7P 2]FX!$?>  1#X
ME $/^:H!#OG& 0[Y[0$-]O\!#?3_ 0WS_P$-\_\!#?/_ 0WS_P&9HP  BZP
M 'RU  !MO@  7\8  %+-  !%T@  .=@  "_>   FX@  '^H  !S[!@ 9_PX
M%_\3 !3_&@ 2_R$ $/\H  [_,  -_SD "_]#  G_3@ &_UP !/]L  +_@  !
M_Y8  /^M  #_R@  __   /__  #__P  __\  /__  #__P"-JP  ?;4  &Z_
M  !@R   4M   $/7   WW0  *^(  "+F   9Z@  %?D  !+_   0_P@ #O\.
M  S_$0 )_Q8 !O\<  /_(@  _RH  /\S  #_/0  _TD  /]7  #_:0  _WX
M /^5  #_K   _\<  /_H  #_^@  __H  /_Z  #_^@" M0  <+\  &')  !2
MTP  0]L  #7A   IY@  'NH  !7N   0^   #O\   O_   (_P  !/\&  #_
M"@  _PX  /\1  #_%0  _QL  /\C  #_*P  _S8  /]#  #_4P  _V4  /]Z
M  #_D0  _Z8  /^X  #_SP  _\\  /_/  #_SP#_'"\!_R L ?\A+ '_'BX!
M_QHS ?\4/ '_#T8!_PU4 O\+80+_"6\"_PE[ O\)A@+_"9 "_PF9 O\)H +_
M":<"_PFM O\)M +_";P!_PG% ?\)T0+_">,"_PGO O\)^0'_"O\!_PK_ ?\*
M_P+_"O\"_PK_ O\+_P/_"_\#_PO_ _\+_P/_'RT!_R,I ?\D*0'_(BL!_QXP
M ?\8. '_%$,!_Q%0 O\07@+_#FL"_PYW O\.@P+_#HT"_PZ5 O\.G0+_#J0"
M_PZJ O\.L0+_#KD"_P[! O\.S0+_#M\"_P[L O\.^ +_#O\"_P[_ O\/_P/_
M#_\#_P__!/\0_P3_$/\$_Q#_!/\0_P3_(RH!_R8F ?\H)0'_)R<!_R,K ?\>
M,P'_&T !_QE- O\66@+_%&<"_Q-S O\3?@+_$XD#_Q.1 _\3F0/_$Z "_Q.G
M _\3K@/_$[4#_Q.^ _\3R0/_$]H#_Q3I _X4]@/[%/\#^17_ _D5_P3X%?\%
M^!7_!O@5_P;X%?\&^!7_!O@5_P;_)B8!_RHB ?\L( #_*R(!_R@F ?\G, '_
M)#P!_R)) O\?50+_'6("_QMN _\;>@/_&H0#_QJ- _\:E0/_&IP$_QJC!/\;
MJ@3_&[($_QNZ!/\;Q03\&],$^1OG!/4<] 3R'/\%\1S_!O <_P?O'?\([QW_
M">\<_PGN'/\)[AS_">X<_PG_*B(!_RX= /\P&P#_,!P _S B /\P+ '_+C<!
M_RM$ O\H40+_)ET#_R1I _\C=03_(W\$_B.(!/TCD07[(Y@%^B.@!?@CIP;W
M(ZX&]2.W!O0CP0;R),\&[B3D!NHE\@;H)?X(YB3_"N0E_POC)?\,XR3_#.(D
M_PSA)/\-X23_#>$D_PW_+AX _S,8 /\U%@#_-14 _S@= /\X)P'_-S,!_S0_
M ?\R2P+_+U@#^RYD!/@M;P3U+'H%\RR#!O$LC ;O+)0'[2R<".PLHPCJ+*L(
MZ2RS".<LO@GF+,P)XBWB"-XM\0K;+/X,UBW_#M0L_P_2+/\0T2S_$,\L_Q#.
M+?\0SBW_$,XM_Q#_,AD _S<4 /\Z$0#_/!( _S\9 /] (@#_/BT!_SPY ?HZ
M10+T.%(#\#=>!.PV:@7I-70&YC5^".0TAPCB-) )X#28"MXTGPK<,Z<+VC.P
M#-@SNPS5,\D-TC3?#<XT\ _*-/T2QS3_$\4T_Q3#-/\5PS/_%< T_Q6_-/\4
MOS3_%+\T_Q3_-A4 _SL0 /\^#0#_0P\ _T84 /]&' #_1B8 ]D0R >]"/P'I
M0$P#Y#]9!-\^9 ;;/6\(V#QY"M0\@@S1.XL-SSN3#\TZFA#+.J(1R3JK$L@Z
MM1/&.L(3Q#K5%, [ZQ6\.OL7N3K_&+<Z_QFV.O\9M3K_&+([_QBQ._\8L3O_
M&+$[_QC_.1( _S\- /]#"0#_2 P _TL0 /],%0#U3!\ ZTHJ .1)-P'=248"
MU4=3!-!&7PC,16D+R41S#<9#?!##0H02P4*,$[]!E16]09T6NT"F%[I L!BX
M0+P9MD#,&K-!YAJO0?<<K4'_':M!_QVI0?\<J4'_'*9!_QNE0?\;I4'_&Z5!
M_QO_/1  _T() /](!0#_30@ _U + /E1#P#K4!4 X4\@ -A0,0#/4$$"R4].
M!<1.6@G 3&0-O4MM$+I*=A.W27X5M4B'%[-'CQFQ1Y<;KT:@'*U&JAZK1;8?
MJ47&'Z=&X""D1O0@H4;_(9]'_R">1_\@GD?_'YM'_QZ:1_\>FD?_'II'_Q[_
M0 T _T8$ /],  #X4@( Z%4$ .%5" #B50T U549 ,Q7+ #%5SP"OU9*!KI5
M50JV4U\.LE)H$J]0<16L3WD8JDZ!&JA-BAVE3)(?HTR<(*%+IB*?2[$CG4O
M))M+V"692_ EEDS_))5,_R243/\CDTS_(I%-_R&13?\AD4W_(9%-_R'_0@H
M_TD  /]1  #F5P  W5L! -5<!0#26PD RUP4 ,->* "\7C@"MEU&!K%;40JM
M65L/J5AD$Z96;!>C570:H%1]'9Y3A1^;4HXBF5&7))=0H2:54*TGDE"\*)%0
MT"B.4.PHC5'^)XM1_R:+4?\EBE+_)(E2_R.(4O\CB%+_(XA2_R/_10< _TL
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M+75?_RMU7_\I=5__*'5>_R9U7O\F=5[_)G5>_R;_2P  \%4  -Y?  #-9P
MPVP  +MO  "U<   KV\* *AQ&@"C<BL!G7(Y!)AP10F3;D\.CVU8%(MK8!B'
M:6<<A&AO((%G=R-]9H F>F2**7=CE"QU8Z$N<F*O+W!BP3!O8M\P;F/W+F]C
M_RQO8_\J;V/_*&]B_R=O8O\G;V+_)V]B_R?_30  ZU@  -EC  #):@  OW
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M*6!O_RA@;O\H8&[_*&!N_RCQ50  WF(  ,IM  "]=0  LWL  *N   "B@@
MF($  )&##P"-A1\ B(4N H.$.P5^@T4*>H%.#W6 5A1Q?UX8;GUF'&I\;2!G
M>W8C8WJ )V!YBRI=>)@L6G>F+EAWN"]7=]$O5W?Q+EAV_RQ8=O\J677_*5IT
M_RA:=/\G6G3_)UIT_R?M60  UV8  ,5Q  "Y>@  KX   *:$  "=A@  D8<
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M)$:*_R38:0  PW8  +6!  "KB@  GX\  )63  "*E@  ?IH  '"=  !KGPX
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M#S.SK1 RL\40,K+I$#&P_A(PKO\4+ZW_%2^L_Q8OK/\6+ZS_%B^L_Q:[@0
MKHX  *&5  "6F@  B:   'VF  !QJP  9:\  %FT  !.MP  0[P% $"]$0 _
MO1X /KXK #R^-@ [OT$ .;]+ 3>_5 (UP%\",\!J!#' =P4OP(8&+<"7!RO
MJ@@JP<((*L#G!RF]_0HHO/\,)[K_#2>Y_PXGN?\.)[G_#B>Y_PZRC   I90
M )F:  "-H0  ?Z<  '*M  !FLP  6K@  $^[  !$OP  .L0" ##)"  NRA$
M+<H= "S+*0 KRS4 *\Q  "K-2@ HS58 )\YA ";.;P$DSG\!(\^1 B'/I0(@
MT+T"(,_D A_-^@,>R_\$'LK_!1W)_P8=R?\&'<G_!AW)_P:HE   G)H  )"A
M  ""J   =*\  &>V  !;O   3L   $/#   YQP  +\P  "?0!  ?U@H &]H0
M !O;&@ :VR8 &MPQ !G=/  8W4@ &-Y5 !??8@ 6X'( %>"% !3AF@ 3XK$
M$N// !+@]  2WO\!$=W_ 1';_P(1V_\"$=O_ A';_P*>F@  DJ$  (2I  !V
ML0  :+@  %N_  !.Q   0L@  #?,   MT   )-4  !S;   5WP4 %.D. !+J
M%  1ZQT $.LF  [L,  .[3H #>Y&  ON4P *[V( "?!T  CQB0 '\J  !?*Z
M  3QY  "\?T  N__  /M_P #[?\  ^W_  /M_P"5H0  AJD  'BR  !IN@
M6\(  $W(  ! S   --$  "K6   AVP  &>   !+D   /\ $ #?D*  OZ#P )
M^Q4 !_L<  3\)  !_"P  /PW  #\0@  _%   /QA  #]=0  _(P  /RD  #\
MP0  _.L  /S_  #]_P  _?\  /W_  #]_P")J0  >;(  &J[  !<Q   3LP
M #_1   RUP  )]T  !WA   5Y0  #N@   KQ   (_0  !?\#  '_"0  _PX
M /\2  #_%P  _Q\  /\G  #_,0  _SX  /]-  #_7P  _W4  /^-  #_I@
M_\(  /_G  #__   __\  /__  #__P!\LP  ;+P  %W&  !.SP  /]8  #'=
M   EX@  &N8  !'J   ,[@  !?(   #_    _P   /\   #_    _P4  /\*
M  #_#@  _Q(  /\8  #_(0  _RL  /\Y  #_2@  _UT  /]S  #_C   _Z0
M /^Y  #_U   _]X  /_>  #_W@#_&"P _QDI /\9* #_%2L _Q P /\+. '_
M T0!_P!1 ?\ 7@'_ &P!_P!X ?\ @@'_ (P!_P"4 ?\ G #_ *( _P"H /\
MKP#_ +8 _P"^ /\ R #_ -< _P#G /\ \P#_ /T _P#_ /\ _P#_ /\ _P#_
M /\ _P#_ /\ _P#_ /\ _P#_&RD _QTF /\<)0#_&2< _Q,L /\.- #_"T !
M_PA. ?\%6P'_ V@!_P)T ?\"?P'_ H@!_P*1 ?\"F '_ I\!_P&E /\!K #_
M ;( _P&Z /\!Q #_ =$ _P#D /\ \0#_ /P _ '_ /P"_P#\ _\ _ 3_ ?P%
M_P'\!?\!_ 7_ ?P%_P'_'R8 _R$B /\@(0#_'B, _Q@G /\3, #_$3P!_PY*
M ?\-5P'_"V,!_PIO ?\*>@'_"H0!_PJ- ?\*E '_"IL!_PJB ?\*J '_"J\!
M_PJW ?\*P #_"LP _PK@ /L*[P#W"OH ]0O_ ?4,_P'T#?\!] W_ O0-_P+T
M#?\"] W_ O0-_P+_(B( _R0= /\D' #_(AT _QXB /\<+ #_&3@ _Q9% ?\3
M4@'_$EX!_Q!J ?\0=0'_$'\!_Q"( ?\0D '_$)<!_Q"> ?\0I0']$*P!_!"S
M ?H0O0'Y$<D!]1'= ?$1[0'N$?D![!+_ NL3_P+J$_\#Z1/_ ^D3_P/I$_\#
MZ1/_ ^D3_P/_)AT _R@8 /\H%@#_)A8 _R8= /\F* #_(S0 _R!  /\=30'_
M&UD!_QEE ?X9< '\&'H!^1B# ?<8C 'V&),!]!B: ?,8H0'Q&:@!\!FP NX9
MN@+M&<8"ZAK9 N8:ZP'B&_D"X!O_ ]X<_P3='/\%W!S_!=P<_P7;'/\%VQS_
M!=L<_P7_*AD _RT3 /\M$0#_+1$ _RX9 /\M(@#_+"X _RDZ /\F1P'Z)%0!
M]B-@ ?(B:P'O(G4"[2)^ NLBAP+I(H\"YR*6 N4BG@+D(J4"XB*M N$CMP+?
M(\,"W2/6 M@DZ@/2)/D%SR7_!LTE_P?+)?\(RB7_",HD_PC*)/\(RB3_",HD
M_PC_+A0 _S$0 /\R#0#_- X _S44 /\U' #_,R< ^C$T /,O00#N+4X!Z2Q:
M >4L90+B+' "WRMY MTK@@/:*XL#V"N2!-4KF@33*Z($T2NJ!<\KLP7-*[\&
MS"S/!L@MYP?$+?<)P2W_"K\M_PN]+?\,O"W_#+PL_PR[+/\,NRS_#+LL_PS_
M,1$ _S4, /\V!P#_.@L _SP0 /\[%0#X.1\ [S<K .<V.0#A-4< W#54 =4U
M8 +1-6H#SC1S!,PT? 7*-(4&R#2-!\8SE C$,YP)PC.E"<$SK@J_,[D+O3/(
M"[LTX0NW-/,-M#3_#[$T_P^P-/\0KS3_$*XT_P^N-/\/KC3_#ZXT_P__-0X
M_S@' /\\ @#_0 8 _T$+ /I!#P#M/Q8 XSPB -H],0#2/D$ S#Y/ L@^6@/$
M/60%P3UN![\\=@B\/'X*NCN'"[@[CPRW.Y<-M3J?#K,ZJ0^Q.K00KSK"$:XZ
MV1&J.^\2ISO_$Z4[_Q2D._\3HSO_$Z([_Q.B._\2HCO_$J([_Q+_. H _SP
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M'H9,_QV%3/\<A4W_&H5,_QF%3/\9A4S_&85,_QG_0   _$<  .50  #55@
MRED  ,):  "]6 , N%<. +%9'@"L6B\!IUH] J)9206>6%,)FU=;#)=69!"5
M56L2DE1S%8]3>Q>-4H0:BU&-'(A1EQZ&4*,?A%"P(()0P2& 4-TA?E'T('U1
M_Q]]4?\=?5'_''U1_QM]4?\:?5'_&GU1_QK_0@  \$H  -]4  #.6@  Q%X
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M'VI>_QYJ7O\=:E[_'6I>_QWY2@  XU4  ,]?  #!90  MVH  *]L  "G;
MGVH! )EK$0"4;2( D&XQ 8MM/02';$<'@VM0"W]J6 ]\:& 3>&=G%G9G;QES
M9G@<<&6!'FUDC"%J8Y@C:&*F)69BMB9D8LPF9&+L)61B_R-D8O\A96+_'V5B
M_QYE8O\=96+_'65B_QWR3   WU@  ,IB  "]:0  LVX  *MP  "B<   F6X
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M'55O_QWE5P  S60  +YM  "R=0  J'L  )]^  "3?0  AWT  (!_!P!\@!4
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M&D.*JAM"BK\;08KA&T&(^1M!AO\;087_&T*%_QI"A/\:0H3_&D*$_QK-9P
MO'0  *]^  "EA@  FHH  (Z,  ""C0  =9   &>4  !AE0@ 7I<4 %R7(P!:
MF"\ 5Y@Z 5281 -2ETP%3Y=4!TR77 E)EF4,1Y9O#D25>A%!E8@3/Y27%3V4
MJ!8[E+T6.Y3?%CJ2^!<ZD/\7.H__%SJ._Q<ZCO\7.H[_%SJ._Q?%;@  MGL
M *J%  ">BP  E(\  (B2  ![E   ;I<  &*;  !7G@  4J . %&@&P!/H2@
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M R.W] 0BM?\%(;3_!B&S_P<ALO\'(;+_!R&R_P>MB@  H)$  )67  "(G0
M>Z,  &ZH  !AK0  5;$  $JT   _MP  -+L  "N^ P DP@P (L(4 "+#'P A
MPRH (,0T !_$/P >Q4H '<96 !S&8P ;QW, &L>% !G'F0 8R*X %\C+ !?&
M\0$7Q/\!%L/_ A;!_P,6P?\#%L'_ Q;!_P.CD0  F)@  (N>  !]I0  <*L
M &*Q  !6M@  2KD  #Z]   TP   *L0  "+(   9S 0 $] * !'2$0 0TAH
M$-,E  _3,  .U#P #M1(  W55@ -U64 #-9X  S6C0 +V*0 "MB^  G9Y@ *
MUOX "]3_  O2_P +TO\!"]+_ 0O2_P&:F   CI\  ("F  !RK0  9+0  %>Z
M  !)OP  /<(  #+&   HR0  '\T  !?1   1U@  #-L%  C>"P &WQ$ !=\:
M  3@)  "X2X  >(Z  #C1P  Y%8  .1G  #E>P  YI(  .:J  #GR   Y_
M .C_  #H_P  Z/\  .C_  #H_P"1GP  @J<  '2O  !EMP  5[X  $G#   \
MQP  ,,L  "7/   <U   %-D   [=   )X0   N4   #I!@  Z0T  .D1  #J
M&   ZR$  .TK  #O-P  \44  /)6  #S:   \WX  /27  #UL   ]M   /?S
M  #W_P  ]_\  /?_  #W_P"%IP  =K   &:X  !8P0  2L@  #O,   NT0
M(]8  !G<   1X   #.,   3G    Z@   /4   #T    ]04  /4+  #V#P
M]A0  /@=  #Z)P  _#0  /]#  #_50  _VD  /^!  #_F@  _[(  /_/  #_
M[0  __D  /_Y  #_^0!XL   :+H  %G#  !+RP  .]$  "W8   AW0  %N(
M  [F   (Z@   .T   #P    ^    /\   #_    _P   /\   #_!@  _PP
M /\0  #_&   _R(  /\P  #_0   _U,  /]I  #_@0  _YD  /^O  #_PP
M_]4  /_5  #_U0#_$R@ _Q,E /\1)0#_#2< _P8M /\ -0#_ $$ _P!/ /\
M7 #_ &D _P!T /\ ?@#_ (@ _P"0 /\ EP#_ )T _P"D /\ J@#_ +  _P"W
M /\ P #_ ,P _P#? /\ [ #_ /@ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\
M_P#_ /\ _P#_%B4 _Q8B /\4(0#_$", _PHH /\ , #_ #T _P!+ /\ 6 #_
M &0 _P!P /\ >@#_ (0 _P", /\ DP#_ )H _P"@ /\ I@#_ *T _P"T /\
MO #^ ,@ _0#9 /L Z0#Z /8 ^0#_ /@ _P#X /\ ^ #_ /@ _P#Y /\ ^0#_
M /D _P#_&B( _QH> /\8'0#_$QX _PXB /\*+ #_!SD _P-& /\ 4P#_ &
M_P!K /\ =@#_ '\ _P"( /\ CP#_ )8 _P"= /\ HP#^ *D _ "P /H N0#W
M ,0 ]0#2 /, Y@#R /0 \0#_ /  _P#O /\ [P#_ .\ _P#P /\ \ #_ /
M_P#_'AT _QX9 /\<%P#_%Q@ _Q,> /\1* #_#C0 _PQ! /\*3@#_"%L _P=F
M /\&<0#_!GH _P:# /X&BP#\!I( ^@:9 /@&GP#V!J8 ] :M /(&M0#P!<
M[07. .L%Y #I!O, Y@C_ .4*_P#D"_\ Y O_ >0+_P'D"_\!Y O_ >0+_P'_
M(1@ _R$3 /\@$0#_&Q( _QP: /\:) #_%B\ _Q,\ /\120#_$%4 _ YA /D.
M:P#V#G4 ] Y^ /(.A@#P#HX [@Z5 .T.FP#K#J( Z@ZJ .@.LP#F#[T Y0_,
M .$/XP#=$/, V1'_ =82_P'4$_\!TQ/_ M(3_P+2$_\"TA/_ M(3_P+_)1,
M_R40 /\D#0#_(PX _R,4 /\B'@#_'RD _QPU /D90P#T&$\ [Q=; .P79@#I
M%W  YA=Y .07@0#B%XD X!>1 -\7F #=%Y\ VQ>G -D8L0#6&+L U!G* - :
MX0',&_,!R1S_ L8<_P+$'/\#PQS_ \,<_P/#'/\#PQS_ \,<_P/_*!  _RD+
M /\H!@#_*PL _RL0 /\I%P#])B( ]",N .PA.P#F($D XB!5 -X@8 #:(6H
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M"Y\U_PR=-?\,G37_"YPU_PN<-?\+G#7_"YPU_PO_,P( _S4  /8Z  #E/@
MW$   -0]! #2-PD RS@5 ,,Z)@"]/38 N#Y$ ;0^4 &Q/5H#KCUC!*P]:P6I
M/',&ISQ["*8\@PFD.XL*HCN4"Z [G0R>.Z@-G3NT#IL[Q0Z9.^ .ECOT#Y0\
M_P^2//\/DCS_#I$\_PV1//\-D3S_#9$\_PW_-0  _SD  .I!  #=1@  T$<
M ,E&  #&004 P$ 1 +E"(0"S1#( KT5  :M%2P*G154#I$1>!:%$9@>?0VX(
MG4-V"IM"?@N90H8-ET&/#I5!F0^30:01D4&P$I!!P!*.0=D2BT'Q$HE"_Q*(
M0O\1B$+_$(="_Q"'0O\/AT+_#X="_P__.   \ST  .-'  #23   R$X  ,!-
M  "[2@( MD<. +!)'0"K2RT IDP[ :),1P*>2U$$FTM:!IE*8@B626H*E$EQ
M#))(>0Z/2((/C4>+$8M'E1*)1J 4AT:L%85&NQ:$1M$6@D?N%H!'_Q5_1_\4
M?T?_$G]'_Q%_1_\1?T?_$7]'_Q'_.P  [D,  -Q,  #,40  P50  +E4  "T
M40  KDT+ *A/&0"C42D GE(W 9I20P*744X$E%%6!I%07@F.3V8+C$YM#8E.
M=0^'37X1A4V'$X),D16 3)P6?DNI%WQ+N!A[2\T8>4SK&'A,_A=W3/\5=TS_
M%'=,_Q-W3/\2=TS_$G=,_Q+_/@  Z$<  -50  #&5@  O%@  +19  "M5@
MIU,' *%4%0"<5B4 F%<T 9170 *05TH$C593!HI56PF'5&,+A%1J#H)3<A"
M4GH2?5*#%'M1CA9X4)D8=E"F&710M1IS4,D:<5#H&G!1_!AP4?\7<%'_%7!1
M_Q1Q4/\3<5#_$W%0_Q/U0   Y$L  ,]4  #!6@  MUT  *]>  "G6P  H5@#
M )M9$@"66R( DEPQ 8Y</0**7$<$AUM0!H-:6 F!66 ,?EEG#GM8;Q!Y5W<3
M=E: %716BQ=R5989;U6C&FU4LAML5,8;:E7F&VI5^QEJ5?\7:E7_%FI5_Q5K
M5?\4:U7_%&M5_Q3R0P  WT\  ,M8  "]70  LV$  *MB  "B8   FUP  )5>
M$ "08!\ C&$N (AA.@*$8$4$@6!.!GY?5@E[7ET+>%UE#G9<;!!S7'03<%M]
M%6Y:B!=K6I09:5FA&V=9L!QE6<,<9%GC'&19^AID6?\89%G_%V59_Q5E6?\4
M95G_%&59_Q3O1@  VE(  ,9;  "Z80  L&4  *9F  "=8P  E6$  (]B#@"+
M9!P AV4K (-E-P%_94(#?&1+!GAC4PAU8UL+<V)B#G!A:A!M8'(3:V![%6A?
MAA=F7I$98UZ?&V%=KAQ@7<$<7UWA'%]=^!I?7?\87UW_%V!=_Q9@7?\58%W_
M%6!=_Q7K2@  U%8  ,->  "V90  K&D  *)I  "89P  CV4  (EF# "%:!D
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M&5%MJ!I/;;L;3FW9&DYL]!E/:_\83VO_%U!J_Q90:O\54&K_%5!J_Q7=50
MQ6$  +=J  "L<0  HG4  )1T  ")=   ?',  '9U  !Q=Q  ;W@= &QY*P!I
M>3<!9GE  V-Y205@>%$'77=8"5MW8 Q8=F@.575Q$5)U?!-0=(@63727%TMS
MIAA)<[D92'/5&4ER\QA)<?\72G'_%DIP_Q5+</\42W#_%$MP_Q346@  P&8
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M#C:-[PXUB_\.-8G_#S6(_P\VA_\/-H?_#S:'_P^^;0  L'D  *6"  "9AP
MC(@  '^(  !RB@  9HT  %J1  !0E0  29<) $>8$P!%F"  1)DK $.9-@!!
MFD  0)I( 3Z:40(\FEH".IID S>:;P4UF7T&,YF,!S&9G0@OF; (+IG*""Z8
M[0@NEO\*+93_"BV3_PLMDO\++9+_"RV2_PNV=0  JH$  )Z(  "3C0  AHX
M 'B/  !KD@  7Y4  %29  !)G0  0*   #JB#0 XHQ< -Z,B #:D+0 UI#<
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M !"Z_P$0NO\!$+K_ 1"Z_P&?CP  E)4  (>;  !YH0  :Z<  %ZL  !2L0
M1;0  #JV   ON0  );P  !V_   5PP  #\8%  O*#0 )RA0 ",H=  ?*)P '
MRC( !LL^  7+2P $S%H  \QJ  +,?@ !S)0  ,RK  #-R   S.T  ,S_  #+
M_P !RO\  <K_  '*_P"7E@  BIP  'RC  !NJ@  8+   %*V  !%N0  .;P
M "Z_   CPP  &\8  !/*   -S0  "-$   '4"0  U X  -45  #6'@  V"<
M -DQ  #;/@  W$L  -U;  #>;@  WH0  -^;  #?M   WMD  -_W  #?_P
MW_\  -__  #?_P"-G0  ?Z4  '"L  !ALP  4[H  $6_   XP@  +,8  "')
M   8S0  $-$   O5   $V@   -X   #@ 0  X0D  .(.  #D$P  Y1L  .<D
M  #I+P  ZSP  .U+  #N70  [G$  .^)  #PH@  \+P  /#C  #O^0  \/\
M /#_  #P_P"!I0  <JT  &.U  !4O0  1L0  #?(   JS   ']   !75   .
MV@  !]X   #B    Y@   .D   #J    [    .X%  #O#   \1   /,7  #U
M(   ^"L  /LY  #]2@  _EX  /]T  #_C0  _Z8  /_   #_X0  __4  /_U
M  #_]0!TK@  9;<  %;   !'R   .,T  "K2   =V   $]T   SB   #Y@
M .D   #L    \    /,   #T    ]@   /@   #Z    _0<  /\-  #_$@
M_QL  /\H  #_-P  _TH  /]>  #_=@  _X\  /^F  #_N@  _]$  /_1  #_
MT0#_#R0 _PXB /\+(0#_ R0 _P I /\ ,@#_ #X _P!, /\ 60#_ &4 _P!P
M /\ >@#_ (0 _P", /\ D@#_ )D _P"? /\ I0#_ *L _P"R /\ N@#_ ,4
M_P#3 /\ YP#_ /0 _P#_ /X _P#_ /\ _@#_ /X _P#^ /\ _@#_ /X _P#_
M$2$ _Q > /\-'0#_!Q\ _P C /\ +0#_ #H _P!( /\ 50#_ &$ _P!L /\
M=@#_ '\ _P"' /\ C@#_ )4 _P"; /\ H0#_ *< _@"N /T M@#\ ,  ^P#-
M /D X@#X /  ]P#\ /8 _P#U /\ ]0#_ /4 _P#U /\ ]0#_ /4 _P#_%1T
M_Q,: /\0&0#_"QD _P = /\ *0#_ #8 _P!# /\ 4 #_ %P _P!G /\ <0#_
M 'H _@"# /P B@#Z )$ ^0"7 /@ G0#W *, ]0"J /0 L@#R +L \0#( .\
MW #N .P [0#Z .L _P#J /\ Z@#_ .H _P#J /\ Z@#_ .H _P#_&!D _Q85
M /\3$P#_#A, _PL: /\') #_ C  _P ^ /\ 2P#_ %< _P!B /P ; #X '4
M]0!^ /( A0#Q (P [P"3 .X F0#L *  ZP"F .D K@#G +< Y@## .0 U #B
M .D X0#W -\ _P#= /\ W0#_ -T _P#= /\ W0#_ -T _P#_&Q, _QH0 /\6
M#@#_$@X _Q(5 /\/'P#_#"L _PDX /\&10#[ U$ ]P)< /("9@#N G  Z@)X
M .<"@ #F X< Y .. .(#E0#A YP WP2C -T$JP#;!+0 V 7  -8%T #3!N<
MT CX ,X*_P#,"_\ RPS_ ,L,_P#+"_\ RPO_ ,L+_P#_'Q  _QX+ /\:!P#_
M&0L _Q@1 /\6&0#_$B0 ^A P /,./@#N#4H Z0Q6 .4,80#B#&H W@US -L-
M>P#9#8, U@V* -0-D0#2#9D T Z@ ,\.J0#-#K, RPZ_ ,H/T #&$>D PA+Y
M +\3_P"]$_\!O!/_ ;P3_P&\$_\!NQ/_ ;L3_P'_(@P _R$$ /\@  #_(04
M_Q\, /\<$0#V&!P [!4H .43-@#?$D, V1-/ -,46@#0%60 S19M ,L6=0#)
M%WT QQ>% ,48C #$&)0 PAF< , 9I0"^&:\ O1J[ +L:RP"X&^4!M!SV ;(=
M_P*P'?\"KQW_ JX=_P*N'?\"KAW_ JX=_P+_)@8 _R4  /\F  #[)P  \24#
M / A"P#H'!( WAD= -0;+0#-'3P R!]) ,4@50#!(5\ OR)H +PB< "Z(W@
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M"(LV_P>*-?\'BC7_!XHU_P?_+P  \C0  .(\  #200  QT(  ,!   "[.@$
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M$P":2", EDDR ))*/@&/2D@"C$I1 XI)602'26 %A4EH!X-(;PB!2'<*?T>
M"WU'B@UZ1Y4.>$:B#W9&L!!U1L(0<T;@$')']P]Q1_\.<4?_#7%'_PQQ1_\+
M<4;_"W%&_POS.0  X$0  ,Q,  "^40  M%,  *I2  "B3@  G4H! )=+$0"3
M32  CT\N (Q/.@&(3T4"A4]. X-/5@2 3ET&?DYD!WQ-; EY370+=TQ]#'5,
MAPYS3)(/<4N?$6]+K1)M2[\2;$O<$FM,]1%J3/\/:DS_#FI+_PUJ2_\,:DO_
M#&I+_PSP/0  VT@  ,=0  "Z50  L%@  *56  "<4P  ET\  )%0#@",4AP
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M$EQ8IQ1;6+@465G0%%E8\!-96/\16EC_$%I8_PY:5_\-6E?_#5I7_PWC2
MRU,  +M;  "P80  I&(  )=A  ".7P  A5P  ']>!P![7Q, >&$A '5B+@!R
M8CD!;V)# FQA2P-J85,%9V%:!V5@8@EC8&H+8%]S#5Y>?0];7HD165V6$E==
MI1-57;845%W.%%1=[A-47?\155S_$%5<_PY56_\.5EO_#59;_PW>3   QU8
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M$4-MZA!$;/\/1&O_#D5K_PU%:O\-16K_#45J_PW+6   NF,  *UL  "A<0
MDG   (5O  !Z;P  ;G   &5S  !@=0< 7782 %MW'P!9>"L 5W@V %5X/P%3
M>$@"47A/ T]W5P1,=U\%2G=H!TAV<PE%=G\+0W6-#$%UG0X_=:X./G7%#CUU
MZ X^<_T-/G+_#3YQ_PP_<?\,/W#_##]P_PS%7@  M6D  *EQ  "<=0  C70
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M!2>-_P4GC/\%)XS_!2>,_P6Q=   I7X  )F%  "*A   ?80  &^%  !CB
M6(L  $V/  !#DP  .I<  #*:!P NFQ  +9L: "R<)  KG"X *ITX "F=00 H
MG4L )YY5 ":>80 EGFX (YY^ 2*>D $@GJ,!'YZY 1Z>W0$>G/@"'IK_ AZ9
M_P,>E_\#'I?_ QZ7_P.J?0  GH4  ).+  "%B@  =8L  &B.  !;D0  4)4
M $:9   [G0  ,J   "JC   BI@D 'Z<1 !ZG&@ =J"0 '*@M !NH-P :J4$
M&:E, !BI6  7JF8 %JIV !6JB0 4JIX $ZNT !*KTP 2J/4 $Z?_ 1.E_P$3
MI?\!$Z3_ 1.D_P&CA@  EXP  (V1  !]D@  ;94  &"8  !4G   2*   #ZD
M   TIP  *JL  "&N   9L0  $K,'  ^U$  .M1< #K4A  VU*P -M38 #+9!
M  NV3@ *MEP ";9L  BV?P 'MI0 !K:J  6VQ0 &MNH ![7_  BT_P (L_\
M";+_  FR_P":C0  D),  (28  !TG   9:   %>D  !+J   0*P  #6P   J
MLP  (;4  !BX   1NP  #+X"  ; "P "P!$  <$9  #!(@  PBL  ,(V  ##
M0@  PU   ,1?  #$<0  Q(<  ,2=  #$M0  Q-H  ,3V  ##_P  P_\  ,/_
M  ##_P"3E   AYH  'B@  !JI@  7*P  $^Q  !!M0  -;<  "FZ   ?O0
M%L   !##   *Q@   \H   #,!0  S P  ,T1  #.&   SB$  - J  #1-0
MTT,  -12  #48P  U7@  -6/  #5IP  UL(  -;I  #6_0  UO\  -;_  #6
M_P"*FP  >Z(  &RI  !>L   4+8  $*Z   TO0  *,$  !W$   4QP  #<L
M  ;.    T@   -<   #9    V@4  -P+  #=$   WQ4  .$=  #C)P  Y3,
M .="  #H5   Z&<  .E^  #IEP  ZJ\  .K.  #K[P  Z_X  .O_  #K_P!]
MHP  ;JL  %^R  !1N@  0L   #3#   GQP  &\L  !+/   +TP   M@   #=
M    X0   .0   #E    YP   .D   #K!P  [0T  .\1  #Q&0  ]"0  /<Q
M  #Y00  ^E4  /IJ  #[A   ^YT  /RV  #\T@  _>T  /WT  #]] !QK
M8;4  %*]  !$Q   -,D  ";-   :T@  $-@   C=    X0   .4   #H
M[    .\   #Q    \P   /4   #W    ^0$  /L(  #^#@  _Q4  /\A  #_
M+P  _T$  /]6  #_;0  _X<  /^@  #_M@  _\H  /_4  #_U #_"R  _P<>
M /\ '0#_ "  _P E /\ +@#_ #L _P!) /\ 5@#_ &( _P!M /\ =@#_ '\
M_P"' /\ C@#_ )0 _P": /\ H #_ *8 _P"M /\ M0#_ +X _P#+ /\ X0#_
M /  _@#] /T _P#] /\ _0#_ /T _P#\ /\ ^0#_ /D _P#_#1T _PL: /\$
M&0#_ !H _P ? /\ *@#_ #< _P!% /\ 40#_ %X _P!H /\ <@#_ 'H _P""
M /\ B0#_ )  _P"6 /\ G #^ *( _ "I /L L #Y +D ^ #& /8 V0#U .L
M] #Y /, _P#R /\ \P#_ /, _P#S /\ \P#_ /, _P#_$!D _PX5 /\(% #_
M !0 _P 9 /\ )0#_ #( _P!  /\ 3 #_ %D _P!C /X ;0#\ '4 ^@!] /D
MA #W (L ]@"1 /0 EP#S )X \@"D /  K #N +0 [0#  .L SP#I .8 Z #U
M .8 _P#G /\ Y@#_ .4 _P#E /\ Y0#_ .4 _P#_$A0 _Q 0 /\,#P#_ Q
M_P 5 /\ ( #_ "P _P Z /\ 1P#Z %, ]P!> /0 9P#Q '  [P!X .T ?P#K
M (8 Z@", .@ DP#G )D Y0"@ ., IP#A +  WP"Z -T R0#; .  V #P -<
M_@#5 /\ U #_ -, _P#3 /\ TP#_ -, _P#_%1  _Q(, /\."0#_"PP _PD2
M /\#&@#_ "8 _0 S /0 0 #O $T ZP!8 .@ 80#E &H X@!R .  >@#> (
MW "' -H C@#8 )4 U "< -( HP#0 *P S@"V ,P Q #* -D R #M ,< ^P#%
M /\ Q '_ ,,!_P#$ ?\ Q '_ ,0!_P#_& L _Q4% /\0  #_$ 8 _P\- /\,
M% #\!Q\ \0,K .< .0#B $8 W@%1 -H"6P#5 F0 T@-L ,\#= #-!'L RP2"
M ,H$B0#(!9  Q@68 ,0%H #"!JD P0:T +\&P0"]"-4 NPGL +@+_0"V#/\
MM0W_ +0-_P"T#?\ M W_ +0-_P#_&P4 _Q@  /\7  #_%@  ^Q,& /H0#@#N
M#!8 XPDB -H), #3"CX S@M* ,H,50#'#5X Q0UG ,(.;P#!#G8 OPY^ +T/
MA0"\#XT NA"5 +@0G0"W$*< M1&R +,1P "R$=4 KA/N *L4_@"I%?\ IQ7_
M *<5_P"F%/\!IA3_ :84_P'_'P  _QP  /H>  #K'@  XQP  -\5!0#>#@T
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M!'HU_P3U+0  Y#<  - _  #"0P  MT0  *U   "G.@  HS8& )TW$P"9.2(
ME3HO )(\.P"//$8 C#Q/ 8H\5P&(/%X"ACQE H0\;0."/'4$@#Q]!'\\AP5]
M/)(&>SN>!WD[K =W.[P(=CS5"'0\\0AS//\'<CS_!G(\_P5R//\%<CO_!7([
M_P7Q,@  WCT  ,E$  "\2   L$D  *9&  "?00  FST! )4]$ "1/QT C4$K
M (I". "'0T( A$-+ 8)#4P& 0UL"?D)B WQ":01Z0G$%>$)Z!G9!A =T08\(
M<D&;"'!!J0EO0;D*;4'0"FQ![@EK0O\(:D+_!VI!_P9J0?\&:D'_!6I!_P7M
M-P  UD(  ,1)  "W30  JTT  *!*  "81P  DT(  (Y##0")11H AD8H (-'
M- " 2#\ ?DA( 7M(4 )Y2%<"=TA? W5(9@1S1VX%<4=V!F]'@ =M1HP):T:8
M"FE&I@MG1K8+9D;,"V5&[ MD1_\)9$;_"&1&_P=D1O\&9$7_!F1%_P;H.P
MT$8  +]-  "S40  I5$  )I.  "22P  C4<  (=("P"#2A8 ?TLD 'U,,0!Z
M33P =TU% 75-30)S354"<4U< V]-8P1M3&L%:TQS!VE+?0AF2XD)9$N6"F)+
MI MA2[0,7TO*#%Y+Z@M>2_X*7DO_"5Y*_PA>2O\'7DK_!UY*_P?C/P  RTD
M +Q1  "P50  H50  )92  "-4   ATP  (%-" !]3Q, >E A '=1+@!T4CD
M<E)" 6]22P%M4E(":U%9 VE1801G46@&95!Q!V-0>PAA4(8*7T^3"UU/H0Q;
M3[(-64_'#5E/Z Q83_T+6$__"5E/_PA93O\'64[_!UE._P??0P  QTT  +A4
M  "L60  G5<  )%5  "(5   @5   'M2! !W4Q$ =%0> '%5*P!O5C8 ;%9
M 6I62 %H5E "9E97 V167@1B568%8%5O!UU5> A;5(0*6521"U=4H Q54[ -
M5%/%#5-3Y@Q34_P+4U/_"512_PA44O\(5%+_!U12_P?:1@  PU   +58  "H
M6P  F5H  (U8  "$5P  >U0  '96 0!Q5P\ ;ED; &Q:* !I6C, 9UL] 65;
M10%C6TT"85I5 U]:7 1=6F0%6UEL!EA9=@A668()5%B/"U)8G@Q06*X-3UC#
M#4Y8Y Q.6/L+3U?_"4]7_PA/5O\(4%;_!U!6_P?32@  P%0  +)<  "C7@
ME5T  (E<  !_6P  =ED  '!:  !K7 T :%T8 &9>) !D7S  8E\Z &!?0P%>
M7TL"7%]2 EI?6@-87V$%55YJ!E->= =177\)3UV-"DU=G M+7:P,2EW!#$E=
MXPQ)7/H*25O_"4I;_PA*6O\(2EK_!TI:_P?.3@  O%@  *Y@  "?80  D6
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M!SAL_P8Y:_\&.6K_!CEJ_P:]7   KV8  *)M  "1;   @FL  '=K  !L;
M86X  %=P  !0<P  3'4* $EV$P!'=Q\ 1G<I $5X,P!#>#P 0GA$ $%X30$_
M>%4!/7A> CMX: (Y>'0#-WB"!#5XDP4S=Z0%,G>Y!3%XUP4Q=O4%,73_!3%S
M_P4Q<O\%,G+_!3)R_P6W8P  JFT  )QQ  "+<   ?7   ')P  !G<0  7',
M %%W  !*>@  0GT# #]^#@#_XGT024-#7U!23T9)3$4 "Q(]?Q@ /'\C #N
M+0 Z@#8 .8$_ #B!2  V@5  -8%: 3.!9 $Q@7 !+X%_ BV!CP,L@:$#*H&V
M RF!T@,I?_,#*7W_ RE\_P,I>_\#*7O_ RE[_P.Q:@  I70  )5V  "%=0
M>'4  &UU  !A=P  5WH  $Q^  !#@0  .X4  #6("0 RB1$ ,8D; #"))0 O
MBB\ +HHX "V+00 LBTH *HM4 "F+7P HBVL )HMZ 22+BP$CBYX!(HNS 2&,
MS@$ABO$!((C_ B"&_P(@A?\"(87_ B&%_P*K<@  H7P  (][  " >@  <WH
M &9\  !;?P  4((  $:&   \B@  -(T  "R1   FDPP ))03 ".4'  BE28
M(94O ""5.  ?ED( 'I9, !V66  <EF0 &I=T !F7A@ 8EYD %Y>N !67R0 6
ME>X %I/_ 1:2_P$6D?\!%I#_ 1:0_P&E>P  F8,  (F!  ![@   ;((  %^$
M  !4B   28L  #^0   UE   +9<  "6:   =G@$ %J , !2A$@ 4H1L $Z$E
M !*A+@ 1HC@ $:)# !"B3P /HEP #J-K  VC?0 -HY( #*.G  JBP  +HN8
M#*#^  V?_P -GO\ #9W_  V=_P">A   DHD  (.(  !SB   98L  %B.  !,
MD@  09<  #>;   NG@  )*(  !RE   5J   #ZL$  JN#  'K1( !JT;  6M
M)  $KBX  JXY  &N10  KE(  *YA  "N<P  KH<  *Z=  "NM   KM4  *WT
M  "M_P  K/\  *O_  "K_P"6BP  C)   'N0  !KD@  798  %":  !$GP
M.:,  "^G   EJP  '*X  !2Q   .M   ";<   &X"0  N X  +D4  "Y'
MNB4  +HO  "[.@  O$<  +Q6  "\9P  O'L  +R1  "\J0  O,0  +SK  "[
M_@  N_\  +O_  "[_P"0D@  @Y@  '.;  !CGP  5:,  $>H   [K0  ,+$
M "6T   ;MP  $KH   R]   %OP   ,,   #$ @  Q0H  ,4.  #&%   QQL
M ,@D  #*+@  S#H  ,U)  #-60  S6P  ,Z#  #.FP  S;4  ,[:  #.]@
MS?\  ,W_  #-_P"&F0  =Z   &FF  !:K   3+(  #ZV   PN0  )+P  !F_
M   1P@  "L4   +)    S    -    #1    T@$  -,(  #5#0  UQ$  -H8
M  #<(0  WRP  .$Z  #B2@  XUT  .1R  #DBP  Y:4  .7   #EY@  Y?@
M .7_  #E_P!ZH0  :ZD  %RO  !-M@  /[P  #"_   CPP  %\<   _*   '
MS@   -$   #6    W    -\   #@    X@   .0   #F P  Z D  .D.  #L
M%0  [AX  /$K  #T.@  ]4T  /9A  #W>0  ^),  /BM  #YQ@  ^>0  /GS
M  #Y\P!MJ@  7K(  $^Z  ! P0  ,<4  "+)   6S@  #=(   38    W0
M .$   #D    Z    .L   #M    [P   /$   #S    ]@   /@#  #Z"P
M_1$  /\;  #_*0  _SL  /]/  #_9@  _W\  /^9  #_KP  _\,  /_6  #_
MU@#_!!P _P 9 /\ &0#_ !P _P B /\ *P#_ #@ _P!& /\ 4P#_ %X _P!I
M /\ <@#_ 'H _P"" /\ B0#_ (\ _P"5 /\ FP#_ *$ _P"H /\ KP#_ +D
M_P#% /\ V0#^ .P _0#[ /L _P#[ /\ ^P#_ /H _P#T /\ \ #_ /  _P#_
M!Q@ _P$5 /\ % #_ !8 _P ; /\ )@#_ #0 _P!" /\ 3@#_ %H _P!D /\
M;0#_ '4 _P!] /\ A #_ (H _0"0 /P E@#Z )T ^0"C /@ JP#W +0 ]0"_
M /0 S@#S .8 \0#V /  _P#O /\ [P#_ .X _P#N /\ Z@#_ .H _P#_"Q0
M_P81 /\ $ #_ !  _P 6 /\ (@#_ "X _P \ /\ 20#_ %0 _@!? /L : #Y
M '  ]P!X /4 ?P#S (4 \@"+ /  D@#O )@ [0"? .P I@#J *X Z "Y .<
MQP#E -X XP#P .( _@#@ /\ X #_ .$ _P#A /\ X0#_ .$ _P#_#1  _PD-
M /\!# #_  P _P 2 /\ ' #_ "@ _  V /D 0P#V $X \@!9 .\ 8@#L &L
MZ@!R .@ >0#F (  Y "& .( C #A ), WP": -T H0#; *H V "T -4 P #2
M -, T #J ,X ^@#- /\ S0#_ ,T _P#, /\ S #_ ,P _P#_$ P _PP' /\#
M @#_  @ _P . /\ %@#V "( \  O .P / #I $@ Y0!3 .$ 7 #> &4 VP!L
M -< <P#4 'H T@"  -  AP#. (X S "5 ,H G0#( *4 Q@"O ,0 NP#" ,L
MP #E +X ]0"] /\ O #_ +P _P"\ /\ O #_ +P _P#_$04 _PX  /\*  #_
M" $ _P0* /@ $ #I !H XP H -X -0#9 $$ TP!, ,\ 5@#+ %\ R0!F ,8
M;@#$ '0 P@![ ,$ @@"_ (D O0"0 +P F "Z *$ N "K +8 MP"T ,< L@#@
M +$!\@"O O\ K@/_ *T$_P"M!/\ K03_ *T$_P#_%   _Q   /\/  #R#0
MZ@H  .D#"0#= !( U  ? ,T!+0#( CH Q -% , #4 "]!%D NP5A +D%: "W
M!F\ M09V +0'?0"R!X0 L0B, *\(E0"M"9X JPFH *H*M0"H"L4 I@O? *0-
M] "B#O\ H [_ )\._P"?#O\ GP[_ )\._P#_%P  _Q,  .\8  #D&0  VQ8
M -(0 @#/"0L R @6 ,$*) "\##( MPT^ +0.20"Q#E, KQ!; *T08P"K$&H
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M 7PH_P%\*/\!?"C_ 7PH_P'U)   XRX  ,\U  #!.   M#8  *LQ  "E+
MHB8& )XF$P"9*"$ E2HN )(K.0"/+$0 C2U, (LM5 ")+EP ARYC (8N:@&$
M+G(!@BYZ 8$OA %_+X\"?2^: GLOIP)Z+[<">"_, G8PZ@)U,/X"<S#_ G,P
M_P)S+_\"<R__ G,O_P+P*@  W#4  ,<[  "Z/P  K#P  *(X  "<,P  F"\
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M8SO_ F,[_P+E-0  S3\  +U&  "N1P  GT4  )5#  ".0   B3P  (0\"@"
M/10 ?3XB 'H_+@!X0#@ =4%" '-!2@!R05$!<$%9 6Y!8 )L06<":D%P VA!
M>0-G080$94&1!6-!GP5A0:X&8$'"!EY!X@9>0?D%74'_!%U _P-=0/\#74#_
M UU _P/?.0  R$,  +E*  "I2P  FTD  )!'  "(1   @T$  'Y!!@!Z0A$
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M!5).F 903J@'3DZ[!TU.V0=-3O4&34[_!4U-_P1-3?\$3DS_ TY,_P/.1
MO$X  *Y4  "<4P  CE(  (-1  !Z4   <DT  &Q/  !H4 L 95$5 &-2(0!A
M4RP 7U,V %U4/P!;5$< 6E1. 5A45@%65%T"5%1F U)3;P-04WL$3E.(!4Q3
MEP9+4Z<'25.Z!TA3U0=(4O,&2%+_!4A1_P1)4?\$25#_ TE0_P/*2   N5(
M *I7  "85@  BE4  ']4  !V4P  ;%$  &=3  !B5 @ 7U82 %U7'@!;5RD
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M!3ACS04X8N\$.&'_!#A@_P,X7_\#.5[_ SE>_P.\50  K5\  )Q@  "+7P
M?5\  ')?  !H7P  76   %5B  !/9   2V8* $EG$@!':!T 16@G $1I,0!#
M:3D 0FI" $!J2@ _:E( /6I; 3QJ90$Z:G ".&I^ C9IC0,T:9\#,VFR S%I
MRP,Q:.T#,6?_ S%F_P,R9?\#,F3_ S)D_P.W6P  J60  )9D  "&8P  >&,
M &UC  !D9   664  %!H  !):P  0VT$ $!N#@ ^;Q@ /6\B #QP*P Z<#0
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M !F _P$9?_\!&7[_ 1E^_P&F<   E7,  (1R  !V<0  :W$  %YS  !4=@
M27D  #]]   W@0  +X0  ">(   @BP4 &XT. !J-%0 9C1X &(XG !>.,  6
MCCD %8Y# !2/3P 3CUL $H]J !&/>P 0CX\ #X^D  Z/NP -C^  #HWZ  ^+
M_P 0BO\ $(G_ !")_P"A>@  CGD  'YW  !R=P  9'@  %A[  !-?@  0H(
M #F&   OB@  )XX  ""1   8E0  $I@%  Z:#@ -FA0 #)H=  N:)@ +FC
M"IH[  F:1@ (FE, !IMA  6:<@ $FH8  IJ;  ":L0 !F<\  IGP  *8_P $
ME_\ !9;_  66_P"9@0  AW\  'I^  !K?@  78$  %"%  !%B0  .XT  #&2
M   HE@  'YD  !B=   1H   #*,"  :E"@ !I1   *46  "F'P  IB@  *8R
M  "G/0  ITH  *=8  "G:   IWP  *>1  "FJ   IL,  *7I  "E_   I?\
M *3_  "D_P"1AP  @H8  '*&  !CB   58P  $F1   ]E@  ,IH  "B>   ?
MH@  %Z8  !"I   +K   !*\   "Q!@  L0P  +(1  "R%P  LQ\  +,H  "T
M,@  M3\  +5-  "U70  M7   +6&  "UG0  M;8  +7<  "T]P  M/\  +3_
M  "T_P"+CP  >HX  &J1  !;E0  39H  $"?   UI   *J@  ""L   6L
M#[0   FW   !N0   +T   "^    O@8  +\,  # $   P18  ,(=  ##)P
MQ3(  ,9   #&40  QV,  ,=X  #'D0  QZD  ,?'  #'[   Q_X  ,?_  #'
M_P"#EP  <9H  &&>  !2HP  1:D  #BN   LLP  (+<  !:Z   .O0  !L
M  ##    QP   ,D   #*    S    ,T#  #."0  T X  -(3  #4&P  V"4
M -LR  #=0@  W50  -YI  #>@0  WIP  -^U  #?V0  W_,  -__  #?_P!W
MGP  :*8  %FM  !*LP  .[@  "V[   ?OP  %,(   S&   #R0   ,P   #0
M    U0   -D   #:    W    -X   #@    X@4  .0+  #G$   ZA@  .TD
M  #P,@  \40  /)8  #S;P  ](H  /2D  #TOP  ]-\  /3S  #T] !JJ
M6Z\  $RW   ]O0  +<$  !_&   3R@  "\X   #2    UP   -P   #@
MY0   .<   #I    ZP   .T   #O    \0   /,   #V!P  ^0X  /P6  #_
M(@  _S,  /]'  #_70  _W8  /^1  #_J0  _[X  /_8  #_VP#_ !@ _P 6
M /\ %0#_ !@ _P > /\ )P#_ #8 _P!# /\ 3P#_ %H _P!D /\ ;0#_ '4
M_P!] /\ A #_ (H _P"0 /\ E@#_ )P _P"C /\ JP#_ +0 _@"_ /T SP#[
M .< ^@#X /D _P#Y /\ ^0#_ /4 _P#N /\ Z0#_ .< _P#_ !0 _P 1 /\
M$0#_ !( _P 7 /\ (P#_ #$ _P ^ /\ 2@#_ %8 _P!@ /\ : #_ '  _P!X
M /T ?@#\ (4 ^@"+ /D D0#X )@ ]P"> /4 I@#T *X \@"Y /$ QP#O .
M[@#R .P _P#L /\ [ #_ .L _P#E /\ X #_ -X _P#_ Q  _P . /\ #0#_
M  T _P 3 /\ '@#_ "L _P X /\ 10#^ %  ^P!: /@ 8P#U &L \P!R /$
M>0#O '\ [@"& .P C #J )( Z0"9 .< H #F *D Y "S .$ P #@ -, W@#K
M -P ^P#; /\ V@#_ -H _P#9 /\ U #_ -( _P#_!PT _P ) /\ !@#_  D
M_P / /\ & #[ "4 ^  R /4 /P#R $H [0!4 .H 70#G &4 Y !L .( <P#@
M 'H W@"  -P A@#: (T UP"4 -0 FP#2 *0 SP"M ,T N0#+ ,D R0#D ,@
M]@#& /\ Q0#_ ,8 _P#' /\ QP#_ ,< _P#_"@8 _P$  /\   #_  0 _P +
M /0 $@#O !\ Z@ L .4 . #B $, W0!. -D 5P#4 %\ T0!G ,X ;0#, '0
MR@!Z ,@ @ #& (< Q0". ,, E@#! )X OP"H +T LP"Z ,( N0#; +< \ "U
M /\ M@#_ +4 _P"U /\ M0#_ +4 _P#_#   _P0  /\   #^    ]@ # .@
M#0#@ !< V0 D -$ ,0#- #P R@!' ,8 40## %D P !@ +X 9P"\ &X N@!T
M +D >P"W (( M0") +, D0"R )H L "D *X KP"L +T J@#0 *@ ZP"G /L
MI@#_ *8 _P"E /\ I0#_ *4 _P#_#0  _P<  /0)  #J"0  X@0  -H !P#/
M !$ R  < ,( *0"^ #4 NP!  +< 2@"T %, L@!; +  8@"N &@ K !O *L
M=0"I 'T J "$ *8 C0"D )8 HP"@ *$ JP"? ;D G0/, )P$Z ":!OD F0?_
M )@(_P"7"/\ EPC_ )<(_P#_$   ]Q   .@4  #<%0  SA$  ,8-  #"! L
MO  4 +<!(0"R RX K@4Z *L&1 "H"$T I@A5 *0)7 "B"F, H IJ )\+<0"=
M"W@ G N  )H,B0"9#), EPR> )4-J@"4#;@ D@W, ) .Z@".$/P C!#_ (L0
M_P"+$/\ BQ#_ (H0_P#[$P  [1H  -T@  #,(0  OQT  +<7  "S$0  L@L-
M *L-&0"G#B8 HP\S )\0/@"=$4< FA%0 )@25P"6$EX E1-E ),3; "2$W,
MD!1\ (\4A0"-%8\ BQ6: (H5IP"(%K4 AA;) (07YP""&/L @!G_ '\9_P!_
M&?\ ?QC_ '\8_P#U&@  Y",  ,\I  # *@  LR8  *HB  "E'   I!4( * 4
M$P";%B$ EQ@M )09. "1&D( CQM+ (T<4@"+'%D B1U@ (@=9P"&'F\ A1YW
M (,?@ ""'XL @!^7 'X@HP!](+( >R#% 'DAY !W(OD =B+_ '4B_P!T(?\
M="'_ '0A_P#O(0  VRL  ,<Q  "V,0  J2X  * J  ";)@  F"$! )4>$ "0
M(!L C2$H (DC,P"')#T A21& (,E3@"!)E4 ?R9< 'XF8P!\)VL >R=S 'DG
M? !X*(< =BB3 '0HH %R**\!<2G! 6\IX %M*?<!;"G_ 6LI_P%K*?\!:RC_
M 6LH_P'H*   T#(  , X  "N-P  H34  )@R  "2+0  CBD  (LG# "'*!<
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M EP[EP);.Z<"63NX U@[T@-7._$"5CO_ E8[_P)6.O\!5CK_ 58Y_P'4-P
MP$$  *]$  "=0P  D$(  (5   !^/@  >3L  '0Z  !Q.@X ;3P8 &L]) !I
M/B\ 9S\X &4_0 !D0$@ 8D!/ &% 5P!?0%X!74!F 5Q ;P%:0'H"6$"' E9
ME0)40*0#4T"V U) SP-10.\#4$#_ E __P)0/_\"43[_ 5$^_P'/.P  O44
M *I'  "91@  BT4  (%$  !Y0@  =#X  &\_  !K0 P 9T$5 &5"(0!C0RL
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M T)-R -!3>H#04S_ D%,_P)"2_\"0DK_ D)*_P+"1P  LT\  )Y/  "-3@
M@$X  '5-  !L3   8TH  %Y,  !:30( 5DX. %1/& !24"( 45$L $]1-0!.
M4CT 35)% $Q230!*4E0 25)= 4=29@%%4G$!0U)^ D%2C0(_4IT#/E*O SU2
MQ@,\4ND"/%'^ CQ0_P(]3_\"/4__ CU._P*^2P  KE,  )I2  ")40  ?%$
M '%0  !H4   7DX  %A1  !44@  45,, $Y4% !,51\ 2U8I $E6,@!(5CH
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M 2I@_P$K7_\!*U__ 2M>_P&Q60  GEP  (M<  ![6P  ;UL  &5;  !<7
M45X  $E@  !#8@  /&4  #AG"@ U:!( -&@; #-I)  R:2T ,6DU "]J/0 N
M:D8 +6I/ "QJ60 K:V4 *6MR "AK@@ F:Y, )&NG "-KO0 B:N  (VGY 2-G
M_P$C9O\!(V;_ 21E_P&L8   F&   (5@  !V7P  :E\  &%@  !78   36,
M $1F   ]:   -FL  #!N!  L< X *G$5 "EQ'@ H<28 )W(O "9R-P E<D
M)')* ")R5  A<V  ('-M !YS?0 =<Y  &W.C !ISN0 9<]P &G'W !IP_P ;
M;_\ &V[_ 1MM_P&F9@  D64  ']D  !Q9   9F0  %UD  !29@  2&D  #]L
M   W;P  ,',  "EV   B>0@ 'WL0 !Y[%P <>Q\ &WLH !I[,  9?#D &'Q#
M !=\3@ 6?%H %7QG !1]>  2?8L $7V? !!]M0 /?=4 $'OU !%Y_P 1>/\
M$G?_ !)W_P">:P  BFH  'II  !M:0  8FD  %=J  !,;0  0W   #ET   Q
M>   *7L  ")_   ;@@  %(4) !&&$  1AA< $(<? !"'*  .AS$ #H<[  V'
M1@ ,AU, "X=A  J'<0 )AX0 !X>8  :&K@ %ALD !H7L  >$_P (@_\ "8+_
M  F"_P"5<0  @V\  '1N  !I;@  7&\  %!R  !&=0  /'D  #)]   J@0
M(H4  !N)   4C   #X\#  J2"P &DA$ !)(8  *2(  !DBD  )(S  "3/@
MDTL  )-9  "3:0  DWL  )*0  "2I@  D;\  )'E  "0^@  C_\  (__  "/
M_P"-=P  ?74  '!T  !B=0  57@  $E\   _@   -(0  "N)   BC0  &I$
M !.4   .EP  "9L   &="   G0X  )T3  ">&@  GB(  )\K  "?-0  H$(
M *!0  "@7P  H'$  *"'  "?G0  G[4  )[:  "=]@  G?\  )S_  "<_P"&
M?0  >'P  &E\  !;?P  3H,  $&(   VC   +)$  ".6   :F@  $IX   VA
M   &I    *<   "I P  J0H  *H.  "K$P  K!D  *TB  "N*P  KS<  *]%
M  "O5   KV8  *][  "NE   KJL  *[)  "N[P  K?\  *W_  "M_P"!A
M<80  &&'  !3BP  1I   #F6   NFP  (Z   !JD   2J   #*P   2O
ML@   +8   "W    MP(  +@(  "Y#0  NA(  +L8  "](0  OBL  , X  #
M2   P%H  ,%N  #!A@  P:   ,&Z  #!XP  P/D  ,#_  # _P!YC0  :)
M %F4  !+F@  /:   #&E   EJP  &J\  !&S   +N    KL   "^    P0
M ,0   #%    Q@   ,<   #(!0  R@L  ,P/  #.%0  T!\  -,K  #5.@
MU4P  -9@  #8=P  V)(  -BL  #9R0  V>P  -G[  #8_P!PF0  8)X  %&D
M  !#J@  -;   "BV   <N@  $;X   G!    Q0   ,@   #+    SP   -(
M  #3    U@   -@   #;    W0   -\'  #B#0  Y1,  .@=  #L*@  [3P
M .U1  #N9P  [X$  .^<  #PMP  \-,  /#L  #P] !GI@  6*T  $FT   Z
MN@  *KX  !S"   0Q@  !\H   #.    T@   -8   #<    X    .,   #D
M    Y@   .@   #K    [0   .\   #R @  ]0H  /@1  #\'   _RP  /\_
M  #_50  _VX  /^*  #_I   _[H  /_1  #_X0#_ !0 _P 2 /\ $@#_ !0
M_P 9 /\ )0#_ #( _P _ /\ 2P#_ %8 _P!@ /\ : #_ '  _P!X /\ ?P#_
M (4 _P"+ /\ D0#_ )@ _P"> /X I@#] *X _ "Y /H R #Y .( ^ #T /<
M_P#V /\ ]@#_ .\ _P#G /\ X@#_ -X _P#_ !$ _P . /\ #@#_  \ _P 4
M /\ ( #_ "T _P Z /\ 1@#_ %$ _P!; /\ 8P#^ &L _ !S /H >0#Y (
M]P"& /8 C #U )( \P"9 /( H #P *D [@"S .T P0#K -8 Z@#N .D _@#G
M /\ YP#_ .4 _P#= /\ U0#_ -$ _P#_  T _P * /\ " #_  D _P 0 /\
M&P#_ "@ _P U /\ 0 #Z $L ]@!5 /, 7@#Q &8 [@!M .P = #K 'H Z0"
M .< A@#F (T Y "3 .( FP#@ *, W@"M -P N0#: ,H UP#F -0 ^ #2 /\
MT@#_ -( _P#. /\ R0#_ ,8 _P#_  @ _P # /\   #_  , _P - /P %@#W
M "( \P N .\ .@#L $4 Z !/ .0 6 #A &  W@!G -L ;0#9 '0 U0!Z -,
M@ #1 (< SP". ,T E0#+ )X R0"G ,< LP#% ,( PP#< ,$ \0"_ /\ OP#_
M +X _P"^ /\ O0#_ +L _P#_    _P   /\   #_    ]@ ( .X $0#G !L
MX0 G -T ,P#9 #X TP!) ,\ 4@#+ %D R !A ,8 9P#$ &T P@!S ,  >@"_
M (  O0"( +L D "Y )@ N "B +4 K0"S +L L0#. +  Z@"O /P K0#_ *T
M_P"N /\ K@#_ *X _P#_ @  _P   /T   #R    Z    -X # #3 !4 S  A
M ,@ + #$ #@ P0!" +T 2P"Z %, N !: +8 80"T &< L@!M +  = "O 'H
MK0"" *P B@"J ), J "= *8 J "D +4 H@#& *$ XP"? /8 G@#_ )X _P">
M /\ G@#_ )X _P#_!@  ^P   .X%  #B!   U0   ,L !@##  \ O0 9 +@
M)0"T #$ L0 [ *X 10"L $T J0!5 *< 6P"E &( I !H *( ;@"A '4 GP!\
M )X A0"< (X F@"8 )@ I "6 +  E0#! ), W "2 /( D0#_ )  _P"0 /\
MCP#_ (\ _P#]"@  \ X  .$1  #.$   P@T  +L'  "W  H L0 2 *P '@"H
M "D I0 T *( /@"? $< G0!/ )L 5@"9 5P EP%C )8":0"4 G  DP-X )$#
M@ "0!(H C@25 (P%H0"*!:X B0:^ (<(V "&"?  A K_ (,+_P"#"_\ @PO_
M (,+_P#V$   YA<  -(<  # &@  LQ8  *P2  "H#0  I@<- *(%%@"=!R(
MF0DN )8*. "4"T$ D@Q* ) ,40".#5@ C U> (L-90")#6P B YT (8.?0"%
M#H< @PZ3 ($/GP" $*T ?A"^ 'T0VP!Z$?0 >!+_ '<2_P!W$O\ =Q+_ '<2
M_P#O%P  VR$  ,8D  "T(P  J"   * <  ";%P  F1$$ )@.$ "3$!L CQ$G
M (P2,@")$SP AQ-$ (443 "#%%, @15: ( 58 !^%F@ ?19O 'L6> !Y%X,
M>!>/ '88G !T&*H <QF[ '(9U !O&O$ ;AO_ &T;_P!M&O\ ;1K_ &T:_P#G
M(   T"D  +PK  "K*@  GB@  )8D  "0(   C1P  (P7# "(&!8 A!HB ($;
M+0!^'#< ?!U  'H=2 !Y'D\ =QY5 '8?7 !T'V, <Q]K '$@= !P('\ ;B&+
M &PAF !K(:< :2*X &@BSP!F(NX 92/_ &0C_P!D(O\ 9"+_ &0A_P#@)@
MR"\  +0Q  "C,   EBX  (TK  "'*   A"0  ((@" !^(!( >R(> '@C*0!U
M)#, <R4\ '$E0P!P)DL ;B92 &TG60!K)V  :B=H &DH<0!G*'L 92B( &0I
ME0!B*:0 8"FU %\IRP!>*NP 7"K_ %PI_P!<*?\ 7"G_ %PH_P#8+   PS4
M *TU  "=-   D#,  (8Q  " +0  ?"L  'DH P!V)Q  <BD: ' J)0!M*R\
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M 4LZPP%*.N4!23K\ 4DY_P%).?\!23C_ 4HX_P''.@  LT   )X_  "./P
M@3X  '<]  !P.P  :C@  &8X  !B.0< 7SH1 %P[&P!:.R4 63PN %<]-P!6
M/3X 5#Y& %,^30!2/E4 43Y= $\_9@!-/W  3#]] 4H_BP%(/YL!1S^L 44_
MP0%$/^,!1#[[ 40^_P%$/?\!1#W_ 44\_P'#/@  KT,  )I"  "*0@  ?4$
M '-   !K/P  93P  & \  !</@0 63X/ %<_& !50"( 4T$K %)!- !00CP
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M 35+_P$U2O\!-DG_ 39)_P&X20  HDL  (Y*  !^2@  <DH  &A*  !?20
M54@  %!*  !,2P  24P' $9-$ !$3AD 0D\B $%/*P! 4#, /U [ #Y00P \
M44H .U%3 #I17  X46< -U%S #51@@ S49,!,E&E 3!1N@$O4=H!+U#V 2]/
M_P$P3O\!,$[_ 3!-_P&T30  G4T  (I-  !Z30  ;DT  &1-  !;30  44T
M $M/  !&4   0E(# #]3#0 ]5!4 /%0> #I5)P Y52\ .%4W #=6/P V5D<
M-590 #-660 R5V0 ,%=Q "]7@  M5Y$ *U>C "I7N  I5]8 *5;U "E5_P J
M5/\!*E/_ 2I2_P&O40  F%$  (51  !V4   :E   &!0  !840  3E(  $=3
M  !!50  .U@  #A9"@ U6A$ -%H: #-;(@ R6RL ,5LS "]<.P N7$, +5Q,
M "Q<5@ K76  *5UM "A=?  F78X )%VA "-=M0 B7=( (ESS ");_P C6O\
M(UG_ "18_P"H50  DE0  (!4  !Q5   9E0  %Q4  !450  2E8  $-8   \
M6P  -ET  #!@!0 M80X *V$5 "IB'0 I8B4 *&(N "=C-@ F8SX )6-' "-C
M40 B9%P (61I !]D>0 >9(H '&2> !MDLP 99,X &F/Q !MA_P ;8/\ '&#_
M !Q?_P"A60  C%@  'M8  !M6   8E@  %E8  !060  1UL  #Y>   W8
M,6,  "IF   D:0D (6H0 "!J%P ?:B  'FLH !UK,  <:SD &VM" !IL3  9
M;%@ %VQE !9L=  4;(8 $VR: !)LKP 1;,H $6OO !)I_P 3:/\ $VC_ !-G
M_P"970  A5T  '5<  !H7   7EP  %5<  !+7@  0F$  #ED   R9P  *VH
M "1M   >< $ %W,+ !5T$0 4=!@ $W0A !)U*0 1=3( $74[ !!U1@ /=5(
M#G5?  UU;@ ,=8$ "W65  IUJ@ (=,, "73G  IS_0 +<?\ #''_  QP_P"1
M8@  ?V$  '!A  !D80  6F$  $]B  !%90  /&@  #-L   K;P  )'(  !UV
M   7>0  $7P$  U_#  +?Q( "G\9  E_(@ (?RH !G\T  5_/P $?TL  G]8
M  %_9P  ?WD  '^.  !_HP  ?KL  'W@  !]]P  ?/\  'O_  ![_P")9P
M>&<  &MF  !A9@  5&<  $EI   _;0  -7$  "QU   D>0  '7P  !:    0
M@P  #(8"  :)"@ !B0\  (D4  "*&P  BB,  (LL  "+-P  BT,  (M0  "+
M7P  BW$  (N&  "+G   BK,  (G3  "(\P  B/\  (?_  "'_P"";0  <VP
M &AL  !:;0  3F\  $)S   X=P  +GL  "6    =A   %8@  !",   +CP
M!)(   "4!@  E0P  )40  "6%0  EQP  )@D  "8+@  F3D  )E'  "95@
MF6@  )E]  "9E   F*L  )?(  "6[@  EO\  )7_  "5_P![=   ;W,  &%S
M  !3=@  1GH  #M_   PA   )H@  !V-   4D@  #I8   F9   !G    *
M  "A    H@8  *(,  "D$   I10  *4<  "G)   J"\  *@]  "I3   J5X
M *ER  "HB0  J*(  *B\  "GY0  IOL  *;_  "E_P!W>P  :'L  %E^  !+
M@@  /H<  #*-   GD@  '9<  !2<   .H   !Z0   "H    JP   *X   "O
M    L    +$$  "S"@  M X  +43  "V&P  N"0  +HQ  "Z0   NE(  +ME
M  "[?0  NI<  +JQ  "ZT@  NO,  +G_  "Y_P!O@P  7X8  %&+  !#D
M-I<  "J=   ?H@  %:<   VL   %L    +0   "W    NP   +X   "_
MP    ,$   ## 0  Q <  ,4-  #'$0  RAD  ,TD  #.,P  ST0  -!8  #0
M;@  T8@  -"D  #0P0  T>8  -'X  #1_P!GCP  5Y0  $F:   [H0  +J<
M "&M   6LP  #K@   :\    P    ,,   #&    RP   ,T   #.    T
M -$   #4    U@   -H"  #<"0  WP\  .,7  #F)   YS8  .A)  #I7P
MZG@  .N4  #KKP  Z\P  .SH  #L]@!?G@  4*0  $*K   TL@  )KD  !F^
M   .P@  !,4   #*    S0   -$   #8    VP   -\   #@    X@   .0
M  #F    Z0   .L   #N    \04  /4-  #Y%@  _"4  /TY  #^3P  _V<
M /^"  #_G0  _[4  /_+  #_Y #_ !$ _P / /\ #P#_ !$ _P 6 /\ (@#_
M "\ _P [ /\ 1P#_ %( _P!; /\ 9 #_ &P _P!S /\ >@#_ (  _P"& /\
MC #^ ), _0"9 /L H0#Z *D ^ "T /< P@#V -H ]0#Q /0 _P#S /\ \P#_
M .D _P#@ /\ V #_ -, _P#_  X _P + /\ "@#_  L _P 1 /\ '0#_ "H
M_P V /\ 00#_ $P _P!6 /X 7P#[ &8 ^0!M /< = #U 'H ] "  /( A@#P
M (T [P"4 .T FP#L *0 Z@"N .D N@#G ,T Y0#I .0 ^P#C /\ X@#_ -X
M_P#1 /\ S #_ ,@ _P#_  D _P $ /\  0#_  0 _P . /\ & #_ "0 _0 P
M /L .P#W $8 \P!0 .\ 60#L &  Z@!G .< ;@#F '0 Y !Z .( @ #@ (<
MW@". -P E0#: )X U@"H -0 LP#1 ,, SP#? ,X ] #, /\ RP#_ ,L _P#%
M /\ OP#_ +P _P#_  ( _P   /\   #_    _0 + /< $P#Q !X [0 J .H
M-0#G $  X@!* -T 4@#9 %H U0!A -( 9P#0 &T S@!S ,P >@#* (  R "'
M ,8 CP#$ )@ P@"A ,  K0"^ +L O #0 +H [0"Y /X N #_ +@ _P"W /\
MLP#_ +  _P#_    _P   /\   #Y    [@ % .4 #@#> !@ V  C -( +@#/
M #D RP!# ,< 3 #$ %0 P0!; +\ 80"\ &< NP!M +D <P"W 'H M0"! +0
MB0"R )( L "; *\ IP"L +0 JP#& *D Y "G /@ I@#_ *8 _P"E /\ I0#_
M *0 _P#_    _P   /4   #J    W@   -  "@#( !( P@ = +X * "[ #,
MN0 ] +4 1@"R $T L !5 *T 6P"L &$ J@!G *@ ;0"G ', I0!Z *0 @@"B
M (P H "6 )\ H0"= *X FP"^ )D V "7 /$ E@#_ )8 _P"7 /\ EP#_ )<
M_P#_    ]0   .<!  #4    R0   ,  ! "X  X LP 6 *\ (0"K "P J  V
M *8 /P"C $< H0!/ )\ 50"= %L FP!A )H 9P"8 &X EP!U )4 ?0"4 (8
MD@"1 )  G ". *D C "X (L S0") .L B #] (@ _P"( /\ B #_ (@ _P#Y
M!@  Z0P  -0.  ###   MPD  + "  "K  D I@ 0 *( &@"> "4 FP P )@
M.0"6 $$ E !) )( 4 "0 %8 C@!< (T 8@"+ &D B@!P (@ > "' ($ A0",
M (0 F "" *4 @ "T 'X R !] >< ? +Y 'L#_P![!/\ >P3_ 'L$_P#Q#@
MWA4  ,45  "T%   J1$  *$.  ">"@  FP,, )< $P"3 !X D $I (T",P"*
M SP B 1# (8%2P"%!E$ @P97 (('7@" !V0 ?PAL 'T(= !\"'X >@F) '@)
ME@!W"J, =0JS ',+QP!R#.8 < W[ ' -_P!O#?\ ;PW_ &\-_P#H%@  T!X
M +D=  "I'   G1H  )46  "0$P  CPX# (X*#@")"Q< A@PC (,-+0" #38
M?@X^ 'P.1@![#DT >0]3 '@06@!V$&$ =1!H ',0<0!Q$7L <!&' &X1E !L
M$:( :Q*R &D2QP!H$^< 9A/] &44_P!E%/\ 91/_ &43_P#?'@  QB0  + D
M  "@(P  E"$  (L?  "&&P  @Q<  ((2" !_$1( ?!(= 'D4* !V%#$ =!4Z
M '(600!Q%D@ ;Q=/ &X75@!L%UT :QAD &D8;0!H&7< 9AF# &09D !C&I\
M81JO & :Q !>&^0 71S[ %P<_P!<&_\ 7!O_ %P;_P#5)0  O2H  *@I  "8
M*0  C"@  (,E  !](@  >1\  '@; P!V&0\ <AH8 &\<(P!M'2T :QTU &D>
M/0!H'D0 9A]+ &4?4@!C(%D 8B!A &$@:0!?(7, 72%_ %PAC0!:(IP 62*L
M %<BP !6(^$ 52/Y %0C_P!4(O\ 5"+_ %0B_P#-*P  MBX  *(N  "2+@
MA2T  'PK  !V*   <B8  &\C  !M(0P :B(5 &<C'P!E)"D 8R0Q &(E.0!@
M)D$ 7R9( %TF3P!<)U8 6R== %DG9@!8*'  5BA\ %0HB@!3*9D 42FJ % I
MO@!/*=X 3BGW $TI_P!-*?\ 32C_ $XH_P#(,   L#(  )PR  ",,@  @#$
M '8P  !P+0  :RL  &@I  !F* D 8R@1 & I' !>*B4 7"LN %LK-@!9+#T
M6"Q$ %<M3 !5+5, 5"U; %,M8P!1+FX 4"YZ $XNB !,+Y< 2R^H $DONP!(
M+]L 2"_V $<O_P!'+O\ 1RW_ $@M_P#$-   JS4  )<U  "'-0  >S4  '(T
M  !K,@  9B\  &(N  !?+04 7"X0 %HO& !8,"( 5C K %4Q,P!3,3H 4C)"
M %$R20!0,E  3C-8 $TS80!+,VL 2C-W $@TA0!'-)4 132F $,TN0!"--8
M0C3T $(T_P!",_\ 0C+_ $(R_P# .   IS@  ),X  "#.   =S@  &TW  !F
M-@  83,  %TR  !9,@( 5S,- %0T%0!2-1\ 434H $\V, !.-C@ 3#<_ $LW
M1@!*-TX 23A6 $<X7P!&.&D 1#AU $,X@P!!.9, 0#FD #XYN  ].=, /#GS
M #PX_P ]-_\ /3?_ #TV_P"[.P  HCL  (\[  !_.P  <SL  &HZ  !B.0
M73<  %@V  !4-P  43@+ $\Y$P!-.1P 2SHE $HZ+0!(.S4 1SL\ $8\1 !%
M/$L 1#Q3 $(\7 !!/6< /SUS #X]@0 \/9$ .CVC #D]M@ X/=$ -SWR #<\
M_P X._\ .#O_ #@Z_P"V/0  GCX  (L^  !\/@  ;SX  &8]  !>/0  6#L
M %,Z  !/.P  3#P( $D]$0!'/AD 1C\B $0_*@!#/S( 0D Z $% 00! 0$D
M/D%1 #U!6@ \060 .D%P #A!?P W08\ -4*A #1"M  R0LX ,D'P #) _P S
M0/\ ,S__ #0^_P"Q0   FD   (=   !X00  ;$$  &)   !;0   5#\  $X_
M  !*0   1D$% $1"#@!"0Q8 0$,? #]$)P ^1"\ /$0W #M%/@ Z148 .45.
M #A&6  V1F( -49N #-&?  Q1HT ,$:? "Y&LP M1LP +4;O "U%_P N1/\
M+D/_ "Y#_P"L0P  ED,  (-#  !T0P  :$,  %]#  !70P  4$,  $A#  !$
M10  048! #Y'#  \2!, .D@< #E))  X22P -DDT #5*.P T2D, ,TI, #)*
M50 P2U\ +TMK "U+>@ L2XL *DN= "A+L0 G2\H )TOM "=*_P H2?\ *$C_
M "E'_P"G1@  D48  ']&  !P1@  948  %M&  !41@  3$<  $1(   _2@
M.TL  #=,"0 U31  ,TX8 #).(  Q3R@ ,$\P "]/.  N3T  +%!( "M04@ J
M4%P *%!H "=0=P E4(@ )%"; ")0KP A4,@ (%#K "%/_P B3O\ (DW_ "--
M_P"A20  C$D  'I)  !L2@  84H  %A*  !02@  24L  $!,   [3@  -5
M #%2!  M4PT +%04 "I4'  I520 *%4L "=5,P F53P )59% "163@ B5ED
M(59E !]6=  >5H4 '%:8 !M6K  95L4 &5;I !I5_P ;5/\ &U/_ !Q2_P";
M30  ADT  '5-  !H30  74T  %1-  !-3@  14\  #Q1   V4P  ,54  "M8
M   F6@D (UL0 ");%P A7!\ (%PG !]<+@ =7#< '%U  !M=2@ :754 &%UA
M !==<  578$ %%V5 !-=J@ 17<( $5WG !);_@ 36O\ $UK_ !19_P"440
M@%$  '!1  !D40  65$  %%1  !)4@  05,  #A6   R60  *UL  "5>   ?
M80, &F,, !AD$0 79!D %F0A !5D*0 493$ $V4Z !)E1  195  $&5=  ]E
M:P .97T #661  QEI0 *9+P "F3@  MC^0 ,8O\ #6'_  UA_P"-50  >E4
M &M5  !?50  5E4  $Y5  !$5P  /%D  #1<   L7P  )F(  !]E   9:
M$VL% !!M#0 .;A( #6X:  QN(@ ,;BL "VXT  IN/@ (;DH !VY7  9N90 $
M;G8  FZ*  !MGP  ;;8  &S6  !L\P !:_\  FK_  -J_P"%6@  =%H  &9:
M  !<60  4UD  $A:   _70  -F   "YC   F9P  'VH  !EM   3<0  #G0#
M  IW"@ %=Q   7<5  !W'   =R0  '@M  !X-P  >$,  'A0  !X7@  >&\
M 'B$  !XF0  =[   ';-  !U\   =?\  '3_  !T_P!^7P  ;E\  &)>  !9
M7@  35\  $)B   Y90  ,&@  "=L   ?<   &'0  !)W   ->P  "'X   *
M"   @0T  ($1  ""%P  @QX  (,F  "$,   A#L  (1(  "$5P  A&@  (1\
M  "$DP  @ZH  (+%  "!ZP  @?X  (#_  " _P!W90  :60  %]C  !29
M1V<  #QK   Q;P  *',  "!W   8?   $7\   R#   &AP   (H   ", P
MC D  (T.  ".$0  CQ<  ) >  "1)P  DC(  )(_  "23@  DE\  ))S  "2
MBP  D:(  )&\  "0Y0  C_P  ([_  "._P!Q:P  9FH  %AK  !+;0  /W$
M #1V   J>P  ((   !>%   0B0  "XT   21    E0   )@   "9    F@,
M )L(  "<#0  GA$  )\6  "@'@  HB@  *(U  "C1   HU4  *-I  "B@
MHIH  *&S  "@V   H/8  )__  "?_P!N<0  7W(  %%U  !$>0  -WX  "R$
M   AB@  %X\  !"4   *F0   9T   "@    I    *<   "H    J0   *H
M  "L!@  K0L  *\0  "P%0  LAX  +0I  "T.0  M$H  +5=  "U<P  M8X
M +6H  "TQ@  L^T  ++_  "R_P!F>@  5WT  $F"   \AP  +XX  ".4   8
MF@  $)\   FD    J0   *T   "P    M    +<   "X    N0   +L   "\
M    O@(  , (  #"#@  Q!0  ,<>  #(+   R3T  ,I0  #*9@  RG\  ,J;
M  #*N   RMT  ,KU  #*_P!>A@  3XL  $&1   SF   )Y\  !NE   1JP
M";    "U    N0   +T   #!    Q@   ,@   #)    RP   ,P   #.
MT    -(   #4!0  V0P  -T2  #A'@  XBX  .-"  #D5P  Y6\  .:,  #F
MJ   Y<4  .7G  #F]@!6E   2)L  #JB   LJ0  '[   !.V   +O    ,$
M  #%    R0   ,T   #2    U@   -H   #;    W@   .    #B    Y
M .<   #I    [0   / *  #T$0  ^!\  /DR  #Z2   ^U\  /QZ  #]EP
M_:\  /W'  #]Y #_  X _P - /\ # #_  X _P 3 /\ '@#_ "H _P V /\
M0@#_ $T _P!7 /\ 7P#_ &< _P!N /\ = #_ 'H _P"! /T AP#\ (T ^@"4
M /D G #W *4 ]0"O /0 O #S ,\ \0#L /  _@#O /\ [P#_ ., _P#7 /\
MS@#_ ,H _P#_  H _P & /\ ! #_  @ _P 0 /\ &0#_ "4 _P Q /\ /0#_
M $< _@!1 /L 60#Y &$ ]@!H /0 ;@#S '0 \0!Z .\ @0#N (< [ ". .H
ME@#H )\ Y@"I ., M0#B ,8 X #C -\ ^ #= /\ W0#_ -0 _P#) /\ P@#_
M +X _P#_  , _P   /\   #_  $ _P - /\ % #] "  ^@ K /< -@#S $$
M[P!+ .P 5 #H %L Y@!B ., : #A &X WP!T -P >@#: ($ V "( -0 D #2
M )@ SP"B ,T K@#+ +P R0#3 ,< \ #& /\ Q #_ ,0 _P"[ /\ M@#_ +,
M_P#_    _P   /\   #_    ]P ( /  $ #K !H YP E .0 , #A #L W !%
M -4 30#1 %4 S@!; ,L 8@#) &< QP!M ,4 <P## 'H P0"! +\ B0"] )(
MNP"< +D IP"W +4 M0#( +, Y@"R /L L0#_ +  _P"N /\ J@#_ *< _P#_
M    _P   /X   #Q    Y0 " -P #0#3 !0 S0 ? ,H *@#' #0 Q  ^ ,
M1P"\ $X N@!5 +< 6P"U &$ LP!G +( ;0"P ', K@!Z *P @@"J (L J "5
M *< H "E *T HP"^ *$ VP"@ /0 GP#_ )X _P"? /\ G0#_ )L _P#_
M_    .X   #@    T    ,4 " "^ !  N0 9 +4 (P"S "X L  W *T 0 "J
M $@ J !/ *4 50"C %L H@!@ *  9@"? &P G0!S )L >P": (0 F ". )8
MF@"5 *< DP"W )$ S "0 .P CP#_ (X _P". /\ C@#_ (\ _P#\    [P
M -L   #)    O0   +4  @"N  P J0 3 *4 '0"B "< H  Q )T .@": $(
MF !) )8 3P"4 %4 DP!; )$ 8 "0 &< C@!M (T =0"+ 'X B0") (@ E0"&
M *( A0"Q (, Q "! .0 @ #Y '\ _P"  /\ @ #_ (  _P#T @  X D  ,<(
M  "W!P  K ,  *8   "@  < FP / )@ %P"5 "$ D@ J (\ ,P"- #P BP!#
M (D 20"' %  A@!5 (0 6P"# &$ @0!H (  < !^ 'D ? "$ 'L D !Y )T
M> "L '8 O@!U -T <P#T ', _P!S /\ <P#_ ', _P#I#0  SQ   +D0  "I
M$   G@X  )<+  "3!@  D  + (P $0") !H A@ D (, +@"! #8 ?P ^ 'T
M1 !\ $L >@!1 'D 5P!W %T =@!D '0 ; !S 74 <0&  &\"C0!N IH ; .J
M &L#NP!I!-8 : ;Q &@'_P!G!_\ 9P?_ &<'_P#?%   PQ<  *X7  ">%@
MDQ4  (L2  "&$   A P" (,&#0"  Q0 ? 4> 'D'* !W"#  =0@X ',)0 !R
M"48 < I, &\*4P!M"UD ; MA &H+:0!I#'( 9PQ^ &8,BP!D#9D 8@VI &$-
MNP!@#=@ 7@[S %T._P!=#O\ 70[_ %T._P#4'   N1T  *0>  "5'0  B1P
M ($:  ![%P  >!,  '@0!@!W#0\ <PX8 ' .(@!N#RL ;! S &H0.P!I$$(
M9Q%) &813P!D$58 8Q)= &$29@!@$F\ 7A)[ %P3B !;$Y< 61.G %<4N@!6
M%-4 517S %05_P!4%?\ 5!7_ %04_P#*(@  L"(  )TC  "-(P  @2(  'DA
M  !S'@  ;QL  &X7  !M$PP :A04 &<5'@!E%B< 8Q8O &$7-P!@%SX 7AA%
M %T82P!<&5( 6AE: %D98@!7&FP 5AIW %0:A0!2&Y0 41ND $\;MP!.&]
M31SQ $P<_P!,'/\ 31S_ $T;_P##)@  JB<  )8G  "'*   >R<  '(F  !L
M)   :"$  &8>  !D&P@ 8AL1 %\<&@!='2, 6QXK %H>,P!8'SH 5Q]! %8@
M2 !4($\ 4R!7 %$A7P!0(6D 3B%T $TA@@!+(I$ 22*B $@BM !'(LT 1B/O
M $4C_P!%(O\ 1B+_ $8A_P"\*@  I"L  )$K  ""+   =BL  &TJ  !F*0
M8B8  %\D  !=(@0 6R$. %@B%@!6(Q\ 5"0H %,D, !2)3< 4"4^ $\F10!.
M)DP 3"94 $LG7 !))V8 2"=Q $8G?P!%*(\ 0RB@ $$HL@! *,L /RCM #\H
M_P _*/\ 0"?_ $ G_P"W+0  GRX  (PO  !]+P  <2\  &@N  !A+0  72L
M %HH  !7)P  5"<, %(H$P!0*1P 3BDE $TJ+ !+*C0 2BL[ $DK0@!(+$D
M1BQ1 $4L6@!$+&0 0BUO $ M?0 _+8T /2V> #PML  Z+<@ .BWK #HM_P Z
M+?\ .BS_ #HL_P"R,   FS$  (@R  !Y,@  ;3(  &0R  !=,0  6"\  %4L
M  !1+   3RT) $PM$0!*+AD 22\B $<O*@!&,#$ 13 X $,P/P!",4< 03%/
M $ Q5P ^,6$ /3)M #LR>P Y,HL .#*< #8RKP U,L< -#+I #0R_P U,?\
M-3'_ #4P_P"M,P  EC0  (0U  !U-0  :34  & U  !9-   5#,  % P  !,
M,0  23$& $<R#P!%,Q8 0S,? $(T)P! -"X /S4V #XU/0 ]-40 /#9, #HV
M50 Y-E\ -S9K #8V>  T-XD ,C>: #$WK0 O-\4 +S?H "\V_@ P-?\ ,#7_
M # T_P"I-@  DC8  ( W  !R.   9C@  %TW  !6-P  4#8  $LT  !'-0
M1#8# $$W#0 _.!0 /C@< #PY)  [.2P .CDS #DZ.@ X.D( -CI* #4Z4P T
M.UT ,CMH # [=@ O.X< +3N9 "P[K  J.\, *3OF "HZ_0 J.O\ *SG_ "PX
M_P"D.   CCD  'PZ  !N.@  8SH  %HZ  !3.@  33H  $8X  !".@  /SL
M #P\"P Z/!$ .#T9 #<](0 V/BD -#XP #,^-P R/S\ ,3]' # _4  N/UH
M+4!F "M =  I0(0 *$"7 "9 J@ E0,$ )$#E "0__  E/O\ )CW_ "8]_P"?
M.P  BCP  '@]  !J/0  7ST  %8]  !//0  23T  $(]   \/@  .3\  #9!
M"  T00\ ,D(6 #%"'@ O0R4 +D,M "U#-  L1#P *T1$ "I$30 H1%@ )T5C
M "5%<0 C18( (D65 "!%J  ?1;\ 'D3C !]$^P ?0_\ ($+_ "%!_P":/@
MA3\  '1   !G0   7$   %-   !,0   1D   #Y!   X0P  -$4  #!& P M
M1PT *T@2 "I(&@ I2"( *$DI "=),0 E23D )$E! "-*2@ B2E4 ($IA !]*
M;P =2G\ &TJ2 !I*I@ 82KT %TK@ !A)^@ 92/\ &D?_ !I'_P"50@  @$(
M '!#  !C0P  6$,  %!#  !)0P  0D0  #M%   U1P  ,$D  "M+   F30D
M)$X0 ").%@ A3QT ($\E !]/+  >3S4 '4\] !Q01P :4%$ &5!= !=0:P 6
M4'P %%"/ !-0I  14+H $5#> !%/^  23O\ $TW_ !1-_P"/10  >T8  &M&
M  !?1P  54<  $U'  !&1P  /T<  #=*   Q3   *TX  "90   @4P, '%4,
M !I6$0 95A@ %U8@ !96)P 55C  %%8Y !-70@ 25TT $5=9 !!7:  /5WD
M#E>,  U7H  +5[8 "U;4  M6]  ,5?\ #53_  Y3_P"(20  =DH  &=*  !;
M2@  44H  $I*  !#2@  .TP  #-.   L40  )E0  "%6   ;60  %5P' !%>
M#0 07A, $%X:  Y>(@ .7BH #5XS  Q>/0 +7D@ "EY4  A>8@ '7G, !5Z&
M  ->FP "7K$  EW,  )=[@ #7/\ !%O_  5;_P"!3@  <$X  &).  !73@
M3DX  $=.   ^3P  -E$  "Y4   G5P  (5H  !M=   58   $&,#  QF"P (
M9Q  !F<5  5G'  $9R0  F<M  %G-P  9T(  &=.  !G7   9VT  &>   !F
ME0  9JP  &7'  !EZP  9/P  &3_  !C_P!Z4@  :E,  %U2  !44@  2U(
M $)3   Y50  ,%@  "A;   A7P  &F(  !1E   0:   #&L!  9N"0  ;PX
M &\2  !O&   <!\  ' G  !Q,   <3L  '%(  !Q5@  <68  '%Y  !QCP
M<*<  &_!  !OYP  ;OP  &W_  !M_P!S6   95<  %I7  !15@  1E<  #Q:
M   R70  *F$  ")D   ::   %&P   YO   *<@  !'8   !X!0  > L  'D.
M  !Z$P  >QD  'P@  !]*0  ?3,  'U   !]3@  ?5X  'UR  !]B   ?*$
M 'RZ  ![X@  >OH  'G_  !X_P!M70  8%P  %=<  !+70  0%\  #5C   K
M9P  (VL  !IO   3<P  #G<   A[   "?@   ((   "# 0  A 8  (4+  "&
M#P  B!,  (D9  "*(0  BRL  (LW  ",1@  BU8  (MI  "+@   BYD  (JS
M  ")V   B/<  (C_  "'_P!H8P  7F(  %%B  !$90  .&D  "YN   D<P
M&G@  !-]   -@0  !H4   ")    C0   )    "2    D@   )0%  "5"@
MEPX  )@2  ":&   FR$  )PM  "=/   G4P  )Q?  "<=@  FY$  )NK  ":
MR0  FO   )G_  "8_P!E:0  5VD  $EL   ]<0  ,'8  "5\   ;@0  $H<
M  R,   $D0   )4   "9    G0   *    "A    H@   *0   "E 0  IP<
M *D,  "J$0  K1@  *\B  "O,   KT$  *]4  "O:P  KH4  *ZA  "NO@
MK>8  *S\  "L_P!><0  3W0  $)Y   U?P  *(4  !V,   3D@  #)@   .=
M    H@   *8   "J    K@   +    "Q    LP   +0   "V    N    +H$
M  "\"@  OA   ,$7  ##)   PS4  ,1)  #$7@  Q7<  ,63  #%KP  Q=$
M ,/R  ##_P!6?   1X(  #J(   LCP  ()8  !2=   -HP   ZD   "N
ML@   +<   "[    OP   ,(   #"    Q0   ,8   #(    R@   ,T   #/
M    T@@  -4.  #;&   W2<  -XZ  #?4   X&@  ."$  #AH0  X;T  .'B
M  #@] !.BP  0)(  #*9   EH0  &*@   ZO   %M0   +H   "_    Q
M ,@   #.    T0   -0   #5    V    -H   #=    WP   .(   #D
MYP   .L%  #O#@  ]!D  /4K  #V00  ]U@  /AR  #YD   ^:L  /C$  #X
MX0#_  L _P ( /\ "0#_  P _P 2 /\ &@#_ "8 _P R /\ /@#_ $@ _P!2
M /\ 6@#_ &( _P!I /\ ;P#_ '4 _@![ /P @0#[ (@ ^0"/ /< EP#U *
M\P"J /( MP#O ,D [0#F .P ^P#K /\ ZP#_ -T _P#. /\ Q@#_ ,( _P#_
M  0 _P   /\   #_  4 _P - /\ %0#_ "$ _P L /\ . #_ $, _0!, /D
M5 #W %P ] !C /( :0#P &\ [@!U .P >P#J (( Z ") .< D0#D )H X@"D
M .  L #= ,  V@#< -@ ] #5 /\ TP#_ ,L _P#! /\ NP#_ +< _P#_
M_P   /\   #_    _P * /T $0#Y !L ]@ G /0 ,@#P #P [ !& .@ 3@#D
M %8 X0!< -X 8P#< &@ V0!N -4 = #2 'L T "" ,T B@#+ ), R "= ,8
MJ #$ +< P0#, ,  ZP"^ /\ O0#_ +T _P"T /\ K@#_ *L _P#_    _P
M /\   #Z    \@ % .H #@#E !8 X  A -T *P#; #8 TP _ ,X 2 #* $\
MQP!6 ,0 7 #" &$ P !G +X ;0"\ ', N@!Z +@ @@"V (L M "6 +( H0"P
M *\ K@#! *T X "K /< J@#_ *D _P"F /\ H0#_ )\ _P#_    _P   /<
M  #H    W    -  "@#* !$ Q0 ; ,( )0"_ "\ O  X +@ 00"U $@ L@!/
M +  50"N %L K !A *H 9@"H &P IP!S *4 >P"C (0 H0". )\ F@"= *<
MFP"X )H T "9 .\ F #_ )< _P"6 /\ E #_ )( _P#_    ]@   .0   #2
M    Q0   +L !0"U  X L  5 *P 'P"J "D J  R *4 .@"B $( H !) )X
M3P"< %4 F@!: )@ 8 "6 &8 E0!L ), = "2 'T D "' (X DP", *$ BP"P
M (H Q0"( .8 AP#[ (8 _P"' /\ AP#_ (8 _P#X    Y0   ,T   "]
MLP   *H   "C  H GP 1 )L &0"9 ", EP L )4 - "2 #P D !# (X 20",
M $\ B@!4 (D 6@"' &  A@!F (0 ;@"# '< @0"! '\ C0!^ )L ? "J 'L
MO !Z -L > #U '@ _P!X /\ > #_ '@ _P#M    T0(  +L"  "L 0  H@
M )L   "6  4 D0 - (T % "+ !T B  F (8 +@"$ #8 @@ ] (  0P!^ $D
M?0!/ 'P 50!Z %L >0!A '< :0!U '$ = !\ '( B !Q )8 ;P"E &X M@!M
M ,X ; #N &L _P!K /\ :P#_ &L _P#?"P  P@P  *X,  ">#   DPL  (P'
M  "( @  A0 ) ($ $ !_ !< ?  @ 'H * !X #  =@ X '0 /@!S $0 <0!*
M '  4 !N %8 ;0!= &P 9 !J &T : !W &< A !E )( 9 "A &, L@!A ,D
M8 #I &  _ !@ /\ 8 #_ &  _P#0$   MA$  *(2  "3$@  B!$  ( /  !\
M#0  >0D! '@#"P!U !$ <P : '  (P!N 2L ; $S &H".0!I T  9P-& &8$
M3 !E!%( 8P59 &(%80!@!6H 7P9T %T&@0!<!X\ 6@>? %D'L !7!\8 5@GG
M %8*^P!5"O\ 50K_ %8*_P#&%0  K1<  )D8  "*&   ?Q<  '86  !Q$P
M;A   &T-!0!M"0T :@D4 &<*'0!E"B8 8PLN &(,-0!@##P 7PQ" %X-2 !<
M#4\ 6PU6 %D-7@!8#F@ 5@YS %4.@ !3#H\ 40Z? % .L0!.#L@ 31#J $T0
M_0!-$/\ 31#_ $T0_P"\&P  I1P  )(=  "#'@  =QT  &\<  !I&@  9A<
M &04  !D$ @ 8@\0 %\0& !=$"$ 6Q$I %H1,0!8$C@ 5Q(^ %8210!4$DP
M4Q-3 %$36P!0$V4 3A1P $P4?0!+%(P 212< $<5K@!&%<4 117H $46_@!%
M%O\ 117_ $45_P"U'P  GB$  (LB  !\(@  <2(  &@A  !B'P  7QT  %P:
M  !;%P( 6A4- %<6% !5%AT 5!<E %(8+0!1&#0 3Q@[ $X90@!-&4@ 2QI0
M $H:6 !(&F( 1QIM $4;>@!#&XD 0AN: $ ;K  _&\( /ASE #T<_  ^'/\
M/AO_ #X;_P"O(P  F"0  (8E  !W)@  ;"8  &,E  !=)   62(  %8?  !4
M'0  4QP+ %$<$@!.'1H 31TB $L>*0!*'C$ 21\W $<?/@!&($4 12!- $,@
M50!"(%\ 0"%J #\A=P ](8< .R&8 #DAJ@ X(L  -R+C #<B^P W(O\ ."'_
M #@A_P"J)@  E"<  ($I  !S*0  9RD  %\I  !8*   5"8  %$C  !/(@
M3"(' $HB$ !((A< 1R,? $4D)@!$)"X 0B0T $$E.P! )4, /R5* #TF4P \
M)EP .B9G #DF=0 W)X0 -2>6 #0GJ  R)[X ,2?A #$G^0 R)O\ ,B;_ #,E
M_P"E*0  CRH  'TL  !O+   9"T  %LL  !5*P  4"H  $PH  !*)@  1R<$
M $0G#0!"*!0 02@< #\I(P ^*2L /2DR #PJ.0 [*D  .2I( #@K4  V*UH
M-2ME #,K<@ Q*X( ,"R4 "XLIP L++P *RS> "PL^  L*_\ +2K_ "TJ_P"A
M+   BRT  'DN  !K+P  8"\  %@O  !1+@  3"X  $@L  !%*P  02L  #\L
M"P ]+!$ .RT9 #HN(0 Y+B@ -RXO #8O-@ U+SX -"]% #,O3@ Q,%@ ,#!C
M "XP<  L,(  *C"2 "DPI0 G,+H )C#< "8P]P G+_\ *"__ "@N_P"<+@
MAS   '8Q  !H,@  73(  %4R  !.,0  2#$  $0P  ! +P  /#   #HQ"0 W
M,1  -C(6 #4R'@ S,R4 ,C,L #$S,P P-#L +S1# "TT3  L-%8 *C5A "DU
M;@ G-7X )360 ",UHP B-;D (379 "$T]@ B-/\ (S/_ ",R_P"8,0  @S,
M '(T  !E-   6C4  %$U  !+-   130  $ T   Z,P  -S0  #0U!@ R-@X
M,#<3 "\W&P N-R( +3@I "LX,0 J.#@ *3E  "@Y20 F.5, )3E? ",Y;  A
M.GP (#J. !XZH@ <.K< &SG5 !PY]0 =./\ '3C_ !XW_P"3-   ?S8  &XW
M  !A-P  5S<  $XW  !(-P  0C<  #PW   U.   ,CD  "\Z @ L.PL *CP1
M "D\&  H/1\ )CTF "4]+@ D/34 (SX] "(^1@ @/E  'SY< !T_:0 ;/WD
M&C^, !@_H  6/[4 %3[2 !8^\P 7/?\ &#S_ !@\_P".-P  >C@  &HY  !>
M.@  4SH  $LZ  !%.@  /SH  #DZ   R/   +CX  "E    F00@ )$(. ")"
M%  A0AL ($,C !]#*@ >0S( '$,Z !M$0P :1$T &$19 !=$9P 51'< $T2*
M !)$G@ 11+, $$30 !!#\@ 10O\ $D+_ !-!_P").P  =CP  &8]  !:/0
M4#T  $@]  !"/0  /#T  #8^   O0   *D(  "5$   A1@, '4@, !M)$0 9
M21< &$D> !=))@ 622X %4HV !1*0  32DH $4I6 !!*9  /2G0 #DJ'  U*
MFP ,2K  "DK*  M)[  ,2/\ #4?_  U'_P"#/@  <3\  &)   !60   34
M $5    _0   .4$  #)"   K10  )D<  "%)   <2P  %DX' !-0#@ 24!,
M$5 9 !!0(0 /4"D #E Q  U0.P -448 "U%1  I17P )46\ !U"!  50E@ #
M4*L  E#%  -/Z  #3_L !4[_  9-_P!]0@  :T,  %U$  !21   2D0  $-#
M   \1   -44  "Y'   G2@  (4P  !Q/   740  $E0#  Y7"@ +6!  "E@5
M  A8'  '6"0 !E@L  58-@ #6$   5A,  !86@  6&D  %A\  !8D0  5Z<
M %?   !6Y0  5OD  %7_  !5_P!V1P  9D<  %E(  !/1P  1T<  $!'   X
M2   ,$H  "E-   B4   '%,  !95   16   #5L"  E>"0 $7PX  %\2  !?
M&   8!\  & G  !@,   8#L  &!'  !@5   8&,  &!V  !@BP  7Z(  %^[
M  !?X@  7OD  %W_  !=_P!O2P  84P  %5,  !,2P  1$L  #M,   R3@
M*U$  "-4   <5P  %EL  !%>   -8   "&,   )F!P  9PP  &</  !H$P
M:1D  &HA  !J*0  :C0  &I   !J30  :ET  &IO  !JA0  :IT  &FV  !H
MW0  :/<  &?_  !F_P!I40  7%   %)0  !*3P  /U   #53   M5@  )%D
M !U=   68   $&0   QG   &:@   &X   !O P  < @  '$-  !R$   =!0
M '4;  !V(P  =RP  '<X  !V1@  =E8  '9H  !V?@  =I<  '6Q  !TTP
M<_4  '/_  !R_P!C5@  6%4  %!4  !$50  .5@  "];   F7P  '6,  !5G
M   0;   "G    1S    =@   'H   !\    ? ,  'X(  !_#   @1   ((4
M  "$&P  A20  (8O  "&/0  ADT  (5?  "%=0  A8\  (2I  "#R0  @O$
M ('_  " _P!?6P  5EH  $E;   ]7@  ,F$  "=F   >:P  %7    YU   )
M>0   7X   "!    A0   (@   "*    BP   (T!  ".!@  D L  )$/  "3
M%   E1L  )<F  "7-   ET0  )=6  "6;   E88  )6B  "4P0  D^H  )+_
M  "2_P!=80  3V$  $)D   V:0  *FX  !]T   5>0  #G\   >$    B0
M (X   "2    E@   )@   ":    FP   )T   "?    H0,  *,(  "E#0
MIQ,  *D<  "J*   JCD  *I+  "J80  J7H  *B9  "HM0  I]T  *?X  "F
M_P!6:   2&P  #IP   N=@  (GT  !>$   .B@  !Y    "6    F@   )\
M  "C    IP   *H   "K    K0   *\   "Q    LP   +4   "X!0  N@P
M +T2  # '   P"T  ,!   "_50  OVX  +Z+  "^J   OLD  +WO  "\_@!.
M=   0'D  #)_   EAP  &8X  !"5   'G    *(   "G    K    +    "U
M    N0   +P   "]    OP   ,$   ##    Q@   ,@   #*    S0(  - +
M  #5$@  UB$  -<T  #820  V6   -I\  #:F@  V[4  -O9  #;\@!&@@
M.(D  "N0   =F   $J    JG    K@   +0   "Y    O@   ,(   #(
MRP   ,X   #/    T@   -0   #6    V@   -T   #?    X@   .8   #J
M"@  [Q,  / E  #R.@  \U$  /1K  #TB0  ]:4  /6_  #UW0#_  8 _P #
M /\ !0#_  L _P 0 /\ %P#_ "( _P M /\ .0#_ $0 _P!- /\ 50#_ %T
M_P!D /\ :@#_ '  _0!V /L ? #Y (, ]P"* /4 D@#S )L \ "F .X LP#K
M ,0 Z0#D .< ^0#F /\ Y0#_ -, _P#' /\ OP#_ +L _P#_    _P   /\
M  #_  ( _P + /\ $@#_ !T _P H /\ ,P#_ #X _ !' /@ 3P#T %< \0!=
M .X 8P#L &D Z@!O .@ =0#F 'P Y "# .( BP#? )4 W "? -D JP#5 +L
MT@#4 ,\ \@#- /\ S #_ ,4 _P"Z /\ M #_ +  _P#_    _P   /\   #_
M    _P & /D #P#U !< \P B /$ +0#M #< YP!  .( 20#? %  VP!7 -<
M70#4 &, T0!H ,\ ;@#, '4 R@!\ ,@ A #% (T P@"8 ,  I "] +( NP#&
M +D Z "X /T MP#_ +8 _P"M /\ IP#_ *, _P#_    _P   /\   #U
MZP ! .0 # #> !, V0 < -, )@#1 #  S  Z ,@ 0@#$ $H P !0 +T 5@"[
M %P N0!A +< 9P"U &T LP!T +$ ? "O (4 K0"0 *H G "H *H I@"[ *4
MV@"C /4 HP#_ *( _P"> /\ F@#_ )< _P#_    _@   .\   #?    T
M ,< !P#!  \ O  7 +D ( "W "H M0 S +  .P"M $, JP!) *@ 3P"F %4
MI !: *, 8 "A &8 GP!M )T = "< 'T F@"( )@ E "6 *( E "R )( R0"1
M .L D0#_ )  _P"0 /\ C #_ (H _P#\    [    -D   #'    N@   +$
M @"K  P IP 2 *0 &P"A "0 H  L )X -0"; #P F !# )8 20"4 $\ D@!4
M )  6@"/ %\ C0!F (L ;0") '8 B "  (8 C "$ )H @@"J ($ O@"  .
M@ #Y '\ _P!_ /\ ?P#_ 'X _P#Q    V    ,(   "S    J    *    "9
M  < E0 . )( %0"0 !X C@ F (T +@"* #8 AP ] (4 0P"$ $D @@!. ($
M5 !_ %D ?@!@ 'P 9P!Z &\ >0!Z '< A@!U )0 = "C '( M0!R ,\ <0#Q
M '  _P!P /\ < #_ '$ _P#A    Q    +    "B    EP   )$   "+  (
MA@ + (, $0"! !@ ?P A 'T *0!\ #  >0 W '@ /0!V $, = !) ', 3@!R
M %0 < !: &\ 8@!M &H :P!T &H @ !H (X 9P"= &4 KP!E ,8 9 #H &0
M_0!C /\ 8P#_ &0 _P#/!0  M@<  *,(  "4"   B0<  ((#  !^    >P &
M '< #@!U !, <@ ; '$ (P!O "L ;0 R &P . !J #X :0!$ &< 20!F $\
M90!6 &, 70!B &4 8 !O %\ >P!= (D 7 "9 %L J@!9 +\ 60#A %@ ^ !8
M /\ 6 #_ %D _P#"#   J@T  )<.  ")#@  ?0X  '8-  !Q"@  ;P8  &T
M"@!K !  :0 6 &< '@!E "8 8P M &$ ,P!@ #D 7P _ %T 10!< $L 6P!2
M %H 60!8 &( 5P!L %4 > !3 (8 4@"6 %$ IP!0 +L 3P'; $X"] !. _\
M3@3_ $X#_P"X$   H1(  (X3  !_$P  =!,  &P2  !G$   90X  &,+ P!C
M!@P 8001 %X#&0!<!"$ 6P4H %D&+P!8!C4 5@<[ %4'0@!4!T@ 4PA/ %$(
M5@!0"5\ 3@EI $T)=@!+"H0 20J4 $@*I@!'"KH 1@K8 $4+\P!%#/\ 10S_
M $4,_P"P%   F18  (<8  !X&0  ;1@  &47  !?%@  7!,  %H1  !:#@8
M6@P- %<,% !5#!P 4PTD %(-*P!0#3$ 3PXX $X./@!-#D4 2PY- $H.50!(
M#UX 1P]H $4/=0!#$(0 01"5 $ 0I@ ^$+L /1#< #T1]@ ]$?\ /1#_ #X0
M_P"I&0  DAL  ($<  !R'0  9QT  %\<  !9&P  51D  %,6  !2$P  4A$*
M % 0$ !.$1@ 3!$@ $H2)P!)$BX 2!,T $<3.P!%$T( 1!-) $,44@!!%%L
M/Q1E #X5<@ \%8$ .A62 #@5I  W%;D -178 #46]0 V%O\ -A;_ #<5_P"C
M'   C1X  'L@  !M(0  8B$  %HA  !4'P  4!X  $T;  !,&0  2Q8& $D6
M#@!'%Q4 11<< $08) !"&"H 01@Q $ 9.  _&3\ /1E& #P:3P Z&E@ .1IC
M #<;;P U&WX ,QN0 #(;H@ P&[< +QO3 "\<\P O&_\ ,!O_ # ;_P"='P
MB"(  '<C  !I)   7B0  %8D  !0(P  2R(  $@@  !&'0  11P" $,<# !!
M'!( /QT9 #X=(0 \'B< .QXN #H?-0 Y'SP -Q]$ #8?3  T(%8 ,R!@ #$@
M;0 O('P +2&. "PAH  J(;4 *2'0 "DA\@ I(?\ *B#_ "L@_P"9(@  A"4
M ',F  !E)P  6R<  %,G  !,)@  1R4  $0D  !"(0  /R$  #TA"0 [(1
M.2(6 #@B'@ V(R4 -2,K #0D,@ S)#D ,B1! # D2@ O)5, +25> "LE:P J
M)7H *"6, "8EGP D);, (R7. ",E\  D)?\ )23_ "4D_P"4)0  @"<  &\I
M  !B*@  5RH  $\J  !)*0  1"@  $ G   ])@  .B4  #<F!@ U)@X -"<4
M #(G&P Q*"( ,"@I "\H,  M*3< +"D_ "LI1P I*5$ *"I< "8J:0 D*G@
M(RJ* "$JG0 ?*K( 'BK, !XJ[P ?*?\ ("G_ "$H_P"0*   ?"H  &PK  !?
M+   5"P  $PL  !&+   02L  #PK   X*@  -2H  #(K P P*PP +BP1 "TL
M&  L+!\ *BTF "DM+0 H+30 )RX\ "8N10 D+D\ (RY: "$O9P ?+W8 '2^(
M !POFP :+[  &"_* !@N[0 9+O\ &RW_ !LM_P",*P  >"T  &@N  !;+P
M42\  $DO  !#+P  /BX  #DN   T+@  ,"X  "TO   K, H *3$0 "<Q%0 F
M,1P )3(C "0R*@ C,C$ (3,Y " S0@ ?,TP '3-7 !LS9  :-'0 &#2& !8T
MF@ 4,ZX $S/( !,S[  4,_\ %3+_ !8Q_P"'+@  ="\  &4Q  !8,0  3C(
M $8R  ! ,0  .S$  #8Q   Q,0  *S,  "@T   E-08 (S8- "$V$@ @-QD
M'S<@ !XW)P =."X &S@V !HX/P 9.$D %SE5 !4Y8@ 4.7$ $CF$ !$YF  0
M.:T #CC'  XXZP 0./\ $#?_ !$V_P"#,0  <#(  &$T  !5-   2S0  $0T
M   ]-   .#0  #,T   M-0  *#<  "0Y   @.@( '3L+ !L\$  9/14 &#T<
M !<](P 6/2L %3XS !0^/  2/D8 $3Y2 ! ^7P //F\ #CZ!  P^E0 +/JD
M"C[!  H]Y  +/?L ##S_  T[_P!]-   :S8  %TW  !1-P  2#<  $$W   [
M-P  -3<  # W   J.0  )3L  " ]   </P  %T$& !1##0 20Q( $4,8 !%#
M'P 01"< #T0O  Y$.0 -1$, #$1.  M$6P )1&H !T1\  9$D  $0Z4  D.]
M  -#X  #0_8 !$+_  9!_P!X.   9SD  %DZ  !..@  13H  #XZ   X.@
M,SH  "T[   G/0  (4   !Q"   71   $T8#  ])"@ -2@\ #$H4  M*&P )
M2B, "$HK  =*-  %2CX !$I)  )*5@  2F4  $IW  !*BP  2J$  $FY  !)
MW0  2?4  $C_  !(_P!R/   8CT  %4^  !*/@  0CT  #P]   V/0  +SX
M "E    C0@  '44  !='   32@  #TP"  M/"0 '4 T  U$1  !1%P  41X
M %$F  !1+P  43D  %%$  !240  4F   %%R  !1AP  49T  %&U  !0V
M4/4  $__  !/_P!L0   74$  %%!  !'00  0$   #E    R00  *D,  "1&
M   >2   %TL  !).   .40  "U,!  96!P  5PP  %@0  !8$P  61D  %HA
M  !:*0  6C,  %H_  !:3   6EH  %IL  !:@0  69D  %FQ  !8T0  6/0
M %?_  !7_P!E10  6$4  $U%  !%1   /D0  #5%   M1P  )4H  !Y-   8
M4   $E,   Y6   *60  !%P   !>!   7PD  & -  !A$   8A4  &,;  !D
M(P  9"T  &0X  !D10  9%0  &1F  !D>P  8Y,  &.M  !BS   8?(  &'_
M  !@_P!?2@  4TH  $I)  !#2   .4D  "],   G3P  'U(  !A5   260
M#5T   A@   "8P   &8   !H 0  :04  &H*  !K#0  ;1$  &X6  !P'0
M<28  '$Q  !P/@  <$X  '!?  !P<P  ;XT  &^G  !NQ@  ;>\  &S_  !L
M_P!:3P  4$X  $A-   ]3@  ,U$  "E4   @6   &%P  !%@   ,9   !F@
M  !K    ;P   '(   !T    =0   '<$  !X"0  >@T  'P0  !]%@  ?QX
M ( H  " -0  @$4  ']6  !_:P  ?X0  'Z@  !]O@  ?.D  'O_  !Z_P!6
M5   3E,  $)4   W5@  +%H  ")?   88P  $6@   MM   #<@   '8   !Z
M    ?0   (    "#    A    (8   "' @  B0<  (L,  "-$   D!8  )(?
M  "2+   DCL  ))-  "18@  D7H  (^7  "/M   CN$  (S[  ",_P!560
M2%H  #M=   O80  )&8  !EL   1<@  "G<   )]    @@   (8   "+
MC@   )$   "3    E0   )<   "9    FP   )T$  "?"@  H@\  *06  "F
M(0  IC$  *9#  "E5P  I'   *..  "CJP  H=   *#U  "?_P!.80  0&0
M #-I   G;@  &W4  !%\   +@P   (D   ".    DP   )@   "=    H0
M *0   "E    IP   *D   "K    K0   +    "R    M0@  +@.  "\%@
MO"4  +PW  "[3   NF0  +F!  "WH@  M\   +?J  "W_ !&:P  .7   "MW
M   ??P  $X8   N.   !E0   )L   "A    I@   *L   "P    LP   +<
M  "W    N@   +P   "_    P0   ,0   #'    R@   ,T%  #1#@  U!D
M -0K  #40   TU@  --T  #3D@  TK   -+3  #2\@ ^>0  ,8   ".(   7
MD0  #9D   .@    IP   *X   "S    N    +T   #"    Q@   ,H   #*
M    S0   ,\   #2    U0   -D   #=    WP   .,   #G!0  ZP\  .P?
M  #M,P  [DL  .]D  #O@@  \)\  /&Y  #QV #_    _P   /\ ! #_  D
M_P . /\ %0#_ !X _P I /\ - #_ #\ _P!( /\ 4 #_ %@ _P!> /\ 90#]
M &L ^P!Q /D =P#X 'X ]@"% /, C0#Q )< [@"B .L KP#H ,  Y@#@ .,
M^ #B /\ VP#_ ,L _P#! /\ N0#_ +0 _P#_    _P   /\   #_    _P )
M /\ $ #_ !D _P C /\ +@#] #D ^0!" /4 2@#R %( [@!8 .L 7@#I &0
MY@!J .0 < #B '8 WP!] -T A@#9 (\ U0": -$ IP#. +8 RP#. /_B?1!)
M0T-?4%)/1DE,10 ,$LD \ #' /\ Q0#_ +L _P"T /\ K0#_ *D _P#_
M_P   /\   #_    ^P " /8 #0#Q !, [0 > .P * #I #( XP [ -T 1 #8
M $L TP!1 -  6 #- %T RP!C ,D : #& &\ Q !V ,( ?@"_ (< O "2 +H
MGP"W *T M0#! +( Y "Q /T KP#_ *P _P"E /\ H #_ )P _P#_    _P
M /L   #N    Y    -P " #3 !  SP 8 ,L (@#) "L Q@ T ,$ /0"] $0
MN@!+ +< 40"U %8 L@!< +  80"N &< K !N *H =@"H '\ I@"* *, E@"A
M *4 GP"V )T T0"< /, FP#_ )P _P"6 /\ DP#_ )  _P#_    ]@   .<
M  #3    Q@   +T  P"X  T LP 3 +$ ' "O "4 K@ N *D -@"F #T HP!$
M *$ 2@"? $\ G0!5 )L 6@": &  F !F )8 ;@"4 '< D@"! )  C@". )P
MC "M (H PP") .@ B #_ (D _P"' /\ A0#_ (( _P#S    XP   ,P   "\
M    L    *<   "A  @ G@ / )L %@"9 !\ F  G )8 +P"3 #< D0 ] (X
M0P", $D BP!. (D 5 "' %D A0!@ (0 9P"" &\ @ !Z 'X A@!\ )0 >@"D
M 'D N !X -@ =P#W '@ _P!X /\ =P#_ '4 _P#F    RP   +<   "H
MG@   )8   "/  0 BP , (@ $@"' !D A0 A (0 *0"" #  ?P W 'T /0!\
M $, >@!( 'D 30!W %, =@!9 '0 80!R &D <0!S &\ ?P!M (T ; "= &H
MKP!I ,@ : #M &D _P!I /\ :0#_ &D _P#2    N    *4   "7    C0
M (8   "!    ?  ( 'D #@!W !0 =@ < '0 (P!S "L <0 Q &\ -P!N #T
M; !# &L 2 !J $X : !4 &< 6P!E &, 8P!M &( > !@ (< 7P"6 %T J !=
M +X 7 #D %P ^P!< /\ 7 #_ %P _P#"    J@$  )@#  ")!   ?P(  '@
M  !T    <  $ &T # !K !$ :0 7 &@ '@!F "4 90 L &, ,@!B #@ 8  ]
M %\ 0P!> $D 7 !/ %L 5@!: %X 6 !H %< <P!5 ($ 5 "1 %( HP!1 +<
M40#6 %$ ]0!1 /\ 40#_ %( _P"V!P  GPD  (T+  !^#   <PL  &P*  !H
M!P  90,  &, !P!A  T 7P 3 %T &@!< "$ 6P G %D +0!8 #, 5@ Y %4
M/P!4 $4 4P!+ %$ 4@!0 %H 3P!D $T ;P!, 'T 2@"- $D GP!( +( 1P#,
M $< [P!& /\ 1P#_ $< _P"L#   E0X  (,0  !U$   :Q   &,/  !>#@
M6PP  %H) @!9! H 5P / %4 %0!3 !P 4@ C %$ *0!/ "\ 3@ U $T!.P!,
M 4$ 2@)( $D"3P!( E< 1@-A $4#;0!# WH 0@.+ $ #G  _ Z\ /@/( #T$
MZ@ ]!?P /0;_ #X&_P"D$   CA(  'P3  !N%   9!0  %P3  !6$@  4Q$
M %$.  !0# 4 4 D, $\'$0!-!Q< 2P@? $D()0!("2L 1PDQ $8). !$"CX
M0PI% $(*30! "U4 /PM? #T+:P \"WD .@R* #@,G  W#*\ -0S' #4,Z0 U
M#?T -0W_ #8,_P"=$P  AQ4  '87  !I&   7A@  %88  !0%P  314  $H3
M  !)$0  20X' $@-#@!&#1, 1 T: $,.(0!"#B@ 0 XN #\.-0 ^#SP /0]#
M #L02P Z$%0 .!!> #80:P T$'D ,A"* #$0G  O$+  +1#) "T1[  M$?\
M+A'_ "\0_P"7%@  @AD  '$;  !D'   61P  %$<  !,&P  1QH  $08  !#
M%0  0A," $$2"P! $1  /A(7 #P2'@ [$R4 .A,K #@3,@ W$SD -A1  #04
M2  S%%$ ,11< # 5:  N%7< +!6( "H5F@ H%:X )Q7' "85Z@ G%?\ *!7_
M "D5_P"1&@  ?1P  &T>  !@'P  5A\  $X?  !('@  0QT  $ <   ^&@
M/1@  #L7!P Y%@X .!<4 #87&P U&"( ,Q@H #(8+P Q&38 ,!D] "X91@ M
M&D\ *QI9 "H:9@ H&G0 )AJ& "0:F0 B&JT (1K% " :Z  A&OX (AK_ ",:
M_P"-'0  >1\  &DA  !<(@  4B(  $HB  !$(0  /R$  #P@   Y'@  .!L
M #4<!  T' T ,AP2 # =&  O'1\ +ATE "T>+  K'C, *AX[ "D?0P G'TT
M)A]7 "0?9  B'W( (!^$ !\?EP ='ZL &Q_# !L?YP ;'_T '1__ !X>_P")
M(   =2(  &4C  !9)   3R4  $<E  !!)   /",  #@C   U(@  ,R   # @
M 0 N(0H +"$0 "LA%0 J(AP *"(C "<B*0 F(S  )2,X ",C00 B)$H (215
M !\D80 =)'  &R2" !DDE0 7)*H %B3! !4DY0 6)/P %R/_ !DC_P"%(@
M<20  &(F  !6)P  3"<  $0G   ^)P  .28  #4F   Q)0  +B0  "LE   I
M)0< )R8. "4F$P D)QD (R<@ "(G)P A*"X ("@V !XH/@ =*$@ &RE3 !DI
M7P 8*6X %BF  !0IE  2*:@ $2G  !$HY  1*/L $RC_ !0G_P" )0  ;B<
M %\H  !3*0  22H  $(I   [*0  -BD  #(H   N*   *B@  "8I   D*@0
M(BL, " K$0 ?+!8 '2P= !PL)  ;+2L &BTS !@M/  7+44 %BY0 !0N70 2
M+FP $2Y^ ! ND@ .+J< #2V]  TMWP -+?D #BS_ ! L_P!\*   :BH  %LK
M  !0+   1BP  #\L   Y+   -"L  "\K   K*P  )BP  "(N   ?+P  '# )
M !HQ#@ 9,1, %S$: !8R(0 5,B@ %#(P !,R.0 2,T, $3-. ! S6P .,VD
M#3-Z  PSC@ *,Z( "#*Y  @RV0 (,O0 "C'_  LQ_P!W*P  9BT  %@N  !-
M+P  0R\  #PN   V+@  ,2X  "TN   I+@  (S   !\R   ;,P  %S4% !0V
M#  2-Q$ $3<6 !$W'0 0."0 #S@L  XX-0 -.#\ ##A*  LX5P ).&4 !SAV
M  4XB@ #.)\  3>U  $WTP "-_$  S;_  4V_P!S+@  8C   %0Q  !),0
M03$  #DQ   T,0  +S   "LP   E,@  (#,  !LV   7.   $SH" ! \"0 -
M/0X ##T3  L]&0 */2$ "3TI  @],0 &/CL !3Y&  ,^4@ !/F$  #YR   ^
MA@  /9P  #VR   ]T   //   #S_   \_P!M,@  73,  % T  !&-   /C0
M #<T   R,P  +3,  "<T   B-@  '3@  !@Z   4/0  $#\"  U!"  )0PT
M!D01  -$%@ "1!T  $0D  !$+0  1#8  $1!  !$3@  1%P  $1M  !$@0
M1)@  $.O  !#S0  0O   $+_  !"_P!H-@  6#<  $PX  !#.   .S<  #4V
M   P-@  *3<  ",Y   >.P  &#T  !-    00@  #44!  A'!P #20P  $D/
M  !*$P  2QD  $L@  !+*   2S(  $L]  !,20  3%<  $MH  !+?0  2Y0
M $JL  !*R@  2>\  $G_  !)_P!B.@  5#L  $D[  ! .P  .3H  #,Y   L
M.@  )3P  !\_   900  $T0  !!'   ,20  "$P   )/!0  4 H  % -  !1
M$   4A4  %0;  !4(P  5"P  %0W  !41   5%(  %1C  !4=P  5(\  %.H
M  !2Q@  4NT  %'_  !1_P!</P  3S\  $4_   ^/@  -ST  "\^   G0
M($,  !E&   320  #TP   M/   &4@   %0   !7 @  6 <  %D+  !:#@
M6Q$  %T6  !>'0  7R8  %\Q  !>/0  7DP  %Y=  !><0  78D  %VC  !<
MP0  6^L  %K_  !:_P!61   2T,  $-"   \00  ,D(  "E%   A2   &DL
M !-.   .4@  "E4   -9    6P   %X   !@    8@(  &,&  !E"@  9@X
M &@1  !J%P  :Q\  &LI  !K-@  :T4  &M6  !J:@  :H(  &F=  !HNP
M9^<  &;_  !E_P!12   2$@  $%&   W1P  +$H  "--   ;40  $U4   Y9
M   (70   6$   !D    9P   &H   !L    ;@   '    !R!0  <PD  '4-
M  !W$0  >A@  'LA  ![+@  >CT  'I.  !Y8@  >7D  'B6  !WLP  =>
M '3\  !S_P!.30  1TP  #M-   P3P  )E,  !Q8   37   #6$   9F
M:@   &\   !R    =@   'D   !\    ?0   '\   "!    @P(  (8'  "(
M#   BQ$  (X8  ".)   CC,  (U$  ",6   BV\  (J,  ")J@  B,\  (;W
M  "%_P!-40  05,  #15   I6@  'E\  !1E   -:@  !7    !V    >P
M '\   "#    AP   (H   "-    C@   )$   "3    E0   )@   ":!0
MG0P  * 1  "C&@  HR@  *(Z  "A3@  H&4  *"!  ">H   G<$  )ON  ":
M_P!&60  .5P  "UA   A9P  %FX   YU   %>P   ($   "'    C0   )(
M  "6    F@   )T   "?    H0   *0   "F    J    *L   "N    L0,
M +0+  "X$0  N1X  +DO  "X0P  MUH  +5V  "TEP  M+4  +'B  "P_  _
M9   ,6D  "5O   8=P  #W\   :'    C@   )0   ":    H    *4   "J
M    K@   +$   "R    M0   +<   "Z    O    +\   ##    Q@   ,D
M  #."@  TA,  -(C  #1-P  T$\  ,YJ  #-B@  RJL  ,O+  #+[P W<0
M*7@  !V    1B0  ")$   ":    H0   *<   "M    LP   +D   "^
MP@   ,4   #&    R0   ,P   #.    T@   -4   #:    W@   .$   #E
M    Z@L  .L7  #J*P  ZD,  .I>  #J>@  ZYD  .NU  #KU0#_    _P
M /\  0#_  < _P - /\ $@#_ !L _P E /\ +P#_ #H _P!# /\ 2P#_ %,
M_P!: /T 8 #[ &8 ^@!K /@ <@#V '@ ] "  /$ B0#O )( [ "= .D J@#F
M +P XP#< -\ ]P#= /\ S #_ +X _P"U /\ L #_ *T _P#_    _P   /\
M  #_    _P & /\ #0#_ !0 _P ? /\ *0#[ #, ]P ] /, 10#O $T [ !3
M .@ 60#E %\ XP!E .  :@#= '$ V@!X -8 @ #2 (H SP"5 ,P H@#( +(
MQ0#) ,( [0#  /\ NP#_ +  _P"H /\ I #_ *$ _P#_    _P   /T   #Z
M    ^    /  "0#L !$ Z  9 .< (P#E "T W@ V -8 /@#1 $8 S0!, ,H
M4@#( %@ Q0!= ,, 8P#  &D O@!P +P > "Y ($ MP"- +0 F@"Q *D K@"\
M *P X0"J /P J #_ *  _P"9 /\ E@#_ )0 _P#_    ^0   /(   #G
MVP   -$ ! #*  T QP 4 ,0 '0#" "8 OP O +L -P"W #\ M !% +$ 2P"N
M %$ K !6 *H 7 "H &$ I@!H *, < "A 'D GP"$ )T D0": *  F "Q )8
MS "5 /$ E #_ )$ _P"+ /\ B #_ (8 _P#W    [    -X   #)    O
M +0   "O  H JP 0 *D %P"H "  IP H *( , "? #@ G  ^ )H 1 "8 $H
ME@!/ )0 50"3 %H D0!A (\ : "- '$ BP![ (D B "' )< A0"H (, O@"!
M .0 @ #_ (  _P!\ /\ >P#_ 'D _P#I    UP   ,$   "Q    I@   )T
M  "7  4 E  - )( $@"0 !H CP B (X *@"+ #$ B0 X (< /@"% $, @P!(
M ($ 3@!_ %0 ?@!: 'P 80!Z &D > !S '8 ?P!U (X <P"? '$ LP!P -
M;P#V &\ _P!O /\ ;0#_ &P _P#:    OP   *P   ">    DP   (P   "%
M    @@ ) '\ #P!^ !4 ?0 < 'P ) !Z "L =P Q '4 -P!T #T <@!" '$
M2 !O $T ;@!3 &P 6@!K &( :0!L &< > !F (8 9 "7 &( J@!A ,( 8 #K
M &$ _P!A /\ 80#_ &  _P#%    K0   )L   "-    @P   'P   !W
M<@ % '  # !N !$ ;  7 &P '@!K "4 :0 L &< ,0!F #< 9  ] &, 0@!B
M $@ 8 !. %\ 50!= %T 7 !F %H <@!9 (  5P"0 %8 HP!5 +D 5 #> %0
M^P!4 /\ 50#_ %4 _P"V    GP   (T   !_    =0   &X   !I    9@ !
M &, "0!A  X 8  3 %\ &0!> "  70 F %L + !: #( 6  W %< /0!6 $,
M50!) %, 4 !2 %@ 40!A $\ ; !. 'H 3 "* $L G !* +$ 20#. $D \P!)
M /\ 20#_ $H _P"J 0  E 4  (('  !T"   :@@  &,&  !>!   6P   %D
M!0!7  P 5@ 0 %0 %0!3 !L 4@ B %$ * !0 "T 3@ S $T . !, #X 2P!%
M $H 3 !( %0 1P!= $8 : !$ '4 0P"% $$ F !  *L 0 #% #\ Z@ _ /\
M0 #_ $  _P"@"   B@L  'D-  !L#0  80T  %H-  !5"P  4@D  % &  !/
M @@ 3@ - $P $@!+ !< 2@ > $D (P!' "D 1@ O $4 - !$ #H 0@!! $$
M2 !  %  /@!: #T 9  \ '( .@"" #D E  X *< -P"^ #8 XP V /D -@#_
M #< _P"8#0  @PX  '(0  !E$0  6Q$  %,0  !.$   2@X  $@-  !'"@,
M1P<* $4$#@!$ A, 0@(: $$"( !  R4 /@,K #T$,0 \!#< .P0^ #H%10 Y
M!4X -P57 #8%8@ T!G  ,@:  #$&D@ P!J4 +P6[ "X%W0 N!O4 +0?_ "X'
M_P"1$   ?1$  &P3  !?%   510  $X4  !($P  1!(  $$0  ! #@  0 T&
M $ *#  ^"1  / D6 #L*'  Y"B( . HH #<++@ V"S4 -0L[ #,+0P R#$P
M, Q6 "\,80 M#&\ *PQ_ "H,D@ H#*4 )PR[ "4,W0 E#?4 )@W_ "<-_P"+
M$@  =Q0  &<6  !;%P  41@  $D7  !#%P  /Q4  #P4   Z$@  .1$! #D/
M"  X#@T -PX2 #4.&  T#A\ ,@XE #$/+  P#S( +Q Z "T00@ L$$L *A!5
M "@080 F$&\ )!"  ",0DP A$*< 'Q"] !X0X  >$?< 'Q#_ " 0_P"&%
M<Q<  &,9  !7&@  31L  $4:  ! &@  .QD  #@8   U%@  -!0  #,2!  R
M$@L ,1(0 "\2%0 M$AP +!,B "L3*0 J$S  *!,W "<4/P F%$@ )!13 "(4
M7P @%6T 'Q5^ !T5D0 ;%:4 &16[ !@5W@ 8%?@ &13_ !H4_P""%P  ;QH
M %\<  !3'0  2AT  $(=   \'0  -QP  #0;   Q&@  +QD  "X6   L%P@
M*Q8. "D7$P H%QD )Q@@ "48)@ D&"T (Q@T "(9/0 @&48 'AE1 !T970 ;
M&FL &1I\ !<:CP 5&J, %!FZ !(9VP 3&?8 %!G_ !48_P!]&@  :QT  %P?
M  !0(   1R   #\@   Y'P  -!\  #$>   M'0  *QP  "D;   G&P4 )1L,
M "0<$0 B'!8 (1P= " =(P ?'2H 'ATR !P>.@ ;'D0 &1Y. !<>6P 6'FD
M%!]Z !(>C0 1'J( $!ZX  X>V  /'O4 $!W_ !$=_P!Z'0  9Q\  %DA  !-
M(@  1"(  #PB   V(@  ,B$  "XA   J(   )R   "0?   B( ( (" * !XA
M#P =(10 '"$: !LB(0 9(B< &"(O !<B.  5(T$ %"-, !(C6  1(V< $"-X
M  XCBP -(Y\ #".T  LCT  +(O  #"+_  TA_P!V'P  9"(  %8C  !+)
M020  #HD   T)   +R,  "LC   H(P  )",  " C   =)   &R4' !DF#0 7
M)A$ %B87 !4G'@ 4)R4 $R<L !(G-0 1*#\ $"A*  XH5@ -*&0 #"AT  HH
MAP )*)L !R>Q  4GS  &)^P !R;^  @F_P!Q(@  8"0  %,F  !()P  /R<
M #<F   Q)@  +28  "DE   E)0  (B4  !TG   9*   %BH$ !0K"P 2+!
M$2P4 ! L&P 0+"( #BPI  XM,@ -+3L "RU&  HM4@ (+6  !BUP  0M@P "
M+9@  "RN   LR0  +.L  2O\  (K_P!M)0  72<  $\H  !%*0  /"D  #4I
M   O*   *R@  "<G   C)P  'R@  !LJ   7+   $RX" ! P"  .,0T #3$2
M  PQ%P +,1X "C$F  @R+@ ',C< !3)"  ,R3@ !,EP  #)L   R?P  ,I4
M #&L   QQP  ,.H  ##\   P_P!H*0  6"H  $PK  !!+   .2P  #(K   M
M*P  *2H  "4J   @*P  '"P  !<N   3,   $#("  XT!P *-PP !S<0  4W
M%  #-QL  C<B   W*@  .#,  #@^   X2@  .%@  #AH   X?   -Y(  #>I
M   VQ0  -NH  #;]   U_P!C+   5"X  $@O   ^+P  -BX  # N   K+0
M)RT  "(M   =+P  &#$  !0S   0-0  #C<!  HZ!P &.PL  CP.   ]$@
M/A<  #X>   ^)@  /B\  #XZ   ^1@  /E0  #YD   ^=P  /H\  #VG   ]
MPP  /.D  #S]   [_P!>,   4#$  $0R   [,@  -#$  "XP   I+P  )#
M !XR   9-   %#8  ! Y   -.P  "CT   5 !0  00H  $(-  !#$   1!0
M $4:  !&(@  1BL  $8U  !&00  1D\  $9?  !&<P  18H  $6D  !$P
M0^@  $/^  !"_P!8-   2S4  $$U   Y-0  ,C0  "TS   F-   (#4  !HX
M   4.@  $#T   U    )0@  !$4   !' P  2 <  $H+  !+#@  3!$  $X5
M  !/'   3R4  $\O  !//   3TH  $]:  !.;0  3H4  $V@  !,O   2^<
M $O^  !*_P!3.0  1SD  #XY   W.   ,3<  "DW   A.0  &SP  !4_   0
M0@  #$4   =(   "2@   $T   !/    400  %('  !4"P  50X  %<1  !9
M%P  6A\  %DI  !9-@  640  %E4  !89P  6'\  %>:  !6MP  5>,  %3]
M  !4_P!./0  0ST  #P\   U.P  +#P  "0^   <00  %40  !!(   +2P
M!4X   !1    5    %<   !9    6P   %T"  !>!@  8 L  &(.  !D$@
M9Q@  &<B  !F+@  9CP  &9-  !E8   97<  &23  !CL0  8=T  &#\  !?
M_P!)0@  04$  #H_   P0   )D,  !Y&   52@  $$X   I2   #5@   %H
M  !=    8    &,   !E    9P   &D   !K 0  ;04  &\*  !R#@  =1(
M '<;  !V)@  =C4  '5&  !T60  =&\  '.+  !RJ0  <,T  &_W  !N_P!&
M1@  0$4  #5&   J2   ($P  !=1   05@  "5H   %?    8P   &@   !K
M    ;P   '(   !U    =P   'D   ![    ?0   ( #  "#"   A@T  (D3
M  "*'0  BBL  (D\  "(3P  AF8  (6!  "$H   @L(  ('P  !__P!&2P
M.DP  "Y/   C4P  &%@  !!>   )9    &D   !O    =    '@   !\
M@0   (0   "'    B    (L   ".    D    ),   "6    F0<  )T-  "A
M%   H"$  * Q  ">1   G5L  )QV  "9E@  F;4  );E  "5_@ _4@  ,E4
M "9:   ;8   $6<   EM    =    'L   "!    A@   (L   "0    E
M )<   "9    G    )\   "A    I    *<   "J    K0   +$&  "U#0
MN!8  +<F  "V.0  M5   +1J  "RB0  L*H  *[/  "M]0 W7   *V$  !YH
M   3<   "W@   "     AP   (X   "5    F@   )\   "D    J    *P
M  "M    L    +,   "U    N    +L   "_    PP   ,<   #+!0  T0X
M -$;  #0+@  ST4  ,U?  #+?@  R9X  ,B^  #%Z0 O:0  (W   !9Y   -
M@0   8L   "3    FP   *(   "H    K@   +0   "X    O0   ,    #"
M    Q0   ,@   #+    S@   -$   #6    VP   -\   #D    Z 8  .L1
M  #J(P  ZCH  .E4  #G<@  Y9,  ..S  #CU #_    _P   /\   #_  0
M_P + /\ $ #_ !< _P A /\ *P#_ #4 _P ^ /\ 1P#_ $X _P!5 /P 6P#Z
M &$ ^ !F /8 ;0#T ', \@![ .\ A #M (X Z@"9 .8 IP#C +D WP#5 -L
M]P#6 /\ P #_ +( _P"J /\ I0#_ *( _P#_    _P   /X   #\    _  #
M /X "P#_ !$ _P : /T ) #Y "X ]  X /  0 #L $@ Z0!. .8 5 #B %H
MWP!? -P 90#8 &L U !R -  >P#- (4 R@"1 ,< G@## *X P #% +T ZP"[
M /\ L #_ *0 _P"< /\ F #_ )4 _P#_    ^@   /0   #Q    \@   .H
M!0#G  X X@ 5 .$ '@#A "@ V  Q -  .0#+ $  R !' ,4 30#" %, OP!8
M +T 7@"[ &0 N0!K +8 <P"T 'P L0"( *X E0"K *0 J "X *8 W "C /L
MGP#_ )4 _P"/ /\ BP#_ (D _P#Y    [P   .<   #?    SP   ,@   #!
M  H OP 1 +P & "[ "$ N0 J +0 ,@"Q #H K@!  *L 1@"H $P I@!1 *,
M5@"A %P GP!C )T :@"; ', F0!^ )8 C "4 )L D@"M )  QP". /  C0#_
M (8 _P"  /\ ?0#_ 'P _P#M    X    -$   "_    LP   *H   "F  4
MH@ - *$ $P"@ !L GP C )L *P"8 #( E0 Y ), /P"1 $0 CP!* (X 3P",
M %4 B@!; (@ 8P"& &L A !V (( @@"  )( ?@"C 'P N@!Z .$ >0#_ '<
M_P!R /\ < #_ &\ _P#=    RP   +8   "G    G0   )0   ".  $ BP *
M (D $ "( !4 AP = (< )0"$ "P @@ R '\ . !] #T >P!# 'D 2 !X $X
M=@!4 '4 6P!S &, <0!N &\ >@!M (D ; ": &H K@!I ,P : #V &< _P!E
M /\ 9 #_ &, _P#*    M    *$   "3    B0   ((   ![    >  % '8
M# !U !$ =  8 ', 'P!R "4 <  L &X ,@!L #< :@ \ &D 0@!H $@ 9@!.
M &4 50!C %T 8@!F &  <@!> (  70"2 %L I0!: +X 60#I %D _P!9 /\
M6 #_ %@ _P"Y    H@   )    "#    >0   '$   !M    :0 ! &8 "0!E
M  X 9  3 &, &0!C "  80 F &  + !> #$ 7  W %L / !: $( 6 !( %<
M3P!6 %< 5 !@ %, ; !1 'D 4 "* $\ G@!. +0 30#: $T ^P!- /\ 30#_
M $T _P"J    E    ((   !U    :P   &0   !@    70   %H !0!8  P
M5P 0 %8 %0!6 !L 50 A %, )P!2 "P 40 Q $\ -P!. #T 30!# $P 2@!*
M %( 20!; $@ 9@!& ', 10"$ $0 EP!# *P 0@#) $( \0!" /\ 0P#_ $,
M_P">    B0   '@#  !J!   800  %H#  !5 0  4@   %   @!.  D 30 -
M $P $0!+ !< 2@ < $D (@!( "< 1P M $4 ,@!$ #@ 0P ^ $( 10!! $T
M/P!6 #X 80 ] &X .P!^ #H D0 Y *8 . "_ #@ Z  X /\ .0#_ #D _P"5
M P  @ <  &\)  !B"@  6 L  %$*  !,"   208  $<#  !&  8 1  + $,
M#P!" !, 00 8 $$ '@ _ ", /@ I #T +@ [ #0 .@ Z #D 00 X $D -P!2
M #8 70 T &H ,P!Z #( C  Q *$ , "X "\ W@ O /D +P#_ #  _P","0
M> P  &@-  !<#@  4@X  $L.  !%#0  00P  #\*   ^" ( /00( #P!#0 [
M !  .@ 5 #D &@ X "  -@ E #4 *P T #  ,P W #( /@ Q $8 +P!0 "X
M6@ M &< *P!W "H B0 I )T * "S "< T0 G /( )P#_ "< _P"&#   <@X
M &,0  !6$0  31$  $41  ! $   / \  #D.   W#0  -@L$ #8("@ U!@X
M- 42 #($%P Q!1P , 4B "\%*  N!BX +08T "L&/  J!D0 *0=. "<'60 F
M!V4 ) =U ",'AP B!YL ( :P " &RP ?!>T 'P;^ !\'_P" #@  ;1$  %X2
M  !2$P  2!,  $$3   [$P  -Q(  #01   R$   , \! # -!@ P"PL +PH0
M "T*%  L"QD *@L? "D+)0 H#"L )PPR "8,.@ D#$, (PQ- "$-6  @#64
M'@UU !P-B  :#9P &0VQ !@,R@ 7#.L %PW\ !@,_P![$0  :1,  %H5  !.
M%@  118  #T6   X%0  ,Q4  # 4   M$P  *Q(  "H0 P J#P@ *0X- "@.
M$0 F#A8 )0\= "0/(P C#RD (1 Q " 0.0 >$$( '1!, !L06  9$&8 %Q!V
M !40B0 4$)X $A"S !$0S@ 1$.X $A#^ !(0_P!W$P  914  %<7  !+&
M0AD  #H9   T&   ,!<  "P7   I%@  )Q4  "84 0 E$@0 (Q(+ "(2#P A
M$A0 (!(: !X3(  =$R< '!,N !H3-@ 9%$  %Q1* !845@ 4%&0 $A1T !$4
MAP 0%)P #A2Q  T4R@ -%.L #A/^  X3_P!S%0  81@  %,:  !(&P  /QL
M #<;   R&@  +1H  "D9   F&   )!@  "(7   @%@$ 'A8( !T6#0 ;%Q(
M&A<7 !D7'0 8&"0 %A@K !48-  4&#T $AE( !$95  0&6( #AER  T9A  ,
M&9@ "AFM  D8Q@ )&.< "1CZ  H7_P!O&   7AH  % <  !%'0  /!T  #4=
M   O'0  *AP  "8;   C&P  (1H  !X:   <&@  &AL% !@;#  6'!  %1P5
M !0<&P 3'"( $ATI !$=,0 0'3L #AU%  T>40 ,'EX "AYM  D>@  ''I0
M!1VJ  ,=P@ #'>8 !!SX  4<_P!K&@  6QT  $T>  !"'P  .A\  #(?   M
M'P  *!X  "0>   A'0  'AT  !P=   8'@  %1\" !,@"0 2(0X $"$2 ! A
M&  .(1\ #B(F  TB+@ ,(C< "B)!  DB30 '(EH !2)I  ,B?  !(I$  "*H
M   AP   (>4  "#X   @_P!G'0  5Q\  $HA  ! (0  -R(  # A   J(0
M)B   "(@   ?'P  '!\  !D@   6(0  $B," ! D!P .)@P #"80  LF%0 *
M)AP "28B  @F*@ &)S, !"<]  ,G20 !)U8  "=F   G>0  )X\  ":F   F
MOP  )>0  "7Y   D_P!C(   5"(  $<C   ])   -"0  "XC   H(P  )"(
M "$B   >(0  &B(  !<C   3)   $"8"  XH!P +*@L ""L.  8K$P $*Q@
M BL?  $L)P  +#   "PZ   L10  +%,  "QC   L=@  +(P  "ND   KO@
M*N0  "KZ   I_P!?(P  4"4  $0F   Z)@  ,B8  "LF   F)0  (R0  !\D
M   ;)   %R4  !0G   1*0  #BL"  LM!@ '+PL !# .   P$0  ,14  #$<
M   Q(P  ,BP  #(V   R0@  ,D\  #)?   R<@  ,8D  #&B   PO   ,.0
M "_[   O_P!:)P  3"@  $ I   W*0  +RD  "DH   E)P  (28  !PG   8
M*   %"H  !$L   .+@  "S !  <R!0 #- D  #4,   V#P  -Q(  #@8   X
M(   ."@  #@R   Y/0  .4L  #E;   X;@  .(4  #>?   WN@  -N0  #7\
M   U_P!5*@  2"P  #TL   T+   +2L  "@J   D*0  'BH  !DK   4+0
M$2\   TQ   *-   !S8   (X!   .@<  #L*   ]#0  /A   $ 4  ! &P
M0"0  $ N  ! .0  0$<  $!6  ! :0  0(   #^;   ^MP  />,  #S\   \
M_P!0+P  0R\  #DO   R+P  +"T  "<L   @+0  &B\  !4Q   1,P  #38
M  DX   %.P   #T   !  0  000  $,'  !%"P  1@X  $@1  !*%@  2AX
M $HH  !*-   24(  $E1  !)9   2'L  $B7  !'M   1N   $7\  !$_P!*
M,P  /S,  #8S   P,0  *C   ",Q   <,P  %C4  !$X   -.P  "#X   -!
M    0P   $8   !(    2@   $P$  !.!P  3PL  %$.  !4$@  51D  %4B
M  !4+@  5#P  %1+  !37@  4W0  %*0  !1K@  4-<  $_[  !._P!%-P
M/#<  #4V   O-   )C4  !XW   7.@  $3T   Q!   '1    $@   !*
M30   %    !3    50   %<   !8 @  6P8  %T+  !?#@  8A,  &(;  !B
M)P  8C0  &%%  !@5P  8&T  %^)  !=IP  7,P  %KX  !9_P!!/   .CL
M #0Y   J.@  (3P  !A    10P  #$<   9+    3P   %,   !6    60
M %P   !?    80   &,   !E    9P$  &H%  !M"@  < X  ',5  !R(
M<BT  '$]  !P3P  ;V4  &Z   !MGP  :\$  &GQ  !H_P _0   .3X  "X_
M   D0@  &D8  !)*   ,3P  !%0   !8    70   &$   !E    :    &L
M  !N    <0   ',   !U    >    'L   !^ P  @0H  (4/  "'%P  AB0
M (4T  "$1@  @ET  (%V  !_E@  ?K8  'SG  !Z_P _1   ,T4  "A(   =
M3   $U(   Q7   #70   &,   !H    ;0   '$   !V    >@   'X   "!
M    @P   (8   ")    BP   (X   "2    E0$  )D)  ">$   GAH  )TI
M  "</   FE(  )AL  "6BP  E*H  )+4  "0^@ X2P  +$X  "!3   560
M#6    -G    ;@   '0   !Z    @    (0   "*    C@   )(   "5
MEP   )H   "=    H    *,   "G    JP   *\   "T"0  N!   +<>  "U
M,   LT8  +%@  "O?@  K*   *O!  "I[@ Q50  )%L  !AA   .:0  !7$
M  !Y    @0   (@   "/    E    )H   "?    I    *@   "I    K
M *\   "S    M0   +D   "]    P0   ,8   #+    T0H  -,4  #1)0
MT#L  ,U4  #*<0  R)(  ,6S  ##W@ I8@  '&D  !%Q   '>P   (0   "-
M    E0   )T   "C    J0   *\   "T    N0   +P   "^    P@   ,4
M  #(    S    -    #4    V@   -\   #D    Z@   .X,  #M&@  ["\
M .I)  #H90  YH8  .2E  #BQ@#_    _P   /\   #\  $ _  ( /X #@#_
M !0 _P = /\ )@#_ #  _P Z /\ 0@#_ $D _@!0 /L 5@#Y %P ]@!B /0
M: #R &\ \ !V .T ?P#J (D YP"5 .0 HP#@ +4 VP#0 -4 ]@#* /\ M@#_
M *@ _P"? /\ F@#_ )8 _P#_    ^P   /8   #S    \P   /8 "0#Z  X
M_0 6 /L ( #W "H \@ S .T .P#I $, Y@!) .( 3P#> %4 VP!; -8 8 #2
M &< SP!N ,P =@#) (  Q@", ,( F@"_ *H NP#! +@ Z0"V /\ IP#_ )H
M_P"2 /\ C0#_ (H _P#Z    \0   .H   #G    YP   .0  0#@  L VP 1
M -H &@#; ", T0 L ,H - #& #L P@!" +\ 2 "\ $X N@!3 +@ 60"V %\
MLP!F +$ ;@"N '< K "# *D D0"F *$ HP"U *  V "> /L E0#_ (L _P"%
M /\ @ #_ 'X _P#O    XP   -H   #3    Q@   +\   "Y  8 MP . +0
M% "T !T LP E *X +0"K #0 IP [ *0 00"A $8 GP!, )T 40"; %< F0!>
M )< 90"5 &X DP!Y )  AP". )< C "I (D Q "( .\ A0#_ 'P _P!V /\
M<P#_ '( _P#@    T    ,8   "V    J0   *$   "=  $ F0 * )@ $ "8
M !8 EP > )0 )@"1 "T CP T (P .@"* #\ B !% (< 2@"% %  @P!6 ($
M7@"  &8 ?@!Q 'P ?0!Y (T =P"@ '4 M@!S -\ <@#_ &X _P!I /\ 9P#_
M &4 _P#,    O@   *L   "=    DP   (H   "%    @@ % (  #0!_ !$
M?P 8 (  ( !] "8 >@ M '< ,P!U #@ =  ^ '( 0P!P $D ;P!/ &T 5@!L
M %X :@!H &@ =0!G (0 90"6 &0 JP!B ,D 80#V &  _P!< /\ 6P#_ %H
M_P"]    J0   )<   ")    ?@   '@   !S    ;P ! &T "0!L  X :P 3
M &L &0!J "  :  F &8 + !E #( 8P W &( / !@ $( 7P!( %T 3P!< %<
M6@!A %D ;0!7 'L 5@". %4 H@!3 +L 4@#I %( _P!0 /\ 3P#_ $\ _P"M
M    F    (8   !X    ;@   &<   !C    8    %T !0!<  L 6P 0 %L
M%0!; !L 6@ A %@ )@!6 "P 5  Q %, -@!2 #P 40!" $\ 20!. %$ 30!;
M $L 9@!* '0 20"% $@ F0!' +$ 1@#8 $8 _ !% /\ 10#_ $4 _P"?
MB0   '@   !L    8@   %L   !6    4P   %$  @!/  @ 3P - $X $0!.
M !8 30 < $P (0!* "8 20 L $@ ,0!' #< 10 ] $0 1 !# $P 0@!5 $
M8  _ &X /@!^ #T D@ \ *D .P#' #L \P [ /\ .P#_ #P _P"3    ?@
M &X   !A    6    %$   !,    20   $<   !%  4 1  + $, #@!# !(
M0P 7 $( '0!  "( /P G #X +  ] #( .P X #H /P Y $< . !0 #< 6P U
M &@ - !X #, C  R *( ,0"\ #$ YP Q /\ ,@#_ #, _P")    =@,  &8%
M  !9!P  4 <  $D&  !#!0  0 ,  #X!   \  , .P ( #H #0 Z !  .0 4
M #D &0 W !X -@ C #4 *  T "X ,P T #( .P P $, +P!, "X 5P M &0
M+ !S "L AP J )P *0"U "D W  I /L *0#_ "H _P"!!   ;@@  %\*  !3
M"P  2@L  $(+   ]"@  .0D  #8(   U!0  - (& #, "@ R  X ,0 1 #$
M%0 P !H +P ? "X )  L "H *P P "H -P I #\ * !) "< 5  F &  ) !O
M ", @@ B )< (0"N "$ S  A /, (0#_ "( _P!["0  : P  %H-  !.#@
M10X  #T.   X#0  ,PT  # ,   N"P  +0D# "T&"  L! P *P(/ "H!$@ I
M 1< * $< "< (0 F "< )0 M "0 -  C 3T (@%& "$!40 ? 5T '@%L !P!
M?P ; )0 &@"J !H Q0 : .L &0#_ !H _P!U#   9 X  %4/  !*$   0!
M #D0   S$   +P\  "P.   I#@  )PT! "<,!0 G"@H )@@- "4'$  D!A0
M(@89 "$&'P @!R0 'P<K !X',@ =!SH ' A$ !H(3P 9"%P %PAK !8(?0 5
M!Y$ % >G !,&OP 2!>0 $@7Z !(%_P!Q#@  7Q   %$1  !&$@  /1(  #82
M   P$@  *Q$  "@1   E$   (Q   "(.!  A#0< (0P+ " +#@ ?"Q( '0L7
M !P,'  ;#"( &@PI !D,,0 8##D %@U# !4-3P 3#5P $@UK ! -?@ /#9(
M#@VG  T,O@ -#.  #0SU  T,_P!M$   7!$  $X3  !#%   .A0  #(4   M
M%   *!,  "43   B$@  (!$  !X1 P <$ 4 ' \( !L/#  :#A  &0\4 !</
M&@ 6#R$ %1 H !00,  2$#D $1!$ ! 04  .$%T #1!K  P0?  +$)  "1"E
M  @0O  '$-\ !Q#T  </_P!I$0  6!0  $L5  ! %@  -Q8  # 6   J%@
M)A4  "(5   ?%   '1,  !H3 @ 9$@0 %Q(& !82"@ 5$@X %!(2 !(2&  1
M$QX $1,E ! 3+@ .$S< #11   P42P +%%@ "11G  <4>  &%(T !!2C  ,3
MNP "$]T  1+T  (2_P!E$P  518  $@7   ]&   -!@  "T8   H&   (Q<
M " 7   =%@  &A4  !@5 @ 6%00 %!4% !(6"  1%@T $!<0  X7%0 .%QL
M#1<B  P7*0 +&#( "1@\  <81P %&%0 !!AC  (8=0 !&(L  !>A   7N0
M%]T  !;U   6_P!A%@  4A@  $4:   [&@  ,AH  "L:   E&@  (1D  !X8
M   ;&   &!<  !87 @ 4%P, $A@% ! 9!P .&PL #!L/  L;$P *&Q@ "!P?
M  <<)@ %'"\ !!PX  (<1   '5$  !U@   =<@  '(@  !R@   ;N0  &]X
M !KV   :_P!>&   3QH  $(<   X'   +QT  "D<   C'   'QL  !P:   9
M&0  %QD! !09 @ 2&@, $!L$  X=!P ,'@L "1\.  8@$0 %(!8  R <  $A
M(P  (2L  "$U   A0   (4X  "%=   A;P  (88  "">   @N   ']X  ![X
M   >_P!:&P  2QT  #\>   U'P  +1\  "<>   B'0  'AT  !L<   8&P
M%1L  !(<   0'0( #A\$  PA!@ )(@H !2,-  (D$   )1,  "49   F(
M)B@  "8R   F/0  )DH  "9:   F;   )H,  "6<   EMP  )-\  "/Y   C
M_P!5'@  1R   #PA   R(0  *R$  "4@   @'P  '1X  !H=   6'@  $QX
M ! @   .(0  #","  @E!0 %)PD  "@+   J#@  *Q$  "P6   L'0  +"4
M "PN   L.@  +$<  "Q6   L:0  +(   "N:   JM0  *=\  "G[   H_P!1
M(@  1",  #@D   O)   *",  ",B   ?(0  '"   !<@   3(0  $",   XD
M   +)@  ""@   0J!   + <  "X)   P#   ,0\  #,3   S&0  ,R$  #,J
M   S-0  ,T,  #-2   S90  ,GL  #*7   QLP  ,-X  "_[   N_P!,)0
M/R8  #4G   M)@  )R4  "(D   >(P  &2,  !0D   1)@  #B@   LJ   '
M+    R\    Q @  ,P0  #4'   W"@  .0T  #H0   [%0  .QT  #LF   [
M,0  .SX  #M.   [8   .G<  #F2   XL   -]L  #;\   U_P!'*0  .RH
M #(J   K*0  )2<  "$F   ;)P  %2@  !$J   .+   "B\   8Q   !-
M #8    X    .P$  #T$   _!P  00H  $,.  !%$0  11@  $4A  !%+
M1#D  $1(  !$6P  0W$  $*-  !!JP  0-(  #_Z   ^_P!"+0  ."X  "\M
M   I*P  )"H  !TJ   7+   $2X   TQ   )-   !#<    Z    /    #\
M  !!    1    $8   !( P  2@<  $P+  !.#@  4!,  % <  !0)P  3S0
M $]#  !/50  3FH  $V&  !,I   2LH  $GX  !(_P ^,@  -3$  "XO   I
M+@  ("X  !DQ   2,P  #C<   DZ   "/0   $    !$    1P   $D   !,
M    3P   %$   !3    50$  %@&  !:"P  70X  %\5  !>(   7BP  %T\
M  !<3@  6V,  %I^  !8G0  5\   %7R  !4_P Z-@  ,S0  "TR   D,P
M&S8  !,Y   ./0  "$$   !%    20   $P   !0    4P   %8   !9
M6P   %T   !@    8@   &4   !H!0  :PL  &\0  !O&   ;B4  &TT  !M
M1@  :UL  &IU  !HE   9K8  &3I  !B_P X.0  ,C<  "@Y   >.P  %3\
M  Y$   '20   $T   !2    5@   %H   !>    8@   &4   !H    :P
M &T   !P    <P   '8   !Y    ?00  ($+  "%$0  A!T  ((L  " /@
M?E0  'YK  ![B@  >JH  '?6  !U_0 X/0  +#X  ")!   71@  #TL   =1
M    5P   %P   !B    9@   &L   !O    =    '@   ![    ?@   (
M  "#    A@   (H   "-    D0   )8#  ";#   G1,  )LA  ":,P  ETD
M )1B  "3?P  D*   ([%  ",\P Q1   )4@  !I-   04P  "%H   !A
M:    &X   !T    >0   '\   "$    B0   (T   "1    DP   )8   "9
M    G0   *    "D    J    *P   "R P  MPT  +<7  "U*   LCX  +!6
M  "L<P  JI0  *FT  "EY0 J3P  'E0  !);   *8@   &H   !S    >P
M ((   ")    C@   )0   ":    GP   *0   "F    J0   *T   "P
MLP   +<   "[    P    ,4   #+    T00  -4.  #3'0  T#(  ,U+  #*
M9@  QH<  ,*I  #!RP B6P  %F(   QK   !=    'T   "'    D    )<
M  ">    I    *L   "Q    M@   +H   "\    P    ,0   #(    RP
M ,\   #4    V@   .    #F    ZP   /$&  #P$P  [B<  .P_  #J6P
MYWH  .2;  #@NP#_    ^P   /8   #S    ]  % /8 # #Z !$ _P 9 /\
M(@#_ "P _P U /\ /0#_ $4 _ !, /H 4@#W %@ ]0!> /, 9 #Q &H [@!R
M .P >@#I (4 Y0"1 .$ H #= +( V #. -( ]@#! /\ K0#_ )X _P"6 /\
MD #_ (P _P#Z    \@   .P   #I    Z0   .P !0#R  P ^  2 /< &P#U
M "4 \  N .L -P#F #X X@!% -T 2P#8 %  TP!6 -  7 #- &( R@!J ,@
M<@#% 'P P@"( +X E@"Z *@ MP"_ +0 Z "N /\ G0#_ )  _P"( /\ @P#_
M (  _P#P    Y0   -X   #:    VP   -P   #8  < T0 . -$ %0#2 !X
MRP G ,4 +P#  #< O0 ] +H 1 "W $D M0!/ +( 50"P %L K@!A *P :0"I
M ', IP!_ *0 C0"A )X G@"R )L U0"9 /P C #_ (( _P![ /\ =@#_ '0
M_P#B    TP   ,H   #'    O    +8   "P  $ KP + *P $0"M !@ K0 @
M *@ * "D "\ H  V )T / "; $( F0!' )< 30"5 %, DP!9 )$ 80"/ &H
MC !U (H @P"( )0 A@"G (, P@"" /  ? #_ ', _P!M /\ :@#_ &@ _P#/
M    P0   +D   "M    H    )@   "4    D0 & )  #0"0 !( CP 9 (X
M(0"+ "@ B  O (8 -0"$ #H @@!  (  10!^ $L ? !2 'H 60!X &( =@!L
M '0 >0!R (D <0"= &\ M !M -\ ; #_ &4 _P!@ /\ 7@#_ %P _P"^
ML0   *    "2    B0   ((   !\    >@ ! '@ "0!W  X >  4 '< &@!T
M "$ <@ G '  +0!N #, ;  X &L /@!I $0 : !* &8 40!D %H 8P!D &$
M< !? '\ 7@"3 %T J0!< ,@ 6P#W %< _P!4 /\ 4@#_ %$ _P"P    GP
M (T   !_    =    &X   !J    9@   &4 ! !C  L 8P 0 &, %0!C !L
M80 A %\ )P!= "P 7  R %H -P!9 #T 5P!# %8 2P!5 %, 4P!< %( : !0
M '< 3P") $X GP!- +H 3 #I $L _P!) /\ 1P#_ $< _P"B    C0   'P
M  !N    90   %X   !9    5P   %4  0!4  < 4P - %, $0!4 !8 4@ ;
M %$ (0!/ "8 3@ K $P ,0!+ #< 2@ ] $D 1 !' $P 1@!6 $0 80!# '
M0@"! $$ EP!  *\ /P#7 #\ _P ^ /\ /0#_ #X _P"4    ?P   &\   !C
M    60   %$   !-    2@   $@   !'  0 1P * $8 #@!& !$ 1P 6 $4
M' !$ "$ 0@ F $$ *P!  #$ /@ W #T /@ \ $< .@!0 #D 6P X &D -P!Z
M #8 CP U *< -0#& #0 ]0 T /\ - #_ #4 _P"(    =    &4   !8
M3P   $@   !#    /P   #T    \  ( /  ' #L #  [  \ .P 2 #H %P Y
M !P -P A #8 )@ U "P -  R #, .0 Q $$ , !+ "\ 5@ N &, +0!S "P
MB  L *  *P"[ "L Z@ K /\ *P#_ "P _P!_    ;    %T!  !1 @  2 ,
M $ #   [ @  -P   #0    S    ,@ % #( "0 R  T ,0 0 #$ $P P !@
M+P = "T (@ L "@ *P N "H -0 I #T * !& "< 40 F %X )0!N "0 @@ C
M )D (P"S "( W@ B /\ (P#_ "0 _P!W    900  %8&  !+!P  0@@  #H(
M   U!P  , 8  "T%   L P  *P # "H !P I  L *0 . "D $0 H !4 )P 9
M "8 '@ E "0 )  J ", ,0 B #D (0!# "  3@ ? %H '@!I !T ?  < ),
M&P"L !L S0 ; /8 &P#_ !P _P!P!0  7P@  %$*  !&"P  /0L  #4+   P
M"P  *PH  "@)   E"   ) <" ",$!@ C @D (@$, "( #P A !( (  6 !\
M&P > "  '0 F !P +@ ; #8 &@ _ !D 2@ 8 %< %P!F !8 >  5 (\ %0"F
M !0 PP 4 .X % #_ !4 _P!K"   6PL  $T,  !"#0  .0T  #$-   L#0
M)PT  ",,   A#   'PL! !X*!0 =" @ '08+ !P%#0 <!!  &P04 !D$&  9
M!!X & 0C !<$*P 6!#, %00\ !0$1P 3 U0 $@-C !$#=0 0 HH $ &B  \
MO  / .4 #P#^ !  _P!G"P  5PT  $D.   ^#P  -0\  "X/   H#P  ) X
M " .   =#@  &PT! !D-!  8# < & L) !<)#  7"0X %@D2 !4)%@ 4"1L
M$PDA !()*  2"3  $0DZ ! )10 /"5( #@EA  T)<P ,"(@ "PB?  H'MP *
M!ML "@7V  H$_P!C#0  4PX  $80   [$0  ,A$  "L1   E$   (1   !T0
M   :#P  & \! !8.!  5#@< % T) !,-"P 3# T $@P0 !$,%  0#!D $ P?
M  \,)P .#2\ #0TY  P-10 +#5$ "0U@  @-<0 &#88 !0V=  0,M  ##-(
M @SQ  (+_P!?#@  4!   $,1   X$@  +Q(  "@2   C$@  'A$  !L1   8
M$0  %1 " !00!0 2$ < $0\) ! /"@ 0#@P #@X.  X/$@ -#Q< #! =  P0
M)  *$"P "1 V  @000 &$$X !1!=  ,0;P !$(0  !"<   /M   #M0   [S
M   ._P!<$   31(  $ 3   V%   +10  "84   A$P  '!,  !D2   6$@
M%!$# !(1!@ 1$0@ $! *  X0"P -$0L #!$-  L2$0 *$A4 "1(:  @2(0 &
M$RD !1,S  ,3/@ "$TL  !-:   3;   $X(  !*;   2M   $=<  !'U   1
M_P!8$@  210  #T5   S%@  *Q8  "05   ?%0  &A0  !<4   4$P$ $Q($
M !$2!P 0$@D #A()  T2"0 +$PH "10-  <5#P &%A, !!88  ,6'P "%B<
M !<P   7.P  %T@  !=8   7:@  %H   !:9   5M   %=D  !3W   3_P!5
M%   1A8  #H7   P&   *!@  "(7   =%@  &18  !85   3% , $A,& ! 3
M!P /$P< #10'  L5"  )%@D !A@,  ,:#@ !&A$  !H6   ;'   &R0  !LM
M   ;.   &T8  !Q5   ;9P  &WT  !N7   :LP  &=L  !CY   7_P!1%@
M0Q@  #<9   N&@  )AH  " 9   ;&   &!<  !46 0 3%04 $14$  \5!  -
M%@0 "Q<%  D9!@ &&@@  AP*   >#0  (!   " 3   @&0  ("$  "$J   A
M-0  (4(  "%2   @9   ('H  !^5   ?L0  'ML  !WZ   <_P!-&0  /QL
M #0<   K'   )!P  !X;   :&@  %Q@  !07 @ 2%P( $!@!  T9 0 +&@(
M"!P#  4=!  "'P8  "$(   C"P  )0X  "81   F%@  )AX  "<G   G,@
M)S\  "9.   F8   )G<  "62   DKP  (]H  "+[   A_P!('0  /!X  #$?
M   H'@  (AX  !T<   9&P  %AH  !(:   0&P  #1P   L=   ('P  !"$
M  $C @  )00  "<&   I"0  + P  "X/   N$P  +AH  "XC   N+@  +CL
M "Y*   M7   +7(  "R.   KK   *M0  "G[   H_P!$(   ."$  "XA   F
M(0  ("   !P>   8'0  %!T  ! >   .'P  "R$   <C   #)0   "<    I
M    + $  "X#   P!@  ,PH  #4-   V$0  -A<  #8?   V*0  -C8  #9%
M   U5P  -6T  #2)   RJ   ,<\  ##Z   O_P _)   -"0  "LD   D(P
M'R$  !L@   6(   $2$   XC   *)0  !B@   (J    +0   "\    R
M-    #<    Y P  .P8  #X*  ! #@  01(  $$:  ! )0  0#$  $!    _
M4@  /F<  #V"   \H@  .L<  #GX   X_P Z*   ,"@  "DG   C)0  'R,
M !@D   2)0  #B@   HJ   %+0   #     S    -@   #@    [    /@
M $    !"    10(  $<&  !*"@  30X  $T5  !,'P  3"L  $LZ  !*3
M26$  $A\  !'FP  1;\  $/S  !"_P V+   +2L  "<I   C)P  &R@  !0J
M   .+0  "C    0S    -P   #H    ]    0    $,   !&    2    $L
M  !-    4    %,!  !6!@  60L  %L0  !;&0  6B4  %DT  !81@  5UH
M %5T  !4DP  4K4  %#J  !/_P S,   +"X  "<L   >+0  %B\  ! R   *
M-@   SH    _    0@   $8   !)    3    $\   !2    50   %@   !:
M    70   &    !C    9P8  &L,  !L$@  :QX  &LL  !I/0  9U(  &9J
M  !DB0  8:L  %_<  !=_P Q,P  +#$  "(R   9-0  $3D   H]   "0@
M $<   !,    4    %0   !8    6P   %\   !B    90   &@   !K
M;@   '$   !U    >0   'T&  ""#0  @A8  ( D  !^-0  ?$D  'MA  !X
M?P  =I\  '/&  !P]P Q-@  )C@  !P[   20   "T4   )+    40   %8
M  !;    8    &4   !I    ;@   '(   !V    >0   'P   !^    @@
M (4   ")    C@   ),   "8!@  G X  )L:  "8*P  ED   ))9  "1<P
MC94  (NU  "(Z  K/@  ($$  !5'   -30   E0   !;    80   &@   !N
M    <P   'D   !^    @P   (@   ",    CP   )(   "5    F0   )T
M  "A    I0   *H   "P    MP<  +@1  "U(0  LC4  *]-  "J:0  J(@
M *:H  "BT0 C2   &$X   Y4   $7    &0   !M    =0   'P   "#
MB0   (\   "5    FP   *    "C    I@   *D   "M    L0   +4   "Y
M    O@   ,0   #*    T@   -H*  #6%@  TBD  ,Y!  #*7   Q7P  ,*=
M  #!O0 <50  $5P   =E    ;@   '<   !_    B    )    "8    GP
M *4   "M    LP   +@   "Z    O@   ,(   #&    R@   ,X   #3
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M____________________________________________
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M1TE*2TU.3U!24U155UA96UQ=7F!A8F-E9F=I:FML;F]P<7-T=7=X>7I\?7Z
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MH->:B*#7FHB@UYJ(H->:B*#7FHB@UYJ(H->:B*#7_Z B!?^>+0S_HC<4_ZU
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M0.+I4E?2Z%IMP>!B@+'49Y&ARFN>E,-NJ(F]<;" N72V>;9WNG2T>[UNLH'
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MQ7.NH<9RK:W$<JFPP'*IL,!RJ;# <JFPP'*IL,!RJ;# <JFPP'*IL,!RJ;#
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M'0+%[#$.NO5 'J[W12ZC]4H\FO102)#S6E.&\V-;?O)L8G?Q<VAQ[GIM;.N
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MDY=[T9.7>]&3_X$: _]^) ;_C"8'_Y@N"O^B-A#_J3X8_Z]&(_BU33#PMU9
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MKL^58J[/E6*NSY5BKL^58J[/E6*NSY5BKL^5_X<7 O^1&@/_HB #_[(E _7
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MJC9&_[,W1/^_.$3_Q3A$_\4X1/_%.$3_Q3A$_\4X1/_%.$3_Q3A$_\4XP;,
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MZKTU">#&/!#2Q$0CQ;U/-;JW6$:OL5]4I:MF8)RF;6J4HG-SC)YZ>H:;@8"
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M99[C>F6>XWIEGN-Z_W88 O^)$P'_FA8!_ZD8 ?:X&P'GQQH!V]D< <W6, O
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M+S[_S3 ^_\TP/O_-,#[_S3 ^_\TP/O_-,#[_S3 ^_\TPN[$  *R\  "?R0
MD]D  (G\"P& _Q<"=O\@!6S_* ED_S -7?\X$%?_0!-1_T<63?].&$K_5AE'
M_UP:1/]C'$+_:1U _W >/_]X'CW_@!\[_X@@.O^1(3C_FR(W_Z0B-O^M(S7_
MN",U_[DC-?^Y(S7_N2,U_[DC-?^Y(S7_N2,U_[DCK;8  )_$  "2T@  A.$
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M;&.;[FQCF^YL8YON;&.;[FQCF^YL_W03 ?^'$ '_F!  _J<0 .>W#0#6Q0L
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M%G3Q0QUL\4LC9O%4*6'Q72U=\68Q6?%N-5;Q=C=3\7\Z4/*(/$WRDCY+\IU
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MI"8Z_Z\F.?^Z)SC_RB<X_]PH./_<*#C_W"@X_]PH./_<*#C_W"@X_]PHM:\
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M7W2']U]TA_=?=(?W7W2']U]TA_=?_VD5 ?]Z$ '_BA$ _Y<2 /FC% #JKA4
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MN$=%X<Q'1>#H1T7?]D9%WO]$1=[_1$7>_T1%WO]$1=[_1$7>_T1%WO]$V9<
M ,>F  "XL   K+D! *+% @"8T08 C^L- (GN'P* [BL&>.TT#'#M/1-H[489
M8NU.'EWM5R-9[6 G5>UH*E+M<2U/[7DO3.V#,DKNC31'[I@U1>ZE-T/OLSA"
M\,0X0?#?.4'O[SA [?TX0.S_.$#L_SA [/\X0.S_.$#L_SA [/\XRZ   +JK
M  "MM   H<   );, 0"+V04 A/@1 7SX'P)T^"D&;/@R"F3X.P]>^4,36/E+
M%U/Y4QI0^5L=3?ID'TKZ;"%(^G0C1OI^)43[B"9!^Y,H0/N>*3[\JRH]_+DK
M._W+*SO]XBLZ_/0K.OSW*SK\]RLZ_/<K.OSW*SK\]RLZ_/<KO:@  *ZP  "A
MO   E<@  (G4  !^Z 4 =_\2 6__' )G_R8%8/\O"%G_-PM4_S\.3_]'$4O_
M3A-'_U851/]=%D+_9!A _VP9/?]U&CO_?ALY_XD<-_^4'3;_H!XU_ZP?,_^Y
M'S/_R!\R_^(@,O_G(#+_YR R_^<@,O_G(#+_YR R_^<@L*T  **W  "5Q
MA]   'O=  !R_0D :O\1 6'_&0):_R(#5/\J!4[_,@=)_SH)1?]!"T'_2 P^
M_TX.._]5#SC_6Q V_V(1-/]I$3+_<A(O_WL3+?^&%"O_DA4J_YX5*?^I%BC_
MLQ8G_\(6)__'%B?_QQ8G_\<6)__'%B?_QQ8G_\<6I+0  );   "'S   >MH
M &WK  !D_P4 7/\. 53_% %-_QP"2/\D!$+_+ 4^_S,&.O\Y!S;_0 @S_T4(
M,/]+"2[_40HK_U<**?]="R?_9 LD_VP,(O]V#2#_@ T>_XP.'?^7#AS_H0X;
M_ZP/&_^N#QO_K@\;_ZX/&_^N#QO_K@\;_ZX/E[P  (C)  !YU@  :^,  %_V
M  !6_P  3O\* $?_$ %!_Q8"//\= C?_) ,R_RH#+_\P!"O_-@4G_SL%)?]
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M3X1Y_T^$>?]/A'G_3X1Y_T^$>?]/_V$5 ?]P$ '_?A$ _XH2 /^4%0#PG1D
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MLEE/KL993Z[D6%&N]E13KO]05*S_352L_TU4K/]-5*S_352L_TU4K/]-_WT
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M.T+:]#I"V?XZ0]C_.4/8_SE#V/\Y0]C_.4/8_SE#V/\YT)8  ,&C  "RK
MI[4  )S   "1R@, A]8' (#I$0!YZ2 "<NDL!6OI-@IDZ3\/7NE(%%GI41E5
MZ%H<4>EB($[I:R-+Z70E2.E])T;IB"I#Z9,K0>J@+4#JKRX^Z\ N/>S;+CWJ
M[RX]Z/PN/>?_+3WG_RT]Y_\M/>?_+3WG_RT]Y_\MQ9\  +6I  "HL0  G+P
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M$"'_T! A_] 0(?_0$"'_T! A_] 0G[(  )&^  "#R@  ==8  &?B  !;\0
M5/\& $[_#@!(_Q0!0O\< CW_) (Y_RL#-?\R!#'_. 0N_SX%*_]#!2C_208E
M_T\&(_]6!R'_70<>_V4('/]O"!G_>@D7_X<)%O^4"17_GPH4_ZH*%/^S"A3_
MLPH4_[,*%/^S"A3_LPH4_[,*D[L  (3'  !UTP  9^$  %CH  !.^P  2/\
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M ?]Y'P+_?B<#^8 P!?"!.0KG@$,1X'Q0&M9W6R3/<F8NR6UO-<1J>#O 9X%
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M?)U8=7NI6W)ZN%QQ>LI<<GSH6'5^^5%W@/],=X#_1W> _T9W@/]&=X#_1G>
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M34ZJ\DE0JOY&4JG_0U*I_T)2J?]"4JG_0E*I_T)2J?]"\GP  ->,  #(F0
MO:,  +*K  "IL@  H+L" )?$"0"2Q1L B\0L!(/".@Q[P405=+].'6Z]5B1H
MO%TJ8[MD,%^Z;#1:N70Y5KA\/%.WAS]/MY)"3+:?1$JVK49(ML!&2+?=14FV
M\D-*M?]!2[7_/DNT_SU+M/\]2[3_/4NT_SU+M/\]XH,  ,V2  #!GP  M*<
M *JO  "@N   EL # (S*!P"&S10 @<TF GK,-0ASRT$/;,I*%V;)4QUAR%LC
M7,=B*%C&:BQ4QG(P4,5\,TW%AC9*Q)(Y1\2?.T7$KCQ$Q<$\0\7?/$3$\SM$
MP_\Y1<+_-T7!_S=%P?\W1<'_-T7!_S=%P?\WU8L  ,6:  "WI   JZP  *"T
M  "6O@  B\<$ ('0" !XV0X ==D@ 6_8+P1IV#P)8]9&$%[64!59U5@:5=1@
M'U'4:").U'$F2]-[*4C3A2M%TY(N0M2?+T'4KS _U<(Q/]7A,#_3\C _TOTO
M/]'_+C_0_RX_T/\N/]#_+C_0_RX_T/\NRI0  +NA  "MJ0  HK$  ):[  "+
MQ   @,T# '78" !OY!$ :N0@ 63D+0->Y#@'6>1!"U7D2P]1Y%023>1=%DKD
M91A'Y&X;1>1W'4+D@A] Y(XA/N6;(SSEJB0[YKPD.N;3)#GE[B0YX_HC.>+_
M)#GB_R0YXO\D.>+_)#GB_R0YXO\DOYX  *^F  "CK@  E[@  (K"  !^S
M<]8" &GE"0!D[Q0 7_ @ 5GP*P-4\#4%3_ ^!TOQ1@I'\4X,1/%7#D+Q7Q _
M\F<2/?)P%#KR>Q4X\X<6-O.4&#7THADS]+$9,O7%&C'UXAHQ]/$9,?'^&3'Q
M_QDQ\?\9,?'_&3'Q_QDQ\?\9LJ0  *6K  "8M@  B\   '[*  !QU0  9=X
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M&O_?"QK_WPL:_]\+F[$  (V\  !^QP  <-(  &/>  !5Y   2_4  $;_!0!
M_PX ._\4 #?_&P$S_R,!+_\I BO_, (H_S4")?\[ R+_00,?_T<#'?]. QK_
M5008_UX$%?]H!1/_= 41_X(%$/^0!A#_G08/_ZD&#O^U!@[_N@8._[H&#O^Z
M!@[_N@8._[H&CKH  '_%  !PT0  8MX  %3E  !&ZP  /_X  #G_   T_PD
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M >2 +0/:?SL(SWI)$L=U5!O!<5\DNVUH*[9J<#&R9WDVKV6 .JMCB#VH89!
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M?VZI3GQMMT][;<E0>F[F37QQ^$9^<_]!?W3_/8!U_SJ =?\Z@'7_.H!U_SJ
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M35Z*\$A@B_Y#8HO_/V.,_SQCC/\\8XS_/&.,_SQCC/\\_VH  .9Z  #5A@
MR9$  ,"9 0"XGP$ L*4  *BI#@"BJ2$!FJ@Q!I.E/@^+HT@8A*!1('Z>62=X
MG& M<YIG,F^8;C=JEG4\9I5]/V*4AT-?DI%&6Y*=25F1JTI7D;M+5I'32U>2
M[T=:DOU"7)/_/EV3_SM=D_\[79/_.UV3_SM=D_\[_VX  .!^  #.BP  Q)4
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M-$BO_S-(K_\S2*__,TBO_S-(K_\SVX(  ,>0  "[G   KJ,  *2J  "9L0
MC[D  (3  P![Q@T >,8> '/&+@-MQ3H(9\1%#F+#3A-=PU886<)>'57!9B%1
MP6XD3L!W*$O @2M(OXPM1;^:+T._J#%!O[HQ0<#2,4&^[C!!O?TO0;S_+D&\
M_RU!O/\M0;S_+4&\_RU!O/\MSHH  +^8  "QH   IJ@  )NP  "0N   A;\
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M$"SK_Q LZ_\0K:(  *"I  "3LP  AKT  'G&  !LSP  8-@  %7>  !.\PH
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M16QT[T!N=OXZ;W?_-G%X_S)Q>/\Q<7C_,7%X_S%Q>/\Q_U\" /=L  #>=P
MT($  ,>( 0# C0, N9$# +*3$0"KDR,!HY$S!IR.0 V5BTH5CXA3'(F&6R*$
M@V(H@(%I+7Q_<#%X?G<U='R .'%[B3QN>I,_:WF>0FAXJT1F>+M%9'C1169Y
M[D!H>_TZ:GO_-FM\_S)K?/\R:WS_,FM\_S)K?/\R_V$  .IO  #9>@  S(0
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M-5F._S)9CO\Q68[_,5F._S%9CO\Q[6T  -E[  #(AP  O9   +28  "JG0
MH:$  )>F! "1IQ4 C*<G H6F-09_I$ ->:)*%'.@4AINGUD?:9U@)&6<9RAA
MFV\L7IIW,%J8@#-6EXLV4Y>7.5&6I3M/EK0\3I;)/$Z6Z#I/EODV49;_,U*6
M_S!2EO\P4I;_,%*6_S!2EO\PYG(  -"   #"C   N)8  *V<  "CH0  F:8
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M(SVV_R,]MO\CQX@  +F5  "LG0  H:0  ):K  "*L@  ?[D  '._ 0!HQ@4
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MB00>^9H%'/FK!1OZP 4:^MX%&OGR!1KW_049]O\%&?;_!1GV_P49]O\%GJ8
M )&O  "#N0  =<(  &?+  !:TP  3=H  $+?   XY0  -?L' #'_#P N_Q8
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M.7EC[S1Z9?XO>V;_*WQG_RA\9_\F?&?_)GQG_R9\9_\F_U4# /]@  #C:@
MU7(  ,QX 0#%>P, P'T% +E^$@"Q?B4!JGTU!*-Z00J==TP1EW15%Y)R71R.
M<&0@BFYK)(=L<BB$:WHK@6J"+GYIBS%[9Y4T>&>@-G9FK#AT9KPY<V;1.G-G
M[39T:?TP=6K_+'9K_REW:_\G=VO_)W=K_R=W:_\G_U<  /9C  #?;0  T74
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M+F9W_RMG=_\I9W?_*6=W_REG=_\I_U\  .-L  #0=@  Q7\  +R%  "TB@
MK(P  *.."@"=CAH EXXK I",. :*BD,,A(=,$G^%51AZA%P==H)C(7. :B5O
M?W$I;'YY+&A]@B]E?(PR8GN8-5]ZI#==>K,X7'K'.5QZY3=>>_@R7WO_+F!\
M_RMA?/\I87S_*6%\_REA?/\I]6(  -YO  #,>@  P(,  +>)  "OC@  II$
M )V2!@"7DQ< D9,H 8N2-@6%D$$+?XY*$7J,4A9UBEH;<8AA'VV':"-JAF\G
M9H1W*V.#@"Y@@HHQ78&6-%J!HS98@+(W5H#%-U: XS98@?<Q68'_+5N"_RI;
M@O\I6X+_*5N"_RE;@O\I[&8  -AS  #'?@  O(<  +..  "ID@  H)4  ):8
M 0"0F1, BIDD 868,@1_ECX)>91(#G234!1OD5<9:Y!>'6B.92%DC6TE8(QU
M*%V+?BM:BH@N5XF4,52)H3-2B+ T48C#-5"(XC12B/8P4XC_+%2(_RE5B/\H
M58C_*%6(_RA5B/\HYFL  -!X  #"@P  MXP  *V2  "CE@  FIH  (Z>  "'
MGQ  @Y\@ 'Z?+P)XG3L'<YQ%#&Z;31%IF54699A<&F&78QY>EFHA6Y5R)5>4
M?"A4DX8K49*2+DZ2H#!,DJ\Q2Y+",4J1X#%,D?4M39'_*DZ0_RA.D/\F3I#_
M)DZ0_R9.D/\FWG   ,E]  "\B0  LI(  *>7  "=FP  DY\  (:D  !^I@P
M>J8; '6F*@%PIC<$;*5!"6>C2@UCHE(27Z%9%ENA81E8H&@=5)]P(%&>>B-.
MG80F2YV1*4B<GBI&G*XL19S!+$6<WRM%F_0I1IK_)T>:_R5'FO\D1YK_)$>:
M_R1'FO\DU'<  ,*$  "VCP  JY8  *&<  "6H   BZ4  '^J  !TK@4 ;Z\4
M &RO) !HKS("9*X]!5^M1@E;K$\-6*Q6$52K7A11JF873JIN&DNI>!U(J8,@
M1:B/(D.HG21!J*TE0*C )3^HWR4_IO0C0*7_(D"E_R% I/\@0*3_($"D_R!
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MFQ(UPZL3,\/ $S/#X!,SP?43,L#_%#*__Q0QOO\4,;[_%#&^_Q0QOO\4N)
M *N9  "?H   DZ<  (>N  ![M   ;KL  &/   !8Q0$ 3<H% $3/# !#T!<
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M A3UN@(3]=8"$_3O A+R_ (2\/\"$O#_ A+P_P(2\/\"FJ0  (VM  !_M@
M<;\  &/'  !6S@  2=,  #W:   SWP  *N,  ";T!0 D^PT (?P3 ![]&P <
M_2( &?XI !?^,0 5_SD $_]! !'_2@ 0_U4 #O]A  S_;P$,_X !"O^3 0G_
MI@$(_[H!!__4 0?_ZP$&__8!!O_V 0;_]@$&__8!CZP  ("V  !ROP  8\D
M %;1  !(V   .]T  ##B   FY@  '_   !S_   9_PD %O\. !3_$P 1_QD
M#_\>  W_)  +_RL "?\R  ;_.P #_T0  /]/  #_7   _VL  /]]  #_D
M_Z,  /^T  #_Q@  _]8  /_6  #_U@  _]8 @K4  '._  !DR0  5M,  $?;
M   ZX   +N4  "/I   :[0  %?T  !+_   0_P( #O\)  O_#0 (_Q  !/\3
M  '_&   _QX  /\D  #_*P  _S,  /\]  #_20  _U8  /]F  #_>   _XH
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M*HQ2\B:+5/\BBU7_'HM6_QR+5O\:BU;_&HM6_QJ+5O\:_TP$ /]3  #L7
MWV(  -1F 0#.: 4 RV<( ,)G%@"Z:"@!LV<X ZUE10>H8U ,HV%9$9]?816;
M76@8F%QP&Y5:=QZ367\AD%B'(XY7CR6,5YDGB5:C*8=6KRJ%5;\KA%;5+(-7
M[RF#6/XD@UG_((1:_QZ$6O\<A%K_'(1:_QR$6O\<_TX! /]7  #E7P  V&8
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M)'%F_R%Q9O\?<6;_'W%F_Q]Q9O\?_U0  .A?  #7:0  RG   ,!U  "Y>
MLG@  *MX#0"D>1T GG@M 9=W.@62=44*C').#HAP5A.$;UX7@&UD&GUL:QUZ
M:W,@=VI[(W1I@R9R:(TI;V>9+&QFI2YJ9K,O:6;&,&AFY"]J:/<I:VG_)6QI
M_R)L:O\@;&K_(&QJ_R!L:O\@_U<  .1B  #2;   QG,  +UX  "U>P  K7P
M *5\"@"??1H F7PJ 9-[. 2->4,)B'=,#H-U5!)_<UL6>W)B&7AP:1UU;W @
M<FYX(V]M@29L;(LI:FR7+&=KHRYE:[(O9&O$,&)KX2]D;/8J9FW_)F9M_R-G
M;O\@9V[_(&=N_R!G;O\@]ED  .!E  #.;P  PG8  +E\  "Q?P  J8   *"
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M(%QW_R!<=_\@ZF   -5L  #%=@  NGX  +&$  "HB   GXD  )2*  "-BA$
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M@_\?WFD  ,EU  "\@   LH@  /_B?1!)0T-?4%)/1DE,10 /$JB-  "=D0
MDY,  (66  !^EPL >9<9 '67* %QES4#;)8_!FB52 IDE% -89-7$5V27A5:
MD6885Y!N&U2/=QY1CH$@3HZ-(TN-FB5)C:DF2(V[)T>-U"='C/ D2(S_(DF+
M_R!*B_\>2HO_'DJ+_QY*B_\>U6X  ,-[  "WA0  K(T  **2  "7E@  C)D
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M%#2K_Q0TJ_\4NX4  *^0  "CEP  F)T  (RC  " J   =*T  &BR  !<M@
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M=P 0[HH #N^>  [PLP -\,T #._L  SM_  ,Z_\ #.O_  SK_P ,Z_\ EZ,
M (FK  ![M   ;;P  %_$  !2R@  1<X  #G3   OV   )=T  !WA   8[ (
M%O<+ !3W$0 1^!< $/@>  [Y)0 -^2T "_HU  G[/P '^TH !/Q7  /]9@ "
M_G<  /V+  #]GP  _+4  /S1  #\[0  _/P  /S]  #\_0  _/T BZL  'VT
M  !NO0  8,8  %+-  !$T@  -]@  "S=   BX0  &>4  !/J   0^@  #O\&
M  W_#  *_Q  !_\4  3_&@ !_R   /\G  #_,   _SH  /]%  #_4P  _V(
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M ^8<_P/E'/\#Y1O_ ^4;_P/E&_\#_RT; /\P%P#_,14 _S 6 /\Q( #_,"H
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M"ZTZ_PNM.O\+_SP- /] !@#_100 _TD) /]+#0#Y2A$ [4D: .-&)@#:1C8
MT49% <M%40/&1%P%PD)F"+]";PJ\07<+ND!_#;@_A@ZV/XX0M#Z5$;(^G1*P
M/J83KSZP%*T^O12K/LT5J3[F%:8_]Q.D0/\2HT#_$*) _P^B0/\.HD'_#J)!
M_PZB0?\._S\) /]$  #_2@  ]TX" .Q0!@#J3PL XTP0 -9,'@#-33  QDT_
M <!,3 2[2U<&MTEA";1(:0RQ1W$.KD9Y$*Q&@!&J18@3J$20%*9$F!:D0Z$7
MHD.K&*!#MQF?0\<9G4/@&IM$\Q>91?\5F$;_$YA&_Q&81O\0ET;_$)=&_Q"7
M1O\0_T(% /]'  #W3P  Y5,  -U5 0#7508 U5(+ ,M3&0##5"L O%0[ ;92
M2 2Q45('K5!<"JE.9 VF36P/I$QT$:%+>Q.?2H(5G4J*%YM)DQB929P:ETBF
M&Y5(LAR42,$=DDC8'9!)[QN/2OX8CTO_%HY+_Q2.3/\2CDS_$HY,_Q*.3/\2
M_T4  /]+  #I4P  WE@  --;  #-6P0 RE@' ,)8%0"Z6B< LUHW :Y81 2I
M5T\'I%58"J%48 V>4V@0FU%O$YA0=A664'X7E$^&&9).CAJ/3I@<C4VB'8M-
MKA^*3;P@B$W0((=-ZQ^&3_P;AE#_&(90_Q:&4/\4AE'_%(91_Q2&4?\4_T<
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M)6]:X25P6_8@<5S_''%=_QIQ7?\8<5W_%W%=_Q=Q7?\7_4\  .59  #38@
MQV@  +UL  "V;0  KVP  *=K"P"@;!D FVPJ 95K-P*0:4,%BVA,"8=F5 R#
M95L0@&-B$WUB:15Z87 8>&%X&G5@@1US7XL?<%Z6(FY>HB1L7K E:U[!)FE>
MWB9J7_0A:V#_'6MA_QML8?\9;&'_&&QA_QAL8?\8]5$  .)<  #/90  PVL
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M'UQM_QQ=;?\:76W_&5UM_QE=;?\9Z%H  -)F  ##;P  N'8  *][  "F?@
MG7X  )%\  "*? \ A7T> (%]+0%\?#D#=WI#!G-Y2PEP>%,,;'=:$&EV81-F
M=6@68W1O&&%S>!M><H(>6W*-(%EQFB)7<:@D57&Y)51QT"54<>XB5G'^'E=Q
M_QQ7<?\:6''_&5AQ_QE8<?\9XUX  ,UI  "_<P  M'H  *M_  "B@@  F(,
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M%T6%_Q=%A?\7S6T  +UX  "Q@@  IXH  )R.  "2D   AI,  'F5  !LEP
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M#@!+JQH 2JLG $BK,P!&JST!1*M& 4*K3@) JU8#/JM?!3NK: 8YJG,(-ZJ
M"32JCPLRJI\,,:JP##"JQPPPJ><,+Z?Z#2^F_PTOI?\-+Z7_#2^E_PTOI?\-
MMH0  *J.  ">E   E)D  (>>  ![HP  ;Z@  &.L  !7KP  2[(  $&U!@ ^
MMA$ /;8> #NV*0 ZMS0 .;<^ #>W1P VMU !-+=: 3*W9 (PMV\#+K=\!"RW
MBP4JMYP%*;>N!BBXQ04HM^8%)[7Y!R:S_P<FLO\()K+_"":R_P@FLO\(KXT
M **4  "7F@  BZ   'ZF  !QJP  9;   %FT  !-MP  0KL  #B^ 0 OP@D
M+<,2 "S#'@ KPRD *L0S "G$/0 HQ4< )\51 ";%7  EQF@ (\9V 2+&A@$@
MQI@!'\:K 1['P0$>QN0!'<3X AS"_P,<P?\#','_!!S!_P0<P?\$I90  )J:
M  ".H0  @:<  '.N  !GM   6KD  $Z]  !"P   .,,  "_'   FRP0 'M *
M !O1$0 :TAH &=(E !C3+P 8TSH %]1$ !;44  5U5T %-5K !/6?  2UX\
M$=BD !#9NP 0V=X $-7S !#3_P 0TO\!$-'_ 1#1_P$0T?\!G)H  )&A  "#
MJ   =;   &BW  !;O0  3L$  $+%   WR   +<P  "30   <U0  %=H% !#B
M"P 0XQ$ #N0:  [D(P -Y2T #.4W  OF0@ *YD\ ">==  CG;0 &YH  !>:5
M  3FJP "YL0  >;F  #G^0  Y_\  .;_  #F_P  YO\ DZ$  (6I  !WL0
M:;D  %O   !.Q@  0<H  #7.   JT@  (=8  !G;   2WP  #>,   OQ"  )
M\PX !_,3  3R&@ "\B(  /(J  #R-   \C\  /),  #R7   \FT  /*"  #R
MF   \ZT  //&  #TY0  ]/8  /3[  #T^P  ]/L AZD  'FR  !JN@  7,(
M $[)  ! S@  ,],  "C8   >W0  %>$   _D   *Z   !?,   /] 0  _ @
M /L-  #[$0  ^Q8  /P>  #\)@  _#   /T\  #^20  _EH  /YM  #_@@
M_Y@  /^L  #_P   _]@  /_D  #_Y   _^0 >[(  &R[  !=Q   3\T  $#2
M   RV0  )MX  !OB   2Y@  #.H   7M    ]    /\   #_    _P   /\$
M  #_"0  _PX  /\2  #_&   _R$  /\K  #_-P  _T8  /]8  #_:P  _X
M /^5  #_I@  _[,  /^[  #_NP  _[L _QLF /\<) #_&B0 _Q4G /\0+0#_
M"C8 _P5# /\!4 '_ %X!_P!K ?\ =@'_ ($ _P"* /\ D@#_ )H _P"@ /\
MI@#_ *P _P"R /\ N0#_ ,( _P#- /\ WP#_ .P _P#X /\ _P#] /\ _0#_
M /T _P#] /\ _0#_ /T _P#] /\ _Q\C /\?(0#_'B$ _QDC /\3*0#_#C(
M_PQ  /\)30'_!UH!_P1G ?\#<P'_ WT!_P.' ?\#CP#_ I8 _P*< /\"H@#_
M J@ _P*O /\!M@#_ ;X _P') /\!VP#_ .H _ #V /@ _P#W O\ ]P/_ /8$
M_P#V!/\ ]@7_ /8%_P#V!?\ _R(? /\B' #_(1P _QX? /\8) #_%2\ _Q(\
M /\020#_#E8!_PQB ?\+;@'_"WD!_PN" ?\+BP'_"Y(!_PJ9 ?\*GP#_"J4
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M M ;_P+0&_\"_RT2 /\N#P#_+@T _R\0 /\O%P#_+B$ _RPM /\I.0#Y)D8
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M_S<' /\Z  #_/@  ^D$! /%!!@#Q/PT YCP2 -LZ'P#0.S$ RCQ  ,0\30'
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M&(%(Y!B!2O<5@$K_$H!+_Q" 2_\/@$O_#H!+_PZ 2_\._T,  .Q+  #=4P
MSE@  ,1:  "]6@  N%<! +%4#@"J5AX I58N )]6.P&;548#EU10!9-36 B0
M4E\*C5%F#(M0;0Z(3W00AD]\$H1.A1."3HX5@$V9%WY-I!A\3;(9>DW#&GE-
MWQIX3O07>$__%'A/_Q)X4/\0>%#_#WA0_P]X4/\/_48  .=/  #65P  R%P
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M%V9;_Q5F7/\39US_$F=<_Q)G7/\2[4X  -I9  #(80  O&<  +-J  "K;
MHFH  )EG @"29Q$ C6<A (AG+P&$9CL"?V5$!'MD309X8U0)=6);"W)A80UP
M86D/;6!P$FM?>11I7X,79EZ.&61>FAMB7J@<85ZX'5]>SAU?7NP;8%_]&&%?
M_Q5A7_\38E__$F)?_Q)B7_\2ZE$  -1<  #$9   N6H  +!N  "G<   GFX
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M$U)L_Q-2;/\3W%P  ,=G  "Y;P  KW8  *5[  "<?   D7P  ()X  !Z>0<
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MC0\\C9P0.HVL$3F-P1$XC>$0.(OV$#B*_P\YB?\/.8G_#CF)_PXYB?\.OW(
M +)]  "GA@  G(H  )&.  "&D0  >I,  &V5  !?EP  5)D! $^9#P!.FAH
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M B*RNP(ALML"(:_S R"N_P,@K?\$'ZS_!!^L_P0?K/\$JHL  )V1  "3EP
MAYP  'JB  !MIP  8*L  %6O  !)L0  /K0  #.W   JN@, )+P- "*]%0 A
MO2  (;TJ ""],P ?OCT 'KY' !V^4@ <OUX &K]L !F_?  8OXX %\"A !;
MM@ 4P-, %;[Q !6\_P$5N_\!%+K_ A2Z_P(4NO\"H9(  ):8  "*G@  ?:0
M &^J  !BKP  5K0  $JW   ^N@  ,[T  "K    AQ   &<<% !/+"P 1S!(
M$<P; !#,)0 /S2\ #LTZ  [-1@ -S5( #<Y@  S.<  +SH, "LZ7  G.K  (
MSL8 ",[H  C-^P )R_\ "<O_  G+_P )R_\ F)@  (V>  !_I0  <:P  &2S
M  !7N0  2KT  #[    RPP  *,8  !_*   7S0  $=$   S6!0 (V0P !MD2
M  7:&P $VB0  ]LN  ';.0  W$4  -U2  #>8@  WG,  -Z(  #?G0  W[,
M -_.  #@[@  W_H  -__  #?_P  W_\ CY\  (&F  !SK@  9;4  %B]  !*
MP@  /<4  #')   FS   '=   !34   .V0  "=T   /A    XP<  .,-  #D
M$@  Y1D  .8B  #G*P  Z38  .M#  #L4@  [&(  .UV  #NC   [J$  .^W
M  #OT0  [^L  /#V  #P]@  \/8 A*<  '6O  !GMP  6;\  $O&   \R@
M+\X  "32   :V   $MP   S@   %XP   .<   #K    ZP   .T%  #N"P
M\!   /$5  #S'@  ]"<  /<S  #Y0   ^E$  /MC  #\=P  _8T  /VC  #^
MM@  _LD  /_?  #_WP  _]\ =[   &BY  !:P0  3,H  #S/   NU   (MH
M !?>   0X@  ">8   #I    [    /    #V    ]@   /<   #X    ^@<
M /L-  #]$0  _QD  /\C  #_+P  _SX  /]/  #_8@  _W<  /^-  #_GP
M_ZX  /^Z  #_N@  _[H _Q8C /\5(0#_$B$ _PXD /\&*@#_ #, _P!! /\
M3@#_ %P _P!H /\ = #_ 'X _P"' /\ CP#_ )8 _P"< /\ H@#_ *@ _P"N
M /\ M0#_ +T _P#' /\ U@#_ .< _@#S /X _@#] /\ _ #_ /L _P#[ /\
M^P#_ /L _P#[ /\ _QH@ /\9'@#_%AX _Q @ /\*)0#_!#  _P ] /\ 2P#_
M %@ _P!D /\ < #_ 'H _P"# /\ BP#_ )( _P"8 /\ G@#_ *0 _P"J /\
ML0#] +D ^P## /H T #X ., ]P#Q /8 _ #T /\ ] #_ /, _P#S /\ \P#_
M /, _P#S /\ _QT< /\<&0#_&1D _Q0; /\.(0#_#"P _PDY /\%1@#_ E,
M_P!? /\ :P#_ '4 _P!^ /\ A@#_ (X _P"4 /X FP#\ *$ ^@"G /@ K@#U
M +4 \P"_ /$ RP#P -\ [@#N .P ^0#K /\ Z@#_ .H!_P#I ?\ Z0'_ .D!
M_P#I ?\ _R 7 /\?% #_'!, _Q<5 /\6'0#_$R@ _Q T /\-00#_#$X _PE:
M /\(9@#_"'  _@=Y /P'@0#Z!XD ^ >0 /8&E@#S!IT \0:C .\&J@#M!K(
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M /\K!0#_*P, _RT) /\L#@#_*14 ]R8@ .XC+0#G(3H X1]( -L?5 #5(%\
MT2!H ,X@<0#,(7D RB&! <@AB '&(8\!Q"&6 <,AG@'!(J8!OR*O ;TBNP*\
M(\H"N2/C K4D] *S)/\#L23_ Z\D_P.O)/\#KB3_ ZXD_P.N)/\#_R\& /\O
M  #_,@  _S," /DR" #W+PX ZRL6 .$G(@#8)S( T"E! ,LJ3@#&*ED PRIB
M < J:P&]*G,!NRIZ KDJ@@*X*HD"MBJ0 K0JF .S*J$#L2JJ Z\KM02N*\0$
MK"O;!*@L[P2F+/X%I"S_!*,M_P2B+?\$HBS_!*(L_P2B+/\$_S(  /\S  #Y
M.   Z3D  .(Y  #>-0< WBX- -$O&P#),2P PS,[ +TS2 "Y-%,!MC-< ;,S
M90*P,VT"KC-T ZPR>P.K,H,$J3**!*<RDP6E,IL&I#*E!J(RL >@,KX'GS+1
M!YPSZ@>:,_L'F#3_!Y<T_P:6-/\&EC3_!98T_P66-/\%_S4  /\X  #J/@
MWT(  -5"  #//P, S3@( ,4X%0"].B8 MSLV +(\0P"N/$X!JCM7 J<[8 .E
M.F<#HSIO!*$Z=@6?.7T&G3F%!YLYC0>9.)8(F#B@"98XJPJ4.+@*DSG*"Y$Y
MY0N/.O<*C3K_"8P[_PB,._\'C#O_!XP[_P>,._\'_S@  /$^  #C10  U$D
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M#W)*_PUR2O\+<DK_"W)*_PIR2O\*\D(  .!,  #.4P  P5@  +A:  "P60
MJ58  *)2!P";4A4 EE,D )%3,@"-4SX!B5)' H914 2#45<%@%!>!GY/90A[
M3VP)>4YS"W=.>PUU384.<TV0$'%-G!)O3:D3;DVY%&Q-SA1L3>L3;$[]$&Q/
M_PYL3_\,;$__"VQ/_PML3_\+[D4  -Q0  #)5P  O5P  +1>  "L7@  I%L
M )Q6! "55A( D%<A (M8+P"'5SL!@U9$ G]630-\550%>E1;!G=48@AU4V@)
M<U-P"W%2> UO4H(/;5&-$6M1F1)I4:849U&V%691RQ5E4ND495+[$693_P]F
M4_\-9E/_#&93_PQF4_\,ZDD  -53  #%6@  NE\  +!B  "H8@  GU\  )9:
M  "/6A  BEL> (5;+ "!6S@!?5M! GI:2@-W65$$=%A8!G%87P=O5V8);5=M
M"VM6=@UI5G\/9U6*$655EQ-C5:04856T%6!5R!9?5><58%;Z$F!6_P]A5_\.
M85?_#6%7_PQA5_\,YTP  -%6  #!7@  MF,  *UF  "D9@  FV0  )!>  ")
M7@X A%\; (!?*0!\7S4!>%\_ G1>1P-Q74\$;UQ6!6Q<7 =J6V,):%MK"V9:
M<PUD6GT/8EJ($5]9E!->6:(47%FR%5M9QA9:6>456UKY$EM:_Q!<6O\.7%K_
M#5Q:_PU<6O\-XT\  ,U9  "^80  LV8  *EI  "@:@  EV@  (MB  "#8@P
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MC1!);IL11VVK$D9NOA-%;MP21FWT$49M_P]';?\.1VS_#4=L_PU';/\-S%\
M +QI  "P<0  I7<  )Q[  "1?   AGL  '5X  !K=P  97<, &%X%P!?>"0
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M"C2'N0HSA],*,X;P"3.%_PDSA/\),X/_"3.#_PDS@_\)N7   *UZ  "B@@
MEX<  (V*  "!C   =8X  &B/  !:D   3Y$  $>2"@!$DA, 0Y,? $&3*@!
MDS0 /Y,] #V310 [DTT!.I-6 3B37P(VDVD#-)-U S*2@P0PDI,%+I*D!BV2
MMP8LDM$&+)'O!BN/_P8KCO\&*XW_!RN-_P<KC?\'LW@  *>"  "<B   D8P
M (>0  !ZDP  ;94  &&7  !5F0  29L  #^< 0 YG0X -YT7 #:>(@ TGBP
M,YXU #*>/@ QGD< ,)]0 "Z?6@ MGV0!*Y]Q 2F>?P(GGI ")IZA B2>M0(C
MGLX"(YWN R.;_@,BFO\$(IG_!"*9_P0BF?\$K($  *"(  "5C@  BY(  '^6
M  !RF@  99T  %F@  !.HP  0J0  #>F   NJ 4 *:D/ "BI&  GJB( )JHL
M "6J-0 DJC\ (ZI( "*K4P AJUX (*MJ !ZK>0 =JXL &ZN= !JKL0 9J\H
M&:KL 1FH_0$8I_\"&*;_ ABF_P(8IO\"I8D  )F/  "/E   @YD  '6>  !H
MH@  7*8  %"I  !$K   .:X  "^P   FLP  'K4& !FW#P 8MQ< %[<A !:W
M*@ 5MS0 %+@^ !.X20 2N%0 $KEB !&Y<0 0N8, #[F7  ZYK  -N<0 #;CG
M  ZV^P .M?\ #K3_  ZT_P .M/\ G)   )*5  "&FP  >:   &NF  !>JP
M4J\  $:R   ZM0  +[<  "6Z   =O0  %<   !##!@ +Q@X "L45  G%'@ (
MQ2@ !\4R  ;&/0 %QDD !<97  /&9@ "QG<  <:+  #&H   Q;8  ,;2  #%
M[P  Q?P  ,7_  #%_P  Q?\ E98  (F<  ![HP  ;:D  &"O  !3M   1K@
M #J[   NO@  ),$  !O$   3QP  #LH   C. 0 !T H  - 0  #0%@  T1X
M -(G  #3,0  U#P  -5)  #66   UFD  -9\  #6D@  UJ<  -:_  #6X
MUO,  -;^  #6_P  UO\ C)T  'ZD  !OJP  8;(  %2Y  !&O0  .<$  "W$
M   BQP  &<L  !'.   ,T@  !=4   #;    W ,  -T*  #>#P  WQ0  .$<
M  #B)   Y"X  .8Z  #G20  Z%D  .AK  #I@0  Z9@  .FM  #IQ0  Z>(
M .GR  #I]0  Z?4 @*4  '&M  !CM0  5;P  $?"   YQ@  +,H  "#.   6
MT@  #]8   C;    WP   .,   #E    YP   .@!  #J!P  ZPT  .T1  #O
M&   \2$  /,K  #V.   ]T@  /A:  #Y;0  ^H0  /J;  #ZKP  ^L(  /K:
M  #ZWP  ^M\ =*X  &6V  !6O@  2,8  #G+   KT   ']0  !3:   -WP
M!>,   #F    Z0   .T   #O    \0   /,   #U    ]@(  /@)  #Z#@
M_1,  /\<  #_*   _S8  /]'  #_6@  _VX  /^%  #_F@  _ZL  /^Y  #_
MO   _[P _Q$@ /\0'@#_#!X _P0A /\ )P#_ #  _P ^ /\ 3 #_ %D _P!E
M /\ < #_ 'H _P"# /\ BP#_ )( _P"8 /\ G@#_ *0 _P"J /\ L #_ +@
M_P#" /\ S@#_ .( _@#P /T ^P#[ /\ ^P#_ /L _P#Z /\ ^@#_ /H _P#Z
M /\ _Q0< /\2&@#_#AH _P@< /\ (0#_ "T _P Z /\ 2 #_ %4 _P!A /\
M; #_ '8 _P!_ /\ AP#_ (X _P"4 /\ F@#^ *  _0"F /P K #[ +0 ^0"]
M /@ R0#W -P ]0#L /, ^ #S /\ \@#_ /$ _P#P /\ \ #_ /  _P#P /\
M_Q<8 /\5%@#_$14 _PP7 /\%'0#_ "@ _P V /\ 0P#_ %  _P!< /\ 9P#_
M '$ _P!Z /P @@#Z (D ^ "0 /< E@#U )P ] "B /, J #Q +  \ "X .X
MPP#L -, Z@#G .D ]0#G /\ Y@#_ .4 _P#E /\ Y0#_ .4 _P#E /\ _QH3
M /\8$0#_%!  _P\1 /\-&0#_"B0 _P4P /\!/@#_ $L _P!7 /X 8@#Z &P
M]0!U /( ?0#P (0 [@"+ .P D0#K )< Z0"> .< I #F *P Y "T .( OP#@
M ,T W@#C -P \@#: /T V #_ -8 _P#5 ?\ U0'_ -4"_P#5 O\ _QX0 /\<
M#0#_%PL _Q4. /\4%0#_$1\ _PXJ /\+. #]"$4 ^ 91 /0$7 #N!&8 Z@1O
M .8#=P#D!'\ X@2& . $C #>!), W06: -L%H #8!:@ U06Q -(%NP#0!LD
MS@?@ ,P(\0#)"O\ QPO_ ,8,_P#%#/\ Q0S_ ,4,_P#%#/\ _R$, /\@!@#_
M' , _QT* /\;$ #_&!@ _Q0C /81, #O#CX Z@Y* .4-5@#A#6  W0UI -D-
M<0#5#7D TPV! -$-B #/#8\ S0Z6 ,L.G0#*#J4 R ZN ,8/N0#$$,@ PA#?
M +X1\@"[$O\ N1/_ +<3_P&V$_\!MA/_ ;83_P&V$_\!_R4& /\C  #_(P
M_R0# /\A"@#]'1$ \1H; .@6)P#A%#4 VA-# -,43P#.%5D RQ5C ,@6:P#%
M%G, PQ=[ ,$7@@# &(D OAB0 +P8F "[&:  N1FI +<9M "U&L( M!K6 + ;
M[0&M'/P!JQW_ :D=_P&I'?\!J!W_ :@=_P&H'?\!_R@  /\G  #^*@  [RH
M .<G 0#G(@D Y!T0 -D;'0#/'2T R1X\ ,0@20"_(%, O"%= +DA90"W(FT
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M!88T_P6&-/\$A33_!(4T_P2%-/\$_#,  .LZ  #<00  S40  ,-$  "]00
MN#L! +(W#@"K.!P I3DK *$Z. "=.T0 FCM- 9<Z5@&4.ET"DCID I Z:P..
M.7(#C#EZ!(HY@@6).8L%ASF5!H4YH >#.:T'@CF\"($YTPA_.NX(?3K^!WP[
M_P9\._\%?#O_!7P[_P5\._\%]#<  .5   #21P  Q4H  +Q+  "U20  KT,
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M!V9)_P=F2?\'Z$,  -)-  #"4P  MU@  *U9  "D6   G%4  )-.  ",3@X
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MC M469H-4EFJ#E%9O Y06=@.4%GR#5%9_PM16?\*45G_"5%9_PA16?\(U%$
M ,):  "T80  JF8  *!H  "7:0  C&<  'U@  !U7P, ;U\0 &M?' !H8"@
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M"T%IMPQ :<\,0&CN"T%H_PI!9_\)06?_"$)G_PA"9_\(Q5T  +9F  "J;0
MH',  )9V  "+=P  @'8  '!R  !E<0  7' ' %AP$0!6<!T 5'$H %)Q,P!0
M<3P 3W)$ 4UQ2P%+<5,"27%: T=Q8@1%<&P%0W!W!D%PA <_<),(/6^C"3MP
MM0H[<,T*.F_L"3MN_@@[;O\(.VW_!SMM_P<[;?\'OV(  +%K  "F<P  G7D
M ))[  "'?   >WP  &UZ  !@>   5G<! %!W#@!.>!@ 3'@D $MY+@!)>3<
M2'E  $9Y2 %$>4\!0GE7 D%Y8 (_>&D#/'AT!#IX@@4X>)$&-WBA!S5XLP<T
M>,L'-'?K!S1V_0<T=?\'-77_!C5T_P8U=/\&N6@  *UQ  "B>0  F'X  (V
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M B6*^P,EB/\#)8C_ R6'_P,EA_\#K78  *.   "7A0  C8D  (*,  !VC@
M:9   %R2  !0DP  1)0  #J5   QE@@ +9<1 "R7&@ KER0 *I<M "F7-@ H
MF#\ )YA( ":84@ EF%P (YAH "*8=P @F(< 'YB9 1V8K $<F,,!')?E 1R5
M^@$;E/\!&Y/_ AN3_P(;D_\"IW\  )R&  "1BP  AX\  'J2  !ME0  89@
M %6;  !)G0  /9X  #.?   JH0  (:,* !^C$0 >HQH ':0D !RD+0 ;I#8
M&J0_ !FD2@ 8I%4 %J5A !6E<  4I8$ $Z64 !*EJ  1I;\ $*3B !&B^  1
MH?\ $:#_ 1&@_P$1H/\!H(8  )6,  ",D0  ?Y4  '&:  !DG@  6*$  $RD
M  ! I@  -:<  "JI   BK   &:X  !*P"0 0L1  $+$8  ZQ(@ .L2L #;$U
M  VQ0  ,L4L "[%8  JQ9P (L7@ ![&+  6QH  $L+4 !+#0  2P[P %K_X
M!J[_  :N_P &KO\ F(X  (^3  ""F   =9T  &>B  !:IP  3JL  $&M   U
MKP  *[$  "&T   8M@  $;D   V\ P 'O@P  [T2  &]&0  OB(  +XK  "^
M-@  OD$  +].  "_7   OVT  +^   "^E0  OJH  +["  "]Y   O?8  +W_
M  "]_P  O?\ DI0  (6:  !XH   :J8  %RK  !/L   0K,  #6V   JN
M(+L  !>^   0P0  "\0   3'    R0<  ,D-  #)$@  RAD  ,LB  #+*P
MS34  ,Y!  #.4   SV   ,]R  #/AP  SYT  ,^S  #/S@  S^L  ,[X  #.
M_@  SOX B)L  'JB  !LJ   7J\  %"U  !"N0  -;P  "F_   >P@  %<8
M  [)   (S    -    #3    U0   -8&  #8#   V1$  -L6  #<'P  WB@
M . T  #B00  XE$  .-C  #C=P  Y(X  .2D  #DN@  Y=0  .7J  #E\P
MY?, ?*,  &ZJ  !@L@  4;D  $.^   UP@  *,8  !S)   3S0  #-$   35
M    V@   -X   #A    X@   .0   #E P  YPD  .D.  #K$@  [1H  .\D
M  #R,0  ]$$  /13  #U9@  ]7P  /:3  #VJ0  ][P  /?.  #WWP  ]]\
M<*P  &&T  !3NP  1<,  #;'   GS   &]   !'5   *VP   -\   #B
MY0   .D   #L    [0   /    #Q    \P   /4$  #W"@  ^A   /P6  #_
M(0  _RX  /]   #_4P  _V@  /^   #_E@  _Z@  /^V  #_OP  _[\ _PT<
M /\*&P#_ AL _P > /\ ) #_ "X _P \ /\ 2@#_ %8 _P!C /\ ;0#_ '<
M_P!_ /\ AP#_ (X _P"4 /\ F@#_ *  _P"F /\ K #_ +0 _P"] /\ R0#^
M -T _0#M /P ^@#[ /\ ^@#_ /D _P#Z /\ ^@#_ /H _P#Z /\ _Q 9 /\-
M%P#_!A8 _P 8 /\ '@#_ "H _P W /\ 10#_ %( _P!> /\ :0#_ '( _P![
M /\ @@#_ (D _P"0 /X E@#] )P _ "A /L J #Y *\ ^ "X /8 PP#T -(
M\P#G /( ]@#P /\ [P#_ /  _P#O /\ [P#_ .X _P#N /\ _Q(4 /\/$@#_
M"Q( _P 2 /\ &@#_ "4 _P S /\ 0 #_ $T _P!9 /\ 9 #] &T ^P!V /D
M?0#W (0 ]0"+ /0 D0#S )< \0"= /  HP#N *H [ "S .H O0#H ,L YP#A
M .4 \0#C /T XP#_ .( _P#A /\ X0#_ .  _P#@ /\ _Q00 /\1#@#_#0T
M_P</ /\"%0#_ "  _P M /\ .@#_ $< ^0!3 /4 7@#R &@ \ !P .T > #K
M '\ Z0"% .@ C #F )( Y0"8 ., GP#A *8 WP"N -P N #: ,4 U@#9 -0
M[ #2 /D T0#_ ,\ _P#. /\ S@#_ ,X _P#. /\ _Q<, /\4" #_#P4 _PX+
M /\,$0#_!QH _P$F /P - #T $$ [0!- .D 6 #F &( XP!J .  <@#> 'D
MVP"  -D A@#6 (T TP"3 -$ F@#/ *$ S0"J ,L LP#) +\ Q@#0 ,4 Z ##
M /8 P0#_ , "_P"_ _\ OP/_ +\#_P"_ _\ _QL& /\7  #_%   _Q,% /\1
M#0#_#A0 ^0H? / &+ #F SD X -& -P#40#6!%L T@1D ,\%; #,!7, R@5Z
M ,@%@0#&!8< Q0:. ,,&E@#!!IT OP:F +T&L "[![P N0C- +@*Y0"U"_<
MLPW_ +$-_P"P#?\ L [_ *\._P"O#O\ _QX  /\;  #_&P  ^AH  /46!0#V
M$0T ZPX5 .(+(@#8"S$ T P^ ,L-2@#'#54 Q Y> ,$.9@"_#FT O0YT +L/
M>P"Y#X( MQ"* +80D0"T$)H LA"C + 1K0"O$;H K1'* *H2Y0"G%/< I17_
M *,5_P"B%?\ HA7_ *(5_P"B%?\ _R(  /\@  #P(P  YB0  . A  #<&04
MVQ , - 1&0#($RD PA4W +T61 "Y%TX M1=7 +,88 "P&&< KAAN *P9=0"K
M&7P J1F$ *@:C "F&I0 I!J> *,;J "A&[0 GQS% )X<WP":'?,!F![_ 9<>
M_P&6'_\!E1__ 94?_P&5'_\!_R8  /0G  #F+0  VB\  ,\M  #*)P  QQ\(
M ,$<$P"Z'B( M!\Q *\@/0"K(4@ J")2 *8B6@"C(V( H2-I * C;P">(W<
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M W4U_P-U-?\#\#,  -T]  #*0P  OD4  +5&  "M0P  ICT  * V!@"9-A,
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MC09>1YH'7$>I"%M(NPA:2-0(6DCQ!UI)_P9:2?\%6DC_!5I(_P1:2/\$VT0
M ,9-  "X4P  K5<  *-9  ":6   D50  (9.  !]2P@ =TL2 '-,'P!P3"L
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M"$M4M0A+5,P)2E3K"$M4_@=+5/\&2U3_!4M4_P5+5/\%S$X  +M7  "N7@
MI&(  )ID  "19   AF(  '=;  !M6   9E@, &)8%@!?6"( 75DL %M9-@!9
M63X 5UE& %9930%4650!4EE; E%98P-/66P#35EW!$M8A 5)6)('2%BB!T=9
MLPA&6<H(15GJ"$99_09&6/\&1EC_!4=8_P5'6/\%QU(  +A;  "K80  H68
M )AH  ".:0  @V<  ')@  !H7@  85T) %Q=$P!:71X 5UTI %9>,P!47CL
M4EY# %%>2@%/7E(!3EY9 DQ>80)*7FH#2%YU!$9>@@5$79 &0UZ@!T%>L0=
M7L@'0%[H!T!=_ 9!7?\%05W_!4%<_P5!7/\%PU8  +1?  "H9@  GFH  )5M
M  "*;0  ?VP  &]G  !D9   6V(% %9B$ !48AL 4F,E %!C+P!.9#@ 361
M $MD2 !*9$\!2&17 49D7P)%9&@"0V1S T%C?P0_8XX%/6.>!CQCL 8[9,8&
M.V3F!CMC^@4[8O\%.V+_!3QA_P0\8?\$OEL  +!C  "E:@  FV\  )%R  "&
M<@  >W$  &QM  !@:P  56D  $]H#0!-:1< 2VDA $EJ*P!(:C0 1VH] $5K
M1 !$:TP 0FM4 4%K7 $_:F4"/6IP CMJ?0,Y:HP$-VJ<!#9JK@4U:L0%-6KE
M!35I^00U:?\$-6C_!#5H_P0U:/\$N6   *QI  "A<   F'4  (UW  ""=P
M=W<  &ET  !<<P  47$  $AP"@!%<!( 0W$= $)Q)P! <C  /W(X #YR0  ]
M<D@ .W)0 #IR60$X<F,!-G)M C1R>@(S<HD#,7*: R]RK ,N<L$#+G+C RYQ
M^ ,N</\#+F__ RYO_P,N;_\#LV8  *=O  "==@  DWH  (A\  !^?0  <GT
M &1\  !7>P  3'H  $)Y P \>0X .GH7 #EZ(0 X>BH -WLS #9[.P T>T0
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M !2,_P$4C/\!HWT  )B#  ".B   A(P  '>/  !ID0  79,  %"5  !%EP
M.9@  "Z9   EF@  '9L" !:=#  5G1, %)T; !.=)  2G2T $9XW !&>00 0
MGDP #YY8  Z>9P -GG< #)Z*  N=G@ *G;( "9W,  F<[  *F_X "YK_  N9
M_P +F?\ G(0  )&*  "(C@  >Y(  &V6  !@F0  5)P  $B?   \H   ,*$
M ":C   =I0  %:<  !"I!0 +JPT "*H3  >J&P &JB0 !:HN  2J.  "JD0
M :I0  "J7@  JFX  *J!  "JE0  J:H  *G!  "HY   J/8  *?_  "G_P
MI_\ E8L  (R0  !_E0  <9H  &.>  !6H@  2J8  #VH   QJ@  )JL  !VM
M   4L   #K(   FU 0 "M@H  +8/  "V%0  MQT  +<E  "W+P  N#D  +A&
M  "X5   N&0  +AV  "XBP  MZ   +>V  "WTP  MN\  +;\  "V_P  MO\
MCY(  (*7  !TG0  9J(  %BG  !+K   /J\  #&Q   FLP  '+8  !.X   -
MNP  !KX   #!    P@0  ,(+  ##$   Q!4  ,0<  #%)   QBX  ,@Z  #)
M1P  R5<  ,EI  #)?0  R90  ,BJ  #(PP  R.0  ,CT  #(_0  R/T A9D
M '>?  !HI@  6JL  $VQ   _M0  ,;@  "6Z   :O0  $<    O#   #QP
M ,H   #-    S@   ,\#  #0"0  T0X  -,2  #5&0  UR(  -HM  #=.0
MWDD  -Y:  #?;@  WX4  -^<  #?L@  WLL  -[F  #?]   W_0 >:$  &NH
M  !<KP  3K4  $"[   QO@  ),$  !G%   0R   "<P   #/    TP   -D
M  #<    W0   -\   #A    X@4  .0+  #F$   Z!8  .H@  #M*P  \#H
M /%+  #Q7@  \G,  /.+  #SH@  \[8  //)  #SX0  \^$ ;:H  %ZQ  !0
MN0  0;\  #+$   DR   %\P   [0   &U0   -H   #>    X@   .8   #I
M    Z@   .P   #N    \    /(   #T!@  ]@P  /D2  #\'   _RD  /\Z
M  #_30  _V(  /]X  #_D   _Z,  /^S  #_P0  _\$ _P<9 /\!%P#_ !<
M_P : /\ (0#_ "L _P Y /\ 1P#_ %0 _P!? /\ :@#_ ', _P![ /\ @P#_
M (H _P"0 /\ E@#_ )L _P"A /\ J #_ *\ _P"X /\ Q #^ -4 _ #J /L
M^ #Z /\ ^0#_ /@ _P#X /\ ]@#_ /, _P#Q /\ _PL5 /\%$P#_ !, _P 4
M /\ &@#_ "< _P T /\ 0@#_ $\ _P!; /\ 90#_ &X _P!V /\ ?@#_ (4
M_@"+ /T D0#[ )< ^@"= /@ HP#W *L ]@"S /0 O@#S ,P \0#C .\ \P#N
M /\ [0#_ .P _P#K /\ [ #_ .P _P#K /\ _PT1 /\)$ #_  \ _P 0 /\
M%@#_ "( _P O /\ /0#_ $H _P!5 /T 8 #Z &D ^ !Q /8 >0#T '\ \P"&
M /$ C #O )( [@"8 .P GP#K *8 Z0"N .< N #E ,4 XP#: .$ [0#? /L
MW@#_ -T _P#= /\ W0#_ -T _P#= /\ _P\- /\,"P#_ PD _P , /\ $@#_
M !T _P I /L -P#X $0 ]0!0 /( 6@#N &, [ !K .D <P#G 'H Y0"  .,
MA@#A (P WP"3 -T F0#; *$ V0"I -4 L@#2 +X T #. ,X Y@#, /8 R@#_
M ,H _P#) /\ R #_ ,@ _P#( /\ _Q$( /\- @#_!P  _P4( /\ #@#_ !8
M]P B .\ , #K #T Z !) .0 5 #@ %T W0!E -D ;0#5 ', T@!Z -  @ #.
M (< S "- ,H E #( )L Q@"D ,0 K0#" +@ P #' +T WP"\ /$ NP#^ +D
M_P"X /\ N #_ +@ _P"X /\ _Q0  /\/  #_#0  _PP  /\'"0#X 1  Z  :
M ., * #= #8 V !" -( 30#. %< R@!? ,< 9@#% &T PP!T ,$ >@"_ ($
MO0"( +L CP"Y )< MP"? +4 J "S +, L0#" *\ V "N NT K /[ *L%_P"J
M!O\ J0;_ *D&_P"I!O\ _Q8  /\2  #W$@  [!$  .8.  #E!@@ W0,2 -0#
M( #-!"T R 0Z ,,%1@"_!5  O 98 +D&8 "W!V< M0=N +,'=0"Q"'L KPB"
M *X)B@"L"9( J@F; *@*I0"F"K  I0N_ *,,U "A#>T GP[^ )T._P"<#_\
MFP__ )L/_P";#_\ _QH  /<9  #J'@  WQX  -4:  #0$P( S@P+ ,<+%@#
M#24 N@XR +8./P"R#TD KQ!2 *P06@"J$&$ J!%H *81;P"D$78 HA%] *$1
MA0"?$HX G1*7 )P2H@":$ZT F!.\ )<4T "4%>P DA;] ) 7_P"/%_\ CA?_
M (X7_P".%_\ ^AT  .XC  #?*   T"H  ,<G  #!(0  O1D% +D2$ "R%1X
MK18L *@7. "D&$, H1E, )\95 "<&EP FAIB )D::0"7&W  E1MW )0;?P"2
M'(@ D!R2 (\<G0"-':D BQVW (H>R@"('^< AB#Z (0@_P&#(/\!@R#_ 8(@
M_P&"(/\!]20  .4L  #3,0  QC,  +PQ  "V+0  L"4  *P=# "F'A@ H2 F
M )PA,@"9(CT E2)' ),C3P"1(U8 CR-= (TD9 "+)&L B21R (@D>@"&)(,
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MD )M,YT";#.K FHTO )I--4#:#7Q F<U_P)G-?\"9C7_ F8U_P)F-/\"XC8
M ,P_  "]1   LD<  *A'  "@1   F#\  ) Y  "(- T @S47 '\V) !\-R\
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M!%5#LP140\D$5$/I!%-#_0-30_\#5$/_ U1#_P)40_\"T$(  +]*  "R4
MIU,  )U4  "44P  BE   ']*  !U10( ;D,. &M$&0!G120 944N &)%-P!A
M13\ 7T5& %U%30!;150 6D9; 5E&8P%71FP"5D9W E1&@P-31I$#44:A!%!'
ML01/1\<$3D?G!$Y'^P1.1_\#3D?_ T]'_P-/1_\#S$8  +M.  "O5   I%<
M )I8  "15P  AE0  'M.  !P2@  :4@- &5(%@!B22$ 7TDK %U)- !;23P
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M!#]4^ - 4_\#0%/_ T!3_P- 4O\#P%   +)8  "F7@  G&(  ))E  "(90
M?6(  &Y<  !C60  658# %16#@!15A@ 3U8B $U7+ !,5S0 2E<\ $E81 !(
M6$L 1UA3 $586P%$6&0!0EAN 4!8>P(_6(D"/5B9 SQ8J@,[6;\#.EG@ SI8
M]P,Z6/\#.U?_ SM7_P,[5_\#O%0  *Y<  "C8P  F6<  )!I  "%:0  >6<
M &MB  !@8   55T  $Y;# !+6Q0 25P? $=<* !&73$ 15TY $-=00!"74@
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M 2AI_P(H:?\"KF0  *-L  "9<P  CG8  (1X  !Y>0  ;7@  &!W  !3=@
M2'4  #YS   T<@H ,7,1 #!S&@ O<R, +G,K "UT-  L=#P *W1$ "ET30 H
M=5< )W5C "5U;P D=7\ (G60 "%UH@ @=;< 'W72 !]T\0 ?<_\!'W+_ 2!Q
M_P$@<?\!J6L  )YS  "4>0  BGP  (!^  !T?P  9W\  %I_  !-?@  0WX
M #A]   O?0( *'T- "9]%  D?1P (WXE ")^+0 A?C8 (7X_ !]_2  >?U(
M'7]> !Q_:P :?WH &7^, !=_GP 6?[, %7_. !5^[P 6?/\ %GO_ !9[_P 7
M>_\ I'(  )IZ  "/?P  A8(  'N$  !MA@  8(<  %2'  !(B   /(@  #*(
M   HB   ((@% !J)#@ 9B14 &(D= !>*)@ 6BBX %8HW !2*00 3BDP $HM8
M !&+90 0BW4 #XN'  Z*FP -BJ\ #(K(  R)Z@ -A_P #H?_  Z&_P .AO\
MGWL  )2!  "*A0  @(@  '.+  !EC0  68\  $R0  !!D@  -)(  "J2   A
MDP  &90  !*6!@ .EPX #9<5  R7'0 ,ER8 "Y<O  J7.0 )ET0 ")=0  :7
M7@ %EVX  Y:   &6E   E:@  )6^  "4X   E/0  )/_  &2_P !DO\ F((
M (Z(  "%C   =X\  &J2  !=E0  4)@  $2:   XFP  +)P  "*=   9G@
M$J    VB @ 'HPL  :,0  "C%P  HQ\  *,G  "C,0  I#P  *1(  "D5@
MI&4  *-W  "CBP  HZ   **V  "AT@  H?   *#[  "@_P  H/\ D8H  (F.
M  ![D@  ;9<  &";  !3G@  1J$  #FC   MI   (Z8  !FH   1J@  #*P
M  6N    KP<  *\-  "O$0  L!@  + @  "Q*   L3(  +(^  "R3   LEL
M +)L  "R@0  L9<  +&L  "PQ@  L.@  *_W  "O_P  K_\ C)   '^5  !Q
MF@  8Y\  %6D  !'J   .JH  "VL   BK@  &+   !"S   *M0   K@   "[
M    NP   +P'  "\#0  O1$  +X6  "_'@  P"<  ,$R  #"0   PT\  ,-@
M  ##=   PXL  ,.A  ##N   PM<  ,+O  #"^@  P?X @9<  '.=  !EHP
M5Z@  $FM   [L0  +;,  "&V   6N0  #KL   >^    P0   ,4   #'
MR    ,D   #*!0  RPL  ,T/  #.%   T!P  -,F  #6,@  V$$  -A3  #9
M9@  V7P  -F4  #9JP  V<,  -GA  #9\   V?0 =I\  &>F  !9K   2[(
M #RW   NN@  (;T  !7    -Q   !<<   #*    S@   -(   #5    U@
M -D   #;    W0   -\'  #A#   XQ$  .89  #I)   [#(  .U#  #N5@
M[VL  .^$  #OG   [[(  ._&  #OW0  [^0 :J@  %NO  !,M@  /KP  "_
M   @Q   %,@   S,   "T    -0   #9    W@   .(   #E    Y@   .@
M  #I    [    .X   #P @  \@D  /4/  #X%P  _",  /\S  #_1@  _UH
M /]Q  #_B0  _Y\  /^Q  #_P   _\8 _P 5 /\ % #_ !0 _P 7 /\ '0#_
M "@ _P W /\ 1 #_ %$ _P!< /\ 9@#_ &\ _P!W /\ ?@#_ (4 _P"+ /\
MD0#_ )< _P"= /\ I #_ *L _P"T /X OP#] ,X ^P#F /D ]@#X /\ ]P#_
M /< _P#W /\ \ #_ .P _P#I /\ _P,2 /\ $ #_ !  _P 1 /\ %P#_ "0
M_P R /\ /P#_ $P _P!7 /\ 80#_ &H _P!R /\ >0#] (  _ "& /H C #Y
M )( ^ "8 /8 GP#U *8 ] "N /( N0#P ,8 [@#> .T \ #K /X Z@#_ .D
M_P#I /\ YP#_ ., _P#@ /\ _P<. /\ #0#_  L _P , /\ $P#_ !\ _P L
M /\ .@#_ $8 _@!2 /L 7 #X &4 ]0!L /, = #Q 'H [P"! .X AP#L (T
MZ@"3 .D F@#G *$ Y@"I ., LP#A +\ WP#0 -T Z0#: /D V0#_ -< _P#5
M /\ U0#_ -4 _P#4 /\ _PD* /\!!0#_  , _P ) /\ $ #_ !D ^P F /<
M- #T $  \@!, .X 5@#J %\ YP!G .0 ;@#B '0 X ![ -X @0#< (< V@"-
M -8 E #4 )L T0"C ,\ K0#, +@ R@#' ,@ X #& /, Q0#_ ,, _P## /\
MPP#_ ,, _P## /\ _PL! /\#  #_    _P # /\ "P#S !( [@ ? .H +0#F
M #H X@!% -X 3P#9 %@ U !@ -$ : #. &X S !T ,H >P#( ($ Q@"' ,0
MC@#" )8 P "> +X IP"[ +( N0#  +< U "U .P LP#[ +, _P"R /\ L@#_
M +$ _P"Q /\ _PT  /\&  #_ P  ]P   /0  P#G  T X  8 -H )0#3 #(
MS@ ^ ,H 20#& %( PP!: ,  80"^ &@ O !N +H = "X 'L M@"! +0 B "R
M )  L "9 *X H@"L *T J@"Z *@ RP"F .8 I0#W *0 _P"C /\ H@#_ *(
M_P"B /\ _Q   /L,  #O#@  Y@T  -\)  #:  8 T  1 ,D '0#$ "H OP W
M +L 0@"W $L M !4 +( 6P"O &( K0!H *L ;@"I '4 J ![ *8 @P"D (L
MH@"4 *  G@"> :@ G *U )L#Q@"9!>( F ;T )8(_P"5"?\ E G_ )0)_P"4
M"?\ _!$  /$5  #C&0  UAD  ,P5  #'$   Q <* +T#% "W!"$ L@8N *X(
M.@"J"40 IPE- *0*50"B"EP H IB )X+:0"<"V\ FPMV )D,?@"7#(8 E@R0
M )0,F@"2#:8 D0VS (\-Q0"-#N( BQ#V (D0_P"($?\ AQ'_ (<1_P"'$?\
M]AD  .<@  #6)   R"4  +\B  "Y'   M!0! +$-#@"J#AD I0\G *$0,P"=
M$3X FA%' )@23P"5$E8 DQ)< )$28P"0$VD CA-P (P3> "+$X$ B12+ (<4
ME@"&%:( A!6P (,6P0"!%]T ?QCT 'T9_P!\&?\ ?!G_ 'L9_P![&?\ [R$
M -TI  #*+0  OB\  +4L  "N)P  J"   *,7" ">%A, F1<A )09+0"1&C@
MCAI! (L;20")&U  AQM7 (4<7@"$'&0 @AQK ( <<P!_'7P ?1V& 'P>D0!Z
M'IX >!^K '<?O !V(-0 ="'P '(A_P!Q(O\ <2'_ '$A_P!Q(?\ Z"@  -(P
M  #"-0  MS<  *TU  "E,0  GBL  )@C @"2'A  C2 ; (DA)P"&(C( @R,\
M ($C1 !^(TL ?"12 'LD60!Y)%\ =R1F '8E;@!T)7< <R6! '$FC0!O)ID
M;B:G &TGN !L)\X!:BCM 6DI_P%H*?\!:"G_ 6@H_P%H*/\!X2X  ,LV  "\
M.P  L3T  *<]  "?.0  ES,  (\M  "()PP @R<6 '\H(@!\*2T >2HW '<J
M/P!U*D< <RM. '$K5 !P*UL ;BMB &PK:@!K+'( :2Q] &@LB0!F+98!92VD
M 60NM %C+LH!82_I 6 O_0%@+_\!8"__ 6 O_P%@+O\!VC0  ,4\  "W00
MK$,  *)#  "90   D#H  (@T  " +@@ >BT2 '<N'@!S+RD <3 S &\P.P!M
M,$, :S%* &DQ40!G,5< 9C%> &0Q9@!C,F\ 83)Y & RA0%?,I(!73.A 5PS
ML0%;-,8!6C3F 5DU^P%9-?\!633_ 5DT_P%9-/\!TC@  ,!   "S10  J$@
M )Y(  "51@  BT   (([  !Y-00 <S,0 &\T&@!L-"4 :34O &<U-P!E-C\
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M DA"]@)(0O\"2$+_ 4A!_P%(0?\!Q40  +5+  "I4   GE0  )54  "+4P
M@%   '5*  !J1@  84(( %Q!$0!90AL 5T(E %5"+@!30C4 44(] $]"0P!/
M0TL 3D-2 $U$6@!+1&, 2D1N 4E%>@%'18@!1D68 D5&J0)$1KT"0T;< D-&
M]0)#1O\"0T;_ 4-%_P%#1?\!P4<  +)/  "F5   G%<  ))8  "(6   ?E4
M '%/  !F2@  7$8% %=&#P!41A@ 448B $]&*P!.1C, 3$<Z $M'00!*1TD
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M 312_P$T4O\!ME(  *E:  ">8   E&0  (MF  " 90  =&,  &9>  !<7
M45@  $=5!P!"51  0%48 #]6(0 ]5BH /%8R #M6.0 Z5T$ .5=) #A740 W
M6%H -5AE #18<0 R6( !,5B0 2]9H@$N6;4!+5G/ 2U9[P$N6/\!+E?_ 2Y7
M_P$N5O\!LE<  *5?  ";90  D6D  (=J  !\:@  <6@  &-E  !88@  35\
M $-= @ \6PT .EP4 #A<'0 W7"8 -5TN #1=-@ S73X ,EU& #%>3@ P7E<
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M9P <;G8 &FZ' !EOF@ 8;ZX %F_& !9NZ0 7;?P &&S_ !AK_P 8:_\ I&D
M )IQ  "0=@  AGD  'Q[  !Q>P  9'L  %=Z  !*>0  /W@  #5X   K=P
M(G8' !UV#P <=Q8 &W<> !IW)@ 9=RX &'<W !=X0  5>$H %'A6 !-X8P 2
M>'( $7B# !!XEP />*L #GC#  YWY@ .=OH #W7_ !!U_P 0=/\ GW$  )5X
M  "+?   @G\  '>!  !J@@  78(  %""  !$@@  .((  "Z"   D@@  '((
M !2""0 1@Q  $(,6 !"#'@ .@R< #H,P  V#.0 -@T0 #(-0  N#70 )@VP
M"(-^  :#D0 %@J4  X*[  2!VP $@?( !8#_  9__P &?_\ FGD  )!^  "&
M@P  ?84  &^'  !BB0  58H  $F+   ]C   ,8P  ":,   =C0  %8X   ^/
M P *D P !I 1  2/&  #CR   8\I  "/,@  D#T  )!)  "/5@  CV4  (]V
M  "/B@  CI\  (ZT  "-SP  C.X  (S[  "+_P  B_\ E(   (N%  ""B0
M=(P  &:/  !9D0  3),  $"5   TE@  *)8  !Z7   5F   #YH   J;   "
MG D  )P.  "<$P  G!H  )PB  "=*P  G34  )U   "=3@  G5P  )UN  "<
M@0  G)<  )RL  ";Q@  FN@  )GY  "9_P  F/\ CH@  (:,  !XD   :I0
M %R7  !/F@  0IT  #:>   IGP  'Z$  !6B   .I   "*8   "H    J00
M *D*  "I#@  J1,  *H:  "J(@  JRL  *PV  "L1   K%,  *QC  "L=P
MJXX  *ND  "KO   JMX  *GT  "I_0  J?\ B8X  'N3  !MEP  7YP  %&@
M  !$I   -J8  "JH   >J0  %*L   VN   &L    +(   "U    M0   +4#
M  "V"0  MPX  +@2  "X&0  NB$  +LK  "\.   O4<  +U8  "]:P  O8$
M +V9  "]L   O<P  +SJ  "\]P  N_X ?I4  '";  !BH   4Z4  $:J   X
MK0  *J\  !ZQ   3M   #+<   .Y    O    +\   #"    P@   ,,   #$
M    Q@8  ,<,  #($   RA8  ,P@  #/*P  T#H  -%+  #17@  TG,  -*+
M  #2I   T[L  -/8  #3[0  T_8 <YT  &2C  !6J0  1Z\  #FS   JM@
M';D  !*\   *OP   ,,   #&    R0   ,T   #/    T    -(   #4
MU@   -D"  #;"   W@X  .$3  #D'0  Z"H  .@\  #I3P  Z60  .I\  #K
ME0  ZZP  .O"  #LU0  [.4 9J8  %BL  !)LP  .[D  "N\   =P   $<0
M  G(    S    ,\   #3    V0   -T   #@    X0   .,   #E    YP
M .H   #L    [@0  /$+  #U$@  ^!P  /LK  #]/@  _E,  /YJ  #_@P
M_YL  /^N  #_O@  _\H _P 2 /\ $ #_ !$ _P 3 /\ &0#_ "8 _P T /\
M00#_ $T _P!8 /\ 8@#_ &L _P!S /\ >@#_ ($ _P"' /\ C0#_ ), _^)]
M$$E#0U]04D]&24Q% ! 2_P"9 /\ H #_ *< _@"O /P N@#Z ,D ^0#A /@
M\P#W /\ ]@#_ /4 _P#Q /\ Z0#_ .0 _P#A /\ _P / /\ #0#_  T _P .
M /\ % #_ "$ _P N /\ / #_ $@ _P!3 /\ 70#_ &8 _@!M /P =0#[ 'L
M^0"" /@ B #W (X ]@"4 /0 FP#S *( \0"J .\ M #M ,$ ZP#5 .H [ #H
M /P YP#_ .4 _P#F /\ X #_ -D _P#4 /\ _P + /\ " #_  8 _P ) /\
M$ #_ !P _P I /\ -@#_ $( ^P!. /< 5P#T &  \@!H .\ ;P#M '8 [ !\
M .H @@#H (@ YP". .4 E0#C )P X0"D -\ K@#= +D V@#* -< Y #4 /8
MT0#_ -  _P#0 /\ SP#_ ,L _P#' /\ _P # /\   #_    _P $ /\ #0#Z
M !8 ]@ C /, , #P #P [0!' .D 40#E %H X@!B -\ :0#= &\ V@!V -@
M? #4 (( T@"( -  CP#- )8 RP"> ,D J #' +, Q0#! ,( V #  .\ OP#^
M +X _P"] /\ O #_ +P _P"\ /\ _P(  /\   #_    _P   /0 !P#M !$
MZ  < ., *0#? #4 VP!! -8 2P#1 %0 S0!< ,H 8P#( &D Q@!O ,, =0#!
M 'L OP"" +X B "\ )  N@"8 +@ H@"U *P LP"Y +$ RP"O .< K@#X *P
M_P"K /\ K #_ *P _P"K /\ _P0  /\   #V    [@   .<   #?  P U@ 5
M ,\ (@#* "X QP Z ,, 1 #  $T O !5 +D 7 "W &, M0!I +, ;P"Q '4
MKP![ *T @@"K (H J0"2 *< G "E *8 HP"S *$ PP"? -X G@#R )T _P"<
M /\ G #_ )L _P"; /\ _P<  /8)  #I"P  WPH  -4$  #.  4 Q@ 0 ,
M&@"[ "< MP R +, /0"P $8 K0!/ *H 5@"H %P I@!C *0 : "B &\ H0!U
M )\ ? "= (0 FP"- )D EP"7 *( E0"N ), O0"1 -, D #M (\ _ ". /\
MC0'_ (T!_P"- ?\ ^0X  .H2  #<%0  S14  ,01  "^#   N@(* +0 $@"N
M !X J@ J *8 -0"B #\ H !( )T!4 "; E8 F0)< )<#8P"5 VD DP-O )$$
M=@"0!'\ C@6( (P%D@"*!IX B :J (8'N@"%",\ A KK ((+_ "!#/\ @ S_
M ( ,_P" #/\ \14  . =  #-(   P2$  +@=  "Q%P  K!   *@)#0"B!Q8
MG0DC )D*+@"5"S@ DPQ! ) ,20".#5  C U7 (H-70"(#6, APUJ (4.<0"#
M#GH @@Z$ ( .CP!^#YL ? ^H 'L0N !Z$,X >!'L '82_P!U$O\ =!/_ '03
M_P!T$_\ Z!X  -,F  ##*@  N"H  *XH  "G(P  H!P  )L3 P"6#Q  D! ;
M (P1)P")$C( AA,[ (030P""%$L @!11 'X45P!\%%X >Q5E 'D5; !W%70
M=A9^ '06B@!R%Y8 <1>D &\8M !N&,D ;1GH &L:_ !J&_\ :AO_ &H;_P!J
M&_\ X"8  ,HM  "\,0  L#,  *<Q  "?+   ER8  ) ?  "*%PP A1@6 ($9
M(@!^&BP >QLV 'D;/@!W'$4 =1Q, ',<4P!Q'5D <!U@ &X=9P!M'G  :QYZ
M &H>A0!H'Y( 9Q^@ &4@L !D(<4 8R'D &(B^@!A(O\ 82+_ &$B_P!A(O\
MURP  ,,T  "V.   JCD  *$X  "8-0  D"\  (@H  " (0@ >R 2 '<A'0!T
M(B< <2(Q &\C.0!M(T$ :R-( &DC3@!H)%4 9B1; &4D8P!C)6L 8B5U &$E
M@0!?)HX 7B:= %TGK0!;*,$ 6RC@ %HI]P!9*?\ 62G_ %DI_P!9*/\ SS(
M +XY  "Q/0  IC\  )P_  "3/   BC8  ($P  !Y*@, <B8/ &XG&0!K*",
M:2@L &8I-0!E*3P 8RE# &$J2@!@*E$ 7BI7 %TJ7P!<*V@ 6BMR %DL?0!8
M+(L 5BV: %4MJ@!4+KT 4R[< %(O]0!2+_\ 4B[_ %(N_P!2+O\ RC8  +H]
M  "M0@  HD0  )A$  "/00  A3P  'LW  !R,0  :RP, &<M%0!D+1\ 82XH
M %\N,0!=+CD 7"]  %HO1@!8+TT 5R]4 %8P7 !5,&0 4S%N %(Q>@!1,8@
M4#*7 $XRJ !-,[L 3338 $PT\P!,-/\ 3#3_ $PS_P!,,_\ QCH  +9"  "I
M1@  GDD  )5)  "+1P  @4(  '<]  !M-P  9#() & R$@!=,AP 6C(E %@S
M+0!6,S4 53,\ %,T0P!2-$H 4311 % T60!/-6$ 335L $PV=P!+-H4 2C>5
M $@WI@!'.+@!1SC3 48X\0%&./\!1CC_ $8X_P!&-_\ P3X  +)%  "F2@
MG$T  ))-  "(2P  ?D<  '-"  !I/0  7S<& %HV$ !7-Q@ 5#<B %(W*@!0
M-S( 3S@Y $TX0 !,.$< 2SA. $HY5@!).5\ 2#II $<Z=0!%.X, 1#N3 $,\
MI %"/+8!03W0 4$]\ %!/?\!03S_ 4$\_P%!//\ OD(  *])  "C3@  F5
M (]1  "%4   >TP  &]&  !E0@  6CT" %0[#@!1.Q4 3SL? $T[)P!+.R\
M23PV $<\/0!'/$0 1CU+ $4]5 !$/EP 0SYG $(_<P! /X$ /S^1 #Y H@ ]
M0+4!/$'. 3Q![@$\0?\!/$#_ 3Q _P$]/_\!ND4  *Q,  "A40  EU0  (U5
M  "#5   >%$  &Q+  !A1P  5D(  $] # !,/Q, 24 < $= ) !&0"P 1$ S
M $- .@!"04( 04%) $!"40 _0EH /D-E #U#<0 [0W\ .D2/ #E$H  X1;,!
M-T7+ 3=%[ $W1?\!-T3_ 3A$_P$X0_\ MTD  *E0  ">50  E%@  (M9  "
M6   =E8  &A0  !=3   4T@  $I%"0!&1!$ 1$09 $)$(@!!12D /T4Q #Y%
M.  ]13\ /$9' #M&3P Z1U@ .4=B #A(;@ V2'P -4B- #1)G@ S2;$ ,DG)
M #%)ZP R2?X ,DC_ #)(_P S2/\ M$P  *=4  "<60  DEP  (A=  !^70
M<UH  &55  !;4@  4$X  $9*!0! 20X /DD6 #U)'@ [2B8 .DHN #E*-0 X
M2ST -TM$ #9+30 T3%8 ,TQ@ #),;  Q37H ,$V+ "Y-G  M3J\ +$[' "Q.
MZ0 L3?T +4W_ "U,_P M3/\ L%   *18  "970  CV$  (9B  ![80  <%\
M &);  !86   3E4  $-1 0 [3PP .$\3 #9/&P U3R, -% K #-0,@ R4#H
M,5!" #!12@ N45, +5)= "Q2:0 K4G@ *5*( "A3F@ G4ZT )E/% "93YP F
M4_P )U+_ "=1_P G4?\ K%4  *!<  "68@  C68  (-G  !X9@  ;64  &!A
M  !57@  2EL  #]8   U5@@ ,540 #!6%P N5A\ +58G "Q6+P K5S8 *E<^
M "E71P H5U  )EA: "589P D6'4 (UF& "%9F  @6:L 'UG" !]9Y0 ?6/H
M(%C_ "!7_P A5_\ J%H  )UB  "39P  BFL  ']L  !U;   :FL  %UH  !1
M90  1F,  #M@   Q7@, *ET- "A=$P F71L )5XC "1>*@ C7C( (EXZ "%>
M0P @7TP 'U]7 !Y?8P <8'$ &V"" !E@E0 88*D %V#  !9@X@ 77_D &%[_
M !E>_P 97?\ I&   )EH  "0;@  AG   'QR  !R<@  9G$  %AN  !,;
M06L  #9I   M9P  (V8( !]F#P =9A4 '&8= !MF)0 :9BT &6<U !AG/@ 7
M9T@ %F=3 !5H7P 3:&X $FA_ !%HD@ 0:*8 #VB]  YHX  09_< $&;_ !%E
M_P 19?\ GV<  )9O  ",<P  @G8  'AX  !M>   8'<  %-V  !&=   .W,
M #%R   G<0  'G$  !9P"@ 3<!  $W 7 !)P'P 1<2< $'$O !!Q.  .<4(
M#G%.  UQ6P ,<6D "W%Z  IQC0 (<:$ !G&V  9PT@ '<.\ "&__  EN_P )
M;O\ FV\  )%U  "'>0  ?GP  '1^  !F?@  67X  $U^  ! ?0  -7T  "I\
M   A?   &'P  !%\!  ,? P "GP1  E\&0 (?"$ !WPI  9\,@ $?#T  WQ(
M  %\50  ?&,  'QT  !\AP  >YP  'NQ  !ZRP  >>L  'GZ  !Y_P  >/\
MEG<  (Q\  "#@   >8,  &R$  !>A0  488  $6'   YAP  +8<  ".'   :
MAP  $H<   V( 0 &B0H  8D/  ")%   B!L  (@C  ")+   B38  (E"  "(
M3@  B%T  (AM  "(@0  AY4  (>K  "&Q   A>8  (3X  "$_P  A/\ D'X
M (>#  !^AP  <8D  &.+  !6C0  28\  #R1   PD0  ))$  !J2   2DP
M#90   :5    E@8  )8,  "5$   EA4  )8=  "6)   EBX  )8Y  "61@
MEE4  )9E  "6>   E8X  )6D  "4O   D]\  )/U  "2_P  DO\ BX8  (.*
M  !UC0  9Y   %F4  !,EP  /YD  #*:   FFP  &YP  !*=   ,GP  !*
M  "B    HP$  *,'  "C#   HQ   *05  "D'   I24  *8O  "F/   IDL
M *9;  "F;@  I80  *6;  "DLP  H]   */O  "B_   HO\ AHT  'B1  !J
ME0  7)D  $Z=  !!H   ,Z(  ":C   ;I0  $:<   JI   !JP   *T   "O
M    L    +    "P!0  L0L  +(/  "S%   M!L  +4D  "W,   MS\  +=0
M  "W8@  MW@  +>0  "VJ0  ML(  +;D  "V]0  M?X >Y,  &V8  !?G0
M4*(  $*F   TJ0  )JL  !JM   0KP  ";(   "T    MP   +H   "\
MO0   +X   "^    P (  ,$(  #"#0  Q!(  ,89  #))   RC(  ,M#  #+
M50  S&H  ,R#  #,G   R[4  ,S.  #,Z0  S/8 <)L  &&A  !2I@  1*L
M #:P   GL@  &K4  !"X   'NP   +X   #!    Q    ,@   #+    RP
M ,T   #.    T    -(   #5 P  V H  -L0  #>&   XB0  .,U  #D2
MY5P  .9S  #FC0  YJ4  .:\  #FTP  Y^< 8Z0  %6J  !&L   .+4  "BY
M   :O   #\    7$    QP   ,L   #/    U    -@   #<    W0   -\
M  #A    XP   .4   #H    Z@   .T&  #Q#@  ]18  /@E  #Y.   ^4T
M /IC  #[?   _)4  /RJ  #\NP  _<L _P / /\ #@#_  X _P 0 /\ %@#_
M ", _P P /\ /0#_ $D _P!4 /\ 7@#_ &8 _P!N /\ =@#_ 'P _P"" /\
MB0#_ (\ _P"5 /X FP#] *, ^P"K /H M0#Y ,, ]P#; /8 \ #T /\ \P#_
M /( _P#L /\ X@#_ -P _P#6 /\ _P , /\ "0#_  @ _P * /\ $@#_ !X
M_P K /\ . #_ $0 _P!/ /\ 60#^ &$ _ !I /H < #X '< ]P!] /8 @P#T
M (D \@"/ /$ E@#O )T [0"E .P KP#J +P Z #- .8 Z #D /H XP#_ .(
M_P#@ /\ U0#_ ,X _P#+ /\ _P & /\  0#_    _P $ /\ #@#_ !D _P E
M /T ,@#[ #X ]P!) /, 4P#P %P [@!C .P :@#J '$ Z !W .8 ?0#D (,
MX@") .  D #> )< W "? -D J0#6 +0 TP#$ -  W@#. /, S #_ ,L _P#*
M /\ R #_ ,( _P"^ /\ _P   /\   #_    _P   /L "P#V !, \0 @ .T
M+ #J #@ YP!# ., 30#@ %8 W != -D 9 #5 &L T@!Q -  =@#. 'P S "#
M ,H B0#( )$ Q@"9 ,0 HP#! *T OP"[ +T SP"[ .L N0#\ +< _P"W /\
MM@#_ +0 _P"Q /\ _P   /\   #_    ]@   .X !0#G  \ X0 9 -L )0#5
M #$ T@ \ ,X 1@#* $\ QP!7 ,0 7@#! &0 OP!J +T < "[ '8 N0!\ +@
M@P"V (H LP"3 +$ G "O *< K0"S *L Q0"I .$ IP#U *8 _P"E /\ I #_
M *0 _P"D /\ _P   /P   #Q    Z    .    #4  L S  3 ,< 'P#" "H
MOP U +P /P"X $@ M0!0 +, 5P"P %X K@!D *P :0"K &\ J0!U *< ? "E
M (0 HP", *$ E@"? *$ G0"M )H O "8 -( EP#N )4 _@"4 /\ E0#_ )4
M_P"5 /\ _ $  / %  #C!P  U04  ,P   #%  0 O@ . +@ %P"S ", KP N
M *L . "I $$ I@!* *, 40"A %< GP!= )T 8P"; &D F@!O )@ =@"6 'T
ME "& )( D "0 )L C@"G (P M@"* ,D B #G (< ^0"' /\ A@#_ (8 _P"&
M /\ ] P  .00  #1$@  Q1$  +T.  "V"   L0 ( *L $0"F !L H0 F )X
M,0": #H F !# )4 2@"3 %$ D0!7 (\ 70". &, C !I (H < "( '< A@"
M (0 BP"" )8 @ "C 'X L0!] ,0 >P+A 'H#]0!Z!?\ >07_ '@&_P!X!O\
MZA,  -8:  #&'0  NAP  +$9  "J$P  I T  )\%# "9 !0 E0 ? )$"*0"-
M S, BP0\ (@%1 "&!DL A 91 (('5P"!!UT ?P=C 'T(:@!["'( >@A\ '@)
MA@!V"9( = J@ ',*KP!Q"\$ < S? &\-]@!N#O\ ;0[_ &T._P!M#O\ X1P
M ,LC  "\)@  L28  *@D  "@'@  F1@  ),0 @"."PX B L7 (0,(@"!#2P
M?@TU 'P./0!Z#D4 > Y+ '<.40!U#U@ <P]> '$090!P$&X ;A!W &P0@@!K
M$(\ :1&= &@1K0!F$L  91+? &03]@!C%/\ 8Q3_ &(4_P!B%/\ UB0  ,,J
M  "U+@  JB\  * M  "8*   D"(  (D;  ""$P@ ?1$2 'D2' !V$R< <Q0P
M '$4. !O%3\ ;15& &P53 !J%E, :!99 &<680!E%FD 9!=R &(7?@!A&(L
M7QB9 %X9J0!<&;P 7!K8 %H;\P!:'/\ 61S_ %D<_P!9'/\ S2H  +TQ  "O
M-0  I#8  )LT  "2,0  B2L  ($E  !Y'0, <Q@. &\9& !L&B( :1LK &<;
M,P!E'#L 9!Q! &(=2 !@'4X 7QU5 %T=7 !<'F0 6QYN %D?>0!8'X< 5B"6
M %4@I@!4(;@ 4R'2 %(B\0!2(_\ 4B/_ %(B_P!2(O\ R"\  +@V  "K.@
MH#P  )8[  "-.   @S(  'HM  !R)@  :B , &8@$P!C(1T 82$F %\B+P!=
M(C8 6R(] %HC1 !8(TH 5R-1 %4C6 !4)&$ 4R1J %$E=@!0)8, 3R:3 $XG
MHP!,)[4 3"C. $LH[@!+*?\ 2RC_ $LH_P!+*/\ PS0  +,[  "G/P  G$$
M ))   ")/@  ?SD  '4S  !L+0  8R<( %XF$0!<)AD 62<B %<G*P!5*#(
M5"@Y %(H0 !1*$8 4"E- $XI50!-*5T 3"IG $LJ<P!)*X  2"N0 $<LH0!&
M+;, 12W+ $4N[ !$+O\ 1"[_ $4M_P!%+?\ OC@  + _  "D0P  F44  (]%
M  "%0P  >SX  '$Y  !G-   7BX$ %@K#@!5*Q8 4BP? % L)P!/+"\ 32TV
M $PM/ !*+4, 22U* $@N4@!'+EH 1B]D $4O< !#,'X 0C"- $$QG@! ,K$
M/S+( #\SZ@ _,_X /S+_ #\R_P _,O\ NSP  *U#  "A1P  EDD  (Q)  "#
M2   >$0  &T^  !C.0  6C0  %(P# !/,!, 3# < $HP) !),2L 1S$R $8Q
M.0!$,4  0S)' $(R3P!!,U@ 0#-B #\T;0 ^-'L /36+ #PVG  [-J\ .C?&
M #DWZ  Y-_P .C?_ #HV_P Z-O\ MT   *I&  ">2P  E$T  (I.  " 3
M=4@  &I#  !@/@  5CD  $TU"0!)-!$ 1S49 $4U(0!#-2@ 034O $ U-@ _
M-CT /C9% #TW30 \-U4 .SA@ #HX:P Y.7D .#F) #<ZFP U.JT -3O$ #0[
MY@ T._L -3O_ #4Z_P U.O\ M$,  *=*  "<3@  DE$  (A2  !^4   <TT
M &=(  !<1   4C\  $@Z!@!$.0\ 03D6 #\Y'@ ^.28 /#DM #LZ-  Z.CL
M.3M" #@[2@ W/%, -CQ= #4]:0 T/7< ,SZ' #$^F0 P/ZL +S_" "\_Y  O
M/_H ,#__ # ^_P P/O\ L4<  *1-  "94@  CU4  (96  !\50  <5(  &1,
M  !920  3T4  $5  P _/@T /#X3 #H^&P Y/B, -SXJ #8_,0 U/S@ -#]
M #- 2  R0%$ ,4%; #!!9P N0G4 +4*% "Q#EP K0ZH *D/  "E$X@ J0_D
M*D/_ "M"_P K0O\ KDH  *%1  "75@  C5D  (-:  !Y6@  ;E<  &%2  !7
M3@  34L  $-'   Z0PH -D,1 #1#&  S0R  ,D0G #%$+P P1#8 +T4] "U%
M1@ L14\ *T99 "I&9  I1W( *$># "9'E0 E2*@ )$B^ "-(X  D2/< )4?_
M "5'_P F1_\ JD\  )]5  "46@  BUX  (%?  !W7@  :UP  %]8  !550
M2U$  $!-   U2@< ,$D. "Y)%0 M21T +$DD "M**P J2C, *$H[ "=+0P F
M2TP )4M6 "1,8@ C3'  (4R  "!-DP ?3:8 'DV[ !U.W0 >3?8 'DS_ !],
M_P @2_\ IU,  )Q:  "27P  B&,  'YD  !T8P  :6$  %Q>  !26P  1U@
M #Q5   R4@( *E , "=/$@ F4!D )5 @ "10*  C4"\ (E$W "%10  @44D
M'E)3 !U27P <4FT &E-] !E3D  84Z0 %E.Y !53V0 64_0 %U+_ !A1_P 9
M4?\ HUD  )A@  "/90  A6@  'MI  !Q:0  9F<  %ED  !-80  0E\  #A<
M   N6@  )5@( "!7#@ >5Q0 '5<< !Q8(P ;6"L &E@S !E8/  86$4 %EE0
M !596P 466D $UIZ !):C0 16J$ $%JW  Y:U0 06?, $%G_ !%8_P 16/\
MGU\  )5F  ",:P  @FT  'AN  !N;P  8FT  %5J  !(:   /F8  #-E   I
M8P  (&$! !A@"P 58!  %& 7 !-@'@ 28"8 $F N !%A-P 084  #V%+  YA
M6  -868 #&)V  MBB0 *89T "6&R  AARP (8>L "6#]  I?_P +7_\ FV8
M ))M  "(<0  ?G,  '5U  !J=   7',  $]R  !#<   .&\  "UN   D;
M&VL  !-K!  .:@P #6H2  QJ&0 +:B$ "FHI  EJ,@ (:CP !VM'  5K4P $
M:V$  FMQ  !JA   :I@  &JM  !IQ@  :><  &GX  !H_P  :/\ EVT  (US
M  "$=P  >WH  '![  !C>P  5GH  $EZ   ]>0  ,7@  "=W   ==@  %78
M  ]V @ )=@H !'8/  !V%0  =AP  '8D  !U+   =38  '5!  !U3@  =5P
M '5L  !U?@  =),  '2H  !SP   <^,  '+W  !R_P  <?\ DG4  (EZ  "
M?@  =H   &F!  !;@@  3H(  $&"   U@P  *8(  !^!   6@0  $((   J"
M   "@P<  ((-  ""$0  @A<  ((>  "")@  @B\  (([  ""1P  @E4  (%E
M  "!>   @8T  ("B  !_N@  ?]T  '[T  !]_P  ??\ C7P  (2!  ![A
M;H8  &"(  !2B@  18L  #F,   LC   (8P  !>,   0C0  "8X   */
MD ,  (\)  "/#@  CQ(  ) 8  "0'P  D"@  ) R  "0/P  D$T  )!=  "/
M<   CX4  (Z<  ".LP  C=   (SP  "+_@  B_\ B(0  ("(  !RBP  9(T
M %:0  !(DP  .Y4  "Z6   BE@  %Y<   ^8   (F0   )L   "=    G0
M )T#  "="0  G0T  )X1  ">%P  GQ\  )\I  "@-0  H$,  *!4  "@9@
MGWL  )Z3  ">JP  G<8  )WI  "<^0  G/\ @XL  '6.  !GD@  698  $N9
M   ]G   ,)X  ".?   7H   #J(   >D    I@   *@   "J    J@   *H
M  "K 0  JP<  *P,  "M$   KA8  *\>  "Q*0  L3@  +%(  "Q6@  L6\
M +&(  "QH   L+H  *_=  "O\@  K_T >)$  &J6  !<F@  39\  #^C   Q
MI@  (Z<  !>I   .JP  !:X   "P    L@   +4   "W    MP   +@   "Y
M    N@   +P#  "]"0  O@X  , 4  ##'@  Q2L  ,4\  #&3@  QF(  ,9Z
M  #&E   QJT  ,;(  #%Y0  Q?, ;)D  %Z>  !/I   0:@  #*L   DKP
M%K$   VT   #MP   +H   "]    P    ,0   #&    Q@   ,@   #)
MRP   ,P   #.    T 8  -,-  #8$P  W!X  -XM  #?0   X%0  .%K  #A
MA0  X9\  .&W  #ASP  X>8 8*$  %*G  !#K0  -+(  "6U   7N0  #;P
M  &_    PP   ,<   #*    SP   -,   #6    UP   -H   #<    WP
M .$   #C    Y@   .D!  #L"P  \!(  /,?  #T,0  ]D8  /=<  #X=
M^(\  /FF  #YN   ^,D _P - /\ "P#_  L _P . /\ $P#_ !\ _P L /\
M.0#_ $4 _P!0 /\ 60#_ &( _P!J /\ <0#_ '< _P!^ /\ A #^ (H _0"0
M /P EP#Z )X ^0"G /< L0#V +X ]0#2 /, [ #Q /X \ #_ /  _P#F /\
MW #_ -( _P#- /\ _P ' /\ ! #_  ( _P & /\ $ #_ !L _P G /\ ,P#_
M #\ _P!* /X 5 #[ %T ^0!D /< :P#U '( \P!X /( ?@#P (0 [P"* .T
MD0#L )D Z@"A .@ JP#F +8 Y #' .( XP#@ /< W@#_ -T _P#9 /\ S #_
M ,4 _P#! /\ _P   /\   #_    _P ! /\ #0#_ !8 _  B /D +@#V #D
M\P!% .\ 3@#L %< Z0!> .8 90#D &P X@!R .  =P#? 'X W0"$ -L BP#8
M )( U0"; -( I #/ *\ S0"^ ,L U0#) .\ QP#_ ,4 _P#$ /\ O@#_ +@
M_P"U /\ _P   /\   #_    _@   /< "0#Q !$ ZP < .< * #D #, X0 ^
M -T 2 #8 %$ TP!8 -  7P#. &4 S !K ,H <0#( '< Q@!] ,0 A #" (P
MP "4 +X G@"[ *@ N0"V +< R "U .8 LP#Z +$ _P"P /\ L #_ *P _P"I
M /\ _P   /\   #Z    \0   .@  P#@  T V  6 -$ (@#- "T R@ W ,8
M00#" $H OP!2 +T 60"Z %\ N !E +< :@"U '  LP!V +$ ?0"O (4 K0"-
M *L EP"I *$ IP"N *4 O@"B -@ H #R )\ _P"> /\ G@#_ )X _P"< /\
M_P   /<   #K    X0   -8   #+  D Q0 1 +\ &P"[ "8 MP Q +0 .@"Q
M $, K@!+ *L 4@"I %@ IP!> *8 9 "D &D H@!P *  =@"> 'X G "& )H
MD "8 )L E@"G )0 M@"2 ,H D #I (\ _ ". /\ C0#_ (P _P"- /\ ^
M .D"  #; P  S $  ,0   "]  ( M@ - +  %0"K "  IP J *0 - "A #P
MG@!$ )P 2P": %( F !8 )8 70"5 &, DP!I )$ < "/ '< C0"  (L B@")
M )4 AP"A (4 KP"# ,$ @0#@ (  ]0!_ /\ ?P#_ '\ _P!_ /\ [@H  -P.
M  #*$   O@X  +4+  "O P  J0 ' *, $ "> !@ F0 C )8 + "3 #4 D  ^
M (X 10", $L B@!1 (@ 5P"& %T A0!C (, :@"! '$ ?P!Z 'T A ![ (\
M>0"< '< J@!U +L = #4 '( \ !R /\ <@#_ '$ _P!Q /\ XQ$  ,T7  "_
M&0  LQD  *H5  "C$   G0H  )<!"@"1 !( C0 ; (D )0"% "\ @P W (
M/@!^ $4 ?0!+ 'L 40!Y %< > != '8 9 !T 6L <@%T ' "?P!N HL ; .8
M &L#I@!I!+< : 7. &<'[ !F"/T 9@G_ &4)_P!E"?\ UAH  ,0@  "V(P
MJR,  *$@  "9&P  DA0  (P. 0"&!PT @ 04 'P&'@!Y!R@ =@@P '0(. !R
M"3\ < E% &\*3 !M"E( ; I8 &H+7P!H"V< 9PMP &4,>@!C#(< 8@R5 & -
MI !?#;8 7@W. %P.[0!<#_\ 6Q#_ %L0_P!;$/\ S2$  +PH  "O*P  I"L
M )HI  "2)   B1\  ((8  ![$04 =0T/ '$-%P!N#B$ :PXJ &D/,@!G$#D
M91!  &001@!C$$T 81!3 %\16@!>$6( 7!%K %L1=@!9$H, 6!*2 %83H@!5
M$[0 5!/+ %,4[ !2%?\ 4A;_ %(5_P!2%?\ QB@  +8N  "I,@  GS(  )4Q
M  ",+0  @R<  'HA  !R&@  :Q,+ &<3$P!D%!P 810E %\5+0!=%30 7!4[
M %L60@!9%D@ 6!9/ %875@!5%UX 4Q=G %(8<@!0&'\ 3QF. $X:GP!,&K
M2QO' $L;Z0!*'/T 2AS_ $H<_P!*'/\ P2T  +$T  "E-P  FC@  ) W  "'
M-   ?2\  '0I  !L(P  9!P' %X9$ !;&A@ 61LA %<;*0!5&S  5!PW %(<
M/0!1'$0 3QU+ $X=4@!-'5H 2QYC $H>;@!)'WP 1Q^+ $8@G !%(:X 1"'$
M $,BY@!#(OP 0R+_ $,B_P!#(O\ O#(  *TX  "A/   ESX  (T]  "#.@
M>34  &\P  !F*@  7B0" %<@#0!4(!0 42 = $\A)0!.(2P 3"$S $LB.@!)
M(D  2")' $<B3@!&(U< 1"-@ $,D:P!")'D 026( #\FF0 ^)JL /2?! #TG
MXP ]*/H /2C_ #TG_P ])_\ N#8  *H]  ">0   E$(  (I"  " /P  =CL
M &PV  !B,   62H  %$E"P!-)1$ 2R49 $DE(0!')B@ 128O $0F-@!#)CT
M0B=$ $$G2P _*%0 /BA= #TI:0 \*78 .RJ& #DKEP X*ZD -RR_ #<LX  W
M+/@ -RS_ #<L_P X+/\ M3H  *=   "<1   D48  (=&  !]1   <T   &@[
M  !?-@  53$  $PK!P!'*0\ 12H6 $,J'@!!*B4 /RHL #XK,P ]*SD /"M!
M #LL2  Z+%$ .2U; #@N9@ V+G, -2^# #0OE0 S,*< ,C"] #$QW@ Q,?<
M,C'_ #(P_P S,/\ L3X  *1$  "92   CTH  (5*  ![20  <$4  &5   !;
M.P  4C8  $@Q! !"+@T /RX3 #TN&P [+B( .2\I #@O+P W+S8 -C ^ #4P
M1@ T,4\ ,S%9 #(R9  Q,G$ ,#.! "\TDP N-*8 +#6[ "PUVP L-?4 +37_
M "TT_P N-/\ KD$  *)(  "73   C4X  (-.  !Y30  ;DH  &)%  !80
M3CP  $4W   ],PL .3,1 #<S&  V,Q\ -#,F #,S+0 R-#0 ,30\ # U1  O
M-4P +C96 "TV8@ L-V\ *S=_ "HXD0 H.*0 )SFY "8YV  G.?0 *#G_ "@X
M_P I./\ JT4  )]+  "43P  BU(  (%3  !W4@  ;$\  %])  !61@  3$(
M $(]   X. @ -#@/ #(X%0 Q.!T +S@D "XX*P M.3( +#DY "LZ00 J.DH
M*3M4 "@[7P G/&T )3Q] "0]CP C/:( (CVW "$^U  A/O, (CW_ ",]_P C
M//\ J$D  )U/  "24P  B58  ']7  !U5@  :E,  %U/  !33   2D@  $!$
M   V0 4 +ST- "T]$P K/1H *CXA "D^*  H/B\ )SXW "8_/P D/T@ (T!2
M ") 70 A06H ($%Z !Y!C0 =0J  '$*U !M"T0 ;0O$ '$+_ !U!_P >0?\
MI4T  )I3  "06   AEL  'U<  !R6P  9U@  %M4  !14@  2$X  #U*   S
M1P  *D,+ "9#$  E0Q8 )$,> "-$)0 B1"P (40T "!%/  >144 '45/ !Q&
M6@ ;1F@ &49X !A'B@ 71YX %D>S !1(S@ 51^\ %D?_ !=&_P 71O\ HE(
M )=8  "-70  A&   'IA  !P8   95X  %E:  !/6   1%0  #E1   O3@
M)DL& "!*#@ >2A, '4H: !Q*(0 ;2R@ &DLP !E+.  72T( %DQ, !5,5P 4
M3&4 $TUU !)-B  139P $$VQ  Y.S  /3>X $$W_ !%,_P 13/\ GE<  )1=
M  "+8@  @64  '=F  !M9@  8V0  %9A  !*7@  /UL  #58   K5@  (E0!
M !I2"@ 64A  %5(6 !12'0 34B0 $E(L !%2-  14CX $%-(  ]35  .4V(
M#51R  Q4A  +5)@ "52M  A4Q0 )5.< "E/[  M2_P +4O\ FUT  )%D  "(
M:   ?FL  '1L  !K;   7VH  %)G  !%9   .F(  #!@   F7@  '5T  !5;
M!0 06@P #EH1  Y:&  -6R  #%LG  M;,  *6SH "5M%  =;40 &6UX !%MM
M  -;@  !6Y0  %NH  !;P   6N(  %KV  %:_P "6?\ EV0  (YK  "$;@
M>W   ')R  !G<0  67   $QN  ! ;   -6L  "II   A9P  &&8  !%F 0 ,
M90H !V4/  1E%  #9!L  F0C  !D+   9#4  &1   !D3   9%H  &1I  !D
M>P  9(\  &.D  !CNP  8MT  &+T  !B_P  8?\ DVP  (EQ  " =0  >'<
M &UX  !@=P  4G8  $9U   Y=   +G0  "-R   :<0  $G$   UQ   &<0@
M ' -  !P$@  <!<  &\?  !O)@  ;S   &\[  !O1P  ;U0  &]D  !O=0
M;HH  &V@  !MM@  ;-8  &OR  !K_P  :_\ CG,  (5X  !]>P  <WT  &5^
M  !8?@  2WX  #Y^   R?@  )GT  !Q\   3?   #7P   9]    ?04  'P+
M  !\#P  ?!,  'P9  !\(0  ?"D  'PT  ![0   >TX  'M>  ![;P  >H0
M 'J:  !YL0  >,X  '?O  !V_@  =O\ B7H  (%_  !X@@  :X,  %V%  !/
MA@  0H<  #6(   IAP  '8<  !2'   -B   !HD   "*    B@   (D&  ")
M#   B0\  (D3  ")&@  BB(  (HL  "*.   BD8  (E6  "):   B7P  (B4
M  "'JP  AL8  (7J  "%^P  A/\ A8(  'V&  !OB   88L  %.-  !%CP
M.)$  "N1   ?D@  %)(   V3   $E    )8   "7    F    )<   "7!0
MEPL  )@.  "8$P  F1H  )DB  ":+@  FCT  )E-  "97@  F7,  )B+  "8
MHP  E[P  );B  "6]P  E?\ @(D  '*,  !DCP  5I,  $B6   ZF0  +)H
M !^;   4G   #)X   .?    H0   *,   "E    I0   *4   "E    I@(
M *<(  "G#0  J!$  *D9  "K(P  JS$  *M!  "L4P  K&<  *N   "JF@
MJK,  *K0  "I[P  J?L =8\  &>4  !9F   2IP  #R?   MH@  (*,  !.E
M   +IP   :D   "K    K@   +$   "R    L@   +,   "T    M0   +8
M  "X!   N0L  +L0  "]&   OR0  +\U  # 1P  P%L  ,!R  # C0  P:8
M ,#!  "_XP  OO, :I<  %N<  !-H0  /J4  "^I   AJP  $ZT   NP
MLP   +4   "X    O    +\   #!    P0   ,,   #$    Q@   ,<   #)
M    RP   ,X(  #1#P  U1@  -@G  #9.0  VDT  -MD  #;?@  W)D  -RP
M  #<R0  W., 79\  $^E  ! J@  ,J\  "*R   4M0  "K@   "[    OP
M ,,   #&    RP   ,X   #1    T0   -0   #6    V0   -L   #>
MX    .0   #G!@  ZPX  .\9  #P*@  \C\  /-5  #T;0  ](@  /2A  #T
MM@  ],< _P ) /\ !@#_  < _P , /\ $0#_ !P _P H /\ - #_ $$ _P!,
M /\ 50#_ %T _P!E /\ ; #_ '( _@!X /P ?@#[ (0 ^@"+ /D D@#W )D
M]@"B /0 K #S +D \0#+ /  Z #N /L [0#_ .P _P#A /\ T@#_ ,D _P#$
M /\ _P ! /\   #_    _P $ /\ #@#_ !< _P C /\ +P#_ #L _0!& /H
M4 #W %@ ] !? /( 9@#P &P [P!R .T > #L 'X Z@"% .D C #G ), Y0"<
M ., I@#A +$ WP#! -T W0#; /0 V0#_ -8 _P#/ /\ Q #_ +T _P"Y /\
M_P   /\   #_    _P   /\ "P#\ !, ]P > /0 *@#R #4 [@!  .D 2@#F
M %( XP!9 .  8 #> &8 W !L -H <@#7 '@ U !^ -( A0#0 (T S@"5 ,P
MGP#) *H QP"X ,4 S0## .L P #^ +\ _P"^ /\ M@#_ +  _P"M /\ _P
M /\   #_    ^0   /( !@#K  \ Y@ 9 .$ ) #> "\ V@ Y -, 0P#/ $P
MS !3 ,D 6@#' &  Q0!F ,, :P#! '$ OP!W +T ?@"[ (8 N0". +< F "U
M *, LP"P +$ P@"N .  K #W *L _P"J /\ J #_ *, _P"@ /\ _P   /\
M  #U    ZP   .$   #6  P SP 3 ,H '@#& "D P@ S +\ /0"[ $4 N !-
M +8 5 "S %H L0!? +  90"N &H K !P *L =P"I '\ IP"' *4 D0"C )P
MH "I )X N "< ,X F@#N )D _P"7 /\ E@#_ )8 _P"3 /\ _0   /$   #E
M    V0   ,T   #$  8 O0 / +< & "S "( L  L *T -@"I #X IP!& *0
M30"B %, H !9 )\ 7@"= &0 FP!J )H < "8 '< E@"  )0 B@"1 )4 CP"B
M (T L "+ ,, B0#C (@ ^0"& /\ A@#_ (8 _P"& /\ \P   .,   #1
MQ0   +T   "V    K@ + *@ $@"D !P H  F )P +P": #< EP _ )4 1@"2
M $P D0!2 (\ 6 "- %T BP!C (H :@"( '$ A@!Y (0 @P"" (\ ?P"; 'X
MJ0!\ +L >@#5 '@ \@!X /\ =P#_ '< _P!W /\ YP<  -$,  ###0  N P
M *X(  "H    H@ % )L #@"6 !4 D@ ? (X * "+ #$ B  Y (8 0 "$ $8
M@@!, (  4@!_ %< ?0!= 'L 8P!Z &L > !S '8 ?0!T (@ <0"5 '  I !N
M +0 ; #* &L Z@!J /P :@#_ &H _P!J /\ VA   ,84  "X%@  K14  *02
M  "<#@  E@<  )  "0"* !  A0 8 ($ (0!^ "H >P R 'D .0!W $  =0!&
M ', 3 !R %$ < !7 &X 7@!M &4 :P!N &D =P!G (, 90"1 &, GP!B *\
M8 #$ %\ Y !? ?@ 7@+_ %X"_P!> O\ SA@  +T=  "P(   I1\  )L<  "3
M%P  BQ$  (0,  !^! L >0 2 '4 &P!R ", ;P K &T!,P!K 3H :0)  &<#
M1@!F TP 9 12 &,$60!A!&  7P5I %X%<P!<!G\ 6@:- %D'G !7"*T 5@C!
M %4)X0!4"_8 5 O_ %0+_P!4"_\ QA\  +8E  "I*   GB@  )0E  "+(0
M@QL  'L4  !T#@, ;@D- &D(% !F"1T 9 HE &(*+0!@"S0 7@LZ %T+0 !;
M#$< 6@Q- %@,5 !7#5P 50UD %0-;P!2#7L 4 Z* $\.F@!.#JP 3 _" $P0
MXP!+$/D 2Q#_ $L1_P!+$/\ OR8  + K  "D+P  F2\  (\M  "&*0  ?20
M '0>  !L%P  91$' %\.$ !<#Q< 6A ? %@0)P!6$"X 5! U %,0.P!2$4(
M4!%( $\14 !.$5< 3!)@ $L2:P!)$G@ 2!.' $83EP!%%*D 1!2^ $,5WP!#
M%O@ 0Q;_ $,6_P!#%O\ NBL  *LQ  "@-   E34  (LT  "!,0  >"L  &\F
M  !F(   7AD! %<4#0!4%!, 410; $\5(P!.%2H 3!4Q $L6-P!)%CX 2!9$
M $<73 !%%U0 1!== $,89P!!&'0 0!F# #\:E  ]&J8 /!N[ #L;VP ['/8
M/!S_ #P<_P \'/\ M3   *@V  "<.0  D3L  (<Z  !^-P  <S(  &HM  !A
M)P  62$  %$;"0!,&1  2AH7 $@:'P!&&B8 11LM $,;,P!"&SH 01Q! $ <
M2  ^'%  /1U9 #P>9  ['G$ .1^  #@?D@ W(*0 -B"X #4AU@ U(?0 -2+_
M #4A_P V(?\ LC0  *0Z  "9/@  CS\  (4_  ![/   <#@  &<R  !=+0
M5"@  $PB!0!&'PX 0Q\4 $$?&P _'R( /B I #T@,  [(#8 .B$] #DA10 X
M(DT -R)7 #8C8@ T(VX ,R1^ #(DCP Q):( +R6V "\FT@ O)O( +R;_ # F
M_P P)O\ KS@  *(^  "60@  C$,  ()#  !X00  ;CT  &,X  !:,P  42X
M $@H 0! ) P /2,1 #LD&  Y)!\ ."0F #8D+  U)3, -"4Z #,F0@ R)DH
M,2=4 # G7P O*&P +BA[ "PIC0 K*J  *BJT "DJSP I*_  *BO_ "HJ_P K
M*O\ K#P  )]"  "41@  BD<  (!'  !V10  ;$(  &$]  !7.   3C,  $0N
M   \*0D -R@0 #4H%0 S*!P ,B@C # H*0 O*3  +RHW "XJ/P M*T@ +"M2
M "LL70 J+&H *"UY "<MBP F+IX )2ZS "0OS0 D+^X )2__ "4O_P F+O\
MJ3\  )U%  "220  B$L  'Y,  !T2@  :D<  %Y"  !4/0  2SD  $$T   X
M+P8 ,BT- # M$P N+1D +2T@ "LM)P J+BX *2XU "DO/0 H+T8 )S!/ "4P
M6P D,6@ (S%W "(RB0 A,IT 'S.Q !XSRP >,^T 'S/_ " S_P A,O\ ID,
M )I)  "030  AD\  'Q0  !S3P  :$P  %Q&  !20P  23\  #\[   V-@(
M+C(, "LR$0 I,A< *#(> "8R)  E,RL )#,R ",T.@ B-$, (35- " U6  ?
M-F4 'C9U !PWAP ;-YL &C>O !DXR  9..L &CC_ !LW_P ;-_\ HT<  )A-
M  ".40  A%,  'M4  !Q4P  9E   %I,  !020  1T4  #U!   S/0  *CD)
M "4W#@ C-Q0 (C@; "$X(@ @."@ 'S@P !XY.  =.4$ '#I+ !HZ5@ 9.V,
M&#MR !8[A0 5/)D %#RM !,]Q@ 3/>D %#S] !4\_P 6._\ H$L  )51  "+
M50  @E@  'E9  !N6   9%8  %A1  !.3P  14L  #I'   P0P  )T % " ^
M#0 =/A$ '#X7 !L^'@ :/B4 &3XM !@_-0 6/SX %3]( !1 4P 30&  $D%P
M !%!@@ 009< #T&L  Y"Q  .0N< #T'\ !!!_P 00/\ G5   )-6  ")6@
M@%T  '9>  !L70  8EL  %97  !,50  05$  #9.   L2P  (T@  !M%"0 7
M1 \ %404 !1%&P 312( $D4I !%%,0 113L $$9%  ]&4  .1UX #4=M  Q'
M?P +1Y, "4>G  A'O@ (1^  "4?V  I&_P +1O\ FE4  )!;  "'8   ?6(
M '-C  !J8@  8&$  %->  !'6@  /%<  #)5   H4@  'U   !=.!  13 P
M#TP1  Y,%P .3!X #4TE  Q-+@ +33< "DU"  E-30 '3EH !DYI  1.>P "
M3H\  4ZD  !-N@  3=L  4WR  %-_P "3/\ EEL  (UB  "$9@  >F@  '%I
M  !H:0  7&<  $]D  !"80  -U\  "U<   C6@  &E@  !)7 0 -5@D "54.
M  =5$P &51H !%4B  -5*@ "530  %4^  !52@  5E<  %9E  !5=P  58L
M %6@  !5M@  5-0  %3Q  !3_0  4_\ DV(  (IH  " ;   =VX  &]O  !C
M;@  5FP  $EJ   ]:   ,F8  "=E   =8P  %6(   YA   )8 @  V -  !?
M$0  7Q<  %\>  !?)@  7R\  %\Z  !?10  7U,  %]A  !><@  7H<  %V<
M  !=L@  7,\  %SO  !;_0  6_\ D&H  (9O  !]<@  =70  &IU  !==
M3W,  $)R   V<   *V\  "!N   7;0  $&P   IL   ":P8  &L+  !J#P
M:A0  &H:  !J(0  :2H  &DT  !I0   :4X  &E<  !I;0  :((  &B8  !G
MK@  9LH  &7M  !E_   9/\ BW$  ()V  !Z>0  <'L  &)[  !5>P  2'H
M #MZ   O>@  (WD  !EX   1=P  "G<   -W    =P(  '<(  !V#0  =A
M '85  !V&P  =B,  '8N  !U.@  =4<  '56  !U:   ='P  '22  !SJ@
M<L0  ''I  !P^P  </\ AGD  ']]  !V?P  :($  %J"  !,@@  /X,  #*$
M   E@P  &H,  !&#   *@P   H,   "$    A0   (0#  "#"   @PT  (,0
M  "#%0  A!P  (0F  "$,@  A#\  (-/  "#8   @G4  (*,  "!I   @+T
M '_C  !^^0  ?O\ @H   'J$  !LA@  7H@  %"*  !"BP  -8T  ">-   ;
MC0  $8X   J.    CP   )$   "2    D@   )(   "2 0  D@<  )(,  "2
M$   DQ4  ),=  "4*   E#8  )1%  "35P  DVL  )."  "2G   D;8  )#8
M  "/\P  C_\ ?H<  '"*  !AC0  4Y   $63   WE0  *98  !R7   1F
M"9D   ";    G    )X   "@    H    *    "@    H0   *$$  "B"0
MHPX  *04  "E'0  IBH  *8Z  "F3   I6   *5X  "ED@  I*P  *3)  "C
MZP  HOH <XX  &21  !6E0  1YD  #F<   JG@  ':   !&A   (HP   *4
M  "G    J0   *P   "N    K@   *X   "O    L    +$   "R    LP8
M +4-  "W$P  N1X  +DN  "Z0   NE0  +MJ  "ZA0  N:$  +F[  "ZW@
MN?( 9Y4  %B9  !*G@  .Z(  "RF   =J   $:H   >L    KP   +$   "T
M    N    +L   "\    O    +X   "_    P    ,(   #$    Q@   ,@#
M  #+"P  SQ(  -$@  #1,@  TD8  --=  #4=@  U)(  -6K  #5Q   U.(
M6YT  $RB   ]IP  +ZP  !^O   1L0  ![4   "X    NP   +X   #"
MQP   ,H   #,    S    ,X   #0    T@   -4   #8    VP   -\   #B
M    Y@L  .L3  #L)   [3@  .Y.  #O9P  \((  /"<  #PL@  \<4 _P #
M /\  0#_  0 _P ) /\ #P#_ !@ _P D /\ , #_ #P _P!' /\ 40#_ %D
M_P!@ /T 9P#\ &T ^@!S /D >0#X '\ ]@"% /4 C #S )0 \@"= /  IP#N
M +, [ #$ .L X0#J /@ Z0#_ .< _P#9 /\ RP#_ ,( _P"] /\ _P   /\
M  #_    _P   /\ # #_ !0 _P @ /\ *P#^ #< ^@!" /8 2P#R %, \ !;
M .X 80#L &< Z@!M .@ <P#G 'D Y0!_ ., A@#A (X WP"6 -T H #; *P
MV "[ -0 T0#3 /  T #_ ,X _P#( /\ O0#_ +8 _P"R /\ _P   /\   #_
M    _P   /T " #W !  \P : .\ )@#M #$ Z  [ ., 10#@ $T W !5 -D
M6P#6 &$ TP!G -$ ; #/ '( S0!X ,L ?P#) (< QP"0 ,4 F@## *4 P "R
M +X Q0"\ .4 N@#[ +@ _P"W /\ L #_ *D _P"E /\ _P   /\   #^
M]0   .P  P#E  T WP 5 -H ( #4 "H T  U ,L /@#( $< Q0!. ,( 50#
M %L O@!A +P 9@"Z &P N !R +8 > "U (  LP"( +$ D@"N )X K "J *D
MNP"H -4 I@#S *0 _P"C /\ H0#_ )L _P"8 /\ _P   /L   #P    Y0
M -@   #.  D QP 1 ,( &@"^ "0 NP N +< . "T $  L0!( *X 3@"L %0
MJ@!: *D 7P"G &4 I0!K *0 <0"B '@ H "! )X BP"< )8 F0"C )< L@"6
M ,< DP#H )( _@"1 /\ D #_ (T _P"+ /\ ^0   .L   #=    SP   ,8
M  "\  0 M0 - +  %0"L !X J  H *4 ,0"B #D GP!! )T 2 "; $X F0!3
M )< 60"6 %X E !D )( :@"0 '$ C@!Z (P @P"* (\ B "< (8 J@"$ +P
M@@#< ($ ]@"  /\ ?P#_ '\ _P!^ /\ [    -H   #)    O@   +8   "N
M    IP ) *$ $ "< !@ F  B )4 *@"2 #( D  Z (T 00"+ $< B0!- (<
M4@"& %@ A != (( 9 "! &L ?P!S 'T ?0![ (@ > "5 '8 HP!U +0 <P#,
M '$ [0!P /\ < #_ '  _P!P /\ WP4  ,H*  "\"P  L0D  *@$  "A
MFP # )0 # "/ !, B@ ; (< ) "$ "P @0 S '\ .@!] $$ >P!' 'D 3 !W
M %( =@!7 '0 70!R &0 < !M &\ =@!L (( :@"/ &D G0!G *X 90## &0
MY !C /H 8P#_ &( _P!C /\ T X  +\2  "R$P  IQ(  )T0  "5"P  CP,
M (D !P""  X ?@ 5 'H '@!V "4 =  M '$ - !O #H ;@!  &P 1@!J $P
M:0!2 &< 6 !F %\ 9 !G &( <0!@ 'P 7@") %P F !; *D 60"\ %@ W !8
M /0 6 #_ %< _P!7 /\ QA8  +8:  "J'0  GQP  )49  "-%   A0\  'X)
M  !W 0H <@ 0 &X %P!J !\ :  G &4 +@!D #0 8@ [ &  0 !? $8 70!,
M %P 4P!: %H 6 !B %< ; !5 '< 4P"% %( E !0 :4 3P&X $X"T@!-!/
M307_ $T%_P!-!?\ OQT  + B  "C)0  F24  (\B  "%'0  ?1@  '42  !N
M#0( 9P8, &,#$0!? AD 70,A %L$* !9!"\ 5P4U %8%.P!4!D$ 4P9' %$&
M3@!0!U4 3@=> $T(9P!+"', 20F! $@)D@!'"J, 10JV $0+T !$#.\ 0PW_
M $,-_P!$#?\ N20  *HI  ">+   E"P  (HJ  " )@  =R$  &X;  !F%
M7P\% %D+#0!5"A, 4PL; %$+(@!/#"D 30PO $P,-@!+#3P 20U" $@-20!&
M#5$ 10Y: $0.9 !"#G  0 Y_ #\/D  ^$*( /!"V #L0T0 [$?$ .Q'_ #L1
M_P \$?\ M"D  *8O  ":,@  D#(  (8Q  !\+0  <B@  &DC  !A'0  618
M %$1" !,#Q  2A 6 $@0'0!&$"0 11 K $,1,0!"$3< 01$^ $ 110 ^$DT
M/1)6 #P280 Z$VT .1-\ #<4C0 V%)\ -16S #05S0 S%NX -!;_ #06_P T
M%O\ KRX  *(T  "7-P  C#@  ((V  !X-   ;BX  &4J  !<)   5!X  $P8
M! !&% T 0A02 $ 4&0 _%"  /14G #P5+0 [%30 .18Z #@60@ W%DH -A=3
M #477@ S&&H ,AEY # 9B@ O&IT +AJQ "T;R@ M&^P +1S_ "X;_P N&_\
MK#(  )\X  "4.P  BCP  ( \  !V.0  :S0  &(O  !9*@  4"4  $<?  !
M&@H /!D0 #H9%@ X&1T -AHC #4:*0 T&C  ,QHW #(;/@ Q&T< +QQ0 "X=
M6P M'6< +!YV "H>B  I'YL *!^N "<@QP F(.H )R#^ "@@_P H(/\ J38
M )T\  "2/P  AT$  'U   !T/@  :3H  %\U  !6,   32L  $0E   [( <
M-AX. #,>$P R'AD ,!X@ "\>)@ N'RT +1\T "P@.P K($0 *B%. "DA6  G
M(F4 )B)T "4CA0 C(YD (B2M "$DQ0 A)>@ (B7] "(D_P C)/\ ICH  )H_
M  "/0P  A44  'M$  !R0P  9S\  %TZ  !3-@  2C$  $$L   X)@, ,2,,
M "XB$0 L(A8 *B(= "DB(P H(RH )R,Q "8D.0 E)4$ )"5+ ",F5@ B)F,
M(2=R !\G@P >*)< '2BK !LIPP ;*>8 '"G[ !TI_P >*/\ HSX  )A#  "-
M1P  @TD  'I)  !P1P  9D0  %H_  !1.P  1S<  #XR   U+0  +"@) "@G
M#P G)Q0 )2<: "0G(0 C*"< (B@N "$I-@ @*3\ 'RI) !XJ5  =*V  &RMO
M !HL@0 9+)4 %RVI !8MP0 6+>0 %RWZ !@M_P 9+?\ H4$  )5'  "+2P
M@DT  'A-  !N3   9$D  %A$  !/0   1CT  #TX   S-   *B\& "0L#0 A
M+!( ("P8 !\M'@ >+24 '2TL !PN-  ;+CP &B]& !@O40 7,%X %C!M !4Q
M?P 3,9, $C&H !$ROP 1,N( $C+Y !,Q_P 3,?\ GD4  )-+  ")3P  @%$
M '92  !M4   8DX  %9)  !-1@  1$,  #L_   Q.@  )S8# !\R"P <,A
M&S(5 !DR&P 8,B( %S,I !8S,0 5-#H %#1$ !,T3P 2-5P $35K ! V?0 /
M-I$ #C:F  TWO  --]T #3;V  XV_P /-O\ FTD  )%/  "'4P  ?E8  '56
M  !J50  8%,  %5/  !,3   0DD  #A%   N00  )#T  !PZ"  6. X %3@2
M !0X&  3.1\ $CDF !$Y+@ 0.3< #SI!  XZ3  -.UD #3MH  L[>@ *.XT
M"3RB  <\N  '/-4 "#SP  D[_P *._\ F$X  (Y4  "%6   ?%L  ');  !H
M6@  7E@  %-5  !)4@  /DX  #1+   J1P  (40  !A" P 20 L $#\0  X_
M%0 ./QP #4 C  Q *P +0#0 "D ^  E!2@ '058 !D%E  1!=@ #08H  4&?
M  !!M   0=   4'N  %!_  "0/\ E50  (Q9  "#7@  >6   '!@  !F8
M75X  %%;  !%5P  .E0  "]1   E3P  '$P  !1*   .2 @ "T<.  A'$@ '
M1QD !D<@  5(*  #2#$  D@[  !(1P  2%,  $AB  !(<P  2(8  $B;  !(
ML0  1\P  $?M  !'^P  1_\ DEH  (E@  " 8P  =V4  &YF  !E9@  660
M $Q@  ! 70  -5L  "I9   @5P  %U4  !!3   +4@< !5$-  %0$0  4!8
M % =  !0)0  4"X  % X  !00P  4%   %!>  !0;P  4(,  $^8  !/K@
M3LD  $[K  !-^P  3?\ CV$  (9F  !]:0  =&P  &QM  !A:P  4VD  $9G
M   Z9   +V,  "1A   :7P  $EX   Q<   &7 8  %L+  !:#P  6A,  %H9
M  !9(0  62D  %DS  !9/P  64P  %E:  !9:P  6'X  %B4  !7JP  5\4
M %;I  !5^P  5?\ C&@  ()M  !Z<   <G(  &=R  !:<0  3'   #]N   S
M;0  *&L  !UJ   4:   #6<   =G    9@,  &8)  !E#0  91$  &05  !D
M'   9"0  &0N  !D.@  8T<  &-5  !C9@  8WH  &*0  !AIP  8,$  %_F
M  !?^@  7O\ AV\  ']T  !X=P  ;G@  &!X  !2=P  17<  #AV   K=@
M('0  !9S   .<P  !W(   !R    <@   '$%  !Q"@  <0X  ' 1  !P%P
M<!X  ' G  !P,P  ;T   &]0  !O8   ;G0  &Z+  !MH@  ;+P  &OB  !J
M^   :?\ @W<  'Q[  !S?0  97X  %=_  !)?P  /'\  "^    B?P  %WX
M  ]^   '?@   '\   !_    ?P   'X   !^!0  ?@H  'X-  !^$0  ?A<
M 'X@  !^*P  ?3D  'U(  !]60  ?&T  'R$  ![G   >K8  'G:  !X]0
M=_\ @'\  '>"  !I@P  6X4  $V&   _B   ,HD  "2)   8B0  #XD   >*
M    BP   (P   "-    C0   (P   ",    C ,  (P(  "-#0  C1$  (T7
M  ".(@  CB\  (X_  "-4   C60  (Q[  ",E0  BZX  (K-  ")[P  B?\
M>X4  &V(  !>B@  4(T  $*/   TD0  )I(  !F3   .E   !I4   "6
MF    )H   ";    FP   )L   ";    FP   )P   "=!0  G0L  )X0  "?
M%P  H"0  * T  "@1@  H%D  )]P  "?B@  GJ4  )["  "=Z   G/D <(P
M &&/  !3D@  1)8  #:9   GFP  &9P   ^=   %GP   *$   "C    I0
M *@   "I    J0   *D   "J    JP   *P   "M    K@$  + )  "R#P
MLQ@  +0G  "T.0  M4T  +1D  "T?@  LYH  +.T  "SU0  L_  9),  %67
M  !'FP  .)\  "FB   :I   #J8   2H    JP   *T   "P    M    +8
M  "X    N    +D   "Z    O    +T   "_    P    ,,   #%!P  R0\
M ,H:  #++   S$   ,U6  #.;P  S8L  ,RH  #,P@  S.( 6)L  $F@   Z
MI0  +*D  !RK   /K@  !+$   "T    MP   +H   "^    PP   ,8   #(
M    R    ,H   #+    S0   ,\   #2    U0   -D   #=    X04  .8/
M  #G'@  Z#(  .E(  #J8   ZWL  .N7  #LK@  [,( _P   /\   #_
M_P & /\ #0#_ !4 _P A /\ + #_ #@ _P!# /\ 3 #^ %0 ^P!; /H 8@#X
M &@ ]@!N /4 = #T 'H \@"  /$ AP#O (\ [0"7 .L H0#I *T YP"] .4
MV #D /, X@#_ .  _P#0 /\ Q #_ +P _P"V /\ _P   /\   #_    _P
M /\ "0#_ !$ _P < /T )P#Y #( ]0 ] /$ 1@#M $\ ZP!6 .@ 7 #F &(
MY !H ., ;@#A ', WP!Y -T @ #: (@ V "1 -0 FP#2 *8 SP"T ,P R0#)
M .D R #_ ,< _P#! /\ MP#_ *\ _P"K /\ _P   /\   #_    _P   /@
M!0#R  X [@ 7 .H (@#F "P X0 W -T 0 #8 $D TP!0 -  5@#. %P S !B
M ,H 9P#( &T Q@!S ,0 >0#" ($ P "* +X E "\ )\ N0"L +8 O@"T -T
MLP#W +$ _P"P /\ J #_ *( _P"> /\ _P   /\   #Y    [P   .8   #?
M  L U@ 2 -  ' #, "8 R  P ,0 .@#  $( O0!* +L 4 "X %8 M@!; +4
M80"S &8 L0!L +  <@"N 'H K "" *D C "G )@ I0"E *, M "@ ,L GP#N
M )T _P"< /\ F0#_ )0 _P"1 /\ _P   /8   #J    W0   ,\   #'  8
MP  / +L %P"W "  LP J +  ,P"M #L J@!# *< 20"E $\ HP!5 *( 6@"@
M %\ G@!E )T :P"; '( F0![ )< A0"4 )  D@"= )  K ". +\ C #B (L
M^@") /\ B0#_ (8 _P"# /\ ]    .0   #4    R    +\   "U  $ K@ +
M *D $@"E !L H0 C )X + "; #0 F  \ )8 0P"4 $D D@!. )  4P". %D
MC0!> (L 9 ") &L AP!S (4 ?0"# (@ @0"5 '\ I !] +4 >P#/ 'D \0!X
M /\ =P#_ '< _P!U /\ Y0   -$   ##    N    *\   "H    H  & )H
M#@"5 !4 D0 > (X )@"+ "T B  U (8 / "$ $( @@!' (  30!_ %( ?0!8
M 'L 7@!Y &4 > !M '8 =@!S ($ <0". &\ G0!M *X ; #$ &H YP!I /T
M: #_ &@ _P!I /\ U0,  ,,'  "V"   JP8  *(   ";    E    (T "@"(
M !  @P 8 '\ ( !\ "< >@ N '< -0!U #L = !! '( 1P!P $P ;P!2 &T
M6 !K %\ :0!F &< < !E 'L 8P"( &( EP!@ *< 7@"[ %T W !< /8 7 #_
M %L _P!; /\ R0T  +D0  "L$0  H1   )<-  "/"   B    (( !0![  T
M=P 2 ', &@!O "$ ;  H &H +P!H #4 9P [ &4 00!C $8 8@!, &  4@!?
M %D 70!A %L :@!9 '4 5P"" %4 D0!4 *( 4P"U %$ SP!0 .\ 4 #_ %
M_P!0 /\ OQ0  + 8  "D&@  F1D  (\6  "'$0  ?PT  '<&  !Q  @ :P .
M &< % !D !L 80 B %X *0!= "\ 6P U %D .P!8 $$ 5@!& %4 30!3 %0
M4@!< %  90!. '  3 !] $L C0!) )X 2 "P $< QP!& .D 1@#[ $8 _P!%
M /\ N!L  *H@  ">(@  DR(  (D?  " &@  =Q4  &\0  !H"P  800* %T
M$ !9 !8 5@ = %0 (P!2 "H 4  P $\ -0!. #L 3 !! $L 2 !) $\ 1P%7
M $8!80!$ FP 0P)Y $$#B0!  YH /@2M #T$Q  \!>4 / ?X #P'_P \!_\
MLB(  *4G  "9*0  CBD  (0G  ![(P  <1X  &D8  !A$@  6@T# %,(# !/
M!1$ 3 47 $H&'@!(!B0 1P8J $4', !$!S8 0P@] $$(0P! "$L /@E3 #T)
M70 ["F@ .@IV #@+AP W"YD -0NL #0,P@ S#.0 ,PWY #,-_P T#?\ K2<
M * L  "5+P  BR\  ( N  !W*@  ;24  &0@  !<&@  5!0  $P/!@!&# T
M0PP2 $$,&  _#!\ /@PE #P-*P [#3( .@TX #@-/P W#D< -@Y0 #0.6@ S
M#F8 ,0]T # /A0 N$)@ +1"K "P0PP K$>4 +!'Z "P1_P M$?\ JBP  )TQ
M  "2-   AS4  'TT  !T,0  :BL  & G  !8(0  3QL  $<6  ! $0D .Q /
M #D0%  W$!L -A A #00)P S$2T ,A$T #$1.P P$4, +A)- "T25P L$F,
M*A-Q "D3@@ G%)4 )A2I "45P  D%>, )1;Z "86_P F%?\ IC$  )HV  "/
M.0  A3H  'LY  !Q-@  9S$  %TM  !4*   3"(  $,=   [%P4 -10- #(3
M$0 Q%!< +Q0= "X4)  L%"H *Q4Q "H5.  I%D  *!9* "<75  F%V  )!AO
M ",8@  A&9, (!FG !\9O@ >&N  'QKX " :_P @&O\ HS0  )@Z  "-/0
M@SX  'D]  !O.P  93<  %LR  !2+0  22@  $ C   X'@$ ,!D* "P8#P J
M&!0 *1@: "<8(  F&2< )1DM "0:-0 C&CX (AM' "$;4@ @'%X 'QUL !T=
M?@ <'9$ &AZE !D>O  8']T &1_V !H?_P ;'O\ H3@  )4]  "+00  @4(
M '="  !M0   8SP  %DW  !/,P  1BX  #TI   U)   +2 ' "<=#0 E'1(
M(QT7 "$='0 A'20 (!XK !\>,@ >'SL '1]% !P@3P :(5P &2%J !@B>P 6
M(H\ %2*C !0CN@ 3(]H %"/U !4C_P 6(_\ GCP  )-!  ")1   ?T8  '5&
M  !L1   8D$  %<\  !-.   1#0  #PP   S*P  *B8# ",B"P @(1  'B$5
M !PB&P ;(B$ &B(H !HC,  9(S@ &"1" !8E30 5)5D %"9H !,F>0 2)HT
M$2>B ! GN  .)]8 $"CT !$G_P 1)_\ G$   )%%  "'2   ?4H  '1*  !J
M20  8$8  %5!  !,/@  0SH  #HV   Q,@  *"T  " I"0 ;)PX &2<2 !@G
M&  6)Q\ %2@E !0H+0 3*#8 $BE  !(I2P 1*E< $"IF  XK=P .*XL #2R?
M  PLM0 ++,\ #"SO  TL_P -*_\ F40  (])  "%3   ?$X  '-/  !I3@
M7DL  %-'  !*1   0D   #D]   O.   )30  !TP!0 6+0P %"P0 !,M%0 2
M+1P $2TC ! M*@ /+C, #BX]  TO2  -+U4 ##!C  HP=  ),(@ "#&<  8Q
ML0 &,<L !C'K  <P_  (,/\ ET@  (U-  "#40  >E,  '%4  !G4@  75
M %),  !)2@  0$8  #5"   K/@  (CH  !HW 0 2- D #S,.  XS$P -,QD
M#3,@  PT*  +-#$ "C4[  @U1@ '-5( !39@  0V<0 "-H0  #:9   VKP
M-L@  #;H   V^0 !-?\ E$T  (I2  "!5@  >%@  &]9  !E6   6U4  %%2
M  !'3P  /$P  #%(   G1   'D$  !8_   0/ < "SH-  DZ$0 (.Q< !CL>
M  4[)@ $.RX  CLX  $\0P  /$\  #Q>   \;@  /($  #R7   \K   .\4
M #OG   [^   ._\ D5(  (A8  !_7   =ET  &U>  !C70  6EP  $Y8  !"
M5   -U$  "U.   C2P  &DD  !)&   -1 8 !T,,  -#$   0Q4  $,;  !#
M(P  0RL  $,U  !#0   0TT  $-;  !#:P  0WX  $.4  !"J@  0L,  $'F
M  !!^0  0?\ CE@  (9>  !]80  <V,  &MD  !B8P  5V$  $E=   ]6@
M,E@  "=5   >4P  %5$   Y/   )304  DT+  !,#@  3!,  $L8  !+'P
M2R@  $LR  !+/0  2TD  $M7  !+9P  2GL  $J0  !)IP  2<   $CD  !(
M^   1_\ BU\  (-D  !Z9P  <6D  &EJ  !>:0  4&8  $-D   W80  +%\
M "%=   86P  $%D   I8   #5P,  %<)  !6#0  51   %45  !4&P  5",
M %0M  !4.0  5$4  %13  !49   4W<  %.-  !2I   4;T  %#B  !0^
M3_\ B&<  ']K  !W;@  ;W   &5P  !7;@  2FP  #UK   P:0  )6@  !IF
M   19   "V,   1B    8@$  &$&  !@"P  8 X  %\2  !?%P  7QX  %XH
M  !>,P  7D   %Y/  !>7P  77(  %V(  !<H   6[D  %K?  !9]P  6/\
MA&X  'QR  !U=0  :W8  %UU  !/=   0G,  #5S   H<@  '7   !-O   ,
M;@  !&X   !N    ;@   &P"  !L!P  :PL  &L.  !K$@  :AD  &HB  !J
M+0  :CH  &E)  !I6@  :6P  &B#  !GFP  9K4  &78  !D]0  9/\ @'4
M 'IY  !P>P  8GL  %1\  !&?   .7P  "Q\   ?>P  %'H   UZ   $>@
M 'H   !Z    >@   'D   !Y 0  > 8  '@+  !X#@  >!,  '@:  !X)0
M>#(  '=!  !W4@  =V4  '9\  !UE0  =*\  '/.  !R\0  <?\ ?GT  '6
M  !G@0  6((  $J#   \A   +H4  "&%   5A0  #84   .%    A@   (<
M  "(    B    (<   "'    AP   (<$  "'"0  APX  (@3  "('   B"D
M (@X  "'2@  AUT  (9S  "&C0  A:<  (3%  "#[   @OX >(0  &J&  !<
MB   38H  #^,   QC@  (X\  !:/   -D    I$   "2    DP   )4   "6
M    E@   )8   "6    E@   )<   "7    EP<  )@-  "9$P  FA\  )HM
M  ":/P  FE(  )IH  "9@P  F9\  )BZ  "7X@  EO@ ;8H  %^-  !0D
M09,  #.6   DEP  %I@   V9   !FP   )T   "?    H0   *0   "E
MI    *4   "E    I@   *<   "H    J0   *H$  "L#   KA,  *XA  "N
M,P  KD<  *Y=  "N=@  KI,  *ZN  "MS0  K.\ 89$  %.5  !$F   -9P
M ":?   7H0  #:,   "E    IP   *H   "L    L    +(   "T    LP
M +0   "U    MP   +@   "Y    NP   +T   "_ 0  PPL  ,45  #%)0
MQCD  ,=/  #':   QH4  ,:B  #&O   QMX 59D  $>=   XH@  *:8  !FH
M   -JP   *T   "Q    M    +<   "Z    OP   ,$   #$    PP   ,4
M  #&    R    ,H   #-    SP   -(   #6    VP   . ,  #A&   XRL
M .1!  #E6@  YG0  .:1  #EK   Y<0 _P   /\   #_    _P ! /\ "@#_
M !( _P = /\ * #_ #0 _P ^ /T 2 #Z %  ]P!7 /4 70#T &, \@!I /
M;P#O '0 [0![ .L @0#I (D Z "2 .8 G #D *@ X@"W -\ S0#< .X V0#_
M -D _P#* /\ O@#_ +4 _P"P /\ _P   /\   #_    _P   /\ !@#_  \
M_  8 /@ (P#T "X \  X .L 0@#H $H Y0!1 .( 6 #@ %T W@!C -P : #9
M &X U@!T -0 >P#1 (( SP"+ ,T E0#* *$ R "O ,4 P0#" ., P #[ ,
M_P"[ /\ L #_ *@ _P"D /\ _P   /\   #_    ^P   /,  0#M  P Z  3
M ., '@#@ "@ V@ R -, / #/ $0 S !+ ,D 40#& %< Q != ,( 8@#! &<
MOP!M +T = "[ 'L N0"$ +< C@"T )D L@"G *\ MP"M -  JP#R *H _P"I
M /\ H0#_ )L _P"7 /\ _P   /\   #T    Z0   .    #5  @ S@ 0 ,D
M& #% "( P0 K +P -0"Y #T M@!% +, 2P"Q %$ KP!6 *X 6P"L &$ J@!F
M *D ;0"F '0 I !\ *( A@"@ )( G@"? )P K@"9 ,, EP#G )8 _P"5 /\
MD@#_ (T _P"* /\ _    /    #C    U    ,@   "_  , N0 - +, $P"O
M !P K  E *D +@"E #8 HP ^ *  1 "> $H G0!0 )L 50"9 %H EP!? )8
M9@"4 &P D@!U )  ?@". (H BP"7 (D I@"' +@ A0#6 (0 ]@"" /\ @0#_
M 'X _P!\ /\ [0   -T   #,    P0   +@   "N    IP ) *( $ "> !<
MF@ ? )< )P"4 "\ D0 W (\ /0"- $, BP!) (D 3@"( %, A@!9 (0 7P""
M &4 @ !M 'X =P!\ (( >@"/ '@ G@!U *\ <P#' '( [ !Q /\ < #_ '
M_P!N /\ W0   ,D   "\    L0   *D   "A    F0 # ), # ". !( B@ 9
M (< (0"$ "D @0 P '\ -P!] #T >P!" 'D 2 !X $T =@!2 '0 6 !R %\
M<0!G &\ < !L 'L :@"( &@ EP!F *@ 90"\ &, X0!B /H 80#_ &$ _P!A
M /\ S0$  +P%  "O!0  I0(  )P   "4    C0   (8 " "!  X ?  4 '@
M&P!U ", <@ I '  , !N #8 ;0 \ &L 00!I $< : !, &8 4@!D %D 8P!@
M &$ :0!? '0 70"! %L D !9 *$ 5P"T %8 T !5 /( 50#_ %0 _P!5 /\
MP0P  +(.  "F#P  FPX  )(+  ")!0  @@   'L  @!U  L <  0 &P %@!H
M !T 9@ C &, *@!A #  8  V %X .P!= $$ 6P!& %H 3 !8 %, 5@!; %0
M9 !2 &X 40![ $\ B@!- )L 3 "N $L Q@!* .H 20#^ $D _P!) /\ N1(
M *H6  ">%P  E!8  (H3  "!$   >0L  '$#  !K  8 90 - &$ $0!= !@
M6@ > %@ ) !6 "H 5  P %, -@!1 #L 4 !! $X 1P!- $X 2P!6 $D 7P!'
M &D 1@!V $0 A0!# )< 00"I $  OP _ .( /P#X #X _P _ /\ LAD  *0>
M  "8'P  CA\  (0<  !Z&   <A(  &H.  !B"   7 $( %< #@!3 !, 4  9
M $X 'P!, "4 2@ K $@ , !' #8 1@ \ $0 0@!# $D 00!1 #\ 6@ ^ &4
M/ !R #H @0 Y ), . "E #8 N@ V -L -0#T #4 _P U /\ K"   )\D  "4
M)@  B28  '\D  !U(   ;!L  &05  !<$   5 P! $X&"@!* @\ 1P 4 $0
M&@!" "  0  E #\ *P ^ 3$ / $W #L"/@ Y D4 . -- #8#5@ U!&$ ,P1N
M #$%?@ P!9  +P6C "T&N  L!M0 + ?P "P(_P L"/\ J"4  )LJ  "0+
MABT  'LK  !R)P  :"(  %\=  !7%P  3Q(  $@.! !!"@L /@<0 #L&%0 Y
M!QL . <A #8()@ U""P ,P@R #().0 Q"4$ +PE) "X*4P L"EX *PML "D+
M?  H#(\ )@RB "4,MP D#-, (PWP "0-_P E#?\ I"H  )@O  "-,@  @S(
M 'DQ  !O+@  92D  %PD  !3'P  2QD  $,3   \$ 8 -0T, #,,$0 Q#!8
M+PP< "X-(@ M#2@ *PTN "H--0 I#3T )PY& "8.4  D#EP (P]J "(/>P @
M$(X 'Q"B !T0MP <$-0 '1'R !T1_P >$?\ H2\  )4S  "*-@  @#<  '8V
M  !M,P  8R\  %DJ  !0)0  2"   #\:   X%0  ,!$( "P0#@ J$!( *! 8
M "<0'@ E$"0 )! J ",1,@ B$3H (1%# " 23@ >$EH '1-H !L3>  :$XL
M&!2@ !<4M0 6%-$ %A7Q !<5_P 8%/\ GC,  ),W  "(.@  ?CL  '0[  !K
M.   830  %<O  !.*P  128  #TA   T'   +1<% "83#  C$Q  (A,5 " 3
M&@ ?$R$ 'A0G !T4+P <%3< &Q5! !H62P 9%E< %Q=E !87=@ 4&(D $QB>
M !(8LP 1&<X $1GO !(9_P 3&?\ G#8  )$[  "&/@  ?#\  ',_  !I/0
M7SD  %4U  !,,   0RP  #HG   R(@  *AX! "(9"0 >%PX '!<2 !H7%P 9
M&!X &1@D !@9+  7&30 %AH^ !4:20 3&U4 $AMC !$<=  0'(< #QV<  X=
ML0 -'<L #1WL  X=_P /'?\ F3H  (\_  "$0@  >T0  '%#  !H0@  7CX
M %,Z  !*-@  03(  #DM   Q*0  *"4  " @!@ :'0P %QP0 !4<%0 4'1L
M%!TB !,=*0 2'C( $1\\ ! ?1@ 0(%, #B!A  TA<0 ,(84 "R*9  HBK@ )
M(L< "2+G  HB^P +(?\ ESX  (Q#  "#1@  >4@  '!(  !G1@  7$0  %(_
M  !).P  0#@  #@T   O,   )RP  !XG P 6(PH $B$. !$A$P 0(AD $"(@
M  \B)P .(R\ #20Y  PD1  +)5  "B5>  DF;P ')H( !B:6  0FK  #)L0
M!";E  0F]P &)O\ E4(  (I'  "!2@  >$P  &],  !E2P  6T@  %!$  !'
M00  /SX  #<[   M-@  )#$  !LM   3*@< #R@-  TG$0 -*!8 #"@=  LH
M)0 **2T "2DW  <J0@ &*DX !"M<  ,K;  !*W\  "N4   KJ0  *\$  "OC
M   K]@  *O\ DD8  (A+  !_3P  =E$  &U1  !C4   6DT  $]*  !'1P
M/D0  #-    I/   (#@  !<T   1,04 #"\,  DN$  '+A4 !B\;  4O(P #
M+RL  C U   P/P  ,$P  #%9   Q:0  ,7P  #&1   QIP  ,+\  ##A   P
M]0  +_\ D$L  (90  !]5   =58  &M6  !B50  6%,  $Y0  !%30  .DD
M "]%   E0@  '#X  !0[   ..04 "3<+  0V#P !-A,  #89   V(   -BD
M #8R   W/0  -TD  #=7   W9P  -WD  #>/   VI0  -KT  #;@   U]0
M-?\ C5   (16  !\6@  <EL  &E;  !@6P  5UD  $Q6  ! 4@  -4X  "I+
M   @2   %T8  !!#   +000 !$ *   _#@  /A$  #X6   ^'0  /B8  #XO
M   ^.@  /D8  #Y4   ^9   /G8  #V,   ]HP  /+L  #S>   []0  ._\
MBE<  ()<  !Y7P  <&$  &AA  !?80  5%X  $=;   Z5P  +U4  "52   ;
M4   $DT   Q+   &2@,  $D)  !(#0  1Q   $<4  !&&@  1B(  $8L  !&
M-P  1D,  $91  !&8   17,  $6)  !$H   1+@  $/<  !"]0  0O\ B%T
M ']B  !W90  ;F<  &=H  !;9@  3F,  $%A   T7@  *5P  !]:   55P
M#E8   =4    4P$  %(&  !1"P  40X  % 1  !/%@  3QX  $\G  !/,@
M3S\  $]-  !.70  3F\  $Z%  !-G0  3+4  $O8  !*]0  2O\ A64  'QI
M  !T;   ;6X  &)M  !4:P  1VD  #IG   M90  (F0  !AB   08   "5\
M  !>    7@   %T#  !<"   6PP  %H/  !:$P  61D  %DB  !9+0  63H
M %E(  !86   6&L  %>!  !7F0  5K(  %72  !4]   4_\ @6P  'EP  !S
M<P  :',  %IR  !,<0  /W   #)O   E;@  &FP  !%K   ):@   &H   !I
M    :0   &@   !G P  9@@  &8,  !F#P  910  &4<  !E)P  9#0  &1#
M  !D4P  9&4  &-[  !BE   8:T  &#-  !?\0  7O\ ?70  '=W  !N>0
M7WD  %%Y  !#>0  -G@  "EX   <=P  $78   IU    =0   '4   !V
M=0   '0   !T    <P(  ','  !S#   <A   '(5  !R(   <BP  '([  !Q
M3   <5\  '%T  !PC@  ;Z@  &[&  !L[0  :_\ >WL  ')^  !D?@  57\
M $>    Y@0  *X(  !Z!   2@0  "H$   "!    @@   (,   "#    @P
M ((   ""    @@   ((   ""!0  @@H  ((/  ""%P  @B,  ((R  ""0P
M@58  (%L  " A@  ?Z$  'Z]  !]Y@  ?/P =H(  &B#  !9A0  2X<  #R)
M   NB@  ((L  !.+   *BP   (P   "-    CP   )$   "2    D0   )$
M  "1    D0   )$   "2    D@(  ),)  "4#P  E!D  )0G  "4.   E$P
M )-B  "3?   DY@  )*S  "1V   D/8 :H@  %R*  !-C0  /Y   #"2   A
ME   %)4   J6    EP   )D   ";    G0   )\   "@    H    *    "@
M    H0   *(   "C    I    *4   "F!P  J!   *@<  "H+0  J4   *E6
M  "I;P  J8L  *BH  "GQP  INP 7X\  %"2  !!E@  ,YD  ".<   4G0
M"I\   "A    HP   *8   "H    K    *X   "O    KP   +    "P
ML@   +,   "T    M@   +<   "Z    O0<  +\0  "_'P  P#,  ,!)  #
M8@  P'X  ,";  # MP  O]@ 4Y<  $2;   UGP  )J,  !:E   +IP   *H
M  "M    L    +,   "V    NP   +T   #     OP   ,$   #"    Q
M ,8   #(    R@   ,P   #/    TP   -H'  #;$P  W24  -X[  #?4P
MX&X  -^,  #=J0  W<( _P   /\   #_    _P   /\ !P#_ !  _P 9 /\
M) #_ "\ _  Z /D 0P#U $L \P!2 /$ 60#O %X [0!D .L :0#I &\ YP!U
M .8 ? #D (0 X@"- .  EP#= *( V@"Q -4 Q0#2 .@ T #_ ,\ _P#$ /\
MN #_ *\ _P"I /\ _P   /\   #_    _P   /\  @#[  T ]P 5 /, 'P#O
M "D Z@ T .8 /0#B $4 W@!, -L 4P#8 %@ U !> -( 8P#0 &D S@!N ,P
M=0#* 'T R "% ,8 D #" )L P "I +X N@"[ -D N0#W +@ _P"T /\ J0#_
M *( _P"= /\ _P   /\   #_    ]@   .X   #G  H X0 1 -P &@#7 ",
MT  N ,L -P#' #\ Q !& ,$ 30"_ %( O0!8 +L 70"Y &( N !H +8 ;@"T
M '4 L0!^ *\ B "M ), J@"A *@ L0"F ,@ I #M *( _P"B /\ FP#_ )4
M_P"1 /\ _P   /P   #N    XP   -@   #-  4 Q@ . ,$ %0"] !X N0 G
M +4 , "R #@ KP!  *P 1@"J $P J !1 *< 5@"E %L HP!A *$ 9P"? &X
MG@!V )L @ "9 (P EP"9 )0 J "2 +P D #? (X ^P". /\ BP#_ (8 _P"#
M /\ ^    .D   #<    S    ,$   "X    L@ * *P $0"H !@ I0 A *(
M*0"> #( G  Y )D /P"7 $4 E0!* )0 4 "2 %4 D !: (\ 8 "- &< BP!O
M (D > "& (0 A "1 (( H "  +( ?0#, 'P \0![ /\ >@#_ '< _P!U /\
MY@   -,   #&    NP   +$   "G    H0 % )L #0"7 !, DP ; )  (P",
M "L B@ R (@ . "& #X A !$ (( 20"! $X ?P!3 'T 60![ &  >0!H '<
M<0!U 'P <P") '  F !O *D ;0"_ &L Y@!J /\ :0#_ &D _P!G /\ TP
M ,,   "U    JP   *,   ";    D@   (P "@"' !  @P 6 '\ '0!] "0
M>@ K '@ ,@!V #@ =  ] '( 0@!Q $@ ;P!- &T 4P!L %D :@!A &@ :@!F
M '0 9 "! &$ D0!? *( 7@"V %P U0!; /< 6P#_ %H _P!: /\ Q0   +8"
M  "I @  GP   )8   ".    AP   (  !0!Z  P =0 1 '$ & !N !X :P E
M &D *P!G #$ 9@ W &0 / !C $$ 80!' %\ 30!> %, 7 !; %H 9 !8 &X
M5@![ %0 B@!2 )L 40"N %  R !/ .X 3@#_ $X _P!- /\ NPH  *P-  "@
M#0  E0P  (P(  "# @  ?    '4   !N  @ :0 . &4 $P!B !D 7P ? %T
M)0!; "L 60 Q %@ -@!6 #L 50!! %, 1P!1 $X 4 !5 $X 7@!, &@ 2@!U
M $@ A !' )4 10"H $0 OP!# .0 0@#\ $( _P!" /\ LA$  *44  "9%0
MCA,  (01  ![#0  <P@  &P   !E  , 7P + %L #P!7 !0 5  : %$ 'P!/
M "4 3@ K $P , !+ #8 20 \ $@ 0@!& $@ 10!0 $, 60!! &, /P!O #X
M?@ \ )  .P"C #H N  Y -D . #U #@ _P X /\ K!<  )\;  "3'0  B1P
M '\9  !U%0  ;!   &0,  !=!@  5@ & %$ # !- !  2@ 5 $< &@!% "
M1  F $( *P!! #$ /P V #X /0 \ $0 .P!+ #D 5  W %\ -@!K #0 >@ R
M (P ,0"> #  LP O ,X +P#O "X _P N /\ IQX  )HB  "/)   A"0  'HA
M  !Q'0  9Q@  %\3  !7#@  4 H  $D#" !%  T 00 1 #X %@ \ !L .@ A
M #D )@ W "P -@ R #0 .  S #\ ,0!' #  4  N %L +0!G "L =@ J (@
M* "< "< L  F ,D )0#J "4!^P#_XGT024-#7U!23T9)3$4 $1(E ?\ HB,
M )8H  "+*@  @2H  '<H  !M)0  9"   %L;  !2%0  2Q   $,, @ ]!PD
M.0,. #8!$@ S 1< ,0$< # !(@ O B< +0(M "P#-  J SL *01# "@$30 F
M!5@ )05E ",&=  B!H8 ( :: !\'K@ >!\8 '0?G !T(^  ="?\ GR@  ),M
M  "(+P  ?B\  '0N  !J*P  828  %@A  !/'   1Q<  #\2   X#@0 ,0L*
M "X(#@ K!Q( *0<7 "@('0 G"", )0@I "0),  C"3< (0I  " *2@ ?"U4
M'0MB !L,<@ :#(4 & R9 !<,K0 6#,8 %0WF !4-^0 6#?\ G"T  ) Q  "&
M-   ?#0  '(S  !H,0  7RP  %4G  !,(P  1!T  #P8   T$P  +1 & "8-
M"P D# \ (@P3 "$,&0 ?#!\ '@TE !T-+  ;#30 &@X] !D.1P 7#E, %@YA
M !0/<0 3$(0 $A"8 !$0K@ 0$,8 $!#H ! 0^P 1$/\ F3$  (XU  "$.
M>CD  ' X  !G-@  73(  %,M  !**   0B0  #D?   Q&@  *A4! ",1!P =
M$ T &P\0 !D/%0 8$!L %Q A !80*0 5$#$ %!$Z !,110 2$E$ $1)? ! 2
M;P .$X( #A.6  T3JP +$\( "Q3C  P4^@ -$_\ ES4  (PY  ""/   >#T
M &\]  !E.@  6S<  %(R  !)+@  0"H  #<E   O(0  *!P  " 8 P 9% H
M%1(. !02$@ 3$Q@ $A,? !$4)@ 1%"X $!0X  \50@ .%D\ #19<  P7;  +
M%W\ "1B3  @8J  &&+\ !QC@  <8]0 )&/\ E3@  (H]  " 0   =T$  &U!
M  !D/P  6CP  % X  !',P  /C   #8K   N)P  )R,  !\?   7&@@ $A<-
M ! 7$0 /%Q8 #A@<  X8(P -&2P #!HU  L:0  *&TP "1M:  <<:0 %''P
M!!V1  (=I@ !';P  AS=  (<\@ #'/\ DSP  (A!  !_1   =44  &Q%  !C
M1   64$  $\]  !&.0  /C8  #4R   N+@  )2H  !TE   4(00 #QT+  T=
M$  ,'10 "QT:  H>(@ ('BH !Q\S  8@/@ $($H  R%7  $A9P  (7D  "&.
M   AI   (;H  "';   A\@  (/X D$   (9%  !]2   =$H  &M*  !B20
M6$8  $Y"  !%/P  /3P  #4Y   K-   (B\  !DK   2* 0 #20*  DC#@ &
M(Q( !2,9  0D(  ")"@  24Q   E/   )4@  "95   F90  )G<  ":,   F
MH@  )KD  ";9   E\@  )?X CD4  (1)  ![30  <T\  &I/  !@3@  5TL
M $U(  !$10  /$(  #$]   G.0  'C4  !4R   /+@, "BP*  4K#@ !*A$
M "H6   J'@  *B8  "LO   K.0  *T4  "Q3   L8@  +'4  "R*   KH
M*[<  "O6   J\@  *O\ C$D  ().  !Z4@  <50  &A4  !?4P  5E$  $Q.
M  !#2P  -T<  "U#   C/P  &CP  !(X   ,-@, !C,)   R#0  ,A   #$4
M   Q&P  ,2,  #$L   R-P  ,D,  #)0   R8   ,G(  #*'   QG@  ,;4
M ##4   P\@  +_\ B4\  (!4  !X5P  ;UD  &99  !>60  55<  $E3   ^
M3P  ,DP  "A(   >10  %4(   Y    (/0(  3P(   [#   .@\  #D2   Y
M&   .2   #DI   Y-   .4   #E.   Y70  .6\  #B%   XG   -[,  #?2
M   V\@  -?\ AU4  ']:  !V70  ;5\  &5?  !=7P  4EP  $18   X50
M+5(  ")/   83   $$H   I(   #1@$  $4&  !$"@  0PT  $(0  !!%0
M01T  $$F  !!,0  03T  $%*  !!6@  06P  $"!   _F0  /[$  #[0   ]
M\@  //\ A%P  'Q@  !S8P  ;&4  &1F  !99   2V$  #Y>   R6P  )ED
M !Q6   25   #%(   11    3P   $X#  !-"   3 P  $L.  !+$@  2AD
M $HB  !*+   2CD  $I'  !*5@  26@  $E^  !(E@  1Z\  $;-  !%\0
M1/\ @6,  'EG  !R:@  :VP  &!K  !2:0  1&8  #=D   J8@  'V   !5>
M   -70  !EL   !:    60   %@   !7!   5@@  %8,  !5$   5!0  %0=
M  !4)P  5#0  %1"  !34@  4V0  %)Y  !2D@  4:L  %#*  !/[P  3O\
M?FH  '=N  !P<0  9G$  %AP  !*;P  /&T  "]L   B:@  %VD   YG   &
M9@   &4   !E    90   &,   !B    8@0  &$(  !A#0  8!   & 7  !@
M(0  7RX  %\\  !?30  7EX  %YT  !=C0  7*<  %O%  !:[0  6?\ >W(
M '5V  !K=P  778  $]V  !!=0  ,W4  "9T   9<P  $'(   =Q    <0
M '$   !Q    <0   &\   !O    ;@   &X"  !N"   ;0P  &T1  !M&@
M;28  &PU  !L1@  :U@  &MM  !JA@  ::$  &B^  !GZ   9OX >7H  '!\
M  !A?   4WT  $1]   V?@  *'X  !M]   0?0  !WT   !]    ?0   'X
M  !_    ?@   'T   !]    ?    'P   !\    ? 8  'P,  !\$@  ?!T
M 'PL  !\/   ?$\  'ME  ![?@  >IH  'FV  !XWP  =_H <X   &6!  !6
M@P  2(0  #F&   KAP  '8<  !&'   'B    (@   ")    B@   (P   "-
M    C0   (P   ",    C    (P   ",    C0   (T$  ".#   CA,  (\A
M  ".,@  CD8  (Y;  "-=   C9   (RM  "+S@  BO, :(8  %J(  !+BP
M/(T  "V/   >D   $9$   >2    DP   )4   "7    F0   )L   "<
MFP   )L   "<    G    )T   ">    G@   )\   "A P  H@P  *(6  "C
M)@  HSH  *-/  "C:   HH8  **B  "BP   H>@ 7(T  $V0   _DP  ,)8
M "&9   2F@  !YL   "=    H    *(   "D    J    *H   "K    J@
M *L   "L    K0   *X   "O    L0   +(   "T    MP$  +D-  "Y&@
MNBT  +I#  "Z6P  NG<  +N4  "[L0  N=( 4)4  $&8   RG   (Z   !.B
M   (I    *<   "J    K    *\   "R    MP   +D   "[    N@   +P
M  "]    OP   ,    #"    Q    ,8   #)    S0   -(!  #4#P  U1\
M -<U  #830  V&D  ->&  #7HP  UKT _P   /\   #_    _P   /\  P#_
M  T _P 5 /\ ( #\ "L ^  U /0 /P#P $< [@!. .L 5 #I %H YP!? .4
M9 #C &H X0!P -\ =@#= 'X VP"' -@ D0#3 )T SP"K ,T O0#+ .  R0#[
M ,< _P"] /\ L0#_ *D _P"C /\ _P   /\   #_    _P   /P   #V  L
M\0 1 .T &P#I "4 Y  P -\ .0#: $$ U0!( -$ 3@#/ %0 S0!9 ,L 7@#)
M &, QP!I ,4 ;P## '< P !_ +X B@"[ )4 N "C +8 M "T ,T L@#R +
M_P"L /\ HP#_ )P _P"7 /\ _P   /\   #Z    \0   .@   #@  8 V0 .
M -( %@#. !\ R  I ,0 ,@#  #H O0!! +H 2 "X $T M@!3 +0 6 "R %T
ML !B *X :0"L &\ J@!X *@ @@"F (X I "; *$ JP"? ,  G0#F )L _P":
M /\ E #_ (X _P"* /\ _P   /8   #H    W    ,X   #&  $ OP + +H
M$0"V !H L@ B *X *P"J #0 J  [ *4 00"C $< H0!, )\ 40"> %8 G !<
M )H 8@"9 &@ EP!P )4 >@"2 (8 D "3 (T H@"+ +4 B0#3 (< ]P"& /\
MA #_ '\ _P!\ /\ \@   .,   #2    Q0   +H   "Q    JP ' *4 #@"A
M !0 G@ < )H )0"7 "T E  T )( .@"0 $  C@!% (T 2@"+ %  B0!5 (@
M6P"& &$ A !I (( <@!_ 'T ?0"+ 'L F@!X *L =@#$ '0 ZP!S /\ <P#_
M '  _P!N /\ WP   ,P   "_    M    *L   "A    F@ " )0 "P"0 !
MC  7 (@ '@"% "8 @P M ($ ,P!_ #D ?0 _ 'L 1 !Y $D > !. '8 5 !T
M %H <P!B '  :P!N '4 ; "# &H D@!H *, 9@"X &0 W@!C /L 8@#_ &(
M_P!@ /\ S    +P   "O    I0   )T   "4    C    (8 !P"!  T ?  2
M '@ &0!U !\ <P F '$ +0!O #( ;0 X &L /0!J $( : !( &< 3@!E %0
M8P!; &$ 9 !? &X 70![ %L B@!9 )L 5P"O %8 RP!5 /( 5 #_ %0 _P!4
M /\ O@   +    "D    F0   )    "(    @0   'D  @!S  H ;P / &L
M% !G !H 90 @ &, )@!A "P 7P R %X -P!< #P 6P!" %D 1P!7 $X 5@!5
M %0 7@!2 &@ 4 !T $X @P!, )4 2@"H $D P !( .@ 1P#_ $< _P!' /\
MM D  *8+  ";#   D H  (8%  !^    =@   &\   !H  4 8P , %\ $ !;
M !4 6  : %8 (0!4 "8 4P L %$ ,0!0 #8 3@ \ $T 0@!+ $@ 20!0 $@
M6 !& &( 1 !N $( ?0!  (X /P"B #T N  ] -T / #X #P _P \ /\ K!
M )\2  "4$@  B1$  '\/  !V#   ;@4  &8   !@  $ 60 ( %4 #0!1 !$
M3@ 6 $L &P!) "$ 2  F $8 *P!% #$ 0P V $( / !  $, /@!+ #T 4P [
M %T .0!I #< >  V (D - "< #, L0 R ,X ,@#Q #$ _P Q /\ IA8  )H9
M  ".&@  A!H  'H6  !P$@  : X  %\*  !8 P  40 $ $P "@!(  X 1  2
M $$ %@ _ !L /0 A #P )@ Z "P .0 Q #< -P V #X - !& #, 3P Q %D
M+P!E "X <P L (4 *P"8 "H K0 I ,8 * #J "@ _@ H /\ H1P  )4@  "*
M(0  ?R$  '4?  !L&@  8Q8  %H1  !2#0  2P<  $0 !@!   L /  / #@
M$@ V !< -  < #, (0 Q "< ,  L "X ,P M #H *P!" "H 2P H %4 )@!A
M "4 <  D ($ (@"5 "$ J0 @ ,$ ( #D !\ ^0 ? /\ G2(  )$F  "&*
M?"<  '(E  !I(@  7QT  %<8  !.$P  1@X  #\+   X!0< -  , #$ $  N
M !, +  8 "H '0 I "( )P H "8 +@ D #8 (P ^ "( 1P @ %( 'P!> !T
M;0 < 'X &@"2 !D IP 8 +T %P#? !<!]0 7 O\ FB<  (XK  "$+0  >2T
M ' K  !F*   720  %0?  !+&@  0Q0  #L0   T#0( +0D) "D%#0 F Q
M) $3 "("&0 A AX ( (D !X#*@ = S( &P0Z !H%1  9!4\ %P9< !8&:@ 4
M!WP $P>0 !('I0 1![L $ ?; ! (\@ 0"?\ ERL  (PO  "!,0  =S(  &XQ
M  !D+@  6RH  %$E  !)(   0!L  #@6   Q$@  *0X$ ",,"0 ?"0T '0<0
M !L'%0 9"!H & @@ !<))P 6"2X %0HW !,*00 2"TT $0M: ! +:0 .#'L
M#@R0  T,I0 ,#;L "PW9  L-\0 ,#?\ E2\  (HS  !_-@  =C8  &PU  !C
M,P  62\  % K  !')@  /B$  #8=   N&   )Q,  " 0!0 9#@H %0P. !0,
M$0 3#!8 $@P< !$-(P 0#2L #PTT  X./P -#DH # ]8  L/9P *$'D "!"-
M  <0H@ &$+@ !1#4  40[P &$/\ DC,  (@W  !^.@  =#L  &LZ  !A.
M6#4  $XP  !%+   /2<  #4C   M'P  )AH  !X6 0 7$P8 $1 +  X.#@ .
M#Q, #1 9  T0(  ,$"@ "Q$R  H1/  ($D@ !Q)5  8390 $$W8  Q.+  $4
MH   $[8  !/1   3[@  $_L D#8  (8[  !\/@  <S\  &H_  !@/0  5SD
M $TV  !$,0  /"X  #0J   L)@  )2(  !X>   6&@( $!4)  P3#@ *$Q(
M"107  @4'P '%28 !A4O  06.@ #%D8  1=3   78@  &'0  !B)   8GP
M&+4  !?0   7[0  %_L CCH  (0_  ![0@  <D,  &A#  !?0@  5C\  $P[
M  !#-P  .S0  #,P   L+   )"D  !LD   3'P( #1L)  D9#0 &&1$ !!D6
M  (9'0 !&B0  !HM   ;.   &T0  !Q1   <8   '7(  !V'   <G0  '+,
M !S.   ;[0  &_P C#X  ()#  !Y1@  <$@  &A(  !>1@  540  $M   !#
M/0  .SH  #,W   J,@  ("T  !<I   0)0( "R()  4@#0 !'Q   !\4   ?
M&P  ("(  " K   A-@  (4$  "%/   A7@  (G   "*%   AFP  (;(  "'-
M   @[0  '_P BD,  (!(  !X2P  ;TP  &9-  !=2P  5$D  $I&  !"0P
M.D   "\[   E-P  '#,  !,O   -+ ( !RD(  $G#   )@X  "42   F&0
M)B$  "8I   F,P  )S\  "=-   G7   )VT  ">"   GF0  )K   "7,   E
M[@  )/T B$@  '],  !V4   ;E$  &52  !<40  4T\  $I,  !!20  -40
M "M    A/   %SD  ! V   *,@$  S '   O"P  +@X  "T1   M%@  +1X
M "TG   M,0  +3T  "U*   M60  +6L  "V    LEP  +*\  "O+   J[@
M*OX A4T  'U2  !U50  ;%<  &-7  !;5@  4U4  $=1   [30  ,$D  "5&
M   <0P  $S\   T]   &.@   #@%   W"0  -@T  #4/   T%   -!L  #0D
M   T+@  -#H  #1'   T5P  -&@  #1]   SE0  ,JT  #'*   Q[@  ,/\
M@U,  'M8  !S6P  :ET  &)=  !;70  3UH  $)6   V4@  *D\  "!,   6
M20  #D<   A$    0@   $$#   _!P  /@L  #T.   ]$0  /!@  #PA   \
M*P  /#<  #Q$   \4P  /&4  #MZ   ZD@  .JL  #G(   X[0  -_\ @5H
M 'E>  !Q80  :6,  &)D  !78@  25X  #Q;   O6   )%4  !E3   040
M"D\   %-    3    $H   !)!   2 @  $<,  !&#P  1A0  $4<  !%)P
M13,  $5   !%4   1&$  $1V  !#CP  0J@  $'&  ! [   /_\ ?F$  '9E
M  !O:   :&H  %UI  !/9@  0F0  #1A   H7P  '5T  !);   +60   E@
M  !6    5@   %0   !3    4@0  %$)  !0#0  4!   $\8  !/(@  3RX
M $\\  !/2P  3ET  $YR  !-BP  3*4  $O"  !)Z@  2/\ >VD  '1L  !N
M;P  9&\  %5M  !';   .6H  "QI   @9P  %&4   UD   #8@   &(   !A
M    8    %\   !>    70   %P$  !<"0  6PT  %L2  !;'   6B@  %HV
M  !:1@  65@  %EM  !8A0  5Z   %:]  !5Z   4_X >7   '-T  !I=0
M6W0  $QS   ^<P  ,'(  "-Q   6;P  #6X   1M    ;0   &T   !M
M;    &L   !J    :0   &D   !I P  : D  &@.  !H%0  9R$  &<O  !G
M/P  9E(  &9F  !E?P  9)H  &.W  !BX0  8?P =W@  &UZ  !?>@  4'H
M $)Z   S>P  )7L  !AZ   .>0  !'D   !Y    >0   'H   !Z    >@
M '@   !X    =P   '<   !W    =P$  '<(  !W#@  =Q@  '<F  !V-@
M=DD  '5?  !U=P  =),  '.O  !RTP  <?< <7X  &-_  !4@   18(  #:#
M   HA   &H0   Z#   $A    (0   "%    A@   (@   ")    B    (<
M  "'    AP   (<   "'    B    (@   "(!P  B1   (D<  ")+   B#\
M (A5  "(;0  AXD  (:G  "%QP  A.\ 9H0  %>&  !(B   .8H  "J,   ;
MC0  #XT   2.    D    )$   "3    E0   )<   "8    E@   )<   "7
M    EP   )@   "8    F0   )H   ";    G0<  )T1  "=(0  G3,  )U)
M  "<8@  G'\  )R<  "<N0  F^( 6HL  $N.   \D0  +9,  !Z5   0E@
M!)@   ":    G    )X   "A    I    *8   "G    I@   *<   "G
MJ    *D   "J    K    *T   "O    L0   +,)  "S%0  M"<  +0]  "U
M50  M7   +2.  "TK   M,P 39(  #^6   OF@  ()T  !&?   %H0   *,
M  "F    J0   *P   "O    LP   +4   "W    M@   +<   "X    N@
M +L   "]    OP   ,$   #$    QP   ,L   #-#   SAH  ,\O  #/2
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M__________________________________________\
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M_/W^_VUF=#$      P$A   !                     0
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M_______@@SP      "Z'[?____________________________^L4Q
M !=MUO____________________________N ,0        EAS/__________
M_________________]): @        !=S/__________________________
M_Z@U          !<T____________________________WT-          !4
MUO__________________________[GU%          !$U/______________
M_____________*ID+P(   0B-TE8SO___________________________^FD
M:T$H/V-_E:>ZVO______________________________U;*LLLSD^O______
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________Y;N7=V+(________________________
M_________]N>9S8*  *,________________________________R'\_!0
M  !>S______________________________9@3D        \JO__________
M__________________^>3          CD/__________________________
M_]QO&@         0??G__________________________Z](
M;^[__________________________X03            9.;_____________
M____________[%$             5][_________________________N!4
M            2-;_________________________=!0             .,__
M_______________________YHEH3            (\7_________________
M________WYM<+           #;K__________________________^^Q?54Y
M(A$' 0(1(K+______________________________]^_I9F8FJ"LO=K_____
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_________________________________________________________^.^
MG8!\^_________________________________*WA%<P#@ =K/__________
M____________________THI,%0      <O/_________________________
M___6?S8         2\G___________________________J1/@
M+ZO__________________________\!:            &I7_____________
M_____________XTD            "(3_________________________YUX
M             '?_________________________M"4              &K_
M________________________?0               %OT________________
M_______]*P               $SK______________________^E
M         #SA______________________\P#                "W9____
M_________________YF*82<              "?7____________________
M___MOHE5)P           "7<__________________________[*G79=2CPR
M+2PP.4?>_______________________________]YMW6TM#3V>3_________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________[]2[UO__________________________
M_______GN(]J2R\5;_______________________________Y*%G- <
M/,G____________________________6@CL         $I?_____________
M_____________^V%,0           &___________________________Z9"
M             %#A________________________[&D              #?)
M________________________LR\              "*V________________
M________>0               !"G_______________________R-
M          "9______________________^I                  ",____
M__________________]&                  !_____________________
M_]\                   !T_____________________Y<
M      !J_____________________\X                   !C________
M______________\I(@$               !A______________________^Y
MHX!7-Q<           !H___________________________ZTZZ4AGQU<7!R
M=X&4________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____________________________________]NZG8)I:=/_____________
M_________________\B393T9    '9[____________________________;
MCDP3         &[__________________________]M\+            $77
M_________________________XLJ             "*T________________
M________PD0               .7________________________?0$
M          !________________________G-@                !J____
M__________________^=                  !8____________________
M__]&                  !'^/___________________^D
M       UZ?___________________Y8                    EV_______
M_____________[P                    8SO___________________^L
M                   /PO____________________\
M   *N?____________________\G                   *M?__________
M__________]P                   -N?_____________________@G(QP
M54(S)AL4#PT.$AHFO_____________________________GDV-+.S,O,S];@
M_/__________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_________^O3O./________________________________2J85E2"P2 87_
M___________________________QJW$\#P       $_@________________
M_________]5_-0           !^R________________________XW4=
M          ")________________________D",               !G____
M___________________50P                !(]O__________________
M__^*                   NW?____________________\X
M       7R/___________________[X                    $MO______
M_____________YP                     I?___________________[H
M                    D____________________]P
M    @O____________________\                     =/__________
M__________\3                    :/____________________]"
M                8/____________________]Z
M7?_____________________1                    8?______________
M________)                   9O______________________R:R9B7UV
M<6QI9V9G:W!ZC/______________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_________________^+%JI%Y87?_____________________________W:9W
M4"P,     #'$_________________________^"23A,           "/____
M____________________TG =              !@____________________
M___N;P\                WXO____________________^6'
M       4P/____________________]                     H_______
M_____________ZX                     B?___________________YX
M                    <O___________________[P
M    7____________________]H                     3?__________
M__________H                     ._____________________\.
M                *OG___________________\S
M&^G___________________]>                    #]O_____________
M______^/                    !M#____________________0
M             ,K_____________________*P                   ,C_
M____________________@                    ,O_________________
M____]Q8!!04# 0       08-&,O_______________________SKX=C/S,W/
MT-+4U]SBZO__________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________________________________________QVL;_____
M__________________________'&HX1H33(8 !6K____________________
M______^Y?$88          !Q________________________UWPO
M       [X______________________?9 D                ,M?______
M______________]T P                  C?___________________\45
M                    :O___________________YD
M    2____________________[8                     ,/W_________
M_________]<                     &>?___________________8
M                !=/___________________\.
M ,'___________________\O                     *______________
M______]2                     )[___________________]Y
M             ([___________________^E                     (#_
M___________________8                     '3_________________
M____-@                   &W_____________________?
M         &G_____________________UPT                  &C_____
M_________________W                   &'_____________________
M__]0/$9.5%E=861H;'!V?HG_____________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_________________________________________________________^_5
MNZ.+<UJ5___________________________XOXYD02$%      !2_/______
M________________]YU6&              7P?_____________________E
M;!8                 C?____________________]C
M    7O___________________YT                     -?S_________
M_________Z$                     $=G__________________\H
M                 +O__________________^X
M *'___________________\,                     (K_____________
M______\M                     ';___________________]-
M             &3___________________]O                     %+_
M__________________^4                     $#_________________
M__^\                     ##____________________J#@
M         "+_____________________1                    !7_____
M________________@0                    OU____________________
MR L                   +L_____________________UX
M      #E_____________________\D<                  #:________
M______________^= 0             '#A?%________________________
MU;F\P<?.U=OAYNWT^___________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________________________^-_/________________________
M_____^S&I8AM5#LA!P RWO_______________________]>262D
M    H/______________________B38                 9___________
M__________]F                    ,O;__________________Y4
M                 \C__________________Z<
M *#__________________]<                      'S_____________
M______\                      %[___________________\E
M             $/___________________](                     "S_
M__________________]J                     !C_________________
M__^+                      7S__________________^O
M          #A___________________5                      #/____
M________________)                     "^____________________
M5                     "N____________________BP
M      "?____________________RPX                   "2________
M_____________U<                   "&_____________________ZH*
M                  !Y______________________]M
M  !F_______________________W50                !%____________
M_____________VHC*S4_2E5@:G5^AY&<____________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________________________________HS[:=@VE.N?__________
M_______________LLH-<.AT"        >_______________________Q6TI
M                0/____________________^#&P
M!\O__________________Y(                      )C_____________
M_____Z0                      &K__________________]T
M             $'___________________\.                     !W_
M__________________\Y                      #H________________
M__]@                      #.__________________^%
M          "W__________________^H                      "C____
M_______________+                      "0___________________O
M%@                    !]____________________/@
M      !L____________________:0                    !:________
M____________F0                    !)____________________TA8
M                   Y_____________________U@
M   I_____________________Z(                    9____________
M__________56                   $______________________^[+P
M                ^/______________________JRD
MS________________________\E'      <3("X^4FB$[?______________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M______________35R?____________________________K2L))W74(H#
M2O_______________________\5]11<             $=C_____________
M_______$4                    )___________________Z(,
M             &C__________________Y0                      #;_
M_________________]H                       ?L________________
M__\5                      #$__________________](
M          "B__________________]U                      "#____
M______________^=                      !I___________________#
M                      !2___________________G#P
M       ^____________________,P                     K________
M____________6                      8____________________@0
M                   %____________________K
M    ____________________WB(                     \O__________
M_________UP                     W____________________Y\
M                S/___________________^A*
MM_____________________^@%@                  G/______________
M________>@(                 =________________________WH+
M           %3/________________________^B5VAT@(V<J[S0Y_______
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________________MX___________________________TJ-Z
M6#HI(QP6#@8  )______________________K%(.                 &G_
M_________________^1#                     #3_________________
M_WD                       #C_________________\T
M          "R__________________\3                      "%____
M______________]/                      !=__________________^#
M                       Z__________________^R
M       <___________________; P                     "________
M____________*@                      ^___________________3P
M                    Y___________________=
M    U/__________________FP                      P/__________
M________Q <                     K?__________________\#,
M                FO___________________V<
MAO___________________Z,                     <O______________
M_____^-$                    7/____________________^1!@
M            0?_____________________K7P                  '?__
M____________________RDL                  /__________________
M_____\M7   ,&"0Q/TY@=(NGQ___________________________U^?R____
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________Z]3-Q\*^NK>SL*VIJ*7____________________=?E,_,",9$0D"
M          #;_________________W8                       "G____
M_____________[H                       !U__________________\'
M                      !&__________________].
M       :__________________^,                        _?______
M___________!                        V__________________Q&0
M                    OO__________________1
M    I/__________________:P                      C?__________
M________D0                      >?__________________MP
M                9O__________________WB$
M4____________________TH                     /_______________
M_____W<                     *____________________ZP*
M            %O___________________^=%                     /__
M__________________^*                     /__________________
M___630                   /W_____________________IRX
M         -7______________________Y@J           &&"U%8.#_____
M__________________^H8W2!CYRKN\WB^O__________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________________________________________________B
M,X!)0T-?4%)/1DE,10 2$O______________________________________
M________________________Y\NWJ9V5CHF$@'QX='!L:&60____________
M_____[QJ2"T9"@                 Q__________________\
M               #__________________]"
MW/________________^.                        LO______________
M___.                        C?__________________*0
M            :___________________6@                      3O__
M________________A@                      -/__________________
MK@                      'O__________________U!<
M        "O__________________^CT                      /______
M_____________V4                      /___________________XX
M                     /___________________[P9
M     .____________________%.                     -C_________
M__________^+                     +_____________________,0P
M                 *'_____________________D1D
M 'K_____________________\G0*                $5______________
M_________^AT$Q\L.$538G*%F[32]?__________________________U^CT
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________________________________________[]_/Q[NSKZ^SQ
M___________________9LIF'>6UD75912T9!/#@R+2@CQ/______________
M__]+)0L                     DO________________^(
M            9O_________________7                        /?__
M________________,P                      &/__________________
M;                        /__________________G0
M         /__________________R0P                      /;_____
M____________\34                      -___________________UL
M                     ,O__________________X(
M     +?__________________ZD&                     */_________
M_________],O                     (W___________________]>
M                 '?___________________^3!P
M %[____________________-0P                   $#_____________
M________AQ                   !S_____________________V%X
M              #______________________[].       .'"P^4FJ&I<C_
M_______________________"?(R:I[;%UNC]________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________________________NX=?/R<.^NK:QK:FGIJ:GKO__
M______________^^AFU;3$ W+R@B'!80"P0     %/_________________7
M!0                       /__________________-
M         /;_________________=@                       -+_____
M____________L                        ++_________________X20
M                     );__________________U$
M     'S__________________WD                      &;_________
M_________Z                       %'__________________\<C
M                 #S__________________^Y+
M "?___________________]T                     !#_____________
M______^C%@                    #____________________83
M              #_____________________B \                   #_
M____________________RU,                   #_________________
M_____Z4X           )'31.:XS_______________________^9.4-17VY]
MCJ"UR^7_____________________________Z_G_____________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________Z\RYK*&9D8N&@7QX='!K:&9F:/'_____
M____________844R(Q@.!@               )[_________________?@
M                     '7_________________PP
M     %+_________________^S<                      #+_________
M_________VH                      !;__________________Y8
M                  #__________________[\;
M  #__________________^9"                      #_____________
M______]I                      #___________________^0 @
M              #___________________^Y+                     #T
M___________________H7                     #9________________
M____D1@                   "\____________________RE,
M          "=_____________________Y@N             ! I1F;$____
M_________________^Y_'0P:*#=&5VE^E:_,[O______________________
M___GH*JYR-CI_/______________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M______________________________________________WU\.OFXM_;V-32
MT=#2U^#_________________SIZ*?'%I85M644Q(0SXZ-C(O+C'_________
M________TB41 P                    #__________________T(
M                  #__________________WT
M  #__________________[ +                      #V____________
M_____]TY                      #<__________________]B
M              #%__________________^)                      "O
M__________________^O(@                    "9________________
M___62                     ""____________________<@
M          !I____________________H2@                   !.____
M________________TUP                    S____________________
M_Y8N               5,E)W_____________________^!R$P   0\?+T)8
M<(NHR.S________________________*;VY^CIZPP]CO________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M______________________________________G@TLC NK6PK*BEHI^=FYN<
MH*?__________________X)D5DM#/#8P*R<B'1@3#@D$  #4____________
M_____Y(                       "M_________________\P>
M              "+__________________M2                      !M
M__________________^                       !1________________
M__^I&P                     Z___________________00@
M           C___________________U:                      ,____
M________________CQ0                     ____________________
MN#X                     ____________________Y6T#
M        _____________________Y\W               0+U!T________
M_____________]UR%      &%RI!6G64MMK_______________________^\
M6$149'6&FJ_(X_______________________________TLWA\?__________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____/OZ^_W______________________^ZYJ)V6CXJ&@G][>'9T<G-U>'^0
M_________________^M/.C H(1L5$ L' @         C________________
M__]I                        __________________^;"@
M            ___________________(.0                      ____
M_______________P8P                      ____________________
MB@X                     ____________________L#0
M        ____________________U5L                     ________
M_____________X4:                   #[/___________________[%)
M               8.5V!_____________________^5['@      #"$X4F^/
ML]G_______________________^[6"DY25IL@)>PS>W_________________
M____________LYZTQ=?K________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________________________________________^N_GX=S9UM32
MT-#0T=/9X.OW__________________^XBGYW<6QH9&%>6UE85U=97F5Q____
M______________^_,1\6$ H%                ___________________M
M5@                      Z/__________________@@0
M        S/__________________JR\                     L_______
M____________TE<                     F___________________]WP0
M                    A?___________________Z(W
M  4KE/___________________\MA @            PL4':>T?__________
M__________6-,       #2,[5W:9ON7________________________#8Q@J
M.TQ?=(VGQN?_____________________________J'^6J+O0Y___________
M__________________________W_________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________W<[%O[RYMK2SL;*R
MM;G R=7C____________________EVQD7EE544],2DA'1DA+4%EFH?______
M____________IR8.!P(                 5O__________________SE
M                    .O__________________]'D+
M    (?___________________Y\R                    #O__________
M_________\18                "#%:A/___________________^E_'P
M        !B=+<9K"Z?____________________^G20     "%R]*:(JNU?S_
M_______________________3=1XF.$I>=8^KR^______________________
M________KG*%F*S"V_;__________________________________]_O____
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_________________________________________[^RJJ:CH:"?GZ&CIJRT
MP,W=[/___________________XI:4T]+2$9$0T)!0D-'3EEI??__________
M_________YXN!@                   /___________________\-6
M               50?___________________^=[&@             )-&"+
MM/____________________^?/P         $)4IQF<+K________________
M_______&9@\    3*D1B@Z?-]?_________________________KCC4K/E%H
M@9V\WO______________________________OG9_E*G!W/G_____________
M_____________________]+8\___________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________________________________________________]O+P
M[^_O\?/X_?____________________________BPGYJ7EI:6F)N?I*RVPM'A
M[O____________________Z.4$I'141$1$5&1TM16FB#J?______________
M______^F00$           <V8X^ZX?_____________________&90H
M  0G3'.<Q.S________________________EB"\  !,J1&*"ILST________
M____________________JU V2F%[EK36^O__________________________
M____TH=\F+'+Z?___________________________________]3.[?______
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________[>7CX^3F
MZ.WQ^?_____________________________]L922DI69G:.ILKS0[?______
M____________________G5-'24U15F!SBJ_6_/______________________
M____LE8 &C50;8NNTO?_____________________________S6\^7WN9M]?Y
M________________________________[I^#IL+A____________________
M_________________^/.Z_______________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____________P
M
M
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M2_\ 2'']L#_PU#__ !=?5%%'U&'</K4NQ\K_ /#_ *\2_P#2'']L#_PU#_\
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M<?VP/_#4/_\ %U]444?48=P^M2['RO\ \/\ KQ+_ -(<?VP/_#4/_P#%T?\
M#_KQ+_TAQ_; _P##4/\ _%U]444?48=P^M2['RO_ ,/^O$O_ $AQ_; _\-0_
M_P 71_P_Z\2_](<?VP/_  U#_P#Q=?5%%'U&'</K4NQ\K_\ #_KQ+_TAQ_;
M_P##4/\ _%T?\/\ KQ+_ -(<?VP/_#4/_P#%U]444?48=P^M2['RO_P_Z\2_
M](<?VP/_  U#_P#Q='_#_KQ+_P!(<?VP/_#4/_\ %U]444?48=P^M2['RO\
M\/\ KQ+_ -(<?VP/_#4/_P#%T?\ #_KQ+_TAQ_; _P##4/\ _%U]444?48=P
M^M2['RO_ ,/^O$O_ $AQ_; _\-0__P 71_P_Z\2_](<?VP/_  U#_P#Q=?5%
M%'U&'</K4NQ\K_\ #_KQ+_TAQ_; _P##4/\ _%T?\/\ KQ+_ -(<?VP/_#4/
M_P#%U]444?48=P^M2['RO_P_Z\2_](<?VP/_  U#_P#Q='_#_KQ+_P!(<?VP
M/_#4/_\ %U]444?48=P^M2['RO\ \/\ KQ+_ -(<?VP/_#4/_P#%T?\ #_KQ
M+_TAQ_; _P##4/\ _%U]444?48=P^M2['RO_ ,/^O$O_ $AQ_; _\-0__P 7
M1_P_Z\2_](<?VP/_  U#_P#Q=?5%%'U&'</K4NQ\K_\ #_KQ+_TAQ_; _P##
M4/\ _%T?\/\ KQ+_ -(<?VP/_#4/_P#%U]444?48=P^M2['RO_P_Z\2_](<?
MVP/_  U#_P#Q='_#_KQ+_P!(<?VP/_#4/_\ %U]444?48=P^M2['RO\ \/\
MKQ+_ -(<?VP/_#4/_P#%T?\ #_KQ+_TAQ_; _P##4/\ _%U]444?48=P^M2[
M'RO_ ,/^O$O_ $AQ_; _\-0__P 71_P_Z\2_](<?VP/_  U#_P#Q=?5%%'U&
M'</K4NQ\K_\ #_KQ+_TAQ_; _P##4/\ _%T?\/\ KQ+_ -(<?VP/_#4/_P#%
MU]444?48=P^M2['QQXB_X.1O#GA#Q;H/@#Q9_P $M/VH]+UWQ3)<)X:T74?A
M^D%WJS0(KS"UA>4/<&-65G" [0P)P",[_P#P_P"O$O\ TAQ_; _\-0__ ,77
M!_\ !0__ )2R_L,_]A;QY_Z:[*ON2HC@X-M7V+EB9))VW/E?_A_UXE_Z0X_M
M@?\ AJ'_ /BZ/^'_ %XE_P"D./[8'_AJ'_\ BZ^J**OZC#N1]:EV/E?_ (?]
M>)?^D./[8'_AJ'_^+H_X?]>)?^D./[8'_AJ'_P#BZ^J**/J,.X?6I=CY7_X?
M]>)?^D./[8'_ (:A_P#XNC_A_P!>)?\ I#C^V!_X:A__ (NOJBBCZC#N'UJ7
M8^5_^'_7B7_I#C^V!_X:A_\ XNC_ (?]>)?^D./[8'_AJ'_^+KZHHH^HP[A]
M:EV/E?\ X?\ 7B7_ *0X_M@?^&H?_P"+H_X?]>)?^D./[8'_ (:A_P#XNOJB
MBCZC#N'UJ78^5_\ A_UXE_Z0X_M@?^&H?_XNC_A_UXE_Z0X_M@?^&H?_ .+K
MZHHH^HP[A]:EV/E?_A_UXE_Z0X_M@?\ AJ'_ /BZ/^'_ %XE_P"D./[8'_AJ
M'_\ BZ^J**/J,.X?6I=CY7_X?]>)?^D./[8'_AJ'_P#BZ/\ A_UXE_Z0X_M@
M?^&H?_XNOJBBCZC#N'UJ78^5_P#A_P!>)?\ I#C^V!_X:A__ (NC_A_UXE_Z
M0X_M@?\ AJ'_ /BZ^J**/J,.X?6I=CY7_P"'_7B7_I#C^V!_X:A__BZ/^'_7
MB7_I#C^V!_X:A_\ XNOJBBCZC#N'UJ78^5_^'_7B7_I#C^V!_P"&H?\ ^+H_
MX?\ 7B7_ *0X_M@?^&H?_P"+KZHHH^HP[A]:EV/E?_A_UXE_Z0X_M@?^&H?_
M .+H_P"'_7B7_I#C^V!_X:A__BZ^J**/J,.X?6I=CY7_ .'_ %XE_P"D./[8
M'_AJ'_\ BZ/^'_7B7_I#C^V!_P"&H?\ ^+KZHHH^HP[A]:EV/E?_ (?]>)?^
MD./[8'_AJ'_^+H_X?]>)?^D./[8'_AJ'_P#BZ^J**/J,.X?6I=CY7_X?]>)?
M^D./[8'_ (:A_P#XNC_A_P!>)?\ I#C^V!_X:A__ (NOJBBCZC#N'UJ78^5_
M^'_7B7_I#C^V!_X:A_\ XNC_ (?]>)?^D./[8'_AJ'_^+KZHHH^HP[A]:EV/
ME?\ X?\ 7B7_ *0X_M@?^&H?_P"+H_X?]>)?^D./[8'_ (:A_P#XNOJBBCZC
M#N'UJ78^5_\ A_UXE_Z0X_M@?^&H?_XNC_A_UXE_Z0X_M@?^&H?_ .+KZHHH
M^HP[A]:EV/E?_A_UXE_Z0X_M@?\ AJ'_ /BZ/^'_ %XE_P"D./[8'_AJ'_\
MBZ^J**/J,.X?6I=CY7_X?]>)?^D./[8'_AJ'_P#BZ/\ A_UXE_Z0X_M@?^&H
M?_XNOJBBCZC#N'UJ78^5_P#A_P!>)?\ I#C^V!_X:A__ (NC_A_UXE_Z0X_M
M@?\ AJ'_ /BZ^J**/J,.X?6I=CY7_P"'_7B7_I#C^V!_X:A__BZ/^'_7B7_I
M#C^V!_X:A_\ XNOJBBCZC#N'UJ78^5_^'_7B7_I#C^V!_P"&H?\ ^+H_X?\
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MJ,.X?6I=CY7_ .'_ %XE_P"D./[8'_AJ'_\ BZ/^'_7B7_I#C^V!_P"&H?\
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M_AJ'_P#BZ/\ A_UXE_Z0X_M@?^&H?_XNOJBBCZC#N'UJ78^5_P#A_P!>)?\
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MZC#N1]:EV/E?_A_UXE_Z0X_M@?\ AJ'_ /BZ/^'_ %XE_P"D./[8'_AJ'_\
MBZ^J**/J,.X?6I=CY7_X?]>)?^D./[8'_AJ'_P#BZ/\ A_UXE_Z0X_M@?^&H
M?_XNOJBBCZC#N'UJ78^5_P#A_P!>)?\ I#C^V!_X:A__ (NC_A_UXE_Z0X_M
M@?\ AJ'_ /BZ^J**/J,.X?6I=CY7_P"'_7B7_I#C^V!_X:A__BZ/^'_7B7_I
M#C^V!_X:A_\ XNOJBBCZC#N'UJ78^5_^'_7B7_I#C^V!_P"&H?\ ^+H_X?\
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MB7_I#C^V!_X:A_\ XNC_ (?]>)?^D./[8'_AJ'_^+KZHHH^HP[A]:EV/E?\
MX?\ 7B7_ *0X_M@?^&H?_P"+H_X?]>)?^D./[8'_ (:A_P#XNOJBBCZC#N'U
MJ78^5_\ A_UXE_Z0X_M@?^&H?_XNC_A_UXE_Z0X_M@?^&H?_ .+KZHHH^HP[
MA]:EV/E?_A_UXE_Z0X_M@?\ AJ'_ /BZ/^'_ %XE_P"D./[8'_AJ'_\ BZ^J
M**/J,.X?6I=CY7_X?]>)?^D./[8'_AJ'_P#BZ/\ A_UXE_Z0X_M@?^&H?_XN
MOJBBCZC#N'UJ78^5_P#A_P!>)?\ I#C^V!_X:A__ (NC_A_UXE_Z0X_M@?\
MAJ'_ /BZ^J**/J,.X?6I=CY7_P"'_7B7_I#C^V!_X:A__BZ/^'_7B7_I#C^V
M!_X:A_\ XNOJBBCZC#N'UJ78^5_^'_7B7_I#C^V!_P"&H?\ ^+H_X?\ 7B7_
M *0X_M@?^&H?_P"+KZHHH^HP[A]:EV/E?_A_UXE_Z0X_M@?^&H?_ .+H_P"'
M_7B7_I#C^V!_X:A__BZ^J**/J,.X?6I=CY7_ .'_ %XE_P"D./[8'_AJ'_\
MBZ/^'_7B7_I#C^V!_P"&H?\ ^+KZHHH^HP[A]:EV/E?_ (?]>)?^D./[8'_A
MJ'_^+H_X?]>)?^D./[8'_AJ'_P#BZ^J**/J,.X?6I=CY7_X?]>)?^D./[8'_
M (:A_P#XNC_A_P!>)?\ I#C^V!_X:A__ (NOJBBCZC#N'UJ78^5_^'_7B7_I
M#C^V!_X:A_\ XNC_ (?]>)?^D./[8'_AJ'_^+KZHHH^HP[A]:EV/E?\ X?\
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M71_P_P"O$O\ TAQ_; _\-0__ ,77U111]1AW#ZU+L?*__#_KQ+_TAQ_; _\
M#4/_ /%T?\/^O$O_ $AQ_; _\-0__P 77U111]1AW#ZU+L?*_P#P_P"O$O\
MTAQ_; _\-0__ ,71_P /^O$O_2'']L#_ ,-0_P#\77U111]1AW#ZU+L?*_\
MP_Z\2_\ 2'']L#_PU#__ !='_#_KQ+_TAQ_; _\ #4/_ /%U]444?48=P^M2
M['RO_P /^O$O_2'']L#_ ,-0_P#\71_P_P"O$O\ TAQ_; _\-0__ ,77U111
M]1AW#ZU+L?*__#_KQ+_TAQ_; _\ #4/_ /%T?\/^O$O_ $AQ_; _\-0__P 7
M7U111]1AW#ZU+L?*_P#P_P"O$O\ TAQ_; _\-0__ ,71_P /^O$O_2'']L#_
M ,-0_P#\77U111]1AW#ZU+L?*_\ P_Z\2_\ 2'']L#_PU#__ !='_#_KQ+_T
MAQ_; _\ #4/_ /%U]444?48=P^M2['RO_P /^O$O_2'']L#_ ,-0_P#\71_P
M_P"O$O\ TAQ_; _\-0__ ,77U111]1AW#ZU+L?*__#_KQ+_TAQ_; _\ #4/_
M /%T?\/^O$O_ $AQ_; _\-0__P 77U111]1AW#ZU+L?*_P#P_P"O$O\ TAQ_
M; _\-0__ ,71_P /^O$O_2'']L#_ ,-0_P#\77U111]1AW#ZU+L?*_\ P_Z\
M2_\ 2'']L#_PU#__ !='_#_KQ+_TAQ_; _\ #4/_ /%U]444?48=P^M2['RO
M_P /^O$O_2'']L#_ ,-0_P#\71_P_P"O$O\ TAQ_; _\-0__ ,77U111]1AW
M#ZU+L?*__#_KQ+_TAQ_; _\ #4/_ /%T?\/^O$O_ $AQ_; _\-0__P 77U11
M1]1AW#ZU+L?*_P#P_P"O$O\ TAQ_; _\-0__ ,71_P /^O$O_2'']L#_ ,-0
M_P#\77U111]1AW#ZU+L?*_\ P_Z\2_\ 2'']L#_PU#__ !='_#_KQ+_TAQ_;
M _\ #4/_ /%U]444?48=P^M2['RO_P /^O$O_2'']L#_ ,-0_P#\71_P_P"O
M$O\ TAQ_; _\-0__ ,77U111]1AW#ZU+L?*__#_KQ+_TAQ_; _\ #4/_ /%T
M?\/^O$O_ $AQ_; _\-0__P 77U111]1AW#ZU+L?*_P#P_P"O$O\ TAQ_; _\
M-0__ ,71_P /^O$O_2'']L#_ ,-0_P#\77U111]1AW#ZU+L?*_\ P_Z\2_\
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M5%%'U&'</K4NQ\K_ /#_ *\2_P#2'']L#_PU#_\ Q='_  _Z\2_](<?VP/\
MPU#_ /Q=?5%%'U&'</K4NQ\K_P##_KQ+_P!(<?VP/_#4/_\ %T?\/^O$O_2'
M']L#_P -0_\ \77U111]1AW#ZU+L?*__  _Z\2_](<?VP/\ PU#_ /Q='_#_
M *\2_P#2'']L#_PU#_\ Q=?5%%'U&'</K4NQ\K_\/^O$O_2'']L#_P -0_\
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M2_\ 2'']L#_PU#__ !=?5%%'U&'</K4NQ\K_ /#_ *\2_P#2'']L#_PU#_\
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M'U&'</K4NQ\K_P##_KQ+_P!(<?VP/_#4/_\ %T?\/^O$O_2'']L#_P -0_\
M\77U111]1AW#ZU+L?*__  _Z\2_](<?VP/\ PU#_ /Q='_#_ *\2_P#2'']L
M#_PU#_\ Q=?5%%'U&'</K4NQ\K_\/^O$O_2'']L#_P -0_\ \71_P_Z\2_\
M2'']L#_PU#__ !=?5%%'U&'</K4NQ\K_ /#_ *\2_P#2'']L#_PU#_\ Q='_
M  _Z\2_](<?VP/\ PU#_ /Q=?5%%'U&'</K4NQ\K_P##_KQ+_P!(<?VP/_#4
M/_\ %T?\/^O$O_2'']L#_P -0_\ \77U111]1AW#ZU+L?*__  _Z\2_](<?V
MP/\ PU#_ /Q='_#_ *\2_P#2'']L#_PU#_\ Q=?5%%'U&'</K4NQ\K_\/^O$
MO_2'']L#_P -0_\ \71_P_Z\2_\ 2'']L#_PU#__ !=?5%%'U&'</K4NQ\K_
M /#_ *\2_P#2'']L#_PU#_\ Q='_  _Z\2_](<?VP/\ PU#_ /Q=?5%%'U&'
M</K4NQ\K_P##_KQ+_P!(<?VP/_#4/_\ %T?\/^O$O_2'']L#_P -0_\ \77U
M111]1AW#ZU+L?*__  _Z\2_](<?VP/\ PU#_ /Q='_#_ *\2_P#2'']L#_PU
M#_\ Q=?5%%'U&'</K4NQ\K_\/^O$O_2'']L#_P -0_\ \71_P_Z\2_\ 2'']
ML#_PU#__ !=?5%%'U&'</K4NQ\K_ /#_ *\2_P#2'']L#_PU#_\ Q='_  _Z
M\2_](<?VP/\ PU#_ /Q=?5%%'U&'</K4NQ\K_P##_KQ+_P!(<?VP/_#4/_\
M%T?\/^O$O_2'']L#_P -0_\ \77U111]1AW#ZU+L?*__  _Z\2_](<?VP/\
MPU#_ /Q='_#_ *\2_P#2'']L#_PU#_\ Q=?5%%'U&'</K4NQ\K_\/^O$O_2'
M']L#_P -0_\ \71_P_Z\2_\ 2'']L#_PU#__ !=?5%%'U&'</K4NQ\K_ /#_
M *\2_P#2'']L#_PU#_\ Q='_  _Z\2_](<?VP/\ PU#_ /Q=?5%%'U&'</K4
MNQ\K_P##_KQ+_P!(<?VP/_#4/_\ %T?\/^O$O_2'']L#_P -0_\ \77U111]
M1AW#ZU+L?*__  _Z\2_](<?VP/\ PU#_ /Q='_#_ *\2_P#2'']L#_PU#_\
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MT97H8':1QXO=?UV"BBBN\XPHHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *^&_^"T'_(]?
MLA?]G<>$_P#T:]?<E?#?_!:#_D>OV0O^SN/"?_HUZSJ_!_7<NG_$1]R4445H
M0%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110!\-_\%#_^4LO[#/\ V%O'G_IKLJ^Y
M*^&_^"A__*67]AG_ +"WCS_TUV5?<E9P^.7K^B-)_#'T_5A1116AF%%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!\$?\
M'*/_ "BO\1_]C5HW_I4*^]Z^"/\ @Y1_Y17^(_\ L:M&_P#2H5][UE'^++Y?
MJ:2_A1^?Z!1116IF%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110!XQ_P4>_Y1Y?'G_LC'BC_TTW-<M_P2 _Y1B_!'_L0;
M/^1KJ?\ @H]_RCR^//\ V1CQ1_Z:;FN6_P""0'_*,7X(_P#8@V?\C6?_ "^^
M1?\ RZ^9](4445H0%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 5\-_\$+O^1%_:1_[.X\8_^BK"ON2OAO\ X(7?\B+^
MTC_V=QXQ_P#15A6<OXD?F7'X'\C[DHHHK0@**** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KXO_9W_P"4W_[1?_9+O"7_
M *"]?:%?%_[._P#RF_\ VB_^R7>$O_07K.IO'U-*>TO3]4?:%%%%:&84444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'S-_P $4O\ DXS]L_\
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M[V^1"J1E4<%NK?B;M%%%9%A1110 4444 %%%% !1110!\-_\%#_^4LO[#/\
MV%O'G_IKLJ^Y*^&_^"A__*67]AG_ +"WCS_TUV5?<E9P^.7K^B-)_#'T_5A1
M116AF%%%% !1110 4444 %%%% !117Y4_P#!<C2[[QI^VI\.OA])JTD%O?\
MA2S@B)7>MO)<:E<Q/*$R,G"ID9&=@&:ZL'AOK=?V=[;N^^QAB*SH4N9*Y^JU
M%?F9JG_!OIXOT.P?5_ '[6T$NLV^V33DN_"<EE&9 PY,\=W*\>.H8(QR/QJ7
M_@FO^V-^T7\&OVI)?V!_VK-;N]1#7,NGZ9/J]X9Y]+O(HR\<:3')EMYD4*@)
M(!:(H54L#T2P%*=*4Z%7GY=6K-.WS,HXJI&:C5ARWT6J>I^EU%%%>:=@4444
M %%%% !1110!YK\=_P!L']G+]F?6M%\._&_XBKH=YXAW_P!D0G2[JX\\*R*Q
M)@B<1@&11\^,Y/H<>E5^97_!>7_DMOPA_P"O6[_]*;>ON_\ :[^#WBS]H#]F
MSQ=\&_ WB6'2-5U_3/L]E?W$CI$C>8CE':,%@CA2C$ _*YX/2NVIAJ<*-&=[
M<][^5G8YXU92JU(V^&UONN>C45\Y_P#!,S]C[XH?L8?!+4_AQ\4_&^FZO=WW
MB"2_MH-%N)I+6SC,4:;5:9(VRQ0LV$ R1UZU]&5S58PA5<8RNEU[FM.4I03D
MK/L%%%%9EA17RW_P5%_8?^+O[;?@?PKX<^$WC?1]+DT+4[BXOK37;F>*WNED
MC55?,,<F70J0,KC$C<CH?=OV?OA[X@^$OP/\)?#'Q5XF.LZEH'A^UL;W4R6/
MVB2.,(S O\Q'&!GG&,^E;2ITU0C-2NWNNQFIS=1QMHNIUU%%%8F@4444 %<'
M^T#^T[\#?V6O#5EXN^._CI="L-1OOL=C.=-N;DRS;&?;MMXW8?*I.2 !TSDB
MN\KX%_X.!?\ DW[P-_V.3_\ I)+73@Z,<1B8TY;,QQ%25&C*:W1]V^&/$>B>
M,?#6G^+_  U?"YT[5;&*[L+D1LHE@E171P& (RK X(!]15VN$_9;_P"39?AU
M_P!B)I'_ *115W=82BHR:1JG=7"BBBI&%%%% !1110 4444 %%%% 'P1_P '
M*/\ RBO\1_\ 8U:-_P"E0K[WKX(_X.4?^45_B/\ [&K1O_2H5][UE'^++Y?J
M:2_A1^?Z!1116IF%%%% !1110 4444 %%%% !1110 4444 %%?%G_!>/4+VS
M_8NTVVM;N2..[\?6,5RJ' E06MY(%;U&Y%;'JH]*^;_V:_\ @B+_ ,-#? GP
MQ\:A^TV-(_X2/3%O/[,_X0O[1]GR2-GF?;4W].NT?2O1HX.A+#*M5J<J;MLW
M^1QU<35C6]G3AS:7W2/UCK(^('CSPE\+_!&J_$?Q[K"Z?HVBV,EYJ=ZT3R"&
M%%W,VR,%F^BJ2>PS7Y.P>/\ ]LO_ ((Z_M!:+X.^(WC:;Q-X(U-4F.GI?RSV
M&H68VQRF!9>;:XC&WH!RJ [XR,_H=^WOJEAKW[!7Q(UO2;I;BTN_ US/;3QG
MY9(WB#*P]B"#^-36P/LJM/WN:,]FO77YET\1[2,M+2CNF=U\"_V@O@_^TMX(
M/Q&^"7C!=;T5;V2T:]%C/;[9D"ED*3HCC =3G;CYAC-=C7Q=_P $(O\ DRF^
M_P"Q[O\ _P!)[6OM&L,52C0Q,J<=DS2A-U:,9OJDPHHHKG-0HHHH **** "B
MBB@ HHHH ***^$/VP_\ @HE\?/'GQAU+]B[]@;P!J%]XKM)Y;'7_ !*;9=UE
M(IVR"#>?+A53\K7$I"@D[0#M>M\/AZF)GRQZ;M[)=V9U:L*4;R_X+/N^BORF
M_P""*^E>+_#G_!0OXB^&?'VJRWNM:?X/U:UUFZENFG,UU%JMC'(YD;F3+!OF
M/)SGO7ZLU>,PWU2M[/FOHG?U(P]?ZQ3YK6"BBBN4W"BBB@ HHHH **** "BB
MB@ HHHH **** /&/^"CW_*/+X\_]D8\4?^FFYKEO^"0'_*,7X(_]B#9_R-=3
M_P %'O\ E'E\>?\ LC'BC_TTW-<M_P $@/\ E&+\$?\ L0;/^1K/_E]\B_\
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M>BT::.+4C_9=U:F%I Q3*W$49.0C<J".#7HE?G'_ ,&]'_(J_%/_ +"&D?\
MH%W7Z.5&-H0PV*E2CLN_H5AJLJU",Y;L****Y3<**** "BBB@ HHHH ****
M"BBOSZ_:%_9Y_P""CW[=/[1OBWP--XZNOA_\*M"U9K+3))?.MH=2A7&)4AC(
M>]9OO[I&$0Y"L"-M;X>C&M)\TE%+=O\ 3N9U:CIQTBV_(_06BOR"_:A_X)C_
M +0__!/+PF/VC_@O^T#<:I8Z3)"-6U'2;>72;VQ,DH1&V+-()8=S(I^?.7&4
M*Y8??/\ P3(_:O\ $7[7G[,%IXZ\<B%O$6CZE)I&N3P *+F:)(W6XV  (7CE
M0D#Y=V[;@84=&(P4:=!5J4^>-[;6L_0QHXESJ>SG'EEOW/H2BBBN Z@HHHH
M**** "BBB@ HHHH **** "BBB@ KX;_X(7?\B+^TC_V=QXQ_]%6%?<E?#?\
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M?%_[._\ RF__ &B_^R7>$O\ T%ZSJ;Q]32GM+T_5'VA1116AF%%%% !1110
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MU/H#[5^(&GZ3\3X_B5\//C_X[\0WTNJ^.O%9U*VU":1A/,(K](FN-^<Y,HE
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M&VK-/=V27($\:PX>*7_5M&R2,O+@'@YKNIO^"\7QWT[0C\/=2_91M(_':1B
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MN94CCD6X5/X-Z2+D#C>KXP,*/CKXH7O_  7LU3X7^(M3^(5IY'A:XT&[EUN
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M;#AT=2&1AV8$$=1BOA__ (+R_P#);?A#_P!>MW_Z4V]?:/\ P4,_Y,?^*/\
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M;XI_9*_:EEDN_$WAFUFGM=0O(DCNU,$R07%K/L 61E9U*O\ >P'R6X(H?\'
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MC_V)MY_Z!6-3$493HT:-^6+W?5MFM.E4BJE2IO+HNED?F3^PI\7_ -NGQO\
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M@@-UVDN=_7Z<_P"":&KZ=H?_  3O^'VO:U>K;VEEX>N9[JXE;Y8HDN)V9CZ
M*#7RKXD_X*>_MY?M<?$C5O!?_!/OX1&+1-/F\N'5GTJ.XN=KMLCFGEN3]FMM
MV"RHPR &RS!21QX6G6A7JJDHV3M>6RU_4Z:\Z<J4.=N[Z+=G$?%;5_\ @K#_
M ,$RM6TGXF?$GXWW/C'P]>:@EO,]YXBN=8T^:3:7^S2"[59H"RJ^&0*?E.&K
M]-O OQH\->-_@-I?[0$,$T.E:CX5CUUX!\\D4+6XG:/MN91E>W(K\FOV[_\
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M,Z,2%?!!&T';M!KQO1_^"DW[=W[$7B6R\ ?M_P#P/DUC1IIQ#;^*;&*.*>5
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M')+$+[M\2/\ @G-^Q'\3_#\OA[6/V;/"NG!XW6.\\-Z3%IEQ"QQAUDM@A)!
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M#VTL<:^1<PK$V)&1LL?EV[AD@5'_ ,%,?^"CWQ4^$_Q-L/V2/V3M/,_CG4!
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M5(/%>E*$*57V:=)06EF]?._F<*G*<.=J?-W2T^7D?H7\(/VC/!'Q@_9PTO\
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MN2OAO_@M!_R/7[(7_9W'A/\ ]&O6=7X/Z[ET_P"(C[DHHHK0@**** "BBB@
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M,1P2+2+(_#(K[XHIU<=2EAY4:=-13MUOMZ[_ *"AAIQJJI.=VKK8_.?XO_\
M!4O]LO\ 8Z^/_C+PC\<?@*/$'A%/%-]_PB=Y<V[Z:[Z<TTOV41W4<;Q2KY83
MDHS_ "L&;=T\=^./QH_:;_X+*^-O"G@#X<?L[#0="T>^D<:J));J*S\X1K++
M<7C1QH$41EA&JAFZ8=@M?KU154\?0I6G"BE-+>[M]VQ,\+5G>,JC<>UE^9\W
M_MZ_L-R?M,?LC67P8\%WT?\ ;WA*.VN/"US?,$%Q)!"83"[#A1+&6&?NA]A/
M KXS^#7_  5._:Q_83\*67P _:3_ &<;K58M MOL.CMJUQ-I=XD2;?+0S&*6
M.>-$PJE5'R[/F('/ZN45E0QL84O95H<\;WWLT_5&E7#RE/GIRY9;=_P/S=\+
M?\%./V__ -L3QSHWAO\ 9A_9S/AO0Y]8M3J6MQVC:B8;;S LH>[GC2V1#MFR
M?+W_ "[5.5);](J**RQ%:E5:]G!12^?WLTI4YP3YY<S"OQ$_;Q_:Y\3?'7]L
M34H_CCH>HZCX,\%^);K3]/\  ]IJIT\>1!*T;9D\N39+*4#22;6;!V*5"J5_
M;NBM,#BX8.HYN',[=[6,\30EB(**E;Y7N?F'X2_X+Y^&? GAFQ\&^#/V(K72
M]*TVV6WL-/L?'0CB@C7HJJ-/X'_ZZ^E_^">__!2__ANWQ;XC\+'X)2>%O[ T
MZ&Z^U#Q#]N2;S)"FP_Z/%L/&1][/S=,5]2T4ZV(P52#4*-F^O,W^8J5'$PFG
M*I==K)!1117"=04444 %%%% !1110 4444 %%%% !1110 5\-_\ !"[_ )$7
M]I'_ +.X\8_^BK"ON2OAO_@A=_R(O[2/_9W'C'_T585G+^)'YEQ^!_(^Y***
M*T("BBB@ HHHH **** "BBB@ HHHH **** "OR[_ ."!EI=P?'+XGF>UD3R=
M&@CEW1GY'^TO\K9Z'Y6X/H?2OU$HKIHXGV5"I2M\=OE8QJ4>>K"=_AO^(444
M5S&Q^9OPK@G3_@O_ *\)(FXN+]VR/X3H_!^AR,?45^F5%%=.)Q'UAQ=K<L4O
MNZF5&E[)2UW;?WGYE?\ !&F&:+]NGXSB6)EV6MZK[AC:?[3'!]#P?RJQ_P %
M/_A)^T'^S_\ ML:'^W]\*/!$WB#2K9+.6[:.RDGBL;BWC$#1W*QG<D4D>W$G
MRC<S#(;:6_2VBNEYB_K;K<NC5FNZM8Q^JKV'L[[.]_.]S\S'_P""T7[5W[15
ME'\-OV5_V4Q;>*;Q1"VHV]W)JWDNP_UJ1>1''#C:[9F9T &6R%-2?\$)/#/B
M+PG\<_C'X9\4PD:CI4=K9ZF1\P6X2ZN4<9_WD;\J_2^BB>.H^PG2I4E%2MUN
M]'YBCAJGM8SG.[5^EMUY'P9^V3_P4'_;+_8N_:G\0#4?@X/$GPJGCL9-!FNM
M/>!$7[-!]H6.]B0@-YYE!$JN5W+@!< _/_[2?[=?[0__  5/\,V'[/'P9_94
MDMK5]7@N[F2TO)-1E69 ZJ6N#%#%;18E^8N.W+@$BOUSHHHX[#TE&7L5SKK=
M_?8*F&JU&U[1\KZ67YGD/PS_ &4M(T#]BG3OV0_'.H"]@/@QM&U>[@Y!EEC;
MS9(L@<+([%"1D;5)YK\[/AO\4/VW?^"-_BW6_AYXJ^%!\3>!+W5/M0N)(YDL
M;K&U#<6MT@98)'38K)(K%2$RG'/ZXT5E0QKIN:J14HRU:??NGT-*N'4^5Q?*
MUL_ZW/S.OO\ @MU^TU\;XO\ A$?V7OV0MNMS*T1E%W<ZV\3./D=8H8(0I"K(
M?GW*<9(PK!OOC]F*7XS7'P!\*7/[0KD^-)M)23Q"&BAC*SL2=I6$"-2%*@A1
MC(KN:*C$5Z%2*C2IJ*]6W]['2I5(.\Y\S^[\@KXM_;N_:E_X*#?LI_'>3Q=\
M,/A+#XO^%]UI-LJ1-H;W"V5SN*REY;;;+"[-M ,NZ,AU"C=G'VE16="K"E4Y
MI14EV9=2$IQLI6]#\Q=>_P""_/Q4\4Z0?#'PP_96M;7Q',I2&>YUZ74%#A&W
M%;:.WB8D$;L%S@ YSUKIO^"6/["WQ]?X_:A^W!^U?HU_IFKSM=3Z/8:O%Y5[
M<WMUO6:ZFA(S H1Y$6-@K$R9 557=^BE%=<\=3C2E3H4U#FT;NV[?,YXX:;F
MI59\UMM$D%%%%><=@4444 %%%% !1110 4444 %%%% !1110 5\7_L[_ /*;
M_P#:+_[)=X2_]!>OM"OB_P#9W_Y3?_M%_P#9+O"7_H+UG4WCZFE/:7I^J/M"
MBBBM#,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "OR[^+]E=M_P7ZT@):R'S-9TB2/$9^9%TB+<P]AM;GMM/I7ZB45TX7$_5
MI2=K\T6OOZF-:C[;EUM9I_<><?M7?LR> _VMO@MJGP>\=IY:72^;I>I)&#+I
MUXH/E3IGT)(89&Y&9<@-7P5_P3$_:%^*G[&_[2%[_P $\_VB-.NH;/4-7:'0
MBZLXLK]_F0QGO;7(PP(R Y5N [FOT\HJJ.*]G0E1FN:+_!]T*I0YZL:D79K\
M5V/SE_X*/?LG?M'?!3]J>T_X*"_LCZ+=:E.&CN-<L=-M#/-:7$</DR2-"OS2
MV\T(Q)MY!,A. P88NG_\%_?B/;:>/"NM_LC6TWBCYK<M;^))H8S=$E4'V1K9
MY.I4&/S=Q(.",\?II16T<=2E3C&O24^71.[3M\MS*6&J*;E2GRWU:LG^9\G_
M /!.SX]?MS_M'>-_$WQ'_:1^'I\*^"Y=,@7PII1T7[(K3%\F1#-FXE!C RY;
MRR2-H'0>B_\ !0[]GY?VDOV1/%_P]L[$SZM;V!U/0 @)?[9;?O450.ID >+Z
M2GZU[77D'[>7[1/_  RW^RQXI^*UD^-4CLQ9Z"N#S?3GRXFZ$80DR'.,B,C.
M2*QC4E5QD94HJ+NK)?U]YLX1A0<9NZL[MGY7?\$^O"_C?]L3]JSX6?#'QR6O
M?#_PRTZ2Y>%H21%8V]U)=!)/7?<3Q0DG'R%!SMY_;"OA7_@A;^SO=>"?@EK?
M[17BJT?^U/'5]Y6G27"'S!I\#,-^3S^]F:0GCD1(V3GC[JKIS>LJN+<8[1T^
M>[_$PP%-PPZ<MWK_ )?@%?&'_!=U&?\ 8HL61&(7QU8EB!D8^SW7)_&OL^BN
M'#U?85XU+7L[G35I^UI.'='CO_!/B"6#]B+X71W$;(?^$-LSM92" 8\@_B,?
MG7YQ_P#!9_X)>(?@9^UFWQA\$R75EI_Q'TB4RRV6Y!]I\K[->0$C[PDC='8?
MQ>>PQ7Z_45T8;&O#8IUK73O=>IE7PRK4%3O:UM?0\*_X)N?L[G]F?]D3PMX'
MU.R$.L:C!_;'B $8;[9<A7*-Q]Z.,11'_KE7R'_P6JMYI/VP_@OY<3-YD,*1
MX&=S?V@G ]3R/SK],:*FCC)4L6Z\E=N_XE5*"G05).R5OP,CXB12R_#[7(8D
M9G;1[I551R3Y3\#^5?GY_P &]*,/"7Q3D*'!U'20IQQD)=9'ZBOT:HJ*>(]G
MAIT;?%;7M8<J7-5C.^U_Q/S-_;9@G_X?:_"C]TV&N/#SKQU47<N2/;@_D:^Z
M/VP/V==._:J_9V\2?!&^O8[2;5;4/IM_(A(MKN)Q)#(<<[=ZA6QR59AWKTJB
MJJ8N4_9N*LX)+[NHH4(QYT]5)_I8_)/X)?MJ?MG_ /!*_3G^ 'QS^ ,VL>&=
M/O9FTU+^66U""0N2+2]5)(I(6DW28V,<EP"I) [C4O\ @K]^VY^TZA\'?L>_
MLJOIU[<@1-J4"RZS):N"-SAS#%;Q !HAF9&5<G/WEV_II173+'X:<N>5!.?>
M[M?T,5A:T5RJJ^7M97^\\;_:?U[]IWP?^QEJ/B#X+V<U_P#$ZPTC39(XK/3X
MKIYYUGM_M@2':4?,7GX55S_<&=M?%>F?\%[?C)X5TMO"'Q,_9.M)?%*KY?FQ
MZQ/8()"@"%K22"1S\W.T2#(( QU/Z<45ST,1AX0<:M)2UONT_P .AK5I59RO
M"?+\KGYS?\$M?V?_ -H#XF_M;>*?V]_C7X!E\*VFK+>2:=8R6+6WVVYNV!9H
MHI/G\E$W?O#]]F4AFP]:G_!=?]G[XE>,M(\#_'GX<>'+[48_#+7-IK1T^W\V
M2T21XI()BJ@ML#I("W12R=,\_H+16G]H5/KBKV6FB72VUB?JL?J[I7>O7K>]
M[GPC^Q+_ ,%</BS^UI\;/"GP7;]G6VMHYH)_^$L\26>I2RQ0[+:21)5C\I5M
MU:2/;M=WW;P <]>&_P""EW['?[0WP:_:=M_V^_V3]%N[Z3[1'>ZO;:19F>?3
MKN*,(\S0J"9;>6,?O" <$R;\*P-?I/11'&PHXCVE&FHJUFKWOW!X:52CR5)7
M=[IVM8_,:+_@OQ\6CHH\(2?LHV#>+]WD&5-;G$)N-^-OV+R#+G'R[/.SGG/\
M-;?_  3R_8[_ &COCI^U'+^W]^V'IEWITL=PUYHFG:E;&">\N3%Y<+B$_-#;
MPQX\L'!8K'C(!)_1ZBJECJ4:<HT*2@Y:-W;T\NQ,<--S3JSYK:K1(^!_^#@2
M.0_L]>!Y@C%1XS92V. 3:2X'XX-?8'[+J-'^S1\.XI4((\"Z0"I'(/V*'@UW
M%%<T\1SX6%&WPMN_J;1I<M:52^]OP/S*_P""XT,S_M/_  =*0N=]J50A?O'[
M;'D#WY'YU^BWQ9^&OA_XQ_"_Q!\*?%*$Z=XBTBXT^[9 -R+*A3>OHRD[AZ$"
MM^BG5Q+J4:<$K<E]?5W"%%1G.5_BM^"L?D=\-_BA^V[_ ,$;_%NM_#SQ5\*#
MXF\"7NJ?:A<21S)8W6-J&XM;I RP2.FQ6216*D)E..?0+[_@MU^TU\;XO^$1
M_9>_9"VZW,K1&47=SK;Q,X^1UBA@A"D*LA^?<IQDC"L&_3&BNJ6/P]5\]2BG
M/O=I/U1@L+5A[L*C4>UD_P 3Q[PA??M2Q_L-R:IXLW-\7CX"O9XD%K;!AJY@
ME:W7RT40;@_EJ5QLSP<\U\2>'/\ @N3^T7\&K<^"?VE_V5TO-?M0(WE:\FT2
M9BI96:2&2WE&XD ?)L *GCG _3RBN>CB*$>;VM)23=][6]+=/(UJ4:LK<DW&
MWHS\OOV/_AU^TC^W=_P4!T_]N/XE?"UO"/AW1GBNS<I920Q7300>5!# 9OFN
M&+ ,\@^4*I&5.Q:_4&BBHQ6)>)FG:R2LEV15&BJ,6KW;=VPHHHKF-@HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^9O\ @BE_
MR<9^V?\ ]G!/_P"D:44?\$4O^3C/VS_^S@G_ /2-**\*I_$9ZT/@1=_X.-_^
M4=UK_P!E:\*?^G&.OHROG/\ X.-_^4=UK_V5KPI_Z<8Z^C*[L#M(Y<7NOZ[!
M1117><84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %?#?_!:#_D>OV0O^SN/"?_HUZ^Y*
M^&_^"T'_ "/7[(7_ &=QX3_]&O6=7X/Z[ET_XB/N2BBBM" HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** /AO_@H?_P I9?V&?^PMX\_]-=E7W)7PW_P4/_Y2R_L,
M_P#86\>?^FNRK[DK.'QR]?T1I/X8^GZL****T,PHHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /@C_@Y1_P"45_B/_L:M
M&_\ 2H5][U\$?\'*/_**_P 1_P#8U:-_Z5"OO>LH_P 67R_4TE_"C\_T"BBB
MM3,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@#QC_@H]_P H\OCS_P!D8\4?^FFYKEO^"0'_ "C%^"/_ &(-G_(UU/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_P *_1NBCZS6[A[&EV/SD^W?\'!W_1H?[/O_ (7][_A1]N_X.#O^C0_V??\
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MO^#@[_HT/]GW_P +^]_PK]&Z*/K-;N'L:78_.3[=_P '!W_1H?[/O_A?WO\
MA7RI_P %-9_^"M<_BW]G'_AI3]G_ .$.BW<?[1/AY_AY%X>\8W<ZZAXA#O\
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MO_A?WO\ A1]N_P"#@[_HT/\ 9]_\+^]_PK]&Z*/K-;N'L:78_.3[=_P<'?\
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M??\ PO[W_"C[=_P<'?\ 1H?[/O\ X7][_A7Z-T4?6:W</8TNQ^07[=/['?\
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MO_A?WO\ A1]N_P"#@[_HT/\ 9]_\+^]_PK]&Z*/K-;N'L:78_.3[=_P<'?\
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M4?6:W</8TNQ^<GV[_@X._P"C0_V??_"_O?\ "C[=_P '!W_1H?[/O_A?WO\
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M4?6:W</8TNQ^<GV[_@X._P"C0_V??_"_O?\ "C[=_P '!W_1H?[/O_A?WO\
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M04444#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ K\_/^"ZW_)1_V*?^SS?!W_HYZ_0.
MOS\_X+K?\E'_ &*?^SS?!W_HYZ:W _0.BBBD 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% 'Y^?\%-O^4R'_  3[_P"PW\0O_3585^@=?GY_P4V_Y3(?\$^_^PW\
M0O\ TU6%?H'3>P!1112 **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ KX,_9C_Y6!OVGO^R2^#O_ $77WG7P9^S'_P K W[3W_9)?!W_ *+H$S[S
MHHHH&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!\&?\$>?^
M3K_VWO\ LXZ?_P!)5HH_X(\_\G7_ +;W_9QT_P#Z2K10Q+8/^#C7_E'A9_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MM'A3]NW]M^Y\4:;;W'[9'Q5DCDU"%9(Y/B'J95E+@$$>?R/:OZ6*_E1\&?\
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MHRB!AA=N %+ ?H%17Y ?!']L7_@LA_PTM\2O^"+'A?Q;I/B;XA^$-9BN;?\
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M?C1\0=9U7Q'K!^">CZOK%]?WCW%[J<XTN.61Y)9"6DE<@DNQ)9FR2237Q?\
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M1M'=01#RUN('<)N7EPDA.[;YC-_X*._M;_M/^-?VQ/A[_P $J?V$/'MGX/\
M&OC/1)_$?Q"^(TVGQWDGA3P[&73=;PR_(UQ,Z,JD\KF/&W?YL98#[MK\WO\
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M1ZKXA\'?'3Q>GB;3-8TZ.0>?$BO#'Y#;&+%E&YE4A7C8JZ_:M@-*_P""E'[
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M&Y^:A@>\T5^:'[+_ , OV]O^"N7PLL_VQOVI?VY_B?\ !/P9XR8:E\-?A?\
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M7Z!U^?G_  76_P"2C_L4_P#9YO@[_P!'/36X'Z!T444@"BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH _/S_@IM_RF0_X)]_]AOXA?^FJPK] Z_/S_@IM_P ID/\
M@GW_ -AOXA?^FJPK] Z;V ****0!1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %?!G[,?_*P-^T]_P!DE\'?^BZ^\Z^#/V8_^5@;]I[_ +)+X._]
M%T"9]YT444#,7QYX(\+?$_P-K7PU\<Z5]NT3Q#I5SIFL67G/%]HM9XFBECWQ
MLKIN1V&Y2&&>"#S7S3_PX\_X)=?]&P_^7KK?_P FU]845O1Q6*PZ:I3<;]FU
M^1E5H4*S3J03]4F?*-E_P1)_X)B:?>17]I^S+LE@E62)_P#A,]:.U@00<&\]
M?6OJZBBE6Q.(Q%O:S<K;7;?YCIT:-%?NXJ/HK!7A?_!4+_E&A^T1_P!D+\7?
M^F:[KW2O./VP_@[X@_:)_9(^*?[/WA/4K.RU7QU\.=;\/:;>:@SBW@N+VPFM
MHWE**S",-*"VU6. < GBL5N:'SY_P0R\/:!XK_X(T?!/PWXIT.SU+3[SPA-'
M=V&H6J30SH;VXRKHX*L/8BOG[]GCPYIW_!(7_@ME<?LA>#8VTGX&?M.:)+K?
M@31 S&TT/Q-; _:+:W&2(D=58;0 ,7%H@XB%?:O_  3-_9@\=_L8?L)?#;]E
M_P")NL:1J&O^#]#>SU.\T&>62SDD:XEES$TL<;LN' RR*<@\5YO_ ,%AO^">
M'Q+_ &]_A!X*U/\ 9T\9:+X;^*_PO\>V/B?P%K_B"YFAM(9(W'G12O!#+(JL
M%CD&U"3);Q@D*6-.^H'I7_!4+_E&A^T1_P!D+\7?^F:[KS#_ ((S>#O#/Q#_
M ."+_P '?A_XSTF'4-'UWX:/I^K6$ZYCN;:=IXI8F'<,C,I]C7N7[5WP?\<_
MM%?L7_$KX Z==Z38^)O'7POUGP_!<3SR_8;>^O=.FME9G$9D\E9)02P0MM&=
MI/%87_!.']FSQO\ L??L-?#3]F;XDZOI5_KO@WPVFGZI=Z'-+):2RAW8F)I8
MXW9?F'+(I]J.@=3\^_\ @EU^V/I'_!*WX'_M0?L)?M*:V\LO[+.H7^O^#UN9
MOWVL>'[V3S+1(\X!>2YG@Z!5W:E&,=:^FO\ @A%^S=XZ^$W['$W[1'QS1Y/B
M;\??$$_C_P ;SSHZR1F].^UML.=R*D#*^P\HTTB\X%>=_P#!5/\ X(4S_P#!
M0K]M_P"&G[2?ASQQI&A^'(K>#2OC7I5S=745QX@TBUNXKJ"&%84:.5V*M&WF
M-&$"0N"YC"C]&+6UM;&VCL[.WCAAAC"111(%6-0,!0!P  ,8%#8'YN_\$HO^
M4T/[?O\ V,'A3_TGOJ_2:ODC]B7]@CXN_LV_\% ?VG_VK_'7B7PW=>'_ (TZ
MKHESX5L=)N[B2]M4LXKE)1=K) B1DF9-HC>0$;LE<#.?\=_V3_\ @J?X1^/W
MBCX\_L,_M\Z%/HWB:2&ZD^$/QH\/37^C65U&D,9%I>VS?:;.!UC.88E"AI)'
M^=G#(!T-W_@KE^PE^S1^V/\ LC^,M9^,WAK3+'Q!X/\ "6H:IX2^((@6/4/#
MD]O"]PLJ7 VN(-\8:2+=L< GA@K*S_@B'^T!\5?VG_\ @EG\(?C'\:IKBX\1
MWNB7-E>ZA=MF6_2ROKBRBNG)P2\L=NCLQ^\S%N=V3Y'\4/V&O^"Q/[?/@R?X
M'?MY?M8?"#X>_#G495C\4:+^SUHFIR7_ (@LN2]K)=ZJV;9&) 8(KAE7#!@6
M4_<GP>^$GP^^ ?PK\/?!;X4^'HM)\-^%](@TW1=.B)(@MXD"("3RQP,EB26)
M))).:.@'2U^;_P#P;??\D[_:=_[.P\4?^B;.OT@KY,_X),_L&_%G]@WPK\8M
M"^+?B;P[J4WQ!^.&M>,=%;PY=3RK#87<=NL4<QFAB*S@Q-N5=Z#(P[9.#H!X
MEX6_Y6F_$G_9I\?_ *=;6OT$^)__ "33Q%_V KO_ -$O7S/HO[!WQ;T__@L_
MK'_!1>Y\2>'#X)O_ ((+X.@TI+J<ZJ+\7T$_F-&81"(=D;#<)2V<#9@Y'U'X
MOT>?Q#X3U3P_:RHDM]IT]O&\F=JL\;*"<=LFCJ!^?_\ P:V?\H?_  ?_ -C3
MKO\ Z725F_\ !'W_ )2V?\%#/^Q\\*?^B]8KWG_@C+^PU\5_^"=?[!V@?LO?
M&KQ%X>U3Q!I>LZE=W-WX7NIYK-DN+EY4"O/#"Y(4C.4&#D#(YKRSXL?\$[O^
M"@OP#_;N^(/[<7_!,3XQ?"N,_%VRL4^('@'XR6.H_P!G&ZM8C''>03:<#*7Z
MD(=H!GFR6!55-V!S7_!U7I.NZA_P21UF\TF*1K>P\=:)/J90'"0&9X@6P.GF
MR1#GN1[5U'A#_@C%HOCKPGI?C;PU_P %C/VYKC3M9TZ"^L)U_:"!$D$L:R(W
M%F1RK \9KZ6TW]GCQG\>/V,[G]G'_@H'?^&_&6K>*=#N]/\ '4_A6PELM/G6
M:60H+59"9(C%&8@LA(;?$)!M. /DSX/?L,?\%JOV ?"=M\"/V(/VLO@M\2/A
MKI;2Q^&=/^/^C:K!J.A6F4,5K'/I6?M"I^\4;RJJ,;452$C$!WOPG_X(;?!_
MX=?M,> _VJ?'/[:W[27Q0\1?#B[N;GPM:?%;XEPZS:6SSPF*7"O9K(@8%6(C
MD3<T:;MP7%><_P#!P/\ \E$_8O\ ^SL/#O\ Z.2OH']E?]F__@H7;_&6/]H#
M]N?]M+2]::#27M]-^%'PO\.OIOAJQGF ,LLLUPSW.H%"2D1EV;0@<Y+E5RO^
M"H/[!WQ<_;:\6_L^:Y\+?$OAS3H/A3\;])\8^(QK]W<1O<6%M(K21VPAAD#S
M$#Y5<QJ3C+BA/4#ZTK\W_P#@H'_RL$?L/_\ 8%\9?^FR>OT@KY,_:@_8-^+7
MQN_X*A_LY_MM>%_$WAVW\*_"+3O$$'B73K^ZN%U"Y:^LY(83:HD+1N [C?OD
MCP!D;CQ0@6YXW_P=._\ *(7Q/_V-^A_^E8K]"/"O_(L:;_UX0_\ H KY?_X+
M0_L+?%O_ (*+_L*:Q^S%\$O$7AS2]?U'7=-O8+SQ5>3P6:QV\XD<,T$$S[B!
MP A!/4BOJ;1[)M-TFUTYW#M;VZ1LP'4JH&?TI= /SJ_9/_Y65_VJ/^R1^&/_
M $ETVOH[_@L+_P HL?V@?^R3ZU_Z2O7/?!/]@[XK_#7_ (*Y?&C]OO6_$WAV
M;PC\1_ NCZ+HVEVMS.=2@N+2*UCD:=&A$2H3;L5*R,3N&5%>K_MX_ 7Q;^U'
M^QA\4/V<_ 6IZ=9:UXV\#ZCH^E76KRR):Q7$\#1HTK1H[J@8C)5&('0'I3Z@
M<3_P1Z_Y18_L_?\ 9)]%_P#25*^D*\E_8.^ OBW]ES]C#X7_ +.?CW4].O=:
M\$^!].T?5;K2)9'M9;B"!8W:)I$1V0L#@LBDCJ!TKUJD]P/SF^%_[7'_  4E
M_P""K7C_ .(TW["GQ.\$_!#X/^!?%UUX2M?'VO>$O^$A\0:UJ5OL:>XM[625
M;6. *\94/D_O!DL=RQ?,G_!63]G#]OKX*_%']E;6OVN?^"DG_"[-(O/VC] @
MTK1/^%.Z5X;_ +/N?/1C<>=92,TN4#)L88^;/45]1>$O^";_ /P4N_8$^)_Q
M U3_ ():?'WX1:C\/_B+XNN/$MU\.?CAI&I+#H%_<#]^]I=:83+*#LB4*X4!
M%4$,R&23D?VB?^"./_!1/]K7X@?"C]HW]I+]L[POXD\;>"OBSH>NS^#],MKK
M2_"GA[1+=O-O8-.B$4TUY>R2I"5GN?++(I4LH %4K7 ^H_\ @M%_RBC^/O\
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MO[-'[8'@OQ/X;M?#?P:N-9?Q18:I=7"7UT+N&-(OLJ1PO&^&4[O,DCP,8W=
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M_P""AEW:67_!P%^P]->7,<*-I/B^,/*X4%WTZ9$7)[EF4 =R0!S7Z25^3?\
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MW=W$R06%W';K%',9H8BLX,3[E4,@XP[9."^X'E__  = ?\H<?B#_ -AW0/\
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MB?#7BCPUX^TB6ZT'Q18*XDB2=[<^?;D.D09HU8D11E2A1A+YM^TE_P $Z?\
M@K[_ ,%#/@;XJ^&O[:/[7?PN\*6,WAV_BT'X?_!.QU.UTG6]4,'^@RZMJ%\K
MW7V6.<!GMXHV5@ >2  P/:/^"=G_ "A&^%__ &;]:_\ IL-<#_P;*_\ *&+X
M5_\ 7_XA_P#3Y?5]"?LJ?LQ^./@9_P $[O!?[(OBW6=*N/$7A[X7P>&[^^TV
M:5[)[M+/R&>-GC61HM_()16(YV@\5S'_  1__8P^)W_!/W_@G[X)_93^,?B#
M0=3\1>'+C59;^\\,W,\UD_VG4KFZC$;SPPR'$<R!LQKAMP&0 2-C/ OAK_RM
M(_$'_LT:#_T]:;7Z+U\H^$/V%?BQH'_!9?Q5_P %$[WQ)X=;P7K?P-B\%VFE
M174YU1;Y=0M+DRO&81$(=ENPR)2VYA\@&2/JZDQ!1110 4444 %%%% 'P9_P
M1Y_Y.O\ VWO^SCI__25:*/\ @CS_ ,G7_MO?]G'3_P#I*M%#$M@_X.-?^4>%
MG_V5KPI_Z<HZ^\Z^#/\ @XU_Y1X6?_96O"G_ *<HZ^\Z.@!1110,**** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "OS\_X+K?\ )1_V*?\ L\WP=_Z.>OT#K\_/^"ZW_)1_
MV*?^SS?!W_HYZ:W _0.BBBD 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'Y^?\
M!3;_ )3(?\$^_P#L-_$+_P!-5A7Z!U^37_!QA\6?'7P*_;'_ &/OB]\--4CL
M=>T"+XBW6EW4ELDPCE&F:: Q20%6X)X((KYE_P"'[W_!3/\ Z+?IW_A'Z;_\
M8KU\OR;%YE2<Z322=M6_\F<&,S'#X*:C4OKV/W_HK\ /^'[W_!3/_HM^G?\
MA'Z;_P#&*/\ A^]_P4S_ .BWZ=_X1^F__&*[_P#57,OYH_>_\CD_M[ ^?W?\
M$_?^BOP _P"'[W_!3/\ Z+?IW_A'Z;_\8H_X?O?\%,_^BWZ=_P"$?IO_ ,8H
M_P!5<R_FC][_ ,@_M[ ^?W?\$_?^BOP _P"'[W_!3/\ Z+?IW_A'Z;_\8H_X
M?O?\%,_^BWZ=_P"$?IO_ ,8H_P!5<R_FC][_ ,@_M[ ^?W?\$_?^BOP _P"'
M[W_!3/\ Z+?IW_A'Z;_\8H_X?O?\%,_^BWZ=_P"$?IO_ ,8H_P!5<R_FC][_
M ,@_M[ ^?W?\$_?^BOP _P"'[W_!3/\ Z+?IW_A'Z;_\8H_X?O?\%,_^BWZ=
M_P"$?IO_ ,8H_P!5<R_FC][_ ,@_M[ ^?W?\$_?^BOP _P"'[W_!3/\ Z+?I
MW_A'Z;_\8H_X?O?\%,_^BWZ=_P"$?IO_ ,8H_P!5<R_FC][_ ,@_M[ ^?W?\
M$_?^BOP _P"'[W_!3/\ Z+?IW_A'Z;_\8H_X?O?\%,_^BWZ=_P"$?IO_ ,8H
M_P!5<R_FC][_ ,@_M[ ^?W?\$_?^BOP _P"'[W_!3/\ Z+?IW_A'Z;_\8H_X
M?O?\%,_^BWZ=_P"$?IO_ ,8H_P!5<R_FC][_ ,@_M[ ^?W?\$_?^BOP _P"'
M[W_!3/\ Z+?IW_A'Z;_\8H_X?O?\%,_^BWZ=_P"$?IO_ ,8H_P!5<R_FC][_
M ,@_M[ ^?W?\$_?^BOP _P"'[W_!3/\ Z+?IW_A'Z;_\8H_X?O?\%,_^BWZ=
M_P"$?IO_ ,8H_P!5<R_FC][_ ,@_M[ ^?W?\$_?^BOP _P"'[W_!3/\ Z+?I
MW_A'Z;_\8H_X?O?\%,_^BWZ=_P"$?IO_ ,8H_P!5<R_FC][_ ,@_M[ ^?W?\
M$_?^BOP _P"'[W_!3/\ Z+?IW_A'Z;_\8H_X?O?\%,_^BWZ=_P"$?IO_ ,8H
M_P!5<R_FC][_ ,@_M[ ^?W?\$_?^BOP _P"'[W_!3/\ Z+?IW_A'Z;_\8H_X
M?O?\%,_^BWZ=_P"$?IO_ ,8H_P!5<R_FC][_ ,@_M[ ^?W?\$_?^BOP _P"'
M[W_!3/\ Z+?IW_A'Z;_\8H_X?O?\%,_^BWZ=_P"$?IO_ ,8H_P!5<R_FC][_
M ,@_M[ ^?W?\$_?^BOP _P"'[W_!3/\ Z+?IW_A'Z;_\8H_X?O?\%,_^BWZ=
M_P"$?IO_ ,8H_P!5<R_FC][_ ,@_M[ ^?W?\$_?^BOP _P"'[W_!3/\ Z+?I
MW_A'Z;_\8H_X?O?\%,_^BWZ=_P"$?IO_ ,8H_P!5<R_FC][_ ,@_M[ ^?W?\
M$_?^BOP _P"'[W_!3/\ Z+?IW_A'Z;_\8H_X?O?\%,_^BWZ=_P"$?IO_ ,8H
M_P!5<R_FC][_ ,@_M[ ^?W?\$_?^BOP _P"'[W_!3/\ Z+?IW_A'Z;_\8H_X
M?O?\%,_^BWZ=_P"$?IO_ ,8H_P!5<R_FC][_ ,@_M[ ^?W?\$_?^BOP _P"'
M[W_!3/\ Z+?IW_A'Z;_\8H_X?O?\%,_^BWZ=_P"$?IO_ ,8H_P!5<R_FC][_
M ,@_M[ ^?W?\$_?^BOP _P"'[W_!3/\ Z+?IW_A'Z;_\8H_X?O?\%,_^BWZ=
M_P"$?IO_ ,8H_P!5<R_FC][_ ,@_M[ ^?W?\$_?^BOP _P"'[W_!3/\ Z+?I
MW_A'Z;_\8H_X?O?\%,_^BWZ=_P"$?IO_ ,8H_P!5<R_FC][_ ,@_M[ ^?W?\
M$_?^BOP _P"'[W_!3/\ Z+?IW_A'Z;_\8H_X?O?\%,_^BWZ=_P"$?IO_ ,8H
M_P!5<R_FC][_ ,@_M[ ^?W?\$_?^BOP _P"'[W_!3/\ Z+?IW_A'Z;_\8H_X
M?O?\%,_^BWZ=_P"$?IO_ ,8H_P!5<R_FC][_ ,@_M[ ^?W?\$_?^BOP _P"'
M[W_!3/\ Z+?IW_A'Z;_\8H_X?O?\%,_^BWZ=_P"$?IO_ ,8H_P!5<R_FC][_
M ,@_M[ ^?W?\$_?^BOP _P"'[W_!3/\ Z+?IW_A'Z;_\8H_X?O?\%,_^BWZ=
M_P"$?IO_ ,8H_P!5<R_FC][_ ,@_M[ ^?W?\$_?^BOP _P"'[W_!3/\ Z+?I
MW_A'Z;_\8H_X?O?\%,_^BWZ=_P"$?IO_ ,8H_P!5<R_FC][_ ,@_M[ ^?W?\
M$_?^BOP _P"'[W_!3/\ Z+?IW_A'Z;_\8H_X?O?\%,_^BWZ=_P"$?IO_ ,8H
M_P!5<R_FC][_ ,@_M[ ^?W?\$_?^BOP _P"'[W_!3/\ Z+?IW_A'Z;_\8H_X
M?O?\%,_^BWZ=_P"$?IO_ ,8H_P!5<R_FC][_ ,@_M[ ^?W?\$_?^BOP _P"'
M[W_!3/\ Z+?IW_A'Z;_\8H_X?O?\%,_^BWZ=_P"$?IO_ ,8H_P!5<R_FC][_
M ,@_M[ ^?W?\$_?^BOP _P"'[W_!3/\ Z+?IW_A'Z;_\8H_X?O?\%,_^BWZ=
M_P"$?IO_ ,8H_P!5<R_FC][_ ,@_M[ ^?W?\$_?^BOP _P"'[W_!3/\ Z+?I
MW_A'Z;_\8H_X?O?\%,_^BWZ=_P"$?IO_ ,8H_P!5<R_FC][_ ,@_M[ ^?W?\
M$_?^BOP _P"'[W_!3/\ Z+?IW_A'Z;_\8H_X?O?\%,_^BWZ=_P"$?IO_ ,8H
M_P!5<R_FC][_ ,@_M[ ^?W?\$_?^BOP _P"'[W_!3/\ Z+?IW_A'Z;_\8H_X
M?O?\%,_^BWZ=_P"$?IO_ ,8H_P!5<R_FC][_ ,@_M[ ^?W?\$_?^BOP _P"'
M[W_!3/\ Z+?IW_A'Z;_\8H_X?O?\%,_^BWZ=_P"$?IO_ ,8H_P!5<R_FC][_
M ,@_M[ ^?W?\$_?^BOP _P"'[W_!3/\ Z+?IW_A'Z;_\8H_X?O?\%,_^BWZ=
M_P"$?IO_ ,8H_P!5<R_FC][_ ,@_M[ ^?W?\$_?^BOP _P"'[W_!3/\ Z+?I
MW_A'Z;_\8H_X?O?\%,_^BWZ=_P"$?IO_ ,8H_P!5<R_FC][_ ,@_M[ ^?W?\
M$_?^BOP _P"'[W_!3/\ Z+?IW_A'Z;_\8H_X?O?\%,_^BWZ=_P"$?IO_ ,8H
M_P!5<R_FC][_ ,@_M[ ^?W?\$_?^BOP _P"'[W_!3/\ Z+?IW_A'Z;_\8H_X
M?O?\%,_^BWZ=_P"$?IO_ ,8H_P!5<R_FC][_ ,@_M[ ^?W?\$_?^BOP _P"'
M[W_!3/\ Z+?IW_A'Z;_\8H_X?O?\%,_^BWZ=_P"$?IO_ ,8H_P!5<R_FC][_
M ,@_M[ ^?W?\$_?^BOP _P"'[W_!3/\ Z+?IW_A'Z;_\8H_X?O?\%,_^BWZ=
M_P"$?IO_ ,8H_P!5<R_FC][_ ,@_M[ ^?W?\$_?^BOP _P"'[W_!3/\ Z+?I
MW_A'Z;_\8H_X?O?\%,_^BWZ=_P"$?IO_ ,8H_P!5<R_FC][_ ,@_M[ ^?W?\
M$_?^BOP _P"'[W_!3/\ Z+?IW_A'Z;_\8H_X?O?\%,_^BWZ=_P"$?IO_ ,8H
M_P!5<R_FC][_ ,@_M[ ^?W?\$_?^BOP _P"'[W_!3/\ Z+?IW_A'Z;_\8H_X
M?O?\%,_^BWZ=_P"$?IO_ ,8H_P!5<R_FC][_ ,@_M[ ^?W?\$_?^BOP _P"'
M[W_!3/\ Z+?IW_A'Z;_\8H_X?O?\%,_^BWZ=_P"$?IO_ ,8H_P!5<R_FC][_
M ,@_M[ ^?W?\$_?^BOP _P"'[W_!3/\ Z+?IW_A'Z;_\8H_X?O?\%,_^BWZ=
M_P"$?IO_ ,8H_P!5<R_FC][_ ,@_M[ ^?W?\$_?^BOP _P"'[W_!3/\ Z+?I
MW_A'Z;_\8H_X?O?\%,_^BWZ=_P"$?IO_ ,8H_P!5<R_FC][_ ,@_M[ ^?W?\
M$_?^BOP _P"'[W_!3/\ Z+?IW_A'Z;_\8H_X?O?\%,_^BWZ=_P"$?IO_ ,8H
M_P!5<R_FC][_ ,@_M[ ^?W?\$_?^BOP _P"'[W_!3/\ Z+?IW_A'Z;_\8H_X
M?O?\%,_^BWZ=_P"$?IO_ ,8H_P!5<R_FC][_ ,@_M[ ^?W?\$_?^BOP _P"'
M[W_!3/\ Z+?IW_A'Z;_\8H_X?O?\%,_^BWZ=_P"$?IO_ ,8H_P!5<R_FC][_
M ,@_M[ ^?W?\$_?^BOP _P"'[W_!3/\ Z+?IW_A'Z;_\8H_X?O?\%,_^BWZ=
M_P"$?IO_ ,8H_P!5<R_FC][_ ,@_M[ ^?W?\$_?^BOP _P"'[W_!3/\ Z+?I
MW_A'Z;_\8H_X?O?\%,_^BWZ=_P"$?IO_ ,8H_P!5<R_FC][_ ,@_M[ ^?W?\
M$_?^BOP _P"'[W_!3/\ Z+?IW_A'Z;_\8H_X?O?\%,_^BWZ=_P"$?IO_ ,8H
M_P!5<R_FC][_ ,@_M[ ^?W?\$_?^BOP _P"'[W_!3/\ Z+?IW_A'Z;_\8H_X
M?O?\%,_^BWZ=_P"$?IO_ ,8H_P!5<R_FC][_ ,@_M[ ^?W?\$_?^BOP _P"'
M[W_!3/\ Z+?IW_A'Z;_\8H_X?O?\%,_^BWZ=_P"$?IO_ ,8H_P!5<R_FC][_
M ,@_M[ ^?W?\$_?^BOP _P"'[W_!3/\ Z+?IW_A'Z;_\8H_X?O?\%,_^BWZ=
M_P"$?IO_ ,8H_P!5<R_FC][_ ,@_M[ ^?W?\$_?^BOP _P"'[W_!3/\ Z+?I
MW_A'Z;_\8H_X?O?\%,_^BWZ=_P"$?IO_ ,8H_P!5<R_FC][_ ,@_M[ ^?W?\
M$_?^BOP _P"'[W_!3/\ Z+?IW_A'Z;_\8H_X?O?\%,_^BWZ=_P"$?IO_ ,8H
M_P!5<R_FC][_ ,@_M[ ^?W?\$_?^BOP _P"'[W_!3/\ Z+?IW_A'Z;_\8H_X
M?O?\%,_^BWZ=_P"$?IO_ ,8H_P!5<R_FC][_ ,@_M[ ^?W?\$_?^BOP _P"'
M[W_!3/\ Z+?IW_A'Z;_\8H_X?O?\%,_^BWZ=_P"$?IO_ ,8H_P!5<R_FC][_
M ,@_M[ ^?W?\$_?^BOP _P"'[W_!3/\ Z+?IW_A'Z;_\8H_X?O?\%,_^BWZ=
M_P"$?IO_ ,8H_P!5<R_FC][_ ,@_M[ ^?W?\$_?^BOP _P"'[W_!3/\ Z+?I
MW_A'Z;_\8H_X?O?\%,_^BWZ=_P"$?IO_ ,8H_P!5<R_FC][_ ,@_M[ ^?W?\
M$_?^BOP _P"'[W_!3/\ Z+?IW_A'Z;_\8H_X?O?\%,_^BWZ=_P"$?IO_ ,8H
M_P!5<R_FC][_ ,@_M[ ^?W?\$_?^BOP _P"'[W_!3/\ Z+?IW_A'Z;_\8H_X
M?O?\%,_^BWZ=_P"$?IO_ ,8H_P!5<R_FC][_ ,@_M[ ^?W?\$_?^BOP _P"'
M[W_!3/\ Z+?IW_A'Z;_\8H_X?O?\%,_^BWZ=_P"$?IO_ ,8H_P!5<R_FC][_
M ,@_M[ ^?W?\$_?^BOP _P"'[W_!3/\ Z+?IW_A'Z;_\8H_X?O?\%,_^BWZ=
M_P"$?IO_ ,8H_P!5<R_FC][_ ,@_M[ ^?W?\$_?^BOP _P"'[W_!3/\ Z+?I
MW_A'Z;_\8H_X?O?\%,_^BWZ=_P"$?IO_ ,8H_P!5<R_FC][_ ,@_M[ ^?W?\
M$_?^BOP _P"'[W_!3/\ Z+?IW_A'Z;_\8H_X?O?\%,_^BWZ=_P"$?IO_ ,8H
M_P!5<R_FC][_ ,@_M[ ^?W?\$_?^BOP _P"'[W_!3/\ Z+?IW_A'Z;_\8H_X
M?O?\%,_^BWZ=_P"$?IO_ ,8H_P!5<R_FC][_ ,@_M[ ^?W?\$_?^BOP _P"'
M[W_!3/\ Z+?IW_A'Z;_\8H_X?O?\%,_^BWZ=_P"$?IO_ ,8H_P!5<R_FC][_
M ,@_M[ ^?W?\$_?^BOP _P"'[W_!3/\ Z+?IW_A'Z;_\8H_X?O?\%,_^BWZ=
M_P"$?IO_ ,8H_P!5<R_FC][_ ,@_M[ ^?W?\$_?^BOP _P"'[W_!3/\ Z+?I
MW_A'Z;_\8H_X?O?\%,_^BWZ=_P"$?IO_ ,8H_P!5<R_FC][_ ,@_M[ ^?W?\
M$_?^BOP _P"'[W_!3/\ Z+?IW_A'Z;_\8H_X?O?\%,_^BWZ=_P"$?IO_ ,8H
M_P!5<R_FC][_ ,@_M[ ^?W?\$_?^BOP _P"'[W_!3/\ Z+?IW_A'Z;_\8H_X
M?O?\%,_^BWZ=_P"$?IO_ ,8H_P!5<R_FC][_ ,@_M[ ^?W?\$_?^BOP _P"'
M[W_!3/\ Z+?IW_A'Z;_\8H_X?O?\%,_^BWZ=_P"$?IO_ ,8H_P!5<R_FC][_
M ,@_M[ ^?W?\$_?^BOP _P"'[W_!3/\ Z+?IW_A'Z;_\8H_X?O?\%,_^BWZ=
M_P"$?IO_ ,8H_P!5<R_FC][_ ,@_M[ ^?W?\$_?^BOP _P"'[W_!3/\ Z+?I
MW_A'Z;_\8H_X?O?\%,_^BWZ=_P"$?IO_ ,8H_P!5<R_FC][_ ,@_M[ ^?W?\
M$_?^BOP _P"'[W_!3/\ Z+?IW_A'Z;_\8H_X?O?\%,_^BWZ=_P"$?IO_ ,8H
M_P!5<R_FC][_ ,@_M[ ^?W?\$_?^BOP _P"'[W_!3/\ Z+?IW_A'Z;_\8H_X
M?O?\%,_^BWZ=_P"$?IO_ ,8H_P!5<R_FC][_ ,@_M[ ^?W?\$_?^BOP _P"'
M[W_!3/\ Z+?IW_A'Z;_\8H_X?O?\%,_^BWZ=_P"$?IO_ ,8H_P!5<R_FC][_
M ,@_M[ ^?W?\$_?^BOP _P"'[W_!3/\ Z+?IW_A'Z;_\8H_X?O?\%,_^BWZ=
M_P"$?IO_ ,8H_P!5<R_FC][_ ,@_M[ ^?W?\$_?^BOP _P"'[W_!3/\ Z+?I
MW_A'Z;_\8H_X?O?\%,_^BWZ=_P"$?IO_ ,8H_P!5<R_FC][_ ,@_M[ ^?W?\
M$_?^BOP _P"'[W_!3/\ Z+?IW_A'Z;_\8H_X?O?\%,_^BWZ=_P"$?IO_ ,8H
M_P!5<R_FC][_ ,@_M[ ^?W?\$_?^BOP _P"'[W_!3/\ Z+?IW_A'Z;_\8H_X
M?O?\%,_^BWZ=_P"$?IO_ ,8H_P!5<R_FC][_ ,@_M[ ^?W?\$_?^BOP _P"'
M[W_!3/\ Z+?IW_A'Z;_\8H_X?O?\%,_^BWZ=_P"$?IO_ ,8H_P!5<R_FC][_
M ,@_M[ ^?W?\$_?^BOP _P"'[W_!3/\ Z+?IW_A'Z;_\8H_X?O?\%,_^BWZ=
M_P"$?IO_ ,8H_P!5<R_FC][_ ,@_M[ ^?W?\$_?^BOP _P"'[W_!3/\ Z+?I
MW_A'Z;_\8H_X?O?\%,_^BWZ=_P"$?IO_ ,8H_P!5<R_FC][_ ,@_M[ ^?W?\
M$_?^BOP _P"'[W_!3/\ Z+?IW_A'Z;_\8H_X?O?\%,_^BWZ=_P"$?IO_ ,8H
M_P!5<R_FC][_ ,@_M[ ^?W?\$_?^BOP _P"'[W_!3/\ Z+?IW_A'Z;_\8H_X
M?O?\%,_^BWZ=_P"$?IO_ ,8H_P!5<R_FC][_ ,@_M[ ^?W?\$_?^BOP _P"'
M[W_!3/\ Z+?IW_A'Z;_\8H_X?O?\%,_^BWZ=_P"$?IO_ ,8H_P!5<R_FC][_
M ,@_M[ ^?W?\$_?^BOP _P"'[W_!3/\ Z+?IW_A'Z;_\8H_X?O?\%,_^BWZ=
M_P"$?IO_ ,8H_P!5<R_FC][_ ,@_M[ ^?W?\$_?^BOP _P"'[W_!3/\ Z+?I
MW_A'Z;_\8H_X?O?\%,_^BWZ=_P"$?IO_ ,8H_P!5<R_FC][_ ,@_M[ ^?W?\
M$_?^BOP _P"'[W_!3/\ Z+?IW_A'Z;_\8H_X?O?\%,_^BWZ=_P"$?IO_ ,8H
M_P!5<R_FC][_ ,@_M[ ^?W?\$_?^BOP _P"'[W_!3/\ Z+?IW_A'Z;_\8H_X
M?O?\%,_^BWZ=_P"$?IO_ ,8H_P!5<R_FC][_ ,@_M[ ^?W?\$_?^BOP _P"'
M[W_!3/\ Z+?IW_A'Z;_\8H_X?O?\%,_^BWZ=_P"$?IO_ ,8H_P!5<R_FC][_
M ,@_M[ ^?W?\$_?^BOP _P"'[W_!3/\ Z+?IW_A'Z;_\8H_X?O?\%,_^BWZ=
M_P"$?IO_ ,8H_P!5<R_FC][_ ,@_M[ ^?W?\$_?^BOP _P"'[W_!3/\ Z+?I
MW_A'Z;_\8H_X?O?\%,_^BWZ=_P"$?IO_ ,8H_P!5<R_FC][_ ,@_M[ ^?W?\
M$_?^BOP _P"'[W_!3/\ Z+?IW_A'Z;_\8H_X?O?\%,_^BWZ=_P"$?IO_ ,8H
M_P!5<R_FC][_ ,@_M[ ^?W?\$_?^BOP _P"'[W_!3/\ Z+?IW_A'Z;_\8H_X
M?O?\%,_^BWZ=_P"$?IO_ ,8H_P!5<R_FC][_ ,@_M[ ^?W?\$_?^BOP _P"'
M[W_!3/\ Z+?IW_A'Z;_\8H_X?O?\%,_^BWZ=_P"$?IO_ ,8H_P!5<R_FC][_
M ,@_M[ ^?W?\$_?^O@S]F/\ Y6!OVGO^R2^#O_1=?GG_ ,/WO^"F?_1;]._\
M(_3?_C%?1'_!!KX\_$_]IG_@HY\9_C9\8M<CU+Q)K/PGT$:A>Q6<5NLGDW]U
M!'^[B557$<:#@<XSU-<./R3%Y;156JTTW;1OS?9=CJPF98;&U.2G>]KZKT_S
M/UWHHHKQST HHHH **** "BBB@ HHHH **AU#4+#2+"?5M6OH;6UM86EN;FX
ME"1PQJ-S.S-@*H ))/  KXG\(_\ !>7]F+XD^+;:W^$W[-O[0/BWP/=:W_9<
M?QA\._"6XG\*";S?))-V9%D""3:I;RN-PS@9( /MZBBB@ HHKQ3XO?MW_"#X
M*_MA_"S]B7Q7X?\ $<WBKXO6FIW'AK4+"S@?3[9;&W>>47,CS+*A94(79'("
M2,E1S0![71110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %>0_MX_LV>-/VP?V2?&W[,?@3XRGP#=^-=*_L
MRY\4+H9U%K>S>1?M,8@\^#=YL(DA)\P;1*3@D 5Z]10!P_[-?P%\$_LN? 'P
M=^SK\.8671?!GAZVTJP:3[\JPQA3*_7YW;<[?[3FNXHHH **** "BBB@ HHH
MH ^;_P!H#_@GVGQT_P""@OP/_;L?XM'2Q\&;'6;?_A%1H7G?VO\ ;[62 -]I
M\]?L_E[]V/*DW8QE<Y'TA110 45XI\$?V[_@_P#'O]K#XL_L=^#M \1V_B?X
M-_V9_P )/>ZE9P)877VZ$RQ?9729Y'VJ,-YD<>#]W<.:]KH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ KYV_X*D_L$?\ #RK]C_6/V4?^%K_\(7_:VJV-Y_;W]A?VCY7V:=9=GD>?
M!NW;<9\P8SG!Z5]$T4 0:;9)IFG6^G)(66"!(PQZG: ,_I4]%% 'S?\ \% ?
M^"?:?MU^)?@MX@D^+1\+K\(?BSIOC4PC0OMO]KBU<-]CW>?%]GWXQYN)-O\
M<-?2%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 ?-?@[_@GDNG_\%,_%7_!23XB_%]_$=_?>";;POX#\*G1#;Q>%;)=K
M7!$_VA_M+S2"1]WEQ[//D&&R"/I2BB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** /@S_@CS_R=?^V]_P!G'3_^DJT4?\$>?^3K_P!M[_LXZ?\
M])5HH8EL'_!QK_RCPL_^RM>%/_3E'7WG7P9_P<:_\H\+/_LK7A3_ -.4=?>=
M'0 HHHH&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !7Y^?\ !=;_ )*/^Q3_ -GF^#O_
M $<]?H'7Y^?\%UO^2C_L4_\ 9YO@[_T<]-;@?H'1112 **** "BBB@ HHHH
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M17K7["_P%\*?M/\ [6G@CX">.-4U"STGQ+JC6]_=:3)&ERB+#))^[:1'4$E
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M5T^J-*M*I0FX5%9A1116IF%%?7EC_P $_P#X2W7_  2.O?V^W\5>(QXNMO$
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M5OB'^R_\3_%]QX@N/@5\7M7\%Z/K%Y(SS3:; 4:%&+$D[',RJ,X6,1H  @R
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M0^"OP<^(WCZPT_3K:SM4"RZO+87,R?:VG+\/(K)O\U?F\J,1;O\ P4[\'?\
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M'XI9O#7B+P/H<&F*$N;6:W=]MEY<5PKP7,HS(KC#JPY5" #W>BBOEG_@LO\
MMF^-/V$O^"??C+XU_"VV\SQC=-;:%X./EJ_DZC>RB&.?:P(<Q*7E"$$,T84C
M!-(#V/XO_M;_ +*7[/>HV^D_'W]ISX>^![N[!-K:^,/&ECIDDP 4G8MS*A;
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M:/A_P_;ZEXG\.^%=?UZ6]M=*OIH(H8K.U:;,D=HUPJ2E&9VWSS-N.X >9?\
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MU[Q!>6UGI,/A?0X+*UCU6[*6RWGD1H(M\,*O(J[-I:)0006HL!]1_%[]K_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110!\&?\$>?^3K_P!M[_LXZ?\
M])5HH_X(\_\ )U_[;W_9QT__ *2K10Q+8/\ @XU_Y1X6?_96O"G_ *<HZ^\Z
M^#/^#C7_ )1X6?\ V5KPI_Z<HZ^\Z.@!1110,**** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "OS\_X+K?\E'_8I_[/-\'?^CGK] Z_/S_@NM_R4?\ 8I_[/-\'?^CGIK<#
M] Z***0!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 ?CQ_P=(_\ )>OV5_\ L'?$
M;_TW:97YC5^G/_!TC_R7K]E?_L'?$;_TW:97YC5]]PE_N4_\7Z(^3XA_CP]/
MU"OTV_:(_P"5<GX3_P#8U1_^ENIU^9-?L;\//VA/AG^S1_P0N^%'Q(^+/[.&
MA?%/2CJCV8\+^(F@%N)7O[\K/^^MIUW)L('R9^8X(KOSF4X/#RC'F:J+3:^C
M[G-E48RC64G9<CU/B3_@BYXZ^.OA[]O?P/X6^$.JZI]@U;4'3Q5I=K*QM9M.
M$3>?).GW,(H#*QY#J@!R0#;_ ."YT'@:#_@I%XS'@I;56>RTY]:%F!M^W&UC
M\PG:<;RNPMWW$YYR:^]?V(_VL_A%^VW\#OB%\-/V"_A?X;_9Z^+5KI!N[>WT
MGP_826]Q'E467S([>(.N\I$[-&&B,D;@/]VOR8\%?#3QQ\7/VP-'^#?Q<O=0
M7Q'XF^)%OHGB6XU.1FNEO+B_6"X:5FY,@=WW$\Y!K'"5'7S.IB*D>1PC9QW;
MZW=M+=K7-<1!4<OIT82YU.5T^BZ6[_D>G_LB?\$D_P!LO]LWPU!X]^'7A'3M
M&\,73NMIXE\5WS6MM<E-P8Q+&DDTJ[E*;TC*[CC/#8O?M:?\$=?VU?V/_!T_
MQ'\9^&M(\1^'+) VI:WX.OY+J*R!S\TL<L44RH,<R>647(RPR*_1_P#X*@?\
M$X_VS_VOYO#'PJ_9U^)7@GPM\*?"^A06UKX5U#6+ZU\ZY3*!I([>TD1XXXA%
M'&&8[<.0!O.8?^"5_P#P37_;._8I\5^(/"OQV^)W@OQ'\-/$6@36USX5TS6;
MZZ2.[9UQ*L%Q:1QA6C,R2 ,-V]<AMHQQ?V]4]E]8]K#_ *]V=[?XK_%;RL=/
M]D4O:^QY)?X[Z7].WS/S/_X)"?\ *23X3_\ 8?E_]))ZO_\ !9O_ )29?%3_
M *_]/_\ 3;:5I?\ !.#PYI7@W_@KOX.\(Z#=+-8Z5X_U*SLID?>)(HH[I$(;
M^+*J.?>L_P#X+,N\?_!3;XI.CE674=/*L#@@C3;3!S7K*2EGB:_Y]?\ MQY\
MHN.4.+Z5/_;3H_V?_P#@A?\ M]?'OPQ;^,9/">B>"M/O;;S[%_'&I26TTR9
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M^EW_ (QU2_E@TF>>(D-]G8Q>?<+D%=R0D*<!MIKF?^"0G_*23X3_ /8?E_\
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M?$NE".QOK7Q.\QO+58D"1PL)CO550*%7H%"XXQ7Z&?\ !1K_ )0>?LT?]?\
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MM]'^'GA*QTZQL(%VQPO/&+IF Z+F.6!,#C$2UZ;_ ,$,?^3,_P!JC_L54_\
M3=J5?*O_  5LU"ZU/_@HY\6;F\DW.OB00J<?P1V\4:C\%4#\*^O_ /@WW\1:
M9X0_9P_:-\5ZWX;@UJRTS3+.[N]'NMHBOHHK/4':!]RL-KJI4Y5A@\@]*\+%
MP5'AR"7:'WMI_BSVL--U,]FWWE^"L?FE\,_&'Q'\!^.--\1_"3Q#J^F>(H;N
M,:7<Z'/(EUYQ8;%3R_F8EL?+SGI@U^F?_!P^]K>_!CX$ZM\1+*SM_B'-8W!U
MB&)4$R*;>V-PIVG_ %:W!PO\.2VWJ<]/_P $_?\ @IY^P5\8/VAM+^&MA^P)
MX+^#OB;77^P^%O%7A_3=.N&^UR8$<+21V,#Q%VP%.'4OM!P#D?#W_!6?PK^T
MWX*_;2\0^'?VI/B+<^*M42))?#^N26XMX;G279VMS! OR0(#YBM&F0)%DY8Y
M8Z1G4QF;T_:0]FX)O5IN2>FC6EEUU,N6&&RN;A+G4VEIM&VNM];OT/J3_@B)
MJ-[I'["/[4FJZ7=R6]U:^&Y);>>)MK1NNEWS*P/8@@$?2JW_  5ETRP_;6_8
M%^$'_!2GPK9A]4LK%-$\<>0G^JWR,A+!>$2.^29%Z$_;$XZ 2?\ !%/_ ),
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M@W6/_3;<5A0BGDF(K*WO\\K+[.EK=-5;4VKR?]JT:;^QRJ[Z^9YC_P %-O\
ME('\7_\ L?;_ /\ 1AKPNOU/_;!_X*C_ +(/PI_:B\>?#CQE_P $FOAOXOU7
M1/$UU::AXHU.73Q<:G*CD&>3S-*D;<QY.78^YKX=_;A_:@^$/[5'CS1_%GP>
M_9-\-?".RTW2#9W>D>&7@,=[+YKOY[^1:VZ[MK!?N$X7[W0#T\NKXJ=*G"=%
MQCRK6\7T[)WU.#'4:"K3E&HF[O2S[][6T/$J***]4\T_3[XM?\JUW@'_ +&3
M_P!S=_7Y[_LZ_ CQC^TY\:_#WP'^'][IUMK'B6]-K8W&K3/';1L$9RTC(CL
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MQGT2"PU[3HH9;B"VO([B,QRQK(C*\9((*L/<=#7"UTWQ;@^+=AX\O-!^./\
MPD"^)=*$=C?6OB=YC>6JQ($CA83'>JJ@4*O0*%QQBN9KVJ7,Z:YFF[;K9^AY
M%7E51\J:79[H****T("BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M/X5?>_JYHZ"/SC_X(B?LO_L6M\=/VE/V%/VROV8_AAXF^*_@_P",.HZSI?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110!\&?\$>?^3K_P!M[_LXZ?\ ])5HH_X(\_\ )U_[
M;W_9QT__ *2K10Q+8/\ @XU_Y1X6?_96O"G_ *<HZ^\Z^#/^#C7_ )1X6?\
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MKJ/'WQK^,OQ5T[2]&^*/Q;\3^)+/0XFBT6TU_7[B\BL(RJ*5@69V$0*QH"%
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MQ [+P\L<;(&[KD(3E"J^A?\ !1K_ )0>?LT?]?\ IO\ Z;+ROS-KI/$/Q?\
MBUXM\%:7\-?%?Q2\1ZGX<T0YT70-0UN>>RL#@C,,#N8XC@D?*!P3ZUG'+'3I
MX>$975)WUZZ-?J5+,%.=:4H_Q%;T/H[X7_\ !'W]I3]H;]F;PO\ M)?LS:MH
M/C5-;%Q'JWAJ'4X+.]TFYBN'B\IFGD6)_D"2\NC@2 !",,WVQ\#O O[0_P"Q
MA_P3!^,VA?\ !33QA NCZIHD^G^!?"FN:[#J5U%.]K,@@B='D4^9*T#1QI(?
M*,+R8C&6K\F/AS\7OBQ\']4?7/A)\3_$7A:]D79)>>'-:GL96&",%X74D8)[
M]S3?B)\6OBK\7]737_BS\3?$'BB^C7:E[XBUJ>^F5< 8#S.S8PJCKV'I4XG
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MHU>#;=D[.ZMH94\32I4JM."=I6M?I;N>S?\ !+W]L^Z_8B_:OT;XBZG=2?\
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M7S=_P0B4I_P4S\$JP((TW6,@C_J'7%?,?PT^-/QB^"U_<ZM\'?BSXF\)W=[
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %?HU_P;-?\ )XOQ3_[)1I'_ *=;ZOSEK]&O^#9K_D\7XI_]DHTC
M_P!.M]7S/%?_ "+8_P")?E(]S(/]\E_A_5'[34445^>GV 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MS'XL?^&ZU/\ ^,4?6<-_.OO0>PK?RO[CR>BO6/\ A@K]N7_HS'XL?^&ZU/\
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M -&8_%C_ ,-UJ?\ \8H^LX;^=?>@]A6_E?W'D]%>L?\ #!7[<O\ T9C\6/\
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M3_\ C%'_  P5^W+_ -&8_%C_ ,-UJ?\ \8H^LX;^=?>@]A6_E?W'D]%>L?\
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MH_X8*_;E_P"C,?BQ_P"&ZU/_ .,4?6<-_.OO0>PK?RO[CR>BO6/^&"OVY?\
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ML?\ ANM3_P#C%'UG#?SK[T'L*W\K^X\GHKUC_A@K]N7_ *,Q^+'_ (;K4_\
MXQ1_PP5^W+_T9C\6/_#=:G_\8H^LX;^=?>@]A6_E?W'D]%>L?\,%?MR_]&8_
M%C_PW6I__&*/^&"OVY?^C,?BQ_X;K4__ (Q1]9PW\Z^]!["M_*_N/)Z*]8_X
M8*_;E_Z,Q^+'_ANM3_\ C%'_  P5^W+_ -&8_%C_ ,-UJ?\ \8H^LX;^=?>@
M]A6_E?W'D]%>L?\ #!7[<O\ T9C\6/\ PW6I_P#QBC_A@K]N7_HS'XL?^&ZU
M/_XQ1]9PW\Z^]!["M_*_N/)Z*]8_X8*_;E_Z,Q^+'_ANM3_^,4?\,%?MR_\
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MPK?RO[CR>BO6/^&"OVY?^C,?BQ_X;K4__C%'_#!7[<O_ $9C\6/_  W6I_\
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M_E?W'D]%>L?\,%?MR_\ 1F/Q8_\ #=:G_P#&*/\ A@K]N7_HS'XL?^&ZU/\
M^,4?6<-_.OO0>PK?RO[CR>BO6/\ A@K]N7_HS'XL?^&ZU/\ ^,4?\,%?MR_]
M&8_%C_PW6I__ !BCZSAOYU]Z#V%;^5_<>3T5ZQ_PP5^W+_T9C\6/_#=:G_\
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MKZW!;7>LRQ!3)':0R.'N&0.A81ABH=<XR*Z2OS<_X+!?\I;/^">?_8^>*_\
MT7H]?I'2 YOXH_%_X2_ WPH_CSXU_%'PYX/T-+B.!]9\4ZW!I]HLKG"1F:=T
M0,QX SDGI725^;G_  =8?\HD]6_['S1/_1DE?I'0!XCJ7_!3#_@G#H^H3Z1J
M_P#P4"^"5K=VL[0W5K<_%;1XY(I%)5D96N058$$$'D$8KTOX9_%WX3_&GPW'
MXR^#GQ/\.^+=(E ,6J^&=:@O[9P>A$L#LIZ>M?E)_P &R_[%7[&WQ_\ ^":
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MWCGP5\-/"=_X^^(_C#2_#^A:5;M<:IK6MZA':6EG".LDLTK*D:CNS$ >M/\
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M_AQX&U:[M!=6NE^,?'%AIEQ- 691*D=S,C,A9&7<!C*D9X-<G_P]"_X)H?\
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MT#K\_/\ @IM_RF0_X)]_]AOXA?\ IJL*_0.F]@"BBBD 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MIO\ @N_^R]\3-2^&WA'_ (*0?LKV)'Q@_9SU,Z[IH@MS(^JZ(?\ C_LG1?\
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M^B'@CQOX/^)?@_3/B!\/_$UEK6AZU91WFE:MIMPLL%W!(H9)$=3AE((((HZ
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M*RL.""""#[U^<G_!J?\ \HD])_['S6__ $9'26P'T?\ LA'_ (+!?\+/NO\
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M/$X8"2/2;:-UX[JZLI'8J1VKX*_:C^%W[/7P^_X.3-%U_P#;A^%'@[Q%\/\
MXX_!]=&\'7'C_0+74-,CUVVEMU"*+E&CCN +=(PQ&<7Z*#^\Q26X'K7Q*^#/
M_!L#\3_A?<?"G4?%7[(VDVDUL88M6\->-/#NG:I;G8561+V"99RZYW?.S D#
M<&QBK'_!!K]LWQ5X^_8C^)/ACXP_%-O'8^ 7CG6?#EGX\CODNO[?T2SB$UK=
M"96*S9CWJK[FW1K&V]B2:^FO^'7O_!-#_I'=\"__  TFC?\ R-6CX1^ /[+U
MC\ /'/PB_8_\#?#SPOI.O6VI:;J=O\/=*L;.T74GMC;N9ULT">>H\M6W#> J
M@] *+@?"O_!'O]CKX4_\%*_ VL_\%9O^"@GPVTKXF>+/BCXDU)?!NA^-;%-1
MTOPQH%K<RVD-E;VD^Z$XDBF_>,F<!6 #,[OY)_P<5?\ !*WX(_LQ_L9>,/VI
M/V.YV^&>F:E?Z79?$GX<>'H_+T'Q'&^H0FVN%M ?*M+B"?RRK1*JF,NH"[FW
M_3__  ;/_%C3M?\ ^"9^E_LYZS.MKXT^#GBC6?#?C309F N=/G;4KJYB$B#H
M"LIC##(9H)!DE6QP_P#P=7?M,?!7P-_P3EU/]FO7O&UL/''C?5],N-!\.P'S
M+AK:UO8IIKF4#_50@)L#MC<[!5SAMKUN!^DOPP_Y)IX=_P"P%:?^B4JYXJ\*
M>%_'?AC4?!/C?PW8:SHNKV,MGJVD:K9I<6M[;2H4DAEBD!22-U8JR,"&!(((
M-4_AA_R33P[_ -@*T_\ 1*5N5('Y&?"[]B+]B_4/^#DKXD? N_\ V1/A?/X(
ML?V:8-4L?!TW@#3FTJWOCJ.EH;I+0P^2DQ621?,"[L.PSAC7WO\ M"^)/@?_
M ,$P?V&?B/\ &'X'_ [PKX8T;P;X>OM<MO#'A70[?2[*[U#RPL>Z.V15!DD$
M*,^TM@#K@"OE;X921Z1_P=/_ !#74Y4@.J?LJ0#3A*X!N"-2TPD(.Y AE./1
M&/:OI?\ X*[?!?QE^T)_P3/^-/PE^'NFR7VMZEX'N9=+L8?OW4UN5N5A3U=_
M)V =RP''6GU ^>O^"7__  2M^"'Q8^ >A_MM_P#!0KX>Z5\9_C'\7M(M_$FO
MZM\2-*AU.WTNVND\^VL+2TG#P6T<4,JY"H#O+ ;55$3SS_@KY^Q/\-O^"9G@
MW3/^"M7_  3J\#6OPU\5?#3Q!IH\;>&/!T(L='\4Z%<7:6\UI<6<0\E/GFC!
M=(^%);&Y(WC^N_\ @CQ^U)\/OVM/^"<OPI^('@;Q#:7=UI?@W3]#\36EO)\]
MAJEE;1V]Q#(A^:,EH]Z@CYHY$895@3XO_P ''?Q6TU_V!KC]C;P<T.J?$GXY
M>)-(\.>!O"L#%[N\<:C;7$LRQKR(U6((9#A5:5,GG!-;@?=_@GQ9I?C[P;I'
MCG1-_P!BUG3(+^S\P8;RIHUD3(]<,*U*YSX0> T^%GPE\+_#".Z$R^&_#MEI
M:S*#B06\"1!N>>=F>:Z.D!^)W_!%;_@GSX6_;.^,7QU\?_M0W4?BGX6> ?VC
MO$\OA?X77QWZ9=^(YS"+G4;^W(V70CMDM(X4DW*"\QVC)W?9'_!3WQS\(_\
M@C7_ ,$V/B?\8/V+?@QX6\ Z]X@O+:STF'POH<%E:QZK=E+9;SR(T$6^&%7D
M5=FTM$H((+5Q'_!M]_R3O]IW_L[#Q1_Z)LZW_P#@YJ^"OC3XS?\ !)3QE-X'
MTJ6^G\'ZSIWB.^MH!E_L5O(RW$F/2.*5I6]%B8]L&GN". _8^^ __!OA\$/A
M+90?'S]I7]F+XM_$;5X4OO'OCOXG_$'P_KU[J>J2(IG=&O9Y1#&&RJJF/E +
M%V+.W#_!#XG_ +'_ .Q%_P %F_AC\*?^":'QW\'Z]\(/V@M(U*S\=?#WP%XW
MM=8T[0M=M(#);ZC&D,TOV5I5$<>S*AE64C<%54^P?V4/V4/^"1'[7G[/'A/]
MHKX4_L(? #4M(\3Z-#=K)9_"C1B+>8H/.MW'V;*21R;D9&Y5E(->E>"?V.O^
M"<OP-^+.AZC\.?V6?@GX/\=%9[CPU/HO@?2-/U;:L96:2V:*%)L"-V5V3HK$
M'@TK@6OVN?V&O@?^W#:^&_#G[1$GB#5/"_A[47OI_!=EKTUII6MS?NS$=0BA
M*M=+$R;DC+A,NVY7R,>)_MH_\$7O^":7Q1_91\8^"='_ &.OA]X2OK7PO=S:
M+XE\'>$[33=1L;F&!GAF%Q;QJ\N'12RR%E<9# Y->>_\%6_BM\:OBU_P4$_9
M[_X)=^$OCOKWPN\$_%:RU75?''BKPE>_8M7U&*SAED33+6[Y,'F&$JV!EO.7
M.X QO3_:A_X(1_\ !%+X/_ KQE\=/C5\'G%UI6@W5Y?>-?&/Q6UWS9KH1-Y<
MDKM?JDDC/L4+M^=MJA23@B ]!_X(<?M6^+?B[_P1O\ ?'CXUZW=ZGJ7AO0M5
MM-8U2ZG,L]W!IEU<Q1RN[DEY#;PQAF8Y9@S$\UX=_P $>_V.OA3_ ,%*_ VL
M_P#!6;_@H)\-M*^)GBSXH^)-27P;H?C6Q34=+\,:!:W,MI#96]I/NA.)(IOW
MC)G 5@ S.[]/_P &[O@ZX^(G_!!O1OA_9SK%+KL7BS3XI6/"-->WD8)Z]"V>
M];O_  ;/_%C3M?\ ^"9^E_LYZS.MKXT^#GBC6?#?C309F N=/G;4KJYB$B#H
M"LIC##(9H)!DE6PP/F#_ (.*O^"5OP1_9C_8R\8?M2?L=SM\,],U*_TNR^)/
MPX\/1^7H/B.-]0A-M<+: ^5:7$$_EE6B55,9=0%W-O\ TW_:1_:2MOV/_P#@
MGSXD_:;GTI;]_!?PW_M*TL'DVK<W*VRB")F[*TI12>< DU\7_P#!U=^TQ\%?
M W_!.74_V:]>\;6P\<>-]7TRXT'P[ ?,N&MK6]BFFN90/]5" FP.V-SL%7.&
MV_2W_!2CX+^,?VA/^"0OQ'^$OP]TV2^UO4OA6LNEV,/W[J:WBBN5A3U=_)V
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MO@.P2QTGQ1HAMF6ZTV\L(=MO\T>6254#+(%<[B%9-G_@WZ\36_P@^('[4O[
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M.0"$8C]$_&_C?P?\-/!^I_$#X@>)K+1=#T6RDO-5U;4KA8H+2"-2SR.['"J
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M37Q;_P &^7P ^(7[.'_!)SX8>"OBAID]AK.I0WVN2Z;<QNDEI#>WDMQ!&ZN
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M:E5J23LV[-=%VUNNG<R>)JUJV(]^T(*VBU3MJ^^FO4Y;_@B5^UK^T_\ M>?
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ME_M.?"O_ (0SQC??$R)-2T Z5<V/E)&-0CB?R+IFEBW1JK8<G.=PX8"O4/\
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M9S^("^';[6_$%S!J5U_9-I=F2*. ,J 744BKRV20 >!SC-7?AW^V/^T]K/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M?V:/^"G7P>L_@[^TA9ZO!%I6IB_T37O#=W%;ZCILV-K^5)+%*FV1/E='1E(
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MCJ=IH7C70I]*U2ZT:>..[BAE7:S1-)'(BN.Q9&'J#5G]G[X(^$?V;_@-X/\
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M -.4=?>=?!G_  <:_P#*/"S_ .RM>%/_ $Y1U]YT= "BBB@9\W_\%8OV>_\
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M?^";&H>&];@D^QZMXMU>WFQ\I>*2&"-BI_[Z&?4>U<<)*/#:?_3PZDO^%O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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ME^)O[0?Q9T#P=H,,JQ-JGB'4X[:)I&.%C4N07<]E7)//'% '945\<_#+_@X
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M/VTOV5OV)O\ @A?\)_B#^U1\;]#\&:9<:CXD6R.IS,T]XR:S?.ZV]O$KS7#
M?PQHQY QDC+MH-'ZCT5X1^R'_P %-?V$/V\+F[T[]E']I+1/%5_8Q&6ZT?R;
MBQU!(@=IE^R7D44[1@X!<(5!9<GD9]TGGAM87NKJ9(HHD+R22, JJ!DDD] !
MWI"'T5\?_$S_ (+X_P#!(3X1^/7^&OC+]MSP^^JQ2^7*=$TG4=4M8W\QHRK7
M5E;2VZD,IR#)\HP3@$$_2WP:^-_P?_:'^']E\5O@5\3-$\6^&]0W"SUKP_J,
M=U;NRG#IN0D*ZGY60X92"" >* .JHKSCX@?M;?L]?"SX]^#OV8_B!\1HM,\;
M^/[#4+WPGHTVGW++>V]C \]TYN%C,$(CB1W_ 'LB$A3MR>*\L^%'_!9#_@F=
M\<_VB(OV5/A'^UIH>O\ CBYGD@LM-T_3[UK:[E1-[)!>F 6LYVY.(Y6SM;&=
MIP ?35%>6?M2?ML_LG_L4^%(_&G[4WQXT#P997"R-9QZG<EKJ\V*6<06T0::
MX( Z1HQR0,9(!\X_9>_X+'?\$S?VRO&T7PU_9Y_:WT#5_$-S(8['1-2L[S2;
MN]<*6*V\6H0P-<-M!.(@QP">QP ?35%%?)WQY_X+E?\ !)_]FOQE-\/_ (L?
MMH^'(]7MKB6"[L_#]A?:T;:6/;OCE;3K>=8G!8 JY!W!UZHP !]8UXS^WC^V
M_P#"C_@GY^SW>?'_ .+%AJ>I+_:%OI?A_P .Z' );_7-4N&*P65NA(#2-M=S
MSPD;L 2-IZ3]F_\ :M_9P_:^\!GXF?LR_&;0?&FBI/Y-Q=Z)?"1K6;:&\J>,
MXD@DVD-LD56PP.,$&ORB_P""Y7_!4W]@?XD?M$_L_?"32?CP;V;X.?M0:;J'
MQ=TUO"^J*FDVEA="*[D)>U"77EXF7$!E9N=H8$9:6H'WY^R=^V3^W=\8_BQ!
MX)_:9_X)9>(/A#X>U/3I;K1_%[_$O3-=CRB[A%=P6R))92,I7"ON^;<IQMR?
MJ.OA?_B)3_X(I?\ 1Z/_ )CGQ)_\KJ^2/^"1G_!?[]COX4^"?BY8?MT_MR>)
M+K4-5^->L:CX$;Q+I?B#6G3P])%;BU6%TMIOL\(99=MN2A0ECL7=R68'[/T5
MS_PX^*7@/XM?##0_C-X!\0)>^&?$>AV^L:/JDD$D"SV4\2S13%)E5XP8V#8=
M58=P""*^7_B9_P %\?\ @D)\(_'K_#7QE^VYX??58I?+E.B:3J.J6L;^8T95
MKJRMI;=2&4Y!D^48)P""4!]@45ROP:^-_P '_P!H?X?V7Q6^!7Q,T3Q;X;U#
M<+/6O#^HQW5N[*<.FY"0KJ?E9#AE(((!XK"^('[6W[/7PL^/?@[]F/X@?$:+
M3/&_C^PU"]\)Z--I]RRWMO8P//=.;A8S!"(XD=_WLB$A3MR>* /1Z*^9?A1_
MP60_X)G?'/\ :(B_94^$?[6FAZ_XXN9Y(++3=/T^]:VNY43>R07I@%K.=N3B
M.5L[6QG:<?35 !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 ?GY_P4V_Y3(?\$^_^PW\0O_3585^@=?GY_P %-O\ E,A_P3[_
M .PW\0O_ $U6%?H'3>P!1112 **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_P!AW0/_ $ZVU?;?P-_Y(IX/_P"Q6T__ -)HZ70#J:_-S_@C[_REL_X*&?\
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MR/BG^T+^S%JEP==M?AQ/JWAG5+2V/FP1/$KF[1)%)#1P,TP#+QLY P:^</\
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MSQ[_ ",L/4K5:*E5CRR?0****Y38**** "BBB@ HHHH **** "BBB@ HHHH
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M:/X._';1M-2PBURX7:IL+^W7"17&YXXP4'WY8@?,$OF#TC_@X%^*?Q-^"O\
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MM!^!_P!JCQW\/A?^//AQ;WL'@S73JEW'_9R7<317 \B.589MR.PS*CE<Y7!
M->CT44 >4_M2_L._LD?ML>&H?"G[5'P#\/>,[:VCD2RGU.U*W=F)%*OY%U$5
MG@R#G,;J<A6ZJ"/)/@3_ ,$,_P#@DY^S?XK3QQ\+?V*?#(U2&XAGMKOQ'=WN
MN?9IHMQCDA74IYUA<%MVY IW*ASE%(^L:* &3P0W4+VMU"DL4J%)(Y%!5E(P
M00>H([5\@^+O^"!7_!'_ ,;?$0?%#6_V'/#4>IBY6?R-+U+4+&P9PY< V%M<
M1VC+DG*F+:1A2"!BOL&B@#R3P/\ L*?LD_#/XX:3^T7\./@AI6@>+-!\"CP;
MHUWHTDUM:V6ABX:X%G'91N+5!YK,V\1>9SC=CBM;XZ_LG_ #]I;Q!X&\4_&[
MP -<O_AMXMM_$_@J<ZG=6_\ 9VJP,&BN-L$J+-M90=DH=#CE37HM% !7S!^U
M!_P1G_X)E?ME?$N3XQ?M$_LH:/K7BB?'VW6;'5K_ $N:](5%#7!L;B$7#!41
M0TH8@# ('%?3]% &+X.^'O@?X?\ P_TOX5>"_"UEIWAO1=(ATK2M%MX0+>WL
MHHA%' J'C8L:A<'L*^4OBC_P;_?\$>_C!XNG\;>,/V(]"AO[@'SE\.ZYJFC6
MY)=G+?9]/NH80<N>0F<8&<* /L>B@#@OV?\ ]EW]G+]E/PI-X'_9L^"/AGP1
MI=U<>?>6GAO2(K7[5-T\R9D :9P/E#.6(4  X  J^/OV2?V>_BC^T'X'_:H\
M=_#X7_CSX<6][!X,UTZI=Q_V<EW$T5P/(CE6&;<CL,RHY7.5P0#7H]% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_B9XWOO$&D:?X:;7=!FU>Y>>>P,=Q;V\L*2N2WE,+A&"'(4J2N-S9\T\ ?\
M!"'QW\4OV:[?]K#XV_M@V>CSZEX47Q!]GFT-]1"61M%GB,UY+=Q;6\L@$;65
M !AFK-_X-L?^3YO%?_9)[[_TYZ77U6(E#$Y7B%.JJKA_=Y>5]D^IX%)3P^/I
M.%-TU*_VK\WJNG]=CD?VM/\ E/ __99_#O\ Z-L:_0W_ (+9_M\^-?V,/@1I
M'A?X/ZJECXR\=74]O8ZF$#2:=9P*AN)XP00)"98D4D<;V8<J"/SR_:T_Y3P/
M_P!EG\._^C;&O:/^#F?P_K,/Q,^%7BB2V?\ L^?0]2M(IA]WSHYH7=?8[9$/
MOSZ&E.A2Q.,P,*BNN2]N]DF4JM2CA\7.&_._Q=CAOV3/^",7[1?[>?P<B_:V
M^)W[4$^C:GK[2W7AIM8M)]5O+\+))B>XN&N$> -,"00)6PQ?&2 ?JO2/A)^V
M/^SQ_P $A?CK\+/VN?&$FK:GHMCJUOX3U8:V;UIM(%I L924GS!%O\[8DH61
M5RI55VBOHS_@EQXZ\)_$#_@G]\)]2\(W=O)%8>#++3+Q()=WE7=K&()U;NK>
M9&S$'^\#T(JI_P %&O&7A'Q9^P'\<+/PMXKT[4Y=&\+7]AJ\6GWT<S6-TL*N
MT$P0DQ2A71BC88!E.,$5Y&(S/%XC'>PJ)<JFK*WPVE;?\[GHT,%AZ&']K!N[
MCJ[O6Z/AS_@V/N;@^(?C%9M<OY(L]#<1[SM#%[T;L=,X &:\.^--[>'_ (+_
M -E.UW*9/^%_:!%O\PYV?;+--N?3;\N/3BO;_P#@V*_Y&KXQ_P#8/T/_ -#O
MJ\"_:2U>Q\%?\%W3XE\43BSL].^.>AWMY/-P(X%NK24N?;9\WTKVXJ^>XI?W
M/TB>4V_[(P_^/]9'ZR?\%7YIH/\ @G3\6Y+>5D8^%F4LK8X,L88?0@D>XKXR
M_P"#8N>=M#^,UL9F,:7>@,D1;Y58IJ 8@>IPOY"OK+_@L?\ $#P;X(_X)W_$
M2S\7>)+6QFUW3$T[1H9G^>\NGE1EBC4<LVU68\<!23@ FODS_@V&_P"0/\:?
M^OGP_P#^@ZC7BX6+7#-=V^TOSB>G7:_MFBO[K_)GQ-\)?&7[4\'[?'BSPU^R
MCKMU#X]\;^(]8T2UOTGQ,B3W3O-+YC'"%4C9C*<E &<88!AZ5_P4-_X)B_M#
M?\$^/#?AK]J"_P#VCKGQ1J&JZLEGJVN6)GM;W3M2>%W39.TSRSHR12@2_NS\
MH!4;A5+_ ()N_P#*:C0/^Q]\0_\ I-?U]^_\'&/_ "8+IO\ V4;3O_26]KWL
M3C:N'S:A1@ERS2YM%=[JU_+H>72PT*V K5)-WBY6U>EM=O,^5_V;O@Q_P42_
MX+6^!8;WXR?M-7/AKX;^%X$TF.\%DTPU>^BC&Z1[6.6(74H5U\R>5P!OP@)+
M@><_L*_%?]H+_@FY_P %*;#]EO7?&TLVCW'CB#PQXJT>&>5]/NTN)EBCO(XF
MQM=?-25'"A\$J<AF4_?'_!N[_P H^Y/^Q\U+_P!%VU? O[6G_*>!_P#LL_AW
M_P!&V-8T*WUC&8G!2BE3C%V226JZ^NO^1I5I>QP]#$J3YVXW;;V:O8_>:BBB
MO@SZ<**** "BBB@ HHHH *_/S_@NM_R4?]BG_L\WP=_Z.>OT#KX _P""YJVK
M?$C]BS[7-(@'[9'A QF.(,6?SFPIRPP#W;DCT--;@??]%%%( HHHH **** "
MBBB@ HHHH _-S]BG_E9(_;-_[$/P=_Z:-,K](Z_-S]BG_E9(_;-_[$/P=_Z:
M-,K](Z&(_+W]O&*'X,?\''/[)OQ9\&!K:_\ B#X2U?PWXI2-L+?6L4=P(MX[
ME6N%;/?R(_[M4O\ @OG\;OAA^S=_P41_81^.OQI\3_V+X5\,>+?%E[KFJ_8I
M[G[- $T8%_*@1Y'Y(X16/M6K\4)+?]M;_@Y.^'OAWP*QO?#_ .R_\.[O4?&>
MI6S!HX=7OTE2*S+YP' FM7VC+9BF4@;&(U_^"P7_ "EL_P"">?\ V/GBO_T7
MH]5U0SN_^(E/_@BE_P!'H_\ F.?$G_RNKX\_X*@_\%5?V"?^"@/[0/[(7@7]
MD;X[_P#"6ZKH/[3'AZ_U6U_X1?5+#R+=KN&,/NO;6%6^<@84D]\8YK]JZ_-G
M_@X+_P"2J?L5_P#9U6@?^CXJ2M<#HO\ @YW^(GB#P!_P2#\<V7A_4);9O$>N
M:/I%W+"V&-N]Y'+(F>H#"'8P[JQ!X)K[1_9T^'&A_!_]G_P1\*/#.G06FG^&
M_"6G:;9V]M&%1(X+:.,  ?[OO7R9_P ''/P-\2_'7_@D;\2[+PC:-<7_ (7-
MCXD%NJ$E[>SN4>Y/'39;&:3_ (!COFOH?]@7]H7PG^U5^Q?\,OCYX.U.*ZMO
M$/@VPFNA%*KFVO%A6.YMW*\;XIUEC8?WD-'0#U^OS2^&,:?"+_@Z+^(?AOPU
M;B"P^)_[.]IK.MVT60DM];7%M!'.5' 81VSKGOYK'JQ)_2VOS3_83O=,_;!_
MX+U?M&?MD^#(WN?"'PO\&V7PST;689 UMJ&H^9'+>%&Q\QBDMYD^4E=LB-GY
MUH0%G_@L%_REL_X)Y_\ 8^>*_P#T7H]?I'7YN?\ !8+_ )2V?\$\_P#L?/%?
M_HO1Z_2.A[ ?FQ_P=.^$K.3_ ()HVOQEL9)+7Q'\//B1HNK^&-4MVVRVEPTK
M6Y(/IB4-@\;HT/\ "*Z/_@X&\3W'C;_@@9\2/&5Y"L<NKZ)X2O98TZ*TNO:3
M(0/8%JY7_@Y/\0S_ !F^#WPG_P"":_PXD6[\=?'+XHZ=;VUC"0\EII=JQ>>\
M=<C:B2-"<L0I5)3G]V<=S_P<8:'8>%_^"&GQ:\,Z4K"UTZS\,6ML'.2(X_$.
ME(H)^@%'8#G_ ("?\'%G_!&_P5\"O!?@WQ-^V']FU+2/"6FV6H6W_"OO$+^5
M/%:QI(FY-/*MAE(RI(.."17F7_!43_@O3_P2>_:+_P"">WQ<^!WP;_:K_MCQ
M3XH\&75AH6E_\(-KMO\ :;A\;4\V>Q2-,XZNRCWK])_V6O\ DV/X<_\ 8AZ1
M_P"D45>+_P#!;#_E$[\?/^R=7O\ ):%:X+8Z#_@DU_RC _9[_P"R->'/_3=!
M7T'7SY_P2:_Y1@?L]_\ 9&O#G_IN@KZ#I %%%% !1110 4444 %%%% 'Y^?\
M%-O^4R'_  3[_P"PW\0O_3585^@=?FA_P6SU'XTZ-_P49_8CUG]FOPSX?UOX
MAVVI^.SX4T?Q3J4MK874AL--$HF>)&( B+D?,GS!>N<#O/\ A<O_  <7?]&:
M_LX_^%Y?_P"-/H!]YT5\&?\ "Y?^#B[_ *,U_9Q_\+R__P :/^%R_P#!Q=_T
M9K^SC_X7E_\ XT6%<^\Z*^#/^%R_\'%W_1FO[./_ (7E_P#XT?\ "Y?^#B[_
M *,U_9Q_\+R__P :+!<^\Z*^#/\ A<O_  <7?]&:_LX_^%Y?_P"-'_"Y?^#B
M[_HS7]G'_P +R_\ \:+!<^\Z*^#/^%R_\'%W_1FO[./_ (7E_P#XT?\ "Y?^
M#B[_ *,U_9Q_\+R__P :+!<^\Z*^#/\ A<O_  <7?]&:_LX_^%Y?_P"-'_"Y
M?^#B[_HS7]G'_P +R_\ \:+!<^\Z*^#/^%R_\'%W_1FO[./_ (7E_P#XT?\
M"Y?^#B[_ *,U_9Q_\+R__P :+!<^\Z*^#/\ A<O_  <7?]&:_LX_^%Y?_P"-
M'_"Y?^#B[_HS7]G'_P +R_\ \:+!<^\Z*^#/^%R_\'%W_1FO[./_ (7E_P#X
MT?\ "Y?^#B[_ *,U_9Q_\+R__P :+!<^\Z*^#/\ A<O_  <7?]&:_LX_^%Y?
M_P"-'_"Y?^#B[_HS7]G'_P +R_\ \:+!<^\Z*^#/^%R_\'%W_1FO[./_ (7E
M_P#XT?\ "Y?^#B[_ *,U_9Q_\+R__P :+!<^\Z*^#/\ A<O_  <7?]&:_LX_
M^%Y?_P"-'_"Y?^#B[_HS7]G'_P +R_\ \:+!<^\Z*^#/^%R_\'%W_1FO[./_
M (7E_P#XT?\ "Y?^#B[_ *,U_9Q_\+R__P :+!<^\Z*^#/\ A<O_  <7?]&:
M_LX_^%Y?_P"-'_"Y?^#B[_HS7]G'_P +R_\ \:+!<^\Z*^#/^%R_\'%W_1FO
M[./_ (7E_P#XT?\ "Y?^#B[_ *,U_9Q_\+R__P :+!<^\Z*^#/\ A<O_  <7
M?]&:_LX_^%Y?_P"-'_"Y?^#B[_HS7]G'_P +R_\ \:+!<^\Z*^#/^%R_\'%W
M_1FO[./_ (7E_P#XT?\ "Y?^#B[_ *,U_9Q_\+R__P :+!<^\Z*^#/\ A<O_
M  <7?]&:_LX_^%Y?_P"-'_"Y?^#B[_HS7]G'_P +R_\ \:+!<^\Z*^#/^%R_
M\'%W_1FO[./_ (7E_P#XT?\ "Y?^#B[_ *,U_9Q_\+R__P :+!<^\Z*^#/\
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M7E__ (T?\+E_X.+O^C-?V<?_  O+_P#QHL%S[SHKX,_X7+_P<7?]&:_LX_\
MA>7_ /C1_P +E_X.+O\ HS7]G'_PO+__ !HL%S[SHKX,_P"%R_\ !Q=_T9K^
MSC_X7E__ (T?\+E_X.+O^C-?V<?_  O+_P#QHL%S[SHKX,_X7+_P<7?]&:_L
MX_\ A>7_ /C1_P +E_X.+O\ HS7]G'_PO+__ !HL%S[SHKX,_P"%R_\ !Q=_
MT9K^SC_X7E__ (T?\+E_X.+O^C-?V<?_  O+_P#QHL%S[SHKX,_X7+_P<7?]
M&:_LX_\ A>7_ /C1_P +E_X.+O\ HS7]G'_PO+__ !HL%S[SHKX,_P"%R_\
M!Q=_T9K^SC_X7E__ (T?\+E_X.+O^C-?V<?_  O+_P#QHL%S[SHKX,_X7+_P
M<7?]&:_LX_\ A>7_ /C1_P +E_X.+O\ HS7]G'_PO+__ !HL%S[SHKX,_P"%
MR_\ !Q=_T9K^SC_X7E__ (T?\+E_X.+O^C-?V<?_  O+_P#QHL%S[SHKX,_X
M7+_P<7?]&:_LX_\ A>7_ /C1_P +E_X.+O\ HS7]G'_PO+__ !HL%S[SHKX,
M_P"%R_\ !Q=_T9K^SC_X7E__ (T?\+E_X.+O^C-?V<?_  O+_P#QHL%S[SHK
MX,_X7+_P<7?]&:_LX_\ A>7_ /C1_P +E_X.+O\ HS7]G'_PO+__ !HL%S[S
MHKX,_P"%R_\ !Q=_T9K^SC_X7E__ (T?\+E_X.+O^C-?V<?_  O+_P#QHL%S
M[SHKX,_X7+_P<7?]&:_LX_\ A>7_ /C1_P +E_X.+O\ HS7]G'_PO+__ !HL
M%S[SHKX,_P"%R_\ !Q=_T9K^SC_X7E__ (T?\+E_X.+O^C-?V<?_  O+_P#Q
MHL%S[SHKX,_X7+_P<7?]&:_LX_\ A>7_ /C1_P +E_X.+O\ HS7]G'_PO+__
M !HL%S[SHKX,_P"%R_\ !Q=_T9K^SC_X7E__ (T?\+E_X.+O^C-?V<?_  O+
M_P#QHL%S[SHKX,_X7+_P<7?]&:_LX_\ A>7_ /C3IOC+_P '$WGM]F_8W_9U
M,>X[#)X[O@Q7MD!B >G<_6BPS[QHKX,_X7+_ ,'%W_1FO[./_A>7_P#C1_PN
M7_@XN_Z,U_9Q_P#"\O\ _&BPKGWG17P9_P +E_X.+O\ HS7]G'_PO+__ !H_
MX7+_ ,'%W_1FO[./_A>7_P#C18+GWG17P9_PN7_@XN_Z,U_9Q_\ "\O_ /&C
M_A<O_!Q=_P!&:_LX_P#A>7_^-%@N?>=%?!G_  N7_@XN_P"C-?V<?_"\O_\
M&C_A<O\ P<7?]&:_LX_^%Y?_ .-%@N?>=%?!G_"Y?^#B[_HS7]G'_P +R_\
M\:/^%R_\'%W_ $9K^SC_ .%Y?_XT6"Y]YT5\&?\ "Y?^#B[_ *,U_9Q_\+R_
M_P :/^%R_P#!Q=_T9K^SC_X7E_\ XT6"Y]YT5\&?\+E_X.+O^C-?V<?_  O+
M_P#QH_X7+_P<7?\ 1FO[./\ X7E__C18+GWG17P9_P +E_X.+O\ HS7]G'_P
MO+__ !H_X7+_ ,'%W_1FO[./_A>7_P#C18+GWG17P9_PN7_@XN_Z,U_9Q_\
M"\O_ /&C_A<O_!Q=_P!&:_LX_P#A>7_^-%@N?>=%?!G_  N7_@XN_P"C-?V<
M?_"\O_\ &C_A<O\ P<7?]&:_LX_^%Y?_ .-%@N?>=%?!G_"Y?^#B[_HS7]G'
M_P +R_\ \:/^%R_\'%W_ $9K^SC_ .%Y?_XT6"Y]YT5\&?\ "Y?^#B[_ *,U
M_9Q_\+R__P :/^%R_P#!Q=_T9K^SC_X7E_\ XT6"Y]YT5\&?\+E_X.+O^C-?
MV<?_  O+_P#QH_X7+_P<7?\ 1FO[./\ X7E__C18+GWG17P9_P +E_X.+O\
MHS7]G'_PO+__ !H_X7+_ ,'%W_1FO[./_A>7_P#C18+GWG17P9_PN7_@XN_Z
M,U_9Q_\ "\O_ /&C_A<O_!Q=_P!&:_LX_P#A>7_^-%@N?>=%?!G_  N7_@XN
M_P"C-?V<?_"\O_\ &C_A<O\ P<7?]&:_LX_^%Y?_ .-%@N?>=%?!G_"Y?^#B
M[_HS7]G'_P +R_\ \:/^%R_\'%W_ $9K^SC_ .%Y?_XT6"Y]YT5\&?\ "Y?^
M#B[_ *,U_9Q_\+R__P :/^%R_P#!Q=_T9K^SC_X7E_\ XT6"Y]YT5\&?\+E_
MX.+O^C-?V<?_  O+_P#QH_X7+_P<7?\ 1FO[./\ X7E__C18+GWG17P9_P +
ME_X.+O\ HS7]G'_PO+__ !H_X7+_ ,'%W_1FO[./_A>7_P#C18+GWG17P9_P
MN7_@XN_Z,U_9Q_\ "\O_ /&C_A<O_!Q=_P!&:_LX_P#A>7_^-%@N?>=%?!G_
M  N7_@XN_P"C-?V<?_"\O_\ &C_A<O\ P<7?]&:_LX_^%Y?_ .-%@N?>=%?!
MG_"Y?^#B[_HS7]G'_P +R_\ \:/^%R_\'%W_ $9K^SC_ .%Y?_XT6"Y]YT5\
M&?\ "Y?^#B[_ *,U_9Q_\+R__P :/^%R_P#!Q=_T9K^SC_X7E_\ XT6"Y]YT
M5\&?\+E_X.+O^C-?V<?_  O+_P#QIL?QE_X.,"N9/V-/V<<[C_S/E^.,\?Q'
MMC_ZW2BPS[UHKX,_X7+_ ,'%W_1FO[./_A>7_P#C1_PN7_@XN_Z,U_9Q_P#"
M\O\ _&BPKGWG17P9_P +E_X.+O\ HS7]G'_PO+__ !H_X7+_ ,'%W_1FO[./
M_A>7_P#C18+GWG17P9_PN7_@XN_Z,U_9Q_\ "\O_ /&C_A<O_!Q=_P!&:_LX
M_P#A>7_^-%@N?>=%?!G_  N7_@XN_P"C-?V<?_"\O_\ &C_A<O\ P<7?]&:_
MLX_^%Y?_ .-%@N?>=%?!G_"Y?^#B[_HS7]G'_P +R_\ \:/^%R_\'%W_ $9K
M^SC_ .%Y?_XT6"Y]YT5\&?\ "Y?^#B[_ *,U_9Q_\+R__P :/^%R_P#!Q=_T
M9K^SC_X7E_\ XT6"Y]YT5\&?\+E_X.+O^C-?V<?_  O+_P#QH_X7+_P<7?\
M1FO[./\ X7E__C18+GWG17P9_P +E_X.+O\ HS7]G'_PO+__ !H_X7+_ ,'%
MW_1FO[./_A>7_P#C18+GWG17P9_PN7_@XN_Z,U_9Q_\ "\O_ /&C_A<O_!Q=
M_P!&:_LX_P#A>7_^-%@N?>=%?!G_  N7_@XN_P"C-?V<?_"\O_\ &C_A<O\
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M_A<O_!Q=_P!&:_LX_P#A>7_^-%@N?>=%?!G_  N7_@XN_P"C-?V<?_"\O_\
M&C_A<O\ P<7?]&:_LX_^%Y?_ .-%@N?>=%?!G_"Y?^#B[_HS7]G'_P +R_\
M\:/^%R_\'%W_ $9K^SC_ .%Y?_XT6"Y]YT5\&?\ "Y?^#B[_ *,U_9Q_\+R_
M_P :/^%R_P#!Q=_T9K^SC_X7E_\ XT6"Y]YT5\&?\+E_X.+O^C-?V<?_  O+
M_P#QH_X7+_P<7?\ 1FO[./\ X7E__C18+GWG17P9_P +E_X.+O\ HS7]G'_P
MO+__ !H_X7+_ ,'%W_1FO[./_A>7_P#C18+GWG17P9_PN7_@XN_Z,U_9Q_\
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M,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MQ'J+_?N[N<@;V))PH 5<L0-S,S>;_MX?L%_%W]J+]N#]EC]IGP#XE\.6>A_
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M-_$+_P!-5A7Z!TWL 4444@"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MH'1112 **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#\_/^"FW_*9#_@GW_V&_B%_
MZ:K"OT#K\_/^"FW_ "F0_P""??\ V&_B%_Z:K"OT#IO8 HHHI %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 5\&?LQ_\K W[3W_ &27P=_Z+K[S
MKX,_9C_Y6!OVGO\ LDO@[_T70)GWG1110,**** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@#X,_X(\_\G7_ +;W_9QT_P#Z2K11_P $>?\ DZ_]
MM[_LXZ?_ -)5HH8EL'_!QK_RCPL_^RM>%/\ TY1U]YU\&?\ !QK_ ,H\+/\
M[*UX4_\ 3E'7WG1T ****!A1110 57OKZTTRRFU*_N%AMX(VEGED;"HJC))/
MH!S^%6*X3]IZZN++]FWXA7=K)LEB\#ZL\;C'RL+.4@_GBJA'GFH]PV3/Q>_X
M)7F[_:\_X+"P?&?Q?";H-K&L^+KN.89V/ME-OC^Z(YIH"HZ#RP*_2S_@N'_R
MBZ^)_P#W!?\ T]V%?GW_ ,&VEE;S_MK^+;R2%6DA^&%WY189VEM0T\$CT../
MH3ZU^@G_  7#_P"477Q/_P"X+_Z>["OK<T=N(J$%M%P2^\^?P6N359O>7.W]
MQ\P_\&QG_(H?&'_L):)_Z+O:^7_^"L.BZ=XD_P""SOB?P]K5L)K2_P#$?A>V
MNH2<!XGTS359>/4$BOJ#_@V,_P"10^,/_82T3_T7>U\U?\%2/^4W6M_]C;X3
M_P#3=IE=V'TXEQ/^#]('/52>44%_>7_MQT'_  2F\7Z_^P7_ ,%7=4_9D\<7
MZI9:WJ=YX/U"1S\DEPLI:QG7IDR2)&BG'W;H\9/'ZT_MP_M%6O[*/[*7C;X[
M2W")=Z-HKC1D<*?-U"7$-JN&ZCSG0G@_*&.#BORR_P"#@_X,:O\ !?\ ;)\+
M?M0^#/-M/^$NTV&;[?$H'EZKIS(F\$=#Y/V0C/4HV"<<7_\ @M1_P4'TG]I3
M]FSX+> / EXJKXMT2+QAXHL[8_+!/A[:*UZECLG%Z"IXS'&WS<$<F(P2S;$8
M7$I:35I>L=_OU7R.BCB?[/H5Z/\ ([Q]);?UYGQL/@1JE[^Q/KG[6_B3SI);
MOXLZ=X<TNZE?)G8Z=J%W>LV>3\PL_F[G=Z<?L-_P;[_\HZ=,_P"QLU3_ -&+
M7S'_ ,%,/V=#^RQ_P1,^#'PBO=/%OJEO\0-/O=?4Q;7%_<Z;JD\ZOGDE&D\K
M)[1@< 8KZ<_X-]_^4=.F?]C9JG_HQ:O.,5]<R>51;>TLO172_P R<MH?5LQ]
MF]^37U;39^;G_!"#_E)EX)_[!NL?^FVXK]_J_ '_ ((0?\I,O!/_ &#=8_\
M3;<5^_U>?Q5_R,E_A7YLZ,A_W'YO]#\ ?"O_ "G@E_[.>O?_ $^RU^_U?@#X
M5_Y3P2_]G/7O_I]EK] OV]?^"X9_8?\ VDM3_9[/[+<OB4Z986EQ_;$GC'[
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M"#M#-KF<98?)8PI3]K'FNYWO;LNO]>I."E&MF;E./LY*-E'OYWZ_UV#X(?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 5\&?LQ_\K W[3W_9)?!W_HNOO.O@S]F/_E8&
M_:>_[)+X._\ 1= F?>=%%% PHHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MYK[Q-_;M[JFZ"6X9X8OM5ZB3S;4(Y=1MSL7*JI/T/0 4444 %%%% !17S?\
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M2C_L4_\ 9YO@[_T<]-;@?H'1112 **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#\
M_/\ @IM_RF0_X)]_]AOXA?\ IJL*_0.OS\_X*;?\ID/^"??_ &&_B%_Z:K"O
MT#IO8 HHHI %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5\&?LQ
M_P#*P-^T]_V27P=_Z+K[SKX,_9C_ .5@;]I[_LDO@[_T70)GWG1110,\G_;U
M_P"3&?C/_P!DG\1_^FRXK^9>OZIO'G@CPM\3_ VM?#7QSI7V[1/$.E7.F:Q9
M><\7VBUGB:*6/?&RNFY'8;E(89X(/-?-/_#CS_@EU_T;#_Y>NM__ ";7TF1Y
MSA<LI3C53=W?2WZM'BYKEM?'5(RIM*RZW_R9^ /@S_D<-*_["4'_ *,6OZKJ
M^4;+_@B3_P $Q-/O(K^T_9EV2P2K)$__  F>M':P((.#>>OK7U=66>YKA\T=
M-TDURWO>W6W9OL:95@*V C)5&G>VW_#(*\+_ ."H7_*-#]HC_LA?B[_TS7=>
MZ5X7_P %0O\ E&A^T1_V0OQ=_P"F:[KP%N>L<#_P0WFB@_X)%_ F::541/ J
M,[NV H$TI))/08KYP_;5^)'A'_@I9_P5O_9N_9B_9BUFU\6Z/\ O&;?$#XM>
M*]"N!-9:+/;2Q-9V+7"9C,K2V[(\2[FS(HROER[.4_X)2_\ !!W_ ()2?M*?
M\$[/A+\=OC5^RM_;7BKQ/X42\US5?^$XUVV^TSF212_E07R1IPHX55''2OTS
M^ ?[,_[/G[+/@UOA]^SG\&_#O@O1GG,\UCX=TJ.V6>4YS)(4 :5^VYB2   <
M "GLP6Q\H?\ !RG_ ,H4OC1_W+G_ *DFEU\\_P#!2+2-3_8R;]CS_@L?X'@E
MC@\ :5HGA+XLI:Q_-=^&[^T10[[<-)Y1DN%52'_>7$+ #9D_0W_!RG_RA2^-
M'_<N?^I)I=>Q>(/V:_"/[8G_  3!M/V9/'"*-/\ &?P@L-.\\J";6=K")H+E
M<@C?%,L<J\'YHQP>E"#J>^Z3JNG:[I5MK>CWL=S:7END]K<0MN26-U#*X/<$
M$$'WK\Z_V5Y$_P""C'_!:3XD_MB7*)>_#K]FJQD^'OPVE9%>*Y\0S#.JWD9*
M [HU9X<Y(*RPLK8XKQ/]E+_@K+XM_9G_ ."'/COP'X]=U^./P'U>3X3:7H2A
MY;F?5G:2VTED3=ND$<:2C P6&FR[1T%??_\ P2G_ &-!^P?^PIX&^ &JL)?$
M4=@=4\:WID+M<ZS=MY]VQ<\OM=O*5CR4A7/-&P'S'_P;6_\ )*_VE?\ LZKQ
M+_Z(LZB_:@_9X_;;_P""<?[?WC'_ (*<?L/_  FF^+G@3XGV%HOQJ^$^GRA-
M7ADM8PD=_IPP6N& W,(E5WW2RKL*N'AE_P"#:W_DE?[2O_9U7B7_ -$6=?I-
M0]P/F7]AG_@K=^Q7^W_=R^#OA%\0)]'\<V/FKK'PU\8VO]GZ[8218\Y&MW)$
MOEG(=HF<*00Q!!%?35?GE_P<*?L?? _Q%^QIXJ_;JTNUM?!_Q?\ A1;6FL>$
MOB5HZBUU'S(;F-$LY9DVM,C^84C5R?+D=2N,LK?8G[&_Q4\8?'3]D;X7?&OX
M@Z2+'7?%_P /-&UK6;,)M$5U=6,,\JA<#:-[G"X!'0@$8H Z7XPZA?Z3\)/%
M.JZ9>2V]S:^'+Z6WN(7*O'(MNY5E(Y!! ((KY+_X-Y/BQ\4?C;_P26^&GQ&^
M,WQ(U[Q;XAO;S74O=?\ $VKS7][<"/6;U(Q)/.S2/M150;F.%50,  5]7_'+
M_DBGC#_L5M0_])I*^,?^#97_ )0Q?"O_ *__ !#_ .GR^HZ ?/G@+XN?\%3/
MCS_P5R_:J_8X_9B^.=WH7A*/Q)H4NK>/?$UY)JL?P_TQ+*8/;:/I\[F%+J]D
MF!! "*+1F(SM9>S_ &YOV0_VYO\ @F?^S]K7[>?[)O\ P4X^-GC[6_ RIJWC
M7P3\9O$46MZ+K5@)%%TMO;>5&MB%#O)M0Y$:%4=&5373_P#!+#_E-1^WY_V&
MO"'_ *27E?2'_!87_E%C^T#_ -DGUK_TE>CJ"&^*O GA_P#X*N?L7_#;XB>%
M?VA_B]\)-/\ %&G:9XMM=2^$OC'^Q=5VSV3G[#<3B*020J;@ED P9((V!PO/
MYG_\$+O^"8__  TQ\"OBYXF_X>$?M/\ P^_L']H'7]#_ +.^&/Q8_LJUU'R+
M6P?[==1_9G\Z\D\W;)-D;ECC&T;>?TE_X(N_\HH_@%_V333O_1=?//\ P;)_
M\FQ_'O\ [.M\4_\ I%I5/H%SW/\ X*1?MD:U_P $T/V,?#UM\-;6^\=_$;7=
M0TKP+\,;/Q/?F>YUO69D$45S>RC:96"QM-(WR^9)A<IYFX>:^'/^"0_[7'Q1
M\.6WQ _:K_X+%_M$V_Q(N;;S;NW^$_BZ'0?#5A.6:188]/2W(N(XV<(78HTJ
MH,A 0J^4_P#!S-X:;6]?_9'N-=\;>(/"_AO_ (: LK/6_%7AC4/L>H:/YSP%
M;NUN"I$%S'''<212$':\8;!P:]H_X<<?]9@OVZ/_ !('_P"XJ70!G_!/?]JK
M]ISX:_MN>/?^"4?[;OQ+M?'GB;POX9A\5_#CXF+IT=E<>)-!DD2-H[J"(>6M
MQ [A-R\N$D)W;?,;R?\ X+-?M5?MH?L__P#!3K]F/P=^Q[J.KZKJOBWP_P")
M=/MO C:U<Q:+JFHSVYMK2[U"WB8)/#:23+=,6&52W;#+]X?0O[)W_!&_X/?L
MJ_M4+^V/<_M3?'7XG^-X_"DWAVWO_B[X[@UKR;&2592BO]DCE&U@VU?,*#S7
M.W)R/'?^"@?_ "L$?L/_ /8%\9?^FR>A6 ]?_9J_X)G?M!?"?XJ^&_VA_C!_
MP5(^.GCCQ5$3+XS\,7NOPKX0U-WB*M%;:4(0MI&K[65E;=\G;>U<-X;^-'Q@
MF_X.1/$'P)G^*GB)_!$/[,::G%X.?6ISI<=]_:=LOVI;0MY0GVLR^:%W[6*Y
MP<5]]5^;_A;_ )6F_$G_ &:?'_Z=;6@#G?\ @L/^TU^W)\%?^"J7[,O@#]BK
M4+_6-8\5^&/$EK!X"OO$EQ::#J=Y);R0PWFHP1N$GCL]_P!K((W8MB%9201W
M7Q,_X)1?M]:I\/+WXR:)_P %A_CA)\;[?39;NRL]/U:WL_!<U]Y3L+0:,D.P
M0EVV"1V8@;6*$J ,'_@H!_RL+_L2?]B_XN_]-MU7Z347L!^3O[ O[5G_  4S
M_P""Y7P;T-QXXN_@%\._#EL^E?$SX@^"!$NO>,]852'@TIYHV&EPK&\,DDRJ
M765S'&2 P7;\:W_[4_\ P1C_ &Y?@CX;U7]M#XC?&+X"_&_Q8OA+6++XPZVF
MKZQX>UF;RTMKF*_*HWDL[JVP*$5(Y@RLS(XZG_@UN_Y1IZG_ -E<\0?^A04S
M_@XF_P";2?\ LZ_PU_[5I]; ?I#1167XV\7Z)\/_  ;J_CWQ-<&+3=$TRXU#
M4)5&2D$,;22-COA5)J0/CK7/^";O[;G[3FH7_BO]L#_@J-\3?"+W%\TND>#O
MV;-33PSIVD0C(CB-Y+!)=7QPSEVEV[F9?E C2O*O@3\1?VN_^";_ /P5=\"_
M\$]?C=^UAXB^,?PG^,OA6_NOA]K7C[9<:]H>HV44DLD-Q>* ]RKK$5W/D$RQ
M;5C*N7M_LU_&K_@KK_P5L^%[?M/_  #_ &A?!'[-7PJUW4[F/P J_#^/Q1XD
MOK2VN)('N+M;N5;6/?+&ZX09 3C( DD\+^*WP/\ VP_@E_P7>_8YL?VO?VYO
M^%WWM^OB*31+_P#X5EI_AK^RHEL9A)'LLG83[R5.Y\%=N!UJ@/JG_@X\^,7Q
M:^!/_!+/Q1\1O@E\4/$/@_Q!:^)=%CM];\+ZS/87D2/>HKHLT#*X5E.&&<$'
M!R*S? _[$7_!0C]OOPK#\<?VX/VZ?BE\$CK8^V^&OA)^S_XDBT4>'+5\F"*_
MU'RI);^X\MOWHPJ!\;<;0JYW_!TG_P H?_&'_8TZ%_Z71U^@7A7_ )%C3?\
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M;0;8H-6LRF]T7)VK)')%)M!*JS.@)"9KPC_@V^_Y)W^T[_V=AXH_]$V=5_\
M@W.">)HOVK?B]X>0/X8\5?M0>()_#E['CR[J$,)-\>."NV:/YAP>0#\IJQ_P
M;??\D[_:=_[.P\4?^B;.GW ^@?VF_P!D_P#;<_:D^,5[H\7[<^I_"3X06]A'
M%8Z3\)K)(/$^JS/$!/+<ZG<QN+,(6E6);=#P4D9@Z@#X[_;L\"?MC?\ !#WP
MMX:_;8^"W_!0GXN_%?X<V'C"QL/B?\/OC?XA3Q!-=6-PXC,MG=-%&UNP/ 5
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M#?@37_AA\*] ^'OBGXD:MXPU#1M+BM+SQ1KP3[9J;HN#/-Y8"[VZG %>1?\
M!)K_ )1@?L]_]D:\.?\ IN@KZ#H; Y;XY?\ )%/&'_8K:A_Z325^/?\ P0?^
M"'[?/[8G_!.3P;\*['X_:Q\"_@CX;N]7@M]?^'EQ&OBGQK<3:C=2W#17<J,-
M,MH#*T*LBM(TL3-T V_L)\<O^2*>,/\ L5M0_P#2:2OC'_@V5_Y0Q?"O_K_\
M0_\ I\OJ.@'E_CW7/VL_^"+W[:?P3\.:S^V+\0_C-\ _C5XN3PCJUI\6M235
MM;\.ZM,56WN([_8CO&S2[R@4*(X95*EO+8?HO\>K3XY7_P (M;L/V:]5\-V/
MCB>V6/0+_P 7PS2:=:R-(H>:5(/GDV1EV5!@,ZHK$*21\!?\')/_ "+W[+'_
M &='X?\ _0)J^K/^"G'[>?A__@F_^R%KW[36L>#+CQ'>6ES;Z=X?\/V\XB.H
M:C</LAC9\$J@^9V*AFVH=H)P* /%]2_X(]?M"_$&QC\6?%W_ (+/?M/OXW\D
M&2]\#^*K7P_H0FR7R-)MH"AC#LWRF3)3:A.%%0?\$9_VLOVH/''Q ^.G[!W[
M:/Q%L_&?C[X">++:R@\;6VGI:OKNE7:RM;2RQH OFJ(<L< [98PQ=E:1ET;]
MFC_@O-\;= L/''Q%_P""GW@+X*ZK=VXFN/!7P_\ @;9:_;69?YO*DNM3N#(T
MD8(0[,J2#AGX8^(_\$//!OQ8^'O_  5J_;4\&?'+XT?\+$\66#^&H];\:?\
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MX_:Q\"_@CX;N]7@M]?\ AY<1KXI\:W$VHW4MPT5W*C#3+: RM"K(K2-+$S=
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MGA:C1JX.;G%/WNJ3Z(^8SZM6IUX*$FM.C?<]I_X>.?M\?]'C?$?_ ,*ZZ_\
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M5_S\E][/:?\ AXY^WQ_T>-\1_P#PKKK_ .+H_P"'CG[?'_1XWQ'_ /"NNO\
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M /"NNO\ XNO%J*/JF%_Y]Q^Y!]:Q7_/R7WL]I_X>.?M\?]'C?$?_ ,*ZZ_\
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M_"NNO_BZ/^'CG[?'_1XWQ'_\*ZZ_^+KQ:BCZIA?^?<?N0?6L5_S\E][/:?\
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MXWQ'_P#"NNO_ (NO%J*/JF%_Y]Q^Y!]:Q7_/R7WL]I_X>.?M\?\ 1XWQ'_\
M"NNO_BZ/^'CG[?'_ $>-\1__  KKK_XNO%J*/JF%_P"?<?N0?6L5_P _)?>S
MVG_AXY^WQ_T>-\1__"NNO_BZ/^'CG[?'_1XWQ'_\*ZZ_^+KQ:BCZIA?^?<?N
M0?6L5_S\E][/:?\ AXY^WQ_T>-\1_P#PKKK_ .+H_P"'CG[?'_1XWQ'_ /"N
MNO\ XNO%J*/JF%_Y]Q^Y!]:Q7_/R7WL]I_X>.?M\?]'C?$?_ ,*ZZ_\ BZ/^
M'CG[?'_1XWQ'_P#"NNO_ (NO%J*/JF%_Y]Q^Y!]:Q7_/R7WL]I_X>.?M\?\
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M? WQ5\-?VT?VN_A=X4L9O#M_%H/P_P#@G8ZG:Z3K>J&#_09=6U"^5[K[+'.
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M*_"+3O$$'B73K^ZN%U"Y:^LY(83:HD+1N [C?ODCP!D;CQ4O_!9[]A7XL_\
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M<,CCE756&" :^%O@]^PQ_P %JOV ?"=M\"/V(/VLO@M\2/AKI;2Q^&=/^/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MFHX4JBDUT3"K@\50ASU(-(]%_;;_ ."</[07[ MGX5O?C=?^'+A/%T-PUB-
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MW@=3]Y#(XD8$;66$J?O8-3_@K%_P4#^*7[67[1GB3P5IOC.^MOA]X;U>?3=
MT"TNF2VNA [1M>3("!+)(RLRE\[$8*,?-GRJ^*Q-7&?5<-9-*\I-7M?9):7?
MX6/1HX>A3POUBO=INR2TOW=^PS]I;_@BM^W9^S+X7O/'6K^"]+\5Z'IUOY^H
MZGX*U![L6L8!9G>&6.*?:H!+,(RJ@9)QS7R97K_[)W[<_P"TK^Q=XNC\4_ _
MX@W%O;%P;[P[?R/-IFH+S\LUON )Y.'4JZY.UADY\FQ/J%YMB@+RSR_+'&G+
M,3P ![UUX98R#<:[371I6OWNM;?><]=X623HII]4]?N9],_L5?\ !)G]I_\
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M[+4-/NKV==1E=3;@M%&L!B*_Z2GWI%/RMQTSX;7Z;?LG_P#*O!\:/^QJNO\
MT/2Z,QQ-7#4X.'6<5\F]0P&'IXBI)3Z1;^:/A#]E']E_XC?MC?&_2_@'\*KO
M2[;6-5BN)8[K6KF2*UA2&)I79VC1WQA<#:A))''>OL'_ (ALOVYO^BK?"?\
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M;HX2K7"QE=R)N !9L@@XH T_#7[<O[$_C3X@_P#"I?!W[8?PLU;Q5]LDM?\
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M(KTO3=3TW6=.@U?1M0@N[2YB66VNK:99(Y4895E920P(.01Q7S7X!_X(R?\
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M9]M88O$8#$93"CAVG-\O*E\2=UTW5M;LVPU'&4<RE5K)J*O=O9K6WKT/+/\
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MBAJ'_H&GUQ'_  0 ^.FB^'/VCO$?[+/CW9-X=^*WAV6T-I.^(Y+R".1@A/!
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M?%+X>?$;6='\1PSF9=9L-0DCN&<G+;W!RX;^(-D,"00037Z/_P#!."\\!?\
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MQ0LO_0[FIQ6+GBLIQ"E9\KBN:.TM5^77<>'PT,/F-!QNN9/W7NM&?-W_  2
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MN#!&0>HD/!Z'TOX1?\$/OB]X8$WQ,_X* >.M$^#_ ,/M'(DU:[N-?M+J_NU
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M52&S3Z^0LMHUJ-::J1<?<ENK=CQ7_@@A_P I)_"__8#U?_TCDKZ$_:^^#/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** /ZP****_%S],"BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "O@S]F/_ )6!OVGO^R2^#O\
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M_AB7R=0UC1HM04OIL5QC=;":9X-\B\^6DB_Q$5ZM_P &[/\ S=M_V=?XE_\
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MO?6>L7.GWK)%=2P2H8G=O)AF.4^67)'W0:]:N/\ @F+_ ,$RK6![JZ_X)Z_
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M@9^T/X<@\'?'_P""_A/QUI%I?+>6NE>,?#EKJ=M#<JCHLR17*.JR!))%#@9
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MBX_>!2ZR2%9 2#V(X7X^_P#*SY\"_P#LW/5?_2C5*_0+XG_\DT\1?]@*[_\
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M$$%37TE_P=46=U=?\$CM<GMX2Z6WC?1))V'\"F=DR?\ @3*/Q%/J!]E_"_\
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M)GBSXH^)-27P;H?C6Q34=+\,:!:W,MI#96]I/NA.)(IOWC)G 5@ S.[^2?\
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M:*L9WY;Y,97;SUK]<:_-GP;_ ,K4/BS_ +-5C_\ 3E95]L_M??M;_!+]A[X
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MF7"ZC\4_B#=MYCS3'!6QM257R[2'HJA5#%0=JJL<<9Y@7/\ @H[X/TSX(?\
M!'?XP_#7X<6AM]-\,_ /5=&TJ%%QY-G#I3VR@!< ;8AVP!BC_@BG;V]M_P $
MG_@'':A0A^'-BQ"X^\P+-T]R:]H_:?\ A!;_ +07[-GQ!^!%TL;)XT\$ZKH9
M\UB%'VJTE@!R.1@N#D<C&:^/_P#@W+_:#M/B%_P3RTK]FWQ=<)8_$/X(:M?^
M$/''AJXD NM/>"[F^S[X^R^61%N&Y2\$@SE2 = ZGN7_  5NM+>]_P""7G[0
M<5U%O1?@]X@<*>S)83,I_ @'\*QO^"*DTMQ_P2?^ ;S2%B/AQ8J"?15( _
M"N!_X. ?VAM(^%?_  3Q\3? W1$.J>/?C08_!/@'PK:-NN]4NKV1(I?+09)5
M(68ECA=[1J2#(N?HW]E3X1Z%^Q]^QQX!^#&NZU:VEE\._A_8:?JVJ7<Z10H;
M2T07%Q(YPJJ61Y&8X !)Z4= .T^*'Q-\!?!?X=ZU\6?BEXHM-$\.^'=-EO\
M6=6OI0D5M;QJ69V/T' &220 "2!7P)_P17\&_$3]J?\ :"^,G_!9KXL^%;S0
MHOC%+!H7PIT/4XQ]IM/"UGL5)CQ\JW#PPM@8#- \@WK(CGCI/^$X_P"#AG]H
M,)#+J>C?L6?#;7QO*F2VE^+.LV\F<<@.-.A8 =LDYR92/LOZ@Z3I.D^'])M=
M!T'2[>QL;&W2WLK*TA6*&WA10J1HB@!%50 % P  !1L!SWQN\5_$WP+\)M>\
M7_!GX2CQWXIT_3WFT/P<=>ATO^UIQC$'VN<&.#//SN"HQS7YM?MR_MT_\%L-
M8^!^K^&]:_X)B^)O@CX:U+3YK;Q+X_\ !'B/3/B-K.FV;@)++;6%G<V9B8([
M,9F+[ K, "-Z?IS=>// ]EXRMOAU>>,])B\0WMD]Y9Z%+J,2WD]NC;6F2 MO
M:-3P6 (![UISSPVL+W5U,D442%Y))& 55 R22>@ [TD,^8/^".5O^Q!I/[ ?
M@OPK_P $_P#QX/$?@328I()M3NLK?R:DQ\ZZ-]&55HKDO)N*%0%5D"?N]AKS
MO_@Y#\#6_CC_ ((W?%T/ 7GTA-'U.U94!V-%JUGO/_?II1GL#WZ'S'_@@S;:
M%XE_:^_;5^,?P&FC'P;\0?%JU@\&?V>3_9]UJ$(NVU"YM0/D$;F: ADX9&CP
M,*H'H'_!R[X[B\$_\$;_ (H60G*7&OW>B:9:D'&6;5K660?C%#*/QI]1'U3^
MQCX\D^*?['OPH^)TTK2-XC^&NA:HSNY8L;C3X)<DGJ?GZUZ77G_[)_@&7X5_
MLL_#3X7W-LT,GAOX?Z-I;PNNTQM;V,,14@]""F,>U>@4@"BBB@#X,_X(\_\
M)U_[;W_9QT__ *2K11_P1Y_Y.O\ VWO^SCI__25:*&);!_P<:_\ */"S_P"R
MM>%/_3E'7WG7P9_P<:_\H\+/_LK7A3_TY1U]YT= "BBB@84444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %?GY_P76_Y*/^Q3_V>;X._P#1SU^@=?GY_P %UO\ DH_[%/\
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M9?C!H?P[O?A#HOQ6\26?A/4I_/U+PO:Z[<1Z==R?(=\MLKB)VS''RRD_(O\
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M:-91V>E:5IMLL-O:6\:A4BC10 JJH   [5IT4K@>*? /]A'X/_LZ?M._%_\
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M;JEWH?\ 8]L_Q>^)#ZS%I]F98Y?+MX1%%''\T2X;:6 W $!B#](T4 %? /\
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MX(&?LK:;XLUGQ)^S7^T-\>_@19>(;^2]UWPQ\%/BE+H^E7UP^ SM;/%,$'!
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M$44BE8=&TW?';QS+UV3R&XA&> S(<'&1^C=<!X3_ &7O@9X(_:#\6?M4>'/
MYB\?>-],LM.\1^(9]3NIVFM+1 L$$44LK16L8P&98$C$C_.^YOFI =_1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% 'Y+_P#!QQ\*O'GQN_:__9 ^$WPNT+^T_$&NP_$2VTJP^U10>?*=-TTA
M?,E9$7@'EF ]Z^5_^''G_!47_HV'_P O71/_ )-K]#?^"FW_ "F0_P""??\
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M%'^M>8_RP^Y__)!_J_@_YI?>O\C^>_\ X<>?\%1?^C8?_+UT3_Y-H_X<>?\
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M_P TOO7^1_/?_P .//\ @J+_ -&P_P#EZZ)_\FT?\.//^"HO_1L/_EZZ)_\
M)M?T(44?ZUYC_+#[G_\ )!_J_@_YI?>O\C^>_P#X<>?\%1?^C8?_ "]=$_\
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M%1?^C8?_ "]=$_\ DVC_ (<>?\%1?^C8?_+UT3_Y-K^A"BC_ %KS'^6'W/\
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M8?<__D@_U?P?\TOO7^1_/?\ \.//^"HO_1L/_EZZ)_\ )M'_  X\_P""HO\
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M3_Y-K^A"BC_6O,?Y8?<__D@_U?P?\TOO7^1_/?\ \.//^"HO_1L/_EZZ)_\
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M_P"7KHG_ ,FU_0A11_K7F/\ +#[G_P#)!_J_@_YI?>O\C^>__AQY_P %1?\
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M? CP;^T)X$L;^VT7QQX8L==TJVU6)([J&WNH$FC298W=%D"N P5V7(.&(P2
M=C1110 4444 %%%% !1165XV\<^"OAIX3O\ Q]\1_&&E^']"TJW:XU36M;U"
M.TM+.$=9)9I65(U'=F( ]: -6BLWPAXO\)?$'PMI_CGP%XHT[6]$U>SCN]*U
MC1[Z.YM;VW=0R2Q2QDI(C*00RD@@Y!K2H **** "BBB@ HHHH **** "BBB@
M HHJKK>K6N@:+=Z[?!S!96LEQ,(URQ1%+' SR< T 6J*\=_81_;8^%'_  4*
M_9JT;]JCX+:%X@TSP_KEU>6]K9>)[2""]C>VN)+=]Z033( 6C)&'.01G!R![
M%0 4444 %%%% !1110 4444 %%%% !1110 4444 %%5=;U:UT#1;O7;X.8+*
MUDN)A&N6*(I8X&>3@&O)_P!A']MCX4?\%"OV:M&_:H^"VA>(-,\/ZY=7EO:V
M7B>T@@O8WMKB2W?>D$TR %HR1ASD$9P<@ 'L5%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 45XI^QI^W?\'_ -N/_A8G_"I-!\1V'_"L_B'?>#M=
M_P"$ALX(?M%]:[?,EM_)FEW0'<-K/L<X.47C/M= !1110 445X[^VG^W1^SW
M^P1\,[+XF?'[7+]5UC5XM)\.:#H6FO?:GK=_)DI:VMNG,CD \DJHX!8%E! /
M8J*^?/V-/^"AWA;]LGQ-K7@F/]E[XV_"W6M$LH[V32_C'\/'T.6[MG?8)8#Y
MLB2+ORI&X,,'C'-?0= !17*_%?XX_!7X#^'_ /A+?CC\8/"W@O2O^@GXK\06
MVG6_WT3_ %EPZ+]Z2->O5U'5A4'P?_:%^ 7[0ND7'B#X _''P?XYL+2;RKJ]
M\'^)K74X89.NUWMI'53[$YH [&BBN)^,7[2?[.O[.]E;:E^T!\?/!7@6VO)1
M%9S^,?%5II:3N0Q"(US(@8D(YP.<(WH: .VHKFOA;\9?A!\<_#*>-O@G\5?#
M?C'1I&*QZOX6UVWU"U8@E2!+ [H2"I!YZ@^E=+0 45Y-?_MY?L-:5XY7X8:G
M^V=\)[;Q*TT<*^'9_B+IB7S22*K1H+<S^9N964J-N2&!&<BO5T=74/&P*D9!
M!X(H =117-_%3XP_"3X%^$)?B%\;?BEX<\':!!-'#/KGBK6X-/LXY'.U$::=
MT0,QX )R3TH Z2BLOP7XW\&?$GPII_CSX=^+M+U_0]6M5N=*UK1=0CNK2\A;
M[LD4T19)$/9E)!K4H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH ^#/^"//_)U_P"V]_V<=/\ ^DJT4?\ !'G_ ).O_;>_[..G_P#25:*&
M);!_P<:_\H\+/_LK7A3_ -.4=?>=?!G_  <:_P#*/"S_ .RM>%/_ $Y1U]YT
M= "BBB@84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %?GY_P76_Y*/^Q3_P!GF^#O_1SU
M^@=?GY_P76_Y*/\ L4_]GF^#O_1STUN!^@=%%%( HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** /S\_X*;?\ *9#_ ()]_P#8;^(7_IJL*_0.OS\_X*;?\ID/^"??
M_8;^(7_IJL*_0.F]@"BBBD 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !7P9^S'_P K W[3W_9)?!W_ *+K[SKX,_9C_P"5@;]I[_LDO@[_ -%T
M"9]YT444#/)_V]?^3&?C/_V2?Q'_ .FRXK^9>OZ:/V]?^3&?C/\ ]DG\1_\
MILN*_F7K[OA+_=JOJOR/E.(?XT/1FEX,_P"1PTK_ +"4'_HQ:_JNK^5'P9_R
M.&E?]A*#_P!&+7]5U<_%_P 5'_M[]#HX=_AU/5?J%>:?MA_M.>!_V,OV8/&_
M[47Q&!DTGP9H,M_):I*J/=S<)!:HS<!YIGBB7/\ %(*]+K\W?^#JW6M2TO\
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M_P""H7_*-#]HC_LA?B[_ -,UW7RA_P %@O\ E+9_P3S_ .Q\\5_^B]'KZO\
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M(I+>Y@M52.16W+D[=Q7>A)21E)H!]F_\%HO^44?Q]_[)IJ/_ *+K:_X)-?\
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MM!H'Q\_:B^'7@>_NE9K:R\7^-K#3)I0H4DJES*C, '0D@?QKZBO%_P#@M?\
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MT_A+<^)!=26Q\/6_Q&TQ[X3)N+Q>0)S)O7:V5VY&TY'%?&W[>MMXJ_X*3_\
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MT_\ Z2K11_P1Y_Y.O_;>_P"SCI__ $E6BAB6P?\ !QK_ ,H\+/\ [*UX4_\
M3E'7WG7P9_P<:_\ */"S_P"RM>%/_3E'7WG1T ****!A1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 5^?G_!=;_DH_P"Q3_V>;X._]'/7Z!U^?G_!=;_DH_[%/_9YO@[_
M -'/36X'Z!T444@"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _/S_@IM_RF0_X)
M]_\ 8;^(7_IJL*_0.OS\_P""FW_*9#_@GW_V&_B%_P"FJPK] Z;V ****0!1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MTSX)_&GQ3XKT.TT3Q7:>(]'UGP7JD5GJ%G?V\<T<<D<DL,JCY)Y1]S()!!!
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M\$D]4M;'_@K%^WYX.OG\G4&\>^&[^.W<@-);O;WV'49R0-R$G&!YB>M>^_\
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MY;J$58YF"R1R?(BIN,>\H%4L0B;2^H'YM?\ !P/_ ,$HO^"2G[!7[!UUX[^
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MH_%?XY>+=%25/#'B#X[^/9/$,N@K(%W?8XVCCAB8$;A(8S(K$E6'&#0#S/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !7P9^S'_P K W[3W_9)?!W_ *+K[SKX,_9C_P"5@;]I
M[_LDO@[_ -%T"9]YT444#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH ^#/^"//_ "=?^V]_V<=/_P"DJT4?\$>?^3K_ -M[_LXZ?_TE6BAB
M6P?\'&O_ "CPL_\ LK7A3_TY1U]YU\&?\'&O_*/"S_[*UX4_].4=?>='0 HH
MHH&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !7Y^?\%UO^2C_L4_]GF^#O\ T<]?H'7Y
M^?\ !=;_ )*/^Q3_ -GF^#O_ $<]-;@?H'1112 **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@#\_/^"FW_*9#_@GW_V&_B%_Z:K"OT#K\_/^"FW_ "F0_P""??\
MV&_B%_Z:K"OT#IO8 HHHI %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 5\&?LQ_\K W[3W_ &27P=_Z+K[SKX,_9C_Y6!OVGO\ LDO@[_T70)GW
MG1110,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#X,_X(\_
M\G7_ +;W_9QT_P#Z2K11_P $>?\ DZ_]M[_LXZ?_ -)5HH8EL'_!QK_RCPL_
M^RM>%/\ TY1U]YU\&?\ !QK_ ,H\+/\ [*UX4_\ 3E'7WG1T ****!A1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 5^?G_!=;_DH_[%/_ &>;X._]'/7Z!U^?G_!=;_DH
M_P"Q3_V>;X._]'/36X'Z!T444@"BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _/S
M_@IM_P ID/\ @GW_ -AOXA?^FJPK] Z_/S_@IM_RF0_X)]_]AOXA?^FJPK]
MZ;V ****0!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?!G[,?_
M "L#?M/?]DE\'?\ HNOO.O@S]F/_ )6!OVGO^R2^#O\ T70)GWG1110,****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#X,_X(\_\ )U_[;W_9
MQT__ *2K11_P1Y_Y.O\ VWO^SCI__25:*&);$?\ P<@&\'_!.)&TU('NE^)W
MAHVB7,K1QO.+T&,.RJQ"E]H.%/!/3J)/^%R_\'%W_1FO[./_ (7E_P#XT?\
M!QK_ ,H\+/\ [*UX4_\ 3E'7WG3Z ?!G_"Y?^#B[_HS7]G'_ ,+R_P#\:/\
MA<O_  <7?]&:_LX_^%Y?_P"-?>=%%PL?!G_"Y?\ @XN_Z,U_9Q_\+R__ ,:/
M^%R_\'%W_1FO[./_ (7E_P#XU]YT47"Q\&?\+E_X.+O^C-?V<?\ PO+_ /QH
M_P"%R_\ !Q=_T9K^SC_X7E__ (U]YT47"Q\&?\+E_P"#B[_HS7]G'_PO+_\
MQH_X7+_P<7?]&:_LX_\ A>7_ /C7WG11<+'P9_PN7_@XN_Z,U_9Q_P#"\O\
M_&C_ (7+_P '%W_1FO[./_A>7_\ C7WG11<+'P9_PN7_ (.+O^C-?V<?_"\O
M_P#&C_A<O_!Q=_T9K^SC_P"%Y?\ ^-?>=%%PL?!G_"Y?^#B[_HS7]G'_ ,+R
M_P#\:/\ A<O_  <7?]&:_LX_^%Y?_P"-?>=%%PL?!G_"Y?\ @XN_Z,U_9Q_\
M+R__ ,:/^%R_\'%W_1FO[./_ (7E_P#XU]YT47"Q\&?\+E_X.+O^C-?V<?\
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MN_Z,U_9Q_P#"\O\ _&OO.BBX6/@S_A<O_!Q=_P!&:_LX_P#A>7_^-'_"Y?\
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MWG11<+'P9_PN7_@XN_Z,U_9Q_P#"\O\ _&C_ (7+_P '%W_1FO[./_A>7_\
MC7WG11<+'P9_PN7_ (.+O^C-?V<?_"\O_P#&C_A<O_!Q=_T9K^SC_P"%Y?\
M^-?>=%%PL?!G_"Y?^#B[_HS7]G'_ ,+R_P#\:/\ A<O_  <7?]&:_LX_^%Y?
M_P"-?>=%%PL?!G_"Y?\ @XN_Z,U_9Q_\+R__ ,:/^%R_\'%W_1FO[./_ (7E
M_P#XU]YT47"Q\&?\+E_X.+O^C-?V<?\ PO+_ /QH_P"%R_\ !Q=_T9K^SC_X
M7E__ (U]YT47"Q\&?\+E_P"#B[_HS7]G'_PO+_\ QH_X7+_P<7?]&:_LX_\
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MWG11<+'P9_PN7_@XN_Z,U_9Q_P#"\O\ _&C_ (7+_P '%W_1FO[./_A>7_\
MC7WG11<+'P9_PN7_ (.+O^C-?V<?_"\O_P#&C_A<O_!Q=_T9K^SC_P"%Y?\
M^-?>=%%PL?!G_"Y?^#B[_HS7]G'_ ,+R_P#\:/\ A<O_  <7?]&:_LX_^%Y?
M_P"-?>=%%PL?!G_"Y?\ @XN_Z,U_9Q_\+R__ ,:/^%R_\'%W_1FO[./_ (7E
M_P#XU]YT47"Q\&?\+E_X.+O^C-?V<?\ PO+_ /QH_P"%R_\ !Q=_T9K^SC_X
M7E__ (U]YT47"Q\&?\+E_P"#B[_HS7]G'_PO+_\ QITWQE_X.)O/;[-^QO\
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M\'%W_1FO[./_ (7E_P#XT?\ "Y?^#B[_ *,U_9Q_\+R__P :^\Z*+A8^#/\
MA<O_  <7?]&:_LX_^%Y?_P"-'_"Y?^#B[_HS7]G'_P +R_\ \:^\Z*+A8^#/
M^%R_\'%W_1FO[./_ (7E_P#XT?\ "Y?^#B[_ *,U_9Q_\+R__P :^\Z*+A8^
M#/\ A<O_  <7?]&:_LX_^%Y?_P"-'_"Y?^#B[_HS7]G'_P +R_\ \:^\Z*+A
M8^#/^%R_\'%W_1FO[./_ (7E_P#XT?\ "Y?^#B[_ *,U_9Q_\+R__P :^\Z*
M+A8^#/\ A<O_  <7?]&:_LX_^%Y?_P"-'_"Y?^#B[_HS7]G'_P +R_\ \:^\
MZ*+A8^#/^%R_\'%W_1FO[./_ (7E_P#XT?\ "Y?^#B[_ *,U_9Q_\+R__P :
M^\Z*+A8^#/\ A<O_  <7?]&:_LX_^%Y?_P"-'_"Y?^#B[_HS7]G'_P +R_\
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M7E__ (T?\+E_X.+O^C-?V<?_  O+_P#QK[SHHN%CX,_X7+_P<7?]&:_LX_\
MA>7_ /C1_P +E_X.+O\ HS7]G'_PO+__ !K[SHHN%CX,_P"%R_\ !Q=_T9K^
MSC_X7E__ (T?\+E_X.+O^C-?V<?_  O+_P#QK[SHHN%CX,_X7+_P<7?]&:_L
MX_\ A>7_ /C1_P +E_X.+O\ HS7]G'_PO+__ !K[SHHN%CX,_P"%R_\ !Q=_
MT9K^SC_X7E__ (T?\+E_X.+O^C-?V<?_  O+_P#QK[SHHN%CX,_X7+_P<7?]
M&:_LX_\ A>7_ /C1_P +E_X.+O\ HS7]G'_PO+__ !K[SHHN%CX,_P"%R_\
M!Q=_T9K^SC_X7E__ (T?\+E_X.+O^C-?V<?_  O+_P#QK[SHHN%CX,_X7+_P
M<7?]&:_LX_\ A>7_ /C1_P +E_X.+O\ HS7]G'_PO+__ !K[SHHN%CX,_P"%
MR_\ !Q=_T9K^SC_X7E__ (T?\+E_X.+O^C-?V<?_  O+_P#QK[SHHN%CX,_X
M7+_P<7?]&:_LX_\ A>7_ /C1_P +E_X.+O\ HS7]G'_PO+__ !K[SHHN%CX,
M_P"%R_\ !Q=_T9K^SC_X7E__ (T?\+E_X.+O^C-?V<?_  O+_P#QK[SHHN%C
MX,_X7+_P<7?]&:_LX_\ A>7_ /C1_P +E_X.+O\ HS7]G'_PO+__ !K[SHHN
M%CX,_P"%R_\ !Q=_T9K^SC_X7E__ (T?\+E_X.+O^C-?V<?_  O+_P#QK[SH
MHN%CX,_X7+_P<7?]&:_LX_\ A>7_ /C1_P +E_X.+O\ HS7]G'_PO+__ !K[
MSHHN%CX,_P"%R_\ !Q=_T9K^SC_X7E__ (T?\+E_X.+O^C-?V<?_  O+_P#Q
MK[SHHN%CX,_X7+_P<7?]&:_LX_\ A>7_ /C1_P +E_X.+O\ HS7]G'_PO+__
M !K[SHHN%CX,_P"%R_\ !Q=_T9K^SC_X7E__ (T?\+E_X.+O^C-?V<?_  O+
M_P#QK[SHHN%CX,_X7+_P<7?]&:_LX_\ A>7_ /C1_P +E_X.+O\ HS7]G'_P
MO+__ !K[SHHN%CX,_P"%R_\ !Q=_T9K^SC_X7E__ (T?\+E_X.+O^C-?V<?_
M  O+_P#QK[SHHN%CX,_X7+_P<7?]&:_LX_\ A>7_ /C1_P +E_X.+O\ HS7]
MG'_PO+__ !K[SHHN%CX,_P"%R_\ !Q=_T9K^SC_X7E__ (T?\+E_X.+O^C-?
MV<?_  O+_P#QK[SHHN%CX,_X7+_P<7?]&:_LX_\ A>7_ /C1_P +E_X.+O\
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MO+__ !H_X7+_ ,'%W_1FO[./_A>7_P#C7WG11<+'P9_PN7_@XN_Z,U_9Q_\
M"\O_ /&C_A<O_!Q=_P!&:_LX_P#A>7_^-?>=%%PL?!G_  N7_@XN_P"C-?V<
M?_"\O_\ &C_A<O\ P<7?]&:_LX_^%Y?_ .-?>=%%PL?!G_"Y?^#B[_HS7]G'
M_P +R_\ \:/^%R_\'%W_ $9K^SC_ .%Y?_XU]YT47"Q\&?\ "Y?^#B[_ *,U
M_9Q_\+R__P :/^%R_P#!Q=_T9K^SC_X7E_\ XU]YT47"Q\&?\+E_X.+O^C-?
MV<?_  O+_P#QH_X7+_P<7?\ 1FO[./\ X7E__C7WG11<+'P9_P +E_X.+O\
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M]YT47"Q\&?\ "Y?^#B[_ *,U_9Q_\+R__P :/^%R_P#!Q=_T9K^SC_X7E_\
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M?^#B[_HS7]G'_P +R_\ \:/^%R_\'%W_ $9K^SC_ .%Y?_XU]YT47"Q\&?\
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M>%/_ $Y1U]YU\&?\'&O_ "CPL_\ LK7A3_TY1U]YTN@@HHHH&%%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !7Y^?\%UO^2C_L4_\ 9YO@[_T<]?H'7Y^?\%UO^2C_ +%/
M_9YO@[_T<]-;@?H'1112 **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#\_/^"FW_
M "F0_P""??\ V&_B%_Z:K"OT#K\_/^"FW_*9#_@GW_V&_B%_Z:K"OT#IO8 H
MHHI %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5\&?LQ_\ *P-^
MT]_V27P=_P"BZ^\Z^#/V8_\ E8&_:>_[)+X._P#1= F?>=%%% PHHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** /@S_@CS_P G7_MO?]G'3_\
MI*M%'_!'G_DZ_P#;>_[..G_])5HH8EL'_!QK_P H\+/_ +*UX4_].4=?>=?!
MG_!QK_RCPL_^RM>%/_3E'7WG1T ****!A1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5^
M?G_!=;_DH_[%/_9YO@[_ -'/7Z!U^?G_  76_P"2C_L4_P#9YO@[_P!'/36X
M'Z!T444@"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _/S_@IM_RF0_X)]_]AOXA
M?^FJPK] Z_/S_@IM_P ID/\ @GW_ -AOXA?^FJPK] Z;V ****0!1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %?!G[,?_*P-^T]_P!DE\'?^BZ^
M\Z^#/V8_^5@;]I[_ +)+X._]%T"9]YT444#"BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH ^#/^"//_)U_P"V]_V<=/\ ^DJT4?\ !'G_ ).O
M_;>_[..G_P#25:*&);!_P<:_\H\+/_LK7A3_ -.4=?>=?!G_  <:_P#*/"S_
M .RM>%/_ $Y1U]YT= "BBB@84444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?GY_P76_Y*
M/^Q3_P!GF^#O_1SU^@=?GY_P76_Y*/\ L4_]GF^#O_1STUN!^@=%%%( HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %?!G[,?\ RL#?M/?]DE\'?^BZ^\Z^#/V8_P#E8&_:>_[)+X._]%T"9]YT
M444#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH *_?/_@@=_RC9\,?]AW5O_2R2OP,K]\_^"!W_*-GPQ_V'=6_]+)*
M^:XJ_P"18O\ $OR9[G#_ /ODO\+_ #1]FT445^>'V 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5\
M&?LQ_P#*P-^T]_V27P=_Z+K[SKX,_9C_ .5@;]I[_LDO@[_T70)GWG1110,*
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M*W^!_A)X\LT@UKPWXVO=.U.**3>@FA@N$8JW\2DC(/<$'O5?_@L#K6J>&_\
M@J9\2/$.A7KVU]8:UIES9W$9&Z*5-.LV5QGN& -=2JSEFZC&7N^SNM=+\V]C
M!TZ<<MYI1L_:6?>W+L?1/Q:_9Z_X(S_\$V=5T_X'_M9^ ?B#\5O'<^CP7NL7
M>B7,MO;V9??C8D=Y:*JOU"EIF 122N3GXY_;AC_8=G\>Z/KO["4_B2'P_J.D
MO-K.C>)1(9=+N_/E @1GR63RO+(/F2\$9?=D#ZTD_P""A_\ P3N_X*(Z%H_A
MK_@I3\&]4\+^-;&PBL;?XG>#Y6*;=Q+.ZH"\2Y8D1/%<HN^0@I7S[_P4I_X)
MSW/["OB#PUXE\&_$6'QAX!\<6;W7A7Q!&J+(P58W,<FPE&RDL3K*I"R*Q("[
M2*Y<OE.GB(PQ,IJJ[Z-WA+_#T\[:,Z,;&,Z$IT(P=/39>]'UZ_F?,%%%%?0'
MAA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %?OG_P $#O\ E&SX8_[#NK?^EDE?@97[Y_\
M! [_ )1L^&/^P[JW_I9)7S7%7_(L7^)?DSW.'_\ ?)?X7^:/LVBBBOSP^P"B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %?OG_ ,$#O^4;/AC_ +#NK?\ I9)7X&5^^?\ P0._Y1L^&/\
ML.ZM_P"EDE?-<5?\BQ?XE^3/<X?_ -\E_A?YH^S:***_/#[ **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH *^#/V8_^5@;]I[_LDO@[_P!%U]YU\&?LQ_\ *P-^T]_V27P=_P"BZ!,^
M\Z***!A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_P"SS?!W_HYZ:W _0.BBBD 4444 %%%% !1110 4444 %%%% !1110 4444
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M_/PE_D']B9A_*OO1^1M%?KE_Q#%^$O\ H\34?_"(3_Y,H_XAB_"7_1XFH_\
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M_P"$0G_R91_K'E'_ #\_"7^0?V)F'\J^]'Y&T5^N7_$,7X2_Z/$U'_PB$_\
MDRC_ (AB_"7_ $>)J/\ X1"?_)E'^L>4?\_/PE_D']B9A_*OO1^1M%?KE_Q#
M%^$O^CQ-1_\ "(3_ .3*/^(8OPE_T>)J/_A$)_\ )E'^L>4?\_/PE_D']B9A
M_*OO1^1M%?KE_P 0Q?A+_H\34?\ PB$_^3*/^(8OPE_T>)J/_A$)_P#)E'^L
M>4?\_/PE_D']B9A_*OO1^1M%?KE_Q#%^$O\ H\34?_"(3_Y,H_XAB_"7_1XF
MH_\ A$)_\F4?ZQY1_P _/PE_D']B9A_*OO1^1M%?KE_Q#%^$O^CQ-1_\(A/_
M ),H_P"(8OPE_P!'B:C_ .$0G_R91_K'E'_/S\)?Y!_8F8?RK[T?D;17ZY?\
M0Q?A+_H\34?_  B$_P#DRC_B&+\)?]'B:C_X1"?_ "91_K'E'_/S\)?Y!_8F
M8?RK[T?D;17ZY?\ $,7X2_Z/$U'_ ,(A/_DRC_B&+\)?]'B:C_X1"?\ R91_
MK'E'_/S\)?Y!_8F8?RK[T?D;17ZY?\0Q?A+_ */$U'_PB$_^3*/^(8OPE_T>
M)J/_ (1"?_)E'^L>4?\ /S\)?Y!_8F8?RK[T?D;17ZY?\0Q?A+_H\34?_"(3
M_P"3*/\ B&+\)?\ 1XFH_P#A$)_\F4?ZQY1_S\_"7^0?V)F'\J^]'Y&T5^N7
M_$,7X2_Z/$U'_P (A/\ Y,H_XAB_"7_1XFH_^$0G_P F4?ZQY1_S\_"7^0?V
M)F'\J^]'Y&T5^N7_ !#%^$O^CQ-1_P#"(3_Y,H_XAB_"7_1XFH_^$0G_ ,F4
M?ZQY1_S\_"7^0?V)F'\J^]'Y&T5^N7_$,7X2_P"CQ-1_\(A/_DRC_B&+\)?]
M'B:C_P"$0G_R91_K'E'_ #\_"7^0?V)F'\J^]'Y&T5^N7_$,7X2_Z/$U'_PB
M$_\ DRC_ (AB_"7_ $>)J/\ X1"?_)E'^L>4?\_/PE_D']B9A_*OO1^1M%?K
ME_Q#%^$O^CQ-1_\ "(3_ .3*/^(8OPE_T>)J/_A$)_\ )E'^L>4?\_/PE_D'
M]B9A_*OO1^1M%?KE_P 0Q?A+_H\34?\ PB$_^3*/^(8OPE_T>)J/_A$)_P#)
ME'^L>4?\_/PE_D']B9A_*OO1^1M%?KE_Q#%^$O\ H\34?_"(3_Y,H_XAB_"7
M_1XFH_\ A$)_\F4?ZQY1_P _/PE_D']B9A_*OO1^1M%?KE_Q#%^$O^CQ-1_\
M(A/_ ),H_P"(8OPE_P!'B:C_ .$0G_R91_K'E'_/S\)?Y!_8F8?RK[T?D;17
MZY?\0Q?A+_H\34?_  B$_P#DRC_B&+\)?]'B:C_X1"?_ "91_K'E'_/S\)?Y
M!_8F8?RK[T?D;17ZY?\ $,7X2_Z/$U'_ ,(A/_DRC_B&+\)?]'B:C_X1"?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !7P9^S'_P K W[3W_9)?!W_ *+K[SKX,_9C_P"5@;]I[_LDO@[_ -%T"9]Y
MT444#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^#/^"//_
M "=?^V]_V<=/_P"DJT4?\$>?^3K_ -M[_LXZ?_TE6BAB6P?\'&O_ "CPL_\
MLK7A3_TY1U]YU\&?\'&O_*/"S_[*UX4_].4=?>='0 HHHH&%%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !7Y^?\%UO^2C_L4_]GF^#O\ T<]?H'7Y^?\ !=;_ )*/^Q3_
M -GF^#O_ $<]-;@?H'1112 **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#\_/^"F
MW_*9#_@GW_V&_B%_Z:K"OT#K\_/^"FW_ "F0_P""??\ V&_B%_Z:K"OT#IO8
M HHHI %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5\&?LQ_\K W
M[3W_ &27P=_Z+K[SKX,_9C_Y6!OVGO\ LDO@[_T70)GWG1110,**** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@#X,_X(\_\G7_ +;W_9QT_P#Z
M2K11_P $>?\ DZ_]M[_LXZ?_ -)5HH8EL'_!QK_RCPL_^RM>%/\ TY1U]YU\
M&?\ !QK_ ,H\+/\ [*UX4_\ 3E'7WG1T ****!A1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !7P9^S'_ ,K W[3W_9)?
M!W_HNOO.O@S]F/\ Y6!OVGO^R2^#O_1= F?>=%%% PHHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MW/K/_@G_ /\ #\/_ (:-LO\ ANG9_P *]_LN[^V[O^$;S]IV?N,?V=^_SO\
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M2/%8VENGWY76*5AN*J C$L*]4ICQ12,CR1JS(VY"RY*G!&1Z'!(_$T ?EO\
M'C]OO_@JOX'_ &_/V4_#7Q,TKP[\*? ?QM\;W^GR_"ZSAMM6U8Z=;&Q^?4[Z
M2(K#<2"]_P!3:%1%Y?S2R%L)^I=?F=_P6B_Y2O?\$[_^RD^(O_0]$K],:;V
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M-S*%-?9-8OPX^'WA'X3?#W0OA9X!T:+3M"\-Z1;:7HUA @5+:UMXEBBC4
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MPS_P6[T+Q1?VN'MO#_B;]F[1K"POF_YYSW%I*T\28R=T:EL@>M=+_P $I_\
M@I-\2/VP=;^)'[,G[4WPSL/!WQL^#&L)IOC?3='E=]/U%&+I'?6F_++&[1M\
MI9^&C<,1( .^\;?\%<O^"7G@#PI?>,M;_P""@7P@N;73X#--!HGC^PU*ZD4=
MHK:TEDFF;T5$9CZ5\R?\$9?AA\5_C)^V]^TA_P %4O%OPSU?P;X/^+M_9Z=\
M.=*\1V;6]_J&GV@$9OWA;#0HZPPE0P^8N^"54,SZ >[?\%+/^"FT'[$5[X.^
M!WP=^$UU\3/C9\3[TVGP^^'EC<B$2 '#WMW+@^3;(<Y/&[:W*(DDD?G^F_LH
M?\%Y/BI8P>,?B%_P5H\#?"K5+F$&X\'?#WX"V&N:=:$DM@76IS"=V&[8>JX0
M$$DDGS;]A6,?M$?\'$/[5GQO\80"ZE^$_A?1O!_A(.3MT^&= 9=@Q]YI+:X;
M<>GGN!P>/TXHV _.RP_X*+?MR?\ !//]H[P?^S__ ,%8O#_A#7? GQ$U6/2O
M!?Q[\ VDEG:PZDX4)::G:2$B L=Q,B[453N&]5E,7Z)U\<?\%^O@SX;^-?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5
M\&?LQ_\ *P-^T]_V27P=_P"BZ^\Z^#/V8_\ E8&_:>_[)+X._P#1= F?>=%%
M% PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MWP/X>EB2\U=I+#38V2(N<Y56,AVH_"'..M=1_P /E/V\_P#I W\=/_!A'_\
M(U6O^"FW_*9#_@GW_P!AOXA?^FJPK] Z?0#\\O\ A\I^WG_T@;^.G_@PC_\
MD:C_ (?*?MY_](&_CI_X,(__ )&K]#:*-!'YY?\ #Y3]O/\ Z0-_'3_P81__
M "-1_P /E/V\_P#I W\=/_!A'_\ (U?H;11H!^>7_#Y3]O/_ *0-_'3_ ,&$
M?_R-1_P^4_;S_P"D#?QT_P#!A'_\C5^AM%&@'YY?\/E/V\_^D#?QT_\ !A'_
M /(U'_#Y3]O/_I W\=/_  81_P#R-7Z&T4: ?GE_P^4_;S_Z0-_'3_P81_\
MR-1_P^4_;S_Z0-_'3_P81_\ R-7Z&T4: ?GE_P /E/V\_P#I W\=/_!A'_\
M(U'_  ^4_;S_ .D#?QT_\&$?_P C5^AM%&@'YY?\/E/V\_\ I W\=/\ P81_
M_(U'_#Y3]O/_ *0-_'3_ ,&$?_R-7Z&T4: ?GE_P^4_;S_Z0-_'3_P &$?\
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MY3]O/_I W\=/_!A'_P#(U?H;11H!^>7_  ^4_;S_ .D#?QT_\&$?_P C4?\
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M_D:C_A\I^WG_ -(&_CI_X,(__D:OT-HHT _/+_A\I^WG_P!(&_CI_P"#"/\
M^1J/^'RG[>?_ $@;^.G_ (,(_P#Y&K]#:*- /SR_X?*?MY_](&_CI_X,(_\
MY&H_X?*?MY_](&_CI_X,(_\ Y&K]#:*- /SR_P"'RG[>?_2!OXZ?^#"/_P"1
MJ/\ A\I^WG_T@;^.G_@PC_\ D:OT-HHT _/+_A\I^WG_ -(&_CI_X,(__D:C
M_A\I^WG_ -(&_CI_X,(__D:OT-HHT _/+_A\I^WG_P!(&_CI_P"#"/\ ^1J/
M^'RG[>?_ $@;^.G_ (,(_P#Y&K]#:*- /SR_X?*?MY_](&_CI_X,(_\ Y&H_
MX?*?MY_](&_CI_X,(_\ Y&K]#:*- /SR_P"'RG[>?_2!OXZ?^#"/_P"1J/\
MA\I^WG_T@;^.G_@PC_\ D:OT-HHT _/+_A\I^WG_ -(&_CI_X,(__D:C_A\I
M^WG_ -(&_CI_X,(__D:OT-HHT _/+_A\I^WG_P!(&_CI_P"#"/\ ^1J/^'RG
M[>?_ $@;^.G_ (,(_P#Y&K]#:*- /SR_X?*?MY_](&_CI_X,(_\ Y&H_X?*?
MMY_](&_CI_X,(_\ Y&K]#:*- /SR_P"'RG[>?_2!OXZ?^#"/_P"1J/\ A\I^
MWG_T@;^.G_@PC_\ D:OT-HHT _/+_A\I^WG_ -(&_CI_X,(__D:GW'_!8_\
M;O@N)(8_^"$?QRE5'*K*E^@5\9Y&;8'!K]"J*-!GYY?\/E/V\_\ I W\=/\
MP81__(U'_#Y3]O/_ *0-_'3_ ,&$?_R-7Z&T4:"/SR_X?*?MY_\ 2!OXZ?\
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M .1J/^'RG[>?_2!OXZ?^#"/_ .1J_0VBC0#\\O\ A\I^WG_T@;^.G_@PC_\
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M?_2!OXZ?^#"/_P"1J_0VBC0#\\O^'RG[>?\ T@;^.G_@PC_^1J/^'RG[>?\
MT@;^.G_@PC_^1J_0VBC0#\\O^'RG[>?_ $@;^.G_ (,(_P#Y&H_X?*?MY_\
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MPC_^1J_0VBC0#\\O^'RG[>?_ $@;^.G_ (,(_P#Y&H_X?*?MY_\ 2!OXZ?\
M@PC_ /D:OT-HHT _/+_A\I^WG_T@;^.G_@PC_P#D:C_A\I^WG_T@;^.G_@PC
M_P#D:OT-HHT _/+_ (?*?MY_](&_CI_X,(__ )&H_P"'RG[>?_2!OXZ?^#"/
M_P"1J_0VBC0#\\O^'RG[>?\ T@;^.G_@PC_^1JY#_@E7\;?B'^T5_P %BOVB
M/BY\4_V>/$7PKUO4/AEX:AN?!7BF9'O+1(3L21BH4[9%^<95>#QNY(_3RO@S
M]F/_ )6!OVGO^R2^#O\ T70!]YT444AA1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 ?!W_!'Z-(_VKOVVBLZON_:+G)"J1L/V8#:<@<\9XR,
M$<YR 4W_ ((\_P#)U_[;W_9QT_\ Z2K10P0?\'&O_*/"S_[*UX4_].4=?>=?
M!G_!QK_RCPL_^RM>%/\ TY1U]YT=!!1110,**** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ KX,_9C_Y6!OVGO\ LDO@[_T77WG7P9^S'_RL#?M/
M?]DE\'?^BZ!,^\Z***!A1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 ?!G_!'G_DZ_P#;>_[..G_])5HH_P""//\ R=?^V]_V<=/_ .DJT4,2
MV#_@XU_Y1X6?_96O"G_IRCK[SKX,_P"#C7_E'A9_]E:\*?\ IRCK[SHZ %%%
M% PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH *_/S_@NM_P E'_8I_P"SS?!W_HYZ_0.O
MS\_X+K?\E'_8I_[/-\'?^CGIK<#] Z***0!1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 ?GY_P %-O\ E,A_P3[_ .PW\0O_ $U6%?H'7Y^?\%-O^4R'_!/O_L-_
M$+_TU6%?H'3>P!1112 **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ KX,_9C_P"5@;]I[_LDO@[_ -%U]YU\&?LQ_P#*P-^T]_V27P=_Z+H$S[SH
MHHH&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!\&?\ !'G_
M ).O_;>_[..G_P#25:*/^"//_)U_[;W_ &<=/_Z2K10Q+8/^#C7_ )1X6?\
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M_*Y11_JA#_G]_P"2_P#!#_6+_IU_Y-_P#^J/_A:/PS_Z*)H7_@WA_P#BJ/\
MA:/PS_Z*)H7_ (-X?_BJ_E<HH_U0A_S^_P#)?^"'^L7_ $Z_\F_X!_5'_P +
M1^&?_11-"_\ !O#_ /%4?\+1^&?_ $430O\ P;P__%5_*Y11_JA#_G]_Y+_P
M0_UB_P"G7_DW_ /ZH_\ A:/PS_Z*)H7_ (-X?_BJ/^%H_#/_ **)H7_@WA_^
M*K^5RBC_ %0A_P _O_)?^"'^L7_3K_R;_@']4?\ PM'X9_\ 11-"_P#!O#_\
M51_PM'X9_P#11-"_\&\/_P 57\KE%'^J$/\ G]_Y+_P0_P!8O^G7_DW_  #^
MJ/\ X6C\,_\ HHFA?^#>'_XJC_A:/PS_ .BB:%_X-X?_ (JOY7**/]4(?\_O
M_)?^"'^L7_3K_P F_P" ?U1_\+1^&?\ T430O_!O#_\ %4?\+1^&?_11-"_\
M&\/_ ,57\KE%'^J$/^?W_DO_  0_UB_Z=?\ DW_ /ZH_^%H_#/\ Z*)H7_@W
MA_\ BJ/^%H_#/_HHFA?^#>'_ .*K^5RBC_5"'_/[_P E_P""'^L7_3K_ ,F_
MX!_5'_PM'X9_]%$T+_P;P_\ Q5'_  M'X9_]%$T+_P &\/\ \57\KE%'^J$/
M^?W_ )+_ ,$/]8O^G7_DW_ /ZH_^%H_#/_HHFA?^#>'_ .*H_P"%H_#/_HHF
MA?\ @WA_^*K^5RBC_5"'_/[_ ,E_X(?ZQ?\ 3K_R;_@']4?_  M'X9_]%$T+
M_P &\/\ \51_PM'X9_\ 11-"_P#!O#_\57\KE%'^J$/^?W_DO_!#_6+_ *=?
M^3?\ _JC_P"%H_#/_HHFA?\ @WA_^*H_X6C\,_\ HHFA?^#>'_XJOY7**/\
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MAG_T430O_!O#_P#%4?\ "T?AG_T430O_  ;P_P#Q5?RN44?ZH0_Y_?\ DO\
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MWA_^*H_X6C\,_P#HHFA?^#>'_P"*K^5RBC_5"'_/[_R7_@A_K%_TZ_\ )O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M<?@;X9_\%!_'EEKNH.L6FW'B*S\BT60L  [3Z5;)SG !E3D]>*^;_P#@H?\
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M9?!CX*:"EWJ=VC375U=2%+73[92-]Q/( =D:Y Z%F+*JAF95/VCXD_X)O_\
M!)']EK46^'/[9W_!0C7I?&4,:&_T[P/IA,=A)@EHI5CL[UE;D8\PQL1\Q0;@
M!Q8C'X?#5%3=W+>T4V[=[(ZZ&"KUZ;J*RCW;27XGYST5]A_M7_\ !,KX;>"/
MV?[_ /:]_8V_:AT?XG_#W2;J&+7HF"P:EI'G3"&+S4S\V7>,$,D3_.K",IEA
M\>5MA\31Q4.:F]M'HTT^S3U1E7P]7#3Y9KS[W04445N8A1110 4444 %%%%
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M7P9^S'_RL#?M/?\ 9)?!W_HN@3/O.BBB@84444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MO3#Y5RBQN2J1R6%FTA& S&-V*HK$H1R/%?V&O^"63?M)?!?6?VJ_CW\;=/\
MAG\+=%>6,Z]>P"6:\="$;RU9T5$$C",,2S/)^[1"3D?4/[#_ ,$/^"*?@?\
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MMEZ3\/\ PQX@GE_L+PYH\8NM8U"""XEAFDV!7:/YH)%7;#-R5+8.$;V/0?\
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MVMW!C5KB*%((5 "G<%*PR/\ +GRRHWGY1\1Q0V__  5-OX84543X_P H54&
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MM7S2MIV2NOO/G'_@H!^P-\1_V!OBG:>#O%.MVNNZ!KML]WX3\46,6R+4K=2
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MUO[J^]G&_P#!NK\"=!^(W[6^N_%WQ'IWVE? 7ASS=+#Q@K%?W3F%)#GN(5N
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MT']D#XD$ZAKMU]FN;OP;>6ULP:5R&,\T:1(I'.YF ]Z^TO\ @J/J^A_LL_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ KX,_9C_Y6!OVGO\ LDO@[_T7
M7WG7P9^S'_RL#?M/?]DE\'?^BZ!,^\Z***!A1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 ?!G_!'G_DZ_P#;>_[..G_])5HH_P""//\ R=?^
MV]_V<=/_ .DJT4,2V#_@XU_Y1X6?_96O"G_IRCK[SKX,_P"#C7_E'A9_]E:\
M*?\ IRCK[SHZ %%%% PHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *_/S_@NM_P E'_8I
M_P"SS?!W_HYZ_0.OS\_X+K?\E'_8I_[/-\'?^CGIK<#] Z***0!1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MXI/^":G[4?QHA^&NI:5JDMQX;\1WI$=I,KWCWB2-+(1$"DLLB-'(R;D*E6W
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M"+XDZ%XITN#P%8VLFI>'M6AO;=9EN+MVC\V%F4L%=20#QN%=G_P;X?'+X+_
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !7P9^S'_ ,K W[3W_9)?!W_HNOO.O@S]F/\
MY6!OVGO^R2^#O_1= F?>=%%% PHHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M -HK_HXSP7_X!7?_ ,11_;N4_P#/U?C_ )!_9&8_\^_Q7^9^:E%?I7_Q#/\
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ME/\ S]7X_P"0?V1F/_/O\5_F?FI17Z5_\0S_ .T5_P!'&>"__ *[_P#B*/\
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MYGYJ45^E?_$,_P#M%?\ 1QG@O_P"N_\ XBC_ (AG_P!HK_HXSP7_ . 5W_\
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MX+_\ KO_ .(H_P"(9_\ :*_Z.,\%_P#@%=__ !%']NY3_P _5^/^0?V1F/\
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M/_/O\5_F?FI17Z5_\0S_ .T5_P!'&>"__ *[_P#B*/\ B&?_ &BO^CC/!?\
MX!7?_P 11_;N4_\ /U?C_D']D9C_ ,^_Q7^9^:E%?I7_ ,0S_P"T5_T<9X+_
M / *[_\ B*/^(9_]HK_HXSP7_P" 5W_\11_;N4_\_5^/^0?V1F/_ #[_ !7^
M9^:E%?I7_P 0S_[17_1QG@O_ , KO_XBC_B&?_:*_P"CC/!?_@%=_P#Q%']N
MY3_S]7X_Y!_9&8_\^_Q7^9^:E%?I7_Q#/_M%?]'&>"__  "N_P#XBC_B&?\
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M9_\ :*_Z.,\%_P#@%=__ !%']NY3_P _5^/^0?V1F/\ S[_%?YGYJ45^E?\
MQ#/_ +17_1QG@O\ \ KO_P"(H_XAG_VBO^CC/!?_ (!7?_Q%']NY3_S]7X_Y
M!_9&8_\ /O\ %?YGYJ45^E?_ !#/_M%?]'&>"_\ P"N__B*/^(9_]HK_ *.,
M\%_^ 5W_ /$4?V[E/_/U?C_D']D9C_S[_%?YGYJ45^E?_$,_^T5_T<9X+_\
M *[_ /B*/^(9_P#:*_Z.,\%_^ 5W_P#$4?V[E/\ S]7X_P"0?V1F/_/O\5_F
M?FI17Z5_\0S_ .T5_P!'&>"__ *[_P#B*/\ B&?_ &BO^CC/!?\ X!7?_P 1
M1_;N4_\ /U?C_D']D9C_ ,^_Q7^9^:E%?I7_ ,0S_P"T5_T<9X+_ / *[_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?!G_!'G_D
MZ_\ ;>_[..G_ /25:*/^"//_ "=?^V]_V<=/_P"DJT4,2V#_ (.-?^4>%G_V
M5KPI_P"G*.OO.O@S_@XU_P"4>%G_ -E:\*?^G*.OO.CH 4444#"BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KX,_9C_Y6!OVG
MO^R2^#O_ $77WG7P9^S'_P K W[3W_9)?!W_ *+H$S[SHHHH&%%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110!\&?\$>?^3K_VWO\ LXZ?_P!)
M5HH_X(\_\G7_ +;W_9QT_P#Z2K10Q+8/^#C7_E'A9_\ 96O"G_IRCK[SKX,_
MX.-?^4>%G_V5KPI_Z<HZ^\Z.@!1110,**** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OS\
M_P""ZW_)1_V*?^SS?!W_ *.>OT#K\_/^"ZW_ "4?]BG_ +/-\'?^CGIK<#]
MZ***0!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 ?GY_P4V_Y3(?\$^_^PW\0O\
MTU6%?H'7Y^?\%-O^4R'_  3[_P"PW\0O_3585^@=-[ %%%%( HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "O@S]F/\ Y6!OVGO^R2^#O_1=?>=?
M!G[,?_*P-^T]_P!DE\'?^BZ!,^\Z***!A1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ KX,_9C_Y6!OVGO^R2^#O_ $77WG7P9^S'_P K W[3W_9)
M?!W_ *+H$S[SHHHH&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MT4: ?!G_ !$:?\$\/^@/\6O_  U&I?\ Q%'_ !$:?\$\/^@/\6O_  U&I?\
MQ%?>=%&@'P9_Q$:?\$\/^@/\6O\ PU&I?_$4?\1&G_!/#_H#_%K_ ,-1J7_Q
M%?>=%&@'P9_Q$:?\$\/^@/\ %K_PU&I?_$4?\1&G_!/#_H#_ !:_\-1J7_Q%
M?>=%&@'P9_Q$:?\ !/#_ * _Q:_\-1J7_P 11_Q$:?\ !/#_ * _Q:_\-1J7
M_P 17WG11H!\&?\ $1I_P3P_Z _Q:_\ #4:E_P#$4?\ $1I_P3P_Z _Q:_\
M#4:E_P#$5]YT4: ?!G_$1I_P3P_Z _Q:_P##4:E_\11_Q$:?\$\/^@/\6O\
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M$\/^@/\ %K_PU&I?_$4?\1&G_!/#_H#_ !:_\-1J7_Q%?>=%&@'P9_Q$:?\
M!/#_ * _Q:_\-1J7_P 11_Q$:?\ !/#_ * _Q:_\-1J7_P 17WG11H!\&?\
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M _Q:_P##4:E_\17WG11H!\&?\1&G_!/#_H#_ !:_\-1J7_Q%'_$1I_P3P_Z
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M ?XM?^&HU+_XBOO.BC0#X,_XB-/^">'_ $!_BU_X:C4O_B*/^(C3_@GA_P!
M?XM?^&HU+_XBOO.BC0#X,_XB-/\ @GA_T!_BU_X:C4O_ (BC_B(T_P"">'_0
M'^+7_AJ-2_\ B*^\Z*- /@S_ (B-/^">'_0'^+7_ (:C4O\ XBC_ (B-/^">
M'_0'^+7_ (:C4O\ XBOO.BC0#X,_XB-/^">'_0'^+7_AJ-2_^(H_XB-/^">'
M_0'^+7_AJ-2_^(K[SHHT ^#/^(C3_@GA_P! ?XM?^&HU+_XBC_B(T_X)X?\
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M_P"&HU+_ .(H_P"(C3_@GA_T!_BU_P"&HU+_ .(K[SHHT$?!G_$1I_P3P_Z
M_P 6O_#4:E_\11_Q$:?\$\/^@/\ %K_PU&I?_$5]YT4: ?!G_$1I_P $\/\
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M6O\ PU&I?_$4?\1&G_!/#_H#_%K_ ,-1J7_Q%?>=%&@'P9_Q$:?\$\/^@/\
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M1&G_  3P_P"@/\6O_#4:E_\ $4?\1&G_  3P_P"@/\6O_#4:E_\ $5]YT4:
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M'_$1I_P3P_Z _P 6O_#4:E_\17WG11H!\&?\1&G_  3P_P"@/\6O_#4:E_\
M$4?\1&G_  3P_P"@/\6O_#4:E_\ $5]YT4: ?!G_ !$:?\$\/^@/\6O_  U&
MI?\ Q%'_ !$:?\$\/^@/\6O_  U&I?\ Q%?>=%&@'P9_Q$:?\$\/^@/\6O\
MPU&I?_$4?\1&G_!/#_H#_%K_ ,-1J7_Q%?>=%&@'P9_Q$:?\$\/^@/\ %K_P
MU&I?_$4?\1&G_!/#_H#_ !:_\-1J7_Q%?>=%&@'P9_Q$:?\ !/#_ * _Q:_\
M-1J7_P 11_Q$:?\ !/#_ * _Q:_\-1J7_P 17WG11H!\&?\ $1I_P3P_Z _Q
M:_\ #4:E_P#$4?\ $1I_P3P_Z _Q:_\ #4:E_P#$5]YT4: ?!G_$1I_P3P_Z
M _Q:_P##4:E_\11_Q$:?\$\/^@/\6O\ PU&I?_$5]YT4: ?!G_$1I_P3P_Z
M_P 6O_#4:E_\11_Q$:?\$\/^@/\ %K_PU&I?_$5]YT4: ?!G_$1I_P $\/\
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M'_$1I_P3P_Z _P 6O_#4:E_\17WG11H!\&?\1&G_  3P_P"@/\6O_#4:E_\
M$4?\1&G_  3P_P"@/\6O_#4:E_\ $5]YT4: ?!G_ !$:?\$\/^@/\6O_  U&
MI?\ Q%'_ !$:?\$\/^@/\6O_  U&I?\ Q%?>=%&@'P9_Q$:?\$\/^@/\6O\
MPU&I?_$4?\1&G_!/#_H#_%K_ ,-1J7_Q%?>=%&@'P9_Q$:?\$\/^@/\ %K_P
MU&I?_$4?\1&G_!/#_H#_ !:_\-1J7_Q%?>=%&@'P9_Q$:?\ !/#_ * _Q:_\
M-1J7_P 11_Q$:?\ !/#_ * _Q:_\-1J7_P 17WG11H!\&?\ $1I_P3P_Z _Q
M:_\ #4:E_P#$4?\ $1I_P3P_Z _Q:_\ #4:E_P#$5]YT4: ?!G_$1I_P3P_Z
M _Q:_P##4:E_\11_Q$:?\$\/^@/\6O\ PU&I?_$5]YT4: ?!G_$1I_P3P_Z
M_P 6O_#4:E_\11_Q$:?\$\/^@/\ %K_PU&I?_$5]YT4: ?!G_$1I_P $\/\
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M^@=-[ %%%%( HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "O@S]F/_E8&_:>_[)+X._\ 1=?>=?!G[,?_ "L#?M/?]DE\'?\
MHN@3/O.BBB@84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'P
M9_P1Y_Y.O_;>_P"SCI__ $E6BC_@CS_R=?\ MO?]G'3_ /I*M%#$M@_X.-?^
M4>%G_P!E:\*?^G*.OO.O@S_@XU_Y1X6?_96O"G_IRCK[SHZ %%%% PHHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH *_/S_ (+K?\E'_8I_[/-\'?\ HYZ_0.OS\_X+K?\
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M]K[]DGXB?LQSZVNFMXV\*7FEVVI/%YBVD\D9\F5EZLJ2!&(&"0" 0>:^2?\
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M?X;>.?\ @EG\._'VM*%@?XE>%/CA9Z5HK$X3[0]A>0F\VJ09'5,$JV$4$8H
M]8_X)J_\%&=+_;[\(^+=(\3_  EU/X>?$GX:ZZ-$^)7@'5[A9I-*O2'VM'(H
M'F02&.4(Y5<F)NH 9O!_@O\ \K-OQB_[-ETS_P!+["O6/^"57[!GQ>_91B^)
MW[0/[4WC+1-:^,/QR\4QZ_X[;PQ;M'IFG+$L@MM/M]_S.L/GS?.W)W@9;;O?
MS+]LK]E3]NSX&_\ !3S3/^"I/["'P;T'XJ#5?AK_ ,(9X^^&NI>*H-$O+F%;
ME)DGMKNX'DKS';D[\D?9V 5O,&P ^W/CE_R13QA_V*VH?^DTE?$G_!K_ /\
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M_A.?^&<)/^23?VC_ &3]B^VP>5_R$/WWFYW[OX?NX[UZU_P<#_\ )1/V+_\
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M/\C/Z:**_F7_ .&]?VY?^CSOBQ_X<74__C]'_#>O[<O_ $>=\6/_  XNI_\
MQ^C_ %2Q/_/U?<P_UAH_R,_IHHK^9?\ X;U_;E_Z/.^+'_AQ=3_^/T?\-Z_M
MR_\ 1YWQ8_\ #BZG_P#'Z/\ 5+$_\_5]S#_6&C_(S^FBBOYE_P#AO7]N7_H\
M[XL?^'%U/_X_1_PWK^W+_P!'G?%C_P .+J?_ ,?H_P!4L3_S]7W,/]8:/\C/
MZ:**_F7_ .&]?VY?^CSOBQ_X<74__C]'_#>O[<O_ $>=\6/_  XNI_\ Q^C_
M %2Q/_/U?<P_UAH_R,_IHHK^9?\ X;U_;E_Z/.^+'_AQ=3_^/T?\-Z_MR_\
M1YWQ8_\ #BZG_P#'Z/\ 5+$_\_5]S#_6&C_(S^FBBOYE_P#AO7]N7_H\[XL?
M^'%U/_X_1_PWK^W+_P!'G?%C_P .+J?_ ,?H_P!4L3_S]7W,/]8:/\C/Z:**
M_F7_ .&]?VY?^CSOBQ_X<74__C]'_#>O[<O_ $>=\6/_  XNI_\ Q^C_ %2Q
M/_/U?<P_UAH_R,_IHHK^9?\ X;U_;E_Z/.^+'_AQ=3_^/T?\-Z_MR_\ 1YWQ
M8_\ #BZG_P#'Z/\ 5+$_\_5]S#_6&C_(S^FBBOYE_P#AO7]N7_H\[XL?^'%U
M/_X_1_PWK^W+_P!'G?%C_P .+J?_ ,?H_P!4L3_S]7W,/]8:/\C/Z:**_F7_
M .&]?VY?^CSOBQ_X<74__C]'_#>O[<O_ $>=\6/_  XNI_\ Q^C_ %2Q/_/U
M?<P_UAH_R,_IHHK^9?\ X;U_;E_Z/.^+'_AQ=3_^/T?\-Z_MR_\ 1YWQ8_\
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MHHK^9?\ X;U_;E_Z/.^+'_AQ=3_^/T?\-Z_MR_\ 1YWQ8_\ #BZG_P#'Z/\
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M_C]'_#>O[<O_ $>=\6/_  XNI_\ Q^C_ %2Q/_/U?<P_UAH_R,_IHHK^9?\
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MEN'564TU>VGS_P CMP.:4\=6=.,6K*_Y?YGUM1117A'J!1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!7P9^S'_ ,K W[3W_9)?!W_HNOO.O@S]F/\ Y6!OVGO^R2^#O_1= F?>=%%%
M PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /@S_ ((\_P#)
MU_[;W_9QT_\ Z2K11_P1Y_Y.O_;>_P"SCI__ $E6BAB6P?\ !QK_ ,H\+/\
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MNZ*_*75/^#G"WL=3N;.T_8H>6**=TBED^(P1G4$@,5&G,%)'.,G'J:N>"?\
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MXF' Y_<9!R-IQFOES]M#]A']H']A#QU:^"_C?HEJ8-4CEDT+7=*G,UEJ21L
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5\&?LQ_\
M*P-^T]_V27P=_P"BZ^\Z^#/V8_\ E8&_:>_[)+X._P#1= F?>=%%% PHHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_P#9^L+M;@Y_LVYXQZ\'\J_?ZN'BK_D91_PK\V;Y#_N/S?Z'X ^%?^4\$O\
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MO^"1W_!1'5/V^_@IJ<OC[1H++QGX.N+>U\1R6*[;:^297,%U&N28RXBD#IR
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M72?!R>/--UU!J<23)=S++8M]YV=I'9HXRQF4?/LW  [+]J7_ (+;?!O]CO\
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MFMO;K>USZ%Y=AHUO8NG[O\_.K^MK_A8^ ?\ @D)_RDD^$_\ V'Y?_22>K_\
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M:ZMJ!K;PQ10I<XFOK8/Y:A^0K?-<.2<FO'/V&?V,/V/_ -B']I#1/V@/#_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %?!G[,?_ "L#?M/?]DE\'?\ HNOO.O@S]F/_ )6!OVGO^R2^#O\
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MB:[N?BKXN3P_X>_X1W3H9UMYB\*-/<F6:/9"IGCR4WO\WRHV#7T#7S?_ ,%
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M&?#MQX5^+NG>()_$NHW]K<-J%LUC9R30BU=)EC0%T&_?')D' VGFOK.OS?\
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MT(R5G$L,LDOELBLX/E9V@D@8(K[GGGAM87NKJ9(HHD+R22, JJ!DDD] !WH
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M;A'DGO;@JS+!;PQAI)I2%8[5!P%).%!(^8+O_@O[^SMX6)\2?%S]C?\ :?\
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MC3_^$)^VRA%>XL(Q&B.QX!EA\R,L< -+N)P#7YA_L1?\%%_VB/\ @D7)XF^
M_P 7?V;;_4+'4=2^W?\ "/ZY=RZ1<V=Z$2-YHY&@E$D;QI'G"$'8C*V"=W[Q
M45AA,U5'#RP]>G[2$G>UVG?U1MB<"ZM:-:E/DDE:]KJWH?B!^S+^RA^U3_P5
MF_;@'[6'Q\\ W6B>"Y]8M=1UO4;BQDM[2XM( @AT^R$G,VZ.-$+@D*I9V.X@
M-^W]%%<^89A/'SC[JC&*M%+HC3"82.%B];N3NV^K"BBBO/.L**** "BBB@ K
M\_/^"ZW_ "4?]BG_ +/-\'?^CGK] Z_/S_@NM_R4?]BG_L\WP=_Z.>FMP/T#
MHHHI %%%% !1110 4444 %%%% !7XP_\$\_^"G/[$'_!.7]LC]M/P-^V?\9Y
M?!.K>)/VE]<U/1;.;PKJMZ;FT-Y=%90;.UE500Z$;B"0P(!'-?L]10!^;O[1
M_P#P7I_9Q_:'^#/B'X*_\$OO#GC+X[?$_P 4Z7-HVBZ=X;\!ZG;V>D3W4,J)
M=WTU[! L<"89S@G.P[BBAW3VK_@G3_P3^\??L8?\$I],_8RN/%-NGC:7PKJI
MU+5+:?=!::M?^=(?+<*"R0O*B!L?-Y6[OBOKBBG<#\@/^"3O_!33]D7_ ().
M_L::3^PS_P %!_#'BCX)_$GP?K.JIJEIK'@'4KB+Q-++>2S+>VT]E!,LZ^5)
M!%O8A2(TV%HRAK*^*/[3WQ&_;!_X+G_L=?&.X_9F\6^ / 0O?%6F^ [_ ,<V
MOV/4_$:P6#O=7IL6_>6MO^]@$7F?-(I9SC[H_92BBX'YP?\ !P(CR?$?]BY$
M!+']K#PX  .I\Y*_1^BBD!^<'_!0!'?_ (.!_P!A]5!)_L3QD< 9X&F3D_I7
MZ/T44,#\X/"T4W_$4QXD8(V/^&38VSCM_:UJ,_GQ6_\ \%H/V4OVD+WXH?!?
M_@I;^QC\/I/&7Q ^ ^N3OJ?@>!R)M?T.X7%Q% !RTRCS%"+EF6X<J'9%1OT
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M(-4E,6F:'H'Q(TN\O+MPI8K%##.SR':&.%!. 3VI[ ?&?_!5:*:S_P""UW[
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MM(K3QEH'QXT[PM/?PC;)>Z3?K(T]I(1]Y"D4R#/*BYDQC<:W_P#@Z3_Y0_\
MC#_L:="_]+HZ\^_:X^,/@C_@LQ_P40^!_P"RA^R7J:^,OAE\%O'<7COXO?$3
M1B9M%6XM5!M-.@NE_=W#R R1DQE@?M&5.(I2OH/_  =)_P#*'_QA_P!C3H7_
M *71T=A,^R/V2/V;?@Q^R;^SWX9^!WP$\#VN@>'-)TV/R;2V7YYI613)/,Y^
M:6:1OF>1LEB?ICX4\"Z=8_"'_@Z4\6:)X$@^P67Q(_9UBU;Q59VYVPW=]%=1
MQI<L@X,@2V4;N#F20Y^=L_I+X5_Y%C3?^O"'_P! %?G#JG_*U5IW_9KC?^ET
MM"&S[S^./BK]G#X2:/;_ !__ &B]9\':!9^$Q+]A\7>+7MH!I1GVJZPW$^#$
MTNQ%*H09"JKAB *^+/VJ/^"]7_!$SQ_\(/'OP'\6?M9:5KJZSX;O]*N=/B\$
M:U>VEVTMNZ!%FCL7A<$L,.K%0><\5P'_  6UU+X<^#O^"F?[)OQ!_;?TY[G]
MFZQGU>/7/[3LY+G1(/$+02"S>_B 9&7<;<KO7&Q)R<HLHKWK]J#_ (*W?\$\
M/AW\$KOX8? 3XR>&OB=XJ\3Z5<Z/X)^'/P8OK;6[Z]NI8)%2,163,EK&,EF>
M4HJJK$;CA2) <1_P;KW/B/XJ_P#!#SP/X4U7Q%/',UOXCT:QO]Q,EM"=1O$C
M(.<_NP^%Z8"J!C%>,?\ !,_]M71O^"*/P9T[_@G1_P %._@[K_PR30O$VH1^
M%OB_;:'->^&?%"75U/<([7=NC&.;YF4*RG;%&AE,6T@>C?\ !O-\3;'X*_\
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MZL=6U[3[:(W<2L2!OG(N41L@;Y%)(7- CE/V=/\ @J3\,_V6O@CX:^ 'P?\
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MM:)?QW-M<(>Z21DJ?0C.0>#S7XO_ /!+O_@HIHO@_P#:&_:._;"\>_\ !/\
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MN;;>@;RY4R=DBYPRY.""*.@&7\7?&-Q\._A1XH^(%G LLNA>'KW4(HG'#M#
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M%G_V5KPI_P"G*.OO.O@S_@XU_P"4>%G_ -E:\*?^G*.OO.CH 4444#"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ K\_/^"ZW_)1_V*?^SS?!W_HYZ_0.OS\_X+K?\E'_
M &*?^SS?!W_HYZ:W _0.BBBD 4444 %%%% !1110 5\=?%__ (+\?\$C_@/\
M4_$'P7^*7[74.G^)?"NKSZ7K^GP>"]<NUM;R%S'+#YMO921.R.&5MKL P(Z@
MU]BU^;G_  07_P"3G/V\/^SK==_]+;R@#U;X9_\ !P9_P2%^,/Q'\/\ PD^'
M7[7/]H^(?%.MVFD:%I__  @.OP_:KRYF6&"+S);!43=(ZKN=E49R2 ":^S:*
M\V_: _:Z_9Y_9;UCP3H/QW^(8T&Z^(OBNW\->#HCI5W<_P!H:I.P6*WW6\4@
MAR6 WRE$&>6% 'I-%%>;_#3]K?\ 9[^,'QT\>?LU_#KX@C4/&WPR-D/&^B?V
M5=PG3?M<9D@_?2Q+%-N4$_NG?;T;!.* /2**\Y\??M:?L]_"_P"/W@W]E_Q[
M\1(].\<_$"QU"\\(Z++IURRWT%C \]TYG6(P0^7$CMB5T)"_+D\5X9XT_P""
M\/\ P2,\ ?$\_"#Q+^V_X7&LI/Y,CV%E?7EA&^YE*O?V]N]JF"I!W2C'&<9&
M2S ^N:*S_"_BGPQXX\.67C#P5XBL-8TC4[9+G3M4TN[2XMKN%QE9(I8R5D1@
M00RD@BO-?VJ_V[/V0/V(= M_$G[57[0'A_P;#>)(]A::C<-)>7BH"7:"UA5Y
MYP. ?+1N64=6 (!ZU17S5^R[_P %@O\ @FI^V7XNA^'_ .SM^UOX=UC7[J9X
MK'0M1@NM*O;UU4.RV\&H0P23D*=W[M6X5S_ V/CK_@X<_P""NGP2^$?PBUO]
MDGX$_M8^(?"GQN\/>,M"FUG3/#$&KZ?=6]@ZQW4@^WPQ)"R-!-$S(DQ+!MI!
M(*AV _5JO++;]M3]F*\_:RN/V&[?XJP-\4[7PZ-<G\*'3KH,MB=I\SSS%]G+
M8=6\H2>9M.[;@$U\U?\ $2G_ ,$4O^CT?_,<^)/_ )74G['O[5O_  1*_;C_
M ."@=]\>_P!DWQK;>)_CRW@:6WO-8;1?$%BQT:)X8WQ'>PQ6F\%X5W*OG%20
M"5#46 ^Z:*IZ[KVA>%=%NO$GB?6K33M.L8&GO;^_N5AAMXE&6=W<A44#DDG
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M_!3/_HB&G?\ A8:;_P#'Z^E_M3+?^?T?_ D>'_9^._Y]O[CX^HK[!_X<0_\
M!3/_ *(AIW_A8:;_ /'Z/^'$/_!3/_HB&G?^%AIO_P ?H_M3+?\ G]'_ ,"0
M?V?CO^?;^X^/J*^P?^'$/_!3/_HB&G?^%AIO_P ?H_X<0_\ !3/_ *(AIW_A
M8:;_ /'Z/[4RW_G]'_P)!_9^._Y]O[CX^HK[!_X<0_\ !3/_ *(AIW_A8:;_
M /'Z/^'$/_!3/_HB&G?^%AIO_P ?H_M3+?\ G]'_ ,"0?V?CO^?;^X^/J*^P
M?^'$/_!3/_HB&G?^%AIO_P ?H_X<0_\ !3/_ *(AIW_A8:;_ /'Z/[4RW_G]
M'_P)!_9^._Y]O[CX^HK[!_X<0_\ !3/_ *(AIW_A8:;_ /'Z/^'$/_!3/_HB
M&G?^%AIO_P ?H_M3+?\ G]'_ ,"0?V?CO^?;^X^/J*^P?^'$/_!3/_HB&G?^
M%AIO_P ?H_X<0_\ !3/_ *(AIW_A8:;_ /'Z/[4RW_G]'_P)!_9^._Y]O[CX
M^HK[!_X<0_\ !3/_ *(AIW_A8:;_ /'Z/^'$/_!3/_HB&G?^%AIO_P ?H_M3
M+?\ G]'_ ,"0?V?CO^?;^X^/J*^P?^'$/_!3/_HB&G?^%AIO_P ?H_X<0_\
M!3/_ *(AIW_A8:;_ /'Z/[4RW_G]'_P)!_9^._Y]O[CX^HK[!_X<0_\ !3/_
M *(AIW_A8:;_ /'Z/^'$/_!3/_HB&G?^%AIO_P ?H_M3+?\ G]'_ ,"0?V?C
MO^?;^X^/J*^P?^'$/_!3/_HB&G?^%AIO_P ?H_X<0_\ !3/_ *(AIW_A8:;_
M /'Z/[4RW_G]'_P)!_9^._Y]O[CX^HK[!_X<0_\ !3/_ *(AIW_A8:;_ /'Z
M/^'$/_!3/_HB&G?^%AIO_P ?H_M3+?\ G]'_ ,"0?V?CO^?;^X^/J*^P?^'$
M/_!3/_HB&G?^%AIO_P ?H_X<0_\ !3/_ *(AIW_A8:;_ /'Z/[4RW_G]'_P)
M!_9^._Y]O[CX^HK[!_X<0_\ !3/_ *(AIW_A8:;_ /'Z/^'$/_!3/_HB&G?^
M%AIO_P ?H_M3+?\ G]'_ ,"0?V?CO^?;^X^/J*^P?^'$/_!3/_HB&G?^%AIO
M_P ?H_X<0_\ !3/_ *(AIW_A8:;_ /'Z/[4RW_G]'_P)!_9^._Y]O[CX^HK[
M!_X<0_\ !3/_ *(AIW_A8:;_ /'Z/^'$/_!3/_HB&G?^%AIO_P ?H_M3+?\
MG]'_ ,"0?V?CO^?;^X^/J*^P?^'$/_!3/_HB&G?^%AIO_P ?H_X<0_\ !3/_
M *(AIW_A8:;_ /'Z/[4RW_G]'_P)!_9^._Y]O[CX^HK[!_X<0_\ !3/_ *(A
MIW_A8:;_ /'Z/^'$/_!3/_HB&G?^%AIO_P ?H_M3+?\ G]'_ ,"0?V?CO^?;
M^X^/J*^P?^'$/_!3/_HB&G?^%AIO_P ?H_X<0_\ !3/_ *(AIW_A8:;_ /'Z
M/[4RW_G]'_P)!_9^._Y]O[CX^HK[!_X<0_\ !3/_ *(AIW_A8:;_ /'Z/^'$
M/_!3/_HB&G?^%AIO_P ?H_M3+?\ G]'_ ,"0?V?CO^?;^X^/J*^P?^'$/_!3
M/_HB&G?^%AIO_P ?H_X<0_\ !3/_ *(AIW_A8:;_ /'Z/[4RW_G]'_P)!_9^
M._Y]O[CX^HK[!_X<0_\ !3/_ *(AIW_A8:;_ /'Z/^'$/_!3/_HB&G?^%AIO
M_P ?H_M3+?\ G]'_ ,"0?V?CO^?;^X^/J*^P?^'$/_!3/_HB&G?^%AIO_P ?
MH_X<0_\ !3/_ *(AIW_A8:;_ /'Z/[4RW_G]'_P)!_9^._Y]O[CX^HK[!_X<
M0_\ !3/_ *(AIW_A8:;_ /'Z/^'$/_!3/_HB&G?^%AIO_P ?H_M3+?\ G]'_
M ,"0?V?CO^?;^X^/J*^P?^'$/_!3/_HB&G?^%AIO_P ?H_X<0_\ !3/_ *(A
MIW_A8:;_ /'Z/[4RW_G]'_P)!_9^._Y]O[CX^HK[!_X<0_\ !3/_ *(AIW_A
M8:;_ /'Z/^'$/_!3/_HB&G?^%AIO_P ?H_M3+?\ G]'_ ,"0?V?CO^?;^X^/
MJ*^P?^'$/_!3/_HB&G?^%AIO_P ?H_X<0_\ !3/_ *(AIW_A8:;_ /'Z/[4R
MW_G]'_P)!_9^._Y]O[CX^HK[!_X<0_\ !3/_ *(AIW_A8:;_ /'Z/^'$/_!3
M/_HB&G?^%AIO_P ?H_M3+?\ G]'_ ,"0?V?CO^?;^X^/J*^P?^'$/_!3/_HB
M&G?^%AIO_P ?H_X<0_\ !3/_ *(AIW_A8:;_ /'Z/[4RW_G]'_P)!_9^._Y]
MO[CX^HK[!_X<0_\ !3/_ *(AIW_A8:;_ /'Z/^'$/_!3/_HB&G?^%AIO_P ?
MH_M3+?\ G]'_ ,"0?V?CO^?;^X^/J*^P?^'$/_!3/_HB&G?^%AIO_P ?H_X<
M0_\ !3/_ *(AIW_A8:;_ /'Z/[4RW_G]'_P)!_9^._Y]O[CX^HK[!_X<0_\
M!3/_ *(AIW_A8:;_ /'Z/^'$/_!3/_HB&G?^%AIO_P ?H_M3+?\ G]'_ ,"0
M?V?CO^?;^X^/J*^P?^'$/_!3/_HB&G?^%AIO_P ?H_X<0_\ !3/_ *(AIW_A
M8:;_ /'Z/[4RW_G]'_P)!_9^._Y]O[CX^HK[!_X<0_\ !3/_ *(AIW_A8:;_
M /'Z/^'$/_!3/_HB&G?^%AIO_P ?H_M3+?\ G]'_ ,"0?V?CO^?;^X^/J*^P
M?^'$/_!3/_HB&G?^%AIO_P ?H_X<0_\ !3/_ *(AIW_A8:;_ /'Z/[4RW_G]
M'_P)!_9^._Y]O[CX^HK[!_X<0_\ !3/_ *(AIW_A8:;_ /'Z/^'$/_!3/_HB
M&G?^%AIO_P ?H_M3+?\ G]'_ ,"0?V?CO^?;^X^/J*^P?^'$/_!3/_HB&G?^
M%AIO_P ?H_X<0_\ !3/_ *(AIW_A8:;_ /'Z/[4RW_G]'_P)!_9^._Y]O[CX
M^HK[!_X<0_\ !3/_ *(AIW_A8:;_ /'Z/^'$/_!3/_HB&G?^%AIO_P ?H_M3
M+?\ G]'_ ,"0?V?CO^?;^X^/J*^P?^'$/_!3/_HB&G?^%AIO_P ?H_X<0_\
M!3/_ *(AIW_A8:;_ /'Z/[4RW_G]'_P)!_9^._Y]O[CX^HK[!_X<0_\ !3/_
M *(AIW_A8:;_ /'Z/^'$/_!3/_HB&G?^%AIO_P ?H_M3+?\ G]'_ ,"0?V?C
MO^?;^X^/J*^P?^'$/_!3/_HB&G?^%AIO_P ?H_X<0_\ !3/_ *(AIW_A8:;_
M /'Z/[4RW_G]'_P)!_9^._Y]O[CX^HK[!_X<0_\ !3/_ *(AIW_A8:;_ /'Z
M/^'$/_!3/_HB&G?^%AIO_P ?H_M3+?\ G]'_ ,"0?V?CO^?;^X^/J*^P?^'$
M/_!3/_HB&G?^%AIO_P ?H_X<0_\ !3/_ *(AIW_A8:;_ /'Z/[4RW_G]'_P)
M!_9^._Y]O[CX^HK[!_X<0_\ !3/_ *(AIW_A8:;_ /'Z/^'$/_!3/_HB&G?^
M%AIO_P ?H_M3+?\ G]'_ ,"0?V?CO^?;^X^/J*^P?^'$/_!3/_HB&G?^%AIO
M_P ?H_X<0_\ !3/_ *(AIW_A8:;_ /'Z/[4RW_G]'_P)!_9^._Y]O[CX^HK[
M!_X<0_\ !3/_ *(AIW_A8:;_ /'Z/^'$/_!3/_HB&G?^%AIO_P ?H_M3+?\
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MY=RD$"*BEG9F) Y))/)-<=XL_8@_8L\?^/$^*7CO]D+X7:UXGCN$GC\1ZMX
MTZYOUE1]Z.+B2$R!E<[@=V0>1S7J-% $-C8V.EV,.FZ;9Q6UM;1+%;V\$81(
MD4 *JJ.%    ' %97Q ^&_PZ^+/A>Y\$?%/P#HOB71;M&2[TCQ!I4-[:SJRL
MC!XIE9&!5F4@CD,1T)K;HH \Y^$/[('[)?[/NJSZ[\!?V7?AUX(O;H*+F\\(
M>";#399MH=5W/;Q(6P)) ,G@.P[G/HU%% !7EOQ3_8>_8J^.?C";XA?&S]C_
M .%WC'7[B*.*?7/%/P_T[4+R6-%VHC37$+.RJN  3@#@5ZE10!X7_P .O?\
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M@2#D5I>*?"?A;QSH5QX6\:^&M/UC3+M=MUIVJ64=Q!,N<X>.0%6&<<$5HT4
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M:JW_  2AUKQ+INFO<QZ#XYT#4+Y4S\L*W@CR3@X&^1%R?[U) S]#J_-+2_\
ME:JU'_LUQ?\ TNBK]"O!OQ;^&7Q \.>'?%G@[QYI.H6'BVP%[X9N+>_C8:G
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M'P9_P1Y_Y.O_ &WO^SCI_P#TE6BC_@CS_P G7_MO?]G'3_\ I*M%#$M@_P"#
MC7_E'A9_]E:\*?\ IRCK[SKX,_X.-?\ E'A9_P#96O"G_IRCK[SHZ %%%% P
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH *_/S_@NM_R4?]BG_L\WP=_Z.>OT#K\_/^"Z
MW_)1_P!BG_L\WP=_Z.>FMP/T#HHHI %%%% !1110 4444 %>;_ C]DG]GO\
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MM[_LXZ?_ -)5HH8EL'_!QK_RCPL_^RM>%/\ TY1U]YU\&?\ !QK_ ,H\+/\
M[*UX4_\ 3E'7WG1T ****!A1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5^?G_!=;_DH_
M[%/_ &>;X._]'/7Z!U^?G_!=;_DH_P"Q3_V>;X._]'/36X'Z!T444@"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH _/S_@IM_P ID/\ @GW_ -AOXA?^FJPK] Z_
M/S_@IM_RF0_X)]_]AOXA?^FJPK] Z;V ****0!1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %?!G[,?_ "L#?M/?]DE\'?\ HNOO.O@S]F/_ )6!
MOVGO^R2^#O\ T70)GWG1110,**** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@#X,_X(\_\ )U_[;W_9QT__ *2K11_P1Y_Y.O\ VWO^SCI__25:
M*&);$'_!R-J5AH__  3AAU75;I+>UMOBIX6EN)Y#A8D74$9F8]@ "<FO:_\
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MX)H?]([O@7_X:31O_D:C_AU[_P $T/\ I'=\"_\ PTFC?_(U&@&)_P /@?\
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M_P"D=WP+_P##2:-_\C4: 8G_  ^!_P""6?\ TD"^$W_A;6G_ ,71_P /@?\
M@EG_ -) OA-_X6UI_P#%UM_\.O?^":'_ $CN^!?_ (:31O\ Y&H_X=>_\$T/
M^D=WP+_\-)HW_P C4: 8G_#X'_@EG_TD"^$W_A;6G_Q='_#X'_@EG_TD"^$W
M_A;6G_Q=;?\ PZ]_X)H?]([O@7_X:31O_D:C_AU[_P $T/\ I'=\"_\ PTFC
M?_(U&@&)_P /@?\ @EG_ -) OA-_X6UI_P#%T?\ #X'_ ()9_P#20+X3?^%M
M:?\ Q=;?_#KW_@FA_P!([O@7_P"&DT;_ .1J/^'7O_!-#_I'=\"__#2:-_\
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M6G_Q=;?_  Z]_P"":'_2.[X%_P#AI-&_^1J/^'7O_!-#_I'=\"__  TFC?\
MR-1H!B?\/@?^"6?_ $D"^$W_ (6UI_\ %T?\/@?^"6?_ $D"^$W_ (6UI_\
M%UM_\.O?^":'_2.[X%_^&DT;_P"1J/\ AU[_ ,$T/^D=WP+_ /#2:-_\C4:
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M^1J/^'7O_!-#_I'=\"__  TFC?\ R-1H!B?\/@?^"6?_ $D"^$W_ (6UI_\
M%T?\/@?^"6?_ $D"^$W_ (6UI_\ %UM_\.O?^":'_2.[X%_^&DT;_P"1J/\
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M6G_Q=;?_  Z]_P"":'_2.[X%_P#AI-&_^1J/^'7O_!-#_I'=\"__  TFC?\
MR-1H!B?\/@?^"6?_ $D"^$W_ (6UI_\ %T?\/@?^"6?_ $D"^$W_ (6UI_\
M%UM_\.O?^":'_2.[X%_^&DT;_P"1J/\ AU[_ ,$T/^D=WP+_ /#2:-_\C4:
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M^1J/^'7O_!-#_I'=\"__  TFC?\ R-1H!B?\/@?^"6?_ $D"^$W_ (6UI_\
M%T?\/@?^"6?_ $D"^$W_ (6UI_\ %UM_\.O?^":'_2.[X%_^&DT;_P"1J/\
MAU[_ ,$T/^D=WP+_ /#2:-_\C4: 8G_#X'_@EG_TD"^$W_A;6G_Q='_#X'_@
MEG_TD"^$W_A;6G_Q=;?_  Z]_P"":'_2.[X%_P#AI-&_^1J/^'7O_!-#_I'=
M\"__  TFC?\ R-1H!B?\/@?^"6?_ $D"^$W_ (6UI_\ %T?\/@?^"6?_ $D"
M^$W_ (6UI_\ %UM_\.O?^":'_2.[X%_^&DT;_P"1J/\ AU[_ ,$T/^D=WP+_
M /#2:-_\C4: 8G_#X'_@EG_TD"^$W_A;6G_Q='_#X'_@EG_TD"^$W_A;6G_Q
M=;?_  Z]_P"":'_2.[X%_P#AI-&_^1J/^'7O_!-#_I'=\"__  TFC?\ R-1H
M!B?\/@?^"6?_ $D"^$W_ (6UI_\ %T?\/@?^"6?_ $D"^$W_ (6UI_\ %UM_
M\.O?^":'_2.[X%_^&DT;_P"1J/\ AU[_ ,$T/^D=WP+_ /#2:-_\C4: 8G_#
MX'_@EG_TD"^$W_A;6G_Q='_#X'_@EG_TD"^$W_A;6G_Q=;?_  Z]_P"":'_2
M.[X%_P#AI-&_^1J/^'7O_!-#_I'=\"__  TFC?\ R-1H!B?\/@?^"6?_ $D"
M^$W_ (6UI_\ %T?\/@?^"6?_ $D"^$W_ (6UI_\ %UM_\.O?^":'_2.[X%_^
M&DT;_P"1J/\ AU[_ ,$T/^D=WP+_ /#2:-_\C4: 8G_#X'_@EG_TD"^$W_A;
M6G_Q='_#X'_@EG_TD"^$W_A;6G_Q=;?_  Z]_P"":'_2.[X%_P#AI-&_^1J/
M^'7O_!-#_I'=\"__  TFC?\ R-1H!B?\/@?^"6?_ $D"^$W_ (6UI_\ %T?\
M/@?^"6?_ $D"^$W_ (6UI_\ %UM_\.O?^":'_2.[X%_^&DT;_P"1J/\ AU[_
M ,$T/^D=WP+_ /#2:-_\C4: 8G_#X'_@EG_TD"^$W_A;6G_Q='_#X'_@EG_T
MD"^$W_A;6G_Q=;?_  Z]_P"":'_2.[X%_P#AI-&_^1J/^'7O_!-#_I'=\"__
M  TFC?\ R-1H!B?\/@?^"6?_ $D"^$W_ (6UI_\ %T?\/@?^"6?_ $D"^$W_
M (6UI_\ %UM_\.O?^":'_2.[X%_^&DT;_P"1J/\ AU[_ ,$T/^D=WP+_ /#2
M:-_\C4: 8G_#X'_@EG_TD"^$W_A;6G_Q='_#X'_@EG_TD"^$W_A;6G_Q=;?_
M  Z]_P"":'_2.[X%_P#AI-&_^1J/^'7O_!-#_I'=\"__  TFC?\ R-1H!B?\
M/@?^"6?_ $D"^$W_ (6UI_\ %T?\/@?^"6?_ $D"^$W_ (6UI_\ %UM_\.O?
M^":'_2.[X%_^&DT;_P"1J/\ AU[_ ,$T/^D=WP+_ /#2:-_\C4: 8L?_  5\
M_P""7,S%8?V_/A2Y"EB$\9VI( !)/#]  23V S2?\/@?^"6?_20+X3?^%M:?
M_%UNQ_\ !,3_ ()K6[^9!_P3T^!J$J5)3X3:,"0001_Q[=""0?8TW_AU[_P3
M0_Z1W? O_P -)HW_ ,C4: 8G_#X'_@EG_P!) OA-_P"%M:?_ !='_#X'_@EG
M_P!) OA-_P"%M:?_ !=;?_#KW_@FA_TCN^!?_AI-&_\ D:C_ (=>_P#!-#_I
M'=\"_P#PTFC?_(U&@&)_P^!_X)9_]) OA-_X6UI_\71_P^!_X)9_]) OA-_X
M6UI_\76W_P .O?\ @FA_TCN^!?\ X:31O_D:C_AU[_P30_Z1W? O_P -)HW_
M ,C4: 8G_#X'_@EG_P!) OA-_P"%M:?_ !='_#X'_@EG_P!) OA-_P"%M:?_
M !=;?_#KW_@FA_TCN^!?_AI-&_\ D:C_ (=>_P#!-#_I'=\"_P#PTFC?_(U&
M@&)_P^!_X)9_]) OA-_X6UI_\71_P^!_X)9_]) OA-_X6UI_\76W_P .O?\
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MO?\ @FA_TCN^!?\ X:31O_D:C0#$_P"'P/\ P2S_ .D@7PF_\+:T_P#BZ/\
MA\#_ ,$L_P#I(%\)O_"VM/\ XNMO_AU[_P $T/\ I'=\"_\ PTFC?_(U'_#K
MW_@FA_TCN^!?_AI-&_\ D:C0#$_X? _\$L_^D@7PF_\ "VM/_BZ/^'P/_!+/
M_I(%\)O_  MK3_XNMO\ X=>_\$T/^D=WP+_\-)HW_P C4?\ #KW_ ()H?]([
MO@7_ .&DT;_Y&HT Q/\ A\#_ ,$L_P#I(%\)O_"VM/\ XNC_ (? _P#!+/\
MZ2!?";_PMK3_ .+K;_X=>_\ !-#_ *1W? O_ ,-)HW_R-1_PZ]_X)H?]([O@
M7_X:31O_ )&HT Q/^'P/_!+/_I(%\)O_  MK3_XNC_A\#_P2S_Z2!?";_P +
M:T_^+K;_ .'7O_!-#_I'=\"__#2:-_\ (U'_  Z]_P"":'_2.[X%_P#AI-&_
M^1J- ,3_ (? _P#!+/\ Z2!?";_PMK3_ .+H_P"'P/\ P2S_ .D@7PF_\+:T
M_P#BZV_^'7O_  30_P"D=WP+_P##2:-_\C4?\.O?^":'_2.[X%_^&DT;_P"1
MJ- ,3_A\#_P2S_Z2!?";_P +:T_^+H_X? _\$L_^D@7PF_\ "VM/_BZV_P#A
MU[_P30_Z1W? O_PTFC?_ "-1_P .O?\ @FA_TCN^!?\ X:31O_D:C0#$_P"'
MP/\ P2S_ .D@7PF_\+:T_P#BZ/\ A\#_ ,$L_P#I(%\)O_"VM/\ XNMO_AU[
M_P $T/\ I'=\"_\ PTFC?_(U'_#KW_@FA_TCN^!?_AI-&_\ D:C0#$_X? _\
M$L_^D@7PF_\ "VM/_BZ/^'P/_!+/_I(%\)O_  MK3_XNMO\ X=>_\$T/^D=W
MP+_\-)HW_P C4?\ #KW_ ()H?]([O@7_ .&DT;_Y&HT Q/\ A\#_ ,$L_P#I
M(%\)O_"VM/\ XNC_ (? _P#!+/\ Z2!?";_PMK3_ .+K;_X=>_\ !-#_ *1W
M? O_ ,-)HW_R-1_PZ]_X)H?]([O@7_X:31O_ )&HT Q/^'P/_!+/_I(%\)O_
M  MK3_XNC_A\#_P2S_Z2!?";_P +:T_^+K;_ .'7O_!-#_I'=\"__#2:-_\
M(U'_  Z]_P"":'_2.[X%_P#AI-&_^1J- ,3_ (? _P#!+/\ Z2!?";_PMK3_
M .+I%_X+!_\ !+-N1_P4"^$_7OXUM/\ XNMS_AU[_P $T/\ I'=\"_\ PTFC
M?_(U'_#KW_@FA_TCN^!?_AI-&_\ D:C0#$_X? _\$L_^D@7PF_\ "VM/_BZ/
M^'P/_!+/_I(%\)O_  MK3_XNMO\ X=>_\$T/^D=WP+_\-)HW_P C4?\ #KW_
M ()H?]([O@7_ .&DT;_Y&HT Q/\ A\#_ ,$L_P#I(%\)O_"VM/\ XNC_ (?
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MC0#$_P"'P/\ P2S_ .D@7PF_\+:T_P#BZ/\ A\#_ ,$L_P#I(%\)O_"VM/\
MXNMO_AU[_P $T/\ I'=\"_\ PTFC?_(U'_#KW_@FA_TCN^!?_AI-&_\ D:C0
M#$_X? _\$L_^D@7PF_\ "VM/_BZ/^'P/_!+/_I(%\)O_  MK3_XNMO\ X=>_
M\$T/^D=WP+_\-)HW_P C4?\ #KW_ ()H?]([O@7_ .&DT;_Y&HT Q/\ A\#_
M ,$L_P#I(%\)O_"VM/\ XNC_ (? _P#!+/\ Z2!?";_PMK3_ .+K;_X=>_\
M!-#_ *1W? O_ ,-)HW_R-1_PZ]_X)H?]([O@7_X:31O_ )&HT Q/^'P/_!+/
M_I(%\)O_  MK3_XNC_A\#_P2S_Z2!?";_P +:T_^+K;_ .'7O_!-#_I'=\"_
M_#2:-_\ (U'_  Z]_P"":'_2.[X%_P#AI-&_^1J- ,3_ (? _P#!+/\ Z2!?
M";_PMK3_ .+H_P"'P/\ P2S_ .D@7PF_\+:T_P#BZV_^'7O_  30_P"D=WP+
M_P##2:-_\C4?\.O?^":'_2.[X%_^&DT;_P"1J- ,3_A\#_P2S_Z2!?";_P +
M:T_^+H_X? _\$L_^D@7PF_\ "VM/_BZV_P#AU[_P30_Z1W? O_PTFC?_ "-1
M_P .O?\ @FA_TCN^!?\ X:31O_D:C0#$_P"'P/\ P2S_ .D@7PF_\+:T_P#B
MZ/\ A\#_ ,$L_P#I(%\)O_"VM/\ XNMO_AU[_P $T/\ I'=\"_\ PTFC?_(U
M'_#KW_@FA_TCN^!?_AI-&_\ D:C0#$_X? _\$L_^D@7PF_\ "VM/_BZ/^'P/
M_!+/_I(%\)O_  MK3_XNMO\ X=>_\$T/^D=WP+_\-)HW_P C4?\ #KW_ ()H
M?]([O@7_ .&DT;_Y&HT Q/\ A\#_ ,$L_P#I(%\)O_"VM/\ XNC_ (? _P#!
M+/\ Z2!?";_PMK3_ .+K;_X=>_\ !-#_ *1W? O_ ,-)HW_R-1_PZ]_X)H?]
M([O@7_X:31O_ )&HT Q/^'P/_!+/_I(%\)O_  MK3_XNC_A\#_P2S_Z2!?";
M_P +:T_^+K;_ .'7O_!-#_I'=\"__#2:-_\ (U'_  Z]_P"":'_2.[X%_P#A
MI-&_^1J- ,3_ (? _P#!+/\ Z2!?";_PMK3_ .+H_P"'P/\ P2S_ .D@7PF_
M\+:T_P#BZV_^'7O_  30_P"D=WP+_P##2:-_\C4?\.O?^":'_2.[X%_^&DT;
M_P"1J- ,3_A\#_P2S_Z2!?";_P +:T_^+H_X? _\$L_^D@7PF_\ "VM/_BZV
M_P#AU[_P30_Z1W? O_PTFC?_ "-1_P .O?\ @FA_TCN^!?\ X:31O_D:C0#$
M_P"'P/\ P2S_ .D@7PF_\+:T_P#BZ/\ A\#_ ,$L_P#I(%\)O_"VM/\ XNMO
M_AU[_P $T/\ I'=\"_\ PTFC?_(U'_#KW_@FA_TCN^!?_AI-&_\ D:C0#$_X
M? _\$L_^D@7PF_\ "VM/_BZ/^'P/_!+/_I(%\)O_  MK3_XNMO\ X=>_\$T/
M^D=WP+_\-)HW_P C4?\ #KW_ ()H?]([O@7_ .&DT;_Y&HT Q/\ A\#_ ,$L
M_P#I(%\)O_"VM/\ XNC_ (? _P#!+/\ Z2!?";_PMK3_ .+K;_X=>_\ !-#_
M *1W? O_ ,-)HW_R-1_PZ]_X)H?]([O@7_X:31O_ )&HT Q/^'P/_!+/_I(%
M\)O_  MK3_XNC_A\#_P2S_Z2!?";_P +:T_^+K;_ .'7O_!-#_I'=\"__#2:
M-_\ (U'_  Z]_P"":'_2.[X%_P#AI-&_^1J- ,3_ (? _P#!+/\ Z2!?";_P
MMK3_ .+H_P"'P/\ P2S_ .D@7PF_\+:T_P#BZV_^'7O_  30_P"D=WP+_P##
M2:-_\C4?\.O?^":'_2.[X%_^&DT;_P"1J- ,3_A\#_P2S_Z2!?";_P +:T_^
M+H_X? _\$L_^D@7PF_\ "VM/_BZV_P#AU[_P30_Z1W? O_PTFC?_ "-1_P .
MO?\ @FA_TCN^!?\ X:31O_D:C0#$_P"'P/\ P2S_ .D@7PF_\+:T_P#BZ/\
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M_P#"VM/_ (NC_A\#_P $L_\ I(%\)O\ PMK3_P"+K;_X=>_\$T/^D=WP+_\
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MPF_\+:T_^+K;_P"'7O\ P30_Z1W? O\ \-)HW_R-1_PZ]_X)H?\ 2.[X%_\
MAI-&_P#D:C0#$_X? _\ !+/_ *2!?";_ ,+:T_\ BZ/^'P/_  2S_P"D@7PF
M_P#"VM/_ (NMO_AU[_P30_Z1W? O_P -)HW_ ,C4?\.O?^":'_2.[X%_^&DT
M;_Y&HT Q/^'P/_!+/_I(%\)O_"VM/_BZ/^'P/_!+/_I(%\)O_"VM/_BZV_\
MAU[_ ,$T/^D=WP+_ /#2:-_\C4?\.O?^":'_ $CN^!?_ (:31O\ Y&HT Q/^
M'P/_  2S_P"D@7PF_P#"VM/_ (NC_A\#_P $L_\ I(%\)O\ PMK3_P"+K;_X
M=>_\$T/^D=WP+_\ #2:-_P#(U'_#KW_@FA_TCN^!?_AI-&_^1J- ,3_A\#_P
M2S_Z2!?";_PMK3_XNC_A\#_P2S_Z2!?";_PMK3_XNMO_ (=>_P#!-#_I'=\"
M_P#PTFC?_(U'_#KW_@FA_P!([O@7_P"&DT;_ .1J- ,3_A\#_P $L_\ I(%\
M)O\ PMK3_P"+H_X? _\ !+/_ *2!?";_ ,+:T_\ BZV_^'7O_!-#_I'=\"__
M  TFC?\ R-1_PZ]_X)H?]([O@7_X:31O_D:C0#$_X? _\$L_^D@7PF_\+:T_
M^+H_X? _\$L_^D@7PF_\+:T_^+K;_P"'7O\ P30_Z1W? O\ \-)HW_R-1_PZ
M]_X)H?\ 2.[X%_\ AI-&_P#D:C0#$_X? _\ !+/_ *2!?";_ ,+:T_\ BZ/^
M'P/_  2S_P"D@7PF_P#"VM/_ (NMO_AU[_P30_Z1W? O_P -)HW_ ,C4?\.O
M?^":'_2.[X%_^&DT;_Y&HT Q/^'P/_!+/_I(%\)O_"VM/_BZ/^'P/_!+/_I(
M%\)O_"VM/_BZV_\ AU[_ ,$T/^D=WP+_ /#2:-_\C4?\.O?^":'_ $CN^!?_
M (:31O\ Y&HT Q/^'P/_  2S_P"D@7PF_P#"VM/_ (NC_A\#_P $L_\ I(%\
M)O\ PMK3_P"+K;_X=>_\$T/^D=WP+_\ #2:-_P#(U'_#KW_@FA_TCN^!?_AI
M-&_^1J- ,3_A\#_P2S_Z2!?";_PMK3_XNC_A\#_P2S_Z2!?";_PMK3_XNMO_
M (=>_P#!-#_I'=\"_P#PTFC?_(U'_#KW_@FA_P!([O@7_P"&DT;_ .1J- ,3
M_A\#_P $L_\ I(%\)O\ PMK3_P"+H_X? _\ !+/_ *2!?";_ ,+:T_\ BZV_
M^'7O_!-#_I'=\"__  TFC?\ R-1_PZ]_X)H?]([O@7_X:31O_D:C0#$_X? _
M\$L_^D@7PF_\+:T_^+H_X? _\$L_^D@7PF_\+:T_^+K;_P"'7O\ P30_Z1W?
M O\ \-)HW_R-1_PZ]_X)H?\ 2.[X%_\ AI-&_P#D:C0#$_X? _\ !+/_ *2!
M?";_ ,+:T_\ BZ/^'P/_  2S_P"D@7PF_P#"VM/_ (NMO_AU[_P30_Z1W? O
M_P -)HW_ ,C4?\.O?^":'_2.[X%_^&DT;_Y&HT Q/^'P/_!+/_I(%\)O_"VM
M/_BZ/^'P/_!+/_I(%\)O_"VM/_BZV_\ AU[_ ,$T/^D=WP+_ /#2:-_\C4?\
M.O?^":'_ $CN^!?_ (:31O\ Y&HT Q/^'P/_  2S_P"D@7PF_P#"VM/_ (NC
M_A\#_P $L_\ I(%\)O\ PMK3_P"+K;_X=>_\$T/^D=WP+_\ #2:-_P#(U'_#
MKW_@FA_TCN^!?_AI-&_^1J- ,3_A\#_P2S_Z2!?";_PMK3_XNC_A\#_P2S_Z
M2!?";_PMK3_XNMO_ (=>_P#!-#_I'=\"_P#PTFC?_(U'_#KW_@FA_P!([O@7
M_P"&DT;_ .1J- ,3_A\#_P $L_\ I(%\)O\ PMK3_P"+H_X? _\ !+/_ *2!
M?";_ ,+:T_\ BZV_^'7O_!-#_I'=\"__  TFC?\ R-1_PZ]_X)H?]([O@7_X
M:31O_D:C0#$_X? _\$L_^D@7PF_\+:T_^+H_X? _\$L_^D@7PF_\+:T_^+K;
M_P"'7O\ P30_Z1W? O\ \-)HW_R-1_PZ]_X)H?\ 2.[X%_\ AI-&_P#D:C0#
M$_X? _\ !+/_ *2!?";_ ,+:T_\ BZ/^'P/_  2S_P"D@7PF_P#"VM/_ (NM
MO_AU[_P30_Z1W? O_P -)HW_ ,C4?\.O?^":'_2.[X%_^&DT;_Y&HT Q/^'P
M/_!+/_I(%\)O_"VM/_BZ/^'P/_!+/_I(%\)O_"VM/_BZV_\ AU[_ ,$T/^D=
MWP+_ /#2:-_\C4?\.O?^":'_ $CN^!?_ (:31O\ Y&HT Q/^'P/_  2S_P"D
M@7PF_P#"VM/_ (NC_A\#_P $L_\ I(%\)O\ PMK3_P"+K;_X=>_\$T/^D=WP
M+_\ #2:-_P#(U'_#KW_@FA_TCN^!?_AI-&_^1J- ,3_A\#_P2S_Z2!?";_PM
MK3_XNC_A\#_P2S_Z2!?";_PMK3_XNMO_ (=>_P#!-#_I'=\"_P#PTFC?_(U'
M_#KW_@FA_P!([O@7_P"&DT;_ .1J- ,3_A\#_P $L_\ I(%\)O\ PMK3_P"+
MH_X? _\ !+/_ *2!?";_ ,+:T_\ BZV_^'7O_!-#_I'=\"__  TFC?\ R-1_
MPZ]_X)H?]([O@7_X:31O_D:C0#$_X? _\$L_^D@7PF_\+:T_^+H_X? _\$L_
M^D@7PF_\+:T_^+K;_P"'7O\ P30_Z1W? O\ \-)HW_R-1_PZ]_X)H?\ 2.[X
M%_\ AI-&_P#D:C0#$_X? _\ !+/_ *2!?";_ ,+:T_\ BZ/^'P/_  2S_P"D
M@7PF_P#"VM/_ (NMO_AU[_P30_Z1W? O_P -)HW_ ,C4?\.O?^":'_2.[X%_
M^&DT;_Y&HT Q/^'P/_!+/_I(%\)O_"VM/_BZ/^'P/_!+/_I(%\)O_"VM/_BZ
MV_\ AU[_ ,$T/^D=WP+_ /#2:-_\C4?\.O?^":'_ $CN^!?_ (:31O\ Y&HT
M Q/^'P/_  2S_P"D@7PF_P#"VM/_ (NC_A\#_P $L_\ I(%\)O\ PMK3_P"+
MK;_X=>_\$T/^D=WP+_\ #2:-_P#(U'_#KW_@FA_TCN^!?_AI-&_^1J- ,3_A
M\#_P2S_Z2!?";_PMK3_XNC_A\#_P2S_Z2!?";_PMK3_XNMO_ (=>_P#!-#_I
M'=\"_P#PTFC?_(U'_#KW_@FA_P!([O@7_P"&DT;_ .1J- ,3_A\#_P $L_\
MI(%\)O\ PMK3_P"+H_X? _\ !+/_ *2!?";_ ,+:T_\ BZV_^'7O_!-#_I'=
M\"__  TFC?\ R-1_PZ]_X)H?]([O@7_X:31O_D:C0#$_X? _\$L_^D@7PF_\
M+:T_^+H_X? _\$L_^D@7PF_\+:T_^+K;_P"'7O\ P30_Z1W? O\ \-)HW_R-
M1_PZ]_X)H?\ 2.[X%_\ AI-&_P#D:C0#$_X? _\ !+/_ *2!?";_ ,+:T_\
MBZ/^'P/_  2S_P"D@7PF_P#"VM/_ (NMO_AU[_P30_Z1W? O_P -)HW_ ,C4
M?\.O?^":'_2.[X%_^&DT;_Y&HT Q/^'P/_!+/_I(%\)O_"VM/_BZ/^'P/_!+
M/_I(%\)O_"VM/_BZV_\ AU[_ ,$T/^D=WP+_ /#2:-_\C4?\.O?^":'_ $CN
M^!?_ (:31O\ Y&HT Q/^'P/_  2S_P"D@7PF_P#"VM/_ (NC_A\#_P $L_\
MI(%\)O\ PMK3_P"+K;_X=>_\$T/^D=WP+_\ #2:-_P#(U'_#KW_@FA_TCN^!
M?_AI-&_^1J- ,3_A\#_P2S_Z2!?";_PMK3_XNC_A\#_P2S_Z2!?";_PMK3_X
MNMO_ (=>_P#!-#_I'=\"_P#PTFC?_(U'_#KW_@FA_P!([O@7_P"&DT;_ .1J
M- ,3_A\#_P $L_\ I(%\)O\ PMK3_P"+H_X? _\ !+/_ *2!?";_ ,+:T_\
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M_P"+H_X? _\ !+/_ *2!?";_ ,+:T_\ BZV_^'7O_!-#_I'=\"__  TFC?\
MR-1_PZ]_X)H?]([O@7_X:31O_D:C0#$_X? _\$L_^D@7PF_\+:T_^+H_X? _
M\$L_^D@7PF_\+:T_^+K;_P"'7O\ P30_Z1W? O\ \-)HW_R-1_PZ]_X)H?\
M2.[X%_\ AI-&_P#D:C0#$_X? _\ !+/_ *2!?";_ ,+:T_\ BZ/^'P/_  2S
M_P"D@7PF_P#"VM/_ (NMO_AU[_P30_Z1W? O_P -)HW_ ,C4?\.O?^":'_2.
M[X%_^&DT;_Y&HT Q/^'P/_!+/_I(%\)O_"VM/_BZ/^'P/_!+/_I(%\)O_"VM
M/_BZV_\ AU[_ ,$T/^D=WP+_ /#2:-_\C4?\.O?^":'_ $CN^!?_ (:31O\
MY&HT Q/^'P/_  2S_P"D@7PF_P#"VM/_ (NC_A\#_P $L_\ I(%\)O\ PMK3
M_P"+K;_X=>_\$T/^D=WP+_\ #2:-_P#(U'_#KW_@FA_TCN^!?_AI-&_^1J-
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GSX%>#? ECJ-P+C4++P;X8M-+BN90NT22);1H'8+P&()QQ128'__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140075272373520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Oct. 28, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36201<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Immunic, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">56-2358443<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1200 Avenue of the Americas<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">New York,<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">10036<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">332<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">255-9818<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.0001 par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">IMUX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,261,547<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001280776<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140075271935120">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 72,771<span></span>
</td>
<td class="nump">$ 86,863<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Other current assets and prepaid expenses</a></td>
<td class="nump">13,878<span></span>
</td>
<td class="nump">18,125<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">86,649<span></span>
</td>
<td class="nump">104,988<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">159<span></span>
</td>
<td class="nump">152<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">32,970<span></span>
</td>
<td class="nump">32,970<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets, net</a></td>
<td class="nump">1,263<span></span>
</td>
<td class="nump">948<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other long-term assets</a></td>
<td class="nump">42<span></span>
</td>
<td class="nump">42<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">121,083<span></span>
</td>
<td class="nump">139,100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">4,172<span></span>
</td>
<td class="nump">3,745<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">6,623<span></span>
</td>
<td class="nump">7,071<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">719<span></span>
</td>
<td class="nump">585<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">11,514<span></span>
</td>
<td class="nump">11,401<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Long term liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities</a></td>
<td class="nump">759<span></span>
</td>
<td class="nump">584<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total long-term liabilities</a></td>
<td class="nump">759<span></span>
</td>
<td class="nump">584<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">12,273<span></span>
</td>
<td class="nump">11,985<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 4)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.0001 par value; 20,000,000 authorized and no shares issued or outstanding at September 30, 2022 and December 31, 2021</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value; 130,000,000 shares authorized and 30,564,995 and 26,335,418 shares issued and outstanding as of September 30, 2022 and December&#160;31, 2021, respectively</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">369,999<span></span>
</td>
<td class="nump">324,237<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(386)<span></span>
</td>
<td class="num">(252)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(260,806)<span></span>
</td>
<td class="num">(196,873)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">108,810<span></span>
</td>
<td class="nump">127,115<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 121,083<span></span>
</td>
<td class="nump">$ 139,100<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140075272337696">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in USD per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">20,000,000<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in USD per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">130,000,000<span></span>
</td>
<td class="nump">130,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">30,564,995<span></span>
</td>
<td class="nump">26,335,418<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">30,564,995<span></span>
</td>
<td class="nump">26,335,418<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140075271886896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 16,537<span></span>
</td>
<td class="nump">$ 15,480<span></span>
</td>
<td class="nump">$ 50,520<span></span>
</td>
<td class="nump">$ 42,737<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">3,579<span></span>
</td>
<td class="nump">2,907<span></span>
</td>
<td class="nump">11,641<span></span>
</td>
<td class="nump">9,957<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_RoyaltySettlementAgreementSalesNet', window );">4SC Royalty Settlement (see Note 4)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">17,250<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">20,116<span></span>
</td>
<td class="nump">18,387<span></span>
</td>
<td class="nump">62,161<span></span>
</td>
<td class="nump">69,944<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(20,116)<span></span>
</td>
<td class="num">(18,387)<span></span>
</td>
<td class="num">(62,161)<span></span>
</td>
<td class="num">(69,944)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">230<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="nump">343<span></span>
</td>
<td class="nump">51<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="num">(1,338)<span></span>
</td>
<td class="num">(915)<span></span>
</td>
<td class="num">(2,115)<span></span>
</td>
<td class="num">(1,867)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other expense</a></td>
<td class="num">(1,108)<span></span>
</td>
<td class="num">(905)<span></span>
</td>
<td class="num">(1,772)<span></span>
</td>
<td class="num">(1,816)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (21,224)<span></span>
</td>
<td class="num">$ (19,292)<span></span>
</td>
<td class="num">$ (63,933)<span></span>
</td>
<td class="num">$ (71,760)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share, basic (in dollars per share)</a></td>
<td class="num">$ (0.69)<span></span>
</td>
<td class="num">$ (0.76)<span></span>
</td>
<td class="num">$ (2.16)<span></span>
</td>
<td class="num">$ (3.33)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share, diluted (in dollars per share)</a></td>
<td class="num">$ (0.69)<span></span>
</td>
<td class="num">$ (0.76)<span></span>
</td>
<td class="num">$ (2.16)<span></span>
</td>
<td class="num">$ (3.33)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average common shares outstanding, basic (in shares)</a></td>
<td class="nump">30,564,995<span></span>
</td>
<td class="nump">25,320,091<span></span>
</td>
<td class="nump">29,655,946<span></span>
</td>
<td class="nump">21,559,964<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average common shares outstanding, diluted (in shares)</a></td>
<td class="nump">30,564,995<span></span>
</td>
<td class="nump">25,320,091<span></span>
</td>
<td class="nump">29,655,946<span></span>
</td>
<td class="nump">21,559,964<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_RoyaltySettlementAgreementSalesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty Settlement Agreement, Sales Net</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_RoyaltySettlementAgreementSalesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140075272352624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (21,224)<span></span>
</td>
<td class="num">$ (19,292)<span></span>
</td>
<td class="num">$ (63,933)<span></span>
</td>
<td class="num">$ (71,760)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive income (loss):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation</a></td>
<td class="nump">274<span></span>
</td>
<td class="nump">598<span></span>
</td>
<td class="num">(134)<span></span>
</td>
<td class="nump">3,312<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Total comprehensive loss</a></td>
<td class="num">$ (20,950)<span></span>
</td>
<td class="num">$ (18,694)<span></span>
</td>
<td class="num">$ (64,067)<span></span>
</td>
<td class="num">$ (68,448)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140075266355744">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Stockholders&#8217; Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>July 2021 Equity Issuance</div></th>
<th class="th"><div>Public Offering</div></th>
<th class="th"><div>4SC Royalty Settlement</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th">
<div>Common Stock </div>
<div>July 2021 Equity Issuance</div>
</th>
<th class="th">
<div>Common Stock </div>
<div>Public Offering</div>
</th>
<th class="th">
<div>Common Stock </div>
<div>4SC Royalty Settlement</div>
</th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th">
<div>Additional Paid-In Capital </div>
<div>July 2021 Equity Issuance</div>
</th>
<th class="th">
<div>Additional Paid-In Capital </div>
<div>Public Offering</div>
</th>
<th class="th">
<div>Additional Paid-In Capital </div>
<div>4SC Royalty Settlement</div>
</th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss)</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,168,240<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="nump">$ 158,785<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 266,823<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (4,112)<span></span>
</td>
<td class="num">$ (103,928)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(34,534)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(34,534)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">1,579<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,579<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Foreign exchange translation adjustment</a></td>
<td class="nump">2,991<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,991<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,749,439<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2021</a></td>
<td class="nump">137,446<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">277,027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,121)<span></span>
</td>
<td class="num">(138,462)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,168,240<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="nump">158,785<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">266,823<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,112)<span></span>
</td>
<td class="num">(103,928)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(71,760)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,249,439<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2021</a></td>
<td class="nump">145,465<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">321,950<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(800)<span></span>
</td>
<td class="num">(175,688)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,749,439<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Mar. 31, 2021</a></td>
<td class="nump">137,446<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">277,027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,121)<span></span>
</td>
<td class="num">(138,462)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(17,934)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(17,934)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">1,507<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,507<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Foreign exchange translation adjustment</a></td>
<td class="num">(277)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(277)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">581,199<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,749,439<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2021</a></td>
<td class="nump">120,742<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">278,534<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,398)<span></span>
</td>
<td class="num">(156,396)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(19,292)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(19,292)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">1,397<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,397<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Foreign exchange translation adjustment</a></td>
<td class="nump">598<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">598<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 42,020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 42,019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,249,439<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2021</a></td>
<td class="nump">$ 145,465<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">321,950<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(800)<span></span>
</td>
<td class="num">(175,688)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2021</a></td>
<td class="nump">26,335,418<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,335,418<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="nump">$ 127,115<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">324,237<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(252)<span></span>
</td>
<td class="num">(196,873)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(20,808)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(20,808)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">2,069<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,069<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Foreign exchange translation adjustment</a></td>
<td class="num">(58)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(58)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">852<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,904,113<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock</a></td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29,638<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29,638<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,240,383<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2022</a></td>
<td class="nump">$ 137,961<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">355,949<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(310)<span></span>
</td>
<td class="num">(217,681)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2021</a></td>
<td class="nump">26,335,418<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,335,418<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="nump">$ 127,115<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">324,237<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(252)<span></span>
</td>
<td class="num">(196,873)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (63,933)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2022</a></td>
<td class="nump">30,564,995<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,564,995<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2022</a></td>
<td class="nump">$ 108,810<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">369,999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(386)<span></span>
</td>
<td class="num">(260,806)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,240,383<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Mar. 31, 2022</a></td>
<td class="nump">137,961<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">355,949<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(310)<span></span>
</td>
<td class="num">(217,681)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(21,901)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(21,901)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">2,062<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,062<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Foreign exchange translation adjustment</a></td>
<td class="num">(350)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(350)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,612<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock</a></td>
<td class="nump">130<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,946<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,946<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,564,995<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2022</a></td>
<td class="nump">127,848<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">368,087<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(660)<span></span>
</td>
<td class="num">(239,582)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(21,224)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(21,224)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">1,912<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,912<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Foreign exchange translation adjustment</a></td>
<td class="nump">$ 274<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">274<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2022</a></td>
<td class="nump">30,564,995<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,564,995<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2022</a></td>
<td class="nump">$ 108,810<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 369,999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (386)<span></span>
</td>
<td class="num">$ (260,806)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11178-113907<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126961718&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140075274632720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Stockholders&#8217; Equity (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Issuance costs</a></td>
<td class="nump">$ 308<span></span>
</td>
<td class="nump">$ 918<span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140075266287296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statement of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (63,933)<span></span>
</td>
<td class="num">$ (71,760)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">58<span></span>
</td>
<td class="nump">45<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized', window );">Unrealized foreign currency loss</a></td>
<td class="nump">4,217<span></span>
</td>
<td class="nump">3,202<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">6,043<span></span>
</td>
<td class="nump">4,483<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable', window );">Common Stock issued in connection with the 4SC royalty settlement (see Note 4)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">8,625<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Other current assets and prepaid expenses</a></td>
<td class="nump">2,061<span></span>
</td>
<td class="num">(6,305)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">1,151<span></span>
</td>
<td class="num">(261)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities', window );">Accrued expenses</a></td>
<td class="nump">465<span></span>
</td>
<td class="nump">2,760<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Other liabilities</a></td>
<td class="num">(102)<span></span>
</td>
<td class="num">(341)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(50,040)<span></span>
</td>
<td class="num">(59,552)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(113)<span></span>
</td>
<td class="num">(48)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(113)<span></span>
</td>
<td class="num">(48)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans', window );">Proceeds from shares issued in connection with the Company's employee stock purchase plan</a></td>
<td class="nump">130<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">39,719<span></span>
</td>
<td class="nump">42,020<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate changes on cash and cash equivalents</a></td>
<td class="num">(3,658)<span></span>
</td>
<td class="nump">572<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net change in cash and cash equivalents</a></td>
<td class="num">(14,092)<span></span>
</td>
<td class="num">(17,008)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, beginning of period</a></td>
<td class="nump">86,863<span></span>
</td>
<td class="nump">127,452<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, end of period</a></td>
<td class="nump">72,771<span></span>
</td>
<td class="nump">110,444<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental disclosure of noncash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssued1', window );">Common Stock issued in connection with the 4SC royalty settlement (see Note 4)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">8,625<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Operating lease right-of use asset obtained in exchange for lease obligation</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">435<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=vtl_PublicOfferingMember', window );">Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from Issuance of Common Stock</a></td>
<td class="nump">39,584<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=vtl_July2021PublicEquityOfferingMember', window );">July 2021 Public Equity Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from Issuance of Common Stock</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 42,020<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of acquirer's equity interest issued and issuable as part of consideration transferred in asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126928898&amp;loc=d3e9215-128498<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126928898&amp;loc=d3e9212-128498<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=127000608&amp;loc=d3e9135-128495<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124440516&amp;loc=d3e30840-110895<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=125521441&amp;loc=d3e30690-110894<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossUnrealized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in current liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of shares under share-based payment arrangement. Excludes option exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of stock issued in noncash financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=vtl_PublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=vtl_PublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=vtl_July2021PublicEquityOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=vtl_July2021PublicEquityOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140075274613232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows (Parenthetical)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=vtl_July2021PublicEquityOfferingMember', window );">July 2021 Public Equity Offering</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Issuance costs</a></td>
<td class="nump">$ 2,980<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=vtl_July2021PublicEquityOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=vtl_July2021PublicEquityOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140075272362832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business and Basis of Financial Statements<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">Description of Business and Basis of Financial Statements</a></td>
<td class="text">Description of Business and Basis of Financial Statements<div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Description of Business</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Immunic, Inc. ("Immunic" or the "Company") is a clinical-stage biopharmaceutical company with a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases. The Company is headquartered in New York City with its main operations in Gr&#228;felfing near Munich, Germany.  The Company currently has approximately 65 employees.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company is currently pursuing three development programs. These include the vidofludimus calcium (IMU-838) program, which is focused on the development of oral formulations of a small molecule inhibitor of the enzyme dihydroorotate dehydrogenase (&#8220;DHODH&#8221;); the IMU-935 program, which is focused on an inverse agonist of retinoic acid receptor-related orphan nuclear receptor gamma truncated (&#8220;ROR&#947;t&#8221;), an immune cell-specific isoform of ROR&#947;; and the IMU-856 program, which involves the development of a drug targeting the restoration of intestinal barrier function and regeneration of bowel epithelium. These product candidates are being developed to address diseases such as multiple sclerosis ("MS"), psoriasis and gastrointestinal diseases. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company&#8217;s business, operating results, financial condition and growth prospects are subject to significant risks and uncertainties, including the failure of its clinical trials to meet their endpoints, failure to obtain regulatory approval and the inability to obtain on acceptable terms, if at all, additional funding to complete the development and commercialization of the Company's three development programs.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity and Financial Condition</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immunic has no products approved for commercial sale and has not generated any revenue from product sales. It has never been profitable and has incurred operating losses in each year since inception in 2016.  The Company has an accumulated deficit of approximately $260.8 million as of September 30, 2022 and $196.9 million as of December 31, 2021.  Substantially all of Immunic's operating losses resulted from expenses incurred in connection with its research and development programs and from general and administrative costs associated with its operations.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immunic expects to incur significant expenses and increasing operating losses for the foreseeable future as it initiates and continues the preclinical and clinical development of its product candidates and adds personnel necessary to advance its clinical pipeline of product candidates.  Immunic expects that its operating losses will fluctuate significantly from quarter-to-quarter and year-to-year due to timing of clinical development programs.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From inception through October 31, 2022, Immunic has raised net cash of approximately $355.5 million from private and public offerings of preferred and common stock. As of September 30, 2022, the Company had cash and cash equivalents of approximately $72.8 million.  With these funds, and the $56.4 million of cash raised in October 2022, Immunic expects to be able to fund its operations beyond twelve months from the date of the issuance of the accompanying condensed consolidated financial statements.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation and Consolidation</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements have been prepared in conformity with United States generally accepted accounting principles, ("U.S. GAAP") and include the accounts of Immunic and its wholly-owned subsidiaries, Immunic AG (which began operations in 2016) and Immunic Research GmbH (which began operations in 2016 and was merged into Immunic AG in September, 2022) and Immunic Australia Pty Ltd. (which began operations in 2018).  All intercompany accounts and transactions have been eliminated in consolidation. Immunic manages its operations as a single reportable segment for the purposes of assessing performance and making operating decisions. </span></div>Unaudited Interim Financial InformationImmunic has prepared the accompanying interim unaudited condensed consolidated financial statements in accordance with United States generally accepted accounting principles, (&#8220;US GAAP&#8221;), for interim financial information and with the instructions to Form 10-Q and Regulation S-X of the SEC. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. These interim unaudited condensed consolidated financial statements reflect all adjustments consisting of normal recurring accruals which, in the opinion of management, are necessary to present fairly Immunic&#8217;s consolidated financial position, consolidated results of operations, consolidated statement of stockholders&#8217; equity and consolidated cash flows for the periods and as of the dates presented. The Company&#8217;s fiscal year ends on December 31. The condensed consolidated balance sheet as of December 31, 2021 was derived from audited consolidated financial statements but does not include all disclosures required by U.S. GAAP. These condensed consolidated financial statements should be read in conjunction with the annual consolidated financial statements and the notes thereto included on the Company's Annual Report on Form 10-K filed on February 24, 2022. The nature of Immunic&#8217;s business is such that the results of any interim period may not be indicative of the results to be expected for the entire year.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI https://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI https://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140075358330608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">Summary of Significant Accounting Policies<div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires the Company to make certain estimates and assumptions that affect the reported amounts of assets, liabilities, expenses and the disclosure of contingent assets and liabilities in the Company&#8217;s consolidated financial statements. The most significant estimates in the Company&#8217;s financial statements and accompanying notes relate to clinical trial expenses and share-based compensation. Management believes its estimates to be reasonable under the circumstances. Actual results could differ materially from those estimates and assumptions.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Translation and Presentation</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s reporting currency is United States (&#8220;U.S.&#8221;) dollars. Immunic AG and Immunic Research GmbH&#8217;s operations are located in Germany with the euro being their functional currency. Immunic Australia Pty Ltd.&#8217;s functional currency is the Australian dollar. All amounts in the financial statements where the functional currency is not the U.S. dollar are translated into U.S. dollar equivalents at exchange rates as follows:</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:180%">&#8226; assets and liabilities at reporting period-end rates;</span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:180%">&#8226; income statement accounts at average exchange rates for the reporting period; and</span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:180%">&#8226; components of equity at historical rates.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gains and losses from translation of the financial statements into U.S. dollars are recorded in stockholders&#8217; equity as a component of accumulated other comprehensive income (loss). Realized and unrealized gains and losses resulting from foreign currency transactions denominated in currencies other than the functional currency are reflected as general and administrative expenses in the Consolidated Statements of Operations. Foreign currency transaction gains and losses related to long-term intercompany loans that are payable in the foreseeable future are recorded in Other Income (Expense). The Consolidated Statements of Cash Flows were prepared by using the average exchange rate in effect during the reporting period which reasonably approximates the timing of the cash flows.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents consist of cash on hand and deposits in banks located in the U.S., Germany and Australia. The Company maintains cash and cash equivalent balances denominated in Euro and U.S. dollars with major financial institutions in the U.S. and Germany in excess of the deposit limits insured by the government. Management periodically reviews the credit standing of these financial institutions and believes that the Company is not exposed to any significant credit risk. The Company currently deposits its cash and cash equivalents with two large financial institutions. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurement</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the price that would be received to sell an asset or be paid to transfer a liability in an orderly transaction between market participants on the measurement date. Accounting guidance establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The standard describes three levels of inputs that may be used to measure fair value:</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;1&#8212;Quoted prices in active markets for identical assets or liabilities. Level 1 assets consisted of money market funds for the periods presented. The Company had no Level 1 liabilities for the periods presented.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;2&#8212; Inputs other than observable quoted prices for the asset or liability, either directly or indirectly; these include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. The Company had no Level 2 assets or liabilities for the periods presented.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;3&#8212;Unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of assets or liabilities. The Company had no Level 3 assets or liabilities for the periods presented.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying value of cash and cash equivalents, other current assets and prepaid expenses, accounts payable, accrued expenses, and other current liabilities approximates fair value due to the short period of time to maturity.</span></div><div style="margin-top:18pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment is stated at cost. Depreciation is computed using the straight-line method based on the estimated service lives of the assets, which range from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8zNC9mcmFnOjZlNmZlYmNmYmQwYTRlNDE5NDE0ZWFhMGNlYTdjMWU2L3RleHRyZWdpb246NmU2ZmViY2ZiZDBhNGU0MTk0MTRlYWEwY2VhN2MxZTZfNDU2Mg_7c753206-cde1-40ce-856d-422289b6506b">three</span> to thirteen years. Depreciation expense was $17,000 and $16,000 for the three months ended September 30, 2022 and 2021, respectively. Depreciation expense was $58,000 and $45,000 for the nine months ended September 30, 2022 and 2021, respectively.</span></div><div style="margin-top:18pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-Lived Assets</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records impairment losses on long-lived assets used in operations when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets&#8217; carrying amount. Impaired assets are then recorded at their estimated fair value. There were no impairment losses during the three and nine months ended September 30, 2022 and 2021.</span></div><div style="margin-top:12pt;padding-left:20.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:174%">Goodwill</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Business combinations are accounted for under the acquisition method. The total purchase price of an acquisition is allocated to the underlying identifiable net assets, based on their respective estimated fair values as of the acquisition date. Determining the fair value of assets acquired and liabilities assumed requires management&#8217;s judgment and often involves the use of significant estimates and assumptions, including assumptions with respect to future cash inflows and outflows, probabilities of success, discount rates, and asset lives, among other items. Assets acquired and liabilities assumed are recorded at their estimated fair values. The excess of the purchase price over the estimated fair values of the net assets acquired is recorded as goodwill.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill is tested for impairment at the reporting unit level annually in the fourth quarter, or more frequently when events or changes in circumstances indicate that the asset might be impaired. Examples of such events or circumstances include, but are not limited to, an unfavorable clinical trial result, a significant adverse change in legal or business climate, industry market conditions, an adverse regulatory action, sustained decrease in stock price or unanticipated competition. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When conducting the Company&#8217;s interim goodwill impairment assessment, we considered the Company&#8217;s history of reported losses and negative cash flows from operating activities, along with the downturn in macroeconomic conditions and the broader mid-cap and micro-cap equity markets in 2022. Given the period of time between the commencement of the downturn in macroeconomic and general equity market conditions as of September 30, 2022, management believes that the fluctuation in prices of our common stock, consistent with the broader market, is not other-than-temporary and not indicative of any fundamental change in the value or prospects of the underlying business as of the measurement date.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As another data point, the Company also performed a quantitative goodwill impairment analysis comparing the estimated fair value of the Company&#8217;s reporting unit to its carrying or book value as of the current period presented herein. In performing the quantitative analysis, the Company compared the fair value of the reporting unit to its carrying or book value to determine if the fair value of the reporting unit exceeded its carrying value as of the testing date, in which case the standard indicates that goodwill would not be impaired, and no further testing was necessary. The fair value of a reporting unit refers to the price that would be received to sell the reporting unit as a whole in an orderly transaction between market participants at the measurement date. Quoted market prices in active markets are considered to be the best evidence of fair value and should be used as the basis for fair value measurement, if available. When using quoted market prices to estimate the fair value of a reporting unit, we consider all available evidence. In certain circumstances, such as a distressed market, it may be appropriate to consider recent trends in the Company&#8217;s stock price, instead of a single day&#8217;s stock price in evaluating fair value. In these circumstances, averages over relatively short periods of time are used to determine representative market values.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subsequent to September 30, 2022, the company raised $60&#160;million of common stock at a premium to the company's market pricing.  Management further considered this as an indication of the value and related premium to market values prior to and as of September 30, 2022.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on this qualitative analysis,  the Company concluded that goodwill was not &#8220;more likely than not&#8221; impaired as of September 30, 2022.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 20, 2022, the Company announced the outcome of a  significant interim analysis of its Phase 1b clinical trial of IMU-935 in patients with moderate-to-severe psoriasis that were not deemed positive progress. On October 21, 2022, the Company experienced a significant decrease in the Company's market capitalization.  The Company considered this to be a triggering event indicating that it is more likely than not that goodwill is impaired.  As a result, the Company anticipates it will incur an approximately $33.0&#160;million goodwill impairment charge in the fourth quarter of 2022 as a result of this analysis (See Note 10).</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Research and Development Expenses</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">These costs primarily include external development expenses and internal personnel expenses for the three development programs, vidofludimus calcium, IMU-935 and IMU-856. Immunic has spent the majority of its research and development resources on vidofludimus calcium, the Company's lead development program for clinical trials in RRMS, UC and COVID-19.  </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses consist of expenses incurred in research and development activities, which include clinical trials, contract research services, certain milestone payments, salaries and related employee benefits, allocated facility costs and other outsourced services. Research and development expenses are charged to operations as incurred.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into agreements with contract research organizations (&#8220;CROs&#8221;) to provide clinical trial services for individual studies and projects by executing individual work orders governed by a Master Service Arrangement (&#8220;MSA&#8221;). The MSAs and associated work orders provide for regular recurrent payments and payments upon the completion of certain milestones. The Company regularly assesses the timing of payments against actual costs incurred to ensure a proper accrual of related expenses in the appropriate accounting period.</span></div><div style="margin-top:18pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration Arrangements</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain collaboration and license agreements may include payments to or from the Company of one or more of the following: non-refundable or partially refundable upfront or license fees; development, regulatory and commercial milestone payments; payment for manufacturing supply services; partial or complete reimbursement of research and development costs; and royalties on net sales of licensed products. The Company assesses whether such contracts are within the scope of Financial Accounting Standards Board (FASB) Accounting Standards Update (&#8220;ASU&#8221;) 2014-09 &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; and ASU No. 2018-18, &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ("ASU 2018-18"). ASU 2018-18, clarifies that certain elements of collaborative arrangements could qualify as transactions with customers in the scope of ASC 606.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, the Company entered into an option and license agreement (the "Daiichi Sankyo Agreement") with Daiichi Sankyo Co., Ltd. ("Daiichi Sankyo") which granted the Company the right to license a group of compounds, designated by the Company as IMU-856, as a potential new oral treatment option for gastrointestinal diseases such as celiac disease, inflammatory bowel disease, irritable bowel syndrome with diarrhea and other barrier function associated diseases. During the option period, the Company performed agreed upon research and development activities for which it was reimbursed by Daiichi </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sankyo up to a maximum agreed-upon limit. Such reimbursement was recorded as other income. There are no additional research and development reimbursements expected under this agreement.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On January 5, 2020, the Company exercised its option to obtain the exclusive worldwide right to commercialization of IMU-856. Among other things, the option exercise grants Immunic AG the rights to Daiichi Sankyo&#8217;s patent application related to IMU-856, for which the Company received a notice of allowance from the US Patent &amp; Trademark Office in August 2022. In connection with the option exercise, the Company paid a one-time upfront licensing fee to Daiichi Sankyo. Under the Daiichi Sankyo Agreement, Daiichi Sankyo is also eligible to receive future development, regulatory and sales milestone payments, as well as royalties related to IMU-856.</span></div><div style="margin-top:18pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative Expenses</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses consist primarily of salaries and related costs for personnel in executive, finance, business development and other support functions. Other general and administrative expenses include, but are not limited to, stock-based compensation, insurance costs, professional fees for legal, accounting and tax services, consulting, related facility costs and travel.</span></div><div style="margin-top:18pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation&#160;</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures the cost of employee and non-employee services received in exchange for equity awards based on the grant-date fair value of the award recognized generally as an expense (i) on a straight-line basis over the requisite service period for those awards whose vesting is based upon a service condition, and (ii) on an accelerated method for awards whose vesting is based upon a performance condition, but only to the extent it is probable that the performance condition will be met. Stock-based compensation is (i) estimated at the date of grant based on the award&#8217;s fair value for equity classified awards and (ii) final measurement date for liability classified awards. Forfeitures are recorded in the period in which they occur.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates the fair value of stock options using the Black-Scholes-Merton option-pricing model ("BSM"), which requires the use of estimates and subjective assumptions, including the risk-free interest rate, the fair value of the underlying common stock, the expected dividend yield of the Company&#8217;s common stock, the expected volatility of the price of the Company&#8217;s common stock, and the expected term of the option. These estimates involve inherent uncertainties and the application of management&#8217;s judgment. If factors change and different assumptions are used, the Company&#8217;s stock-based compensation expense could be materially different in the future.</span></div><div style="margin-top:18pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:18pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company leases office space and office equipment. The underlying lease agreements have lease terms of less than 12 months and up to 60 months. Leases with terms of 12 months or less at inception are not included in the operating lease right of use asset and operating lease liability.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has two existing leases for office space. At inception of a lease agreement, the Company determines whether an agreement represents a lease and at commencement each lease agreement is assessed as to classification as an operating or financing lease. The Company's two leases have been classified as operating leases and an operating lease right-of-use asset and an operating lease liability have been recorded on the Company&#8217;s balance sheet. A right-of-use lease asset represents the Company&#8217;s right to use the underlying asset for the lease term and the lease obligation represents its commitment to make the lease payments arising from the lease. Right-of-use lease assets and obligations are recognized at the commencement date based on the present value of remaining lease payments over the lease term. As the Company&#8217;s leases do not provide an implicit rate, the Company has used an estimated incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. The right-of-use lease asset includes any lease payments made prior to commencement and excludes any lease incentives. The lease term used in estimating future lease payments may include options to extend when it is reasonably certain that the Company will exercise that option. Operating lease expense is recognized on a straight-line basis over the lease term, subject to any changes in the lease or changes in expectations regarding the lease term. Variable lease costs such as common area costs and property taxes are expensed as incurred. Leases with an initial term of twelve months or less are not recorded on the balance sheet.</span></div><div style="margin-top:18pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Income (Loss)</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive income (loss) is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. Accumulated other comprehensive income (loss) has been reflected as a separate component of stockholders&#8217; equity in the accompanying Consolidated Balance Sheets and consists of foreign currency translation adjustments (net of tax).</span></div><div style="margin-top:18pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to corporate income tax laws and regulations in the U.S., Germany and Australia. Tax regulations within each jurisdiction are subject to the interpretation of the related tax laws and regulations and require significant judgment in their application.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company utilizes the asset and liability method of accounting for income taxes which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the audited consolidated financial statements. Deferred income tax assets and liabilities are determined based on the differences between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of changes in tax rates on deferred tax assets and liabilities is recognized in operations in the period that includes the enactment date. Deferred taxes are reduced by a valuation allowance when, in the opinion of management, it is more likely than not some portion or the entire deferred tax asset will not be realized.  As of September 30, 2022 and 2021, respectively, the Company maintained a full valuation allowance against the balance of deferred tax assets.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is the Company&#8217;s policy to provide for uncertain tax positions and the related interest and penalties based upon management&#8217;s assessment of whether a tax benefit is more likely than not to be sustained upon examination by tax authorities. The Company recognizes interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense.  The Company is subject to U.S. federal, New York, California, Texas, German and Australian income taxes. The Company is subject to U.S. federal or state income tax examination by tax authorities for tax returns filed for the years 2003 and forward due to the carryforward of NOLs. Tax years 2016 through 2021 are subject to audit by German and Australian tax authorities. The Company is not currently under examination by any tax jurisdictions.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss Per Share</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share attributable to common stockholders is calculated by dividing the net loss by the weighted-average number of common shares outstanding for the period, without consideration for common stock equivalents. Diluted net loss per share attributable to common stockholders is computed by dividing the net loss by the weighted-average number of common shares and, if dilutive, common stock equivalents outstanding for the period determined using the treasury-stock method. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company&#8217;s net loss position.</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Potentially dilutive securities, not included in the calculation of diluted net loss per share attributable to common stockholders because to do so would be anti-dilutive, are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"><tr><td style="width:1.0%"/><td style="width:73.751%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.953%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.955%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,799,573&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,045,960&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued and/or Adopted Accounting Standards</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are no recently issued accounting standards that would have a significant impact on the company's consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140075274870112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Details<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">Balance Sheet Details</a></td>
<td class="text">Balance Sheet Details<div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Current Assets and Prepaid Expenses</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other Current Assets and Prepaid Expenses consist of (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.315%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.157%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.969%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.059%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid clinical and related costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,938&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,853&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">VAT receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">279&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Australian research and development tax incentive</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,150&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,871&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,549&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,122&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,878&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,125&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Payable</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts Payable consist of (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.046%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.969%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.474%"/><td style="width:0.1%"/></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,748&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,427&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legal and audit costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">310&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,172&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,745&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Expenses</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consist of (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.484%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued clinical and related costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,504&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,214&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued legal and audit costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">881&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">674&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,623&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,071&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Current Liabilities</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other Current Liabilities consist of (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.469%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.527%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.912%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.740%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">395&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">408&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">324&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">719&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">585&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -URI https://asc.fasb.org/topic&amp;trid=2122208<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140075277814096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies<div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Leases</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases certain office space under non-cancelable operating leases. The leases terminate on April 30, 2023 for the New York City office and on June 30, 2025 for the Gr&#228;felfing, Germany office.  These leases include both lease (e.g., fixed rent) and non-lease components (e.g., common-area and other maintenance costs). The non-lease components are deemed to be executory costs and are therefore excluded from the minimum lease payments used to determine the present value of the operating lease obligation and related right-of-use asset. The New York City lease has renewal options, but they were not included in calculating the right of use asset and liabilities.  On April 7, 2020, the Company signed a five year lease for its facility in Gr&#228;felfing, Germany. On March 1, 2021, and August 1, 2022, the Company added additional lease space at the Gr&#228;felfing, Germany office.  Renewal options were not included in calculating the right of use asset and liabilities for this facility. The leases do not have concessions, leasehold improvement incentives or other build-out clauses. Further, the leases do not contain contingent rent provisions. The New York City lease had a six month rent holiday at the beginning of the lease.  There were net additions to right of use assets of $435,000 and $642,000 as a result of signing for additional lease space at the Gr&#228;felfing, Germany office in March 2021 and August 2022, respectively.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;The leases do not provide an implicit rate and, due to the lack of a commercially salable product, the Company is generally considered unable to obtain commercial credit. Therefore, the Company estimated its incremental interest rate to be 6%, considering the quoted rates for the lowest investment-grade debt and the interest rates implicit in recent financing leases. Immunic used its estimated incremental borrowing rate and other information available at the lease commencement date in determining the present value of the lease payments.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;Immunic&#8217;s operating lease costs and variable lease costs were $232,000 and $133,000 for the three months ended September 30, 2022 and 2021, respectively and $498,000 and $372,000 for the nine months ended September 30, 2022 and 2021, respectively.  Variable lease costs consist primarily of common area maintenance costs, insurance and taxes which are paid based upon actual costs incurred by the lessor.</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of the operating lease obligation are as follows as of September 30, 2022 (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.660%"><tr><td style="width:1.0%"/><td style="width:84.079%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.596%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.925%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">528&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">454&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">227&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,378&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PV of obligation</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,274&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:22.5pt"><span><br/></span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contractual Obligations</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2022, the Company has non-cancelable contractual obligations under certain agreements related to its development programs IMU-838, IMU-935 and IMU-856 totaling approximately $2.7 million, which is expected to be paid over the next twelve months.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Commitments and Obligations</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2016, the Company entered into a purchase agreement (the &#8220;Agreement&#8221;) with 4SC AG, whereby the Company acquired certain assets, including the rights to patents and patent applications, trademarks and know-how. This transaction has </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">been accounted for as an asset acquisition under Accounting Standards Update 2017-01 - Business Combinations (Topic 805): Clarifying the Definition of a Business. The Agreement included payments (Tranches III and IV) that were contingent upon the occurrence of certain events and required the Company to pay royalties equal to 4.4% of the aggregated net sales for a certain period as defined in the Agreement (Tranche III) upon commercialization of the acquired assets. Effective April 12, 2019, the parties agreed to settle Tranche IV by issuing 120,070 shares of the Company&#8217;s common stock, immediately following the Transaction, to 4SC AG while keeping Tranche III in effect. Approximately $1.5 million of expense was recorded as a result of the issuance of these shares on April 12, 2019. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 31, 2021, Immunic AG, a wholly-owned subsidiary of the Company, and 4SC AG entered into a Settlement Agreement, pursuant to which Immunic AG settled its remaining obligation of the 4.4% royalty on net sales for $17.25&#160;million (Tranche III of the Agreement). The payment was made 50% in cash and 50% in shares of Immunic&#8217;s common stock (the &#8220;Shares&#8221;). Pursuant to the Agreement, the Company filed a resale shelf registration statement on Form S-3 covering the resale of the Shares. With the execution of the Agreement, no further payment obligations remain between Immunic AG and 4SC AG.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Proceedings</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is not currently a party to any litigation, nor is it aware of any pending or threatened litigation, that it believes would materially affect its business, operating results, financial condition or cash flows. However, its industry is characterized by frequent claims and litigation including securities litigation, claims regarding patent and other intellectual property rights and claims for product liability. As a result, in the future, the Company may be involved in various legal proceedings from time to time.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140075274816384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value</a></td>
<td class="text">Fair Value<div style="margin-bottom:6pt;margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following fair value hierarchy tables present information about each major category of the Company&#8217;s financial assets and liabilities measured at fair value on a recurring basis (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"/><td style="width:50.888%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.092%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.830%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.092%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.830%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.240%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.830%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.098%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurement at September 30, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair&#160;Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level&#160;3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,471&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,471&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets at fair value</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,471&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,471&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"/><td style="width:50.888%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.092%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.830%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.092%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.830%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.240%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.830%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.098%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurement at Fair&#160;Value&#160;Measurement&#160;at&#160;December&#160;31,&#160;2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair&#160;Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level&#160;3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,630&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,630&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,630&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,630&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no transfers between Level&#160;1, Level&#160;2 or Level&#160;3 assets during the periods presented.  </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the Company&#8217;s money market funds, which are included as a component of cash and cash equivalents on the consolidated balance sheet, realized gains and losses are included in interest income (expense) on the consolidated statements of operations. </span></div>The carrying amounts of other current assets and prepaid expenses, accounts payable, accrued expenses, and other current liabilities approximate their fair values due to their short-term nature. The fair value and book value of the money market funds presented in the table above are the same.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140075274686928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Common Stock</a></td>
<td class="text">Common StockIn November 2020, Immunic filed a shelf registration statement on Form S-3. The 2020 Shelf Registration Statement permits the offering, issuance and sale of up to $250.0&#160;million of common stock, preferred stock, warrants, debt securities, and/or units in one or more offerings and in any combination of the foregoing.  As of October 31, 2022, there is $75.0&#160;million remaining on this shelf registration statement <div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, the Company filed a Prospectus Supplement for the offering, issuance and sale of up to a maximum aggregate offering price of $50.0&#160;million of common stock that may be issued and sold under an at-the-market sales agreement ("December 2020 ATM") with SVB Leerink as agent. The Company has used, and intends to continue to use the net proceeds from the offering to continue to fund the ongoing clinical development of its product candidates and for other general corporate purposes, including funding existing and potential new clinical programs and product candidates. The December 2020 ATM will terminate upon the earlier of (i) the issuance and sale of all of the shares through SVB Leerink on the terms and subject to the conditions set forth in the December 2020 ATM or (ii) termination of the December 2020 ATM as otherwise permitted thereby. The December 2020 ATM may be terminated at any time by either party upon ten days&#8217; prior notice, or by SVB Leerink at any time in certain circumstances, including the occurrence of a material adverse effect on the Company.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of October 31, 2022, $8.4&#160;million in capacity remains under the December 2020 ATM.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2022, the Company filed a Prospectus Supplement for the offering, issuance and sale of up to a maximum aggregate offering price of $80.0&#160;million of common stock that may be issued and sold under another at-the-market sales agreement ("May 2022 ATM") with SVB Leerink as agent. The Company intends to use the net proceeds from the offering to continue to fund the ongoing clinical development of its product candidates and for other general corporate purposes, including funding existing and potential new clinical programs and product candidates. The May 2022 ATM will terminate upon the earlier of (i) the issuance and sale of all of the shares through SVB Leerink on the terms and subject to the conditions set forth in the May 2022 ATM or (ii) termination of the May 2022 ATM as otherwise permitted thereby. The May 2022 ATM may be terminated at any time by either party upon ten days&#8217; prior notice, or by SVB Leerink at any time in certain circumstances, including the occurrence of a material adverse effect on the Company.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of October 31, 2022, $80.0&#160;million in capacity remains under the May 2022 ATM.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;The Company has agreed to pay SVB Leerink a commission equal to 3.0% of the gross proceeds from the sales of common shares pursuant to both ATM's and has agreed to provide SVB Leerink with customary indemnification and contribution rights.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the three months ended September 30, 2022, the Company did not raise any proceeds under its ATM facilities.  In the nine months ended September 30, 2022, the Company raised gross proceeds of $40.9&#160;million pursuant to the December 2020 ATM through the sale of 4,204,113 shares of common stock at a weighted average price of $9.72 per share. The net proceeds from the December 2020 ATM were $39.6&#160;million after deducting underwriter commissions of $1.2&#160;million. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company did not have any ATM activity during the three or nine months ended September 30, 2021.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Public Equity Offerings</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">July 2021 Public Equity Offering</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 15, 2021, the Company entered into an underwriting agreement with Piper Sandler &amp; Co., in connection with the</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Company&#8217;s public offering of 4,500,000 shares of the Company&#8217;s common stock, $0.0001 par value per share, at a public</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">offering price of $10.00 per share.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 19, 2021, the Company closed the Offering. The net proceeds to the Company from the Offering was</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">approximately $42.0&#160;million, after deducting underwriting discounts and commissions and estimated offering expenses payable</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">by the Company.</span></div><div style="margin-top:12pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Common Stock</span></div><div style="margin-top:12pt;padding-right:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2022, the Company&#8217;s certificate of incorporation, as amended and restated, authorized the Company to issue 130,000,000 shares of common stock, par value of $0.0001 per share. The voting, dividend and liquidation rights of the holders of the Company&#8217;s common stock are subject to and qualified by the rights, powers and preferences of any holders of preferred stock.</span></div><div style="margin-top:12pt;padding-right:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each share of common stock entitles the holder to one vote on all matters submitted to a vote of the Company&#8217;s stockholders. Common stockholders are entitled to receive dividends, as may be declared by the board of directors, if any. Through September 30, 2022, no cash dividends had been declared or paid.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preferred Stock</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s certificate of incorporation, as amended and restated, authorizes the Company to issue 20 million shares of $0.0001 par value preferred stock, having rights and preferences to be set by the Board of Directors. No preferred shares were outstanding as of September 30, 2022.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Reserved for Future Issuance</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares reserved for future issuance at September 30, 2022 are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:86.162%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.638%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of<br/>Shares</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock reserved for issuance for:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;2021 Employee stock Purchase Plan    </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162,630&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,799,573&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock options available for future grant:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2014 Equity Incentive Plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,311&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2017 Inducement Equity Incentive Plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019 Omnibus Equity Incentive Plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180,770&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total common shares reserved for future issuance</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,232,534&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=SL126733271-114008<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140075274654512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation Plans<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation Plans</a></td>
<td class="text">Stock-Based Compensation Plans<div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2021 Employee Stock Purchase Plan</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 25, 2021, the Company adopted the 2021 Employee Stock Purchase Plan ("ESPP"), which was approved by stockholder vote at the 2021 Annual Meeting of Stockholders held on June 10, 2021. The ESPP provides eligible employees of the Company with an opportunity to purchase common stock of the Company through accumulated payroll deductions, which are included in other current liabilities until they are used to purchase Company shares. Eligible employees participating in the bi-annual offering period can choose to have up to the lesser of 15% of their annual base earnings or the IRS annual share purchase limit of $25,000 in aggregate market value to purchase shares of the Company&#8217;s common stock. The purchase price of the stock is the lesser of (i) 85% of the closing market price on the date of purchase and (ii) the closing market price at the beginning of the bi-annual offering period. The maximum number of shares reserved for delivery under the plan is 200,000 shares.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">     </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company issued  zero and 24,612 shares under the ESPP for the three and nine months ended September 30, 2022 and 37,370 shares life to date.  The Company recognized ESPP expense of $21,000 and $18,000  for the three months ended September 30, 2022 and 2021, respectively, and  ESPP expense of $74,000 and $18,000 related to the nine months ended September 30, 2022 and 2021, respectively. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Option Programs</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2019, the Company&#8217;s stockholders approved the 2019 Omnibus Equity Incentive Plan (the &#8220;2019 Plan&#8221;) which was adopted by the Board with an effective date of June 14, 2019. The 2019 Plan allows for the grant of equity awards to employees, consultants and non-employee directors. An initial maximum of 1,500,000 shares of the Company&#8217;s common stock were available for grant under the 2019 Plan. The 2019 Plan includes an evergreen provision that allows for the annual addition of up to 4% of the Company&#8217;s fully-diluted outstanding stock, with a maximum allowable increase of 4,900,000 shares over the term of the 2019 Plan. In accordance with this provision, the shares available for grant were increased in 2020 through 2022 by a total of 2,481,195 shares. The 2019 Plan is currently administered by the Board, or, at the discretion of the Board, by a committee of the Board, which determines the exercise prices, vesting schedules and other restrictions of awards under the 2019 Plan at its discretion. Options to purchase stock may not have an exercise price that is less than the fair market value of underlying shares on the date of grant, and may not have a term greater than ten years. Incentive stock options granted to employees typically vest over four years. Non-statutory options granted to employees, officers, members of the Board, advisors, and consultants of the Company typically vest over <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80OS9mcmFnOjlhN2M1MTczZGE1ZTQ5ZjViYTk4YWRiODZhZWYwOWJkL3RleHRyZWdpb246OWE3YzUxNzNkYTVlNDlmNWJhOThhZGI4NmFlZjA5YmRfNTQ5NzU1ODI1NDIw_e9f71a48-2105-4fda-bdd7-59ddc0e82852">three</span> or four years. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares that are expired, terminated, surrendered or canceled under the 2019 Plan without having been fully exercised will be available for future awards. </span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Movements during the year </span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock option activity for the nine months ended September 30, 2022 and 2021, respectively, for the 2019 Plan:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.929%"><tr><td style="width:1.0%"/><td style="width:52.444%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.307%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.307%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.759%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.421%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term&#160;(Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of January 1, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,157,460&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.54&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,837,513&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.90&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(852)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.67&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited or expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(194,548)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.62&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of September 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,799,573&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.59</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,400&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options vested and expected to vest as of September 30, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,799,573&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.59</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,400&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercisable as of September 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,248,875&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.63&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.64</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.883%"><tr><td style="width:1.0%"/><td style="width:51.442%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.531%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.570%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.531%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.570%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.993%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.570%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.693%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term&#160;(Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of January 1, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,117,160&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.96&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,033,809&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.95&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited or expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(105,009)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of September 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,045,960&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.90&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.91</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,460&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options vested and expected to vest as of September 30, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,045,960&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.90&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.91</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,460&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercisable as of September 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">665,168&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.33</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,121&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Measurement</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average assumptions used in the BSM option pricing model to determine the fair value of the employee and non-employee stock option grants relating to the 2019 Plan were as follows:</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk-Free Interest Rate</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The risk-free rate assumption is based on U.S. Treasury instruments with maturities similar to the expected term of the stock options.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Dividend Yield</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company has not issued any dividends and does not expect to issue dividends over the life of the options. As a result, the Company has estimated the dividend yield to be zero.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Volatility</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the Company&#8217;s limited operating history and a lack of company specific historical and implied volatility data, the Company estimates expected volatility based on the historical volatility of its own stock combined with a group of comparable companies that are publicly traded. The historical volatility data was computed using the daily closing prices for the selected companies&#8217; shares during the equivalent period of the calculated expected term of the stock-based awards.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Term </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The expected term of options is estimated considering the vesting period at the grant date, the life of the option and the average length of time similar grants have remained outstanding in the past.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average grant date fair value of stock options granted under the 2019 Plan during the nine months ended September 30, 2022 and 2021 was $6.94 and $11.14, respectively. The following are the underlying assumptions used in the Black-Scholes-Merton option pricing model to determine the fair value of stock options granted to employees and to non-employees under this stock plan:</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.812%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.445%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine  Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.04%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.88%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97.8%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92.4%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term of options (years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.00</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.95</span></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation Expense</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total stock-based compensation expense for all stock awards recognized in the accompanying unaudited condensed consolidated statements of operations is as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.391%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.115%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.186%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months<br/>&#160;Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months<br/>&#160;Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">831,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">456,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,392,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,279,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,081,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">941,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,651,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,204,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,912,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,397,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,043,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,483,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2022, there was $17.6 million in total unrecognized compensation expense relating to the 2019 Plan to be recognized over a weighted average period of 2.91 years.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Summary of Equity Incentive Plans Assumed from Vital</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon completion of the Transaction with Vital Therapies ("Vital") on April 12, 2019, Vital&#8217;s 2012 Stock Option Plan (the &#8220;2012 Plan&#8221;), Vital&#8217;s 2014 Equity Incentive Plan (the &#8220;2014 Plan&#8221;) and Vital&#8217;s 2017 Inducement Equity Incentive Plan (the &#8220;Inducement Plan&#8221;), were assumed by the Company. All awards granted under these plans have either been forfeited or expired.  </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There remain 43,311 shares available for grant under the 2014 Plan as of September 30, 2022.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 2017, Vital&#8217;s board of directors approved the Inducement Plan, which was amended and restated in November 2017. Under the Inducement Plan 46,250 shares of Vital&#8217;s common stock were reserved to be used exclusively for non-qualified grants to individuals who were not previously employees or directors as an inducement material to a grantee's entry into employment within the meaning of Rule 5635(c)(4) of the Nasdaq Listing Rules.  </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No expense was recorded for the plans assumed from Vital during the three and nine months ended September 30, 2022 and 2021, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140075274816384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Changes in Board of Directors<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_ChangesInBoardOfDirectorsDisclosureTextBlock', window );">Changes in Board of Directors</a></td>
<td class="text">Changes in Board of Directors<div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 6, 2022, the Company announced the appointment of Monika Maria T&#246;rns&#233;n as a member of the Board of Directors of the Company, effective as of July 5, 2022. As a Class III director, Ms. T&#246;rns&#233;n&#8217;s term lasts until the Company&#8217;s 2023 annual meeting of stockholders.  Ms. T&#246;rns&#233;n is not a party to, and does not have any direct or indirect material interest in, any transaction requiring disclosure under Item 404(a) of Regulation S-K. There are no arrangements or understandings between Ms. T&#246;rns&#233;n and any other persons pursuant to which she was selected as a director.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with her appointment as director, Ms. T&#246;rns&#233;n was granted a long-term equity incentive grant in the form of an option to purchase a total of 30,000 shares of the Company&#8217;s common stock, with an exercise price of $4.30 per share, which is equal to the closing price of the Company's common stock on The Nasdaq Stock Market on the date of grant, July 8, 2022. The option to purchase 10,000 shares vests in monthly increments over a period of one year from the grant date, and the option to purchase 20,000 shares vests in monthly increments over a period of three years from the grant date. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, Ms. T&#246;rns&#233;n and the Company entered into the Company&#8217;s standard form of indemnification agreement for directors and executive officers.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Concurrently, the Company also announced that current Class III director, Jan Van den Bossche, resigned from the Board. The Board accepted Mr. Van den Bossche&#8217;s resignation effective July 5, 2022. Mr. Van den Bossche&#8217;s decision to resign did not result from any disagreement with the Company on any matter relating to Company operations, policies or practices.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_ChangesInBoardOfDirectorsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Changes In Board of Directors Disclosure</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_ChangesInBoardOfDirectorsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140075274566096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text">Related Party Transactions<div style="margin-top:12pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Executive Chairman Agreement with Duane Nash</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 15, 2020, the compensation committee of the Board of Directors of the Company independently reviewed and approved entering into an employment agreement with the current Chairman of the Board, Duane Nash, MD, JD, MBA (the &#8220;Executive Chairman Agreement&#8221;) and pursuant to such approval, on April 17, 2020, the Company and Dr. Nash entered into the Executive Chairman Agreement. The Executive Chairman Agreement establishes an &#8220;at will&#8221; employment relationship pursuant to which Dr. Nash serves as Executive Chairman and contemplated a term that ends on October 15, 2020, which was subsequently extended to April 15, 2021. On April 15, 2021, the Company and Dr. Nash entered into an addendum (the &#8220;Addendum&#8221;) to extend the term of the Executive Chairman Agreement to April 15, 2022.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Addendum, the Company made a one-time award to Dr. Nash of an option to purchase 90,000 shares of Company common stock, which vests monthly commencing on May 15, 2021, and to increase Dr. Nash&#8217;s monthly base salary to $27,960 from $25,417. Effective March 15, 2022, the Company extended the term of employment from April 15, 2022 to December 31, 2022 with a base salary of $29,358 per month (which includes the cash retainer payable for serving on the Company&#8217;s Board or for acting as the Chairman of the Board). In connection with this extension, the Company made a one-time award to Dr. Nash of an option to purchase 75,000 shares of the Company&#8217;s common stock, which vests monthly commencing on April 10, 2022.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All other terms of the Executive Chairman Agreement remain the same.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI https://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140075274291168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text">Subsequent Events <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$60 Million Private Placement Equity Financing</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 10, 2022, Immunic entered into a Securities Purchase Agreement (the &#8220;Purchase Agreement&#8221;) for a private placement (the &#8220;Private Placement&#8221;) with select accredited investors and certain existing investors (each, a &#8220;Purchaser&#8221; and collectively, the &#8220;Purchasers&#8221;). Pursuant to the Purchase Agreement, the Company agreed to sell to the Purchasers (i) 8,696,552 shares of the Company&#8217;s common stock, par value $0.0001 per share (the &#8220;Shares&#8221;), at a purchase price of $4.35 per Share, and (ii) 5,096,552 pre-funded warrants (the &#8220;Pre-Funded Warrants&#8221;) to purchase Common Stock (the &#8220;Warrant Shares&#8221; and together with the Shares and the Pre-Funded Warrants, the &#8220;Securities&#8221;), at a purchase price of $4.34 per Pre-Funded Warrant. The Pre-Funded Warrants will have an exercise price of $0.01 per share of Common Stock, be immediately exercisable and remain exercisable until exercised in full. The holders of Pre-Funded Warrants may not exercise a Pre-Funded Warrant if the holder, together with its affiliates, would beneficially own more than 9.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise. The holders of Pre-Funded Warrants may increase or decrease such percentages not in excess of 19.99% by providing at least 61 days&#8217; prior notice to the Company.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Private Placement closed on October 12, 2022. The gross proceeds of the Private Placement were approximately $60.0&#160;million, before deducting offering expenses payable by the Company. The Company intends to use the net proceeds from the Private Placement to fund the ongoing clinical development of its three lead product candidates, vidofludimus calcium (IMU-838), IMU-935 and IMU-856, and for other general corporate purposes.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Purchase Agreement provides for the registration for resale of the Securities (including the Warrant Shares) pursuant to a registration statement (the &#8220;Registration Statement&#8221;) to be filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;) on or prior to December 9, 2022. The Company has agreed to use its best efforts to cause the Registration Statement to be declared effective as soon as possible, but in no event later than 60 days after the closing of the Private Placement (or 90 days in the event of a review of the Registration Statement by, and comments from, the SEC), and to keep the Registration Statement continuously effective from the date on which the SEC declares the Registration Statement to be effective until such date that all Registrable Securities (as such term is defined in the Purchase Agreement) covered by the Registration Statement have been sold pursuant to a registration statement under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), or under Rule 144 as promulgated by the SEC under the Securities Act, or otherwise shall have ceased to be Registrable Securities.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pre-Planned Phase 1b Interim Analysis of IMU-935 in Moderate-to-Severe Psoriasis</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On October 20, 2022, Immunic announced the outcome of a pre-planned interim group-level data analysis of its Phase 1b clinical trial of IMU-935 in patients with moderate-to-severe psoriasis. The overall trial is ongoing and remains blinded. The pre-planned interim analysis revealed that the group averages for Psoriasis Area and Severity Index ("PASI&#8221;) reductions in the two active arms did not separate from placebo at four weeks. Although the active arms performed in line with prior expectations, based on similarly designed trials, the trial experienced a greater decrease than expected in PASI in the placebo arm. Although the safety data remains blinded, administration of IMU-935 and placebo in this trial were demonstrated to be safe and well-tolerated, and no new safety signals were observed. The Company expects to continue IMU-935&#8217;s development in psoriasis and will further analyze the available data to determine next steps for the program.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Goodwill Impairment Analysis</span></div>Following the announcement of our interim group level data of the Phase 1b clinical trial of IMU-935 in Psoriasis on October 20, 2022, our stock price experienced a significant decline from the prices preceding the announcement.  The Company considered this to be a triggering event indicating that it is more likely than not that goodwill is impaired.  As a result, the Company anticipates it will incur a full impairment of its goodwill of approximately $33.0&#160;million in the quarter ended December 31, 2022.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI https://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140075272434080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation and Consolidation</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation and Consolidation</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements have been prepared in conformity with United States generally accepted accounting principles, ("U.S. GAAP") and include the accounts of Immunic and its wholly-owned subsidiaries, Immunic AG (which began operations in 2016) and Immunic Research GmbH (which began operations in 2016 and was merged into Immunic AG in September, 2022) and Immunic Australia Pty Ltd. (which began operations in 2018).  All intercompany accounts and transactions have been eliminated in consolidation. Immunic manages its operations as a single reportable segment for the purposes of assessing performance and making operating decisions. </span></div>Unaudited Interim Financial InformationImmunic has prepared the accompanying interim unaudited condensed consolidated financial statements in accordance with United States generally accepted accounting principles, (&#8220;US GAAP&#8221;), for interim financial information and with the instructions to Form 10-Q and Regulation S-X of the SEC. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. These interim unaudited condensed consolidated financial statements reflect all adjustments consisting of normal recurring accruals which, in the opinion of management, are necessary to present fairly Immunic&#8217;s consolidated financial position, consolidated results of operations, consolidated statement of stockholders&#8217; equity and consolidated cash flows for the periods and as of the dates presented. The Company&#8217;s fiscal year ends on December 31. The condensed consolidated balance sheet as of December 31, 2021 was derived from audited consolidated financial statements but does not include all disclosures required by U.S. GAAP. These condensed consolidated financial statements should be read in conjunction with the annual consolidated financial statements and the notes thereto included on the Company's Annual Report on Form 10-K filed on February 24, 2022. The nature of Immunic&#8217;s business is such that the results of any interim period may not be indicative of the results to be expected for the entire year.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires the Company to make certain estimates and assumptions that affect the reported amounts of assets, liabilities, expenses and the disclosure of contingent assets and liabilities in the Company&#8217;s consolidated financial statements. The most significant estimates in the Company&#8217;s financial statements and accompanying notes relate to clinical trial expenses and share-based compensation. Management believes its estimates to be reasonable under the circumstances. Actual results could differ materially from those estimates and assumptions.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency Translation and Presentation</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Translation and Presentation</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s reporting currency is United States (&#8220;U.S.&#8221;) dollars. Immunic AG and Immunic Research GmbH&#8217;s operations are located in Germany with the euro being their functional currency. Immunic Australia Pty Ltd.&#8217;s functional currency is the Australian dollar. All amounts in the financial statements where the functional currency is not the U.S. dollar are translated into U.S. dollar equivalents at exchange rates as follows:</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:180%">&#8226; assets and liabilities at reporting period-end rates;</span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:180%">&#8226; income statement accounts at average exchange rates for the reporting period; and</span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:180%">&#8226; components of equity at historical rates.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gains and losses from translation of the financial statements into U.S. dollars are recorded in stockholders&#8217; equity as a component of accumulated other comprehensive income (loss). Realized and unrealized gains and losses resulting from foreign currency transactions denominated in currencies other than the functional currency are reflected as general and administrative expenses in the Consolidated Statements of Operations. Foreign currency transaction gains and losses related to long-term intercompany loans that are payable in the foreseeable future are recorded in Other Income (Expense). The Consolidated Statements of Cash Flows were prepared by using the average exchange rate in effect during the reporting period which reasonably approximates the timing of the cash flows.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents.</span></div>Cash and cash equivalents consist of cash on hand and deposits in banks located in the U.S., Germany and Australia. The Company maintains cash and cash equivalent balances denominated in Euro and U.S. dollars with major financial institutions in the U.S. and Germany in excess of the deposit limits insured by the government. Management periodically reviews the credit standing of these financial institutions and believes that the Company is not exposed to any significant credit risk. The Company currently deposits its cash and cash equivalents with two large financial institutions.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value Measurement</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurement</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the price that would be received to sell an asset or be paid to transfer a liability in an orderly transaction between market participants on the measurement date. Accounting guidance establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The standard describes three levels of inputs that may be used to measure fair value:</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;1&#8212;Quoted prices in active markets for identical assets or liabilities. Level 1 assets consisted of money market funds for the periods presented. The Company had no Level 1 liabilities for the periods presented.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;2&#8212; Inputs other than observable quoted prices for the asset or liability, either directly or indirectly; these include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. The Company had no Level 2 assets or liabilities for the periods presented.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;3&#8212;Unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of assets or liabilities. The Company had no Level 3 assets or liabilities for the periods presented.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying value of cash and cash equivalents, other current assets and prepaid expenses, accounts payable, accrued expenses, and other current liabilities approximates fair value due to the short period of time to maturity.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text">Property and EquipmentProperty and equipment is stated at cost. Depreciation is computed using the straight-line method based on the estimated service lives of the assets, which range from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8zNC9mcmFnOjZlNmZlYmNmYmQwYTRlNDE5NDE0ZWFhMGNlYTdjMWU2L3RleHRyZWdpb246NmU2ZmViY2ZiZDBhNGU0MTk0MTRlYWEwY2VhN2MxZTZfNDU2Mg_7c753206-cde1-40ce-856d-422289b6506b">three</span> to thirteen years.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text">Impairment of Long-Lived AssetsThe Company records impairment losses on long-lived assets used in operations when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets&#8217; carrying amount. Impaired assets are then recorded at their estimated fair value.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy', window );">Goodwill</a></td>
<td class="text"><div style="margin-top:12pt;padding-left:20.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:174%">Goodwill</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Business combinations are accounted for under the acquisition method. The total purchase price of an acquisition is allocated to the underlying identifiable net assets, based on their respective estimated fair values as of the acquisition date. Determining the fair value of assets acquired and liabilities assumed requires management&#8217;s judgment and often involves the use of significant estimates and assumptions, including assumptions with respect to future cash inflows and outflows, probabilities of success, discount rates, and asset lives, among other items. Assets acquired and liabilities assumed are recorded at their estimated fair values. The excess of the purchase price over the estimated fair values of the net assets acquired is recorded as goodwill.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill is tested for impairment at the reporting unit level annually in the fourth quarter, or more frequently when events or changes in circumstances indicate that the asset might be impaired. Examples of such events or circumstances include, but are not limited to, an unfavorable clinical trial result, a significant adverse change in legal or business climate, industry market conditions, an adverse regulatory action, sustained decrease in stock price or unanticipated competition. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When conducting the Company&#8217;s interim goodwill impairment assessment, we considered the Company&#8217;s history of reported losses and negative cash flows from operating activities, along with the downturn in macroeconomic conditions and the broader mid-cap and micro-cap equity markets in 2022. Given the period of time between the commencement of the downturn in macroeconomic and general equity market conditions as of September 30, 2022, management believes that the fluctuation in prices of our common stock, consistent with the broader market, is not other-than-temporary and not indicative of any fundamental change in the value or prospects of the underlying business as of the measurement date.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As another data point, the Company also performed a quantitative goodwill impairment analysis comparing the estimated fair value of the Company&#8217;s reporting unit to its carrying or book value as of the current period presented herein. In performing the quantitative analysis, the Company compared the fair value of the reporting unit to its carrying or book value to determine if the fair value of the reporting unit exceeded its carrying value as of the testing date, in which case the standard indicates that goodwill would not be impaired, and no further testing was necessary. The fair value of a reporting unit refers to the price that would be received to sell the reporting unit as a whole in an orderly transaction between market participants at the measurement date. Quoted market prices in active markets are considered to be the best evidence of fair value and should be used as the basis for fair value measurement, if available. When using quoted market prices to estimate the fair value of a reporting unit, we consider all available evidence. In certain circumstances, such as a distressed market, it may be appropriate to consider recent trends in the Company&#8217;s stock price, instead of a single day&#8217;s stock price in evaluating fair value. In these circumstances, averages over relatively short periods of time are used to determine representative market values.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subsequent to September 30, 2022, the company raised $60&#160;million of common stock at a premium to the company's market pricing.  Management further considered this as an indication of the value and related premium to market values prior to and as of September 30, 2022.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on this qualitative analysis,  the Company concluded that goodwill was not &#8220;more likely than not&#8221; impaired as of September 30, 2022.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 20, 2022, the Company announced the outcome of a  significant interim analysis of its Phase 1b clinical trial of IMU-935 in patients with moderate-to-severe psoriasis that were not deemed positive progress. On October 21, 2022, the Company experienced a significant decrease in the Company's market capitalization.  The Company considered this to be a triggering event indicating that it is more likely than not that goodwill is impaired.  As a result, the Company anticipates it will incur an approximately $33.0&#160;million goodwill impairment charge in the fourth quarter of 2022 as a result of this analysis (See Note 10).</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Research and Development Expenses</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">These costs primarily include external development expenses and internal personnel expenses for the three development programs, vidofludimus calcium, IMU-935 and IMU-856. Immunic has spent the majority of its research and development resources on vidofludimus calcium, the Company's lead development program for clinical trials in RRMS, UC and COVID-19.  </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses consist of expenses incurred in research and development activities, which include clinical trials, contract research services, certain milestone payments, salaries and related employee benefits, allocated facility costs and other outsourced services. Research and development expenses are charged to operations as incurred.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into agreements with contract research organizations (&#8220;CROs&#8221;) to provide clinical trial services for individual studies and projects by executing individual work orders governed by a Master Service Arrangement (&#8220;MSA&#8221;). The MSAs and associated work orders provide for regular recurrent payments and payments upon the completion of certain milestones. The Company regularly assesses the timing of payments against actual costs incurred to ensure a proper accrual of related expenses in the appropriate accounting period.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementAccountingPolicy', window );">Collaboration Arrangements</a></td>
<td class="text"><div style="margin-top:18pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration Arrangements</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain collaboration and license agreements may include payments to or from the Company of one or more of the following: non-refundable or partially refundable upfront or license fees; development, regulatory and commercial milestone payments; payment for manufacturing supply services; partial or complete reimbursement of research and development costs; and royalties on net sales of licensed products. The Company assesses whether such contracts are within the scope of Financial Accounting Standards Board (FASB) Accounting Standards Update (&#8220;ASU&#8221;) 2014-09 &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; and ASU No. 2018-18, &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ("ASU 2018-18"). ASU 2018-18, clarifies that certain elements of collaborative arrangements could qualify as transactions with customers in the scope of ASC 606.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, the Company entered into an option and license agreement (the "Daiichi Sankyo Agreement") with Daiichi Sankyo Co., Ltd. ("Daiichi Sankyo") which granted the Company the right to license a group of compounds, designated by the Company as IMU-856, as a potential new oral treatment option for gastrointestinal diseases such as celiac disease, inflammatory bowel disease, irritable bowel syndrome with diarrhea and other barrier function associated diseases. During the option period, the Company performed agreed upon research and development activities for which it was reimbursed by Daiichi </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sankyo up to a maximum agreed-upon limit. Such reimbursement was recorded as other income. There are no additional research and development reimbursements expected under this agreement.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On January 5, 2020, the Company exercised its option to obtain the exclusive worldwide right to commercialization of IMU-856. Among other things, the option exercise grants Immunic AG the rights to Daiichi Sankyo&#8217;s patent application related to IMU-856, for which the Company received a notice of allowance from the US Patent &amp; Trademark Office in August 2022. In connection with the option exercise, the Company paid a one-time upfront licensing fee to Daiichi Sankyo. Under the Daiichi Sankyo Agreement, Daiichi Sankyo is also eligible to receive future development, regulatory and sales milestone payments, as well as royalties related to IMU-856.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock', window );">General and Administrative Expenses</a></td>
<td class="text"><div style="margin-top:18pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative Expenses</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses consist primarily of salaries and related costs for personnel in executive, finance, business development and other support functions. Other general and administrative expenses include, but are not limited to, stock-based compensation, insurance costs, professional fees for legal, accounting and tax services, consulting, related facility costs and travel.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><div style="margin-top:18pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation&#160;</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures the cost of employee and non-employee services received in exchange for equity awards based on the grant-date fair value of the award recognized generally as an expense (i) on a straight-line basis over the requisite service period for those awards whose vesting is based upon a service condition, and (ii) on an accelerated method for awards whose vesting is based upon a performance condition, but only to the extent it is probable that the performance condition will be met. Stock-based compensation is (i) estimated at the date of grant based on the award&#8217;s fair value for equity classified awards and (ii) final measurement date for liability classified awards. Forfeitures are recorded in the period in which they occur.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates the fair value of stock options using the Black-Scholes-Merton option-pricing model ("BSM"), which requires the use of estimates and subjective assumptions, including the risk-free interest rate, the fair value of the underlying common stock, the expected dividend yield of the Company&#8217;s common stock, the expected volatility of the price of the Company&#8217;s common stock, and the expected term of the option. These estimates involve inherent uncertainties and the application of management&#8217;s judgment. If factors change and different assumptions are used, the Company&#8217;s stock-based compensation expense could be materially different in the future.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div style="margin-top:18pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:18pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company leases office space and office equipment. The underlying lease agreements have lease terms of less than 12 months and up to 60 months. Leases with terms of 12 months or less at inception are not included in the operating lease right of use asset and operating lease liability.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has two existing leases for office space. At inception of a lease agreement, the Company determines whether an agreement represents a lease and at commencement each lease agreement is assessed as to classification as an operating or financing lease. The Company's two leases have been classified as operating leases and an operating lease right-of-use asset and an operating lease liability have been recorded on the Company&#8217;s balance sheet. A right-of-use lease asset represents the Company&#8217;s right to use the underlying asset for the lease term and the lease obligation represents its commitment to make the lease payments arising from the lease. Right-of-use lease assets and obligations are recognized at the commencement date based on the present value of remaining lease payments over the lease term. As the Company&#8217;s leases do not provide an implicit rate, the Company has used an estimated incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. The right-of-use lease asset includes any lease payments made prior to commencement and excludes any lease incentives. The lease term used in estimating future lease payments may include options to extend when it is reasonably certain that the Company will exercise that option. Operating lease expense is recognized on a straight-line basis over the lease term, subject to any changes in the lease or changes in expectations regarding the lease term. Variable lease costs such as common area costs and property taxes are expensed as incurred. Leases with an initial term of twelve months or less are not recorded on the balance sheet.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Income (Loss)</a></td>
<td class="text"><div style="margin-top:18pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Income (Loss)</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive income (loss) is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. Accumulated other comprehensive income (loss) has been reflected as a separate component of stockholders&#8217; equity in the accompanying Consolidated Balance Sheets and consists of foreign currency translation adjustments (net of tax).</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="margin-top:18pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to corporate income tax laws and regulations in the U.S., Germany and Australia. Tax regulations within each jurisdiction are subject to the interpretation of the related tax laws and regulations and require significant judgment in their application.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company utilizes the asset and liability method of accounting for income taxes which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the audited consolidated financial statements. Deferred income tax assets and liabilities are determined based on the differences between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of changes in tax rates on deferred tax assets and liabilities is recognized in operations in the period that includes the enactment date. Deferred taxes are reduced by a valuation allowance when, in the opinion of management, it is more likely than not some portion or the entire deferred tax asset will not be realized.  As of September 30, 2022 and 2021, respectively, the Company maintained a full valuation allowance against the balance of deferred tax assets.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is the Company&#8217;s policy to provide for uncertain tax positions and the related interest and penalties based upon management&#8217;s assessment of whether a tax benefit is more likely than not to be sustained upon examination by tax authorities. The Company recognizes interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense.  The Company is subject to U.S. federal, New York, California, Texas, German and Australian income taxes. The Company is subject to U.S. federal or state income tax examination by tax authorities for tax returns filed for the years 2003 and forward due to the carryforward of NOLs. Tax years 2016 through 2021 are subject to audit by German and Australian tax authorities. The Company is not currently under examination by any tax jurisdictions.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss Per Share</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share attributable to common stockholders is calculated by dividing the net loss by the weighted-average number of common shares outstanding for the period, without consideration for common stock equivalents. Diluted net loss per share attributable to common stockholders is computed by dividing the net loss by the weighted-average number of common shares and, if dilutive, common stock equivalents outstanding for the period determined using the treasury-stock method. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company&#8217;s net loss position.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Issued and/or Adopted Accounting Standards</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued and/or Adopted Accounting Standards</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are no recently issued accounting standards that would have a significant impact on the company's consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementAccountingPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for collaborative arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementAccountingPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13279-108611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -URI https://asc.fasb.org/topic&amp;trid=2175825<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=2144439<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -URI https://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140075274741520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Potentially Dilutive Securities Not Included in Calculation of Diluted Net Loss per Share</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Potentially dilutive securities, not included in the calculation of diluted net loss per share attributable to common stockholders because to do so would be anti-dilutive, are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"><tr><td style="width:1.0%"/><td style="width:73.751%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.953%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.955%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,799,573&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,045,960&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140075278183360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Details (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock', window );">Schedule of Other Current Assets and Prepaid Expenses</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other Current Assets and Prepaid Expenses consist of (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.315%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.157%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.969%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.059%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid clinical and related costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,938&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,853&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">VAT receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">279&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Australian research and development tax incentive</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,150&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,871&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,549&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,122&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,878&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,125&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Schedule of Accounts Payable and Accrued Expenses</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts Payable consist of (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.046%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.969%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.474%"/><td style="width:0.1%"/></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,748&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,427&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legal and audit costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">310&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,172&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,745&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consist of (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.484%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued clinical and related costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,504&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,214&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued legal and audit costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">881&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">674&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,623&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,071&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCurrentLiabilitiesTableTextBlock', window );">Schedule of Other Current Liabilities</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other Current Liabilities consist of (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.469%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.527%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.912%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.740%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">395&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">408&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">324&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">719&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">585&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCurrentLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCurrentLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amounts of other current assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140075274654512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Maturities of Operating Lease Obligation</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of the operating lease obligation are as follows as of September 30, 2022 (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.660%"><tr><td style="width:1.0%"/><td style="width:84.079%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.596%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.925%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">528&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">454&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">227&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,378&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PV of obligation</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,274&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140075274751312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following fair value hierarchy tables present information about each major category of the Company&#8217;s financial assets and liabilities measured at fair value on a recurring basis (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"/><td style="width:50.888%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.092%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.830%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.092%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.830%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.240%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.830%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.098%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurement at September 30, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair&#160;Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level&#160;3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,471&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,471&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets at fair value</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,471&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,471&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"/><td style="width:50.888%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.092%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.830%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.092%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.830%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.240%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.830%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.098%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurement at Fair&#160;Value&#160;Measurement&#160;at&#160;December&#160;31,&#160;2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair&#160;Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level&#160;3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,630&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,630&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,630&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,630&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140075273366160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock', window );">Shares Reserved for Future Issuance</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares reserved for future issuance at September 30, 2022 are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:86.162%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.638%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of<br/>Shares</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock reserved for issuance for:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;2021 Employee stock Purchase Plan    </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162,630&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,799,573&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock options available for future grant:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2014 Equity Incentive Plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,311&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2017 Inducement Equity Incentive Plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019 Omnibus Equity Incentive Plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180,770&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total common shares reserved for future issuance</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,232,534&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Common Stock Reserved For Future Issuance [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140075274311568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation Plans (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Option Activity</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock option activity for the nine months ended September 30, 2022 and 2021, respectively, for the 2019 Plan:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.929%"><tr><td style="width:1.0%"/><td style="width:52.444%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.307%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.307%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.759%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.421%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term&#160;(Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of January 1, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,157,460&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.54&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,837,513&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.90&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(852)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.67&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited or expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(194,548)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.62&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of September 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,799,573&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.59</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,400&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options vested and expected to vest as of September 30, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,799,573&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.59</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,400&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercisable as of September 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,248,875&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.63&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.64</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.883%"><tr><td style="width:1.0%"/><td style="width:51.442%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.531%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.570%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.531%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.570%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.993%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.570%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.693%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term&#160;(Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of January 1, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,117,160&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.96&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,033,809&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.95&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited or expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(105,009)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of September 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,045,960&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.90&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.91</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,460&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options vested and expected to vest as of September 30, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,045,960&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.90&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.91</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,460&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercisable as of September 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">665,168&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.33</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,121&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Valuation Assumptions Used</a></td>
<td class="text">The following are the underlying assumptions used in the Black-Scholes-Merton option pricing model to determine the fair value of stock options granted to employees and to non-employees under this stock plan:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.812%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.445%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine  Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.04%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.88%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97.8%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92.4%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term of options (years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.00</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.95</span></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Stock-based Compensation Expense for Stock Awards Recognized</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total stock-based compensation expense for all stock awards recognized in the accompanying unaudited condensed consolidated statements of operations is as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.391%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.115%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.186%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months<br/>&#160;Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months<br/>&#160;Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">831,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">456,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,392,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,279,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,081,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">941,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,651,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,204,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,912,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,397,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,043,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,483,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140075265435152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business and Basis of Financial Statements (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">102 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Oct. 12, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($) </div>
<div>employee </div>
<div>program</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityNumberOfEmployees', window );">Number of employees | employee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_NumberOfDevelopmentProgramsPursued', window );">Number of development programs pursued | program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 260,806<span></span>
</td>
<td class="nump">$ 196,873<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 72,771<span></span>
</td>
<td class="nump">$ 86,863<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from issuance of private placement</a></td>
<td class="nump">$ 60,000<span></span>
</td>
<td class="nump">$ 355,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndFederalFundsSold', window );">Cash funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 56,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityNumberOfEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of persons employed by the Entity</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityNumberOfEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndFederalFundsSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of cash and cash equivalents plus Federal Funds Sold. Cash and cash equivalents consist of short term, highly liquid investments that are readily convertible to known amounts of cash and are so near their maturity that they present negligible risk of changes in value due to changes in interest rates -- usually with an original maturity less than 90 days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.1,2,3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndFederalFundsSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_NumberOfDevelopmentProgramsPursued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Development Programs Pursued</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_NumberOfDevelopmentProgramsPursued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140075269070976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="3">9 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Nov. 03, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>financialInstitution </div>
<div>lease</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_NumberOfFinancialInstitutionsUsedForCashDeposits', window );">Number of financial institutions used for cash deposits | financialInstitution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,000<span></span>
</td>
<td class="nump">$ 16,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 58,000<span></span>
</td>
<td class="nump">$ 45,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TangibleAssetImpairmentCharges', window );">Impairment losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_LesseeOperatingLeasesNumberOfExistingLeases', window );">Number of existing leases | lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock at premium</a></td>
<td class="nump">$ 60,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember', window );">Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill Impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 33,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term (in months)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">13 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term (in months)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TangibleAssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The charge against earnings resulting from the aggregate write down of tangible assets from their carrying value to their fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2921-110230<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TangibleAssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_LesseeOperatingLeasesNumberOfExistingLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Leases, Number Of Existing Leases</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_LesseeOperatingLeasesNumberOfExistingLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_NumberOfFinancialInstitutionsUsedForCashDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of Financial Institutions Used For Cash Deposits</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_NumberOfFinancialInstitutionsUsedForCashDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140075272226064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Potentially Dilutive Securities Not Included in Calculation of Diluted Net Loss per Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember', window );">Options to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Options to purchase common stock ( in shares)</a></td>
<td class="nump">3,799,573<span></span>
</td>
<td class="nump">2,045,960<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140075272269616">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Details - Schedule of Other Current Assets and Prepaid Expenses (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_PrepaidClinicalAndRelatedCostsCurrent', window );">Prepaid clinical and related costs</a></td>
<td class="nump">$ 8,938<span></span>
</td>
<td class="nump">$ 14,853<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValueAddedTaxReceivableCurrent', window );">VAT receivable</a></td>
<td class="nump">241<span></span>
</td>
<td class="nump">279<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_ResearchAndDevelopmentTaxIncentiveCurrent', window );">Australian research and development tax incentive</a></td>
<td class="nump">3,150<span></span>
</td>
<td class="nump">1,871<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other</a></td>
<td class="nump">1,549<span></span>
</td>
<td class="nump">1,122<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Total</a></td>
<td class="nump">$ 13,878<span></span>
</td>
<td class="nump">$ 18,125<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValueAddedTaxReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of value added taxes due either from customers arising from sales on credit terms, or as previously overpaid to tax authorities. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValueAddedTaxReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_PrepaidClinicalAndRelatedCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid Clinical And Related Costs, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_PrepaidClinicalAndRelatedCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_ResearchAndDevelopmentTaxIncentiveCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research And Development Tax Incentive, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_ResearchAndDevelopmentTaxIncentiveCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140075272378656">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Details - Schedule of Accounts Payable (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_ClinicalCostsPayableCurrent', window );">Clinical costs</a></td>
<td class="nump">$ 3,748<span></span>
</td>
<td class="nump">$ 3,427<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_LegalAndAuditCostsPayableCurrent', window );">Legal and audit costs</a></td>
<td class="nump">114<span></span>
</td>
<td class="nump">72<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableOtherCurrent', window );">Other</a></td>
<td class="nump">310<span></span>
</td>
<td class="nump">246<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Total</a></td>
<td class="nump">$ 4,172<span></span>
</td>
<td class="nump">$ 3,745<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableOtherCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligations incurred classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableOtherCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_ClinicalCostsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Clinical Costs Payable, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_ClinicalCostsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_LegalAndAuditCostsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Legal And Audit Costs Payable, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_LegalAndAuditCostsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140075265492192">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Details - Schedule of Accrued Expenses (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_AccruedClinicalCostsCurrent', window );">Accrued clinical and related costs</a></td>
<td class="nump">$ 5,504<span></span>
</td>
<td class="nump">$ 6,214<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_AccruedLegalAndAuditCostsCurrent', window );">Accrued legal and audit costs</a></td>
<td class="nump">85<span></span>
</td>
<td class="nump">96<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_AccruedCompensationCurrent', window );">Accrued compensation</a></td>
<td class="nump">881<span></span>
</td>
<td class="nump">674<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Accrued other</a></td>
<td class="nump">153<span></span>
</td>
<td class="nump">87<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total</a></td>
<td class="nump">$ 6,623<span></span>
</td>
<td class="nump">$ 7,071<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_AccruedClinicalCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Clinical Costs, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_AccruedClinicalCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_AccruedCompensationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Compensation, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_AccruedCompensationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_AccruedLegalAndAuditCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Legal And Audit Costs, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_AccruedLegalAndAuditCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140075274167584">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Details - Schedule of Other Current Liabilities (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Lease liabilities</a></td>
<td class="nump">$ 395<span></span>
</td>
<td class="nump">$ 408<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherSundryLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">324<span></span>
</td>
<td class="nump">177<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Total</a></td>
<td class="nump">$ 719<span></span>
</td>
<td class="nump">$ 585<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherSundryLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Obligations not otherwise itemized or categorized in the footnotes to the financial statements that are due within one year or operating cycle, if longer, from the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=99376301&amp;loc=d3e1243-112600<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherSundryLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140075273152816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 01, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>May 31, 2016</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Apr. 07, 2020</div></th>
<th class="th"><div>Apr. 12, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_OperatingLeaseIncrementalBorrowingRate', window );">Incremental borrowing rate on operating leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_OperatingAndVariableLeasesCost', window );">Operating and variable lease costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 232<span></span>
</td>
<td class="nump">$ 133<span></span>
</td>
<td class="nump">$ 498<span></span>
</td>
<td class="nump">$ 372<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Contractual obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_AssetPurchaseAgreementRoyaltiesAsPercentOfAggregatedNetSales', window );">Asset purchase agreement, royalties as percent of aggregated net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,564,995<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,564,995<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,335,418<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120,070<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_RoyaltySettlementAgreementSalesNet', window );">4SC Royalty Settlement (see Note 4)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 17,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=vtl_ImmunicAGMember', window );">Immunic AG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_AssetPurchaseAgreementRoyaltiesAsPercentOfAggregatedNetSales', window );">Asset purchase agreement, royalties as percent of aggregated net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_RoyaltySettlementAgreementSalesNet', window );">4SC Royalty Settlement (see Note 4)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_RoyaltySettlementAgreementCashPaymentPercent', window );">Royalty settlement agreement, cash payment, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_RoyaltySettlementAgreementSharesPaymentPercent', window );">Royalty settlement agreement, shares payment, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=vtl_GrafelfingGermanyMember', window );">Grafelfing, Germany</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_IncreaseDecreaseInOperatingLeaseRightOfUseAsset', window );">Additions to right-of-use assets</a></td>
<td class="nump">$ 642<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 435<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=vtl_NewYorkCityMember', window );">New York City</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_LesseeOperatingLeaseRentHolidayPeriod', window );">Rent holiday period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_AssetPurchaseAgreementRoyaltiesAsPercentOfAggregatedNetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Asset Purchase Agreement, Royalties As Percent Of Aggregated Net Sales</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_AssetPurchaseAgreementRoyaltiesAsPercentOfAggregatedNetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_IncreaseDecreaseInOperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Operating Lease, Right-Of-Use Asset</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_IncreaseDecreaseInOperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_LesseeOperatingLeaseRentHolidayPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Rent Holiday Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_LesseeOperatingLeaseRentHolidayPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_OperatingAndVariableLeasesCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating And Variable Leases, Cost</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_OperatingAndVariableLeasesCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_OperatingLeaseIncrementalBorrowingRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Incremental Borrowing Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_OperatingLeaseIncrementalBorrowingRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_RoyaltySettlementAgreementCashPaymentPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty Settlement Agreement, Cash Payment, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_RoyaltySettlementAgreementCashPaymentPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_RoyaltySettlementAgreementSalesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty Settlement Agreement, Sales Net</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_RoyaltySettlementAgreementSalesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_RoyaltySettlementAgreementSharesPaymentPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty Settlement Agreement, Shares Payment, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_RoyaltySettlementAgreementSharesPaymentPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=vtl_ImmunicAGMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=vtl_ImmunicAGMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=vtl_GrafelfingGermanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=vtl_GrafelfingGermanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=vtl_NewYorkCityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=vtl_NewYorkCityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140075266255632">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Maturities of Operating Lease Obligation (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2022</a></td>
<td class="nump">$ 169<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2023</a></td>
<td class="nump">528<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2024</a></td>
<td class="nump">454<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2025</a></td>
<td class="nump">227<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2026</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total</a></td>
<td class="nump">1,378<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Interest</a></td>
<td class="nump">104<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">PV of obligation</a></td>
<td class="nump">$ 1,274<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140075273325184">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value - Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - Fair Value, Measurements, Recurring - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets at fair value</a></td>
<td class="nump">$ 31,471<span></span>
</td>
<td class="nump">$ 31,630<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets at fair value</a></td>
<td class="nump">31,471<span></span>
</td>
<td class="nump">31,630<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets at fair value</a></td>
<td class="nump">31,471<span></span>
</td>
<td class="nump">31,630<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets at fair value</a></td>
<td class="nump">31,471<span></span>
</td>
<td class="nump">31,630<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level&#160;2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level&#160;2 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level&#160;3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level&#160;3 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets at fair value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140075268789824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock - Shelf Registration Statement (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($) </div>
<div>d</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($) </div>
<div>d </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 10, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 05, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 30, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration', window );">Maximum aggregate offering price of securities under shelf registration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock', window );">Commission, percent of gross proceeds from sale of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 130<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_ShelfRegistrationStatementAmountRemaining', window );">Shelf registration statement, amount remaining</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=vtl_December2020ATMMember', window );">December 2020 ATM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration', window );">Maximum aggregate offering price of securities under shelf registration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_ShelfRegistrationTerminationPriorWrittenNotice', window );">Shelf registration, termination, prior written notice | d</a></td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Shares issued (in shares)</a></td>
<td class="nump">$ 40,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,204,113<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_SharesIssuedWeightedAverageSharePricePerShare', window );">Issuance of stock (in USD per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from Issuance of Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 39,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForCommissions', window );">Underwriter commissions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=vtl_December2020ATMMember', window );">December 2020 ATM | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_SaleOfStockRemainingCapacity', window );">Sale of stock, remaining capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=vtl_May2022ATMMember', window );">May 2022 ATM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration', window );">Maximum aggregate offering price of securities under shelf registration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 80,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_ShelfRegistrationTerminationPriorWrittenNotice', window );">Shelf registration, termination, prior written notice | d</a></td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_SaleOfStockRemainingCapacity', window );">Sale of stock, remaining capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 80,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForCommissions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for commissions during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForCommissions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum Aggregate Offering Price Of Securities Under Shelf Registration</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_SaleOfStockRemainingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Remaining Capacity</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_SaleOfStockRemainingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_SharesIssuedWeightedAverageSharePricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares Issued, Weighted Average Share Price Per Share</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_SharesIssuedWeightedAverageSharePricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shelf Registration Agreement, Commission, Percent Of Gross Proceeds On Sale Of Common Stock</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_ShelfRegistrationStatementAmountRemaining">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shelf Registration Statement, Amount Remaining</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_ShelfRegistrationStatementAmountRemaining</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_ShelfRegistrationTerminationPriorWrittenNotice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shelf Registration, Termination, Prior Written Notice</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_ShelfRegistrationTerminationPriorWrittenNotice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=vtl_December2020ATMMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=vtl_December2020ATMMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=vtl_May2022ATMMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=vtl_May2022ATMMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140075273110576">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Common Stock - Public Equity Offering (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th"><div>Jul. 19, 2021</div></th>
<th class="th"><div>Jul. 15, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=vtl_July2021PublicEquityOfferingMember', window );">July 2021 Public Equity Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares issued in private placement transaction (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Proceeds from sale of stock</a></td>
<td class="nump">$ 42.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=vtl_July2021PublicEquityOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=vtl_July2021PublicEquityOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140075269137648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock - Common Stock (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">130,000,000<span></span>
</td>
<td class="nump">130,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in USD per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareDeclared', window );">Common stock, cash dividends declared (in USD per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareCashPaid', window );">Common stock, cash dividends paid (in USD per share)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDividendsPerShareCashPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends paid during the period for each share of common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDividendsPerShareCashPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDividendsPerShareDeclared">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends declared during the period for each share of common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDividendsPerShareDeclared</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140075274216672">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Common Stock - Preferred Stock (Details) - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">20,000,000<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in USD per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140075269124832">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Common Stock - Shares Reserved for Future Issuance (Details)<br></strong></div></th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total common shares reserved for future issuance (in shares)</a></td>
<td class="nump">4,232,534<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Outstanding stock options</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total common shares reserved for future issuance (in shares)</a></td>
<td class="nump">3,799,573<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=vtl_A2021EmployeeStockPurchasePlanMember', window );">2021 Employee stock Purchase Plan | Outstanding stock options</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total common shares reserved for future issuance (in shares)</a></td>
<td class="nump">162,630<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=vtl_TwoThousandFourteenEquityIncentivePlanMember', window );">2014 Equity Incentive Plan | Common stock options available for future grant:</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total common shares reserved for future issuance (in shares)</a></td>
<td class="nump">43,311<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=vtl_A2017InducementEquityIncentivePlanMember', window );">2017 Inducement Equity Incentive Plan | Common stock options available for future grant:</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total common shares reserved for future issuance (in shares)</a></td>
<td class="nump">46,250<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=vtl_TwoThousandNineteenOmnibusEquityIncentivePlanMember', window );">2019 Omnibus Equity Incentive Plan | Common stock options available for future grant:</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total common shares reserved for future issuance (in shares)</a></td>
<td class="nump">180,770<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=vtl_A2021EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=vtl_A2021EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=vtl_TwoThousandFourteenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=vtl_TwoThousandFourteenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=vtl_EmployeeStockOptionsforFutureGrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=vtl_EmployeeStockOptionsforFutureGrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=vtl_A2017InducementEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=vtl_A2017InducementEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=vtl_TwoThousandNineteenOmnibusEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=vtl_TwoThousandNineteenOmnibusEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140075265647024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation Plans - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="3">9 Months Ended</th>
<th class="th" colspan="1">17 Months Ended</th>
<th class="th" colspan="1">21 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 25, 2021</div></th>
<th class="th"><div>Jul. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield (as percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Total unrecognized compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Period over which compensation cost will be recognized (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 10 months 28 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=vtl_A2021EmployeeStockPurchasePlanMember', window );">2021 Employee stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent', window );">Maximum annual contributions per employee (as a percent)</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate', window );">Purchase price of the stock, at discount from market price at purchase date (as a percent)</a></td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">RSUs granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,612<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,612<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,370<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,000<span></span>
</td>
<td class="nump">$ 18,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 74,000<span></span>
</td>
<td class="nump">$ 18,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=vtl_A2019OmnibusEquityIncentivePlanMember', window );">2019 Omnibus Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term of options (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">5 years 11 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield (as percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Options granted in period, weighted-average grant date fair value (in USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.94<span></span>
</td>
<td class="nump">$ 11.14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=vtl_A2019OmnibusEquityIncentivePlanMember', window );">2019 Omnibus Equity Incentive Plan | Incentive stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=vtl_A2019OmnibusEquityIncentivePlanMember', window );">2019 Omnibus Equity Incentive Plan | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term of options (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=vtl_A2019OmnibusEquityIncentivePlanMember', window );">2019 Omnibus Equity Incentive Plan | Maximum | Non-statutory options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=vtl_A2019OmnibusEquityIncentivePlanMember', window );">2019 Omnibus Equity Incentive Plan | Minimum | Non-statutory options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=vtl_TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember', window );">2019 Omnibus Equity Incentive Plan, Evergreen Provision</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent', window );">Additional shares authorized, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Additional shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,481,195<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=vtl_TwoThousandFourteenEquityIncentivePlanMember', window );">2014 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,311<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,311<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,311<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=vtl_A2017InducementEquityIncentivePlanMember', window );">2017 Inducement Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46,250<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discount rate from fair value on purchase date that participants pay for shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement By Share-Based Payment Award, Additional Shares Authorized, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=vtl_A2021EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=vtl_A2021EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=vtl_A2019OmnibusEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=vtl_A2019OmnibusEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=vtl_IncentiveEmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=vtl_IncentiveEmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=vtl_NonStatutoryEmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=vtl_NonStatutoryEmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=vtl_TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=vtl_TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=vtl_TwoThousandFourteenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=vtl_TwoThousandFourteenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=vtl_A2017InducementEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=vtl_A2017InducementEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140075273333520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation Plans - Summary of Stock Option Activity (Details) - 2019 Omnibus Equity Incentive Plan - Outstanding stock options - USD ($)<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, beginning balance (in shares)</a></td>
<td class="nump">2,157,460<span></span>
</td>
<td class="nump">1,117,160<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">1,837,513<span></span>
</td>
<td class="nump">1,033,809<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="num">(852)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Forfeited or expired (in shares)</a></td>
<td class="num">(194,548)<span></span>
</td>
<td class="num">(105,009)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, ending balance (in shares)</a></td>
<td class="nump">3,799,573<span></span>
</td>
<td class="nump">2,045,960<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Options vested and expected to vest, ending balance (in shares)</a></td>
<td class="nump">3,799,573<span></span>
</td>
<td class="nump">2,045,960<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options exercisable, ending balance (in shares)</a></td>
<td class="nump">1,248,875<span></span>
</td>
<td class="nump">665,168<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted- Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, beginning balance (usd per share)</a></td>
<td class="nump">$ 13.54<span></span>
</td>
<td class="nump">$ 12.96<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (usd per share)</a></td>
<td class="nump">8.90<span></span>
</td>
<td class="nump">14.95<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (usd per share)</a></td>
<td class="nump">5.67<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Forfeited or expired (usd per share)</a></td>
<td class="nump">11.62<span></span>
</td>
<td class="nump">14.32<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, ending balance (usd per share)</a></td>
<td class="nump">11.40<span></span>
</td>
<td class="nump">13.90<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Options vested and expected to vest, weighted-average exercise price, ending balance (usd per share)</a></td>
<td class="nump">11.40<span></span>
</td>
<td class="nump">13.90<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Options exercisable, weighted-average exercise price, ending balance (usd per share)</a></td>
<td class="nump">$ 13.63<span></span>
</td>
<td class="nump">$ 13.39<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Other Disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding, Weighted-Average Remaining Contractual Term, Ending balance</a></td>
<td class="text">8 years 7 months 2 days<span></span>
</td>
<td class="text">8 years 10 months 28 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Options vested and expected to vest , Weighted-Average Remaining Contractual Term, Ending balance</a></td>
<td class="text">8 years 7 months 2 days<span></span>
</td>
<td class="text">8 years 10 months 28 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Options exercisable, Weighted-Average Remaining Contractual Term, Ending balance</a></td>
<td class="text">7 years 7 months 20 days<span></span>
</td>
<td class="text">8 years 3 months 29 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding, Aggregate Intrinsic Value, Ending balance</a></td>
<td class="nump">$ 2,400<span></span>
</td>
<td class="nump">$ 74,460<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Options vested and expected to vest , Aggregate Intrinsic Value, Ending balance</a></td>
<td class="nump">2,400<span></span>
</td>
<td class="nump">74,460<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Options exercisable, Aggregate Intrinsic Value, Ending balance</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 43,121<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=vtl_TwoThousandNineteenOmnibusEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=vtl_TwoThousandNineteenOmnibusEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140075269114208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation Plans - Ranges of Underlying Assumptions Used in BSM Option Pricing Model to Determine Fair Value of Stock Options Granted to Employees and Nonemployees (Detail)<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield (as percent)</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=vtl_A2019OmnibusEquityIncentivePlanMember', window );">2019 Omnibus Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate (as percent)</a></td>
<td class="nump">2.04%<span></span>
</td>
<td class="nump">0.88%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield (as percent)</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility (as percent)</a></td>
<td class="nump">97.80%<span></span>
</td>
<td class="nump">92.40%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term of options (years)</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">5 years 11 months 12 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=vtl_A2019OmnibusEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=vtl_A2019OmnibusEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140075273195888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation Plans - Schedule of Stock-based Compensation Expense for Stock Awards Recognized (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,043<span></span>
</td>
<td class="nump">$ 4,483<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=vtl_EmployeeMember', window );">Employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 1,912,000<span></span>
</td>
<td class="nump">$ 1,397,000<span></span>
</td>
<td class="nump">6,043,000<span></span>
</td>
<td class="nump">4,483,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=vtl_EmployeeMember', window );">Employees | Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">831,000<span></span>
</td>
<td class="nump">456,000<span></span>
</td>
<td class="nump">2,392,000<span></span>
</td>
<td class="nump">1,279,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=vtl_EmployeeMember', window );">Employees | General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 1,081,000<span></span>
</td>
<td class="nump">$ 941,000<span></span>
</td>
<td class="nump">$ 3,651,000<span></span>
</td>
<td class="nump">$ 3,204,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=vtl_EmployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=vtl_EmployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140075269244128">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Changes in Board of Directors (Details) - Director<br> shares in Thousands</strong></div></th>
<th class="th">
<div>Jul. 06, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">30<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Options granted in period, weighted-average grant date fair value (in USD per share) | $ / shares</a></td>
<td class="nump">$ 4.30<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_DirectorMember', window );">Options Vesting In One Year</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period (in years)</a></td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_DirectorMember', window );">Options Vesting In Three Years</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period (in years)</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=vtl_OptionsVestingInOneYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=vtl_OptionsVestingInOneYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=vtl_OptionsVestingInThreeYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=vtl_OptionsVestingInThreeYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140075273060976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions - Additional Information (Details) - Executive Chairman Agreement - Affiliated Entity - Duane Nash, MD, JD, MBA - Board of Directors Chairman - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">4 Months Ended</th>
<th class="th" colspan="1">8 Months Ended</th>
<th class="th" colspan="1">10 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 15, 2022</div></th>
<th class="th"><div>Apr. 15, 2021</div></th>
<th class="th"><div>May 14, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">75,000<span></span>
</td>
<td class="nump">90,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_SalaryCostsMonthlyBaseSalary', window );">Monthly base salary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,417<span></span>
</td>
<td class="nump">$ 27,960<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=vtl_ExecutiveChairmanAgreementMember', window );">Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_SalaryCostsMonthlyBaseSalary', window );">Monthly base salary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29,358<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_SalaryCostsMonthlyBaseSalary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Salary Costs, Monthly Base Salary</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_SalaryCostsMonthlyBaseSalary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=vtl_ExecutiveChairmanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=vtl_ExecutiveChairmanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=vtl_DuaneNashMDJDMBAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=vtl_DuaneNashMDJDMBAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_BoardOfDirectorsChairmanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_BoardOfDirectorsChairmanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140075271841216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">102 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 12, 2022</div></th>
<th class="th"><div>Oct. 10, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Oct. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember', window );">Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill Impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 33.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from issuance of private placement</a></td>
<td class="nump">$ 60.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 355.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares issued in private placement transaction (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,696,552<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price (in USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_EquityMethodInvestmentWarrantsExercisableOwnershipLimitationPercentage', window );">May not exercise of percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=vtl_PreFundedWarrantsMember', window );">Pre-Funded Warrants | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares issued in private placement transaction (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,096,552<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price (in USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_EquityMethodInvestmentWarrantsExercisableOwnershipLimitationMaximumIncreaseDecreasePercent', window );">Increase or decrease not in excess of percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_EquityMethodInvestmentWarrantsExercisableSharesChangeLimitationNoticePeriod', window );">Increase or decrease not In excess of prior notice period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">61 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_EquityMethodInvestmentWarrantsExercisableOwnershipLimitationMaximumIncreaseDecreasePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investment, Warrants, Exercisable Ownership Limitation, Maximum Increase (Decrease), Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_EquityMethodInvestmentWarrantsExercisableOwnershipLimitationMaximumIncreaseDecreasePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_EquityMethodInvestmentWarrantsExercisableOwnershipLimitationPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investment, Warrants, Exercisable Ownership Limitation, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_EquityMethodInvestmentWarrantsExercisableOwnershipLimitationPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_EquityMethodInvestmentWarrantsExercisableSharesChangeLimitationNoticePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investment, Warrants, Exercisable Shares Change Limitation, Notice Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_EquityMethodInvestmentWarrantsExercisableSharesChangeLimitationNoticePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=vtl_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=vtl_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>vtl-20220930_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:vtl="http://vitaltherapies.com/20220930"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="vtl-20220930.xsd" xlink:type="simple"/>
    <context id="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i47193a7aeac443c69053141ff75cc655_I20221028">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
        </entity>
        <period>
            <instant>2022-10-28</instant>
        </period>
    </context>
    <context id="ib2ba0b84078f4de2bc3079e992921b92_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i12246a01749f40d394a9437cb9938c91_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i25a8ea2d7c9f4bfd8f72223c8ac18c65_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ib52579de36d54242a791b9e3f8019a00_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i69e8bcaae5bf44c9a03cf7f5bd08e6b8_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i10cadb43ee4f4d5983a19400b011767c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i009a2206cca94447b0821da5d321afd8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i385e3bff38de43c684e65b2b3be869c2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3f4fa8cb61dc4846bc63aadbbe138fd4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ida6ee8360c724bafba15cd5fadf3f86c_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="icd575a0576f94d6abe3a754e65a57231_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i5bfbb29080414e03b068322088956131_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i833e88d808f64f8db575748a84d92e85_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i5521d4c179a3424b8300e7e1aa3bb508_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i48e85fbb9eaf443d833e5d74dad1457f_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i85e99d9786824edc9811205ccff0e2c1_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="if0fe92136184445b9b403e48c306c7a0_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i37699bd784b74eff9b8044aa3d0f82c7_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i695cece83a314ed69b003d1805aa445f_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i9f48eb2e56ec4c62bea71dbf94048968_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i70f7507e4b224e59ba619f034e88a2d9_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i85803ab216eb4675941bdbd496da6ed9_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i737e66e4d7604e7294bf339bc188faf1_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i8ff3b5d8c53f48e598eabdf159ffe5a8_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i2e65e2ba034b476992065fd432154ff5_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="iff0dfca8fc4744b889817f531d94648d_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i1888877c44594a0cbbf03d306681d074_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i22a1a97b6019485d898b3ada299277d4_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i0620912ded354506af6d332f0bc83206_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i1d21953862a4496690291cb9fd6c7a94_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i8e38d9d8fc034a00a625f8563c6b5b60_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="iafd4cef3856c4625a9d0b5d421a2c12c_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="idb62eb795df54275a27ebfed4e80d684_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ib052a6f4a0df4d008a91d46f1ee57c9c_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i1fd2b9d5dc8348c987bb258a78754f1b_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i0c6bb7a44c4b41a48b75959b450bca0a_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="if2f7ecfa268042c1b6d8341deccf977e_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i866042db0ec3492ab88b30fc3d7eb0bf_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i5b62286d567e4f259000b5a1b4c2dbbe_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i8b90293a84aa4674a7bcf0617b17717e_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="icbddd86c41c74f1ea8d5a18c99ee0215_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i854438f7be7f47f196c8a2c22e9b5e77_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i607bec8e45eb4e6d838d65f04d1d719f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if567f5fc4bef457ba7f7d0fa94a8a6ef_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iea3035acf49d4db7a54e9ead049bc20b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i77530ee1861747fda1f023dbac2a8d90_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib8e90b6ab1f24717b294f892b4a059b4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i26792f62773c456c934cf59dcefb4260_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i7eb4374d1ee742ffa761b98e61b09caf_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ie46dbf54043c469594e16cf8b3942872_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i26d6ec96c4a24603b58ef52fcbe09dbe_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="iff342baa477241189847103920c9390b_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:A4SCRoyaltySettlementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i79dafe91dc2b4583bc7281b9ac581921_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:A4SCRoyaltySettlementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i47c50e6a28d840f58afe00251ea7cb63_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:A4SCRoyaltySettlementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ic1b52eb993194bc79abd0bdb3ac2fb16_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i1e4e96801dd14e038268468354ac544d_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i36785e9a44f44fa498d7a9e39d281de6_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="id8c73d5dc8b3435d90082da759d26561_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ie158d385723a4b6c94e8384571358a19_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="iec8caa356ace43cea23a50885d4ce99a_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="idbd4b40aa73a4833999ce49448a575c1_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i727b0a04077a4a8f8ed3d895673d106c_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i4fcf02a24eb5413182bd309637981b5f_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i3be90c8090ab461c8c2b38fd4278056a_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ia452dd2fae424bb3853dcf4cf9a6a5f7_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i3af9d520bc33490fb02d4e0e45e64528_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i7cf65f44be454209a8ed367a2d506669_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i016c5728112e4750b50b637d6c871fe3_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i72dd476a4160417bb81e51d19d04fec4_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i39aae3cf38724522a40a6fc4e3254d97_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ie8f986adcd0d4adb96a54c85ecec772d_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i75df6ae240184d6cbec2048c440c2cfd_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:July2021EquityIssuanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i5876ecf1449d4c42a057445d55680cd9_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:July2021EquityIssuanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i1c0c6c63355f4b9f94038593d420a3b7_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:July2021EquityIssuanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i8803b9920af74191be48fe8d2de93d42_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ic6c0192051924752911d006055eb26b5_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i53b949b08f1f4426aa11fcca407bc625_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ib7a3b6923515465ba7ed8a9c9f8c50a2_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i1c5dd6f726174024bdc176efa6738fd9_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i3d48326594df4b61bdc5572faf307bb8_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i9ea948d1a371446296c8cfe8ac8d3534_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="if312c4804f8b4c99a0562a9d7368b18e_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:July2021PublicEquityOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="iefba5660e6154047a65570c20050a670_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:July2021PublicEquityOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="id96591a4131743fabd2bef215e14e27d_D20140417-20221031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-04-17</startDate>
            <endDate>2022-10-31</endDate>
        </period>
    </context>
    <context id="ied30ae8dfbe54606808411695b6e7a4d_I20221031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-31</instant>
        </period>
    </context>
    <context id="ia09dc4bf851844ccaa07c02cfa96d7c3_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i946f069c215c45208da865ab19d790c4_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="iceee2385dd3a4cafb879b0088a931d62_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="id906393de2c04b61842e3087515a35aa_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i0635b165f76f479694e7564645ca75f5_D20221001-20221103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-11-03</endDate>
        </period>
    </context>
    <context id="ic5a53880f9da458c8abd6926ff69ddd8_D20221001-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ib99098d9e41b4f74a0e5c17f2558443e_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ic3f8af6eaf2d4e90a82b6ef6ea30ec32_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ic3a03035d5534d539979b07aedea62c1_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="id8129f471bae49039a917f1451ac8087_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iefd1980314f44440b5198657ab592ad5_I20200407">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">vtl:GrafelfingGermanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-07</instant>
        </period>
    </context>
    <context id="id2f24df2744547978cca7abe63d3ddfa_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">vtl:NewYorkCityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i707a1cd4886c4397999788b4d4817cc8_D20210301-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">vtl:GrafelfingGermanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i23801a5cc9424606a18bc0c74d94ebc9_D20220801-20220801">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">vtl:GrafelfingGermanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-01</endDate>
        </period>
    </context>
    <context id="i85fd4b228c8e4e22aa84564d8a1092a4_D20160501-20160531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
        </entity>
        <period>
            <startDate>2016-05-01</startDate>
            <endDate>2016-05-31</endDate>
        </period>
    </context>
    <context id="i13be27ffd0404758995be06dca534f38_I20190412">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
        </entity>
        <period>
            <instant>2019-04-12</instant>
        </period>
    </context>
    <context id="i7ce199652934499fa56ce12df1fabbef_D20210331-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">vtl:ImmunicAGMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-31</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i42d359c425714cf8b47c82373a440814_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">vtl:ImmunicAGMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ia5d5d1c95a774f429ad29d595bac0585_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i8e0b1222c30b4269aa3c56e6ebee8dc4_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="idc57905cd80143b29ea902574f63d2e8_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="if643e711815d4b749376bea335780421_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i5a48bc4ae7d7408f97f6eeb1dca78e8b_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ib3b80cda8b6f452eb05a40cc72183236_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="iecbaf68de7c649b39d49d2cd525bbdaf_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i5815b7ec2c4048eaa79c592705f78a05_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i026a14121f5e41e6b31d1f3647017fab_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i66caad9103ff476d8d79ca94f9ff9ca7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i26c3332665024e968525d075f51dd2c3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ieb7c3038fa504039b4299ec811876236_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7c78af0997974f8888e346839bbbb526_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ieeee9cf1b4db4ae799c2820e753b57d4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibbf0f0e07da94302ac3cd78120a72738_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic2d55028ecbe47369972c9dc27a4983b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i452fc01435184aa6b440569b104a7b6a_I20201130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
        </entity>
        <period>
            <instant>2020-11-30</instant>
        </period>
    </context>
    <context id="i37de57482ffb4464ab59f455ab94a18c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:December2020ATMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2867d1aebe414721a791386480b70c8f_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:December2020ATMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ia9434666be04407c90f384a6f8cee2f8_I20221031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:December2020ATMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-31</instant>
        </period>
    </context>
    <context id="i731d9157c77642cf8b53fdb984854e80_I20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:May2022ATMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-10</instant>
        </period>
    </context>
    <context id="ie383b6c67b2d4562a2b5fa326cbe5000_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:May2022ATMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i9843b826ca9942c9abbeb49451438b66_I20220505">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:May2022ATMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-05</instant>
        </period>
    </context>
    <context id="ic64d3d20dd7f42ebab0773713f0e2f62_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:December2020ATMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i13dc9f1a4e524f93b1138a442b35c8d0_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:December2020ATMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="id7f3ba2151e24a8694efe8eededbb089_D20210715-20210715">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:July2021PublicEquityOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-15</startDate>
            <endDate>2021-07-15</endDate>
        </period>
    </context>
    <context id="i837eb6ff329b46d1b9063702464b7004_I20210715">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:July2021PublicEquityOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-15</instant>
        </period>
    </context>
    <context id="ic1deecff015c411d9b86fcc68ba1683c_D20210719-20210719">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:July2021PublicEquityOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-19</startDate>
            <endDate>2021-07-19</endDate>
        </period>
    </context>
    <context id="iee6bdacd518b494c838da43db583331a_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2021EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ica07e01c9d0f47a59cbaee95aef0d158_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i8d6a85cd1f8b48108c4b2aac7ded4bf3_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vtl:EmployeeStockOptionsforFutureGrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:TwoThousandFourteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i66a3a4fa022d420ebf30bfd5b338b14a_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vtl:EmployeeStockOptionsforFutureGrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2017InducementEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i4b8e8ab0f2aa4d60b8640f5f1ddff361_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vtl:EmployeeStockOptionsforFutureGrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:TwoThousandNineteenOmnibusEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ic696ef9959af49cdbf3fd974759bd0bc_D20210425-20210425">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2021EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-25</startDate>
            <endDate>2021-04-25</endDate>
        </period>
    </context>
    <context id="i08aa60800326487fbf99175d815ab200_I20210425">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2021EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-25</instant>
        </period>
    </context>
    <context id="i6c48924db6c34718b6db57f2bcd38c0b_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2021EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ie7370ee1ee9943cdacd5aaf69e8a6815_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2021EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i2f6d9566f1a34310806423b83a871513_D20210425-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2021EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-25</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ib000cfab8d3c42d09670f1d425af5286_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2021EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i590665700dea49f8bbef5c2cd33f5ab6_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2021EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i0364a2ce088c4ade8ed67e8b0967db85_I20190731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2019OmnibusEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-07-31</instant>
        </period>
    </context>
    <context id="i97b48810b19f420aaff9dc7f71a98c22_D20190701-20190731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-07-31</endDate>
        </period>
    </context>
    <context id="if69ea9bc126c4fa5a73a13a32babfa2b_D20200101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="id40d762aabfc48f4a2944687c1be6b40_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2019OmnibusEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i8925c9f347c0462dafcba58c8ff77fc0_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vtl:IncentiveEmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2019OmnibusEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i8141d9aff5674330883906a3d1d82d52_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vtl:NonStatutoryEmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2019OmnibusEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="iaf64f27642a24cfd90a8b4b8fd99a4e3_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vtl:NonStatutoryEmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2019OmnibusEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i7f827301d88e484985fc3a70f1380d98_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:TwoThousandNineteenOmnibusEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i89cb4fe99d71444395e3fc22f0e7e477_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:TwoThousandNineteenOmnibusEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i33c46859f4e1425b90a6f987327175f6_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:TwoThousandNineteenOmnibusEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i1986a58a2c504c0b9c41f5d536a9502c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:TwoThousandNineteenOmnibusEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0c4254621dc64047a9c2d671aa842886_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:TwoThousandNineteenOmnibusEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i3fc8f323372c48c49a066aa56341ee03_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:TwoThousandNineteenOmnibusEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i491c0053bc5f4054a60885ff43fbbc87_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2019OmnibusEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i3b24c8dadaf44185922659d4e669111d_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2019OmnibusEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i65018cf301294210aa0bfac659e1638e_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vtl:EmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i0c3b29676a4440ad86911f00449ac95c_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vtl:EmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i51d6b668f708464ebb2ff34b8eee66d8_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vtl:EmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i83d76f6d51a84bfaaf85c435fc1d50f8_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vtl:EmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i9e6c05b057b542f6a6dc60098a6d004a_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vtl:EmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ifcca3d7bc3b04230b95c604feca1b658_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vtl:EmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i600a6a4da2a14932ac6ebff843b1dc82_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vtl:EmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ia17d3b4067d84bec848071ef0c64a422_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vtl:EmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i13791407fd49427ea3348fc4827a4293_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vtl:EmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ib938f3761273465cb69e3854e10882fd_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vtl:EmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i0c121149163740e0a14cb0c4c82c1e7a_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vtl:EmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i73bcd6c9a1664c7bbdd7d9ed12c94b42_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vtl:EmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i6e53bb714b6644b6844692585589b9a1_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:TwoThousandFourteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i84a3ff1a38eb4f16b75117d13dc1cdf2_I20170930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2017InducementEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-09-30</instant>
        </period>
    </context>
    <context id="if4028463febd40cfa3197e55e2ea9e63_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2017InducementEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i991eea4739be41089733f8422d8cbd37_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2017InducementEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i6197809d315e4cd680ef948f2e4723c8_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2017InducementEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i5d76381e3d7b4d5e846b0b465a4f3f9a_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2017InducementEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i0b4e3048cb3144a99e1401eb94392689_D20220706-20220706">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-06</startDate>
            <endDate>2022-07-06</endDate>
        </period>
    </context>
    <context id="ifaeb8f92093c46299d0fff82d6b11f23_D20220706-20220706">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vtl:OptionsVestingInOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-06</startDate>
            <endDate>2022-07-06</endDate>
        </period>
    </context>
    <context id="ibb08e53d8ed6456987432dc116d4c52f_D20220706-20220706">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vtl:OptionsVestingInThreeYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-06</startDate>
            <endDate>2022-07-06</endDate>
        </period>
    </context>
    <context id="i7842ca3ec7d941b397d15eae864cf058_D20210415-20210415">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vtl:DuaneNashMDJDMBAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">vtl:ExecutiveChairmanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-15</startDate>
            <endDate>2021-04-15</endDate>
        </period>
    </context>
    <context id="i4e522a1cd2c5463883ece885e48da850_D20210515-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vtl:DuaneNashMDJDMBAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">vtl:ExecutiveChairmanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-15</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic77ff01be43a48cfa612a7cac5ec9de0_D20210101-20210514">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vtl:DuaneNashMDJDMBAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">vtl:ExecutiveChairmanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-05-14</endDate>
        </period>
    </context>
    <context id="i8af8b2227bd540f38b6dc794af632800_D20220315-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vtl:DuaneNashMDJDMBAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">vtl:ExecutiveChairmanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-15</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="iac9f9142fce04841b7cdeea2bfcabdb6_D20220315-20220315">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vtl:DuaneNashMDJDMBAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">vtl:ExecutiveChairmanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-15</startDate>
            <endDate>2022-03-15</endDate>
        </period>
    </context>
    <context id="id3d63a41fa5847168bff487d8106b2f5_D20221010-20221010">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-10</startDate>
            <endDate>2022-10-10</endDate>
        </period>
    </context>
    <context id="i04004da4d23642dd85e9052de2144a17_I20221010">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-10</instant>
        </period>
    </context>
    <context id="icc5700f8c4a44461ab5894f373a0d8ac_D20221010-20221010">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-10</startDate>
            <endDate>2022-10-10</endDate>
        </period>
    </context>
    <context id="i1910349757c84c67942eeea2127e5dc4_I20221010">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-10</instant>
        </period>
    </context>
    <context id="i4346a7f60eba4d42bfc2b801e8e1dc2b_D20221012-20221012">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-12</startDate>
            <endDate>2022-10-12</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="employee">
        <measure>vtl:employee</measure>
    </unit>
    <unit id="program">
        <measure>vtl:program</measure>
    </unit>
    <unit id="financialinstitution">
        <measure>vtl:financialInstitution</measure>
    </unit>
    <unit id="lease">
        <measure>vtl:lease</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="d">
        <measure>utr:D</measure>
    </unit>
    <dei:DocumentFiscalYearFocus
      contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80L2ZyYWc6ZmE4MGM5YTI1YTYzNGM3YWI0NmZmZTljMDQxZWE4ZjUvdGFibGU6NjI2OTVmM2ZlOTMzNDI0ZjlmNzdhMjAzYTdhMmM4NWYvdGFibGVyYW5nZTo2MjY5NWYzZmU5MzM0MjRmOWY3N2EyMDNhN2EyYzg1Zl8yLTEtMS0xLTMwNTAw_30266e45-0bbb-4bdd-91e2-77bc4fa443cb">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80L2ZyYWc6ZmE4MGM5YTI1YTYzNGM3YWI0NmZmZTljMDQxZWE4ZjUvdGFibGU6NjI2OTVmM2ZlOTMzNDI0ZjlmNzdhMjAzYTdhMmM4NWYvdGFibGVyYW5nZTo2MjY5NWYzZmU5MzM0MjRmOWY3N2EyMDNhN2EyYzg1Zl8zLTEtMS0xLTMwNTAw_d1182955-6aab-492f-a519-180c091b5527">Q3</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80L2ZyYWc6ZmE4MGM5YTI1YTYzNGM3YWI0NmZmZTljMDQxZWE4ZjUvdGFibGU6NjI2OTVmM2ZlOTMzNDI0ZjlmNzdhMjAzYTdhMmM4NWYvdGFibGVyYW5nZTo2MjY5NWYzZmU5MzM0MjRmOWY3N2EyMDNhN2EyYzg1Zl80LTEtMS0xLTMwNTAw_cc74a2a0-6508-464f-8bfd-206c4e2c4541">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate
      contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80L2ZyYWc6ZmE4MGM5YTI1YTYzNGM3YWI0NmZmZTljMDQxZWE4ZjUvdGV4dHJlZ2lvbjpmYTgwYzlhMjVhNjM0YzdhYjQ2ZmZlOWMwNDFlYThmNV8zOA_82a2040e-54d0-412a-8eac-5df3ebeaaf43">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:EntityCentralIndexKey
      contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80L2ZyYWc6ZmE4MGM5YTI1YTYzNGM3YWI0NmZmZTljMDQxZWE4ZjUvdGV4dHJlZ2lvbjpmYTgwYzlhMjVhNjM0YzdhYjQ2ZmZlOWMwNDFlYThmNV82Nw_e84f4836-bf68-4c86-8cda-6717abfe9daa">0001280776</dei:EntityCentralIndexKey>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="ia09dc4bf851844ccaa07c02cfa96d7c3_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8zNC9mcmFnOjZlNmZlYmNmYmQwYTRlNDE5NDE0ZWFhMGNlYTdjMWU2L3RleHRyZWdpb246NmU2ZmViY2ZiZDBhNGU0MTk0MTRlYWEwY2VhN2MxZTZfNDU2Mg_7c753206-cde1-40ce-856d-422289b6506b">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i8141d9aff5674330883906a3d1d82d52_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80OS9mcmFnOjlhN2M1MTczZGE1ZTQ5ZjViYTk4YWRiODZhZWYwOWJkL3RleHRyZWdpb246OWE3YzUxNzNkYTVlNDlmNWJhOThhZGI4NmFlZjA5YmRfNTQ5NzU1ODI1NDIw_e9f71a48-2105-4fda-bdd7-59ddc0e82852">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <dei:DocumentType
      contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xL2ZyYWc6M2NiYWU3NWQ5ZGUzNDc4OTgxZTg2MDFjYzE1NDg1ZDUvdGV4dHJlZ2lvbjozY2JhZTc1ZDlkZTM0Nzg5ODFlODYwMWNjMTU0ODVkNV84Mg_59d7e16c-70c1-4c4a-b82e-6515d0fcbc3a">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xL2ZyYWc6M2NiYWU3NWQ5ZGUzNDc4OTgxZTg2MDFjYzE1NDg1ZDUvdGFibGU6MjE1M2ZlMmEyODQyNDA4OGI2ZjU4NTIxOTU0NmRlNjkvdGFibGVyYW5nZToyMTUzZmUyYTI4NDI0MDg4YjZmNTg1MjE5NTQ2ZGU2OV8wLTAtMS0xLTMwNTAw_148c0911-ad3a-4ec1-837a-34166658293a">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xL2ZyYWc6M2NiYWU3NWQ5ZGUzNDc4OTgxZTg2MDFjYzE1NDg1ZDUvdGV4dHJlZ2lvbjozY2JhZTc1ZDlkZTM0Nzg5ODFlODYwMWNjMTU0ODVkNV8xMzA_79d086c3-2bc6-452b-ab35-7438c4a45264">2022-09-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xL2ZyYWc6M2NiYWU3NWQ5ZGUzNDc4OTgxZTg2MDFjYzE1NDg1ZDUvdGFibGU6YmJlMDFhNTg1ZTJiNDY3MzhlM2I3MmE4NjY4YmY3YTMvdGFibGVyYW5nZTpiYmUwMWE1ODVlMmI0NjczOGUzYjcyYTg2NjhiZjdhM18wLTAtMS0xLTMwNTAw_05c23095-d0bb-4376-80e2-49492ea69e23">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xL2ZyYWc6M2NiYWU3NWQ5ZGUzNDc4OTgxZTg2MDFjYzE1NDg1ZDUvdGV4dHJlZ2lvbjozY2JhZTc1ZDlkZTM0Nzg5ODFlODYwMWNjMTU0ODVkNV8yMzg_c6ca9b49-a169-439a-afea-fd18572efb93">001-36201</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xL2ZyYWc6M2NiYWU3NWQ5ZGUzNDc4OTgxZTg2MDFjYzE1NDg1ZDUvdGV4dHJlZ2lvbjozY2JhZTc1ZDlkZTM0Nzg5ODFlODYwMWNjMTU0ODVkNV8yNDM_f35652cd-e834-478b-9271-db73bb9dcf7e">Immunic, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xL2ZyYWc6M2NiYWU3NWQ5ZGUzNDc4OTgxZTg2MDFjYzE1NDg1ZDUvdGFibGU6MjljZGRhMTYyNGUxNDBiZWJlOGVmODk3NmEzMDUxN2IvdGFibGVyYW5nZToyOWNkZGExNjI0ZTE0MGJlYmU4ZWY4OTc2YTMwNTE3Yl8wLTAtMS0xLTMwNTAw_8d92a07a-20a5-4760-92af-5707e482d00c">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xL2ZyYWc6M2NiYWU3NWQ5ZGUzNDc4OTgxZTg2MDFjYzE1NDg1ZDUvdGFibGU6MjljZGRhMTYyNGUxNDBiZWJlOGVmODk3NmEzMDUxN2IvdGFibGVyYW5nZToyOWNkZGExNjI0ZTE0MGJlYmU4ZWY4OTc2YTMwNTE3Yl8wLTItMS0xLTMwNTAw_6d601f14-9ccb-4a01-ab85-b5d476d5f04d">56-2358443</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xL2ZyYWc6M2NiYWU3NWQ5ZGUzNDc4OTgxZTg2MDFjYzE1NDg1ZDUvdGFibGU6MjljZGRhMTYyNGUxNDBiZWJlOGVmODk3NmEzMDUxN2IvdGFibGVyYW5nZToyOWNkZGExNjI0ZTE0MGJlYmU4ZWY4OTc2YTMwNTE3Yl8zLTAtMS0xLTMwNTAw_ec8bb7a2-9364-4e7e-a5d8-60b6d5299a01">1200 Avenue of the Americas</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xL2ZyYWc6M2NiYWU3NWQ5ZGUzNDc4OTgxZTg2MDFjYzE1NDg1ZDUvdGFibGU6MjljZGRhMTYyNGUxNDBiZWJlOGVmODk3NmEzMDUxN2IvdGFibGVyYW5nZToyOWNkZGExNjI0ZTE0MGJlYmU4ZWY4OTc2YTMwNTE3Yl80LTAtMS0xLTMwNTAw_4b45fce2-c209-4f95-b896-d01d6ff80f0e">Suite 200</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xL2ZyYWc6M2NiYWU3NWQ5ZGUzNDc4OTgxZTg2MDFjYzE1NDg1ZDUvdGFibGU6MjljZGRhMTYyNGUxNDBiZWJlOGVmODk3NmEzMDUxN2IvdGFibGVyYW5nZToyOWNkZGExNjI0ZTE0MGJlYmU4ZWY4OTc2YTMwNTE3Yl81LTAtMS0xLTMwNTAw_a7095ba2-e79d-4a34-aaf1-18b5dc9381a9">New York,</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xL2ZyYWc6M2NiYWU3NWQ5ZGUzNDc4OTgxZTg2MDFjYzE1NDg1ZDUvdGFibGU6MjljZGRhMTYyNGUxNDBiZWJlOGVmODk3NmEzMDUxN2IvdGFibGVyYW5nZToyOWNkZGExNjI0ZTE0MGJlYmU4ZWY4OTc2YTMwNTE3Yl81LTEtMS0xLTMwNTAw_80c783e3-db01-4af5-ad3d-c57f68110f1a">NY</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xL2ZyYWc6M2NiYWU3NWQ5ZGUzNDc4OTgxZTg2MDFjYzE1NDg1ZDUvdGFibGU6MjljZGRhMTYyNGUxNDBiZWJlOGVmODk3NmEzMDUxN2IvdGFibGVyYW5nZToyOWNkZGExNjI0ZTE0MGJlYmU4ZWY4OTc2YTMwNTE3Yl81LTItMS0xLTMwNTAw_280ad49a-d72f-4c28-8696-4b07f36872aa">10036</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xL2ZyYWc6M2NiYWU3NWQ5ZGUzNDc4OTgxZTg2MDFjYzE1NDg1ZDUvdGV4dHJlZ2lvbjozY2JhZTc1ZDlkZTM0Nzg5ODFlODYwMWNjMTU0ODVkNV8xOTY1_7511a2c7-a14b-413d-864b-8784d1132f89">332</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xL2ZyYWc6M2NiYWU3NWQ5ZGUzNDc4OTgxZTg2MDFjYzE1NDg1ZDUvdGV4dHJlZ2lvbjozY2JhZTc1ZDlkZTM0Nzg5ODFlODYwMWNjMTU0ODVkNV8xOTY2_ab25996d-889f-450f-aa63-34715eef2f4c">255-9818</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xL2ZyYWc6M2NiYWU3NWQ5ZGUzNDc4OTgxZTg2MDFjYzE1NDg1ZDUvdGFibGU6OTk2MTk5Y2Q1NDg3NDg2MGE5Mzg0NGQxNmMzZTdhYWMvdGFibGVyYW5nZTo5OTYxOTljZDU0ODc0ODYwYTkzODQ0ZDE2YzNlN2FhY18xLTAtMS0xLTMwNTAw_b8e930ad-be58-4f75-9747-9a4aaec308f1">Common Stock, $0.0001 par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xL2ZyYWc6M2NiYWU3NWQ5ZGUzNDc4OTgxZTg2MDFjYzE1NDg1ZDUvdGFibGU6OTk2MTk5Y2Q1NDg3NDg2MGE5Mzg0NGQxNmMzZTdhYWMvdGFibGVyYW5nZTo5OTYxOTljZDU0ODc0ODYwYTkzODQ0ZDE2YzNlN2FhY18xLTEtMS0xLTMwNTAw_663091a4-2780-4a73-bc46-3bc24203e6c2">IMUX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xL2ZyYWc6M2NiYWU3NWQ5ZGUzNDc4OTgxZTg2MDFjYzE1NDg1ZDUvdGFibGU6OTk2MTk5Y2Q1NDg3NDg2MGE5Mzg0NGQxNmMzZTdhYWMvdGFibGVyYW5nZTo5OTYxOTljZDU0ODc0ODYwYTkzODQ0ZDE2YzNlN2FhY18xLTItMS0xLTMwNTAw_e1d8621b-b667-400e-9a36-52d7017272d1">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xL2ZyYWc6M2NiYWU3NWQ5ZGUzNDc4OTgxZTg2MDFjYzE1NDg1ZDUvdGV4dHJlZ2lvbjozY2JhZTc1ZDlkZTM0Nzg5ODFlODYwMWNjMTU0ODVkNV83ODc_cd78f4a8-70e5-4ff4-9d43-fc2266b35612">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xL2ZyYWc6M2NiYWU3NWQ5ZGUzNDc4OTgxZTg2MDFjYzE1NDg1ZDUvdGV4dHJlZ2lvbjozY2JhZTc1ZDlkZTM0Nzg5ODFlODYwMWNjMTU0ODVkNV8xMTI0_e7529060-6bbe-424d-8edc-6672e9f84b93">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xL2ZyYWc6M2NiYWU3NWQ5ZGUzNDc4OTgxZTg2MDFjYzE1NDg1ZDUvdGFibGU6ZGIzYmU2YmMwMjE0NGI4NmE5NDYyYzdlZWRkMDY4OTYvdGFibGVyYW5nZTpkYjNiZTZiYzAyMTQ0Yjg2YTk0NjJjN2VlZGQwNjg5Nl8yLTAtMS0xLTMwNTAw_2955a591-2aa8-4e06-aa4b-d7316365d3e8">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xL2ZyYWc6M2NiYWU3NWQ5ZGUzNDc4OTgxZTg2MDFjYzE1NDg1ZDUvdGFibGU6ZGIzYmU2YmMwMjE0NGI4NmE5NDYyYzdlZWRkMDY4OTYvdGFibGVyYW5nZTpkYjNiZTZiYzAyMTQ0Yjg2YTk0NjJjN2VlZGQwNjg5Nl8yLTMtMS0xLTMwNTAw_e52a517b-2231-4dd6-8984-45cfb6ebb6dc">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xL2ZyYWc6M2NiYWU3NWQ5ZGUzNDc4OTgxZTg2MDFjYzE1NDg1ZDUvdGFibGU6ZGIzYmU2YmMwMjE0NGI4NmE5NDYyYzdlZWRkMDY4OTYvdGFibGVyYW5nZTpkYjNiZTZiYzAyMTQ0Yjg2YTk0NjJjN2VlZGQwNjg5Nl80LTMtMS0xLTMwNTAw_6b6fc215-2986-401c-9688-caa673e5ea75">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xL2ZyYWc6M2NiYWU3NWQ5ZGUzNDc4OTgxZTg2MDFjYzE1NDg1ZDUvdGV4dHJlZ2lvbjozY2JhZTc1ZDlkZTM0Nzg5ODFlODYwMWNjMTU0ODVkNV8xODY4_5efca3c4-b8ab-44aa-8d4f-983ac69d0652">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i47193a7aeac443c69053141ff75cc655_I20221028"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xL2ZyYWc6M2NiYWU3NWQ5ZGUzNDc4OTgxZTg2MDFjYzE1NDg1ZDUvdGV4dHJlZ2lvbjozY2JhZTc1ZDlkZTM0Nzg5ODFlODYwMWNjMTU0ODVkNV8xOTAx_37c4484a-70ba-48d3-9027-1784020eb423"
      unitRef="shares">39261547</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ib2ba0b84078f4de2bc3079e992921b92_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMC9mcmFnOjI3ZDM3ZTYwMzc3ODRlZTI5N2MzNDExNTk2NzI5YjJjL3RhYmxlOjk4ZGJlMzgxOWNiNTQxMDI5NjVjOTUzMmQwYWIyNzhlL3RhYmxlcmFuZ2U6OThkYmUzODE5Y2I1NDEwMjk2NWM5NTMyZDBhYjI3OGVfNC0xLTEtMS0zMDUwMA_1d68dede-e430-4cbc-b590-ee58a197ae38"
      unitRef="usd">72771000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i12246a01749f40d394a9437cb9938c91_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMC9mcmFnOjI3ZDM3ZTYwMzc3ODRlZTI5N2MzNDExNTk2NzI5YjJjL3RhYmxlOjk4ZGJlMzgxOWNiNTQxMDI5NjVjOTUzMmQwYWIyNzhlL3RhYmxlcmFuZ2U6OThkYmUzODE5Y2I1NDEwMjk2NWM5NTMyZDBhYjI3OGVfNC0zLTEtMS0zMDUwMA_b3e47a48-3079-4fd0-aae4-7a7218e68399"
      unitRef="usd">86863000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="ib2ba0b84078f4de2bc3079e992921b92_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMC9mcmFnOjI3ZDM3ZTYwMzc3ODRlZTI5N2MzNDExNTk2NzI5YjJjL3RhYmxlOjk4ZGJlMzgxOWNiNTQxMDI5NjVjOTUzMmQwYWIyNzhlL3RhYmxlcmFuZ2U6OThkYmUzODE5Y2I1NDEwMjk2NWM5NTMyZDBhYjI3OGVfNS0xLTEtMS0zMDUwMA_5770780f-73a2-48ab-94e7-d89ca3570658"
      unitRef="usd">13878000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i12246a01749f40d394a9437cb9938c91_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMC9mcmFnOjI3ZDM3ZTYwMzc3ODRlZTI5N2MzNDExNTk2NzI5YjJjL3RhYmxlOjk4ZGJlMzgxOWNiNTQxMDI5NjVjOTUzMmQwYWIyNzhlL3RhYmxlcmFuZ2U6OThkYmUzODE5Y2I1NDEwMjk2NWM5NTMyZDBhYjI3OGVfNS0zLTEtMS0zMDUwMA_7f6e7f19-fa36-4c87-b601-b257eb2d125c"
      unitRef="usd">18125000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="ib2ba0b84078f4de2bc3079e992921b92_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMC9mcmFnOjI3ZDM3ZTYwMzc3ODRlZTI5N2MzNDExNTk2NzI5YjJjL3RhYmxlOjk4ZGJlMzgxOWNiNTQxMDI5NjVjOTUzMmQwYWIyNzhlL3RhYmxlcmFuZ2U6OThkYmUzODE5Y2I1NDEwMjk2NWM5NTMyZDBhYjI3OGVfNi0xLTEtMS0zMDUwMA_af6ec076-7427-4ec5-9b95-aef7254082d1"
      unitRef="usd">86649000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i12246a01749f40d394a9437cb9938c91_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMC9mcmFnOjI3ZDM3ZTYwMzc3ODRlZTI5N2MzNDExNTk2NzI5YjJjL3RhYmxlOjk4ZGJlMzgxOWNiNTQxMDI5NjVjOTUzMmQwYWIyNzhlL3RhYmxlcmFuZ2U6OThkYmUzODE5Y2I1NDEwMjk2NWM5NTMyZDBhYjI3OGVfNi0zLTEtMS0zMDUwMA_69741c7a-60db-4a0d-99ef-2ee50603e217"
      unitRef="usd">104988000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ib2ba0b84078f4de2bc3079e992921b92_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMC9mcmFnOjI3ZDM3ZTYwMzc3ODRlZTI5N2MzNDExNTk2NzI5YjJjL3RhYmxlOjk4ZGJlMzgxOWNiNTQxMDI5NjVjOTUzMmQwYWIyNzhlL3RhYmxlcmFuZ2U6OThkYmUzODE5Y2I1NDEwMjk2NWM5NTMyZDBhYjI3OGVfNy0xLTEtMS0zMDUwMA_2e1910a5-ac71-413f-b21b-e7e26b54d1e3"
      unitRef="usd">159000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i12246a01749f40d394a9437cb9938c91_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMC9mcmFnOjI3ZDM3ZTYwMzc3ODRlZTI5N2MzNDExNTk2NzI5YjJjL3RhYmxlOjk4ZGJlMzgxOWNiNTQxMDI5NjVjOTUzMmQwYWIyNzhlL3RhYmxlcmFuZ2U6OThkYmUzODE5Y2I1NDEwMjk2NWM5NTMyZDBhYjI3OGVfNy0zLTEtMS0zMDUwMA_ac76fe07-2aac-467f-9fdb-53c0e268ae55"
      unitRef="usd">152000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Goodwill
      contextRef="ib2ba0b84078f4de2bc3079e992921b92_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMC9mcmFnOjI3ZDM3ZTYwMzc3ODRlZTI5N2MzNDExNTk2NzI5YjJjL3RhYmxlOjk4ZGJlMzgxOWNiNTQxMDI5NjVjOTUzMmQwYWIyNzhlL3RhYmxlcmFuZ2U6OThkYmUzODE5Y2I1NDEwMjk2NWM5NTMyZDBhYjI3OGVfOC0xLTEtMS0zMDUwMA_c59488e6-8e99-40bd-b8aa-f9c7b110223c"
      unitRef="usd">32970000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i12246a01749f40d394a9437cb9938c91_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMC9mcmFnOjI3ZDM3ZTYwMzc3ODRlZTI5N2MzNDExNTk2NzI5YjJjL3RhYmxlOjk4ZGJlMzgxOWNiNTQxMDI5NjVjOTUzMmQwYWIyNzhlL3RhYmxlcmFuZ2U6OThkYmUzODE5Y2I1NDEwMjk2NWM5NTMyZDBhYjI3OGVfOC0zLTEtMS0zMDUwMA_58c8bf16-3285-44bd-a718-4e369739159f"
      unitRef="usd">32970000</us-gaap:Goodwill>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ib2ba0b84078f4de2bc3079e992921b92_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMC9mcmFnOjI3ZDM3ZTYwMzc3ODRlZTI5N2MzNDExNTk2NzI5YjJjL3RhYmxlOjk4ZGJlMzgxOWNiNTQxMDI5NjVjOTUzMmQwYWIyNzhlL3RhYmxlcmFuZ2U6OThkYmUzODE5Y2I1NDEwMjk2NWM5NTMyZDBhYjI3OGVfOS0xLTEtMS0zMDUwMA_7c984c9a-0faf-4ac3-be9f-880d06045bd8"
      unitRef="usd">1263000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i12246a01749f40d394a9437cb9938c91_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMC9mcmFnOjI3ZDM3ZTYwMzc3ODRlZTI5N2MzNDExNTk2NzI5YjJjL3RhYmxlOjk4ZGJlMzgxOWNiNTQxMDI5NjVjOTUzMmQwYWIyNzhlL3RhYmxlcmFuZ2U6OThkYmUzODE5Y2I1NDEwMjk2NWM5NTMyZDBhYjI3OGVfOS0zLTEtMS0zMDUwMA_0eaa0ea5-c7bc-4a83-8d79-d1adc274b881"
      unitRef="usd">948000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ib2ba0b84078f4de2bc3079e992921b92_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMC9mcmFnOjI3ZDM3ZTYwMzc3ODRlZTI5N2MzNDExNTk2NzI5YjJjL3RhYmxlOjk4ZGJlMzgxOWNiNTQxMDI5NjVjOTUzMmQwYWIyNzhlL3RhYmxlcmFuZ2U6OThkYmUzODE5Y2I1NDEwMjk2NWM5NTMyZDBhYjI3OGVfMTAtMS0xLTEtMzA1MDA_9966dc1c-5bcc-4409-b2ac-46439222844c"
      unitRef="usd">42000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i12246a01749f40d394a9437cb9938c91_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMC9mcmFnOjI3ZDM3ZTYwMzc3ODRlZTI5N2MzNDExNTk2NzI5YjJjL3RhYmxlOjk4ZGJlMzgxOWNiNTQxMDI5NjVjOTUzMmQwYWIyNzhlL3RhYmxlcmFuZ2U6OThkYmUzODE5Y2I1NDEwMjk2NWM5NTMyZDBhYjI3OGVfMTAtMy0xLTEtMzA1MDA_83fd39a3-aa01-4035-909a-18552265f875"
      unitRef="usd">42000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="ib2ba0b84078f4de2bc3079e992921b92_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMC9mcmFnOjI3ZDM3ZTYwMzc3ODRlZTI5N2MzNDExNTk2NzI5YjJjL3RhYmxlOjk4ZGJlMzgxOWNiNTQxMDI5NjVjOTUzMmQwYWIyNzhlL3RhYmxlcmFuZ2U6OThkYmUzODE5Y2I1NDEwMjk2NWM5NTMyZDBhYjI3OGVfMTEtMS0xLTEtMzA1MDA_61865b2c-679e-4fda-87cd-96fb3c4add94"
      unitRef="usd">121083000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i12246a01749f40d394a9437cb9938c91_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMC9mcmFnOjI3ZDM3ZTYwMzc3ODRlZTI5N2MzNDExNTk2NzI5YjJjL3RhYmxlOjk4ZGJlMzgxOWNiNTQxMDI5NjVjOTUzMmQwYWIyNzhlL3RhYmxlcmFuZ2U6OThkYmUzODE5Y2I1NDEwMjk2NWM5NTMyZDBhYjI3OGVfMTEtMy0xLTEtMzA1MDA_c908a451-9991-4e26-bb7a-d663d676541c"
      unitRef="usd">139100000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="ib2ba0b84078f4de2bc3079e992921b92_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMC9mcmFnOjI3ZDM3ZTYwMzc3ODRlZTI5N2MzNDExNTk2NzI5YjJjL3RhYmxlOjk4ZGJlMzgxOWNiNTQxMDI5NjVjOTUzMmQwYWIyNzhlL3RhYmxlcmFuZ2U6OThkYmUzODE5Y2I1NDEwMjk2NWM5NTMyZDBhYjI3OGVfMTQtMS0xLTEtMzA1MDA_6691a322-4e9e-4d42-a4b2-bf6eba7e096a"
      unitRef="usd">4172000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i12246a01749f40d394a9437cb9938c91_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMC9mcmFnOjI3ZDM3ZTYwMzc3ODRlZTI5N2MzNDExNTk2NzI5YjJjL3RhYmxlOjk4ZGJlMzgxOWNiNTQxMDI5NjVjOTUzMmQwYWIyNzhlL3RhYmxlcmFuZ2U6OThkYmUzODE5Y2I1NDEwMjk2NWM5NTMyZDBhYjI3OGVfMTQtMy0xLTEtMzA1MDA_b551caec-64fe-442b-95af-3b80fd21dc4d"
      unitRef="usd">3745000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="ib2ba0b84078f4de2bc3079e992921b92_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMC9mcmFnOjI3ZDM3ZTYwMzc3ODRlZTI5N2MzNDExNTk2NzI5YjJjL3RhYmxlOjk4ZGJlMzgxOWNiNTQxMDI5NjVjOTUzMmQwYWIyNzhlL3RhYmxlcmFuZ2U6OThkYmUzODE5Y2I1NDEwMjk2NWM5NTMyZDBhYjI3OGVfMTUtMS0xLTEtMzA1MDA_3e77b0a7-af52-45e4-82a9-22e9294096af"
      unitRef="usd">6623000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i12246a01749f40d394a9437cb9938c91_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMC9mcmFnOjI3ZDM3ZTYwMzc3ODRlZTI5N2MzNDExNTk2NzI5YjJjL3RhYmxlOjk4ZGJlMzgxOWNiNTQxMDI5NjVjOTUzMmQwYWIyNzhlL3RhYmxlcmFuZ2U6OThkYmUzODE5Y2I1NDEwMjk2NWM5NTMyZDBhYjI3OGVfMTUtMy0xLTEtMzA1MDA_d8df8501-4ec6-466a-9aa8-10fee6a09903"
      unitRef="usd">7071000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="ib2ba0b84078f4de2bc3079e992921b92_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMC9mcmFnOjI3ZDM3ZTYwMzc3ODRlZTI5N2MzNDExNTk2NzI5YjJjL3RhYmxlOjk4ZGJlMzgxOWNiNTQxMDI5NjVjOTUzMmQwYWIyNzhlL3RhYmxlcmFuZ2U6OThkYmUzODE5Y2I1NDEwMjk2NWM5NTMyZDBhYjI3OGVfMTYtMS0xLTEtMzA1MDA_15600d3d-a834-41c9-b7fb-dadea07c6b0b"
      unitRef="usd">719000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i12246a01749f40d394a9437cb9938c91_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMC9mcmFnOjI3ZDM3ZTYwMzc3ODRlZTI5N2MzNDExNTk2NzI5YjJjL3RhYmxlOjk4ZGJlMzgxOWNiNTQxMDI5NjVjOTUzMmQwYWIyNzhlL3RhYmxlcmFuZ2U6OThkYmUzODE5Y2I1NDEwMjk2NWM5NTMyZDBhYjI3OGVfMTYtMy0xLTEtMzA1MDA_eb343cb0-7c45-465d-9eda-2dcbeff30ce6"
      unitRef="usd">585000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ib2ba0b84078f4de2bc3079e992921b92_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMC9mcmFnOjI3ZDM3ZTYwMzc3ODRlZTI5N2MzNDExNTk2NzI5YjJjL3RhYmxlOjk4ZGJlMzgxOWNiNTQxMDI5NjVjOTUzMmQwYWIyNzhlL3RhYmxlcmFuZ2U6OThkYmUzODE5Y2I1NDEwMjk2NWM5NTMyZDBhYjI3OGVfMTctMS0xLTEtMzA1MDA_1d32781c-0220-4966-95cf-f559c4ccc3b9"
      unitRef="usd">11514000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i12246a01749f40d394a9437cb9938c91_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMC9mcmFnOjI3ZDM3ZTYwMzc3ODRlZTI5N2MzNDExNTk2NzI5YjJjL3RhYmxlOjk4ZGJlMzgxOWNiNTQxMDI5NjVjOTUzMmQwYWIyNzhlL3RhYmxlcmFuZ2U6OThkYmUzODE5Y2I1NDEwMjk2NWM5NTMyZDBhYjI3OGVfMTctMy0xLTEtMzA1MDA_683f5358-4bc4-4f9c-a9cd-124c0f5ca402"
      unitRef="usd">11401000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ib2ba0b84078f4de2bc3079e992921b92_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMC9mcmFnOjI3ZDM3ZTYwMzc3ODRlZTI5N2MzNDExNTk2NzI5YjJjL3RhYmxlOjk4ZGJlMzgxOWNiNTQxMDI5NjVjOTUzMmQwYWIyNzhlL3RhYmxlcmFuZ2U6OThkYmUzODE5Y2I1NDEwMjk2NWM5NTMyZDBhYjI3OGVfMTktMS0xLTEtMzA1MDA_ac0093c3-aeba-4b91-9b4f-d5bb73870f21"
      unitRef="usd">759000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i12246a01749f40d394a9437cb9938c91_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMC9mcmFnOjI3ZDM3ZTYwMzc3ODRlZTI5N2MzNDExNTk2NzI5YjJjL3RhYmxlOjk4ZGJlMzgxOWNiNTQxMDI5NjVjOTUzMmQwYWIyNzhlL3RhYmxlcmFuZ2U6OThkYmUzODE5Y2I1NDEwMjk2NWM5NTMyZDBhYjI3OGVfMTktMy0xLTEtMzA1MDA_5d023fd8-0243-4c95-bb16-792d4401bb1c"
      unitRef="usd">584000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="ib2ba0b84078f4de2bc3079e992921b92_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMC9mcmFnOjI3ZDM3ZTYwMzc3ODRlZTI5N2MzNDExNTk2NzI5YjJjL3RhYmxlOjk4ZGJlMzgxOWNiNTQxMDI5NjVjOTUzMmQwYWIyNzhlL3RhYmxlcmFuZ2U6OThkYmUzODE5Y2I1NDEwMjk2NWM5NTMyZDBhYjI3OGVfMjAtMS0xLTEtMzA1MDA_9ef448d2-b86d-4620-a2aa-55d9b9f70180"
      unitRef="usd">759000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="i12246a01749f40d394a9437cb9938c91_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMC9mcmFnOjI3ZDM3ZTYwMzc3ODRlZTI5N2MzNDExNTk2NzI5YjJjL3RhYmxlOjk4ZGJlMzgxOWNiNTQxMDI5NjVjOTUzMmQwYWIyNzhlL3RhYmxlcmFuZ2U6OThkYmUzODE5Y2I1NDEwMjk2NWM5NTMyZDBhYjI3OGVfMjAtMy0xLTEtMzA1MDA_391c2a16-6566-48e1-98b1-7ede491e03e5"
      unitRef="usd">584000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="ib2ba0b84078f4de2bc3079e992921b92_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMC9mcmFnOjI3ZDM3ZTYwMzc3ODRlZTI5N2MzNDExNTk2NzI5YjJjL3RhYmxlOjk4ZGJlMzgxOWNiNTQxMDI5NjVjOTUzMmQwYWIyNzhlL3RhYmxlcmFuZ2U6OThkYmUzODE5Y2I1NDEwMjk2NWM5NTMyZDBhYjI3OGVfMjEtMS0xLTEtMzA1MDA_a1cfda26-338c-4f47-ba5a-f54196787e6b"
      unitRef="usd">12273000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i12246a01749f40d394a9437cb9938c91_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMC9mcmFnOjI3ZDM3ZTYwMzc3ODRlZTI5N2MzNDExNTk2NzI5YjJjL3RhYmxlOjk4ZGJlMzgxOWNiNTQxMDI5NjVjOTUzMmQwYWIyNzhlL3RhYmxlcmFuZ2U6OThkYmUzODE5Y2I1NDEwMjk2NWM5NTMyZDBhYjI3OGVfMjEtMy0xLTEtMzA1MDA_ae3e8622-33fa-41c3-8561-12d6884b96c1"
      unitRef="usd">11985000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="ib2ba0b84078f4de2bc3079e992921b92_I20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMC9mcmFnOjI3ZDM3ZTYwMzc3ODRlZTI5N2MzNDExNTk2NzI5YjJjL3RhYmxlOjk4ZGJlMzgxOWNiNTQxMDI5NjVjOTUzMmQwYWIyNzhlL3RhYmxlcmFuZ2U6OThkYmUzODE5Y2I1NDEwMjk2NWM5NTMyZDBhYjI3OGVfMjItMS0xLTEtMzA1MDA_460d53bf-0750-447a-87ff-5076bdc24122"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i12246a01749f40d394a9437cb9938c91_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMC9mcmFnOjI3ZDM3ZTYwMzc3ODRlZTI5N2MzNDExNTk2NzI5YjJjL3RhYmxlOjk4ZGJlMzgxOWNiNTQxMDI5NjVjOTUzMmQwYWIyNzhlL3RhYmxlcmFuZ2U6OThkYmUzODE5Y2I1NDEwMjk2NWM5NTMyZDBhYjI3OGVfMjItMy0xLTEtMzA1MDA_2aa2bb36-5330-44ca-9f5d-0c6624cf8707"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i12246a01749f40d394a9437cb9938c91_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMC9mcmFnOjI3ZDM3ZTYwMzc3ODRlZTI5N2MzNDExNTk2NzI5YjJjL3RhYmxlOjk4ZGJlMzgxOWNiNTQxMDI5NjVjOTUzMmQwYWIyNzhlL3RhYmxlcmFuZ2U6OThkYmUzODE5Y2I1NDEwMjk2NWM5NTMyZDBhYjI3OGVfMjQtMC0xLTEtMzA1MDAvdGV4dHJlZ2lvbjo1YjljYjFkNWYwNmQ0ZmI2YjA5MzI3MWJmZTFhZjU1M18yMQ_50d65f47-0a1e-4c68-be6e-091a969bf814"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="ib2ba0b84078f4de2bc3079e992921b92_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMC9mcmFnOjI3ZDM3ZTYwMzc3ODRlZTI5N2MzNDExNTk2NzI5YjJjL3RhYmxlOjk4ZGJlMzgxOWNiNTQxMDI5NjVjOTUzMmQwYWIyNzhlL3RhYmxlcmFuZ2U6OThkYmUzODE5Y2I1NDEwMjk2NWM5NTMyZDBhYjI3OGVfMjQtMC0xLTEtMzA1MDAvdGV4dHJlZ2lvbjo1YjljYjFkNWYwNmQ0ZmI2YjA5MzI3MWJmZTFhZjU1M18yMQ_7c37944c-9641-4b13-9542-eb40177ce1ab"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="ib2ba0b84078f4de2bc3079e992921b92_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMC9mcmFnOjI3ZDM3ZTYwMzc3ODRlZTI5N2MzNDExNTk2NzI5YjJjL3RhYmxlOjk4ZGJlMzgxOWNiNTQxMDI5NjVjOTUzMmQwYWIyNzhlL3RhYmxlcmFuZ2U6OThkYmUzODE5Y2I1NDEwMjk2NWM5NTMyZDBhYjI3OGVfMjQtMC0xLTEtMzA1MDAvdGV4dHJlZ2lvbjo1YjljYjFkNWYwNmQ0ZmI2YjA5MzI3MWJmZTFhZjU1M18zNQ_050d30e1-0a01-448e-bb75-9b05df2ed6e7"
      unitRef="shares">20000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i12246a01749f40d394a9437cb9938c91_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMC9mcmFnOjI3ZDM3ZTYwMzc3ODRlZTI5N2MzNDExNTk2NzI5YjJjL3RhYmxlOjk4ZGJlMzgxOWNiNTQxMDI5NjVjOTUzMmQwYWIyNzhlL3RhYmxlcmFuZ2U6OThkYmUzODE5Y2I1NDEwMjk2NWM5NTMyZDBhYjI3OGVfMjQtMC0xLTEtMzA1MDAvdGV4dHJlZ2lvbjo1YjljYjFkNWYwNmQ0ZmI2YjA5MzI3MWJmZTFhZjU1M18zNQ_58d7ed56-ec07-43d0-a3c2-919a1d0475d8"
      unitRef="shares">20000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i12246a01749f40d394a9437cb9938c91_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMC9mcmFnOjI3ZDM3ZTYwMzc3ODRlZTI5N2MzNDExNTk2NzI5YjJjL3RhYmxlOjk4ZGJlMzgxOWNiNTQxMDI5NjVjOTUzMmQwYWIyNzhlL3RhYmxlcmFuZ2U6OThkYmUzODE5Y2I1NDEwMjk2NWM5NTMyZDBhYjI3OGVfMjQtMC0xLTEtMzA1MDAvdGV4dHJlZ2lvbjo1YjljYjFkNWYwNmQ0ZmI2YjA5MzI3MWJmZTFhZjU1M181Mw_11d64d49-8554-4816-9d2e-aa99f82b2faf"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="ib2ba0b84078f4de2bc3079e992921b92_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMC9mcmFnOjI3ZDM3ZTYwMzc3ODRlZTI5N2MzNDExNTk2NzI5YjJjL3RhYmxlOjk4ZGJlMzgxOWNiNTQxMDI5NjVjOTUzMmQwYWIyNzhlL3RhYmxlcmFuZ2U6OThkYmUzODE5Y2I1NDEwMjk2NWM5NTMyZDBhYjI3OGVfMjQtMC0xLTEtMzA1MDAvdGV4dHJlZ2lvbjo1YjljYjFkNWYwNmQ0ZmI2YjA5MzI3MWJmZTFhZjU1M181Mw_3acceb37-8d7c-4cd7-91e5-0e147311e58e"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i12246a01749f40d394a9437cb9938c91_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMC9mcmFnOjI3ZDM3ZTYwMzc3ODRlZTI5N2MzNDExNTk2NzI5YjJjL3RhYmxlOjk4ZGJlMzgxOWNiNTQxMDI5NjVjOTUzMmQwYWIyNzhlL3RhYmxlcmFuZ2U6OThkYmUzODE5Y2I1NDEwMjk2NWM5NTMyZDBhYjI3OGVfMjQtMC0xLTEtMzA1MDAvdGV4dHJlZ2lvbjo1YjljYjFkNWYwNmQ0ZmI2YjA5MzI3MWJmZTFhZjU1M181Mw_598d0e75-dc1d-4854-b8b8-59f1d85c8ee9"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="ib2ba0b84078f4de2bc3079e992921b92_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMC9mcmFnOjI3ZDM3ZTYwMzc3ODRlZTI5N2MzNDExNTk2NzI5YjJjL3RhYmxlOjk4ZGJlMzgxOWNiNTQxMDI5NjVjOTUzMmQwYWIyNzhlL3RhYmxlcmFuZ2U6OThkYmUzODE5Y2I1NDEwMjk2NWM5NTMyZDBhYjI3OGVfMjQtMC0xLTEtMzA1MDAvdGV4dHJlZ2lvbjo1YjljYjFkNWYwNmQ0ZmI2YjA5MzI3MWJmZTFhZjU1M181Mw_a01b9a65-77f3-4c92-a9bc-d93f52f2adee"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue
      contextRef="ib2ba0b84078f4de2bc3079e992921b92_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMC9mcmFnOjI3ZDM3ZTYwMzc3ODRlZTI5N2MzNDExNTk2NzI5YjJjL3RhYmxlOjk4ZGJlMzgxOWNiNTQxMDI5NjVjOTUzMmQwYWIyNzhlL3RhYmxlcmFuZ2U6OThkYmUzODE5Y2I1NDEwMjk2NWM5NTMyZDBhYjI3OGVfMjQtMS0xLTEtMzA1MDA_5927107f-f4d8-48cf-9ef4-3251f517f6a2"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="i12246a01749f40d394a9437cb9938c91_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMC9mcmFnOjI3ZDM3ZTYwMzc3ODRlZTI5N2MzNDExNTk2NzI5YjJjL3RhYmxlOjk4ZGJlMzgxOWNiNTQxMDI5NjVjOTUzMmQwYWIyNzhlL3RhYmxlcmFuZ2U6OThkYmUzODE5Y2I1NDEwMjk2NWM5NTMyZDBhYjI3OGVfMjQtMy0xLTEtMzA1MDA_e483dfc8-e912-4456-9993-9fcecf483a4c"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i12246a01749f40d394a9437cb9938c91_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMC9mcmFnOjI3ZDM3ZTYwMzc3ODRlZTI5N2MzNDExNTk2NzI5YjJjL3RhYmxlOjk4ZGJlMzgxOWNiNTQxMDI5NjVjOTUzMmQwYWIyNzhlL3RhYmxlcmFuZ2U6OThkYmUzODE5Y2I1NDEwMjk2NWM5NTMyZDBhYjI3OGVfMjUtMC0xLTEtMzA1MDAvdGV4dHJlZ2lvbjpjNmIzZTgyZjY1OGQ0NTVjOGYwMzM3MmI4MDdmZGNjYV8xOA_567a8182-ccba-4977-9e44-9e519ac902ca"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ib2ba0b84078f4de2bc3079e992921b92_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMC9mcmFnOjI3ZDM3ZTYwMzc3ODRlZTI5N2MzNDExNTk2NzI5YjJjL3RhYmxlOjk4ZGJlMzgxOWNiNTQxMDI5NjVjOTUzMmQwYWIyNzhlL3RhYmxlcmFuZ2U6OThkYmUzODE5Y2I1NDEwMjk2NWM5NTMyZDBhYjI3OGVfMjUtMC0xLTEtMzA1MDAvdGV4dHJlZ2lvbjpjNmIzZTgyZjY1OGQ0NTVjOGYwMzM3MmI4MDdmZGNjYV8xOA_dfec121d-3269-401f-bd00-b2c3d72320b9"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ib2ba0b84078f4de2bc3079e992921b92_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMC9mcmFnOjI3ZDM3ZTYwMzc3ODRlZTI5N2MzNDExNTk2NzI5YjJjL3RhYmxlOjk4ZGJlMzgxOWNiNTQxMDI5NjVjOTUzMmQwYWIyNzhlL3RhYmxlcmFuZ2U6OThkYmUzODE5Y2I1NDEwMjk2NWM5NTMyZDBhYjI3OGVfMjUtMC0xLTEtMzA1MDAvdGV4dHJlZ2lvbjpjNmIzZTgyZjY1OGQ0NTVjOGYwMzM3MmI4MDdmZGNjYV8zMg_5939c97d-9522-45e6-9158-142269f3251f"
      unitRef="shares">130000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i12246a01749f40d394a9437cb9938c91_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMC9mcmFnOjI3ZDM3ZTYwMzc3ODRlZTI5N2MzNDExNTk2NzI5YjJjL3RhYmxlOjk4ZGJlMzgxOWNiNTQxMDI5NjVjOTUzMmQwYWIyNzhlL3RhYmxlcmFuZ2U6OThkYmUzODE5Y2I1NDEwMjk2NWM5NTMyZDBhYjI3OGVfMjUtMC0xLTEtMzA1MDAvdGV4dHJlZ2lvbjpjNmIzZTgyZjY1OGQ0NTVjOGYwMzM3MmI4MDdmZGNjYV8zMg_5b953ef0-4b2c-4d43-9055-15e4de75a4fd"
      unitRef="shares">130000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="ib2ba0b84078f4de2bc3079e992921b92_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMC9mcmFnOjI3ZDM3ZTYwMzc3ODRlZTI5N2MzNDExNTk2NzI5YjJjL3RhYmxlOjk4ZGJlMzgxOWNiNTQxMDI5NjVjOTUzMmQwYWIyNzhlL3RhYmxlcmFuZ2U6OThkYmUzODE5Y2I1NDEwMjk2NWM5NTMyZDBhYjI3OGVfMjUtMC0xLTEtMzA1MDAvdGV4dHJlZ2lvbjpjNmIzZTgyZjY1OGQ0NTVjOGYwMzM3MmI4MDdmZGNjYV81NDk3NTU4MTQwODM_b6d4b937-2288-43d1-882b-b545a49c746a"
      unitRef="shares">30564995</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ib2ba0b84078f4de2bc3079e992921b92_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMC9mcmFnOjI3ZDM3ZTYwMzc3ODRlZTI5N2MzNDExNTk2NzI5YjJjL3RhYmxlOjk4ZGJlMzgxOWNiNTQxMDI5NjVjOTUzMmQwYWIyNzhlL3RhYmxlcmFuZ2U6OThkYmUzODE5Y2I1NDEwMjk2NWM5NTMyZDBhYjI3OGVfMjUtMC0xLTEtMzA1MDAvdGV4dHJlZ2lvbjpjNmIzZTgyZjY1OGQ0NTVjOGYwMzM3MmI4MDdmZGNjYV81NDk3NTU4MTQwODM_bc7d2389-479e-4bc3-9ff4-c93425842548"
      unitRef="shares">30564995</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i12246a01749f40d394a9437cb9938c91_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMC9mcmFnOjI3ZDM3ZTYwMzc3ODRlZTI5N2MzNDExNTk2NzI5YjJjL3RhYmxlOjk4ZGJlMzgxOWNiNTQxMDI5NjVjOTUzMmQwYWIyNzhlL3RhYmxlcmFuZ2U6OThkYmUzODE5Y2I1NDEwMjk2NWM5NTMyZDBhYjI3OGVfMjUtMC0xLTEtMzA1MDAvdGV4dHJlZ2lvbjpjNmIzZTgyZjY1OGQ0NTVjOGYwMzM3MmI4MDdmZGNjYV81NDk3NTU4MTQwOTY_7d1e5e09-7431-4377-843e-396a990cc952"
      unitRef="shares">26335418</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i12246a01749f40d394a9437cb9938c91_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMC9mcmFnOjI3ZDM3ZTYwMzc3ODRlZTI5N2MzNDExNTk2NzI5YjJjL3RhYmxlOjk4ZGJlMzgxOWNiNTQxMDI5NjVjOTUzMmQwYWIyNzhlL3RhYmxlcmFuZ2U6OThkYmUzODE5Y2I1NDEwMjk2NWM5NTMyZDBhYjI3OGVfMjUtMC0xLTEtMzA1MDAvdGV4dHJlZ2lvbjpjNmIzZTgyZjY1OGQ0NTVjOGYwMzM3MmI4MDdmZGNjYV81NDk3NTU4MTQwOTY_c008ebf9-2748-445a-a66a-ba76a5fa10f7"
      unitRef="shares">26335418</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="ib2ba0b84078f4de2bc3079e992921b92_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMC9mcmFnOjI3ZDM3ZTYwMzc3ODRlZTI5N2MzNDExNTk2NzI5YjJjL3RhYmxlOjk4ZGJlMzgxOWNiNTQxMDI5NjVjOTUzMmQwYWIyNzhlL3RhYmxlcmFuZ2U6OThkYmUzODE5Y2I1NDEwMjk2NWM5NTMyZDBhYjI3OGVfMjUtMS0xLTEtMzA1MDA_0abd64b5-ffa4-43b0-8d24-7bc1622e41e7"
      unitRef="usd">3000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i12246a01749f40d394a9437cb9938c91_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMC9mcmFnOjI3ZDM3ZTYwMzc3ODRlZTI5N2MzNDExNTk2NzI5YjJjL3RhYmxlOjk4ZGJlMzgxOWNiNTQxMDI5NjVjOTUzMmQwYWIyNzhlL3RhYmxlcmFuZ2U6OThkYmUzODE5Y2I1NDEwMjk2NWM5NTMyZDBhYjI3OGVfMjUtMy0xLTEtMzA1MDA_ed02c6af-7d41-4dca-94e2-1a8d5897ea29"
      unitRef="usd">3000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="ib2ba0b84078f4de2bc3079e992921b92_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMC9mcmFnOjI3ZDM3ZTYwMzc3ODRlZTI5N2MzNDExNTk2NzI5YjJjL3RhYmxlOjk4ZGJlMzgxOWNiNTQxMDI5NjVjOTUzMmQwYWIyNzhlL3RhYmxlcmFuZ2U6OThkYmUzODE5Y2I1NDEwMjk2NWM5NTMyZDBhYjI3OGVfMjYtMS0xLTEtMzA1MDA_476b1008-ef99-4362-95f5-6f8629545109"
      unitRef="usd">369999000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i12246a01749f40d394a9437cb9938c91_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMC9mcmFnOjI3ZDM3ZTYwMzc3ODRlZTI5N2MzNDExNTk2NzI5YjJjL3RhYmxlOjk4ZGJlMzgxOWNiNTQxMDI5NjVjOTUzMmQwYWIyNzhlL3RhYmxlcmFuZ2U6OThkYmUzODE5Y2I1NDEwMjk2NWM5NTMyZDBhYjI3OGVfMjYtMy0xLTEtMzA1MDA_e0c57c0e-ef32-4dcd-bf60-fb147ede5572"
      unitRef="usd">324237000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ib2ba0b84078f4de2bc3079e992921b92_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMC9mcmFnOjI3ZDM3ZTYwMzc3ODRlZTI5N2MzNDExNTk2NzI5YjJjL3RhYmxlOjk4ZGJlMzgxOWNiNTQxMDI5NjVjOTUzMmQwYWIyNzhlL3RhYmxlcmFuZ2U6OThkYmUzODE5Y2I1NDEwMjk2NWM5NTMyZDBhYjI3OGVfMjctMS0xLTEtMzA1MDA_bb0200ed-833e-4055-a61d-1094a1ab7304"
      unitRef="usd">-386000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i12246a01749f40d394a9437cb9938c91_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMC9mcmFnOjI3ZDM3ZTYwMzc3ODRlZTI5N2MzNDExNTk2NzI5YjJjL3RhYmxlOjk4ZGJlMzgxOWNiNTQxMDI5NjVjOTUzMmQwYWIyNzhlL3RhYmxlcmFuZ2U6OThkYmUzODE5Y2I1NDEwMjk2NWM5NTMyZDBhYjI3OGVfMjctMy0xLTEtMzA1MDA_0778fd0b-4681-4c2a-809b-c283e7ae6aa1"
      unitRef="usd">-252000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ib2ba0b84078f4de2bc3079e992921b92_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMC9mcmFnOjI3ZDM3ZTYwMzc3ODRlZTI5N2MzNDExNTk2NzI5YjJjL3RhYmxlOjk4ZGJlMzgxOWNiNTQxMDI5NjVjOTUzMmQwYWIyNzhlL3RhYmxlcmFuZ2U6OThkYmUzODE5Y2I1NDEwMjk2NWM5NTMyZDBhYjI3OGVfMjgtMS0xLTEtMzA1MDA_adce3dc4-062c-4c16-8fae-0ec78492f6d8"
      unitRef="usd">-260806000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i12246a01749f40d394a9437cb9938c91_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMC9mcmFnOjI3ZDM3ZTYwMzc3ODRlZTI5N2MzNDExNTk2NzI5YjJjL3RhYmxlOjk4ZGJlMzgxOWNiNTQxMDI5NjVjOTUzMmQwYWIyNzhlL3RhYmxlcmFuZ2U6OThkYmUzODE5Y2I1NDEwMjk2NWM5NTMyZDBhYjI3OGVfMjgtMy0xLTEtMzA1MDA_919bdbcf-9bf7-431e-8ba0-11de0a999301"
      unitRef="usd">-196873000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="ib2ba0b84078f4de2bc3079e992921b92_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMC9mcmFnOjI3ZDM3ZTYwMzc3ODRlZTI5N2MzNDExNTk2NzI5YjJjL3RhYmxlOjk4ZGJlMzgxOWNiNTQxMDI5NjVjOTUzMmQwYWIyNzhlL3RhYmxlcmFuZ2U6OThkYmUzODE5Y2I1NDEwMjk2NWM5NTMyZDBhYjI3OGVfMjktMS0xLTEtMzA1MDA_10a427d1-daa8-41d2-baad-694f119d6878"
      unitRef="usd">108810000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i12246a01749f40d394a9437cb9938c91_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMC9mcmFnOjI3ZDM3ZTYwMzc3ODRlZTI5N2MzNDExNTk2NzI5YjJjL3RhYmxlOjk4ZGJlMzgxOWNiNTQxMDI5NjVjOTUzMmQwYWIyNzhlL3RhYmxlcmFuZ2U6OThkYmUzODE5Y2I1NDEwMjk2NWM5NTMyZDBhYjI3OGVfMjktMy0xLTEtMzA1MDA_d9a885e7-4aee-4f0e-a11c-9c449f5a77c2"
      unitRef="usd">127115000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="ib2ba0b84078f4de2bc3079e992921b92_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMC9mcmFnOjI3ZDM3ZTYwMzc3ODRlZTI5N2MzNDExNTk2NzI5YjJjL3RhYmxlOjk4ZGJlMzgxOWNiNTQxMDI5NjVjOTUzMmQwYWIyNzhlL3RhYmxlcmFuZ2U6OThkYmUzODE5Y2I1NDEwMjk2NWM5NTMyZDBhYjI3OGVfMzAtMS0xLTEtMzA1MDA_24d21bda-ee3c-4635-bae7-2b777c4436b8"
      unitRef="usd">121083000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i12246a01749f40d394a9437cb9938c91_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMC9mcmFnOjI3ZDM3ZTYwMzc3ODRlZTI5N2MzNDExNTk2NzI5YjJjL3RhYmxlOjk4ZGJlMzgxOWNiNTQxMDI5NjVjOTUzMmQwYWIyNzhlL3RhYmxlcmFuZ2U6OThkYmUzODE5Y2I1NDEwMjk2NWM5NTMyZDBhYjI3OGVfMzAtMy0xLTEtMzA1MDA_33476811-031d-47da-b1fc-99308c413f02"
      unitRef="usd">139100000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i25a8ea2d7c9f4bfd8f72223c8ac18c65_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMy9mcmFnOjg4YzY5ZTc3YzFlYjQ2MjhiMTQ1OWVhNzg2ZjlkNmYyL3RhYmxlOjZmNGIwMTVmYzUwODRkZDBhOWE5ZWU3MjFiYjg0NjU1L3RhYmxlcmFuZ2U6NmY0YjAxNWZjNTA4NGRkMGE5YTllZTcyMWJiODQ2NTVfMy01LTEtMS0zMDUwMA_c216096b-4131-4c59-aa12-2d8221eb962f"
      unitRef="usd">16537000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ib52579de36d54242a791b9e3f8019a00_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMy9mcmFnOjg4YzY5ZTc3YzFlYjQ2MjhiMTQ1OWVhNzg2ZjlkNmYyL3RhYmxlOjZmNGIwMTVmYzUwODRkZDBhOWE5ZWU3MjFiYjg0NjU1L3RhYmxlcmFuZ2U6NmY0YjAxNWZjNTA4NGRkMGE5YTllZTcyMWJiODQ2NTVfMy03LTEtMS0zMDUwMA_552889ba-c8c8-4c29-8ac4-6bb08877722a"
      unitRef="usd">15480000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMy9mcmFnOjg4YzY5ZTc3YzFlYjQ2MjhiMTQ1OWVhNzg2ZjlkNmYyL3RhYmxlOjZmNGIwMTVmYzUwODRkZDBhOWE5ZWU3MjFiYjg0NjU1L3RhYmxlcmFuZ2U6NmY0YjAxNWZjNTA4NGRkMGE5YTllZTcyMWJiODQ2NTVfMy05LTEtMS0zMDUwMA_e50f2622-93bc-41c5-b3a9-2e7265f6e92b"
      unitRef="usd">50520000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i69e8bcaae5bf44c9a03cf7f5bd08e6b8_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMy9mcmFnOjg4YzY5ZTc3YzFlYjQ2MjhiMTQ1OWVhNzg2ZjlkNmYyL3RhYmxlOjZmNGIwMTVmYzUwODRkZDBhOWE5ZWU3MjFiYjg0NjU1L3RhYmxlcmFuZ2U6NmY0YjAxNWZjNTA4NGRkMGE5YTllZTcyMWJiODQ2NTVfMy0xMS0xLTEtMzA1MDA_15af8217-1c77-47c8-927e-91f680c7da33"
      unitRef="usd">42737000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i25a8ea2d7c9f4bfd8f72223c8ac18c65_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMy9mcmFnOjg4YzY5ZTc3YzFlYjQ2MjhiMTQ1OWVhNzg2ZjlkNmYyL3RhYmxlOjZmNGIwMTVmYzUwODRkZDBhOWE5ZWU3MjFiYjg0NjU1L3RhYmxlcmFuZ2U6NmY0YjAxNWZjNTA4NGRkMGE5YTllZTcyMWJiODQ2NTVfNC01LTEtMS0zMDUwMA_727f2419-cff4-4c08-abd1-b821b3625054"
      unitRef="usd">3579000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="ib52579de36d54242a791b9e3f8019a00_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMy9mcmFnOjg4YzY5ZTc3YzFlYjQ2MjhiMTQ1OWVhNzg2ZjlkNmYyL3RhYmxlOjZmNGIwMTVmYzUwODRkZDBhOWE5ZWU3MjFiYjg0NjU1L3RhYmxlcmFuZ2U6NmY0YjAxNWZjNTA4NGRkMGE5YTllZTcyMWJiODQ2NTVfNC03LTEtMS0zMDUwMA_b7ccf7bf-c0e7-4d46-ad3f-59c2296b56cd"
      unitRef="usd">2907000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMy9mcmFnOjg4YzY5ZTc3YzFlYjQ2MjhiMTQ1OWVhNzg2ZjlkNmYyL3RhYmxlOjZmNGIwMTVmYzUwODRkZDBhOWE5ZWU3MjFiYjg0NjU1L3RhYmxlcmFuZ2U6NmY0YjAxNWZjNTA4NGRkMGE5YTllZTcyMWJiODQ2NTVfNC05LTEtMS0zMDUwMA_7c25a501-5bf9-4499-952f-eab4ca9e7d8e"
      unitRef="usd">11641000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i69e8bcaae5bf44c9a03cf7f5bd08e6b8_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMy9mcmFnOjg4YzY5ZTc3YzFlYjQ2MjhiMTQ1OWVhNzg2ZjlkNmYyL3RhYmxlOjZmNGIwMTVmYzUwODRkZDBhOWE5ZWU3MjFiYjg0NjU1L3RhYmxlcmFuZ2U6NmY0YjAxNWZjNTA4NGRkMGE5YTllZTcyMWJiODQ2NTVfNC0xMS0xLTEtMzA1MDA_6bd22c85-69a4-4a18-9d80-205898587da1"
      unitRef="usd">9957000</us-gaap:GeneralAndAdministrativeExpense>
    <vtl:RoyaltySettlementAgreementSalesNet
      contextRef="i25a8ea2d7c9f4bfd8f72223c8ac18c65_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMy9mcmFnOjg4YzY5ZTc3YzFlYjQ2MjhiMTQ1OWVhNzg2ZjlkNmYyL3RhYmxlOjZmNGIwMTVmYzUwODRkZDBhOWE5ZWU3MjFiYjg0NjU1L3RhYmxlcmFuZ2U6NmY0YjAxNWZjNTA4NGRkMGE5YTllZTcyMWJiODQ2NTVfNS01LTEtMS0zMDUwMA_98e23c97-1155-45be-aa20-f85f1d439bd0"
      unitRef="usd">0</vtl:RoyaltySettlementAgreementSalesNet>
    <vtl:RoyaltySettlementAgreementSalesNet
      contextRef="ib52579de36d54242a791b9e3f8019a00_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMy9mcmFnOjg4YzY5ZTc3YzFlYjQ2MjhiMTQ1OWVhNzg2ZjlkNmYyL3RhYmxlOjZmNGIwMTVmYzUwODRkZDBhOWE5ZWU3MjFiYjg0NjU1L3RhYmxlcmFuZ2U6NmY0YjAxNWZjNTA4NGRkMGE5YTllZTcyMWJiODQ2NTVfNS03LTEtMS0zMDUwMA_cf8dd1bb-7c5c-4d76-a4df-fd6ba4a0f992"
      unitRef="usd">0</vtl:RoyaltySettlementAgreementSalesNet>
    <vtl:RoyaltySettlementAgreementSalesNet
      contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMy9mcmFnOjg4YzY5ZTc3YzFlYjQ2MjhiMTQ1OWVhNzg2ZjlkNmYyL3RhYmxlOjZmNGIwMTVmYzUwODRkZDBhOWE5ZWU3MjFiYjg0NjU1L3RhYmxlcmFuZ2U6NmY0YjAxNWZjNTA4NGRkMGE5YTllZTcyMWJiODQ2NTVfNS05LTEtMS0zMDUwMA_6b169cbb-c796-45bb-a731-c8b4456d5435"
      unitRef="usd">0</vtl:RoyaltySettlementAgreementSalesNet>
    <vtl:RoyaltySettlementAgreementSalesNet
      contextRef="i69e8bcaae5bf44c9a03cf7f5bd08e6b8_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMy9mcmFnOjg4YzY5ZTc3YzFlYjQ2MjhiMTQ1OWVhNzg2ZjlkNmYyL3RhYmxlOjZmNGIwMTVmYzUwODRkZDBhOWE5ZWU3MjFiYjg0NjU1L3RhYmxlcmFuZ2U6NmY0YjAxNWZjNTA4NGRkMGE5YTllZTcyMWJiODQ2NTVfNS0xMS0xLTEtMzA1MDA_36ade33d-df8c-44d0-9636-9a5f1e5e0e50"
      unitRef="usd">17250000</vtl:RoyaltySettlementAgreementSalesNet>
    <us-gaap:OperatingExpenses
      contextRef="i25a8ea2d7c9f4bfd8f72223c8ac18c65_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMy9mcmFnOjg4YzY5ZTc3YzFlYjQ2MjhiMTQ1OWVhNzg2ZjlkNmYyL3RhYmxlOjZmNGIwMTVmYzUwODRkZDBhOWE5ZWU3MjFiYjg0NjU1L3RhYmxlcmFuZ2U6NmY0YjAxNWZjNTA4NGRkMGE5YTllZTcyMWJiODQ2NTVfNi01LTEtMS0zMDUwMA_3ef283b2-4ea8-473e-a315-a8e05b5083a3"
      unitRef="usd">20116000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="ib52579de36d54242a791b9e3f8019a00_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMy9mcmFnOjg4YzY5ZTc3YzFlYjQ2MjhiMTQ1OWVhNzg2ZjlkNmYyL3RhYmxlOjZmNGIwMTVmYzUwODRkZDBhOWE5ZWU3MjFiYjg0NjU1L3RhYmxlcmFuZ2U6NmY0YjAxNWZjNTA4NGRkMGE5YTllZTcyMWJiODQ2NTVfNi03LTEtMS0zMDUwMA_ceeb73f9-58a0-47fc-96a9-e3a2bbb018a8"
      unitRef="usd">18387000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMy9mcmFnOjg4YzY5ZTc3YzFlYjQ2MjhiMTQ1OWVhNzg2ZjlkNmYyL3RhYmxlOjZmNGIwMTVmYzUwODRkZDBhOWE5ZWU3MjFiYjg0NjU1L3RhYmxlcmFuZ2U6NmY0YjAxNWZjNTA4NGRkMGE5YTllZTcyMWJiODQ2NTVfNi05LTEtMS0zMDUwMA_4369f36f-b328-458d-af0a-c6eba2c6c4bd"
      unitRef="usd">62161000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i69e8bcaae5bf44c9a03cf7f5bd08e6b8_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMy9mcmFnOjg4YzY5ZTc3YzFlYjQ2MjhiMTQ1OWVhNzg2ZjlkNmYyL3RhYmxlOjZmNGIwMTVmYzUwODRkZDBhOWE5ZWU3MjFiYjg0NjU1L3RhYmxlcmFuZ2U6NmY0YjAxNWZjNTA4NGRkMGE5YTllZTcyMWJiODQ2NTVfNi0xMS0xLTEtMzA1MDA_c005f132-b802-4e5b-a328-44792a671731"
      unitRef="usd">69944000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i25a8ea2d7c9f4bfd8f72223c8ac18c65_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMy9mcmFnOjg4YzY5ZTc3YzFlYjQ2MjhiMTQ1OWVhNzg2ZjlkNmYyL3RhYmxlOjZmNGIwMTVmYzUwODRkZDBhOWE5ZWU3MjFiYjg0NjU1L3RhYmxlcmFuZ2U6NmY0YjAxNWZjNTA4NGRkMGE5YTllZTcyMWJiODQ2NTVfNy01LTEtMS0zMDUwMA_9cfc6e99-1122-45d3-a0c9-c695aeea4e9c"
      unitRef="usd">-20116000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ib52579de36d54242a791b9e3f8019a00_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMy9mcmFnOjg4YzY5ZTc3YzFlYjQ2MjhiMTQ1OWVhNzg2ZjlkNmYyL3RhYmxlOjZmNGIwMTVmYzUwODRkZDBhOWE5ZWU3MjFiYjg0NjU1L3RhYmxlcmFuZ2U6NmY0YjAxNWZjNTA4NGRkMGE5YTllZTcyMWJiODQ2NTVfNy03LTEtMS0zMDUwMA_c1acd441-75e7-49ff-b63d-3778a595b424"
      unitRef="usd">-18387000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMy9mcmFnOjg4YzY5ZTc3YzFlYjQ2MjhiMTQ1OWVhNzg2ZjlkNmYyL3RhYmxlOjZmNGIwMTVmYzUwODRkZDBhOWE5ZWU3MjFiYjg0NjU1L3RhYmxlcmFuZ2U6NmY0YjAxNWZjNTA4NGRkMGE5YTllZTcyMWJiODQ2NTVfNy05LTEtMS0zMDUwMA_7f6a8983-c885-4f99-9663-308fc2e028e4"
      unitRef="usd">-62161000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i69e8bcaae5bf44c9a03cf7f5bd08e6b8_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMy9mcmFnOjg4YzY5ZTc3YzFlYjQ2MjhiMTQ1OWVhNzg2ZjlkNmYyL3RhYmxlOjZmNGIwMTVmYzUwODRkZDBhOWE5ZWU3MjFiYjg0NjU1L3RhYmxlcmFuZ2U6NmY0YjAxNWZjNTA4NGRkMGE5YTllZTcyMWJiODQ2NTVfNy0xMS0xLTEtMzA1MDA_53dd8384-0681-4649-9663-7dc542962d12"
      unitRef="usd">-69944000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i25a8ea2d7c9f4bfd8f72223c8ac18c65_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMy9mcmFnOjg4YzY5ZTc3YzFlYjQ2MjhiMTQ1OWVhNzg2ZjlkNmYyL3RhYmxlOjZmNGIwMTVmYzUwODRkZDBhOWE5ZWU3MjFiYjg0NjU1L3RhYmxlcmFuZ2U6NmY0YjAxNWZjNTA4NGRkMGE5YTllZTcyMWJiODQ2NTVfOS01LTEtMS0zMDUwMA_6b848d6b-36c4-44a0-bc7d-81810f92f3cc"
      unitRef="usd">230000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="ib52579de36d54242a791b9e3f8019a00_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMy9mcmFnOjg4YzY5ZTc3YzFlYjQ2MjhiMTQ1OWVhNzg2ZjlkNmYyL3RhYmxlOjZmNGIwMTVmYzUwODRkZDBhOWE5ZWU3MjFiYjg0NjU1L3RhYmxlcmFuZ2U6NmY0YjAxNWZjNTA4NGRkMGE5YTllZTcyMWJiODQ2NTVfOS03LTEtMS0zMDUwMA_8f5e0e6b-b4ce-4863-9e2b-9f6821a800e3"
      unitRef="usd">10000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMy9mcmFnOjg4YzY5ZTc3YzFlYjQ2MjhiMTQ1OWVhNzg2ZjlkNmYyL3RhYmxlOjZmNGIwMTVmYzUwODRkZDBhOWE5ZWU3MjFiYjg0NjU1L3RhYmxlcmFuZ2U6NmY0YjAxNWZjNTA4NGRkMGE5YTllZTcyMWJiODQ2NTVfOS05LTEtMS0zMDUwMA_725b982b-8cad-4a2f-9e6d-c818e350b141"
      unitRef="usd">343000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i69e8bcaae5bf44c9a03cf7f5bd08e6b8_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMy9mcmFnOjg4YzY5ZTc3YzFlYjQ2MjhiMTQ1OWVhNzg2ZjlkNmYyL3RhYmxlOjZmNGIwMTVmYzUwODRkZDBhOWE5ZWU3MjFiYjg0NjU1L3RhYmxlcmFuZ2U6NmY0YjAxNWZjNTA4NGRkMGE5YTllZTcyMWJiODQ2NTVfOS0xMS0xLTEtMzA1MDA_1c8ec57a-a462-42df-88f2-c61a5993d795"
      unitRef="usd">51000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i25a8ea2d7c9f4bfd8f72223c8ac18c65_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMy9mcmFnOjg4YzY5ZTc3YzFlYjQ2MjhiMTQ1OWVhNzg2ZjlkNmYyL3RhYmxlOjZmNGIwMTVmYzUwODRkZDBhOWE5ZWU3MjFiYjg0NjU1L3RhYmxlcmFuZ2U6NmY0YjAxNWZjNTA4NGRkMGE5YTllZTcyMWJiODQ2NTVfMTAtNS0xLTEtMzA1MDA_fed80e72-600a-4fbc-aad8-d4fa0c197814"
      unitRef="usd">-1338000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ib52579de36d54242a791b9e3f8019a00_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMy9mcmFnOjg4YzY5ZTc3YzFlYjQ2MjhiMTQ1OWVhNzg2ZjlkNmYyL3RhYmxlOjZmNGIwMTVmYzUwODRkZDBhOWE5ZWU3MjFiYjg0NjU1L3RhYmxlcmFuZ2U6NmY0YjAxNWZjNTA4NGRkMGE5YTllZTcyMWJiODQ2NTVfMTAtNy0xLTEtMzA1MDA_e9180067-4b4d-4ef8-a440-5429cf2c621d"
      unitRef="usd">-915000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMy9mcmFnOjg4YzY5ZTc3YzFlYjQ2MjhiMTQ1OWVhNzg2ZjlkNmYyL3RhYmxlOjZmNGIwMTVmYzUwODRkZDBhOWE5ZWU3MjFiYjg0NjU1L3RhYmxlcmFuZ2U6NmY0YjAxNWZjNTA4NGRkMGE5YTllZTcyMWJiODQ2NTVfMTAtOS0xLTEtMzA1MDA_60a4538c-1fec-458b-ab35-7a76eba803d7"
      unitRef="usd">-2115000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i69e8bcaae5bf44c9a03cf7f5bd08e6b8_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMy9mcmFnOjg4YzY5ZTc3YzFlYjQ2MjhiMTQ1OWVhNzg2ZjlkNmYyL3RhYmxlOjZmNGIwMTVmYzUwODRkZDBhOWE5ZWU3MjFiYjg0NjU1L3RhYmxlcmFuZ2U6NmY0YjAxNWZjNTA4NGRkMGE5YTllZTcyMWJiODQ2NTVfMTAtMTEtMS0xLTMwNTAw_477f48c3-b5c1-4bb0-85a9-925a426dcaeb"
      unitRef="usd">-1867000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i25a8ea2d7c9f4bfd8f72223c8ac18c65_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMy9mcmFnOjg4YzY5ZTc3YzFlYjQ2MjhiMTQ1OWVhNzg2ZjlkNmYyL3RhYmxlOjZmNGIwMTVmYzUwODRkZDBhOWE5ZWU3MjFiYjg0NjU1L3RhYmxlcmFuZ2U6NmY0YjAxNWZjNTA4NGRkMGE5YTllZTcyMWJiODQ2NTVfMTEtNS0xLTEtMzA1MDA_a3eaaa45-bc1f-42f9-b660-2631135377e8"
      unitRef="usd">-1108000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="ib52579de36d54242a791b9e3f8019a00_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMy9mcmFnOjg4YzY5ZTc3YzFlYjQ2MjhiMTQ1OWVhNzg2ZjlkNmYyL3RhYmxlOjZmNGIwMTVmYzUwODRkZDBhOWE5ZWU3MjFiYjg0NjU1L3RhYmxlcmFuZ2U6NmY0YjAxNWZjNTA4NGRkMGE5YTllZTcyMWJiODQ2NTVfMTEtNy0xLTEtMzA1MDA_79548cc7-b8a0-4849-87c0-18292343d9da"
      unitRef="usd">-905000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMy9mcmFnOjg4YzY5ZTc3YzFlYjQ2MjhiMTQ1OWVhNzg2ZjlkNmYyL3RhYmxlOjZmNGIwMTVmYzUwODRkZDBhOWE5ZWU3MjFiYjg0NjU1L3RhYmxlcmFuZ2U6NmY0YjAxNWZjNTA4NGRkMGE5YTllZTcyMWJiODQ2NTVfMTEtOS0xLTEtMzA1MDA_b5e737ae-8981-458a-a60b-7712754b2de5"
      unitRef="usd">-1772000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i69e8bcaae5bf44c9a03cf7f5bd08e6b8_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMy9mcmFnOjg4YzY5ZTc3YzFlYjQ2MjhiMTQ1OWVhNzg2ZjlkNmYyL3RhYmxlOjZmNGIwMTVmYzUwODRkZDBhOWE5ZWU3MjFiYjg0NjU1L3RhYmxlcmFuZ2U6NmY0YjAxNWZjNTA4NGRkMGE5YTllZTcyMWJiODQ2NTVfMTEtMTEtMS0xLTMwNTAw_592e117a-07ce-4ea6-8e29-c113539139b2"
      unitRef="usd">-1816000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="i25a8ea2d7c9f4bfd8f72223c8ac18c65_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMy9mcmFnOjg4YzY5ZTc3YzFlYjQ2MjhiMTQ1OWVhNzg2ZjlkNmYyL3RhYmxlOjZmNGIwMTVmYzUwODRkZDBhOWE5ZWU3MjFiYjg0NjU1L3RhYmxlcmFuZ2U6NmY0YjAxNWZjNTA4NGRkMGE5YTllZTcyMWJiODQ2NTVfMTItNS0xLTEtMzA1MDA_13eccc70-1fa7-4f5d-a3ff-a8135cf3864f"
      unitRef="usd">-21224000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ib52579de36d54242a791b9e3f8019a00_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMy9mcmFnOjg4YzY5ZTc3YzFlYjQ2MjhiMTQ1OWVhNzg2ZjlkNmYyL3RhYmxlOjZmNGIwMTVmYzUwODRkZDBhOWE5ZWU3MjFiYjg0NjU1L3RhYmxlcmFuZ2U6NmY0YjAxNWZjNTA4NGRkMGE5YTllZTcyMWJiODQ2NTVfMTItNy0xLTEtMzA1MDA_56ac083e-7639-4aa0-921a-9dba73801f08"
      unitRef="usd">-19292000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMy9mcmFnOjg4YzY5ZTc3YzFlYjQ2MjhiMTQ1OWVhNzg2ZjlkNmYyL3RhYmxlOjZmNGIwMTVmYzUwODRkZDBhOWE5ZWU3MjFiYjg0NjU1L3RhYmxlcmFuZ2U6NmY0YjAxNWZjNTA4NGRkMGE5YTllZTcyMWJiODQ2NTVfMTItOS0xLTEtMzA1MDA_ac090655-5665-47eb-a615-d5a144987334"
      unitRef="usd">-63933000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i69e8bcaae5bf44c9a03cf7f5bd08e6b8_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMy9mcmFnOjg4YzY5ZTc3YzFlYjQ2MjhiMTQ1OWVhNzg2ZjlkNmYyL3RhYmxlOjZmNGIwMTVmYzUwODRkZDBhOWE5ZWU3MjFiYjg0NjU1L3RhYmxlcmFuZ2U6NmY0YjAxNWZjNTA4NGRkMGE5YTllZTcyMWJiODQ2NTVfMTItMTEtMS0xLTMwNTAw_9237b974-1b0a-47f1-8ec0-acf23471139d"
      unitRef="usd">-71760000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i25a8ea2d7c9f4bfd8f72223c8ac18c65_D20220701-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMy9mcmFnOjg4YzY5ZTc3YzFlYjQ2MjhiMTQ1OWVhNzg2ZjlkNmYyL3RhYmxlOjZmNGIwMTVmYzUwODRkZDBhOWE5ZWU3MjFiYjg0NjU1L3RhYmxlcmFuZ2U6NmY0YjAxNWZjNTA4NGRkMGE5YTllZTcyMWJiODQ2NTVfMTQtNS0xLTEtMzA1MDA_d6d8dca0-ec23-4ffd-b7c2-089cfffda6a2"
      unitRef="usdPerShare">-0.69</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i25a8ea2d7c9f4bfd8f72223c8ac18c65_D20220701-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMy9mcmFnOjg4YzY5ZTc3YzFlYjQ2MjhiMTQ1OWVhNzg2ZjlkNmYyL3RhYmxlOjZmNGIwMTVmYzUwODRkZDBhOWE5ZWU3MjFiYjg0NjU1L3RhYmxlcmFuZ2U6NmY0YjAxNWZjNTA4NGRkMGE5YTllZTcyMWJiODQ2NTVfMTQtNS0xLTEtMzA1MDA_f70ebb75-e703-453f-903b-cc1c0c60b817"
      unitRef="usdPerShare">-0.69</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ib52579de36d54242a791b9e3f8019a00_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMy9mcmFnOjg4YzY5ZTc3YzFlYjQ2MjhiMTQ1OWVhNzg2ZjlkNmYyL3RhYmxlOjZmNGIwMTVmYzUwODRkZDBhOWE5ZWU3MjFiYjg0NjU1L3RhYmxlcmFuZ2U6NmY0YjAxNWZjNTA4NGRkMGE5YTllZTcyMWJiODQ2NTVfMTQtNy0xLTEtMzA1MDA_3c514ae2-c067-4785-9ce5-bfb3668ad25f"
      unitRef="usdPerShare">-0.76</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="ib52579de36d54242a791b9e3f8019a00_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMy9mcmFnOjg4YzY5ZTc3YzFlYjQ2MjhiMTQ1OWVhNzg2ZjlkNmYyL3RhYmxlOjZmNGIwMTVmYzUwODRkZDBhOWE5ZWU3MjFiYjg0NjU1L3RhYmxlcmFuZ2U6NmY0YjAxNWZjNTA4NGRkMGE5YTllZTcyMWJiODQ2NTVfMTQtNy0xLTEtMzA1MDA_47abcf9c-1cca-48a2-a03b-ae625b3ca587"
      unitRef="usdPerShare">-0.76</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMy9mcmFnOjg4YzY5ZTc3YzFlYjQ2MjhiMTQ1OWVhNzg2ZjlkNmYyL3RhYmxlOjZmNGIwMTVmYzUwODRkZDBhOWE5ZWU3MjFiYjg0NjU1L3RhYmxlcmFuZ2U6NmY0YjAxNWZjNTA4NGRkMGE5YTllZTcyMWJiODQ2NTVfMTQtOS0xLTEtMzA1MDA_1e62b304-6f3e-42a7-8832-981ea11b287a"
      unitRef="usdPerShare">-2.16</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMy9mcmFnOjg4YzY5ZTc3YzFlYjQ2MjhiMTQ1OWVhNzg2ZjlkNmYyL3RhYmxlOjZmNGIwMTVmYzUwODRkZDBhOWE5ZWU3MjFiYjg0NjU1L3RhYmxlcmFuZ2U6NmY0YjAxNWZjNTA4NGRkMGE5YTllZTcyMWJiODQ2NTVfMTQtOS0xLTEtMzA1MDA_baea6b49-0444-4f2d-afb7-88dac205c0e0"
      unitRef="usdPerShare">-2.16</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i69e8bcaae5bf44c9a03cf7f5bd08e6b8_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMy9mcmFnOjg4YzY5ZTc3YzFlYjQ2MjhiMTQ1OWVhNzg2ZjlkNmYyL3RhYmxlOjZmNGIwMTVmYzUwODRkZDBhOWE5ZWU3MjFiYjg0NjU1L3RhYmxlcmFuZ2U6NmY0YjAxNWZjNTA4NGRkMGE5YTllZTcyMWJiODQ2NTVfMTQtMTEtMS0xLTMwNTAw_9e7b6145-7f47-4ff0-8216-8521e69485ee"
      unitRef="usdPerShare">-3.33</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i69e8bcaae5bf44c9a03cf7f5bd08e6b8_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMy9mcmFnOjg4YzY5ZTc3YzFlYjQ2MjhiMTQ1OWVhNzg2ZjlkNmYyL3RhYmxlOjZmNGIwMTVmYzUwODRkZDBhOWE5ZWU3MjFiYjg0NjU1L3RhYmxlcmFuZ2U6NmY0YjAxNWZjNTA4NGRkMGE5YTllZTcyMWJiODQ2NTVfMTQtMTEtMS0xLTMwNTAw_c708b409-b4c3-4c24-b579-8239f1e2512d"
      unitRef="usdPerShare">-3.33</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i25a8ea2d7c9f4bfd8f72223c8ac18c65_D20220701-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMy9mcmFnOjg4YzY5ZTc3YzFlYjQ2MjhiMTQ1OWVhNzg2ZjlkNmYyL3RhYmxlOjZmNGIwMTVmYzUwODRkZDBhOWE5ZWU3MjFiYjg0NjU1L3RhYmxlcmFuZ2U6NmY0YjAxNWZjNTA4NGRkMGE5YTllZTcyMWJiODQ2NTVfMTYtNS0xLTEtMzA1MDA_25c0d990-a353-41b6-9a38-518a7d40ab9e"
      unitRef="shares">30564995</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i25a8ea2d7c9f4bfd8f72223c8ac18c65_D20220701-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMy9mcmFnOjg4YzY5ZTc3YzFlYjQ2MjhiMTQ1OWVhNzg2ZjlkNmYyL3RhYmxlOjZmNGIwMTVmYzUwODRkZDBhOWE5ZWU3MjFiYjg0NjU1L3RhYmxlcmFuZ2U6NmY0YjAxNWZjNTA4NGRkMGE5YTllZTcyMWJiODQ2NTVfMTYtNS0xLTEtMzA1MDA_2d6d8ff8-f349-4e61-a35e-475bd51c14ec"
      unitRef="shares">30564995</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ib52579de36d54242a791b9e3f8019a00_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMy9mcmFnOjg4YzY5ZTc3YzFlYjQ2MjhiMTQ1OWVhNzg2ZjlkNmYyL3RhYmxlOjZmNGIwMTVmYzUwODRkZDBhOWE5ZWU3MjFiYjg0NjU1L3RhYmxlcmFuZ2U6NmY0YjAxNWZjNTA4NGRkMGE5YTllZTcyMWJiODQ2NTVfMTYtNy0xLTEtMzA1MDA_03a083fb-7c11-4a81-92ad-9335b0a94b24"
      unitRef="shares">25320091</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ib52579de36d54242a791b9e3f8019a00_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMy9mcmFnOjg4YzY5ZTc3YzFlYjQ2MjhiMTQ1OWVhNzg2ZjlkNmYyL3RhYmxlOjZmNGIwMTVmYzUwODRkZDBhOWE5ZWU3MjFiYjg0NjU1L3RhYmxlcmFuZ2U6NmY0YjAxNWZjNTA4NGRkMGE5YTllZTcyMWJiODQ2NTVfMTYtNy0xLTEtMzA1MDA_853c153f-a882-4d93-9c52-23257d30eac0"
      unitRef="shares">25320091</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMy9mcmFnOjg4YzY5ZTc3YzFlYjQ2MjhiMTQ1OWVhNzg2ZjlkNmYyL3RhYmxlOjZmNGIwMTVmYzUwODRkZDBhOWE5ZWU3MjFiYjg0NjU1L3RhYmxlcmFuZ2U6NmY0YjAxNWZjNTA4NGRkMGE5YTllZTcyMWJiODQ2NTVfMTYtOS0xLTEtMzA1MDA_40b5a33b-8509-4429-b57f-b379023c9432"
      unitRef="shares">29655946</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMy9mcmFnOjg4YzY5ZTc3YzFlYjQ2MjhiMTQ1OWVhNzg2ZjlkNmYyL3RhYmxlOjZmNGIwMTVmYzUwODRkZDBhOWE5ZWU3MjFiYjg0NjU1L3RhYmxlcmFuZ2U6NmY0YjAxNWZjNTA4NGRkMGE5YTllZTcyMWJiODQ2NTVfMTYtOS0xLTEtMzA1MDA_a7bdb752-33ac-48a5-8444-5d8e7aae1114"
      unitRef="shares">29655946</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i69e8bcaae5bf44c9a03cf7f5bd08e6b8_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMy9mcmFnOjg4YzY5ZTc3YzFlYjQ2MjhiMTQ1OWVhNzg2ZjlkNmYyL3RhYmxlOjZmNGIwMTVmYzUwODRkZDBhOWE5ZWU3MjFiYjg0NjU1L3RhYmxlcmFuZ2U6NmY0YjAxNWZjNTA4NGRkMGE5YTllZTcyMWJiODQ2NTVfMTYtMTEtMS0xLTMwNTAw_6bebae0f-6394-4dff-9496-b4953983aa97"
      unitRef="shares">21559964</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i69e8bcaae5bf44c9a03cf7f5bd08e6b8_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xMy9mcmFnOjg4YzY5ZTc3YzFlYjQ2MjhiMTQ1OWVhNzg2ZjlkNmYyL3RhYmxlOjZmNGIwMTVmYzUwODRkZDBhOWE5ZWU3MjFiYjg0NjU1L3RhYmxlcmFuZ2U6NmY0YjAxNWZjNTA4NGRkMGE5YTllZTcyMWJiODQ2NTVfMTYtMTEtMS0xLTMwNTAw_97a812ee-d46a-4f64-8039-86420ddcaabd"
      unitRef="shares">21559964</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:NetIncomeLoss
      contextRef="i25a8ea2d7c9f4bfd8f72223c8ac18c65_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xNi9mcmFnOmNhNTFhNDQ0OTY0MTQzZmNhZWZhYWI5NjUxOWZhZjdiL3RhYmxlOjUzYzg3ZDkyZGY2YTQ1N2Q5Nzk4NGE5NDQ0YzA2ZDAxL3RhYmxlcmFuZ2U6NTNjODdkOTJkZjZhNDU3ZDk3OTg0YTk0NDRjMDZkMDFfMi01LTEtMS0zMDUwMA_496b4f71-0c20-4611-a1b1-e5c749aca3bb"
      unitRef="usd">-21224000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ib52579de36d54242a791b9e3f8019a00_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xNi9mcmFnOmNhNTFhNDQ0OTY0MTQzZmNhZWZhYWI5NjUxOWZhZjdiL3RhYmxlOjUzYzg3ZDkyZGY2YTQ1N2Q5Nzk4NGE5NDQ0YzA2ZDAxL3RhYmxlcmFuZ2U6NTNjODdkOTJkZjZhNDU3ZDk3OTg0YTk0NDRjMDZkMDFfMi03LTEtMS0zMDUwMA_ae88da84-a8ef-4794-a661-a46cb4760cc6"
      unitRef="usd">-19292000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xNi9mcmFnOmNhNTFhNDQ0OTY0MTQzZmNhZWZhYWI5NjUxOWZhZjdiL3RhYmxlOjUzYzg3ZDkyZGY2YTQ1N2Q5Nzk4NGE5NDQ0YzA2ZDAxL3RhYmxlcmFuZ2U6NTNjODdkOTJkZjZhNDU3ZDk3OTg0YTk0NDRjMDZkMDFfMi05LTEtMS0zMDUwMA_ac090655-5665-47eb-a615-d5a144987334"
      unitRef="usd">-63933000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i69e8bcaae5bf44c9a03cf7f5bd08e6b8_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xNi9mcmFnOmNhNTFhNDQ0OTY0MTQzZmNhZWZhYWI5NjUxOWZhZjdiL3RhYmxlOjUzYzg3ZDkyZGY2YTQ1N2Q5Nzk4NGE5NDQ0YzA2ZDAxL3RhYmxlcmFuZ2U6NTNjODdkOTJkZjZhNDU3ZDk3OTg0YTk0NDRjMDZkMDFfMi0xMS0xLTEtMzA1MDA_9237b974-1b0a-47f1-8ec0-acf23471139d"
      unitRef="usd">-71760000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i25a8ea2d7c9f4bfd8f72223c8ac18c65_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xNi9mcmFnOmNhNTFhNDQ0OTY0MTQzZmNhZWZhYWI5NjUxOWZhZjdiL3RhYmxlOjUzYzg3ZDkyZGY2YTQ1N2Q5Nzk4NGE5NDQ0YzA2ZDAxL3RhYmxlcmFuZ2U6NTNjODdkOTJkZjZhNDU3ZDk3OTg0YTk0NDRjMDZkMDFfNC01LTEtMS0zMDUwMA_bbff4caa-3f69-4371-ab91-f745d48a3e8e"
      unitRef="usd">274000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="ib52579de36d54242a791b9e3f8019a00_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xNi9mcmFnOmNhNTFhNDQ0OTY0MTQzZmNhZWZhYWI5NjUxOWZhZjdiL3RhYmxlOjUzYzg3ZDkyZGY2YTQ1N2Q5Nzk4NGE5NDQ0YzA2ZDAxL3RhYmxlcmFuZ2U6NTNjODdkOTJkZjZhNDU3ZDk3OTg0YTk0NDRjMDZkMDFfNC03LTEtMS0zMDUwMA_9e5c394a-d4e7-4fb1-a820-8106c5990c67"
      unitRef="usd">598000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xNi9mcmFnOmNhNTFhNDQ0OTY0MTQzZmNhZWZhYWI5NjUxOWZhZjdiL3RhYmxlOjUzYzg3ZDkyZGY2YTQ1N2Q5Nzk4NGE5NDQ0YzA2ZDAxL3RhYmxlcmFuZ2U6NTNjODdkOTJkZjZhNDU3ZDk3OTg0YTk0NDRjMDZkMDFfNC05LTEtMS0zMDUwMA_429fc883-7200-47d9-89a3-3eb2bea08409"
      unitRef="usd">-134000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i69e8bcaae5bf44c9a03cf7f5bd08e6b8_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xNi9mcmFnOmNhNTFhNDQ0OTY0MTQzZmNhZWZhYWI5NjUxOWZhZjdiL3RhYmxlOjUzYzg3ZDkyZGY2YTQ1N2Q5Nzk4NGE5NDQ0YzA2ZDAxL3RhYmxlcmFuZ2U6NTNjODdkOTJkZjZhNDU3ZDk3OTg0YTk0NDRjMDZkMDFfNC0xMS0xLTEtMzA1MDA_7ef2869f-60c8-443d-b036-66c6c5e4e93d"
      unitRef="usd">3312000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i25a8ea2d7c9f4bfd8f72223c8ac18c65_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xNi9mcmFnOmNhNTFhNDQ0OTY0MTQzZmNhZWZhYWI5NjUxOWZhZjdiL3RhYmxlOjUzYzg3ZDkyZGY2YTQ1N2Q5Nzk4NGE5NDQ0YzA2ZDAxL3RhYmxlcmFuZ2U6NTNjODdkOTJkZjZhNDU3ZDk3OTg0YTk0NDRjMDZkMDFfNi01LTEtMS0zMDUwMA_7b909d95-f218-41d6-96a1-46146e716c28"
      unitRef="usd">-20950000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ib52579de36d54242a791b9e3f8019a00_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xNi9mcmFnOmNhNTFhNDQ0OTY0MTQzZmNhZWZhYWI5NjUxOWZhZjdiL3RhYmxlOjUzYzg3ZDkyZGY2YTQ1N2Q5Nzk4NGE5NDQ0YzA2ZDAxL3RhYmxlcmFuZ2U6NTNjODdkOTJkZjZhNDU3ZDk3OTg0YTk0NDRjMDZkMDFfNi03LTEtMS0zMDUwMA_68989145-3728-4779-8db2-228f752ca191"
      unitRef="usd">-18694000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xNi9mcmFnOmNhNTFhNDQ0OTY0MTQzZmNhZWZhYWI5NjUxOWZhZjdiL3RhYmxlOjUzYzg3ZDkyZGY2YTQ1N2Q5Nzk4NGE5NDQ0YzA2ZDAxL3RhYmxlcmFuZ2U6NTNjODdkOTJkZjZhNDU3ZDk3OTg0YTk0NDRjMDZkMDFfNi05LTEtMS0zMDUwMA_33d363c0-364b-4d52-9dbd-69b120d3bd20"
      unitRef="usd">-64067000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i69e8bcaae5bf44c9a03cf7f5bd08e6b8_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xNi9mcmFnOmNhNTFhNDQ0OTY0MTQzZmNhZWZhYWI5NjUxOWZhZjdiL3RhYmxlOjUzYzg3ZDkyZGY2YTQ1N2Q5Nzk4NGE5NDQ0YzA2ZDAxL3RhYmxlcmFuZ2U6NTNjODdkOTJkZjZhNDU3ZDk3OTg0YTk0NDRjMDZkMDFfNi0xMS0xLTEtMzA1MDA_48a382ae-dffc-4e2c-94fe-be2d75c0fbb8"
      unitRef="usd">-68448000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i10cadb43ee4f4d5983a19400b011767c_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjM1OTg4NDc0ZGQ4ZDRiMjM5ZTA1OTA2NjJkMzEwMTk0L3RhYmxlcmFuZ2U6MzU5ODg0NzRkZDhkNGIyMzllMDU5MDY2MmQzMTAxOTRfMy0xLTEtMS0zMDUwMA_b53ca6b6-0418-42e4-b567-711821a65dc9"
      unitRef="shares">26335418</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i10cadb43ee4f4d5983a19400b011767c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjM1OTg4NDc0ZGQ4ZDRiMjM5ZTA1OTA2NjJkMzEwMTk0L3RhYmxlcmFuZ2U6MzU5ODg0NzRkZDhkNGIyMzllMDU5MDY2MmQzMTAxOTRfMy0zLTEtMS0zMDUwMA_06063696-56ba-40b2-acce-c2f531ae95c9"
      unitRef="usd">3000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i009a2206cca94447b0821da5d321afd8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjM1OTg4NDc0ZGQ4ZDRiMjM5ZTA1OTA2NjJkMzEwMTk0L3RhYmxlcmFuZ2U6MzU5ODg0NzRkZDhkNGIyMzllMDU5MDY2MmQzMTAxOTRfMy01LTEtMS0zMDUwMA_b81ff215-4d30-4a26-abe7-a1d2d0f07ff7"
      unitRef="usd">324237000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i385e3bff38de43c684e65b2b3be869c2_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjM1OTg4NDc0ZGQ4ZDRiMjM5ZTA1OTA2NjJkMzEwMTk0L3RhYmxlcmFuZ2U6MzU5ODg0NzRkZDhkNGIyMzllMDU5MDY2MmQzMTAxOTRfMy03LTEtMS0zMDUwMA_1ce7ef53-fd71-403c-ba19-5dcccaeb9101"
      unitRef="usd">-252000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i3f4fa8cb61dc4846bc63aadbbe138fd4_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjM1OTg4NDc0ZGQ4ZDRiMjM5ZTA1OTA2NjJkMzEwMTk0L3RhYmxlcmFuZ2U6MzU5ODg0NzRkZDhkNGIyMzllMDU5MDY2MmQzMTAxOTRfMy05LTEtMS0zMDUwMA_2d88497f-174b-442f-8b50-20d329e0fd4f"
      unitRef="usd">-196873000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i12246a01749f40d394a9437cb9938c91_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjM1OTg4NDc0ZGQ4ZDRiMjM5ZTA1OTA2NjJkMzEwMTk0L3RhYmxlcmFuZ2U6MzU5ODg0NzRkZDhkNGIyMzllMDU5MDY2MmQzMTAxOTRfMy0xMS0xLTEtMzA1MDA_8fdb07e5-f987-4252-8f09-74fa65961efb"
      unitRef="usd">127115000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="ida6ee8360c724bafba15cd5fadf3f86c_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjM1OTg4NDc0ZGQ4ZDRiMjM5ZTA1OTA2NjJkMzEwMTk0L3RhYmxlcmFuZ2U6MzU5ODg0NzRkZDhkNGIyMzllMDU5MDY2MmQzMTAxOTRfNC05LTEtMS0zMDUwMA_171e8aef-705c-4445-a81e-8338b31277ee"
      unitRef="usd">-20808000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="icd575a0576f94d6abe3a754e65a57231_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjM1OTg4NDc0ZGQ4ZDRiMjM5ZTA1OTA2NjJkMzEwMTk0L3RhYmxlcmFuZ2U6MzU5ODg0NzRkZDhkNGIyMzllMDU5MDY2MmQzMTAxOTRfNC0xMS0xLTEtMzA1MDA_a86027e2-ed93-4020-be84-1e0db4b80957"
      unitRef="usd">-20808000</us-gaap:NetIncomeLoss>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i5bfbb29080414e03b068322088956131_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjM1OTg4NDc0ZGQ4ZDRiMjM5ZTA1OTA2NjJkMzEwMTk0L3RhYmxlcmFuZ2U6MzU5ODg0NzRkZDhkNGIyMzllMDU5MDY2MmQzMTAxOTRfNS01LTEtMS0zMDUwMA_c81201d9-6b5a-413c-900b-cea0bcfb81e5"
      unitRef="usd">2069000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="icd575a0576f94d6abe3a754e65a57231_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjM1OTg4NDc0ZGQ4ZDRiMjM5ZTA1OTA2NjJkMzEwMTk0L3RhYmxlcmFuZ2U6MzU5ODg0NzRkZDhkNGIyMzllMDU5MDY2MmQzMTAxOTRfNS0xMS0xLTEtMzA1MDA_35bd23b2-9145-48ce-b4e2-1c2fd4266a90"
      unitRef="usd">2069000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i833e88d808f64f8db575748a84d92e85_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjM1OTg4NDc0ZGQ4ZDRiMjM5ZTA1OTA2NjJkMzEwMTk0L3RhYmxlcmFuZ2U6MzU5ODg0NzRkZDhkNGIyMzllMDU5MDY2MmQzMTAxOTRfNi03LTEtMS0zMDUwMA_be6cb8d7-4a0b-487c-8233-2273dcc78c32"
      unitRef="usd">-58000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="icd575a0576f94d6abe3a754e65a57231_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjM1OTg4NDc0ZGQ4ZDRiMjM5ZTA1OTA2NjJkMzEwMTk0L3RhYmxlcmFuZ2U6MzU5ODg0NzRkZDhkNGIyMzllMDU5MDY2MmQzMTAxOTRfNi0xMS0xLTEtMzA1MDA_e4976b0a-5b8e-445b-a008-334123b9cc8b"
      unitRef="usd">-58000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i5521d4c179a3424b8300e7e1aa3bb508_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjM1OTg4NDc0ZGQ4ZDRiMjM5ZTA1OTA2NjJkMzEwMTk0L3RhYmxlcmFuZ2U6MzU5ODg0NzRkZDhkNGIyMzllMDU5MDY2MmQzMTAxOTRfNy0xLTEtMS0zMDUwMA_65078156-aed2-4c53-b8d9-32c3a2e16e97"
      unitRef="shares">852</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i5bfbb29080414e03b068322088956131_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjM1OTg4NDc0ZGQ4ZDRiMjM5ZTA1OTA2NjJkMzEwMTk0L3RhYmxlcmFuZ2U6MzU5ODg0NzRkZDhkNGIyMzllMDU5MDY2MmQzMTAxOTRfNy01LTEtMS0zMDUwMA_1758e85a-7a89-45f5-957c-8dceb32482c9"
      unitRef="usd">5000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="icd575a0576f94d6abe3a754e65a57231_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjM1OTg4NDc0ZGQ4ZDRiMjM5ZTA1OTA2NjJkMzEwMTk0L3RhYmxlcmFuZ2U6MzU5ODg0NzRkZDhkNGIyMzllMDU5MDY2MmQzMTAxOTRfNy0xMS0xLTEtMzA1MDA_3b8ddb1a-e418-449f-9d62-b7e5e8e77205"
      unitRef="usd">5000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="icd575a0576f94d6abe3a754e65a57231_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjM1OTg4NDc0ZGQ4ZDRiMjM5ZTA1OTA2NjJkMzEwMTk0L3RhYmxlcmFuZ2U6MzU5ODg0NzRkZDhkNGIyMzllMDU5MDY2MmQzMTAxOTRfOS0wLTEtMS0zMTM5MS90ZXh0cmVnaW9uOmU0MTExNGVkNDIyNjRiN2FhM2EwOGJhYzQ3M2YxOGE0XzIxOTkwMjMyNTU2NDU_73af9e60-4758-4934-8cb9-1ebb9e5d59df"
      unitRef="usd">918000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i48e85fbb9eaf443d833e5d74dad1457f_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjM1OTg4NDc0ZGQ4ZDRiMjM5ZTA1OTA2NjJkMzEwMTk0L3RhYmxlcmFuZ2U6MzU5ODg0NzRkZDhkNGIyMzllMDU5MDY2MmQzMTAxOTRfOS0xLTEtMS0zMTM5MQ_89fa3e9e-f2db-481b-94c0-2651960af032"
      unitRef="shares">2904113</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i85e99d9786824edc9811205ccff0e2c1_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjM1OTg4NDc0ZGQ4ZDRiMjM5ZTA1OTA2NjJkMzEwMTk0L3RhYmxlcmFuZ2U6MzU5ODg0NzRkZDhkNGIyMzllMDU5MDY2MmQzMTAxOTRfOS01LTEtMS0zMTM5MQ_14bbdc44-6d3e-4db9-b205-f2d01300168f"
      unitRef="usd">29638000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="if0fe92136184445b9b403e48c306c7a0_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjM1OTg4NDc0ZGQ4ZDRiMjM5ZTA1OTA2NjJkMzEwMTk0L3RhYmxlcmFuZ2U6MzU5ODg0NzRkZDhkNGIyMzllMDU5MDY2MmQzMTAxOTRfOS0xMS0xLTEtMzEzOTE_91df78e2-0244-4a41-b781-21e4b58488e8"
      unitRef="usd">29638000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i37699bd784b74eff9b8044aa3d0f82c7_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjM1OTg4NDc0ZGQ4ZDRiMjM5ZTA1OTA2NjJkMzEwMTk0L3RhYmxlcmFuZ2U6MzU5ODg0NzRkZDhkNGIyMzllMDU5MDY2MmQzMTAxOTRfOS0xLTEtMS0zMDUwMA_2c4253d9-191e-4a5c-b3b3-e94347a15a4d"
      unitRef="shares">29240383</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i37699bd784b74eff9b8044aa3d0f82c7_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjM1OTg4NDc0ZGQ4ZDRiMjM5ZTA1OTA2NjJkMzEwMTk0L3RhYmxlcmFuZ2U6MzU5ODg0NzRkZDhkNGIyMzllMDU5MDY2MmQzMTAxOTRfOS0zLTEtMS0zMDUwMA_7d1de858-c4c1-475b-9c07-c2e1dd8561d9"
      unitRef="usd">3000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i695cece83a314ed69b003d1805aa445f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjM1OTg4NDc0ZGQ4ZDRiMjM5ZTA1OTA2NjJkMzEwMTk0L3RhYmxlcmFuZ2U6MzU5ODg0NzRkZDhkNGIyMzllMDU5MDY2MmQzMTAxOTRfOS01LTEtMS0zMDUwMA_622f1119-4531-4175-815b-b4cd6ec6a7c8"
      unitRef="usd">355949000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9f48eb2e56ec4c62bea71dbf94048968_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjM1OTg4NDc0ZGQ4ZDRiMjM5ZTA1OTA2NjJkMzEwMTk0L3RhYmxlcmFuZ2U6MzU5ODg0NzRkZDhkNGIyMzllMDU5MDY2MmQzMTAxOTRfOS03LTEtMS0zMDUwMA_1dba3be5-0130-4c69-b0c9-c7b3c5aeb0bf"
      unitRef="usd">-310000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i70f7507e4b224e59ba619f034e88a2d9_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjM1OTg4NDc0ZGQ4ZDRiMjM5ZTA1OTA2NjJkMzEwMTk0L3RhYmxlcmFuZ2U6MzU5ODg0NzRkZDhkNGIyMzllMDU5MDY2MmQzMTAxOTRfOS05LTEtMS0zMDUwMA_3e81c4b5-0265-40fa-ae1a-085bde961517"
      unitRef="usd">-217681000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i85803ab216eb4675941bdbd496da6ed9_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjM1OTg4NDc0ZGQ4ZDRiMjM5ZTA1OTA2NjJkMzEwMTk0L3RhYmxlcmFuZ2U6MzU5ODg0NzRkZDhkNGIyMzllMDU5MDY2MmQzMTAxOTRfOS0xMS0xLTEtMzA1MDA_0d09fc1b-2dfe-4f98-b2ce-f7ab4eeb64e3"
      unitRef="usd">137961000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i737e66e4d7604e7294bf339bc188faf1_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjM1OTg4NDc0ZGQ4ZDRiMjM5ZTA1OTA2NjJkMzEwMTk0L3RhYmxlcmFuZ2U6MzU5ODg0NzRkZDhkNGIyMzllMDU5MDY2MmQzMTAxOTRfMTAtOS0xLTEtMzA1MDA_d843f785-2bfa-4e16-9cac-054ed54c279d"
      unitRef="usd">-21901000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i8ff3b5d8c53f48e598eabdf159ffe5a8_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjM1OTg4NDc0ZGQ4ZDRiMjM5ZTA1OTA2NjJkMzEwMTk0L3RhYmxlcmFuZ2U6MzU5ODg0NzRkZDhkNGIyMzllMDU5MDY2MmQzMTAxOTRfMTAtMTEtMS0xLTMwNTAw_8965452d-1225-4a2e-8c53-4d47c5ae29f5"
      unitRef="usd">-21901000</us-gaap:NetIncomeLoss>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i2e65e2ba034b476992065fd432154ff5_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjM1OTg4NDc0ZGQ4ZDRiMjM5ZTA1OTA2NjJkMzEwMTk0L3RhYmxlcmFuZ2U6MzU5ODg0NzRkZDhkNGIyMzllMDU5MDY2MmQzMTAxOTRfMTEtNS0xLTEtMzA1MDA_3779d24e-1d59-460b-9a02-df1f5348d64a"
      unitRef="usd">2062000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i8ff3b5d8c53f48e598eabdf159ffe5a8_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjM1OTg4NDc0ZGQ4ZDRiMjM5ZTA1OTA2NjJkMzEwMTk0L3RhYmxlcmFuZ2U6MzU5ODg0NzRkZDhkNGIyMzllMDU5MDY2MmQzMTAxOTRfMTEtMTEtMS0xLTMwNTAw_245d29c3-1ab7-48ae-b480-10cd1ab35509"
      unitRef="usd">2062000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="iff0dfca8fc4744b889817f531d94648d_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjM1OTg4NDc0ZGQ4ZDRiMjM5ZTA1OTA2NjJkMzEwMTk0L3RhYmxlcmFuZ2U6MzU5ODg0NzRkZDhkNGIyMzllMDU5MDY2MmQzMTAxOTRfMTItNy0xLTEtMzA1MDA_29bf3549-4e95-4359-9880-be9d8cdce222"
      unitRef="usd">-350000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i8ff3b5d8c53f48e598eabdf159ffe5a8_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjM1OTg4NDc0ZGQ4ZDRiMjM5ZTA1OTA2NjJkMzEwMTk0L3RhYmxlcmFuZ2U6MzU5ODg0NzRkZDhkNGIyMzllMDU5MDY2MmQzMTAxOTRfMTItMTEtMS0xLTMwNTAw_ede385ff-b313-431e-a601-7dc017a8e40a"
      unitRef="usd">-350000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i1888877c44594a0cbbf03d306681d074_D20220401-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjM1OTg4NDc0ZGQ4ZDRiMjM5ZTA1OTA2NjJkMzEwMTk0L3RhYmxlcmFuZ2U6MzU5ODg0NzRkZDhkNGIyMzllMDU5MDY2MmQzMTAxOTRfMTMtMS0xLTEtMzEzNDE_1e2c7369-4def-4643-8ea3-5d338648aa06"
      unitRef="shares">24612</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i2e65e2ba034b476992065fd432154ff5_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjM1OTg4NDc0ZGQ4ZDRiMjM5ZTA1OTA2NjJkMzEwMTk0L3RhYmxlcmFuZ2U6MzU5ODg0NzRkZDhkNGIyMzllMDU5MDY2MmQzMTAxOTRfMTMtNS0xLTEtMzEzNDE_6e153c73-2b54-4a4b-8248-6bb2cdebd4e5"
      unitRef="usd">130000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i8ff3b5d8c53f48e598eabdf159ffe5a8_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjM1OTg4NDc0ZGQ4ZDRiMjM5ZTA1OTA2NjJkMzEwMTk0L3RhYmxlcmFuZ2U6MzU5ODg0NzRkZDhkNGIyMzllMDU5MDY2MmQzMTAxOTRfMTMtMTEtMS0xLTMxMzQx_048f8ad7-8fe1-40ba-8088-50832572856f"
      unitRef="usd">130000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="i8ff3b5d8c53f48e598eabdf159ffe5a8_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjM1OTg4NDc0ZGQ4ZDRiMjM5ZTA1OTA2NjJkMzEwMTk0L3RhYmxlcmFuZ2U6MzU5ODg0NzRkZDhkNGIyMzllMDU5MDY2MmQzMTAxOTRfMTQtMC0xLTEtMzEzNDEvdGV4dHJlZ2lvbjo0MmRmOWMzMGY0Mzk0MDBlOWQ0NDhkMTQ2NzUwOTYxMl81NDk3NTU4MTM5ODE_3bcee1ae-ba45-472b-9937-e9184be86a53"
      unitRef="usd">308000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i22a1a97b6019485d898b3ada299277d4_D20220401-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjM1OTg4NDc0ZGQ4ZDRiMjM5ZTA1OTA2NjJkMzEwMTk0L3RhYmxlcmFuZ2U6MzU5ODg0NzRkZDhkNGIyMzllMDU5MDY2MmQzMTAxOTRfMTQtMS0xLTEtMzEzNDE_3aedbcd6-25c0-4147-af69-5c866e0f3707"
      unitRef="shares">1300000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i0620912ded354506af6d332f0bc83206_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjM1OTg4NDc0ZGQ4ZDRiMjM5ZTA1OTA2NjJkMzEwMTk0L3RhYmxlcmFuZ2U6MzU5ODg0NzRkZDhkNGIyMzllMDU5MDY2MmQzMTAxOTRfMTQtNS0xLTEtMzEzNDE_d3db38ae-12c2-4b08-8d94-4edc94df2ef6"
      unitRef="usd">9946000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i1d21953862a4496690291cb9fd6c7a94_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjM1OTg4NDc0ZGQ4ZDRiMjM5ZTA1OTA2NjJkMzEwMTk0L3RhYmxlcmFuZ2U6MzU5ODg0NzRkZDhkNGIyMzllMDU5MDY2MmQzMTAxOTRfMTQtMTEtMS0xLTMxMzQx_7ae214fa-5004-4afa-91e4-55bdda116971"
      unitRef="usd">9946000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i8e38d9d8fc034a00a625f8563c6b5b60_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjM1OTg4NDc0ZGQ4ZDRiMjM5ZTA1OTA2NjJkMzEwMTk0L3RhYmxlcmFuZ2U6MzU5ODg0NzRkZDhkNGIyMzllMDU5MDY2MmQzMTAxOTRfMTMtMS0xLTEtMzA1MDA_0cb59213-f087-4e3a-ae27-cc3548acceec"
      unitRef="shares">30564995</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i8e38d9d8fc034a00a625f8563c6b5b60_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjM1OTg4NDc0ZGQ4ZDRiMjM5ZTA1OTA2NjJkMzEwMTk0L3RhYmxlcmFuZ2U6MzU5ODg0NzRkZDhkNGIyMzllMDU5MDY2MmQzMTAxOTRfMTMtMy0xLTEtMzA1MDA_0b1a6092-0dca-4006-8a2c-c14c9d73ccc5"
      unitRef="usd">3000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iafd4cef3856c4625a9d0b5d421a2c12c_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjM1OTg4NDc0ZGQ4ZDRiMjM5ZTA1OTA2NjJkMzEwMTk0L3RhYmxlcmFuZ2U6MzU5ODg0NzRkZDhkNGIyMzllMDU5MDY2MmQzMTAxOTRfMTMtNS0xLTEtMzA1MDA_23543736-15ab-4895-b449-efdd14a36169"
      unitRef="usd">368087000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="idb62eb795df54275a27ebfed4e80d684_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjM1OTg4NDc0ZGQ4ZDRiMjM5ZTA1OTA2NjJkMzEwMTk0L3RhYmxlcmFuZ2U6MzU5ODg0NzRkZDhkNGIyMzllMDU5MDY2MmQzMTAxOTRfMTMtNy0xLTEtMzA1MDA_f0774e4f-6d2b-47b9-8d26-818eea6897c0"
      unitRef="usd">-660000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib052a6f4a0df4d008a91d46f1ee57c9c_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjM1OTg4NDc0ZGQ4ZDRiMjM5ZTA1OTA2NjJkMzEwMTk0L3RhYmxlcmFuZ2U6MzU5ODg0NzRkZDhkNGIyMzllMDU5MDY2MmQzMTAxOTRfMTMtOS0xLTEtMzA1MDA_d8988bc4-5e76-40e1-ae9b-214b451ae682"
      unitRef="usd">-239582000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i1fd2b9d5dc8348c987bb258a78754f1b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjM1OTg4NDc0ZGQ4ZDRiMjM5ZTA1OTA2NjJkMzEwMTk0L3RhYmxlcmFuZ2U6MzU5ODg0NzRkZDhkNGIyMzllMDU5MDY2MmQzMTAxOTRfMTMtMTEtMS0xLTMwNTAw_3aaf77b0-f8e2-41bf-a32f-956a85972074"
      unitRef="usd">127848000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i0c6bb7a44c4b41a48b75959b450bca0a_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjM1OTg4NDc0ZGQ4ZDRiMjM5ZTA1OTA2NjJkMzEwMTk0L3RhYmxlcmFuZ2U6MzU5ODg0NzRkZDhkNGIyMzllMDU5MDY2MmQzMTAxOTRfMTQtOS0xLTEtMzA1MDA_2b816646-6f7b-42b3-a1de-f1963ae8ce12"
      unitRef="usd">-21224000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i25a8ea2d7c9f4bfd8f72223c8ac18c65_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjM1OTg4NDc0ZGQ4ZDRiMjM5ZTA1OTA2NjJkMzEwMTk0L3RhYmxlcmFuZ2U6MzU5ODg0NzRkZDhkNGIyMzllMDU5MDY2MmQzMTAxOTRfMTQtMTEtMS0xLTMwNTAw_97d5d863-dca8-4a5a-925a-ab506ded9d2d"
      unitRef="usd">-21224000</us-gaap:NetIncomeLoss>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="if2f7ecfa268042c1b6d8341deccf977e_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjM1OTg4NDc0ZGQ4ZDRiMjM5ZTA1OTA2NjJkMzEwMTk0L3RhYmxlcmFuZ2U6MzU5ODg0NzRkZDhkNGIyMzllMDU5MDY2MmQzMTAxOTRfMTUtNS0xLTEtMzA1MDA_bd2fac42-61dc-4ee9-bc1a-23e082a7d5ca"
      unitRef="usd">1912000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i25a8ea2d7c9f4bfd8f72223c8ac18c65_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjM1OTg4NDc0ZGQ4ZDRiMjM5ZTA1OTA2NjJkMzEwMTk0L3RhYmxlcmFuZ2U6MzU5ODg0NzRkZDhkNGIyMzllMDU5MDY2MmQzMTAxOTRfMTUtMTEtMS0xLTMwNTAw_dcd1d7a7-9a78-4ae7-971f-9110a7dbeb2e"
      unitRef="usd">1912000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i866042db0ec3492ab88b30fc3d7eb0bf_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjM1OTg4NDc0ZGQ4ZDRiMjM5ZTA1OTA2NjJkMzEwMTk0L3RhYmxlcmFuZ2U6MzU5ODg0NzRkZDhkNGIyMzllMDU5MDY2MmQzMTAxOTRfMTYtNy0xLTEtMzA1MDA_487eab83-ecfe-44eb-9794-e68f18288b6f"
      unitRef="usd">274000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i25a8ea2d7c9f4bfd8f72223c8ac18c65_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjM1OTg4NDc0ZGQ4ZDRiMjM5ZTA1OTA2NjJkMzEwMTk0L3RhYmxlcmFuZ2U6MzU5ODg0NzRkZDhkNGIyMzllMDU5MDY2MmQzMTAxOTRfMTYtMTEtMS0xLTMwNTAw_51c02a47-7181-4e49-8b00-e704412bb459"
      unitRef="usd">274000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i5b62286d567e4f259000b5a1b4c2dbbe_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjM1OTg4NDc0ZGQ4ZDRiMjM5ZTA1OTA2NjJkMzEwMTk0L3RhYmxlcmFuZ2U6MzU5ODg0NzRkZDhkNGIyMzllMDU5MDY2MmQzMTAxOTRfMTgtMS0xLTEtMzA1MDA_f9180108-0de1-47ba-b23d-ffc609ad219a"
      unitRef="shares">30564995</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i5b62286d567e4f259000b5a1b4c2dbbe_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjM1OTg4NDc0ZGQ4ZDRiMjM5ZTA1OTA2NjJkMzEwMTk0L3RhYmxlcmFuZ2U6MzU5ODg0NzRkZDhkNGIyMzllMDU5MDY2MmQzMTAxOTRfMTgtMy0xLTEtMzA1MDA_e44bbd74-acc6-496a-a9e0-0f7e70f05423"
      unitRef="usd">3000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i8b90293a84aa4674a7bcf0617b17717e_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjM1OTg4NDc0ZGQ4ZDRiMjM5ZTA1OTA2NjJkMzEwMTk0L3RhYmxlcmFuZ2U6MzU5ODg0NzRkZDhkNGIyMzllMDU5MDY2MmQzMTAxOTRfMTgtNS0xLTEtMzA1MDA_e10b279b-78a5-4191-8532-0dac32281663"
      unitRef="usd">369999000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="icbddd86c41c74f1ea8d5a18c99ee0215_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjM1OTg4NDc0ZGQ4ZDRiMjM5ZTA1OTA2NjJkMzEwMTk0L3RhYmxlcmFuZ2U6MzU5ODg0NzRkZDhkNGIyMzllMDU5MDY2MmQzMTAxOTRfMTgtNy0xLTEtMzA1MDA_82bd8f93-fb07-4807-a8dc-c1ca08d1f779"
      unitRef="usd">-386000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i854438f7be7f47f196c8a2c22e9b5e77_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjM1OTg4NDc0ZGQ4ZDRiMjM5ZTA1OTA2NjJkMzEwMTk0L3RhYmxlcmFuZ2U6MzU5ODg0NzRkZDhkNGIyMzllMDU5MDY2MmQzMTAxOTRfMTgtOS0xLTEtMzA1MDA_a1208d53-9c9a-456a-ad50-32f597882e65"
      unitRef="usd">-260806000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib2ba0b84078f4de2bc3079e992921b92_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjM1OTg4NDc0ZGQ4ZDRiMjM5ZTA1OTA2NjJkMzEwMTk0L3RhYmxlcmFuZ2U6MzU5ODg0NzRkZDhkNGIyMzllMDU5MDY2MmQzMTAxOTRfMTgtMTEtMS0xLTMwNTAw_099f64ad-a38e-4455-b773-ea8bd290b902"
      unitRef="usd">108810000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i607bec8e45eb4e6d838d65f04d1d719f_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjY2NzM1ZjJmYmQ2YTQyNWJhOTQxMjljMDA3N2FiNjljL3RhYmxlcmFuZ2U6NjY3MzVmMmZiZDZhNDI1YmE5NDEyOWMwMDc3YWI2OWNfMy0xLTEtMS0zMDUwMA_0e3cba6d-b0db-43eb-8a8d-aba7285e4360"
      unitRef="shares">21168240</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i607bec8e45eb4e6d838d65f04d1d719f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjY2NzM1ZjJmYmQ2YTQyNWJhOTQxMjljMDA3N2FiNjljL3RhYmxlcmFuZ2U6NjY3MzVmMmZiZDZhNDI1YmE5NDEyOWMwMDc3YWI2OWNfMy0zLTEtMS0zMDUwMA_0a248566-95b5-4286-a420-f300b0652383"
      unitRef="usd">2000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if567f5fc4bef457ba7f7d0fa94a8a6ef_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjY2NzM1ZjJmYmQ2YTQyNWJhOTQxMjljMDA3N2FiNjljL3RhYmxlcmFuZ2U6NjY3MzVmMmZiZDZhNDI1YmE5NDEyOWMwMDc3YWI2OWNfMy01LTEtMS0zMDUwMA_7d51b44a-9cce-4fc6-8770-fe9e7ad71f22"
      unitRef="usd">266823000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iea3035acf49d4db7a54e9ead049bc20b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjY2NzM1ZjJmYmQ2YTQyNWJhOTQxMjljMDA3N2FiNjljL3RhYmxlcmFuZ2U6NjY3MzVmMmZiZDZhNDI1YmE5NDEyOWMwMDc3YWI2OWNfMy03LTEtMS0zMDUwMA_006ab16f-7f56-489e-844a-6613b8c3089a"
      unitRef="usd">-4112000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i77530ee1861747fda1f023dbac2a8d90_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjY2NzM1ZjJmYmQ2YTQyNWJhOTQxMjljMDA3N2FiNjljL3RhYmxlcmFuZ2U6NjY3MzVmMmZiZDZhNDI1YmE5NDEyOWMwMDc3YWI2OWNfMy05LTEtMS0zMDUwMA_9dd57d3f-0034-4806-9b81-a38dc6738b79"
      unitRef="usd">-103928000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib8e90b6ab1f24717b294f892b4a059b4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjY2NzM1ZjJmYmQ2YTQyNWJhOTQxMjljMDA3N2FiNjljL3RhYmxlcmFuZ2U6NjY3MzVmMmZiZDZhNDI1YmE5NDEyOWMwMDc3YWI2OWNfMy0xMS0xLTEtMzA1MDA_688674a1-c037-4645-bcac-e2ef0a4743da"
      unitRef="usd">158785000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i26792f62773c456c934cf59dcefb4260_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjY2NzM1ZjJmYmQ2YTQyNWJhOTQxMjljMDA3N2FiNjljL3RhYmxlcmFuZ2U6NjY3MzVmMmZiZDZhNDI1YmE5NDEyOWMwMDc3YWI2OWNfNC05LTEtMS0zMDUwMA_1c01c331-71ee-4bf6-9c02-4fe0a6834137"
      unitRef="usd">-34534000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i7eb4374d1ee742ffa761b98e61b09caf_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjY2NzM1ZjJmYmQ2YTQyNWJhOTQxMjljMDA3N2FiNjljL3RhYmxlcmFuZ2U6NjY3MzVmMmZiZDZhNDI1YmE5NDEyOWMwMDc3YWI2OWNfNC0xMS0xLTEtMzA1MDA_c9daf492-9ffc-41d8-bc6c-b0b77fc2a6e7"
      unitRef="usd">-34534000</us-gaap:NetIncomeLoss>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ie46dbf54043c469594e16cf8b3942872_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjY2NzM1ZjJmYmQ2YTQyNWJhOTQxMjljMDA3N2FiNjljL3RhYmxlcmFuZ2U6NjY3MzVmMmZiZDZhNDI1YmE5NDEyOWMwMDc3YWI2OWNfNS01LTEtMS0zMDUwMA_ddb3063a-77cd-4f8f-b746-9cd19690f622"
      unitRef="usd">1579000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i7eb4374d1ee742ffa761b98e61b09caf_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjY2NzM1ZjJmYmQ2YTQyNWJhOTQxMjljMDA3N2FiNjljL3RhYmxlcmFuZ2U6NjY3MzVmMmZiZDZhNDI1YmE5NDEyOWMwMDc3YWI2OWNfNS0xMS0xLTEtMzA1MDA_7ed6bc95-72f9-4c0e-98c8-251d3414c43b"
      unitRef="usd">1579000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i26d6ec96c4a24603b58ef52fcbe09dbe_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjY2NzM1ZjJmYmQ2YTQyNWJhOTQxMjljMDA3N2FiNjljL3RhYmxlcmFuZ2U6NjY3MzVmMmZiZDZhNDI1YmE5NDEyOWMwMDc3YWI2OWNfNi03LTEtMS0zMDUwMA_7d374309-a9fb-4b6b-a8d5-073836f029d0"
      unitRef="usd">2991000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i7eb4374d1ee742ffa761b98e61b09caf_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjY2NzM1ZjJmYmQ2YTQyNWJhOTQxMjljMDA3N2FiNjljL3RhYmxlcmFuZ2U6NjY3MzVmMmZiZDZhNDI1YmE5NDEyOWMwMDc3YWI2OWNfNi0xMS0xLTEtMzA1MDA_5a579f1e-220e-461b-89e7-b4ff99c73a2c"
      unitRef="usd">2991000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="iff342baa477241189847103920c9390b_D20210401-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjY2NzM1ZjJmYmQ2YTQyNWJhOTQxMjljMDA3N2FiNjljL3RhYmxlcmFuZ2U6NjY3MzVmMmZiZDZhNDI1YmE5NDEyOWMwMDc3YWI2OWNfNy0xLTEtMS0zMTIyMg_efc40351-3af0-4574-ac08-5b766b2974a5"
      unitRef="shares">581199</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i79dafe91dc2b4583bc7281b9ac581921_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjY2NzM1ZjJmYmQ2YTQyNWJhOTQxMjljMDA3N2FiNjljL3RhYmxlcmFuZ2U6NjY3MzVmMmZiZDZhNDI1YmE5NDEyOWMwMDc3YWI2OWNfNy01LTEtMS0zMTIyMg_dee0f55d-a201-4535-9fdb-c9eefd38e9b1"
      unitRef="usd">8625000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i47c50e6a28d840f58afe00251ea7cb63_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjY2NzM1ZjJmYmQ2YTQyNWJhOTQxMjljMDA3N2FiNjljL3RhYmxlcmFuZ2U6NjY3MzVmMmZiZDZhNDI1YmE5NDEyOWMwMDc3YWI2OWNfNy0xMS0xLTEtMzEyMjI_29f1bded-de68-43c8-b9fa-a7004908055f"
      unitRef="usd">8625000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ic1b52eb993194bc79abd0bdb3ac2fb16_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjY2NzM1ZjJmYmQ2YTQyNWJhOTQxMjljMDA3N2FiNjljL3RhYmxlcmFuZ2U6NjY3MzVmMmZiZDZhNDI1YmE5NDEyOWMwMDc3YWI2OWNfOC0xLTEtMS0zMDUwMA_14f132a9-1526-4423-bbca-37afc57bb2df"
      unitRef="shares">21749439</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ic1b52eb993194bc79abd0bdb3ac2fb16_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjY2NzM1ZjJmYmQ2YTQyNWJhOTQxMjljMDA3N2FiNjljL3RhYmxlcmFuZ2U6NjY3MzVmMmZiZDZhNDI1YmE5NDEyOWMwMDc3YWI2OWNfOC0zLTEtMS0zMDUwMA_3f9ccfea-40b3-4869-854a-ea20acc9c612"
      unitRef="usd">2000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i1e4e96801dd14e038268468354ac544d_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjY2NzM1ZjJmYmQ2YTQyNWJhOTQxMjljMDA3N2FiNjljL3RhYmxlcmFuZ2U6NjY3MzVmMmZiZDZhNDI1YmE5NDEyOWMwMDc3YWI2OWNfOC01LTEtMS0zMDUwMA_880ecadb-3a11-4acd-a0cb-6686ea5a3898"
      unitRef="usd">277027000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i36785e9a44f44fa498d7a9e39d281de6_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjY2NzM1ZjJmYmQ2YTQyNWJhOTQxMjljMDA3N2FiNjljL3RhYmxlcmFuZ2U6NjY3MzVmMmZiZDZhNDI1YmE5NDEyOWMwMDc3YWI2OWNfOC03LTEtMS0zMDUwMA_10c63d8e-144f-43a3-b6af-b48a3b479ce2"
      unitRef="usd">-1121000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id8c73d5dc8b3435d90082da759d26561_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjY2NzM1ZjJmYmQ2YTQyNWJhOTQxMjljMDA3N2FiNjljL3RhYmxlcmFuZ2U6NjY3MzVmMmZiZDZhNDI1YmE5NDEyOWMwMDc3YWI2OWNfOC05LTEtMS0zMDUwMA_8629e835-fca7-4f37-bb94-e872f4c425c3"
      unitRef="usd">-138462000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie158d385723a4b6c94e8384571358a19_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjY2NzM1ZjJmYmQ2YTQyNWJhOTQxMjljMDA3N2FiNjljL3RhYmxlcmFuZ2U6NjY3MzVmMmZiZDZhNDI1YmE5NDEyOWMwMDc3YWI2OWNfOC0xMS0xLTEtMzA1MDA_3b581627-cf3b-42da-8c0b-39268b900ecf"
      unitRef="usd">137446000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="iec8caa356ace43cea23a50885d4ce99a_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjY2NzM1ZjJmYmQ2YTQyNWJhOTQxMjljMDA3N2FiNjljL3RhYmxlcmFuZ2U6NjY3MzVmMmZiZDZhNDI1YmE5NDEyOWMwMDc3YWI2OWNfOS05LTEtMS0zMDUwMA_29b8e8f2-fc20-4361-8d2b-e4556359f64a"
      unitRef="usd">-17934000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="idbd4b40aa73a4833999ce49448a575c1_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjY2NzM1ZjJmYmQ2YTQyNWJhOTQxMjljMDA3N2FiNjljL3RhYmxlcmFuZ2U6NjY3MzVmMmZiZDZhNDI1YmE5NDEyOWMwMDc3YWI2OWNfOS0xMS0xLTEtMzA1MDA_dbcf73c9-dea3-4a62-a92d-0ec04d4a9923"
      unitRef="usd">-17934000</us-gaap:NetIncomeLoss>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i727b0a04077a4a8f8ed3d895673d106c_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjY2NzM1ZjJmYmQ2YTQyNWJhOTQxMjljMDA3N2FiNjljL3RhYmxlcmFuZ2U6NjY3MzVmMmZiZDZhNDI1YmE5NDEyOWMwMDc3YWI2OWNfMTAtNS0xLTEtMzA1MDA_25eb00a1-ead1-463e-90e0-e2336f8faf15"
      unitRef="usd">1507000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="idbd4b40aa73a4833999ce49448a575c1_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjY2NzM1ZjJmYmQ2YTQyNWJhOTQxMjljMDA3N2FiNjljL3RhYmxlcmFuZ2U6NjY3MzVmMmZiZDZhNDI1YmE5NDEyOWMwMDc3YWI2OWNfMTAtMTEtMS0xLTMwNTAw_0445f739-2a29-44e0-b64d-6d81950784bc"
      unitRef="usd">1507000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i4fcf02a24eb5413182bd309637981b5f_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjY2NzM1ZjJmYmQ2YTQyNWJhOTQxMjljMDA3N2FiNjljL3RhYmxlcmFuZ2U6NjY3MzVmMmZiZDZhNDI1YmE5NDEyOWMwMDc3YWI2OWNfMTEtNy0xLTEtMzA1MDA_a913b567-22f1-440c-8003-409e2bee76cf"
      unitRef="usd">-277000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="idbd4b40aa73a4833999ce49448a575c1_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjY2NzM1ZjJmYmQ2YTQyNWJhOTQxMjljMDA3N2FiNjljL3RhYmxlcmFuZ2U6NjY3MzVmMmZiZDZhNDI1YmE5NDEyOWMwMDc3YWI2OWNfMTEtMTEtMS0xLTMwNTAw_24a96e05-7f55-40c3-8e5d-2c333f888caa"
      unitRef="usd">-277000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i3be90c8090ab461c8c2b38fd4278056a_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjY2NzM1ZjJmYmQ2YTQyNWJhOTQxMjljMDA3N2FiNjljL3RhYmxlcmFuZ2U6NjY3MzVmMmZiZDZhNDI1YmE5NDEyOWMwMDc3YWI2OWNfMTUtMS0xLTEtMzA1MDA_56604dcf-aced-43ed-b38d-953a892739b3"
      unitRef="shares">21749439</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i3be90c8090ab461c8c2b38fd4278056a_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjY2NzM1ZjJmYmQ2YTQyNWJhOTQxMjljMDA3N2FiNjljL3RhYmxlcmFuZ2U6NjY3MzVmMmZiZDZhNDI1YmE5NDEyOWMwMDc3YWI2OWNfMTUtMy0xLTEtMzA1MDA_c001f595-459b-42f7-87c2-a84fa1a34248"
      unitRef="usd">2000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia452dd2fae424bb3853dcf4cf9a6a5f7_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjY2NzM1ZjJmYmQ2YTQyNWJhOTQxMjljMDA3N2FiNjljL3RhYmxlcmFuZ2U6NjY3MzVmMmZiZDZhNDI1YmE5NDEyOWMwMDc3YWI2OWNfMTUtNS0xLTEtMzA1MDA_b3fa30ca-0747-4f1b-b9b1-dab450afb525"
      unitRef="usd">278534000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i3af9d520bc33490fb02d4e0e45e64528_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjY2NzM1ZjJmYmQ2YTQyNWJhOTQxMjljMDA3N2FiNjljL3RhYmxlcmFuZ2U6NjY3MzVmMmZiZDZhNDI1YmE5NDEyOWMwMDc3YWI2OWNfMTUtNy0xLTEtMzA1MDA_612cf3f2-a01a-4fa0-b4d2-c0e8cfe4d1c8"
      unitRef="usd">-1398000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7cf65f44be454209a8ed367a2d506669_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjY2NzM1ZjJmYmQ2YTQyNWJhOTQxMjljMDA3N2FiNjljL3RhYmxlcmFuZ2U6NjY3MzVmMmZiZDZhNDI1YmE5NDEyOWMwMDc3YWI2OWNfMTUtOS0xLTEtMzA1MDA_1e7d93a5-72b5-49bf-91a3-9a1ff196f573"
      unitRef="usd">-156396000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i016c5728112e4750b50b637d6c871fe3_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjY2NzM1ZjJmYmQ2YTQyNWJhOTQxMjljMDA3N2FiNjljL3RhYmxlcmFuZ2U6NjY3MzVmMmZiZDZhNDI1YmE5NDEyOWMwMDc3YWI2OWNfMTUtMTEtMS0xLTMwNTAw_eba91e4f-d7f7-44e3-9e2f-e3f5c094993e"
      unitRef="usd">120742000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i72dd476a4160417bb81e51d19d04fec4_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjY2NzM1ZjJmYmQ2YTQyNWJhOTQxMjljMDA3N2FiNjljL3RhYmxlcmFuZ2U6NjY3MzVmMmZiZDZhNDI1YmE5NDEyOWMwMDc3YWI2OWNfMTYtOS0xLTEtMzA1MDA_fe8a2af5-7ebb-4ad3-bb53-a702b3e0f770"
      unitRef="usd">-19292000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ib52579de36d54242a791b9e3f8019a00_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjY2NzM1ZjJmYmQ2YTQyNWJhOTQxMjljMDA3N2FiNjljL3RhYmxlcmFuZ2U6NjY3MzVmMmZiZDZhNDI1YmE5NDEyOWMwMDc3YWI2OWNfMTYtMTEtMS0xLTMwNTAw_0d30cd09-7335-4789-929b-c45197d3cca8"
      unitRef="usd">-19292000</us-gaap:NetIncomeLoss>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i39aae3cf38724522a40a6fc4e3254d97_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjY2NzM1ZjJmYmQ2YTQyNWJhOTQxMjljMDA3N2FiNjljL3RhYmxlcmFuZ2U6NjY3MzVmMmZiZDZhNDI1YmE5NDEyOWMwMDc3YWI2OWNfMTctNS0xLTEtMzA1MDA_094927ba-f4c7-4717-835e-09c41d5db76b"
      unitRef="usd">1397000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ib52579de36d54242a791b9e3f8019a00_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjY2NzM1ZjJmYmQ2YTQyNWJhOTQxMjljMDA3N2FiNjljL3RhYmxlcmFuZ2U6NjY3MzVmMmZiZDZhNDI1YmE5NDEyOWMwMDc3YWI2OWNfMTctMTEtMS0xLTMwNTAw_b72481f4-6537-4c7a-a943-8103002e5959"
      unitRef="usd">1397000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ie8f986adcd0d4adb96a54c85ecec772d_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjY2NzM1ZjJmYmQ2YTQyNWJhOTQxMjljMDA3N2FiNjljL3RhYmxlcmFuZ2U6NjY3MzVmMmZiZDZhNDI1YmE5NDEyOWMwMDc3YWI2OWNfMTgtNy0xLTEtMzA1MDA_ad6b4048-e465-4df9-af23-92b90e1c1c9e"
      unitRef="usd">598000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ib52579de36d54242a791b9e3f8019a00_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjY2NzM1ZjJmYmQ2YTQyNWJhOTQxMjljMDA3N2FiNjljL3RhYmxlcmFuZ2U6NjY3MzVmMmZiZDZhNDI1YmE5NDEyOWMwMDc3YWI2OWNfMTgtMTEtMS0xLTMwNTAw_9e132896-9e41-4b1c-b538-5fcc7bd3d6f4"
      unitRef="usd">598000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i75df6ae240184d6cbec2048c440c2cfd_D20210701-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjY2NzM1ZjJmYmQ2YTQyNWJhOTQxMjljMDA3N2FiNjljL3RhYmxlcmFuZ2U6NjY3MzVmMmZiZDZhNDI1YmE5NDEyOWMwMDc3YWI2OWNfMTktMS0xLTEtMzA1MDA_735bf044-89ce-4fdd-852c-dfee6c7b11b0"
      unitRef="shares">4500000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i75df6ae240184d6cbec2048c440c2cfd_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjY2NzM1ZjJmYmQ2YTQyNWJhOTQxMjljMDA3N2FiNjljL3RhYmxlcmFuZ2U6NjY3MzVmMmZiZDZhNDI1YmE5NDEyOWMwMDc3YWI2OWNfMTktMy0xLTEtMzA1MDA_38910698-dc16-4bc6-9018-f3c74a3c17e9"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i5876ecf1449d4c42a057445d55680cd9_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjY2NzM1ZjJmYmQ2YTQyNWJhOTQxMjljMDA3N2FiNjljL3RhYmxlcmFuZ2U6NjY3MzVmMmZiZDZhNDI1YmE5NDEyOWMwMDc3YWI2OWNfMTktNS0xLTEtMzA1MDA_19b2785a-61e6-44cb-9a98-434ec650ec84"
      unitRef="usd">42019000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i1c0c6c63355f4b9f94038593d420a3b7_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjY2NzM1ZjJmYmQ2YTQyNWJhOTQxMjljMDA3N2FiNjljL3RhYmxlcmFuZ2U6NjY3MzVmMmZiZDZhNDI1YmE5NDEyOWMwMDc3YWI2OWNfMTktMTEtMS0xLTMwNTAw_12bdf5ab-a19c-41dc-ab6a-426648057697"
      unitRef="usd">42020000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i8803b9920af74191be48fe8d2de93d42_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjY2NzM1ZjJmYmQ2YTQyNWJhOTQxMjljMDA3N2FiNjljL3RhYmxlcmFuZ2U6NjY3MzVmMmZiZDZhNDI1YmE5NDEyOWMwMDc3YWI2OWNfMjAtMS0xLTEtMzA1MDA_ad09559f-ca84-4660-b8a0-8dba9ceaaab4"
      unitRef="shares">26249439</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i8803b9920af74191be48fe8d2de93d42_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjY2NzM1ZjJmYmQ2YTQyNWJhOTQxMjljMDA3N2FiNjljL3RhYmxlcmFuZ2U6NjY3MzVmMmZiZDZhNDI1YmE5NDEyOWMwMDc3YWI2OWNfMjAtMy0xLTEtMzA1MDA_47eac112-5eb1-49a1-b949-5bbb0f36dd19"
      unitRef="usd">3000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic6c0192051924752911d006055eb26b5_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjY2NzM1ZjJmYmQ2YTQyNWJhOTQxMjljMDA3N2FiNjljL3RhYmxlcmFuZ2U6NjY3MzVmMmZiZDZhNDI1YmE5NDEyOWMwMDc3YWI2OWNfMjAtNS0xLTEtMzA1MDA_9b343787-82af-4d76-b73d-aa57732bb94a"
      unitRef="usd">321950000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i53b949b08f1f4426aa11fcca407bc625_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjY2NzM1ZjJmYmQ2YTQyNWJhOTQxMjljMDA3N2FiNjljL3RhYmxlcmFuZ2U6NjY3MzVmMmZiZDZhNDI1YmE5NDEyOWMwMDc3YWI2OWNfMjAtNy0xLTEtMzA1MDA_15397a89-0a1f-4d1d-ad52-715a43dc0aca"
      unitRef="usd">-800000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib7a3b6923515465ba7ed8a9c9f8c50a2_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjY2NzM1ZjJmYmQ2YTQyNWJhOTQxMjljMDA3N2FiNjljL3RhYmxlcmFuZ2U6NjY3MzVmMmZiZDZhNDI1YmE5NDEyOWMwMDc3YWI2OWNfMjAtOS0xLTEtMzA1MDA_373946ca-de3a-486f-b393-b018a5dc1d44"
      unitRef="usd">-175688000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i1c5dd6f726174024bdc176efa6738fd9_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8xOS9mcmFnOjc4N2JkNDlkZWM3ZTQ0Y2E5NTY0OWE1NDMzNzM2ZWM0L3RhYmxlOjY2NzM1ZjJmYmQ2YTQyNWJhOTQxMjljMDA3N2FiNjljL3RhYmxlcmFuZ2U6NjY3MzVmMmZiZDZhNDI1YmE5NDEyOWMwMDc3YWI2OWNfMjAtMTEtMS0xLTMwNTAw_3058ceaa-5d84-4109-b72e-8caabd1f8fd7"
      unitRef="usd">145465000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8yNS9mcmFnOjVhMzRmMjNmOTE1YzQzMzI5YTc3YjI2MDc3YTk5MWJjL3RhYmxlOjBlNTMzMzJkM2YzNjRmY2I5YjQ1OGIyYWFmZmYwNWY5L3RhYmxlcmFuZ2U6MGU1MzMzMmQzZjM2NGZjYjliNDU4YjJhYWZmZjA1ZjlfMy0xLTEtMS0zMDUwMA_5fe1b7ec-985e-4839-827f-9ddda6552a19"
      unitRef="usd">-63933000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i69e8bcaae5bf44c9a03cf7f5bd08e6b8_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8yNS9mcmFnOjVhMzRmMjNmOTE1YzQzMzI5YTc3YjI2MDc3YTk5MWJjL3RhYmxlOjBlNTMzMzJkM2YzNjRmY2I5YjQ1OGIyYWFmZmYwNWY5L3RhYmxlcmFuZ2U6MGU1MzMzMmQzZjM2NGZjYjliNDU4YjJhYWZmZjA1ZjlfMy0zLTEtMS0zMDUwMA_ee6a5aed-76d1-49ac-b4f1-ec6e6c36d5ee"
      unitRef="usd">-71760000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8yNS9mcmFnOjVhMzRmMjNmOTE1YzQzMzI5YTc3YjI2MDc3YTk5MWJjL3RhYmxlOjBlNTMzMzJkM2YzNjRmY2I5YjQ1OGIyYWFmZmYwNWY5L3RhYmxlcmFuZ2U6MGU1MzMzMmQzZjM2NGZjYjliNDU4YjJhYWZmZjA1ZjlfNS0xLTEtMS0zMDUwMA_9e90db6e-9400-4bef-9fc8-e39a520b133c"
      unitRef="usd">58000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i69e8bcaae5bf44c9a03cf7f5bd08e6b8_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8yNS9mcmFnOjVhMzRmMjNmOTE1YzQzMzI5YTc3YjI2MDc3YTk5MWJjL3RhYmxlOjBlNTMzMzJkM2YzNjRmY2I5YjQ1OGIyYWFmZmYwNWY5L3RhYmxlcmFuZ2U6MGU1MzMzMmQzZjM2NGZjYjliNDU4YjJhYWZmZjA1ZjlfNS0zLTEtMS0zMDUwMA_a542e721-e995-4cc1-b3c8-71cb3a4711d5"
      unitRef="usd">45000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ForeignCurrencyTransactionGainLossUnrealized
      contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8yNS9mcmFnOjVhMzRmMjNmOTE1YzQzMzI5YTc3YjI2MDc3YTk5MWJjL3RhYmxlOjBlNTMzMzJkM2YzNjRmY2I5YjQ1OGIyYWFmZmYwNWY5L3RhYmxlcmFuZ2U6MGU1MzMzMmQzZjM2NGZjYjliNDU4YjJhYWZmZjA1ZjlfNi0xLTEtMS0zMDUwMA_8e4a2675-83ac-4386-a18a-a5dd4c513ce5"
      unitRef="usd">-4217000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
    <us-gaap:ForeignCurrencyTransactionGainLossUnrealized
      contextRef="i69e8bcaae5bf44c9a03cf7f5bd08e6b8_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8yNS9mcmFnOjVhMzRmMjNmOTE1YzQzMzI5YTc3YjI2MDc3YTk5MWJjL3RhYmxlOjBlNTMzMzJkM2YzNjRmY2I5YjQ1OGIyYWFmZmYwNWY5L3RhYmxlcmFuZ2U6MGU1MzMzMmQzZjM2NGZjYjliNDU4YjJhYWZmZjA1ZjlfNi0zLTEtMS0zMDUwMA_dc7733c0-826c-4794-9d57-6eaa9243f02b"
      unitRef="usd">-3202000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
    <us-gaap:ShareBasedCompensation
      contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8yNS9mcmFnOjVhMzRmMjNmOTE1YzQzMzI5YTc3YjI2MDc3YTk5MWJjL3RhYmxlOjBlNTMzMzJkM2YzNjRmY2I5YjQ1OGIyYWFmZmYwNWY5L3RhYmxlcmFuZ2U6MGU1MzMzMmQzZjM2NGZjYjliNDU4YjJhYWZmZjA1ZjlfOC0xLTEtMS0zMDUwMA_70fbc184-fb0f-4252-845c-b6e9630fbe3b"
      unitRef="usd">6043000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i69e8bcaae5bf44c9a03cf7f5bd08e6b8_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8yNS9mcmFnOjVhMzRmMjNmOTE1YzQzMzI5YTc3YjI2MDc3YTk5MWJjL3RhYmxlOjBlNTMzMzJkM2YzNjRmY2I5YjQ1OGIyYWFmZmYwNWY5L3RhYmxlcmFuZ2U6MGU1MzMzMmQzZjM2NGZjYjliNDU4YjJhYWZmZjA1ZjlfOC0zLTEtMS0zMDUwMA_4d20290c-101d-4be4-ae2b-d15c797fdc5e"
      unitRef="usd">4483000</us-gaap:ShareBasedCompensation>
    <us-gaap:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable
      contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8yNS9mcmFnOjVhMzRmMjNmOTE1YzQzMzI5YTc3YjI2MDc3YTk5MWJjL3RhYmxlOjBlNTMzMzJkM2YzNjRmY2I5YjQ1OGIyYWFmZmYwNWY5L3RhYmxlcmFuZ2U6MGU1MzMzMmQzZjM2NGZjYjliNDU4YjJhYWZmZjA1ZjlfOS0xLTEtMS0zMDUwMA_875d6184-dbca-4a30-9191-49f9d2516ae8"
      unitRef="usd">0</us-gaap:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable>
    <us-gaap:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable
      contextRef="i69e8bcaae5bf44c9a03cf7f5bd08e6b8_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8yNS9mcmFnOjVhMzRmMjNmOTE1YzQzMzI5YTc3YjI2MDc3YTk5MWJjL3RhYmxlOjBlNTMzMzJkM2YzNjRmY2I5YjQ1OGIyYWFmZmYwNWY5L3RhYmxlcmFuZ2U6MGU1MzMzMmQzZjM2NGZjYjliNDU4YjJhYWZmZjA1ZjlfOS0zLTEtMS0zMDUwMA_a72a46cb-69d2-48cb-add6-a997ad09c468"
      unitRef="usd">-8625000</us-gaap:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8yNS9mcmFnOjVhMzRmMjNmOTE1YzQzMzI5YTc3YjI2MDc3YTk5MWJjL3RhYmxlOjBlNTMzMzJkM2YzNjRmY2I5YjQ1OGIyYWFmZmYwNWY5L3RhYmxlcmFuZ2U6MGU1MzMzMmQzZjM2NGZjYjliNDU4YjJhYWZmZjA1ZjlfMTEtMS0xLTEtMzA1MDA_140ed609-4b45-4c5a-b536-2706162c9c82"
      unitRef="usd">-2061000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i69e8bcaae5bf44c9a03cf7f5bd08e6b8_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8yNS9mcmFnOjVhMzRmMjNmOTE1YzQzMzI5YTc3YjI2MDc3YTk5MWJjL3RhYmxlOjBlNTMzMzJkM2YzNjRmY2I5YjQ1OGIyYWFmZmYwNWY5L3RhYmxlcmFuZ2U6MGU1MzMzMmQzZjM2NGZjYjliNDU4YjJhYWZmZjA1ZjlfMTEtMy0xLTEtMzA1MDA_9a6a9377-c040-44b5-a1e6-cb77e140ad03"
      unitRef="usd">6305000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8yNS9mcmFnOjVhMzRmMjNmOTE1YzQzMzI5YTc3YjI2MDc3YTk5MWJjL3RhYmxlOjBlNTMzMzJkM2YzNjRmY2I5YjQ1OGIyYWFmZmYwNWY5L3RhYmxlcmFuZ2U6MGU1MzMzMmQzZjM2NGZjYjliNDU4YjJhYWZmZjA1ZjlfMTItMS0xLTEtMzA1MDA_802953a7-ee13-4603-9568-c1b53a4d98a1"
      unitRef="usd">1151000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i69e8bcaae5bf44c9a03cf7f5bd08e6b8_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8yNS9mcmFnOjVhMzRmMjNmOTE1YzQzMzI5YTc3YjI2MDc3YTk5MWJjL3RhYmxlOjBlNTMzMzJkM2YzNjRmY2I5YjQ1OGIyYWFmZmYwNWY5L3RhYmxlcmFuZ2U6MGU1MzMzMmQzZjM2NGZjYjliNDU4YjJhYWZmZjA1ZjlfMTItMy0xLTEtMzA1MDA_42448723-8d76-4487-a4b1-0c2eb5daf5eb"
      unitRef="usd">-261000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInOtherCurrentLiabilities
      contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8yNS9mcmFnOjVhMzRmMjNmOTE1YzQzMzI5YTc3YjI2MDc3YTk5MWJjL3RhYmxlOjBlNTMzMzJkM2YzNjRmY2I5YjQ1OGIyYWFmZmYwNWY5L3RhYmxlcmFuZ2U6MGU1MzMzMmQzZjM2NGZjYjliNDU4YjJhYWZmZjA1ZjlfMTMtMS0xLTEtMzA1MDA_e03294f0-f203-467d-9cf2-43d530068a20"
      unitRef="usd">465000</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherCurrentLiabilities
      contextRef="i69e8bcaae5bf44c9a03cf7f5bd08e6b8_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8yNS9mcmFnOjVhMzRmMjNmOTE1YzQzMzI5YTc3YjI2MDc3YTk5MWJjL3RhYmxlOjBlNTMzMzJkM2YzNjRmY2I5YjQ1OGIyYWFmZmYwNWY5L3RhYmxlcmFuZ2U6MGU1MzMzMmQzZjM2NGZjYjliNDU4YjJhYWZmZjA1ZjlfMTMtMy0xLTEtMzA1MDA_8dac7dc8-8c9f-4b0a-8814-8b554692b046"
      unitRef="usd">2760000</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8yNS9mcmFnOjVhMzRmMjNmOTE1YzQzMzI5YTc3YjI2MDc3YTk5MWJjL3RhYmxlOjBlNTMzMzJkM2YzNjRmY2I5YjQ1OGIyYWFmZmYwNWY5L3RhYmxlcmFuZ2U6MGU1MzMzMmQzZjM2NGZjYjliNDU4YjJhYWZmZjA1ZjlfMTQtMS0xLTEtMzA1MDA_b7cdc444-83b8-4bad-8663-24afd0a38699"
      unitRef="usd">-102000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i69e8bcaae5bf44c9a03cf7f5bd08e6b8_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8yNS9mcmFnOjVhMzRmMjNmOTE1YzQzMzI5YTc3YjI2MDc3YTk5MWJjL3RhYmxlOjBlNTMzMzJkM2YzNjRmY2I5YjQ1OGIyYWFmZmYwNWY5L3RhYmxlcmFuZ2U6MGU1MzMzMmQzZjM2NGZjYjliNDU4YjJhYWZmZjA1ZjlfMTQtMy0xLTEtMzA1MDA_448aed0c-1077-4630-a73b-6fa295efa1b5"
      unitRef="usd">-341000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8yNS9mcmFnOjVhMzRmMjNmOTE1YzQzMzI5YTc3YjI2MDc3YTk5MWJjL3RhYmxlOjBlNTMzMzJkM2YzNjRmY2I5YjQ1OGIyYWFmZmYwNWY5L3RhYmxlcmFuZ2U6MGU1MzMzMmQzZjM2NGZjYjliNDU4YjJhYWZmZjA1ZjlfMTUtMS0xLTEtMzA1MDA_5dcb7ea1-5b49-4098-8027-c1088cc09aa6"
      unitRef="usd">-50040000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i69e8bcaae5bf44c9a03cf7f5bd08e6b8_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8yNS9mcmFnOjVhMzRmMjNmOTE1YzQzMzI5YTc3YjI2MDc3YTk5MWJjL3RhYmxlOjBlNTMzMzJkM2YzNjRmY2I5YjQ1OGIyYWFmZmYwNWY5L3RhYmxlcmFuZ2U6MGU1MzMzMmQzZjM2NGZjYjliNDU4YjJhYWZmZjA1ZjlfMTUtMy0xLTEtMzA1MDA_77deac30-b13f-4007-853f-86221d3d4913"
      unitRef="usd">-59552000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8yNS9mcmFnOjVhMzRmMjNmOTE1YzQzMzI5YTc3YjI2MDc3YTk5MWJjL3RhYmxlOjBlNTMzMzJkM2YzNjRmY2I5YjQ1OGIyYWFmZmYwNWY5L3RhYmxlcmFuZ2U6MGU1MzMzMmQzZjM2NGZjYjliNDU4YjJhYWZmZjA1ZjlfMjAtMS0xLTEtMzA1MDA_29599090-d3ff-4a5c-b9fa-a1a506b1a5c9"
      unitRef="usd">113000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i69e8bcaae5bf44c9a03cf7f5bd08e6b8_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8yNS9mcmFnOjVhMzRmMjNmOTE1YzQzMzI5YTc3YjI2MDc3YTk5MWJjL3RhYmxlOjBlNTMzMzJkM2YzNjRmY2I5YjQ1OGIyYWFmZmYwNWY5L3RhYmxlcmFuZ2U6MGU1MzMzMmQzZjM2NGZjYjliNDU4YjJhYWZmZjA1ZjlfMjAtMy0xLTEtMzA1MDA_f8999838-b149-4f68-b17d-29c6f1171b6f"
      unitRef="usd">48000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8yNS9mcmFnOjVhMzRmMjNmOTE1YzQzMzI5YTc3YjI2MDc3YTk5MWJjL3RhYmxlOjBlNTMzMzJkM2YzNjRmY2I5YjQ1OGIyYWFmZmYwNWY5L3RhYmxlcmFuZ2U6MGU1MzMzMmQzZjM2NGZjYjliNDU4YjJhYWZmZjA1ZjlfMjItMS0xLTEtMzA1MDA_b6fe01c3-32c1-466a-98a7-9b27d807316a"
      unitRef="usd">-113000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i69e8bcaae5bf44c9a03cf7f5bd08e6b8_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8yNS9mcmFnOjVhMzRmMjNmOTE1YzQzMzI5YTc3YjI2MDc3YTk5MWJjL3RhYmxlOjBlNTMzMzJkM2YzNjRmY2I5YjQ1OGIyYWFmZmYwNWY5L3RhYmxlcmFuZ2U6MGU1MzMzMmQzZjM2NGZjYjliNDU4YjJhYWZmZjA1ZjlfMjItMy0xLTEtMzA1MDA_56230233-54a6-46d6-bde6-656194bbe9bd"
      unitRef="usd">-48000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i3d48326594df4b61bdc5572faf307bb8_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8yNS9mcmFnOjVhMzRmMjNmOTE1YzQzMzI5YTc3YjI2MDc3YTk5MWJjL3RhYmxlOjBlNTMzMzJkM2YzNjRmY2I5YjQ1OGIyYWFmZmYwNWY5L3RhYmxlcmFuZ2U6MGU1MzMzMmQzZjM2NGZjYjliNDU4YjJhYWZmZjA1ZjlfMjUtMS0xLTEtMzA1MDA_ab26036d-6146-4482-9c8f-e8f680337d78"
      unitRef="usd">39584000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i9ea948d1a371446296c8cfe8ac8d3534_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8yNS9mcmFnOjVhMzRmMjNmOTE1YzQzMzI5YTc3YjI2MDc3YTk5MWJjL3RhYmxlOjBlNTMzMzJkM2YzNjRmY2I5YjQ1OGIyYWFmZmYwNWY5L3RhYmxlcmFuZ2U6MGU1MzMzMmQzZjM2NGZjYjliNDU4YjJhYWZmZjA1ZjlfMjUtMy0xLTEtMzA1MDA_888b3d3b-22db-4c2b-bd89-9f4bea97f038"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8yNS9mcmFnOjVhMzRmMjNmOTE1YzQzMzI5YTc3YjI2MDc3YTk5MWJjL3RhYmxlOjBlNTMzMzJkM2YzNjRmY2I5YjQ1OGIyYWFmZmYwNWY5L3RhYmxlcmFuZ2U6MGU1MzMzMmQzZjM2NGZjYjliNDU4YjJhYWZmZjA1ZjlfMjYtMS0xLTEtMzA1MDA_1b11d516-a4fe-44f9-b66d-b278f9cd72af"
      unitRef="usd">5000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i69e8bcaae5bf44c9a03cf7f5bd08e6b8_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8yNS9mcmFnOjVhMzRmMjNmOTE1YzQzMzI5YTc3YjI2MDc3YTk5MWJjL3RhYmxlOjBlNTMzMzJkM2YzNjRmY2I5YjQ1OGIyYWFmZmYwNWY5L3RhYmxlcmFuZ2U6MGU1MzMzMmQzZjM2NGZjYjliNDU4YjJhYWZmZjA1ZjlfMjYtMy0xLTEtMzA1MDA_4a61feb8-52a8-4a84-88be-e319706989c4"
      unitRef="usd">0</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
      contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8yNS9mcmFnOjVhMzRmMjNmOTE1YzQzMzI5YTc3YjI2MDc3YTk5MWJjL3RhYmxlOjBlNTMzMzJkM2YzNjRmY2I5YjQ1OGIyYWFmZmYwNWY5L3RhYmxlcmFuZ2U6MGU1MzMzMmQzZjM2NGZjYjliNDU4YjJhYWZmZjA1ZjlfMjctMS0xLTEtMzA1MDA_62a3ae1d-cc7b-4aa1-85fe-bd52bf7202ae"
      unitRef="usd">130000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
      contextRef="i69e8bcaae5bf44c9a03cf7f5bd08e6b8_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8yNS9mcmFnOjVhMzRmMjNmOTE1YzQzMzI5YTc3YjI2MDc3YTk5MWJjL3RhYmxlOjBlNTMzMzJkM2YzNjRmY2I5YjQ1OGIyYWFmZmYwNWY5L3RhYmxlcmFuZ2U6MGU1MzMzMmQzZjM2NGZjYjliNDU4YjJhYWZmZjA1ZjlfMjctMy0xLTEtMzA1MDA_c3db5943-ed63-497d-a009-058978cc0072"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="if312c4804f8b4c99a0562a9d7368b18e_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8yNS9mcmFnOjVhMzRmMjNmOTE1YzQzMzI5YTc3YjI2MDc3YTk5MWJjL3RhYmxlOjBlNTMzMzJkM2YzNjRmY2I5YjQ1OGIyYWFmZmYwNWY5L3RhYmxlcmFuZ2U6MGU1MzMzMmQzZjM2NGZjYjliNDU4YjJhYWZmZjA1ZjlfMjktMC0xLTEtMzA1MDAvdGV4dHJlZ2lvbjphZGUyMDMxYjdmYWY0Y2E4YTY5ZTMxMzUxYjk5MGNkMV83Nw_7d1e8f9c-a3f3-44a4-a6c9-dff50d7d48d8"
      unitRef="usd">2980000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="if312c4804f8b4c99a0562a9d7368b18e_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8yNS9mcmFnOjVhMzRmMjNmOTE1YzQzMzI5YTc3YjI2MDc3YTk5MWJjL3RhYmxlOjBlNTMzMzJkM2YzNjRmY2I5YjQ1OGIyYWFmZmYwNWY5L3RhYmxlcmFuZ2U6MGU1MzMzMmQzZjM2NGZjYjliNDU4YjJhYWZmZjA1ZjlfMjktMS0xLTEtMzA1MDA_f541a157-6283-474c-bf7e-177f31276ad2"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="iefba5660e6154047a65570c20050a670_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8yNS9mcmFnOjVhMzRmMjNmOTE1YzQzMzI5YTc3YjI2MDc3YTk5MWJjL3RhYmxlOjBlNTMzMzJkM2YzNjRmY2I5YjQ1OGIyYWFmZmYwNWY5L3RhYmxlcmFuZ2U6MGU1MzMzMmQzZjM2NGZjYjliNDU4YjJhYWZmZjA1ZjlfMjktMy0xLTEtMzA1MDA_9fa464ef-917a-4c43-a8b8-469c1f8397a0"
      unitRef="usd">42020000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8yNS9mcmFnOjVhMzRmMjNmOTE1YzQzMzI5YTc3YjI2MDc3YTk5MWJjL3RhYmxlOjBlNTMzMzJkM2YzNjRmY2I5YjQ1OGIyYWFmZmYwNWY5L3RhYmxlcmFuZ2U6MGU1MzMzMmQzZjM2NGZjYjliNDU4YjJhYWZmZjA1ZjlfMzAtMS0xLTEtMzA1MDA_f5bb3e48-ce65-4170-914f-bbc25aa7748f"
      unitRef="usd">39719000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i69e8bcaae5bf44c9a03cf7f5bd08e6b8_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8yNS9mcmFnOjVhMzRmMjNmOTE1YzQzMzI5YTc3YjI2MDc3YTk5MWJjL3RhYmxlOjBlNTMzMzJkM2YzNjRmY2I5YjQ1OGIyYWFmZmYwNWY5L3RhYmxlcmFuZ2U6MGU1MzMzMmQzZjM2NGZjYjliNDU4YjJhYWZmZjA1ZjlfMzAtMy0xLTEtMzA1MDA_27b717d9-0d95-4213-9e7c-7fbd4e760f91"
      unitRef="usd">42020000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8yNS9mcmFnOjVhMzRmMjNmOTE1YzQzMzI5YTc3YjI2MDc3YTk5MWJjL3RhYmxlOjBlNTMzMzJkM2YzNjRmY2I5YjQ1OGIyYWFmZmYwNWY5L3RhYmxlcmFuZ2U6MGU1MzMzMmQzZjM2NGZjYjliNDU4YjJhYWZmZjA1ZjlfMzEtMS0xLTEtMzA1MDA_cdac0694-7dc8-4c26-bd82-6148035ce886"
      unitRef="usd">-3658000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i69e8bcaae5bf44c9a03cf7f5bd08e6b8_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8yNS9mcmFnOjVhMzRmMjNmOTE1YzQzMzI5YTc3YjI2MDc3YTk5MWJjL3RhYmxlOjBlNTMzMzJkM2YzNjRmY2I5YjQ1OGIyYWFmZmYwNWY5L3RhYmxlcmFuZ2U6MGU1MzMzMmQzZjM2NGZjYjliNDU4YjJhYWZmZjA1ZjlfMzEtMy0xLTEtMzA1MDA_fdc30af5-fd6f-410e-bf09-2deda8ad641e"
      unitRef="usd">572000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8yNS9mcmFnOjVhMzRmMjNmOTE1YzQzMzI5YTc3YjI2MDc3YTk5MWJjL3RhYmxlOjBlNTMzMzJkM2YzNjRmY2I5YjQ1OGIyYWFmZmYwNWY5L3RhYmxlcmFuZ2U6MGU1MzMzMmQzZjM2NGZjYjliNDU4YjJhYWZmZjA1ZjlfMzItMS0xLTEtMzA1MDA_427923b1-e267-47cc-8d25-d10cd7c1c124"
      unitRef="usd">-14092000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i69e8bcaae5bf44c9a03cf7f5bd08e6b8_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8yNS9mcmFnOjVhMzRmMjNmOTE1YzQzMzI5YTc3YjI2MDc3YTk5MWJjL3RhYmxlOjBlNTMzMzJkM2YzNjRmY2I5YjQ1OGIyYWFmZmYwNWY5L3RhYmxlcmFuZ2U6MGU1MzMzMmQzZjM2NGZjYjliNDU4YjJhYWZmZjA1ZjlfMzItMy0xLTEtMzA1MDA_08ea4e2c-7f14-41a8-b8c2-a8d8d8287ff8"
      unitRef="usd">-17008000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i12246a01749f40d394a9437cb9938c91_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8yNS9mcmFnOjVhMzRmMjNmOTE1YzQzMzI5YTc3YjI2MDc3YTk5MWJjL3RhYmxlOjBlNTMzMzJkM2YzNjRmY2I5YjQ1OGIyYWFmZmYwNWY5L3RhYmxlcmFuZ2U6MGU1MzMzMmQzZjM2NGZjYjliNDU4YjJhYWZmZjA1ZjlfMzMtMS0xLTEtMzA1MDA_a90477ac-244b-4b9a-a8b4-ef3a7767b374"
      unitRef="usd">86863000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ib8e90b6ab1f24717b294f892b4a059b4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8yNS9mcmFnOjVhMzRmMjNmOTE1YzQzMzI5YTc3YjI2MDc3YTk5MWJjL3RhYmxlOjBlNTMzMzJkM2YzNjRmY2I5YjQ1OGIyYWFmZmYwNWY5L3RhYmxlcmFuZ2U6MGU1MzMzMmQzZjM2NGZjYjliNDU4YjJhYWZmZjA1ZjlfMzMtMy0xLTEtMzA1MDA_49d1d2c2-0b20-492d-9c7d-c58f0cd70119"
      unitRef="usd">127452000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ib2ba0b84078f4de2bc3079e992921b92_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8yNS9mcmFnOjVhMzRmMjNmOTE1YzQzMzI5YTc3YjI2MDc3YTk5MWJjL3RhYmxlOjBlNTMzMzJkM2YzNjRmY2I5YjQ1OGIyYWFmZmYwNWY5L3RhYmxlcmFuZ2U6MGU1MzMzMmQzZjM2NGZjYjliNDU4YjJhYWZmZjA1ZjlfMzQtMS0xLTEtMzA1MDA_92cecfa7-8d4d-400f-8998-66ef757adf0e"
      unitRef="usd">72771000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i1c5dd6f726174024bdc176efa6738fd9_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8yNS9mcmFnOjVhMzRmMjNmOTE1YzQzMzI5YTc3YjI2MDc3YTk5MWJjL3RhYmxlOjBlNTMzMzJkM2YzNjRmY2I5YjQ1OGIyYWFmZmYwNWY5L3RhYmxlcmFuZ2U6MGU1MzMzMmQzZjM2NGZjYjliNDU4YjJhYWZmZjA1ZjlfMzQtMy0xLTEtMzA1MDA_a7096726-844c-42a6-8961-9fefc5bd9f3f"
      unitRef="usd">110444000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:StockIssued1
      contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8yNS9mcmFnOjVhMzRmMjNmOTE1YzQzMzI5YTc3YjI2MDc3YTk5MWJjL3RhYmxlOjBlNTMzMzJkM2YzNjRmY2I5YjQ1OGIyYWFmZmYwNWY5L3RhYmxlcmFuZ2U6MGU1MzMzMmQzZjM2NGZjYjliNDU4YjJhYWZmZjA1ZjlfMzktMS0xLTEtMzA1MDA_6915e0b2-bad8-4b51-bdb8-259fa60300fc"
      unitRef="usd">0</us-gaap:StockIssued1>
    <us-gaap:StockIssued1
      contextRef="i69e8bcaae5bf44c9a03cf7f5bd08e6b8_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8yNS9mcmFnOjVhMzRmMjNmOTE1YzQzMzI5YTc3YjI2MDc3YTk5MWJjL3RhYmxlOjBlNTMzMzJkM2YzNjRmY2I5YjQ1OGIyYWFmZmYwNWY5L3RhYmxlcmFuZ2U6MGU1MzMzMmQzZjM2NGZjYjliNDU4YjJhYWZmZjA1ZjlfMzktMy0xLTEtMzA1MDA_8cb51d60-a3af-47d6-a9dc-285150640aa1"
      unitRef="usd">8625000</us-gaap:StockIssued1>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8yNS9mcmFnOjVhMzRmMjNmOTE1YzQzMzI5YTc3YjI2MDc3YTk5MWJjL3RhYmxlOjBlNTMzMzJkM2YzNjRmY2I5YjQ1OGIyYWFmZmYwNWY5L3RhYmxlcmFuZ2U6MGU1MzMzMmQzZjM2NGZjYjliNDU4YjJhYWZmZjA1ZjlfNDAtMS0xLTEtMzA1MDA_52c4c2e1-4e8e-442f-818f-92f7c5d7de67"
      unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i69e8bcaae5bf44c9a03cf7f5bd08e6b8_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8yNS9mcmFnOjVhMzRmMjNmOTE1YzQzMzI5YTc3YjI2MDc3YTk5MWJjL3RhYmxlOjBlNTMzMzJkM2YzNjRmY2I5YjQ1OGIyYWFmZmYwNWY5L3RhYmxlcmFuZ2U6MGU1MzMzMmQzZjM2NGZjYjliNDU4YjJhYWZmZjA1ZjlfNDAtMy0xLTEtMzA1MDA_8d411792-82a2-4676-9ab0-8974fb441311"
      unitRef="usd">435000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock
      contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8zMS9mcmFnOjQ1NGJjMjRjY2NiNjQ3ZjBiNjVhZTVmNTA3YzM2MmQwL3RleHRyZWdpb246NDU0YmMyNGNjY2I2NDdmMGI2NWFlNWY1MDdjMzYyZDBfNTQ2Mw_85bea815-491a-40d1-adee-3e59fadf0f4a">Description of Business and Basis of Financial Statements&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Description of Business&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Immunic, Inc. ("Immunic" or the "Company") is a clinical-stage biopharmaceutical company with a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases. The Company is headquartered in New York City with its main operations in Gr&#xe4;felfing near Munich, Germany.  The Company currently has approximately 65 employees.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company is currently pursuing three development programs. These include the vidofludimus calcium (IMU-838) program, which is focused on the development of oral formulations of a small molecule inhibitor of the enzyme dihydroorotate dehydrogenase (&#x201c;DHODH&#x201d;); the IMU-935 program, which is focused on an inverse agonist of retinoic acid receptor-related orphan nuclear receptor gamma truncated (&#x201c;ROR&#x3b3;t&#x201d;), an immune cell-specific isoform of ROR&#x3b3;; and the IMU-856 program, which involves the development of a drug targeting the restoration of intestinal barrier function and regeneration of bowel epithelium. These product candidates are being developed to address diseases such as multiple sclerosis ("MS"), psoriasis and gastrointestinal diseases. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company&#x2019;s business, operating results, financial condition and growth prospects are subject to significant risks and uncertainties, including the failure of its clinical trials to meet their endpoints, failure to obtain regulatory approval and the inability to obtain on acceptable terms, if at all, additional funding to complete the development and commercialization of the Company's three development programs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Liquidity and Financial Condition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Immunic has no products approved for commercial sale and has not generated any revenue from product sales. It has never been profitable and has incurred operating losses in each year since inception in 2016.  The Company has an accumulated deficit of approximately $260.8 million as of September 30, 2022 and $196.9 million as of December 31, 2021.  Substantially all of Immunic's operating losses resulted from expenses incurred in connection with its research and development programs and from general and administrative costs associated with its operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Immunic expects to incur significant expenses and increasing operating losses for the foreseeable future as it initiates and continues the preclinical and clinical development of its product candidates and adds personnel necessary to advance its clinical pipeline of product candidates.  Immunic expects that its operating losses will fluctuate significantly from quarter-to-quarter and year-to-year due to timing of clinical development programs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From inception through October 31, 2022, Immunic has raised net cash of approximately $355.5 million from private and public offerings of preferred and common stock. As of September 30, 2022, the Company had cash and cash equivalents of approximately $72.8 million.  With these funds, and the $56.4 million of cash raised in October 2022, Immunic expects to be able to fund its operations beyond twelve months from the date of the issuance of the accompanying condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation and Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying consolidated financial statements have been prepared in conformity with United States generally accepted accounting principles, ("U.S. GAAP") and include the accounts of Immunic and its wholly-owned subsidiaries, Immunic AG (which began operations in 2016) and Immunic Research GmbH (which began operations in 2016 and was merged into Immunic AG in September, 2022) and Immunic Australia Pty Ltd. (which began operations in 2018).  All intercompany accounts and transactions have been eliminated in consolidation. Immunic manages its operations as a single reportable segment for the purposes of assessing performance and making operating decisions. &lt;/span&gt;&lt;/div&gt;Unaudited Interim Financial InformationImmunic has prepared the accompanying interim unaudited condensed consolidated financial statements in accordance with United States generally accepted accounting principles, (&#x201c;US GAAP&#x201d;), for interim financial information and with the instructions to Form 10-Q and Regulation S-X of the SEC. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. These interim unaudited condensed consolidated financial statements reflect all adjustments consisting of normal recurring accruals which, in the opinion of management, are necessary to present fairly Immunic&#x2019;s consolidated financial position, consolidated results of operations, consolidated statement of stockholders&#x2019; equity and consolidated cash flows for the periods and as of the dates presented. The Company&#x2019;s fiscal year ends on December 31. The condensed consolidated balance sheet as of December 31, 2021 was derived from audited consolidated financial statements but does not include all disclosures required by U.S. GAAP. These condensed consolidated financial statements should be read in conjunction with the annual consolidated financial statements and the notes thereto included on the Company's Annual Report on Form 10-K filed on February 24, 2022. The nature of Immunic&#x2019;s business is such that the results of any interim period may not be indicative of the results to be expected for the entire year.</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <dei:EntityNumberOfEmployees
      contextRef="ib2ba0b84078f4de2bc3079e992921b92_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8zMS9mcmFnOjQ1NGJjMjRjY2NiNjQ3ZjBiNjVhZTVmNTA3YzM2MmQwL3RleHRyZWdpb246NDU0YmMyNGNjY2I2NDdmMGI2NWFlNWY1MDdjMzYyZDBfNzE0NjgyNTU5MzczOA_b4c82b56-66d0-4195-927e-32ab45b2b22f"
      unitRef="employee">65</dei:EntityNumberOfEmployees>
    <vtl:NumberOfDevelopmentProgramsPursued
      contextRef="ib2ba0b84078f4de2bc3079e992921b92_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8zMS9mcmFnOjQ1NGJjMjRjY2NiNjQ3ZjBiNjVhZTVmNTA3YzM2MmQwL3RleHRyZWdpb246NDU0YmMyNGNjY2I2NDdmMGI2NWFlNWY1MDdjMzYyZDBfMTA5OTUxMTYzNTM5NA_e1d95e58-64e8-486c-abf2-8d9cd86db70c"
      unitRef="program">3</vtl:NumberOfDevelopmentProgramsPursued>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ib2ba0b84078f4de2bc3079e992921b92_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8zMS9mcmFnOjQ1NGJjMjRjY2NiNjQ3ZjBiNjVhZTVmNTA3YzM2MmQwL3RleHRyZWdpb246NDU0YmMyNGNjY2I2NDdmMGI2NWFlNWY1MDdjMzYyZDBfMTA5OTUxMTY0MDk2Mg_3cddd271-e32d-49e8-b6f4-b45290becadf"
      unitRef="usd">-260800000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i12246a01749f40d394a9437cb9938c91_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8zMS9mcmFnOjQ1NGJjMjRjY2NiNjQ3ZjBiNjVhZTVmNTA3YzM2MmQwL3RleHRyZWdpb246NDU0YmMyNGNjY2I2NDdmMGI2NWFlNWY1MDdjMzYyZDBfMTA5OTUxMTYzODUyNA_061cbf6e-8719-44b6-96e6-c0ef2eb752bc"
      unitRef="usd">-196900000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="id96591a4131743fabd2bef215e14e27d_D20140417-20221031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8zMS9mcmFnOjQ1NGJjMjRjY2NiNjQ3ZjBiNjVhZTVmNTA3YzM2MmQwL3RleHRyZWdpb246NDU0YmMyNGNjY2I2NDdmMGI2NWFlNWY1MDdjMzYyZDBfNTQ5NzU1ODI3MzE2_d1aef92a-0f74-4d33-86ad-624bf2aa9257"
      unitRef="usd">355500000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ied30ae8dfbe54606808411695b6e7a4d_I20221031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8zMS9mcmFnOjQ1NGJjMjRjY2NiNjQ3ZjBiNjVhZTVmNTA3YzM2MmQwL3RleHRyZWdpb246NDU0YmMyNGNjY2I2NDdmMGI2NWFlNWY1MDdjMzYyZDBfNTQ5NzU1ODI3MjA5_5cbf2073-5186-4c45-b25a-33e218913bbd"
      unitRef="usd">72800000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashCashEquivalentsAndFederalFundsSold
      contextRef="ied30ae8dfbe54606808411695b6e7a4d_I20221031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8zMS9mcmFnOjQ1NGJjMjRjY2NiNjQ3ZjBiNjVhZTVmNTA3YzM2MmQwL3RleHRyZWdpb246NDU0YmMyNGNjY2I2NDdmMGI2NWFlNWY1MDdjMzYyZDBfNTQ5NzU1ODI3MzIz_ad64a7d3-4a51-48b2-8bfe-590c01b42092"
      unitRef="usd">56400000</us-gaap:CashCashEquivalentsAndFederalFundsSold>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8zMS9mcmFnOjQ1NGJjMjRjY2NiNjQ3ZjBiNjVhZTVmNTA3YzM2MmQwL3RleHRyZWdpb246NDU0YmMyNGNjY2I2NDdmMGI2NWFlNWY1MDdjMzYyZDBfNTQ2Ng_d3fa6ecd-5174-4688-8a2b-c7cc691277a9">&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation and Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying consolidated financial statements have been prepared in conformity with United States generally accepted accounting principles, ("U.S. GAAP") and include the accounts of Immunic and its wholly-owned subsidiaries, Immunic AG (which began operations in 2016) and Immunic Research GmbH (which began operations in 2016 and was merged into Immunic AG in September, 2022) and Immunic Australia Pty Ltd. (which began operations in 2018).  All intercompany accounts and transactions have been eliminated in consolidation. Immunic manages its operations as a single reportable segment for the purposes of assessing performance and making operating decisions. &lt;/span&gt;&lt;/div&gt;Unaudited Interim Financial InformationImmunic has prepared the accompanying interim unaudited condensed consolidated financial statements in accordance with United States generally accepted accounting principles, (&#x201c;US GAAP&#x201d;), for interim financial information and with the instructions to Form 10-Q and Regulation S-X of the SEC. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. These interim unaudited condensed consolidated financial statements reflect all adjustments consisting of normal recurring accruals which, in the opinion of management, are necessary to present fairly Immunic&#x2019;s consolidated financial position, consolidated results of operations, consolidated statement of stockholders&#x2019; equity and consolidated cash flows for the periods and as of the dates presented. The Company&#x2019;s fiscal year ends on December 31. The condensed consolidated balance sheet as of December 31, 2021 was derived from audited consolidated financial statements but does not include all disclosures required by U.S. GAAP. These condensed consolidated financial statements should be read in conjunction with the annual consolidated financial statements and the notes thereto included on the Company's Annual Report on Form 10-K filed on February 24, 2022. The nature of Immunic&#x2019;s business is such that the results of any interim period may not be indicative of the results to be expected for the entire year.</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8zNC9mcmFnOjZlNmZlYmNmYmQwYTRlNDE5NDE0ZWFhMGNlYTdjMWU2L3RleHRyZWdpb246NmU2ZmViY2ZiZDBhNGU0MTk0MTRlYWEwY2VhN2MxZTZfMTc1MzE_ec8d69a6-f451-45bc-92c2-2bfa60b49e97">Summary of Significant Accounting Policies&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with U.S. GAAP requires the Company to make certain estimates and assumptions that affect the reported amounts of assets, liabilities, expenses and the disclosure of contingent assets and liabilities in the Company&#x2019;s consolidated financial statements. The most significant estimates in the Company&#x2019;s financial statements and accompanying notes relate to clinical trial expenses and share-based compensation. Management believes its estimates to be reasonable under the circumstances. Actual results could differ materially from those estimates and assumptions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Foreign Currency Translation and Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s reporting currency is United States (&#x201c;U.S.&#x201d;) dollars. Immunic AG and Immunic Research GmbH&#x2019;s operations are located in Germany with the euro being their functional currency. Immunic Australia Pty Ltd.&#x2019;s functional currency is the Australian dollar. All amounts in the financial statements where the functional currency is not the U.S. dollar are translated into U.S. dollar equivalents at exchange rates as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:180%"&gt;&#x2022; assets and liabilities at reporting period-end rates;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:180%"&gt;&#x2022; income statement accounts at average exchange rates for the reporting period; and&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:180%"&gt;&#x2022; components of equity at historical rates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Gains and losses from translation of the financial statements into U.S. dollars are recorded in stockholders&#x2019; equity as a component of accumulated other comprehensive income (loss). Realized and unrealized gains and losses resulting from foreign currency transactions denominated in currencies other than the functional currency are reflected as general and administrative expenses in the Consolidated Statements of Operations. Foreign currency transaction gains and losses related to long-term intercompany loans that are payable in the foreseeable future are recorded in Other Income (Expense). The Consolidated Statements of Cash Flows were prepared by using the average exchange rate in effect during the reporting period which reasonably approximates the timing of the cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents consist of cash on hand and deposits in banks located in the U.S., Germany and Australia. The Company maintains cash and cash equivalent balances denominated in Euro and U.S. dollars with major financial institutions in the U.S. and Germany in excess of the deposit limits insured by the government. Management periodically reviews the credit standing of these financial institutions and believes that the Company is not exposed to any significant credit risk. The Company currently deposits its cash and cash equivalents with two large financial institutions. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value Measurement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value is defined as the price that would be received to sell an asset or be paid to transfer a liability in an orderly transaction between market participants on the measurement date. Accounting guidance establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The standard describes three levels of inputs that may be used to measure fair value:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level&#160;1&#x2014;Quoted prices in active markets for identical assets or liabilities. Level 1 assets consisted of money market funds for the periods presented. The Company had no Level 1 liabilities for the periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level&#160;2&#x2014; Inputs other than observable quoted prices for the asset or liability, either directly or indirectly; these include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. The Company had no Level 2 assets or liabilities for the periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level&#160;3&#x2014;Unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of assets or liabilities. The Company had no Level 3 assets or liabilities for the periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying value of cash and cash equivalents, other current assets and prepaid expenses, accounts payable, accrued expenses, and other current liabilities approximates fair value due to the short period of time to maturity.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment is stated at cost. Depreciation is computed using the straight-line method based on the estimated service lives of the assets, which range from &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8zNC9mcmFnOjZlNmZlYmNmYmQwYTRlNDE5NDE0ZWFhMGNlYTdjMWU2L3RleHRyZWdpb246NmU2ZmViY2ZiZDBhNGU0MTk0MTRlYWEwY2VhN2MxZTZfNDU2Mg_7c753206-cde1-40ce-856d-422289b6506b"&gt;three&lt;/span&gt; to thirteen years. Depreciation expense was $17,000 and $16,000 for the three months ended September 30, 2022 and 2021, respectively. Depreciation expense was $58,000 and $45,000 for the nine months ended September 30, 2022 and 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company records impairment losses on long-lived assets used in operations when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets&#x2019; carrying amount. Impaired assets are then recorded at their estimated fair value. There were no impairment losses during the three and nine months ended September 30, 2022 and 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:20.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:174%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Business combinations are accounted for under the acquisition method. The total purchase price of an acquisition is allocated to the underlying identifiable net assets, based on their respective estimated fair values as of the acquisition date. Determining the fair value of assets acquired and liabilities assumed requires management&#x2019;s judgment and often involves the use of significant estimates and assumptions, including assumptions with respect to future cash inflows and outflows, probabilities of success, discount rates, and asset lives, among other items. Assets acquired and liabilities assumed are recorded at their estimated fair values. The excess of the purchase price over the estimated fair values of the net assets acquired is recorded as goodwill.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill is tested for impairment at the reporting unit level annually in the fourth quarter, or more frequently when events or changes in circumstances indicate that the asset might be impaired. Examples of such events or circumstances include, but are not limited to, an unfavorable clinical trial result, a significant adverse change in legal or business climate, industry market conditions, an adverse regulatory action, sustained decrease in stock price or unanticipated competition. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;When conducting the Company&#x2019;s interim goodwill impairment assessment, we considered the Company&#x2019;s history of reported losses and negative cash flows from operating activities, along with the downturn in macroeconomic conditions and the broader mid-cap and micro-cap equity markets in 2022. Given the period of time between the commencement of the downturn in macroeconomic and general equity market conditions as of September 30, 2022, management believes that the fluctuation in prices of our common stock, consistent with the broader market, is not other-than-temporary and not indicative of any fundamental change in the value or prospects of the underlying business as of the measurement date.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As another data point, the Company also performed a quantitative goodwill impairment analysis comparing the estimated fair value of the Company&#x2019;s reporting unit to its carrying or book value as of the current period presented herein. In performing the quantitative analysis, the Company compared the fair value of the reporting unit to its carrying or book value to determine if the fair value of the reporting unit exceeded its carrying value as of the testing date, in which case the standard indicates that goodwill would not be impaired, and no further testing was necessary. The fair value of a reporting unit refers to the price that would be received to sell the reporting unit as a whole in an orderly transaction between market participants at the measurement date. Quoted market prices in active markets are considered to be the best evidence of fair value and should be used as the basis for fair value measurement, if available. When using quoted market prices to estimate the fair value of a reporting unit, we consider all available evidence. In certain circumstances, such as a distressed market, it may be appropriate to consider recent trends in the Company&#x2019;s stock price, instead of a single day&#x2019;s stock price in evaluating fair value. In these circumstances, averages over relatively short periods of time are used to determine representative market values.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Subsequent to September 30, 2022, the company raised $60&#160;million of common stock at a premium to the company's market pricing.  Management further considered this as an indication of the value and related premium to market values prior to and as of September 30, 2022.  &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Based on this qualitative analysis,  the Company concluded that goodwill was not &#x201c;more likely than not&#x201d; impaired as of September 30, 2022.  &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October 20, 2022, the Company announced the outcome of a  significant interim analysis of its Phase 1b clinical trial of IMU-935 in patients with moderate-to-severe psoriasis that were not deemed positive progress. On October 21, 2022, the Company experienced a significant decrease in the Company's market capitalization.  The Company considered this to be a triggering event indicating that it is more likely than not that goodwill is impaired.  As a result, the Company anticipates it will incur an approximately $33.0&#160;million goodwill impairment charge in the fourth quarter of 2022 as a result of this analysis (See Note 10).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;Research and Development Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;These costs primarily include external development expenses and internal personnel expenses for the three development programs, vidofludimus calcium, IMU-935 and IMU-856. Immunic has spent the majority of its research and development resources on vidofludimus calcium, the Company's lead development program for clinical trials in RRMS, UC and COVID-19.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development expenses consist of expenses incurred in research and development activities, which include clinical trials, contract research services, certain milestone payments, salaries and related employee benefits, allocated facility costs and other outsourced services. Research and development expenses are charged to operations as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company enters into agreements with contract research organizations (&#x201c;CROs&#x201d;) to provide clinical trial services for individual studies and projects by executing individual work orders governed by a Master Service Arrangement (&#x201c;MSA&#x201d;). The MSAs and associated work orders provide for regular recurrent payments and payments upon the completion of certain milestones. The Company regularly assesses the timing of payments against actual costs incurred to ensure a proper accrual of related expenses in the appropriate accounting period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Collaboration Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain collaboration and license agreements may include payments to or from the Company of one or more of the following: non-refundable or partially refundable upfront or license fees; development, regulatory and commercial milestone payments; payment for manufacturing supply services; partial or complete reimbursement of research and development costs; and royalties on net sales of licensed products. The Company assesses whether such contracts are within the scope of Financial Accounting Standards Board (FASB) Accounting Standards Update (&#x201c;ASU&#x201d;) 2014-09 &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201d; and ASU No. 2018-18, &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Arrangements&#x201d;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; ("ASU 2018-18"). ASU 2018-18, clarifies that certain elements of collaborative arrangements could qualify as transactions with customers in the scope of ASC 606.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2018, the Company entered into an option and license agreement (the "Daiichi Sankyo Agreement") with Daiichi Sankyo Co., Ltd. ("Daiichi Sankyo") which granted the Company the right to license a group of compounds, designated by the Company as IMU-856, as a potential new oral treatment option for gastrointestinal diseases such as celiac disease, inflammatory bowel disease, irritable bowel syndrome with diarrhea and other barrier function associated diseases. During the option period, the Company performed agreed upon research and development activities for which it was reimbursed by Daiichi &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Sankyo up to a maximum agreed-upon limit. Such reimbursement was recorded as other income. There are no additional research and development reimbursements expected under this agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;On January 5, 2020, the Company exercised its option to obtain the exclusive worldwide right to commercialization of IMU-856. Among other things, the option exercise grants Immunic AG the rights to Daiichi Sankyo&#x2019;s patent application related to IMU-856, for which the Company received a notice of allowance from the US Patent &amp;amp; Trademark Office in August 2022. In connection with the option exercise, the Company paid a one-time upfront licensing fee to Daiichi Sankyo. Under the Daiichi Sankyo Agreement, Daiichi Sankyo is also eligible to receive future development, regulatory and sales milestone payments, as well as royalties related to IMU-856.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;General and Administrative Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;General and administrative expenses consist primarily of salaries and related costs for personnel in executive, finance, business development and other support functions. Other general and administrative expenses include, but are not limited to, stock-based compensation, insurance costs, professional fees for legal, accounting and tax services, consulting, related facility costs and travel.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company measures the cost of employee and non-employee services received in exchange for equity awards based on the grant-date fair value of the award recognized generally as an expense (i) on a straight-line basis over the requisite service period for those awards whose vesting is based upon a service condition, and (ii) on an accelerated method for awards whose vesting is based upon a performance condition, but only to the extent it is probable that the performance condition will be met. Stock-based compensation is (i) estimated at the date of grant based on the award&#x2019;s fair value for equity classified awards and (ii) final measurement date for liability classified awards. Forfeitures are recorded in the period in which they occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company estimates the fair value of stock options using the Black-Scholes-Merton option-pricing model ("BSM"), which requires the use of estimates and subjective assumptions, including the risk-free interest rate, the fair value of the underlying common stock, the expected dividend yield of the Company&#x2019;s common stock, the expected volatility of the price of the Company&#x2019;s common stock, and the expected term of the option. These estimates involve inherent uncertainties and the application of management&#x2019;s judgment. If factors change and different assumptions are used, the Company&#x2019;s stock-based compensation expense could be materially different in the future.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company leases office space and office equipment. The underlying lease agreements have lease terms of less than 12 months and up to 60 months. Leases with terms of 12 months or less at inception are not included in the operating lease right of use asset and operating lease liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has two existing leases for office space. At inception of a lease agreement, the Company determines whether an agreement represents a lease and at commencement each lease agreement is assessed as to classification as an operating or financing lease. The Company's two leases have been classified as operating leases and an operating lease right-of-use asset and an operating lease liability have been recorded on the Company&#x2019;s balance sheet. A right-of-use lease asset represents the Company&#x2019;s right to use the underlying asset for the lease term and the lease obligation represents its commitment to make the lease payments arising from the lease. Right-of-use lease assets and obligations are recognized at the commencement date based on the present value of remaining lease payments over the lease term. As the Company&#x2019;s leases do not provide an implicit rate, the Company has used an estimated incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. The right-of-use lease asset includes any lease payments made prior to commencement and excludes any lease incentives. The lease term used in estimating future lease payments may include options to extend when it is reasonably certain that the Company will exercise that option. Operating lease expense is recognized on a straight-line basis over the lease term, subject to any changes in the lease or changes in expectations regarding the lease term. Variable lease costs such as common area costs and property taxes are expensed as incurred. Leases with an initial term of twelve months or less are not recorded on the balance sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Comprehensive Income (Loss)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Comprehensive income (loss) is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. Accumulated other comprehensive income (loss) has been reflected as a separate component of stockholders&#x2019; equity in the accompanying Consolidated Balance Sheets and consists of foreign currency translation adjustments (net of tax).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is subject to corporate income tax laws and regulations in the U.S., Germany and Australia. Tax regulations within each jurisdiction are subject to the interpretation of the related tax laws and regulations and require significant judgment in their application.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company utilizes the asset and liability method of accounting for income taxes which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the audited consolidated financial statements. Deferred income tax assets and liabilities are determined based on the differences between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of changes in tax rates on deferred tax assets and liabilities is recognized in operations in the period that includes the enactment date. Deferred taxes are reduced by a valuation allowance when, in the opinion of management, it is more likely than not some portion or the entire deferred tax asset will not be realized.  As of September 30, 2022 and 2021, respectively, the Company maintained a full valuation allowance against the balance of deferred tax assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;It is the Company&#x2019;s policy to provide for uncertain tax positions and the related interest and penalties based upon management&#x2019;s assessment of whether a tax benefit is more likely than not to be sustained upon examination by tax authorities. The Company recognizes interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense.  The Company is subject to U.S. federal, New York, California, Texas, German and Australian income taxes. The Company is subject to U.S. federal or state income tax examination by tax authorities for tax returns filed for the years 2003 and forward due to the carryforward of NOLs. Tax years 2016 through 2021 are subject to audit by German and Australian tax authorities. The Company is not currently under examination by any tax jurisdictions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net Loss Per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net loss per share attributable to common stockholders is calculated by dividing the net loss by the weighted-average number of common shares outstanding for the period, without consideration for common stock equivalents. Diluted net loss per share attributable to common stockholders is computed by dividing the net loss by the weighted-average number of common shares and, if dilutive, common stock equivalents outstanding for the period determined using the treasury-stock method. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company&#x2019;s net loss position.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Potentially dilutive securities, not included in the calculation of diluted net loss per share attributable to common stockholders because to do so would be anti-dilutive, are as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.751%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.953%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.955%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,799,573&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,045,960&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Issued and/or Adopted Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There are no recently issued accounting standards that would have a significant impact on the company's consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8zNC9mcmFnOjZlNmZlYmNmYmQwYTRlNDE5NDE0ZWFhMGNlYTdjMWU2L3RleHRyZWdpb246NmU2ZmViY2ZiZDBhNGU0MTk0MTRlYWEwY2VhN2MxZTZfMTc1NDQ_0a6a41e5-fc8a-4f17-bd09-2441d90d0767">&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with U.S. GAAP requires the Company to make certain estimates and assumptions that affect the reported amounts of assets, liabilities, expenses and the disclosure of contingent assets and liabilities in the Company&#x2019;s consolidated financial statements. The most significant estimates in the Company&#x2019;s financial statements and accompanying notes relate to clinical trial expenses and share-based compensation. Management believes its estimates to be reasonable under the circumstances. Actual results could differ materially from those estimates and assumptions.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock
      contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8zNC9mcmFnOjZlNmZlYmNmYmQwYTRlNDE5NDE0ZWFhMGNlYTdjMWU2L3RleHRyZWdpb246NmU2ZmViY2ZiZDBhNGU0MTk0MTRlYWEwY2VhN2MxZTZfMTc1NDc_1fb01afa-509a-4bf4-aac2-d67d7af45d73">&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Foreign Currency Translation and Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s reporting currency is United States (&#x201c;U.S.&#x201d;) dollars. Immunic AG and Immunic Research GmbH&#x2019;s operations are located in Germany with the euro being their functional currency. Immunic Australia Pty Ltd.&#x2019;s functional currency is the Australian dollar. All amounts in the financial statements where the functional currency is not the U.S. dollar are translated into U.S. dollar equivalents at exchange rates as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:180%"&gt;&#x2022; assets and liabilities at reporting period-end rates;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:180%"&gt;&#x2022; income statement accounts at average exchange rates for the reporting period; and&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:180%"&gt;&#x2022; components of equity at historical rates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Gains and losses from translation of the financial statements into U.S. dollars are recorded in stockholders&#x2019; equity as a component of accumulated other comprehensive income (loss). Realized and unrealized gains and losses resulting from foreign currency transactions denominated in currencies other than the functional currency are reflected as general and administrative expenses in the Consolidated Statements of Operations. Foreign currency transaction gains and losses related to long-term intercompany loans that are payable in the foreseeable future are recorded in Other Income (Expense). The Consolidated Statements of Cash Flows were prepared by using the average exchange rate in effect during the reporting period which reasonably approximates the timing of the cash flows.&lt;/span&gt;&lt;/div&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8zNC9mcmFnOjZlNmZlYmNmYmQwYTRlNDE5NDE0ZWFhMGNlYTdjMWU2L3RleHRyZWdpb246NmU2ZmViY2ZiZDBhNGU0MTk0MTRlYWEwY2VhN2MxZTZfMTc1MzM_89678cf2-6de6-42f8-b88d-8bc72cced780">&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents.&lt;/span&gt;&lt;/div&gt;Cash and cash equivalents consist of cash on hand and deposits in banks located in the U.S., Germany and Australia. The Company maintains cash and cash equivalent balances denominated in Euro and U.S. dollars with major financial institutions in the U.S. and Germany in excess of the deposit limits insured by the government. Management periodically reviews the credit standing of these financial institutions and believes that the Company is not exposed to any significant credit risk. The Company currently deposits its cash and cash equivalents with two large financial institutions.</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <vtl:NumberOfFinancialInstitutionsUsedForCashDeposits
      contextRef="ib2ba0b84078f4de2bc3079e992921b92_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8zNC9mcmFnOjZlNmZlYmNmYmQwYTRlNDE5NDE0ZWFhMGNlYTdjMWU2L3RleHRyZWdpb246NmU2ZmViY2ZiZDBhNGU0MTk0MTRlYWEwY2VhN2MxZTZfMjgyNA_4de37a18-60d3-4726-a28d-feed41e15b85"
      unitRef="financialinstitution">2</vtl:NumberOfFinancialInstitutionsUsedForCashDeposits>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8zNC9mcmFnOjZlNmZlYmNmYmQwYTRlNDE5NDE0ZWFhMGNlYTdjMWU2L3RleHRyZWdpb246NmU2ZmViY2ZiZDBhNGU0MTk0MTRlYWEwY2VhN2MxZTZfMTc1Mzg_55f386b7-ed64-4fe1-9b71-cba63cbb340d">&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value Measurement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value is defined as the price that would be received to sell an asset or be paid to transfer a liability in an orderly transaction between market participants on the measurement date. Accounting guidance establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The standard describes three levels of inputs that may be used to measure fair value:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level&#160;1&#x2014;Quoted prices in active markets for identical assets or liabilities. Level 1 assets consisted of money market funds for the periods presented. The Company had no Level 1 liabilities for the periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level&#160;2&#x2014; Inputs other than observable quoted prices for the asset or liability, either directly or indirectly; these include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. The Company had no Level 2 assets or liabilities for the periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level&#160;3&#x2014;Unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of assets or liabilities. The Company had no Level 3 assets or liabilities for the periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying value of cash and cash equivalents, other current assets and prepaid expenses, accounts payable, accrued expenses, and other current liabilities approximates fair value due to the short period of time to maturity.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8zNC9mcmFnOjZlNmZlYmNmYmQwYTRlNDE5NDE0ZWFhMGNlYTdjMWU2L3RleHRyZWdpb246NmU2ZmViY2ZiZDBhNGU0MTk0MTRlYWEwY2VhN2MxZTZfMTc1Mzk_8b023748-9aad-4a0b-99b1-ff27d0736ba8">Property and EquipmentProperty and equipment is stated at cost. Depreciation is computed using the straight-line method based on the estimated service lives of the assets, which range from &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8zNC9mcmFnOjZlNmZlYmNmYmQwYTRlNDE5NDE0ZWFhMGNlYTdjMWU2L3RleHRyZWdpb246NmU2ZmViY2ZiZDBhNGU0MTk0MTRlYWEwY2VhN2MxZTZfNDU2Mg_7c753206-cde1-40ce-856d-422289b6506b"&gt;three&lt;/span&gt; to thirteen years.</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i946f069c215c45208da865ab19d790c4_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8zNC9mcmFnOjZlNmZlYmNmYmQwYTRlNDE5NDE0ZWFhMGNlYTdjMWU2L3RleHRyZWdpb246NmU2ZmViY2ZiZDBhNGU0MTk0MTRlYWEwY2VhN2MxZTZfNDU2OA_0c9b3176-f8a7-44ea-8802-71f912aa057d">P13Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:Depreciation
      contextRef="ib52579de36d54242a791b9e3f8019a00_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8zNC9mcmFnOjZlNmZlYmNmYmQwYTRlNDE5NDE0ZWFhMGNlYTdjMWU2L3RleHRyZWdpb246NmU2ZmViY2ZiZDBhNGU0MTk0MTRlYWEwY2VhN2MxZTZfNDU5Nw_9ecedd5c-fdff-4f1a-a2b8-dd27d61f53a2"
      unitRef="usd">17000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="iceee2385dd3a4cafb879b0088a931d62_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8zNC9mcmFnOjZlNmZlYmNmYmQwYTRlNDE5NDE0ZWFhMGNlYTdjMWU2L3RleHRyZWdpb246NmU2ZmViY2ZiZDBhNGU0MTk0MTRlYWEwY2VhN2MxZTZfNDYwNA_1151ed3b-ecfe-4248-8b66-efe2e8147c35"
      unitRef="usd">16000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i69e8bcaae5bf44c9a03cf7f5bd08e6b8_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8zNC9mcmFnOjZlNmZlYmNmYmQwYTRlNDE5NDE0ZWFhMGNlYTdjMWU2L3RleHRyZWdpb246NmU2ZmViY2ZiZDBhNGU0MTk0MTRlYWEwY2VhN2MxZTZfNDcwMg_48e57e6c-cd51-49f8-b8c8-40a53d333f0f"
      unitRef="usd">58000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="id906393de2c04b61842e3087515a35aa_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8zNC9mcmFnOjZlNmZlYmNmYmQwYTRlNDE5NDE0ZWFhMGNlYTdjMWU2L3RleHRyZWdpb246NmU2ZmViY2ZiZDBhNGU0MTk0MTRlYWEwY2VhN2MxZTZfNDcwOQ_3c3ef925-baf2-46a5-9ddb-0d84334a0c6c"
      unitRef="usd">45000</us-gaap:Depreciation>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8zNC9mcmFnOjZlNmZlYmNmYmQwYTRlNDE5NDE0ZWFhMGNlYTdjMWU2L3RleHRyZWdpb246NmU2ZmViY2ZiZDBhNGU0MTk0MTRlYWEwY2VhN2MxZTZfMTc1MzQ_aec533a9-7961-4ce6-a231-cf9dfc8f8aa0">Impairment of Long-Lived AssetsThe Company records impairment losses on long-lived assets used in operations when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets&#x2019; carrying amount. Impaired assets are then recorded at their estimated fair value.</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:TangibleAssetImpairmentCharges
      contextRef="id906393de2c04b61842e3087515a35aa_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8zNC9mcmFnOjZlNmZlYmNmYmQwYTRlNDE5NDE0ZWFhMGNlYTdjMWU2L3RleHRyZWdpb246NmU2ZmViY2ZiZDBhNGU0MTk0MTRlYWEwY2VhN2MxZTZfNTEyNg_03d19bc8-e687-406f-8ac0-8f003ae7f51a"
      unitRef="usd">0</us-gaap:TangibleAssetImpairmentCharges>
    <us-gaap:TangibleAssetImpairmentCharges
      contextRef="iceee2385dd3a4cafb879b0088a931d62_D20200701-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8zNC9mcmFnOjZlNmZlYmNmYmQwYTRlNDE5NDE0ZWFhMGNlYTdjMWU2L3RleHRyZWdpb246NmU2ZmViY2ZiZDBhNGU0MTk0MTRlYWEwY2VhN2MxZTZfNTEyNg_74057324-8f63-4734-adc0-92559f58467c"
      unitRef="usd">0</us-gaap:TangibleAssetImpairmentCharges>
    <us-gaap:TangibleAssetImpairmentCharges
      contextRef="ib52579de36d54242a791b9e3f8019a00_D20210701-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8zNC9mcmFnOjZlNmZlYmNmYmQwYTRlNDE5NDE0ZWFhMGNlYTdjMWU2L3RleHRyZWdpb246NmU2ZmViY2ZiZDBhNGU0MTk0MTRlYWEwY2VhN2MxZTZfNTEyNg_7ba17b86-ea43-4599-a35a-eee041715fcb"
      unitRef="usd">0</us-gaap:TangibleAssetImpairmentCharges>
    <us-gaap:TangibleAssetImpairmentCharges
      contextRef="i69e8bcaae5bf44c9a03cf7f5bd08e6b8_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8zNC9mcmFnOjZlNmZlYmNmYmQwYTRlNDE5NDE0ZWFhMGNlYTdjMWU2L3RleHRyZWdpb246NmU2ZmViY2ZiZDBhNGU0MTk0MTRlYWEwY2VhN2MxZTZfNTEyNg_8d098a65-a0f8-4695-b2d5-9929dc534222"
      unitRef="usd">0</us-gaap:TangibleAssetImpairmentCharges>
    <us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy
      contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8zNC9mcmFnOjZlNmZlYmNmYmQwYTRlNDE5NDE0ZWFhMGNlYTdjMWU2L3RleHRyZWdpb246NmU2ZmViY2ZiZDBhNGU0MTk0MTRlYWEwY2VhN2MxZTZfMTc1NDA_6fa78a88-248d-4114-a411-d3da7fce1b4c">&lt;div style="margin-top:12pt;padding-left:20.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:174%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Business combinations are accounted for under the acquisition method. The total purchase price of an acquisition is allocated to the underlying identifiable net assets, based on their respective estimated fair values as of the acquisition date. Determining the fair value of assets acquired and liabilities assumed requires management&#x2019;s judgment and often involves the use of significant estimates and assumptions, including assumptions with respect to future cash inflows and outflows, probabilities of success, discount rates, and asset lives, among other items. Assets acquired and liabilities assumed are recorded at their estimated fair values. The excess of the purchase price over the estimated fair values of the net assets acquired is recorded as goodwill.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill is tested for impairment at the reporting unit level annually in the fourth quarter, or more frequently when events or changes in circumstances indicate that the asset might be impaired. Examples of such events or circumstances include, but are not limited to, an unfavorable clinical trial result, a significant adverse change in legal or business climate, industry market conditions, an adverse regulatory action, sustained decrease in stock price or unanticipated competition. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;When conducting the Company&#x2019;s interim goodwill impairment assessment, we considered the Company&#x2019;s history of reported losses and negative cash flows from operating activities, along with the downturn in macroeconomic conditions and the broader mid-cap and micro-cap equity markets in 2022. Given the period of time between the commencement of the downturn in macroeconomic and general equity market conditions as of September 30, 2022, management believes that the fluctuation in prices of our common stock, consistent with the broader market, is not other-than-temporary and not indicative of any fundamental change in the value or prospects of the underlying business as of the measurement date.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As another data point, the Company also performed a quantitative goodwill impairment analysis comparing the estimated fair value of the Company&#x2019;s reporting unit to its carrying or book value as of the current period presented herein. In performing the quantitative analysis, the Company compared the fair value of the reporting unit to its carrying or book value to determine if the fair value of the reporting unit exceeded its carrying value as of the testing date, in which case the standard indicates that goodwill would not be impaired, and no further testing was necessary. The fair value of a reporting unit refers to the price that would be received to sell the reporting unit as a whole in an orderly transaction between market participants at the measurement date. Quoted market prices in active markets are considered to be the best evidence of fair value and should be used as the basis for fair value measurement, if available. When using quoted market prices to estimate the fair value of a reporting unit, we consider all available evidence. In certain circumstances, such as a distressed market, it may be appropriate to consider recent trends in the Company&#x2019;s stock price, instead of a single day&#x2019;s stock price in evaluating fair value. In these circumstances, averages over relatively short periods of time are used to determine representative market values.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Subsequent to September 30, 2022, the company raised $60&#160;million of common stock at a premium to the company's market pricing.  Management further considered this as an indication of the value and related premium to market values prior to and as of September 30, 2022.  &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Based on this qualitative analysis,  the Company concluded that goodwill was not &#x201c;more likely than not&#x201d; impaired as of September 30, 2022.  &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October 20, 2022, the Company announced the outcome of a  significant interim analysis of its Phase 1b clinical trial of IMU-935 in patients with moderate-to-severe psoriasis that were not deemed positive progress. On October 21, 2022, the Company experienced a significant decrease in the Company's market capitalization.  The Company considered this to be a triggering event indicating that it is more likely than not that goodwill is impaired.  As a result, the Company anticipates it will incur an approximately $33.0&#160;million goodwill impairment charge in the fourth quarter of 2022 as a result of this analysis (See Note 10).&lt;/span&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i0635b165f76f479694e7564645ca75f5_D20221001-20221103"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8zNC9mcmFnOjZlNmZlYmNmYmQwYTRlNDE5NDE0ZWFhMGNlYTdjMWU2L3RleHRyZWdpb246NmU2ZmViY2ZiZDBhNGU0MTk0MTRlYWEwY2VhN2MxZTZfNDk0NzgwMjM4NjAwMQ_66b4bea5-bd8b-4597-9512-14a8269be181"
      unitRef="usd">60000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="ic5a53880f9da458c8abd6926ff69ddd8_D20221001-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8zNC9mcmFnOjZlNmZlYmNmYmQwYTRlNDE5NDE0ZWFhMGNlYTdjMWU2L3RleHRyZWdpb246NmU2ZmViY2ZiZDBhNGU0MTk0MTRlYWEwY2VhN2MxZTZfNDk0NzgwMjM4NTk4Ng_9d87a629-1931-4005-aeb9-630d72a05c47"
      unitRef="usd">33000000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8zNC9mcmFnOjZlNmZlYmNmYmQwYTRlNDE5NDE0ZWFhMGNlYTdjMWU2L3RleHRyZWdpb246NmU2ZmViY2ZiZDBhNGU0MTk0MTRlYWEwY2VhN2MxZTZfMTc1MzU_af5da3ca-4a47-4856-8e0b-987cedda5112">&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;Research and Development Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;These costs primarily include external development expenses and internal personnel expenses for the three development programs, vidofludimus calcium, IMU-935 and IMU-856. Immunic has spent the majority of its research and development resources on vidofludimus calcium, the Company's lead development program for clinical trials in RRMS, UC and COVID-19.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development expenses consist of expenses incurred in research and development activities, which include clinical trials, contract research services, certain milestone payments, salaries and related employee benefits, allocated facility costs and other outsourced services. Research and development expenses are charged to operations as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company enters into agreements with contract research organizations (&#x201c;CROs&#x201d;) to provide clinical trial services for individual studies and projects by executing individual work orders governed by a Master Service Arrangement (&#x201c;MSA&#x201d;). The MSAs and associated work orders provide for regular recurrent payments and payments upon the completion of certain milestones. The Company regularly assesses the timing of payments against actual costs incurred to ensure a proper accrual of related expenses in the appropriate accounting period.&lt;/span&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:CollaborativeArrangementAccountingPolicy
      contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8zNC9mcmFnOjZlNmZlYmNmYmQwYTRlNDE5NDE0ZWFhMGNlYTdjMWU2L3RleHRyZWdpb246NmU2ZmViY2ZiZDBhNGU0MTk0MTRlYWEwY2VhN2MxZTZfMTc1NDY_8b36606c-4cf9-4743-8f47-7fb9223de79b">&lt;div style="margin-top:18pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Collaboration Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain collaboration and license agreements may include payments to or from the Company of one or more of the following: non-refundable or partially refundable upfront or license fees; development, regulatory and commercial milestone payments; payment for manufacturing supply services; partial or complete reimbursement of research and development costs; and royalties on net sales of licensed products. The Company assesses whether such contracts are within the scope of Financial Accounting Standards Board (FASB) Accounting Standards Update (&#x201c;ASU&#x201d;) 2014-09 &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201d; and ASU No. 2018-18, &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Arrangements&#x201d;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; ("ASU 2018-18"). ASU 2018-18, clarifies that certain elements of collaborative arrangements could qualify as transactions with customers in the scope of ASC 606.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2018, the Company entered into an option and license agreement (the "Daiichi Sankyo Agreement") with Daiichi Sankyo Co., Ltd. ("Daiichi Sankyo") which granted the Company the right to license a group of compounds, designated by the Company as IMU-856, as a potential new oral treatment option for gastrointestinal diseases such as celiac disease, inflammatory bowel disease, irritable bowel syndrome with diarrhea and other barrier function associated diseases. During the option period, the Company performed agreed upon research and development activities for which it was reimbursed by Daiichi &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Sankyo up to a maximum agreed-upon limit. Such reimbursement was recorded as other income. There are no additional research and development reimbursements expected under this agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;On January 5, 2020, the Company exercised its option to obtain the exclusive worldwide right to commercialization of IMU-856. Among other things, the option exercise grants Immunic AG the rights to Daiichi Sankyo&#x2019;s patent application related to IMU-856, for which the Company received a notice of allowance from the US Patent &amp;amp; Trademark Office in August 2022. In connection with the option exercise, the Company paid a one-time upfront licensing fee to Daiichi Sankyo. Under the Daiichi Sankyo Agreement, Daiichi Sankyo is also eligible to receive future development, regulatory and sales milestone payments, as well as royalties related to IMU-856.&lt;/span&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementAccountingPolicy>
    <us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock
      contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8zNC9mcmFnOjZlNmZlYmNmYmQwYTRlNDE5NDE0ZWFhMGNlYTdjMWU2L3RleHRyZWdpb246NmU2ZmViY2ZiZDBhNGU0MTk0MTRlYWEwY2VhN2MxZTZfMTc1Mjg_c5bebae0-425a-4e28-91f6-d09a9cc2c9af">&lt;div style="margin-top:18pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;General and Administrative Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;General and administrative expenses consist primarily of salaries and related costs for personnel in executive, finance, business development and other support functions. Other general and administrative expenses include, but are not limited to, stock-based compensation, insurance costs, professional fees for legal, accounting and tax services, consulting, related facility costs and travel.&lt;/span&gt;&lt;/div&gt;</us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8zNC9mcmFnOjZlNmZlYmNmYmQwYTRlNDE5NDE0ZWFhMGNlYTdjMWU2L3RleHRyZWdpb246NmU2ZmViY2ZiZDBhNGU0MTk0MTRlYWEwY2VhN2MxZTZfMTc1NDg_1a6a27f3-27c4-405e-b4e0-aa0ac27e831e">&lt;div style="margin-top:18pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company measures the cost of employee and non-employee services received in exchange for equity awards based on the grant-date fair value of the award recognized generally as an expense (i) on a straight-line basis over the requisite service period for those awards whose vesting is based upon a service condition, and (ii) on an accelerated method for awards whose vesting is based upon a performance condition, but only to the extent it is probable that the performance condition will be met. Stock-based compensation is (i) estimated at the date of grant based on the award&#x2019;s fair value for equity classified awards and (ii) final measurement date for liability classified awards. Forfeitures are recorded in the period in which they occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company estimates the fair value of stock options using the Black-Scholes-Merton option-pricing model ("BSM"), which requires the use of estimates and subjective assumptions, including the risk-free interest rate, the fair value of the underlying common stock, the expected dividend yield of the Company&#x2019;s common stock, the expected volatility of the price of the Company&#x2019;s common stock, and the expected term of the option. These estimates involve inherent uncertainties and the application of management&#x2019;s judgment. If factors change and different assumptions are used, the Company&#x2019;s stock-based compensation expense could be materially different in the future.&lt;/span&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8zNC9mcmFnOjZlNmZlYmNmYmQwYTRlNDE5NDE0ZWFhMGNlYTdjMWU2L3RleHRyZWdpb246NmU2ZmViY2ZiZDBhNGU0MTk0MTRlYWEwY2VhN2MxZTZfMTc1NDE_9f792fad-c5b3-4c62-84de-f1e5fa853acc">&lt;div style="margin-top:18pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company leases office space and office equipment. The underlying lease agreements have lease terms of less than 12 months and up to 60 months. Leases with terms of 12 months or less at inception are not included in the operating lease right of use asset and operating lease liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has two existing leases for office space. At inception of a lease agreement, the Company determines whether an agreement represents a lease and at commencement each lease agreement is assessed as to classification as an operating or financing lease. The Company's two leases have been classified as operating leases and an operating lease right-of-use asset and an operating lease liability have been recorded on the Company&#x2019;s balance sheet. A right-of-use lease asset represents the Company&#x2019;s right to use the underlying asset for the lease term and the lease obligation represents its commitment to make the lease payments arising from the lease. Right-of-use lease assets and obligations are recognized at the commencement date based on the present value of remaining lease payments over the lease term. As the Company&#x2019;s leases do not provide an implicit rate, the Company has used an estimated incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. The right-of-use lease asset includes any lease payments made prior to commencement and excludes any lease incentives. The lease term used in estimating future lease payments may include options to extend when it is reasonably certain that the Company will exercise that option. Operating lease expense is recognized on a straight-line basis over the lease term, subject to any changes in the lease or changes in expectations regarding the lease term. Variable lease costs such as common area costs and property taxes are expensed as incurred. Leases with an initial term of twelve months or less are not recorded on the balance sheet.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="ib99098d9e41b4f74a0e5c17f2558443e_I20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8zNC9mcmFnOjZlNmZlYmNmYmQwYTRlNDE5NDE0ZWFhMGNlYTdjMWU2L3RleHRyZWdpb246NmU2ZmViY2ZiZDBhNGU0MTk0MTRlYWEwY2VhN2MxZTZfNTQ5NzU1ODU1MTk4_45079ef0-c849-4ba2-8d65-40996c80bf36">P12M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="ic3f8af6eaf2d4e90a82b6ef6ea30ec32_I20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8zNC9mcmFnOjZlNmZlYmNmYmQwYTRlNDE5NDE0ZWFhMGNlYTdjMWU2L3RleHRyZWdpb246NmU2ZmViY2ZiZDBhNGU0MTk0MTRlYWEwY2VhN2MxZTZfNTQ5NzU1ODU1MjEy_2ba99a5c-af5d-40c2-bf6a-167ed264220d">P60M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <vtl:LesseeOperatingLeasesNumberOfExistingLeases
      contextRef="ib2ba0b84078f4de2bc3079e992921b92_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8zNC9mcmFnOjZlNmZlYmNmYmQwYTRlNDE5NDE0ZWFhMGNlYTdjMWU2L3RleHRyZWdpb246NmU2ZmViY2ZiZDBhNGU0MTk0MTRlYWEwY2VhN2MxZTZfNTQ5NzU1ODU1Mzc1_80079bb7-5c36-473e-82cf-6d052314ddeb"
      unitRef="lease">2</vtl:LesseeOperatingLeasesNumberOfExistingLeases>
    <vtl:LesseeOperatingLeasesNumberOfExistingLeases
      contextRef="ib2ba0b84078f4de2bc3079e992921b92_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8zNC9mcmFnOjZlNmZlYmNmYmQwYTRlNDE5NDE0ZWFhMGNlYTdjMWU2L3RleHRyZWdpb246NmU2ZmViY2ZiZDBhNGU0MTk0MTRlYWEwY2VhN2MxZTZfNTQ5NzU1ODU1Mzc1_8257bf78-4ee9-4959-b0ad-5f2f7728c549"
      unitRef="lease">2</vtl:LesseeOperatingLeasesNumberOfExistingLeases>
    <vtl:LesseeOperatingLeasesNumberOfExistingLeases
      contextRef="ib2ba0b84078f4de2bc3079e992921b92_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8zNC9mcmFnOjZlNmZlYmNmYmQwYTRlNDE5NDE0ZWFhMGNlYTdjMWU2L3RleHRyZWdpb246NmU2ZmViY2ZiZDBhNGU0MTk0MTRlYWEwY2VhN2MxZTZfNTQ5NzU1ODU1NjM1_80079bb7-5c36-473e-82cf-6d052314ddeb"
      unitRef="lease">2</vtl:LesseeOperatingLeasesNumberOfExistingLeases>
    <vtl:LesseeOperatingLeasesNumberOfExistingLeases
      contextRef="ib2ba0b84078f4de2bc3079e992921b92_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8zNC9mcmFnOjZlNmZlYmNmYmQwYTRlNDE5NDE0ZWFhMGNlYTdjMWU2L3RleHRyZWdpb246NmU2ZmViY2ZiZDBhNGU0MTk0MTRlYWEwY2VhN2MxZTZfNTQ5NzU1ODU1NjM1_8257bf78-4ee9-4959-b0ad-5f2f7728c549"
      unitRef="lease">2</vtl:LesseeOperatingLeasesNumberOfExistingLeases>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock
      contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8zNC9mcmFnOjZlNmZlYmNmYmQwYTRlNDE5NDE0ZWFhMGNlYTdjMWU2L3RleHRyZWdpb246NmU2ZmViY2ZiZDBhNGU0MTk0MTRlYWEwY2VhN2MxZTZfMTc1MzY_a0b78c88-c9bb-43d8-91c8-cbbb01643f3b">&lt;div style="margin-top:18pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Comprehensive Income (Loss)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Comprehensive income (loss) is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. Accumulated other comprehensive income (loss) has been reflected as a separate component of stockholders&#x2019; equity in the accompanying Consolidated Balance Sheets and consists of foreign currency translation adjustments (net of tax).&lt;/span&gt;&lt;/div&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8zNC9mcmFnOjZlNmZlYmNmYmQwYTRlNDE5NDE0ZWFhMGNlYTdjMWU2L3RleHRyZWdpb246NmU2ZmViY2ZiZDBhNGU0MTk0MTRlYWEwY2VhN2MxZTZfMTc1Mjk_f9966b2c-38c6-4a07-ae2c-04ca9cdd2500">&lt;div style="margin-top:18pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is subject to corporate income tax laws and regulations in the U.S., Germany and Australia. Tax regulations within each jurisdiction are subject to the interpretation of the related tax laws and regulations and require significant judgment in their application.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company utilizes the asset and liability method of accounting for income taxes which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the audited consolidated financial statements. Deferred income tax assets and liabilities are determined based on the differences between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of changes in tax rates on deferred tax assets and liabilities is recognized in operations in the period that includes the enactment date. Deferred taxes are reduced by a valuation allowance when, in the opinion of management, it is more likely than not some portion or the entire deferred tax asset will not be realized.  As of September 30, 2022 and 2021, respectively, the Company maintained a full valuation allowance against the balance of deferred tax assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;It is the Company&#x2019;s policy to provide for uncertain tax positions and the related interest and penalties based upon management&#x2019;s assessment of whether a tax benefit is more likely than not to be sustained upon examination by tax authorities. The Company recognizes interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense.  The Company is subject to U.S. federal, New York, California, Texas, German and Australian income taxes. The Company is subject to U.S. federal or state income tax examination by tax authorities for tax returns filed for the years 2003 and forward due to the carryforward of NOLs. Tax years 2016 through 2021 are subject to audit by German and Australian tax authorities. The Company is not currently under examination by any tax jurisdictions.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8zNC9mcmFnOjZlNmZlYmNmYmQwYTRlNDE5NDE0ZWFhMGNlYTdjMWU2L3RleHRyZWdpb246NmU2ZmViY2ZiZDBhNGU0MTk0MTRlYWEwY2VhN2MxZTZfMTc1NDI_b799c06d-2569-4a44-8dbb-62004fb5d75e">&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net Loss Per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net loss per share attributable to common stockholders is calculated by dividing the net loss by the weighted-average number of common shares outstanding for the period, without consideration for common stock equivalents. Diluted net loss per share attributable to common stockholders is computed by dividing the net loss by the weighted-average number of common shares and, if dilutive, common stock equivalents outstanding for the period determined using the treasury-stock method. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company&#x2019;s net loss position.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8zNC9mcmFnOjZlNmZlYmNmYmQwYTRlNDE5NDE0ZWFhMGNlYTdjMWU2L3RleHRyZWdpb246NmU2ZmViY2ZiZDBhNGU0MTk0MTRlYWEwY2VhN2MxZTZfMTc1NDk_a5cc9bc0-9375-4997-acb9-9359cae15192">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Potentially dilutive securities, not included in the calculation of diluted net loss per share attributable to common stockholders because to do so would be anti-dilutive, are as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.751%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.953%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.955%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,799,573&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,045,960&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ic3a03035d5534d539979b07aedea62c1_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8zNC9mcmFnOjZlNmZlYmNmYmQwYTRlNDE5NDE0ZWFhMGNlYTdjMWU2L3RhYmxlOmM0ZjViMmM4OTkxYTQ4MDM4NTI2Mzc0NzJiZjk0NTIwL3RhYmxlcmFuZ2U6YzRmNWIyYzg5OTFhNDgwMzg1MjYzNzQ3MmJmOTQ1MjBfMi0xLTEtMS0zMDUwMA_61ae7e72-1a1f-4d1e-9f68-f8e1ddaffcb7"
      unitRef="shares">3799573</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="id8129f471bae49039a917f1451ac8087_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8zNC9mcmFnOjZlNmZlYmNmYmQwYTRlNDE5NDE0ZWFhMGNlYTdjMWU2L3RhYmxlOmM0ZjViMmM4OTkxYTQ4MDM4NTI2Mzc0NzJiZjk0NTIwL3RhYmxlcmFuZ2U6YzRmNWIyYzg5OTFhNDgwMzg1MjYzNzQ3MmJmOTQ1MjBfMi0zLTEtMS0zMDUwMA_907be8b6-4323-4c56-9c6e-fe87cda67373"
      unitRef="shares">2045960</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8zNC9mcmFnOjZlNmZlYmNmYmQwYTRlNDE5NDE0ZWFhMGNlYTdjMWU2L3RleHRyZWdpb246NmU2ZmViY2ZiZDBhNGU0MTk0MTRlYWEwY2VhN2MxZTZfMTc1MzA_6e9d7498-b951-46e6-84fe-04a55fd0af2a">&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Issued and/or Adopted Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There are no recently issued accounting standards that would have a significant impact on the company's consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock
      contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8zNy9mcmFnOmVhYWM3YjljYjM4ZDQyZTM4OTQwZjgyZWE3Y2E4NDJkL3RleHRyZWdpb246ZWFhYzdiOWNiMzhkNDJlMzg5NDBmODJlYTdjYTg0MmRfMzU1_c9346d98-ff99-450a-a5a3-9c827c2c526a">Balance Sheet Details&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other Current Assets and Prepaid Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other Current Assets and Prepaid Expenses consist of (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.315%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.157%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.969%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.059%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid clinical and related costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,938&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;VAT receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Australian research and development tax incentive&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,871&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,549&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accounts Payable&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts Payable consist of (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.046%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.969%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.474%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Clinical costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Legal and audit costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,745&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accrued Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses consist of (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.484%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.864%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued clinical and related costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,504&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued legal and audit costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,071&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other Current Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other Current Liabilities consist of (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.469%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.527%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.912%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.740%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;324&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;719&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;585&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
    <us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock
      contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8zNy9mcmFnOmVhYWM3YjljYjM4ZDQyZTM4OTQwZjgyZWE3Y2E4NDJkL3RleHRyZWdpb246ZWFhYzdiOWNiMzhkNDJlMzg5NDBmODJlYTdjYTg0MmRfMzQ4_b1d6b67a-796e-4b7a-9688-7cfdf127b6b0">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other Current Assets and Prepaid Expenses consist of (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.315%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.157%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.969%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.059%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid clinical and related costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,938&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;VAT receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Australian research and development tax incentive&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,871&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,549&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock>
    <vtl:PrepaidClinicalAndRelatedCostsCurrent
      contextRef="ib2ba0b84078f4de2bc3079e992921b92_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8zNy9mcmFnOmVhYWM3YjljYjM4ZDQyZTM4OTQwZjgyZWE3Y2E4NDJkL3RhYmxlOjIwZWFkZWZjNmY4YzQ5YjlhOGVjZTE2ZDA3ZDU3ZGJhL3RhYmxlcmFuZ2U6MjBlYWRlZmM2ZjhjNDliOWE4ZWNlMTZkMDdkNTdkYmFfMi0xLTEtMS0zMDUwMA_d230af58-3ed8-446c-8d37-81da5e7b9914"
      unitRef="usd">8938000</vtl:PrepaidClinicalAndRelatedCostsCurrent>
    <vtl:PrepaidClinicalAndRelatedCostsCurrent
      contextRef="i12246a01749f40d394a9437cb9938c91_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8zNy9mcmFnOmVhYWM3YjljYjM4ZDQyZTM4OTQwZjgyZWE3Y2E4NDJkL3RhYmxlOjIwZWFkZWZjNmY4YzQ5YjlhOGVjZTE2ZDA3ZDU3ZGJhL3RhYmxlcmFuZ2U6MjBlYWRlZmM2ZjhjNDliOWE4ZWNlMTZkMDdkNTdkYmFfMi0zLTEtMS0zMDUwMA_9561c2ec-ba68-4f89-a6e2-bca89955dd20"
      unitRef="usd">14853000</vtl:PrepaidClinicalAndRelatedCostsCurrent>
    <us-gaap:ValueAddedTaxReceivableCurrent
      contextRef="ib2ba0b84078f4de2bc3079e992921b92_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8zNy9mcmFnOmVhYWM3YjljYjM4ZDQyZTM4OTQwZjgyZWE3Y2E4NDJkL3RhYmxlOjIwZWFkZWZjNmY4YzQ5YjlhOGVjZTE2ZDA3ZDU3ZGJhL3RhYmxlcmFuZ2U6MjBlYWRlZmM2ZjhjNDliOWE4ZWNlMTZkMDdkNTdkYmFfMy0xLTEtMS0zMDUwMA_ea518522-d152-49b7-a442-5c283208ddab"
      unitRef="usd">241000</us-gaap:ValueAddedTaxReceivableCurrent>
    <us-gaap:ValueAddedTaxReceivableCurrent
      contextRef="i12246a01749f40d394a9437cb9938c91_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8zNy9mcmFnOmVhYWM3YjljYjM4ZDQyZTM4OTQwZjgyZWE3Y2E4NDJkL3RhYmxlOjIwZWFkZWZjNmY4YzQ5YjlhOGVjZTE2ZDA3ZDU3ZGJhL3RhYmxlcmFuZ2U6MjBlYWRlZmM2ZjhjNDliOWE4ZWNlMTZkMDdkNTdkYmFfMy0zLTEtMS0zMDUwMA_ad6c83c7-a3d4-4f75-8df4-cd5e87e644bc"
      unitRef="usd">279000</us-gaap:ValueAddedTaxReceivableCurrent>
    <vtl:ResearchAndDevelopmentTaxIncentiveCurrent
      contextRef="ib2ba0b84078f4de2bc3079e992921b92_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8zNy9mcmFnOmVhYWM3YjljYjM4ZDQyZTM4OTQwZjgyZWE3Y2E4NDJkL3RhYmxlOjIwZWFkZWZjNmY4YzQ5YjlhOGVjZTE2ZDA3ZDU3ZGJhL3RhYmxlcmFuZ2U6MjBlYWRlZmM2ZjhjNDliOWE4ZWNlMTZkMDdkNTdkYmFfNC0xLTEtMS0zMDUwMA_8832733b-b1d6-4399-bdad-34b7e26195f7"
      unitRef="usd">3150000</vtl:ResearchAndDevelopmentTaxIncentiveCurrent>
    <vtl:ResearchAndDevelopmentTaxIncentiveCurrent
      contextRef="i12246a01749f40d394a9437cb9938c91_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8zNy9mcmFnOmVhYWM3YjljYjM4ZDQyZTM4OTQwZjgyZWE3Y2E4NDJkL3RhYmxlOjIwZWFkZWZjNmY4YzQ5YjlhOGVjZTE2ZDA3ZDU3ZGJhL3RhYmxlcmFuZ2U6MjBlYWRlZmM2ZjhjNDliOWE4ZWNlMTZkMDdkNTdkYmFfNC0zLTEtMS0zMDUwMA_86f48ccd-cae8-477e-b99d-330211021f28"
      unitRef="usd">1871000</vtl:ResearchAndDevelopmentTaxIncentiveCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="ib2ba0b84078f4de2bc3079e992921b92_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8zNy9mcmFnOmVhYWM3YjljYjM4ZDQyZTM4OTQwZjgyZWE3Y2E4NDJkL3RhYmxlOjIwZWFkZWZjNmY4YzQ5YjlhOGVjZTE2ZDA3ZDU3ZGJhL3RhYmxlcmFuZ2U6MjBlYWRlZmM2ZjhjNDliOWE4ZWNlMTZkMDdkNTdkYmFfNS0xLTEtMS0zMDUwMA_9dda7117-25b3-40bd-bd40-5fbf64b67389"
      unitRef="usd">1549000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="i12246a01749f40d394a9437cb9938c91_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8zNy9mcmFnOmVhYWM3YjljYjM4ZDQyZTM4OTQwZjgyZWE3Y2E4NDJkL3RhYmxlOjIwZWFkZWZjNmY4YzQ5YjlhOGVjZTE2ZDA3ZDU3ZGJhL3RhYmxlcmFuZ2U6MjBlYWRlZmM2ZjhjNDliOWE4ZWNlMTZkMDdkNTdkYmFfNS0zLTEtMS0zMDUwMA_24b61a60-20dd-4252-b5d5-ce568af1185d"
      unitRef="usd">1122000</us-gaap:OtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="ib2ba0b84078f4de2bc3079e992921b92_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8zNy9mcmFnOmVhYWM3YjljYjM4ZDQyZTM4OTQwZjgyZWE3Y2E4NDJkL3RhYmxlOjIwZWFkZWZjNmY4YzQ5YjlhOGVjZTE2ZDA3ZDU3ZGJhL3RhYmxlcmFuZ2U6MjBlYWRlZmM2ZjhjNDliOWE4ZWNlMTZkMDdkNTdkYmFfNi0xLTEtMS0zMDUwMA_11f84083-aab2-4034-9722-dde117982cec"
      unitRef="usd">13878000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i12246a01749f40d394a9437cb9938c91_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8zNy9mcmFnOmVhYWM3YjljYjM4ZDQyZTM4OTQwZjgyZWE3Y2E4NDJkL3RhYmxlOjIwZWFkZWZjNmY4YzQ5YjlhOGVjZTE2ZDA3ZDU3ZGJhL3RhYmxlcmFuZ2U6MjBlYWRlZmM2ZjhjNDliOWE4ZWNlMTZkMDdkNTdkYmFfNi0zLTEtMS0zMDUwMA_cf2584dd-eaa0-4960-9016-6e7d708e4db0"
      unitRef="usd">18125000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock
      contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8zNy9mcmFnOmVhYWM3YjljYjM4ZDQyZTM4OTQwZjgyZWE3Y2E4NDJkL3RleHRyZWdpb246ZWFhYzdiOWNiMzhkNDJlMzg5NDBmODJlYTdjYTg0MmRfMzUz_60d021f7-6318-45f7-bcf2-1796e04d6e9c">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts Payable consist of (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.046%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.969%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.474%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Clinical costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Legal and audit costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,745&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses consist of (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.484%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.864%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued clinical and related costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,504&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued legal and audit costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,071&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <vtl:ClinicalCostsPayableCurrent
      contextRef="ib2ba0b84078f4de2bc3079e992921b92_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8zNy9mcmFnOmVhYWM3YjljYjM4ZDQyZTM4OTQwZjgyZWE3Y2E4NDJkL3RhYmxlOjI2YjExNjY5Njg4OTQ2MjY5ZDhhZTczNWI5OTIzMzQ5L3RhYmxlcmFuZ2U6MjZiMTE2Njk2ODg5NDYyNjlkOGFlNzM1Yjk5MjMzNDlfMi0xLTEtMS0zMDUwMA_dc11b11b-642e-4746-b7e6-2323b21a877b"
      unitRef="usd">3748000</vtl:ClinicalCostsPayableCurrent>
    <vtl:ClinicalCostsPayableCurrent
      contextRef="i12246a01749f40d394a9437cb9938c91_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8zNy9mcmFnOmVhYWM3YjljYjM4ZDQyZTM4OTQwZjgyZWE3Y2E4NDJkL3RhYmxlOjI2YjExNjY5Njg4OTQ2MjY5ZDhhZTczNWI5OTIzMzQ5L3RhYmxlcmFuZ2U6MjZiMTE2Njk2ODg5NDYyNjlkOGFlNzM1Yjk5MjMzNDlfMi0zLTEtMS0zMDUwMA_63aebabd-1ff5-4fa3-9977-34318d469697"
      unitRef="usd">3427000</vtl:ClinicalCostsPayableCurrent>
    <vtl:LegalAndAuditCostsPayableCurrent
      contextRef="ib2ba0b84078f4de2bc3079e992921b92_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8zNy9mcmFnOmVhYWM3YjljYjM4ZDQyZTM4OTQwZjgyZWE3Y2E4NDJkL3RhYmxlOjI2YjExNjY5Njg4OTQ2MjY5ZDhhZTczNWI5OTIzMzQ5L3RhYmxlcmFuZ2U6MjZiMTE2Njk2ODg5NDYyNjlkOGFlNzM1Yjk5MjMzNDlfMy0xLTEtMS0zMDUwMA_96054060-be7c-451d-bb07-a3b74749749d"
      unitRef="usd">114000</vtl:LegalAndAuditCostsPayableCurrent>
    <vtl:LegalAndAuditCostsPayableCurrent
      contextRef="i12246a01749f40d394a9437cb9938c91_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8zNy9mcmFnOmVhYWM3YjljYjM4ZDQyZTM4OTQwZjgyZWE3Y2E4NDJkL3RhYmxlOjI2YjExNjY5Njg4OTQ2MjY5ZDhhZTczNWI5OTIzMzQ5L3RhYmxlcmFuZ2U6MjZiMTE2Njk2ODg5NDYyNjlkOGFlNzM1Yjk5MjMzNDlfMy0zLTEtMS0zMDUwMA_65d67307-a47b-4973-9b39-900d9a2efb63"
      unitRef="usd">72000</vtl:LegalAndAuditCostsPayableCurrent>
    <us-gaap:AccountsPayableOtherCurrent
      contextRef="ib2ba0b84078f4de2bc3079e992921b92_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8zNy9mcmFnOmVhYWM3YjljYjM4ZDQyZTM4OTQwZjgyZWE3Y2E4NDJkL3RhYmxlOjI2YjExNjY5Njg4OTQ2MjY5ZDhhZTczNWI5OTIzMzQ5L3RhYmxlcmFuZ2U6MjZiMTE2Njk2ODg5NDYyNjlkOGFlNzM1Yjk5MjMzNDlfNS0xLTEtMS0zMDUwMA_0b6b8558-995c-4caa-82b2-e0d8a061b4c4"
      unitRef="usd">310000</us-gaap:AccountsPayableOtherCurrent>
    <us-gaap:AccountsPayableOtherCurrent
      contextRef="i12246a01749f40d394a9437cb9938c91_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8zNy9mcmFnOmVhYWM3YjljYjM4ZDQyZTM4OTQwZjgyZWE3Y2E4NDJkL3RhYmxlOjI2YjExNjY5Njg4OTQ2MjY5ZDhhZTczNWI5OTIzMzQ5L3RhYmxlcmFuZ2U6MjZiMTE2Njk2ODg5NDYyNjlkOGFlNzM1Yjk5MjMzNDlfNS0zLTEtMS0zMDUwMA_642cd634-3de9-41bf-a663-9cb88ecf64a7"
      unitRef="usd">246000</us-gaap:AccountsPayableOtherCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="ib2ba0b84078f4de2bc3079e992921b92_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8zNy9mcmFnOmVhYWM3YjljYjM4ZDQyZTM4OTQwZjgyZWE3Y2E4NDJkL3RhYmxlOjI2YjExNjY5Njg4OTQ2MjY5ZDhhZTczNWI5OTIzMzQ5L3RhYmxlcmFuZ2U6MjZiMTE2Njk2ODg5NDYyNjlkOGFlNzM1Yjk5MjMzNDlfNi0xLTEtMS0zMDUwMA_89841f2c-3563-407d-9902-4603b7d96c84"
      unitRef="usd">4172000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i12246a01749f40d394a9437cb9938c91_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8zNy9mcmFnOmVhYWM3YjljYjM4ZDQyZTM4OTQwZjgyZWE3Y2E4NDJkL3RhYmxlOjI2YjExNjY5Njg4OTQ2MjY5ZDhhZTczNWI5OTIzMzQ5L3RhYmxlcmFuZ2U6MjZiMTE2Njk2ODg5NDYyNjlkOGFlNzM1Yjk5MjMzNDlfNi0zLTEtMS0zMDUwMA_7d11af9e-89cd-401c-ab87-39b18dba8949"
      unitRef="usd">3745000</us-gaap:AccountsPayableCurrent>
    <vtl:AccruedClinicalCostsCurrent
      contextRef="ib2ba0b84078f4de2bc3079e992921b92_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8zNy9mcmFnOmVhYWM3YjljYjM4ZDQyZTM4OTQwZjgyZWE3Y2E4NDJkL3RhYmxlOjhjYWQ4MTBiZTM0NjQ4NTY5YzM1ZDJlY2FkMTY0NDYyL3RhYmxlcmFuZ2U6OGNhZDgxMGJlMzQ2NDg1NjljMzVkMmVjYWQxNjQ0NjJfMi0xLTEtMS0zMDUwMA_4fa4e824-da1e-47a7-81ef-5c3f6d9ea2c8"
      unitRef="usd">5504000</vtl:AccruedClinicalCostsCurrent>
    <vtl:AccruedClinicalCostsCurrent
      contextRef="i12246a01749f40d394a9437cb9938c91_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8zNy9mcmFnOmVhYWM3YjljYjM4ZDQyZTM4OTQwZjgyZWE3Y2E4NDJkL3RhYmxlOjhjYWQ4MTBiZTM0NjQ4NTY5YzM1ZDJlY2FkMTY0NDYyL3RhYmxlcmFuZ2U6OGNhZDgxMGJlMzQ2NDg1NjljMzVkMmVjYWQxNjQ0NjJfMi0zLTEtMS0zMDUwMA_4eb7001f-3d0f-4194-8da1-20872f36e887"
      unitRef="usd">6214000</vtl:AccruedClinicalCostsCurrent>
    <vtl:AccruedLegalAndAuditCostsCurrent
      contextRef="ib2ba0b84078f4de2bc3079e992921b92_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8zNy9mcmFnOmVhYWM3YjljYjM4ZDQyZTM4OTQwZjgyZWE3Y2E4NDJkL3RhYmxlOjhjYWQ4MTBiZTM0NjQ4NTY5YzM1ZDJlY2FkMTY0NDYyL3RhYmxlcmFuZ2U6OGNhZDgxMGJlMzQ2NDg1NjljMzVkMmVjYWQxNjQ0NjJfMy0xLTEtMS0zMDUwMA_2d474d36-5134-427f-926e-418fb98b2138"
      unitRef="usd">85000</vtl:AccruedLegalAndAuditCostsCurrent>
    <vtl:AccruedLegalAndAuditCostsCurrent
      contextRef="i12246a01749f40d394a9437cb9938c91_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8zNy9mcmFnOmVhYWM3YjljYjM4ZDQyZTM4OTQwZjgyZWE3Y2E4NDJkL3RhYmxlOjhjYWQ4MTBiZTM0NjQ4NTY5YzM1ZDJlY2FkMTY0NDYyL3RhYmxlcmFuZ2U6OGNhZDgxMGJlMzQ2NDg1NjljMzVkMmVjYWQxNjQ0NjJfMy0zLTEtMS0zMDUwMA_71fa7b0b-a8d2-49fe-81b0-dba3a4e4dfd1"
      unitRef="usd">96000</vtl:AccruedLegalAndAuditCostsCurrent>
    <vtl:AccruedCompensationCurrent
      contextRef="ib2ba0b84078f4de2bc3079e992921b92_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8zNy9mcmFnOmVhYWM3YjljYjM4ZDQyZTM4OTQwZjgyZWE3Y2E4NDJkL3RhYmxlOjhjYWQ4MTBiZTM0NjQ4NTY5YzM1ZDJlY2FkMTY0NDYyL3RhYmxlcmFuZ2U6OGNhZDgxMGJlMzQ2NDg1NjljMzVkMmVjYWQxNjQ0NjJfNC0xLTEtMS0zMDUwMA_66aea635-1fbc-41a7-93d2-685b05e93481"
      unitRef="usd">881000</vtl:AccruedCompensationCurrent>
    <vtl:AccruedCompensationCurrent
      contextRef="i12246a01749f40d394a9437cb9938c91_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8zNy9mcmFnOmVhYWM3YjljYjM4ZDQyZTM4OTQwZjgyZWE3Y2E4NDJkL3RhYmxlOjhjYWQ4MTBiZTM0NjQ4NTY5YzM1ZDJlY2FkMTY0NDYyL3RhYmxlcmFuZ2U6OGNhZDgxMGJlMzQ2NDg1NjljMzVkMmVjYWQxNjQ0NjJfNC0zLTEtMS0zMDUwMA_8323b6ee-9cd6-4601-903d-2cc28e9bdd41"
      unitRef="usd">674000</vtl:AccruedCompensationCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="ib2ba0b84078f4de2bc3079e992921b92_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8zNy9mcmFnOmVhYWM3YjljYjM4ZDQyZTM4OTQwZjgyZWE3Y2E4NDJkL3RhYmxlOjhjYWQ4MTBiZTM0NjQ4NTY5YzM1ZDJlY2FkMTY0NDYyL3RhYmxlcmFuZ2U6OGNhZDgxMGJlMzQ2NDg1NjljMzVkMmVjYWQxNjQ0NjJfNS0xLTEtMS0zMDUwMA_afa51968-59a4-489a-8acb-4ddbdeea2488"
      unitRef="usd">153000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i12246a01749f40d394a9437cb9938c91_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8zNy9mcmFnOmVhYWM3YjljYjM4ZDQyZTM4OTQwZjgyZWE3Y2E4NDJkL3RhYmxlOjhjYWQ4MTBiZTM0NjQ4NTY5YzM1ZDJlY2FkMTY0NDYyL3RhYmxlcmFuZ2U6OGNhZDgxMGJlMzQ2NDg1NjljMzVkMmVjYWQxNjQ0NjJfNS0zLTEtMS0zMDUwMA_45a65edc-db0c-44ff-93c3-4d300556c319"
      unitRef="usd">87000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="ib2ba0b84078f4de2bc3079e992921b92_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8zNy9mcmFnOmVhYWM3YjljYjM4ZDQyZTM4OTQwZjgyZWE3Y2E4NDJkL3RhYmxlOjhjYWQ4MTBiZTM0NjQ4NTY5YzM1ZDJlY2FkMTY0NDYyL3RhYmxlcmFuZ2U6OGNhZDgxMGJlMzQ2NDg1NjljMzVkMmVjYWQxNjQ0NjJfNi0xLTEtMS0zMDUwMA_c44967c6-1ee2-453c-927b-daaaa13d9ed0"
      unitRef="usd">6623000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i12246a01749f40d394a9437cb9938c91_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8zNy9mcmFnOmVhYWM3YjljYjM4ZDQyZTM4OTQwZjgyZWE3Y2E4NDJkL3RhYmxlOjhjYWQ4MTBiZTM0NjQ4NTY5YzM1ZDJlY2FkMTY0NDYyL3RhYmxlcmFuZ2U6OGNhZDgxMGJlMzQ2NDg1NjljMzVkMmVjYWQxNjQ0NjJfNi0zLTEtMS0zMDUwMA_f6663456-7f9a-4814-ae67-92636067e20d"
      unitRef="usd">7071000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OtherCurrentLiabilitiesTableTextBlock
      contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8zNy9mcmFnOmVhYWM3YjljYjM4ZDQyZTM4OTQwZjgyZWE3Y2E4NDJkL3RleHRyZWdpb246ZWFhYzdiOWNiMzhkNDJlMzg5NDBmODJlYTdjYTg0MmRfMzU0_7f880802-5000-492d-8b2b-01ac247ef445">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other Current Liabilities consist of (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.469%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.527%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.912%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.740%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;324&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;719&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;585&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:OtherCurrentLiabilitiesTableTextBlock>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ib2ba0b84078f4de2bc3079e992921b92_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8zNy9mcmFnOmVhYWM3YjljYjM4ZDQyZTM4OTQwZjgyZWE3Y2E4NDJkL3RhYmxlOjAyM2Q4ODJhZDIzNjRhZDhhYzE0ZDdiMDFhNzIxOTUwL3RhYmxlcmFuZ2U6MDIzZDg4MmFkMjM2NGFkOGFjMTRkN2IwMWE3MjE5NTBfMi0xLTEtMS0zMDUwMA_0492016e-12d0-48ad-a5db-4d409a0d7b66"
      unitRef="usd">395000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i12246a01749f40d394a9437cb9938c91_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8zNy9mcmFnOmVhYWM3YjljYjM4ZDQyZTM4OTQwZjgyZWE3Y2E4NDJkL3RhYmxlOjAyM2Q4ODJhZDIzNjRhZDhhYzE0ZDdiMDFhNzIxOTUwL3RhYmxlcmFuZ2U6MDIzZDg4MmFkMjM2NGFkOGFjMTRkN2IwMWE3MjE5NTBfMi0zLTEtMS0zMDUwMA_1ea556c1-8fff-4a8a-a68e-af945455ca88"
      unitRef="usd">408000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OtherSundryLiabilitiesCurrent
      contextRef="ib2ba0b84078f4de2bc3079e992921b92_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8zNy9mcmFnOmVhYWM3YjljYjM4ZDQyZTM4OTQwZjgyZWE3Y2E4NDJkL3RhYmxlOjAyM2Q4ODJhZDIzNjRhZDhhYzE0ZDdiMDFhNzIxOTUwL3RhYmxlcmFuZ2U6MDIzZDg4MmFkMjM2NGFkOGFjMTRkN2IwMWE3MjE5NTBfMy0xLTEtMS0zMDUwMA_9c200a7d-2675-43ed-b1f8-a20e3beda365"
      unitRef="usd">324000</us-gaap:OtherSundryLiabilitiesCurrent>
    <us-gaap:OtherSundryLiabilitiesCurrent
      contextRef="i12246a01749f40d394a9437cb9938c91_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8zNy9mcmFnOmVhYWM3YjljYjM4ZDQyZTM4OTQwZjgyZWE3Y2E4NDJkL3RhYmxlOjAyM2Q4ODJhZDIzNjRhZDhhYzE0ZDdiMDFhNzIxOTUwL3RhYmxlcmFuZ2U6MDIzZDg4MmFkMjM2NGFkOGFjMTRkN2IwMWE3MjE5NTBfMy0zLTEtMS0zMDUwMA_0e8f16b1-6767-49e2-9b2a-f863579230da"
      unitRef="usd">177000</us-gaap:OtherSundryLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="ib2ba0b84078f4de2bc3079e992921b92_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8zNy9mcmFnOmVhYWM3YjljYjM4ZDQyZTM4OTQwZjgyZWE3Y2E4NDJkL3RhYmxlOjAyM2Q4ODJhZDIzNjRhZDhhYzE0ZDdiMDFhNzIxOTUwL3RhYmxlcmFuZ2U6MDIzZDg4MmFkMjM2NGFkOGFjMTRkN2IwMWE3MjE5NTBfNC0xLTEtMS0zMDUwMA_f4c57551-28a3-4185-9ab1-49241afba009"
      unitRef="usd">719000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i12246a01749f40d394a9437cb9938c91_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV8zNy9mcmFnOmVhYWM3YjljYjM4ZDQyZTM4OTQwZjgyZWE3Y2E4NDJkL3RhYmxlOjAyM2Q4ODJhZDIzNjRhZDhhYzE0ZDdiMDFhNzIxOTUwL3RhYmxlcmFuZ2U6MDIzZDg4MmFkMjM2NGFkOGFjMTRkN2IwMWE3MjE5NTBfNC0zLTEtMS0zMDUwMA_aa899fd6-9969-409e-94d5-ff638c4096b3"
      unitRef="usd">585000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80MC9mcmFnOmI3MzFjZTk4M2NmOTRlZWY5MTMzMTgwMzhmYTM5Mzg4L3RleHRyZWdpb246YjczMWNlOTgzY2Y5NGVlZjkxMzMxODAzOGZhMzkzODhfNTE0NQ_e9b2c7a4-2f06-4f9f-ab39-372d6a15eb9a">Commitments and Contingencies&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Operating Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company leases certain office space under non-cancelable operating leases. The leases terminate on April 30, 2023 for the New York City office and on June 30, 2025 for the Gr&#xe4;felfing, Germany office.  These leases include both lease (e.g., fixed rent) and non-lease components (e.g., common-area and other maintenance costs). The non-lease components are deemed to be executory costs and are therefore excluded from the minimum lease payments used to determine the present value of the operating lease obligation and related right-of-use asset. The New York City lease has renewal options, but they were not included in calculating the right of use asset and liabilities.  On April 7, 2020, the Company signed a five year lease for its facility in Gr&#xe4;felfing, Germany. On March 1, 2021, and August 1, 2022, the Company added additional lease space at the Gr&#xe4;felfing, Germany office.  Renewal options were not included in calculating the right of use asset and liabilities for this facility. The leases do not have concessions, leasehold improvement incentives or other build-out clauses. Further, the leases do not contain contingent rent provisions. The New York City lease had a six month rent holiday at the beginning of the lease.  There were net additions to right of use assets of $435,000 and $642,000 as a result of signing for additional lease space at the Gr&#xe4;felfing, Germany office in March 2021 and August 2022, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;The leases do not provide an implicit rate and, due to the lack of a commercially salable product, the Company is generally considered unable to obtain commercial credit. Therefore, the Company estimated its incremental interest rate to be 6%, considering the quoted rates for the lowest investment-grade debt and the interest rates implicit in recent financing leases. Immunic used its estimated incremental borrowing rate and other information available at the lease commencement date in determining the present value of the lease payments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;Immunic&#x2019;s operating lease costs and variable lease costs were $232,000 and $133,000 for the three months ended September 30, 2022 and 2021, respectively and $498,000 and $372,000 for the nine months ended September 30, 2022 and 2021, respectively.  Variable lease costs consist primarily of common area maintenance costs, insurance and taxes which are paid based upon actual costs incurred by the lessor.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Maturities of the operating lease obligation are as follows as of September 30, 2022 (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.660%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.079%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.596%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.925%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;528&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;454&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;PV of obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Contractual Obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September 30, 2022, the Company has non-cancelable contractual obligations under certain agreements related to its development programs IMU-838, IMU-935 and IMU-856 totaling approximately $2.7 million, which is expected to be paid over the next twelve months.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other Commitments and Obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2016, the Company entered into a purchase agreement (the &#x201c;Agreement&#x201d;) with 4SC AG, whereby the Company acquired certain assets, including the rights to patents and patent applications, trademarks and know-how. This transaction has &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;been accounted for as an asset acquisition under Accounting Standards Update 2017-01 - Business Combinations (Topic 805): Clarifying the Definition of a Business. The Agreement included payments (Tranches III and IV) that were contingent upon the occurrence of certain events and required the Company to pay royalties equal to 4.4% of the aggregated net sales for a certain period as defined in the Agreement (Tranche III) upon commercialization of the acquired assets. Effective April 12, 2019, the parties agreed to settle Tranche IV by issuing 120,070 shares of the Company&#x2019;s common stock, immediately following the Transaction, to 4SC AG while keeping Tranche III in effect. Approximately $1.5 million of expense was recorded as a result of the issuance of these shares on April 12, 2019. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 31, 2021, Immunic AG, a wholly-owned subsidiary of the Company, and 4SC AG entered into a Settlement Agreement, pursuant to which Immunic AG settled its remaining obligation of the 4.4% royalty on net sales for $17.25&#160;million (Tranche III of the Agreement). The payment was made 50% in cash and 50% in shares of Immunic&#x2019;s common stock (the &#x201c;Shares&#x201d;). Pursuant to the Agreement, the Company filed a resale shelf registration statement on Form S-3 covering the resale of the Shares. With the execution of the Agreement, no further payment obligations remain between Immunic AG and 4SC AG.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Legal Proceedings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is not currently a party to any litigation, nor is it aware of any pending or threatened litigation, that it believes would materially affect its business, operating results, financial condition or cash flows. However, its industry is characterized by frequent claims and litigation including securities litigation, claims regarding patent and other intellectual property rights and claims for product liability. As a result, in the future, the Company may be involved in various legal proceedings from time to time.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="iefd1980314f44440b5198657ab592ad5_I20200407"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80MC9mcmFnOmI3MzFjZTk4M2NmOTRlZWY5MTMzMTgwMzhmYTM5Mzg4L3RleHRyZWdpb246YjczMWNlOTgzY2Y5NGVlZjkxMzMxODAzOGZhMzkzODhfNDk0NzgwMjMzNTg0Nw_7386c233-f590-4501-93ee-1a3246dadac5">P5Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <vtl:LesseeOperatingLeaseRentHolidayPeriod
      contextRef="id2f24df2744547978cca7abe63d3ddfa_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80MC9mcmFnOmI3MzFjZTk4M2NmOTRlZWY5MTMzMTgwMzhmYTM5Mzg4L3RleHRyZWdpb246YjczMWNlOTgzY2Y5NGVlZjkxMzMxODAzOGZhMzkzODhfNDk0NzgwMjMzNTg0OA_8bd9daa4-8a86-46bb-828d-27011f82acb3">P6M</vtl:LesseeOperatingLeaseRentHolidayPeriod>
    <vtl:IncreaseDecreaseInOperatingLeaseRightOfUseAsset
      contextRef="i707a1cd4886c4397999788b4d4817cc8_D20210301-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80MC9mcmFnOmI3MzFjZTk4M2NmOTRlZWY5MTMzMTgwMzhmYTM5Mzg4L3RleHRyZWdpb246YjczMWNlOTgzY2Y5NGVlZjkxMzMxODAzOGZhMzkzODhfNTQ5NzU1ODIyODk2_41fddddb-d524-47be-9f02-dde6227bfcbb"
      unitRef="usd">435000</vtl:IncreaseDecreaseInOperatingLeaseRightOfUseAsset>
    <vtl:IncreaseDecreaseInOperatingLeaseRightOfUseAsset
      contextRef="i23801a5cc9424606a18bc0c74d94ebc9_D20220801-20220801"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80MC9mcmFnOmI3MzFjZTk4M2NmOTRlZWY5MTMzMTgwMzhmYTM5Mzg4L3RleHRyZWdpb246YjczMWNlOTgzY2Y5NGVlZjkxMzMxODAzOGZhMzkzODhfNDk0NzgwMjMzNjkyMQ_54f92779-ee94-4d3e-b98d-d63002160a58"
      unitRef="usd">642000</vtl:IncreaseDecreaseInOperatingLeaseRightOfUseAsset>
    <vtl:OperatingLeaseIncrementalBorrowingRate
      contextRef="ib2ba0b84078f4de2bc3079e992921b92_I20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80MC9mcmFnOmI3MzFjZTk4M2NmOTRlZWY5MTMzMTgwMzhmYTM5Mzg4L3RleHRyZWdpb246YjczMWNlOTgzY2Y5NGVlZjkxMzMxODAzOGZhMzkzODhfNTQ5NzU1ODIzMjQw_eedec0d8-e61b-44d2-9ece-6b2129522d7e"
      unitRef="number">0.06</vtl:OperatingLeaseIncrementalBorrowingRate>
    <vtl:OperatingAndVariableLeasesCost
      contextRef="i25a8ea2d7c9f4bfd8f72223c8ac18c65_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80MC9mcmFnOmI3MzFjZTk4M2NmOTRlZWY5MTMzMTgwMzhmYTM5Mzg4L3RleHRyZWdpb246YjczMWNlOTgzY2Y5NGVlZjkxMzMxODAzOGZhMzkzODhfNDk0NzgwMjMzNjM4NQ_e5f3b4ea-1c90-4862-8763-c6681f86b7c6"
      unitRef="usd">232000</vtl:OperatingAndVariableLeasesCost>
    <vtl:OperatingAndVariableLeasesCost
      contextRef="ib52579de36d54242a791b9e3f8019a00_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80MC9mcmFnOmI3MzFjZTk4M2NmOTRlZWY5MTMzMTgwMzhmYTM5Mzg4L3RleHRyZWdpb246YjczMWNlOTgzY2Y5NGVlZjkxMzMxODAzOGZhMzkzODhfNDk0NzgwMjMzNjM5NQ_8b4a22c9-5dd5-4a59-a9e1-1c19fdadf26e"
      unitRef="usd">133000</vtl:OperatingAndVariableLeasesCost>
    <vtl:OperatingAndVariableLeasesCost
      contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80MC9mcmFnOmI3MzFjZTk4M2NmOTRlZWY5MTMzMTgwMzhmYTM5Mzg4L3RleHRyZWdpb246YjczMWNlOTgzY2Y5NGVlZjkxMzMxODAzOGZhMzkzODhfNDk0NzgwMjMzNjQwNQ_eaf2de8a-3eb1-4964-8b9a-f885e4b39789"
      unitRef="usd">498000</vtl:OperatingAndVariableLeasesCost>
    <vtl:OperatingAndVariableLeasesCost
      contextRef="i69e8bcaae5bf44c9a03cf7f5bd08e6b8_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80MC9mcmFnOmI3MzFjZTk4M2NmOTRlZWY5MTMzMTgwMzhmYTM5Mzg4L3RleHRyZWdpb246YjczMWNlOTgzY2Y5NGVlZjkxMzMxODAzOGZhMzkzODhfNDk0NzgwMjMzNjQxNQ_68054d1e-87c6-449d-a5e5-b6d2332e2e5e"
      unitRef="usd">372000</vtl:OperatingAndVariableLeasesCost>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80MC9mcmFnOmI3MzFjZTk4M2NmOTRlZWY5MTMzMTgwMzhmYTM5Mzg4L3RleHRyZWdpb246YjczMWNlOTgzY2Y5NGVlZjkxMzMxODAzOGZhMzkzODhfNTE0NA_0d726821-c1c5-469a-93a8-13ad398cca1a">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Maturities of the operating lease obligation are as follows as of September 30, 2022 (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.660%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.079%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.596%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.925%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;528&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;454&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;PV of obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="ib2ba0b84078f4de2bc3079e992921b92_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80MC9mcmFnOmI3MzFjZTk4M2NmOTRlZWY5MTMzMTgwMzhmYTM5Mzg4L3RhYmxlOmMxZTU4ODVkZTJmMDRlNDU4MzM1MTI1MjE5ZGY4Y2FhL3RhYmxlcmFuZ2U6YzFlNTg4NWRlMmYwNGU0NTgzMzUxMjUyMTlkZjhjYWFfMC0yLTEtMS0zMDUwMA_c932ec3e-7aad-4648-9393-29b06a03de33"
      unitRef="usd">169000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="ib2ba0b84078f4de2bc3079e992921b92_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80MC9mcmFnOmI3MzFjZTk4M2NmOTRlZWY5MTMzMTgwMzhmYTM5Mzg4L3RhYmxlOmMxZTU4ODVkZTJmMDRlNDU4MzM1MTI1MjE5ZGY4Y2FhL3RhYmxlcmFuZ2U6YzFlNTg4NWRlMmYwNGU0NTgzMzUxMjUyMTlkZjhjYWFfMS0yLTEtMS0zMDUwMA_10d8478d-7e5b-4024-bdda-6fcf434f613a"
      unitRef="usd">528000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="ib2ba0b84078f4de2bc3079e992921b92_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80MC9mcmFnOmI3MzFjZTk4M2NmOTRlZWY5MTMzMTgwMzhmYTM5Mzg4L3RhYmxlOmMxZTU4ODVkZTJmMDRlNDU4MzM1MTI1MjE5ZGY4Y2FhL3RhYmxlcmFuZ2U6YzFlNTg4NWRlMmYwNGU0NTgzMzUxMjUyMTlkZjhjYWFfMi0yLTEtMS0zMDUwMA_de2f5b64-43cb-40b7-a40a-33675d009f7f"
      unitRef="usd">454000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="ib2ba0b84078f4de2bc3079e992921b92_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80MC9mcmFnOmI3MzFjZTk4M2NmOTRlZWY5MTMzMTgwMzhmYTM5Mzg4L3RhYmxlOmMxZTU4ODVkZTJmMDRlNDU4MzM1MTI1MjE5ZGY4Y2FhL3RhYmxlcmFuZ2U6YzFlNTg4NWRlMmYwNGU0NTgzMzUxMjUyMTlkZjhjYWFfMy0yLTEtMS0zMDUwMA_c7cc130d-1272-4a01-8dfd-857586c80bfd"
      unitRef="usd">227000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="ib2ba0b84078f4de2bc3079e992921b92_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80MC9mcmFnOmI3MzFjZTk4M2NmOTRlZWY5MTMzMTgwMzhmYTM5Mzg4L3RhYmxlOmMxZTU4ODVkZTJmMDRlNDU4MzM1MTI1MjE5ZGY4Y2FhL3RhYmxlcmFuZ2U6YzFlNTg4NWRlMmYwNGU0NTgzMzUxMjUyMTlkZjhjYWFfNC0yLTEtMS0zMDUwMA_fbade485-2f13-4918-889e-4502bf085610"
      unitRef="usd">0</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="ib2ba0b84078f4de2bc3079e992921b92_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80MC9mcmFnOmI3MzFjZTk4M2NmOTRlZWY5MTMzMTgwMzhmYTM5Mzg4L3RhYmxlOmMxZTU4ODVkZTJmMDRlNDU4MzM1MTI1MjE5ZGY4Y2FhL3RhYmxlcmFuZ2U6YzFlNTg4NWRlMmYwNGU0NTgzMzUxMjUyMTlkZjhjYWFfNS0yLTEtMS0zMDUwMA_47baf050-a796-417d-aa53-113a241da6f7"
      unitRef="usd">1378000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="ib2ba0b84078f4de2bc3079e992921b92_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80MC9mcmFnOmI3MzFjZTk4M2NmOTRlZWY5MTMzMTgwMzhmYTM5Mzg4L3RhYmxlOmMxZTU4ODVkZTJmMDRlNDU4MzM1MTI1MjE5ZGY4Y2FhL3RhYmxlcmFuZ2U6YzFlNTg4NWRlMmYwNGU0NTgzMzUxMjUyMTlkZjhjYWFfNi0yLTEtMS0zMDUwMA_ea922b37-8538-426e-9a02-be07933aa682"
      unitRef="usd">104000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="ib2ba0b84078f4de2bc3079e992921b92_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80MC9mcmFnOmI3MzFjZTk4M2NmOTRlZWY5MTMzMTgwMzhmYTM5Mzg4L3RhYmxlOmMxZTU4ODVkZTJmMDRlNDU4MzM1MTI1MjE5ZGY4Y2FhL3RhYmxlcmFuZ2U6YzFlNTg4NWRlMmYwNGU0NTgzMzUxMjUyMTlkZjhjYWFfNy0yLTEtMS0zMDUwMA_e0d136ff-a250-4c76-842e-057e893d3da3"
      unitRef="usd">1274000</us-gaap:OperatingLeaseLiability>
    <us-gaap:ContractualObligation
      contextRef="ib2ba0b84078f4de2bc3079e992921b92_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80MC9mcmFnOmI3MzFjZTk4M2NmOTRlZWY5MTMzMTgwMzhmYTM5Mzg4L3RleHRyZWdpb246YjczMWNlOTgzY2Y5NGVlZjkxMzMxODAzOGZhMzkzODhfNTQ5NzU1ODI0ODAw_0e3491fd-7dc3-497d-ad16-e9d19a440634"
      unitRef="usd">2700000</us-gaap:ContractualObligation>
    <vtl:AssetPurchaseAgreementRoyaltiesAsPercentOfAggregatedNetSales
      contextRef="i85fd4b228c8e4e22aa84564d8a1092a4_D20160501-20160531"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80MC9mcmFnOmI3MzFjZTk4M2NmOTRlZWY5MTMzMTgwMzhmYTM5Mzg4L3RleHRyZWdpb246YjczMWNlOTgzY2Y5NGVlZjkxMzMxODAzOGZhMzkzODhfMzU2NA_e1518e15-4d8a-4bb6-90a5-2e9ec5b70ed5"
      unitRef="number">0.044</vtl:AssetPurchaseAgreementRoyaltiesAsPercentOfAggregatedNetSales>
    <us-gaap:CommonStockSharesIssued
      contextRef="i13be27ffd0404758995be06dca534f38_I20190412"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80MC9mcmFnOmI3MzFjZTk4M2NmOTRlZWY5MTMzMTgwMzhmYTM5Mzg4L3RleHRyZWdpb246YjczMWNlOTgzY2Y5NGVlZjkxMzMxODAzOGZhMzkzODhfMzc4Mg_80b9d73c-2328-4cd2-901d-66231815114e"
      unitRef="shares">120070</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="i13be27ffd0404758995be06dca534f38_I20190412"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80MC9mcmFnOmI3MzFjZTk4M2NmOTRlZWY5MTMzMTgwMzhmYTM5Mzg4L3RleHRyZWdpb246YjczMWNlOTgzY2Y5NGVlZjkxMzMxODAzOGZhMzkzODhfMzkyMw_783e4288-4970-491a-a5f2-c0866b80dde9"
      unitRef="usd">1500000</us-gaap:CommonStockValue>
    <vtl:AssetPurchaseAgreementRoyaltiesAsPercentOfAggregatedNetSales
      contextRef="i7ce199652934499fa56ce12df1fabbef_D20210331-20210331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80MC9mcmFnOmI3MzFjZTk4M2NmOTRlZWY5MTMzMTgwMzhmYTM5Mzg4L3RleHRyZWdpb246YjczMWNlOTgzY2Y5NGVlZjkxMzMxODAzOGZhMzkzODhfNDIwNA_b45d13e6-98df-41da-a8a5-e1a050c3e0ef"
      unitRef="number">0.044</vtl:AssetPurchaseAgreementRoyaltiesAsPercentOfAggregatedNetSales>
    <vtl:RoyaltySettlementAgreementSalesNet
      contextRef="i7ce199652934499fa56ce12df1fabbef_D20210331-20210331"
      decimals="-4"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80MC9mcmFnOmI3MzFjZTk4M2NmOTRlZWY5MTMzMTgwMzhmYTM5Mzg4L3RleHRyZWdpb246YjczMWNlOTgzY2Y5NGVlZjkxMzMxODAzOGZhMzkzODhfNDIzMg_1902f41d-9e48-46b0-8ac9-e86dbf23a705"
      unitRef="usd">17250000</vtl:RoyaltySettlementAgreementSalesNet>
    <vtl:RoyaltySettlementAgreementCashPaymentPercent
      contextRef="i42d359c425714cf8b47c82373a440814_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80MC9mcmFnOmI3MzFjZTk4M2NmOTRlZWY5MTMzMTgwMzhmYTM5Mzg4L3RleHRyZWdpb246YjczMWNlOTgzY2Y5NGVlZjkxMzMxODAzOGZhMzkzODhfNDI4OA_3f4ad396-9dca-48da-9597-38b52cb3f438"
      unitRef="number">0.50</vtl:RoyaltySettlementAgreementCashPaymentPercent>
    <vtl:RoyaltySettlementAgreementSharesPaymentPercent
      contextRef="i42d359c425714cf8b47c82373a440814_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80MC9mcmFnOmI3MzFjZTk4M2NmOTRlZWY5MTMzMTgwMzhmYTM5Mzg4L3RleHRyZWdpb246YjczMWNlOTgzY2Y5NGVlZjkxMzMxODAzOGZhMzkzODhfNDMwMw_dc5e4dfa-f6e5-48f6-a2ac-acd4da0238ee"
      unitRef="number">0.50</vtl:RoyaltySettlementAgreementSharesPaymentPercent>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80My9mcmFnOmNiYTRjYmUyYjAxMDQwYjI4YjFlYWFmZjY2NGJlOWE5L3RleHRyZWdpb246Y2JhNGNiZTJiMDEwNDBiMjhiMWVhYWZmNjY0YmU5YTlfODcw_ee7ada36-0c74-4dea-9949-581824dd5d6c">Fair Value&lt;div style="margin-bottom:6pt;margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following fair value hierarchy tables present information about each major category of the Company&#x2019;s financial assets and liabilities measured at fair value on a recurring basis (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.888%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.092%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.830%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.092%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.830%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.240%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.830%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.098%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value Measurement at September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair&#160;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,471&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,471&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,471&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,471&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.888%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.092%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.830%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.092%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.830%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.240%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.830%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.098%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value Measurement at Fair&#160;Value&#160;Measurement&#160;at&#160;December&#160;31,&#160;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair&#160;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no transfers between Level&#160;1, Level&#160;2 or Level&#160;3 assets during the periods presented.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the Company&#x2019;s money market funds, which are included as a component of cash and cash equivalents on the consolidated balance sheet, realized gains and losses are included in interest income (expense) on the consolidated statements of operations. &lt;/span&gt;&lt;/div&gt;The carrying amounts of other current assets and prepaid expenses, accounts payable, accrued expenses, and other current liabilities approximate their fair values due to their short-term nature. The fair value and book value of the money market funds presented in the table above are the same.</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80My9mcmFnOmNiYTRjYmUyYjAxMDQwYjI4YjFlYWFmZjY2NGJlOWE5L3RleHRyZWdpb246Y2JhNGNiZTJiMDEwNDBiMjhiMWVhYWZmNjY0YmU5YTlfODY2_7cefb7df-0729-4dc1-a4b8-1192f3a0394e">&lt;div style="margin-bottom:6pt;margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following fair value hierarchy tables present information about each major category of the Company&#x2019;s financial assets and liabilities measured at fair value on a recurring basis (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.888%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.092%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.830%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.092%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.830%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.240%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.830%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.098%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value Measurement at September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair&#160;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,471&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,471&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,471&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,471&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.888%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.092%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.830%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.092%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.830%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.240%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.830%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.098%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value Measurement at Fair&#160;Value&#160;Measurement&#160;at&#160;December&#160;31,&#160;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair&#160;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ia5d5d1c95a774f429ad29d595bac0585_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80My9mcmFnOmNiYTRjYmUyYjAxMDQwYjI4YjFlYWFmZjY2NGJlOWE5L3RhYmxlOmVkYTU1ZjQzYmVhNTQ3OGQ4NmJmZjA4NWVjMTc0YjU4L3RhYmxlcmFuZ2U6ZWRhNTVmNDNiZWE1NDc4ZDg2YmZmMDg1ZWMxNzRiNThfMy0xLTEtMS0zMDUwMA_f3202f16-d79a-4132-ab21-efc59356279c"
      unitRef="usd">31471000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i8e0b1222c30b4269aa3c56e6ebee8dc4_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80My9mcmFnOmNiYTRjYmUyYjAxMDQwYjI4YjFlYWFmZjY2NGJlOWE5L3RhYmxlOmVkYTU1ZjQzYmVhNTQ3OGQ4NmJmZjA4NWVjMTc0YjU4L3RhYmxlcmFuZ2U6ZWRhNTVmNDNiZWE1NDc4ZDg2YmZmMDg1ZWMxNzRiNThfMy0zLTEtMS0zMDUwMA_a554f24a-7e28-4295-a765-921d06252420"
      unitRef="usd">31471000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="idc57905cd80143b29ea902574f63d2e8_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80My9mcmFnOmNiYTRjYmUyYjAxMDQwYjI4YjFlYWFmZjY2NGJlOWE5L3RhYmxlOmVkYTU1ZjQzYmVhNTQ3OGQ4NmJmZjA4NWVjMTc0YjU4L3RhYmxlcmFuZ2U6ZWRhNTVmNDNiZWE1NDc4ZDg2YmZmMDg1ZWMxNzRiNThfMy01LTEtMS0zMDUwMA_2debc412-0cd0-45cb-835e-ec14e9c126f0"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="if643e711815d4b749376bea335780421_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80My9mcmFnOmNiYTRjYmUyYjAxMDQwYjI4YjFlYWFmZjY2NGJlOWE5L3RhYmxlOmVkYTU1ZjQzYmVhNTQ3OGQ4NmJmZjA4NWVjMTc0YjU4L3RhYmxlcmFuZ2U6ZWRhNTVmNDNiZWE1NDc4ZDg2YmZmMDg1ZWMxNzRiNThfMy03LTEtMS0zMDUwMA_cda5ed42-0ec4-4365-a5fb-be4d29ad98ee"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i5a48bc4ae7d7408f97f6eeb1dca78e8b_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80My9mcmFnOmNiYTRjYmUyYjAxMDQwYjI4YjFlYWFmZjY2NGJlOWE5L3RhYmxlOmVkYTU1ZjQzYmVhNTQ3OGQ4NmJmZjA4NWVjMTc0YjU4L3RhYmxlcmFuZ2U6ZWRhNTVmNDNiZWE1NDc4ZDg2YmZmMDg1ZWMxNzRiNThfNC0xLTEtMS0zMDUwMA_eb811689-1bef-4bc0-8e4f-ca46cd1b49c6"
      unitRef="usd">31471000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ib3b80cda8b6f452eb05a40cc72183236_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80My9mcmFnOmNiYTRjYmUyYjAxMDQwYjI4YjFlYWFmZjY2NGJlOWE5L3RhYmxlOmVkYTU1ZjQzYmVhNTQ3OGQ4NmJmZjA4NWVjMTc0YjU4L3RhYmxlcmFuZ2U6ZWRhNTVmNDNiZWE1NDc4ZDg2YmZmMDg1ZWMxNzRiNThfNC0zLTEtMS0zMDUwMA_35f40fc1-2c3b-484a-b401-cdb6ba365bdf"
      unitRef="usd">31471000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="iecbaf68de7c649b39d49d2cd525bbdaf_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80My9mcmFnOmNiYTRjYmUyYjAxMDQwYjI4YjFlYWFmZjY2NGJlOWE5L3RhYmxlOmVkYTU1ZjQzYmVhNTQ3OGQ4NmJmZjA4NWVjMTc0YjU4L3RhYmxlcmFuZ2U6ZWRhNTVmNDNiZWE1NDc4ZDg2YmZmMDg1ZWMxNzRiNThfNC01LTEtMS0zMDUwMA_482b3669-1868-423d-8ef5-a747acec73cc"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i5815b7ec2c4048eaa79c592705f78a05_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80My9mcmFnOmNiYTRjYmUyYjAxMDQwYjI4YjFlYWFmZjY2NGJlOWE5L3RhYmxlOmVkYTU1ZjQzYmVhNTQ3OGQ4NmJmZjA4NWVjMTc0YjU4L3RhYmxlcmFuZ2U6ZWRhNTVmNDNiZWE1NDc4ZDg2YmZmMDg1ZWMxNzRiNThfNC03LTEtMS0zMDUwMA_2893bc35-8b9d-4f21-a782-0f8c8b6de3f4"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i026a14121f5e41e6b31d1f3647017fab_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80My9mcmFnOmNiYTRjYmUyYjAxMDQwYjI4YjFlYWFmZjY2NGJlOWE5L3RhYmxlOmNlNzIwMTY0MzdiODQwZDM5YmY2MTI5ZDA3OWI4Mzg5L3RhYmxlcmFuZ2U6Y2U3MjAxNjQzN2I4NDBkMzliZjYxMjlkMDc5YjgzODlfMy0xLTEtMS0zMDUwMA_efddafab-f7bd-435b-9761-dc1661cdcb6f"
      unitRef="usd">31630000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i66caad9103ff476d8d79ca94f9ff9ca7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80My9mcmFnOmNiYTRjYmUyYjAxMDQwYjI4YjFlYWFmZjY2NGJlOWE5L3RhYmxlOmNlNzIwMTY0MzdiODQwZDM5YmY2MTI5ZDA3OWI4Mzg5L3RhYmxlcmFuZ2U6Y2U3MjAxNjQzN2I4NDBkMzliZjYxMjlkMDc5YjgzODlfMy0zLTEtMS0zMDUwMA_c6ee48fc-a18f-4673-af70-7f42104ccf2e"
      unitRef="usd">31630000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i26c3332665024e968525d075f51dd2c3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80My9mcmFnOmNiYTRjYmUyYjAxMDQwYjI4YjFlYWFmZjY2NGJlOWE5L3RhYmxlOmNlNzIwMTY0MzdiODQwZDM5YmY2MTI5ZDA3OWI4Mzg5L3RhYmxlcmFuZ2U6Y2U3MjAxNjQzN2I4NDBkMzliZjYxMjlkMDc5YjgzODlfMy01LTEtMS0zMDUwMA_0a69cc00-bde0-4d0c-9e54-fa9d1dd1cd22"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ieb7c3038fa504039b4299ec811876236_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80My9mcmFnOmNiYTRjYmUyYjAxMDQwYjI4YjFlYWFmZjY2NGJlOWE5L3RhYmxlOmNlNzIwMTY0MzdiODQwZDM5YmY2MTI5ZDA3OWI4Mzg5L3RhYmxlcmFuZ2U6Y2U3MjAxNjQzN2I4NDBkMzliZjYxMjlkMDc5YjgzODlfMy03LTEtMS0zMDUwMA_86ef938b-224e-4178-914e-02377a442d2f"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i7c78af0997974f8888e346839bbbb526_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80My9mcmFnOmNiYTRjYmUyYjAxMDQwYjI4YjFlYWFmZjY2NGJlOWE5L3RhYmxlOmNlNzIwMTY0MzdiODQwZDM5YmY2MTI5ZDA3OWI4Mzg5L3RhYmxlcmFuZ2U6Y2U3MjAxNjQzN2I4NDBkMzliZjYxMjlkMDc5YjgzODlfNC0xLTEtMS0zMDUwMA_54925cc1-4aca-4048-abd1-63664b46bc38"
      unitRef="usd">31630000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ieeee9cf1b4db4ae799c2820e753b57d4_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80My9mcmFnOmNiYTRjYmUyYjAxMDQwYjI4YjFlYWFmZjY2NGJlOWE5L3RhYmxlOmNlNzIwMTY0MzdiODQwZDM5YmY2MTI5ZDA3OWI4Mzg5L3RhYmxlcmFuZ2U6Y2U3MjAxNjQzN2I4NDBkMzliZjYxMjlkMDc5YjgzODlfNC0zLTEtMS0zMDUwMA_e57bb2f2-761b-4d77-b1f2-7697da789435"
      unitRef="usd">31630000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ibbf0f0e07da94302ac3cd78120a72738_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80My9mcmFnOmNiYTRjYmUyYjAxMDQwYjI4YjFlYWFmZjY2NGJlOWE5L3RhYmxlOmNlNzIwMTY0MzdiODQwZDM5YmY2MTI5ZDA3OWI4Mzg5L3RhYmxlcmFuZ2U6Y2U3MjAxNjQzN2I4NDBkMzliZjYxMjlkMDc5YjgzODlfNC01LTEtMS0zMDUwMA_cfce4391-55a9-4869-9179-466c18c7cdea"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ic2d55028ecbe47369972c9dc27a4983b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80My9mcmFnOmNiYTRjYmUyYjAxMDQwYjI4YjFlYWFmZjY2NGJlOWE5L3RhYmxlOmNlNzIwMTY0MzdiODQwZDM5YmY2MTI5ZDA3OWI4Mzg5L3RhYmxlcmFuZ2U6Y2U3MjAxNjQzN2I4NDBkMzliZjYxMjlkMDc5YjgzODlfNC03LTEtMS0zMDUwMA_e673a75f-9aed-43e6-a327-ad1f8e1aa7a0"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80Ni9mcmFnOjM5MzBmZWViZmI2YTRjODdiYWNlNGRlOWQxYjNlMjgwL3RleHRyZWdpb246MzkzMGZlZWJmYjZhNGM4N2JhY2U0ZGU5ZDFiM2UyODBfNzg0MQ_50750d90-d1ce-47e6-87e3-29c6fe557e7e">Common StockIn November 2020, Immunic filed a shelf registration statement on Form S-3. The 2020 Shelf Registration Statement permits the offering, issuance and sale of up to $250.0&#160;million of common stock, preferred stock, warrants, debt securities, and/or units in one or more offerings and in any combination of the foregoing.  As of October 31, 2022, there is $75.0&#160;million remaining on this shelf registration statement &lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2020, the Company filed a Prospectus Supplement for the offering, issuance and sale of up to a maximum aggregate offering price of $50.0&#160;million of common stock that may be issued and sold under an at-the-market sales agreement ("December 2020 ATM") with SVB Leerink as agent. The Company has used, and intends to continue to use the net proceeds from the offering to continue to fund the ongoing clinical development of its product candidates and for other general corporate purposes, including funding existing and potential new clinical programs and product candidates. The December 2020 ATM will terminate upon the earlier of (i) the issuance and sale of all of the shares through SVB Leerink on the terms and subject to the conditions set forth in the December 2020 ATM or (ii) termination of the December 2020 ATM as otherwise permitted thereby. The December 2020 ATM may be terminated at any time by either party upon ten days&#x2019; prior notice, or by SVB Leerink at any time in certain circumstances, including the occurrence of a material adverse effect on the Company.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of October 31, 2022, $8.4&#160;million in capacity remains under the December 2020 ATM.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2022, the Company filed a Prospectus Supplement for the offering, issuance and sale of up to a maximum aggregate offering price of $80.0&#160;million of common stock that may be issued and sold under another at-the-market sales agreement ("May 2022 ATM") with SVB Leerink as agent. The Company intends to use the net proceeds from the offering to continue to fund the ongoing clinical development of its product candidates and for other general corporate purposes, including funding existing and potential new clinical programs and product candidates. The May 2022 ATM will terminate upon the earlier of (i) the issuance and sale of all of the shares through SVB Leerink on the terms and subject to the conditions set forth in the May 2022 ATM or (ii) termination of the May 2022 ATM as otherwise permitted thereby. The May 2022 ATM may be terminated at any time by either party upon ten days&#x2019; prior notice, or by SVB Leerink at any time in certain circumstances, including the occurrence of a material adverse effect on the Company.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of October 31, 2022, $80.0&#160;million in capacity remains under the May 2022 ATM.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;The Company has agreed to pay SVB Leerink a commission equal to 3.0% of the gross proceeds from the sales of common shares pursuant to both ATM's and has agreed to provide SVB Leerink with customary indemnification and contribution rights.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the three months ended September 30, 2022, the Company did not raise any proceeds under its ATM facilities.  In the nine months ended September 30, 2022, the Company raised gross proceeds of $40.9&#160;million pursuant to the December 2020 ATM through the sale of 4,204,113 shares of common stock at a weighted average price of $9.72 per share. The net proceeds from the December 2020 ATM were $39.6&#160;million after deducting underwriter commissions of $1.2&#160;million. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company did not have any ATM activity during the three or nine months ended September 30, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Public Equity Offerings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline"&gt;July 2021 Public Equity Offering&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 15, 2021, the Company entered into an underwriting agreement with Piper Sandler &amp;amp; Co., in connection with the&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Company&#x2019;s public offering of 4,500,000 shares of the Company&#x2019;s common stock, $0.0001 par value per share, at a public&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;offering price of $10.00 per share.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 19, 2021, the Company closed the Offering. The net proceeds to the Company from the Offering was&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;approximately $42.0&#160;million, after deducting underwriting discounts and commissions and estimated offering expenses payable&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;by the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:22.5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;Common Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-right:9pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September 30, 2022, the Company&#x2019;s certificate of incorporation, as amended and restated, authorized the Company to issue 130,000,000 shares of common stock, par value of $0.0001 per share. The voting, dividend and liquidation rights of the holders of the Company&#x2019;s common stock are subject to and qualified by the rights, powers and preferences of any holders of preferred stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-right:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Each share of common stock entitles the holder to one vote on all matters submitted to a vote of the Company&#x2019;s stockholders. Common stockholders are entitled to receive dividends, as may be declared by the board of directors, if any. Through September 30, 2022, no cash dividends had been declared or paid.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Preferred Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s certificate of incorporation, as amended and restated, authorizes the Company to issue 20 million shares of $0.0001 par value preferred stock, having rights and preferences to be set by the Board of Directors. No preferred shares were outstanding as of September 30, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock Reserved for Future Issuance&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Shares reserved for future issuance at September 30, 2022 are as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.162%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.638%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number&#160;of&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common stock reserved for issuance for:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;2021 Employee stock Purchase Plan    &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;162,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,799,573&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common stock options available for future grant:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2014 Equity Incentive Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2017 Inducement Equity Incentive Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2019 Omnibus Equity Incentive Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;180,770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total common shares reserved for future issuance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,232,534&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <vtl:MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration
      contextRef="i452fc01435184aa6b440569b104a7b6a_I20201130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80Ni9mcmFnOjM5MzBmZWViZmI2YTRjODdiYWNlNGRlOWQxYjNlMjgwL3RleHRyZWdpb246MzkzMGZlZWJmYjZhNGM4N2JhY2U0ZGU5ZDFiM2UyODBfNTQ5NzU1ODI5NTky_004fb91a-2ddb-4450-bfcb-319b108f625e"
      unitRef="usd">250000000</vtl:MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration>
    <vtl:ShelfRegistrationStatementAmountRemaining
      contextRef="ied30ae8dfbe54606808411695b6e7a4d_I20221031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80Ni9mcmFnOjM5MzBmZWViZmI2YTRjODdiYWNlNGRlOWQxYjNlMjgwL3RleHRyZWdpb246MzkzMGZlZWJmYjZhNGM4N2JhY2U0ZGU5ZDFiM2UyODBfNTQ5NzU1ODI5NzY3_44af067e-ff7b-40a7-9e7a-df5d3ef585e6"
      unitRef="usd">75000000</vtl:ShelfRegistrationStatementAmountRemaining>
    <vtl:MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration
      contextRef="i37de57482ffb4464ab59f455ab94a18c_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80Ni9mcmFnOjM5MzBmZWViZmI2YTRjODdiYWNlNGRlOWQxYjNlMjgwL3RleHRyZWdpb246MzkzMGZlZWJmYjZhNGM4N2JhY2U0ZGU5ZDFiM2UyODBfNTQ5NzU1ODI5OTYz_4b8f4444-3221-47d2-9e93-0a38a7d18c4d"
      unitRef="usd">50000000</vtl:MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration>
    <vtl:ShelfRegistrationTerminationPriorWrittenNotice
      contextRef="i2867d1aebe414721a791386480b70c8f_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80Ni9mcmFnOjM5MzBmZWViZmI2YTRjODdiYWNlNGRlOWQxYjNlMjgwL3RleHRyZWdpb246MzkzMGZlZWJmYjZhNGM4N2JhY2U0ZGU5ZDFiM2UyODBfNTQ5NzU1ODMwNzUy_bfb6b0d8-08d8-4335-85e2-623831ec448b"
      unitRef="d">10</vtl:ShelfRegistrationTerminationPriorWrittenNotice>
    <vtl:SaleOfStockRemainingCapacity
      contextRef="ia9434666be04407c90f384a6f8cee2f8_I20221031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80Ni9mcmFnOjM5MzBmZWViZmI2YTRjODdiYWNlNGRlOWQxYjNlMjgwL3RleHRyZWdpb246MzkzMGZlZWJmYjZhNGM4N2JhY2U0ZGU5ZDFiM2UyODBfNTQ5NzU1ODMwOTI0_f1c98152-fd70-42a2-9248-0381e119be99"
      unitRef="usd">8400000</vtl:SaleOfStockRemainingCapacity>
    <vtl:MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration
      contextRef="i731d9157c77642cf8b53fdb984854e80_I20220510"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80Ni9mcmFnOjM5MzBmZWViZmI2YTRjODdiYWNlNGRlOWQxYjNlMjgwL3RleHRyZWdpb246MzkzMGZlZWJmYjZhNGM4N2JhY2U0ZGU5ZDFiM2UyODBfNTQ5NzU1ODMxMTE4_735ba211-757c-4f23-b8d6-3d5c364eb5d7"
      unitRef="usd">80000000</vtl:MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration>
    <vtl:ShelfRegistrationTerminationPriorWrittenNotice
      contextRef="ie383b6c67b2d4562a2b5fa326cbe5000_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80Ni9mcmFnOjM5MzBmZWViZmI2YTRjODdiYWNlNGRlOWQxYjNlMjgwL3RleHRyZWdpb246MzkzMGZlZWJmYjZhNGM4N2JhY2U0ZGU5ZDFiM2UyODBfNTQ5NzU1ODMxODU2_8f4f5be8-77f5-48d3-89a7-49d4307ba2ab"
      unitRef="d">10</vtl:ShelfRegistrationTerminationPriorWrittenNotice>
    <vtl:SaleOfStockRemainingCapacity
      contextRef="i9843b826ca9942c9abbeb49451438b66_I20220505"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80Ni9mcmFnOjM5MzBmZWViZmI2YTRjODdiYWNlNGRlOWQxYjNlMjgwL3RleHRyZWdpb246MzkzMGZlZWJmYjZhNGM4N2JhY2U0ZGU5ZDFiM2UyODBfNTQ5NzU1ODMyMDI4_899d5c83-293f-4135-86dd-6be4c3352798"
      unitRef="usd">80000000</vtl:SaleOfStockRemainingCapacity>
    <vtl:ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock
      contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80Ni9mcmFnOjM5MzBmZWViZmI2YTRjODdiYWNlNGRlOWQxYjNlMjgwL3RleHRyZWdpb246MzkzMGZlZWJmYjZhNGM4N2JhY2U0ZGU5ZDFiM2UyODBfNTQ5NzU1ODMyMTQy_31b5daf7-6159-4c39-922e-a37c2f9fc3e7"
      unitRef="number">0.030</vtl:ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ic64d3d20dd7f42ebab0773713f0e2f62_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80Ni9mcmFnOjM5MzBmZWViZmI2YTRjODdiYWNlNGRlOWQxYjNlMjgwL3RleHRyZWdpb246MzkzMGZlZWJmYjZhNGM4N2JhY2U0ZGU5ZDFiM2UyODBfNTQ5NzU1ODMyNzA0_573a4251-2417-4930-b653-20281bd9c9fd"
      unitRef="usd">40900000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i13dc9f1a4e524f93b1138a442b35c8d0_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80Ni9mcmFnOjM5MzBmZWViZmI2YTRjODdiYWNlNGRlOWQxYjNlMjgwL3RleHRyZWdpb246MzkzMGZlZWJmYjZhNGM4N2JhY2U0ZGU5ZDFiM2UyODBfNTQ5NzU1ODMyNzYy_1ba401b6-e6ed-4428-868b-1e261b8d1931"
      unitRef="shares">4204113</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <vtl:SharesIssuedWeightedAverageSharePricePerShare
      contextRef="i13dc9f1a4e524f93b1138a442b35c8d0_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80Ni9mcmFnOjM5MzBmZWViZmI2YTRjODdiYWNlNGRlOWQxYjNlMjgwL3RleHRyZWdpb246MzkzMGZlZWJmYjZhNGM4N2JhY2U0ZGU5ZDFiM2UyODBfNTQ5NzU1ODMyODIw_41097e6d-b0c8-412e-a0b6-d52306ed2aa9"
      unitRef="usdPerShare">9.72</vtl:SharesIssuedWeightedAverageSharePricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i13dc9f1a4e524f93b1138a442b35c8d0_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80Ni9mcmFnOjM5MzBmZWViZmI2YTRjODdiYWNlNGRlOWQxYjNlMjgwL3RleHRyZWdpb246MzkzMGZlZWJmYjZhNGM4N2JhY2U0ZGU5ZDFiM2UyODBfNTQ5NzU1ODMyODg0_81cf45d9-fdab-4e12-9284-08075ee2486a"
      unitRef="usd">39600000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsForCommissions
      contextRef="i13dc9f1a4e524f93b1138a442b35c8d0_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80Ni9mcmFnOjM5MzBmZWViZmI2YTRjODdiYWNlNGRlOWQxYjNlMjgwL3RleHRyZWdpb246MzkzMGZlZWJmYjZhNGM4N2JhY2U0ZGU5ZDFiM2UyODBfNTQ5NzU1ODMyOTMx_18e7e715-9e0f-4408-80eb-0de270e126cd"
      unitRef="usd">1200000</us-gaap:PaymentsForCommissions>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="id7f3ba2151e24a8694efe8eededbb089_D20210715-20210715"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80Ni9mcmFnOjM5MzBmZWViZmI2YTRjODdiYWNlNGRlOWQxYjNlMjgwL3RleHRyZWdpb246MzkzMGZlZWJmYjZhNGM4N2JhY2U0ZGU5ZDFiM2UyODBfNDk0NzgwMjM0NjgyOA_427a09d3-242c-4c31-988e-2fb2c3108b36"
      unitRef="shares">4500000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i837eb6ff329b46d1b9063702464b7004_I20210715"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80Ni9mcmFnOjM5MzBmZWViZmI2YTRjODdiYWNlNGRlOWQxYjNlMjgwL3RleHRyZWdpb246MzkzMGZlZWJmYjZhNGM4N2JhY2U0ZGU5ZDFiM2UyODBfNDk0NzgwMjM0NjgzOQ_271f1b3b-5e0e-44d0-9450-0b5937731865"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i837eb6ff329b46d1b9063702464b7004_I20210715"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80Ni9mcmFnOjM5MzBmZWViZmI2YTRjODdiYWNlNGRlOWQxYjNlMjgwL3RleHRyZWdpb246MzkzMGZlZWJmYjZhNGM4N2JhY2U0ZGU5ZDFiM2UyODBfNDk0NzgwMjM0Njg0OA_6870f454-1f95-45ca-9540-43a666edce11"
      unitRef="usdPerShare">10.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="ic1deecff015c411d9b86fcc68ba1683c_D20210719-20210719"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80Ni9mcmFnOjM5MzBmZWViZmI2YTRjODdiYWNlNGRlOWQxYjNlMjgwL3RleHRyZWdpb246MzkzMGZlZWJmYjZhNGM4N2JhY2U0ZGU5ZDFiM2UyODBfNDk0NzgwMjM0Njg1Ng_39708f2c-0a85-40e8-a0b7-6d5dc087cbae"
      unitRef="usd">42000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ib2ba0b84078f4de2bc3079e992921b92_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80Ni9mcmFnOjM5MzBmZWViZmI2YTRjODdiYWNlNGRlOWQxYjNlMjgwL3RleHRyZWdpb246MzkzMGZlZWJmYjZhNGM4N2JhY2U0ZGU5ZDFiM2UyODBfNTQ5NzU1ODMzMTY2_67e39ee5-133b-47b2-9423-cd4e1719f865"
      unitRef="shares">130000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ib2ba0b84078f4de2bc3079e992921b92_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80Ni9mcmFnOjM5MzBmZWViZmI2YTRjODdiYWNlNGRlOWQxYjNlMjgwL3RleHRyZWdpb246MzkzMGZlZWJmYjZhNGM4N2JhY2U0ZGU5ZDFiM2UyODBfNTQ5NzU1ODMzMjA3_8f657c9e-0f2d-4f6c-8a9e-1de383f1d9ec"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80Ni9mcmFnOjM5MzBmZWViZmI2YTRjODdiYWNlNGRlOWQxYjNlMjgwL3RleHRyZWdpb246MzkzMGZlZWJmYjZhNGM4N2JhY2U0ZGU5ZDFiM2UyODBfNTQ5NzU1ODMzNjcw_48f33ff6-3b8c-47be-af82-85b808191ae3"
      unitRef="usdPerShare">0</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:CommonStockDividendsPerShareCashPaid
      contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80Ni9mcmFnOjM5MzBmZWViZmI2YTRjODdiYWNlNGRlOWQxYjNlMjgwL3RleHRyZWdpb246MzkzMGZlZWJmYjZhNGM4N2JhY2U0ZGU5ZDFiM2UyODBfNTQ5NzU1ODMzNjcw_87b7f66b-d62f-4509-8a74-2553eff0d324"
      unitRef="usdPerShare">0</us-gaap:CommonStockDividendsPerShareCashPaid>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="ib2ba0b84078f4de2bc3079e992921b92_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80Ni9mcmFnOjM5MzBmZWViZmI2YTRjODdiYWNlNGRlOWQxYjNlMjgwL3RleHRyZWdpb246MzkzMGZlZWJmYjZhNGM4N2JhY2U0ZGU5ZDFiM2UyODBfNTQ5NzU1ODMzODM1_8066c3ff-fecf-4470-b556-2a3f5d929170"
      unitRef="shares">20000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="ib2ba0b84078f4de2bc3079e992921b92_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80Ni9mcmFnOjM5MzBmZWViZmI2YTRjODdiYWNlNGRlOWQxYjNlMjgwL3RleHRyZWdpb246MzkzMGZlZWJmYjZhNGM4N2JhY2U0ZGU5ZDFiM2UyODBfNTQ5NzU1ODMzODQ5_da031462-8396-4a4d-ad3d-78204d304f70"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="ib2ba0b84078f4de2bc3079e992921b92_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80Ni9mcmFnOjM5MzBmZWViZmI2YTRjODdiYWNlNGRlOWQxYjNlMjgwL3RleHRyZWdpb246MzkzMGZlZWJmYjZhNGM4N2JhY2U0ZGU5ZDFiM2UyODBfNTQ5NzU1ODMzOTQ3_2915a014-cf24-4932-a63a-21ad2af0b230"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <vtl:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock
      contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80Ni9mcmFnOjM5MzBmZWViZmI2YTRjODdiYWNlNGRlOWQxYjNlMjgwL3RleHRyZWdpb246MzkzMGZlZWJmYjZhNGM4N2JhY2U0ZGU5ZDFiM2UyODBfNzg0Ng_248bf50f-4694-441d-a84f-668caa6c9826">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Shares reserved for future issuance at September 30, 2022 are as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.162%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.638%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number&#160;of&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common stock reserved for issuance for:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;2021 Employee stock Purchase Plan    &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;162,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,799,573&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common stock options available for future grant:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2014 Equity Incentive Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2017 Inducement Equity Incentive Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2019 Omnibus Equity Incentive Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;180,770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total common shares reserved for future issuance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,232,534&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</vtl:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="iee6bdacd518b494c838da43db583331a_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80Ni9mcmFnOjM5MzBmZWViZmI2YTRjODdiYWNlNGRlOWQxYjNlMjgwL3RhYmxlOjI1ZTIzNTIzYzk3MTQyY2NhZjUxZjJjMTgyY2RmZTZiL3RhYmxlcmFuZ2U6MjVlMjM1MjNjOTcxNDJjY2FmNTFmMmMxODJjZGZlNmJfMi0xLTEtMS0zMDUwMA_1cc09a05-5689-4aaf-952c-94c03f0c5b49"
      unitRef="shares">162630</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="ica07e01c9d0f47a59cbaee95aef0d158_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80Ni9mcmFnOjM5MzBmZWViZmI2YTRjODdiYWNlNGRlOWQxYjNlMjgwL3RhYmxlOjI1ZTIzNTIzYzk3MTQyY2NhZjUxZjJjMTgyY2RmZTZiL3RhYmxlcmFuZ2U6MjVlMjM1MjNjOTcxNDJjY2FmNTFmMmMxODJjZGZlNmJfMy0xLTEtMS0zMDUwMA_771da427-71ad-4713-9c08-d5998651e694"
      unitRef="shares">3799573</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i8d6a85cd1f8b48108c4b2aac7ded4bf3_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80Ni9mcmFnOjM5MzBmZWViZmI2YTRjODdiYWNlNGRlOWQxYjNlMjgwL3RhYmxlOjI1ZTIzNTIzYzk3MTQyY2NhZjUxZjJjMTgyY2RmZTZiL3RhYmxlcmFuZ2U6MjVlMjM1MjNjOTcxNDJjY2FmNTFmMmMxODJjZGZlNmJfNS0xLTEtMS0zMDUwMA_b1100c2a-ea77-44ed-8164-0424a0287fbc"
      unitRef="shares">43311</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i66a3a4fa022d420ebf30bfd5b338b14a_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80Ni9mcmFnOjM5MzBmZWViZmI2YTRjODdiYWNlNGRlOWQxYjNlMjgwL3RhYmxlOjI1ZTIzNTIzYzk3MTQyY2NhZjUxZjJjMTgyY2RmZTZiL3RhYmxlcmFuZ2U6MjVlMjM1MjNjOTcxNDJjY2FmNTFmMmMxODJjZGZlNmJfNi0xLTEtMS0zMDUwMA_2d29cbc2-6740-4c9d-8d3e-acd0a60e21cf"
      unitRef="shares">46250</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i4b8e8ab0f2aa4d60b8640f5f1ddff361_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80Ni9mcmFnOjM5MzBmZWViZmI2YTRjODdiYWNlNGRlOWQxYjNlMjgwL3RhYmxlOjI1ZTIzNTIzYzk3MTQyY2NhZjUxZjJjMTgyY2RmZTZiL3RhYmxlcmFuZ2U6MjVlMjM1MjNjOTcxNDJjY2FmNTFmMmMxODJjZGZlNmJfNy0xLTEtMS0zMDUwMA_c0629103-ade0-44b8-8b4b-e9405085d51c"
      unitRef="shares">180770</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="ib2ba0b84078f4de2bc3079e992921b92_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80Ni9mcmFnOjM5MzBmZWViZmI2YTRjODdiYWNlNGRlOWQxYjNlMjgwL3RhYmxlOjI1ZTIzNTIzYzk3MTQyY2NhZjUxZjJjMTgyY2RmZTZiL3RhYmxlcmFuZ2U6MjVlMjM1MjNjOTcxNDJjY2FmNTFmMmMxODJjZGZlNmJfOC0xLTEtMS0zMDUwMA_bb89d25e-b0e4-4e06-a421-925ee5253e02"
      unitRef="shares">4232534</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80OS9mcmFnOjlhN2M1MTczZGE1ZTQ5ZjViYTk4YWRiODZhZWYwOWJkL3RleHRyZWdpb246OWE3YzUxNzNkYTVlNDlmNWJhOThhZGI4NmFlZjA5YmRfNjAzMQ_e25a2cbd-f145-43fd-b520-7dcbc85307c7">Stock-Based Compensation Plans&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2021 Employee Stock Purchase Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 25, 2021, the Company adopted the 2021 Employee Stock Purchase Plan ("ESPP"), which was approved by stockholder vote at the 2021 Annual Meeting of Stockholders held on June 10, 2021. The ESPP provides eligible employees of the Company with an opportunity to purchase common stock of the Company through accumulated payroll deductions, which are included in other current liabilities until they are used to purchase Company shares. Eligible employees participating in the bi-annual offering period can choose to have up to the lesser of 15% of their annual base earnings or the IRS annual share purchase limit of $25,000 in aggregate market value to purchase shares of the Company&#x2019;s common stock. The purchase price of the stock is the lesser of (i) 85% of the closing market price on the date of purchase and (ii) the closing market price at the beginning of the bi-annual offering period. The maximum number of shares reserved for delivery under the plan is 200,000 shares.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;     &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company issued  zero and 24,612 shares under the ESPP for the three and nine months ended September 30, 2022 and 37,370 shares life to date.  The Company recognized ESPP expense of $21,000 and $18,000  for the three months ended September 30, 2022 and 2021, respectively, and  ESPP expense of $74,000 and $18,000 related to the nine months ended September 30, 2022 and 2021, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock Option Programs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2019, the Company&#x2019;s stockholders approved the 2019 Omnibus Equity Incentive Plan (the &#x201c;2019 Plan&#x201d;) which was adopted by the Board with an effective date of June 14, 2019. The 2019 Plan allows for the grant of equity awards to employees, consultants and non-employee directors. An initial maximum of 1,500,000 shares of the Company&#x2019;s common stock were available for grant under the 2019 Plan. The 2019 Plan includes an evergreen provision that allows for the annual addition of up to 4% of the Company&#x2019;s fully-diluted outstanding stock, with a maximum allowable increase of 4,900,000 shares over the term of the 2019 Plan. In accordance with this provision, the shares available for grant were increased in 2020 through 2022 by a total of 2,481,195 shares. The 2019 Plan is currently administered by the Board, or, at the discretion of the Board, by a committee of the Board, which determines the exercise prices, vesting schedules and other restrictions of awards under the 2019 Plan at its discretion. Options to purchase stock may not have an exercise price that is less than the fair market value of underlying shares on the date of grant, and may not have a term greater than ten years. Incentive stock options granted to employees typically vest over four years. Non-statutory options granted to employees, officers, members of the Board, advisors, and consultants of the Company typically vest over &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80OS9mcmFnOjlhN2M1MTczZGE1ZTQ5ZjViYTk4YWRiODZhZWYwOWJkL3RleHRyZWdpb246OWE3YzUxNzNkYTVlNDlmNWJhOThhZGI4NmFlZjA5YmRfNTQ5NzU1ODI1NDIw_e9f71a48-2105-4fda-bdd7-59ddc0e82852"&gt;three&lt;/span&gt; or four years. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Shares that are expired, terminated, surrendered or canceled under the 2019 Plan without having been fully exercised will be available for future awards. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Movements during the year &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes stock option activity for the nine months ended September 30, 2022 and 2021, respectively, for the 2019 Plan:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.929%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.444%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.307%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.554%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.307%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.554%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.759%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.554%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.421%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term&#160;(Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of January 1, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,157,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,837,513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(852)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited or expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(194,548)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,799,573&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.59&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options vested and expected to vest as of September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,799,573&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.59&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options exercisable as of September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,248,875&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.64&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.883%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.442%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.531%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.570%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.531%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.570%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.993%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.570%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.693%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term&#160;(Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of January 1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,117,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,033,809&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited or expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(105,009)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,045,960&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.91&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options vested and expected to vest as of September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,045,960&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.91&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options exercisable as of September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;665,168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.33&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Measurement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted-average assumptions used in the BSM option pricing model to determine the fair value of the employee and non-employee stock option grants relating to the 2019 Plan were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Risk-Free Interest Rate&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The risk-free rate assumption is based on U.S. Treasury instruments with maturities similar to the expected term of the stock options.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Expected Dividend Yield&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company has not issued any dividends and does not expect to issue dividends over the life of the options. As a result, the Company has estimated the dividend yield to be zero.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Expected Volatility&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Due to the Company&#x2019;s limited operating history and a lack of company specific historical and implied volatility data, the Company estimates expected volatility based on the historical volatility of its own stock combined with a group of comparable companies that are publicly traded. The historical volatility data was computed using the daily closing prices for the selected companies&#x2019; shares during the equivalent period of the calculated expected term of the stock-based awards.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Expected Term &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The expected term of options is estimated considering the vesting period at the grant date, the life of the option and the average length of time similar grants have remained outstanding in the past.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted-average grant date fair value of stock options granted under the 2019 Plan during the nine months ended September 30, 2022 and 2021 was $6.94 and $11.14, respectively. The following are the underlying assumptions used in the Black-Scholes-Merton option pricing model to determine the fair value of stock options granted to employees and to non-employees under this stock plan:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.812%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.443%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.445%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine  Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.04%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.88%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97.8%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92.4%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term of options (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.00&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.95&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total stock-based compensation expense for all stock awards recognized in the accompanying unaudited condensed consolidated statements of operations is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.391%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.115%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.408%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.186%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months&lt;br/&gt;&#160;Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months&lt;br/&gt;&#160;Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;831,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;456,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,392,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,279,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,081,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;941,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,651,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,204,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,912,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,397,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,043,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,483,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September 30, 2022, there was $17.6 million in total unrecognized compensation expense relating to the 2019 Plan to be recognized over a weighted average period of 2.91 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Summary of Equity Incentive Plans Assumed from Vital&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon completion of the Transaction with Vital Therapies ("Vital") on April 12, 2019, Vital&#x2019;s 2012 Stock Option Plan (the &#x201c;2012 Plan&#x201d;), Vital&#x2019;s 2014 Equity Incentive Plan (the &#x201c;2014 Plan&#x201d;) and Vital&#x2019;s 2017 Inducement Equity Incentive Plan (the &#x201c;Inducement Plan&#x201d;), were assumed by the Company. All awards granted under these plans have either been forfeited or expired.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There remain 43,311 shares available for grant under the 2014 Plan as of September 30, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 2017, Vital&#x2019;s board of directors approved the Inducement Plan, which was amended and restated in November 2017. Under the Inducement Plan 46,250 shares of Vital&#x2019;s common stock were reserved to be used exclusively for non-qualified grants to individuals who were not previously employees or directors as an inducement material to a grantee's entry into employment within the meaning of Rule 5635(c)(4) of the Nasdaq Listing Rules.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;No expense was recorded for the plans assumed from Vital during the three and nine months ended September 30, 2022 and 2021, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
      contextRef="ic696ef9959af49cdbf3fd974759bd0bc_D20210425-20210425"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80OS9mcmFnOjlhN2M1MTczZGE1ZTQ5ZjViYTk4YWRiODZhZWYwOWJkL3RleHRyZWdpb246OWE3YzUxNzNkYTVlNDlmNWJhOThhZGI4NmFlZjA5YmRfNTQ5NzU1ODIxNjk0_4fc1e24d-8e23-4263-99c9-a7c9e5eebe79"
      unitRef="number">0.15</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate
      contextRef="ic696ef9959af49cdbf3fd974759bd0bc_D20210425-20210425"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80OS9mcmFnOjlhN2M1MTczZGE1ZTQ5ZjViYTk4YWRiODZhZWYwOWJkL3RleHRyZWdpb246OWE3YzUxNzNkYTVlNDlmNWJhOThhZGI4NmFlZjA5YmRfNTQ5NzU1ODIxOTA3_059db86e-0996-4d32-b0f9-96981098cd21"
      unitRef="number">0.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i08aa60800326487fbf99175d815ab200_I20210425"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80OS9mcmFnOjlhN2M1MTczZGE1ZTQ5ZjViYTk4YWRiODZhZWYwOWJkL3RleHRyZWdpb246OWE3YzUxNzNkYTVlNDlmNWJhOThhZGI4NmFlZjA5YmRfNTQ5NzU1ODIyMTE3_d31a9433-be98-45fd-b0c2-682c6272c051"
      unitRef="shares">200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i6c48924db6c34718b6db57f2bcd38c0b_D20220701-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80OS9mcmFnOjlhN2M1MTczZGE1ZTQ5ZjViYTk4YWRiODZhZWYwOWJkL3RleHRyZWdpb246OWE3YzUxNzNkYTVlNDlmNWJhOThhZGI4NmFlZjA5YmRfNTQ5NzU1ODIyMTU1_c67a8281-3b08-4c15-ba4f-6f11b053b9c6"
      unitRef="shares">24612</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="ie7370ee1ee9943cdacd5aaf69e8a6815_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80OS9mcmFnOjlhN2M1MTczZGE1ZTQ5ZjViYTk4YWRiODZhZWYwOWJkL3RleHRyZWdpb246OWE3YzUxNzNkYTVlNDlmNWJhOThhZGI4NmFlZjA5YmRfNTQ5NzU1ODIyMTU1_f1c65fd5-7735-4607-87c9-0a187364867d"
      unitRef="shares">24612</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i2f6d9566f1a34310806423b83a871513_D20210425-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80OS9mcmFnOjlhN2M1MTczZGE1ZTQ5ZjViYTk4YWRiODZhZWYwOWJkL3RleHRyZWdpb246OWE3YzUxNzNkYTVlNDlmNWJhOThhZGI4NmFlZjA5YmRfNTQ5NzU1ODIyMjM0_d7e74c2e-a941-4581-9c20-80df7847c2cb"
      unitRef="shares">37370</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i6c48924db6c34718b6db57f2bcd38c0b_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80OS9mcmFnOjlhN2M1MTczZGE1ZTQ5ZjViYTk4YWRiODZhZWYwOWJkL3RleHRyZWdpb246OWE3YzUxNzNkYTVlNDlmNWJhOThhZGI4NmFlZjA5YmRfNDk0NzgwMjM0MTA5NQ_8a1ebc8a-54b3-4491-96f0-acb451e6d46f"
      unitRef="usd">21000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ib000cfab8d3c42d09670f1d425af5286_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80OS9mcmFnOjlhN2M1MTczZGE1ZTQ5ZjViYTk4YWRiODZhZWYwOWJkL3RleHRyZWdpb246OWE3YzUxNzNkYTVlNDlmNWJhOThhZGI4NmFlZjA5YmRfNDk0NzgwMjM0MTEwNA_5da40c03-6e42-47b5-99d4-6e730c6a19e0"
      unitRef="usd">18000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ie7370ee1ee9943cdacd5aaf69e8a6815_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80OS9mcmFnOjlhN2M1MTczZGE1ZTQ5ZjViYTk4YWRiODZhZWYwOWJkL3RleHRyZWdpb246OWE3YzUxNzNkYTVlNDlmNWJhOThhZGI4NmFlZjA5YmRfNDk0NzgwMjM0MTExMw_3fe0d492-a7a6-4c9b-a972-3c9a9e73e9c3"
      unitRef="usd">74000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i590665700dea49f8bbef5c2cd33f5ab6_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80OS9mcmFnOjlhN2M1MTczZGE1ZTQ5ZjViYTk4YWRiODZhZWYwOWJkL3RleHRyZWdpb246OWE3YzUxNzNkYTVlNDlmNWJhOThhZGI4NmFlZjA5YmRfNDk0NzgwMjM0MTEyMg_b5a5b8a2-7cfb-4a98-b75a-dd592d4d0564"
      unitRef="usd">18000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i0364a2ce088c4ade8ed67e8b0967db85_I20190731"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80OS9mcmFnOjlhN2M1MTczZGE1ZTQ5ZjViYTk4YWRiODZhZWYwOWJkL3RleHRyZWdpb246OWE3YzUxNzNkYTVlNDlmNWJhOThhZGI4NmFlZjA5YmRfNTQ5NzU1ODI0MzQ0_6e940dfe-1a9e-47eb-af6f-b978a772c8ea"
      unitRef="shares">1500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <vtl:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent
      contextRef="i97b48810b19f420aaff9dc7f71a98c22_D20190701-20190731"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80OS9mcmFnOjlhN2M1MTczZGE1ZTQ5ZjViYTk4YWRiODZhZWYwOWJkL3RleHRyZWdpb246OWE3YzUxNzNkYTVlNDlmNWJhOThhZGI4NmFlZjA5YmRfNTQ5NzU1ODI0NTIy_27772d16-d5ae-4fad-bb3e-2fa8b02e2fd1"
      unitRef="number">0.04</vtl:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="i97b48810b19f420aaff9dc7f71a98c22_D20190701-20190731"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80OS9mcmFnOjlhN2M1MTczZGE1ZTQ5ZjViYTk4YWRiODZhZWYwOWJkL3RleHRyZWdpb246OWE3YzUxNzNkYTVlNDlmNWJhOThhZGI4NmFlZjA5YmRfNTQ5NzU1ODI0NjEz_c6d305da-07c1-42a7-9083-de7de7cfbf5f"
      unitRef="shares">4900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="if69ea9bc126c4fa5a73a13a32babfa2b_D20200101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80OS9mcmFnOjlhN2M1MTczZGE1ZTQ5ZjViYTk4YWRiODZhZWYwOWJkL3RleHRyZWdpb246OWE3YzUxNzNkYTVlNDlmNWJhOThhZGI4NmFlZjA5YmRfNTQ5NzU1ODI0Nzcy_261e0ea6-b107-49f5-9b05-6e7dedecc7c7"
      unitRef="shares">2481195</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="id40d762aabfc48f4a2944687c1be6b40_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80OS9mcmFnOjlhN2M1MTczZGE1ZTQ5ZjViYTk4YWRiODZhZWYwOWJkL3RleHRyZWdpb246OWE3YzUxNzNkYTVlNDlmNWJhOThhZGI4NmFlZjA5YmRfNTQ5NzU1ODI1MjA4_39ae4021-16fa-45c8-97c6-8a0a1dd83c6c">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i8925c9f347c0462dafcba58c8ff77fc0_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80OS9mcmFnOjlhN2M1MTczZGE1ZTQ5ZjViYTk4YWRiODZhZWYwOWJkL3RleHRyZWdpb246OWE3YzUxNzNkYTVlNDlmNWJhOThhZGI4NmFlZjA5YmRfNTQ5NzU1ODI1Mjc4_042592a9-dea8-47ff-aa5c-ad577725ca9f">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="iaf64f27642a24cfd90a8b4b8fd99a4e3_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80OS9mcmFnOjlhN2M1MTczZGE1ZTQ5ZjViYTk4YWRiODZhZWYwOWJkL3RleHRyZWdpb246OWE3YzUxNzNkYTVlNDlmNWJhOThhZGI4NmFlZjA5YmRfNTQ5NzU1ODI1NDI3_f9c8b25c-205e-455d-9158-c33bb878bd52">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80OS9mcmFnOjlhN2M1MTczZGE1ZTQ5ZjViYTk4YWRiODZhZWYwOWJkL3RleHRyZWdpb246OWE3YzUxNzNkYTVlNDlmNWJhOThhZGI4NmFlZjA5YmRfNjAzNg_4019d019-dfc0-4b91-b43c-63d175f19163">&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes stock option activity for the nine months ended September 30, 2022 and 2021, respectively, for the 2019 Plan:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.929%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.444%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.307%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.554%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.307%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.554%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.759%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.554%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.421%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term&#160;(Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of January 1, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,157,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,837,513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(852)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited or expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(194,548)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,799,573&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.59&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options vested and expected to vest as of September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,799,573&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.59&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options exercisable as of September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,248,875&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.64&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.883%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.442%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.531%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.570%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.531%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.570%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.993%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.570%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.693%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term&#160;(Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of January 1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,117,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,033,809&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited or expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(105,009)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,045,960&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.91&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options vested and expected to vest as of September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,045,960&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.91&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options exercisable as of September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;665,168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.33&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i7f827301d88e484985fc3a70f1380d98_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80OS9mcmFnOjlhN2M1MTczZGE1ZTQ5ZjViYTk4YWRiODZhZWYwOWJkL3RhYmxlOjFlN2E4MzVmY2UxMDQxYjQ5YmVhZThmOWUxOTAwZTMwL3RhYmxlcmFuZ2U6MWU3YTgzNWZjZTEwNDFiNDliZWFlOGY5ZTE5MDBlMzBfMS0xLTEtMS0zMDUwMA_cdf43e8e-2eac-48a0-b1f0-67e5623f5946"
      unitRef="shares">2157460</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i7f827301d88e484985fc3a70f1380d98_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80OS9mcmFnOjlhN2M1MTczZGE1ZTQ5ZjViYTk4YWRiODZhZWYwOWJkL3RhYmxlOjFlN2E4MzVmY2UxMDQxYjQ5YmVhZThmOWUxOTAwZTMwL3RhYmxlcmFuZ2U6MWU3YTgzNWZjZTEwNDFiNDliZWFlOGY5ZTE5MDBlMzBfMS0zLTEtMS0zMDUwMA_29eda7a1-e8da-45d2-b88c-dc93eea32028"
      unitRef="usdPerShare">13.54</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i89cb4fe99d71444395e3fc22f0e7e477_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80OS9mcmFnOjlhN2M1MTczZGE1ZTQ5ZjViYTk4YWRiODZhZWYwOWJkL3RhYmxlOjFlN2E4MzVmY2UxMDQxYjQ5YmVhZThmOWUxOTAwZTMwL3RhYmxlcmFuZ2U6MWU3YTgzNWZjZTEwNDFiNDliZWFlOGY5ZTE5MDBlMzBfMi0xLTEtMS0zMDUwMA_6fb35b9e-6f8e-421f-9174-a4f1119ea81a"
      unitRef="shares">1837513</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i89cb4fe99d71444395e3fc22f0e7e477_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80OS9mcmFnOjlhN2M1MTczZGE1ZTQ5ZjViYTk4YWRiODZhZWYwOWJkL3RhYmxlOjFlN2E4MzVmY2UxMDQxYjQ5YmVhZThmOWUxOTAwZTMwL3RhYmxlcmFuZ2U6MWU3YTgzNWZjZTEwNDFiNDliZWFlOGY5ZTE5MDBlMzBfMi0zLTEtMS0zMDUwMA_80bdf327-3122-4b04-ac5f-4d41e18b6cdc"
      unitRef="usdPerShare">8.90</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i89cb4fe99d71444395e3fc22f0e7e477_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80OS9mcmFnOjlhN2M1MTczZGE1ZTQ5ZjViYTk4YWRiODZhZWYwOWJkL3RhYmxlOjFlN2E4MzVmY2UxMDQxYjQ5YmVhZThmOWUxOTAwZTMwL3RhYmxlcmFuZ2U6MWU3YTgzNWZjZTEwNDFiNDliZWFlOGY5ZTE5MDBlMzBfMy0xLTEtMS0zMDUwMA_1989018f-43f2-4f7c-833f-ef62dbaad18b"
      unitRef="shares">852</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i89cb4fe99d71444395e3fc22f0e7e477_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80OS9mcmFnOjlhN2M1MTczZGE1ZTQ5ZjViYTk4YWRiODZhZWYwOWJkL3RhYmxlOjFlN2E4MzVmY2UxMDQxYjQ5YmVhZThmOWUxOTAwZTMwL3RhYmxlcmFuZ2U6MWU3YTgzNWZjZTEwNDFiNDliZWFlOGY5ZTE5MDBlMzBfMy0zLTEtMS0zMDUwMA_46fff0ec-ad06-4fb8-a5d1-574cc92096be"
      unitRef="usdPerShare">5.67</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="i89cb4fe99d71444395e3fc22f0e7e477_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80OS9mcmFnOjlhN2M1MTczZGE1ZTQ5ZjViYTk4YWRiODZhZWYwOWJkL3RhYmxlOjFlN2E4MzVmY2UxMDQxYjQ5YmVhZThmOWUxOTAwZTMwL3RhYmxlcmFuZ2U6MWU3YTgzNWZjZTEwNDFiNDliZWFlOGY5ZTE5MDBlMzBfNC0xLTEtMS0zMDUwMA_fdd7f2f2-4b28-4045-952a-d619099b2094"
      unitRef="shares">194548</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="i89cb4fe99d71444395e3fc22f0e7e477_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80OS9mcmFnOjlhN2M1MTczZGE1ZTQ5ZjViYTk4YWRiODZhZWYwOWJkL3RhYmxlOjFlN2E4MzVmY2UxMDQxYjQ5YmVhZThmOWUxOTAwZTMwL3RhYmxlcmFuZ2U6MWU3YTgzNWZjZTEwNDFiNDliZWFlOGY5ZTE5MDBlMzBfNC0zLTEtMS0zMDUwMA_1c5ba5d7-2e6e-4708-a9f7-021357bb158f"
      unitRef="usdPerShare">11.62</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i33c46859f4e1425b90a6f987327175f6_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80OS9mcmFnOjlhN2M1MTczZGE1ZTQ5ZjViYTk4YWRiODZhZWYwOWJkL3RhYmxlOjFlN2E4MzVmY2UxMDQxYjQ5YmVhZThmOWUxOTAwZTMwL3RhYmxlcmFuZ2U6MWU3YTgzNWZjZTEwNDFiNDliZWFlOGY5ZTE5MDBlMzBfNS0xLTEtMS0zMDUwMA_700fccff-4da2-4c1d-8b23-30861b3aa3e6"
      unitRef="shares">3799573</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i33c46859f4e1425b90a6f987327175f6_I20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80OS9mcmFnOjlhN2M1MTczZGE1ZTQ5ZjViYTk4YWRiODZhZWYwOWJkL3RhYmxlOjFlN2E4MzVmY2UxMDQxYjQ5YmVhZThmOWUxOTAwZTMwL3RhYmxlcmFuZ2U6MWU3YTgzNWZjZTEwNDFiNDliZWFlOGY5ZTE5MDBlMzBfNS0zLTEtMS0zMDUwMA_f9c95162-6f63-47d2-b451-ffca0463d762"
      unitRef="usdPerShare">11.40</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i89cb4fe99d71444395e3fc22f0e7e477_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80OS9mcmFnOjlhN2M1MTczZGE1ZTQ5ZjViYTk4YWRiODZhZWYwOWJkL3RhYmxlOjFlN2E4MzVmY2UxMDQxYjQ5YmVhZThmOWUxOTAwZTMwL3RhYmxlcmFuZ2U6MWU3YTgzNWZjZTEwNDFiNDliZWFlOGY5ZTE5MDBlMzBfNS01LTEtMS0zMDUwMA_12a835a7-e22b-4d9d-a1ec-c104335ecefb">P8Y7M2D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i33c46859f4e1425b90a6f987327175f6_I20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80OS9mcmFnOjlhN2M1MTczZGE1ZTQ5ZjViYTk4YWRiODZhZWYwOWJkL3RhYmxlOjFlN2E4MzVmY2UxMDQxYjQ5YmVhZThmOWUxOTAwZTMwL3RhYmxlcmFuZ2U6MWU3YTgzNWZjZTEwNDFiNDliZWFlOGY5ZTE5MDBlMzBfNS03LTEtMS0zMDUwMA_c6a54083-24b8-4d54-b1c0-f681ccd6050a"
      unitRef="usd">2400</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="i33c46859f4e1425b90a6f987327175f6_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80OS9mcmFnOjlhN2M1MTczZGE1ZTQ5ZjViYTk4YWRiODZhZWYwOWJkL3RhYmxlOjFlN2E4MzVmY2UxMDQxYjQ5YmVhZThmOWUxOTAwZTMwL3RhYmxlcmFuZ2U6MWU3YTgzNWZjZTEwNDFiNDliZWFlOGY5ZTE5MDBlMzBfNi0xLTEtMS0zMDUwMA_8a4aff33-94c7-4af8-9223-192de5bdff58"
      unitRef="shares">3799573</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="i33c46859f4e1425b90a6f987327175f6_I20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80OS9mcmFnOjlhN2M1MTczZGE1ZTQ5ZjViYTk4YWRiODZhZWYwOWJkL3RhYmxlOjFlN2E4MzVmY2UxMDQxYjQ5YmVhZThmOWUxOTAwZTMwL3RhYmxlcmFuZ2U6MWU3YTgzNWZjZTEwNDFiNDliZWFlOGY5ZTE5MDBlMzBfNi0zLTEtMS0zMDUwMA_57fefdf7-002b-4318-b664-eef099bd4367"
      unitRef="usdPerShare">11.40</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
      contextRef="i89cb4fe99d71444395e3fc22f0e7e477_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80OS9mcmFnOjlhN2M1MTczZGE1ZTQ5ZjViYTk4YWRiODZhZWYwOWJkL3RhYmxlOjFlN2E4MzVmY2UxMDQxYjQ5YmVhZThmOWUxOTAwZTMwL3RhYmxlcmFuZ2U6MWU3YTgzNWZjZTEwNDFiNDliZWFlOGY5ZTE5MDBlMzBfNi01LTEtMS0zMDUwMA_c262a617-b0a3-484b-8bc8-cf9594c8deb2">P8Y7M2D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="i33c46859f4e1425b90a6f987327175f6_I20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80OS9mcmFnOjlhN2M1MTczZGE1ZTQ5ZjViYTk4YWRiODZhZWYwOWJkL3RhYmxlOjFlN2E4MzVmY2UxMDQxYjQ5YmVhZThmOWUxOTAwZTMwL3RhYmxlcmFuZ2U6MWU3YTgzNWZjZTEwNDFiNDliZWFlOGY5ZTE5MDBlMzBfNi03LTEtMS0zMDUwMA_84b5b624-90ae-4b33-87a9-c38ee7093888"
      unitRef="usd">2400</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i33c46859f4e1425b90a6f987327175f6_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80OS9mcmFnOjlhN2M1MTczZGE1ZTQ5ZjViYTk4YWRiODZhZWYwOWJkL3RhYmxlOjFlN2E4MzVmY2UxMDQxYjQ5YmVhZThmOWUxOTAwZTMwL3RhYmxlcmFuZ2U6MWU3YTgzNWZjZTEwNDFiNDliZWFlOGY5ZTE5MDBlMzBfNy0xLTEtMS0zMDUwMA_ecf6cab2-f4f7-46b2-b53d-58150dae822e"
      unitRef="shares">1248875</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i33c46859f4e1425b90a6f987327175f6_I20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80OS9mcmFnOjlhN2M1MTczZGE1ZTQ5ZjViYTk4YWRiODZhZWYwOWJkL3RhYmxlOjFlN2E4MzVmY2UxMDQxYjQ5YmVhZThmOWUxOTAwZTMwL3RhYmxlcmFuZ2U6MWU3YTgzNWZjZTEwNDFiNDliZWFlOGY5ZTE5MDBlMzBfNy0zLTEtMS0zMDUwMA_a2ba0374-5eb3-4771-aac9-9260ab68a158"
      unitRef="usdPerShare">13.63</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="i89cb4fe99d71444395e3fc22f0e7e477_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80OS9mcmFnOjlhN2M1MTczZGE1ZTQ5ZjViYTk4YWRiODZhZWYwOWJkL3RhYmxlOjFlN2E4MzVmY2UxMDQxYjQ5YmVhZThmOWUxOTAwZTMwL3RhYmxlcmFuZ2U6MWU3YTgzNWZjZTEwNDFiNDliZWFlOGY5ZTE5MDBlMzBfNy01LTEtMS0zMDUwMA_45283b54-501e-4529-9418-edc808a37556">P7Y7M20D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="i33c46859f4e1425b90a6f987327175f6_I20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80OS9mcmFnOjlhN2M1MTczZGE1ZTQ5ZjViYTk4YWRiODZhZWYwOWJkL3RhYmxlOjFlN2E4MzVmY2UxMDQxYjQ5YmVhZThmOWUxOTAwZTMwL3RhYmxlcmFuZ2U6MWU3YTgzNWZjZTEwNDFiNDliZWFlOGY5ZTE5MDBlMzBfNy03LTEtMS0zMDUwMA_cf3955da-b4e4-4f26-9b0e-c0bd9acb94d1"
      unitRef="usd">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i1986a58a2c504c0b9c41f5d536a9502c_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80OS9mcmFnOjlhN2M1MTczZGE1ZTQ5ZjViYTk4YWRiODZhZWYwOWJkL3RhYmxlOmRhZmM1ZTUyMzM2ZDRlY2ZiMmE2MDViNjQ5MTZjNTljL3RhYmxlcmFuZ2U6ZGFmYzVlNTIzMzZkNGVjZmIyYTYwNWI2NDkxNmM1OWNfMS0xLTEtMS0zMDUwMA_aa429bff-446f-49ec-863c-85190bedad98"
      unitRef="shares">1117160</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i1986a58a2c504c0b9c41f5d536a9502c_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80OS9mcmFnOjlhN2M1MTczZGE1ZTQ5ZjViYTk4YWRiODZhZWYwOWJkL3RhYmxlOmRhZmM1ZTUyMzM2ZDRlY2ZiMmE2MDViNjQ5MTZjNTljL3RhYmxlcmFuZ2U6ZGFmYzVlNTIzMzZkNGVjZmIyYTYwNWI2NDkxNmM1OWNfMS0zLTEtMS0zMDUwMA_8ba01d37-fe81-44f9-85b6-a566e6e309ac"
      unitRef="usdPerShare">12.96</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i0c4254621dc64047a9c2d671aa842886_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80OS9mcmFnOjlhN2M1MTczZGE1ZTQ5ZjViYTk4YWRiODZhZWYwOWJkL3RhYmxlOmRhZmM1ZTUyMzM2ZDRlY2ZiMmE2MDViNjQ5MTZjNTljL3RhYmxlcmFuZ2U6ZGFmYzVlNTIzMzZkNGVjZmIyYTYwNWI2NDkxNmM1OWNfMi0xLTEtMS0zMDUwMA_aadbaa9e-647c-48e3-b4c0-f08e16f6c45d"
      unitRef="shares">1033809</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i0c4254621dc64047a9c2d671aa842886_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80OS9mcmFnOjlhN2M1MTczZGE1ZTQ5ZjViYTk4YWRiODZhZWYwOWJkL3RhYmxlOmRhZmM1ZTUyMzM2ZDRlY2ZiMmE2MDViNjQ5MTZjNTljL3RhYmxlcmFuZ2U6ZGFmYzVlNTIzMzZkNGVjZmIyYTYwNWI2NDkxNmM1OWNfMi0zLTEtMS0zMDUwMA_7760116d-e93d-4976-b6ce-3aa22b6f257e"
      unitRef="usdPerShare">14.95</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i0c4254621dc64047a9c2d671aa842886_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80OS9mcmFnOjlhN2M1MTczZGE1ZTQ5ZjViYTk4YWRiODZhZWYwOWJkL3RhYmxlOmRhZmM1ZTUyMzM2ZDRlY2ZiMmE2MDViNjQ5MTZjNTljL3RhYmxlcmFuZ2U6ZGFmYzVlNTIzMzZkNGVjZmIyYTYwNWI2NDkxNmM1OWNfMy0xLTEtMS0zMDUwMA_6914c780-2ea9-4917-845a-50a1a1c1aff3"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i0c4254621dc64047a9c2d671aa842886_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80OS9mcmFnOjlhN2M1MTczZGE1ZTQ5ZjViYTk4YWRiODZhZWYwOWJkL3RhYmxlOmRhZmM1ZTUyMzM2ZDRlY2ZiMmE2MDViNjQ5MTZjNTljL3RhYmxlcmFuZ2U6ZGFmYzVlNTIzMzZkNGVjZmIyYTYwNWI2NDkxNmM1OWNfMy0zLTEtMS0zMDUwMA_8675b8a1-5fd0-465a-841b-dc380b41b458"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="i0c4254621dc64047a9c2d671aa842886_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80OS9mcmFnOjlhN2M1MTczZGE1ZTQ5ZjViYTk4YWRiODZhZWYwOWJkL3RhYmxlOmRhZmM1ZTUyMzM2ZDRlY2ZiMmE2MDViNjQ5MTZjNTljL3RhYmxlcmFuZ2U6ZGFmYzVlNTIzMzZkNGVjZmIyYTYwNWI2NDkxNmM1OWNfNC0xLTEtMS0zMDUwMA_9095fee4-3d3a-45fd-bcc8-6b249a673828"
      unitRef="shares">105009</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="i0c4254621dc64047a9c2d671aa842886_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80OS9mcmFnOjlhN2M1MTczZGE1ZTQ5ZjViYTk4YWRiODZhZWYwOWJkL3RhYmxlOmRhZmM1ZTUyMzM2ZDRlY2ZiMmE2MDViNjQ5MTZjNTljL3RhYmxlcmFuZ2U6ZGFmYzVlNTIzMzZkNGVjZmIyYTYwNWI2NDkxNmM1OWNfNC0zLTEtMS0zMDUwMA_86de6e71-db89-41f7-b129-5829514976db"
      unitRef="usdPerShare">14.32</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i3fc8f323372c48c49a066aa56341ee03_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80OS9mcmFnOjlhN2M1MTczZGE1ZTQ5ZjViYTk4YWRiODZhZWYwOWJkL3RhYmxlOmRhZmM1ZTUyMzM2ZDRlY2ZiMmE2MDViNjQ5MTZjNTljL3RhYmxlcmFuZ2U6ZGFmYzVlNTIzMzZkNGVjZmIyYTYwNWI2NDkxNmM1OWNfNS0xLTEtMS0zMDUwMA_107e2651-e10b-44ae-ac5e-66dd2d04c82e"
      unitRef="shares">2045960</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i3fc8f323372c48c49a066aa56341ee03_I20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80OS9mcmFnOjlhN2M1MTczZGE1ZTQ5ZjViYTk4YWRiODZhZWYwOWJkL3RhYmxlOmRhZmM1ZTUyMzM2ZDRlY2ZiMmE2MDViNjQ5MTZjNTljL3RhYmxlcmFuZ2U6ZGFmYzVlNTIzMzZkNGVjZmIyYTYwNWI2NDkxNmM1OWNfNS0zLTEtMS0zMDUwMA_1e68762e-520b-49fb-88d2-f4934b3cb072"
      unitRef="usdPerShare">13.90</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i0c4254621dc64047a9c2d671aa842886_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80OS9mcmFnOjlhN2M1MTczZGE1ZTQ5ZjViYTk4YWRiODZhZWYwOWJkL3RhYmxlOmRhZmM1ZTUyMzM2ZDRlY2ZiMmE2MDViNjQ5MTZjNTljL3RhYmxlcmFuZ2U6ZGFmYzVlNTIzMzZkNGVjZmIyYTYwNWI2NDkxNmM1OWNfNS01LTEtMS0zMDUwMA_ed3a62f3-965d-4d8f-bcd5-07a38039bf66">P8Y10M28D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i3fc8f323372c48c49a066aa56341ee03_I20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80OS9mcmFnOjlhN2M1MTczZGE1ZTQ5ZjViYTk4YWRiODZhZWYwOWJkL3RhYmxlOmRhZmM1ZTUyMzM2ZDRlY2ZiMmE2MDViNjQ5MTZjNTljL3RhYmxlcmFuZ2U6ZGFmYzVlNTIzMzZkNGVjZmIyYTYwNWI2NDkxNmM1OWNfNS03LTEtMS0zMDUwMA_eef031ee-c4e7-4200-9661-b1aa266cd15e"
      unitRef="usd">74460</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="i3fc8f323372c48c49a066aa56341ee03_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80OS9mcmFnOjlhN2M1MTczZGE1ZTQ5ZjViYTk4YWRiODZhZWYwOWJkL3RhYmxlOmRhZmM1ZTUyMzM2ZDRlY2ZiMmE2MDViNjQ5MTZjNTljL3RhYmxlcmFuZ2U6ZGFmYzVlNTIzMzZkNGVjZmIyYTYwNWI2NDkxNmM1OWNfNi0xLTEtMS0zMDUwMA_379c5f39-b3db-4cf7-9460-a5923aa05e15"
      unitRef="shares">2045960</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="i3fc8f323372c48c49a066aa56341ee03_I20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80OS9mcmFnOjlhN2M1MTczZGE1ZTQ5ZjViYTk4YWRiODZhZWYwOWJkL3RhYmxlOmRhZmM1ZTUyMzM2ZDRlY2ZiMmE2MDViNjQ5MTZjNTljL3RhYmxlcmFuZ2U6ZGFmYzVlNTIzMzZkNGVjZmIyYTYwNWI2NDkxNmM1OWNfNi0zLTEtMS0zMDUwMA_52e637fb-5e8f-4b29-9c0d-01125a6c349f"
      unitRef="usdPerShare">13.90</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
      contextRef="i0c4254621dc64047a9c2d671aa842886_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80OS9mcmFnOjlhN2M1MTczZGE1ZTQ5ZjViYTk4YWRiODZhZWYwOWJkL3RhYmxlOmRhZmM1ZTUyMzM2ZDRlY2ZiMmE2MDViNjQ5MTZjNTljL3RhYmxlcmFuZ2U6ZGFmYzVlNTIzMzZkNGVjZmIyYTYwNWI2NDkxNmM1OWNfNi01LTEtMS0zMDUwMA_1592ae36-485f-4cc6-943e-5fe9dc8e2f07">P8Y10M28D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="i3fc8f323372c48c49a066aa56341ee03_I20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80OS9mcmFnOjlhN2M1MTczZGE1ZTQ5ZjViYTk4YWRiODZhZWYwOWJkL3RhYmxlOmRhZmM1ZTUyMzM2ZDRlY2ZiMmE2MDViNjQ5MTZjNTljL3RhYmxlcmFuZ2U6ZGFmYzVlNTIzMzZkNGVjZmIyYTYwNWI2NDkxNmM1OWNfNi03LTEtMS0zMDUwMA_5d9fd82f-f870-41ac-b09f-6afcc3e3dd6b"
      unitRef="usd">74460</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i3fc8f323372c48c49a066aa56341ee03_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80OS9mcmFnOjlhN2M1MTczZGE1ZTQ5ZjViYTk4YWRiODZhZWYwOWJkL3RhYmxlOmRhZmM1ZTUyMzM2ZDRlY2ZiMmE2MDViNjQ5MTZjNTljL3RhYmxlcmFuZ2U6ZGFmYzVlNTIzMzZkNGVjZmIyYTYwNWI2NDkxNmM1OWNfNy0xLTEtMS0zMDUwMA_699ee8d7-fcc3-4ecd-8246-be3bebb657b7"
      unitRef="shares">665168</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i3fc8f323372c48c49a066aa56341ee03_I20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80OS9mcmFnOjlhN2M1MTczZGE1ZTQ5ZjViYTk4YWRiODZhZWYwOWJkL3RhYmxlOmRhZmM1ZTUyMzM2ZDRlY2ZiMmE2MDViNjQ5MTZjNTljL3RhYmxlcmFuZ2U6ZGFmYzVlNTIzMzZkNGVjZmIyYTYwNWI2NDkxNmM1OWNfNy0zLTEtMS0zMDUwMA_2dabdb38-60a5-4116-b75f-6fd508c3b19f"
      unitRef="usdPerShare">13.39</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="i0c4254621dc64047a9c2d671aa842886_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80OS9mcmFnOjlhN2M1MTczZGE1ZTQ5ZjViYTk4YWRiODZhZWYwOWJkL3RhYmxlOmRhZmM1ZTUyMzM2ZDRlY2ZiMmE2MDViNjQ5MTZjNTljL3RhYmxlcmFuZ2U6ZGFmYzVlNTIzMzZkNGVjZmIyYTYwNWI2NDkxNmM1OWNfNy01LTEtMS0zMDUwMA_03925124-5966-4e4b-bb7f-8c0032afa9f9">P8Y3M29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="i3fc8f323372c48c49a066aa56341ee03_I20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80OS9mcmFnOjlhN2M1MTczZGE1ZTQ5ZjViYTk4YWRiODZhZWYwOWJkL3RhYmxlOmRhZmM1ZTUyMzM2ZDRlY2ZiMmE2MDViNjQ5MTZjNTljL3RhYmxlcmFuZ2U6ZGFmYzVlNTIzMzZkNGVjZmIyYTYwNWI2NDkxNmM1OWNfNy03LTEtMS0zMDUwMA_b1667a76-096b-4041-a14f-8ed2553815ad"
      unitRef="usd">43121</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80OS9mcmFnOjlhN2M1MTczZGE1ZTQ5ZjViYTk4YWRiODZhZWYwOWJkL3RleHRyZWdpb246OWE3YzUxNzNkYTVlNDlmNWJhOThhZGI4NmFlZjA5YmRfNTQ5NzU1ODI3MjA0_cbe89d14-0d61-43ca-981e-ec07694b55f3"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i491c0053bc5f4054a60885ff43fbbc87_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80OS9mcmFnOjlhN2M1MTczZGE1ZTQ5ZjViYTk4YWRiODZhZWYwOWJkL3RleHRyZWdpb246OWE3YzUxNzNkYTVlNDlmNWJhOThhZGI4NmFlZjA5YmRfNTQ5NzU1ODI4MTQz_2ab4481d-fc9e-4f43-81f5-abe5e8845d3a"
      unitRef="usdPerShare">6.94</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i3b24c8dadaf44185922659d4e669111d_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80OS9mcmFnOjlhN2M1MTczZGE1ZTQ5ZjViYTk4YWRiODZhZWYwOWJkL3RleHRyZWdpb246OWE3YzUxNzNkYTVlNDlmNWJhOThhZGI4NmFlZjA5YmRfNTQ5NzU1ODI4MTY0_594ee444-652e-4c43-b292-65772968a00a"
      unitRef="usdPerShare">11.14</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80OS9mcmFnOjlhN2M1MTczZGE1ZTQ5ZjViYTk4YWRiODZhZWYwOWJkL3RleHRyZWdpb246OWE3YzUxNzNkYTVlNDlmNWJhOThhZGI4NmFlZjA5YmRfNjAzMw_ade6bdd9-48da-47c6-b2d3-8aba04dfd60f">The following are the underlying assumptions used in the Black-Scholes-Merton option pricing model to determine the fair value of stock options granted to employees and to non-employees under this stock plan:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.812%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.443%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.445%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine  Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.04%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.88%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97.8%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92.4%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term of options (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.00&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.95&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i491c0053bc5f4054a60885ff43fbbc87_D20220101-20220930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80OS9mcmFnOjlhN2M1MTczZGE1ZTQ5ZjViYTk4YWRiODZhZWYwOWJkL3RhYmxlOjQwYzk3MWU2NzJlZjQxMjFhNDcyZDIxNjQ5MjI2ZWE3L3RhYmxlcmFuZ2U6NDBjOTcxZTY3MmVmNDEyMWE0NzJkMjE2NDkyMjZlYTdfMi0xLTEtMS0zMDUwMA_169b85c5-aaae-4b6c-835f-98f6ee7f4291"
      unitRef="number">0.0204</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i3b24c8dadaf44185922659d4e669111d_D20210101-20210930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80OS9mcmFnOjlhN2M1MTczZGE1ZTQ5ZjViYTk4YWRiODZhZWYwOWJkL3RhYmxlOjQwYzk3MWU2NzJlZjQxMjFhNDcyZDIxNjQ5MjI2ZWE3L3RhYmxlcmFuZ2U6NDBjOTcxZTY3MmVmNDEyMWE0NzJkMjE2NDkyMjZlYTdfMi0yLTEtMS0zMDUwMA_69ddd372-f97d-433a-a062-463dcd80d10a"
      unitRef="number">0.0088</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i491c0053bc5f4054a60885ff43fbbc87_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80OS9mcmFnOjlhN2M1MTczZGE1ZTQ5ZjViYTk4YWRiODZhZWYwOWJkL3RhYmxlOjQwYzk3MWU2NzJlZjQxMjFhNDcyZDIxNjQ5MjI2ZWE3L3RhYmxlcmFuZ2U6NDBjOTcxZTY3MmVmNDEyMWE0NzJkMjE2NDkyMjZlYTdfMy0xLTEtMS0zMDUwMA_20358787-1133-456b-a500-0d4ca4ec0b60"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i3b24c8dadaf44185922659d4e669111d_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80OS9mcmFnOjlhN2M1MTczZGE1ZTQ5ZjViYTk4YWRiODZhZWYwOWJkL3RhYmxlOjQwYzk3MWU2NzJlZjQxMjFhNDcyZDIxNjQ5MjI2ZWE3L3RhYmxlcmFuZ2U6NDBjOTcxZTY3MmVmNDEyMWE0NzJkMjE2NDkyMjZlYTdfMy0yLTEtMS0zMDUwMA_2ed0dd88-fac3-443f-8716-09fecb3635fb"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i491c0053bc5f4054a60885ff43fbbc87_D20220101-20220930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80OS9mcmFnOjlhN2M1MTczZGE1ZTQ5ZjViYTk4YWRiODZhZWYwOWJkL3RhYmxlOjQwYzk3MWU2NzJlZjQxMjFhNDcyZDIxNjQ5MjI2ZWE3L3RhYmxlcmFuZ2U6NDBjOTcxZTY3MmVmNDEyMWE0NzJkMjE2NDkyMjZlYTdfNC0xLTEtMS0zMDUwMA_34390804-bc7a-4d7d-82fe-9a75e3a8ca26"
      unitRef="number">0.978</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i3b24c8dadaf44185922659d4e669111d_D20210101-20210930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80OS9mcmFnOjlhN2M1MTczZGE1ZTQ5ZjViYTk4YWRiODZhZWYwOWJkL3RhYmxlOjQwYzk3MWU2NzJlZjQxMjFhNDcyZDIxNjQ5MjI2ZWE3L3RhYmxlcmFuZ2U6NDBjOTcxZTY3MmVmNDEyMWE0NzJkMjE2NDkyMjZlYTdfNC0yLTEtMS0zMDUwMA_f59219e4-5c59-40fd-9dc1-21eed0c9d931"
      unitRef="number">0.924</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i491c0053bc5f4054a60885ff43fbbc87_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80OS9mcmFnOjlhN2M1MTczZGE1ZTQ5ZjViYTk4YWRiODZhZWYwOWJkL3RhYmxlOjQwYzk3MWU2NzJlZjQxMjFhNDcyZDIxNjQ5MjI2ZWE3L3RhYmxlcmFuZ2U6NDBjOTcxZTY3MmVmNDEyMWE0NzJkMjE2NDkyMjZlYTdfNS0xLTEtMS0zMDUwMA_c98140ad-2364-4925-be44-dc5433e6b720">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i3b24c8dadaf44185922659d4e669111d_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80OS9mcmFnOjlhN2M1MTczZGE1ZTQ5ZjViYTk4YWRiODZhZWYwOWJkL3RhYmxlOjQwYzk3MWU2NzJlZjQxMjFhNDcyZDIxNjQ5MjI2ZWE3L3RhYmxlcmFuZ2U6NDBjOTcxZTY3MmVmNDEyMWE0NzJkMjE2NDkyMjZlYTdfNS0yLTEtMS0zMDUwMA_017a931a-2363-4a6c-aae6-158b5578f1b8">P5Y11M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80OS9mcmFnOjlhN2M1MTczZGE1ZTQ5ZjViYTk4YWRiODZhZWYwOWJkL3RleHRyZWdpb246OWE3YzUxNzNkYTVlNDlmNWJhOThhZGI4NmFlZjA5YmRfNjAyOA_aba01f4f-244d-4df1-bb2a-6d44ee714ea3">&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total stock-based compensation expense for all stock awards recognized in the accompanying unaudited condensed consolidated statements of operations is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.391%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.115%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.408%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.186%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months&lt;br/&gt;&#160;Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months&lt;br/&gt;&#160;Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;831,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;456,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,392,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,279,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,081,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;941,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,651,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,204,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,912,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,397,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,043,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,483,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:ShareBasedCompensation
      contextRef="i65018cf301294210aa0bfac659e1638e_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80OS9mcmFnOjlhN2M1MTczZGE1ZTQ5ZjViYTk4YWRiODZhZWYwOWJkL3RhYmxlOjAxZDg2YjY5NWU0NDQ1ZGFiODZmNDIxZTRmN2UxMWU5L3RhYmxlcmFuZ2U6MDFkODZiNjk1ZTQ0NDVkYWI4NmY0MjFlNGY3ZTExZTlfMi01LTEtMS0zMDUwMA_dabd09fd-f899-40ea-8878-3941ccc20539"
      unitRef="usd">831000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i0c3b29676a4440ad86911f00449ac95c_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80OS9mcmFnOjlhN2M1MTczZGE1ZTQ5ZjViYTk4YWRiODZhZWYwOWJkL3RhYmxlOjAxZDg2YjY5NWU0NDQ1ZGFiODZmNDIxZTRmN2UxMWU5L3RhYmxlcmFuZ2U6MDFkODZiNjk1ZTQ0NDVkYWI4NmY0MjFlNGY3ZTExZTlfMi03LTEtMS0zMDUwMA_4d6bd893-ca77-40fc-98d3-4255cd59c574"
      unitRef="usd">456000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i51d6b668f708464ebb2ff34b8eee66d8_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80OS9mcmFnOjlhN2M1MTczZGE1ZTQ5ZjViYTk4YWRiODZhZWYwOWJkL3RhYmxlOjAxZDg2YjY5NWU0NDQ1ZGFiODZmNDIxZTRmN2UxMWU5L3RhYmxlcmFuZ2U6MDFkODZiNjk1ZTQ0NDVkYWI4NmY0MjFlNGY3ZTExZTlfMi05LTEtMS0zMDUwMA_32e98ba9-f3f7-4baf-85d4-60b0b6f16008"
      unitRef="usd">2392000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i83d76f6d51a84bfaaf85c435fc1d50f8_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80OS9mcmFnOjlhN2M1MTczZGE1ZTQ5ZjViYTk4YWRiODZhZWYwOWJkL3RhYmxlOjAxZDg2YjY5NWU0NDQ1ZGFiODZmNDIxZTRmN2UxMWU5L3RhYmxlcmFuZ2U6MDFkODZiNjk1ZTQ0NDVkYWI4NmY0MjFlNGY3ZTExZTlfMi0xMS0xLTEtMzA1MDA_070e9b23-9c7c-46f9-91ca-d3e13c78c67c"
      unitRef="usd">1279000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i9e6c05b057b542f6a6dc60098a6d004a_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80OS9mcmFnOjlhN2M1MTczZGE1ZTQ5ZjViYTk4YWRiODZhZWYwOWJkL3RhYmxlOjAxZDg2YjY5NWU0NDQ1ZGFiODZmNDIxZTRmN2UxMWU5L3RhYmxlcmFuZ2U6MDFkODZiNjk1ZTQ0NDVkYWI4NmY0MjFlNGY3ZTExZTlfMy01LTEtMS0zMDUwMA_209d2ddf-43d7-4efb-8a44-6708576b131f"
      unitRef="usd">1081000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="ifcca3d7bc3b04230b95c604feca1b658_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80OS9mcmFnOjlhN2M1MTczZGE1ZTQ5ZjViYTk4YWRiODZhZWYwOWJkL3RhYmxlOjAxZDg2YjY5NWU0NDQ1ZGFiODZmNDIxZTRmN2UxMWU5L3RhYmxlcmFuZ2U6MDFkODZiNjk1ZTQ0NDVkYWI4NmY0MjFlNGY3ZTExZTlfMy03LTEtMS0zMDUwMA_164de072-da90-46c5-8f37-530e75a279ed"
      unitRef="usd">941000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i600a6a4da2a14932ac6ebff843b1dc82_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80OS9mcmFnOjlhN2M1MTczZGE1ZTQ5ZjViYTk4YWRiODZhZWYwOWJkL3RhYmxlOjAxZDg2YjY5NWU0NDQ1ZGFiODZmNDIxZTRmN2UxMWU5L3RhYmxlcmFuZ2U6MDFkODZiNjk1ZTQ0NDVkYWI4NmY0MjFlNGY3ZTExZTlfMy05LTEtMS0zMDUwMA_0c4a57fe-ab9b-4c31-866e-d64c0c9c50e4"
      unitRef="usd">3651000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="ia17d3b4067d84bec848071ef0c64a422_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80OS9mcmFnOjlhN2M1MTczZGE1ZTQ5ZjViYTk4YWRiODZhZWYwOWJkL3RhYmxlOjAxZDg2YjY5NWU0NDQ1ZGFiODZmNDIxZTRmN2UxMWU5L3RhYmxlcmFuZ2U6MDFkODZiNjk1ZTQ0NDVkYWI4NmY0MjFlNGY3ZTExZTlfMy0xMS0xLTEtMzA1MDA_bddf6c1c-ac48-4943-acc8-e3cc288ca3ef"
      unitRef="usd">3204000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i13791407fd49427ea3348fc4827a4293_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80OS9mcmFnOjlhN2M1MTczZGE1ZTQ5ZjViYTk4YWRiODZhZWYwOWJkL3RhYmxlOjAxZDg2YjY5NWU0NDQ1ZGFiODZmNDIxZTRmN2UxMWU5L3RhYmxlcmFuZ2U6MDFkODZiNjk1ZTQ0NDVkYWI4NmY0MjFlNGY3ZTExZTlfNC01LTEtMS0zMDUwMA_753dcdc5-85d6-4588-ba91-5b857feea57f"
      unitRef="usd">1912000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="ib938f3761273465cb69e3854e10882fd_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80OS9mcmFnOjlhN2M1MTczZGE1ZTQ5ZjViYTk4YWRiODZhZWYwOWJkL3RhYmxlOjAxZDg2YjY5NWU0NDQ1ZGFiODZmNDIxZTRmN2UxMWU5L3RhYmxlcmFuZ2U6MDFkODZiNjk1ZTQ0NDVkYWI4NmY0MjFlNGY3ZTExZTlfNC03LTEtMS0zMDUwMA_dc68498b-b482-4728-9435-ed25351c20e5"
      unitRef="usd">1397000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i0c121149163740e0a14cb0c4c82c1e7a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80OS9mcmFnOjlhN2M1MTczZGE1ZTQ5ZjViYTk4YWRiODZhZWYwOWJkL3RhYmxlOjAxZDg2YjY5NWU0NDQ1ZGFiODZmNDIxZTRmN2UxMWU5L3RhYmxlcmFuZ2U6MDFkODZiNjk1ZTQ0NDVkYWI4NmY0MjFlNGY3ZTExZTlfNC05LTEtMS0zMDUwMA_cc6d75e2-74d3-42f8-ae6e-ce35487b76bb"
      unitRef="usd">6043000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i73bcd6c9a1664c7bbdd7d9ed12c94b42_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80OS9mcmFnOjlhN2M1MTczZGE1ZTQ5ZjViYTk4YWRiODZhZWYwOWJkL3RhYmxlOjAxZDg2YjY5NWU0NDQ1ZGFiODZmNDIxZTRmN2UxMWU5L3RhYmxlcmFuZ2U6MDFkODZiNjk1ZTQ0NDVkYWI4NmY0MjFlNGY3ZTExZTlfNC0xMS0xLTEtMzA1MDA_238b0887-071b-47a7-b799-37ff79401bd1"
      unitRef="usd">4483000000</us-gaap:ShareBasedCompensation>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="ib2ba0b84078f4de2bc3079e992921b92_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80OS9mcmFnOjlhN2M1MTczZGE1ZTQ5ZjViYTk4YWRiODZhZWYwOWJkL3RleHRyZWdpb246OWE3YzUxNzNkYTVlNDlmNWJhOThhZGI4NmFlZjA5YmRfNDgzMQ_daa715e1-526f-4877-ad16-c511303f3ab6"
      unitRef="usd">17600000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80OS9mcmFnOjlhN2M1MTczZGE1ZTQ5ZjViYTk4YWRiODZhZWYwOWJkL3RleHRyZWdpb246OWE3YzUxNzNkYTVlNDlmNWJhOThhZGI4NmFlZjA5YmRfMjc0ODc3OTA4NTkzNQ_a959ac31-fe4e-4cda-96d6-ccc177e8ac97">P2Y10M28D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i6e53bb714b6644b6844692585589b9a1_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80OS9mcmFnOjlhN2M1MTczZGE1ZTQ5ZjViYTk4YWRiODZhZWYwOWJkL3RleHRyZWdpb246OWE3YzUxNzNkYTVlNDlmNWJhOThhZGI4NmFlZjA5YmRfNTM3NA_a4052869-a5d2-443c-bebc-6d4949c68808"
      unitRef="shares">43311</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i84a3ff1a38eb4f16b75117d13dc1cdf2_I20170930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80OS9mcmFnOjlhN2M1MTczZGE1ZTQ5ZjViYTk4YWRiODZhZWYwOWJkL3RleHRyZWdpb246OWE3YzUxNzNkYTVlNDlmNWJhOThhZGI4NmFlZjA5YmRfNTQ5NzU1ODI5NDgy_3fecbcaa-a8dc-4b8a-9a9c-e26a34300c18"
      unitRef="shares">46250</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="if4028463febd40cfa3197e55e2ea9e63_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80OS9mcmFnOjlhN2M1MTczZGE1ZTQ5ZjViYTk4YWRiODZhZWYwOWJkL3RleHRyZWdpb246OWE3YzUxNzNkYTVlNDlmNWJhOThhZGI4NmFlZjA5YmRfMzI5ODUzNDg4OTM2NQ_367f8e11-8a8b-4c46-b766-c14a3bd24a5b"
      unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i991eea4739be41089733f8422d8cbd37_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80OS9mcmFnOjlhN2M1MTczZGE1ZTQ5ZjViYTk4YWRiODZhZWYwOWJkL3RleHRyZWdpb246OWE3YzUxNzNkYTVlNDlmNWJhOThhZGI4NmFlZjA5YmRfMzI5ODUzNDg4OTM2NQ_53da847f-06eb-416f-9a4e-a71752283a82"
      unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i6197809d315e4cd680ef948f2e4723c8_D20200701-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80OS9mcmFnOjlhN2M1MTczZGE1ZTQ5ZjViYTk4YWRiODZhZWYwOWJkL3RleHRyZWdpb246OWE3YzUxNzNkYTVlNDlmNWJhOThhZGI4NmFlZjA5YmRfMzI5ODUzNDg4OTM2NQ_b3653163-0c4a-4d46-85f7-62d9f606ab97"
      unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i5d76381e3d7b4d5e846b0b465a4f3f9a_D20210701-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV80OS9mcmFnOjlhN2M1MTczZGE1ZTQ5ZjViYTk4YWRiODZhZWYwOWJkL3RleHRyZWdpb246OWE3YzUxNzNkYTVlNDlmNWJhOThhZGI4NmFlZjA5YmRfMzI5ODUzNDg4OTM2NQ_de6f062c-e3e8-4928-aa07-29c37aaf0c4d"
      unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <vtl:ChangesInBoardOfDirectorsDisclosureTextBlock
      contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV83NDgvZnJhZzplMmMwNzAyYTViZjI0MGM3ODAxNGQ2MTg1YzA0MGIxZC90ZXh0cmVnaW9uOmUyYzA3MDJhNWJmMjQwYzc4MDE0ZDYxODVjMDQwYjFkXzQ5NDc4MDIzMjY4MDQ_fa82733c-a051-4e32-9b8f-13ad791e3052">Changes in Board of Directors&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 6, 2022, the Company announced the appointment of Monika Maria T&#xf6;rns&#xe9;n as a member of the Board of Directors of the Company, effective as of July 5, 2022. As a Class III director, Ms. T&#xf6;rns&#xe9;n&#x2019;s term lasts until the Company&#x2019;s 2023 annual meeting of stockholders.  Ms. T&#xf6;rns&#xe9;n is not a party to, and does not have any direct or indirect material interest in, any transaction requiring disclosure under Item 404(a) of Regulation S-K. There are no arrangements or understandings between Ms. T&#xf6;rns&#xe9;n and any other persons pursuant to which she was selected as a director.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with her appointment as director, Ms. T&#xf6;rns&#xe9;n was granted a long-term equity incentive grant in the form of an option to purchase a total of 30,000 shares of the Company&#x2019;s common stock, with an exercise price of $4.30 per share, which is equal to the closing price of the Company's common stock on The Nasdaq Stock Market on the date of grant, July 8, 2022. The option to purchase 10,000 shares vests in monthly increments over a period of one year from the grant date, and the option to purchase 20,000 shares vests in monthly increments over a period of three years from the grant date. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additionally, Ms. T&#xf6;rns&#xe9;n and the Company entered into the Company&#x2019;s standard form of indemnification agreement for directors and executive officers.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Concurrently, the Company also announced that current Class III director, Jan Van den Bossche, resigned from the Board. The Board accepted Mr. Van den Bossche&#x2019;s resignation effective July 5, 2022. Mr. Van den Bossche&#x2019;s decision to resign did not result from any disagreement with the Company on any matter relating to Company operations, policies or practices.&lt;/span&gt;&lt;/div&gt;</vtl:ChangesInBoardOfDirectorsDisclosureTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i0b4e3048cb3144a99e1401eb94392689_D20220706-20220706"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV83NDgvZnJhZzplMmMwNzAyYTViZjI0MGM3ODAxNGQ2MTg1YzA0MGIxZC90ZXh0cmVnaW9uOmUyYzA3MDJhNWJmMjQwYzc4MDE0ZDYxODVjMDQwYjFkXzU0OTc1NTgxNDcyNQ_d2c77abd-817c-42ca-8b7b-fe976b220fed"
      unitRef="shares">30000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i0b4e3048cb3144a99e1401eb94392689_D20220706-20220706"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV83NDgvZnJhZzplMmMwNzAyYTViZjI0MGM3ODAxNGQ2MTg1YzA0MGIxZC90ZXh0cmVnaW9uOmUyYzA3MDJhNWJmMjQwYzc4MDE0ZDYxODVjMDQwYjFkXzU0OTc1NTgxNDc5Mw_aba93bbe-5330-491e-898e-959b5a885b17"
      unitRef="usdPerShare">4.30</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="ifaeb8f92093c46299d0fff82d6b11f23_D20220706-20220706"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV83NDgvZnJhZzplMmMwNzAyYTViZjI0MGM3ODAxNGQ2MTg1YzA0MGIxZC90ZXh0cmVnaW9uOmUyYzA3MDJhNWJmMjQwYzc4MDE0ZDYxODVjMDQwYjFkXzU0OTc1NTgxNDk2MA_906d2af3-2fb2-4ec0-b357-87cbfb62e5f3"
      unitRef="shares">10000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="ifaeb8f92093c46299d0fff82d6b11f23_D20220706-20220706"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV83NDgvZnJhZzplMmMwNzAyYTViZjI0MGM3ODAxNGQ2MTg1YzA0MGIxZC90ZXh0cmVnaW9uOmUyYzA3MDJhNWJmMjQwYzc4MDE0ZDYxODVjMDQwYjFkXzU0OTc1NTgxNTAxNg_41d14482-b097-4d55-805c-dfd5caadf43b">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="ibb08e53d8ed6456987432dc116d4c52f_D20220706-20220706"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV83NDgvZnJhZzplMmMwNzAyYTViZjI0MGM3ODAxNGQ2MTg1YzA0MGIxZC90ZXh0cmVnaW9uOmUyYzA3MDJhNWJmMjQwYzc4MDE0ZDYxODVjMDQwYjFkXzU0OTc1NTgxNTA2OA_c8bcea7b-23b2-4b70-abd2-a9222e9d1efb"
      unitRef="shares">20000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="ibb08e53d8ed6456987432dc116d4c52f_D20220706-20220706"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV83NDgvZnJhZzplMmMwNzAyYTViZjI0MGM3ODAxNGQ2MTg1YzA0MGIxZC90ZXh0cmVnaW9uOmUyYzA3MDJhNWJmMjQwYzc4MDE0ZDYxODVjMDQwYjFkXzU0OTc1NTgxNTEyNA_005050d3-143c-40a0-906a-236b66b1b609">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV81NS9mcmFnOjU0NWNmNzgwODVmZjRlYjlhOGU4MDA0NDk1YWE3MDM1L3RleHRyZWdpb246NTQ1Y2Y3ODA4NWZmNGViOWE4ZTgwMDQ0OTVhYTcwMzVfMTEyMw_468accac-cb3e-4d1d-bf7b-186de2b14564">Related Party Transactions&lt;div style="margin-top:12pt;padding-left:22.5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Executive Chairman Agreement with Duane Nash&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 15, 2020, the compensation committee of the Board of Directors of the Company independently reviewed and approved entering into an employment agreement with the current Chairman of the Board, Duane Nash, MD, JD, MBA (the &#x201c;Executive Chairman Agreement&#x201d;) and pursuant to such approval, on April 17, 2020, the Company and Dr. Nash entered into the Executive Chairman Agreement. The Executive Chairman Agreement establishes an &#x201c;at will&#x201d; employment relationship pursuant to which Dr. Nash serves as Executive Chairman and contemplated a term that ends on October 15, 2020, which was subsequently extended to April 15, 2021. On April 15, 2021, the Company and Dr. Nash entered into an addendum (the &#x201c;Addendum&#x201d;) to extend the term of the Executive Chairman Agreement to April 15, 2022.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the Addendum, the Company made a one-time award to Dr. Nash of an option to purchase 90,000 shares of Company common stock, which vests monthly commencing on May 15, 2021, and to increase Dr. Nash&#x2019;s monthly base salary to $27,960 from $25,417. Effective March 15, 2022, the Company extended the term of employment from April 15, 2022 to December 31, 2022 with a base salary of $29,358 per month (which includes the cash retainer payable for serving on the Company&#x2019;s Board or for acting as the Chairman of the Board). In connection with this extension, the Company made a one-time award to Dr. Nash of an option to purchase 75,000 shares of the Company&#x2019;s common stock, which vests monthly commencing on April 10, 2022.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All other terms of the Executive Chairman Agreement remain the same.&lt;/span&gt;&lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i7842ca3ec7d941b397d15eae864cf058_D20210415-20210415"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV81NS9mcmFnOjU0NWNmNzgwODVmZjRlYjlhOGU4MDA0NDk1YWE3MDM1L3RleHRyZWdpb246NTQ1Y2Y3ODA4NWZmNGViOWE4ZTgwMDQ0OTVhYTcwMzVfNTQ5NzU1ODIwMzY3_bc98f03b-cfb2-4334-994b-df45ef05b7b3"
      unitRef="shares">90000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <vtl:SalaryCostsMonthlyBaseSalary
      contextRef="i4e522a1cd2c5463883ece885e48da850_D20210515-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV81NS9mcmFnOjU0NWNmNzgwODVmZjRlYjlhOGU4MDA0NDk1YWE3MDM1L3RleHRyZWdpb246NTQ1Y2Y3ODA4NWZmNGViOWE4ZTgwMDQ0OTVhYTcwMzVfNTQ5NzU1ODIwNTAx_ded6205c-4d5b-481a-b22e-99fc284434d5"
      unitRef="usd">27960</vtl:SalaryCostsMonthlyBaseSalary>
    <vtl:SalaryCostsMonthlyBaseSalary
      contextRef="ic77ff01be43a48cfa612a7cac5ec9de0_D20210101-20210514"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV81NS9mcmFnOjU0NWNmNzgwODVmZjRlYjlhOGU4MDA0NDk1YWE3MDM1L3RleHRyZWdpb246NTQ1Y2Y3ODA4NWZmNGViOWE4ZTgwMDQ0OTVhYTcwMzVfNTQ5NzU1ODIwNTEw_cb416b89-83aa-4b20-a465-09e6a3be7118"
      unitRef="usd">25417</vtl:SalaryCostsMonthlyBaseSalary>
    <vtl:SalaryCostsMonthlyBaseSalary
      contextRef="i8af8b2227bd540f38b6dc794af632800_D20220315-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV81NS9mcmFnOjU0NWNmNzgwODVmZjRlYjlhOGU4MDA0NDk1YWE3MDM1L3RleHRyZWdpb246NTQ1Y2Y3ODA4NWZmNGViOWE4ZTgwMDQ0OTVhYTcwMzVfNTQ5NzU1ODIwNjQ4_d0ce1c2a-dabb-4622-b1e6-7d1c65ea444e"
      unitRef="usd">29358</vtl:SalaryCostsMonthlyBaseSalary>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="iac9f9142fce04841b7cdeea2bfcabdb6_D20220315-20220315"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV81NS9mcmFnOjU0NWNmNzgwODVmZjRlYjlhOGU4MDA0NDk1YWE3MDM1L3RleHRyZWdpb246NTQ1Y2Y3ODA4NWZmNGViOWE4ZTgwMDQ0OTVhYTcwMzVfNTQ5NzU1ODIwODkw_62e22705-2f4f-430b-bfc9-9b934ec42754"
      unitRef="shares">75000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV81OC9mcmFnOjUzOTAzZDJhY2NjYTQ2NjRiZDg3NDM4Y2UxNjNiMmY0L3RleHRyZWdpb246NTM5MDNkMmFjY2NhNDY2NGJkODc0MzhjZTE2M2IyZjRfNzE0NjgyNTU4MTAzNw_cf77d6af-8a8a-4e53-9de8-5b24fc1def03">Subsequent Events &lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$60 Million Private Placement Equity Financing&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October 10, 2022, Immunic entered into a Securities Purchase Agreement (the &#x201c;Purchase Agreement&#x201d;) for a private placement (the &#x201c;Private Placement&#x201d;) with select accredited investors and certain existing investors (each, a &#x201c;Purchaser&#x201d; and collectively, the &#x201c;Purchasers&#x201d;). Pursuant to the Purchase Agreement, the Company agreed to sell to the Purchasers (i) 8,696,552 shares of the Company&#x2019;s common stock, par value $0.0001 per share (the &#x201c;Shares&#x201d;), at a purchase price of $4.35 per Share, and (ii) 5,096,552 pre-funded warrants (the &#x201c;Pre-Funded Warrants&#x201d;) to purchase Common Stock (the &#x201c;Warrant Shares&#x201d; and together with the Shares and the Pre-Funded Warrants, the &#x201c;Securities&#x201d;), at a purchase price of $4.34 per Pre-Funded Warrant. The Pre-Funded Warrants will have an exercise price of $0.01 per share of Common Stock, be immediately exercisable and remain exercisable until exercised in full. The holders of Pre-Funded Warrants may not exercise a Pre-Funded Warrant if the holder, together with its affiliates, would beneficially own more than 9.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise. The holders of Pre-Funded Warrants may increase or decrease such percentages not in excess of 19.99% by providing at least 61 days&#x2019; prior notice to the Company.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Private Placement closed on October 12, 2022. The gross proceeds of the Private Placement were approximately $60.0&#160;million, before deducting offering expenses payable by the Company. The Company intends to use the net proceeds from the Private Placement to fund the ongoing clinical development of its three lead product candidates, vidofludimus calcium (IMU-838), IMU-935 and IMU-856, and for other general corporate purposes.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Purchase Agreement provides for the registration for resale of the Securities (including the Warrant Shares) pursuant to a registration statement (the &#x201c;Registration Statement&#x201d;) to be filed with the Securities and Exchange Commission (the &#x201c;SEC&#x201d;) on or prior to December 9, 2022. The Company has agreed to use its best efforts to cause the Registration Statement to be declared effective as soon as possible, but in no event later than 60 days after the closing of the Private Placement (or 90 days in the event of a review of the Registration Statement by, and comments from, the SEC), and to keep the Registration Statement continuously effective from the date on which the SEC declares the Registration Statement to be effective until such date that all Registrable Securities (as such term is defined in the Purchase Agreement) covered by the Registration Statement have been sold pursuant to a registration statement under the Securities Act of 1933, as amended (the &#x201c;Securities Act&#x201d;), or under Rule 144 as promulgated by the SEC under the Securities Act, or otherwise shall have ceased to be Registrable Securities.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Pre-Planned Phase 1b Interim Analysis of IMU-935 in Moderate-to-Severe Psoriasis&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On October 20, 2022, Immunic announced the outcome of a pre-planned interim group-level data analysis of its Phase 1b clinical trial of IMU-935 in patients with moderate-to-severe psoriasis. The overall trial is ongoing and remains blinded. The pre-planned interim analysis revealed that the group averages for Psoriasis Area and Severity Index ("PASI&#x201d;) reductions in the two active arms did not separate from placebo at four weeks. Although the active arms performed in line with prior expectations, based on similarly designed trials, the trial experienced a greater decrease than expected in PASI in the placebo arm. Although the safety data remains blinded, administration of IMU-935 and placebo in this trial were demonstrated to be safe and well-tolerated, and no new safety signals were observed. The Company expects to continue IMU-935&#x2019;s development in psoriasis and will further analyze the available data to determine next steps for the program.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Goodwill Impairment Analysis&lt;/span&gt;&lt;/div&gt;Following the announcement of our interim group level data of the Phase 1b clinical trial of IMU-935 in Psoriasis on October 20, 2022, our stock price experienced a significant decline from the prices preceding the announcement.  The Company considered this to be a triggering event indicating that it is more likely than not that goodwill is impaired.  As a result, the Company anticipates it will incur a full impairment of its goodwill of approximately $33.0&#160;million in the quarter ended December 31, 2022.</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="id3d63a41fa5847168bff487d8106b2f5_D20221010-20221010"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV81OC9mcmFnOjUzOTAzZDJhY2NjYTQ2NjRiZDg3NDM4Y2UxNjNiMmY0L3RleHRyZWdpb246NTM5MDNkMmFjY2NhNDY2NGJkODc0MzhjZTE2M2IyZjRfNDk0NzgwMjMzNDg2MQ_95a0f2ca-a26f-4b67-8208-97ac1b3c0263"
      unitRef="shares">8696552</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i04004da4d23642dd85e9052de2144a17_I20221010"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV81OC9mcmFnOjUzOTAzZDJhY2NjYTQ2NjRiZDg3NDM4Y2UxNjNiMmY0L3RleHRyZWdpb246NTM5MDNkMmFjY2NhNDY2NGJkODc0MzhjZTE2M2IyZjRfNDk0NzgwMjMzNDg3Mg_8ad55dac-3031-4629-a9fc-943eb1cc732f"
      unitRef="usdPerShare">0.0001</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SharePrice
      contextRef="i04004da4d23642dd85e9052de2144a17_I20221010"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV81OC9mcmFnOjUzOTAzZDJhY2NjYTQ2NjRiZDg3NDM4Y2UxNjNiMmY0L3RleHRyZWdpb246NTM5MDNkMmFjY2NhNDY2NGJkODc0MzhjZTE2M2IyZjRfNDk0NzgwMjMzNDg4MQ_4b6ac2cf-e7f4-4e39-8da6-6fd5b61501b1"
      unitRef="usdPerShare">4.35</us-gaap:SharePrice>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="icc5700f8c4a44461ab5894f373a0d8ac_D20221010-20221010"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV81OC9mcmFnOjUzOTAzZDJhY2NjYTQ2NjRiZDg3NDM4Y2UxNjNiMmY0L3RleHRyZWdpb246NTM5MDNkMmFjY2NhNDY2NGJkODc0MzhjZTE2M2IyZjRfNDk0NzgwMjMzNDg4OA_97eedfc9-4434-4ff2-909e-7f6e0ed7ca92"
      unitRef="shares">5096552</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SharePrice
      contextRef="i1910349757c84c67942eeea2127e5dc4_I20221010"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV81OC9mcmFnOjUzOTAzZDJhY2NjYTQ2NjRiZDg3NDM4Y2UxNjNiMmY0L3RleHRyZWdpb246NTM5MDNkMmFjY2NhNDY2NGJkODc0MzhjZTE2M2IyZjRfNDk0NzgwMjMzNDg5OQ_fba57657-3fce-4354-b33d-8a1358df85a0"
      unitRef="usdPerShare">4.34</us-gaap:SharePrice>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i1910349757c84c67942eeea2127e5dc4_I20221010"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV81OC9mcmFnOjUzOTAzZDJhY2NjYTQ2NjRiZDg3NDM4Y2UxNjNiMmY0L3RleHRyZWdpb246NTM5MDNkMmFjY2NhNDY2NGJkODc0MzhjZTE2M2IyZjRfNDk0NzgwMjMzNDkwNg_b0a4d3f5-60da-47aa-bc60-f2a7cab36d95"
      unitRef="usdPerShare">0.01</us-gaap:SaleOfStockPricePerShare>
    <vtl:EquityMethodInvestmentWarrantsExercisableOwnershipLimitationPercentage
      contextRef="i04004da4d23642dd85e9052de2144a17_I20221010"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV81OC9mcmFnOjUzOTAzZDJhY2NjYTQ2NjRiZDg3NDM4Y2UxNjNiMmY0L3RleHRyZWdpb246NTM5MDNkMmFjY2NhNDY2NGJkODc0MzhjZTE2M2IyZjRfNDk0NzgwMjM0MDk5MA_3ed642b3-f7b6-418a-9446-d5433e96f720"
      unitRef="number">0.0999</vtl:EquityMethodInvestmentWarrantsExercisableOwnershipLimitationPercentage>
    <vtl:EquityMethodInvestmentWarrantsExercisableOwnershipLimitationMaximumIncreaseDecreasePercent
      contextRef="i1910349757c84c67942eeea2127e5dc4_I20221010"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV81OC9mcmFnOjUzOTAzZDJhY2NjYTQ2NjRiZDg3NDM4Y2UxNjNiMmY0L3RleHRyZWdpb246NTM5MDNkMmFjY2NhNDY2NGJkODc0MzhjZTE2M2IyZjRfNDk0NzgwMjM0MDk5Nw_81881bad-6e16-4c6f-ab70-e8125cd5421f"
      unitRef="number">0.1999</vtl:EquityMethodInvestmentWarrantsExercisableOwnershipLimitationMaximumIncreaseDecreasePercent>
    <vtl:EquityMethodInvestmentWarrantsExercisableSharesChangeLimitationNoticePeriod
      contextRef="i1910349757c84c67942eeea2127e5dc4_I20221010"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV81OC9mcmFnOjUzOTAzZDJhY2NjYTQ2NjRiZDg3NDM4Y2UxNjNiMmY0L3RleHRyZWdpb246NTM5MDNkMmFjY2NhNDY2NGJkODc0MzhjZTE2M2IyZjRfNDk0NzgwMjM0MTAwNA_24b8d435-babf-4cf9-ac8d-897129a7500c">P61D</vtl:EquityMethodInvestmentWarrantsExercisableSharesChangeLimitationNoticePeriod>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="i4346a7f60eba4d42bfc2b801e8e1dc2b_D20221012-20221012"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV81OC9mcmFnOjUzOTAzZDJhY2NjYTQ2NjRiZDg3NDM4Y2UxNjNiMmY0L3RleHRyZWdpb246NTM5MDNkMmFjY2NhNDY2NGJkODc0MzhjZTE2M2IyZjRfNDk0NzgwMjMzNDkxMw_96e40ec1-be0c-4cf6-9b18-9376e614b384"
      unitRef="usd">60000000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="ic5a53880f9da458c8abd6926ff69ddd8_D20221001-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRhN2MzMzNlM2M1ODQzMGViODNlOGU5NTBjNTBkODExL3NlYzpkYTdjMzMzZTNjNTg0MzBlYjgzZThlOTUwYzUwZDgxMV81OC9mcmFnOjUzOTAzZDJhY2NjYTQ2NjRiZDg3NDM4Y2UxNjNiMmY0L3RleHRyZWdpb246NTM5MDNkMmFjY2NhNDY2NGJkODc0MzhjZTE2M2IyZjRfNDk0NzgwMjM0MjY0MQ_049fbe5c-4583-45a9-b8ab-5a5f0702bb47"
      unitRef="usd">33000000</us-gaap:GoodwillImpairmentLoss>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>62
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M"_STU'E7FM!,-V^-#743Z3&?#XMMJT@_)BW?DQ/-*AP&D5D"@MTV(HW_@\"
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MO%R4S13O?R!- ,[/A= O'7/#:&Z4T5]02P,$%     @ E%9C57A>I$ &!0
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MT9#1!$Z=) A&@N59@B5,)A(>4 Y2(#:#5P448:JJ8T70%R8$ND1/DQ$Z/[M
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M0KSJZ:J)9(NR:9DR"2U0.4RA#29< >#]C#&YF:@-FL8Z^@-02P,$%     @
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MENO=!M6_WZY6V^=OKBK_\VK]Z[[&]?\!4$L#!!0    ( )168U6PEZOS.0(
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MZ8#U";2_, :WCC^@_XWE_P!02P,$%     @ E%9C5?R!+D6]!@  (Q\  !@
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M.&Y,F5P7I[ *%9_DRO.Z^FE]TGM3G&^VGM_BRWEY7MNX*8^//U()PDX!>ZS
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M2M25RN$\VW51DIP$7^TS,#QR$5&!3!FH)F9]$/G<M.2U9.+#T%*.P\[-M.W
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MDO>:R:^)L6*)\84I]JXF@<PK':;QCKA&+3:R=F2-*)L66&=%NS7-C=<@TL0
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M&_JAJB$]T4 S#J=NY4EJ= )"%0WT=8K-@7<G!.<>DPFUJ+2$Q()'H72Z5E6
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MH\+=E1<88H!!GQ<4Y04!5*\5,]I".R\<SZ/QO&4!ME^S54F)A_Q8E9I-J?\
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M7&BC?]!&"$6%0P$XP0:4 ALPK?(\1RS(W)<J'213V*8!1)3(*$4"8/[$KM"
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M9'D!GF?&^/8'']!]O[S]&U!+ P04    " "45F-5 ST_LG<=  "R70  &0
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M3@)6]JII>FM*_@8>[;<.!IB[O87>?;_RIC*J-=AI^/3R97%OOS7E%N:_4;8
M1=D2'3PNX>)\^9B'#-^_!]JI%CY_V:S^_;FFU'*O?-'H=D-$Z5P^,GQVC4MO
M5KIE&1@.=MDCY]9&%>^ B*^[:O&9$9_<7Q27=8T#Z5:V,%$(NX;^K%<E-TK[
MIFL#:HEVF'<N,<0B3J=1%E2\)])F0\/Z5.%AUVH-&G[GVDZMX*?7&^2. GB
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M >F(9MVH Q*Y][P!0I*LU^^*U]BP6)(IN7CZW[U#Q4([27J4 V="9[:6(!)
M #1Y8JV1JY.Q7H0NPVL2(T\F:(V"H ]AVT#A5\D"LY+QQ8Y!GJX6 VG<J@I
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M><?CQ:.YH02T:$;Q"TI4;5T>P0FF0!@^;B&'SI 9,W,P$PX%=FPY=B'#8)F
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M8Z&R#O3_(*49/VR"Z=:V_AM02P,$%     @ E%9C5>>V=NF3 @  K@4  !D
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M94'C'[4#T/E:*;LS7(#^#R7]"U!+ P04    " "45F-5=SI;%T,%   M#0
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M)CJ5![JT7M%VQ^C!H&N,=D']>J T'Y06@-)"*%I;5<WJN6U>/G^@&4T/S,]
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M@F.2JP+R_R5CXO5 .:BW*<U^ %!+ P04    " "45F-5(U$O:]@"  !D!P
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MG5!6NNGIS<2JRK?%6V6IR?IA0<\@:A= ^[FB#M=.W '=PSK]#5!+ P04
M" "45F-5:0<Y:0,#  #U!P  &0   'AL+W=O<FMS:&5E=',O<VAE970S,"YX
M;6RME5UOVC 4AO^*E553)W7-%R&T@TB4KMHNIJ+2=A?3+DQR(%:=.+/-Q_;K
M=^R$B$**=K$;L)WS'C_GY7 RW CYHG( 3;8%+]7(R;6NKEU7I3D45%V*"DI\
MLA"RH!JW<NFJ2@+-K*C@;N!Y?;>@K'22H3V;RF0H5IJS$J:2J%514/G[!KC8
MC!S?V1T\L&6NS8&;#"NZA!GHIVHJ<>>V63)60*F8*(F$Q<@9^]>3V,3;@&<&
M&[6W)J:2N1 O9O,U&SF> 0(.J389*'ZM80*<FT2(\:O)Z;17&N'^>I?]SM:.
MM<RI@HG@WUFF\Y$S<$@&"[KB^D%LOD!33V3RI8(K^TDV3:SGD'2EM"@:,1(4
MK*R_Z;;Q84_@]]X0!(T@^%=!V A"6VA-9LNZI9HF0RDV1)IHS&86UANKQFI8
M:7[%F9;XE*%.)S>4TS(%,K,M<PN:,J[(1S+#=LE6'(A8D'N=@R23E910:C)6
M"K0BM,S(5$)%648^;[&I%"AR7B?X@ F>9K?D_.P#.2.L)(^Y6"E4J*&K$=I<
M[:8-X$T-&+P!.(/JDH3>!0F\(.B03T[+;R%%N6_E_FNYBU:U?@6M7X'-%[Z1
M[UXN:<G^4-.#%V0B2B4XRVC=DK4E"EVJ#]"[.U:BOXQR,L-#P/Y'[WZ,YTI+
M[."?77[4 +UN /.OOE8536'D5.8NN08G>?_.[WN?NMSY3\E>>16V7H6GLB>[
M]DCQ 4O1 F.0!(X^X*%0NK,=ZIQ]F]/,H'4RN H'0W>]7]9QD-\;1&$;]8JW
MU_+V3O(^CQ\1+P6VIG,.76RU/MJ[-NCY!V@=,?%5-UC4@D4GP<8KTRZ<43,X
M%5"9YM;+#-8XABO35$33+?[34ESB6.QBCXZX0C_R#N"/@_Q!['?3]UOZ_DEZ
M.SZZB/K'ET6]JP.BCB#?#((NHK@EBD\2/0I->1=1?-Q6X2 ^;+Z.J($?1 =,
M[MY0-B_$;U0N6:D(AP7JO,L8:Y+U2Z;>:%'9.3T7&J>^7>;X7@9I O#Y0@B]
MVYC1W[[ID[]02P,$%     @ E%9C5;8*]&ZT @  "P<  !D   !X;"]W;W)K
M<VAE971S+W-H965T,S$N>&ULK97?3]LP$,?_%2M#$Y,8^=D4L302M$*;M(F*
MPO8P[<%-KHV%8V>VT\+^^IV3$!6:5GO82V.?[WO^W-D])UNI'G4!8,A3R86>
M.(4QU:7KZJR DNIS68' E954)34X56M75PIHWHA*[@:>%[LE9<))D\8V5VDB
M:\.9@+DBNBY+JIZO@<OMQ/&=%\,=6Q?&&MPTJ>@:%F >JKG"F=M'R5D)0C,I
MB(+5Q+GR+Z>Q]6\<OC/8ZITQL9DLI7RTDR_YQ/$L$'#(C(U \;.!*7!N R'&
M[RZFTV]IA;OCE^@W3>Z8RY)JF$K^@^6FF#@7#LEA16MN[N3V,W3YC&R\3'+=
M_))MY^LY)*NUD64G1H*2B?9+G[HZ[ C\Z( @Z 3!OPK"3A VB;9D35HS:FB:
M*+DERGIC-#MH:M.H,1LF["DNC,)5ACJ37E-.109DT5R9&1C*N"8?R0*O2UYS
M(')%KK),UL)H,J?/=(FVT];O _H]+&;D].0#.2%,D/M"UIJ*7">N03:[@YMU
M'-<M1W" 8P'5.0F],Q)X03 @GQZ7SR!#N=_(_==R%RO2ER7HRQ(T\<(#\6[5
MF@KVA]JK=D:F4FC)64[;FR=R,E>@09C6@"6Z80++R"@G"S0"7G,LU\^KI38*
M+^JOH7JT -$P@/WS7NJ*9C!Q*KN7VH"3OG_GQ]ZGH>K\IV"O:A7VM0J/14^G
M:& 9IIY);0:/OM7'C=ZVE4T:CJ.+Q-WLIC#@% 7CWND56M2C14?1OL(:N>R!
MT3IGYC!A&V:TL[GO1V\ ]WW&P3#>J,<;'<6[-06H(9S1WE:A[[W!V?<)HGB8
M)^YYXJ,\]])0/L03[YU-Y.\DWP+M.^$IC]X0N3NMRCX3WZA:,Z$)AQ7*O/,Q
M)J3:UMM.C*R:[K64!GMA,RSPM0)E'7!]):5YF=B&V+]_Z5]02P,$%     @
ME%9C56J5OSG4 @  S <  !D   !X;"]W;W)K<VAE971S+W-H965T,S(N>&UL
MK95=;]HP%(;_BI554RMUS0<D81U$:F'5=C$-E7:[F'9AD@.QZMB9[4"W7S_;
M"1DEH>)B-R2VSWO\G)<3>[SEXDGF  H]%Y3)B9,K55Z[KDQS*+"\XB4PO;+B
MHL!*#\7:E:4 G%E10=W \R*WP(0YR=C.S44RYI6BA,%<(%D5!1:_;X'R[<3Q
MG=W$/5GGRDRXR;C$:UB >BSG0H_<-DM&"F"2<(8$K";.C7\]C4V\#?A&8"OW
MWI&I9,GYDQE\SB:.9X" 0JI,!JP?&Y@"I2:1QOC5Y'3:+8UP_WV7_<[6KFM9
M8@E33K^33.439^2@#%:XHNJ>;S]!4T]H\J6<2ON+MDVLYZ"TDHH7C5@3%(35
M3_S<^+ G\(='!$$C"$X5#!K!P!9:D]FR9ECA9"SX%@D3K;.9%^N-5>MJ"#/_
MXD()O4JT3B6WF&*6 EK8EIF!PH1*] XM=+MD%07$5^@F344%&?KXK'M'@D3G
M==R%CGM<S-#YV04Z0X2AAYQ7$K-,CEVEV<P.;MIPW-8<P1&.!917:.!=HL +
M@A[Y]'7Y#%(M]ZW<?REWM2.M+4%K2V#S#8[D^RK6F)$_V+3:)9IR)CDE&:X[
MCV5H+D "4_6$MNB.,&TCP10M]"3H-E<2_;A92B5TH_[L\Z,&&/8#F(_W6I8X
MA8E3FKW$!ISD[1L_\C[TN?.?DKWP:M!Z-7@M>[)KCU0OD%1;8 P20+4/>I)+
MU=L.=<[(YC1'S28)0V\X=C?[976#HL#_%_0"=]CB#D_"I;!N6'&5$76<M$X7
M[D&,P@/.;LC[J)\R;"G#TTSEA?GH;*/UP85=N)%_0->-B>(C)D8M7G02'E<Y
MB#ZNJ+.G'PX.N+HQH[@?*VZQXE>Q'KC"M \G[C92%!SR=(-B+_8/B-R]L];<
M<U^P6!,F=3NMM,R[BG4]HKX[ZH'BI3U^EUSIP]R^YOJZ!6$"]/J*<[4;F!.]
MO<"3OU!+ P04    " "45F-5QG7\L)4"  !T!@  &0   'AL+W=O<FMS:&5E
M=',O<VAE970S,RYX;6RM55U/VS 4_2M7&9I 8N2C#0661H)6:).8J"AL#],>
MW.2VL7#LS'9:ME\_VPE9H:':PUX:7_N>XW-/;VZ2C9"/JD#4\%0RKL9>H75U
MX?LJ*[ DZD14R,W)4LB2:!/*E:\JB21WH)+Y41"<^B6AW$L3MS>3:2)JS2C'
MF015ER61OZZ0B<W8"[WGC3NZ*K3=\-.D(BN<HWZH9M)$?L>2TQ*YHH*#Q.78
MNPPO)K'-=PE?*6[4UAIL)0LA'FWP.1][@16$##-M&8AYK'&"C%DB(^-GR^EU
M5UK@]OJ9_=K5;FI9$(43P;[17!=C[\R#')>D9OI.;#YA6X\3F FFW"]LVMS
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M:-#93&^W&X*MRC7HGI@0+"T_+FDTHWE10'X_9TQL-XH NU4H)W\#4$L#!!0
M   ( )168U5++[2[H (  %8'   9    >&PO=V]R:W-H965T<R]S:&5E=#,U
M+GAM;)V576_:,!2&_XJ555,K;4UB2 )=B-2"IE5:553:[F+:A0D'8M6Q,]M
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M&6>,3+@@INQP)(01JOVD0#-^,#Y3*0I0>B?@8="W3QH33A5F\GN=1$>@4T_
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M=.AJ6#Y?O\K=OOG\4>O/R/4/JI-A=0S9.1JY!^7IQ^7>P%2.N@=@I'FC8Q\
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M9%FQN (: ]<'J/T+QN3;BDY0?R4R_P]02P,$%     @ E%9C55E@\0 \ P
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M#NRH:)O&4--T,JX#^IMJ3GM3-GZ5;E"Q9ZD_S<UTA.U#K=![17.VL/U%WAK
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M8$])'*>I'P',[R".,02>1AS!'( '#(EC^Q[<>1]%J_=4M/X/W^@W4$L#!!0
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MM7]A]P[;&Z&:M67AXU1JYY>A.M8-2GW ML_Z3R/:\[OQ\WO]=_\ 4$L#!!0
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MD56AR*I09%4HLBH46=5_ROINS/*O_\"U][3697/(9]UOSNDG4$L! A0#%
M  @ E%9C50=!36*!    L0   !               ( !     &1O8U!R;W!S
M+V%P<"YX;6Q02P$"% ,4    " "45F-5-&W&8N\    K @  $0
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M=#(N>&UL4$L! A0#%     @ E%9C5?IMG03^ @  70H  !@
M ("!%Q0  'AL+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    ( )16
M8U5X7J1 !@4  'X5   8              " @4L7  !X;"]W;W)K<VAE971S
M+W-H965T-"YX;6Q02P$"% ,4    " "45F-551O8GS<#  !D"P  &
M        @(&''   >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%
M  @ E%9C5724E(,T$@  &AX! !@              ("!]!\  'AL+W=O<FMS
M:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0    ( )168U6PEZOS.0(  -($   8
M              " @5XR  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"
M% ,4    " "45F-5_($N1;T&   C'P  &               @('--   >&PO
M=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%     @ E%9C5=M!."Y! @
MQ00  !@              ("!P#L  'AL+W=O<FMS:&5E=',O<VAE970Y+GAM
M;%!+ 0(4 Q0    ( )168U7CFPQ&F0@  #X4   9              " @3<^
M  !X;"]W;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#%     @ E%9C5=M=
MWBN?'   RE4  !D              ("!!T<  'AL+W=O<FMS:&5E=',O<VAE
M970Q,2YX;6Q02P$"% ,4    " "45F-5,NYB8'H#  "J"   &0
M    @('=8P  >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    (
M )168U5[Z**4.0H   09   9              " @8YG  !X;"]W;W)K<VAE
M971S+W-H965T,3,N>&UL4$L! A0#%     @ E%9C58/_5U)Z P  ?0@  !D
M             ("!_G$  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"
M% ,4    " "45F-51_P31]<(  !_&@  &0              @(&O=0  >&PO
M=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    ( )168U7DS."CR0P
M -XB   9              " @;U^  !X;"]W;W)K<VAE971S+W-H965T,38N
M>&UL4$L! A0#%     @ E%9C55A'2$@,!0  [ L  !D              ("!
MO8L  'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"% ,4    " "45F-5
MOJE0<&H$  !>"P  &0              @($ D0  >&PO=V]R:W-H965T<R]S
M:&5E=#$X+GAM;%!+ 0(4 Q0    ( )168U5*E5>R; @  ,L4   9
M      " @:&5  !X;"]W;W)K<VAE971S+W-H965T,3DN>&UL4$L! A0#%
M  @ E%9C50,]/[)W'0  LET  !D              ("!1)X  'AL+W=O<FMS
M:&5E=',O<VAE970R,"YX;6Q02P$"% ,4    " "45F-5)?%WJL\"   H!@
M&0              @('RNP  >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+
M 0(4 Q0    ( )168U6K06%OI@,  ,$)   9              " @?B^  !X
M;"]W;W)K<VAE971S+W-H965T,C(N>&UL4$L! A0#%     @ E%9C5>>V=NF3
M @  K@4  !D              ("!U<(  'AL+W=O<FMS:&5E=',O<VAE970R
M,RYX;6Q02P$"% ,4    " "45F-5OM*(2?0"  !H!P  &0
M@(&?Q0  >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    ( )16
M8U519"Z#S0(  %P&   9              " @<K(  !X;"]W;W)K<VAE971S
M+W-H965T,C4N>&UL4$L! A0#%     @ E%9C57<Z6Q=#!0  +0T  !D
M         ("!SLL  'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q02P$"% ,4
M    " "45F-5C8THF14$  ##$P  &0              @(%(T0  >&PO=V]R
M:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    ( )168U4:0"4! @8  +(T
M   9              " @935  !X;"]W;W)K<VAE971S+W-H965T,C@N>&UL
M4$L! A0#%     @ E%9C52-1+VO8 @  9 <  !D              ("!S=L
M 'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q02P$"% ,4    " "45F-5:0<Y
M:0,#  #U!P  &0              @('<W@  >&PO=V]R:W-H965T<R]S:&5E
M=#,P+GAM;%!+ 0(4 Q0    ( )168U6V"O1NM (   L'   9
M  " @1;B  !X;"]W;W)K<VAE971S+W-H965T,S$N>&UL4$L! A0#%     @
ME%9C56J5OSG4 @  S <  !D              ("! >4  'AL+W=O<FMS:&5E
M=',O<VAE970S,BYX;6Q02P$"% ,4    " "45F-5QG7\L)4"  !T!@  &0
M            @($,Z   >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4
M Q0    ( )168U7XCZT\V0<  )%2   9              " @=CJ  !X;"]W
M;W)K<VAE971S+W-H965T,S0N>&UL4$L! A0#%     @ E%9C54LOM+N@ @
M5@<  !D              ("!Z/(  'AL+W=O<FMS:&5E=',O<VAE970S-2YX
M;6Q02P$"% ,4    " "45F-525;.U-\#  #P%@  &0              @(&_
M]0  >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4 Q0    ( )168U77
ME]TFH@<  )]0   9              " @=7Y  !X;"]W;W)K<VAE971S+W-H
M965T,S<N>&UL4$L! A0#%     @ E%9C5<(D!U-K P  :A   !D
M     ("!K@$! 'AL+W=O<FMS:&5E=',O<VAE970S."YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( )168U5D]V-F.@4  *T7   9              "
M@58: 0!X;"]W;W)K<VAE971S+W-H965T-#,N>&UL4$L! A0#%     @ E%9C
M548@"#:0 P  PPL  !D              ("!QQ\! 'AL+W=O<FMS:&5E=',O
M<VAE970T-"YX;6Q02P$"% ,4    " "45F-5\I0ZUP8$   3%@  &0
M        @(&.(P$ >&PO=V]R:W-H965T<R]S:&5E=#0U+GAM;%!+ 0(4 Q0
M   ( )168U5Q7&A,_P(  '$*   9              " @<LG 0!X;"]W;W)K
M<VAE971S+W-H965T-#8N>&UL4$L! A0#%     @ E%9C54-C:Q6% P  G1
M !D              ("! 2L! 'AL+W=O<FMS:&5E=',O<VAE970T-RYX;6Q0
M2P$"% ,4    " "45F-5^<R)-!L%   Q(@  &0              @(&]+@$
M>&PO=V]R:W-H965T<R]S:&5E=#0X+GAM;%!+ 0(4 Q0    ( )168U598/$
M/ ,  .X3   -              "  0\T 0!X;"]S='EL97,N>&UL4$L! A0#
M%     @ E%9C59>*NQS     $P(   L              ( !=C<! %]R96QS
M+RYR96QS4$L! A0#%     @ E%9C59#DYD(#!   6R    \
M ( !7S@! 'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( )168U62+*"6N $
M .<<   :              "  8\\ 0!X;"]?<F5L<R]W;W)K8F]O:RYX;6PN
M<F5L<U!+ 0(4 Q0    ( )168U6,3^J/N@$  .X<   3              "
M 7\^ 0!;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     X #@ /P\  &I  0
!  $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.2.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>191</ContextCount>
  <ElementCount>232</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>45</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>9</UnitCount>
  <MyReports>
    <Report instance="vtl-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="vtl-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="vtl-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="vtl-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - Condensed Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/CondensedConsolidatedStatementsofOperations</Role>
      <ShortName>Condensed Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="vtl-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - Condensed Consolidated Statements of Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/CondensedConsolidatedStatementsofComprehensiveLoss</Role>
      <ShortName>Condensed Consolidated Statements of Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="vtl-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - Condensed Consolidated Statements of Stockholders??? Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity</Role>
      <ShortName>Condensed Consolidated Statements of Stockholders??? Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="vtl-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Statement - Condensed Consolidated Statements of Stockholders??? Equity (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical</Role>
      <ShortName>Condensed Consolidated Statements of Stockholders??? Equity (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="vtl-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Statement - Condensed Consolidated Statement of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows</Role>
      <ShortName>Condensed Consolidated Statement of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="vtl-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Statement - Condensed Consolidated Statements of Cash Flows (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/CondensedConsolidatedStatementsofCashFlowsParenthetical</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="vtl-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - Description of Business and Basis of Financial Statements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/DescriptionofBusinessandBasisofFinancialStatements</Role>
      <ShortName>Description of Business and Basis of Financial Statements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="vtl-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="vtl-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - Balance Sheet Details</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/BalanceSheetDetails</Role>
      <ShortName>Balance Sheet Details</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="vtl-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="vtl-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - Fair Value</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/FairValue</Role>
      <ShortName>Fair Value</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="vtl-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - Common Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/CommonStock</Role>
      <ShortName>Common Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="vtl-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - Stock-Based Compensation Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/StockBasedCompensationPlans</Role>
      <ShortName>Stock-Based Compensation Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="vtl-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - Changes in Board of Directors</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/ChangesinBoardofDirectors</Role>
      <ShortName>Changes in Board of Directors</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="vtl-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="vtl-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0000019 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="vtl-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0000020 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://vitaltherapies.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="vtl-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0000021 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://vitaltherapies.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="vtl-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0000022 - Disclosure - Balance Sheet Details (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/BalanceSheetDetailsTables</Role>
      <ShortName>Balance Sheet Details (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://vitaltherapies.com/role/BalanceSheetDetails</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="vtl-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>0000023 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/CommitmentsandContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://vitaltherapies.com/role/CommitmentsandContingencies</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="vtl-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>0000024 - Disclosure - Fair Value (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/FairValueTables</Role>
      <ShortName>Fair Value (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://vitaltherapies.com/role/FairValue</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="vtl-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>0000025 - Disclosure - Common Stock (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/CommonStockTables</Role>
      <ShortName>Common Stock (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://vitaltherapies.com/role/CommonStock</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="vtl-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>0000026 - Disclosure - Stock-Based Compensation Plans (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/StockBasedCompensationPlansTables</Role>
      <ShortName>Stock-Based Compensation Plans (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://vitaltherapies.com/role/StockBasedCompensationPlans</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="vtl-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>0000027 - Disclosure - Description of Business and Basis of Financial Statements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/DescriptionofBusinessandBasisofFinancialStatementsDetails</Role>
      <ShortName>Description of Business and Basis of Financial Statements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://vitaltherapies.com/role/DescriptionofBusinessandBasisofFinancialStatements</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="vtl-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>0000028 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="vtl-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>0000029 - Disclosure - Summary of Significant Accounting Policies - Schedule of Potentially Dilutive Securities Not Included in Calculation of Diluted Net Loss per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofDilutedNetLossperShareDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Potentially Dilutive Securities Not Included in Calculation of Diluted Net Loss per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="vtl-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>0000030 - Disclosure - Balance Sheet Details - Schedule of Other Current Assets and Prepaid Expenses (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofOtherCurrentAssetsandPrepaidExpensesDetail</Role>
      <ShortName>Balance Sheet Details - Schedule of Other Current Assets and Prepaid Expenses (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="vtl-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>0000031 - Disclosure - Balance Sheet Details - Schedule of Accounts Payable (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofAccountsPayableDetail</Role>
      <ShortName>Balance Sheet Details - Schedule of Accounts Payable (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="vtl-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>0000032 - Disclosure - Balance Sheet Details - Schedule of Accrued Expenses (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofAccruedExpensesDetail</Role>
      <ShortName>Balance Sheet Details - Schedule of Accrued Expenses (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="vtl-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>0000033 - Disclosure - Balance Sheet Details - Schedule of Other Current Liabilities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofOtherCurrentLiabilitiesDetail</Role>
      <ShortName>Balance Sheet Details - Schedule of Other Current Liabilities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="vtl-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>0000034 - Disclosure - Commitments and Contingencies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetails</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="vtl-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>0000035 - Disclosure - Commitments and Contingencies - Maturities of Operating Lease Obligation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseObligationDetails</Role>
      <ShortName>Commitments and Contingencies - Maturities of Operating Lease Obligation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="vtl-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>0000036 - Disclosure - Fair Value - Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails</Role>
      <ShortName>Fair Value - Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="vtl-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>0000037 - Disclosure - Common Stock - Shelf Registration Statement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/CommonStockShelfRegistrationStatementDetails</Role>
      <ShortName>Common Stock - Shelf Registration Statement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="vtl-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>0000038 - Disclosure - Common Stock - Public Equity Offering (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/CommonStockPublicEquityOfferingDetails</Role>
      <ShortName>Common Stock - Public Equity Offering (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="vtl-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>0000039 - Disclosure - Common Stock - Common Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/CommonStockCommonStockDetails</Role>
      <ShortName>Common Stock - Common Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="vtl-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>0000040 - Disclosure - Common Stock - Preferred Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/CommonStockPreferredStockDetails</Role>
      <ShortName>Common Stock - Preferred Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="vtl-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>0000041 - Disclosure - Common Stock - Shares Reserved for Future Issuance (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/CommonStockSharesReservedforFutureIssuanceDetails</Role>
      <ShortName>Common Stock - Shares Reserved for Future Issuance (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="vtl-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>0000042 - Disclosure - Stock-Based Compensation Plans - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails</Role>
      <ShortName>Stock-Based Compensation Plans - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="vtl-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>0000043 - Disclosure - Stock-Based Compensation Plans - Summary of Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/StockBasedCompensationPlansSummaryofStockOptionActivityDetails</Role>
      <ShortName>Stock-Based Compensation Plans - Summary of Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="vtl-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>0000044 - Disclosure - Stock-Based Compensation Plans - Ranges of Underlying Assumptions Used in BSM Option Pricing Model to Determine Fair Value of Stock Options Granted to Employees and Nonemployees (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/StockBasedCompensationPlansRangesofUnderlyingAssumptionsUsedinBSMOptionPricingModeltoDetermineFairValueofStockOptionsGrantedtoEmployeesandNonemployeesDetail</Role>
      <ShortName>Stock-Based Compensation Plans - Ranges of Underlying Assumptions Used in BSM Option Pricing Model to Determine Fair Value of Stock Options Granted to Employees and Nonemployees (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="vtl-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>0000045 - Disclosure - Stock-Based Compensation Plans - Schedule of Stock-based Compensation Expense for Stock Awards Recognized (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/StockBasedCompensationPlansScheduleofStockbasedCompensationExpenseforStockAwardsRecognizedDetails</Role>
      <ShortName>Stock-Based Compensation Plans - Schedule of Stock-based Compensation Expense for Stock Awards Recognized (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="vtl-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>0000046 - Disclosure - Changes in Board of Directors (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/ChangesinBoardofDirectorsDetails</Role>
      <ShortName>Changes in Board of Directors (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://vitaltherapies.com/role/ChangesinBoardofDirectors</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="vtl-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>0000047 - Disclosure - Related Party Transactions - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/RelatedPartyTransactionsAdditionalInformationDetails</Role>
      <ShortName>Related Party Transactions - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="vtl-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>0000048 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/SubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://vitaltherapies.com/role/SubsequentEvents</ParentRole>
      <Position>48</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 2 fact(s) appearing in ix:hidden were eligible for transformation: us-gaap:PropertyPlantAndEquipmentUsefulLife, us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 -  vtl-20220930.htm 4</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-Q" original="vtl-20220930.htm">vtl-20220930.htm</File>
    <File>exhibit42111111.htm</File>
    <File>imux-093022xexhibit311.htm</File>
    <File>imux-093022xexhibit312.htm</File>
    <File>imux-093022xexhibit321.htm</File>
    <File>imux-093022xexhibit322.htm</File>
    <File>vtl-20220930.xsd</File>
    <File>vtl-20220930_cal.xml</File>
    <File>vtl-20220930_def.xml</File>
    <File>vtl-20220930_lab.xml</File>
    <File>vtl-20220930_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>vtl-20220930_g1.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="503">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="31">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>68
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "vtl-20220930.htm": {
   "axisCustom": 0,
   "axisStandard": 18,
   "contextCount": 191,
   "dts": {
    "calculationLink": {
     "local": [
      "vtl-20220930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "vtl-20220930_def.xml"
     ]
    },
    "inline": {
     "local": [
      "vtl-20220930.htm"
     ]
    },
    "labelLink": {
     "local": [
      "vtl-20220930_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "vtl-20220930_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "vtl-20220930.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 368,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 2,
    "http://xbrl.sec.gov/dei/2022": 5,
    "total": 7
   },
   "keyCustom": 31,
   "keyStandard": 201,
   "memberCustom": 24,
   "memberStandard": 20,
   "nsprefix": "vtl",
   "nsuri": "http://vitaltherapies.com/20220930",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtl-20220930.htm",
      "contextRef": "i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Cover Page",
     "role": "http://vitaltherapies.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtl-20220930.htm",
      "contextRef": "i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtl-20220930.htm",
      "contextRef": "i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000010 - Disclosure - Description of Business and Basis of Financial Statements",
     "role": "http://vitaltherapies.com/role/DescriptionofBusinessandBasisofFinancialStatements",
     "shortName": "Description of Business and Basis of Financial Statements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtl-20220930.htm",
      "contextRef": "i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtl-20220930.htm",
      "contextRef": "i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000011 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://vitaltherapies.com/role/SummaryofSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtl-20220930.htm",
      "contextRef": "i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtl-20220930.htm",
      "contextRef": "i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000012 - Disclosure - Balance Sheet Details",
     "role": "http://vitaltherapies.com/role/BalanceSheetDetails",
     "shortName": "Balance Sheet Details",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtl-20220930.htm",
      "contextRef": "i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtl-20220930.htm",
      "contextRef": "i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000013 - Disclosure - Commitments and Contingencies",
     "role": "http://vitaltherapies.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtl-20220930.htm",
      "contextRef": "i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtl-20220930.htm",
      "contextRef": "i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000014 - Disclosure - Fair Value",
     "role": "http://vitaltherapies.com/role/FairValue",
     "shortName": "Fair Value",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtl-20220930.htm",
      "contextRef": "i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtl-20220930.htm",
      "contextRef": "i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000015 - Disclosure - Common Stock",
     "role": "http://vitaltherapies.com/role/CommonStock",
     "shortName": "Common Stock",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtl-20220930.htm",
      "contextRef": "i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtl-20220930.htm",
      "contextRef": "i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000016 - Disclosure - Stock-Based Compensation Plans",
     "role": "http://vitaltherapies.com/role/StockBasedCompensationPlans",
     "shortName": "Stock-Based Compensation Plans",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtl-20220930.htm",
      "contextRef": "i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtl-20220930.htm",
      "contextRef": "i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "vtl:ChangesInBoardOfDirectorsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000017 - Disclosure - Changes in Board of Directors",
     "role": "http://vitaltherapies.com/role/ChangesinBoardofDirectors",
     "shortName": "Changes in Board of Directors",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtl-20220930.htm",
      "contextRef": "i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "vtl:ChangesInBoardOfDirectorsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtl-20220930.htm",
      "contextRef": "i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000018 - Disclosure - Related Party Transactions",
     "role": "http://vitaltherapies.com/role/RelatedPartyTransactions",
     "shortName": "Related Party Transactions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtl-20220930.htm",
      "contextRef": "i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtl-20220930.htm",
      "contextRef": "i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000019 - Disclosure - Subsequent Events",
     "role": "http://vitaltherapies.com/role/SubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtl-20220930.htm",
      "contextRef": "i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtl-20220930.htm",
      "contextRef": "ib2ba0b84078f4de2bc3079e992921b92_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000002 - Statement - Condensed Consolidated Balance Sheets",
     "role": "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets",
     "shortName": "Condensed Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtl-20220930.htm",
      "contextRef": "ib2ba0b84078f4de2bc3079e992921b92_I20220930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AssetsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20220930.htm",
      "contextRef": "i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000020 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "role": "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20220930.htm",
      "contextRef": "i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20220930.htm",
      "contextRef": "i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000021 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "role": "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesTables",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20220930.htm",
      "contextRef": "i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20220930.htm",
      "contextRef": "i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000022 - Disclosure - Balance Sheet Details (Tables)",
     "role": "http://vitaltherapies.com/role/BalanceSheetDetailsTables",
     "shortName": "Balance Sheet Details (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20220930.htm",
      "contextRef": "i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20220930.htm",
      "contextRef": "i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000023 - Disclosure - Commitments and Contingencies (Tables)",
     "role": "http://vitaltherapies.com/role/CommitmentsandContingenciesTables",
     "shortName": "Commitments and Contingencies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20220930.htm",
      "contextRef": "i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20220930.htm",
      "contextRef": "i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000024 - Disclosure - Fair Value (Tables)",
     "role": "http://vitaltherapies.com/role/FairValueTables",
     "shortName": "Fair Value (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20220930.htm",
      "contextRef": "i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20220930.htm",
      "contextRef": "i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "vtl:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000025 - Disclosure - Common Stock (Tables)",
     "role": "http://vitaltherapies.com/role/CommonStockTables",
     "shortName": "Common Stock (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20220930.htm",
      "contextRef": "i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "vtl:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20220930.htm",
      "contextRef": "i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000026 - Disclosure - Stock-Based Compensation Plans (Tables)",
     "role": "http://vitaltherapies.com/role/StockBasedCompensationPlansTables",
     "shortName": "Stock-Based Compensation Plans (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20220930.htm",
      "contextRef": "i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20220930.htm",
      "contextRef": "ib2ba0b84078f4de2bc3079e992921b92_I20220930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityNumberOfEmployees",
      "reportCount": 1,
      "unique": true,
      "unitRef": "employee",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000027 - Disclosure - Description of Business and Basis of Financial Statements (Details)",
     "role": "http://vitaltherapies.com/role/DescriptionofBusinessandBasisofFinancialStatementsDetails",
     "shortName": "Description of Business and Basis of Financial Statements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20220930.htm",
      "contextRef": "ib2ba0b84078f4de2bc3079e992921b92_I20220930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityNumberOfEmployees",
      "reportCount": 1,
      "unique": true,
      "unitRef": "employee",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20220930.htm",
      "contextRef": "ib2ba0b84078f4de2bc3079e992921b92_I20220930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "vtl:NumberOfFinancialInstitutionsUsedForCashDeposits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "financialinstitution",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000028 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)",
     "role": "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
     "shortName": "Summary of Significant Accounting Policies - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20220930.htm",
      "contextRef": "ib2ba0b84078f4de2bc3079e992921b92_I20220930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "vtl:NumberOfFinancialInstitutionsUsedForCashDeposits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "financialinstitution",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20220930.htm",
      "contextRef": "ic3a03035d5534d539979b07aedea62c1_D20220101-20220930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000029 - Disclosure - Summary of Significant Accounting Policies - Schedule of Potentially Dilutive Securities Not Included in Calculation of Diluted Net Loss per Share (Details)",
     "role": "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofDilutedNetLossperShareDetails",
     "shortName": "Summary of Significant Accounting Policies - Schedule of Potentially Dilutive Securities Not Included in Calculation of Diluted Net Loss per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20220930.htm",
      "contextRef": "ic3a03035d5534d539979b07aedea62c1_D20220101-20220930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20220930.htm",
      "contextRef": "ib2ba0b84078f4de2bc3079e992921b92_I20220930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)",
     "role": "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
     "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockSharesOutstanding",
       "us-gaap:PreferredStockSharesOutstanding",
       "us-gaap:PreferredStockSharesIssued",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtl-20220930.htm",
      "contextRef": "ib2ba0b84078f4de2bc3079e992921b92_I20220930",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:PreferredStockSharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20220930.htm",
      "contextRef": "ib2ba0b84078f4de2bc3079e992921b92_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "vtl:PrepaidClinicalAndRelatedCostsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000030 - Disclosure - Balance Sheet Details - Schedule of Other Current Assets and Prepaid Expenses (Detail)",
     "role": "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofOtherCurrentAssetsandPrepaidExpensesDetail",
     "shortName": "Balance Sheet Details - Schedule of Other Current Assets and Prepaid Expenses (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20220930.htm",
      "contextRef": "ib2ba0b84078f4de2bc3079e992921b92_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "vtl:PrepaidClinicalAndRelatedCostsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20220930.htm",
      "contextRef": "ib2ba0b84078f4de2bc3079e992921b92_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "vtl:ClinicalCostsPayableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000031 - Disclosure - Balance Sheet Details - Schedule of Accounts Payable (Detail)",
     "role": "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofAccountsPayableDetail",
     "shortName": "Balance Sheet Details - Schedule of Accounts Payable (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20220930.htm",
      "contextRef": "ib2ba0b84078f4de2bc3079e992921b92_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "vtl:ClinicalCostsPayableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20220930.htm",
      "contextRef": "ib2ba0b84078f4de2bc3079e992921b92_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "vtl:AccruedClinicalCostsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000032 - Disclosure - Balance Sheet Details - Schedule of Accrued Expenses (Detail)",
     "role": "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofAccruedExpensesDetail",
     "shortName": "Balance Sheet Details - Schedule of Accrued Expenses (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20220930.htm",
      "contextRef": "ib2ba0b84078f4de2bc3079e992921b92_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "vtl:AccruedClinicalCostsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:OtherCurrentLiabilitiesTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20220930.htm",
      "contextRef": "ib2ba0b84078f4de2bc3079e992921b92_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseLiabilityCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000033 - Disclosure - Balance Sheet Details - Schedule of Other Current Liabilities (Detail)",
     "role": "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofOtherCurrentLiabilitiesDetail",
     "shortName": "Balance Sheet Details - Schedule of Other Current Liabilities (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:OtherCurrentLiabilitiesTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20220930.htm",
      "contextRef": "ib2ba0b84078f4de2bc3079e992921b92_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseLiabilityCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20220930.htm",
      "contextRef": "ib2ba0b84078f4de2bc3079e992921b92_I20220930",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "vtl:OperatingLeaseIncrementalBorrowingRate",
      "reportCount": 1,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000034 - Disclosure - Commitments and Contingencies - Additional Information (Details)",
     "role": "http://vitaltherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
     "shortName": "Commitments and Contingencies - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20220930.htm",
      "contextRef": "i25a8ea2d7c9f4bfd8f72223c8ac18c65_D20220701-20220930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "vtl:OperatingAndVariableLeasesCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20220930.htm",
      "contextRef": "ib2ba0b84078f4de2bc3079e992921b92_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000035 - Disclosure - Commitments and Contingencies - Maturities of Operating Lease Obligation (Details)",
     "role": "http://vitaltherapies.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseObligationDetails",
     "shortName": "Commitments and Contingencies - Maturities of Operating Lease Obligation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20220930.htm",
      "contextRef": "ib2ba0b84078f4de2bc3079e992921b92_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20220930.htm",
      "contextRef": "i5a48bc4ae7d7408f97f6eeb1dca78e8b_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000036 - Disclosure - Fair Value - Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)",
     "role": "http://vitaltherapies.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
     "shortName": "Fair Value - Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20220930.htm",
      "contextRef": "i5a48bc4ae7d7408f97f6eeb1dca78e8b_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtl-20220930.htm",
      "contextRef": "i452fc01435184aa6b440569b104a7b6a_I20201130",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "vtl:MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000037 - Disclosure - Common Stock - Shelf Registration Statement (Details)",
     "role": "http://vitaltherapies.com/role/CommonStockShelfRegistrationStatementDetails",
     "shortName": "Common Stock - Shelf Registration Statement (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtl-20220930.htm",
      "contextRef": "i452fc01435184aa6b440569b104a7b6a_I20201130",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "vtl:MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtl-20220930.htm",
      "contextRef": "ib2ba0b84078f4de2bc3079e992921b92_I20220930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000038 - Disclosure - Common Stock - Public Equity Offering (Details)",
     "role": "http://vitaltherapies.com/role/CommonStockPublicEquityOfferingDetails",
     "shortName": "Common Stock - Public Equity Offering (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20220930.htm",
      "contextRef": "id7f3ba2151e24a8694efe8eededbb089_D20210715-20210715",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20220930.htm",
      "contextRef": "ib2ba0b84078f4de2bc3079e992921b92_I20220930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000039 - Disclosure - Common Stock - Common Stock (Details)",
     "role": "http://vitaltherapies.com/role/CommonStockCommonStockDetails",
     "shortName": "Common Stock - Common Stock (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20220930.htm",
      "contextRef": "i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:CommonStockDividendsPerShareDeclared",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtl-20220930.htm",
      "contextRef": "i25a8ea2d7c9f4bfd8f72223c8ac18c65_D20220701-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000004 - Statement - Condensed Consolidated Statements of Operations",
     "role": "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofOperations",
     "shortName": "Condensed Consolidated Statements of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtl-20220930.htm",
      "contextRef": "i25a8ea2d7c9f4bfd8f72223c8ac18c65_D20220701-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtl-20220930.htm",
      "contextRef": "ib2ba0b84078f4de2bc3079e992921b92_I20220930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000040 - Disclosure - Common Stock - Preferred Stock (Details)",
     "role": "http://vitaltherapies.com/role/CommonStockPreferredStockDetails",
     "shortName": "Common Stock - Preferred Stock (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "vtl:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20220930.htm",
      "contextRef": "ib2ba0b84078f4de2bc3079e992921b92_I20220930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000041 - Disclosure - Common Stock - Shares Reserved for Future Issuance (Details)",
     "role": "http://vitaltherapies.com/role/CommonStockSharesReservedforFutureIssuanceDetails",
     "shortName": "Common Stock - Shares Reserved for Future Issuance (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "vtl:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20220930.htm",
      "contextRef": "ib2ba0b84078f4de2bc3079e992921b92_I20220930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20220930.htm",
      "contextRef": "i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000042 - Disclosure - Stock-Based Compensation Plans - Additional Information (Details)",
     "role": "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails",
     "shortName": "Stock-Based Compensation Plans - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20220930.htm",
      "contextRef": "i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20220930.htm",
      "contextRef": "i7f827301d88e484985fc3a70f1380d98_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000043 - Disclosure - Stock-Based Compensation Plans - Summary of Stock Option Activity (Details)",
     "role": "http://vitaltherapies.com/role/StockBasedCompensationPlansSummaryofStockOptionActivityDetails",
     "shortName": "Stock-Based Compensation Plans - Summary of Stock Option Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20220930.htm",
      "contextRef": "i7f827301d88e484985fc3a70f1380d98_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20220930.htm",
      "contextRef": "i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000044 - Disclosure - Stock-Based Compensation Plans - Ranges of Underlying Assumptions Used in BSM Option Pricing Model to Determine Fair Value of Stock Options Granted to Employees and Nonemployees (Detail)",
     "role": "http://vitaltherapies.com/role/StockBasedCompensationPlansRangesofUnderlyingAssumptionsUsedinBSMOptionPricingModeltoDetermineFairValueofStockOptionsGrantedtoEmployeesandNonemployeesDetail",
     "shortName": "Stock-Based Compensation Plans - Ranges of Underlying Assumptions Used in BSM Option Pricing Model to Determine Fair Value of Stock Options Granted to Employees and Nonemployees (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20220930.htm",
      "contextRef": "i491c0053bc5f4054a60885ff43fbbc87_D20220101-20220930",
      "decimals": "4",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtl-20220930.htm",
      "contextRef": "i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000045 - Disclosure - Stock-Based Compensation Plans - Schedule of Stock-based Compensation Expense for Stock Awards Recognized (Details)",
     "role": "http://vitaltherapies.com/role/StockBasedCompensationPlansScheduleofStockbasedCompensationExpenseforStockAwardsRecognizedDetails",
     "shortName": "Stock-Based Compensation Plans - Schedule of Stock-based Compensation Expense for Stock Awards Recognized (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20220930.htm",
      "contextRef": "i13791407fd49427ea3348fc4827a4293_D20220701-20220930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20220930.htm",
      "contextRef": "i0b4e3048cb3144a99e1401eb94392689_D20220706-20220706",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000046 - Disclosure - Changes in Board of Directors (Details)",
     "role": "http://vitaltherapies.com/role/ChangesinBoardofDirectorsDetails",
     "shortName": "Changes in Board of Directors (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20220930.htm",
      "contextRef": "i0b4e3048cb3144a99e1401eb94392689_D20220706-20220706",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20220930.htm",
      "contextRef": "iac9f9142fce04841b7cdeea2bfcabdb6_D20220315-20220315",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000047 - Disclosure - Related Party Transactions - Additional Information (Details)",
     "role": "http://vitaltherapies.com/role/RelatedPartyTransactionsAdditionalInformationDetails",
     "shortName": "Related Party Transactions - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20220930.htm",
      "contextRef": "iac9f9142fce04841b7cdeea2bfcabdb6_D20220315-20220315",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtl-20220930.htm",
      "contextRef": "ic5a53880f9da458c8abd6926ff69ddd8_D20221001-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillImpairmentLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000048 - Disclosure - Subsequent Events (Details)",
     "role": "http://vitaltherapies.com/role/SubsequentEventsDetails",
     "shortName": "Subsequent Events (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20220930.htm",
      "contextRef": "id3d63a41fa5847168bff487d8106b2f5_D20221010-20221010",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtl-20220930.htm",
      "contextRef": "i25a8ea2d7c9f4bfd8f72223c8ac18c65_D20220701-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000005 - Statement - Condensed Consolidated Statements of Comprehensive Loss",
     "role": "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofComprehensiveLoss",
     "shortName": "Condensed Consolidated Statements of Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtl-20220930.htm",
      "contextRef": "i25a8ea2d7c9f4bfd8f72223c8ac18c65_D20220701-20220930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtl-20220930.htm",
      "contextRef": "i607bec8e45eb4e6d838d65f04d1d719f_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000006 - Statement - Condensed Consolidated Statements of Stockholders\u2019 Equity",
     "role": "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
     "shortName": "Condensed Consolidated Statements of Stockholders\u2019 Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtl-20220930.htm",
      "contextRef": "i26792f62773c456c934cf59dcefb4260_D20210101-20210331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtl-20220930.htm",
      "contextRef": "i8ff3b5d8c53f48e598eabdf159ffe5a8_D20220401-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000007 - Statement - Condensed Consolidated Statements of Stockholders\u2019 Equity (Parenthetical)",
     "role": "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical",
     "shortName": "Condensed Consolidated Statements of Stockholders\u2019 Equity (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtl-20220930.htm",
      "contextRef": "i8ff3b5d8c53f48e598eabdf159ffe5a8_D20220401-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtl-20220930.htm",
      "contextRef": "i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000008 - Statement - Condensed Consolidated Statement of Cash Flows",
     "role": "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows",
     "shortName": "Condensed Consolidated Statement of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtl-20220930.htm",
      "contextRef": "i60aac70b798a440d9d0d821bc147cdd2_D20220101-20220930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtl-20220930.htm",
      "contextRef": "if312c4804f8b4c99a0562a9d7368b18e_D20220101-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsOfStockIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000009 - Statement - Condensed Consolidated Statements of Cash Flows (Parenthetical)",
     "role": "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofCashFlowsParenthetical",
     "shortName": "Condensed Consolidated Statements of Cash Flows (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtl-20220930.htm",
      "contextRef": "if312c4804f8b4c99a0562a9d7368b18e_D20220101-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsOfStockIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 45,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r441"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r438"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]",
        "terseLabel": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r438"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r438"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r442"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityNumberOfEmployees": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of persons employed by the Entity",
        "label": "Entity Number of Employees",
        "terseLabel": "Number of employees"
       }
      }
     },
     "localname": "EntityNumberOfEmployees",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://vitaltherapies.com/role/DescriptionofBusinessandBasisofFinancialStatementsDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r438"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r438"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r438"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r438"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]",
        "terseLabel": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r437"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r439"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_AffiliatedEntityMember": {
     "auth_ref": [
      "r222",
      "r338",
      "r339",
      "r342",
      "r433"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Affiliated Entity [Member]",
        "terseLabel": "Affiliated Entity"
       }
      }
     },
     "localname": "AffiliatedEntityMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://vitaltherapies.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_BoardOfDirectorsChairmanMember": {
     "auth_ref": [
      "r133"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Board of Directors Chairman [Member]",
        "terseLabel": "Board of Directors Chairman"
       }
      }
     },
     "localname": "BoardOfDirectorsChairmanMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://vitaltherapies.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r35",
      "r37",
      "r82",
      "r83",
      "r180",
      "r190"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://vitaltherapies.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_DirectorMember": {
     "auth_ref": [
      "r133"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Director [Member]",
        "terseLabel": "Director"
       }
      }
     },
     "localname": "DirectorMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://vitaltherapies.com/role/ChangesinBoardofDirectorsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r159",
      "r161",
      "r162",
      "r163",
      "r179",
      "r189",
      "r224",
      "r226",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r396",
      "r398",
      "r434",
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails",
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r159",
      "r161",
      "r162",
      "r163",
      "r179",
      "r189",
      "r224",
      "r226",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r396",
      "r398",
      "r434",
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails",
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r151",
      "r159",
      "r161",
      "r162",
      "r163",
      "r179",
      "r189",
      "r214",
      "r224",
      "r226",
      "r259",
      "r260",
      "r261",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r396",
      "r398",
      "r434",
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Range [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails",
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r151",
      "r159",
      "r161",
      "r162",
      "r163",
      "r179",
      "r189",
      "r214",
      "r224",
      "r226",
      "r259",
      "r260",
      "r261",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r396",
      "r398",
      "r434",
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Range [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails",
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r36",
      "r37",
      "r82",
      "r83",
      "r180",
      "r190"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://vitaltherapies.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioForecastMember": {
     "auth_ref": [
      "r93",
      "r225"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forecast [Member]",
        "terseLabel": "Forecast"
       }
      }
     },
     "localname": "ScenarioForecastMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://vitaltherapies.com/role/RelatedPartyTransactionsAdditionalInformationDetails",
      "http://vitaltherapies.com/role/SubsequentEventsDetails",
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r93",
      "r98",
      "r157",
      "r225"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]",
        "terseLabel": "Scenario, Unspecified [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://vitaltherapies.com/role/RelatedPartyTransactionsAdditionalInformationDetails",
      "http://vitaltherapies.com/role/SubsequentEventsDetails",
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r131",
      "r132",
      "r212",
      "r213",
      "r397",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r131",
      "r132",
      "r212",
      "r213",
      "r397",
      "r420",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r93",
      "r98",
      "r157",
      "r225",
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]",
        "terseLabel": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://vitaltherapies.com/role/RelatedPartyTransactionsAdditionalInformationDetails",
      "http://vitaltherapies.com/role/SubsequentEventsDetails",
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r133",
      "r341"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]",
        "terseLabel": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://vitaltherapies.com/role/ChangesinBoardofDirectorsDetails",
      "http://vitaltherapies.com/role/RelatedPartyTransactionsAdditionalInformationDetails",
      "http://vitaltherapies.com/role/StockBasedCompensationPlansScheduleofStockbasedCompensationExpenseforStockAwardsRecognizedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]",
        "terseLabel": "Relationship to Entity [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://vitaltherapies.com/role/ChangesinBoardofDirectorsDetails",
      "http://vitaltherapies.com/role/RelatedPartyTransactionsAdditionalInformationDetails",
      "http://vitaltherapies.com/role/StockBasedCompensationPlansScheduleofStockbasedCompensationExpenseforStockAwardsRecognizedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r28",
      "r347"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofAccountsPayableDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofAccountsPayableDetail",
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableOtherCurrent": {
     "auth_ref": [
      "r28"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofAccountsPayableDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_AccountsPayableCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligations incurred classified as other, payable within one year or the normal operating cycle, if longer.",
        "label": "Accounts Payable, Other, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "AccountsPayableOtherCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofAccountsPayableDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r30"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofAccruedExpensesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofAccruedExpensesDetail",
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r22",
      "r40",
      "r41",
      "r42",
      "r387",
      "r403",
      "r404"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r39",
      "r42",
      "r50",
      "r51",
      "r52",
      "r85",
      "r86",
      "r87",
      "r299",
      "r335",
      "r399",
      "r400"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r20",
      "r347"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r85",
      "r86",
      "r87",
      "r271",
      "r272",
      "r273",
      "r303"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r228",
      "r276",
      "r277"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": {
     "auth_ref": [
      "r203",
      "r210"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.",
        "label": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs",
        "terseLabel": "Issuance costs"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r264"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Share-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r106"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Options to purchase common stock ( in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofDilutedNetLossperShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r106"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofDilutedNetLossperShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofDilutedNetLossperShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r106"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofDilutedNetLossperShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable": {
     "auth_ref": [
      "r289",
      "r290",
      "r291"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of acquirer's equity interest issued and issuable as part of consideration transferred in asset acquisition.",
        "label": "Asset Acquisition, Consideration Transferred, Equity Interest Issued and Issuable",
        "negatedTerseLabel": "Common Stock issued in connection with the 4SC royalty settlement (see Note 4)"
       }
      }
     },
     "localname": "AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r13",
      "r81",
      "r123",
      "r125",
      "r129",
      "r135",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r296",
      "r300",
      "r315",
      "r345",
      "r347",
      "r377",
      "r386"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r5",
      "r27",
      "r81",
      "r135",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r296",
      "r300",
      "r315",
      "r345",
      "r347"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r306"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "terseLabel": "Total assets at fair value"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r231",
      "r232",
      "r233",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r251",
      "r252",
      "r254",
      "r255",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/ChangesinBoardofDirectorsDetails",
      "http://vitaltherapies.com/role/CommonStockSharesReservedforFutureIssuanceDetails",
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails",
      "http://vitaltherapies.com/role/StockBasedCompensationPlansSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation and Consolidation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "auth_ref": [
      "r3",
      "r84",
      "r120"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Business Description and Basis of Presentation [Text Block]",
        "terseLabel": "Description of Business and Basis of Financial Statements"
       }
      }
     },
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/DescriptionofBusinessandBasisofFinancialStatements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r4",
      "r10",
      "r72"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets",
      "http://vitaltherapies.com/role/DescriptionofBusinessandBasisofFinancialStatementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r73"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsAndFederalFundsSold": {
     "auth_ref": [
      "r379"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of cash and cash equivalents plus Federal Funds Sold. Cash and cash equivalents consist of short term, highly liquid investments that are readily convertible to known amounts of cash and are so near their maturity that they present negligible risk of changes in value due to changes in interest rates -- usually with an original maturity less than 90 days.",
        "label": "Cash, Cash Equivalents, and Federal Funds Sold",
        "terseLabel": "Cash funds"
       }
      }
     },
     "localname": "CashCashEquivalentsAndFederalFundsSold",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/DescriptionofBusinessandBasisofFinancialStatementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r66",
      "r72",
      "r77"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents, end of period",
        "periodStartLabel": "Cash and cash equivalents, beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r66",
      "r318"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net change in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockPublicEquityOfferingDetails",
      "http://vitaltherapies.com/role/CommonStockSharesReservedforFutureIssuanceDetails",
      "http://vitaltherapies.com/role/CommonStockShelfRegistrationStatementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollaborativeArrangementAccountingPolicy": {
     "auth_ref": [
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for collaborative arrangements.",
        "label": "Collaborative Arrangement, Accounting Policy [Policy Text Block]",
        "terseLabel": "Collaboration Arrangements"
       }
      }
     },
     "localname": "CollaborativeArrangementAccountingPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/ChangesinBoardofDirectorsDetails",
      "http://vitaltherapies.com/role/DescriptionofBusinessandBasisofFinancialStatementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r32",
      "r380",
      "r391"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (Note 4)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r153",
      "r154",
      "r155",
      "r164",
      "r421"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r33"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Total common shares reserved for future issuance (in shares)"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockSharesReservedforFutureIssuanceDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockDividendsPerShareCashPaid": {
     "auth_ref": [
      "r210"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate dividends paid during the period for each share of common stock outstanding.",
        "label": "Common Stock, Dividends, Per Share, Cash Paid",
        "terseLabel": "Common stock, cash dividends paid (in USD per share)"
       }
      }
     },
     "localname": "CommonStockDividendsPerShareCashPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockCommonStockDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockDividendsPerShareDeclared": {
     "auth_ref": [
      "r210"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding.",
        "label": "Common Stock, Dividends, Per Share, Declared",
        "terseLabel": "Common stock, cash dividends declared (in USD per share)"
       }
      }
     },
     "localname": "CommonStockDividendsPerShareDeclared",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockCommonStockDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r85",
      "r86",
      "r303"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
      "http://vitaltherapies.com/role/SubsequentEventsDetails",
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in USD per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockCommonStockDetails",
      "http://vitaltherapies.com/role/CommonStockPublicEquityOfferingDetails",
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockCommonStockDetails",
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r18",
      "r203"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "terseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r18",
      "r347"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock issued",
        "verboseLabel": "Common stock, $0.0001 par value; 130,000,000 shares authorized and 30,564,995 and 26,335,418 shares issued and outstanding as of September 30, 2022 and December\u00a031, 2021, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r45",
      "r47",
      "r48",
      "r56",
      "r383",
      "r394"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Total comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for comprehensive income.",
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "terseLabel": "Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractualObligation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.",
        "label": "Contractual Obligation",
        "terseLabel": "Contractual obligation"
       }
      }
     },
     "localname": "ContractualObligation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.",
        "label": "Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent",
        "terseLabel": "Maximum annual contributions per employee (as a percent)"
       }
      }
     },
     "localname": "DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r70",
      "r146"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation expense"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r70",
      "r122"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r230",
      "r231",
      "r265",
      "r266",
      "r268",
      "r278"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "Stock-Based Compensation Plans"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlans"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]",
        "terseLabel": "Disclosure of Compensation Related Costs, Share-based Payments [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r57",
      "r90",
      "r91",
      "r92",
      "r93",
      "r94",
      "r99",
      "r101",
      "r103",
      "r104",
      "r105",
      "r108",
      "r109",
      "r304",
      "r305",
      "r384",
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net loss per share, basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r57",
      "r90",
      "r91",
      "r92",
      "r93",
      "r94",
      "r101",
      "r103",
      "r104",
      "r105",
      "r108",
      "r109",
      "r304",
      "r305",
      "r384",
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net loss per share, diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r106",
      "r107"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r318"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations",
        "terseLabel": "Effect of exchange rate changes on cash and cash equivalents"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansScheduleofStockbasedCompensationExpenseforStockAwardsRecognizedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r267"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Total unrecognized compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Period over which compensation cost will be recognized (in years)"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "terseLabel": "Outstanding stock options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockSharesReservedforFutureIssuanceDetails",
      "http://vitaltherapies.com/role/StockBasedCompensationPlansSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r50",
      "r51",
      "r52",
      "r85",
      "r86",
      "r87",
      "r89",
      "r95",
      "r97",
      "r110",
      "r136",
      "r203",
      "r210",
      "r271",
      "r272",
      "r273",
      "r287",
      "r288",
      "r303",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r325",
      "r335",
      "r399",
      "r400",
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r306",
      "r307",
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r181",
      "r182",
      "r183",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r223",
      "r307",
      "r352",
      "r353",
      "r354"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r306",
      "r307",
      "r308",
      "r309",
      "r312"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/FairValue"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r181",
      "r215",
      "r216",
      "r221",
      "r223",
      "r307",
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r181",
      "r182",
      "r183",
      "r215",
      "r216",
      "r221",
      "r223",
      "r307",
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level\u00a02"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r181",
      "r182",
      "r183",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r223",
      "r307",
      "r354"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level\u00a03"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Fair Value, Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r181",
      "r182",
      "r183",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r223",
      "r352",
      "r353",
      "r354"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r310",
      "r312"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair Value, Measurements, Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r313",
      "r314"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Fair Value Measurement"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ForeignCurrencyTransactionGainLossUnrealized": {
     "auth_ref": [
      "r71",
      "r316",
      "r317"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of foreign currency transaction unrealized gain (loss) recognized in the income statement.",
        "label": "Foreign Currency Transaction Gain (Loss), Unrealized",
        "negatedTerseLabel": "Unrealized foreign currency loss"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionGainLossUnrealized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "auth_ref": [
      "r327"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "terseLabel": "Foreign Currency Translation and Presentation"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r59"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r58"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansScheduleofStockbasedCompensationExpenseforStockAwardsRecognizedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r11",
      "r137",
      "r139",
      "r141",
      "r143",
      "r347",
      "r376"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": {
     "auth_ref": [
      "r142",
      "r143",
      "r144"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.",
        "label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillImpairmentLoss": {
     "auth_ref": [
      "r70",
      "r138",
      "r140",
      "r142",
      "r143"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Impairment Loss",
        "terseLabel": "Goodwill Impairment"
       }
      }
     },
     "localname": "GoodwillImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/SubsequentEventsDetails",
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r145",
      "r150"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "terseLabel": "Impairment of Long-Lived Assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r149",
      "r152"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansScheduleofStockbasedCompensationExpenseforStockAwardsRecognizedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r152"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansScheduleofStockbasedCompensationExpenseforStockAwardsRecognizedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r49",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherCurrentLiabilities": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in current liabilities classified as other.",
        "label": "Increase (Decrease) in Other Current Liabilities",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherCurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Other current assets and prepaid expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r60",
      "r121"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentTypeAxis": {
     "auth_ref": [
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of investments.",
        "label": "Investment Type [Axis]",
        "terseLabel": "Investment Type [Axis]"
       }
      }
     },
     "localname": "InvestmentTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "auth_ref": [
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset obtained to generate income or appreciate in value.",
        "label": "Investments [Domain]",
        "terseLabel": "Investments [Domain]"
       }
      }
     },
     "localname": "InvestmentTypeCategorizationMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Maturities of Operating Lease Obligation"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CommitmentsandContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r333"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseObligationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://vitaltherapies.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseObligationDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseObligationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r333"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseObligationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseObligationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r333"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseObligationDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseObligationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r333"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseObligationDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseObligationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r333"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseObligationDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseObligationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r333"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseObligationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseObligationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r333"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseObligationDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "terseLabel": "Interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseObligationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Lease term (in months)",
        "verboseLabel": "Lease term (in years)"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r29",
      "r81",
      "r126",
      "r135",
      "r168",
      "r169",
      "r170",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r297",
      "r300",
      "r301",
      "r315",
      "r345",
      "r346"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r25",
      "r81",
      "r135",
      "r315",
      "r347",
      "r378",
      "r389"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and Stockholders\u2019 Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r6",
      "r31",
      "r81",
      "r135",
      "r168",
      "r169",
      "r170",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r297",
      "r300",
      "r301",
      "r315",
      "r345",
      "r346",
      "r347"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "auth_ref": [
      "r7",
      "r8",
      "r9",
      "r14",
      "r15",
      "r81",
      "r135",
      "r168",
      "r169",
      "r170",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r297",
      "r300",
      "r301",
      "r315",
      "r345",
      "r346"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.",
        "label": "Liabilities, Noncurrent",
        "totalLabel": "Total long-term liabilities"
       }
      }
     },
     "localname": "LiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Noncurrent [Abstract]",
        "terseLabel": "Long term liabilities"
       }
      }
     },
     "localname": "LiabilitiesNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Loss Contingencies [Line Items]",
        "terseLabel": "Loss Contingencies [Line Items]"
       }
      }
     },
     "localname": "LossContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesTable": {
     "auth_ref": [
      "r156",
      "r158",
      "r159",
      "r160",
      "r161",
      "r165",
      "r166"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.",
        "label": "Loss Contingencies [Table]",
        "terseLabel": "Loss Contingencies [Table]"
       }
      }
     },
     "localname": "LossContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r66",
      "r68",
      "r71"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r2",
      "r43",
      "r46",
      "r52",
      "r54",
      "r71",
      "r81",
      "r88",
      "r90",
      "r91",
      "r92",
      "r93",
      "r96",
      "r97",
      "r102",
      "r123",
      "r124",
      "r127",
      "r128",
      "r130",
      "r135",
      "r168",
      "r169",
      "r170",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r305",
      "r315",
      "r381",
      "r392"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows",
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofComprehensiveLoss",
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofOperations",
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently Issued and/or Adopted Accounting Standards"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncash Investing and Financing Items [Abstract]",
        "terseLabel": "Supplemental disclosure of noncash investing and financing activities:"
       }
      }
     },
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r61"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other expense"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other income (expense):"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r123",
      "r124",
      "r127",
      "r128",
      "r130"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r329"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseObligationDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "PV of obligation"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseObligationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r329"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofOtherCurrentLiabilitiesDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofOtherCurrentLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r329"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r328"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Right-of-use assets, net"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r30"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofAccruedExpensesDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Accrued other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofAccruedExpensesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r26",
      "r347"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofOtherCurrentAssetsandPrepaidExpensesDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofOtherCurrentAssetsandPrepaidExpensesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r12"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other long-term assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r294",
      "r295",
      "r298"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Foreign currency translation"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r44",
      "r47",
      "r50",
      "r51",
      "r53",
      "r55",
      "r203",
      "r319",
      "r324",
      "r325",
      "r382",
      "r393"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Foreign exchange translation adjustment"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]",
        "terseLabel": "Other comprehensive income (loss):"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherCurrentLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of other current liabilities.",
        "label": "Other Current Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Other Current Liabilities"
       }
      }
     },
     "localname": "OtherCurrentLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/BalanceSheetDetailsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r30",
      "r347"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofOtherCurrentLiabilitiesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "terseLabel": "Other current liabilities",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofOtherCurrentLiabilitiesDetail",
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other income (expense), net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherSundryLiabilitiesCurrent": {
     "auth_ref": [
      "r30",
      "r167"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofOtherCurrentLiabilitiesDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Obligations not otherwise itemized or categorized in the footnotes to the financial statements that are due within one year or operating cycle, if longer, from the balance sheet date.",
        "label": "Other Sundry Liabilities, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherSundryLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofOtherCurrentLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForCommissions": {
     "auth_ref": [
      "r67"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid for commissions during the current period.",
        "label": "Payments for Commissions",
        "terseLabel": "Underwriter commissions"
       }
      }
     },
     "localname": "PaymentsForCommissions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockShelfRegistrationStatementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r65"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments of Stock Issuance Costs",
        "terseLabel": "Issuance costs"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofCashFlowsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r63"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r231",
      "r232",
      "r233",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r251",
      "r252",
      "r254",
      "r255",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockSharesReservedforFutureIssuanceDetails",
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails",
      "http://vitaltherapies.com/role/StockBasedCompensationPlansRangesofUnderlyingAssumptionsUsedinBSMOptionPricingModeltoDetermineFairValueofStockOptionsGrantedtoEmployeesandNonemployeesDetail",
      "http://vitaltherapies.com/role/StockBasedCompensationPlansSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r231",
      "r232",
      "r233",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r251",
      "r252",
      "r254",
      "r255",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockSharesReservedforFutureIssuanceDetails",
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails",
      "http://vitaltherapies.com/role/StockBasedCompensationPlansRangesofUnderlyingAssumptionsUsedinBSMOptionPricingModeltoDetermineFairValueofStockOptionsGrantedtoEmployeesandNonemployeesDetail",
      "http://vitaltherapies.com/role/StockBasedCompensationPlansSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r17",
      "r187"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in USD per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockPreferredStockDetails",
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockPreferredStockDetails",
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r17",
      "r187"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockPreferredStockDetails",
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r17",
      "r347"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.0001 par value; 20,000,000 authorized and no shares issued or outstanding at September 30, 2022 and December 31, 2021"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r27"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofOtherCurrentAssetsandPrepaidExpensesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Other current assets and prepaid expenses",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofOtherCurrentAssetsandPrepaidExpensesDetail",
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from Issuance of Common Stock",
        "verboseLabel": "Proceeds from issuance of common stock at premium"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockShelfRegistrationStatementDetails",
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows",
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": {
     "auth_ref": [
      "r64"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.",
        "label": "Proceeds from Issuance of Private Placement",
        "terseLabel": "Proceeds from issuance of private placement"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfPrivatePlacement",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/DescriptionofBusinessandBasisofFinancialStatementsDetails",
      "http://vitaltherapies.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans": {
     "auth_ref": [
      "r64",
      "r270"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Excludes option exercised.",
        "label": "Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Excluding Option Exercised",
        "terseLabel": "Proceeds from shares issued in connection with the Company's employee stock purchase plan"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r64",
      "r270"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from exercise of stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r147",
      "r347",
      "r385",
      "r390"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r147",
      "r422",
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Estimated useful life (in years)"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r222",
      "r338",
      "r339"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "auth_ref": [
      "r222",
      "r338",
      "r339",
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party transaction.",
        "label": "Related Party Transaction [Axis]",
        "terseLabel": "Related Party Transaction [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "auth_ref": [
      "r222"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction between related party.",
        "label": "Related Party Transaction [Domain]",
        "terseLabel": "Related Party Transaction [Domain]"
       }
      }
     },
     "localname": "RelatedPartyTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]",
        "terseLabel": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r222",
      "r338",
      "r342",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]",
        "terseLabel": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r336",
      "r337",
      "r339",
      "r343",
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "Related Party Transactions"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/RelatedPartyTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r280",
      "r362",
      "r436"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansScheduleofStockbasedCompensationExpenseforStockAwardsRecognizedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r280"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r21",
      "r210",
      "r347",
      "r388",
      "r402",
      "r404"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "negatedLabel": "Accumulated deficit",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets",
      "http://vitaltherapies.com/role/DescriptionofBusinessandBasisofFinancialStatementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r85",
      "r86",
      "r87",
      "r89",
      "r95",
      "r97",
      "r136",
      "r271",
      "r272",
      "r273",
      "r287",
      "r288",
      "r303",
      "r399",
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r332",
      "r334"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Operating lease right-of use asset obtained in exchange for lease obligation"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received on stock transaction after deduction of issuance costs.",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "terseLabel": "Proceeds from sale of stock"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockPublicEquityOfferingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockPublicEquityOfferingDetails",
      "http://vitaltherapies.com/role/CommonStockShelfRegistrationStatementDetails",
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows",
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofCashFlowsParenthetical",
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical",
      "http://vitaltherapies.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Shares issued in private placement transaction (in shares)"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockPublicEquityOfferingDetails",
      "http://vitaltherapies.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Sale of stock, price per share (in dollars per share)"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockPublicEquityOfferingDetails",
      "http://vitaltherapies.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.",
        "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accounts Payable and Accrued Expenses"
       }
      }
     },
     "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/BalanceSheetDetailsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r106"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofDilutedNetLossperShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r106"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Potentially Dilutive Securities Not Included in Calculation of Diluted Net Loss per Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r293"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/ChangesinBoardofDirectorsDetails",
      "http://vitaltherapies.com/role/DescriptionofBusinessandBasisofFinancialStatementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r263",
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansScheduleofStockbasedCompensationExpenseforStockAwardsRecognizedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Schedule of Stock-based Compensation Expense for Stock Awards Recognized"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r306",
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/FairValueTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amounts of other current assets.",
        "label": "Schedule of Other Current Assets [Table Text Block]",
        "terseLabel": "Schedule of Other Current Assets and Prepaid Expenses"
       }
      }
     },
     "localname": "ScheduleOfOtherCurrentAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/BalanceSheetDetailsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r147"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r340",
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r227",
      "r229",
      "r231",
      "r232",
      "r233",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r251",
      "r252",
      "r254",
      "r255",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails",
      "http://vitaltherapies.com/role/StockBasedCompensationPlansRangesofUnderlyingAssumptionsUsedinBSMOptionPricingModeltoDetermineFairValueofStockOptionsGrantedtoEmployeesandNonemployeesDetail",
      "http://vitaltherapies.com/role/StockBasedCompensationPlansSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r235",
      "r250",
      "r253"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Summary of Stock Option Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Valuation Assumptions Used"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r16",
      "r17",
      "r18",
      "r79",
      "r111",
      "r112",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r192",
      "r196",
      "r201",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockPublicEquityOfferingDetails",
      "http://vitaltherapies.com/role/CommonStockSharesReservedforFutureIssuanceDetails",
      "http://vitaltherapies.com/role/CommonStockShelfRegistrationStatementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock": {
     "auth_ref": [
      "r279"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption.",
        "label": "Selling, General and Administrative Expenses, Policy [Policy Text Block]",
        "terseLabel": "General and Administrative Expenses"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation",
        "verboseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows",
      "http://vitaltherapies.com/role/StockBasedCompensationPlansScheduleofStockbasedCompensationExpenseforStockAwardsRecognizedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r231"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "terseLabel": "Vesting period (in years)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/ChangesinBoardofDirectorsDetails",
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate": {
     "auth_ref": [
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discount rate from fair value on purchase date that participants pay for shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Discount from Market Price, Purchase Date",
        "terseLabel": "Purchase price of the stock, at discount from market price at purchase date (as a percent)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r247"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "RSUs granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r260"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield (as percent)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails",
      "http://vitaltherapies.com/role/StockBasedCompensationPlansRangesofUnderlyingAssumptionsUsedinBSMOptionPricingModeltoDetermineFairValueofStockOptionsGrantedtoEmployeesandNonemployeesDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility (as percent)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansRangesofUnderlyingAssumptionsUsedinBSMOptionPricingModeltoDetermineFairValueofStockOptionsGrantedtoEmployeesandNonemployeesDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r261"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate (as percent)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansRangesofUnderlyingAssumptionsUsedinBSMOptionPricingModeltoDetermineFairValueofStockOptionsGrantedtoEmployeesandNonemployeesDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails",
      "http://vitaltherapies.com/role/StockBasedCompensationPlansRangesofUnderlyingAssumptionsUsedinBSMOptionPricingModeltoDetermineFairValueofStockOptionsGrantedtoEmployeesandNonemployeesDetail",
      "http://vitaltherapies.com/role/StockBasedCompensationPlansSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized",
        "terseLabel": "Additional shares authorized (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Other Disclosures"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r238"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Options exercisable, ending balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r238"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Options exercisable, weighted-average exercise price, ending balance (usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "auth_ref": [
      "r239"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period",
        "negatedLabel": "Forfeited or expired (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r239"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price of options that were either forfeited or expired.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Forfeited or expired (usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r240"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/ChangesinBoardofDirectorsDetails",
      "http://vitaltherapies.com/role/RelatedPartyTransactionsAdditionalInformationDetails",
      "http://vitaltherapies.com/role/StockBasedCompensationPlansSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Options granted in period, weighted-average grant date fair value (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/ChangesinBoardofDirectorsDetails",
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r269"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Outstanding, Aggregate Intrinsic Value, Ending balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r236",
      "r237"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Outstanding, ending balance (in shares)",
        "periodStartLabel": "Outstanding, beginning balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r236",
      "r237"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Outstanding, ending balance (usd per share)",
        "periodStartLabel": "Outstanding, beginning balance (usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted- Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "auth_ref": [
      "r254"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "terseLabel": "Options vested and expected to vest , Aggregate Intrinsic Value, Ending balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r254"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Options vested and expected to vest, ending balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r254"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Options vested and expected to vest, weighted-average exercise price, ending balance (usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r231",
      "r232",
      "r233",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r251",
      "r252",
      "r254",
      "r255",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Equity Award [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/ChangesinBoardofDirectorsDetails",
      "http://vitaltherapies.com/role/CommonStockSharesReservedforFutureIssuanceDetails",
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails",
      "http://vitaltherapies.com/role/StockBasedCompensationPlansSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r241"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised (usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r240"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted (usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r234",
      "r256",
      "r257",
      "r258",
      "r259",
      "r262",
      "r274",
      "r278"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Share Price",
        "terseLabel": "Share price (in USD per share)"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r258"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term of options (years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails",
      "http://vitaltherapies.com/role/StockBasedCompensationPlansRangesofUnderlyingAssumptionsUsedinBSMOptionPricingModeltoDetermineFairValueofStockOptionsGrantedtoEmployeesandNonemployeesDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r269"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Options exercisable, Aggregate Intrinsic Value, Ending balance"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Options exercisable, Weighted-Average Remaining Contractual Term, Ending balance"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r254"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Outstanding, Weighted-Average Remaining Contractual Term, Ending balance"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r255"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Options vested and expected to vest , Weighted-Average Remaining Contractual Term, Ending balance"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r78",
      "r84"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r34",
      "r50",
      "r51",
      "r52",
      "r85",
      "r86",
      "r87",
      "r89",
      "r95",
      "r97",
      "r110",
      "r136",
      "r203",
      "r210",
      "r271",
      "r272",
      "r273",
      "r287",
      "r288",
      "r303",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r325",
      "r335",
      "r399",
      "r400",
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows",
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofCashFlowsParenthetical",
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r85",
      "r86",
      "r87",
      "r110",
      "r363"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows",
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofCashFlowsParenthetical",
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssued1": {
     "auth_ref": [
      "r74",
      "r75",
      "r76"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value of stock issued in noncash financing activities.",
        "label": "Stock Issued",
        "terseLabel": "Common Stock issued in connection with the 4SC royalty settlement (see Note 4)"
       }
      }
     },
     "localname": "StockIssued1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r17",
      "r18",
      "r203",
      "r210"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Stock issued (in shares)",
        "verboseLabel": "Issuance of common stock (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockShelfRegistrationStatementDetails",
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r17",
      "r18",
      "r203",
      "r210",
      "r241"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Exercised (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r17",
      "r18",
      "r203",
      "r210"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Shares issued (in shares)",
        "verboseLabel": "Issuance of common stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockShelfRegistrationStatementDetails",
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option).",
        "label": "Equity Option [Member]",
        "terseLabel": "Options to purchase common stock"
       }
      }
     },
     "localname": "StockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofDilutedNetLossperShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r18",
      "r23",
      "r24",
      "r81",
      "r134",
      "r135",
      "r315",
      "r347"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets",
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r80",
      "r188",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r202",
      "r210",
      "r211",
      "r302"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStock"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r326",
      "r349"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockShelfRegistrationStatementDetails",
      "http://vitaltherapies.com/role/DescriptionofBusinessandBasisofFinancialStatementsDetails",
      "http://vitaltherapies.com/role/SubsequentEventsDetails",
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r326",
      "r349"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]",
        "terseLabel": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r326",
      "r349"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockShelfRegistrationStatementDetails",
      "http://vitaltherapies.com/role/DescriptionofBusinessandBasisofFinancialStatementsDetails",
      "http://vitaltherapies.com/role/SubsequentEventsDetails",
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r326",
      "r349"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockShelfRegistrationStatementDetails",
      "http://vitaltherapies.com/role/DescriptionofBusinessandBasisofFinancialStatementsDetails",
      "http://vitaltherapies.com/role/SubsequentEventsDetails",
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]",
        "terseLabel": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r348",
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockPublicEquityOfferingDetails",
      "http://vitaltherapies.com/role/CommonStockShelfRegistrationStatementDetails",
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows",
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofCashFlowsParenthetical",
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical",
      "http://vitaltherapies.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": {
     "auth_ref": [
      "r38"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.",
        "label": "Supplemental Balance Sheet Disclosures [Text Block]",
        "terseLabel": "Balance Sheet Details"
       }
      }
     },
     "localname": "SupplementalBalanceSheetDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/BalanceSheetDetails"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TangibleAssetImpairmentCharges": {
     "auth_ref": [
      "r1",
      "r148"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The charge against earnings resulting from the aggregate write down of tangible assets from their carrying value to their fair value.",
        "label": "Tangible Asset Impairment Charges",
        "terseLabel": "Impairment losses"
       }
      }
     },
     "localname": "TangibleAssetImpairmentCharges",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r113",
      "r114",
      "r115",
      "r116",
      "r117",
      "r118",
      "r119"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValueAddedTaxReceivableCurrent": {
     "auth_ref": [
      "r19"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofOtherCurrentAssetsandPrepaidExpensesDetail": {
       "order": 4.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of value added taxes due either from customers arising from sales on credit terms, or as previously overpaid to tax authorities. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.",
        "label": "Value Added Tax Receivable, Current",
        "terseLabel": "VAT receivable"
       }
      }
     },
     "localname": "ValueAddedTaxReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofOtherCurrentAssetsandPrepaidExpensesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r100",
      "r105"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted-average common shares outstanding, diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r99",
      "r105"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted-average common shares outstanding, basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "sharesItemType"
    },
    "vtl_A2017InducementEquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2017 Inducement Equity Incentive Plan [Member]",
        "label": "2017 Inducement Equity Incentive Plan [Member]",
        "terseLabel": "2017 Inducement Equity Incentive Plan"
       }
      }
     },
     "localname": "A2017InducementEquityIncentivePlanMember",
     "nsuri": "http://vitaltherapies.com/20220930",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockSharesReservedforFutureIssuanceDetails",
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vtl_A2019OmnibusEquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2019 Omnibus Equity Incentive Plan [Member]",
        "label": "2019 Omnibus Equity Incentive Plan [Member]",
        "terseLabel": "2019 Omnibus Equity Incentive Plan"
       }
      }
     },
     "localname": "A2019OmnibusEquityIncentivePlanMember",
     "nsuri": "http://vitaltherapies.com/20220930",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails",
      "http://vitaltherapies.com/role/StockBasedCompensationPlansRangesofUnderlyingAssumptionsUsedinBSMOptionPricingModeltoDetermineFairValueofStockOptionsGrantedtoEmployeesandNonemployeesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "vtl_A2021EmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2021 Employee Stock Purchase Plan",
        "label": "2021 Employee Stock Purchase Plan [Member]",
        "terseLabel": "2021 Employee stock Purchase Plan"
       }
      }
     },
     "localname": "A2021EmployeeStockPurchasePlanMember",
     "nsuri": "http://vitaltherapies.com/20220930",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockSharesReservedforFutureIssuanceDetails",
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vtl_A4SCRoyaltySettlementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "4SC Royalty Settlement",
        "label": "4SC Royalty Settlement [Member]",
        "terseLabel": "4SC Royalty Settlement"
       }
      }
     },
     "localname": "A4SCRoyaltySettlementMember",
     "nsuri": "http://vitaltherapies.com/20220930",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "vtl_AccruedClinicalCostsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofAccruedExpensesDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Clinical Costs, Current",
        "label": "Accrued Clinical Costs, Current",
        "terseLabel": "Accrued clinical and related costs"
       }
      }
     },
     "localname": "AccruedClinicalCostsCurrent",
     "nsuri": "http://vitaltherapies.com/20220930",
     "presentation": [
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofAccruedExpensesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vtl_AccruedCompensationCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofAccruedExpensesDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Compensation, Current",
        "label": "Accrued Compensation, Current",
        "terseLabel": "Accrued compensation"
       }
      }
     },
     "localname": "AccruedCompensationCurrent",
     "nsuri": "http://vitaltherapies.com/20220930",
     "presentation": [
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofAccruedExpensesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vtl_AccruedLegalAndAuditCostsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofAccruedExpensesDetail": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Legal And Audit Costs, Current",
        "label": "Accrued Legal And Audit Costs, Current",
        "terseLabel": "Accrued legal and audit costs"
       }
      }
     },
     "localname": "AccruedLegalAndAuditCostsCurrent",
     "nsuri": "http://vitaltherapies.com/20220930",
     "presentation": [
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofAccruedExpensesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vtl_AssetPurchaseAgreementRoyaltiesAsPercentOfAggregatedNetSales": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset Purchase Agreement, Royalties As Percent Of Aggregated Net Sales",
        "label": "Asset Purchase Agreement, Royalties As Percent Of Aggregated Net Sales",
        "terseLabel": "Asset purchase agreement, royalties as percent of aggregated net sales"
       }
      }
     },
     "localname": "AssetPurchaseAgreementRoyaltiesAsPercentOfAggregatedNetSales",
     "nsuri": "http://vitaltherapies.com/20220930",
     "presentation": [
      "http://vitaltherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "vtl_ChangesInBoardOfDirectorsDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Changes In Board of Directors Disclosure",
        "label": "Changes In Board of Directors Disclosure [Text Block]",
        "terseLabel": "Changes in Board of Directors"
       }
      }
     },
     "localname": "ChangesInBoardOfDirectorsDisclosureTextBlock",
     "nsuri": "http://vitaltherapies.com/20220930",
     "presentation": [
      "http://vitaltherapies.com/role/ChangesinBoardofDirectors"
     ],
     "xbrltype": "textBlockItemType"
    },
    "vtl_ClinicalCostsPayableCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofAccountsPayableDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_AccountsPayableCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Clinical Costs Payable, Current",
        "label": "Clinical Costs Payable, Current",
        "terseLabel": "Clinical costs"
       }
      }
     },
     "localname": "ClinicalCostsPayableCurrent",
     "nsuri": "http://vitaltherapies.com/20220930",
     "presentation": [
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofAccountsPayableDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vtl_December2020ATMMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "December 2020 ATM",
        "label": "December 2020 ATM [Member]",
        "terseLabel": "December 2020 ATM"
       }
      }
     },
     "localname": "December2020ATMMember",
     "nsuri": "http://vitaltherapies.com/20220930",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockShelfRegistrationStatementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vtl_DuaneNashMDJDMBAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Duane Nash, MD, JD, MBA",
        "label": "Duane Nash, MD, JD, MBA [Member]",
        "terseLabel": "Duane Nash, MD, JD, MBA"
       }
      }
     },
     "localname": "DuaneNashMDJDMBAMember",
     "nsuri": "http://vitaltherapies.com/20220930",
     "presentation": [
      "http://vitaltherapies.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vtl_EmployeeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee [Member]",
        "label": "Employee [Member]",
        "terseLabel": "Employees"
       }
      }
     },
     "localname": "EmployeeMember",
     "nsuri": "http://vitaltherapies.com/20220930",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansScheduleofStockbasedCompensationExpenseforStockAwardsRecognizedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vtl_EmployeeStockOptionsforFutureGrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee Stock Options for Future Grant [Member]",
        "label": "Employee Stock Options for Future Grant [Member]",
        "terseLabel": "Common stock options available for future grant:"
       }
      }
     },
     "localname": "EmployeeStockOptionsforFutureGrantMember",
     "nsuri": "http://vitaltherapies.com/20220930",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockSharesReservedforFutureIssuanceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vtl_EquityMethodInvestmentWarrantsExercisableOwnershipLimitationMaximumIncreaseDecreasePercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Method Investment, Warrants, Exercisable Ownership Limitation, Maximum Increase (Decrease), Percent",
        "label": "Equity Method Investment, Warrants, Exercisable Ownership Limitation, Maximum Increase (Decrease), Percent",
        "terseLabel": "Increase or decrease not in excess of percentage"
       }
      }
     },
     "localname": "EquityMethodInvestmentWarrantsExercisableOwnershipLimitationMaximumIncreaseDecreasePercent",
     "nsuri": "http://vitaltherapies.com/20220930",
     "presentation": [
      "http://vitaltherapies.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "vtl_EquityMethodInvestmentWarrantsExercisableOwnershipLimitationPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Method Investment, Warrants, Exercisable Ownership Limitation, Percentage",
        "label": "Equity Method Investment, Warrants, Exercisable Ownership Limitation, Percentage",
        "terseLabel": "May not exercise of percentage"
       }
      }
     },
     "localname": "EquityMethodInvestmentWarrantsExercisableOwnershipLimitationPercentage",
     "nsuri": "http://vitaltherapies.com/20220930",
     "presentation": [
      "http://vitaltherapies.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "vtl_EquityMethodInvestmentWarrantsExercisableSharesChangeLimitationNoticePeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Method Investment, Warrants, Exercisable Shares Change Limitation, Notice Period",
        "label": "Equity Method Investment, Warrants, Exercisable Shares Change Limitation, Notice Period",
        "terseLabel": "Increase or decrease not In excess of prior notice period"
       }
      }
     },
     "localname": "EquityMethodInvestmentWarrantsExercisableSharesChangeLimitationNoticePeriod",
     "nsuri": "http://vitaltherapies.com/20220930",
     "presentation": [
      "http://vitaltherapies.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "vtl_ExecutiveChairmanAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Executive Chairman Agreement",
        "label": "Executive Chairman Agreement [Member]",
        "terseLabel": "Executive Chairman Agreement"
       }
      }
     },
     "localname": "ExecutiveChairmanAgreementMember",
     "nsuri": "http://vitaltherapies.com/20220930",
     "presentation": [
      "http://vitaltherapies.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vtl_GrafelfingGermanyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Grafelfing, Germany",
        "label": "Grafelfing, Germany [Member]",
        "terseLabel": "Grafelfing, Germany"
       }
      }
     },
     "localname": "GrafelfingGermanyMember",
     "nsuri": "http://vitaltherapies.com/20220930",
     "presentation": [
      "http://vitaltherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vtl_ImmunicAGMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Immunic AG [Member]",
        "label": "Immunic AG [Member]",
        "terseLabel": "Immunic AG"
       }
      }
     },
     "localname": "ImmunicAGMember",
     "nsuri": "http://vitaltherapies.com/20220930",
     "presentation": [
      "http://vitaltherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vtl_IncentiveEmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incentive Employee Stock Option [Member]",
        "label": "Incentive Employee Stock Option [Member]",
        "terseLabel": "Incentive stock options"
       }
      }
     },
     "localname": "IncentiveEmployeeStockOptionMember",
     "nsuri": "http://vitaltherapies.com/20220930",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vtl_IncreaseDecreaseInOperatingLeaseRightOfUseAsset": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) In Operating Lease, Right-Of-Use Asset",
        "label": "Increase (Decrease) In Operating Lease, Right-Of-Use Asset",
        "terseLabel": "Additions to right-of-use assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseRightOfUseAsset",
     "nsuri": "http://vitaltherapies.com/20220930",
     "presentation": [
      "http://vitaltherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vtl_July2021EquityIssuanceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "July 2021 Equity Issuance",
        "label": "July 2021 Equity Issuance [Member]",
        "terseLabel": "July 2021 Equity Issuance"
       }
      }
     },
     "localname": "July2021EquityIssuanceMember",
     "nsuri": "http://vitaltherapies.com/20220930",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "vtl_July2021PublicEquityOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "July 2021 Public Equity Offering",
        "label": "July 2021 Public Equity Offering [Member]",
        "terseLabel": "July 2021 Public Equity Offering"
       }
      }
     },
     "localname": "July2021PublicEquityOfferingMember",
     "nsuri": "http://vitaltherapies.com/20220930",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockPublicEquityOfferingDetails",
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows",
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofCashFlowsParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "vtl_LegalAndAuditCostsPayableCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofAccountsPayableDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_AccountsPayableCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Legal And Audit Costs Payable, Current",
        "label": "Legal And Audit Costs Payable, Current",
        "terseLabel": "Legal and audit costs"
       }
      }
     },
     "localname": "LegalAndAuditCostsPayableCurrent",
     "nsuri": "http://vitaltherapies.com/20220930",
     "presentation": [
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofAccountsPayableDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vtl_LesseeOperatingLeaseRentHolidayPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Rent Holiday Period",
        "label": "Lessee, Operating Lease, Rent Holiday Period",
        "terseLabel": "Rent holiday period"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRentHolidayPeriod",
     "nsuri": "http://vitaltherapies.com/20220930",
     "presentation": [
      "http://vitaltherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "vtl_LesseeOperatingLeasesNumberOfExistingLeases": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Leases, Number Of Existing Leases",
        "label": "Lessee, Operating Leases, Number Of Existing Leases",
        "terseLabel": "Number of existing leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesNumberOfExistingLeases",
     "nsuri": "http://vitaltherapies.com/20220930",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "vtl_MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum Aggregate Offering Price Of Securities Under Shelf Registration",
        "label": "Maximum Aggregate Offering Price Of Securities Under Shelf Registration",
        "terseLabel": "Maximum aggregate offering price of securities under shelf registration"
       }
      }
     },
     "localname": "MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration",
     "nsuri": "http://vitaltherapies.com/20220930",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockShelfRegistrationStatementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vtl_May2022ATMMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "May 2022 ATM",
        "label": "May 2022 ATM [Member]",
        "terseLabel": "May 2022 ATM"
       }
      }
     },
     "localname": "May2022ATMMember",
     "nsuri": "http://vitaltherapies.com/20220930",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockShelfRegistrationStatementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vtl_NewYorkCityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "New York City",
        "label": "New York City [Member]",
        "terseLabel": "New York City"
       }
      }
     },
     "localname": "NewYorkCityMember",
     "nsuri": "http://vitaltherapies.com/20220930",
     "presentation": [
      "http://vitaltherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vtl_NonStatutoryEmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-Statutory Employee Stock Option [Member]",
        "label": "Non-Statutory Employee Stock Option [Member]",
        "terseLabel": "Non-statutory options"
       }
      }
     },
     "localname": "NonStatutoryEmployeeStockOptionMember",
     "nsuri": "http://vitaltherapies.com/20220930",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vtl_NumberOfDevelopmentProgramsPursued": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Development Programs Pursued",
        "label": "Number Of Development Programs Pursued",
        "terseLabel": "Number of development programs pursued"
       }
      }
     },
     "localname": "NumberOfDevelopmentProgramsPursued",
     "nsuri": "http://vitaltherapies.com/20220930",
     "presentation": [
      "http://vitaltherapies.com/role/DescriptionofBusinessandBasisofFinancialStatementsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "vtl_NumberOfFinancialInstitutionsUsedForCashDeposits": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of Financial Institutions Used For Cash Deposits",
        "label": "Number of Financial Institutions Used For Cash Deposits",
        "terseLabel": "Number of financial institutions used for cash deposits"
       }
      }
     },
     "localname": "NumberOfFinancialInstitutionsUsedForCashDeposits",
     "nsuri": "http://vitaltherapies.com/20220930",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "vtl_OperatingAndVariableLeasesCost": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating And Variable Leases, Cost",
        "label": "Operating And Variable Leases, Cost",
        "terseLabel": "Operating and variable lease costs"
       }
      }
     },
     "localname": "OperatingAndVariableLeasesCost",
     "nsuri": "http://vitaltherapies.com/20220930",
     "presentation": [
      "http://vitaltherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vtl_OperatingLeaseIncrementalBorrowingRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Lease, Incremental Borrowing Rate",
        "label": "Operating Lease, Incremental Borrowing Rate",
        "terseLabel": "Incremental borrowing rate on operating leases"
       }
      }
     },
     "localname": "OperatingLeaseIncrementalBorrowingRate",
     "nsuri": "http://vitaltherapies.com/20220930",
     "presentation": [
      "http://vitaltherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "vtl_OptionsVestingInOneYearMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Options Vesting In One Year",
        "label": "Options Vesting In One Year [Member]",
        "terseLabel": "Options Vesting In One Year"
       }
      }
     },
     "localname": "OptionsVestingInOneYearMember",
     "nsuri": "http://vitaltherapies.com/20220930",
     "presentation": [
      "http://vitaltherapies.com/role/ChangesinBoardofDirectorsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vtl_OptionsVestingInThreeYearsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Options Vesting In Three Years",
        "label": "Options Vesting In Three Years [Member]",
        "terseLabel": "Options Vesting In Three Years"
       }
      }
     },
     "localname": "OptionsVestingInThreeYearsMember",
     "nsuri": "http://vitaltherapies.com/20220930",
     "presentation": [
      "http://vitaltherapies.com/role/ChangesinBoardofDirectorsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vtl_PreFundedWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pre-Funded Warrants",
        "label": "Pre-Funded Warrants [Member]",
        "terseLabel": "Pre-Funded Warrants"
       }
      }
     },
     "localname": "PreFundedWarrantsMember",
     "nsuri": "http://vitaltherapies.com/20220930",
     "presentation": [
      "http://vitaltherapies.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vtl_PrepaidClinicalAndRelatedCostsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofOtherCurrentAssetsandPrepaidExpensesDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaid Clinical And Related Costs, Current",
        "label": "Prepaid Clinical And Related Costs, Current",
        "terseLabel": "Prepaid clinical and related costs"
       }
      }
     },
     "localname": "PrepaidClinicalAndRelatedCostsCurrent",
     "nsuri": "http://vitaltherapies.com/20220930",
     "presentation": [
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofOtherCurrentAssetsandPrepaidExpensesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vtl_PublicOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Public Offering",
        "label": "Public Offering [Member]",
        "terseLabel": "Public Offering"
       }
      }
     },
     "localname": "PublicOfferingMember",
     "nsuri": "http://vitaltherapies.com/20220930",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows",
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofCashFlowsParenthetical",
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "vtl_ResearchAndDevelopmentTaxIncentiveCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofOtherCurrentAssetsandPrepaidExpensesDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research And Development Tax Incentive, Current",
        "label": "Research And Development Tax Incentive, Current",
        "terseLabel": "Australian research and development tax incentive"
       }
      }
     },
     "localname": "ResearchAndDevelopmentTaxIncentiveCurrent",
     "nsuri": "http://vitaltherapies.com/20220930",
     "presentation": [
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofOtherCurrentAssetsandPrepaidExpensesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vtl_RoyaltySettlementAgreementCashPaymentPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty Settlement Agreement, Cash Payment, Percent",
        "label": "Royalty Settlement Agreement, Cash Payment, Percent",
        "terseLabel": "Royalty settlement agreement, cash payment, percent"
       }
      }
     },
     "localname": "RoyaltySettlementAgreementCashPaymentPercent",
     "nsuri": "http://vitaltherapies.com/20220930",
     "presentation": [
      "http://vitaltherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "vtl_RoyaltySettlementAgreementSalesNet": {
     "auth_ref": [],
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty Settlement Agreement, Sales Net",
        "label": "Royalty Settlement Agreement, Sales Net",
        "terseLabel": "4SC Royalty Settlement (see Note 4)"
       }
      }
     },
     "localname": "RoyaltySettlementAgreementSalesNet",
     "nsuri": "http://vitaltherapies.com/20220930",
     "presentation": [
      "http://vitaltherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vtl_RoyaltySettlementAgreementSharesPaymentPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty Settlement Agreement, Shares Payment, Percent",
        "label": "Royalty Settlement Agreement, Shares Payment, Percent",
        "terseLabel": "Royalty settlement agreement, shares payment, percent"
       }
      }
     },
     "localname": "RoyaltySettlementAgreementSharesPaymentPercent",
     "nsuri": "http://vitaltherapies.com/20220930",
     "presentation": [
      "http://vitaltherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "vtl_SalaryCostsMonthlyBaseSalary": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Salary Costs, Monthly Base Salary",
        "label": "Salary Costs, Monthly Base Salary",
        "terseLabel": "Monthly base salary"
       }
      }
     },
     "localname": "SalaryCostsMonthlyBaseSalary",
     "nsuri": "http://vitaltherapies.com/20220930",
     "presentation": [
      "http://vitaltherapies.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vtl_SaleOfStockRemainingCapacity": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale Of Stock, Remaining Capacity",
        "label": "Sale Of Stock, Remaining Capacity",
        "terseLabel": "Sale of stock, remaining capacity"
       }
      }
     },
     "localname": "SaleOfStockRemainingCapacity",
     "nsuri": "http://vitaltherapies.com/20220930",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockShelfRegistrationStatementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vtl_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule Of Common Stock Reserved For Future Issuance [Table Text Block]",
        "label": "Schedule Of Common Stock Reserved For Future Issuance [Table Text Block]",
        "terseLabel": "Shares Reserved for Future Issuance"
       }
      }
     },
     "localname": "ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock",
     "nsuri": "http://vitaltherapies.com/20220930",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "vtl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement By Share-Based Payment Award, Additional Shares Authorized, Percent",
        "label": "Share-based Compensation Arrangement By Share-Based Payment Award, Additional Shares Authorized, Percent",
        "terseLabel": "Additional shares authorized, percent"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent",
     "nsuri": "http://vitaltherapies.com/20220930",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "vtl_SharesIssuedWeightedAverageSharePricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares Issued, Weighted Average Share Price Per Share",
        "label": "Shares Issued, Weighted Average Share Price Per Share",
        "terseLabel": "Issuance of stock (in USD per share)"
       }
      }
     },
     "localname": "SharesIssuedWeightedAverageSharePricePerShare",
     "nsuri": "http://vitaltherapies.com/20220930",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockShelfRegistrationStatementDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "vtl_ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shelf Registration Agreement, Commission, Percent Of Gross Proceeds On Sale Of Common Stock",
        "label": "Shelf Registration Agreement, Commission, Percent Of Gross Proceeds On Sale Of Common Stock",
        "terseLabel": "Commission, percent of gross proceeds from sale of common stock"
       }
      }
     },
     "localname": "ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock",
     "nsuri": "http://vitaltherapies.com/20220930",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockShelfRegistrationStatementDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "vtl_ShelfRegistrationStatementAmountRemaining": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shelf Registration Statement, Amount Remaining",
        "label": "Shelf Registration Statement, Amount Remaining",
        "terseLabel": "Shelf registration statement, amount remaining"
       }
      }
     },
     "localname": "ShelfRegistrationStatementAmountRemaining",
     "nsuri": "http://vitaltherapies.com/20220930",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockShelfRegistrationStatementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vtl_ShelfRegistrationTerminationPriorWrittenNotice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shelf Registration, Termination, Prior Written Notice",
        "label": "Shelf Registration, Termination, Prior Written Notice",
        "terseLabel": "Shelf registration, termination, prior written notice"
       }
      }
     },
     "localname": "ShelfRegistrationTerminationPriorWrittenNotice",
     "nsuri": "http://vitaltherapies.com/20220930",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockShelfRegistrationStatementDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "vtl_TwoThousandFourteenEquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Thousand Fourteen Equity Incentive Plan [Member]",
        "label": "Two Thousand Fourteen Equity Incentive Plan [Member]",
        "terseLabel": "2014 Equity Incentive Plan"
       }
      }
     },
     "localname": "TwoThousandFourteenEquityIncentivePlanMember",
     "nsuri": "http://vitaltherapies.com/20220930",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockSharesReservedforFutureIssuanceDetails",
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vtl_TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Thousand Nineteen Omnibus Equity Incentive Plan, Evergreen Provision",
        "label": "Two Thousand Nineteen Omnibus Equity Incentive Plan, Evergreen Provision [Member]",
        "terseLabel": "2019 Omnibus Equity Incentive Plan, Evergreen Provision"
       }
      }
     },
     "localname": "TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember",
     "nsuri": "http://vitaltherapies.com/20220930",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vtl_TwoThousandNineteenOmnibusEquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Thousand Nineteen Omnibus Equity Incentive Plan",
        "label": "Two Thousand Nineteen Omnibus Equity Incentive Plan [Member]",
        "terseLabel": "2019 Omnibus Equity Incentive Plan"
       }
      }
     },
     "localname": "TwoThousandNineteenOmnibusEquityIncentivePlanMember",
     "nsuri": "http://vitaltherapies.com/20220930",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockSharesReservedforFutureIssuanceDetails",
      "http://vitaltherapies.com/role/StockBasedCompensationPlansSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "domainItemType"
    }
   },
   "unitCount": 9
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(15))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "https://asc.fasb.org/topic&trid=2134479"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/subtopic&trid=2144439"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(23))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12053-110248"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=99376301&loc=d3e1243-112600"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21553-112644"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21484-112644"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21488-112644"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(a)",
   "Topic": "720",
   "URI": "https://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=127000608&loc=d3e9135-128495"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126928898&loc=d3e9212-128498"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126928898&loc=d3e9215-128498"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569643-111683"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org/topic&trid=2122149"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=125521441&loc=d3e30690-110894"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=124440516&loc=d3e30840-110895"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "830",
   "URI": "https://asc.fasb.org/topic&trid=2175825"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918666-209980"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "https://asc.fasb.org/topic&trid=2122745"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "https://asc.fasb.org/topic&trid=2122774"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.1,2,3)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "210",
   "URI": "https://asc.fasb.org/topic&trid=2122208"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 4))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r437": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r438": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r439": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r440": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r441": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r442": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(24))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(25))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(26))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>69
<FILENAME>0001280776-22-000021-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001280776-22-000021-xbrl.zip
M4$L#!!0    ( )568U4$GH2C2!   +!$   3    97AH:6)I=#0R,3$Q,3$Q
M+FAT;>U<Z7/;-A;_OG\%ZFRO&1V6G#19Q\V,:Z=MIFZ2B9W-]M,.2$(2:I)@
M -"*]J_?=P 4*5%VW.VAS&QGFM@2"+SW\([?.YB3S\Y?G5W]\OJY6/@B%Z_?
M?G?QXDP<#,?C=T=GX_'YU;GX\>KG"_%P=#@15U:63GMM2IF/Q\]?'HB#A??5
M\7B\7"Y'RZ.1L?/QU9LQ;O5PG!OCU"CSV<&S$_P$_E0R>_:WD\^&0W%NTKI0
MI1>I5=*K3-1.EW/Q+E/N6@R'8=69J596SQ=>3 ^G4_'.V&M](_E[KWVNGL5]
M3L;\^\F8#CE)3+9Z=I+I&Z&S;P_T],DDF<P>/7[R)$L>'DW3Y'"6',G#B9I.
MTTS)HW]/@,@Q+.=GG%_EZMN#0I?#A<+SCQ].1X\?5?[I4F=^<3PY//S\@)8^
M.YF9TL-Y%I[G'WF;K<V\^N"',M?S\IA8.N!'X]>IR8T]?G!(_SW%;X8S6>A\
M=?SEE2Z4$R_54KPQA2R_'#BXAJ%35L]XH=/_44 3D$>_+IGDQ[!/KDL569A,
MD>CG'Q8ZT1XN=-HEN)_4%&2K[)]/Z^01T'K^_/+LS8O75R]>O12OOA=GIZ]?
M7)U>B,NK5V<_B2WJ=UY%\]V?3?\/JE16YGM%Z<->2E_55LC:+XR%AS*1RDI[
MF0,5)KT6J0&K=]X),Q.3H\,!D(+_"[>05M&GJ2D*4_+R@:BD%3<RKY7X^^$(
M%DY$I2RO'@A99F#,/7M45LV4M7#ZW=N,/@&17BV4F)D\-TMT;.#74JLK])W(
MK %YMX4F7%T4$H7OA 9)%^ 3K88;@+\*1T*KK+G1#IYW Y'4'I8)[41I/&Y4
MY<JKD?C>6.'AW/A)>+SG0!!OKJ13@J0NO.$5RGH]TRF<C@_I,C6V,E82V4@$
M+DI6N5PZ.$=Z 7?16@5WEZQX1U6F^ WLB_2<EF4-S+Q1L,P+V L(+<3D</@3
M'K-<Z'0!ZX =%;P3_"A1 ?Q^W72_F9^Q7"]1KGM%;K]BGI)"G*M4%0E<_=%D
M@-'U<( W!=>YQ#^FD\'DFR>#Z<-=5@Z:X)T'E0#E'@G4]87),V5[E8W4! ()
M1NB,=*U4XL9X-! KE(3;IU/$0N49;F 5J%2&BB+S'(W!X\ZN3@KM/6\A>0-8
MC I&QP0*MLC9(@6-IDT.0(@Z!R6_(:K07"E".['4?@'$N$JE7@1=5CG\$LPX
MTT"I-]:Q7Y.HM>@MU?L:#6 @ $& 2_6K#H&P+7"%1"1*R"17N#5MN]X0><?3
M$@FN-W"I+?$,A^0@P/VRC'Y5NZR37X/HJL8M!-=1R!7Q7U4Y.)P@!5FND-.R
MK5ZWQ8C;;KE]PR!5A=<+3@J.@NNH0>= +#I39>;PX@(YF4IS:=F1D?R-M%GG
MJI$T_&!6XY.YFH.*KH2\D3IG+M"*0*]'X@5?H;I!G M/2)'K][7.R)T.8$?G
M3%ZS+EE0"N:VKG!M[3K,!:>^FT&VG\B>9L.1SBG08JL*J4O<6\[ D,"OKHI
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M'.1BI=T/AN[,"7QD038LV,@"X:$M4X>K/RW@P%0&D"D:,7SQX.C)4_BU=EX
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M-PF8A,&'%=%(NMC #<N4-H#"2Z53\+W&!U Q3--T)7E4AZF,'#@I;(Z/SH/
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MF!3_9_#9#)Y<:X[<94C>9QHK'D_WB71M5]\;3[YR(;$S!7YQIY&I\E*GIYG
M(>B>[=UR?"YN.S5XGTW( BM\90Z;'/K%>O#*9/LL+W#L5=+%'U!+ P04
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MGNRW]SXU:(UL7U:W:L?I_QM71_BPI2[?UK?[U0_HXFV]>EZK;YY_IH@($1@
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MC6AFD9V=G)AT!)YF2> B..8$L<%([&W4##&EA5H>,<TX.SLYD4D4)4<R,$N
M$G%MC< Z(LH@4#;$ZZ41V52SLY.3C^(*46,)%L$R(;EFV'KKF18I;SM-^<Q,
M0ZD,:06)EP*Q((EF-E*JK<-*11/'I)V-*99X_L'FA5?5VV2+/9QLB<D,A:L8
MJ>5>.4Z3T^!:!6-]Q%P#P^1&S4"J"]%O) @>TJ0YRBQ+A!6ZAD?/*,&<Q<B7
MSQIF%DU.7[@Q(A^=4=$QR9A52BLL(Z?8:R:8\DLHW'G(3T]?T."ZE)+20>RB
MF4'.6J!<GB(A%/9(LN43]%0SBS. 96*PT=(*A#53X->TLM1X0P"@I?0+)= Y
MSBPNN18A09#&Q =/.>-(F"@\I20BZU1:?51J4<DH'NEH/,&:4R6(81 S"HV(
MQL[JZ%-Z6K]47%I(6:I E=<>V"&0?X.0$81'Q05UPG+P/*-4P#R+< Y0_F:.
M0OSR(IX;HC$0@;D0*4C#,1"+T1Y!=,L(-L1AXI9&-#/*3T](3-X*$JS4W$?.
MB.2&R&!C\"PHY(5BRR.FV>>G)R0RBS@Q(@+>^<@\0LIH[)F(. 0NG5X>RYIV
M?GI"\L'1$ZL]]\!0F7):26L)5T8JR5G$=GKRF54/('"_5@*]<LRRM'[<2JZY
MMD#@K3/(S&#QW<*KZNR7!D8297#1$*$0 Q]NA0<%QSXX%[648?FD.K.H:/K"
M54* 4+U%P5&FB;%*68JBHQ[X +)Q"84[#WG6Z0L:PB)"E/!<R, BX1J$8+G!
MECF25B!-K[S \H1,OU[WX*8-VI2+H$8Q8YB0S$CK(A)86BPEELLCFAF%3!,2
MD[/>>P51+782^%PPRH/] -'3(2""^?*(:?8ATZ0LBS-&590VR,ADQ%HX98@C
M)&C+@Y1+([)IATP3DH] (!JG N/!LI!XI?*"1\0\]A+KX61&M 0+8J?EE-#$
MUL*F2FR11XCD0F1<6B.C]"@:S8PR(BR/:&;AE"8GIF HHMRXR+1G'H)OSH(.
MQB.FK2/(+H^89NR4)B<R*3E%(6 %# ^<DC<X(D*]-8X I=!H:40V5:<T.?E8
M%32RPE@<"0/^;8EF46EBF4$IF34]^<RJ!XB0FD1!I*2.<>$T92YR[5V(EA&!
M;A<U*J=$_UQ03RBY-*%%/1(X%I5 K4*0C,1HI,!6JP!_D78FSD"J"]%O@0EO
M(V>(@34(S34+6+BH+-6,*$F6SQIFD_^<B7")\"(XB N9(4P@:KD*D9/H;$#:
MV["$PIUY_G,F@HZ1,F*-85(2AK'2"GP[HIH@<&_@[T>"9F-!S_,PZH^G_VRR
M#Z_WNY>FU;_\$/K]5J$32SL[$3]\_A&>V/PCJ;V)06/O@!5R1:V31($S-8XK
MK DNE6DIW-'T%8M)QU$0ABBO&(I<@9HA1#@.1CHKZ,M6K(44J<.6DY#J3F/-
M "BTL1Y9;RG$^]%B,2SZMP3$8GJ53B>UGA('%K10"'M?5#A31"@F%.4,@)PQ
MOS2BF4VETTF)B0J9RM48QB)+^Z1IY:71@6H/3M>'Y;&@6><X)R<RKYRDQ50X
M2QGE7B.DB#>2@\P$%WAI1#;E2J>3DD_ 7'FJ4OU+PZQPF@5%%>,24^ <6$]/
M/C/K :><,90+XU+YY&"@)SA2BJ?IZUJ;16):\Z*JLR=;J1Z$9<@8"7JM*-5:
M@W@U8\IPR=TL K.%Z#=)I$4&^D5*PXR**GCJ4YU70''H);=\UO"2@LKH(B*&
ML& YPQ0K8CU%6E"I%00G<0F%.P\YSND+FMJ@D5-((V.9P.#AB"T*RQ.I$'BZ
MD5=??/E.,=2<U+(XQHGW))J0BO""5#CU+C(7M1&&1[DTHIE1J#DA,5$3M><$
M64<ITRA:1#P+*$U0$R!!M3QBFGVH.2&121<%CXQ9$!(C2)O$780TQ',DA-!+
M([)IAYJ36A2&A>-I> 23P"1'%OX'U,,+IR2.@4Y//C/34$!^)H5A6""&I;4*
M!XX]UAZQ&!R;P=YJ"Z^JM\G6]'=^H]J80%VD2A)P#<1 V"FB8X$2SKR6RR?5
MF85,TQ=N4%$K8;SSR#/CK0:2QISBP04GP9Z74+CS$#)-7]"2^RA,(!#\*@8^
MR09'$%..,>2(BPLEZ!\/N/XS:%VF5QBJP6ZO-S =]S.9+E3@-GMMXDJ*X")F
M:3:^8R3M.L48]YP+A9S7I3:5#ND7JU<YY(03E'*(=:Q.=<2IXIIZ"'D,M0O%
M-IY!LQ92IDHA:E/96A,EPQI#!*MB4)[X4 AV%!G-LRCG /5OAFR36NLK',(@
M&0Y_(&@E&F./D$"<!TN$Y4LCFAFEZR8D)@[VP[1%*N+(&!'&8!R=@U!,6B?(
M$HEI]NFZ"8G,2G!70A/*,6>"6R.#5T8['97CR"P/Z$T[73<A^6#'O1=1DK0Z
M$1%FO<- :J,1,@TEZ>G)9U8] *Y742*X9AZHEL#0 YQ+$DVD*"7O;F]D-<^J
M.E^%0A^QD=6$*)8.1C/EL:$2@C)!4@$(!QS+..4II^SV\IY2EL^P@F=2=<@H
M)HXIQ**RS&D-P;4@1GM)A;)8A>6QRW$(-)3IT,TLLY6&: T7 @6!TS)+:00
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M5&V7+HC2\K1IO6,F2"^!ND<MHPC!8HA"I0K*EDH[?S*SU*;B"D99$5DJM8]
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MP2D&$L8A(B>88</IX\O$DEZ$)LV$)V$J-69(1L\T(S+M3\U4FK.<JM\331>
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M82=-)I"W&3/(9UJ'F)$0.!*(!H(E\ _$5K5Z<D Q%7-?^M'.=WGW%-IR661
MTM#8:2JSNUKIA'Z9_WC^_,>P\]^U3*</X=+VN/]KH5]BT6.PZ/(.\R !:XP,
M4 TG<<8PC1 &89L%&8BPG'D<*& 1?S+M*!,;\VNHDTMLE(8Z*4.]31K /D4,
M2&;$&)<Q(6.F(] '3AT"4U4F<)X,E<R1H2Y]QF*GV_7GS5;K*5F*Y8:627&
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MQ!0" Q0JQY 9U93I9K^M8EO%MG7!MED.@@:G>'3:RI D<"V1Z^A2#! -#<K
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M4A"@NC]SP<!4T4IS!.4=45GK"9C\*.]V1=!:7?BC/:@, Z:K^-QUJ_81WJ]
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M,9@K*EHTT1CQTK+@*$?[N22 A6P. -RD/]D*%W4$L.X&@85D/\#@!JWPT"8
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M8M,8/"\*C/9#WCJ Q2U*K9TH/C0"P<P=A<L):!,E!A?IZ!$TL.05>A>J)H)
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MS3_F;LUKS[-];8OJZE9-=HDTR9API;FW3A)Z:F< IOZA*TG:]DY#4W*:5\4
MUFO<!- WGJ5Z<[0OJ0E4TS_7UNV]F8-<VXEM,6M+C3<[["9SW*S]"::0T;A=
MNKEUX*9*.AL#O#T)I3KA9>-V:-/K5SAFFC+,ER8:H8G7-J9].$>\%:=P4;?7
M'O(?UO-DIRBG$G^GE'!=QRG74>2-1^!2H=%_5B6W6O@LJYMF;3\1/WU[H^VZ
MZ.M\(+;_^ .Q;Q=8_:#YMWW@G:<8H?E=[>J@9.-O67M=.E>'QP"4HUC$,1$
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MQ&X<:<[AU9S#6W..)\<YKF8X1^)&J8K3D#"?8N&#("2)"!7)5!P)R</(CWQ
M)YLN"S:3I8U@'QWGN $]U2HHS$1=SVQ^U95ZP/_6NO""*.8ZQ/4!#4[ ;UI=
M8<K"]$#5\0'KD-4Z9!4DK4IDQ)*8I$G@$1:JD,0L4\1E/ @RZ?*,\CN[,!ZG
MO^*S;M?>&SO88ULGG\A_%Z6S+8L+M#$M:IYQ-X?&8_!>3%6(+NL9YW;&DRE6
M37\0TXU7&\9T[,UT(UUL)(J1)),N5B99].8@G/LD,I@CR"/A^[[R11 SWU5I
M[*M8)0'6!0>![AW[T<;-6W*[3(=?=].+S*E@CRJGXL8M?+CU6<R1_*UK*[2L
MPNV"C9!L4IV-SM;!V3MY)7J%K@;Y:"3@V$K _M?3PV\=__"L=W9XUF%'.Y_&
M1_L()#]='IV=@+1[YQ_2=ZR[\_?YK 1$"7EX)?.];]V\<W5Z#M?T #R"]/RK
MOP=_XW@.<1S]SUGGZL [%HG/0@GB+\N2A+# Y80'W ?,&--(4!'0D,^V-P@\
M%L=>% @>I2QD61S(0 095D>E@HNY".BIJ'AG1PUYWJOF&6*;7A=F_]SXWD<C
MH>XHF$W5X[>VD>+V)!CQ8ZETG?C[E:/^70Y./1T[&S.9?83!+_><?6+'J2?#
M-(PXB1)0QE@*?R5A')-(9#+S:)2&Z7SFP.\06;>FQ78'W3^T][(8P8ME]>HW
MN0]!#FZY1A;>PW_H>[?SG=W1)><%T0/X#Y,P6?U@Z98;W.ZQ5AF?07:>X3(_
M[3S[A9>NSN/WI'Q3\]'<MW#Q/=?%V $=T:R%I]?BA7GM:K;>M*>>Z_7P8+;
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MJ.VW6\['%B*98AW3=N(L[^D6'' OQ_(QIZJ7P8>3O!J6!IQ40Y#VFLO A_?
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M#BR_C\@F&.QOMGMN+X8;_YZG', W%N9P\?&O7H?JYTHB<*-B7R "V%,F-0U
MXR5W@5GIC2$!6%K48%>E*U=B[8@1$)9)Y8F:L,SX ::DY>6@/SR+?C0>MMZ,
MS\ZZU1Y*M=?@5K3#@IU5B$#+3IC ](.@8H +Y&OO N=,A2@4US0EX"626R=,
MXD)89[@EVM?D9-'AVI"3[PGR^P?OOQQQIQ.'?Q #]0HF3*  \H8A;)FV*L!:
M<>#.=^<F('UV!')UT7*QR%X6UBQY8$R"Y,"*P9\M.T(@I:@V\[-4 @.!]:Z$
M^)>-.?EO;1^T-WYMG7=&QZTW__S1^I^8Y>%C<7%]@.LK6C[9'\?P\G@8PV9-
M:48Q^Q! VB=PD7^'"\HVZ<&WGPWZ/D:X)@WZIW.;9_%3V1U17= K9*CE8?-F
MAR[(\J?8[9^=UJZVS+3@MF'L1RT/PRC.KHICY0U:.5A@Z'$ G_7]P5E_D/?>
MV1A^*VZ8RJ&6OR)_9_YO_ P27GP_V;<#QC@,"S[< \B9C@*^\L/ GD[\/XO?
M7\W3TM3"Q':[K>RIR:0O C;4CKIH!]T.7 @/]$OGU_+22C"Q\/&:)PZ/[2!F
MPV?0'W^87ZWZIOE[J@$.Q^X$\*MV&>6)#D6- DN(!<A@N6N'S_*8819_Z>1!
MU<.>X:K+%X-$E"D_[PQC;9QE;U(AK.[BJFFI97@Z,2$7$,H2-@*P;[F+5NR4
M=3RS@]%%-6M7(N52WI*6L,=L=)$3KBBQRA"F)=?8*>SU%=5-=_=>7,M[#RXG
M \"R/W@WR _:V^N/ #GG<!%4D\_8>-X?A&'L36$1_[2PV#Z'_UX<N>2DPT$C
MK.$'9[D<GX@42<HT(]%SKMW&,YC4)51L!>!&M9<^*T^0T%Z9^,TLK" N<] U
M(TD@XSX.1C;_MS/PXU-@Q+#%YE"@@(ZO7+*55LZZ&T0S8X -G^( )#L";/G1
M9*/5>+@U(5P/RV3HK9C,Y5',C^!15QFJ=R$T.?*&2RE=Q)QCY0U.3',KDP:=
M09.^E7T*6PMX2]:.4U/T3WMF?6=TT;"5F[;E_L$N/DK$&TT$12DHC#BUP%8H
MAUW*-(F$&!>-V7BFM_@-9"7OL7KF:^MT6).2E9IC33;/MS1_U]P0:H,2GKJ7
M'H<-I!@)A@CEE9*<^J2=8"DXH[D6/&I<ZW9!&@?M#T.5S^V#Y_Q(,>$L)00I
M6*U<<9<AIX-$+ C/)(].! 6H\FULH,H(N,D0FLC_W6R@&:OG)[9T9N?N$1@Y
M<\.]QKZ9N^XVILW<![ZE51.!(SOII7(T<"%!2SN1+*/2NRA 5316S?<'NOV=
MM_1()YZ$BQHIE03B.C"DC56(F\ 95@""MK%J?B*K!K@(<QKVI34&*(JQSD7'
M#1>$,^WDI#.5P**Q:K[)MKQH[^SR(VT,, V=XT980IQD9X,, 8&UR3UC@BJC
M;\4_KC=K9O%_ZTF$CE1/7_U<]/T6]A2RPCVS"_!42!IH]SQE\3]C !FXZLIM
M V(+.VRQ"MI]8JLNMQ"[5M-M3XC?G]-QOHR#?%*XG_X"4V?XLB9P^[UJ]U4Q
M0F4/3G<5HC_SMCIX=7'$"!!WFQ221!@$.\D@0VE$EBE/DTF>1:#U;,6N^M>$
M8WW(L[V"+U<$?8;N5U00Z&RFC(7F.>!C>:?][XH +HCDH/^I$^*<6!9.[V&+
MP;X89.X>XFFODX#G%GDL$;L@@H..&Y<72BSY\&ELY-V:+Q_#!.70S]'QL 66
M"TS6FW@VJIPQ#&^N< $ T\],I#6PF?GF5Z:K52%?MDPRX4T BU7XZE:K57\?
MZ*H[?EWYFK H%W?T#'C) PL4AY#+[D5G'5:**<(2CC3)"7BH*\#C4O_.A6GN
M%@-SIX3$ORS1\"5)!5:HO#-LE/%-J+'W91L?"<4LIP*FGI/,C!E&3@J65T(3
M%XPW*6P\XWC+W*",9\%@]7G4Q'*<($J6HRO%J(*8!4DB+,!XB.514)X,<X2P
MK)"H8T H KY!#<V87#>(TIOR[7>4I9_8W@)9>G]Q1)SEF#B)HLSI2YQJ(';:
M(1*I)$X'8A@!6=JDF&_"RBU;7;5>6?0K90.K50%J-MS!0+(?XBV]E"^SG] .
MXL-*$ITG-'G4E1"]JT>Y70VRO%6\EY?C:*0%_MX]/^($&Q5E0 Y[#69 IBH8
MA"<(RC ($+76;#PS6XHN"\I9'%3"4KEZ5GOY5ASYYU#-NZBNKQ239=4UH;(O
M8)"[M<-M@= V:NLFX?F CS3QB8M@4 K6(1Y)/AG3'&&-E8B1<BTMD%VS)6]0
M6R7$#Y8LNU*S<Z:PJ/-!)[]Z:3?=F?,\O.#8BY(O]J(_N#23&I)SL[0<M#\?
M$1U55$0@$W$"Q81!,>'H$ Z1*@S"(SV0'+*UC#1SPK*8G?=(K8^#%?;$L?U4
MF1/%NP[/_BD[56823BM;)?M!;S8BR-=8:=]N4LH=?^N,X.O\+=+-7HX=7-BJ
M\L!:DZ/(X6,1@3L];34RP(U^Y9+YK<!@OFKCV=_C;G&DD=;J&5F:D-L?P*_#
M;MCOM<H3$E')[KP!7,+52PIF/C3O7:J'<E(W/;$LSHR7G4Q+WMA>Z,)__]N>
MGOT.]]G:+'[*?J\7*ZU1KH7ON&+>OO?S+R9:GU6+/#TBO;.1!E8^R^?+ F@_
MMUH:'E/40'IB< YK4U0?P1F.)[_,JK[EI,Q+C_M>\4W"'S.,>[=WD%/KJZ$U
MAMI*?;CS$>]]^7#>/FGCO9,/%_O;1YPJBTT .Y]3GYV%!!FM(Z+)4?@#:\=D
M-M4$QIL@?]>9:JNR]>?3MNYCH&FFHI,I,6H<EX$X@R53&)Z<.T"PNI;>HO"L
ML/!GN/5+.]@?E"RIRE?4V&3S@O%E_]415201QQP2$4>@2@$CDU/XL!.&*<6(
MEF+C&=X"H2 K[#([27.?6FB;E?E>P<J:8-X=(YT>5$3I-?C6> I62"4&N)):
M8;#W."+)")1+12 C.$:<62EE##X2 @0^B^5USH*G0E7,*JJ2:Q14,3!3:K;"
M.U)[9Z<AA1-GR>0CK7.[3'%_S./.E-V A[[3B0,),?J4,!&>$Q*,TS)Y+[6S
M1&KFIQ3$3"B(N>'$X7*/_@EF=R?4!5M>1Q\[GV+8OSL)^>F,\OE=3?8^'#&C
ML$[ /[#5L*MQU-D#J) ,(GBLE7<6[ ].;PH$V+S:BY/_")UA70&F.E2\=.KD
MOR.89J<E(FRJ%29U82858]9D/[B+E;% -QJB=9DNE"O]U0"VIG8WH?]:K !R
MQV<LI\2_F1]O?M\BF.F&P]=+,IWKIY6#\4)5<H&I*J"T$GT0X]/*$9/%.=>@
MRM(,;XQ'Q_U!J5XUB_B@ $IL[AVM.D<=[$W-L=*)ATB=9UB9: PU%)@/O3'(
M<04?K\RX[>DX&^OM!F_FE_;!>WHD560F1H$( Y[.E:- T2E#/O!(0)6E0M$)
M*Y;;3=;;0H&-*7^_)R?^%F+2F&W72<3)-CO220KE340XT8!XDAYI"W\"#6*:
M)2! T5]CM,T?IGWJCTKV"* M\)Q>!2O=SG_&.<C\,A)G8OK7Y;)NXPDH5<MF
M0L/SC7,\&H!;+KU7J;?J[B"*_?-\V[JF&VCF'"Q;OJ:$O%U^ZT)1F+OKQ4IG
M\"OTXOIHC>?6'U<+M71"GI,%1MTXG%F1/,&YY@TL9\YG*)'\@*VC/&NP!I.(
M^9P*5%VR>OV&,R71MEI_SGSI9 GR>.KO+_<;5)QX*C_#HJ/J 'S8\UT[N%QM
MU[>#S+S@:OC<J#_(D=)EB;,PUID&*_3D/:#I*V,8K\>HG<G#3KY\IW[0&TOE
M_LS@M7?BSX^X3HRE)!%SVF=U%I%-FB(MG,::&&(CN[[\\5HL^)]V>/S2=IH%
MOW'!M7(J2>E0D#0A+K !;:4XHD*P"$9[8)1O/.OUES35LNHJ-5VG0-,ZM@ L
MN;;N%&;Z.:6G$[:^MJQJ4V'I=A66]/I76+I;Q:1;2\.//L+=>/9R2H3N9CNO
M,^<Y^ ;V\'"M[.'IJGV%2?S3^1)G5 K\2XXTEM(#B4 )-C#B7&'DA)"(6I9$
M@#4A"F\\HRLLX4D<V*5%_$/-WGEI:"S?:Q?^E3@*%C/");!%9B3BE@=D PM(
M:8IY8)BGO/"W.*Y<K"QZ;#]E5W!MZRY:H3GA)99<YMJ.^6-BQ^Q,[)BM=0*4
M_?$H)Z*&I6J@#3^=EZF#5^P(T$)83#CRB?*<$D&1E<PB2FR@-F%'80V>[2WS
MTUDIJN"D!!SW+R>_)*ZO\OS>,6)N/0E($;C6ZP@W_!2K2@@OQKD(?FL2ZOQU
M3_EMBK^7$'Y_',-X(;=P\B O^H/J,29/<9 /A7[F6O!['XXHURZ)'$TK#6P2
M3@!X-4](2NUMIM2:RL7:[C^$058 F'G@I52F2BHO*UZ,5FS)XMB"_9KZW6[_
M?/C;1':K-@Q36ZTTQX&'Z=JS8?QM\LOOH3,\Z]J+WSJ],J3RH=]K*:\-O&S1
M+/3&*6)?O5T;.\9L:<&RO5-W.Z^_N#:%MHHIM-#KIWI/RRTBZ95OXRURY7O7
MW9:0+<GTK6Y[0Y/VM>C%KF_5?&MU:Z6[/5-EF/^8IUK"Z_)453AE]6S]5*SH
M:K?,/>@-JWACL[M;+B] _P_JK#;KU)['B2E P!^_W6+U[];X[\X3F\H_CV=B
M9^L5+/\L(>7/3\^Z_8L8Z]E_.1[X8SN,K9==&&YKIA;<XJ33N\W3RM:'CZC)
MWTJ3(4;I@O5!$)W+F'C-=+"<!2<T8XS8^QRV_FG/,M^K<.!*!O2D3^JK+H G
MN^3P8/?+'OS[_LM'EDLLO*=[QX<G;S\?GOQ]TC[X '^_/CT\..PL=@%LG_P#
M]VJ3]LG>R?Z!_[RW\_?)>_KB=._@Q6G[-!<G^OOD$.C6WNG?J=W!GQ>Z !+O
ML;%8("&U 9O6)F0$]0A6&+.$O8#%WG@&NOTA.E&OQI3[M_+[>D51[52Z1<4Z
M8]N,15UC5_^L5#B[%V*MF(DGB5C>8A4Q\6">):ZL,#G$+QIA8\*!"-T@UB-
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MK6%L12!:=C@<G]8>MC' 0:O3:XW@PC_>M%O]\GKK#-8PYQF>]D/LYCBQ$('
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M..XK7QR\,.O-'T[U,E"JZA9GH)E_N_((_*%HS$HV>^.L/_L_Y8SJTK@H(81
M@[KV;!A_F_SR>^@,X3$N?NOT"IDI'_J]'FIMD60*OA@?G0=:O7W)SK=PQ=#K
M\.SZF^NWM\I;"R=UU7N2;6E"KWP;;Y$KW[ONMD1N<<Z^S6W%K6Y[0[#ZC9%'
M<NG2'QQ@I!<XL%H9 K"7MUVK73'4Y\L,=>[8]FOG:":PY Z5!==[ K.*NTTD
MS5-Z8'(7J7C\:1ZOIP>'G<G!Z&#V8/1;]11^5!&*MSR%^DI3E7_3,ZB\T/D
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M/OZ_+V#&[^3W=K^T3][#?U\=)6!Q0+P]LE@0Q".CR#B=$&$V*&#H# M:J77
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MA,4IYY/84GO6284TQ1H993UQS&,JV<8SO2F-W!2"?AV_/[.#UJ><5G&_9!(
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MVY:6)TOG@Z]G+WDSN636004F'IA+V;LU=3)=#B<OY///OFCL0H<[PY+U.^=
M?_[G]'ZY"]>@5C.S,:MF%G0G0GZ<"_A-S_BRG&=Y=+E6(?#H_J#J?N'M9 >L
M?I;Z&0#5NC:?P,Z5>ASV^Z5D)$C;L .;#C;HN'#G7K\5\VE^*^<U#2I34.*B
M+&M&/UO_Z4J]\ L\IZD_5@<Q5;?-$8MU[MODTU<,WUULUD>IIU7%B[RW*R\>
MS.ROTRR$CS&>77>?.H"@;@<RG80I4E35IWIU.%M]^\FT#6^>X,M;5B9^L4K*
M34LV&)C6T\]G=)N5Z9((EK\T!SMW<O)XZO0JW\#J<^!?X6D^E?/T&B2O&%EQ
M6)7>8T.PK6ZW.R[[+LT,<=N7)2.&L<W63#>A.3F?N_S2H3JI=UGU12&<%X&#
M:1]W/Y2DN?H9\G1?]>7E+@4MS[/? TS0B3O.9]MHTC9F]03?$477)=\VV\"Y
M\U*6A)=E_8EK[9;$T-/6=L]V+X:=0LDF*@;$I=T/N1A 1*,^>A.SB+1>#ON#
MCH5+UV06KE(81,S'D-"E&)+YLKC]\0@@(59(D@\ASNJYZM13E/LCGZ%NUNAY
M'UKX_.6<922=3NI4_8]*1=CY*3V##1(K%S#@_^G,! ^K"3Z;3'!=I"Y7)>Q.
M[I6_K289EPY! /%N5L]U68I5@Y^.%3 RVNZD'D95S 6>:]+4M=*ATS5N;0^B
M+=]45K]J?ACBY]8O&R^WW^Q.]="@XE^YD.S_S]Z;=K>-7.O"?P7+Q\F1[PO1
M!">1]DW64LMVMQ)/QW(G]]XO62!0%!&# !N#9.;7OWNH*A1 D"(UDA3.6B<M
MDT2AAEU[WL^63":[CBE['>4"IJ8JM(I4S%W228A14I+-.$9K>1+G">C]XD>*
M_1#!MLTOF6V:H\Q%@BHV\S(\;MY%%H"H\7F9@JX8N](22<'R!9X+7-I78!ZT
MES)TP_N*SR9P+AX5W0)?)#&E74(DKWA\?C>N7BU5+R*95::>NA,!6T;44CDJ
M8'O^#,A$<TR#2J@L6@Y*[X"#X&F27>2+&:P0G].,"E]$CUV+, 1:"HFH?!9F
M('LCN$YR,H1#@IVM<*AXS&VRRHH"+Y2U 9DFI^9F )(4FBU2M:88F@5&-R9Y
M0NHHD=Y_6*4H&O/1GL +?(%2"D\R BT3^(.8%WH<</7+Q)WM'\,EYO-K'/NT
M$^>PK4%"6Z7X[)TA5'9(-7<ZLF'7<A[FS7F5'^(PC*^5_JU8LC*8D">4^*]E
M\%^E)6[$=@N6%M?)!'P1XXIR#*[,#_#.$!P3HEX)CQB/5O3H =1 0/GVZQ;2
MLDJW"W8I!6LE(1X<I/(&NSCKRTMINU[QM?() 8J&! X99,C^*902!C_0)T)L
M";DJ?7^IZ U^%1#)43]80EMGD*!JD7\6>,$<[4X<FQ]%-"7X/<:0Y""F\:I?
M@5+RUNX9K^_VN\-A>S+RW5Y_Z W=L3\8=0:3R6#D^_Y0N6=DDG:U#&[9/:-N
M6G'1/FY<V?.,W3'M3__^O^U/__.O=F\T&0LLPNT/N_ _[NAX#&=R#,<T:9^T
M.^-Q[^3%7[O=F]PQ2B#^D;L)BD_6Z9<**5O+_&X916Z_N-_F71>W NFY8?D/
M.?8V0#JW/:6F:&BY:*A['T5# ^>)BX;NV@3JL6LIL/D&LS+$X0.-]5+[[4C;
M1;RUG%UQJ-^:UK*LL "%XRR.&!V2?O.-)"[]Y(M&U-N;YJPK5=W5CMF)UN3\
M\FZ9=O)$[Y97VJVDV*T"?]!*IS*=!+YWR>Z"I_X->E51Z(R*6QZYN:JV8%T1
M!T?O/\$IP=4G[[IOO%W[IU)I(F7LDTL$ Y!@(3>]L* ,1SFFBA/7GC&=1JC,
MM?]A$0B*T3<QCQ/"I/^ \)Y.^_A_V,WUHOJ;%Z]THJ%:SYDY^[KWX@MQ"TZY
MX\WRR_[>NHV[^<7%^[,7KPB!ZX,8)SEB'71Z1O^>/%7^1/(IX%MM.(<0$R08
MU(ST/2O-0:?%2E[M;+/5-EX+6^V:_"1/JY_ TJH?50H,\!NP%N67TK6CODC$
M1)!C7'YN6^>1UZ)EHS:+:%F!'[C)#CGUUK(I.%0L9C_^&,<_\*(5=' 0 'GG
MA"T6*-0!(*T,C#:/FBJQ*B^Q#.HNF$9?F,A-"N4F&5>]OK_V1/@4+TN+BQ&Z
MUVG+^K!Z),S> _+YM\P^4G5=29#^X&N%QA]]AN/9UHR052<R&H!/C\4"F!1=
M7KPL21RVK OTVJ?FY:8U<13%E5W(0\SD(,^/;?Z6[4]R?]N2%[,OG'PI8!X6
M[FXY+.T#P6/K.SD680#&9_7.S=S%TD=X;M4/P4!>^@@Y>/5#M-66/JO[(0N
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M<(S*[N,"@ D]ID;'$I497U>_7N@:G(>,YA/#9JP>6:9ZXM.:9U-D0)6J&ZX
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M6*H:D]D:7(DBH:&VNYY:KLY9,,'.R6DL;1?X8*GK2*E=2:G%) 56+P)9'%L
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M+-,DB!ZJXEH34C\L7-,J$X+.5>*ZP=GW6F:=AZL]?>9@3EOJS=]Q -7C7&*
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M:,S55K3RJ*1I#.>+D]#C%T5%>]-B:ZU[\9_L,/'(>H0-A2-@OP1M--#3910
M=;AF# 0W3,H5DJW5HU.=IE!\ID(0(4_R+$](T;Q&8@8^@?8_CE2\%*W&1&@Y
M35^J?YA'*4E&7228G ^2(Y,S<WW?\)H @8@T=9,%KHEG*M5=)9?I:/%&^%?
MR(3QSGDP%[AC^,+EE]'5!44B5AN(<RKMT=+&&+U_E?N'HALDEU$9GX1$6SA=
M$5T%21S1@G&P-)_/X<J (D)&<YQDH&&"W&>+7RH_Z']AW7V>!-[S[A_,>XL.
M4]Q!GT43G.HDCWPXGT24:6,F**$NNCP&G6UFA5J81T+@[XEPS0LB?@H/[!4Z
M]G$.-P'&LHB#B,L%67_(Y[Q@CA2735W4%062&S"],3PVSN DT;B<)G%^.:79
M2NY&/!SU6%^,@?O@R+:Y! %S@YE-6/1&E\!N$Z;H,7QDN'6 SN8Q;@!)*=9#
M\"O: Q@RQ&8*\&Y<FDN"YRKP2>8![\O1R5-,'<:JC("4K9;C7KE!2#>=>EV[
M</VX#R5L)ER5DE6L&,Z4&6UUJ36<2*JPD\(D)1.C]+,D2,4SIO=O;D#<6-(&
MG0MQIS'Z+(#:_6 "C!RY!/)G.-,0-C5;Q:C'PG-SCD$\V]";4A"N8F3+(6ZK
MM/WD)H.@_R&R5*F#,,4 WAX&/X25IS;S##R&5'K2T:(MB52?I)WV!0'SH$M%
MS%N).?;1%_T>\3,WBN(<+B>+P\CZXF4Q:EH=1RIETBDKXZICOC?!#!YTPT4:
MF!%T?/DL]DDR@LX"FW5%0<8T!CL9VX3O!@'LJY;%1A+JFX5&KEB^.C:I('>D
MS_ *V^4&Z+] +SPYS)=5\VZ_;P1ZI&417"FM:IZ/P7Y#CZ!(6$*@#B/@7PD9
M)7[9O6Z=TB_J'*'2C:G]]O0'7H K,&"B+*V9VXD1\T6S S4LEB!*\,C@TLO^
MP(@+80]A'%PN/C#HFF:BO"0L/TA.H.21[8YQ: IS%"HZ?+V(\55P#:^TZY;V
M"M^.:IRZ*4&*,11/_QOL(]8/\<J!F/%1K2-EE5+PR"B8:-,7;)J,+F-=N&H?
M"?8\LCZ#I3N3F]\F,I@$&$ER0?L4X038V:4TF(B*Y 8@-_H0@P)U<=RUCG G
M7^#SU@4]\\U\YD(]\^(5$ D%C6[\*6KV,SQD'%D1MUV<'FG*:(W#,>9S)(N7
MG7Z[):$834(SJ-\V;H;\X-I-I%\-]1(K!54O >U+,.V^!GX/E)B1\1VC@9"P
MC"VN&]M(9/TOJV4D<"]C^.'AD(NV]I?(Y6L2IWAA\Q3,?S!B^""5D;C1(;H@
M:H&]Y#,C=JP>+*3E2SQI:\4ALQX[<Q?(,_!5D@W"=?;A,#' C49@=@R3.F;!
M+@.@KHILLJEX\8]?K(\"7_V##,E+@J1]45J_=?K]$U*U<KCDJ7P;RN'(KVJX
MJ&A1@$F0G\(CBT.S*;W0RE/$\.@'$='2;8QE/ 4N7%;*CA<G\YBLY'D.?Z5(
M\B"Y,+4%7J'4?O$3+B?^0;)&FQ@1D%-A/IL>ESK[&6_\TK:QYHIF ]X9V+IY
M+'4N-PD#3D/ Z%:):9L4(YU*^+V,+2MQ:YZ<')3,$VE?C_\MW2!LF$AG9HHA
M=-PG.'JIIBW/&7:1@AUJVL957_XQ>L=PRZ\#-,^(GU$J!7PDQHM5VR(I5V^,
MCRH\LI<,+C*&_$0@8\0):*:\:R("&;=(940=+PI,-(K!*A4VSAF>*E&S,2"Z
MUT2")JKE!8F7S]!MYY6)@6C/,RU6O*>H:*+WQ@<U$A8H@'H]$@OYD[DC=B"*
MS_J5UF>&2KMZ.304($J/F+L>VA8<UT\E:ZJEI"?>SH,179_@:FE=]_&EUO"N
M4HL9^'K1=?1"K9)ETVI91E*KD%//6#:9.[8'8JDTW342J?2[3811Z8%;R*$F
M?<1,'^GM:OK(S5S[B;9LQ_08_/D9.P<:A:9&H3'%V7J-YA1.,M2L9>\#JDJ?
M( Y.>4$W9AE>HU_>IY0!&9E?,%OV@/_!IK4L2PZX6=;BM78=7E)"M9;8J&CT
MVJU1V1%BI@[7&RMF=$J)LI[=:?=LQ^D:R;LEI04OH,6[A/(!+A"P,T/C&;5.
M.BAL^'D6,O7Z18UYB,[IE]U1:U!>"K%)T"Y0DN.E)BJ[3@+\%"<'0IG$)M=_
M=$H/'X@7YGO!F-93E9D-RX2*_'23[-8]VZ<5*4L<XBHRM/[(@X3=MWNVOI6L
M&8X>;]XXQI*0:[%]8A(IG\B=8GKL1Q1?6]=3$9&\#28T**G$:L!-$IWD8$7"
MR88/PV4.,3",<\I!FP_Q[1Q 1S<TIC'%R4*F9V&('P.<,L3!*5JP>_2.E19'
MRSK-)),#K0%5!S-474KM,$/2U;0 P^)1F4AVN8033C>?P$6D;!@SPT67MG)X
M)!7BQZK%V2L7H5)2.'O'2!E8D=&D,U0H)48&C63DHX6B1PUAFY8(;STO<GF"
MJ#^MV^K:W A%3IAM86;S5S,W\*4K4K_D*1@I28>0I<4%#[ \&9@O91AYDH4E
M!@NCU)8BV(_&>)P(#V/]=*=QEWV!B=&HS,[PJ) >X\34B6UKG&=T6<, 3$*J
M@7ASTU9*JVP 2ZINKL1".$94DS<G&VSWL3-\LMU&.Z,S>/MTVG5YNYP>4QY)
M:S@-Z=E(LR1G-B(OG,P]PJCOG%T$%&8M<KWQ@.FG;[<XR>;D[N?DD ';YOG%
M>4:U-_+TY/7&XFDN[6H.Z7$/2>>,'JOB5L5J35\!Z"-N0G'@,>@NDP!#Q&3T
M'(]=3A!844O+GLRZKTO5M(D@?R75C_A5[YV>8D,;CW^!4P^T"ELC?M@RYU8*
M8E*OXLGJ_'.B@:HSG'6^YC2?AAWS%6..3"FMQ($-E1;T4.4W:,YH)\Y(WB@E
M0\'<0)M"^3(*VXHC;#'F=\N"!)2Q13!HV2II#G@G#E@F3&FSG66?=%P%95F<
MB& VSI-4*,L:(Y]DO!0N#!^3R (P9G 8XM+-03_N05.^\IC3I[%L(L7*MB"=
M<D V#D-W'$MCW0;UUP.5B&A!!7\I$^]2V;8RK%RD7G*H%"@GS5'JJH!W<\Q/
M<)^CG+S%I!!-W01N+8P/N^>E%2NG)N)_+3@:(9J#>QI&C,FL5W%XI7R#8T%2
MMN(4;$[GR4^'8 ?%W.7\HPEP5OPO7"G,4F;YAX%6Z:)%]_-$HB#@Q101:$,>
MZ4<N:D,EB5IX'Y3#6*7Q%,X*XK.&FP)_LY(H&A*X3[^?335$P9R5)G>&,%M%
MK)25'HP?@.QD*"<L1T+?_3+K7>,8+TVB.UB7"7(#",2SS._I[VI^SXX&.*C,
MZW>*ZA%KX=A;,+&X7E1&V-RH"!::X2&E2<C@85HJ,(VEGLA%NE1;Q-6\*JMA
MJ6:6\Q=T&8<L_R@*;6W#R^Z&82!SB<IJ+-W.0I,U%=B6]8VK  W7$#P_U=6Q
M&)V9N3^$%635LDWE9PH79-#F:1&*TZ$QRIDLK;4^\.IZTT!@G=GJF"MG6<G$
M$%D*6I\(2F$^UA(XG9++T(IB&!@$E3QS*CHO@7(S,G:W2FQ++C/6=<HMZ[1:
MO8U)B#A*M?#8];#$KB@\YH!'AD?5LLH5X2KJ2.DRI4BIC*G59;[(ND^S'(BD
MXS509CH-YD5]LEF\.8U#'\&!5*VT'R GDP4A.KN7$O;1EJ&947TZK'#B7@%9
MR1*WG J]J^,^XZ+G"RGRE@_F/@N@[[D.N"D WIL*\'<E[L_<1/$;FRZNU,KA
MV(&18L4@1@ R.+Y,'951CBHOK^$-6<K3('FC?1^W9 C6*="]70)8*,LQ8+\F
M/JZ!18(H"B6$0 9:&(/$BR*9?,'8I4AFSYCUG$]JI0?+)R4[-M8+V.3.ID'B
M,[RWU&2NXSST#;F=(" -,!W$[C6T(.HDP?I CE3C32/8ADM2_YD^*MH_V0@$
M'2<G1(:"26^&B*V07,OBM5,F)M5]S.:AP"0N:R:22PGR@<\;L\7R!TS02>+0
MBJ]D_F^<7 *K5#Y>4F_4<I. <K%] 7<)=P@%LOM39F$_9Y''>X_<((_4F2@J
M!'&$BI<LLI>'0)H6_(@1;4A_)DL^,>&WW#05J)V><N*6+-;GM"!Y*E,WF56@
MNLH14/Q1@4-DDJ>4<NE:,5<+][O765L/AZFPW?:HO>B1";DSR(%GN.@/H-2D
M6Z9?[\+9?B>M4:ED;'*D4UR+"Z0_FR&JE")L7.>$UJG*!S=)YB?"P*1KG7<G
MWZ)<)-08BB3,/!5OU!]O_2"=A^[B31#1K.FAMV7G+#H2*FV':&/YZ\+'T&JS
MGT&VTI1OEE^WZ*M*,R3^#FBUUQVN_+K=<E9^MVY8QVD-G-&MAEW_W;#3?9#)
M=E9_;0Y[0[O2G>A*.MRH?U1]$S2]IM$F:V+OW=.L:HE1<:M5O*V?^+:^7[ZM
MV[2>/9RS-'K%;=&B;K</&MGN?2UX98.\I7$D4UX>ZJ VUMG[:U*_M"/2:>,<
MAO#3I1Z!-:SO<$[U""R0W,?J@%?;'.ZF?<=O.G78P2=JDTB:ZU'.(&6O%&PF
M]AEZLPG[N'6'^J<<XYYZJG.[S]$NG^Z7HBA*IYW=I??G@;;WW:,&O4?]MMWN
M;=_+>H?ZZS8$MU\$-[+[_<Z3$-P]2=\]8-3GT95(;V#4&_6EKMF!_>E+W=V<
MRM:<]$.QM4W5D@,]GM[P24[G^2AK'W1(\XX\8'][TW=']HDSJG?7[)&&<^"G
MU.O8[4[[Z4Z)6,)KB@;L6)QER[#16O-LG\.%[[9M41G7[ 1##;^LQ[QVTRF#
M+<G$)HI,%1V)RRV7$,T0PU<1]45)&3EIT#7;//FXA[(=ENXIC)4?ET("+9FM
MZ(PJYY>]<I<]A%[.HT004(NO^^[IAG7T?FHT-6@Y=0.N+,'F,EQL*Q04'[BS
M&&Z*D7?@8K?T"J 4KMOLGF=BI6"P7&9S<#(/-2H^HR:!# I>BI/7/[!M3U("
MGP]HPXLSD["3U&>]7=OUCZ;"Q>>RSY Q'2HD"/PRJ@CW;31&8<RL@8GJMCQJ
M:2N>X85TUE_(D;%_]W,73QRS-]N-=W%H3,"X.27@-HDPJ\+4L@NU 2%BXT79
M^NK:>.'[]WUOBZQ*%\<O^,+2S=W@,C[T[776WM[*71N4&GAN?GMMSAVCWGI%
M+^#JZ)U2)U%.4;C['=Y-96&MBV"?>=-GU1E&1B$P$75II=04^J7C=&V8#,O/
MWI#^WKX=MDQ&(=@+S$8,KD2X4.WG\#W&K:9.?GGB327)S1.\3;(Q*J8Y4=W#
M+;.8=HO "OOS]$ )S(AN&0G$52+KCEHGFJO<4K&1*8$%;XR,.52 055%1DE\
M,;(L,C0-%SIQ/4JV7L/.GF65VF!7J]0.^([T3!7]ENJ#A,FXW<W K_^6APL>
M41:OJ#*MS07^$\&V?IE,CG]Q0ZKGNYABN\Y3(X/^()CN=]428%7.L$1Q)=9!
M<A]K^0CFI +WR\P+:&8:S&5U01Z5NI<A$DXF*P0*.(TJ( >C:J3&KR<(QZ[[
M9>'[J>TI8Q'Z1<4E<)&YH#%ELP8]AEV @!C&AOH5EOTQTW8EM4_ 0.!C3^G8
M2X43NE:&J@L0_(?4WPA^%%_CMPK 4HY_E]3R)R+\LV)EUA?8-BZ\/PR*_^1F
MJF)/EJP979/99-$KIJH'-Y5YUZEL,[Y\5VX$*JW;&9E>5;LQCYMX/1JVVJ/1
M;?*NA[U69]2[]P1II]7KWB[M^H8$Z>'@Y#X2I.\KH>Q)XP.;YIX>PEJ74C\.
M/ SL#$9H=6\9_-F]>/!.$Q5<H.ZM+M#SCDOV.\-;T.;NY2OM.FWV'C0S^##Y
M9J_?:_CF(]!FO^&;VV];YZ3AFX] FX.&;VZ];=0HK_.VX9L/N<G?X\P-GYIQ
MKBPFVT>R=>SNR1V4T<WVHF&WZQ+J&?2G8;G;TVZ[454??).__H,P-;1#^#ZX
M[SZL^W;^LC);E![H+I"7'^?HSR;6>& "I'-RFVMXCSMU>.G9=X$XHG EYB)&
MGF"03B-*9UQDU118M6HN8/S-M"),[#!;ZN@F[@AD..P.;8UHB"%1^K _@ <Q
MEP?#\65 I4Z1L&(K*"S.9@I2B;C&KQT+B[+L-&Q9!+MO9=<"<?\X;+^/046,
MNF$/HE//0QQIW*&O0-->(+. W\/L<*\.(\Z('10U7 %2H8\9D_17$1(OPN!I
M!A\4[109;YT3[>")29S,,'6"PNJ_MRY:UJ^GIU\YG9=_J@&%X]N_-_(U\?M!
MZH5QFB?4+(QZ/:82 )C @H4Z*WKJW[E_R6,P<B1W+B=T1S&/$X*>)>QPQAFC
M?%+;S/VT#?3W(K=48<$7D^$T$Z*=2F:JF2@K<TSK%DF(P&.*\F*'5;T*V+MI
MD&9Q0A1:X ':U(@VLK)$(,PBS>]*[]:5FP0Q0F)2/H!"KU- OV,1$N2Q2SV>
MW#1F^+PB,Z;2'Y[WBP'N-&O DZ=OQHB,2KD+< !X=XI-=\=QSMOMN4FRP"^O
MW# 7QFXO[5$)XA-FYV,&'# LE])R&6695L78R+QQ H<EI.72YE&F=)KF,]D%
MDI*G=>^Q,4.ZXGV0;%@M$L$"$2,7]TXF$Z4F:?%.\2_D<1?OH/P+1L'DR1'S
M3\15(*Z%+\?R%,]Q"YXS-WE.';U+9$QAG>(EP@;7A!>M<0-_B=W$/PS 0*/@
M8!(D:5;*#(/ELF1%.I#HFU%<0A/VRBGL:[<;VS@S&N-,9-/81[S0!6<3(U7K
M8V=2,=]2>WB(KRQ2>..8N20C+@N0YB'^$[/</\= JATER&_'%+E5!68OA:FX
MIHV@5<!=_)_<!=:6P+WY1ERN*&4A@,OB93>\0N4C+82;J'P\W8:^Z\AT/)D/
MW<;^&[QB?,MI%.7449PF !?O _(+IWW\=_J'&"<Y @-V>G89/O>&9BI$N#NK
M23"B/>S[.5>/& K%!3!3'Z[G8>@0WXG>F$M3)PY:M:R9,6Y%JE8M98^$3T79
M4[I(P6SN>D0FC-1,#7;^.[V91N]47[59ZXX[CQ/X?WD!2SCQNMVNZ'K]8:_;
M%N-A5PS%J-_V^FU_Z#C_.NF^V-E\TW/8;38DNRWD+IB]2 GA=/GA@U#]^YTA
MKECZ?R)$>.M;D/XXA"H'Y1BTOJ&Z<8$ UI3:O&B2ZLVD^I,FJ?[NN_C/#;"1
M2VC(*_- =742LNVI"%FSN8X34MA5GP^9%UQNE()4Q-G57%=EJ 82NUKF-^=,
MSK6C*(M#62 Z.1L5*^S\BY8-&U)8B%DH;Z0 ND'"=D,!R&W.A<H>)=PVFF'%
MTQ7H_@+<'P9,IZ"8'"/,NQ5AYJUH6;^IWC,O>VVC,K!  2=$>U=M(;S@5W@<
MZ&+L1C^4V--F%OP,]";J%!#%Q516'5'+0MV*:A.E2JK^L;20:I<<,,=SSC/7
MU8T2Y+[8)OPJQG9"Y:*UK-0)1IV,7*CN)S.AH=50&UL8.\.T/\A2W#-5BOO^
M)U/)+<32CO(*-$VX8FRQNO.VT8 #J1C-C9Q\>\HQP=4&TE7!Q+TH;%A5:X'#
MHHG,#@^^5"4^0=V+9!N(PH%IEXJZ2[Y,W08\S< Z0=Z!JG."[(5**]4$#":Q
M5%XMU)DFVO:?A%B+(5<\%MFU$,Q2R%/E8[HZ]^BL#$:.GV*R=$/R)-9^G],<
M>U]ASRLYB.*O#/WO^G W4W2M2H=3V>DCO0QFMT&^G.P+B:E1LUG3O:),^SOW
MDEI=#\..JJ4V4[+">1X"N96/3K;'J^[L5/B79(T7U>_$HGQ!_:V0Z1M=:(T?
ML<6\]M02N(#,Q=1AD1VKFG3 &V*?ZQM@I!)A:YHI]98O"LU@E/<YEMO2K_61
M2?E 5"VW(ESH-I$5NT0V%BRUAL .D&G@ZRY@2$L'P4((R#^//-7]2]\%M7YU
M>-C0(O #N!S2WX';X,[GP(Q)7(2Q5WJ^<IOI.G'W$FI89=[;\I65]B"6^*F]
M5[*XPLJD\)4N&VPOA63(A5_6)1PL$:R\6P&U1\MG.?,@530UFR=BB@K]E5 7
M\@B?>$6.MT 6$,K.0I18=/)6E@Z"\/Y0I6SC(L@9&-?;X']A'%VR'D*,4QJ_
M\#%=3^4-G;L+VENE$RVWZ6)O+NXS,_0OM*QSN9#W[+Q^Q5=2ZBU+!UE<B/(]
M0">.X<8?YRDV,:$5V;3W^G#5_<*?.NT_J?FNX-)U7-;675;(3: UQ)*/(# 9
MJK*/J-MGX:<N2.0P[N=IB.C:EU.C+@QVMWK92#)3I1_MJ-JUB<%R5]VSVKU3
M9RY)IL1+RQ1DUXQ,C<%X"NS9J?7GZ .4?>%6A 8J;*C" M2-5\6@AHQ/2YV"
M98^=6E=KJ;P2&==*@VJS/2$#CDJ4RY@E1[Z Y:,NE5:_"O%BU<"0O,(2U/&_
M53O/6G8C&1X*59NL0["8-4H5K ;[#VGXDTH4N%>&6JF9]+79V&BUJ4DA$]>:
M+N;(6=GOCJQ JD6*0< [_LCCK XI9S63,/JS(:\ OGL>Z:9CR'WP1<4+%*M<
MIRANTXG&-EV83-<H0$P\HO&BNK']8F/7+>40O&/O"[%^'DW"<FK2+JWK9K\+
MFQLRVHJX:*KWI8FG)(/#90?$91B/Z7=R TQSO=XCHG_*BBU2IVX*QBRD5@Y*
ME;B&9S,:U4+KSW/4%D@]0L=]4-<V:T,O]6 ?O-2]ED65XG'(0N0K0D/XZ)3>
M,,PT; W[RX&F)UK7>PYN2_VK\+#?=HW[H>Q$*JB/ZT;0$$PA"(C;9K:1JY#F
M0.1702JW![="Q\D) \P+YJ4<%)B:RY )I@6.WYQ- S&QWO\47DY&[1?LDBO8
M0X#??P7M 4<+K0]:=9&_L94UR(8-/$WZL7RED2?BF6<VUV=F'<$*E4X C.5;
MCNU\G:Y[[/2/Q"OZM=/WX5\6_/.5L?Z+HM&O]FJ=LL;GC+H]Z^@%_LK\ZL4K
M6TIOFC NCO]D;D$-7!-&<*%P,J?*M*Q?")L.@500":,X'?NNF\?<%G9&1K2)
M)VZX;ZCYZ3UG;P;[&G ,4H I1TGJ19PPI'+9Y/"\U%S[FWF]U&P=0]KDW\['
MJ% 7NU[::L;\8LO+YLF!PN3;LOT=H0%R3H?,.9+V)#6 A$NCV33!A$P")@$Z
MW/=GTM"$-Q!)2&_5;'.;YJFRZ@HW_'DDVYE+AL7Y@P49<)( W,(-N7.[M5D6
MP.YP,XZ7(YU$L:&>(HT':G-*/6%-;Z'<''DM/-)C_:V1Q>AI;':L% GMGD1*
M10=_6B2#+:AE=[C@M+K*[^WMYGU[76-DZAH;Q>J?9:QUN#K6NOEF#SLOGC9
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MW^=P;RY$%,"E,HZR";N;8??17I4X[\8MRHPRH=O?I]X^W*=>R_J$>3D7[D0
M1S2!$?:1_]W/R9WL@W#KMW3ME$X=O$.X;C?.[P[R"YC0YL>V'9C*9@_!JKUC
MV$K,C7C#.96+'<G-+JAFT++>_YP&8\Q$N'W7K689=\J4_S^_G?]R_OWBP>5
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M"^E2/MPBPE$C40Y?HJPP57J=/ILJPW89]AB$B$_FQ4>192)1\N1S?,7R1'9
M;S=2HI$2SUI*%#>B>]B61V5EC9QX+G("S8Y>SV$TD^Z@@F:29:$H0Y<4+2IA
M?*O+@L+9DR:5C2!I!,G3++]\70Y6BC@-*-8S$".K'5BK<+$T(-;GN&5U;H#%
MDO ^#(KE;(2)U<B71KX\:_E2OC,'*U\ZC7QYUO)E.&B3?#EI]V["7;QM/Z]&
ME#2BY%F+$K..ZW E2;>1)(TD,25)IU:2U!4W.EN+E]/(3X2;6I]R,0U%THB8
M1L0\ZWRNYR%B>HV(:42,*6*ZJUN8U,N9-:ZO1JHT4J6&Z3P>Q-[N+?]Y2)5^
M(U4:J6)*E=[]295?0Q%%UC^G;B@6C3AIQ$GK\4"A=F_YST.<#!IQ\IS%B=/N
M<<1^R.6,F\&Q<%?LOL[]N@F-Y6LP%XEU 7^"G6+]V9W-WUIG#=A7(V&>>:#%
MN$4'*V!.&@'SK 5,KT]%* Z(FE+(?IV]HI%9>BO2BTW9XF9)X/VP_NF&31Y8
M(U*>>?"^>G,.5JP,GU:LZ$-N),N32!:"DNR0Z>+ WR7)\GT:)#41?%GPR_I6
MQVYRQ!HQTXB9.U;/2_=8YV#%S*@1,XV8J8B9SH.*F2:JWXB:)E?L^8F:;KL1
M-8VHJ8B:[H.*FM]$&+K6W^-I.(TGC:!I!,WS3A][+H+FB8OT&T'S](*FW^Z1
MH.GUAZOK]+NKZO3+&#".EC]-I7XC9AK7V49(,.K2'*R0>3R3M9$Q.P8IA@+F
MQ"%(,6=0+=0O(QE+0>*FB)S_R5U8G:HL0=QBH_WDQX]G)%!*(J:1*8U,>>8R
M1=^<@Q4HCV>:-@)E]P2*T^VQQ3(ZZ5>17VYN3:RS8MI:O'#*LCN+HTMJ2'P6
MS^!0%[I!L1HL21OITDB79RU=].UQ#EC$=!\S%[V1, \B88)9_O.X/>H"C?Z4
M<^LZ4DZ<X6Y/8+_Q4;0VOB9!Y 5S-[3>_P09DH$<LKY,X!= Z?,\27,7S),L
MMK[EH;"<KGOL]([<5U:<R$_ZOOID0@+#$$3O?X+HB"Y!$'D9?@UBK&>CD>/Z
M\1SED3D^/$=3@EGKH=QD[$8B/?[R,Q0+-0I(P<Z#FSI[^U/B0Z\S=QP*M3/P
M/^H124:]3NND#Z0VC]. 2"@1H8LG__8Z\+.I9 7F@WPKW[2+1]QQ&H=YMOJ1
MTA5)\]G,31;FY?= ,1')X[.Y#DZTYU2HQ_C?:5+L\*4X'B?"_7'L3F"R;]SP
MVEVD+UZ7%CH+HN/*QE;WA!?YU_\]3EY7R58=$9PR'EJQX0G<ZF/8C]"=I^*-
M^N.M'Z3ST%V\"2):%3WT%O;V$F8A3PEG4!4HN._\=3&Y5ILG*,66?+/\ND5?
M*?(K?3=J]4\Z*[\%)>&6W_6[J]^Y[LEU<^UW6[WNODQVT!KTAGLRUSZ8HONR
MK\Z@U1\--AKV@/2XQO5\B'I<YT8]COM\!_!7H\?M[4\/A@]U6L[_:AC1X3&B
MSET-2F=H_=ZZ:)VU-,MPNOWVC7QEU!XT?*7A*\!7.@U?.42^<E<%I^$K#5^Y
M/5\9C5I-\Z:]9BJWCJ\Z(TS8&9V\%@-G..ABZ_'1:!.PV@L!7(7:8Q+:@#-:
MFP*Z7-NV*XD[3W?K[BFNVJE=>=O:-+SXI&RG^^?_<@;MM]5]J#]*6E)[PP4]
M3:SVZ3:SN(]]OH\'&:D%DGGB-E"-!KQKPJI3+E]8(Z#N6([=B*Q&9 '_:416
M([*VU'(:D=6(+%-D]1Y,9)7*NAN!U0BL4:O7"*Q&8&U),HW >AX"J[UAJY'"
MS-JD1^)AH)$T4JLQLPZDBN,YM#-Q6N>?+W8D.OX4._!_?OGVT3J/TLR-@.N^
MB[T<F6[K839D;W]Z2/1^<?;;<Z?W[^[/.(IG"^O]STQ$*>8T7'A3,7.;"_ ,
M+L#9Z<?F BQ=@#,W]/*04X@^!M&/,99%-]?A\*_#N_<?FNNP=!W>B4D0!97;
M +8O_M'<AL.]#1]/?VENP])M^.B.1=B(A>=T$;Y^>]]<A*6+\#41*1!^HR8]
ML_O0>\9WX2R&V5A?W4MAG2,.@>M1H1)J0]:'(!0-T6\!*R'A!X"6WS@=>H@W
M;QGN8/5#*Z$A5@SSUT?&2QB-6L-^]S9P";W627^SXO-M1AUU6^U>[UG5M&\3
MB=WYQ9Q'/A8WP8"N!8,!(Z+ H </(C/"PFPOGLU!1+M9G"PL(.((/W23!&NQ
MER7SH9SR-D)IYQ=S'EFNYP%OHDC$=9!-K?-,S#B@-V@[1^-71]W.JZ,@H,+[
M;^)2N:LNCO].(>&+]V?P<2A0)?L<M_C);O=XV.D.Z0?=WG'O9#0<V%07%U(Y
M_QOKDR:I/__7L..<O$UAE'F<9*D%@Y/(PQ^?(;G%H?4%I6%15\<_A1VF-RR5
MXKT+4B^,TSP15A"5X0&^PC[%0-GJ;395U'GF"*DUR9,H2*?"Y\<I72"UL%2<
M5]1I=:RI2$06 [D+R\>@N8^!=-Q+QB?,ID%J?8B3F>6TY4Y=!V%H13$&U]4C
MN/8.G"\(=)_^=MY:DYCJ!>=Q*@AN5Q8 \L8Z0U4$:*ZJ95WDWK2ZBIKWP13'
MN"=PXG/,1X"/Q@LK$1-8#!) $.$B8/HP(]C=U*)DA2K>PBE?_^HL;$O\],2<
MJA;Q.X$*//QKZF;T[T1<!BDP#_@LG0N/9AJ&"W,ZJ15DI1G5L) E*7\;:;Z9
M"M# 42DXJDXER:.,#64%_E]>!+Y[XG6[7='U^L->MRW&PZX8BE&_[?7;_M!Q
M_N6TNR_^^J0@5FJTQ]_7D]I]O3C_]?/I]]^_O;_83@T-X%I&L!.C5E_3\F/3
MQ%>C2)FO]Q]YD!!+3S<&::GPA:F;6GX./,%S\Q3Y%7+1A#BUY%TIG!E\ 7P>
M6?)83-UP@AP#!R)F)7^0(7_.D9W1>&Z>3>,$5N>W[K[3-W -\[G.</@(!U1/
M7.>?/OW^^?S,MLX_GRVO>NNE/"FQ@=T+2L-G,(HQIU,J&0QSRO]X_/_]9?'&
MLBRU=8^_*>LR'U^GK\T^R-9-_[=#M/S_#WO\PUV**S90;GT>ZIYQSLA,3<-R
M/ VH%0D:#,T$>6'P>Y/F)2U52VRD!8$DZR)F0&@@&I6#IOUHC+O]J)^4GU()
MI#)*<G/L %!+ P04    " "55F-5S=[8Y@ /   AF0  $    '9T;"TR,#(R
M,#DS,"YX<V3M7>MSXC@2_SY_A8ZKNIJK.H9 DLGC)K-%7G/92@*59'9V/VT)
M6X!J;(N59!+NK[^6_ 2#9?/8\:V9+Q.PNENM7ZO5W9+,IY_>7 =-"1>4>1>-
M]H>#!B*>Q6SJC2X:7U]NFZ>-GSZ_>_?I;\WFKY=/]^B:6;Y+/(FN.,&2V.B5
MRC'Z9A/Q'0TY<]$WQK_3*6XV/VNB*S:9<3H:2]0YZ'06G_+SCV='1R<G!\/F
M::=M-X^.,6X.CH:'3<NR\, ^[=B=X=F_1N>''?O8MLEQ\^#T^+1YU#X]; Z.
MCTZ;G8^')X<=_/'(/CS43-_$N;#&Q,4(%//$^9NX:(REG)RW6J^OKQ]>#S\P
M/FIU#@[:K5\?[I]UTT;8UJ'>][G6;P/N1.T/6^KQ  L2-9]*)VX]I1([<DPX
MGE B/EC,;2E]#\X.#Z+FBAG-84\](;%GQ>QMR9MR-B%B.0T\;JG'2LY!\Z#=
M[+0;"$O)Z<"7Y)9Q]YH,L>_(BX;O_>%CAPXIL0%=ARC\YAJD'DO,1T0^8I>(
M";9((04_OT-(#3QU)XQ+Y&6(AU@,=*<%EYJL@0*0[IF%I;8\U5) 4ZU?IGV+
M.%*H3TWUZ<.;L!NMXE)]T1QA/"DE.4T32 ^_*=.#E,6US\[.6F_*A);W8*E)
MZ/9-]6>SW6D>MDN(765;Q67#IV9$MXT^)-.G7!\BN@W[L'2^K+(%$Z7^+ IV
M0S,2Q/HP8M.636@1.UQLKOY88GG8\YC4].J;\+O)A'I#%GP!7ZGQ.X\&\8D,
M(W>4\79++%7_=XZYQ9EC,.O6A+,)X1*\0]I3:@9C3H87#?"7S<AG_.[@P0?H
M2-0BPW_>$-3C%I 0YSY1)*)56%PT!(R_0X*AJ;#>$T[*Z@TD CRVAOG_77T+
M.V75!Q++=_X2VMMD6%9[(*$>74-Y1?T"SQ&U+QI7#$*\/AY!Y]3W7Y_N\A9V
M+3@AB?A&G),N?3[0_]JHF<2%3:0ID2+]U%HD6&#E"V+WO,_Z[T4S#XG#)CF$
M"P92F&Y^:)>2A5]&8YD[PIY-/""&/P1SJ*V"XTOLJ-7S>4R(%&6&WLC+B$D'
M@'B&P20Q*"%/E&:*0JXH8+O'*S7&?<Q!O3&1%#J\3?#F&1N1/%P'2?1^3LH_
MZXYL/(""#7O@L74?-YV2*Y@:$3TJAFC"'K$A2@3LL4R&_8JYH.$8VM IN6=B
MFY!F>1N1/5X'V3DY2 G:(YR@\"R9]7W,')MP<?.'3^5LBQ O86[$^.,Z&*<%
M_>/OIYWVR;]1('"/=1X<VUR$RT@R6L')=JU@OUZOP K<,!;C6X>];LVUIUD:
M<3XMB;-VZ, >:?Y[&%/+:33HNYK3*P08(3Y;:]&.,:[QU+TFPN)THKBQX:4O
MJ$>$P!ZD.X("(+?4@Y2$8B<9NN)PK\';A'3[0!4JJ+ <)GQ.U(=$B (U$H-
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MW]+?K[5[5(S^3_5_^@*0L,;$Q9_?_0]02P,$%     @ E59C5<D*+Z]@%
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M%E*^R>1U%_2T4,F&KO7\\_H2Z5X_?_?_4$L#!!0    ( )568U6A92^R=$D
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MB.5]P"7QBODUS*?D@"].J9("/ H560%%O.>46#1)LZ1RP@!9!=G:P[R=DJ<
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M.1(_1.3RY/T$IDMR)>ISRI?Z)R/EB"3G,[-U-IBV4/M."B3K,!3-4_%)M?8
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M9C:OOQSE6!P$:>@**;73@?(LV, 9%XX.!^6X$@?3)NY>3@[P^&^+Y-9U0@T
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MT'MK., =H/GWX"OKO<P7SXT./#+/.="-;0H##G1CIYC1JJ(/*,^H!</?-]_
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M:' =SH900$-3[3;"?B<%=Z0M3FE#;C@&RUFT@<P-=,@"YW5,=A!.!!F=DAN
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M/SZUKUT1T%[KZPAV-Q4!$!-=3G50.(A,UXP-+"2ZPHH1,GH9E/,M)K<>>$7
M.FIYN")@'9FN6Q%P^N/Z3X0%_L>__5]02P,$%     @ E59C58U<*]V!<@H
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MVL'2Q7K;)A397VM9^[3PM&:O\5%\E^*JOG+??=EPQ</-]9)592^7C8H/B!Q
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M*FBQ4&K&+)0\$.GA3:(405&*F\"61PAKY;ESWGB?Y>C9MU;8<'(X+J GS!V
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MX /5N<@W7O&&<93_:@_=*11^IL:P$9UHNE8K *+>Z?E >(Y(;/^-_Y09U^R
MWWA$4L<%6H*^5.T'P%Y+]-5 ]NKY%7A -/.NCHAW,*DLDY)V/V7($)/:/M-M
M,YXVK:1>.>)<BZ=<"Q(9_2@;MIS7J<CCJSZ4QU(66=A4F)/#3<K1I'9VSQ0<
MAU>T+>0E9I :_3BZF/X:-=L]R*<RE+5T"[>BFBE9=4T;Q=II$:SMH):!0*3W
M (ARMRM1'@D/:TV37LWP;*")E3&0ZKO"GKW?#2S!H2W'RB_S3ZX:+,OB/[,
MEXFH?28U8%+4SCME\? 9+1.:Y/3/]6^5M3%;JW?*L_8.Z%_);F[96NXL,Z[J
M+)5)M!;*4A'UADG)32JD,]$HAHVW'-';I9^LS])^B9E3U52:LE>NC],\WK)
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M;&1XV$N8!_*J9SI\!6KGW#'X +)F_$$.B;CL1'F>+2&MNB6_&#\@&2T$X8.
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MED=OY8H/@3R,S6)7B%QH$=7#_B#$BU(19\N'1.-1QU>_%K[!](7S1=ZXE;/
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MYRZEKYYG?27Y%+? ?%T"6?3%%"IQ]GI0@Y8D3>BK(8DG @#BT_^JRHOU9=J
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M<]?$J":_C\^+=TM3]&E/6IWQV0H/D(&K=W4"S+.A<BP,,.]"V:)/1\HAMGW
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M? ^MGFX=[H7.B[H3%8D^[(V*^8S^:M,7Q\>X:7Z./8=AK \%H?^/CXV]YQM
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M;KF1R0IAAVR4R&61R;IC%'R,O'HDC1$;KU! NQ:WW/L LEI>KQU1<%Q@&#J
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M\_@-+9<;!O(3ZWNKSP,FJQK+OH44E)9)55W'Q.&"59:/N*]9B[KEC!CJA:J
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MHSH6"MF)JSOR %)3N+677!P"!':H0VTB*YIPL'#O%S5=\';[L3(94M_$5'P
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MC.>85*$63[:\*4T@WB&B _/:8I@>.P\T;BW8M36H=G&J8_> >5O4R=99>GK
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M'6]TT_BY+4%8(%]<GT^-YS^HPM*I@A*#-.(+,+XBT^LJ<$MVW[X>O"8</MC
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M*(:MO@Z:Q)?_HTH(0>USP8&NB>H*P=8V-U0I4#3^2Y\OX-4NSE8(&LP9\7.
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M8KR/BO/?Z7W0@)3;&@7R)6JKZ@:R.\"@L$/4[O.E14BQ0YJH XFQF$Y\1KQ
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M1WIN&*0_HWKI;Q?[T[?J9J>4L_@:_S <MU2%]1@2]"GH-I&2)6A^_=&2S*8
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MI]C[;:YI-WJ]\\Z-AA0?FTJ"30REEW=UY4CJFXOT.@NT7F9"M?&TA!Y&%6V
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MR&?/'I+\;N.3?6^34I:J<_SU%35'7W]-#MY[CP,^^XP"5O^  CLVE0"G7=G
MTSX9^+O$@E#W2!#M%082?()!BE\@R/ / -D!?B OT!<4!/F XB!O  GV!M!@
MKZ?P$,^GJ%"/)]@E ^7KW@'TO9\!JM=ZP [<#;BA;H 7%?2$DQ!WEY61>:.\
MH.12&0)]ED@@+6)HY<<0+/81:"7_<(E$.%^H$!_,UTCG<@WRV9P:Q6QV@_)
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M3ZA+TCSZV@K]PFM_$8-WWF""E?\D@N\_@8/-W^8#N[5IP'%3//#8'@G\=H>
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MI.^P!UD[]H.\G?M X:Z] +)K#X#OM@,HNUT ;T/:\S*@^-O70<G6]P#$\5.
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M(@!OVWH5:_X!%+:?4X9-_WK2L/'CFUU;/CXWOOM?1P[N^VQ\VGU#UVB 0_U
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M(21X6$(T%P,A0E<0A])^"A-8W[PS>9]Y13X?V57"*5:CZ .C0SSI<3#PG?M
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MTEU 7Z8*G&7;P6>Y,HA6;('0E9LA=I42I*[: +FKUT/Q;P%1119<M.2 J*L
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M41.2R(@)<63$RX#(B%>BV8 7.CL4;:'):]$VOD7F1\T.V7<MNV3'NM7E_G-
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M6KT52M9L@9HUFZ%M[2;HG%79"73^$#K_/PCB/X8@/)!%/& !0H0E4EAT+>Q
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MCW3N('(=829,#+?EQ'!W/@P-%,&@&$D,R)!#WV(E]*I5_>;1HO'%O4OKL]N
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MF:^&*/W%$&4^&Z L(3<7FI)L*ST:VNG3T-Z(C@XL!CJPF6CGRXFV\WC0.D4
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MV"5MUI%M_781;:L=PEJW.H:T'B5N.X8L?N,0NOB[0V@+VL_U(@_@-[*'$TT
M>TG_WD;R-Y#^MY+TKX'50M"S1HEJ6VU ;QRSXJY=Y2Q8L=)'HG@D6#9O.%(I
M<WF">NI@NG;20)Y^W+(RHZC^!681?8LM0I<NM0I:NLHFH'>+G7_O8>*FK7_/
M:UO_[F\$VOIW_=-=LH=S=7_/8&<?P"3)'R,=?!GI7YT;^*%UHRPT;M2AS=_
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M4/@&((-,DLE',H5(GAC)DR9Y"B1/E>1ID2P#("4=Z&@'@&Y$(!%#9!%5!/D
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MZRT,.Z-7'WY?KR[\@^Z""-3Y7]H_0W\:?)L'\%<\P*^D^Y[)I,.Q;"8<R!:
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MZ=(3FM+%]W3%"\CXV0C)[R7Y3>O_]SNHG0#Q^T@^R?8\#F!_&L#\/ 7ZOW*
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MEB[*_P9YWRLAP&GR?D=#>#@0I( =P=K8%#(2ZT*LF57!+NRR(!]^;V"H<'%
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M?D _PVRE;F67[NXPK@[\>/P2'A630, T]=< #NL!\2; @N;5> <M 5T[]I@
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MLT1<F@UBTYTA3?=&='H0HC(B$)DA0T2& N$J%<)4!0A552(DLP62S $$9ZY
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MY$L/AR[2S:&W='4<+%T<QT@GITG2T6F&=' ND7SG59+G7"?M-$? ;? Y^#>
M^[N9]L!,]Z+]I&-/@.$\'\RU =C2#UOZ:>VEKT8KO35NTE/C*]TU(=)-$R5=
M-0G219,JG359TE';5CIH.TI[;4_)UPZ4=BZCI:UNHN3H7I9L78FTT:^25OHZ
M<$2R]'? %Y)E^(G7S!'H>TW]*8JT8QQ+[0@PB.=]2<MZ\5X/;.GF:B7=]$[2
M1:>33GI/Z: /D/;Z,,G7QT@[?9*TU;>47$,;R3'D2QM#-VGMVD]:N8Z03+?Q
MDN'VHK1T+Y1T]Q62ZE$+FB3%XR;XG.<_@D>R %VST#N9)?8)4M(A0:;:1X\
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MR,N6IGTI*A&=C1VOXH^Y^*. 1:Z ";^ H"^@@04(G8?A\^B/N:M)6HB)5]\
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MI56RI%MG2IIUCJ3:=)04FU[2PG:()-D^)8EVTR3!;I[$VRV7.+M:B;5K C?
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MA5@FL["FLM"FL>"T9&')P(XL@VF"R0HT%9:RZ(\LR'M6-P!)SH(L9D+2,JH
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M?YII#Y!>U7_0:Z=J/QW-.E4-II<QR4..F.HA*O$SUD1(QD9@QVCL&(L=3['
MC&-R>8J.?8H&/8F@L7QA+//$F$(^!UD>!4$=\5#2:&L2>J-X#*+-7K19C^N<
M::^MTMO3K'. 69^JOZC:RVAS\JOV:8PS)\,3\<ED$K.IV/&\BVF#ZDL,ZA=Q
M\(L(?@%ASS\A,HW^>([Y<@JLYMDW)$V=!]3*=!:0#[XVX&=GVFO3Q]S.8>8D
M6^EKOB]GLCD)5W^(;*Z'-)]58JR%T#=%C)<R[)C/."EGD)7A\-+V$!@X=]%S
M(H5D\_.8J^8>D43\'8Z;_#J;]N!HF$ZLAYC;^93\6G]IWA/RBID$_;+_1'X]
MHT21)/6'8E4O6$V\5C%_;&"L;&#^K&&05=/8]71F)8Y;P_A8 [-9O5.BT1V(
M;G>U!P<3;<:8_?IX':1Y'TJY68\B@ZH68JRYB.G<CFKYM0[2O%=#U28.X(_#
MC)4FYHQ##( #^&(?SMU+HQH70#(W24@_TWU0ZAQBNPEF_\XTZU5UD$5F?<UG
MM#[^&SG-YY(\?H^,^N.]V@^B-A&HO2"7B)&;Q,<M8N,F$]YU.O\:X_0R'7L1
M7UQ88;S_0NU_4/4']7NHZC=9OX9G?DGN_ 7Y^V?&[#=!WB=[?YL,_S[LXA:#
MY#K!>@6&=9% ?0-F= [V=P8'GL2!Q^"81XSWHE1@UAK,JX==G8!7?V@\>T/5
M/]0YG,O,]8>OQ51_4+]%HNH :A_&?3CW#7C557C$5;B,^EV4<V3P)V 21[#C
MD/&W63L;_W*]AT'32/#N)(=O@-O58T<= 5M+D&XF8#;0<=7\OQ)KUF+]:GCF
M"O2J&D2)^0R*CW[1:SIB5MU>=!!NM0]^MP<^TVB\%R4$^3'(;D$W9,@FV,X&
M)JQJ)JLJ)JIU,-BU#-[5#**5V+$<.Y;"=1<33.K72"IH=3GLNE3.HO=S0LOT
M&Z@SS#4(I?N_?Q'=WJ!.QCAL[NS-YD!8AW=6PWY7PSI7PVY621C>C$53"UF
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MZ;#7!H -GMC@^8GT1$^>%X32>#<4_0!"O4T5(5]L\>)]=W=+<76W$;V;K>B
MUMU.G#WLQ='34>R\G<7:1RN6O@:Q\.7#OOX83W;O!\OPRS#]&=<?ZN!/"NO/
MJNA/6N['2NU'.NI[C8[^5+JA*]?'M#LI'D2 8'-%R-M8$<)EGE9B\+ 6G:>U
M:(&SMXTX^MB)G9^#6/DS>00R>(/4 '(S?5F5$H*ALL%IIB,EU)]30U@-0]1/
M;)8 LJ0@; B\#CXSGA#41E6FS'=DA8$@7ONIBA#O>7A;B"O0 ZV/A3C[68JC
MOY78!=J(53"3: B3:9BS:2*)(+@B,#HRT'1KD;$ZDPU@GY%D^)'0I0A6R0CH
M03B92Q@VA'XN^>C,##3=&1:E=@5!H .XYNMGJDJY\:@'6JYI>-\Q&%888B%6
M8;"K"";Z*.R(P1>Q:F)5DQL!%,\7XNF/!!AP ME] G0N?A"88/JYS3BH0RQT
M)(:^B/Z'Y ;1#\B--]\5%LQK?W3Y8(L',/#<A>L:W.N(6%M(@R4D7V)9:..Q
M(Q$[DICPD_%%JM94=D[S,I6[TNB/M'209SIJ(14JE\I*G:)VR< ^6UPV5F9:
MJ]U)8::=0:HJ%(0N/W1Z E=>,]Q%@UL=(&],PV)!TU@H^1)(9=%-QXX,[,AR
M,.U4R=:9;GU4MR"JDH^Z8R@[Q_33+VV@E*T9&ZT6\WDH4R:Y?<9GQA."$O^K
M*N1MWI6DH[T:]#J@UT;IA<BRB/,]T%PAR<:.7!;X=G:F/X-TP([.3'R=/<V[
M5-21T%FFGT+NH$YN@3[G0R/SR*+;G29)^<AX0E!<C&EGD*H*^?'HP6M]O+DB
MA%XKW,ER;-8IYJJ,_%>%!#MZJ#\+.9KOV%%;--4179&FGR;ORQ?Z,$_T)B9Z
M0:%[5K%8'^)[[TI2O/GN,-H;&&>Z,\W07!%"KV4;Y.<^IK.S.=%KWBWR'Q42
M?#+,UG2+LOHSR1/$YQ,$U!@$CU;'\_*ED<P3(Z"XPXB)H5#7P5>-)P3%).*#
M)-.=8:XM&0-,;_9TH46^N9W=S$EF'[.^YKMUFG>+C#$GXJIZH%C\)!*P*4ZF
M6Y?5\?73Z-SG\,5SL/ I@T6>I3\FT1_/0*<GG) $](:GF4X'<L-4;5O3CARC
MWMYFG8/-^E25XDGYM3K2?*?.<^;$N+DZ8KR3155&L*.,V"BE3TIP=!%.+: A
M\\B@7V.,SEG+9W=+=);I=!YU,H\+;;97/NYG3O!'F=NGVO;X73HSY-?JR%SY
M]037<C-9::Z,K"5&JAFS&XB-:N)S/0VNI(%K1HBLPN"5L+KEM1)*/WMW4B<C
M$W^JS:H:I';%J.K$5+/.YM-*5&6DS*RG^;028Q5&3+M$6 :,%8OF7]A5E8K]
MUJ834YL8)X<(^ ,X>R^^V(V"G1C?L$[\>ICNC')"MX5J\T2S7U72KRI S3M$
MU.Z7YLI(\YTY2E=S%:;Y;AFUG4#M#E''*R@RJPCU+>+CGCHIA$GO)O/%-1I]
MF?7C(@U\737H/_^SL+*VL;5W<'32:%WT!E<W#T\O'U\__\"@X)"P\(BHZ)C8
M^(3$I.24U/26&9FM6K?)SFW;+K]]AXZ=NW3MWJ-GKSY]^_4?.&CPT&'#1XP:
M/>:))Y\:-W[",Q,G/SMEZK3G7WAI^LLS9KTR^]77YLXK+"HN*2N?OV#AHL5+
MERU?L6KUFG655>MK-FS<M*5VZ[;Z[0T[=S7NV;MO_\%#38>/'CM^\M3I,^?.
MO_[&Q4N7KUZ[?N/6[3MW[S]X\ZVWWWGW_0_^\N'?/OKXT[]_]OD7__SRZV^^
M_>[['_[]X\^/_N_^]V?[_W_>?@M+U6([U61GVJQ3C7:GU=ZJV0&JW:$T/%*U
M/$XUO05M3U.-SU*MSZ'Y>:K]G7! -^6!WLH% _#!$.6$D<H+8W'#T\H/DY0C
MGL,3+RI7S,07<Y0S"I0W2G%'A?+'$N60E7ADK7))M?+)9IQ2I[RR [?L5GXY
MH!QS!,^<4*XYJWQS >=<4=ZYJ=QS#_\\5 YZ#P_]5;GH$^6C?^"DKY27_J7<
M]-//CR8]]7P+U>]6ULR5%O\=#/^;U\W^^M\X[/_(8__/NNS_VF/_IP[[+W^)
MA86EI965-3ZPM5->P U.SLX:/.&BT^EQAJL;[O#PQ"%&C^ 2?()3\ IN47XQ
M.L842__E&:-C\$NW[FHH,9*&#!LQ:LS8IYZ>,.G9J<^_^/*LV:_-*RHM7[!H
MR?*5J]=6KJ_9N)GAHD;+[CTTT=C"_VJ@*2:,0:$:22MI)NVDH;24IO[U0QK[
MT<<T]]._T^#/__&/+PB2+[_ZZFO:_>UWW_WK7]_3]G__^.-//_W\9_L?7'3P
M_>BR-NOC2[I1#U_7+KG8E+S]W(%>>T_L>?K(X1TSS^S;6G)QS^;BZ[LV%-]N
M6%]RO[ZR].&V=>5O;UU3\5[MZH4?;%ZYY,,_BC]M^-.&/VWXTX8_;?C3AC]M
M^-.&WXK[V/"W*YK,CRYCPQN:)1</)]6?.]@3&\8=-=I05W)Q]Y;BZSLW8D,U
M-E25/JQ;5_9V[=KY[V[&AII5B_[R1X$-/G_!AK]=T8YZ<,%YR<4C"?5G#W7?
M>V+O4T>;=LPXNZ^N^&(C-NS ANW8L T;:K%A\]KR=S>LJ7B_"CO^*.YAPWM7
MG3/_>E4[ZOX%Y\47C\5A0[=]Q_:..WIHQ\RS>[<57]J%#0W84(\-6ZM*WMQ<
M6?K6QG5E[ZQ?4_[>VM4+WO^C4#8\O.:4^<$US:A[%YT67SP>6W^FJ=N^HWO&
M'3NH;*@SV; =&^JJB^]M65_RYL;*DK>JUY6^7;FV[-U5Q,4?Q=U+#CX/KCME
MO'W=>>0=9<.)Z.VG#G7??V3/T\<.[)AY;@\V[,2&;1N+;M?6%-_;M+[X04U5
M\<,J[%B#'<N)BS^*.Y<<O.]CPX.;SB-O77):_,:)Z(83AWKL;]HS_OB^';/.
M[<:&ABU%U^LV%MW:7%-T=T-UT?WUZXL>K,6.E=BQE#'R1W$;&^[=<&IY[Z;3
MB!N7G):>/Q[;<.Q@KP.'=D\XOK=AUKE=V%"_I>A:[:;"6QLW%-Y97U-X;UUU
MX?U5V+$,.Q95EKWU1W'KLH/W'6RX<\MIQ+6+CLO/'(O?<>1@[X,'=D\XL0<;
M=F!#'39LWE1XLWICP>W*#05W5F/'<NQ83+\LJ"I]\X_BYF5'K]LWG=)OW7(:
M>>6BP\J3QY)V-AWH>W#?[HDG=C6\<G[[MJ*+M;6%5S=L+KA>M:G@YAKL6($=
M2VL*[RZL+KI77EUZ_X_BQA5'SYNWG-*NWW0<<_&2P^IC1U,:#QSH?VAWXZ23
M#0VOG-N&#9NV%EQ97UMP;>WF>3=6;IIW<^G&@EN+-A;>GK^AZ$YI3<G=/XIK
M5QT]KM]R:GGEIN.3YRXX51XZDK%[[_Y!30V-DT]NV_'*N=KZPC=JZ@HNK=LZ
M[\K*VGE7EVZ9=WW1YH(;%9L+;Y9M*KI9O+'DUA_%E6N.[E=N.69=N.GX](G7
M76KV'<[>V[!OZ.&ZQF=/;MGYRIF-#07G*^OG75BU;=[%I77S+B_")Q6U!5?+
MZ)_B+<77"K>47/^CN'3-P>O"+<?LLS<=)QT\Z[%YQZ'\?;7[1AS>N'O*B9I=
MKYQ>OZ/@[.J&>>>7;2]X8U%]P86*;847RT!)7=&EPKKBR_.VEOYAO'[=P??L
M;<=VQV\Z/M=X)J!V\Z'.^VOVCSI<M6?*L<K&5TZNW55P>OG.@C.+=Q2<JV@H
M/%_64'2^9'O1ZT7;BU\OJ"]]8VY]V1_&F1OV02?N.'0Z>,MQ>MU5SU55QSKN
M6+-_3-.J?5./K-PSZ]C*W04GEC06GJK857BZ;&?1F9*=Q6>*=I:<+=A1>G;>
MCK*SK^TH_\,X?LLNO.FN0X\=#YRF5+_I6KSR<N::):<';5U\9.+NQ0=F'%JR
M=][1!7N*CI?O+CY1TEA\HJBQY&1!8^G)>8UE)^<VEI]Z==?\/XSO3NC<_W7"
MH\7W1X/Z?G(@:M:EK?G;SFT>OO?4QBE-QS;,.7ZDNN3TH;4EYPZL*KFP;WGI
MY3U+RJXU+BR_L6M^Q:V=98ON["A9>J^A:-7][865#WXO_K3A3QO^M.%/&_ZT
MX?\+-K@H&Y*,-AR,5#;4&VW8]!\VG#?;<,5LP\U=%16W=Y8MO-M0LO0^-CRH
M+ZK\W?CNI(O[=R<]DOYU+! ;(F9=K,NK/[=E&#8\BPVSCQ]6-E06O[Y_3?&E
M/2M+KC8N*[VQ:TG9[1T+Y]]MJ%AP?WO9DH?UI:O?JBU9]^;OQ;<GM6[?G71/
M^M?Q@+Z?' K'AG;UYVJ'[CFU>7+3L8W84%-RYF!5\1O[UA5?WKVZ^/JN%26W
M=BPKO=NPI/Q!_:**AW452][96K'FG8WEZQ[^7B@;OCWEGO2=LJ$I#!O:;C]7
M.P0;)F'#*\</;RPY<Z"Z^(V]E<57&M<6W]RYNN1.P\K2!_7+RQ[6+:UXIW;)
MXO<W+5[];O6"=0]_+[XYI77[YI1;TK<G_+$A=-;%;=BP=?">4UNP8=,KQYLV
M%9\]4%-\8<_ZXJN[*HMO[5A;<J]^=>G#NE7E[]2N6O"^JF%4KUC][KJE:]_Z
MO?CZE,;MF]/*!K^^GQP.F75A6RXV#,*&B=@PZWC3YL*S^S<67]Q34WQMU_KB
MVPV5)0^VP<]4#633F@7OKU^U\(/*-:O>6[UR[5N_%U^>UKA]?=HUZ9N3OGT_
M.1(\ZT)]3L.YNH%[3M4^TW1L\\SC35L*SN[?7'QQ]\;BZSMKBN_4KR]Y4%M9
M^M:F=67O5*\M?W?MFHKW5ZY9^M[*=6O?_KWX0MEPQC7QFU,^?3XY&H0-V=O/
M;1NPY]16;*A]^7C3UGEG]]<67]J]N?CZ]@W%=[96%]_?5%7RL ;.O0[NOQ([
MEJY=^.Z2RI5O_UY\=L;9]:NSAL2O3WEC0^"L"]M;;S]7WQ\;)APZ5O?2\:9M
MKZIZT*6=FXMO;,.&S7#,&CAW957QFZLKB]]:5EGZ]J)U%6\OJ%SZUN_%)V>=
M7;\\JT_\ZK17GT^.^<^ZV)"U_=SV?GM.U8T_=&S[M.--#;//JAK$]LU%UVLW
M%MW> ->MJBZ\MZ:Z\,&*]45O+L8G%57E#\NK%OYN?'C6R?6?Y_2)7Y[Q[//)
M"=]9%W=F;#_7T&?WJ?JG#AW?]>RQ PVS50WB\K8M1=<WP?_7P[O7PKM7PO^7
MPO\7TC?EZ\L>E*RO^-UX[YRCZQ?G=0E?G//H_<E)[UD7=Z75G]_9<_?I7:,.
M'MD]\?CNAMGG&^!UBO_7P'77P?]7P;N78<NB#85W*FJ*%'>^5UQ3_KOQYGD'
MP^=ON"1\_KI;[T_/>,RZM">I_GQCM\8S!P<<V _WWM$PYWP=_'\C7+<*WKT:
MWKU\\[P;B[%EP:;"6^4;BVZ5;"RY7;BQ['?CP>L.AD\O:N(_O:#O]>EYPZQ+
M^V.VO7X@?U?3_L%-.QNGG-J&#5OJ"R]4;RNXM&;KO,LKMLZ[L@1;%FXIN#9_
M2^'U4N*DF'@MW%SZNW'O#0?].Y>=XOYVV:7G1Q>U,R\?"=EZZDCKQL9](X[4
M-3YW:LN..6<WP/_7U<][8^6V>1>6;BNXN*BNX%)%7<'E\JV%ETNV%ETIJBV^
M4E!;>O7WXO8;#KI[5QUC']QTZG'OFM.,RZ<]MNYIZK"O;N^8HYL:GS]9LVO.
MZ2HC_R]0_/]U^/\;"^H++I3#_TOIHV+&3&%=R:5Y=:6_&S<N.KC<NNX8??NV
M4[=KUQQG'SP>OF/KP9X':_8^=:1J]PO'*QOG&/G_"NQ0_'\!_+]\>^'Y4OA_
M\?;B-XKJB]\PUP N_%Y<O>2@N7;#,>K*+<<^9Z\[SMMV.GYKU8&!!]?N>_KP
MFKTO'%N]>\[QE8T%)Y?N*CRU<&?AZ?D["\^4[2@Z6[*C^&S1CI)S!0TEY^8U
ME)U[K:'\_._%I<L.SA=O.L:?O^4X>/<]IU>K+L>N676R5_V*@^,.+-_WPI%E
M>V<?6[:G\/BBW84GYC<6G2QK+#Y5LJOX5-&NDE.%NTI/S]M5=GKNSO+3K^V<
M_[MQ_JJ][NPMA]2#]QV';OB;X<65#\)+%UUMOVK!^>$;*TY.KJ\X^G+C_*;7
M]I8>G'>@Z$#AH8+]14WS]A4?GKNOY A7C[ZZM^SHG+WEQV;OF?^[<>JZG<?1
M._99M?_4]E_[3]^G%W\8/[WTK=S"PML#%LZ[.F[EW(O3*F>_/KUFYKE9FUX^
M,V?+2Z?G;GWA5$'=\Z<*MTT[65S_W,F2^N=.E&V?>J+\=^/103?MHX,!D8_V
MQG3X;F?Z^+=KVRT\OW9,XYFUS^T_M7;.H1-K2XX>6UUZXLCRLM--B\O/':RH
M>/U V<(+^TL67]I7N/3RWGDKKNYY;?6U/:]67M\]9^/U7;,W_6;\:<.?-OQI
MPY\V_+_?!O_(1_NB.WRW*VW\VUO;+CJ_;G3CF753L6'VH>.514>/KBD]>7AE
MZ9E#2\O.'U@X_\*^^0LN[2U==&5/\9)KNPN6WVB<N_IFXVM5MW:\NN'6]E<W
MWOBM>'3(5?OHD%_DH_U1V) ZX:VMN8O.5XXRV;!N5M/QJL)C1]:5G&I:77+V
MX/+2-_8O+KNT=\'\J[O+%UQO+%E\<U?1LML["U;?V3EO_=UM<VMNU\[=</.W
MXC]L:$R9\%9=SF*C#953]I^JFMET?/V\8T>J2DX9ZR K2R[L6U9Z9<^B\NN-
M%14W?ZW#K+Z_K;#J_N:"FMN;"C;<^JUXU&30/FKRC7QT(!(;DK$A>_'YJI'8
M\.S^D^M?;CI6/==8!SFXKOCU_:M++NU947*M<4G9S9T+Y]_9,7_!O>UE2]^L
M+UW]<$MQY8,-1=5WJHLVW/JM,-L0\>A 1(=O=[>8\-:V-M@PPF1#]?2F8S6O
M_5H'65M\>?>JDNN[EI?>WK&D_-[VA15O;JM8\O;6^6O>V5!6^:"JM/K.NM*:
M6[\5/S?IM8\.^T0\.JAL2,*&UM@PO/%,U>3])VM>--:DS'60"WLKBZ\VKBF^
MN6-5R=WMR\O>W+:TXNVMBY>\OVG1ZG>K*BK?7#._^N[J\IK;OQ4_']9K?S;:
M$-[AVSU)$Q[6MUIR?CTVK)^X_^2&YYN.;9IMJH-L,-9!KNU:5WR[84W)_6VK
MR][>:JR!+/UP_?+5[ZY9O.[-E0O7WUVQH.;V;\5/S38<4C8D8D,6-@QK/%,]
M8?_)C=.:CFV>=>*Q.LCUG>N+[VRO*GUSZ[KR=S:MJ7AO_>J%'ZQ;L^J]E2O6
M/5RV=/V]I4NJ[_Q68(/FIR/>$3\?"NOP[=X$DPW5V%#S]/Z3FZ<V':N=<:*I
MMN#L_BW%EW9O*KZ^8T/QW;KU)6]N@O-7KRU[=\V:^>^M6+OTO>5KU[ZU9&75
MO<7+J^_^5OQX1&>RH2D4&^(G/-R>B0U#&\]L?&K?R2V3FX[533_15#?W[/ZM
M)9=VF6H0=[>8]T"LK2QY>\6ZLG<6KUWTSN+*U6\M7%MU?^'J]7=_*Y0-/Q[Q
MBOBI*:3]M_OB)CQL:+GT?,V0QK.;G]AWJNZ9IF/;7SC>U##GK-J+T;"YZ$;M
MAJ([&VJ*[E6N+WJPJJKXS265I6\MJ*QX:W[5LH<5U57WYU>MO_M;\>^C.LV_
MCWJ&_W08&_;'3GBS(7WI^0V#&\_6CMQWJN&I0\<;I_QW#>)6%9Q?[3]85EUT
M?R$^*5]?_F;)^D5OEE2ONE=24WGWM^*'HUK-#\<\PG\\$M3^VP,Q$][<F;KL
M]4W]&\_5#]I[>L_( X=W3S;6(+;7%5W:4EMXK7ISP8VUFPINK=A8<'OQ+_6'
MTGM%-17W"FJ6WBW8L/+.;\7WQ[3.WQ]W#__A:&#[;P]&3GAS5XMEKV_MOO/\
M[AZ[3QX<='!OXY23#<8:1.'%#5L+KE36SKNV<LN\ZTNP9<&FPIO-]8>"C>6W
MYVY<=/NUC4M_,[X^H7'^[H1KV/?'_?._;0K_7^S=9U33]]_X?VQMU=K=VJD=
M5NVN===5]\:!"BJR9>\-V0E)2,@DFX2$#)(0,DC((B$)A!#VD"4"[CUKK=K:
M6MOW[X/VNO[G^I]3Q=_YW;AN?&\\[_1&S^-0*GF]SNN-R6/F[WB=QK6&=L]J
M8YT]O+X&FO^K#9A6E8[8(=7BNX35^!ZN!M];6D4X2E,3^TJ@_S[%T/<J0449
MP*GH U@5\YF[V33]Y5]];\[YK>F#C?<]GR:/6;_D][B_J':Y-EAJ;-%N36U.
MDZH&TR*'9O]R/;Z#K\-WLK2$+D8UH9M:_<_^04/JQ6M*>G%5M*/8*OHS=\8_
M;?J=EM<_N^M_9\.]IIE)IWTSF$W>S_1&9Z!=;8WS*,QY7ID)VRR!9G^!@=#*
M@2Q,/:&=!GU=2G3%G20HHI;<B=>6=.&TU"ZLEO;,C;5,?>E&QRNS;[6_N?[G
MUAF)?0,OD6H;YM>H'/L=4ENB6V+);RROQ30)300?UTAH+H5F?WH-L06:_UO)
MAN)6DH'42C20V_"&DD=S/%;_[!UKG3IMM/NE3RX=?67MR+'ID9[AZ625?[%:
M7!?J$-I27 )K@8=OP33PH-F?54ML8D!13<6^$M.C'4!SL8G<3#26-..-%'^1
MD>K'_5\TT#YURN#1EV8=&YJ^VC<Z_8CN].OX\MY%0JY_GYK5D& LK<^UEM:A
MG"P;P<VP%#?0S,6-E/$[!#/YT1T"L;:DB?#X#J$)5TOS8?\OZNV<^F)O_TLS
M6X^_M,YX_=5HR>69A:5C"\G4@4!N25>DF-R:7DEN+M00O4@=OA%3@_7@3!@W
MOA;E)IB1KF(+PD6RPNO)5EA]B:W0286BV9^UCJZI+[8/3)MM.3-MO>SAC%#.
M[2^2J9>7%Q#.;"O"C1RF8@>36,B^+#ZL)U^4WP67Y':B*K([,+*L=IP\LPVO
MR&@C5J:W%E>FM9*5J2T456H+]9GS]TYYJ6YTRKS*/U]=S0<?[:(_F'^X^,Z:
M!.R-75F(2X=A^6?CL%FG4@GI8]GDE-$":M)Q.#UA&,V(/X9EQ@T5E<8.$5A'
M!HM9,8,E[.@!*B=Z@/;,@=KWIH':SSX"-0M6@.H?#_VDV $;%84)VGG9IA8>
MRM8L(#J:!%17(X?F:6 RO&X:T^<J8?OKB[DM3CR_U8D3MCFPY>T.=$5''4K1
M68>LZK0BJI^I_QC^8_B/X7^KX=UIP#P;,GP/&58?NEFY'392?KBLC9==VR)
MV)K+\(XF(<75R*,V>%BT)A>#T5Q/*6UQDMAM#@*OHZZHK-..+>^RHRNZ;:C*
M;@NRJL>(U'0]2\ \;OCT(V"<OP)H5QVZJ=P&'RD/%;;RL\S^LD*;3X@;WX.X
M&P241C>7ZJLOI;<X:8RV.C*KPT[D=MGP@AXK3M1KQ4B/6M#*HS4H=:\.I>E^
MEH#YG6G  AE,WZT NI6082O\N/B0J%608?8+\Q_O8L2D\3V(U\6G-#O9U-8Z
M!KW#3F%V6TGL7@N!WV?&B?K-6.E #:9R0(M1'55CJGJ>)6 9-WP"&;Z%#"L.
MW51M@0^/&\K2S'Y1KMTG1CD;)42/1TQN<I65M#BXE'9[*;7+2F/T6LBL_EHB
M;]"$%PV9BF3'M#C%H!JGZJO$5?4\2\ R8RJP0H9:R*!??NB&:C-B6'RPO%68
M8O:+L^T^"<+Y7WN0>A&YM8Y?TFEC4WHL#%I?+84Y:"1QAVN(HA$=7GI<C5<,
M*?#*/BE>W?,L >NXX6/(\,UC@WH3XICD8'F;*,G\:!<CA=4WRHH:W%*RSRDF
MM]G+R%U6;LG1VE+JH)'&&#:4<$;UI/(3ZN**4051?JR"J.P7$]6]SQ*POCUN
MF/7(8/CA'\,!<5MY@GE\!^&3%=0WRK$-+CFYV5%!:K>)2#UF ;G?Q*$<,S#I
MHSH:YY2&4GY:0:X8K2#+CY63E/U"DKKW67IDL'TT"YB_'C>$WE!O?&P0QYG]
MTE2;3Y[W^"ZFDN1W_-<]B) \6,,O&=%Q:"<UI>QSE0S1F0I:Q9B(*C\FH"C[
M^27JWF?I_S-\!1F6A=ZHVH \5A$L:9,<,?MER3;?^ Y"B6QT*8G^_]Z#2$C'
M]**2$]5EM+/C.Y *KNB,D"49XS-EPUQZY0"'ICKZ+ ';6X\-%LA0L_2Q0;I/
MTE8196Y1)-I\JLSZ!C6\T:7&M]2I2%T6!:G?*",='W^/HBRGGI4(&1=$Y<*S
M/+[X!(<C.\YB50Z6,E5'GZ5'!OLLR/#E8X-F/?*8+$C2)HVH;5'&VGQ5:8_N
M(%S5.+]=0^ZJ59'Z=0K2<964?&+\#<;X#0:[G'.&+1:?9)9)CS-XBD$Z1]GW
M+/VWP0H9C$M"KVO6(8\I=HD?[2#445:?-LG9:,AI<-6@_%8MJ<LP?@>A*#XF
MDQ6/"*7%C_8/= GC%*VB[ 2M0CI"%2F&* )E_[,$[&].!74S(<,7RX%I<>CU
MZK6H8\IM8FC^-[5J#UN:C4?JO)94C[T&V6+ZYQU$I9(X)%80AGERXLCX_H$B
MI9X@2=EC9+GX.%DJ'R*)E?W/TF/#A[. [7/(L"CTNO9'U+!F8WF'9K>QS;3/
MW.(X9'-:TAIK#:C6\7<0JBKB4:F:T%^F) RR*PGC;P^.D^64XT0YXSA>P1\F
M**5#!$5E_[,$ZMZ8 AP?S 3VN<M![8+0Z[I5Z./ZE<).PT9#AW-3C<=QR&$V
M9WCU->A6C8[8*:\F])17X8_RU/@^IHHP,/[VH+B2/(2OI WA*EE#6*5P$*N6
M]S]+P/'Z%.!\?R:HF[,<6.:'7C,L1X]:Y_.['0NK?9ZU)HL]O%Y?F]5458-N
M4>J)[>-O$ 35^&[V/^\/2JJ*Q]\>]!6IJ="_C]&/5G/[4%6BH\\2<+XV!=2_
M.Q,X9R\'MF]#;UJ^AY_R?ES:T?RIQE:_U:JSQ;C5YAQOI1'=+*LAM KU^':N
MCM#!U#Z^/WC\_H#<4Z2A]& U]%ZTAM6#K.8_4P]=KTYYZ)[QX=^NCW\ =5^&
MWO;,R3TS^&JQL^DKK=:YVZZTQ;EEYMS&BEJ,K]SXSPV"X9\W"/_<'Q!UY$>W
M!U@=K1.M8W8B=>QGZA?/RR_^T?#F!P\:/ESVL'YNZ)7>MQ+;1Z>7&)H75LD=
M(0Z)+=%5;GET@^ M^Q\W",7^DIKBEN(:4@NAYK_O#UHQ!D8;RE#Z3)WQ3GWA
M5]]K[__F>V?IK?89>WI.OAQO&WN-K.A8*A,UA)@$=<E.GBW_GQL$PJ,;!/JC
M&X3B)G+MXQL$@JG$-WZ#@#-1F[%&>C/:R'RF1GU37KC8-OV]G]M?7]P_-GU3
M_;57$]6GWRLJZU_&8[7ODS-]<=6,ANP:NAMAIM7C;"6.HCJ2@^ @UA&=>'MQ
M?9&=!/U3L@MK*W&A;10WRDIS(ZUTS[,TY)\R>;AKVHS!H>F?>\Z_O*WZWMMQ
MPLMS"QDGEQ>3AW:7%A^-$A"ZT\3XCCP9IJU0@6I%*.$M*#7,CZTJ:,9I\GWX
MZCP?09O;5*Q[=(O@+=%G-5(-S]+1UBG/]?5,>],[.NT;_?W7MI8_^"B,^?."
ME.(KZ_.QY_>@T:<BB8C1)$K!L71F[F ..ZN_@)O9!^>G'T4)TGHQPM0>G#"E
M!R]*[B:6)W63Q(E=)9*$3MHSU=D^=9)O8,I;-9>G?2L!,]:QP!=[2 ^6A^'N
M;HU'_K0_O>!J1%[6Q3AXVKD4=/*93%SBZ3Q"_,E"8MP)!.G(&)H<,X8KB1[%
M4Z)&B92H$1(U8H1"BQBFTY\E?^>4YVO')L^0@E>^8(-9RTK =QN*P.I=R+]V
M'"CX/20RXVYX7.+MF.38GY+2HV]D9$5>R\D)OUJ0%W8%D7_X,KH@]#*V\- E
M/.S@)2+\X$4R_,!%*B+D @/Y+ 'MS!> ]O-W0=72^4"Q<?L#R=ZXZX)(]$E.
M.N<HNU#5RBZR^MDE]F86P]'$**WW4MCN1A+7TT#@-S84";T>;'F3!UW1Y$;)
M?6Z$TN>&:YK=,$.S V;T3;3_&/YC^-]G^/ ?PY+YH'+<$!1W31"!/L%-XQYE
M%ZA;V#BKGT.V-[/ICB8FL]Y+9;D;R9R&!B*_T5-4UN3&EOO<Z H?9&AV(91^
M%[S:7P\S^&VPFN:)!G2003?O7:!9/!\H-VS_HV)/W+6R<,P8+XG7P\W5M'#1
M5C^OV.[CT9Q-+(:KD5[J:2AA-WJ*N4UNO*#9A1/YZ]&2EGJ4O+4>H6IUPK6M
M-KB^M19N\$\TH/L ,LQ]%U2/&]9O_T.Z._ZJ, P[QH_G=_.RJEMX2*N?CZ_S
M":CU7@[-W<!D-'JHI4UN$J>YGL!O<>*$K4Z,I,V!DK<[D.H.&US;84+HVO0(
M0\M$ _KW7P#Z.>^ ZD7S@6K=/X;#N-&R(_QN?H:VA0^S-@MP=4UE)?6-/*JG
M@47WNNE,7SV9W>(D\MH<164==1A)IQVEZ+(C-5TF1'6G'JEMUZ#T+1/MOPW:
MA>.&'7_(=B5<$1W"C0JC!5V"-%V+H,#:+,34-8E(KD8!I<'#>;0/\CLII6V.
M8DZ'O:BLRX:1]%C1E;VU2'6O'J7ITJ"T'2JTOG6B/3(8/GML4*_=\;ML9\(5
M\0'<J"A"T%66K&\1YEJ;1:BZIG*BJT%8TNCF47SUI;06!XW9;B>QNZQX0:\%
M*^DS8Y3]>K3JJ 9=U:W$5'?(L?K6B08,[STVZ!9 AC6/#9)@W*@X3- I3-2W
MB+*MS6*XPRO&NQK$)8TN04FSDT-MJV/0N\9O8LP$?G\M3C*HQRH&J["J/B6V
MJD>&J^ZLP.E:)]ICP^S'ABK(( ],N%*Q#S<J.23H+(_3MX@SK,V20H>W N?V
M5)"]+A'9/WX78RNE]IBIS'Y3,>]8#:'B>%61?*BR2-DO+:KJ$>.K.T5X7=M$
M X9W7P UXX;O(<./D&%'XA5I$&Y4&B+H%,?H6R2IUF9IGL,K0[L],E)3O>31
M&Z4N"Z?DJ(E!'S*4<$<UQ9*Q_]K!E!/5O4)B=:> J&N;:*#FW<F/#/I_#(H=
MB5?ENW&CLGV"SHI(?:LTR=HLSW9X%4BW1T%H<LI(;8_>Y@C( S4<ZHB6P3FC
MH(I/BDMDPT)RY8" K.[ED:L[N61=VT1[;/@4,LR?#S2K(</VQ*N*G=A1Q1Y!
MERP,^J:)LS0KT^N\JD*W6U7D<RA)[589J=<D(1_3"2FGQG<@Y:SR4WRF[#B7
M7CG(IJF/LJB:KE**KGVB@9IW)@,C9#",&U;MN*_8EGA5N1T[JMS)[U(<U+4J
MHRW^JN0Z;W6NVUV-]CDTI':+FG14KR =5T)SOTA$/\<3E9]F\:0C3(YBD%&J
MZF,P-=UTAK9CH@'C?QF^FP^J(4/EMJ2KZJV8L:JMO&[5/FV;)LSLU\?:FVK2
M71YCH=>N)W345)'ZU)7%QR2RXE'.H_T#%THZ0A7*AZA\91^%4]5#855W3#1@
MG#$9F#YY!]2,&U;NN*_<DG1-LQ%]0K>!VU,=6-UNV&]JM819?'7QSCI3@<\$
MS9K55<5'Y=#L+U 0AADRTBA9RAPCR44C))E\B%2N[">5J7M)O.K.B09,CPPS
M0,VW\X%VQ8[?U1L3K^O6HDX:5[&/&M>K.VW;#*WNO;5.6X++9"ILUD%?!R4T
M_XNAV9\#.:C0UX.HH T7*;C#>*5D"*]0]N,KU+T$D:9KH@'3VY-![<<S@/&;
M[X!N^8[?J]<FW#"N1)RV+V(.U"^6=_N6:UWUP3:3-=FC-<&:JPR$-JF6T%6F
MP?>45A'Z2E3% P0E91"K+!W$J 0#&+6L#Z-2]V)EFJZ)!FK?F@S,'\T IJ^_
M _IE@0_T*^-^LBTN/-_X9<E(]R=E#8VK:TR.0XYJ2VJ#R@3W*:"YNWQ\_H=F
M__'[@_'; WQ5R:,; G05YRA2(^I%5BMZD%6:KHD&S&].!I99,T#ME]\!P]+
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MLDZE$=).9).21_-+$D?@U/CC*'KL,(YQY!B!&3U$+HT:I+(B!YGLB $N.VQ
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MD?PSJ3#O&@&'OH@E%Y]%,FFG8%S66+Z(-Y(C%1[+5)4/I6LK!M-JI0,I#ME
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M^"V!GW(O3IQ^YX@\ZY<8=<[/T;J\6U&F_%L1MH*?(ER%-\.;83?#NN W#H_
M+X>?AI^). <;B;H ._:$_O<8/IX,<A>\ K+7OP]R=W\."@\N K"H-: @:3O(
MR=H/LI!A?Z87'[F?PDBZE\1-NY-0GG4[3I;[<ZPJ_Z<8;>'-:!/L1I0-<2/2
MC;P>X4==#^]!70D?19V+/(T:BSJ+[(\YASKZA$ !9,B%#'F0(6?]!Z!@Y^<
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MMZQ.5\!KJH:S?%5(9K,*16^I1--:Y1A*N_1) 2)D($ &QA?3@73!&Z!JX;O
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M>G5#\LW*NN1;%;4I?Y?]"1)IAKA9(DB7$4>%_"@T:TS 2OK>6&TZ?ZC3:O'
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M3??/O+^X7W@7_@!\FL%G@0C<E<7 5Y-$N+X4A!8S$.,D Z&'(B+\M1 2:83
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MXG(L&X6EMK51]8Z5D6TN9>%=[.+P?6Z%X9?="B+>LO,CP<J+A'-N!!QS(N!
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M9##I5(^QYZF5INZG=IFYG?[%S.WD:W.78VCE=!1MG ^@K<LNM/O>9>K!H84
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MWUBGH?=8O['GV$83C['CIAYC#TS<-W\V<]N$%JX;T-)]!"T]5G_K)^K!D5:
M[;V4__LI?U,&G[\.H)GJ5^T$R#_ AHPCHI!V5 52CIHP"4<=.+%')_%''PD6
M#C\R13SD<*)TX.&9<GZ'BQ2]#U6K>!YJ5W<[M%33Y= &+>?#Q[2<#SW0<CSP
M6==^'^K;[44#^UUH:+\#C28ZW4C[<'P-EM$>6 '00_5;QNOO B@X )!VG UQ
M9_EARGDIB+Z@!1$7+)G0"Z[LR1?]N/X7P_E]+L8)>5U,%76_F"?N>K%2RNGB
M7!F'BTOD["ZNE[>]=%3>]N)?\M;G/RA9GD45BS.H9GX:-<Q.?>L K<&F\3U
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MQO2S#(D5<2'^9 JAFR*D"P N)#11/$G^(N^_44OU\ZG^]--4G_KN]1NM_2T
M ZJM.E[["=5]"U07:)X _(2#//J[@D242! 9HD2TB!&Q)5Z$;@S&?S&!] &
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M5K*''.=\5/J!\T[I/N>U\BO."V7D/E=&WC-EY'NJ@OQ$X*DR"CR9X#_U354
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MG5)W6_)(S6TQJKOVHH;K0M1PZ_G6>>K!/MK_FUOH7*3Z2WH .A?3&E#MLD&
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MH'1-')1^4P3%WW1!\7<+4+CN#/+7_4#^CRB0NY$,LC<+0>9F(TC?Z@.IVUM
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M4?"@U6ZA_5:GA/9:WQ+::?U29)LUBFTAFZU1?!/92*\G0AN:NSW5=V8!NO,
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M+T CU9XU2'M@%4#B"$#$*(#?)@ 7RJ2VVX7 >KL,6.W0 ,L=QF"QTP[,=WJ
MV:Y ,-T5!<:[DAC#73F,P>Y*EM[N#I;.[@&V]NYM;*W=5]A:.U]Q-+<C5V,;
M\C3&D$]CZ__:0.L_./Y=+.I[2S^MP;_/@*9O (C: A"PC3+H3LK@E(F-#K!!
M^X@P:!Z1!LVC:J!QU!#4CUF#VC$W4#T> "HGHD'Y1 HHG2P"Q9.-H'!R"<B?
MV@ARI\Z"W(GGC-PQ9&2/(DOV,+(G&N[^\EVH-EKSV33W_/6T!ZAV] ZJ3_'4
M=3_5/P1@2)E<\Q2 PCD.2%T2!(DK$B!^11'$?] !L1_,0?1'9^('(G03(O)3
M*@C_/(MT@-#5E2!X]0 (_'H/!'_^#$(_(@A=^0_FJSZJWTGK7KOZRS.@&33O
M*7L _ ]2_RFJ6U(>US\-H'8>0.XRY7#*Y<*_<8'_#R'@W9  [@U%X-S4!M8M
M4V!N.](%D&Z([M#-T!TZX>[29K]'&_S>.KHXTP3N/P/X"_]+-]6?L^;+,Z!4
MZOF4 U3_*(#S20#SLP Z%P&4*:I+_PH@>AU X!8 ZR[E_@<\(D(D !Y2YG]$
MF?\Q9?ZG=@#/Z:;D!8WC)7WXO:23_A4M].O- &\N ?SSDN W&JE^*?WGM%T
M4P^/?P<(P.D<@"G-68OFK/ [S?TFS?U/ ,Y]JOV0O":OQH]<(D0_6XQ( [Q5
M 7BO1S>'UO]^!R/JW^^"U)$^LO7?[UT\)N_^QRRJGT&]CZ&Y!]*\G:BVR54
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M/X[&E$;K5$"H%[QZ^,QK@X^\^?">MP3>\@;@#6\UO.)M@!>\[?",>P@><R_
M(^X=.GUH)/P(=P41[@C]!_,]U*"Z&E* ZI2_E21I+(K4%VU:'S,:CS.-QY_6
M* H^BDZ'=Z)9\$:T!%Z)5L,+T29X)MH)3T07PF/1I?!(= 4\%%T'?XF.P3VQ
M_7!7[!S<$OL3KHN_A%\ED/E9$ID?I9#Y00I95[Z#.E1?A_*^M@B@%F5P+6G:
MUM0+-0,:CPV\4_""5_(A\%0N#OZ62X,'<OEP3ZX<[LC5P6VYN7!3KAMNR"V&
MZW(#\)O<&OA5?@O\++\7?E0X Y<4;S'GE%XRIY61=8(<4T;VT?\#ZE-] R%
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M@1M Z&. !],V\VE@XO/,/75-J*LKZ[Y'/I+W8+1[(5^0KU0LTPCXUHP+TS'
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M]NMCWBISS%UEASFKIL%UM2M<5GO">2  LP<B,7,@&3,&<N$T4 G'@79AZL"
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M2,S?Q(ZW2)+>9O%YA_A\=X?T'LK>PXGO/2>]#ZM[_PLMN)+Y"-,:\7')7<3
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M_6<I''BYY+F*1&\=6.\N;8!7;B39V42BL85%?BN)P#86F.TYKLU_VUK-X[
M/'.;>1SQ)7P'LKSE]RQ.GP-LV.30$KXRAH_[:6\SKY7X.I\VIRU /^T-1:]M
MC>2S09JY&=VF!K,+[#' CI.P8Q_^.( =)V/'*=AQJEF(F5P/U;HV/IVZP/4
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MM\X=*KWH:S,W]/!:@*_3!IF#(,S!A+,_>CV763JG*S*F.K)3KMTIIEJQSTJ
M#^*30V:+,G%Z)G8<P8XCC),C#*ZSFUW7 Y^)D#/.(G&]A>]!GP]]*9WJ4,^
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MG3LS#L)D#\ Z][&0G80=>[!C%_VR \Z]C4^W\E>;L7PC@VN#7F2Z_<)YULO
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MCR*"XJ.)@+@\X9.81H9)*!,>B96$6X+9L \G50(C@ 1F(G'X3N+@,/(WX!U
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M#L]I*3SH)1^A ,3^*'L.,(W9AX5;QD.F#/B(3V;G?X9#[C!&[AS.)/Y7#@9
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MZ60D+O&?X-29<7)=.75E\B!,\)G*J=N/LT%83P@F?Z\%^7%R*K,?A@F@?^1
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MWCTZ[8QC8FZ_37IQCV5>>9=9:76[<6UMO6%==:5)<TF967O>SX*&,!S@3X:
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MR'96_9I!/O91S+1^&Q>(?QD1X3D>',]^R$T+NN>;%W'#JU1TU;,N88C2FC1
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MY>'>5LSP:<CA!%:D\\,+D\-$V?&BY-38E/3$J)QL44197G1X8T%$>'=!1,1
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M'NE_OE*B<V*W?-,K]165+W6WY#TW5!(_M=2*?N)D$OS8U=;O$07K_=#;C?+
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M2/D9=/S+"!(SBB "F"7!AH625%@FA0<%&0?8/-L2=LL;@]+<8Z V7QNT%VB
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M^TOB6?]JB7MW%"2&;NV?<V;XZ)J6(>-]E1>LC^;U8LS$W03'F%,>;B%M7K2
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M6\%SP1;P6;@)N LW0LBB]1"]:!TDSPA@T?NUPQX9<%2:!?A#<D#4F <D_<5
MMEP!))P"N#,V H&_#?"QNP"7OA>P10? N5H),$W*X-1Q"!Q[5<!QZ# XW#X,
M]@^/@-U3-;"=4 >;=^H_K*<TOEA_U9BR^JGQP0JFY7\.NV4 HS@+",IR0%*?
M!Q['%@/%8@50L&N [+41B(';@1"]&_"I^P!7H @N5<K@?%P%,.VJ@.DY DX#
M:N!X4QT<'FB _5--L'NE^=-V\NA7FZFCGZR_:GVP_JDU:0V:TP$N&Z3 $77
M[I\%[DIR0#DR#VBZBX%NO@+HF#7@Z;D9/+@[P#UB+[@E*P(A]Q#@RU4!5W\$
M7$ZJ [9+$YPO' 7,L#8XC>B P[CN3_N7>E_M)O6F;*>.O;/]=NR-[2^]"5O0
MF0[ H0Y.J -^KRR0%>6 KCH7O+47@;?I"O!Q6 L,CRU X^P"BG _D!*4P3WK
M,+B5J(-KC2;@F[4!=TH'7/KT 'M9'S#W#7XY/3'\YO#2:,I^TGC2[I/Q:[MO
MQB_L?QD\LX=CT_$_AUTRX+9'%CSWSP;O0W/!5VL1L(U7 L=N+?BZ;P5OWSU
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ML ].*.R%[FFI.H&.?Q9!XJX@B& 40?Q !J'#? DW6"J)@;^D;&"SC!GLFF4
M2G*Z<$3^*&C/40.#N:I@-D\9;.8K@>." X!;L _<%^X!VJ)=P%JT _B+MT'D
MXBV0M&0S9"W9!"5+-T+-M.1VH;\_.@?!=Q&$^11!/ !!7$!>PA8]%F:P3-(
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M_=A7Q[,&GQTN&T[9/S1^9S]A\L;ND^D+^Q_&XPZ@_]@1=$>=0&O$"8[^&^"
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MN(/#_7V.]@\N.-K??^9H?^^+@_U=M/M_N;D.X,PHP+[M %OV4V#H%!6ZK[)
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MC%ZU<=GTVM)MTT\S]Q$T]AA!P\4>D7.X7 ]PG.S!GGZ +>0,AK:0_B3]UWR
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M=GE)=^P*4CY:%*:A45$ZZA5GH%;)(AA,NCL.X"EI[UO%I'<J:3!;RPPGU[#
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MQ9<W.!2?O^-0?/J+7>$)<BPVOG 'QP!:M@-4+GS\Q\G\<P#!5TF#_P? _@Z
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M_D90.- #\@=V@.R!BR"W[P7([264W!Y"R>XFM!_T-(]\0@U@?A= 22] VGJ
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MV-]Z,I]%^)Z8$Z*%F'PS+5\_K3/R3 J.@S1\?R8%DTYV_Q<BKX5>'_VE-")
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M;6X*YMF\YE?:$DE$8JXMX<Z=3C@_(%._;7/74/LTWMH/>Z#O1 \ZY$S!H*,
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M66Y-P@RW#NDTMW4RJ6Z[9)/=SB*/99+=/PN39Q,!PD,D?_ ,Y\$UC/F$/^8
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MD'6-/X!<EW6->R,]*XY((0*W.,+_P86@;_VXK<E8!_2_W;G?>C#S\5J X\A
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MP%]X6'Z+A\1WN!F\QPWP ]YX/F#!/V"B/Z#(AZO(C:]DC_2 L%1^F',GU+;
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M'M=/*7O<(+GL3>([O90R43>E5-0AM DM":]P#-R@#R99]V--; >&GUN(-2U
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MOKB^@V AURGHKWU)4-%<_1-+Z.\.^K:*W-E'@+B3[(-GR'^._)3G)FQ"O4N
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M/!<BTW,U,KPFD.9U'*G>5Y'J\PY2?'X@1"6\E;C-P.,Q\I^@ZM_+X'0K,<J
M:#G?ZZ-MK;2CQDL;%5[&*/6R0)&7 PJ\W9#G[8M<[Q!D^T0CRR<)F3Z9R/ I
M1+IO)5)]6Y#BUX=DOY5(\M^*!/^CB ^X+,0'O"'$!7Q'B!*@@+^()Z5_$(ME
M.U"1[TX%-A&K&0PMH1W=M*.1=I3[:Z#(SQ#Y_F;(\;=%EO\\9/A[(3T@$*D!
M$4@)B$=R0!J2 O.0&%B.A*!&Q ?U(#9X!6*"-R,ZY+ 0%?*8$!GZ*O%O0A0B
M0_X#W(A29H8.,3#>D<%VR&0[\#F8PLB?OJ&H0U&H##G!!L@,GH'T8"ND!CLA
M.=@#B2%^B \))6(0%YJ,V- <Q(25(#JL'E'AW8@(7X[P\(T(BSB(T(B+0DCD
MR\2WA"B$1"@1&BX*C],'I\EW@-P3.10$N52A?/;SYQ;ZHY+^R*,=Z1%Z2 DW
M06*$!>(C[!$7X8J8"&]$1P0A*C(*D9&)B(C*1'A4$<*B:Q$:W8G@Z*4(BAE#
M8,Q^!,1>$/QC[Q!?$Z+@'R,* 1*B15Q*5&6&R+V%0?%H(<<CG[T4+0U\OY3V
M92=0!<9J(R[&"#$QYHB*L45D[%R$QWHB+#8 H;'A"(F+1W!<.H+B"Q 87X6
MA#;X)2R";\)Z^"3NA7?B)+P2GX=GXE=\_@FO!%$!;^)1<AR3,D/DWD21LKJ4
M?8'H+F([T*[B+*I ME-<DCHB$@T0EFB*T$1+!"<Y(BC)'8%)O@A(#H5_<@S\
MDE/ADY('[Y0*>*6TP#-U(>:GCL(]=3?<TL[!->U9X@NXIOX!MU01;BE*2+<E
M2S?E["#O6*7R=- @GQWE5 #%C(#YNS3:$ITI(#A=#P'I)O!+GPW?=#OX9+C
M.\,+7AE!\,R(POS,)+AG9L,MJQ2N68UPR>K'W*S5<,[>":?L,W#,?H;X%_$
M3EDBG#*5.)VK/*6UC=SKZY2G@_KY;*5XK* MN10+2;0EG+;XYFG!,]<0\_-F
MPCW/"FYY3G#-\X!+OA_FY8=A;GX\G/,SX%A0!(>">M@7],"N< 0VA=MA77@*
M5H5/$9_!JN W6!>(L,YGY$H<I\_WD'\SN=<V*T\']1!-?%W:0"5&6^(HX((K
MJ(;+Y)A7J@_G4A,XELZ&0YD=[,OFP:[,"[9E0; IBX9U>0JLRO-A65X-BXI.
MS*X8@GG%5IA5G,#,BB=@6O$)9I;_"K,RQO022D4<9MD[R#5.L3K2 2SJ4NY,
MJ>M4[DQALR*2]O@U FZTTZY."U9UTS"G;@8LZN9@=IT#9M6YP;S>%V;U89A9
MGP#3^FS,:"B'24,;C!N6PJAA$PP;CF):PW48-'P$P_K[,*RCOJA58I^T.Z>=
MXISB;(C"O;__OW>FQ"V@#_@[3]KE1+LL"=,.'9AT&!(S8=QA!:-.)QAV>A !
M,.B,(M*@WUD,O<Y&Z'8NA$[G>FAU'H!&YV/0Z'@=FAWWH-7.*+Y-"<4)J1Y@
MU0#' \79@B7T 5&X1+DS)6(Q^P$QC[^S(<P(HT5JT%ND!YU%1M!>9 ZM13;0
M7#07&HN\H+8H%/)%"1 6L:,M8B,N8B46K6)'EZ[>I*1=>(<+X5?$;P0CV7Y1
M<5/P.I:[8AG?4IT.*EO)?C "Q/*C@80;84?,(HP)_=4"--;H0%@S#5@SG0-Z
M-L' 9PT#@35<!-=P4EN=IASHJUL)JO!55)ZK*.E'*"M7W@6&?R%$!:2LS"IR
M+V'9G6N :HKEO/54I&- R$9@/F%/S-I$_LWDWP)HL#ALH_K>QL!S*X.^;0P(
MMS$(W&9/N!,,!K9QHM]&7VQCI][6K[P*=BM5^!9*W,T?$C]Q0A(5&&5]5ZSE
M6"!O_3C;@!PI$QR+.P"OG8 C!>MLNM&8BEUO'Z"VG_P'B4,"P:#\$.V0=JD<
MIAV'&0 ><5!NSSW*Q?\H)_NC'-A'V;F/T,%'6-AARNU#E/&'[K&<!X2($7+W
MLYY-K%L)>=/(%4D>[X/*DT&SC[#]CP$Z)P"!KF1PST6..#\%=09 % :/L%TN
ML%T>9;M<I#\N,0"Z)&W;Y21XB8/_$GUQB95\C 4]]A3Q*4%?7/Q3F979SO69
MW!GDC3H*^)Q0G@R:13Y#\FE+V9A'B4O$XZKLR'7BA@I/4*P]J04\I4]Q0*%P
MVQQXGG:\P"#M3K3RJP1?;"+8Z"_2J7<N\ODR\07QLR(K4WD R")W#'G]6#<G
M<L[BGS$DA^95%<^3JBR,E*6XH\+429VI#,E;<N ="J7WV#8?F"EO;OTG@]-/
MN>A]QLGX+@?Y73K^+IU[EQ6Y^P:%W;]0S6Z2>Y+S +D#R.M\A?S\];0G /6G
M5;MA[J@R(U(6YAW\_R=TIK(CGZNR(]^POWYG(%UI /SBH/R*AU\9'/W&L?H[
M!^$#-OP#DCY@!?^XH\H_&*@P=2K$#LJ;4J53(8E0GI I@W)WR-3IE$7XZY8.
MZ9MCMBJ^+>4/*LS?J3I_HQK]E3KS/A6S=#?'U#>T2+>42CM"I!LR_@'E39W*
MG1C:JAR$CBI3(]T2(IW2"8!RAXIT0J:0')54BXTLOX,*NH_E+V;Y*UC^&I8]
MAN^H^^]1<7Y#M?LU.^Z7[#B?L\'N\O^?\E-3MW-(^0]I1\;+JAR$,O<A/)1_
MD/PA98@<6"<OUBF,7(FL0S9K4Z(ZG=+$\CM9<A_+7\SR5[#L-2Q[G.IZ@O7;
MISB=\C8[\AOL1*_RW9<5YW64G%).2CJ1(MTI>T-APW_G'WZ'+NMFPCI9LSZN
MY K OQ#-.J22(X_EE[+\&M:CF=VPD^7WLOQ%+'\%RU[#LC=2L^\@\R%VXS.X
M2>5^G9WI*K["%7KQ$EDD/ ;EO2Z3_V.#,@>A3LYI[&KF;$D'<GF2*X0\<>1(
M9Q?-9_EE++^&Y3>Q_ Z6W\OR%^$R[7@,:W&!:G\2N]D:QVC%!?:.9^B5C_G3
M3XI[98Y N:=H"A(W9RO%!3B?JQ*!;](7+](7S\**_I)V9?BR9</)D<">EL%2
M\SD]E>$L[3C-_G$*[8J=&<=HQQ$,TP/K<(!]8Q__OX=6[.2GM[,F$ZRAU'.W
M*'KP7WC *???ZLHOIWI+79F@?(;]X@;[Q67,))\=Z^-.G@#R1+(>2>3(9.GY
MY"@E1S5'0R-YVLG32^;%Y!C!)O:-<?YF RU;I_#.\XK,V2J.%BG'./(0?N1T
M_RFGE-<XO3UCQ.F/P_HQ3GF3'">G8$3.V>1SQ%ZVR4X$D2>:MB?1VYEL^7R.
MAE+R5).GD3P=Y.ECN<OHC5&.W&U\=0A+6-IBMN"@[&,LE/^$A>HB!HA^#26^
M- '>GL7IE<O>XUQR)CG-GN1[ASGM[E/78^^:3DXK;)3-Q7JY-T;50K!:/08C
M&LD8ULC$D&8^EFN68JEF-19K-6%0JPL+M1:A7WL$O=J;L$!G/[IUSJ%3]TET
MZ'V(=OV?T68@HO4A2)=AW^'2?\V1_,1Q3J_[+1G?<:K=;"C#!ET#K-:=B6$]
M6RS7=\42?5\L,@C%0H-8]!LDH\\@$SW3"M ]K0R=AK7H,&Q#FV$?6@R'T&PX
MAD:C/6@P.H,ZXR=0:_PA:DQ^1O5T48$J%:2=,5(.YB*7_9-<<O>[47L[,[ZT
M92C")7#(1 N+C8PQ8&R!7A,G=$^?C\[I 6B?$8[6&7%HF9&")M-L-)@6HMZT
M$K6FC:B9V86JF4M0:3:*<K,=*#,_@1+S:RB9]0Z*9O^ (@O.> _A)?)?]U3>
M2G*8(= N'X85_'F-"[4WI_J!.7)TFQF@W=P,+;-LT3C;!?6SO5%K$8P:BTA4
MS4E Q9PTE,_)1>F<$I18UJ#8L@V%5@,HL%J%/.MMR+4^BAR;R\BV>1U9MM\A
MRTY4PE:)YZ1#N>0^%40?,.S8%DR=P25F!9?=A?1)%]NGR5H/==8FJ+:9@TH;
M1Y3;>J#4U@_%MJ$HLHM!@5T2\NTRD6M7@!S[2F3;-R'3H1<9#BN0[K@9:4Z'
MD.)T$2G.+R/9^5LDSQ7Y_ M2'N@">8]).9A(^B""/@BCSF XUN/-^))V5#MI
MH<S1""6.YBATLD6^DPMRG;V0XQR(+.<(9#K'(6-N*M+FYB)U;BE2YM4C>5XW
M$EV6(<%E'/&N!Q#G=@&Q;G<0Z_XU8MQ%!6+=E+C!.I\G_V%I9PPU^!BQDJ\'
M:4<G[:BGC67N:BAP,4"NBRFR7*V0X>J$=%</I+KY(<4M!$ENT4AT2T*">Q;B
MW8L0YU&#6(\.1,]?@JCYZQ'IN1<17I,(]WH.X=Y?$G_RM?@?7 U1WA!S@!I_
M&S7X.NEF$H8<_3&,KVA'->THHAU9\_60/M\$*?,MD#3?'HF>+HCW]$*<9R!B
M/",0[16/**]T1'H7(,*["N$^K0CS&42H[RA"_'8CV.\<@OQO(]#_<^(!7XL(
M\E/B$GU_4LH#,?S<PC!C+4/R9=3B/;2CB;95T(X\VI'JJXU$'R/$^YHCUM<&
MT;[.B/3U0(2O'\+]0A'F%XM0_U2$^.<B.* "00'-" P<0$#@&O@'[8)OT!GX
M!C\-G^"[Q.]\+?(])1Z-5M[2NYO<FS(I!:CUES ,[:8]E&THH3^RV%8)01J(
M"9R&R$!3A =:(BS0$2&!;@@.\D%04# "@Z,0$)P$_Y!L^(64PC>T$3ZA?? .
M6P7/L!V8'WX*'N%/$9\2O_%G1DEA2DRR#0Z3;P>YQQAZCN11%DD[4_AS#?U1
MR+9)9Q^)C9 C/$P?(6$F" J;C< P._B'S8-?N"=\PP/@$QX![X@$>$5DPC.R
M&/,CZ^$>U0.WJ)5PC9Z 2_1)S(M^ G-C/N'S5X)14I029Y-4>: \Y0TM*ZC#
M!XBV?,:ZM".?_DEE.T73UJ!H'?A%&\$GV@S>T=;PBG&"9XP'YL?XP2,V%&ZQ
M<7"-38=+7"'FQ=5@;GP7G.-7P#%^*QP2CL,^X0;L$C[B\SX<XD4%'(F3Z5P7
MI#P0>4?+."^5 WU\-C,,+B]@O,O?)=/&"/K*-TD3\Q,-X)XX VZ)<^":: ^7
M)!?,2_*&<U(PG)*CX9B< H?D/-BG5,$NI0,V*<M@G;H95JE'89EZ%7/2WN?S
M9UBFB+ BK)-%Q4FQW>3?1.[5#'N7U"AWIC16LB_0EBS*I'C:$D);O+)DF)>A
M!Z=T8SAFF,,APQKV&<ZPR_" ;:8_;#(C8)V9",NL;,S)*H=%5BMF92^&>?8X
MS+(/PS3["F9DO\OGCYB9)<(LDU$C(=W6L[U"^8_V*QLX+S2R+Q!U]>P+M">5
MMD31O@#ZA4,?#@5:L,XW@&7^=,S)MX!%@1UF%[A@5H$WS M"8%80"]/"#,PH
M+,;TPD:8%"V$<=%Z&!4=@&'1)1@4O07#PA\($48%2DC?&+6UCO-",]<G2N1^
M2L.V=J"*KW,IC1)H5QA_[TT;Y](_UI4"S"IT,:/"$-,K9L*DPA+&%8Z$.XPJ
M_6%8&8%IE<DPJ"R ?F4=]*IZH5NU!CJ5>Z!=^0BT*N\07T&[X@_HE(O0)7:Q
M_$V2/.]D.W0K=Z8TJ6Y(2>]B7^R@#VB3&VVS;Z'^I*TFS6HP:-*#?I,Q])K,
MH=MD YVFN=!N\H)64P@TF^.AWIP-M>9*R)I9<!/U;A,%91/%8^-MXE\$M7^#
MJ, $^=>3;[B/[; 0Z!CDW$CD\74B$3H >%*N.O'W<WJ!&<2T7AFT>W6@UDN=
MVTN]W<L@I)=!0(\KP06PAPM/#P=43XDRN=4C'?NAL%UPG!,/!5PWA5G7?8(V
M=(K8Q'JO6:@\'=2[3'5+[1#U-Q%)^%*FSN73BN^;$@Q-H$/(5C  '6*P-<0
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M\.C6/,]^S?6<JMF>LS3JM5@SO=9JNO=.3?.^0E-]KM.P[]V:[/N4AOS^J,&
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MM!>_[%8'4=@#1C\84\"8"<9\,)9K _^O=>Q*.:J5V&(YM5J&1Y?04A83[8O
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MB[(\>Y3A-47I7O.5ZKU.*=[[E>1]5HD^]RC!YQG%^[RC>-\O%.]GUPU@'F?
M/PA)V&%.9RUPK@J9G>%:%8+'.O#@N!!8:)"GB@/\5> ;I%R?$&7[1"K+-UZ9
MOJE*]\U6FE^14OTJE>S?J"3_"4H,&%)\P!S%!JY13. ^106>463@W8H(?$;A
MEK>1?RC"8M=UX!^#5>XO<QY6MX:!?Q&?1TD.ATB*NK%3*]ZJPUME>"O?ZJT,
M2X#2 H.5$ABJY,!H)08F*L&2KGA+GF(M98H)JE=T4(<B@P84$31;8<&K%6K=
MJQ#K:=FL]\AJ?0;Y,_(EG^TZ ]Y1".->$K MU:[326"[,T@,!]!O G9J)G*J
M24R*(34YX6Y*M?DHWFI1;+!5T<'ABK+&*M*:K AKML*MQ0JSU2C4UJ:0D$EX
M?%36D)4*"MV-7"-+Z)T*"/VA L+>4&#8/_ELURGP+P=[-PQWDUF9@LR'*(Q
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M)V@]"!ILT8TMNACNNK#%!(;B"0R+$_#'!&)B@EGRQ(_'+T)V.(^\[("VM;]
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MGTHD##O6]3SG6)4QZ%J58<1LBONNJPLRW> Q5]=L)LTW8XNU\@<O&*PP,&+
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M)+("Q&W(<)& %" B(.T )23H388"T$Z0A0> &Z0/9 #421V  A<@@ (4$(4
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M7P! 20I 3RN!0OI,11 Y0!JU0(]< V3368@,L" %=,F RZ2 -QD ";[(#H\
M>TF!5@XH0$<*K)PANP0I0#3^6P"YJ2! *9GOG"<%T&0.')K&DA56D1#@$S1.
MA>YA$4,@O7"! @OV)&.*&0X%B)/V.WE$3\AJWK+UBLEM7O>U+AV3?^M]<9OR
MKQ/<TG?TW,ST] R:].==V<]\G"V-]+74E>7.29^0$!/D(RU)*!^ ;.1!*_6/
MR08]9"TFWU8!SI!V@BQ4A]8+[I!?@A0@KWI @ ]DU1V =/\(+4D&#)!>0H\,
M@%28/<D 2+T@=2L4@)1F6\A.CT"WR:&;IF0%A3!HC C=HOH,]0]DE72?':3
M'BC0">T%%" B?_-CC'M$933,O9/6>2R[TBT@.CF_IGV2+*#9E'\SF1OJ:/Q0
M55Z<GY66FOSZ=3+I7F"YMZ7>I;-2XH*\>]AWT%.M#0M6$J"#FFS>0 ;4,7*
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M/\/32$OY@O3QPR("O-R<.QEIJ:![GN3GTR!;FI_VD@'^) ".[-$2Z',=]\D
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M5"_N.G\&8W'4Y6L(:Y[N"QC/ JW5+#=Y*IDM:&ZO 7^WH\/!N\T_G^D+O?Y
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M4Y&FRACO?I3^"=57OCMWK[\>/G='L*+^NO(@O&N>0"^/UM-L K/+6=>1O/&
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M%=M1HC_BW@?YV:M_3)G$3@D &M,KBGZ.7$IDG5Y8$2 T3O7F+X\5\>[57MX
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M*X&-[\),QZ)9T1,*MAJ#I^:N&""K3[+0\U'EDK/([Y%TED(_XNP,ABION2I
MJ*!R$@_=2M#B%RT=G[A[,V?N>6;J3F5_^-$7C[R_BWBKFM&0=ZWF[2QI*Z:/
M%S]O7KW4DYJS=F4$-0=H3I^T0_]>7/M/'DQ=^#]WSLRB'\O9!XGQ40Y:(#1
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ME!E#&PITSJ!I,M8%/XV9XME-(AQG3J&S#LQ\_?:I9;B@F?.; &?8E@KX+7K
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MC$[.NAP1C*:UHGM[R3(8ZAO$]UQZKU(#?D_E%VG;,<O!+#\W! CG?V,8Y)_
M0K/\3;;?3[3\_]*RO]'_1O^O0'^55E8"F2I.!#C>=82C*CH6\GFGD5T51US2
MD (^;)>]:'^Y)A%WY]5W6];IX+.Q;T.UY[F;9*S?"I+V"O_\(!8X*O<X_<Y9
M0$4#/_F$;Y:E*5I9_A(2GBP84F]=O/.4XQ]^FAF20@WX ^H?=?JF[_TK<-^_
MM?O?F@,>UZ<S[!;(X6!0NMO^9\-?_)NYY-E3T@9;%_]0CY/!+8C]&6S6GRU@
M^6N"^^DCC/=O]+_1_T;__PGT<[RK Q3@MPV^""_\Z!*%Y$G.IRC!3O>5AU H
M;NVRM9#977I_V37Z0U>UN8=CMH>JQ/APBBO0OQ<VLPN'C'8$<@P+K?[AL(\"
M8//^[Y\G?J/_C?XW^O_%Z&7J5:A7]D&AN]0G9+%9\/-Z,=H;^I$QEWH%0DE&
M!G3"BJI9<[*!8:(\>8VX9EHS]%#T(><KN6,S>?!NQ-%]T%0MJFSDJQ<+O5>8
MD9:BP;AT5>F%PMNMB2L42^)V[UANN'Q%SL;@&9CPXUC+I1SNNCK;R5F2V:K;
M/QC1[_RF;;_1_T;_&_V_"#WZ'.T5]N$^B"R3NQ*0%;2L31!;Z2/<,47B\%S;
M4'Y7CT*J9I4TP_Q&8YD6[YL82LX)F8E13R.]U3VBMFR1N><.?XZAY&_B]AO]
M;_2_T?\O1P_#$3S7Z2Q36((9*G9$^#@-!3]QEVJ..!($"QJX5D-\.K:8_"3H
MUFBGUZ5K#Q,VQ@<3F3KCR30,.@SR"+)K)4!*WP>5&4RMTWCU1@JEOP])N&5T
MTOZQD&P,V"CF=P;ZC?XW^M_H?Z/_C?XW^M_H?Z/_C?XW^O_#T>/V04?9O:)Z
MB6#2IY19^\CLQ70YK[@O1*/4/R;K6M(J=D9!B<H/ RP>GCY-F:R)]V990DPA
M(1L!^Z#*'=H'_WW0GGZYA:REG]E*&/VXXC[H39#U/FC4AI!+_Y"%KEV>ZB4K
MC]!-IIW^VZEDW_CZS9QOFMK<MR_]N?G7?W3\[>&AY:WC6 ADJAJ_8;(/>H"B
MJ.&9$+\6/F*.;!V/OIC]3VG-N+#P]\\[P.&(!D/LO!R88(REL%.O[X,&S,/A
MSP="#GIN//M7'C7^/?[Q(3G5.XJD6S#2<K$KB635?9#VR&0 P6D%< +)(_ !
M/$D/!OAMYJ^3&IO "CO]%RU4_D\:APA.5,X%NA&6! 2.S_$'+8,MHB%_$P%N
M-U=R_*VCH\,@4[/079UPU'^M/NBX2NF)?\9MHGWD/WU\F$K=!X4N(]IU:-&(
ME<V#6<M*QUY;WMRDLQ;O@\Z#2>( W&Y"(#W^B9LWY-JOS.AK_]E"AX/Q%VX^
M\E=A0>G305>??TEUZ^_Q'Q_U;+2W^Z#Y>UYC(?1VV3#LEMW3!2@CO NQ\4EI
M57T?]# %2",RS^77KU[,?![^KR@9X.D)@LX -,%+,&B@&7Q<C8>HTU2->PD3
M$V6>*68R&)ZJJNM['_ HW',JKG/\'8_U*UU>;].;/G9"?[$D[RZ$TV6I%XBX
M.#5-PFP#E!NF6A04V>A[+5WBFW^=)VO,!%^NA;/%VK$?=5\2S-\=?1[((.K$
M?:BO[R]=W@_% ;\$.T_^0D,#Y"%W!AFI9GS0B@8M\QJ-:%0O;@BAI2).J8T;
M(,^/MZ?)*=T@![2U_??_\2ZR91V)/PQQFN "<U%#R$/3LD==,')O5[<Y>,F)
M([="+6?GK67LN--U0 L)RS8HCGH1JAJY=%K56)@J2?P9,V/'^E_8>\^H)KJV
M;3BH]!)ZAZA4J1:* A(1%;FX,")*%:*BTH2(B$0-&0'I( (""D)04%3 2%=!
M(EU 1$"I2@HB*@E,1,-(VCM<[[.^];S/??_YUG>O]?UY?\P/6&LFL_<^SZ/L
M.??>A[/CDNOI_"-:TVY)@E_1>]_>V-UN)=+X']E?.9JB3+0@;(%0M.^"S80P
MJ(2^) X1QWQF7XP3/&N<*B<[%ML5_$(_*[AMDQ)QR$5\?;DA)@:IM:[BM#Q^
M\S6=?YZA,@AQ9Y$=Z"2U(H.4;LOT0&WP@\#@(V.D=9<<Y:G_9%L5L*GK4D%'
ML*<#\[RJ_J>W5];OT3'X?V) 96ZNM"38G,__<-Z_7<O5:G3GT2SET_5*KQ$R
MN5>\+#O1Z8 ,T0HR&6*XM ^E3B$S"/:/-$23*?224])<4Y+%@72,!5ZC/*Y.
MK_S$W>W/=FY,1U#OOQ BT@"5-C6>.E@QXP!ULHWV@*4ID>V1UB3%!7D?OWT'
M]<6*+AWUO':EM'>DBF $44'L['PR)LM1E!<(4K*L3IKNB\%)+G"FLLBW*T4=
MIF,O?I+8F/GEU#6[HO^^:$,&!EX'(:)O7#!-Y42-"A'?389=_I4CU O:8=FI
M*43T.Y@)$?^U,[7'/W3[;U9C#+]?R\__N?O9_^L+2R*! ;@_QD)$+89?BH,3
M/'K\?VNS&,J7<D$WFG-Y;9/<X2'W2/%O.O\A9$;".G1+,^^ALT 2%O0G*:G8
MU;!GY/=V_U!4,=!_&DTC 1PM*$F(>%@EQ5__D /+URW_?Q/[_[W^Z_)N)]6C
M>-6R7 PP:0 +AHQ_7,O_D(GO#>/FX0#;,4")< <"0#(SBAW>K:L^1K;ZC#D$
M!9,#0J>2D@:<=U>SOR^W7NC=+/_F1[^&[\&-UYP8E-)L"(>=+A1DVS-Z!=H!
M,)AFC__:Q+T"YU F#Y9+=1@&FF]SW'O9$HOKN/7X:.>'^?0K->,YR]I.1\[7
MR'F-I33@/3DL?O,BP>/A]"?B)$KE] WWO2JYNQPW_3CCZW;-21?0FZ(\2!<<
M)6@($7K)^7 4&J-_G1K_'7"<Y_M7R2Z/+^E8U8'WTRGSNSHJ=[15_9;ZB82,
M+6\X>(.]'"F(RC9]?>7+ZMD7]*7KC@8??@7\];%_(#16K##:;,<F9O^W:N0C
ME87?=  \:OGG0 I+ >9)RV[JZMD6\DU_TEZ"*2QZ!N!0#X>XG'?\ZT0MX@>4
M,D"KP38E)5-F=126K.W=U\^^K?7MWOB\8.-FUXBY&*T@U.6)+Z57O4^"A9PL
M?@.%5DP!/;$(H-T!"%N:6K<T:]N)R7P9T$62<[C*D+4SMGYE*-@0,1:[?=^>
MY\?OKV-JI+U(2[30,1VDT')18  9,L R*?![S$">(&HVFW7P(E85"NX<\0_W
MVPD>>!'-N>S^841T^40=GC07L\M;[VYP#:Q?I9E$?2&B_2Q >PA(HFEEI4@(
M6XU'<X@0*NBJ92+!B9%QL9G"?EA^WO?O)@[W3GFCK+:9SFL#S^RBOUWVQ,'8
M)RK*[DT7J O:L5H" SSR..GO<8?=8$K7R]*,QWXO?",L:".+9Y)/[[X3H!+_
M>QW%4HB@):":O%DG00HG TQASG'/"-[/F+-74H 07-)-_! ]LF4VZ]+5/S76
M.V4>QU;NWSW04M(G\S8(&3^WKWW]WUV"M>W>#U/F-%$-+OR;%#7@>]$BQ:+-
MA(=DUPH1B0#Z#'F:2SOGB.VRG&R:Z>TN.L=^).M8R*FSC)B,%^__<S)_7-_J
M_)N60P+19S'HR/"O9,@TA45Z1.S /BO,)%KA]^L"ZC.]NHG@:H>ZP_?(QH&Q
MGQ$)+D*$^=^7+_?+^9XX(>* .LTG.=I IIQ;D 8=-;6>/CA9[,PN3*FQCMM6
M;%^PB^&[;NM&^87<:HD-VW.P4H1S.6A:.0 >QX@3AVSZ"ZFR< #Q+=!JT(2R
M=_)\=RS,!HH+7I](5Y0EMV[,N55RT$OYIG8P3VN.@9U6ZD0UNK!V<2V(XZ@&
M:B91/PR%'.^XD]=-W/S\@VK'ZM>IGVX-S3O>?-VY0M]:82J1WY3X^M?2=#BG
M@$]&AV"A+4 R0+M%J1WOID!>J@5MHD+$]7%&95=XG*'IJ[_,=QXW<PT]42^6
MI7/GGE=."BID@Z+>Z;PB.)H]@/X0 $?EJCO 3J)BY>/PVJ$A0=G3>O1"UF-Z
M-F2*X2G5.]6R@<P&2VF4+,$9\GT<8$[AZ4]MO-E/'-PAKQHS._?.-=EPSYS?
MED-E6?942#^;%07BW!U-^3<!6BVI01JJD\TU)_4L*3HS!A6A\O5?7K7>U/,O
MS_HQI!$L<BOSE@8WHU.:L1^<N=NV[:K-F&BFWK$(^]C)P7?M7__X"W"61%;+
MBYX=@X02KBH<%>&4H*6IE9X%4*]K^P(@133OW.Z/)9A I,JF.T_,!RSHRHYG
M5>FI6@GK#$R.WA[?27YF?$+EYQ!/D<KQYS\'SE"E"2XCE(BE*4"@&K.2VK;I
M^(\VQ1;!3-L'='U#[SY)L<A9YXCE=<0AU6]! E7[K#AW[#J@?5V;%>$$-$1#
M3QDNP<*V&Z, /8E0XMQEZ]ZY/\#8'79U[%GM#5-GG6JQLT'*$K[I7<_W?SHO
MYJZ#X"ZF\\KY3]$A:&B+&1H,C/#F>/-36\\O.F# S7W[=$T^SA=W"N1D'[D8
M#*6BZS,N>WZJ\%"7%Q4M_6ZK>OC8*W$.3*@)6,$G(4),( <E<G+Y)#2-C$7]
M7LJ8T1XQ_#CJQHY\$8%.:GP<,;O=^DE(AX)L<U'M]>,-Z=47G&0.FHE_^TR@
M<C?"/>=$YU=1PK%3:AQ_S/7!,M*U*4[^PZ;G,=2&K&C6XTLSP7E?7#@1R>^S
M6N8^MU[8EOB&V >H&<&_/@"T;VDU9Z\_"I7,XI+]*%D7(3I;C@*2 ^T.5#W\
M8:,&QVWO>2]/&4_7L$_R7>V[]EYP79NV,ESA*:$$JBL\91=.'^0N1" E^)4\
M&!VD5KK;4(UPC!;#ZDF5V%T%%0ZY'_SSLK%WLIB5Z_*%83-5O*_N]^?V$^CS
MC\AWA(@09-8_QPNOG35E^SL[K=0&2II%I]82'(;]=MM[0O$,R^;PP$V44EI-
MM:TMT:_0W*I/XSQ)WZVD,MA1%J8[R5XN7C")E?M%R<8VC\,N=C8VW@'#T(IZ
M[$= 0^L9^-9M#Z$+,Q>S<ON]?,Y<[?/8\VF1Z'7V,/:.CLBJWG[B%<$0"G;?
MX<@)+8'4VC8[AN.L&*[3)]YQ$-L-R 7\0$L0]? )/?9Q9_LY@QJ+5E5CJ1$O
M_LB_?"M$; N5/[TX<8<*GJ>R7-A+'/<1]%DA(I6$^$U6;J1#RY6R;AVE:F.+
M9M/=E[X]Q##O%"AQH7D3O9^? UR!EZ$3R.&7?X+A<2\0(B)1:2C0@Y1 ;?!N
M7XM@!9C*9$87&5 **$1PKZQ2N9'>OASTY*G,Z9E@@AN7XZF6_VI[K\H\20R@
M%5&:>F]88V4%HT!C-D]9B)A5+6:;_;!9+273,"E7>%Z!DG4I;Y>U_M(,W]<Q
MIZ)Q;\<;[G3R+A/98.(GE*;C5KRS0#J#J\/3!RN[T0JA;<ILQQS&.-LH^9SU
M8_KH[[,9A^[<#Z^*.:D]IRZV]T>W1#]M>0\JS@,K!K2_H6@X6A#$X1$\CD]A
M6+8CTP,W@[&IYKQCY?O%FNEQ85>EG\]>+=/9\&S[<R]ME7<2M*^/\,X<7?B&
M1 &U31)[ ]M$9HVS,;2XQ>=9L71L$A;!<]?-02;7'%?"Z=[#;PZ-T<JJEBDW
MCD]6BT0<>4V,]\#>1&T SF$ALQ2>57,7&=K<F\3SKX"*&:CKUK>?1@@1H4B%
M[\/-'&12Y*8;4;%19]4&6EY-1I][MDE?+6=LSX!"U!1Q!ENGQAJ&&7<:$JD&
MVO>@SU"A+2L]0[KXO-?=UC@M: =C/O7>1P+Z:>C7$,&' LY>X]G:*6E'^0*?
M3OW(K(;<U\0'P\>]F51V?2>U@<3DTK*GE#K..]CALGA&E0L%EWYN#8ZWJ!DY
MJ10$Y1%'%Q^V^.U1]GX#J,/:!C<=S:F![C'<EC*IH >@3K"&XCCS*>TSLGS2
M9ZOPW_7>GW6Z%VL<CAQ:039M9_=4*2*^/4BL1>\D'&SE/X4I.)/:!+Q^M7F9
M0V,+$3V6\5@- @Z5V#BHQ1#<+WI:?S_,UJQ*])-?<M>E3+5/WDG2VND> WH'
MF.(_ E26R3R5EIZ9'1 .;OM[Z//L4 K1_*.5;+0K=!6(?K#@9W'/H.;SW7Z2
M68Z[@G=6[]DC$K_)-X6($T/7U@Y.@SNIDID#<AFQ+%_N.=X^R)[F!1[(B:#'
M*=%MVIIF#-DFSL%2-BV/%[97U*59S&6^V^3Q]@+]'<,W0V0U:S\QC+<>JN'Z
MKB4[W(XG1"0<!Q=X5_D/".[L%#JFQU(FD$K8QL;<N&,1P]+R:,CZ4C#R@[TG
M_,$62=';\G[XOU+9QKAGP#E2,JH)TV.NM1<"N%L$[XN,.OB.G$4L=,CAI$42
MO[RZ,V3=N13W=,ROB[E_]VN&7CC5L=W4YKP/,O0^Q0X= LLM6U8T&$QW26O;
M+>@G@3Z64X=F&0>2'@2$<0I0"H1P,3*=OS?D_: !A1/5Y'/"VZ3_KMW^Y[*9
M98F_ )YB'F?@(X ;FD#2J2Q71KAT>$!TX.C9Q"ZOL:A;:3'2_G<B@D\?\;EO
MWW'ZF/[-.N,A91\D#'6T M3/HNSI94%GH+P0,>+6S]]('A0B((,4WL-R#FRV
MGHU?1__*_=DD1)S)SA(B-(!@ #*G]&1/^,\6=N,4H)0.(4+YHCIQ$T$+J_!C
M12WMX:-8M:F8>R73?:F[[E9+<A^-#,Q)EE2(UJY*[\?;\I1G.8T-_!3*260:
MT% ?Z*1:7@9%^O#LZFN[7M:TJW)"KVWO'"K8OD>@<NH@(@<<ZL;=H#0;\92$
M"(&D&]>&)_<28E?WL8MGA[)^#2$7J,J"C3_J%I0@]T9?F9\'_;X77_7OU3__
MZ-2Q?1>>?5F__QH?2];CM[0I\@C0 G<S?HF.8K:P@P3R.-3"2]M)W@X&F27)
M<FQ'%V7Z#S5[%>F\>5IZ.BS =A&1@]UIR5/HG5U*!ACU4"@L2Q_R'T<00MSZ
M<3Q/QD!$N/-RL7Y.^:!4E][,T=05^E$5]3=Z$Q1:#7$7N[(3 QFF]%!1!#MV
M9&59>)%WYS0WR])WF%S1V%)_V^7G@'+M3?9S9K^33I;.GB4@")=,T6B3(_:W
M(2!?KC,/EH;7*;V:XDDU9JV>#%RS>PR__++V"5=+DEUU_1<A8L!7V7XV&N&J
M\CU_>9RGQ&54IEM2:(4H":(5P6DL!JNP($XKS:Y:4!M?R8ZZ^OB=U?.YG"\%
M>_U<CR>XU1K<J7/5'^^&AQ;9CIGR%$@[<QV=N5>([[&@)RJ+BJ2S#U&>5"8+
M='BB[+M$W5IPKD+-_5S3N,RS-RM'<L1OZ_YM,PG#N<8;\1\U*O#+U,Z_1F50
MZX%.>VH*6AT=1E$D!!9SHQ:M,/)0\Z'FE,/USVS S9-N^CNY'KY!I=A=KZ/G
MF7H2DK_38?#YF@*G/J><7]<F"K0?H9P%UA'?N#["IQQCQR83W(,C:-(4I4^^
M(7XE"QUZR<N'TVTDK;SB2[]\49.6E#AZTR4F%D:,3/XSXL9O)+#.T73-> C0
MOCS/&#4%5UK 69T='3;>6JW=J2&/=2U.'C C.3P9*0MX'11A+[)20X3AIMT,
M/6>-:I[G)[=N@B5I8?YW '2!L7"6VLO%I*/KL*Q\Z^M"A+I@';[VHJ5RV.K%
M+3)^OV_=Q]2%G;(24:B0'WB^43I>*\+9</@K"71#_G%W8?V!X90L 7PWF%OW
M@WC3 ^LH& =$A(@(RI1TKY_E=4<)XAB'(M&FW1DTCR_V!,>N%Q*-/I =>J=Q
M&YI-QCB7Z/O^/GWLLF_S/9%#F!XAHAG#]%P[HJQ]AQ 1;"E/G,;6DG@J]K.]
M&=9(A)-N%0,E3KC(OH(O_GO,ZML77<)!L@S1^=RI[EN19XZHS)YZ6C;TX8GI
M=7ZA8&<HNF&(^9EF.:7G7&\SUK83))8\W1_B;TAE>?5MNUXZ)YWON("]10'=
MT6KPS_F@(ZG*O'.0)!TW51X 8CNQ,CP\&\59ZJ[B?AUSV/LF<$,3N)AK,5!S
M:VNU^8Z#V^4#RO9L;1\0X9KN)QX63,\HK4UVTI*OV"8!$9CK0'-L#RH3+1W!
M\P]Z2/ !U7J&%'K)GQJS!EA<]_Q1%X7F$T<W'EN_DJNGV/<*.4D%CPVE"HQ
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MV@(18O^JU91H=KJY$,%(>6\M.FPNLS)Z/??HZ>8[IQ TID\'.[ZI;1W\OE>
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MCK93ZY?2"CL%NB ]1KU!K_]RS,9BS^T'O[G.B/QISGT=M["?H+0VD<RO!L(
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MN_?'[:=;0H9"!$^YA0/#&GL]S(@)?H0X:/\C'AK*8"QD*WXF[(+H%6%N<O'
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M]QZ9.=U^*LOU^,U;+D:.H< -UJ%]$.F&%/,R1,]%RP.J!'8C52E.9(=4BEY
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M1O[T#RYAKU(SOB3O\M06)98E+OVBJG;OE?B.*]]8_$TUUUKN2%:L&;S\/T
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M63N(EPUY._(SDFM4&]U,Q%Y$!E$B'9Y;*@;^EE8LEW?DN53!3-OG\$;$NFD
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MD*49 #;X2(0X["9Y*05?<Z)/9$,KX[AOIA/F:Y&%4,0]+^-#=DERZ8<,JPH
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MLRP_]$D^L30)#8MJ<G=UX""Y]I^7^=19Q6/'!MIYK(C,A>/J]D%- 6E@#W5
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ML^?@M"CCT,(3Y(QGL"@\%2(<+MRM%]I8.M^[Y+3ZV'([3'NK?"?+K,]!$D=
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M].BB]H'YYH]PT0/IX-3>F-P)I_6&WY-Q+\6B?_IY;K%C EL_=,SM\!<^@FY
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MX@NSA@VTWUK.'WJ?)*3+%O[!XT%<OHA 3JYV>Z<2+H:'3=J!;$ID)??V((3
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MN3CFW89"?38[4TV\XR-?Z'V[4E0YQNE5XH'51%0[:8O!_9N.-@C$.\(LJN<
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MI[EM,+ZNR77E^^>,<JW;'3PFSJ9;/'?V7S\_V(KN,&R%T5H8'_\SORJ!<WB
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M+7Z.8&,9C*"*C^9P9*_:A%VU[M3VNO$UQ^'D]H]H2<V='!B@'\9H'UF;[FF
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MY,4,4KQV08)1EX\Y.'W9&^F%>H?NX#'2K 0F&"[LHE99RDO1D%+?'<6Z'&R
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MN6+=,XCH7&FN*6-JS[GM;J38T)>(Q:<J]VT%JG)R:O_8\&%;>\!.=&4]Y&/
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M:U.)?K#0TU;!:Z.'O&#X1_87,]L11,+F%B-@SPP#0R&G6$BQ,+&+&H]U2#L
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M^S-\[Q#B8N3CNC8?![->Z\V&/;N8.HP^0 /%E15@8X$"#@QGRII=A/2OX";
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M[&;ZDI%2(1(B<[<79&=<6?J5@C$O3D8=]2OVMCPL5+(0H?,=#NPS[J;>@]?
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MYY-V_^0YEZ>" GF;F]9 T0></7@H0*DFI1*\R)+X/G*U1'O?YNMR?%C-I^B
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MBB6;.V)-!V*O';FVO>.7!P2A6\)YJ2T[(<\\S14K@WZYDFEYN6(UI(0<7:"
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M,\@N9-*X)3G!B.?..)4A7HPIG+BDF1MPQ<_O,%:O(%'!>?<YY6^1XZ_B<^Y
MBQ+'2P"5($XP4RHB4-S(M&<>6VL!?P8I-D=UT"JEZ0!MSC*5R'BVC;&H][WF
M377\G7V_/LKK/V"^J#-6Q\!'"$PKXOA#^MJB'^0/WP 'ED#K].Z:QH8!KE+Q
M''YO3?W#V==#NN4%]6]B3R(-O6K"OTC^LMJS_\-K32A"H\V0$\?]P=81>&5]
M=):R P/5C9#R4]G%-(ZY?'4M+-5(R3_AFLO( \6R8]OCMI5K>_V*\K]I#M'(
M&N,CHIO,/-67W'*DWYB7Y J@]'X_>7!S^D*_>D+NB5B9<0)E+_F;/+R:RGM
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MP<SX[;M7M4;(VBNLG:/TTXUC7#TL"=N^/DQ^R=C^?0@?7?<M<QA;=[*&"$O
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MZL<S-VO:8]0TM'&++B) 0)52H%< GA!"590;ZS/MBU:Z-E9\.U._GA\-^CY
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M^I-,6ZNQ6/H29*ED/:GACCY=J#IM9S<V6\I;(C?X)^EHA"', BD)X,EH:BR
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M6RKBP1(#$49I[\R<V]C@V77?(_/L8,RS M0[!WO$E.B5AWM_LP%R3\1)RHR
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M3+_OX<_\7)/O%;\,P:,VF'_Q5DRH;X!CROX<DT,[3"G!K'SM'J8B]J_^6?B
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MVC1! \UI2#Q#QV]_%8BA&Q)\#"9KK_%HK-=UUHKT7[DM;>&[6,#R47ACR=3
M]D'';#8N,*O0I&9$K<=R%NGCU&P;A(\AZT89,!]Q>:A37_AR,^-SR*7J5>F2
MACP36P??!^.;([&[,7]Y(CKH'\DEG CQJ!Z--^(,.8J*8"4/+JZE)51!GD H
M=U=BW_S@#*\G@>%6G6F%$&$8@1E%"RSI88T)W_I< 35XIM +98&8KKDO;&!O
M93I+< _5N#L51XK"B!JYA?)V'\46A9RG71TJJOU RSK -299Z< 2A%$YU$>F
M10BEPC'MPSB9X<<(HGZ>3GOFCW3E$5)^D>O=.=L4])&0J'CF3L?A*X]F-SSD
M!QAR+H5C(0C67B^J3[N!;57=T!O&<1]?N1\/9JB"CY)XMG98W-#GC 6&$N#!
M$,'A$3N;I$A$L8@QM/NWVG0>KWK'N :&VHHP+MO(OKHD\;WVGXIXVQ,E,6D\
M$K\0E"LP4!/&$ VC)7-N*0SE!,I3_&GEK#$J+,E()LBET M-B?&I9P->[U!(
MF&Z8>*I66F6/\>(:AL8A*UFN8" ;N*F0P0F9EQRV2]?[0G^*X2#0I6?7V8!R
MH2.IWD (5!IE%'-MR_B]U2$/,/5.(TZ/#F HEMA-<^ZE#39PRZ<=L^47W1+S
M3_5Y_N-:.YYHO.\Z)-5 CR'N05,<0;OC^$$T'$Q O@*7P,L65)M2C8JX;_'M
MUJ*)!4HW@0?O(2=0^/NS7$T<1][6Y9%"#^:S^J'@=00;2#6)#)\UVS["Q)?+
M$CS*!HIUF$_1E"8<&]@')=_A/%0G<<T=5Y/.DLIE S-F<8$K!FJD = )1PD(
M9LI@EV8X1G^R 7#PKRRH2YFL%FWO</_S=2&4]VC2],J6%F*<@YGY.)]3B_!_
M&__;^-_&_Y,9%TR>T63(7;BZR0:J<4L+4CXWNF?*IX-=HSX+:J5L"7:7ZK&D
M.%]PYF U'_I)-D .1;.TKWI,W77 8_[Y%HK_ZLL.___NH;^-_VW\;^/_VXT/
MO0"W#8B%+M/\QXBTH.._#?D+#%OX'>I/W=PQ_YWI6370Y(F-^0M89,$XB@!/
M-K)21FD!'&KSAPTP/*LJ_[N 5?3L?T_ ._JW[;]M_VW[/ZOM%]U4CH%C:GE0
M5]AXMV$Z8R!W)H7*L*B';DVJ5@TT_QV%_K;]M^V_;?^K;/]5$>"_@E.A&PQ1
MNB/SA=&V6/PC9E$0AL Q9R)!6>G@B9 &W8*0BO@/)0WW1,XTP=\VO1;\E9ZS
M^03SFW2+:^UKDFK)L:+_E[5,_C_8N#C(\]]+ ZV BI38B&%B_6B6XG%HK=,O
MZYX]LDOM49\^=NG/9)J?_*1Z0^^_73LH^O\IS++](E&+ZD.&19KH,TZ.F(BA
M;"G?#5JB*L>?(,^WH>+N?MP?K6]OS]O3&OWF=6NT%B(7(\H&2).8-(10BZ*0
M'*N36*?S(K_**;&VC"HP//(,78;J/05O5/UQX@3Y-EFQ'\8%-"Q:2TQ&]U:'
M\+T^,?B[H/RW?O5)(Y.C4U\-*@KZ((\,/!C"@;1A<![KZ!0Q@6ZXD-^/\5 E
MY'SH+ZUTDNX^X!I&%6VSV=0GD .?5;R+6D<SQ!-8/,$D_XEN\O6HYUX**@K2
M5,T8EQ"4SAMC+$:LM2>JHG*/::W'YS/2HA=_1B)[RQ:VU!SSNDQ*/:_\JHD?
ML50.7UM=/2C-KW[X/$;C6T.C'PUZD,%QZEU2;" ZVF=+(AV/3D'4M^1Y4::^
MNASTW =]$(0\L_?!G4#Y%"I^IU[O[+W??'?U=98Q%"L(J)30-3"F2"NG.G2N
MR(8LMGW Q-<)\4[-$=0-G)F]N6.96U]#"H(R":K?-N_]T!WQSXL_H8_]DJ1V
M?GS*I/GPY2RGMY-*N6L?2W-<#MMH64X9>@_T05.)%/-T@NDT@B'>%#&V!>F
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M'OA*,IUL[">S%&0E26&FCNE1CSV4"GL@WYJI0MAYC U<G(T^;7CI<X!=0+*
M\F<]QBBB\-D%9]Z08&<3STH"IDC<X1FK!P?1UB0DT (IZ.X!H2(+H<3:J[_+
M&E(3)3<4#P< *MC<$Y8*84M]]Y4#;$3+]'C4=(H-Q%**2@I2.%$NXQ]'#K:/
M,P?A?A2S.J&TT!9!-C X\%^1PP@;R$RGB[.!\5_;%7<LC'7>09[?O62VGU>U
M*/)_MD&A4-(+XI\\(5"%R(QG'4#/OV[#G5I<767Q(MG X8?;B)\-C/E/2['R
MWZBM"3X9VYFD^D\Y8'^W_TWMGX],MZS^,XHYE;?Q[%\AU/V?H/TOK(0LO4WR
M[<(6%ZU/]"#/L\@N#=&Z.:&W?(\<2<F$/9=C2=Q\!R/<7YC^3$."<<$^AS[=
MI)B\H;[K[FGKMQ6:37II4>!MW'YKH',%5 YM9&*AI*HJE <5=6A.M_H-^.&W
M?OP]DW'K%N@'Q7Q/WK28SSMQ5E#2._2?9&PB&]C8S;G#R;@(SES%U^?8K[((
M+(VF3 FO Z!+\$])&0+\XA!>\<M,>J%)W18/)Z:T<]B(,PK&!MYIL@J6U!8#
M+?P.%NZN=1*E#V#P/EEV3Z:<EIG=O5"*KP<C"2*-7E(N0L\U$C;1+-[VHODI
MI>U:7""FG3!<E?^5#71$2-5_B'W*G;C6IW,M9'U7TE8,2R"%#628S@@Q8VMA
M3*DPA X:;PO]J>=(9*:VB'%N]EZ>\UCXR5PQEM!7;N,K!9=.HT/1R]VG.4/Q
M@AJ!HV\7'74(@HUG=4LMY#A.E862F&<LH$JY?(=]9$9?7,A4\BR#W)NC9G4O
MPI;;Z6:.K![HV]S4%D.KVXG!Q9Z5VK=NE_5]4^[0+8]?,)H]$P)5=8U)8KSE
M0,X8%K\WIP/8@"^&+^*;"?\J$DH^.N3R9)FJJG"]O.S$(8J%Z0_FPY1UU3$5
MN6T1OF]H_.DU#.$RS1?4( GMO'X$FWSW7)/+=+*AZQ^\B0)![7IIVJ?.N2,A
MO0$-?7BYQRFB?=723N<=K1VO5Q-7AE%I22<Q2UL2<VQ L2E<N6']%\K79)=W
M+J[:Y#T=#F;U9\)QR0;!"=J-KQ"'[AG<*PR^WU< ZU5G^<T&ET&JB!1_'*.X
M[ (;J*ZYPED5DA''.3US >IA2E='X\5,^%$'FX<Z6U[Y4[E@S:/?.NLZF?U/
M7L,,6D*5]\'45&IOW-ZC-C\ ZA%9EX9>H,?&7Z/G.LO[CR.</OV\A%Q6;Y;@
M#-^).P2(?6_X$V(6PG[(X]<L0SB&9>M&PM#W+$*VD.^PQ 7&#DY'"*-[+C1Q
MAN[&I"N'OC9(T)G7T1+HCY_0<1&^<Q_1WR/\UZ  2HVS:I!R6?WW-]@ [.WH
MRGH$ #JP+N,UF4_75U@8-^P7S8E1%E\\VH4-$*PN,PL&EAHT$VWR7+P"F-4J
M*1&M*JOD:[>KP],0V<'(R<;,BM;.((^K1C:ZS;QW%8,_A7\=FG65PXI8")QY
ML]!X-)C8D+'Q$PU%USV=DFOBW.1G,!'MJW\4%I?0&5(\VD+X0[Y[X,1>K899
M8696#_WI4O]4 *($0K'Q!]4'&$9<,WU$O";H_@IUF(80=/(NLX-);E>9_UT:
M#]7(6GJXS-U'GT@_LD?_(TAD\5E0%TG8Y3@Z;)X-U."61BFJ(0G3DNGE J*K
M7?7\;>'F03<38$E*^VTR6D[G7U@FD(]A##TR7:JORK7=]3E=WFV?O^$0-M65
ME^TM_4;.>RA[6=G-8\5DY/MZ.J@QBQ\ 58+;5\:YVZ<.@CHD-#!7H/YMW<J#
M<I?%4UL?MVXH*H11>^+$0QK;HQS>'O%%5CUP'DTYM1)O<IP#$$A/(Y0HQ ZS
MEOHO*.=II*TQ3TU=7TI.U82UNO*CR)8[-GM.RPZFZ>LS)I@OT*2GT+JR)3$D
MF9B$EH^0\=P:3?A1L', >7\C1\0F0&6LDE$LVV6I+KC7PC#ZW##]^'9-5^8'
M$QD.I:M9,BB+1LD@R<ZPM@*;/&R(3=<QC;L,E=_6]5^XQR>%EYQV/I'9:VBJ
M^_ZI6\(G5][+M.I?C<]6_#YCUQ=L>"]5Y+VW,>D_KWMI938"-WH#W,X9S^",
M&AHE0'E(J4M8FB\,*?!2G A^ TYU:=C_)JVN_KIUF&>>5:HH3\UG7&0VFLB&
M<)$=&.)B70@!J)N^?&V?5N=M4_)C[?%KA*FU$G4:];A2EL20I>C3K#^\3"EF
M#93T!$.Q3T_![&L*FD''0NOOC(=HPIOSD;)M E05QSH^7U< 'OYL/]W 8Q>2
M6%-P[A,VVF17R$PGD7(>.K$_G0"E(0;7E\-.-465)%S+-W]7E?(S;@IST))V
M+]B>_^T'R^@8K]2&_(5/S46T[&RTCQXDFGEWBEFO7Z/,_<GZ*RW %JS8A+?,
MSF\PI'ZC']!P%)O0K/8:V ]<4FTM-?!:SI@O587839$M]!E-65Y!0-'X/=MU
M1J MAU$\5)VR+LT=H&P'5+A"Y]6O;TB4AZM_D/J^\^TB:9Z*[W=+*KL<W13>
M<WGCXQX#NBFMF?F>0U;2@8AV8=87HNC:.88#&:+@^>50 AG^( ,#U[L=^LIW
M82+':+^KHMQFF&PT_@KK9,0 E&*]0@BCK310';J@X\5D70R9#? Y7K?1_FQM
M"L\\>>LF>J9MQ*M!^_?+,8\[K[YI19\9/71-R"OK6[&]3:8M6&]-FX0N?ISO
MMLHZ$7<^@);:];W%F2[+!OB;9,@"<!:?1B$82(,(0..76C3@,/*F]KP\.:V-
MYRN\S '963&B_>Y FJDY]\50)H=K12^@U.K![5J(/ZCN)1^M1V/7^03N?-S-
MK9Z5'"I4O__=X]D)B<T9SN>YS+=&.IR_5&9)'2R*6)O06FY\<,7QVZCE",HA
MP'VQ?,YVA7 P-W0_(7?,V75O0*+6H6%'YO5M_2TO&J%L:3<UGC!_IYS"!FSS
M;N_8+(XJN8Y;5BW6?>68@XP?FDS7*,7IOE[96E^0"3>P.R91-^(T"K^S"=]B
M"#W"D2;\DS=:U)GY1EZ4.RP2AX[O34A2_% CHY\VM77H1L'C5>0O__)\)@3;
M/0#J(NR:DJ>)G=8BMSJ;NQ/NSO^$.:2%VL%(RNA^W(W%CP/S73G(2T?KT?<1
MKR:SK0>.OB#FTY^<-A-W2+O_7U#>/^\1C,[)_P5EL/;C_KMXZ]_M?[AXZ__!
M[:_R'?Y9<* PT1=""< RBML&6#VC<="UG_+;NE5_017DM]]@[ME6*I-(I'*W
MZ;*@%,'W)*OW9\PJYC9T1=];3]A[YI\((,;W(0>M=?,]A=IPX'[-1/\(#KW
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MB5*71KKR#/-%CX^IE+QL86$S]T^8GY<Q4_7[!3-L\6E/I]4D(C-(=][LY+K
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M!GK'.'6M9 5\HW/F+,_MT]Z->-^PG\\-M%H4\]0=7KOFG!+5M[8.0@@L"I+
M.FAC*.\DP0O<S4/CL=Q00>Y>WD,,_,Q.DA(-;_8V-R^J<MS_I=[+IL\*=Q)2
MS]TJON]V+^4K?YV^-,K?&?N0Q Y::5M,@ZP$#]"[\ [3<YTD!8(ME8WI?./7
MVH"[9>53TA.-'ZKEUIXUNF_9&&_HU;)YVU]Q$L\X(LRY?W2_A*TQ)HMP0A /
MB4)]M+GF]#BLJ$FW"G +K<7V;?)G[H\Z08VQ4=T\?$)OH^YG_9&,]? K$>V?
MVQ;$OJU38*\6OQ#M$M0($1<7Y;Y"NP69 *,$V$QPD*2012<UV.DL9'$G,\K
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M:^V]1C5C7:Y6=^-#>U36_$3Q53QA%D'F9L,NJIAC!-VJ>D$-0(Y.<U=;2(5
M],E5UON V I;Z7/P-</I-G=S,J=D"DW2=?16,O 15X,>[/*8NC'>HNT6W=_5
M*%&/]_V7725MQI'W@7,D4"]BP8T'3'0S%N.PTCI]_%"?V5<5[.$.4^KH'U9<
MAL_'PW57#U'<WUV[_6"'Z&Y1&:RCVUPN7W4'#T5 <A07_)GDL1*'FAHVL%HN
M=/-07F<<1?O2O$$X:H_*O3[]F?NFU>^@<T<&WR]]"==+J:P;(550VYVV$,($
M&11%0B 8^S19+0*^%6D2%.A>)5YM&Q[NLVGIQ1G)PJ@'AFO4-HB>OV&!3;&(
MA[+86>T6K^Y'&KSI(2<:/:NKC^]JNFK0F.VK><<:$:/WA0J:93$[VU&I5+8]
M+H$D0S$F'!EN\F2JC/6$&X4+$7(!/[&3XQM^Y7].L;=:Z$=_=K%^G:9P:A-B
M7326TPT=*4K!++A^QBSG'04[(4E8^W=WK^:>D84(:3AT6/J3=H/PFV&43&*?
MZDW'L-V,:"7<?8)[%/.)K]ZRZ6UY\@UUZ03'R.TEJ%;!;OWGR*#";S]?QQN2
M+]R3/K"AH.]>"LMW08@(QHTBN3!5C/&#>FG#K#G>=MA"CJ%-\3Q/]I[G9=-8
M4?Y%CKS'9'+9:7%Y+X,W==G*(_%22T$V&<H*=H==]L)13+,^9F8OJFY.D-"T
M38AXFIN]G,C?K @Y^_ .P"Y;9XBZG/UU?@,NJ4E\2H@ =\XM8-EC3)UXX!*0
M3!>'9Y"\/\TO.2C<*(ZR&VH?O-9[86[!3.[64]F#SQDY!W9=B#$5V]@["_"E
M&R'Q="%"<C=;CSEWFSHUA:H6(EH7%U T,>PGV#0I6_BGH:Z:SX1D3S%>^&?@
M(F"QY&1V.>M"\.EIE<.3@#W 2*8N)6%N8+F.)JL'GU9QH1)8N@RHPU'6=P(<
M2#SU<$'?#!V'I]13;.WA&GB>?Q*D$/8'L8>&>)V 3,V$S5&V4:L*1HY^_T?X
MFXL79&Q#HW1IOF<KJOO-NF?MX[LB\Q/SP%!(',D[0W!FS\#X2"-#&Q5YA\;X
M1U[7_@QFP=2K04VLU54NQW_SEN7E.@WFOM$6Q?.I.Q^_.W"0?!?^H@^3RD$X
MK"#CQUZZ"CZV!5(1(A)N5%8-\5VF4FT6KB>DSUFM"V8%2V2L^Q#2&:)U0OI:
MT[GR*X$TS%0GZM<]H[%"(4)63(BH?QFVAL1V F"C>  &\H+Q*Y"X'2^8[U##
MF;O=9#1UC^#&GF:>_]8W>@:?99UY*+6P(6;;3%F;U)29D:'LP8B@GRKO5\^:
M8&O<6$]XF%6CH%[$B!$[&]+(Q?,4@]7>HF$\W%K3FM#-R<4!QF/Y@0YO#DYN
M%[<RS?RK[J_3OB<FRKM7$C]1*R/X,E3&RD()[Y01*WUU?2X<)$WC^3O,$H,6
M(4/PAV3@^XI,E[L%U%'-NT%GQ]P^Z%H-6UZ]:A4!2<!RZ(FN @MW'2<7RM=Y
M<AJ)%>11&??IU8HM0!)%1? $V@4TGT!;X*?;G>6,4OB[H\@M%.G/$\R=?9[^
M!Z5K,TI8OKY!=)T@UAFS!,B$<#8?DCK$$7M[']J)O\V702YTY#WPEHH."'W6
M&2THNDP-\#PX>9P4N.?WDPC6^=?-[=&_L/G09B$B^SG?7HBX2$)!#X,NB3R$
MYTLK-("MTVG&@CMS%[H9R)&2X]2AO>D*H$];3CE>@M>6NSE/JBA2N^E.:^2+
M9I6X1Y;[A8C K:DCM=O<[44CL'(8QEULW=!+]M+*]';8HZQ+!*=T.GC1IIZ-
M>OLQKG55[#/#DR?+JY7WV)0?]*H55[MWLR9)]O$F%*@KQB\UXLD"(U3FHL!T
MPNW;7L5R5!:UW(CE#C_&&/ZT&8+*IW$\<Y&AV$J5\D1G<XR9R!A1!S*^][3+
M-D;_HTLC_E=*<9LR_RKV\@U5O7"C^1H_$.#!]M^\!08$; Q:91 (0MZB;Z&L
MY>,XYT&'TY5@:]ES<BD^RCV_VR'P'KFK,%+_1UFYKNV1V4VE'](L2.#>1LBY
MZ"4\W\]PQ*#X=<:0% PD^;#.JLCL86BP:.@M\4Z?K2\XUOY'IW6UO0&TG[.W
M.=FQSZ0[U>9X]N&CUIN"M%+30)?M3Y%I-;VK:\"O><<"%"$]03F&\8(N1]!8
M4>PQS& LCE:==-KTC79(4V-?ZI=R^W#"E8]>S\9>WR<>USRZ1+Z)D0$"J2#\
M<KY"Q%LJVPF;2J])O$79S=<!NZ<\>>1$VG!Z[9E FGJAKWSF>\EVYHV5G=]E
MO'KO_%41=+KK=110A>T@@WIDOD+55!01AC>$$'$)*TKLP4K43!R;Q2!V\C'I
M[>I:E.K:^DRQ^D;/UZY#^Y<ZOL<IK=GW#B;A1LRZMT+$&)*1RU>,XII7",A
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M+(X089?*@8--B>]DR##]GW]J\DA"OXP7(D@AO#O1@3!QPFBO5-& J6E27:=
MW:P-X.N]HH(-F/_\ R= ]\]S12BZ\X?UKU(W/C]WLA>.RA/3B'34,IXN ^/-
MJP8A@OGU7_SVO?U%X;_)*?:WF'^+^;>8?XOYMYA_B_FWF'^+^;>8?XOYMYA_
MB_FWF'^+^;>8__O$A,IU"Y+X!('\_XISUO^S2^^?BKD._\OVN'+HG_^]-\$_
MRL+F0R-TL28[WB'B.ZH"QD^($ O8[)I'32.J!CY2[W]58ZX6].3UFX&YVMLS
M%]S.;8F4KW YC]@GRH[62$)P4* .<F%T&ACA_:.(DC'!?G"Y1!#13%%QQ)QJ
M_#2;XV#O*[7PEZ-^2*/1!_,+)UG>$[;R:WY&\!5:N?O!+!Y!B&C>3]Q&?$_:
M4,-"_L513%Z?+7@8S72X75"90IL?BB#/6NUVT)BUC'"N49G5>[ I@T5:WZ3T
MDF .6D\Y)3:TM\E.?$6K5 R\>E:C[Q.YM>[(_3OEHB]W'GDGMH7AYF"+(.+X
MGD)$#)+<1@;UAU*%B'7KTSN4]3&;4B<2;S>Y,1(??3DSK[ZC(NDT2T<Z;I?)
M@7NSAA]50NY;56I?)/=+Z#Y&9F(8&=1RIW;Z"*H9I6AESHEMHZA\?D4 ..33
M'.*=2>7&^OO;RAN2)LZG^5C)*-S;0KKZPA?Q2JTRY#T^D7L,?GD/7X2S<MO*
MAJ<.T=77@S>G4G%MBLJ/LADXFF;K<!9POJPMLRFG;_YZE,K]\S8:OR\=+-8/
M*2@NKLCZ<73'.+(7I[ZZ^P8PGL &>ISW4*Z5RG8AT4*G?I%:'VJZIA__3)$C
MB/4;,2HYF\H;JC66>,=QU5MNGO@KH+[;]VAE(?FKU/WGWVBF^;A"_\W.GAX>
M!^[0Q@[</*$[>+!X9QH"@1![7")_0D21J9-H9'6.+41XL;/C^FS1+PN]W)NU
MVA;L<K;;&MPXMJ=UGQ*9)$0PTH6(BL2V15!GD2^WTHRI)'5@I"]9D&XUF8<4
M=P.14_GW9RN!ZGDW,^=;D_AS=YCF=TQ]SI@R]B!TOA7KBGRACC1RI<#7/ N@
MV9KJOTCK[("TV#/#B123>8M-D$)%?_!<YM*@_N/Z-%S-TSL%A^VSK]V:_"MU
M5"\%Y2%H(JX%Z[B%@A2T+O$C<>WGY>\&@1V38I_#HG=^=\LY5)/$Q"N;^'N8
M1)S:=/AHH;2%2/^; -A,Z: .?6%E&C5JP]4!?7BF?.M!D^Z)T&8BLKJ_QO.-
MLKM6=0X^:U.?R6V52K\G%TY$W<1JXBTA\?>PO3@($M F!*<W\$ &$*Z!!N'L
M:28UU;#).6JJ-\7BXHM@PEX@M.YCU/;R=<%[=HGEN5QKE<W6"27U->C6J\OQ
MCD.MDU*"1NKY#L%=S&7)P_L]%D_T7:;66ME.?0\)^!2XJR#KA7OAXA) 4,M6
MN3(R:SI>^I8_#8\"-TJ(B(T3(BZB-KD3U$%SGA.Q1XA0X!L7T@QJ,YA.*0V&
MC;YEI;H?*SIU!QR>/K6;B=5LM)1YK[49^'14MQZ%ACI150 KEMW=#FF 9-X%
M(BT"(UO3<XUFZ679:J&86-C'W_]XK-!O9?/4P]F'O096J8UB%S>HI*OPG*!F
M^F;(%+8Z9\#/:<RO51T>H;IXM/2WR:VQ;3F**Z&OGEQ=&;IJ@QPM/.)AMF8\
MV$@?K[1U-Y-279!\P^U]@]&"&L=OU?1[ V";=?;G.TX-K#:HC-G(^!KVM.'!
M? P?:X.YUW>/D+'^W=BL;.[X@='T>]&^M@A"!N\8U(Q1A%;W#E:+5>#&@%9U
M;?9$71PD\\V#57=KF<=KC/\<[,WMOW3.M.^II-R-)4/F4N?-3!%UY-"R\P&4
M#M"L+$2<74Q:W:JACJJO,) =&#DPRG7PE55X\7?G"?S%V<B@^#?==C,OC5OE
MQ-9(357??*34,  PBJGEN';R& F2Q_%WDN3PH8Y"1+P?AVK'28#'7UQRL,T[
M.OZ5$&%J"6Q7BO@8(5G,D_Z9ZRU$N/<=^W/#%4@B&!?@AUN5<V,)#A<,PU@>
M+8$&!T=OKSVM?3!SFV9&]OE]O\HD=JSY366K<%?++74!S>9-2)V%,9X(U(]9
MVQ3(+AX^T5C/KB%W2LJYU@U:841_FG1,FO4OY8I\R+0SV+[F_-&"]2.EGZB,
M-%*M;2]?WH$!L(0(3B>WLP+,(.-MG(=F.>#GL[F.-955>9_:BT8N79-NU_*7
MQ^G/NN6<\C?3>]B3@7T:=K(>M1-HOKA:DR,9PW;&C&"\!;D4<3"QM<&;6ASH
M$33SAIX4/!?3<V)RQO=*KZCQ/FUKD0U7KV<,40KZ%O(=^X/"YJZP<,$956L^
M%]\D]9?V'4%F&&'.&B4/H]@>R4Z@[CR>U JPXYK99T'[Y<+P$$$QCO)YZ7<,
M1N?]TK7RWTT3H^]&TP(W<CM@->"@_C\D5M$Y>+9IP']&\J/9<[&0KE&<4T*3
M\Q09Y2\[<0FM6^XF>RCKS>N?K'=AMXP/EQY)VO-,8E<N*PF&R)Y%F@,D/@#?
M'PW?GT"0Y+BU8L?LN(V@UY2#4I,EL#D6GE&,AVE%@4^_7W\2*UCOY7F<XM;
MTP^]T8N3OUR*L+J#X*%@7-K(I(^&<G>!6)XYN')R@!Q.%@51Q_I^>99IN*L/
M>=[:>GJBP%]&[4[Y/OVD(_-B1W\5[SB#S,(PLC"PY9!&S%JH6ZJ-DHG;V3^>
MF;6ATI2'4\)<V3.?ETI-%4/&2IT_7$S0J(J5"W:9C-64&MT'&]6Z8A##KIOV
MX\M.3V/B*8;?36G>^><88ZD7!UP;4D?<L>YKP@,8.A_M\[12XM_[9N1*-OK_
MR:%<@^7,(S;_(?/E0[G7*P5YVB =$]-D%L[LP3AS[E3WH4=-ZXH\S>]\ZYHD
M8/WH6V_S%^RKVZC;9A_^$FFA,B90JS5G%&_"%O :$T!-MXB??,9!3?^HGC3B
M;*YXJ1!X>^'H[^M7,Q^O4;JA$N?<DERYOB\>>T903O4S G73RC@-G=P400SU
MLH&B=7UB:X:_1V<+^7;>H6&*XN!?QCTF$=9E(TZ^EI$=YEKQ#N^2I?6MGHE]
M"Q*S[K<R>.*.]VO]0[B61WSHKU:66JHIOFGWBT/6"_((=/;5Y'FQN<XD@/%@
M%3<6QU;:)Z5C(0DR9VYJ?U$K>3V88Q "*?*E^L-1E?B<><GGX_2)>;\>F9C^
MA/@U)^HQ^(3T88!1A2T?;@= W:(%-3+435]'L)UB&;4I/Z]Z/C'F!1;,XR\/
M&OPXX;:);6,<<TKUG-2Q-6]G*<4%V6^7%FE1#$P;)@U;Y?V,[3?EQQ(A$W9S
M3,K=T<G39,FM@:GH^2%\T4$?_8)+:@4RW>*^LFU+AX]M&>X>)FT$&--J;D?R
MIQP[668\HU'_D[3W@4+$1HO.EKQ>OE9&K%)[UT@=WZ&M^=9Q-$/DFKB*T^0I
MYRM6-I#X(F_3/]*,(XD]%A$+' 92>EYY(1D(*<:GM]$HZ.&R^=Q-RE'O#^BL
MJRVXF7GP\(TJZ=.\:/GC8M.]+("WU99W"6CN:!B^$49-AN/75B%"#@]P_P_6
MWCNHJ2_\&XR*%"E1I$@-2I,N70&)C29?!%1ZB0J(@(!("S4*TCL(*"I1 >E$
MD-Y"Z(*(2*\I"$@)) +A0@IO^,WLS.[LS.[,[OM/^(-)[CWW.>=3[CG/\SRK
M(8-?TOSPQ4,3">6S:Q:%]]X,RL\9WO5PR120T#'NDG_6]9>)LS^8#QIV"$K5
M9V^GOX]49$PA0:TJ>.X[)]S*:*8D<,PN###U59RN'SC9VJ-869@I$ZATYB2[
MR#G(F[#\H[Q#FI,ZX]3;4B9:FSH01M+7H!RY&%-<]<?%@9XY&\A3JGM^,*)L
M=BE$<LL=<0YJ?*]1'$859O0?@MC1#Y'3Z"[H-S"&6_]) (3;OD:Z9Y:ML3W?
MR$.FZ<.+8X69AH\O@[AB+/BMC%(1&!G$ VP2<Y7%1*H^@0DP&67^MF\\5%03
M=>YO)7ZP=,GVJ?)B@VW!FR$N W=6F;GR-E9#I@;;_<!7Q89!\#%7_SML@V '
M9%:;P$9L8-YX"T!E8H)Y"U M5H@\'2E$<_ZM(CV"4O$>^^S<X__(K-L[+KL>
MQ+HO-:C67!%I3@U"8"X@<.40TEWD]*3#[T.0)VI6 ;\AKI"TX8M#Q>:?J!_3
MP++:.4D3A+94E-U2O6:GS8KS,LK[ZJ^(I')XTO_[_*%C21-QW#,7RZ+<+C3K
MY$!O]CVEGRNZ^>/"MEEUO*H$KZ#?\'^+#9YD,"!Y"-IX2&8J$"KS3NDD\XUB
M<EJW,$\Q087'T;,&NW!$815(HD[VT-@C[?QSKI=37;G?3'(W<KW@./!,O!9^
ME"+O07_1KA*YT&R#"0._RK](6GAS".)I5U]U5IH$QV]673@[-:L898S[]S W
MH._9#*K:_(H?]B:#4YO*3;-C3L8$!N9@;Z.-9-ZM+_9[EW[/?M17:9-V+UA/
MP#-G3T$A%G[^+4:>_=S-K+'4NETG/L=3,U>S/)K-JMYOBE42?VL]T,FV4#^P
M^=Z _"K8LYX&*!D4T_@"]<SQ:.#& ^!2N-2!97,C8UP;ZQD2CH%D_=G7M0U?
M\-GX\[1/<W>>:1$::'RY#(X^4@OCE ')ZPX0L0@6\,SG(\O&:I;LHHX!6]?Z
M9FNY;ZO^^_&^:D?/)^WYG\^77 .,8 *DR2Y?X/(B1B ]_'(<)9J>'6Y3T%GM
M ($ R*[F'9WM6RX&8;&U=;./1^46!HKJ6XXUECQ5^9^5"*-<HB,13\Q?1O)/
MH)CQA<Q,V@)UBV#>M4>4 X:WC)+V?[_3E<=J1S<^*THD7-]_4^UAS'4C7Z$7
MZGT( F3B>LW%(L?LH30^=0H(6"RBZ0#314]4"CS)0*YYYOH-LL^'VOV@AE5Q
MYZN5M2']51A+=J>1 I7I'<MG^AQD\ ;3VYY4H;<J"G8@2/=A,[KX^A0204;V
M+N!.U;=;"_H%+WI=WJDI=I.I[@OE<9L-KTX^*S-EQ<#N,X-U);(;>33'\Q%?
M56(0;LCDA?,D1BE![*SEV*:*BIYJH-[$?PW:W^Z\%(<_?'Y#)_:'"YN$*Q>R
MI.0SCI\$ZX$",GO$'A(;90AX23U*D%9FZ-.@HYL,12,/V6Y(+$*P-NE[@-?@
M;.#%W&K'J2P_D8=+WB^.M9NH_:@JARR\MF!;0A*9A,+"G'=1%0C,;82[DZ\I
MO0S]%!7W%5ZE4HV.:A>&\\Q:C(8+N07DQKNWMC;E7$'YNFGE>QJBQ*?^^%R6
M+M_9ZA368XB3\G/QU%++I>K1CPT9BS\G7%/N9^1/\Q<PM6$!\PJOZ3%,E,+
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MG518F\?#*]2*AS69:F&TJJZ\"D,HVRL/Z[RDB.\%K[H)_*N8VO"3!A%V_U-
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M/VYDQ?SUA,V84D+(P1L]Y%E'>GZK X%;Q'XB@#/>>TLY7--?J:=\2$IU<*G
M1-3'+KPC^=1Q,5O_Y'RTM^D,58$ZT=9:WS2\41:FXN$;1$$C75Y^;I\"CK":
MC3FT%^'VI%9G^?$=-"=<SN>\B=*&GEOY$/]HN7N%]:\[CQZ I%VGNIZ=ZY>
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M#T%:=Z$MQ<GB?LXY#Q/R1<"AH3_-#/51M(9]T<NB>G[\1&B,#/8SHR*\CAJ
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M_)/\E$1T])@PJ,W !5CL8[  #_'E*.%P$W)]!IXH/J 5-N3@./:YMOZEE:E
MB)N;P3&K!"G2L:OEZ8 1]>%1"DDMSS>5./T3D6-8GG#?$H<2CPT]R<4D[MM/
M7L=*U#C\V/CXRK__;^7?)R=&_I8$<M_H,OZ*M!Y'?:JKJXLI:FIJ?"WUK+?
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MY7D(.A<I#_?O#,JK*A5X6S0/SW5LJ$[]1['HU7V2%VPI]9,_L;?I\<PS'NZ
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MGFH-^PR\N]5ZC1+:%[=K[.OM?O?$\<S.'\GL$G_.8MC:GB-)4Y :<YH2 K#
MDL80/&C\%:I1QB&(W9TF0X',+/C,S^I_7]Z?K:?-!JV(_F(KL#1X=M0JVF-X
MNH$2G+B 8-)MK>Q+&E?NTW)/ABK9+?^-C!+ZR4U_>1_9P:QS/X.T]\Q P7PV
M5TF3A+[.X11Q@:0^"%ND-!S1DZ>X<MI+7'CB ;HN??=_D??FX5!&___P5&3+
MOA4B(950LF]3J9 TI9!U*ME#DHR,N8N0/8123&4KVV0O9(PU)&7?9PM9AIED
MW)K%<_M>SQ_/[_OY7M?S7+_?G\\?]_S!=<[]/N>\E]?KW.>\WZV]NZH4\]_B
M8N"D9CC]6CLG:0OF:19DRWD.]P_B]0'D:K"2"Y>GP%N:B OX$<V 0XJW\[QR
M[ZF%.L3G1_;)G&GXJ'+@!]]O3^E90&@+%A@T]HH*) 5P]Z-E.)7F,BA\NVQP
MMUI%#!EX:ASX-ESG8/8#JQLO<Z/>'[-2@%E3OJBXC=9H"RU(+G$/C93K+@EY
M3H=$1-[[V"'V=9_W/>GS5OO4/[P1>N[XDGV84P-XX%+=E8/X(<11AI%##3I<
MWZA[28;O7_B7W'()X[&_Z?L8:2WIKO_@81AN/Z<1'Y :HT1'(,=+G3@EYKJ_
MW0\,L>%OIYTFIYU0MP8$5F]'O'I*&[R%T#U\RG>'4? C$9V[HKZ,".I&2^KX
MQMFX=KPB5P]E0Y +^%9D$FG1P56M'3R0"6XZV&2?4T]K,?KU<)0 IP<7=P3%
M$/=MP4A/N2:,><)JO#%?HJY)<L1IETCO-N-V669Z6HF+A(S/OK04_M\1J<YB
M2OG.A\K]<;_K<FA/@WEI96%B\;)[Q(>.?^WGX[$O:0,A[*<ZV(9G[JS9@OT\
MX@*1Y=]$6:X$F$K1KZ9'M!&ET$8 955DD@!_:JKI77%:J[#HG$YIFUI'U><L
MZ5!/3^_+>X^K'$A8T%@+81[9@F6FP^\066)LR'47)>O@K7X+O9Y2VHL1GV)?
M?44*J._0%K&F^D>JL!RHA(7REM#K94)/N2,CC]FST1%'-PL?K-PXF>$R$?OV
M9L%U1*G?Z(^)B8G6[:*J%R0,/:Y\SGWY4?H4#X2K'>>V8-' K)^2##!>TK4%
M*]8X^F\+QNS@1'-W8:;_(6/9:BRK0_@2T*.MH7+(DQZ3A=?+>U7V?><F$)@B
M47ZW,G,J_A/,J8K?\(TP7!@SA:^$)YL?V(*U%M+#:''T:@>&XZ1J+<1HO"^"
MT47][\-_=[AK5ZO.V2ZV1#7>XS^0L'YATX(:QA:7YPI$,$I)%6_I'MR]7>2-
M6)G%=H(G!2Z LAM%#)>I\9\-*9PZ7/6UYV[';2\G_K98GH0U/&@0QGP"$ABE
M3+F19D7T/49D5[P>\8F29&C0CE1)UY[;D783?9J_8L\_^S-K1SHKH);0&1.O
MF7,C<AYIA!F TR^[B#[&UHT2D&/>K7C!0+03)2C1#CGM)ROF1_1"""_H5V9'
M+#CV/.O[5%#RX07A#U)+Y ?Q_.A</UNB T[^#"<50[8,L*7YKJ72W!7HZ__0
MQT#+8%7+H+$[/5_6V]T2>@\DG,.X<(YZ;NZ^]E3T!UZ);06&TE^UG01'*=C4
M&J2PS\C[_M!25+1][/<1Z6N^>VNJ=4H>/5VV-CUZPG27*Y'0/]'(=.6\JZA8
M!KR)$S8MYL9YA%U("Q)Q[]AB4&#QVV<N%V9WK!OB3H+]$/7 ;3L!7^2$&=ZW
M?P))GNUO=[LE;"RO*7F&D?5N(^=0LD2 -C/ K))?IRKNV5?<Y^H?"HX] -T9
M  ]I+^/IWLRS(T @<FR0C(W#"*&O@9H*[LKT_GB,PF^ZSY*.I4Y\^7SLN-V1
M^LX5Z9<VMWE4\XU/O%$J6O^&M@='Z?XDRUB73KP\]QCH36C0T2E=G-$8+?^[
MY*F6"=.9,CZ@]O+:GO4;)@E4**9/.$Q2D,L&I-0)%H6WF'G;>;ZUSZ1CXM?A
M)I=C#??#,GB_Z^R>(U /[)IIWJZF:\_M5MPN.ESHDU/,EL[F"JK0N8.4W:6,
M72Y#RJ '"=CK$MEXGIX:]Z8!I1(K9%1_9F55,D-%>4K*L,UJN47I[1:,#^]#
M'%]BQ@VNZ &/E!1-]U%?V5A?#'-T%V&<*RI6T(*IN947W"W>TZ2(N;GD5HAQ
M!P@W !(6+@+<0D;CZ6O;B5SJVR+ER8AVXA/'D8FLTB!2J=3@WVG@K(ZE]'1N
MWW.3 _<%'<ZW1O6D[_K\T@DS[V,J_E^%YQ)K)AOALJ@X"_IJ!Y)GS$_H PKA
MZ*]Y1M[FTZU/1Z1;W'YFG?\S1MI?UA:%@E4S1)E43@)&'%7-%8,G*M7QM1*%
MEO!_>1FR[<+Z/:L<#TMND6\F]Y_Q?=;7MO<'OVC;#OV=]KX4[?BSEE^+IG7+
M*:"BO,A))7.OIY.3]1Y^(YY@I![(Q^7OAM2C# PFJ8&A^1@"L =W)Z8R!A>Z
M!1,D?%@4$;QS+$@KR^81.'_WK@6ZC2]G,P*R1W*N!7,'-.W-;)_M16#K,?0+
M 7HLM46,;4$_%!?Y< -.3^Q6ZZ@Y.:%B?EWERZ!"UJ]SXD9A#SQ.P6W7_U_W
MU7''Z:.T898X:K +2R]A[V=YL#6&FQ#,EYIXLL*@N;)O-7'SJQ6*^SWCI<$'
M'NG)9Z>_EJU.2C+%(4(5Y@O96QQ-,8?Y@9PJZC=OE]VJ;_QWY&%@M>&N7M;]
MNYG^3Y(J?MFV[.Q2KDY8"TI1^J^=O2U8)R[J82HAAI/4K AZT!QVRXM*H!"M
M#^KDRI^\M4H);8R1\=UW:6]94N^AX^3'A6^4'$=34 CF)(B@I$ZZ=  ?W3KC
M*Q;,#>A=,<>:K(.TRGD;G/P;/ G\@V,-E_Y8*3_?U(E728KC"US?+)V'@P;:
MS"CP,^O4=IK.F@_FNF#5?+L<+AKM] %TGVQWS-BL\G-XD+PO"G'\=8^TFE@<
M_(18TJ_95"-(;ZH;/W&>XWV0XY"VAY,W;]<C=[&M$'PHYK5/XET&<7KW;[\L
MZM^3IF.BA9*X6#ZFT^A_ W[V_;N$4U)7SL'04%SC"=^"9> X]?AE*N2E!NS?
MI8(J_>Q<@/9E"^:]'\Y-+Y<ZH1G]/UP?7B+U@X:CW"MD;PA0^+=B_]U+:5[+
M?\/['U]]_C>>_^'Z,.Z',9L-J=<2T&W)20"6U[:ST>;GY4R)_C#^?]R3_C]Y
ME%*5_H?;PYC7T+(,P/^XXST!%A_Z_!9L\,%+Y(OAC2DU[BR<@7FZ::[,-36#
M7\:-IPJ -DQ+1CU;C$K63V3YH^U&T<HD0HA"8BGX8+KPDT'4W$9/JI_S5&Z!
M;/\*2\02Z'SX'W>*W<:'S H^,FQ+AYS+1U(]7AW-5M7H&:U13"JD9S,A*A)U
M")+'*+2;JX7Y5@VN4C92) ;._=1:;PRK=S/+O: C<*BV[GK8D0,]'[^1KS]N
M.PY77" J<0]@AJ X)BJ"1H&YJ/0E164PM:!/YPQ_PH1>8\S!J./WS@9WOD]\
M_5I;]74.?7$%[[FZ:03$ 4S3!?@_)^E0BQTVPON&Y^Z]<FC*G6[43'=_2J >
M=7Q]9/S\D7*)*GS(7SY(0SA%W",=C-13G$S=2"];>*LO^9->WX61 8?S0RN%
M.:CL_@/L!;E6_;?48]_NG=E.TPQN(P!-.!5'XQ3Y-QMZO+<@*>U!5#A91*I8
M\?SHYJVMJG@8'G2WZO#O/18#]0")BMB$1VIPNYLAN%\85CL+IUN)3K2UPJM$
M:>7YX#Q%JYBI)+PTX=D9C4-F]DRTF5BJWJO?-U;=)G#+2'#O6I*2B>AYY")1
M4WK5T*P^8'7-.\ 93Z]_F'I.#4\*V8+1[? 3I11+VCF6,ZK_.L,Q07O^IRY.
MPFT,Y6&916[N]_#F*=_C>?#[\ /[F5_WG%[E93)3V6( !?<4\-V"Q0!2^)O:
M*3FY_4_1RNIQ//]<C9/R0JY;G-25[-AW]T+%7,*U?>V!93T[;OG'<)H 4CR^
M5CL9[H,00WMQTM$F!2@JH=EP:';T_NA@TVE/OY&HA:3E%Y^R=%$;1B>:[K2\
M=<]<5*KF:TU$@LJCRY54_(00,YMQ*04KU>1_XQA:B=2K,?PI3>[ G*[:)=7=
MCDYJGCT'ST>'>T]>O\78N^?\54'#!Z^)VD>1$F%N!@XCRY/"EOLL=3*=N]^7
M3G_)&9GY(GH,0GCA*W^51+F#6(DF,3T7(>3>&?"@?Y"0V_0;C6:-F).\/)Z?
MQ:VN*60FI_#S*1J11<>P7,'/LC0@J**^%1DO,V.$E"JKQQ@WU'YFJ;]6XZU
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M4;@<TB]%[SI<'^,FX"3?][KW2%*5:O#;*80TP:%9L,+Z4HS,E_S9*I<UW[
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MY&:WIXKZ,<TEAI_6#.GU[UG$F:>]5W]1*!&R3]["6/G:I[.J)<\^2Z\;_'<
MN(Y]/,/+>;N=/!L\)-H9(,05]*7RRUH.ZUI#GF4G>-5U].90Q;M<FM=IGDNI
M![$Z#H_SDU7-K\3\:O?0=+>%@ H1^-K'P'$[A+0Y(G/%THEY&D?:CSC]^53A
M0]-TG!T-)M-_M,WI*@1^SMAP7SJ/GM[.X<DI,)?"]&+KN#$,):K9UZJ?6C5+
M7TZL.R8^7*CZ_M;N09>RCOY)D405R18]&E WRI9P9+:.-JLMX6MQR^.,G=J)
MW/T,D>*04M\<8ESH.O9:BNRS9V]V=W1^>S$TV9BN C\8^7--=-F()0U&,Q?
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MEZ\(0R1^1"1LU[C@-6[@Y' 5?"@FR*>8@_5?Z#?$I1-,_#=3KNUA*$AL_LS
M-NZ^9/+0D2V+H  Q;(&R_ZJ;%($^]/D$Z$VVC*5-7GY\WK1W\Z;]T^[4IJ6@
M.,T4YY4++"I)J7T+]@A>8[F\0)_G"I8S/'H <?8)$"BU+)LYXR&\?Z"U<B;P
M\F[7%X4^'M2==.IJ%""$T4=?9\"[@A)GU,!NJD;TH6)*@!_U<J,1>4_%]8/_
MCD9)B1!.E>ETCW3=4J8YTNVQKYGXJ69F0&KRL?T"$09LQ]!9B)\;;"AA  (
M_'K%[5-B*D-NXW>N?G, !V*:I/= #7)9.%(_C>22&!#6:K!QAFI'3_G8]TOW
M!2&+#YDS8W=<2,O^8V-:785Y^O^PZQ".J80T1I=3PK:E][<I[85[!8F!_A2O
M&$K [A&N9-'BC[&IR6Y5'\^8F/8H&?[EA<]>JINVGU7N:#KL1O$^OUJ<X)_E
M.DECF'\1Z+38NV:<>7QA1G_RY_W%2%LRGA\@G(!D_"2GCY.-0@MKMXDFC4R$
MN$]]>2VD@(L5] I65!Y2GOF]?]SNKF#2&Q5X)G)OLS2JE!34$22.WL\8.E&$
M(^?>HEX:XM'^O"?-R*XGXD/GZ;\'\1>A3K/A]$OP!$AY9#OV6S*'.9]#OTB2
MF='DY)TK\OXF7Q[.A'MF>8XY6P0.G'?L%:W3\U!I/"#4*3H/T.(856W,%,[[
MIG!&EU5UUDQ7>[/:YZ9!\FO8TAWD'9,6*I E:1;>KU=DKZ;@>>':H?ES:MX1
M!2SU89>KIATA-Y4=RJ[YU>-L*FA*X9C!ZR-PTC3B25C#L]W^2(E)#E8EK6[>
M+CX8@NOJZ[AO%S@&VV767*WI)EQ^*LL(\SU[Y>K54?/NTJGV\_H%#X),?V)#
ML[C*6'O<MP2BVJBHG9O"W&CAMY  C5:S:[=>,A'+>#J2RU]/P3]VWHUG7>6.
M8L5-]:B33SY!&#[Z[,_[G_,FAF/:2\7.--BW'&@]> L],ILZS2J%++O-&" T
MX/]B\#)PNBTD4,]1]L:[^CRD45_O9!_R77#5WXV+*DE)M[*KHC?A:_#3VG!O
M"+.%:JKY(R:[*&U6*H=.<!*->CT>1[^M".\*7I?>W#@GW2PO?,QLU>XJ?DV7
MMG [R7_4OMSG\"3$81WZAX) _0NL2ZD4V8X^O1Y.18"\5=:.QXV]UA46I'^>
M5([&FD9'G>-$6$*M&?QJ\L"<\!F?%1E$DZJC\N.-[_Y$@)1%K,O%+1NP'!>P
MDN@+&=WD2(?AOZDRYP(+<^_,>AX,O2S@E7 VQ?:-9Z:3I2;2'C,#T"V1^S _
MB6*K>'\ 5,_[0B;*@\@N ^$/4SY,Y^$F8=ZAXOM]/.DZK8SJK%MEOQG5TA.G
MJ+W,CRU>Z^I.$WI2=V9&4Y*1Q2$#UV:3>LAR%_Y$A[G=F5[!>(P.$NE62N.5
M<%_<9!MA1FGX_F#P.U2@%T.F24[S]XV:HS_SHPF.GXZ?/[VH:JH8-\ 5!PBB
MS=JH&[:,DUS!'=1R21*T #2%>#W_QF3,P"*7=LKK3WE3=I;8LM0CIY=5CG?L
M7K]?7P75.K+26"+;9*WY)$ XH_5]&G'=J0:_RS8DT,#J8V74^"/T;@GW;[LJ
M1'@KP@D[&9N9^\CJ"KJ?"VA2(Z-9.685]3]>RR =#%]<J*JQ_[7Z);^B=.B/
M**BAU J?1#*+.)_9'E2L**8;*17T5_A0Z ^V0:@_R>V"CV=-34]XI6&<OZ5J
MD>]S',^%XXBK?V794C;DH';L1!"7?Y:^1NUJQ\<US,50B3&5I_(.#*(M"A&^
M$;\\[P06G/C^> N&^CDQM;)08^ :_$>;#1?E"B9NP2S-MF!9#O%;L*_V3$NV
MA %74(B!9'*&,2K<K\BZN-2;#&6&^A// #FO@;*R%Y/2/MJ:K9,6<E\[U%/.
M?57E_V5F' Z6&*5(BEXHR!=QUH2'UM&JIS5'YKWDZD2EW0MU9Q_63VL@0ZL7
M?K 9D&'=!;HY:(4M6%5RP19LP<ZQ$B!$;,&@J')X.ZJD05$E>)2/I<8^QE#:
MWF$X6ORH60159]:0'8LY/KZ0_>+WJO"?HO5UAUUWS0C2ZUULZ5ZN0#0K!#-(
MK)O[P@!(8011&EYD9L'YOOY$'%NUP;-N(V%<O"L[^%[ZGN,J:N&TG)7R^+:!
M[T>&7@\D%BU/6@<VOJYY[Y!E;WA>LSDR'6_Q9P9OBR?58O_<4*K"<A*> 0LE
MG<V&G * ]!I?%[2<2(I QBO5P E9=&YB>,FAW""T'L=\6:^W2S4A)B!0U;.G
M?3YX!\;56U60 P7*J#AN)[RFF);*$L3T.<.7B?1)KH1)KA!A),0/<N-WG";"
M!;2RO<3F%GW:;N??_=QIM'@T>*Q,MQ+E7.*?]6=DD2@:&1?UUMWPSCD#V6]#
M]ZN;.:E=.1Q]#@1P9MU%DY68>F[ [X=NZ"YJ/ZA2SY8*(V<_7D]]RM7CO,[I
M/_]#]_/Z?F>:J6/!Q1MUL?KICN/2DR:T<QZUURJ[8#G_0IC;B<I0YKK V'#H
M%NSM0JA3GHKHT[>V SGI]LK5"-RSJ@F]]R,Y'V25[KF4/C!U_(]O"4\XN.8]
MD#'LP<']$/O!4BJ1YLTX.-II2W$I395$^=L.>NLOA']ZJ4D-';@>H!K <_$A
MA[N^1F2+67#M$&2 M6-Q"_;/4BT<SI::Y-KQ,0!NU^06C+/73^,R*NG/E:O/
M@0?-,MF.TSH?1J[=>UHOK0U43#[,G\('$<&CD,D\)5979+.$,6UXH56T,AU_
MR>=[?C!FIZN?C4*>7ZN*R.SE/M9HVG1!)C.C7AA?LP6+]H/_HK%#MF"WYQ <
M[1K<=V>.W'_\M>3;QYJ[X9K7KZZ'#==-- 9]WJM@Z^K@>RGDKUMZ]4\!JA*H
M@5^V+ #K[0=P "D)$%P]5#?DG>#RV7,P[&*O\FZ+7(77E?L6'Z[CDB!JCDU1
M$@5\L,D3<1W:$*N"U2!C<\QFRVLNHQ"G?/IJ&RTE\JU,WRM?_,R;HN*.,#+%
MAC%&V>*67,&@,G#2:427.([MJV\<#CQ4G\&5-),*.I_Y\I(P227*T'0T83O1
MSBK-FB6OE4"L26T=H4^ <;1=EO!)&<<H$F%V,U^_VKH&]TIIIC,L^+5"P..4
MJY?>,24O!3A/K;A'&)E/)U6F?_.6*2&\+\9KXN65BK"B<!]$+%!MR19K)%NV
MIR;"JV-C&(@+QOGCJ4)@_!L9BB,>KP%?+2]VZ_[X^(_WG.'!!N18*K,:/,<*
M8(N ,?1!IA"()./'ERC#%<\":;2_6-$QZZ!@17L9I(X)*KKB3YJ)[LUW.N=)
M\&G<+LX[^*PK]LD6C*EGN04K;,A%0U&/9YY3@&3:<:K8PHRHN;7N =)P5E?[
MOGU7BZ>X<_<L]XWAYD29^<Y_CLQ^[+CI/Y3*D)H;J?C^G1D\3ORQ[N=1&-=Q
M)1IT5<$L_G-GY3DQM."*IQFR[O7@!TT6F*?IM6!Z]E]!TNBA3<^;\)R^[HQO
MPI_R0G+:< UP$EZI6IM])&CR)%>&&7VC\C<@J<OXT$Y_*YY\YD":VQLS@5NW
M7J3-D!A(H=$!4J58!UG9P41O(PRI_G8-;-!IHWA><E-BGQ3DF$.&WP'T:,,]
MD2Q973Q'QV5T3AB#!0BW\+.RV"H<)S$'R7VIN11W? L&M&[!$I#_K,<A_WR_
M'8C!>/<@Z5:(36OU5H EV@LYQ(S1#P !!?CB$I 2^(#]$:1#Q>7=063MG?(^
M]W-E)LY\[#4=^3AE$WKT;[C-A6N2&_:G%+(T9_'_K9-AR)L>([(+>BG%'& !
M,KJ FL+#9\+9KIFT2TL06?Y(-;)0\S6;]U[H>0BPY6D?%HTA=W+!S<8!GS='
M">+QL]7K:(^9_L["V"BD^\\C4C%'&:./ =(;<ST&MDVH]*FI=0'[YA!.5R @
MX,E X?+#,IS ]9Z/:4TMG\X4&)P1"49: (0FB%9!5G9+JQCR-I.C)BPSU 8Y
MNTT;U)SBZH&$X(#=T;Z,C'8!O6'R3@W_>*\O"1/>'H\2][>USJ8*59N5&B'&
MYT)_Y4=<=0ZK_;NY[.I!.RYU:QIG@ NH-8'PA(HW6SJ"V?8%+L4U XL1E4-!
M;V7%>QE*'5>M0^):^ _6IY!:SI1P:5$!,*T=\I8_D?66RPQ&-0E@B\TLD1UI
MIZFV!NW<0_2PI\=4!T,C#2[G+<CL'K(SO-P=+'7OA%4Q:M-=ZC#/8U<^MK0&
M5P"BV[Q'..\A"Y_VZ'+GJU+4H3N\5?M,I^(3: 'E?R."Y7#/ ^9?"M(\5&3B
ME3"4J6IQ-P1-A65TFJ4.$ 30'G29)8I7*B72XRS#\QGCV#^I5[3E4 $]$Z/;
MU?TSFG(-MS\Z&'7;?]?HR5*CJ,4&EBGA9;OWLN$FC0^J+\P7RBEVW))XDMVH
MUJ?.0)>O?9XGT@,VV$E$R)TM7Z[:@OU8\5\SQE\$2).KF_N:];9@8V\]H5F?
M&IT+C4#!-^4H>%H_1RWOO ;WW"> !:P)'G[W)>0;]/OH?_>!ET&_>%GXQ?^3
M3OX_/>!)I@<4N1[C?5=9JLT0&OL9NI&+WL>"N$M/"[%F@Y..Y -^-_#T-_U^
ME[![^]CL]B/]!\&6665V@-$L"/P9-WDPD*2E;MFD=2>:J1E9_GVFS<3,3,]!
MR3<W+$R#-ZL.$'A_ZIS(^3?1O!N*$,]-):FIXMME,D/[]X-"%_U[\7$SQW^:
M7C6K.N]:^Z7VA_7>Q]^'),.3(E3O/-QU9DJDGVD-N0$U# '/@^%;<-\+]K'T
M4-J4H!1<F<=GQF@*1AGU@.@\I!?I<$X[!/X*I>;S.(TH^.2N5'I?MOE;EA(D
M(=P+/F;0D6<X"O?LXW.@CV10)Q-MRA&$#V6]^JF>8; 7>GVO)0+U_URHBGFF
M(:7!<[3D,<P\E2Y$!=JV8!,($BZ&:\8^-D(>0L,I?3+"-A<;HFS;>M-V'$;Q
M&.O_\CP@?=OS@-@Y"U+_A#HINQV1.',,%"(AXXT#RRFK.UVN]U.%93HM5!8T
MPN<C<[UNZ!]+.I"6%)%80O.REU#V?J^4BZQ<A4 :1.$)?I 5:"<JU6%I+XML
M*?A8)6&,\@RH3L*W"=NY31Q#>IR3-2[L^*0<6)C==\:TI:=P^A)# 8/\S)U$
MTBWZQR*H>$+D)>U'<)BI-CV?8I[JK[;Q".U/[SH;=Z9I<-TJ+6?ZQ3C_V??(
M'=%_=O14Z92*:FTGMT2'%;,51@$?!*@NV_[JM^[J4R41KIZ_7+O<N;:8G"W8
MN2\G=&73=J7J"=C-9J^4M\M'K;IR!EE7N /P/?#;08_,#W/>F6N#Z:,7?[!/
M%/2%Z=:'W%G[96]NW^11VJM!2Q8_?>P;C$_7K&7[2S.6Y0'.,W]!:ZIKR<BG
M-':K)]+0^RM\,!J?,W?63M.>AYP*W,M[&7?TV+VJ1SN;DF MTG^\V?+;%4@[
MH.AHQ6TSY^440I@O,8UA:5T=Z8( />G$=N:2^6-RQ+7AP+YO> ]T1TBHV:"K
MB<W1.I7;IS?.FVUP^3_05;K@.R'^'#M@S5 YGV$[8NK_#I7:$>*[=O[KC[8(
MA:*IS$#'R :+ _N?/%(,<2'2[^#8;Q/)2 X QFW!$-E#,T]%LZ'VQ4I5BGB6
M$$"PQNR$<!]/-2,@M:61.&&ZB.%G/%%4&+RB^VGGEX\NOY>?A_OKJ%$;>/AE
M;'R^'OD\QJDF Z"R(UM2PQ+D#:>?[ "JS\=0&K^X#WB.-BN#>3TF>"GD]#<;
M6W2HY=5@*9JRCI>^O=U=*:W3VP>&CW6Q"ZJY IPMF&>( ^27[O=P% MF'F$B
M ,(GI*3YP45DE6P*W@N(QZ@WC,R#L@S B6Z>5NINY6Q=LQ1TA'Q>[04[6?5]
MZ>MC_G(B,DV6S&).GFD RPE2NT[CC>6-=^C@4;00N3R(>:_R%46*NS>[>T@O
M64[SM,U"I:M'Z,<<[VAT8G]6NC9#W+U\"[9[>0O6-PF,CX+0I/@ZBC)4F*G@
M"98!0!C0B&34=SGD*58SPI8W?,E]\I>'Y#T;_4X2"SYVJ,;-/C6L#]W3KO6G
M]/7'XB'1#^8'(0F$ 5(F%&Q$0^@2@TPMNGZ,W[\(ES$P\>R/_#CG:K1^=^?;
MU)J>Q7:#U=MWQW9$BV@\_J_T<3[81*P4WE-4%M./5&IR#,.AVDCP]B]76\(:
M:&M9KR[7UGJR3--/2MAHW8Y+OS0F5GU2PI]&5 #G6Y7V-.TK89\%HRDFMDH6
M/_YN!M5&VG%O*NAG,93#51^821U6'9TGLN4CR/UBJ&(2HA.8%+4;\/XXP#5D
MAX\VV9(C7)Y>..G;&5"J;5XM_Z0+OAB2D>,&B^,*W(2@_7L.'KZL1Q;EJ#;A
MU$$.(Y5YB8,'2!5;,#&NX']E[/7%"Z!L2''+M-VO_,E;L#CSXXSIBGA/JJCX
MI3W5[J['!L\'24SEG[_%4_)8A/;.209Y';*8ZT"/'SRHGR6,LMB"66MK? 6\
M4A]!)! ;!R<U(VLVEHFL$#8O"% B+2@XIG<B5\*&(=2:Y9P^34B,^Y327?'N
M;D6GE\,Y0L@-#KIAAV(,RY4->?WH^^:Z:.'AOTHQ2'FX)S8N3W>P9KP"+4K5
MCG,WAOC9^P7G,M_F$9*UIZFM_KC=R=K>X$;>ZRN*HY#V)X+#T(!YST/270+E
MV[=@M<3'-4@%5S^QO@*PM:O#V>S+>EYE2/%,U;G08Q)OXZ>;7G@9(;)<TS9.
MXYP_0:UN;5=3*;\148H#U7$M+]XE"W6K8@5J+I>\N9UN6P\36?\-H2I3-;HH
M 1"JF19E>M!'H_]B>47UW10'6QXX?/0%3,L&=(_X\,!U8WJE%2IOA??)_A#M
M[0?5PI8M6;)L:*:BL)AI# RRH>5$.M[M!UJ%BMA#(-M*7J?OS@WQ?==Q[.&'
M3$WE=!D;SQ"%B"<W+<+]7].DUR$05,],&\"3,K%TFR 95#_T:H=XLDDCO_*/
M)KXB'^.+,EG.]M/++%.PG'I:8O/TW&NMOK+?!COWCCZ#QG3P5^I%Z-4M .%T
MC=F9VPE_J)WF4@U1XU-!Z4KJUPZ=,JE02\R;N?5O% IO?'IH:49Q9Q"H6IQ4
M1#?/U/S+%1VYORI.=#FE \&\^K0LRL6'EE+E&@^/78RXD7N*!/=8?;1=<R&.
M(/JD[C(:S2D$O+03 ?%:E!VKJ]D$Q#+XVOZMKQ276"5XW_<?GQ7KE#]:\F+S
MU#&W1).[T*J9JW.[ML^EL&6"R*FM6/!07!? MT3DA_MHJMA5,T;;B#M0,Z/7
M!VLT'PSL4FO.E[/0Q7OZ7K-4_/;>T\EJ2MK>G,!Y#O<4!54M:>$L4Q2"F0!>
M9?&C84,UJ9*_?TR790&"NK<TYPZ;+H4I>?58*[Q*2_OL8"?\T#$*\( 66KN%
MF&BLF$^?9SI!T6T+ME\ZC]IV]7<SWX NQ\6OT\%7,^>PW1W^Z<QQ8PTQE*ZK
M:"H^*%?C\O8!$FAJW;>OC?'@&)C:#RYL);KV(WF*4H>M)*()Q1=?M#8B;W-D
M1M]!++\[$.3#ZGW=D:F*N ^N0RU.0^WOH]W! -D8<R7,=^Y^T(EB>T@OHQ40
MP^SU/>$S\3WQX6/TJ[?!?BH1L0[VJA>1IJ]C3;KB0'P[DUBUP5;X60!B*;;+
M#^1$NU(?>;3-R QIO58]Z2\S^@,_;B'.K0ZH>O19/F?Q@$Z[((</K&9XDW$M
MV#CCK@YBDJ+>1_IJ;(V0;./P>O*EN\\FS^:K9@S'_Y;:^:W]:)25E!_?O#9;
M7OX=V-:&%,;[(D78%HS+H[4<.#-C)*"V+SB@7>5*4\I>&?_DQ-;P]-V1^8\;
MI?]%(%]@Z7>R4VM$$X@B>%\@P5S2]WLV!3'AZ#Q\?S!4(,4B*'B/I.47T:.3
M;O=,%!(X)F]7=B"- ,(5?!!2!""80;%D/Y+2/Y[R@;K?:?0\&$QVN=F\Y#*R
M8FZ#>O=TY\!1F34%V*7V SN_O?G'1XMDN; E.''-,']\31BD/U)%+]_XW*4_
MBC;C]-X^YQOX\ENUU=31E$<RMZ2=XKKP= 1B7(/:3\MDG7&&5LT-(.7G[<]&
MC,Q,=[4 3QSC0O&/=>./VZWXC.U9E"A2J(8M?3K)<U/A 677.)R4!%1J)^!O
MK(ZIM\$%S=5=PV<,1P-73&VI"S:[ 9H_!:<:2,*>H"3?C,&JGCQC97BPR9LK
M*%ZRB*1?#9J,:(-HVVK<1"(V#B,J@SG!*0JU,?JH^%/529<&.\YWI_JKRLM1
MY2<1;M9_IA&_DS$!;(7M\ZH P1+N!0T+7&LG5A/9,D4($7P[<J\KF-'>'\XR
M\94K')[]U;5J'1(>KIHD?7=G5&52Y36WOF>"1'HP\U6Q#W$WWDM3R:HJ86)@
MD)E/;]*O^W'@6H)>79/]N2LM,!ALF1>3-4H>9<ML;)=NC$IG'Z?SM;#P$^I<
M0=P63.C,Z#7.&UT349$)H#7IYU_$LNT5RN?CBRZT0H^0V9A@9EBK.3OC3P+'
MA9/$Y>.. 3Q_S1ZT,;]P/@/DL!GB=-NA>& +)MB/H(\RKUTH4TWTS/B(C9 .
MZ(MJO&N<8[R#9K]9N%W&'4)2L>K;]1"Y \2/M9V:: .&>^LDI?Z1)KNJ,E[M
M6>$_RPS"29NC,:X5O8J"'@&0S'-;,+;,GQ%@/(29QWD!)WW(,6Z2P8IRE;6?
M< ^Z=>ETYK?]>W^B*3W=LELF4/\7C7CW<Q</O^AV:,E :S!.,LF<-^PC+%&T
MY*B"&UH;/$U!)&+4JFH?%Z2'['QZYYVKAT16RK4KSRPG'A/4=G!D.%' '5%A
M[@"D0MH0]JH3?1KZWB/Z,EWJ85Q"8-:5@RYN$^T>0SN.(@1,3Z:NHIL>W=.8
M1X!J<AVLJ]QI>.TH;;;DVT16XGO4G%)LGI"!_J.S]_L4Q>K5=K 8MJJ5<)62
MNG U1[(0,65&@_,4N(&;H'+YU\GQ[3,ZM> D7S1&TE=;0S7;&![_:UK*JKV"
M$G#K,SJC;7I/ENM5XBGS'FCR^%[B\%[]R9 /=A!-9$J<^\ .8,Q54[RR?*1L
M=T<7URSP[(CCO1(SD'1#K'2T'(5D2P9UPND7<9.W-"$]A1P1KS>G"+,'E4A!
M)*]/GX$+HPW 8BI-8]F=[P>Y 16P3!U8F>,O:]7DWJY<N7WBTYRU(F(0X.=V
MYSBV0A1T)Y%YF"Z59BF22__ /N)YUV6G]:6\D<X'AHM_3CPP_%5I2$/F$>F!
MH\M4:,59((TEUDNWI*XNA](S7, .>G['P^9XAL1DQQ9,5+>WS\_ 8*U7:,JL
M75.EI/15Z)UGYCV7/;P.[]J^<5>(:N0*^+*40>1VF>%8R(X/FYNQ)>BC4%L8
M"HLP:)8&+:F1:@<97HFZ/PFAQ7U%XQ?LSAXH2%J0.9-?V;UC< 4)'E.G,2A*
M8X-< 8"2.I%*-JFM?[J>K-/911B<.E]V9Z5V9TDVK\O1OCT!JF^MCCH?YS^0
M0V.[0*)O;W5?1@F=#Q)'S3/E.'GWW<P\K2!&X@!ZOG4YLW_LJ-:F9NOLBT>[
M[UG#'!\#A&_ +K0+(X@KL)\"<A5_)]^;$1JN616;=G)^PWM'\W5A6\GCC5L)
M#ID--P]Z3$H]@B+/_]\":1I (I=?O?BCR9.EX/]P)I\W-Q-+NTK>7%E9*1+O
MX+$^6&U2+29M?UHU#\:3\X&Z*HW>SN^\R3[3#)K1X1UR7='PVZ(B?JG>5*32
MPDK *E=]^NQ8!F*P>Y^M&:)G3;SV.^J6OB9$5PSU^0/1D:Q]DVYGTRW5:2[D
MX70C*6E/G?<'4DC_'*49)I<8ZA"M8]G:,O!D?-SJNM+8&J7YRUX&/E87S/.@
M3SH_?R([\C,IS5]]UZUUP8.=OVEMS8\>KK)ELLGUB0 T90>S4\QEM\M#L&6X
M$H/WA74&!MS@K6(Z-M[OY)_+KA3>F[]_[MM NFO^M^7Q8\.%+"DN%!;.X":P
MS*L_YCFOMDLU1L_H05-G5N;H_'Q&L?KSJ.:OL6+/]=XC35&_,DVB&^K" ('Y
M9:&@).SNVE1AT+L]#7V)_FO",67F,%KIP;\F18?FM5,;XAT^3I7W^GGN68D;
M2*0U>@A:@:E<065(.QYRDFH0,-0H<X*3M[JR!?->C>>*T8>YM0&07<8YE_K*
M]*DUF/V4S?K:&\AH_+"V]ZC)KT O05Y5OFFE/<WRH :)V!8DBCX(!KU+/MG6
M+/V#IANYR];IUW/G<9<S'PDRF_MRF9T)C2]?INA8&^DU(@T!@@K<9PN6"-1V
ML27CR B:,&.DJYN!?%HC< FG_,2261>U&'&[<>S-T4U&:P;YU*[OU"3'GW\?
ML6LYJ1@^$,$5<F0YH:]S:B!^W:<3),T^#OHS1#8(<%[N7K_TE9^W6'*'/P]K
M:1*$0H\U^XG/[;;76@Q[2OW#Z6=.0&JBB&DC[N<*+0:C=X [R$",DOC?""?M
MIEU49*RQJK'T'+;D;-+(<N?7,VIGP#U*ST3LTS*OAX>QY=>H7^"DN4;6&8!@
MV*Q*/%W\?['VY^%0?W_\.#Q*2#'VG5&$K*FD;)-*DB3*ODR])5N,-=N8R<[8
MBE")*4M(3/;=V(4D^Q:S2;+.E,8KL_B-SW7?UWU=]U_W[_>]_WCY;YSS.N?Y
M?"SG/%_G("X#H=0*^VGY<4T9]9D]C5_);]N29,++;N:JXT+\Y+^+1_S<PLQG
MT)X##^@*" ZJZ:8@%=6;T_(HD9BFY--<TIKG@3E9_KN2+.OJ 'OLB3[ZZ#[H
MTOO=PS\A@&+C0)0NB_>@R.<3)3$)Y8-*W---V?9PJ(/*_G)5'7O;5C>E%4S/
M3PG0::O^]WC[1\\EEZ>*Q9L0%9T_R@QA"$V.F6(0Q09P,V:+$21LG68,N%1Z
MR@E2+>/>4=XG5B"@$WZ/=^Q7&B9?/ZQ+N''32>WEMT^I*O^EO"&XK6H!NN8$
MTW3D$7;8JB,DE7O3I"QT[:E5Y65 E:^1YYR4!-Q#Z?^S#A%KL-*T#2C.,$K6
M6;S";+!"Q>R#=K+NO05_L^0*4^O"\R-.EP+"Q-VXNA'NJ^.^U@OF8W4^/)N^
MZ@2K>+2*&^_SMS)'[H VU,3)XIV6T9@Z:*(\Y4"YQ;"$J=//O1"-.2UVJ8A+
M/N4+5P/+5FL5[536:C@S3?BY+C^1[-*9'KL!_CP*Z";23C)3C2X@O^Z#I/[B
M4G$URCU@<==?L+K&Y//MFMN]+- $]D=M-7K"PG/SOW"BFXS*^"7[R7CKC<N2
M.NL02M#[^'> $XMGD 0]'N9QO6ZB;E'?E;)9A2F=7?AXQK%+=ME,QJK_J>K)
M,EX1MDKBS[9C\>6';> \]D'SXCUV=U6]Q:#UL.21Q5<!*]>D)FY?MG]RI.C9
MX>]%$;:E#%FVE%%!41.9:7KBK%S3>ZP3P?KX.1B+9Y&N:4Q)ATD@%S!'&5I4
M# F?\<)['R1D$$*..JEQTTMKY?+HD92OKVKKXP1%S'@R>%(FGAKDLHXETXU_
M7<")L@ZQI^@,A,S$=&T?0MQI;6D%,&2OD-7SV364Q3C%-$/-4O<;1P9-4X6N
M.YS,X%?T7-A!=>-^JWOA_A+!K*=JOWM8Q\()^'@(WSZ(\('MT4TW873;,#:;
M[':5+T\RI$ELC#2O>PFORW/*2RJEGW,Q.5L7:=SL-?52 .?F01X>.=4T:C%A
M),#N!M81UKW:(=!7B?PL[/5\[A1VH:K-YZWY!SV5PP&3CH0E27ZNAW]"90K"
M=>+942T);!9[HMB"]F ]#]63D?8-80JX4?*</^$ 0U*>I8#)AQ[^1$0Z^;9Y
MTZL<S\W9DZ>/^R]Y$P_%0YP.=/I!X<K+W>GJ)0>V06!Q6AP?2TSP[!!>_5A5
M_/#,R05.P:\F(9#:?5 G=K:'D(,C&4)H]L E2D^WW@?#-CG->@!%W-2W;++E
M*.#9%AL1C>98?/YP53)IS?/PJ!:4D 7Y-)#"T@5R:2G .B4&C.Y0IVK\&9K!
MB4J&+$2=G<W1GIUS=#[=V-"0>HFG0FXK/C^)JT.5';$O65\P'.RNO<(W)FY4
MT-U9_1#^X.U$Q]P4(TW',,B %'=L9:[EA$Z^ZM^QAW;UB8]O=MUZV?W4:?C1
MD<(KBLQXY)&#E:X ACD50XO^WYVTKM2">B*>CV$SV29)'(W>$T_!GH\2OCE1
M:2MNUQHS?B_3Z\<?D"8L2_AAXU!U&)8AFL$Z>K#D,<A\BO*"SCE=9SYC2?_J
M$*5N-5+7KV3930CWO\YY]V3OYF)?LN.QX>:VLB\+H&>J.?)/;TMP-1[^&TG[
MQWR#\L"DXVI'4W2VT_ <;9)DZ6V^,#7'O)[&#E5*^_LBS6R%^7/G%@Q['W_3
M]BQ4?&=]R]-R40(89?%M,A-0_\%3(!0S:.P^2 QYFC6 .69@3JIHUIG39)B3
MP(GSOBOOSO61^*Y??+6E%%_\7[*,9W'C4-G;^RH#JUJ;VAXAY<BO$(%@NL3Q
MVE%"FNU%-]>/(QXJH"A+T=^F#&G3,GM7]@")(<$+CJZFZCE986BU8E/.OA-4
MKB)Y6]GT@>L#18>7<B\;E++XG<<84:2CN(>;W$3+--,$QMTH^G6O')8T5=I)
MO><F+C %'OKCTPE&^4VC<1Y]?Y]57 *$<G4;4%:.90F,4,BDT(T_A0CS&1VG
M0,1=JCB)+]/;Z,2T)OZ5WSS+>?1PK9!IYJK(_2>#5"W@HA;K9ND&VRUYV+Q%
MK0(5.Z_3GR)/H;I4H0^T9%A3&-$.#19;$->+;QZN DII8<Q<I";>RT@<@!DN
MJ/I,I#1W#.D<O>MC[G%HX:CUPBG$W,)6X2;<FCW_V\@^3.W/#67*X6X4Q1HS
MFTCXF= AQK@"Z)/S5</>4RYD\&?Y5MB/^LOG3*])6TG=DBR^[!#M)IEY+CLH
MP^2 [%"#OUA+.%I +F1/;Z\!1U@%_[N:T0NA\Z]"]D(:"O>B_XIO)M/OS;.^
M0*O!Z3B?/%\9%PA?F%R4S^V)+:=#/K'\OL1 ,$=)V%32QFVU/[FLHQ4$/*
M3V+Q>&'J80R14%H5<)AJ1\;T\1G)AO;/8,01X>_P1NDSO.XI%NCN+3?9W&>9
MG \%*RH28-E6"I9U.$(Q[@C"@WX-U76"I<#6#2$EPZBJ-0SOM(6:Y=-'YLV5
M)/2/!\:+W_NJ30,[ Z;;SK%XFND&[&E7PSUFJTGQ'C!D@=6/.LPP)1F*=T]'
MB*=K:G5(_M(57Z^8ZWYV>]?W5//SDA=O,9&9SK<@RB'''A3PT4T1E@>W5R.[
M((V6G;CY6-91"RJ>F&G"ECA)TQW'@1%*#SM*=NC#LD[F[4$_8+)&TQ[F3QJ#
ME*:O75NBJIQN;MP;8,C4%@'T7C%<34$LI91M)UU/MS.+ZU)0?&%IE3D/2F!-
M"__OD#*KB^'_+D7G0SV  *=VN^$BGE*KS#3D(<##,<LA+LSU#TMT)=D]>#[F
M3*:@-^M*\YNS"3#U[2.!>G;#,(H_E/'"<A;'^MK3@]N[=+JT+,,'T&&G] WV
M&P0A+@!>6K$=)UA?.R# .Q*?[2&$#96;]"A/KKK*1]>OV#QX)I1C.7JV6F'P
MX<)O\O.6-C"+YU$(;BZ7UL7\@"/D[J&2M^NU#K$=KWL"EK+"=WW+[,?XQQ#.
M3--:_N65\[!:0L"??]C4S[-,;>R(%J#TDU'ZOYT0K-:Q?= O*>NFQ_YXBO,^
M:$Z9=I>R#]JTHT.\Y[DW!BFT_FTV:=<KY7)G:#YFB+N)%"BB27M350HX]R3I
MOA>#)T+R_ ,WG"[I[%VE!-&,F5E0#U^_]5Y\[?9&.V6[\W7VW](Y> B8"U#J
M,2\@\74Q2C/G%3TLABKK,L^^):,!%.O8IF*$QR8'G2\LU^K5_8D-E'<[YY+K
M+:);7%35U._>'6FW((R)SI[YU=E#.!T4_'/5014P-YC5A^.']V:4KB(EJ+=;
MT&=L+W7T!7=5+VBY@Y1__8*5V/S+9RLE2"8L 4KQY]XPH<;>4=+G"V)+_P1R
M-L;[_*B/^HFS85\WKZOS%Y-E2''<JS_3#5Q*$%"**Y8\$O+J<;"%)HGU]T7@
MR80+SS_O@YZ68P=@@!(^%45X!6OH=1QEB,2R>$?IMQ@25/%>C/1Z2QQ2"H!3
M+0?F[6;;P.]Z@BD+<P,EBU\$'>*<&(-NWS^[!7S)-,!4863;CD92S0F)J1V2
M7K7JH7(*E*JBDH7/F_%V30V9IQ1IH Z?WS]9?/-LQ"9@4+*X_R21/(PH9GJ'
MD ]*HD,D#&LW9G32*0Q'7'D57GE]A17^(#*Q*;XXQ";(KS*3>^[F\<=]Q^Y?
MQ .J=BDX0@ZF!A*_HP6HP!E"L61\EQ8? D;A3M[Y$TF$Q2%UQZVUQ#QK+63$
M'1'SOB]*%*_PWOCZ_*&JOLPS6<.?+'XE(!&[AJI.[(8*K@D!Z!E":1)+U1-,
M':L[H7)0#.GJ?(-Z\\&_Z0N*A\0_%HI^O<&]!A4[N- 317@A=V@LK]?U$C,!
MYY$O;NE@K82;ZI#TM/V6^(0WI</<O_F1/,>;S,NB&QT*4QTB%B@/BEW??$9B
MP7JOGLO8)TI.T7DNB]M#'%+?)3:=5SS=A*\H=F?#= Z[^0\&8,Z&*?SOY 3.
M.\R*CB,.K@PE9F;'42"O:X9&U# P)HR(C5_Z_KCK+LJC9OG&8497,7]ES.Q]
M[5^XQM$-,MV $<(L0#A@$7X 'V%4 A_FT^4XN23;3K6+W]21#"Z7&WM5,+>E
M\"@ZQ43P%&^FVQ7DZ@#;OMG@ *69#2J[U1W@&%D+. UCL'5Q_U[NQCZ(RMU]
MS"N"AA2:2I423[(L>*;Q8B\X;1E!LBB7\2YS7N[O2\8VD:DS:4:74%VZN22/
M% /5>5A2FQOEFG=$01('GU=D:-&_&B?"KH/BZ=$2V6L(%+L="#,&^@"><G!E
M-99-O((L#60?[FC;79*LY>W)!>N9-A/*SUOM[:WN4UBWN^I_+H^>X$EZ6WV1
ME_ORD?!MAK@"[=I!D9D'3(8UB#S)Q* >01(+.">U]D%>^5SS>_2NCJ.?)I2:
MXVY^5'B^67@]^#O'O)DDB(S>TV?QX:A<N20PH*#;-;HQG/VD)M&QKC7UC(9(
M>27,W?Y00+9JC\%FB.'Z"(I PO^30+GM@^AZAFPHN2HRT\L]!J,X@?]=VQX8
MI2O;X09]?L( A9\,H2 :@CJZ :<,TUXQZ\]'0<FHE#8KRD\3/4Z40'!3/=^Y
M[GFIV=X</9>TU+5OUQ6>FJZ8UR(RMQ#+F4CTP;=HJ"%EI!%J3J^=9>["S1#R
M85E%TPW9D"5%^<G*>UL2!6), WUT(> /08LA]@Y%R$=]RAUPL2/,=,/GI8G%
MK@K4K0QBX@)-8M.]Q;QX@H-[(VLHYP'GA\LFK2_N?SAI-P>IPS,$L*RCU5A6
MKY$B($LAT^Y1$A/^&NIVUS8F(+S>KU(UFWVB.(]3G,W+!&DI&4M'-&MNV%Z^
M89A$1!KM@X9&,6SIOO']+XRI,J6V<XR$8F19"J)F>;?W0=?:C=XB#G:2I9G%
M;5%T&U27FI$HXPY0\N&[M]R)QD^M8_4:M[=L,YWPGY8LO$3&]85&%:Z*F,RE
M.PP+3S>R#F[)E69+T(("\%0(7 )QC8D)QJ([5*E'-G(C=E,[M)U,2"XW]VS5
M!GUZ/4D@U0\?M?L_%($"@_[,,*3;R?KX1 C%N%V<I)1?(DU/.Z0EYGW&OFR%
M2&AORW8CL$/+&:G3?7 .VC[H/IX-F/:X.64+9@N*4((70[A1?>R!V KO<_N@
M;OZ"BY/G\?QAWOH^OS;?U3745+_6TGAALB+T!35]NDN_^#F'42OE'-&#(7R.
MQ7\84"AD?5Z2A/&$7:7%41)J2X'M+JES+X,;FFIB'.XW)WR':"H)\319Q1]R
MB4;,#.,(:Y"Y 5KX!)10L"3/+#R/?[ITO!&(1I%=A*2W98V)D=>F-156#L[!
M8NS"-,_?$N^?M%D%84^QP\J7/;0L9A*40,#.F1/!&U"BK.[E]H?358B0(@>@
MBG[O]=*CB2VCX9_'6I-?<YU>$7A:KGI5P/@NS S5-246:@>CW-@,C PS+VE,
MVS%3?L#@]7@XN ^*/IO1>W>->^[@G(4'F-D\-FC[LDXRQ)CI++&PJ[UBSP=E
MJUJ)J,1Y/TPXK]Z+$+.W\2Y73ZM>-H@Q)N$NL* (-V;60:&C&JX7&H.AW,'-
MP[M=A8 3='WC]_-LMS*::A#J4^@0UM-[-U9])O?8>39D-JJ,O8Q6?7NUU3/'
M)/?OP.W)QR&1/#HNFK_U4WS*;)U\DIS/FDF#;%ZD\\C'@-N1UY C$+8Y<8?R
MH[H0!P?MXF@_@6-L#N_=2^R#;8R*,Q1S2>+QZO6G6F/%P0&R62[7B"ZI7SZF
MQ*QT[?T+?O9_NA.[R1[X0&9SFP/=&M6E8J! OXL(['B][3I6YWMSH2\BY0@>
ML?>X]OJ, 4AW4,1,P9^+YO=]IO0[JDN;3:2VGPRG9AC",X1;5M?CES,MX^95
M;.Z<-5-:>,H=\2O8,@YZZ"]XSLD&,*.KK<KQC1E JH!(Z]IO;RDZ^94=+]("
MLQ0&A>954EZYS*'3G0(,5E*B*<H,P6V:'G"73?YJE MLLWCD$1L\8A 7QCN4
MPFI)&<DZIRA^B60GD<E@W'%/L<:S\U?=X5Y&J[<5T?"ELQX<]J O6ZR#C5%1
M=HHB>5A?4-6YJ5!OR]FM)X#'>V^[/9?<7DRBG%S&,-O<2J\)Y/G$UW$/U37%
MH-0KKGUX?W;MT!8[%MFZM(O=MMCYS8.ZDQ+6UX@OZSYDR]@"E6F$+MF"Z]&A
MGY;Y]6H5+^.2] [5O.PYGN"I*'G*20;*D'6AWT*(4G09PKEWF:__;DL[@67"
M\'83FN<A_)V(X82&^G:T5Y7[8>8]>:7.S;2O7787?;%.T7OFE!Z666DB:N.(
MUSZHT+I1#4Q,9,,/>V9G>2?8^%/B=R\:V/2@8FFMP&GVZPD@IU]C-U+H0JCN
MK4DLXA11HCY*C25FD9B J[TOI?G2%G7AK^2C[WC-OB[9"+M)*&4)3W'$[UV&
MLGQ-$_9!0)\_IMJ2\?$YG3V\; >SS3SOE;UG>@O\>7LVE)2X*4X-9?'?H,+8
M[.6M-1?$$MD'H2TWOGQK9!,94;>.RK40,OD1T<R:\:R0Q.?\T\Y>&'5D!F!'
M,%QL')TT4M\'U=ID[(-NV]K01O]O[?X][3PX#515=W.=. HHXS:**A@.=.TI
M [<*O54\OX':8]U%GXC%@4&XB!7(T>3*DMO3H[-Q((<7,A!  ;)A3L+.ZM..
M4D:[,Y)GY$+3=19:,X3#]JR[,'1'H&)0NDGY2UB1_0./P>/?,OEYL-+_LQ^#
M,#G48^R\T R+]^!4;1G*1@NR@;9E=)AQLDV_DG&TV"PF-^AZI\>=[#,_7G*[
M=+U4X"$W,L%%OJ!_;/E[BNYL3A=#=5UB*2)<Q[8*H )+7MQ7*.CNO&)?6SI3
MCLMDRVUIPFU<N&OU"8Z0#:E1A'[";W!0)FB!S=7I;&?S36B[MU\':E01W+^R
MK?A[P3V[B'/'?O(^"/0OED8?W<2S^_0&X*8?<BB=;SM%"9QCJ2',X_K[=9M3
MDW8^R\1.7KI5WJF]A&E/J]\S-[W,RSBHD%I%.%'M-M5"B.QAX=X8>S+C"@7&
M4+X!Y!2ZZ5*!"*6]O3?(,CQ8_(60!$5<(>+ZKVG[*68CBS>>W9@\M-HCGIV]
ML,-MD'W0T9D!3/+="_D4+/%'Z:CBG^H%VOHSGM^;)R\]>J0"<>-;JU!\CJ&8
MLSV@Z,R& ]$BDO1S "X-D66$ :_\6S+ZH$FZOBL&$S*BU?6G[(;K$@O+;([?
MD_U0(1-0<)_M6&+2 >@MX&#).Q3HH<P0^]XU3B#.4< V8W5E5@'+<STEAC5/
MQ4&^24\Z)8I8/*5P^ %58 !NV;([B<21%($F^I=CNI:!/O-0=N+$L=5KG?C&
M')6;8#+>/TBVY%QKD?QC'P_QKLL!!5Z2T.0W59#$L@.3\!TWSS]!$F<(#]]D
MYB%<_'.@ BP>[QF6 '4@H4KQT+IEF.8*W0B@:^5<<TKXH<49>\F:XYM>P0_V
M^/C5-;:S.^Z*_!;@8M(N3MA-DCF],?C@W&D&#S?E(QPX63S.QD=E%D?;N)@"
ML0\=$R5ZXS %Q$M $0B0>>D;@-W!_A15MW-1D+^<C$_C@G("W-T-:2W;]UK:
MGY_,'3;.M#GQZ%2Z>.3UXMB3/U?Q<W>);)B'( ?D. #MJG7;AAP8/PLRZ[77
M4!ZJ9\(K;7Y-7%SH4O>''-/G+PD@LU^FE_4MT1!AQ!$*C+A43_4@Y:(USEOR
M Z$6.?L@ARELR5'1^C9OA_R,;_Y<9HJ@H_)VG1B*"8J+<8W)5N6>6JD8B@,V
MQ4BT[5LAT*<N)=Z=#[Z;&O5^HGLZ4E3) %'A3^F>E3C^S2 VXG-ZV"\H\2*;
M?A)0GF>>#9>OXJL]>GP1<-6'#;FDK[5PI8#/_.=7[3D6%'\J61L-[\46_]*S
M3-S)<^$V'M_<>/S8=WQI:&A<%"T=9G6EV!,-,K$!'3D, AV1YAA%^%%AO?A#
M#*69-AC%@ZA"Q:.#F88KWQ@R(:O!N$VO?FWN^9]<%\^-?B64#>C\JZ<'LA:A
M%"<^-P(22VSW81U-(<%CC*0FZ_Y5MID?[&:&9=P"TC[^:O [9*Y1'Y\_\BHY
M1E_[5<H&[Q>00@3RS6+8GTZ:Z]D&("2<;*BD); T9_BC(%ZS2&C)TB^M_OV-
M8W#/28K](8YMQZ!1OH]:(2%G341NN)HIWA>]=SS3;!6T;7;\7RR+YP><+N %
M_02)8:BQVV1["P(5$GW^97&,[^UU-912\<#7%MVQ;%OT<EL>6I3#YIGR%DWJ
M#PZX!.Z<9K$',D87X0+F"-^)&_NK;WN/V\VDPF$;NONK1'(#C$S\@B+$7I@7
M3T;Y;"_8D2&=7D40+H8QU7L:S(7RR&)B0LJN:"[<::X_O"S8_/J0Y,6'GI0S
M'[C?HKJ&._13NJ"4ZVP4%[L2F"O%7$I^[_@L(,?7<=J!FRQR-J,?8P6YQ^HW
M,L@B838B*46DX/&Z-!(TH46L[.N6?773!"%7L:#TY[IKKBN*K@QPP>)1-:,]
MEO&[%T:.%T@#J"(O^+&J"6FGV1Y!:_ 57C>YJ561IRJ%:!!PCL7#1G1E&!V.
MFAM@\VIQA0F$8HKYI[</6HAD?=5#,4\YJOSGQ,V0\=D'J5#8K%M33[1D7C*%
MA<]T82@!6$91]RAK:"8>NO-#-NHG&^!4"J/C_T\/KD4B45TAN.4B5A^4%OZ_
M^N51V-N0?P<'14WO@S(SZ&S"FUL!] \^S])I@KP-MC*1__]'X314#DKX!?FG
M!:O!,6,[%%"_6F]AOW@S+[$SJ!BUW(X<V@?1^(&T?=#[S;,X[8KM)G/F$(K$
M%/R-N,H(BT"^<[E02L60^>LI:\-$KEJJ4V\C4FCBT9^Z[6/.ZS-"7M,U[E^!
MS5=?;LQE7GWV]L<"O;_YM=J:LYN:R^,P7NOT+ZJ1Q^B;JC39N^;M.?-K\S8Y
M2RM'><U$T,9VMC(5AS@X _F,3;0U9$>VDU B1J<8+E1NQBF<&/+D>H?*%"(^
MEF[9JU<WTRAG_=,[/.O<A;&LZ#?'7W<5HF]JHVMLK_H.+N;C>K#S=K14P/"]
M62%#$6"28<<<AHQS)GH*5-NJDS^K&ZL=1X/5!S#;D+O.^!2$.VD;XC,C=YJ=
MV_4:/O=:GV1N6T]ABYL+'CU2=UA^EO.?0[)B07'!WU<F-TMOGUTQ<_8K_B%G
MNP,UQ1%28)(=QZ[2=1$/F#E_P>EZ!Y]Q)"%UG5?ESN*:[ T^6U282)DJU)2%
M.0\MA%8\][_EH7IC)(O%M\C$UM$;J)4#F^*4!CXY+MU*DM),R)$P FPIJBSK
MD8A $1+QG;^U=>9GONC*L%;O54&].M7??^;J2"4U#>GK?_7):46J9TIM,;J:
MTUFP(B@[IPB5J+K<+C@8.8#GAQ(P1MS ,D[4P() ![0,+,CV5<@Q$5].X=X3
M0HG^7RVZ7-!;_]VX<FD1=AC;#TXQHQ [^$O[M 0S> Q'YZ6[BYR:6"/G_/A6
M\GQ95KZ=L@M!SU__5*EZH\1;(!13VE&YN!N!_]PCFE*@U&@T[SC<"#]3%4O<
M[H.CH3SU&<"-#A'$C1F&=IE@1F-8I$/!$+QE>)<8 F_9T-OY3W\&:A(RI'IS
MQ#-(B;25G_Z3Q+VI0[_!L*NQT")A-KG)**&%ZU753D!L7VCN\P\=ND]K;W1R
MS3?_[=RI.CM$V[5H3;DSX;?<V)1PF3+*&>]Z@?M$=J(\.@%M%2=?*?KPTNW
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MPA O;1;:A59NTL=A6W(/GBEVI6,3]:H7+F6[<O?57S^='2;?[\9=_Q(OSAY
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MY2SJ;'AZ%]+*GJ2;$HZ OHR-H1HDN%L?DIEI0=&.<!!R"YX/B"UPQ MR->V
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MT(!6SI@!TY@ >.TT73G/&"0\"]AT3[S.?#_NY92LM"^8FD9).RNI?K\FY4K
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MD1J?"6G.D/D7D"\6<M7KM]=\^,1]5TQ>(WFNGF\REVK%![0HP.[]#E9BT<H
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M;)*RP"_Y(Y.-77>SY'AO\$]JB69\A)U4T#_*E-R"PEF)?J Z?9UA#CJ40>=
ME^D/V,-@4C ,@ FY?C]KE!YO_+CS6W5:-G/$M:^AUA[EIV50);/NG@)0\M"T
M(TBNBWW3^LKL-FS5YY3BTE=2V'FR2+7.19OWO+;DG?6GJ\01GQVV"\'^/Q
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M$"BV=M3MF1/,G=^7R7VK#:NW3 -D1D8,;M''=CB<9CMWLHX'H?;TB=$LQV>
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MI:O+\ :I'A,O2W,J52<ZXP"!]'[U6 6RAD)^HU.>'G=R.H]A3MJUB;/'_;?
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MO'*&<&PL@T8LBXMS/UKV]<'==%J?Q^WH!X7L1URO$8@]",6OL&?I! _@&$>
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M@8F"FO[3Q76;ZIYGKOA!#Y5!<GVE*2W,8Z9E..9XYE74K5F""O-)M3#4C>:
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M,)H*^=S=,H]LC#P+P?DKX6%UU_6\TRWW:2_5K7M\*M]/\9?>U\;ME-]"1G$
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MU-QM0Q[#],W-K:;/#:[.[CQZLIMU81GYKPKBNO4@ASHD#MGK$7.G+2G'T3<
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MXK%GX51]TH;!4"L_(Q:[\)W5)/%7OX[*)U"1JR.Y;:BWJ\NQ4_"1H7:,;/G
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M-@/VOWJ(NM=K^&"S'^(^"2Q1%S'/3_-@PW@-\S=?$?S50ZM)/[,MX%O _\N
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MVZ:=4A9/:51M[_78-3FP$MJL4!]S5%DMX,Z8WNGM63%/=2M8NPT82F @,X9
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M=H^PQQ^%EU(-7SY..Z7G\4[K=8AP:2%R(9KKY)<>J;<\J>AJDUR'U:'?RY@
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M?VIQ,[+6CP&%;C4,#P#+XA9EB &J]-+//PWZ"FB\60E+$F<O?#JJL5O.5>6
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M=CQ)K+@FO^=^%\1;93333_TP>,!@L+B5(%L@0QT"!3LO Z=9ZE3EIOP\]"4
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M95!/J**9[0]6Y0<24$+11=EZD5P(+R ,D[0/:AX:P*46*@X(@OSGI#12X/S
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MKXP1= #K0S(A5T&/D$0&B-'?K__!A=5ZW!^X(BC$+KP/4AO9VJD=W ?=1W#
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M:C:V#XI:>*QR1-36+;GW_WJN-.T7:X(LN/GB/N#![.MH9^990I_F_G??Z@Q
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M6N JN&"H0U@TX]B!3G^W>>YUO]AI/BW[$-?35^2JKLM,KC&:&-T;4". I5E
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M_3>'M%R 3+-&S+=K>5^+S2CRLK\@G8()JT_><IQS8QDN^SBC]5$P()?94VS
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M5!JX1O$:,-4-6*!7]%E\NC9I=T4SZ+RDW>:US2',!BW+UWD(I_SF [TPDZ.
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M\-8-_#1_NC!T?U@N<THA=*/?91&)-9=W?1HI[+-44X"#T298U?R)_>;-Z_@
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M\]9##B#;"FQ.\@>J^SA['[?Y!FT8EQ5,ECON+6<CD!\S_@@J N,89EV&0N_
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M^_G#8\G-^9F7SVE*V&E^=PB=U%LQ@CU(B(G2P2VQ]D->9;A<\VNY:*FOD\#
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M$+5KR+>YL?=(05Y;N-EDD+W]V)F:PS.W5=9N3:SRL?A.> /!]DMSH!W#6MO
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M&;H.[$5^1U:QD!]AM83Y\9@SQFX$U@=R/3-7+?(5V @-*JFOP$;N*["< Z[
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MUYL,WHG"*2,4YS!'J8)82 9I2E,H>1XSFF>(9!>7X-\.-S8&/5:!OY7B'+0
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M-3;N60=7F*W3HWGFO753B=8Y#O@)=#VY"3.+@QA__G/SQ[#\KD"MV6B,OI=
MC\/B:V3Z(YE[+V$,;.OM/+QC@>(5+]5_K=1L^?[)_.>;><KUCZ*<Y G/!"+:
MF'5I!C'E,:11+* B/--10C*1)5[5A0^/,S::W8H)*CF!%11\MZ)Z[JJ/ >O&
MDP'@ZIGY.B'E7R;W- ZA:MP>&678 K6G5=VK+GOF\LX!??,'97MX5H4P/]H)
M,N13]^Z<2,9C%O,<IDABB%EU LYRF\:9,24PCKA3@H/3:&.CAL:?O9$6K,7U
M;/3J!K4;300#L/^3[:[8=0G2.X])N,"\$V,-'8QW7NT# 7@.-W6C$M_F"^:"
M3_/9XD4OAM9Q0IXPIF,-I;2Y55((R EF4"(M1:1CI*C7)C&H=&.CJLZ-5>Q5
M;377G58ZGRV$?0G<2/'5IK9G$GV56?6FWU[0#T37864;E-Y[@75W.>AGD&[+
M1UVOQ&Z YS.S-#5F$8HR01)I4VREV98BF4,F,(=)1#@F<9)GV"N-Y. H8Z/S
MIDC.1LJ.!N=A1-TX]6*<>N9&?XB\B>TD!($(ZO 8@Q+-235W">/TQ7X?OE3%
MY-I8H=):HA^F[&X2Y2+A6:Q@EMJ@,2UL?=,TAB22F1*()EPXG33N/7EL'_A&
M.&"E<_NJ]^$Z_25?!$+?7G0W_9T_V:.Z'OA,2R7^?#=_^L7<4W^AYB_;#W/_
M28-\C$<56'^ QR_H'-YJZS)^7LR?"JGDF^??2B5O9C>S)U7:B-IKL2R>ZL1"
MG#"EXES#/+==LZ.40!91!9$6U![_LS@1GK&OCD-[?;8#!<96)6E79=WBNEC+
M#-A&:.\@4-=Y<%NX^T&W9SZPP%:E8]=BV]YM/_U6HVQC\M<P7Y^'N4LDJ2=B
MX<),70<>.@;5$Y # :J^3PAVFK7>."#"8RDBR/.80YRF&#*B-)2:*:QEHB+M
MUW;YV$ACLRV.G--TVD$<A[?SJ=;H=A(=\0IQLM7+EN+X.*]]NG5Z:W'^!O_(
MQHVC^ZM0,[8HYM6)+&=<LT3&,(XXAIAF9H=!D80YP@IIDBN6.AUU'QUA=)30
MR.9UKGT<O]/??A!4^O[F'0'Q"DH\J?0%L8B'GSM8".))M=J1AZ<O]$_7?O]#
MB2I49AW">'VW4-4 3>BLUD0DVL8D)U%BEO@DAEPJ G.&<(P3G:"(NN9GGQML
M;)_T1MYMB.U&8O?DX+,0G_[40P/7M\_P!&8=ROF=!<\]E3HDB /E3G=Z ;VR
MHUU!.9$.??81@^4_NRK33GAVOJ=KZ(_=C3VT8]6TXBQ*.(4QLD& BG-($RH@
MUPKC+,N14I[Q/KM#C(U'MQ)VC_P[ *3;]N@R>'IF2T]D.H3M'%,^6*S.W@ #
M!^@<4W _*N?HE1WS-*KCW,WI[K90^D1BFB0$QS!#MB=#GD>02*U@FL4B$H@P
M0KS"?(^.-+8/_9OU#S?5:@!; FV#*YZLS)[)$T>A=?OF@P#6]_%,)>,5V :@
MM-HH!$Q9. =%J#2$H^,,FUIP3MV]=(&S-W1CA[KFWOSA<:'NU:PT!L:VFL G
MM;S5W]B/"8YPG$=Y"G-*D V\R(P58'B#Y;'&#%')D5<!#Y=!Q\89'^8+5=S-
M@/HA[LW/%5@NV*R<UH&L3/[GJB9M/P)Q0M^-2T)CVC.M- 4[V_*^+!IR!>Q!
MT%P#(W<XFO%!*1#C. TY*/GX@+#+0U[W=O#S/#Q.Y\]*-;MFEJ5"92F'<77<
MG"01I#+/(<,LRS.<1EGL1#S[CQX;O:RE\ZB>MX.5@WNF,P)].V,:P;HX7EZ"
MX.%FZ0S&4$X59U#\/"D']3[E-WEYPW!>DH."OO")'+ZB<YG@74[;K,!4R,1L
MC"C,D1 0<TV,_1,)&$6,)W%"HBK_P#WJY<187KPT0)A+O542+]9I__)FI\!U
M,V\"0=8SD3G:,U>]5T1S@"M<.>&C(PU=4OB<R@?*"I^]I4-IX8>'U:P0UW]M
MUB01,XU2G4"AC26#<9)!RG,%26*(1.F<*^H4MG[@V6.S8AKQP/5?/8K2[L!U
MWHZY (2^_:0;_3N8,KM >%3?[0[(4-5U/8#Q*YM[6/5397%W[ABN[.UA45^4
MM3URB3\)5?ZBSTVQF,U9T9?Y,YO:4+MK6TA"F)_<ZNL[\]L[ME32<-]7-E7E
M1$98F1T6A2Q!AK$X,HP5IPG4F5(:21JAQ+F7W26"C(W>*EVV)7C86ILKL%CK
M U@)'FN-[&+/-CJ!F;FUM%JY,\)%DWB>1X>:FB$\U&"MQ_;D^0IL5 '75;V=
M:E9N-=BJ4QEE7P><%7=2'VIV!EH!>IXEKT4C!+0G5IB+'C_8<A0"A/;:%>1Y
MW?;N7]34/LULHI;/34PRBV6<)QS!/$,QQ*G$D&69-)9WE@N2FH5,>%4@WA]B
M;(M3(R&H1.P8XWT 2+?M^67P]+Q >"+CO=D^KGR@/?:! 0;=6A]7<'='?>+*
M;I_V9S.3G\S<UB%)69Q1(1 T.VH-L58",BXP1")5RI:+Y,2K#DC[X6/[G*UL
MP K7*0SI!6QNGW!7,'K^>)UQ\.\K>D#A4"U$VX\>MEOH :7V&H,>NL8_7_O]
M;&GSO^M^?5_4XWQAT[ELY/>JG,2$QUBE&D:92,RGFG-(6)Y"FB"6RASE@CEU
MUSLWT-@^VUK632?*C;2@%M<]O?LDNJ>_Z)"8]7WRUQ$NKVQP%RPZ)8>??/!@
MN>(NZK53QYVNOR":J%4VIAEDDA!&&<TC&,>9=2AQ!3F1! J*E134MA_W2L \
M,L[8R* .<A'-RSUUZ$KKA6J4QJDVR$*J40IQ9@!E.4UAIBE2>9I2:DMDN!]+
MAD!UJ"/), BZ648!<.F91NL7K27BU9I2 X=.'4<A9+34@5&&#Y ZKNK!F*@3
MEU_ I778YR<C=O/&*LUCE$0IE!F.(48J@22A!"*E,H:HR@7V#\7<'66</#J=
MS^Z@&>[!J\_H:3@]". 2D ;Y_->1VEL1 W_\QQ (^>GOC3'\AW],S8.?_=&+
M_8_L/BKS+/6RCV7Y:64/ F_U>[-7V_YTP@E"1+($LI0SL[W"9GO%:0QC%9OG
MBECFV#G=U6/<L1%#+:4]:%.-G&!:">I^FN.#^ODCM9ZP[)D_:JFO=IO=6BZI
M ;[58"U\\ZM^ '8_'>L)Z($.PT("[G7RU0&V$P==/D\;[%RK@XKM8ZPNMW>L
M5V3[>+PQ#Y(V#DW-RNJENUXL;'J)?0G?/&\O^<R>[8^N?[<=G>IV0.L^[&RZ
MS08JKWFY7#"QG&0I3;5 $211*B&.5 3-%MRL%=ALN/,DBY7*O6H>]2GMV-:5
MVJ!J">I9*JG7F76S64<S7SVO7942L-("M#4%+55M!;GV=8VZH-+7LG"E\178
MZMR>>_!]K7;("E!#3$^H*E*]RCIL):HA8-^K9C7(H*^S"+W_H1:B*&T<>[U(
M3I"6&&=FI5%2$IM53B"-)8<2BU@S%<DH5T,N/'L2CFZQ:;K[J:V@5T#-I+7]
M.#.7"@5^ZMK?+_S\#K/\7#1K?Z EYWU[TFM-Q[/(')V$D2PL^_+]H1:3H_"&
M7D".#]1MT?AFQBW,PRKGU\W#HZU(9(9\:V2X,[MX1&*&4LXA$EQ G"48<FJC
MR:6(X]30/XJ]3OM.#S<V.M\*6"7*^>X=SF#KQK[A$.N92M>"ULYKT,*ND34<
M&;IA$HC9S@PV*$VY*;[+.8YW=2.0=^IQH411]QM3CU-5\=E,7C_88(3_KMU_
M:<2%BDD,49P:0U)'*62<4$B3/,LE4BG.O:+]7 8=&YFT9:Y:.;&6L'[$XH2Y
M&[V$1K)GDFF+>P4V E=X7KO@Z<TU/@ %8ARG(0?E'1\0=MG'ZU[_H[8Z*^'Y
MJUHNIY4!M<E7J-(1/JGE)!(Y4U3G4 J<01SC&%*64$@XRT0LDCRQG2[<3MC.
M#S<VWL%?WS9Y.68;LQ$;_%0J!3[-EPI@QWVH(]KG3];"8M@SXQR KI7P5 EL
M<YJ"0NA^=A86RH&.S"Z%U.N8S!VA$Z=C#@\9[%#,7:'V69C'79=E=S2Y1IS*
M*$Y38^+EF8(8(009BS*8F3UCG&F<IHE70<J7CQ\;Q[8R&SHE:^V YV:Z=8>D
M9\KT0*-SID<OR5D[#W^5;(_325E'KNKVR1XZ'U_'/CXWOJ?RB[(C27MD_J$H
M!9O^AV*+2<;-ATQR"16-;!N>7$ F=&H@36.$6*2P=@I:NER4L5&!?:G\/OX+
MIL&-*(8!MV=2.1)G<[4)E7Z^LM67N *?62&OP$8?&U)6:P2L2N&HZ')8 ]'6
M!8(,2G&7 [9+AP&>V)$ZMR'BK1!D&2>IYC2%2<H)Q"Q'D&"5P2@C)#+_RQ/E
M55SNX"A>A#=86;EM1'?GW)C#F#I2W*5(]<U>[7R./J*Z3P(0BF<.CC$LA9Q2
M<X\=3E[<,<ABW0WI5MM6B!^F\]^WX5PY22AG(H4LLIV+)*>0YRR'-.-:,YI&
M>>25T7%JL+'9/1M9[7I;-?VLQ'6)N/('VHT40L'7,S=<@)Q_&($#)*$B DX-
M->SAOH/2>^?T+O=T3;2_EM*\0&4UQNVB:J=J%)EP383.J82,I0QBI1FD.4N@
MIBQ6D>(ZHD[T<6Z@L5%'+2MHA+VJ$L:5@12L!?9-M3^"[VG6"(E:SXS1'; .
MR?:GT;@@V?[(@P=.MC^MWGZR_9GKNUD5FV8@-[/'U;+\J)[4-%X7SE>21[GF
M4%$1&U9 .60BHU"1B""5,IEQI],KA['&1@R5;"#V,QQ.8>EF-P1"J&<2V';Q
MN0*UH%>@ 2Q@858/3 +9#:=&&M1L<%!YUVIPN26<K_:;V6X;\V0^JXUBKE)$
M4YK#),:Y(0J<0$HR#E&>I)3D"%/BM?LX/^3X^,+6HZR\$#;*^L&(>>\;9>T
M--&(8IYD,!$*&Z I@@1A 2.F5$1(G&.439[4@L]?!^KVT(.!_:S8H@>LNWNX
MN^/W6IYL*W&U!VQD[M=5?1B?'EW2.P.^NNOY,  N+N8C=U[2MJUV3K4\5M]L
MB/<W]6/YQNCQCXG,(I&B1$/.D8"81A&DE"K#\ 3E.:,ZH9%_W[8SHXZ-W[^*
M>R574V4_DJ;K6%.0Z>-%!9G.HN_&0L$Q[9F(CD((OE<R RLTJ*0.:$EZH12T
M<=NY,5^A<YLC#(=;M[G>[,=+Y6(Y>3M?S<P'_6AKOVYJCRJ>B5P3!',>2XAM
M(B"-D8(IR2,44Y5GR*D.\[$!QL8V;1G]R[<>A?$TEX0 IV?:\,;%F2+.*7^*
M#<R]+28P_]JRP-''#O+!GU-J_6V?O:Y#YQ 4Q?G-3*Y$Y<I^_U^K8OE\,[.E
MVXLG96.)&K](+ DEJ8IAFF;&NDB3''*"-,QXEDG.>*ZH4X4)GT'']KE;L<%6
M;E +#C:2 RNZ1VL)5^Q/\T%?B/;,$4Y@=FBLY(RJ1W..'M =*) Z$,I^#3<\
MX3K57,/U4<,UTO!4[D73#-][+ZCRP,\G$/,C"<2WJV6Y9%5)@K^KXNY^J>3U
MD]G<WJDZ3LK\?+VQ7;&IW>FB2:8526,MH%D8,HAUJB%A<01SDF4HCF*I_#R+
MKZ##V%:;E@I78*T$;+0 &S5 2X_*/W0%WK\H)]&AA,3 +X_;WGGDKT3/RV7(
M,A0'WRQP_LT*7*OB=>8R9#6+@348OM[%ZTS1P8H8KR3*ZQ1::DG<%.*A&N59
M&@D8,UL#EBH,F20(1D);SZ[2F//)HUH4<_EU:3:''LML2#E]&'-7VH&64J[N
MBMEL%/66]J=91PF+8VJC.&(*<20EI F.(4FDD(G0&1%),\UFE?_#3/):UH&F
M>"SUM/;GU\/4>:T9^Z,:,F.KIW5T$D923VM?OC]4/:VC\(:NIW5\H&ZVP;40
MUH=;FJ'L84S[H&9"J,8TRP@4&B-[AIM GDM6%:-(6,:T60Q\MM$GQAK==M?*
MYD?/IY!T(]I ^/1,F6LI02/F57VTW4/;%P<\ K'7J9$&Y2$'E7<9Q>66CMQ@
M>>>;N;<Z!R2QMM8^@PG--,2"&SO0!O=&<8[CB$9IG'BE4+]X^MB^_THX8*7K
MU /S)7*.7W]7//K^WIVA\/_ #ZD<ZI-^\>QA/^)#:NU]M@<OZEC+I,D<_C!?
M&*OBH2A+:RI,(J*DV<"E,-91!K%MU\:QDC")E4KS*,W2U*D1YNEAQO;I_F93
MIW]?%$O;_VXKIF>!D\.(NGW)E^/4\R>]%A#H^0*\=<#(O^S)20A"E3\Y/,BP
M95!.*KI7#N7TU1W=>TV4X:W^NIR+?[QY?CME91U;-<$*,R$$AS)2UHV3(LB9
M$C"+:::XXG$D_"JB'Q]K;#S0#KZLA+7[^$K<)ES0-\'W!,R.CI0PX/7M$NF.
MF[]7XSPBH?P3)T8:UM-P7N4]GX'#+?[!5G]=,*VFNIC=_54M'MCLN8E$2;$D
MQ-;,3KF4QL[',>0\BZ%($.81C[,H=J*,$V.,C2JV8EZ!1E#W$)]C.)[FA$#H
M],P%!X#I$ 1U#"'WF*< 2 T4XN3S*GG%,9V!X$38TK$[!XM2.B-Z.RCIW*7=
M+*1/:FF+(E3)SU+)-\^_E4K>S#9),M=B63Q5$>D33;!(&.$PCO((8D3,GHDK
M#=,HCPE.)8ETXE,2R7UH+U(<H$Z2D1P(6]UC90\]BAF8;_*_V$9H/Q/*8Q[<
M+*I^T.V95"VP5=F4M=C6P/KIMQKEGUMI=M?G8?:VN/P1"V2 >0P\J#WF#\BN
M>=;A"5T+L=S,Q'SQ.%]4BUA5TJ&*P%\\OYU+-:&4,L9X HFR_AXL(TAQA*'*
MTEP@%M,H]JS'<G*\L5EQ3961%S*W:HTTD@,KNF^!EM.XG^:J'M#LF:!" -FA
M<(L3/!?4;SG]_('+N#@INU_-Q>VVCHF]A\M2KL\P,T24S),$"FQ[HB2)A!S1
M#.:*"9&E7#/AU5KI]'!C(Y>Z>D#G6I%GL'6S=L(AUC.!G*IY&_R4V V54(FY
MIP<;-B/72?&]5%RWN[I1R-OYU/RSHJ<GU0IJ*:]GTI:T//+K;^9OI=U4S&?E
MQV*F;I;JH9Q$'$D4$0D1U0)BF7/($AY!3:FD+"$)(5Y-F$(*-S9Z>J';B^"U
MJM-0Z]]U$OWRGLW RYN^6^5 I9VG9SSHK+M1X6O-9<_$.=0T>I-L'W@'HN2@
MH@U*X'V NDOWO8S1;7%XP\JBO-5-O))9@3[/IX5XKO^[K5W"\QPEDBHH;,H>
M3J((<LTI5#2.="92BC*OJ 6W8<=&Z)74]@CNLWGJVFU=L<!;,R5&=MFA#Y_C
M#+A1<'A<>R;7#:1;D:] +2[XWOS92P49/Z0"T:+CH(,2GA\0NU3F>7<WDGJO
MM1++6_W^A[BW9/C%EDV=6?^>_;]-DGYB4U5U:2B7BT(LE;2_,&SZ\@>M*VU;
M>LT(SPV%&6L6XPQ#IED..::I3-,<T=B+T7J0<6ST5ZMH/U;5* D6UOU4_]U\
MQ;/Z;,(28O47M=7%CQ/[F' W GWE:>S;B;B9P;5^X$OE0)Q5AQ]7]1%(2W;;
M F>M5G.)G=V='[Z\PR9*%K.5]30T^]J@46P]SE @EN]#PD&7A!XAWET_^ARJ
M8]SNPIZI+I]ML8VE&<<^^=&:WU47V)3K/%$:\CS+(191 JG4"8PD35*%)->Q
M4XTCE\'&1O]K62L&4&M!K\#,M7&I$\)N-!T*MY[Y=BWF555$IW88O-\B%Z0_
MJ0\DH6)\3PTU;*2O@])[\;XN]UP:]?O^X7$Z?U;JJUH\%4(=R3"<5M-J_G:K
MOR@QOYL5_ZWDYRH?^NV\7#:!K#05F HN84IB#K%,E&V(&D/)XUC$$G$<\6[Q
MP@&E'!M;M2-FUVJ"1L\F<YCO91A?@:VR]L:MNJ#6%U0*7QJK'/+E<./+5Y_R
MGHGV8"KXUG-V9>Q=JYSY;>6M88_%DDVM3F;&'^S.M<\PZAX@#QZ '5+&5PK=
M[@'FXT'??0P6]GAOUR4SD3Q2.M8<QMH6#E$)AR3)8YBD,B=Q*DB2LA!'=[L#
MCVUE:,G]LJ:$IY/"&?C+3L\N@?.U3L:N6N[<0;RYON#U?,RU-^PHCK".@>%Z
M/'7T_HZ9[/(_5^6R^O#LH9?9Q%<'6M_FEBIGHI@J8Y#;V*H']7%>FI\[!G1N
M&CRFFE$FF(:2LLALUG4&B=81C%"4$AD+AIA7NX.^!1X;4;;TM5VQ%VLM[8X?
M3(V&]J<SEXCTOWAFZO?]9K@Q\ICFNV<F;ZE:MQ:V,UII6S5$WRAL71:@5AG\
M9)7^V?[:,W"^EZ:D0TU6J$H(?8L[;'&%@<#?J]<PU+@=RN;CKV^_S)_9=/G\
M52V7TVH%;7+LDA2C5-'<%FU"$+-(08:U@I'.9891'%/I9(F?&6=LZXF1%#2B
M@JVL'G7;3T!ZFM$# M4S$1_&J$N1^Q-@>=2U#P/:0'F>GB^87\GZ\TB<JE)_
MXN[A"M.?5^%%+7J'R[M9_E_4E"UM);W%\KD5U/9N;DOM3J2M%(]0!A'+$XB1
M3B$EB3';I>2:(!HC[A5B?'*TL7%D(RRHI 4M<<'W6F!/I_-IJ-WLX&  ]LR=
M%V#G;6XZ81+(5CP]UJ"&GI/:NU::VTW^)M;;.N[H9O9F;FMQZG>%V:*::2O?
M%:4P^]/5HM5]#_$\$1JG,"&*09P@!&DN"&2$H52R+&?<J6ZF[\!C(YA&=KM3
MKZ2WQUP;^=W-"R_LSQMG?2':MP.T ?/F$)A@*SOX[N+UO QD=Z.N+[ 'LO)<
M00]C]W4!ZX0AZ/6XP2S#+DJV3<5.]W>,!5X?O-FJ2W7]Y77_.4XQT0Q!17D.
M,5<8DI0D4)E--2$\T[E(O")ZCXTT-DIOE9\&954<;/YX.NC2$UDW,S$(7CT3
M]MDX@5KN@.W.G-$)%7QZ=)QA0TC/J;L7"'KVADM#LJYGRT(6TY4]U?JJQ&I1
MN?K>_Q#3E53R@U'!GMVOELV!_7NVL"U RL]J4;TUZ]J-5$:);5U+$[,Y5<:6
MY!01B#06<98C$N5QMUBL$.*-C9G:05AM_<!60;#6$-B7"+1TK"*W&BUM^%4=
MM75I[%60M\"-$%]O;OMFT5>8U@OBKT*B'SSP*HAPKQ1Q%1+8XZ%604?Q;V/^
MK5A:*6Z,??54R!6;_KU8WE<N#6MBW1>/W^9U&9C&IT8QDHFR79DP(Q"32$*&
MC4&:2,:R6,2,*N3:X=QS[+'1?UM2>T[<U##R\V1VF8/3_-PSLCV3;R6Y)=&M
M[ ']FQ=@<T%C==\1!^NYWA&*=COVKH\8N*W@!U8L_L:F*W5=EJN'>O]H@Z9M
M@M7?YE9:6Y'&IF=-B$*:9UD"\P@IB)F*(25(PEQH'"<TSVGNW\FW7YG'QHQK
M*<'31DSP$RO!HUK87L]#-:'SF'1'DW=<4SF@-Z%CHSJK-Z@4!RW-ZWR%Z@79
M*E^EZHZ@>9W_5+UV.SL/B?\8#>[\IR!8R[L.0W=;R=XI7<RL>+/EHN K.Y#-
MV/N5_2@>5@_7LYE92MN_M ;_VHGTN:;1"=:$88$UQ*DM6T,C!4D4$TB48%B*
ME-/8JUE> )G&MA(UL@-6"0]$6WJ[' &U3IZSZQ/KN$*%F$RW%6C@*>IYA6FT
M 6V)JUSB*[">N%JE%U?4?I6U5E>@T2O<VA$0Y$!K0PB)!N7^@!#N<GO(1_L7
MQ?ZH[MBTWM%4C?8XDG&"4@0CK"C$.4*0295 +;GB.159QH5K >R=9X^-2ROQ
M-EX.CQ:%AW [37<7HM$S;?D X564^HC*G0I0[SYKL&+31Y1H%Y8^=DG'(M*V
M+N6G^6R3FE.'Q#<YT1.NA!(D3F%$J$T,S6PX>D)A)!.SGT]9KG*G+]1MN+%]
MM'71SJ+):5&UD#]W*&MR!F4W\R4<=CU_XC5L;4DW>4&-L,=-1/]RTDZHA"HG
M?7JP8<M).RF^5T[:[:Z.'D:V:7KV>5$(M3YGF? LY@I1#6-MTRV9H)!E6D(J
M$YG&-.%*>]5&.C;0V C$RFG]\57HS15XM+)6.Z>R.MC\J9@!:3-J%^7VI[X.
MOF.8.WKE B#9MRN-M9H;FAU+!>+F=#B@U^L,%*%<5<>&&=:_=$;9/:?0N>N[
M5JAX>+"-,<QCJ\>5UZOE_7QA:V%,2$JPS)F R.9YX#S1D(D\A2SE$3;_5[D?
M:9P8:VR\48NZIHV*%DK -N)6Q%'_U),M3N'M1AB!4.R9,QH &\JH!05;24-6
MES@+1[""$L='&KB&Q%F5]\M&G+_ETAB^(ZDDY9OG%[^I@K02+0V^FD*.4 (Q
M01&DD4H@2Q*1*&..8.IGCW218FRDTP[=.IHO55[94ZN7O[XP[,YGXAR-FKZG
MHV^+IZ^9N"!2K@.2P0/B?&1XI;BW#C =#V_K\K!N-/IQVRAKPG(LA+&M()%)
M!G&<2\BXB*!F>4HXYAF2PJ>E:NO97I0W0,_4;W:,[EW"VJBY,5-'+/KVR3H
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M>$P=L%L7^&[5!8V^XVS(=6!"1E*CZ(B0?ZC"1*>![K%YUJ'1NJT=-S.Q4&;
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M1AHR'"L8\4AFYGW#&7$ZY=/3SMQ&A]I4(&M;RSG65J]LU0[?DF!=\/:/ H%
M&YGM&[P:,\NZ5<6 A*0NL-R).Q!H$Q'T4/"\R-@!D@[2[;I[,G)U<*%-HBZ7
M#R\_4==C?,,?ESN^J@0C;++2]H=6[YO=C4;@9L$DD7&"":0B8O: 0@JS%&&(
MHACC3.F494[;RH,MF!O!?MO8(CN-Z$]U;&I;&]_>85XV$D&#]6G\.\MMM7#4
M+AB9KMOG60W/5.;7>C7@2[L;Z@W3QH>PA3 &P1>P/(9?^Y,7S1@$S[E2&L,>
M-(P;][46Z\7,0\T%QD2L# U"G*/4<"#FD$G!H?DO&9D?(I)YU<RXV-+<N.Y0
MXK.N<NA;].(RIFY4%02ID2GI %)CY"@E)GJA"$0OE]N9E$9ZW3VFB_X;AM'"
MQR47RU59%,(6":O"L/UKG,N4ZCA-($YR;+4D##70C,,DB6)-(IKRU*L$86=K
M<Z.'CQOSTIN&OH/5P6P_@NA&UXTD@F$V,E&T[+P!!TM'80LG3 (Q1G=;D[*&
MD]O'S.%VD_]FYIO-#[UU?)=/KI_1>UO:%?0MO>CMH!VUET^:;!_MK /MW;/S
M%P0XY?/-4.YR7?[X>;O<;/]MN]SM]/K39F=EQ8G*5,JPAI'$%%*9XFI(4DCJ
M-&5YQG+G[3*_IN<V/IV>][DIAZO:@1OP:%T ?U0^@'7IQ!7'4[K[I7_%=#RT
M1V:(TX,I-^!;&^C2>E";#SZ-"_05AX&" ?YJ)X*N ?ZZ@T%.V/F<#NI^X.L=
M$7)RM/.<D-L3!LY7=%%H_5%S,P6J%#4/@HUYEBA*$@8U8PK2+*508"DA18D0
M7"69I'ZSE<MMS6TLJ(STG)QT0.DX-0D#T-@3D]+*&U#9.:ZNK@,BH:8E'2U-
M.RGI=_ED2N)PRS!ZV*N/?%@_/NV*C_9H>E3GET2"B1@I0PJ,VT/B7,(,Q1+B
M)*8<<XTBMR.$#FW-CQZ,;?_\3SA!?X_\2*(+4#>2" 33R"1QT%>Z 96AEC",
MJ2 :(5G; 9- --'5TJ0TX>#R,4VXW.(_WZQ/NOU#%W8Y]</ZFT%:_[OFVZ)^
MK6D4(9V+" HB&:0BRZ"9;\8P3V(ADBQ+,^PD6N?2V-R(HCF361ML/@50F@Q*
MF]WG-+T@]T\70T(W^AY)%VH#TB=[X7.?!(:$<:)IW\"7T&M^YPI+QXRN]Q&3
MS>%<G6G/VISON:ZVRH?OCX;%R\-\FZ)89)P2J4@.,Y5:<?)<0BX5AKDM$IG0
M#./(2[SX?#-S8]5][8^#F<,*J!RAZ1: 78_1R/1Y*'UR,!%8&\/7.SF/0>#B
M)D>-O$HED_..7BI;<N'J89_^VV4A5YOB::OO\K9XY)<J3;?,]SO1CFS5W<!8
M:LT2!045&-*<IC"SU<=3Q+%"6*1*8Q^.N-*>N9%)F3)T3DS6YIQ[+@%=VU5N
M!#1A!XR^$W!&H+>EX3M.695 ^ 5BN6NMF90. T%WS)NA'NM'L,5VM_AUN5Y^
M?_I>3P-2DBC),(:8")O#C ED41I!E60":49CYK;B??+DN9%>;9P;NYWBU,U3
M5WD_,N/4=@5<@[KH;1<_F)M:W&#^Z\ +I\^;Y N_Z$;SK5Z^8&"U!/F@U=/*
M?/%WNP>]K4\L5#7>OED!ML.P&,6V% L14"BI((VXAES@'"8$IRJ2"<?8*Z/6
MO>FY?;>-Y;:2<&E[<WBFKGM8GM_ZO-4F_%3[!%//@@;N_>(6KHR#]MB121_0
MOY>FC[/KY8]8*+5_]X:GE>WW!N1$?]__"4-KQ]6BGG?Y^^6:K^62KSYOBF4I
M]]]D]V$4IR0VLS'&M2$TDDG(A#U\RC6-")8<Q<2OIEQ_H[.CLL9F^XGMK0:-
MV2X9A,,[P)&Y L,Z-F==C^B JG3N$ 6K5N?0Y,15[-Q!.*UNYW'O4(FD=]_U
M]GZYOO]EN_EC]V!G6'S]O(@3S04B"21,I)#R&%=A5<:$2GB6$$ZUGTS2V7;F
M1CRU$%!C*ZB,!;6UOF))YZ'MYI> @(U,*0.Q&B";U(G$%=))YY\[L7Q2IW.G
M$DK=EP\H\%/5:?VZ+]-Z>[_5Y0]O>/%0+Z=\KLJ?+6(I,H1$##FGS+""1# 3
M6,(\1CA')G!!,G:N\>/1\-QHXLMI<5O>6'\#I+$?/%8.W#2EXSSJT?CT2#>9
MC(GSR.S20'RP&]P>(+:F-ZO"-^#SJ!![5/T9">JI"O\$A-RO^,\ W+KJ__@\
M;KH20 .<?%$%:,C]5VM[?.;;NVT9AZHR/<PT4"ZV+](X%UFJ[+R4FVDJYR9
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MN$BXD$HF&*(,2TB)3B%'7$&"24SC*!))+/R8J*.U^9%/96RY/:,.YOH24!?
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MGGHT P%W8K6\'R"O-J1S JS\70_Y#-;^&B? [Z4;XU2MNP+&*98 +U@PGT7
M;HB\E@%['N7'CDHO%^_6._.X6Z7,FUO4__JX7&NRR&*5L80S*/(HAE09)N11
M%D/"J&!,XYP*IY./G:W,C>$J0T%MXDWS [#&=I["\P"VF[N"P34R.PU&RIE^
MG) X0S"%EO_M?O/COYO[*VXQ/QPHI?NIDY"&DV,-+;A='.[#QPL2*1K1<E$I
MX^;#9SD46"B8*2R18D1JXI3XV]G*7^K#OUL['CCJ!G;XAS^G"D*#D0KRX7?5
M]!G^X4]4CL?),9</?VB!G&*[6WS134&8V_NM+F6BWEA-;+U]Y-O=LZVH65=U
MY5J:85\JJ"/)K?IT H52$C*="IPB@J5RVO[S:G5NQ-"V$E@S/:OH^D'>31&C
M 3DR90S T)DL!F'2-2TQ#VQ-2<Q_'2C$KZU)*&60^PW%#+OYBII<#YN5N:.H
M2B\M"$5:$9["E$7$\$M.#;_('!*1)BJA2+)8^2C"G3;A12:3*<(5+3O_^9\R
M@M._ UW:.Z JUTM(E8J2A"@-XS1"5F1/04ZX-KC&(E)YFLJ(+*I$AJ\[T[]3
M 'O<W'CP_JSOEVN;A@T$7]D2,E?C&2N$94883!,20<HX-7BFYCT5A+$T3X5B
M28WGN[6:#LVFL3'#/!422+<%N^N@&7D4:QOW+Z N'W>^Z''@*G)G$0E91NYE
M ]/7D3OKX-E"<N>O](^"WRZW6AKH&PE#Q9!"4D,SM\5FXHLC$^5&&":&.!52
M,HVPT^'XTT?/+9YMK'./7H^@Z@]1AP,P]GYF;5C K/S+_EX18QX]<+) \KPC
M[6CQPA7#0L+W?+DM!3'>+@NYVA1/5H&XR;N1YO^$C60BC3-(,6<P4YF DN:Q
MHEJB//+:?NMJ;&[?J+455#(N+6L'%[3HQ-EM8 Z%WL@?^'#@O =F%T0"#=&=
M34TZ6+LX?3QL.]TS0(EXJ]\_K956_\:MWOFN:&0KDB2F=I5*BT1!JE()N381
MNR9IDB1,F%?(:=NJHXVYT84Q$U9V@L90#^W="SAV\T(@=$:F@S/ #%$GOH"0
MAT#Q]4A-I5'L\2KYZ11W0] E57SASNG4BKM-?R%8W'/IT&VZ#W8]SO#E\H=^
MRW>\$:%*A8YBIF*8R#2&-%$*9G$>V=Q-D4190JF;1$]?0W,CO'H+JF4LL-;V
MBE7YH>NZ77<]9M/LV'G#-6##KAN+*_;L+CQXXFV[;O=.=^YZKA^XDLY7NBZ5
MW=1QJ:JWV,+96GU8?S/44]A6S;"$19QQI#B,=4*L$C"&F9 95"Q)4FS7.)A3
M/O>0QN=&&W6]I65IJ:W8_+A=_N [#1Y7YH:R7-/N8/T5=;E\.LAQ870DV,=>
M,C5FVU31TO!V%:RZ*S[LNZ)E?\#%TP&HA5I6]6EZV@77 :"<+,4.>8;_'.]?
MGU;/I>Q6N=IKGVWW(IKP.U$98D1#AE($:812F!$D8,PB09,T1DH[*2[T-30W
M%K.V@DH!KMJ":,QUG]%TXMH_\0N%ULCD<Q&H 7/ [C?1>2(8"KF)9H/^KYK7
MG- %C8Z)8>?MD\T.79QH3Q&=KA\8&,H'K9XL,W_>VG.#NV<K3;B[72O;V*-]
M8<J\\05%.E56T)7%F;*)%QGD"=*0XSQCL:"1TEY2T*X-SXU*&VMO2M','>!K
M!?86UT<J?(M'N_:!8]PW K*C+[I= ZI_C.>)4*CXSK79:6,[3S!.XCK?^X<1
MU8>UW-IC+6]U]>\/Z_UQES?\<;GCJ_WV5$PRF:.40\V5K2U(8I@E20))FI(T
MUTK1F/I0E7O3<R.K-P^VJFMA)TN'X_N\+#]2?F.M^J*>(@@>W>'&6N. /#)O
M-4:#GQJS_V:Q/IR^JTT?93?1'[% /.;1\*1,Y@_(,9<->(+_#+4U$?ZB;99L
M]70N;<Y;AI#BV@17D=044FH(3"B208F$PHG0G!/L.D/M:FAN3-6L^A35JL^V
ML1?(VF#W>5<GOOTSU5"H3;%,=K=?)MN;"MZ$!<Q]HAH*N(DFJL,!])JPNJ#2
M,6'MO'VR":N+$^T)J]/UP^+ 7S=K_?PKW_X_O;/;IOL4#AD9XI08$HT)I-PP
M:)8F,4QP1I,LQBIG7EJJYYN9&VN65H+OI9D@MW;Z17$7P'2+V*Z':&2*K-"I
M+ 2EB0&3.-U0"!1Q76ADTNBJV]'C2*KGZH'%+LKUKX.<G8IC33"'$4LTI(F(
M($.:0<X(3E+&LXCZ5;EX\?BY?>OU<NK0A,XC[-P^\>&(C/QINX/A7ZGBK,^A
M2E2\?/BTM2G..G92E.+\5<,^V"]Z9P9_K9I*%_7XDHHL2=*8P=162:>)3"&C
ME$%[G"*FL40Y<ZI"T=W,W#[@6VGBVJ<5WVD%WNI\:8(AOT_X IING_+U&(W\
M23<&@GTUFO"#=3<(@;[Q"XU,^JUW.WK\S?=</7!GZ4D4^C^>S$3NW8_]#@8C
M<6X^< 83@J0)TV-;F"HU87K,$T98'G,NO7:1SC0RM^_^8",HC1RX270.3L<-
MH2M!&GLEPQ<?__V>#@!"[>V<:V+:?9P.)T_V;+JN'9IP_(W_^4'9&BMF:"O7
M;JHT'[L=DR.J.,RDR,QHGV20H\R>X(\E-F^'(MA)=;JWI;E]^'4.K:VG_=+<
M.JG--^?X$L#=+! 4MK'#^J&(#4@[[D'CBKSC2T^>./&XQ\'3S..^&P;& 75I
M.ZW>;+Y;)>KRT;?VK,-]F4#[\_/ADKIDR>T??*OLV2^K*O+>^%:M)'S>+J5N
M2FB^-8'T@F6I819,H#03!TAS*B"/S)PBD9@@E0EM?N\53XQH[-SH:5_]]=%:
M:C=?=@^ZV8#A.Z!JEX!]N9I%QNI:\]=& 08HFPW]$R\ M]5.;)$MW]3G,5\0
MQPAI)MT^=J1E?8"E$Z#M*&AY"L0S:%]7>PM*=V_ VQ<O1;VV6OI\<R@G;-T.
M&+U-T#FAHL Q39TVFIP ]).H=(HVAPUBQJ#OFW6YH56ONG"IDD1R#J.4<DBI
MIE#@E$"!B$Z(%#227K543EJ8VW!1&5AME_H1_"EX;JQ\%20C4VD;C1$6JBZZ
M'HBH3I\_*;M<=.^8$BY?>&VZ\[X,J-[^,%QQ@7M695>9G^[R+UIN[M?+_S34
M4\IIO=D4NZ(E_8]5@JW@-8I2"2F."61QJB#-D@Q')DX5F=^AN;$LG1NO-([N
MSWQ!<1J@U#5L0+[9UM]<2?P%./@Z-.<Z](O@&''.H7LG##?W8>1A-+]I>E65
MN:AU@IWUZP;<?B^#S#$K%(S> \&SQD/;^4IIYB/!?3DO?:P&)UX/>7EJ\O8'
M7Z[LU_%^L_W%ZD8L-(T3I44$HURDD$8BAB+7.50DYSI1<9Q+/LE:2(^ALQN
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M_WZE(.''Y5I_,#\6BQA'3"(SK!&1"$@53B C',,TXP33*(GC>%AE]7T3<_L
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MO_2YM?']:'[ZG_^E^8WY'YN8^C__R_\'4$L#!!0    ( )568U5DJB;4"V\
M )D!!0 4    =G1L+3(P,C(P.3,P7W!R92YX;6S<O=F6F[>2+GA?3^'>?=NQ
MC7FH555GR9+EH].RI9;DJE-]PX4A(+$W1:I(INRLI^\ F?/( 7_^2.^UMIS*
M3!$Q? A$! (1__(__OPZ^^$[+E?3Q?Q?_\;_SO[V \[3(D_GG__U;[]_>@WN
M;__CW_[IG_[E_P#XWS]]>/O#JT4Z^8KS]0\OEQC6F'_X8[K^\L-_9%S]XX>R
M7'S]X3\6RW],OP> ?]O\HY>+;Z?+Z><OZQ\$$^+F3Y?_;+Q2UK("3O ,2H<
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MWKGL;D_]NL]<'B/,9FCXEQ]O"?$M?>.8=_O$SWR%F;Y8+6;37!LT_!1FM?<
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M<5Q_>RBT#:BF#E#X ==A.L?\<UC.*71876'W%99IFJXG$JWEUED0$NLX@E3
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MI4Y^209BR09*#L(HEE-IWO#M%A'C0J:!8N]_57V E#N R3WMS<^8\3RQE'(
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MDN)DL(6SBNT C+L^>^3#9SA '"W(D8'P0GU\>:OGQ+GSKLB&AES >!-!&?+
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MO*BY=&V@=M:"6"Q3RAEK;>NG<GL1>'3]\BZ+7>X1K;-TFM6N8AY!H300HDG
M<_;<!U%426.(HQ.+-QRV;A4O#Z>W?FW;ZS!=_GN8G> !ENSRWS:R6_<0T\A*
M77SZE:/JLJ@%=2J,B]I:IY;)U:GLKO;'S9%G(9W7JOG F0?H.7K8SAV??0G=
M2$K4*#B@M(F858%V2?80G3&J6!Z5;5UL\"!!XUJ89KBX-0JGF1+ZM1]7F] <
MY@M=:V'3QO>YDZ!&5F1[ZWLYR"!&$PRA(CA?QQ27!,%R#26@X>A"X+)UH>!U
M"IJ\*OBRF-$>6VT_^;?%&N\Z\"P*4:RA$U5G1P=>RK7G60+-(GTG*H:R>9YI
M5^+&M2!'8.+.1P?-U=&O_=CP>T_;E0-2X ]\6JN\]ZX$-[(WEZK?]+.Z6/$#
MSFII^.8V>--R)5::SN^,+["H8F8.-_V%"@7X-ACP2LAZB/D8./=2M4Z('T?Q
MT1,Q=UW]IZNK7VXKD9W,T13(2:<ZF89#2)[VE@TR%!%<DJUO!(\D>5S;]X3X
MO#4E\PE5W:\%?;EY ;2:SG]:A&5>E%?3)2;:(P?EIN[]K%;>V6[$=I6U#U;Z
M.O(, I8"*HL,D1=6$PO)EB0P8.M\U:A9^UKI>*:G-UL]O;O4TUV>B.'!&8%^
M^PQ$82!1\2C <2Y*\CQGQQX!WKYK_A6R\/O@ZFH5ZF"ZZ=?&G5GT]V&YOCI1
M]A 3=^]'-;)PNY':R,#=M]CE/!5F"BE9 #/,D/IK[P]I$:SAQ:OBA&I>#_$8
M34<_;;[G\^]"?S3H$;,!X;.F+:88>(J-(&3:7XD[[YI/@]J#O'&-6%/LW'JQ
M/)"2^C51];42_M<)?=C/WP\L5+WU$<U*M1XBK=5CX1N+7,!(1B,L4PZL=V5[
M+^.LEJ"$09ZM0:=;!U3WT=+B_>?5S[V"81T#VIK,3760>1W<$TMT4+(+2BB;
M,#5_OG<?,>._VCL:!W>]!#U>\#T;CUV**0>O#1VG1G2L6E&=C/(^!^ 6:^I!
M&(K\<P*>F$>)/N<L&N_9 6O?MX73-Q8XW?YYN5T**Q16) 4"DP-E'!VSM8XZ
M9W1T!*LD7>L<_FZ4=5LKN@]*;M6XMU=*!P_"?E_AN_+S:CW]2B[>:A*0LQ!E
M %LHS%36UDK7D*$X#,F+X(IHG1ZY3L&X;P4'@LX10NX (J\72R23OQWZFJZ'
M%_.\^>MLV][[YEYPJKZ2K7V1&-)Y+NI@I: *<:N,=5PRV=Q;/)C8<><"# 2\
MIU%=!Q@]:T=YLQ?P#::RR5HS1/""S+)")2@X)2=36.$"SX%'W[HN:"?"QNUN
M/A#VVJND YQ=5 %=R0:_F9.T3KY><C?1+ HCN :I7*8XADGP/!G:1D%JEPKW
MNG6B;B?"QNT2/I2-:ZZ2#G!V[ZC+F_N'F6!1DP<19)V[;J2%B/7R 1VS3!8G
M2VNH[4K;N*V[!T+;((KI '!OOGZC?;3I$K=\-5U]6ZS"[%UYNYA_?CO]CGG3
MJO*6\=;1*NF$!!0\@"*^P'F*>DHT7H<LHW.MNXL<0N>X7;D' N+@"NL E+\L
M%OF/Z6Q&^^P-:6S^>1IGVZZIJ_,?G9GWQ -:GCQPGLE=)3XAZL)(G,Q+KIF5
MN342=R9NW(;< \%O&-5T@+D/I!XBH+JNK_ [SA8;Z_[SG[4@"<]8<HJ<4^%-
M;960R+8S!0YY B=42)&Q@*+]3>2C9.V$,__,<-9:'1T@[.5B1M]=U ;/W_'%
M<ED+0"I3-S.+DR)=M$AAD=YTF99:05!2 %>\>$[A>1K@;=UNM.V6X67/#&R#
M:*8#Q'W$&?WH\R\XQV6H)OM%_CJ=3ZO$*J=GN^F6M^"11^%\!)X]B9(%#<$5
M#LEKM"5);II7SQY&Z6YH?&X7#D^@M1ZP>>>$T7?G/80NAI%NBO+/MA]+F7-C
M"V LM7<0>;"!L0@Q)R%#<!3BMVZ]< "9NZ'RN=UE#*VO#B#Y%LF/Q<WHA5N[
M2U@KF"%OMDC4H$I"\*D^^9.HC%)"D/?1&'H/D+,;Q)[;K44K^7< I;I'EOB%
MM@EM"=H;BZ]X][4Q0^V<)&?"1UDGB6.DKTA>C!4;G<DRR^97$SO2MAO(GMWU
MQ!":Z0!Q6U8^A3]O\J%8QLR+J!/8:.=84R!2( Y2:>XM5\K(UIGB^VC9#5'/
M[2*BB>0[0-#/83DGV=1)JIO#_B8[0601O<R0T 5000;P9)7!<RVE8/7*KG6I
MU2,D[8:GYW;5T%(/'<#J-_SCBJ"6BSE]F?#*'=VMHQYK6ZO:7[G4*6TQ10A&
M27(BL\W%FZQCZR-Q7QIW ]YSNUH85%//O6YWTT5^N*K=LX]_TIK=NU@:OF(W
M8C+&D!-?,V:@LG9DOG0"@5Q&&[.SS9OT#-C=-7W!?%)G5;R@S\_3V4F-@3]B
M.EE.U[3.SW_6^>.87],>KI[GR?F;PIM&_G)3<:UM\:5 4:'ZG4&#LP&!F K:
M%)6M;3VSOCT7W58"[X.^6RF0<97=KP6]HX'KP>;R_L\:KMOL@(:PS2MCS;P2
MF!TP57AM4Z<A<'+YE,W,&JV0B];M!?OH.7NQX]Y536[K6=?;Z^:-TJ[X(L)Q
M711"REJ!<HZ\DD@QN_("4RG92-6\L='.U/T57KKO@\'[+6=3/780W5PY$[:'
MSNI].*T<U7N;E)8G1-'9&-]SC^N*]7>>858<&#+BT"E/AU%*8&+6 0,+6@YX
MU.]-[[AO-'I"\<"Z[@#75_?I_4S%@M'606FT0^N=HXBU[PX#&X)/SGB67.M;
MD9T(&_=1Q_A(;:^]?IW/!_ID'^R$/OZ9PS?Y'M IW:\=,X:4D(D$R45>+T)J
MOL=Y*"+$HF.]"&E]2CUIJ^_MM>.[;UCK*^:?-_>/YYOF]->PKM'=Z8VM8Z6M
M':H31)YJ1YYZJ;VQZ\9H$7S4,K26R0%D/J>FW_N@[.Z+X^$TV*_QNW@$<["I
MN_D)K;N #VC&'NSYC-)8X4,!YY('56P"CTH!ER:YI(2(K'6MT)"]P"]]SXM5
MMN$3;:TK)_RO!'U:-K^;?ZAIJ3K3=O-^_0;XG=<IZNQKG_LZT9)KB(HVFS#:
MJF"=\ZGU55Y3!CKN-;X/[NX/,)Y:R?U:N"NMP(]RYZY_1OL^Y0/:N1N=J9.U
MBC-CP$NL1<@V@E.9CJ^@@TU8>):M9RNUZ59>^QY>0OR*[&JQ__([YM>+Y>L3
M.JWQ?$SNS=R012T])A"I4""D#)W>T1"B-;),AS;S+CX"A6-IZ*I'^3Y(N-I\
M\LF4T*]9>: #^.$WO8]^YO#MRP<T0T<VB2[<LJ1, 2MJ%H,E.ABS<Q"3Y3DJ
MP0-O?8<Q;A/SRUUV=^WT1HO; NK5B[2>?K\=I)20+?-H(+KZWB21N%PM([->
M16T94YA;WY4?3_6S;F6^#TKO=]^>1.$=9(GOXOA,I"_^",M\E>/JSFY10.?*
MU^WW;L;DRG,?>88J:.(^JMH@*8#-'*-,1G+3^C5O6P[&O2'I#/I/!(2NML'/
MY"8L3A$_DBLUK44&=]F!%[/-1VYN "B"6WR>3_^;Q(7+Z6*KI"NW1E($Q;B"
M7!P)HA0-(=<>F=$Y66*)OOEH^\&8&?=2IHO-,28\^O7%7^$J+:<;0[ H/YVL
MIG-<U>N035)C<=<EV>%CK ]?JY'OWHC9X>LTT7&G17U JJ(G1(E,P67(8)PA
MC.GH36Y]M_L4=9KWO?6N.;;?%O-TSX^OMM#;'%:38@(Y9"B!R2H?GAE$*>H#
M-25K+6'AO/70N/9<=%NGN0_Z[K>WHRB[!X?D>JOM3_3/7OPY74V840X++Z!3
MED#'F8' @@7KC"XY%N>P=0.3>T@9N;_YR AYN#/Z0>KJ$W6O%E_#=#XQVFKE
M<H$@E0,2B ?GJ]MB8E3&"'3-QV/?2TQ7G?4/4_7C\#E [OT!Z%?\&G$Y,2HC
MTTH3Z;+.'' !'",G7%J;I1)*2#[P6(8M(=T!YQ E/PR= R3> 6P:V'#RXO$-
M^=NT$4O24ME,,5[M65%$ :=# E[('V'6)]E\0&Y+^L?-0'5VKHX&C!$W1<;I
MY&?RJ=>GOYW4S7R9=%A-G,@Y!NW!D!--?/B:7=8%T%OGLPO6VX=: :PP_?WS
MXON/M,06UO3%)9H?6'CL.K2Q4+!HJY(1455OC<^)O]*/[_UR\7D9OJ[>GRQ7
M)Y@GV8:HC5$0G:L5Q1(A&G)J@D]$C7$VIAOIRCLOZ!]?:5PS-SJB!E!'!^?X
MAYKHFF,^?R[Y(J63KR>;].PK+-,T74^$)5GYPL"5F&H:EI'7@P68"RX[DJ)1
MK0O7'J=JW,3VZ& <2'W[ ])O 3G'SW7-5OW8$V)>U2>]Y_4P[\K[Y?0[+?%^
M%K;M$2:"2<LMDZ!5'="JA-L._W%9J*SI#]J%C6&Y&V7C3ICH!IH#J+$#>WGW
MI(T7ZY=AN3RE';@I()TD+$PX+B&CJ0ZTM5L'.@DNE9898_,:DIT(&W<H13?0
M;*_$3I!YDZ-Y?HVY=C1]?3+/JX^+69[X$ L63X+2Q)JRQ)!G=#HPU('<DZ#:
MMP+9C;)Q1UATA<W&:NSW%GJWGCDO<I[6M>JLF;)8?MTL?/AU=(-%G[1ET.[L
M#W]!3<"V-D8.T;+:!ZT@>&,EH..^"'11F=9MTI_B@OK>23/;?%AT+')E*8@S
M)M)^UHQBNA(!30[H?0F2#]?GXF':NKU,W@<I]U\F-U3,B$?T:KF>?*A'QN;:
MJ7 =2Y(.;!0*5.V)Y%R18*6/G$6!"7>*I^E3KR")_G:)HFL+]G+MVU*7BV,%
MVP,:SFY^/!&JI=<@HB5O(; ,#IF!9(4LA6,)?B>;N@L>QKQ5.T)9-]5]@.1&
M5OBOT_GTZ\G7,\(CRSX%GH"X9.2].0/.< U912LU.2I)[G2]^HC*KRTZLM(/
M4=FBA?S&5GSX\PKA142#2B!DAP@J)07UR2@8EKGTQ#NFG3R)QQ1_==%Q\O;-
M%'^P_$96_$4QZ<>$\["<+C9F3^@8'>$3LDAL>[4:ZE64M%%G0<&<MCM5Y3P"
M@#L7[^6>>B!'X'B!CXV8,[I_GZ^^8:)X$/-9N0GW%.4[RZ!LNA$QLG<ATUXJ
M3O-L1.2E[/1(YS'4W$? >&=' Z4N6DNX$YC4@>,IK,X+B+P*R#C38(.F@,M'
M <%:!3HJ2SQ98\U.3]1WQ,CUU4<$2!N5W@&2(^3;03KXOJ)'FPI/,EF0VM3$
MH8_@$SG?] 7W7HDL??,2^B/*D0>[PAWT.&JIA#ZQ=+;'6,; R>B"-[2S5&VZ
MXK-UH$64'(W2I7F3W&=69+R7JG<N,MY'[OT!Z,RB8BDJ*(KBK*UW)2IY"-J1
M,Y]0^F1"YK%Y1Z3G5&2\EY)W*C+>1^(]P.;<^=OV8*D/-A?SS8U8W5G)Y,)-
M82"E,G7J.PF*MA-H+,XY9A3?+6^V#WP>(FC<NH^G.<^:*:0#=-W@X6S3"6^<
M5<P"N7NJ7JS6D9Y"02+IV""2='J83D\W"!G9*+53],U)2T=+O0/H7&GA=)Z1
M3%*RFMY*(J@ZXX+7 3T")*:BE4\Y-S=&MXCHH4_648J]/3;P""EW )-[+?';
MBU(1E[GVTA2HC5B)(\4A9A0@.,\E\_HDJ+4/]#A5XY:)/<E)UE@UG3P3N.AD
M\&:^6D_7)YNZI-]7FP9SM:CH%7Y;K*;KU42B*%:8 )&%!,KQ#)YL-PB?M/!"
M.*'+'H\&=EUW7 O56N=W/ P81 $]6S+BK9S,WDX+;<>8JVG/D%BME_2;X:TZ
M04I!9!XLIM"Z;\X.9(U[Z3$0Y(922P=(HQVR1-I!54,U>>*#C@I,2'4* S,0
MH^#@@_<"+1<LM_:JKJX_;H9R8.P<+.@.0/(IS#]/ZQ"8VJGYS==O8;JL@GGY
M)2P_XVH2A7-*, 5.^5(?]A,CGB%X+HSDJ(U.K6.XARD:-S4P,) :*J,#:-W]
M;.5**#+QT1M5N(-D"H+2%-?X%"CZ99*'DE $^S0/CZX0-:['/OPIUU E!V/L
M.R[CHA'*?EDL\A_3V>QRN[Q=K%83]$**8CB4HDA*$35$2T>W)0N<45,@W?R\
MNYN2<1]C#(RG!L+OP%#=-8#E$RZ_UITQW]9@"ZEY8MI#4,2'2G4P=3$2@G.U
MOTW)ZL'> ZTFYERG:B=H#3;&>V!H-5;*R&F%N[A97?13^'.ZNOSN)'JOZX,Y
M0"VP-H\3$)@.X+1/-F0CL[I15W!G1F&/)7<"DGMF0!I2[,_]'=AY8G!1WB_6
MM/ TS&:GKVZ-A/YML7XSWTZ%GLY?AEFJ[^$WK3\WOXOY-]P8_&]GDZ&'?DDV
M,-E/^A;M*54P_&LVIJ5!GQ@4Y^H]5I;D-EJ$HI#,,I<EIM+X?'R*UVS'3DK?
M)->3\5;'G(%A2J!"$.""<% $TTXI$U"TGN75EH-N7\;M@[H'QN$^M9([<'F/
MY/FGT[L_8'.G+;.H3Q$8,!\<*"<DN)(B:/+-L@G!&=?\9>MP[/3RYN_I4;KH
M$S+=[I[?PM?S>K,LK=G,S:MWZ: L,>4"\2-92DZ(D%1I?AP^0M/(1KP7\.P$
MZ@,UV0$RKTPJ.2OT4(+%E*6'Y)(%)40";YT"$YDJF!/]K'EIZ$TB>L3>H3J^
M5<=WC, [0,R1._,R1L=<(K=U^).H,;JL%;&.1!E-E-IB]BJW;NW0BO9>GO,]
M]S/^,# \_TWPXFN-4";:>73*<\C*;2KT(GAA"JA<G"F!A=A\ %@3PGLTST-C
MKBWP#P! ORG$G\*LW@M^_(*X/DLG72:KWM5_\/)D636[G>X<YOG]$K^%:?[Y
MSSH%"L]&_AR0!6RU<J-$WB"":)2+>[?\'.;3_][P]7(Q7RUFT[S=LALJ+GA^
M=]=,IHL$BD@N6^\38(PU@6(UQ))<K4&W06>;M&G]Z*P)X<=<Q9SIZ"7];)K"
MC):].D3M3*,3&=!D9@2(E&DKHR2AH-<0K..&V:BEW*6L<Z?%QK6_3X^DJS<T
M[;71@3NQZ7KY(M,N_Q3^_( )I]^K:W;.#?>:2-8<A(^9#JIH:V-KA%(,BN(E
M+[SU9?+#%(WK_XX'P 'T-?(]<QV#3HO7GJQ7.JL35V_H()M7[^:<*<&]874F
M61*6@E[E-#B&'&3VUHK <KH9KMUIX'9><-P*T'&-W#!:Z<#0;9R@K?=SSH%.
M%EU(6 O(''F^C(&/&*#D($)BCBL36[L4MZ@8MTIT?(-VI%XZ0-9U3YH$=P=+
MGNO$21C@+290G'MBJ<Y]4DQ8D8G; ?K6/TK6N 6DXV.OM>8.!^."PKK1 N6S
M:^O5^W!:?8EA8N*[%WF*\'<']KJ*=*/$:'T19.\*^7!>.7 Z.@B)?F*T85RU
M'L,W>J1['E1M0JDS19WOP,Q\YE';VC60D:-A&,1$&SXR9C';DIVS.[A_#RSQ
M5XAJ]T'-58>OE>1'KUK]O G)7YSDZ?HN7M ZIH6(M0>/ %4214954@898T+Q
ME(/9 46/K?-7B$\/A5)3'73@V-TX.*ZF42<B<L&#DQ!%'<7 1($0LP>!M&.<
M84F:UAW5'B#GKQ"Q'H*ZUIKJ#W07B1T>K#,2@1430$6;:O-+#A%C$"4IEIO'
MJG=3\E>(5QM"[1#]/-\P87F" U^=W;W($X4)C['759B0"P\)DX"@L;Y<4P8B
MYYPP[8JVFG!G6]>NCAXFG.GHFL]Z8>>+X#[(VAZ88G3E+ >7?;W;9AQM%HA%
M[N#@/;#$7R%,V <U5WV[5I(?.4PX8^.VIWK.2^#9&IX0@LL("IV%@(Z!B&B1
M1^3FYNN0AU!T[SI_A3#A2"BUT4$?>*H5-W1J; 5Z?A&<D?S,HH$A13R*PAL(
MI02PJ)!"G<(9ICWLT>T5_@I._['FZ$BY=^#O;U/.9UMB&N)TMJGG.N<FYIR2
MSQ9LK+=LKM"N*(J!SXH;VB9%-2_4>YBBOX+_?PCJ!M!7!^B[GY&4HD\)Z^33
M.M+<>)*6$!YBB2$[68(3MC'PCL-<Y_=4QV"NC9:>:=AY-9ES10+#5V[>7NRI
MBS4?8;>K<-0(+F4BZ-&QRPB)NG:X8!DB&K*')3">_U+UF1=$7.O8<*ZQT_,-
M:G5M2,HB2)<#J"+I/$A* +)8DN7%M^_&\C!%?X4@=A^LW3J_V^FK@_-[8RT^
MGLSS\O2.TX%9DD8D5SAPU*"RS^"XBE!<(2EQKK1L_9S_08+^"E'O4=AKIJU>
MH'>7!\QD""X$H$"+V+!<@I.:_!*>DDW*R_:O..\AY:\0(!\-MR,UU*_36%L!
M3M<;:85YKIVVR*CC?(#9\8>NU,A=;,)H(U_Q"BTO;M#R:KI*L\7J9(D7X/4<
MG9/<0#&UZYE+!-ZH':ADE7;!A-#<^=F+P*.[\2U6JVM+;)^UELRYM58"DYR8
M+9&!JP4TO/!$!+O@7/,.?'=2,JZO-QQ6;C7@.UX/8X]W/+?\O^#B,QF +YL7
M1K5EA/>^/A+E4'@=?IM#AD " 0KO?38F<[1-)CS>1\"X&&JAV;NFQ1XEYK&Q
M@I]OLG#6'4(E9;(V"+K0Z:[0<(@Q,0A2":4DZN1WZN7R&%;N(Z"#B;''*7;1
M6LHC7T_]L@P%9X5VSR](WL'\]*SQ!Y=6)Q,BJ!AT'0]0P =5P$@EI8@)<]JE
M;^<]'S\B#-HH;=%6@F//B<$__G.Q_,?+Z?J<^"Q-+$X&R#)8(CYX\#)I*#:A
M845P+>,.ZK_UP>,-G6^O^..D-J+*,TZWE;@_T[&Y/MT80>VX+(H9\$*7FM52
M$ 190E:"D9$Y+\-##6]6F/[^>?']1_KH[;E 7UP>"7<L.&ZBIZ'3<*PP1\;!
MENJSG1"$S5$H#=4^ 4'?@6,F \G F>2]1?70&[3'07!UM7'.@*/5M6@@NY'-
M_9NO7T_FT_3BES.S95PD"V4LN%H*H8(HX%SV8%-0(D9/UFR7BJ8;'SN>?@_7
MRZ*-D#K(O=ZR<&\O6@ME&P(K3M>>;ECA7LC?Y1Z<3R6KX+04K<?@W$_-N!G8
MAN= 8\'W *''AQ8XIKA@%L%1Q$0<N00.I0'NN5+""B="ZRO=1I,DGBX?<:#^
M]Y\@L8\R1IUV<]\P@P\DWO^YN00Y?8_+Z2)/4D1?Z@ ?9%J XE;01DP!A,0@
ME,O.L%WZ>NRT6&<>Z7&P&4;$8_LM\[2L3+S"[7_?S&\P-_W\9?VN_+[:SAR;
MY%@,.IN!8F\2G"PD,]QTL(O6B\1BBKO4^^^Y;&<GVO$X&E+L(R/J.B,;1FN2
M(,Q^6BR7BS_H!Q_"FOP!Q@1+JD;S-9\3>";?CQ%;$9US*A7E=G&0=UMMW/+9
M ? S@)![@<V+>?[WL)Q6IW$[>*>^4IB@E"E12%DW@"*36M- 2G!@3HKLDLE\
MIRG*#Z\R;L7KD# Y7J@=.,_G7ME)F+V+L^GGC68F.7&6ZU#G8HE^E8B=*&P!
MP1VJY%5"+QO[RW<2,NX<OX%<Y.-%/O93H7I\OC]9IB^$^A>?E[BQDQ\6IV&V
MF0]0._36%FOORHO/]-//83LQZ6.8X6IB"FHTN;;&KM<-2>8Z.LY#B@F#DY9)
M$78P.L?0,.X(OP%,TI,II N#=3$W==,%>E5'JF*>L,24#B6"$68S_E) +)M2
M,*M\L=F[T+I"]!Y2QAWL-YC1.E[L?:%GTW]TDJ4VOI(><N2$?A? %^' 2%-+
M%"73L74[NYLT[(07_WSQLK^@Q^[GNC&<IQ]QO9YM+.F%2=U83+*<$W2<:\4-
M*%48*&;(RS,Z@F;<Q)#0A)WNG1]?:;<D(7LFZ!A NMUBY658?7D?3NN79\?O
MA%NG?& <M*^Q0:2C-IJH@$Y:*ZV)UG)]%&INK[D;?IY+EGE0B7>+I.V!>X,S
M*ZS03C'@BOA1WHG:6M8"SYP5(83.GAUG@>Y8=3<T/:?D\X!2[W?8R -U^+^&
M]=D<ED6YGA"[C%4'>7^PS\+#/T<X6 RCO$Z0+"E9.]9P3YZXLIL7V4Q#2(+<
M<R94MJW[K#[MZX0[;H@NWCN>[=#5!ZQU%+D.&7]-%(39?V)83CB/P3LOP3MC
M0>6:K56\@$Y)*JN5$*:U: ZG]CF]<M@'<[M<$@^@SP[BS9TX?76"OY'=^/0'
MSK[CKR3W+ZN)L$EK<G;!:%% :>(SBJ3 VQ*C-RQ[^Q05"[O0.NZ%=&>H/5:7
MSPBS=3]^^F,Q<>02<9X-I, ILI=<0:!/!2E1,^:)5=;ZLF!/$L>]ZNX/H8=H
M[KD!DY"&$U:"-20S2%G6IWB9@5>8@2.7*CJNL+ECM#>1X]ZC=PK.O;7WS.#Y
M>G&RG)#SXJPI=!HP5?LY,P3/K 5)O,501$JL=7^!?6D<]_:^3W#NK;MGA,V)
M+2JF$A3$XFL>17CP'BT891U'YUW18QWFXQ8#](?%O735K/O%0!C\?9Y)BK4?
M>6U<G>A7S\;[HF182D#(,NI:I:? U9Z8(DMNDO0YWIP).BP@[R-TW**"3M#9
M1(L=F,M[V)O8Z 5%;,1&;36C2GU]F<VF57Z4AK&<FO?#N(>4<8L,G@YN+33Q
M5T_$3VX4OC]A*IZ6[BH9?U,4%^GX'P]7TNLP76YJ&"Y;6U[TN;H80GZE.=6O
M1!G!/X?UQ;]<S#_4^?9+HONGL)JN#K]!&9"81HI\*G$UNFFY6/32<%WV+$M:
M&)TL Q=KSS*!"H+V#(IEHDCA2I*MO>&'Z#GV6+OX[*T>7MRIAW>7PJ=?^&TQ
M7U[3Q?;EH;-HDR&O,\D8*/R)=39XYH H96#&"FE;]U1N1ORXMRS-\';SI!Q'
MN1TX:Q>,_W1Z\>7_G))=6J8OIV_KZ.?-Z_DZGTWX4,<ZUUF\F@6(EENP4B:E
M(^K4O*WO;I1U@L>GA<U]X&VGPYZ0>2;'C7=SF[^S#@ F6Y>J<ZQL*!0CU=&_
M7GO(B;9_EI:C:CT8;2\".\%I0X3<!\+FZNH)BV_FWT[6JXW$^%G/",EX]MI2
M.)[JH)&2%7AF)#A$791%2>?24,B[34XG.&L/@OO@=J1&.@67.&-%)(KZR8N!
MHFV-_GF@2-U;B$QJ:56PW ]V[MXF9]QBA7'!=8A&.@67/&,E,2^2]0Z*"N:L
M ;1B";)TT2AT:$SKA-P#Y(Q;9S NN [12$_@^NGTBMA>+_&_3G">MGVW-F]V
M!280V0F*RG*]<8D>F/$AY<RS58-E >XGJQ-+UDO8T$1[/0'R+H;.]FZ=^<M8
MXL 44^0=&&))902&UA>G&<;FUQ [D-6)W]8*"CL$!\?HI5.HK2YV[$5[V"P+
MDI"LJG.Y CD+D7,#B6NNC5.81>OQ\+O0U0G86H%AETCT&,UT@+8W\^^XVESP
M?*)_L=F/S*H<F5/ G"4?Q-2.UM:0-^IYM($[D; UMFY3T8G3-NHY>J1NND/7
MR[#&SXOEV<R:L_VBG @QHP"9$@E(&@'1^ A<QDQ'@;%.YD'1=A=5X]JQ8_7^
M((R.5D('L/IU,<?37\/R'[A^?3+/JS,NT#HGM3-@HR,A18.U#M""T8$EI34%
M.JTGUM]-24_P.5[?B^;"[P!"+2S\VROO7+-*]74K;@JI8D+P 149?87)6PP^
M#.;ZMV!@W&KW/D[;\1#1P7;8\GS'+?C%);A#GIRF#2V$2.37,@O!*0\Q!UM8
M5EIAZXK/1XGJ)-QX>L#<G-_<5'L]PW'"E68F<5''>$5RA,@'BDQ&8D3QX*QC
MT3P9#,>%7V.E[PJIO330=XWG1><LG)4/^'E:Q58_^6+8TW$M%7;^^(:UFH>Q
MU*AH[^?_.JE#,<[AIS39M#H/IQA7._E*#\$(!"PZ:FX59_&AH3"';-7K%!QK
MA<Y+)=^5C5!_.GTY"ZLS3T,KP;-T#$2V9*ZUK2U'F '4(: N*=./&S/W #GC
M6J(C]'[3[+02>0=GV,>3N)KF:5B>U@Y:9PQM@GD46:".%C2K F(E0<14JPJ<
M=BY;9EGKIHCW$C,N<IJI^R:,FLB^!Q!=DO];^$I??EJ&^8IV62VNWV:T(VH;
M=)' *<@&9;VOCWCJPW%70C F*VQ=]/LX52/#JHWZ;X*JK2Y&;FSV"M,F<4/*
M92\^_7J6Q2F^!)N\!.E9)OEX 2'XZC=&48VX1;]+!\4[/WQD3#36WJ*E*$?&
MPJ_AM*KPDG:5F$J2!6"U2E,57B!(X\D*)Q=DE!CC+BT1;W[NN,41 R+@* 'V
M<,R0P=S<DZY__G[MVB$@+U9I8(Y$H9 I,I?6@2N"V8BR%!D&\%3N(&5DZ SH
MIQPK]S[A<[:A1.!H4U* KDY=9W4Z*B-N6/ A(;.6MW=.[B-F?)_D:%4_#I\#
MY-X?@,Z-J$3GR%9N)N>1#:Y3M8..$)/1G$FO<QD8/%TX+FV4_#!T#I!X![#9
M6.$SFWPEDTYG-6><@[-!@HJJ@!-(?AA3&46R6;C6J9D["1FWA&6H(^MXF8_N
M[/XY_7KR]6+FQKM")$SGG]\OIZE*J][/;*YP?J]M+F]E4B<B<2NT1ZC]#$ I
M1MN#"P%HHG(INA22W\DW/HJ,D9N2'@^"Q3@:&1E\]R?FMRU9MNU5B?=)#!0Z
M&*\@\$Q^@2\:8B&F)&*QF+@K.XT?W'G!D?N%-@74,%+N#3IU@.MTOOF2=LIB
M^1^T2=8X_VVQIFTS23$(XH).\60#J% GNR)&L)*C=K0IC-IEHM-^JX[<TG-8
M$+63]]A(NDR$7.R$E^%;2+6%CTS,H-&;:GSB@[,"T68'.LA,@4G,6,PNN'E@
MC9%[:[9%22M9CHV)FVB_G-]16P"M5A7UY_/*?EDN5JOWRT5"S*MW\ZT,KEP_
M3X1A7,:0H3CB68G"(4BD/W+)%*(4+]TN:>2F1(W<-'-8V_1DVNH@ZML0O1UT
M]NIDXR=N9E%OZE1^PS\V/UE-G!*1'$,#/F0%"@4)V3L%.0=MO _<J.87]+L0
M-G*_S&8P'$X;_4)L.WSFDBLZTJ7QUH(5D=4XVD$H=;2LD";&[*26K0O.=Z-L
MY+:73P6R8_0Q^GE[.:[Q/[#.0,?\XCLNPV?<_&@3^[ZOT2[]9:(4C]H; T))
M<B3H?Q!T5!2FT/;A(7IQLUO#/>?I'HN.W,NR\7DYE+0[,%;G1_MK$F)E,<S3
MC0/>6'0QJ 0D)DL'O,H0DK>0BDP\*X/8O"_<HT2-.U^SO8EJJX4>8'76T_KU
M8GGI5*XF.J04D3/(0M>G0\5N)V)SKK.-J(F9U@78=U,R\@S. 1!TO,"?1;WU
M^Y,XFZ9MT>AYJK=)I?5#']R^QGIG-H:IKK96,^D4(2)G#HIG!TZCAVPKR))B
MHODHJJ>KKJ:5<^0L 4I)X4*H T)=+)"$<-'($"6V?D_W7*JK]]'[/M75^XB\
M@]/I_A)/I0IZZ27D4&^#1-'DO3D'Q7KM4-ML<NO9X<^PNGHO=>]<7;V/['L
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M@@;,(F5O4\BZ]?'XD8TC.,0;/)SG/0#GUBT+_%KSH'<SG6_N9SI/A7=,295
M*_)*E"^<PB_2Q"R%9UH8K4WKV:H[+[+'>[P[ >/QNLH1I-1O=<%&8>_O'74O
M6)VD-*MO\.SMG"SXE_4G^]<8[/ND1I4&30AM5&]P,W![W43P>C4?\EFMA_IY
ML3I?K>$7;FW8J^L\-7?:E#KBTOM2\TRF@$-Z912A+JK LF]=^7C8BAO6,^SM
MZFQVHQCJ)"5.&Y'-Y-H8AQ RY_4N!QHAO<'2/)INM?AI3>XS8O:)VHIG%'\'
MKL.=['((3AHN.?"4:C<=6KNS*@-QMGB4WHG4.K;NLA+C.2'P5-W&+O+H"$N7
MX9W,7%HK!$7YCH+^FM=QVGDHDHG@<L&DQJKKZ>% <'])/EVWL0M;I\^J;B\Q
MT,H;KZ4FUGBVZ4KI?"!..9DS>IF]WN;W'67=QDYRW+5N8Q>F3@\2[K<F\IQP
M/+'@@2%1I5RR@#9K<(9;EBDB,WEHWGWKP[JJU#@ )HW9>DP9]]??\K*.M)F_
M7RZ^S58W)]$R&B9]82#0DY/(T9(A%@6,D4QGED/&'0M_]E_,-.9H)'#LFZAO
M(JE^H+F]*BK5L9(Z6U":"S+-H8 7I-\AB,@$^88VJ-T0V*;T[+FJB/8U:*,Q
MN8/];U!UE&(J\4AQA"YU7',. ;R1"G*.@0DODLP#"US;E9X]5\W0(;M@<^9.
M")C5\OST0PU#UU%%<4)'0;Y=*;7QK8\97$$!4KDH/29T8M!1$WWKK>B*WMU$
M5G<>V$U!T 0!^OZ<[P$N5RCGA65<M]ZK"05+L4'0#,%(CH4Y4]#E5H"9TL<Y
M0%CWQ;T'YR86^.4X[*M(T"@MM Q06)UI%G2=*,,-V()HDLY)L4$G^5M$?N>A
M$PM]'Y$M6O!O:L'/YK<6'IV0 IVL6R:A/FGRGP/78'/AW/&27!HTX&6;X&\_
M=)H-HIG@]^9?!X>O=^L/?4H:F9$U:>QHAXL*O/<&I)="*8>9(KO)2X>?HUAD
MPJ/\_272 9Q&*?B*P1J==02-F:*R0MKIM. @/"/Z41GDK;/*+[W0>"=8/4>A
M\2XRGCCROHX#'R]<Q1(D&0 &VL=2IV5I< QI.S!U V#&*SUD<.KV)[W 4N*=
MD+ 832P3@^SW6O*%YQ?T%]\?)TADDY12'KBH^XR,%DBK%83:O":PX$H:D@0;
M]+ 76$F\+]3:"^<8MN['&/SK=9FCS4$HX1BPXFA74>0\D^=,%)OL<_3TWCS[
M1KUUU=,>6/;A<SZS[#M ^ZM<:.E$[OQ\.0L75Q67ET'\R7Q^@6>W/ZRM3*]4
MG5[6K>94N*!E2@E06/*D!'.UJC=!#B8H+Y,.LG4U=(-E=^XR-$;:8EJQ=X#T
MO3E>ZRH7%_/S.EK\-US^*Y]O1K-<EHV\PO,ZGD7J(&(&@368L#:#XZR S3')
M*'@V;-#)\'-8_ 'T=.[CC*L;W0#EF)7F[JBUDV\X.ZN[\YO%<GW#[%0Z97UT
M"J0A?U!E&0&])PN2Z3^724S-NY"/1<O$AW5'JBPM 7+,BG*54U^=+R_6WNV[
M>C7FXV><7U[-7+-C]79.V^YLD4XYAA2"#R"X<?5</8*WZ"%J-(6K)(2RO2C.
MCK1-'($<J2*-": .%.OD;/TW.3W,H-=_UI?Y-/,4;>+D?3K%:N\C!NB<(-)H
M1XW*9=9\4/BPE0T"M7ZAH!Y!>!.?1^[-T)LKC/?;]5_%4P8+<E7((73UDH-1
M=?:LX* YJF+J.9P=4J,]W@H'0=F\,"AW)/0.K/'![M[C'#D-O$1/KAWM1**.
M.+4)/$9)D9)S/$O.A6P]\6I$<@8IBWUARM(;3'K1F+"=%>$^*][@;+F>NW&R
M6EU\V;AR=<.,M)U^S,LO_#079Y(PZ^FO-6U3!#BM(I1B970:9;'-Q^:.1LT@
M?7$O65^F!TDOZK+75EM__#VOSF?S3YM(AY^ZH(MCKL[K$ZJVD6/@A3? E,]:
M)^>%'%3#]QP[R@/K'Z02_B6KQ!1 .&8E>,H<7 TC_%"/H=':D(+VX+PL)!GD
M@"E(D,HR(TO@['YASG2:,92H80D]]I>^/ -FCEF)'CPV^T>>??I,'#GYEI?X
M:=,FKR9TKKEWJES6SH<,03LD]O@ @7L&(J$2:$QTYMG;P+8E<9B"O=24><]X
MZD#=KNN_\O+;+.:'N?7[8OZ-=N:\V:17'Q?GM<S@YO/:H^CWQ?D_\_F''!>?
MYNN SWJAM,X"D/X%A4F"3U$!YU;'S),IS<\%1B-FF J]U,QZ'QAYR<JR,2YO
M%LO+7]6_HQC0Q^AD%"#UNKZS> A!2@BQ]L]Q*5DCCT6#'J1PF%J]U!Q\QV@Z
MRK::?UQ\^8++[XMRJY;Y))Z3+WS^?93NFD,>.'Z3S9W)[J/7IK2D(];7,0$Y
M@1)*@@M,@N*V,)--\.VK3U](KTUF>*%8+H$5SA+KM*&(3I$-XIH%SH,QO'6+
MN;]Z;>Z*V?%Z;>XB_@Z<ICL= 542"AV+D%*HEY25H#C)1@@4&1FO:2/2?_7:
M; R!IWIM[B*/CK!T-4K!)2&5MU <7\\XY^"SRI"5R4@>F$%L7537TYW8_27Y
M=*_-7=C:3P^RP=/1?!8L<[+BDB52'L7)$:Y-EA(J3P1'QW=M1=9T(-US=>+<
M2<H'#J3;A>4=F)E[E\V]+RK0NI.OLWPHK ,O*(Y2,M+RI+="M@[#^QQ(-^&F
MM;]$.H#3*)=_33!1T;-JH;TC;MH,*+0#:VP*/)<H\*^N$CMVE=@%5L_156(7
M&7> \\?ODMNBF+ *@<Q_H>B)8B;G!"-+0";!>?1.M ;K?U+/B9UP,GA\W2Y"
MZP!]#4YS578V!/*AC6 :5.((Z)4'2[M6R2E'Q;K)!?_:W82R"=V#9Y;],:/]
M,JW][N)\=4XN_&S^Z</B[.S-8ED_/$VA6/1"@_:EUK5+!][X*@0KHY662=[-
MA>@G*>G<RC?&8^.:AP;@>%DJLJEO/\W9%\X-!Z%+G2\A GA=!%A-,B'BR7RU
MC@2;$W&DBM$0F>,IRQXPV5M/OJZ3O'^<X_*\"VVY6R?URW*Q6IU&YU,0Q(-L
M6:UD]QD"<P4D,]I[X8N[W]]K<GUY@(PC[:K1K\8<"I4>]I8:+=6)I3F]NEA>
MEZQO;CW=GM#\^L^\C#/BPVD417$4'CAC=3A##!2D$=N)Z!@2(XKOWQ,]7!EV
M7N61-L48$>OC"GIW*/L-E.?Y4\U8=V'ZB<\ES^H,W]7)/+W^\^MLN?Z&F^8%
MAD7C@M<0HJS:3<QQ11C03DHK(H^BG\YZ0XDZTK87_6X+;6'T(C3K1]]2><UT
MC 5B%F1<T')PQBG@6'30*7&/HUP>??80I+_>&OUJSF$P.3 $>3WO0U?^OBF3
M75N.S47:1?W5C[RQ/G%C10)NJZ2"K%T<A ,9/=D1'[AK7S[W3+0=::C2QZG7
M* #J(58YD"^7GFT]I+]D %F1F@RU((14H%3.9.M0 6/,D7];2LRMJ_B:$W&D
MD4X?JG(8)%Z 3MPR"O>N!%[%@>L>HM5!*)<.0D0AO)%ULF=*H%CR)"^7P!3A
MG/5.%=N;TNQ.Y9$&17UHU<B@^L]1NU/NO7+<.F"IUN]P3\XX218*PVQ8R9&B
MO>/4M1>3OAD%X=,HY$YP.YZ$SZ/U&D-NQM]E$#+CA26#2OSQY#&'VA"X]M"6
M5NBB4/-A(UN?I5AQ9_*.-.KJ5"<G@MTQ[([;6'-%_3#N*)LDA;$15,RUHS#]
M< (],(/9)Y>S1]:;4NY$X9&&>$>JE^.![QA4\]#<QI/,*HYIY5D QQB2?Z$+
M($/R+V)(V<BB.JI+;4'PD4:1G2IN-]!\ 7H\-"(0BGGDL8"(]7)=,1*PB$(!
M@L[9)6)9\[[V/06@QY"\.P;=' -N_S'IOJ=#]N"UYK;>]:HW4C$:\!P3E,Q%
M_2PDV<T@HR84'ZG>]G$R^XQ@>P&;Y*WLT)-L<5+$C,8 5SF <K5E 8\*;"P>
MH^.6EVYF(NU&VM&/W.@DN=@,/B] JVYF*]QT,;II3>1X,AZ3AJ03J_73"1R&
M M8$89QSP;/>]K,G"3KZ.1Q3:E [J/2B-V$[,\+./O2'7&]/T^_7(W.)-1=X
M5J<OB%.O3(X,&23FB462>_!!&3!)2^N4%4J-DC]\7C*/.Y?8$.2MQGH\$^)>
M@%(^XE _OO4_QCE^:KDKP6 &AN12JT@FU^4D(%G-+-.9QS!*74T7U!]WZK%?
M%9X(GR] L_=AD9*,FV D,"V(1=J0)Q_J;%.'62K/DW6CC)![7C*/.QW9KZZ.
MC;A>E++-.?);XL1LOIK%S;B*($60(5@HRKM-DQ^4V8)1OMCD9>(J=!8W/DK,
M<:<-1U:PR='S M1H^S'PR:=/R_7]P7N,0B5DJ D:GI4'Q:6!X&2!(+A --9R
MWEM!ZM[$'FFFH7LU?![T]:*F;1R"NXP@9QRY]KDD$+4^MU[3!V>C!E6TPJ"#
ME*&W@YW'J3G2+,,Q.92'X.<HAZA\J#Q:+<K?YH2>L^_5J-S,%_P;_1^S^4]_
M_+9A5$W#T!_\MDBD 8M7F=;]93:_F85V9R3)IFXWI_/%5<?)=0?IQ3Q?O=T,
M*[G+O4-'M$Q/SO@#8*:G\8[(^A@O4\CY=+IDX.M1'2@TD-5P4$)1@AMO([:^
MY/U2QLN0SVY+BA&TEKDV:\_@965=B2)'YAVSS6O7_AHOLR-FQQLOLXOX.W 6
M[PS!\(77=K$2!$9R=*/DX%C.(&(2V2#+)K7NCO(2Q\OL!(&GQLOL(H^.L'39
M5ML6J9.Q"$Z:>E&!97"F:-!HBC?<1>Y;CRCKJ3G^_I)\>KS,+FR=>+S,B6#<
M;YUN@C845VK1NRH4%&!0$*R4@#QSPXVVQF]S80<_K ](["/)Q9AL[<!X-*@9
M8DFC-BZ#-IIB2ND5^)(52%=X*,4P%4;)@QVTZI<RGN:03>^997_,:+\.-6\%
MJ1]FJW^]6>9ZVI()/^<?R%L^)8=7$]L#H \"E! %R _6(#/WC!ABL^ZF3==0
MHHZTXFI/E+92DE$@\])TZ"HI\&KV;9;R/*T94@J:P+$VS"R!Q$6&#6.)D(R*
MEKNLA'KV*]Z'$G6D)4\=ZM#!D'FI.O3WQ1E]S1GYI6N66"<L:JY!&,%!><8A
M:)4@VEBLI% HYZ/0HKMD'6DY4L=Z= !L>M&D?;)F3[%D4VWE X_&D!&Q/B10
M!CG49H'@'/="6I'3.',@1J'F2*N,&NK-]" YRM3J5:AZF6/[@8N5'?-5+HOE
M^O,UVU8?<EQ\FL_^CW;I=:YMU38_VFA-XR<YQV!>'YE*CKYPGPK(XCP%+<:#
M=R("<B&=]E$)V_J4N9=,Y?7LR;S\-HOY$=MVMOY*>O6NW ATTYIDO=+-\8TV
M]5*=9%"BMJ!*+1B)5D)F+KA0>#&Z>2'K&(0<=09S%RP_GL&<"A83.F&KY?GI
MQ]EYI?[M/-5X[ +/UHF7I,E5-"R##9F!BN1/8HD.!&?.J6B<D8-P34^XA6EZ
M=X/G1Q_>2SYS,D L6DJG-WC]8W;^>:W7U1?[//OZ<?%Z?D[!RV5RQUM6$'D"
M$6K1:!&.=!D-,!.U*9; 8P<Y[;L"[^EE30/)1@!X"DX-I3%QTO1*6Z_2>"4$
MI>IPZE#OOW%/')**@^.R)%LB,T%N<6!__-:.8-!2<(LF7.S@,.'MG)SZ_ >)
M9!T5_GIIF=<J$TP(,A6RP"(@*)02?(H*(M:[5UEXI5M/47UB.;VD+Z?>XUI+
MKE\07BIFRLKQ9 7I49'$I&0@"'I;K$%3F"<:R_/ L(=BGV9B'P:G/630 : ^
MD$QH 9]/YNE5_I;/%E\K39='#Y>&VA@O,0E/NH<<5-(,'"H!ELMH;$C%^-:-
M> 8LJTMP[0."Q;@2Z0!DO^1Y7I)W.4\GZ<ML/JNA=:V,NDN41(R6_ ?(L1[B
M%FL!L::ZD4NA8G(RMYZH.6AATVZGXP&MO50Z@%H;G^,FLR"X)S>45$LH)+_#
M&P0?O06=M%.Y%$;<:0S*QB1,G!3MSAN<$B$=*,C#])XFBOD58Q%\D )HW61(
MO)<0"R=.<YV?JW'EM-OZI. 8E-#?25)[X^U;7H;%N&G%GS^O+_G-YC\M<)D6
MY=5LF2-A=[5_5G#K5S9*ZNVV]$8YN7?+3TA 6R_XY\5\M3B;I0T<Y^G]+6+>
ME3>S.<[C#,^NO8:;=(;26=H4)3"L9S=*$(X\A4"&>V3,<I=*ZWKL)@MOEZ'[
M>7%&GR\VOL[M6NJ3]470^,C''^G5BA92C\2NJJLS*]PA),\-L3(F0"MK?SOR
MS#&:H$>\5-B*BFG-[?-C^O$4W22XZ"V!LCX<*4$GRW."S(,"99VA\")HL,(Y
M64HH5@Q*WQ]S?FX:-&Q-SNTBFMZPM26K0 &K+$XC6(ZR#J50X+64$!S3T8JH
MF/DK.;<;  Y(SNTBC8F!=N5]71Y8..5<9((<[:S68[@T^<=,0U8>%4:!RK:H
M+KC[U(Y@TE*PBR9<[B#JW5R*HS]>*Y&C54;-&5GBVO)&DQ(YBQHBHP^,M!A5
M:\_MS@)Z2=!-NLD=+IH.<+7_#<T;LLG5O7L'N:"U(EM+NJ4IPB=%!5_H54Q>
M&I.T+KQU&F\,.J9UY0Z 5;,QDHUD/''QRZU>?>MVF>_F^9\9KS:"))(4Q@MP
MHM0[QH+V$RP2G(H.4V:>X;V#PP=K89Y\2.=W3$>7_V(,872&JH\$CC4IJTM:
M,M,L>\,@&$][2AUR[!FK/<<]M]R+8.^/,QL$K/O/Z?SNY938.D@D'6S.#=R;
M6R?Y/DF43 !R2WZS90HPU7M&65NOO2&'N/6-R9;K[R4+V(7+.1DP.E"*0WN<
MWIU5_\MRL5J=6NV4%UQ2)$E[CXH>R4($"1F+,;$$5./,*VE+QK1>QG28;-S3
M^5" O#@=N3?!8?WA*SR_Z5!Z&HVMY31UXE\='Z\C Z^$!1:U5,$D[EEOK=1W
M)'%:+^N%ZE9;8!VSWJU_7/JM&][PTXR&9,,<\)Q(3K$D"H.$ 1T,T]R0#=+=
MC&)]8/W3.FS'KS&'0J+?^_B7%U??X_+\^VV&WW2??SLOB^6739WHWL4T>SVF
M48'-X20V*KIY="'7UX,58O96@TN:()6L@U!X D/VU<54I/*M7=]M:VI7*O/8
MDW[Z?N>3=3SF"PJK>*%0+->!'"H0(R('[A/+(5B76>OJ[;T6.JV7WQ1/C]>R
MC"6X#GR$1TA;G_)K$[,+T4+QM:.ORP:0D;M3A FV<%=9^#S*V%,IRVA@^.'B
M2AO)] NRJQ1Z8IJ\& LYU#G8)DI 5PI$9^I!J(I"M[\/]<2"NC1INXM]&)SV
MD,'4E\?_S/&B.LH_?Z; [ O.3SXM\]IWO;H(+;S3.0I2.IW(YK,(06@'Q"&E
M34G!\4'7R;<\ITN8["/.Q4B\[=?PW+/5:]T24J1@G >)J,A49PWH2ZCMZQV%
M,ZIXUGHPQ/#5]5+A,O'>=ZC<.D/DI;)F$9&'Q"":B* "\<A9S4%H%"7*R)4;
M$WD=;WH'R_L)6.W!_(D+,T]*F9W-*@&;"L1+DZPB+5$(6KRLZ>F@:E=$6<#S
M)'*P,7(QJ+QI2X'FPT_O!S;[R'/1E+D3P^/GQ47M=/ZU,N-Z*(LM9&JYBN0B
MUO)4$P2@<((L<?)6R1"E'W2,L 4<#SV[EQ3YV'M6$]Y/C)T/^>O%,G[&5;YV
M^.Z3=-6LR%FOLD80.95:J,S( 2RU8L!9Q[U1.0^:N; %4(,7-%VE^.$R7XPM
M@(DCM5<7.,^_X^KS;Z_^Y]5O/YU<VM2B=)3"&RA&U"C6)O"!&[!94& 20U#^
MWIW)!^.SA[]].CR,),)%4W[V=HEIHS3>LV0,L2+6/!*+Y-(E>NN41#*XRK F
MF]3^%^3&Z]7]K+O4X=SO#3Y;+N=H'7B)04-)T8'R,55%(VU+CMXX(R4.ZB/W
MLN_ [02  ^[ [2*-B8&V;D3P[J81P=5QV%544!P]T6I@JAIPBD3!)2: .V%$
M5$&R,BABWX*KIU?1$8Q:"GXQBA0FQM/U+?L_8I[C<K98*Q[/WJ*-GE8L:?=/
M+D/(6H*5T65?D@K#^@MN@=&##Q^$'OTR]KW#N3\U?"[7_;?YZFN.LS++Z5*U
M5$+)3,SU9#^!LN3[N2)353)14N:!#>LSM U"CRU@.B/40*B+UASN!"9O%F0P
M<765L]$^:\-$ 4[Q)R@M-3@6"J!+2GM?>RJUQ,C=IT\(D#8B?0 D!_"WLPS$
M+8O[ZW5]H3-<\5QLG9%82UU5@6!I<V4A&([2I12?*1__ZT[7;<SQ[U:CR*@#
MS(UQ"4)J[@+/&0I/M6TZ6?GU49N+,@OFE>3]%"3W>DNF+<Z>X>;++D*?^/3S
M#SS#Y?=U \/?%O/SSV??*Z&;WY[J',NZ378RZQL\9!Q<41%2=MQI&X5G0VI4
MGGK&M#4#HR"K*5O[K4C_XR*L\O]>T)>]_E8O"1PPU^V1;VHUC6W(0AN5CM]_
MUG6)K^?1:R,]!&8MN?PE@[>1 ;(8C&7<2M.Z2O6QM1R\3=[]WHT?@4+IDLF?
M](XQ4$98<-PP$+$8%URR0K4>AO'0.B8NOVTA_1\VJ$/9W8-G133,THR,'YE
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M6UZ=UUCBZL#[]9]Y&6>KNO&_^_><'OAY]O77V9?91E2D!+&*[5,^#2X$[U(
MT@=B%W>V#H WX+3W7I8HZ.> #$.;U73E-1T&KHE$=,2@_ W_G'VY^/)V'I<9
M5_E5WOQ[R8C35+PR,170*M3 )Y,0M&#KFP[!!"N]&!NH3Z]PXGM%/8&WH2B/
M!= ;/W4SS_F&$;\OSC<^QVR13FGWP% 4AU1R)H?5)4#F TC/LRK$$&2\)8*W
M+VGBRP630;:QL#IP#]\O%S'GM'I#7*[!$LXCN;WDU'S#\_S^#./ZI+&VD&(Y
M!P\R6U<3ZK2+"*N!R]I#D66O7>M88]C*!B'1'@421Q1)!T#[9;%(_YZ=G;W]
M\K5>2:[<JK<3G L2:VM.5B(9<J<=!&XR< JGBG(.O6I=DO#P2@8!R1T5D!JP
M?/R*_\L/ZH] 6_U__]?_ U!+ 0(4 Q0    ( )568U4$GH2C2!   +!$   3
M              "  0    !E>&AI8FET-#(Q,3$Q,3$N:'1M4$L! A0#%
M  @ E59C57AZBU&N!P  ,R$  !H              ( !>1   &EM=7@M,#DS
M,#(R>&5X:&EB:70S,3$N:'1M4$L! A0#%     @ E59C5;'!,L2A!P  *"$
M !H              ( !7Q@  &EM=7@M,#DS,#(R>&5X:&EB:70S,3(N:'1M
M4$L! A0#%     @ E59C527ELB^M!   KQ(  !H              ( !."
M &EM=7@M,#DS,#(R>&5X:&EB:70S,C$N:'1M4$L! A0#%     @ E59C594!
MQ]:F!   I1(  !H              ( !'24  &EM=7@M,#DS,#(R>&5X:&EB
M:70S,C(N:'1M4$L! A0#%     @ E59C58AIUS0/L@$ **41 !
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M,C R,C Y,S!?9S$N:G!G4$L! A0#%     @ E59C5=1-B%PBJ@  MRD' !0
M             ( !4+P, '9T;"TR,#(R,#DS,%]L86(N>&UL4$L! A0#%
M  @ E59C562J)M0+;P  F0$% !0              ( !I&8- '9T;"TR,#(R
B,#DS,%]P<F4N>&UL4$L%!@     ,  P )@,  .'5#0    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
